﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Saito, M
   Iida, T
   Kano, M
   Itagaki, K
AF Saito, Masaaki
   Iida, Tomohiro
   Kano, Mariko
   Itagaki, Kanako
TI Five-year results of photodynamic therapy with and without supplementary
   antivascular endothelial growth factor treatment for polypoidal
   choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Ranibizumab;
   Vascular endothelial growth factor; Branching vascular network;
   Age-related macular degeneration; Retinal pigment epithelial detachment
   Optical coherence tomography; Fluorescein angiography; Indocyanine green
   angiography
ID MACULAR DEGENERATION; JAPANESE PATIENTS; FOLLOW-UP; RANIBIZUMAB;
   VERTEPORFIN; EFFICACY
AB Background To clarify the long-term efficacy of photodynamic therapy (PDT) in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
   We retrospectively reviewed 60 naive eyes of 59 patients (45 men, 14 women; mean age, 73.8 years) treated with full-fluence PDT (PDT group) and followed for at least 60 months. Retreatment was either antivascular endothelial growth factor (VEGF) therapy or intravitreal triamcinolone acetonide if PDT alone was ineffective (supplemental retreatment group).
   The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) levels at baseline and 60 months were 0.66 and 0.71, respectively. The mean change at 60 months was a decrease of 0.50 line. In the PDT group (36 eyes), the mean BCVAs at baseline and month 60 were 0.73 and 0.68, respectively (p = 0.60). In the supplemental retreatment group (24 eyes), the mean BCVAs at baseline and month 60 were 0.55 and 0.74, respectively (p = 0.076). The percentage of eyes with decreased BCVA at the time of the additional anti-VEGF treatment was significantly (p = 0.031) higher than at month 60. The risk factors identified by multiple regression analysis with a significant decrease in BCVA at month 60 were a large greatest linear dimension (GLD), classic choroidal neovascularization at baseline, and a hemorrhage over the arcade vessels after PDT.
   The efficacy of PDT for PCV depends on the GLD. Twenty-four of the 60 eyes needed additional treatment other than only PDT during 60 months of follow-up. Additional anti-VEGF treatment may help maintain the BCVA of patients with exudative or anatomic recurrence.
C1 [Saito, Masaaki; Iida, Tomohiro; Kano, Mariko; Itagaki, Kanako] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Fukushima Medical University; Tokyo Women's Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kang HM, 2012, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2012.09.020, DOI 10.1016/J.AJ0.2012.09.020]
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 23
TC 12
Z9 12
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2014
VL 252
IS 2
BP 227
EP 235
DI 10.1007/s00417-013-2433-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA3LS
UT WOS:000330994600006
PM 23918094
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Yang, E
   Lee, WK
   Lee, GKY
   Mathur, R
   Cheng, J
   Wong, D
   Wong, TY
   Lai, TYY
AF Cheung, Chui Ming Gemmy
   Yang, Elizabeth
   Lee, Won Ki
   Lee, Gary K. Y.
   Mathur, Ranjana
   Cheng, Jacob
   Wong, Doric
   Wong, Tien Yin
   Lai, Timothy Y. Y.
TI The natural history of polypoidal choroidal vasculopathy: a multi-center
   series of untreated Asian patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Natural history; Visual outcome;
   Untreated; Observation
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; CLINICAL-FEATURES; JAPANESE
   PATIENTS; INTRAVITREAL BEVACIZUMAB; NEOVASCULARIZATION; VERTEPORFIN;
   EFFICACY; OUTCOMES
AB We aimed to evaluate the long-term natural history of polypoidal choroidal vasculopathy (PCV) in untreated patients.
   This is a retrospective observational case series. Patients with symptomatic PCV who did not receive any treatment for at least 12 months were included from the records of three ophthalmic clinics in Asia. The medical records and imaging data were reviewed. Visual outcomes at month 12 and at last follow-up were analyzed. The influence of demographics and presenting features on visual outcome was analyzed.
   A total of 32 eyes (32 patients) were included in this analysis. The mean follow-up was 59.9 months (range, 18-119 months), the mean age was 65.7 years and 21 (65.6 %) patients were male. The mean presenting logMAR visual acuity was 0.79 (Standard deviation [SD] 0.49). The center of the fovea was involved by the PCV complex in 25 eyes (78.1 %). The mean greatest linear dimension (GLD) of the PCV complex was 2584 mu m (SD 880). Twenty-three eyes (71.9 %) had a cluster-of-grapes configuration on indocyanine green angiography. Leakage of fluorescein angiography was present in 29 eyes (90.6 %). The mean logMAR vision deteriorated from 0.79 at baseline to 0.88 at month 12 (p = 0.11), and further to 1.14 (p = 0.003) at the last follow-up. The proportion of eyes that improved, remained unchanged and worsened was 21.9 %, 31.3 % and 46.9 %, respectively, at month 12; and 28.1 %, 9.4 % and 62.5 %, respectively, at last follow-up. The proportion of eyes with logMAR vision worse than 1.0 was 28.1 % at presentation, and increased to 31.3 % at month 12 and further to 53.1 % at last follow-up. Reasons for poor vision were due to retinal, subretinal or vitreous hemorrhage, and retinal pigment epithelium (RPE) atrophy and scarring. None of the presenting features were found to significantly influence visual outcome.
   Half of eyes presenting with symptomatic PCV had a relatively benign course without treatment and some even had vision improvement. However, in the remaining eyes, vision deteriorated significantly, mainly due to hemorrhage and scarring. There may be subtypes of PCV with divergent natural history.
C1 [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Cheng, Jacob; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Med Retina Serv, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Wong, Doric; Wong, Tien Yin] Duke NUS Grad Med Sch, Eye Acad Clin Program, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Yang, Elizabeth] Univ Oxford, Sch Med, Oxford, England.
   [Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Seoul, South Korea.
   [Lee, Gary K. Y.; Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
C3 Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore; University of Oxford; Catholic
   University of Korea; Seoul St. Mary's Hospital; Chinese University of
   Hong Kong
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Lai, Timothy Y Y/AAC-2120-2020; Wong, Tien Yin/AAC-9724-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428; Wong, Tien
   Yin/0000-0002-8448-1264; Wong, Damon/0000-0003-4601-9121; Cheung, Chui
   Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [NMRC/NIG/1003/2009]
FX This study was supported by National Medical Research Council grant
   NMRC/NIG/1003/2009.
CR Bessho H, 2011, RETINA, V31, P501
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 25
TC 43
Z9 45
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2015
VL 253
IS 12
BP 2075
EP 2085
DI 10.1007/s00417-015-2933-2
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CX0ZV
UT WOS:000365426900003
PM 25619667
DA 2022-11-30
ER

PT J
AU Taylor, HR
AF Taylor, Hugh R.
TI Global Blindness: The Progress We Are Making and Still Need to Make
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE blindness; cataract; eye care; myopia
AB The actual numbers of people blind or with poor vision continue to increase despite so excellent progress that is being made in reducing the prevalence or percentage of people affected. More attention is required to provide quality outcomes for cataract surgery, prevent and manage myopia, detect and treat diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD). Although more ophthalmologists are needed to provide this eye care, it is important that ophthalmologists work in effective teams with allied eye health personal to be able to meet the community needs.
C1 [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Level 5,207 Bouverie St, Carlton, Vic 3053, Australia.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Indigenous Eye Hlth, Level 5,207 Bouverie St, Carlton, Vic 3053, Australia.
C3 University of Melbourne; University of Melbourne
RP Taylor, HR (通讯作者)，Univ Melbourne, Melbourne Sch Populat & Global Hlth, Level 5,207 Bouverie St, Carlton, Vic 3053, Australia.; Taylor, HR (通讯作者)，Univ Melbourne, Melbourne Sch Populat & Global Hlth, Indigenous Eye Hlth, Level 5,207 Bouverie St, Carlton, Vic 3053, Australia.
EM h.taylor@unimelb.edu.au
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Chua J, 2018, ASIA-PAC J OPHTHALMO, V7, P3, DOI 10.22608/APO.2017511
   Directorate General of Health Services Ministry of Health & Family Welfare Government of India., 2012, NAT PROGR CONTR BLIN
   Keel S, 2018, BRIT J OPHTHALMOL, V102, P1419, DOI 10.1136/bjophthalmol-2017-311257
   Ramke J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172342
   United Nations, 2018, TRANSF ACH SUST DEV, DOI DOI 10.22022/TNT/07-2018.15347
   WHO, 2015, WHO GLOBAL ACTION PL
   Wolffsohn JS, 2019, INVEST OPHTH VIS SCI, V60, pM1, DOI 10.1167/iovs.18-25980
NR 9
TC 22
Z9 24
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD NOV-DEC
PY 2019
VL 8
IS 6
BP 424
EP 428
DI 10.1097/APO.0000000000000264
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JT1UH
UT WOS:000500782400003
PM 31789642
OA Green Published
DA 2022-11-30
ER

PT J
AU Mukai, R
   Matsumoto, H
   Nagai, K
   Akiyama, H
AF Mukai, Ryo
   Matsumoto, Hidetaka
   Nagai, Kazuki
   Akiyama, Hideo
TI Comparison of the regressive effects of aflibercept and brolucizumab on
   pigment epithelial detachment
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Brolucizumab; Pigment
   epithelial detachment
ID MACULAR DEGENERATION; EXTEND REGIMEN; RANIBIZUMAB; PEGAPTANIB
AB Background To compare the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment (PED) in age-related macular degeneration. Methods Eighty-three eyes of 83 patients diagnosed with type 1 macular neovascularization were included and retrospectively analysed using multimodal imaging. Forty-nine eyes were treated with intravitreal aflibercept injections (IVA group), and 34 eyes were treated with brolucizumab (IVBr group), with three consecutive injections administered as induction therapy. Before treatment and 1, 2, and 3 months after the first treatment, the maximum height (MH) and maximum diameter (MD) of the PED were measured using optical coherence tomography in each treatment group. Results In the IVA group, MH at baseline (228 +/- 169 mu m) diminished to 180 +/- 150 (P = 0.2558), 165 +/- 140 (P = 0.0962), and 150 +/- 129 mu m (P = 0.0284) at 1, 2, and 3 months after treatment, respectively; the reduction at 3 months was significant. In contrast, in the IVBr group, the MH was 307 +/- 254 mu m before treatment, and it decreased to 183 +/- 156 mu m (P = 0.0113), 139 +/- 114 mu m (P = 0.0003), and 125 +/- 126 mu m (P < 0.0001) at 1, 2, and 3 months after treatment, respectively, and the reduction at 1 month was significant. In both groups, the MD did not regress significantly. Conclusions The results suggested that the MH of PED after IVBr treatment regressed faster than that after IVA treatment.
C1 [Mukai, Ryo; Matsumoto, Hidetaka; Nagai, Kazuki; Akiyama, Hideo] Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-35-15 Showa Cho, Maebashi, Gumma 3718511, Japan.
C3 Gunma University
RP Mukai, R (通讯作者)，Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-35-15 Showa Cho, Maebashi, Gumma 3718511, Japan.
EM ryohmukai@gmail.com
OI Mukai, Ryo/0000-0003-1796-9232
CR Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Fukuda Y, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091164
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J D, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P990
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-10578-1
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Mukai RG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259879
   Pellegrini M, 2021, GRAEF ARCH CLIN EXP, V259, P911, DOI 10.1007/s00417-020-04957-5
   Rispoli M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060668
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamashiro T, 2022, GRAEF ARCH CLIN EXP, V260, P1857, DOI 10.1007/s00417-021-05517-1
NR 22
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 29
PY 2022
VL 22
IS 1
AR 387
DI 10.1186/s12886-022-02617-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Z0DI
UT WOS:000861889600001
PM 36175862
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Nielsen, MK
   Molbech, CR
   Oishi, A
   Singh, A
   Nissen, MH
   Sorensen, TL
AF Subhi, Yousif
   Nielsen, Marie Krogh
   Molbech, Christopher Rue
   Oishi, Akio
   Singh, Amardeep
   Nissen, Mogens Holst
   Sorensen, Torben Lykke
TI Polypoidal Choroidal Vasculopathy Associate With Diminished Regulatory T
   Cells That Are Polarized Into a T Helper 2-Like Phenotype
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; neovascular age-related macular
   degeneration; t cells; interleukin-33
ID MACULAR DEGENERATION; MEDITERRANEAN DIET; PARAINFLAMMATION;
   DYSREGULATION; EXPRESSION; SUBSETS
AB PURPOSE. To investigate possible roles of T helper (Th) cells, regulatory T cells (Tregs), and the recently mapped Th-like Tregs in patients with polypoidal choroidal vasculopathy (PCV).
   METHODS. In this prospective case-control study, we obtained fresh venous blood from patients with PCV (n = 24), age-matched healthy controls (n = 32), and patients with neovascular AMD (n = 45). All participants underwent a comprehensive ocular examination including fluorescein and indocyanine green angiography for where retinal disease was suspected. Using flow cytometry, we identified Th subsets, Tregs, and Th-like Tregs. Plasma samples were stored at similar to 80 degrees C to investigate plasma cytokines of interest.
   RESULTS. Compared to healthy controls, patients with PCV had lower percentages of Tregs (8.7% +/- 2.8% vs. 7.3% +/- 1.7%, P = 0.027), which were significantly more Th2-like polarized (42.6% 6 13.3% vs. 50.5% 6 13.0%, P = 0.029). These changes differed from that observed in neovascular AMD, which compared to healthy controls had fewer Th1/Th17 cells (3.6% +/- 2.7% vs. 2.4% +/- 2.5%, P = 0.049), comparable Treg levels, and no distinct polarization of Th-like Tregs. Because of these findings, we measured plasma IL-4 and IL-33 levels. Plasma IL-33 in patients with PCV (median 0.30 pg/mL) was twice as high compared to healthy controls (median 0.16 pg/mL; P = 0.037).
   CONCLUSIONS. PCV associate with diminished Tregs that are polarized more into a Th2-like phenotype. This is correlated to IL-33 levels, which we also find increased in patients with PCV. Our findings suggest a possible role for Th2-like Tregs and IL-33 in PCV.
C1 [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Singh, Amardeep; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Subhi, Yousif; Nielsen, Marie Krogh; Molbech, Christopher Rue; Nissen, Mogens Holst; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Oishi, Akio] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Singh, Amardeep] Skane Univ Hosp Malmo Lund, Dept Ophthalmol, Lund, Sweden.
   [Nissen, Mogens Holst] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; Kyoto University; Lund University; Skane
   University Hospital; University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020; Oishi, Akio/AAE-9996-2020; Singh,
   Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Oishi, Akio/0000-0002-0977-9458;
   Krogh Nielsen, Marie/0000-0003-3804-7296
FU Danish Eye Research Foundation; Fight for Sight Denmark; Velux
   Foundation; University of Copenhagen
FX Supported by the Danish Eye Research Foundation, Fight for Sight
   Denmark, and the Velux Foundation. In addition, author YS is the
   recipient of a faculty stipend from the University of Copenhagen that
   covers salary. The authors alone are responsible for the content and
   writing of the paper.
CR Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
   Alberts B., 2002, GARLAND SCI
   Balestrieri ML, 2008, CARDIOVASC RES, V78, P250, DOI 10.1093/cvr/cvn029
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Corthay A, 2009, SCAND J IMMUNOL, V70, P326, DOI 10.1111/j.1365-3083.2009.02308.x
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799
   Dudley AC, 2005, BIOCHEM J, V390, P427, DOI 10.1042/BJ20050351
   Duhen T, 2012, BLOOD, V119, P4430, DOI 10.1182/blood-2011-11-392324
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Halim L, 2017, CELL REP, V20, P757, DOI 10.1016/j.celrep.2017.06.079
   Hass PE, 2016, Patent CA, Patent No. [2960297A1, 2960297]
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Imai A, 2012, INVEST OPHTH VIS SCI, V53, P7299, DOI 10.1167/iovs.12-10182
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2011, EXP EYE RES, V92, P180, DOI 10.1016/j.exer.2011.01.003
   Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.3
   Lin Tony, 2013, Cytokine, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932
   Madelung CF, 2015, CLIN OPHTHALMOL, V9, DOI 10.2147/OPTH.S82116
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Subhi Y, 2017, CASE REP OPHTHALMOL, V2017, DOI 10.1155/2017/9650287
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 1982, ANN M MAC SOC MIAM F
   Yates-Binder CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040812
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang HF, 2016, DNA CELL BIOL, V35, P96, DOI 10.1089/dna.2015.3105
   Zhao MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131429
NR 51
TC 7
Z9 7
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2019
VL 60
IS 7
BP 2583
EP 2590
DI 10.1167/iovs.19-26882
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IE9UB
UT WOS:000472721000022
PM 31219532
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, SY
   Chhabra, R
AF Liu, Siyin
   Chhabra, Ramandeep
TI Real-world outcomes of combined therapy of photodynamic therapy with
   anti-vascular endothelial growth factor for polypoidal choroidal
   vasculopathy
SO EYE
LA English
DT Article
ID MACULAR DEGENERATION; PREDICTIVE FACTORS; RANIBIZUMAB; VERTEPORFIN;
   COMBINATION; AFLIBERCEPT; EVEREST; TRIAL; PCV
AB Objectives To describe the real-world outcomes of photodynamic therapy (PDT) as a rescue therapy in eyes with polypoidal choroidal vasculopathy (PCV) refractory to anti-vascular endothelial growth factor (VEGF) monotherapy in a British cohort of patients. Methods This is a retrospective chart review of 53 eyes with PCV. Based on the timing of PDT, the eyes were stratified into two groups (9 in the Initial-PDT group, 44 in the Deferred group). The number of anti-VEGF injections/year and the best corrected visual acuity (BCVA) before and after PDT were analysed. Multivariate regression model was created to identify factors predictive of visual outcome and treatment burden after PDT. Results The Deferred group received a mean of 9.4 injections/year but significantly reduced to 7.2 after PDT (p < 0.001). The Initial-PDT group required significantly fewer injections after PDT compared to the Deferred group (p = 0.004). The Deferred group experienced improvement in BCVA from 58.7 letters at baseline to 63.8 at 18-months follow-up (p < 0.001), but no significant increase was observed in the Initial-PDT group (p = 0.310). Better baseline BCVA is associated with higher likelihood of achieving good BCVA >= 70 letters after PDT (Odd Ratio=1.12, 95% CI: 1.03-1.21, p = 0.006), while increased number of anti-VEGF injections/year before PDT reduces the likelihood of easing treatment burden to >= 12 weeks apart between each injection after PDT (Odd Ratio=0.724, 95% CI: 0.58-0.91, p = 0.006). Conclusions PDT as a rescue therapy is beneficial in the long-term management of PCV, particularly in eyes that had experienced a significant period of prior exposure to anti-VEGF monotherapy.
C1 [Liu, Siyin; Chhabra, Ramandeep] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Liu, Siyin; Chhabra, Ramandeep] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Chhabra, Ramandeep] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester
RP Liu, SY (通讯作者)，Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.; Liu, SY (通讯作者)，Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
EM siyin.liu@mft.nhs.uk
FU National Institute of Health Research [ACF-2019-06-009]
FX SL is supported by the National Institute of Health Research
   (ACF-2019-06-009). All authors have contributed significantly as per
   ICMJE requirements.
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Ratanasukon M, 2018, CLIN OPHTHALMOL, V12, P2177, DOI 10.2147/OPTH.S178228
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 24
TC 2
Z9 2
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2022
VL 36
IS 10
BP 1934
EP 1939
DI 10.1038/s41433-021-01773-x
EA SEP 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4S0NN
UT WOS:000701604900005
PM 34584234
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Okubo, A
   Arimura, N
   Abematsu, N
   Sakamoto, T
AF Okubo, Akiko
   Arimura, Noboru
   Abematsu, Noriko
   Sakamoto, Taiji
TI Predictable signs of benign course of polypoidal choroidal vasculopathy:
   based upon the long-term observation of non-treated eyes
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE benign; clinical course; polypoidal choroidal vasculopathy; predictable
   sign; visual prognosis
ID INTRAVITREAL BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION
AB Purpose:
   To find predictable signs of benign polypoidal choroidal vasculopathy (PCV).
   Methods:
   Medical records of 13 eyes from 12 patients who were followed up for 5 years or longer without treatment among 258 consecutive patients with PCV were reviewed retrospectively. The main outcomes measured were best corrected visual acuity (BCVA) and fundus findings during the follow-up period.
   Results:
   The average age at presentation was 68 years, and the average follow-up period after diagnosis was 80 months (range, 62-119 months). The initial mean logarithmic value of the minimal angle of resolution (logMAR) BCVA was 0.28 +/- 0.26, and the final mean logMAR BCVA was 0.62 +/- 0.72. The difference in the logMAR BCVA values between the two points was not statistically significant (p > 0.05). The trend of change from baseline at 2-year follow-up was consistent with those at 5-year follow-up in nine eyes. Fundus findings at the initial examination were classified into two patterns: (i) reddish-orange nodules and detachment of the retinal pigment epithelium with/without detachment of the neurosensory retina (nine eyes); (ii) reddish-orange nodules alone, or nodules and small subretinal haemorrhage (four eyes). In the eyes with the first pattern, clinical course and visual prognosis were variable. An absence of hard exudates could be a sign to maintain a benign clinical course or stable vision with this pattern. The eyes with the second pattern took a benign clinical course with stable vision.
   Conclusions:
   There is certainly a group of PCV eyes with a benign prognosis. Considering the huge cost and risk of current therapies, the initial ocular findings could be deciding factors that determine the necessity for further treatment.
C1 [Okubo, Akiko; Arimura, Noboru; Abematsu, Noriko; Sakamoto, Taiji] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BYEON SH, 2009, ACTA OPHTHALMOL
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pai SA, 2009, ACTA OPHTHALMOL, V87, P806, DOI 10.1111/j.1755-3768.2008.01330.x
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 30
TC 10
Z9 11
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2010
VL 88
IS 4
BP e107
EP e114
DI 10.1111/j.1755-3768.2009.01850.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603BD
UT WOS:000278182000025
PM 20337601
OA Bronze
DA 2022-11-30
ER

PT J
AU Ghoshal, R
   Sharanjeet-Kaur, S
   Fadzil, NM
   Ghosh, S
   Ngah, NF
   Abd Aziz, RAB
AF Ghoshal, Rituparna
   Sharanjeet-Kaur, Sharanjeet
   Fadzil, Norliza Mohamad
   Ghosh, Somnath
   Ngah, Nor Fariza
   Abd Aziz, Roslin Azni Binti
TI Visual Parameters and Retinal Morphology for Polypoidal Choroidal
   Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without
   Photodynamic Therapy: A Short-Term Prospective Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE combination therapy; polypoidal choroidal vasculopathy; retinal
   morphology; visual functions
AB The objective of this study was to compare visual parameters and retinal layers' morphology pre-treatment (baseline) and 6 months post-treatment in polypoidal choroidal vasculopathy (PCV) eyes. A single centre, longitudinal, prospective study was conducted at a public tertiary hospital of Malaysia. Visual parameters including distance and near visual acuity (DVA and NVA), contrast sensitivity (CS), reading speed (RS), and different qualitative and quantitative optical coherence tomography (OCT) parameters were evaluated pre- and 6 months post-treatment. Thirty-three naive PCV eyes of 32 patients (mean age of 67.62 years) were evaluated pre- and post-treatment of intravitreal ranibizumab with and without photodynamic therapy. After treatment, sub retinal fluid decreased from 27 eyes (84.35%) at baseline to 7 eyes (21.88%) at 6 months while pigment epithelium detachment decreased from 32 eyes (100%) at base line to 15 eyes (46.87%) at 6 months. Mean pre-treatment quantitative morphological OCT retinal parameters including thickness and volume of central sub field, center thickness, center minimum, and maximum thickness reduced significantly. Similarly, all visual parameters including DVA, NVA, CS, and RS showed statistically significant improvement. While 89% of the eyes showed improvement in CS, 78%, 71%, and 65% of the eyes showed improvement in NVA, RS, and DVA, respectively. Thus, CS was the most treatment responsive visual parameter.
C1 [Ghoshal, Rituparna; Sharanjeet-Kaur, Sharanjeet; Fadzil, Norliza Mohamad] Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
   [Ghosh, Somnath] Brainware Univ, Dept Allied Hlth Sci, Kalkata 700125, W Bengal, India.
   [Ngah, Nor Fariza; Abd Aziz, Roslin Azni Binti] Hosp Shah Alam, Dept Ophthalmol, Seksyen 7, Shah Alam 40000, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Sharanjeet-Kaur, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
EM rituparna4ab@yahoo.co.in; sharanjeet@ukm.edu.my;
   norlizafadzil@ukm.edu.my; somnath4ab@yahoo.co.in;
   drfarizangah@gmail.com; roslinazni@gmail.com
OI Kaur, Sharanjeet/0000-0003-0734-5151
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Buari Noor Halilah, 2014, J Optom, V7, P210, DOI 10.1016/j.optom.2013.12.009
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Chhablani JK, 2011, GRAEF ARCH CLIN EXP, V249, P791, DOI 10.1007/s00417-010-1478-7
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Ghoshal R, 2018, SAINS MALAYS, V47, P2447, DOI 10.17576/jsm-2018-4710-21
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mohamad NA, 2017, INT J OPHTHALMOL-CHI, V10, P1889, DOI 10.18240/ijo.2017.12.16
   Nazima SA, 2016, MED HEALTH-KUALA LUM, V11, P245, DOI 10.17576/MH.2016.1102.13
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Schwartz S.H., 2010, VISUAL PERCEPTION CL
   Sharanjeet-Kaur S., 2018, MALAYS J PUBLIC HLTH, V1, P124
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Snedecor G., 1989, AMES IOWA STATE U PR, V8
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wood JM, 2005, OPTOMETRY VISION SCI, V82, P698, DOI 10.1097/01.opx.0000175562.27101.51
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang Yi, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V37, P165
NR 35
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAR
PY 2021
VL 18
IS 5
AR 2581
DI 10.3390/ijerph18052581
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA QV7NU
UT WOS:000628154100001
PM 33806713
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tan, CS
   Lim, LW
   Ngo, WK
   Lim, TH
AF Tan, Colin S.
   Lim, Louis W.
   Ngo, Wei Kiong
   Lim, Tock Han
CA EVEREST Study Grp
TI EVEREST Report 5: Clinical Outcomes and Treatment Response of Polypoidal
   Choroidal Vasculopathy Subtypes in a Multicenter, Randomized Controlled
   Trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; ophthalmic imaging; fluorescein
   angiography; indocyanine green angiography; visual acuity
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; JAPANESE PATIENTS;
   VISUAL-ACUITY; RANIBIZUMAB; CLASSIFICATION
AB PURPOSE. The purpose of this study was to describe the characteristics of polypoidal choroidal vasculopathy (PCV) subtypes among patients from a multicenter randomized controlled trial and to determine the impact of PCV subtypes on clinical outcomes.
   METHODS. This was a prospective cohort study of 61 patients with macular PCV from the EVEREST study. Indocyanine green (ICGA) and fluorescein angiography (FA) obtained using standardized imaging protocols were graded to classify PCV into three subtypes. Type A PCV had polyps with interconnecting channels, type B had polyps with branching vascular networks, but no significant leakage on FA, and type C had polyps with branching vascular networks and leakage on FA. The best-corrected visual acuity (BCVA) and proportion of patients with BCVA >= 20/40 were compared among the three PCV subtypes.
   RESULTS. Of the 61 patients, 54 were gradable for PCV subtype. Among these, 8 had type A PCV (14.8%), 27 had type B (50%), and 19 had type C (35.2%). At baseline, BCVA was 67.1 letters for type A, 58.7 for type B, and 43.5 for type C (P < 0.001). At 6 months, BCVA was highest among patients with type A compared with types B and C (80.1 letters versus 67.2 versus 50.4, respectively; P < 0.001). Type A PCV gained 13 letters compared with 8.5 (type B) and 6.9 (type C). BCVA >= 20/40 was highest for type A compared with types B and C (100% vs. 51.9% vs. 10.5%; P < 0.001). On performing ANCOVA, PCV subtype and baseline BCVA significantly affected final BCVA.
   CONCLUSIONS. The visual outcome following treatment varies with PCV subtype classification. The distinction in clinical outcomes between the PCV subtypes is observed in the initial months following the start of treatment.
C1 [Tan, Colin S.; Lim, Tock Han] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Tan, Colin S.; Lim, Louis W.; Ngo, Wei Kiong; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
C3 Tan Tock Seng Hospital
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU National Medical Research Council [NMRC/TA/0039/2015]; National
   Healthcare Group
FX Supported by grants from the National Medical Research Council
   (NMRC/TA/0039/2015) and grants from National Healthcare Group.
CR Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Bressler SB, 2012, ARCH OPHTHALMOL-CHIC, V130, P1153, DOI 10.1001/archophthalmol.2012.1107
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 20
TC 19
Z9 20
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2018
VL 59
IS 2
BP 889
EP 896
DI 10.1167/iovs.17-22683
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8LO
UT WOS:000426346300031
PM 29435588
OA gold
DA 2022-11-30
ER

PT J
AU Zhao, M
   Zhou, HY
   Xu, J
   Zhang, F
   Wei, WB
   Liu, NP
AF Zhao, Meng
   Zhou, Hai-Ying
   Xu, Jun
   Zhang, Feng
   Wei, Wen-Bin
   Liu, Ning-Pu
TI Combined photodynamic therapy and ranibizumab for polypoidal choroidal
   vasculopathy: a 2-year result and systematic review
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; photo-dynamic therapy; intravitreal
   ranibizumab injection; Meta analysis
ID ENDOTHELIAL GROWTH-FACTOR; COMBINED INTRAVITREAL RANIBIZUMAB; FOLLOW-UP;
   BEVACIZUMAB; INJECTIONS; COMBINATION; EFFICACY
AB AIM: To report a cohort of patients with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT) followed by intravitreal ranibizumab injection 24-48h later, and to compare the results between eyes with PCV treated by PDT followed by intravitreal anti-vascular endothelial growth factor (VEGF) injection and intravitreal anti-VEGF injection followed by PDT by Meta-analysis.
   METHODS: Retrospective study and systematic literature review. Medical records of patients with PCV who were initially treated using PDT followed by intravitreal ranibizumab injection 24-48h after PDT and had completed at least 2y follow-up were reviewed and analyzed. Clinical data, including age, sex, best-corrected visual acuity (BCVA), fundus photograph, fluorescein angiography, indocyanine green angiography and optical coherence tomography were investigated. A systematic literature review was also conducted, and a visual outcome of studies over 1y was compared using Meta-analysis.
   RESULTS: A total of 52 patients were included in the study. Mean BCVA at baseline and follow-up at 1 or 2y were 0.71 +/- 0.61, 0.51 +/- 0.36 and 0.68 +/- 0.51 logMAR, respectively. The cumulative hazard rate for recurrence at 1 and 2y follow-up was 15.4% and 30.3% respectively. The percentage of eyes with polyps regression at 3, 12 and 24mo follow-up was 88.5%, 84.6% and 67.3% respectively. A Meta-analysis based on 22 independent studies showed the overall vision improvements at 1, 2 and 3y follow-up were 0.13 +/- 0.04 (P<0.001), 0.12 +/- 0.03 (P<0.001), 0.16 +/- 0.06 (P<0.001), respectively. The proportion of polyps regression at 1y follow-up was 64.6% (95%CI: 51.5%, 77.7%, P<0.001) in 434 eyes treated by intravitreal anti-VEGF agents before PDT and 76.0% (95%Cl: 64.8%, 87.3%, P=0.001) in 199 eyes treated by intravitreal anti-VEGF agents after PDT.
   CONCLUSION: Intravitreal ranibizumab injection 24-48h following PDT effectively stabilizes visual acuity in the eye with PCV. PDT followed by intravitreal anti-VEGF agents may contribute to a relatively higher proportion of polyps' regression as compared to that of intravitreal anti-VEGF before PDT.
C1 [Zhao, Meng; Zhou, Hai-Ying; Xu, Jun; Zhang, Feng; Wei, Wen-Bin; Liu, Ning-Pu] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
C3 Capital Medical University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Beutelspacher SC, 2009, KLIN MONATSBL AUGENH, V226, P115, DOI 10.1055/s-2008-1027913
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2011, RETINA-J RET VIT DIS, V31, P857, DOI 10.1097/IAE.0b013e3181fecda9
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee JH, 2015, RETINA-J RET VIT DIS, V35, P1561, DOI 10.1097/IAE.0000000000000498
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Nowak-Sliwinska P, 2010, ANGIOGENESIS, V13, P281, DOI 10.1007/s10456-010-9185-x
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Wong IY, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0061-8
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 39
TC 7
Z9 8
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2017
VL 10
IS 3
BP 413
EP 422
DI 10.18240/ijo.2017.03.14
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8WM
UT WOS:000396971200014
PM 28393033
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Zhao, XY
   Zhang, WF
   Meng, LH
   Wang, DY
   Chen, YX
AF Zhao, Xin-yu
   Zhang, Wen-fei
   Meng, Li-hui
   Wang, Dong-yue
   Chen, You-xin
TI The polyp regression rate and treatment prognosis of different
   interventions for polypoidal choroidal vasculopathy: a systematic review
   and meta-analysis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Anti-vascular
   endothelial growth factor; Polyp regression rate; Meta-analysis
ID VERTEPORFIN PHOTODYNAMIC THERAPY; COMBINATION THERAPY; RANIBIZUMAB;
   MONOTHERAPY; INJECTIONS; DIAGNOSIS; EFFICACY; SAFETY
AB Purpose To estimate the polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy (PCV) and clarify its baseline characteristics. Methods The PubMed, EMBASE, and Ovid were searched up to January 2020 to identify related studies. R software version 3.6.3 was used to perform the statistical analyses. Results in proportion with 95% confidence interval (CI) were calculated by means of the Freeman-Tukey variant of arcsine square transformation. Chi-squared test and I-2 statistics were used to evaluate the statistical heterogeneity. Sensitivity analysis and subgroup analyses were performed to identify the source of heterogeneity. Results This meta-analysis included 104 studies with 5816 patients. The pooling results indicated the general rate of complete polyp regression at post-treatment 12 months was 64% (95% CI [57 similar to 71%]), 89% (95% CI [81 similar to 95%]) for photodynamic therapy (PDT) monotherapy, 78% (95% CI [68 similar to 86%]) for PDT plus anti-vascular endothelial growth factor (anti-VEGF), and 42% (95% CI [35 similar to 49%]) for anti-VEGF monotherapy; PDT plus anti-VEGF showed the best efficacy in visual improvement and achieved the highest rate of dry macula (91%, 95% CI [78 similar to 99%]), while anti-VEGF monotherapy achieved the lowest polyp recurrence rate (14%, 95% CI [8 similar to 20%]); PDT monotherapy showed the best efficacy in pigment epithelial detachment regression (66%, 95% CI [58 similar to 83%]). Additionally, the baseline characteristics of PCV were also well described. Conclusion PDT plus anti-VEGF is still valuable for the management of PCV; it could achieve not only satisfactory anatomical outcomes like dry macula rate and polyp regression rate but also ideal visual prognosis like BCVA improvement.
C1 [Zhao, Xin-yu; Zhang, Wen-fei; Meng, Li-hui; Wang, Dong-yue; Chen, You-xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhao, Xin-yu; Zhang, Wen-fei; Meng, Li-hui; Wang, Dong-yue; Chen, You-xin] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
EM 478252553@qq.com
RI meng, li/GVT-2063-2022
OI Chen, Youxin/0000-0002-7231-5058
CR Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2013, RETINA-J RET VIT DIS, V33, P2126, DOI 10.1097/IAE.0b013e3182899296
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Doble B, 2020, JAMA OPHTHALMOL, V138, P251, DOI 10.1001/jamaophthalmol.2019.5628
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gu XY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1156-4
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kauppinen A, 2020, CELL MOL LIFE SCI, V77, P779, DOI 10.1007/s00018-019-03418-5
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Torrón Fernández-Blanco C, 2003, Arch Soc Esp Oftalmol, V78, P471
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Weng HY, 2019, BMC PHARMACOL TOXICO, V20, DOI 10.1186/s40360-019-0310-1
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
NR 30
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2021
VL 259
IS 4
BP 855
EP 872
DI 10.1007/s00417-020-04977-1
EA OCT 2020
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RH0XW
UT WOS:000584935900001
PM 33119802
DA 2022-11-30
ER

PT J
AU Sakai, T
   Ohkuma, Y
   Kohno, H
   Hayashi, T
   Watanabe, A
   Tsuneoka, H
AF Sakai, Tsutomu
   Ohkuma, Yasuhiro
   Kohno, Hideo
   Hayashi, Takaaki
   Watanabe, Akira
   Tsuneoka, Hiroshi
TI Three-year visual outcome of photodynamic therapy plus intravitreal
   bevacizumab with or without subtenon triamcinolone acetonide injections
   for polypoidal choroidal vasculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; FOLLOW-UP; RANIBIZUMAB; VERTEPORFIN; EFFICACY
AB Purpose To compare the 3-year visual outcome after double therapy of photodynamic therapy (PDT) with intravitreal bevacizumab (IVB) and triple therapy of PDT combined with IVB and subtenon triamcinolone acetonide (STTA) injections for polypoidal choroidal vasculopathy (PCV).
   Design Retrospective, comparative, interventional case series.
   Methods Medical records for 36 eyes in 36 patients (33 men, 3 women; mean age 73.5 years old; range 63-82 years old) with treatment-naive subfoveal PCV were reviewed retrospectively. Of the 36 eyes, 17 were treated with double therapy and 19 with triple therapy.
   Results The change in visual acuity after triple therapy was significantly better than that after double therapy (p<0.05). At 36 months, improvement in visual acuity was seen in 5 eyes (29.4%) in the double therapy group and 10 eyes (52.6%) in the triple therapy group. Retreatment using the initial treatment was performed for six eyes (35.3%) in the double therapy group and five eyes (26.3%) in the triple therapy group, and treatment-free period was significantly longer in the triple therapy group (p<0.05). The mean number of additional antivascular endothelial growth factor therapy was higher in the double therapy group. Post-treatment vitreous haemorrhage or retinal pigment epithelium tear occurred only in the double therapy group, in one eye (5.9%) and one eye (5.9%), respectively.
   Conclusions Initial therapy consisting of a single session of PDT combined with IVB and STTA improves vision in treatment-naive subfoveal PCV. Compared with double therapy, this triple therapy may be more effective for PCV.
C1 [Sakai, Tsutomu; Ohkuma, Yasuhiro; Kohno, Hideo; Hayashi, Takaaki; Watanabe, Akira; Tsuneoka, Hiroshi] Jikei Univ, Sch Med, Dept Ophthalmol, Tokyo 1058461, Japan.
C3 Jikei University
RP Sakai, T (通讯作者)，Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.
EM tstmski@jikei.ac.jp
FU Vehicle Racing Commemorative Foundation
FX This study was supported by grants from the Vehicle Racing Commemorative
   Foundation.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
NR 34
TC 12
Z9 12
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1642
EP 1648
DI 10.1136/bjophthalmol-2014-305189
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0AB
UT WOS:000345284300008
PM 25053762
DA 2022-11-30
ER

PT J
AU Baba, T
   Bhutto, IA
   Merges, C
   Grebe, R
   Emmert, D
   McLeod, DS
   Armstrong, D
   Lutty, GA
AF Baba, Takayuki
   Bhutto, Imran A.
   Merges, Carol
   Grebe, Rhonda
   Emmert, David
   McLeod, D. Scott
   Armstrong, Donald
   Lutty, Gerard A.
TI A Rat Model for Choroidal Neovascularization Using Subretinal Lipid
   Hydroperoxide Injection
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RETINAL DEGENERATION; MACULAR DEGENERATION; AGE;
   MACROPHAGES; EYES; HETEROGENEITY; LOCALIZATION; CELLS; PATHOGENESIS
AB The purpose of this study was to develop and characterize a rat model of choroidal neovascularization (CNV) as occurs in age-related macular degeneration. The lipid hydroperoxide 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid (HpODE) is found in submacular Bruch's membrane in aged humans and has been reported to generate neovascularization in a rabbit model. Three weeks after a single subretinal injection of 30 mu g of HpODE, eyes of Sprague-Dawley rats were harvested. Follow-up fluorescein angiography was done on other animals until 5 weeks postinjection. Histological studies, immunohistochemical staining, and flatmount choroids for CNV measurements were performed. In addition, we used murine neuronal, bovine endothelial, and human ARPE19 cells for testing the in vitro effects of HpODE. CNV developed in 85.7% of HpODE-injected eyes. The neovascular areas were significantly greater in HpODE-injected eyes compared with those in control eyes (P = 0.023). The CNV had maximum dye leakage at 3 weeks, which subsided by the 5th week. Histologically, CNV extended from the choriocapillaris into the subretinal space. ED1-positive macrophages were recruited to the site. In vitro assays demonstrated that only 30 ng/ml HpODE induced cell proliferation and migration of endothelial cells. HpODE-induced CNV was highly reproducible, and its natural course seems to be ideal for evaluating therapeutic modalities. Because HpODE has been isolated from aged humans, the HpODE-induced rat model seems to be a relevant experimental model for CNV in age-related macular degeneration. (Ant J Prathol 2010, 1763085-3097 DOI: 10.2353/ajpath.2010.090989)
C1 [Baba, Takayuki; Bhutto, Imran A.; Merges, Carol; Grebe, Rhonda; Emmert, David; McLeod, D. Scott; Lutty, Gerard A.] Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA.
   [Armstrong, Donald] Univ Florida, Dept Ophthalmol, Gainesville, FL USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; State University
   System of Florida; University of Florida
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
FU National Institutes of Health [R01-016151, EY-01765]; Altsheler-Durell
   Foundation; NATIONAL EYE INSTITUTE [R01EY016151, P30EY001765] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health (grants R01-016151 to &
   G.A.L. and EY-01765 to Wilmer) and by the Altsheler-Durell Foundation.
   T.B. was a Bausch and Lomb Japan Vitreoretinal Research Fellow, an
   Uehara Memorial Foundation Research Fellow, and a Japan Society for the
   Promotion of Science Postdoctoral Fellow for Research Abroad. G.A.L.
   received a Research to Prevent Blindness Senior Scientific Investigator
   Award in 2008.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ARMSTRONG D, 1982, EXP EYE RES, V35, P157, DOI 10.1016/S0014-4835(82)80063-8
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DAMOISEAUX JGMC, 1989, J LEUKOCYTE BIOL, V46, P556, DOI 10.1002/jlb.46.6.556
   DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Fukushima I, 1997, JPN J OPHTHALMOL, V41, P284, DOI 10.1016/S0021-5155(97)00058-0
   GOLDBERG MF, 1976, INVEST OPHTH VISUAL, V15, P443
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Iwai S, 2006, CURR EYE RES, V31, P337, DOI 10.1080/02713680600577780
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Matsubara A, 2005, EXP EYE RES, V81, P193, DOI 10.1016/j.exer.2005.01.021
   MCMENAMIN PG, 1994, INVEST OPHTH VIS SCI, V35, P3234
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Suzuki M, 2007, MOL VIS, V13, P772
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yamada Y, 1998, J CLIN BIOCHEM NUTR, V25, P121
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zhou JH, 2005, MOL VIS, V11, P414
NR 46
TC 33
Z9 34
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2010
VL 176
IS 6
BP 3085
EP 3097
DI 10.2353/ajpath.2010.090989
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 609WU
UT WOS:000278689700048
PM 20395434
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Long-Term Outcomes of Switching from Fixed-Dose to As-Needed Regimen for
   Treating Submacular Hemorrhage Secondary to Polypoidal Choroidal
   Vasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy; hemorrhage; fixed-dose regimen;
   as-needed regimen; anti-vascular endothelial growth factor;
   reactivation; recurrence
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; DIAGNOSIS; ANXIETY
AB Background: The aim of this study was to evaluate outcomes in patients with submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV) after switching treatment from a fixed-dose to an as-needed regimen. Methods: This retrospective study included 19 patients with submacular hemorrhage secondary to PCV who were treated with fixed-dose intravitreal aflibercept during the first 56 weeks. After 56 weeks, the treatment regimen was switched to an as-needed regimen. The incidence and timing of lesion reactivation during the as-needed phase were evaluated. The best-corrected visual acuity (BCVA) at baseline (beginning of the regimen) and the final follow-up were compared. Multivariate analysis was performed to determine the factors associated with lesion reactivation. Results: During the mean follow-up period of 27 +/- 7.3 months, lesion reactivation was noted in 10 patients (52.6%; mean time period: 12.2 +/- 9.1 months) in the as-needed phase. Reactivations were treated with anti-vascular endothelial growth factor (VEGF) injections (mean, 4.1 +/- 2.6). The mean logarithm of the minimum angle of resolution (logMAR) BCVA was 0.26 +/- 0.34 at baseline and 0.31 +/- 0.38 at final follow-up (p= 0.212). Deterioration of >= 0.2 logMAR BCVA was noted in two patients (10.5%). In multivariate analysis, large lesion size was closely associated with a high risk of lesion reactivation (p= 0.009). Conclusion: Visual acuity was relatively stable after switching from a fixed-dose to an as-needed regimen, with no definite visual deterioration in the majority of patients. We conclude that patients with large lesions should be carefully monitored when switching to an as-needed regimen.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul 150034, South Korea.
EM kimoph@gmail.com; kjwood@kimeye.com; chulgukim@kimeye.com;
   mediceye@kimeye.com
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P71, DOI 10.1016/j.jcjo.2015.11.003
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Doble B, 2020, JAMA OPHTHALMOL, V138, P251, DOI 10.1001/jamaophthalmol.2019.5628
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HG, 2018, CLIN EXP OPHTHALMOL, V46, P916, DOI 10.1111/ceo.13198
   Kim JH, 2020, GRAEF ARCH CLIN EXP, V258, P107, DOI 10.1007/s00417-019-04474-0
   Kim JH, 2018, GRAEF ARCH CLIN EXP, V256, P469, DOI 10.1007/s00417-017-3877-5
   Kim JH, 2018, JPN J OPHTHALMOL, V62, P54, DOI 10.1007/s10384-017-0549-2
   Kim JH, 2017, J OCUL PHARMACOL TH, V33, P445, DOI 10.1089/jop.2016.0098
   Kim JH, 2017, OPTOMETRY VISION SCI, V94, P556, DOI 10.1097/OPX.0000000000001066
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Munk MR, 2018, OPHTHALMOL RETINA, V2, P288, DOI 10.1016/j.oret.2017.07.010
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yiu G, 2014, DEV OPHTHALMOL, V54, P213, DOI 10.1159/000360469
NR 38
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2637
DI 10.3390/jcm9082637
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NL2YQ
UT WOS:000567287700001
PM 32823822
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, H
   Zhang, LY
   Li, XX
   Wu, MQ
AF Liu, Hui
   Zhang, Lu-yi
   Li, Xiao-xia
   Wu, Miao-qin
TI 23-Gauge vitrectomy with external drainage therapy as a novel procedure
   to displace massive submacular hemorrhage secondary to polypoidal
   choroidal vasculopathy
SO MEDICINE
LA English
DT Article
DE 23-gauge vitrectomy; external drainage therapy; polypoidal choroidal
   vasculopathy; subretinal hemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   PHOTODYNAMIC THERAPY; PNEUMATIC DISPLACEMENT; SUBRETINAL HEMORRHAGE;
   MACULAR DEGENERATION
AB Introduction: Massive subretinal hemorrhage (SRH) due to polypoidal choroidal vasculopathy (PCV) remains a challenging field and the best treatment is still not certain. In the present study, we performed a novel surgical method which combined 23-gauge vitrectomy with external drainage therapy for displace massive SRH secondary to PCV.
   Methods: From April 2015 to July 2015, 4 consecutive patients with massive SRH secondary to PCV received 23-gauge transconjunctival sutureless vitrectomy with external drainage therapy. Massive SRH was drained by scleral tunnel which was created using 30-gauge ultrathin needles during vitrectomy. We assessed the feasibility and safety of this procedure by analyzing best-corrected vision acuity (BCVA), central foveal thickness (CFT), and complication.
   Results: Four patients had a mean age of 63.8 +/- 6.4 years (range: 59-73 years). The average interval between onset of symptoms of SRH and surgery was 23.8 +/- 11.1 days (range: 10-35 days). Mean follow-up duration was 7.0 +/- 0.8 months. All patients completed 6 months follow-up. Mean BCVA gradually improved during the follow-up period. At 6 months after treatment, mean BCVA was significantly improved in comparison to preoperative findings (P = 0.043, paired t test). One month after treatment, mean CFT was significantly thinner than baseline (P = 0.002, paired t test). No serious ocular or systemic adverse events were observed to be associated with combination of 23-gauge vitrectomy with external drainage therapy during the 6 months follow-up period.
   Conclusions: Our results show that a combination of 23-gauge vitrectomy with external drainage therapy is a novel effective and safe procedure that may be a good alternative for massive SRH due to PCV.
C1 [Liu, Hui; Zhang, Lu-yi; Li, Xiao-xia; Wu, Miao-qin] Zhejiang Prov Peoples Hosp, Dept Ophthalmol, Hangzhou 310014, Zhejiang, Peoples R China.
C3 Zhejiang Provincial People's Hospital
RP Wu, MQ (通讯作者)，Zhejiang Prov Peoples Hosp, Dept Ophthalmol, Hangzhou 310014, Zhejiang, Peoples R China.
EM wumq@zjheart.com
FU Major science and program of Science Technology Department of Zhejiang
   Province [2014C03042-1]; Chinese Medicine Scientific Research Foundation
   of Zhejiang Province [2016ZA033]
FX This study was supported by Major science and program of Science
   Technology Department of Zhejiang Province (no. 2014C03042-1) and
   Chinese Medicine Scientific Research Foundation of Zhejiang Province
   (no. 2016ZA033).
CR Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Isizaki E, 2016, INT OPHTHALMOL, V36, P199, DOI 10.1007/s10792-015-0102-6
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Nayak S, 2015, SEMIN OPHTHALMOL, V30, P53, DOI 10.3109/08820538.2013.807849
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 13
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2016
VL 95
IS 32
AR e4192
DI 10.1097/MD.0000000000004192
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DU5IX
UT WOS:000382246500003
PM 27512837
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mast, N
   Bederman, IR
   Pikuleva, IA
AF Mast, Natalia
   Bederman, Ilya R.
   Pikuleva, Irina A.
TI Retinal Cholesterol Content Is Reduced in Simvastatin-Treated Mice Due
   to Inhibited Local Biosynthesis Albeit Increased Uptake of Serum
   Cholesterol
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID MACULAR DEGENERATION; REDUCTASE INHIBITORS; SCAVENGER RECEPTORS;
   DRUG-INTERACTIONS; DEUTERATED WATER; LIPID-METABOLISM; OUTER SEGMENTS;
   FATTY-ACID; AGE; LIPOPROTEIN
AB Statins, a class of cholesterol-lowering drugs, are currently being investigated for treatment of age-related macular degeneration, a retinal disease. Herein, retinal and serum concentrations of four statins (atorvastatin, simvastatin, pravastatin, and rosuvastatin) were evaluated after mice were given a single drug dose of 60 mg/kg body weight. All statins, except rosuvastatin, were detected in the retina: atorvastatin and pravastatin at 1.6 pmol and simvastatin at 4.1 pmol. Serum statin concentrations (pmol/ml) were 223 (simvastatin), 1401 (atorvastatin), 2792 (pravastatin), and 9050 (rosuvastatin). Simvastatin was then administered to mice daily for 6 weeks at 60 mg/kg body weight. Simvastatin treatment reduced serum cholesterol levels by 18% and retinal content of cholesterol and lathosterol (but not desmosterol) by 24% and 21%, respectively. The relative contributions of retinal cholesterol biosynthesis and retinal uptake of serum cholesterol to total retinal cholesterol input were changed as well. These contributions were 79% and 21%, respectively, in vehicle-treated mice and 69% and 31%, respectively, in simvastatin-treated mice. Thus, simvastatin treatment lowered retinal cholesterol because a compensatory upregulation of retinal uptake of serum cholesterol was not sufficient to overcome the effect of inhibited retinal biosynthesis. Simultaneously, simvastatin-treated mice had a 2.9-fold increase in retinal expression of Cd36, the major receptor clearing oxidized low-density lipoproteins from Bruch's membrane. Notably, simvastatin treatment essentially did not affect brain cholesterol homeostasis. Our results reveal the statin effect on the retinal and brain cholesterol input and are of value for future clinical investigations of statins as potential therapeutics for age-related macular degeneration.
C1 [Mast, Natalia; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert Rd, Cleveland, OH 44106 USA.
   [Bederman, Ilya R.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert Rd, Cleveland, OH 44106 USA.
EM iap8@case.edu
OI Pikuleva, Irina/0000-0001-9742-6232
FU National Institutes of Health National Eye Institute [EY018383,
   EY011373]; NATIONAL EYE INSTITUTE [R01EY018383, P30EY011373] Funding
   Source: NIH RePORTER
FX This work was supported in part by the National Institutes of Health
   National Eye Institute [Grants EY018383 and EY011373]. I.A.P. is a Carl
   F. Asseff Professor of Ophthalmology.
CR Akanuma S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-29
   Atchaneeyasakul LO, 1998, AM J MED GENET, V80, P501, DOI 10.1002/(SICI)1096-8628(19981228)80:5<501::AID-AJMG12>3.0.CO;2-J
   Boullier A, 2001, ANN NY ACAD SCI, V947, P214
   BROWN MS, 1981, NEW ENGL J MED, V305, P515, DOI 10.1056/NEJM198108273050909
   Calabro P, 2005, CURR OPIN CARDIOL, V20, P541, DOI 10.1097/01.hco.0000181482.99067.bf
   Christians U, 1998, PHARMACOL THERAPEUT, V80, P1, DOI 10.1016/S0163-7258(98)00016-3
   Cicero AFG, 2013, ADV CLIN EXP MED, V22, P69
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DUGGAN DE, 1990, DRUG METAB REV, V22, P333, DOI 10.3109/03602539009041088
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   El-Darzi N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00827
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Fernandez-Navarro J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154800
   FLIESLER SJ, 1995, BIOCHEM BIOPH RES CO, V210, P695, DOI 10.1006/bbrc.1995.1715
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   FLIESLER SJ, 1995, EXP EYE RES, V60, P57, DOI 10.1016/S0014-4835(05)80084-3
   Fliesler SJ, 2015, J LIPID RES, V56, P1, DOI 10.1194/jlr.C056358
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Fujii S, 2015, DRUG METAB DISPOS, V43, P1956, DOI 10.1124/dmd.115.066266
   Gazzerro P, 2012, PHARMACOL REV, V64, P102, DOI 10.1124/pr.111.004994
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   GORDON B, 1991, AM J OPHTHALMOL, V112, P385, DOI 10.1016/S0002-9394(14)76244-0
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hoffman KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042866
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hosoya K, 2009, J PHARMACOL EXP THER, V329, P87, DOI 10.1124/jpet.108.146381
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Hu X, 2015, NAT CHEM BIOL, V11, P141, DOI [10.1038/nchembio.1714, 10.1038/NCHEMBIO.1714]
   HYMAN BT, 1981, ATHEROSCLEROSIS, V40, P321, DOI 10.1016/0021-9150(81)90142-8
   Jones PH, 2003, AM J CARDIOL, V92, P152, DOI 10.1016/S0002-9149(03)00530-7
   JONES PJH, 1993, ARTERIOSCLER THROMB, V13, P247, DOI 10.1161/01.ATV.13.2.247
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Karlson B, 2016, EUR HEART J-CARD PHA, V2, P212, DOI 10.1093/ehjcvp/pvw006
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Martin PD, 2003, CLIN THER, V25, P2822, DOI 10.1016/S0149-2918(03)80336-3
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Mast N, 2010, BBA-MOL CELL BIOL L, V1801, P674, DOI 10.1016/j.bbalip.2010.03.005
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   National Research Council, 2011, GUIDE CARE USE LAB A, VEighth, DOI [10.17226/12910, DOI 10.17226/12910]
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Prueksaritanont T, 1997, DRUG METAB DISPOS, V25, P1191
   Raichur S, 2007, J MOL ENDOCRINOL, V39, P29, DOI 10.1677/jme.1.00010
   Russell C, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0721-2
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Santori FR, 2015, CELL METAB, V21, P286, DOI 10.1016/j.cmet.2015.01.004
   Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Urlep Z, 2017, SCI REP-UK, V7, DOI 10.1038/srep40775
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
NR 68
TC 15
Z9 15
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
EI 1521-009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD NOV 1
PY 2018
VL 46
IS 11
BP 1528
EP 1537
DI 10.1124/dmd.118.083345
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HD4FY
UT WOS:000452484200009
PM 30115644
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Hoerster, R
   Muether, PS
   Hermann, MM
   Koch, K
   Kirchhof, B
   Fauser, S
AF Hoerster, Robert
   Muether, Philipp S.
   Hermann, Manuel M.
   Koch, Konrad
   Kirchhof, Bernd
   Fauser, Sascha
TI Subjective and functional deterioration in recurrences of neovascular
   AMD are often preceded by morphologic changes in optic coherence
   tomography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY;
   BEVACIZUMAB; MACULOPATHY; PREVALENCE
AB Background Different tests were applied to test the sensitivity of patient self-control; Amsler grid and visual acuity (VA) assessment, as well as fundus examinations to reveal recurrent choroidal neovascularisation (CNV) activity in age-related macular degeneration as detected by spectral domain optical coherence tomography (SD-OCT) in monthly controls.
   Methods A prospective interventional case series of patients with exudative age-related macular degeneration was examined, which received ranibizumab injections until complete resolution of fluid in SD-OCT. Analysis of changes in subjective perception, Amsler grid, early treatment diabetic retinopathy study (ETDRS) VA, Radner reading VA and fundus examination was conducted in the case of OCT-confirmed CNV recurrences.
   Results Out of 40 morphological recurrences determined by SD-OCT, six (15%) were noticed by subjective patient perception. Amsler grid testing revealed deterioration in 12 cases (30%); 11 recurrences (28%) were accompanied by loss of >= 5 letters in ETDRS VA and/or >= 1 line in Radner VA; fundus examination showed signs of novel CNV activity in 10 out of 40 recurrences (25%). The combined sensitivity of all diagnostic methods compared to SD-OCT for recurrence detection was 67.5% (27 out of 40 recurrences).
   Conclusion Subjective patient perception, Amsler grid, VA as well as fundus examination lead to pronounced underestimations of CNV recurrences. Morphologic recurrences can be detected prior to functional deterioration. As any delay of treatment can result in irreversible vision loss, attempts should be made to provide monthly OCT controls to detect recurrences as early as possible.
C1 [Muether, Philipp S.] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM philmuether@mac.com
FU University of Cologne
FX Supported by the Koeln Fortune Program/Faculty of Medicine, University
   of Cologne.
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Parravano M, 2009, RETINA, V30, P1017
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
NR 18
TC 20
Z9 21
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2011
VL 95
IS 10
BP 1424
EP 1426
DI 10.1136/bjo.2010.201129
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 822VL
UT WOS:000295078000019
PM 21768186
DA 2022-11-30
ER

PT J
AU Aquaron, R
   Murati, JL
   Fayet, G
   Aquaron, C
   Ridings, B
AF Aquaron, R
   Murati, JL
   Fayet, G
   Aquaron, C
   Ridings, B
TI Simple, reliable and fast spectrofluorometric method for determination
   of plasma Verteporfin (Visudyne (R)) levels during photodynamic therapy
   for choroidal neovascularization
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE benzoporphyrin derivative; choroidal neovascularization; photodynamic
   therapy; spectrofluorometry; Verteporfin
ID MOUSE-TUMOR MODEL; MACULAR DEGENERATION; BENZOPORPHYRIN;
   BIODISTRIBUTION; PHOTOSENSITIZER; PHASE-1; TISSUE; BPD
AB Photodynamic therapy with Verteporfin, a potent photosensitizer dye, is a very effective treatment for age related macular degeneration due to choroidal neovascularization. Photodynamic therapy offers the potential for selective tissue injury in part attributable to preferential localization of Verteporfin, administrated by intraveinous infusion, to the choroidal neovascularization complex and irradiation of the complex with non-laser thermal light at 690 nm resulting in at least temporary thrombosis and vessel closure. Verteporfin is a benzoporphyrin derivative monoacid ring A formulated as a unilamellar liposome. In the blood Verteporfin is associated with lipoprotein fractions and is rapidly cleared via a receptor-mediated uptake mechanism due the high expression of LDL receptors in neovascular tissues. Verteporfin was undetectable in plasma 24 hr after infusion of the recommended dose: 6 mg/m(2) of body surface area. The main side effect is photosensitivity of skin which is usually short-lived (24-48 hr) with a low incidence (2.3%). As skin photosensitivity depends on circulating rather than tissue drug levels, we investigate the possibility of developing a simple, fast and reliable spectrofluorometric method to measure plasma Verteporfin levels. Fluorescence emission spectrum (550-750 nm) of 1:10 saline diluted plasma with lambda exc= 430 nm showed a characteristic emission peak at 692 nm, the height being proportional to the Verteporfin levels. The sensitivity is around 100 ng/ml and the pharmacokinetics of Verteporfin has been studied from 0 to 5 hr after infusion in six patients older than 65 years with age-related macular degeneration.
C1 Univ Mediterranee, Fac Med, Lab Biochim & Biol Mol, F-13385 Marseille 05, France.
   Hop Adultes Timone, Serv Ophtalmol, F-13385 Marseille, France.
   Hop Adultes Timone, Biol Lab, F-13385 Marseille 05, France.
C3 UDICE-French Research Universities; Aix-Marseille Universite; Universite
   de Franche-Comte; UDICE-French Research Universities; Aix-Marseille
   Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French
   Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille
RP Aquaron, R (通讯作者)，Univ Mediterranee, Fac Med, Lab Biochim & Biol Mol, 27 Blvd Jean Moulin, F-13385 Marseille 05, France.
EM robert.aquaron@medecine.univ-mrs.fr
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   ALLISON BA, 1990, PHOTOCHEM PHOTOBIOL, V52, P501, DOI 10.1111/j.1751-1097.1990.tb01792.x
   AQUARON R, 1999, ANN DERMATOL VENER, V126, P97
   AQUARON R, 2000, REV MED INTERN S, V21, pS504
   Cahill MT, 2002, AM J OPHTHALMOL, V134, P281, DOI 10.1016/S0002-9394(02)01475-7
   Fine SL, 1999, ARCH OPHTHALMOL-CHIC, V117, P1400, DOI 10.1001/archopht.117.10.1400
   Houle JM, 2002, RETINA-J RET VIT DIS, V22, P691, DOI 10.1097/00006982-200212000-00002
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Kang SW, 2002, AM J OPHTHALMOL, V134, P907, DOI 10.1016/S0002-9394(02)01752-X
   Lin GC, 1998, PHOTOCHEM PHOTOBIOL, V68, P575, DOI 10.1562/0031-8655(1998)068<0575:SNDTPA>2.3.CO;2
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Soubrane G, 2002, J FR OPHTALMOL, V25, P753
   Soubrane G, 2001, J FR OPHTALMOL, V24, P411
   2002, RETINA, V22, P6
NR 19
TC 10
Z9 11
U1 1
U2 11
PU CELLULAR & MOLECULAR BIOLOGY
PI NOISY-LE-GRAND
PA PROF R WEGMANN RESIDENCE HAUSSMANN 1 AVENUE DU PAVE NEUF, 93160
   NOISY-LE-GRAND, FRANCE
SN 0145-5680
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PD DEC
PY 2002
VL 48
IS 8
BP 925
EP 930
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 658BA
UT WOS:000181700700014
PM 12699252
DA 2022-11-30
ER

PT J
AU Kuo, SC
   Chio, CC
   Yeh, CH
   Ma, JT
   Liu, WP
   Lin, MT
   Lin, KC
   Chang, CP
AF Kuo, Shu-Chun
   Chio, Chung-Ching
   Yeh, Chao-Hung
   Ma, Jui-Ti
   Liu, Wen-Pin
   Lin, Mao-Tsun
   Lin, Kao-Chang
   Chang, Ching-Ping
TI Mesenchymal stem cell-conditioned medium attenuates the retinal
   pathology in amyloid-beta-induced rat model of Alzheimer's disease:
   Underlying mechanisms
SO AGING CELL
LA English
DT Article
DE Alzheimer&apos; s disease; amyloid&#8208; beta; retina pigment
   epithelium; secretome; stem cell
AB Amyloid-beta (A beta) oligomer is known to contribute to the pathophysiology of age-related macular degeneration. Herein, we aimed to elucidate the in vivo and in vitro effects of A beta(1-42) application on retinal morphology in rats. Our in vivo studies revealed that intracerebroventricular administration of A beta(1-42) oligomer caused dysmorphological changes in both retinal ganglion cells and retinal pigment epithelium. In addition, in vitro studies revealed that ARPE-19 cells following A beta(1-42) oligomer application had decreased viability along with apoptosis and decreased expression of the tight junction proteins, increased expression of both phosphor-AKT and phosphor-GSK3 beta and decreased expression of both SIRT1 and beta-catenin. Application of conditioned medium (CM) obtained from mesenchymal stem cells (MSC) protected against A beta(1-42) oligomer-induced retinal pathology in both rats and ARPE-19 cells. In order to explore the potential role of peptides secreted from the MSCs, we applied mass spectrometry to compare the peptidomics profiles of the MSC-CM. Gene ontology enrichment analysis and String analysis were performed to explore the differentially expressed peptides by predicting the functions of their precursor proteins. Bioinformatics analysis showed that 3-8 out of 155-163 proteins in the MSC-CM maybe associated with SIRT1/pAKT/pGSK3 beta/beta-catenin, tight junction proteins, and apoptosis pathway. In particular, the secretomes information on the MSC-CM may be helpful for the prevention and treatment of retinal pathology in age-related macular degeneration.
C1 [Kuo, Shu-Chun] Chi Mei Med Ctr, Dept Ophthalmol, Tainan, Taiwan.
   [Kuo, Shu-Chun; Yeh, Chao-Hung] Chung Hwa Univ Med Technol, Dept Optometry, Tainan, Taiwan.
   [Chio, Chung-Ching; Yeh, Chao-Hung] Chi Mei Med Ctr, Dept Surg, Div Neurosurg, Tainan, Taiwan.
   [Ma, Jui-Ti; Liu, Wen-Pin; Lin, Mao-Tsun; Chang, Ching-Ping] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.
   [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Holist Care, Tainan, Taiwan.
   [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan.
C3 Chi Mei Hospital; Chung Hua University; Chi Mei Hospital; Chi Mei
   Hospital; Chi Mei Hospital; Chi Mei Hospital
RP Chang, CP (通讯作者)，Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.; Lin, KC (通讯作者)，Chi Mei Med Ctr, Dept Holist Care, Tainan, Taiwan.
EM gaujang@mail2000.com.tw; jessica.cpchang@gmail.com
RI Kuo, Jesseanna/AAT-8331-2021; smile, chien/AAA-1053-2022
OI Chang, Ching-Ping/0000-0003-0890-9414
FU Ministry of Science and Technology [MOST106-2314-B-384-001-MY3,
   MOST105-2314-B-384-001-MY3]; Chi Mei Medical Center [CMFHT10802]
FX Ministry of Science and Technology, Grant/Award Number:
   MOST106-2314-B-384-001-MY3 and MOST105-2314-B-384-001-MY3; Chi Mei
   Medical Center, Grant/Award Number: CMFHT10802
CR Abulfadl YS, 2018, HUM EXP TOXICOL, V37, P1092, DOI 10.1177/0960327118755256
   Balaiya S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3187594
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Chan VTT, 2019, OPHTHALMOLOGY, V126, P497, DOI 10.1016/j.ophtha.2018.08.009
   Chang CP, 2016, MOL NEUROBIOL, V53, P7329, DOI 10.1007/s12035-015-9623-2
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Chen ZQ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002238
   Chidlow G, 2017, J ALZHEIMERS DIS, V56, P655, DOI 10.3233/JAD-160823
   Chou WW, 2013, TOXICOL IN VITRO, V27, P1728, DOI 10.1016/j.tiv.2013.05.002
   Colligris P, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8538573
   CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305
   DAVIES DC, 1995, BRIT J OPHTHALMOL, V79, P596, DOI 10.1136/bjo.79.6.596
   Dewing JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010039
   Dreixler JC, 2014, INVEST OPHTH VIS SCI, V55, P3785, DOI 10.1167/iovs.13-11683
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Haraguchi Y, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1033-0
   Ho CY, 2014, BRAIN PATHOL, V24, P25, DOI 10.1111/bpa.12070
   Kitagishi Y, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt265
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Kusne Y, 2017, ACTA OPHTHALMOL, V95, pe668, DOI 10.1111/aos.13319
   La Morgia C, 2016, ANN NEUROL, V79, P90, DOI 10.1002/ana.24548
   Lazaldin MAM, 2018, INT J NEUROSCI, V128, P952, DOI 10.1080/00207454.2018.1446953
   McGill TJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.43
   Morroni F, 2016, BEHAV BRAIN RES, V314, P106, DOI 10.1016/j.bbr.2016.08.002
   Nakamaru Y, 2009, FASEB J, V23, P2810, DOI 10.1096/fj.08-125468
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Osakada F, 2009, J PHARMACOL SCI, V109, P168, DOI 10.1254/jphs.08R19FM
   Ramzaoui H, 2018, J ALZHEIMERS DIS, V66, P901, DOI 10.3233/JAD-180043
   Singh AK, 2020, INDIAN J OPHTHALMOL, V68, P555, DOI 10.4103/ijo.IJO_999_19
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Wan J, 2014, CELL REP, V9, P285, DOI 10.1016/j.celrep.2014.08.048
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zhou MW, 2018, INT J MOL MED, V42, P13, DOI 10.3892/ijmm.2018.3623
NR 36
TC 2
Z9 2
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD MAY
PY 2021
VL 20
IS 5
AR e13340
DI 10.1111/acel.13340
EA MAR 2021
PG 14
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA SE6PZ
UT WOS:000634865200001
PM 33783931
OA Green Published
DA 2022-11-30
ER

PT J
AU Ali, Z
   Mukwaya, A
   Biesemeier, A
   Ntzouni, M
   Ramskold, D
   Giatrellis, S
   Mammadzada, P
   Cao, RH
   Lennikov, A
   Marass, M
   Gerri, C
   Hildesjo, C
   Taylor, M
   Deng, QL
   Peebo, B
   del Peso, L
   Kvanta, A
   Sandberg, R
   Schraermeyer, U
   Andre, H
   Steffensen, JF
   Lagali, N
   Cao, YH
   Kele, J
   Jensen, LD
AF Ali, Zaheer
   Mukwaya, Anthony
   Biesemeier, Antje
   Ntzouni, Maria
   Ramskold, Daniel
   Giatrellis, Sarantis
   Mammadzada, Parviz
   Cao, Renhai
   Lennikov, Anton
   Marass, Michele
   Gerri, Claudia
   Hildesjo, Camilla
   Taylor, Michael
   Deng, Qiaolin
   Peebo, Beatrice
   del Peso, Luis
   Kvanta, Anders
   Sandberg, Rickard
   Schraermeyer, Ulrich
   Andre, Helder
   Steffensen, John F.
   Lagali, Neil
   Cao, Yihai
   Kele, Julianna
   Dahl Jensen, Lasse
TI Intussusceptive Vascular Remodeling Precedes Pathological
   Neovascularization
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE choroidal neovascularization; hypoxia; intussusception; macular
   degeneration; zebrafish
ID HYPOXIA-INDUCIBLE FACTORS; GROWTH-FACTOR; RETINAL ANGIOGENESIS; VESSEL
   FUSION; GENE-TRANSFER; TARGET GENES; TUMOR-GROWTH; VEGF; ZEBRAFISH;
   MODEL
AB Objective- Pathological neovascularization is crucial for progression and morbidity of serious diseases such as cancer, diabetic retinopathy, and age-related macular degeneration. While mechanisms of ongoing pathological neovascularization have been extensively studied, the initiating pathological vascular remodeling (PVR) events, which precede neovascularization remains poorly understood. Here, we identify novel molecular and cellular mechanisms of preneovascular PVR, by using the adult choriocapillaris as a model. Approach and Results- Using hypoxia or forced overexpression of VEGF (vascular endothelial growth factor) in the subretinal space to induce PVR in zebrafish and rats respectively, and by analyzing choriocapillaris membranes adjacent to choroidal neovascular lesions from age-related macular degeneration patients, we show that the choriocapillaris undergo robust induction of vascular intussusception and permeability at preneovascular stages of PVR. This PVR response included endothelial cell proliferation, formation of endothelial luminal processes, extensive vesiculation and thickening of the endothelium, degradation of collagen fibers, and splitting of existing extravascular columns. RNA-sequencing established a role for endothelial tight junction disruption, cytoskeletal remodeling, vesicle- and cilium biogenesis in this process. Mechanistically, using genetic gain- and loss-of-function zebrafish models and analysis of primary human choriocapillaris endothelial cells, we determined that HIF (hypoxia-induced factor)-1 alpha-VEGF-A-VEGFR2 signaling was important for hypoxia-induced PVR. Conclusions- Our findings reveal that PVR involving intussusception and splitting of extravascular columns, endothelial proliferation, vesiculation, fenestration, and thickening is induced before neovascularization, suggesting that identifying and targeting these processes may prevent development of advanced neovascular disease in the future. Visual Overview-An online visual overview is available for this article.
C1 [Ali, Zaheer; Dahl Jensen, Lasse] Linkoping Univ, Dept Med & Hlth Sci, Div Cardiovasc Med, Linkoping, Sweden.
   [Mukwaya, Anthony; Lennikov, Anton; Peebo, Beatrice; Lagali, Neil] Linkoping Univ, Dept Clin & Expt Med, Div Ophthalmol, Linkoping, Sweden.
   [Ntzouni, Maria] Linkoping Univ, Fac Med, Electromicroscopy & Histol Lab, Linkoping, Sweden.
   [Hildesjo, Camilla] Linkoping Univ, Dept Clin & Expt Med, Div Surg Orthoped & Oncol, Linkoping, Sweden.
   [Biesemeier, Antje; Schraermeyer, Ulrich] Univ Tubingen, Ctr Ophthalmol, Expt Vitreoretinal Surg, Tubingen, Germany.
   [Ramskold, Daniel; Giatrellis, Sarantis; Sandberg, Rickard] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.
   [Mammadzada, Parviz; Kvanta, Anders; Andre, Helder] Karolinska Inst, Dept Clin Neurosci, Sect Ophthalmol & Vis, Erik Eye Hosp, Stockholm, Sweden.
   [Cao, Renhai; Cao, Yihai] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Deng, Qiaolin; Kele, Julianna] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Marass, Michele; Gerri, Claudia] Max Planck Inst Lung & Heart Res, Dept Dev Genet, Bad Nauheim, Germany.
   [Taylor, Michael] Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, 425 N Charter St, Madison, WI 53706 USA.
   [del Peso, Luis; Dahl Jensen, Lasse] Univ Autonoma Madrid, Dept Biochem, Madrid, Spain.
   [del Peso, Luis; Dahl Jensen, Lasse] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain.
   [Steffensen, John F.] Univ Copenhagen, Biol Inst, Marine Biol Sect, Helsingor, Denmark.
   [Lennikov, Anton] Univ Missouri, Dept Ophthalmol, Columbia, MO 65211 USA.
   [Peebo, Beatrice] Bayer AB, Med Affairs, Solna, Sweden.
C3 Linkoping University; Linkoping University; Linkoping University;
   Linkoping University; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; Karolinska Institutet; Karolinska Institutet;
   Karolinska Institutet; Karolinska Institutet; University of Wisconsin
   System; University of Wisconsin Madison; Autonomous University of
   Madrid; Autonomous University of Madrid; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones
   Biomedicas Alberto Sols (IIBM); University of Copenhagen; University of
   Missouri System; University of Missouri Columbia; Bayer AG
RP Jensen, LD (通讯作者)，Linkoping Univ, Dept Med & Hlth Sci, Ingang 68, SE-58185 Linkoping, Sweden.
EM lasse.jensen@liu.se
RI Deng, Qiaolin/AAD-6905-2020; Mukwaya, Anthony/K-2335-2019; Lagali,
   Neil/H-3580-2019; Gerri, Claudia/AAN-4277-2020; Andre,
   Helder/AAC-5220-2019; del Peso, Luis/K-9391-2014; Steffensen, John
   Fleng/F-6778-2010
OI Mukwaya, Anthony/0000-0002-9645-8942; Lagali, Neil/0000-0003-1079-4361;
   Gerri, Claudia/0000-0002-9046-3820; Andre, Helder/0000-0002-2926-2376;
   del Peso, Luis/0000-0003-4014-5688; Ramskold,
   Daniel/0000-0003-2892-673X; Mammadzada, Parviz/0000-0003-4171-5291;
   Biesemeier, Antje/0000-0002-3462-8803; Steffensen, John
   Fleng/0000-0002-4477-8039; Deng, Qiaolin/0000-0001-5934-7816; Kele,
   Julianna/0000-0003-3418-1412
FU Crown Princess Margareta Association for the Visually Impaired; Edwin
   Jordan Foundation; Swedish Eye Foundation; Svenska Sallskapet for
   Medicinsk Forskning; Linkoping Universitet; Eva och Oscar Ahrens
   Stiftelse; Ollie och Elof Ericssons Stiftelse; Carmen och Bertil Ragners
   Stiftelse; Gosta Fraenkels Stiftelse; Ake Wibergs Stiftelse; Lions
   Forskningsfond; Karin Sandbergs Stiftelse; Cancerfonden; Karolinska
   Institutets Stiftelser och Fonder; Vetenskapsradet
FX This study is supported by The Crown Princess Margareta Association for
   the Visually Impaired, Edwin Jordan Foundation, The Swedish Eye
   Foundation, Svenska Sallskapet for Medicinsk Forskning, Linkoping
   Universitet, Eva och Oscar Ahrens Stiftelse, Ollie och Elof Ericssons
   Stiftelse, Carmen och Bertil Ragners Stiftelse, Gosta Fraenkels
   Stiftelse, Ake Wibergs Stiftelse, Lions Forskningsfond, Karin Sandbergs
   Stiftelse, Cancerfonden, and Karolinska Institutets Stiftelser och
   Fonder and Vetenskapsradet.
CR Agarwal A, 2015, CURR OPIN OPHTHALMOL, V26, P177, DOI 10.1097/ICU.0000000000000152
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Alvarez Y, 2010, DIS MODEL MECH, V3, P236, DOI 10.1242/dmm.003772
   Augustin HG, 2017, SCIENCE, V357, DOI 10.1126/science.aal2379
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaser BW, 2017, J EXP MED, V214, P1011, DOI 10.1084/jem.20161616
   Blum Y, 2008, DEV BIOL, V316, P312, DOI 10.1016/j.ydbio.2008.01.038
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Burri PH, 2004, DEV DYNAM, V231, P474, DOI 10.1002/dvdy.20184
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   Cao YH, 2014, NAT REV ENDOCRINOL, V10, P530, DOI 10.1038/nrendo.2014.114
   Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149
   Cao YH, 2011, INT J DEV BIOL, V55, P557, DOI 10.1387/ijdb.103236yc
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Cao ZQ, 2010, NAT PROTOC, V5, P1903, DOI 10.1038/nprot.2010.149
   diIorio PJ, 2005, DEV BIOL, V282, P55, DOI 10.1016/j.ydbio.2005.02.036
   Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286
   Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Fior R, 2017, P NATL ACAD SCI USA, V114, pE8234, DOI 10.1073/pnas.1618389114
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Gaudenzi G, 2017, ENDOCRINE, V57, P214, DOI 10.1007/s12020-016-1048-9
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gerri C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15492
   Gianni-Barrera R, 2014, BIOCHEM SOC T, V42, P1637, DOI 10.1042/BST20140234
   Gianni-Barrera R, 2013, ANGIOGENESIS, V16, P123, DOI 10.1007/s10456-012-9304-y
   Gray C, 2007, ARTERIOSCL THROM VAS, V27, P2135, DOI 10.1161/ATVBAHA.107.143990
   Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865
   Hedlund EME, 2013, P NATL ACAD SCI USA, V110, P654, DOI 10.1073/pnas.1209310110
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Herwig L, 2011, CURR BIOL, V21, P1942, DOI 10.1016/j.cub.2011.10.016
   Hlushchuk R, 2008, AM J PATHOL, V173, P1173, DOI 10.2353/ajpath.2008.071131
   Hlushchuk R, 2011, ARTERIOSCL THROM VAS, V31, P2836, DOI 10.1161/ATVBAHA.111.231811
   Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hupe M, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag2476
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jensen LD, 2015, P NATL ACAD SCI USA, V112, pE5944, DOI 10.1073/pnas.1510245112
   Jensen LD, 2012, CELL REP, V2, P231, DOI 10.1016/j.celrep.2012.07.005
   Jensen LD, 2011, BIRTH DEFECTS RES C, V93, P182, DOI 10.1002/bdrc.20203
   Jensen LDE, 2009, P NATL ACAD SCI USA, V106, P18408, DOI 10.1073/pnas.0907608106
   Jinn SW, 2005, DEVELOPMENT, V132, P5199, DOI 10.1242/dev.02087
   Julien S, 2008, MOL VIS, V14, P1358
   Kaufman R, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861-015-0066-9
   Khurana R, 2005, CIRCULATION, V112, P1813, DOI 10.1161/CIRCULATIONAHA.105.535294
   Kikuchi K, 2011, DEV CELL, V20, P397, DOI 10.1016/j.devcel.2011.01.010
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711
   Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106
   Lenard A, 2013, DEV CELL, V25, P492, DOI 10.1016/j.devcel.2013.05.010
   Lin JH, 2016, BLOOD, V128, P249, DOI 10.1182/blood-2016-03-704460
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Liu Z, 2009, J CELL SCI, V122, P3294, DOI 10.1242/jcs.048942
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mammadzada P, 2016, ACTA OPHTHALMOL, V94, P805, DOI [10.1111/aos.13119, 10.1111/j.1755-3768.2016.0399]
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Marin-Juez R, 2016, P NATL ACAD SCI USA, V113, P11237, DOI 10.1073/pnas.1605431113
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Mukwaya A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32137
   Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Oh WJ, 2013, SEMIN CELL DEV BIOL, V24, P156, DOI 10.1016/j.semcdb.2012.12.001
   Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205
   Paku S, 2011, AM J PATHOL, V179, P1573, DOI 10.1016/j.ajpath.2011.05.033
   Peebo BB, 2011, ANGIOGENESIS, V14, P393, DOI 10.1007/s10456-011-9223-3
   Pitulescu ME, 2010, NAT PROTOC, V5, P1518, DOI 10.1038/nprot.2010.113
   Rezzola S, 2016, BBA-MOL BASIS DIS, V1862, P1291, DOI 10.1016/j.bbadis.2016.04.009
   Ribatti D, 2016, ONCOTARGET, V7, P46668, DOI 10.18632/oncotarget.8694
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouhi P, 2010, NAT PROTOC, V5, P1911, DOI 10.1038/nprot.2010.150
   Sauteur L, 2014, CELL REP, V9, P504, DOI 10.1016/j.celrep.2014.09.024
   Schraermeyer U, 2015, GRAEF ARCH CLIN EXP, V253, P681, DOI 10.1007/s00417-014-2733-0
   Schweighofer B, 2009, THROMB HAEMOSTASIS, V102, P544, DOI 10.1160/TH08-12-0830
   Seiler C, 2010, DEV DYNAM, V239, P2806, DOI 10.1002/dvdy.22420
   Semenza GL, 2000, GENE DEV, V14, P1983
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720
   Takemoto A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42186
   Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007
   Tsuchihara K, 2009, NUCLEIC ACIDS RES, V37, P2249, DOI 10.1093/nar/gkp066
   Umans RA, 2017, DEV BIOL, V425, P101, DOI 10.1016/j.ydbio.2017.03.017
   Vanhollebeke B, 2015, ELIFE, V4, DOI 10.7554/eLife.06489
   Wary Kishore K, 2003, Mol Cancer, V2, P25, DOI 10.1186/1476-4598-2-25
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Whitesell TR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090590
   Yuan XC, 2018, AM J TRANSL RES, V10, P2372
   Zouache MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35754
   Zygmunt T, 2011, DEV CELL, V21, P301, DOI 10.1016/j.devcel.2011.06.033
NR 94
TC 13
Z9 13
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUL
PY 2019
VL 39
IS 7
BP 1402
EP 1418
DI 10.1161/ATVBAHA.118.312190
PG 17
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA IF3GP
UT WOS:000472969200016
PM 31242036
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Schmidt, AF
   Hunt, NB
   Gordillo-Maranon, M
   Charoen, P
   Drenos, F
   Kivimaki, M
   Lawlor, DA
   Giambartolomei, C
   Papacosta, O
   Chaturvedi, N
   Bis, JC
   O'Donnell, CJ
   Wannamethee, G
   Wong, A
   Price, JF
   Hughes, AD
   Gaunt, TR
   Franceschini, N
   Mook-Kanamori, DO
   Zwierzyna, M
   Sofat, R
   Hingorani, AD
   Finan, C
AF Schmidt, Amand F.
   Hunt, Nicholas B.
   Gordillo-Maranon, Maria
   Charoen, Pimphen
   Drenos, Fotios
   Kivimaki, Mika
   Lawlor, Deborah A.
   Giambartolomei, Claudia
   Papacosta, Olia
   Chaturvedi, Nishi
   Bis, Joshua C.
   O'Donnell, Christopher J.
   Wannamethee, Goya
   Wong, Andrew
   Price, Jackie F.
   Hughes, Alun D.
   Gaunt, Tom R.
   Franceschini, Nora
   Mook-Kanamori, Dennis O.
   Zwierzyna, Magdalena
   Sofat, Reecha
   Hingorani, Aroon D.
   Finan, Chris
TI Cholesteryl ester transfer protein (CETP) as a drug target for
   cardiovascular disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MENDELIAN RANDOMIZATION; RISK; METAANALYSIS;
   LOCI; INCREASES; NUMBER
AB Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that previous failure of CETP inhibitors are likely compound and not drug target-related.
   Development of cholesteryl ester transfer protein (CETP) inhibitors for coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and drug target Mendelian randomization of CETP protein concentration, comparing this to Mendelian randomization of proprotein convertase subtilisin/kexin type 9 (PCSK9). We show that previous failures of CETP inhibitors are likely compound related, as illustrated by significant degrees of between-compound heterogeneity in effects on lipids, blood pressure, and clinical outcomes observed in trials. On-target CETP inhibition, assessed through Mendelian randomization, is expected to reduce the risk of CHD, heart failure, diabetes, and chronic kidney disease, while increasing the risk of age-related macular degeneration. In contrast, lower PCSK9 concentration is anticipated to decrease the risk of CHD, heart failure, atrial fibrillation, chronic kidney disease, multiple sclerosis, and stroke, while potentially increasing the risk of Alzheimer's disease and asthma. Due to distinct effects on lipoprotein metabolite profiles, joint inhibition of CETP and PCSK9 may provide added benefit. In conclusion, we provide genetic evidence that CETP is an effective target for CHD prevention but with a potential on-target adverse effect on age-related macular degeneration.
C1 [Schmidt, Amand F.; Gordillo-Maranon, Maria; Charoen, Pimphen; Drenos, Fotios; Chaturvedi, Nishi; Hughes, Alun D.; Zwierzyna, Magdalena; Hingorani, Aroon D.; Finan, Chris] UCL, Fac Populat Hlth, Inst Cardiovasc Sci, London, England.
   [Schmidt, Amand F.; Gordillo-Maranon, Maria; Hughes, Alun D.; Zwierzyna, Magdalena; Hingorani, Aroon D.; Finan, Chris] UCL British Heart Fdn Res Accelerator, London, England.
   [Schmidt, Amand F.; Finan, Chris] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands.
   [Hunt, Nicholas B.] Univ Utrecht, Utrecht Inst Pharmaceut Sci UIPS, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands.
   [Charoen, Pimphen] Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Bangkok, Thailand.
   [Charoen, Pimphen] Mahidol Univ, Integrat Computat BioSci ICBS Ctr, Bangkok, Thailand.
   [Drenos, Fotios] Brunel Univ London, Coll Hlth Med & Life Sci, Dept Life Sci, Uxbridge, Middx, England.
   [Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England.
   [Lawlor, Deborah A.; Gaunt, Tom R.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
   [Lawlor, Deborah A.; Gaunt, Tom R.] Univ Bristol, Bristol Med Sch, Populat Hlth, Bristol, Avon, England.
   [Lawlor, Deborah A.; Gaunt, Tom R.] Univ Hosp Bristol Natl Hlth Serv Fdn Trust, Bristol NIHR Bristol Biomed Res Ctr, Bristol, Avon, England.
   [Lawlor, Deborah A.; Gaunt, Tom R.] Univ Bristol, Bristol, Avon, England.
   [Giambartolomei, Claudia] Ist Italiano Tecnol, Cent RNA Lab, Genoa, Italy.
   [Papacosta, Olia; Wannamethee, Goya] UCL, Primary Care & Populat Hlth, London, England.
   [Chaturvedi, Nishi; Wong, Andrew; Hughes, Alun D.] UCL, MRC Unit Lifelong Hlth & Ageing, London, England.
   [Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
   [O'Donnell, Christopher J.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [O'Donnell, Christopher J.] VA Boston Healthcare Syst, Dept Med, Boston, MA USA.
   [Price, Jackie F.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.
   [Franceschini, Nora] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA.
   [Mook-Kanamori, Dennis O.] Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands.
   [Sofat, Reecha] UCL, Inst Hlth Informat, London, England.
   [Hingorani, Aroon D.; Finan, Chris] Hlth Data Res UK, London, England.
C3 University of London; University College London; Utrecht University;
   Utrecht University Medical Center; Utrecht University; Mahidol
   University; Mahidol University; Brunel University; University of London;
   University College London; University of Bristol; University of Bristol;
   University of Bristol; Istituto Italiano di Tecnologia - IIT; University
   of London; University College London; University of London; University
   College London; University of Washington; University of Washington
   Seattle; Harvard University; Brigham & Women's Hospital; Harvard Medical
   School; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Harvard University; VA Boston Healthcare System;
   University of Edinburgh; University of North Carolina; University of
   North Carolina Chapel Hill; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; University of London;
   University College London
RP Schmidt, AF (通讯作者)，UCL, Fac Populat Hlth, Inst Cardiovasc Sci, London, England.; Schmidt, AF (通讯作者)，UCL British Heart Fdn Res Accelerator, London, England.; Schmidt, AF (通讯作者)，Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands.
EM amand.schmidt@ucl.ac.uk
RI Hughes, Alun David/N-3781-2013; Schmidt, Amand Floriaan/G-6602-2017
OI Hughes, Alun David/0000-0001-5432-5271; Hunt,
   Nicholas/0000-0003-1677-6025; Schmidt, Amand
   Floriaan/0000-0003-1327-0424; Chaturvedi, Nishi/0000-0002-6211-2775;
   Gordillo-Maranon, Maria/0000-0003-2993-6577; Kivimaki,
   Mika/0000-0002-4699-5627; Hingorani, Aroon/0000-0001-8365-0081; Price,
   Jackie/0000-0003-3251-3970; Finan, Chris/0000-0002-3319-1937; Lawlor,
   Debbie A/0000-0002-6793-2262
FU BHF [PG/18/5033837, FS/17/70/33482]; UCL BHF [AA/18/6/34223]; National
   Institute for Health Research University College London Hospitals
   Biomedical Research Centre; UKRI/NIHR Strategic Priorities Award in
   Multimorbidity Research [MR/V033867/1]; National Institutes of Health
   (USA) [R01 LM010098]; Rosetrees and Stoneygate Trust; British Heart
   Foundation Program Grant [RG/10/12/28456]; UK Medical Research Council
   [MC_UU_00011/4, MC_UU_12019/1, MR/S011676/1, MR/R024227/1,
   MC_UU_00011/6]; Dutch Science Organization (ZonMW-VENI Grant)
   [916.14.023]; UK Medical Research [MC_UU_12019/1]; Wellcome Trust
   [221854/Z/20/Z]; National Institute on Aging (NIH), US [R01AG062553];
   Academy of Finland [311492]; Bristol BHF Accelerator Award
   [AA/18/7/34219]; BHF Chair [CH/F/20/90003]; University of Bristol;
   National Institute of Health Research Senior Investigator
   [NF-0616-10102]; National Institutes of Health [R01-MD012765,
   R01-DK117445, R21- HL140385]; Thailand Research Fund [MRG6280088]; Welsh
   Assembly Government; British Heart Foundation; National Heart, Lung, and
   Blood Institute [R01HL105756];  [12113]
FX This research has been conducted using the UK Biobank Resource under
   Application Number 12113. The authors are grateful to UK Biobank
   participants. We gratefully acknowledge the support of UCLEB and CHARGE.
   Funding and role of funding sources: A.F.S. is supported by BHF grant
   PG/18/5033837 and the UCL BHF Research Accelerator AA/18/6/34223. C.F.
   and A.F.S. received additional support from the National Institute for
   Health Research University College London Hospitals Biomedical Research
   Centre. M.G.M. is supported by a BHF Fellowship FS/17/70/33482. A.D.H.
   is an NIHR Senior Investigator. This work was supported by the UKRI/NIHR
   Strategic Priorities Award in Multimorbidity Research (MR/V033867/1).
   This work was additionally supported by a grant [R01 LM010098] from the
   National Institutes of Health (USA). We further acknowledge support from
   the Rosetrees and Stoneygate Trust. The UCLEB Consortium is supported by
   a British Heart Foundation Program Grant (RG/10/12/28456). T.R.G.
   receives support from the UK Medical Research Council (MC_UU_00011/4).
   D.O.M.K. is supported by the Dutch Science Organization (ZonMW-VENI
   Grant 916.14.023). A D.H. receives support from the UK Medical Research
   (MC_UU_12019/1). M.K. is supported by the Wellcome Trust
   (221854/Z/20/Z), the UK Medical Research Council (MR/S011676/1,
   MR/R024227/1), National Institute on Aging (NIH), US (R01AG062553), and
   the Academy of Finland (311492). D.A.L. is supported by a Bristol BHF
   Accelerator Award (AA/18/7/34219) and BHF Chair (CH/F/20/90003) and
   works in a unit that receives support from the University of Bristol and
   the UK Medical Research Council (MC_UU_00011/6). D.A.L. is a National
   Institute of Health Research Senior Investigator (NF-0616-10102). N.F.
   is supported by the National Institutes of Health (R01-MD012765,
   R01-DK117445, R21- HL140385). P.C. is supported by the Thailand Research
   Fund (MRG6280088. UK Biobank was established by the Wellcome Trust
   medical charity, Medical Research Council, Department of Health,
   Scottish Government, and the Northwest Regional Development Agency. It
   has also had funding from the Welsh Assembly Government and the British
   Heart Foundation. Infrastructure for the CHARGE Consortium is supported
   in part by the National Heart, Lung, and Blood Institute grant
   R01HL105756. The preliminary meta-analysis of RCT data were presented at
   BPS 2018 by NH.
CR Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764
   Armitage J, 2019, J AM COLL CARDIOL, V73, P477, DOI 10.1016/j.jacc.2018.10.072
   Blauw LL, 2019, EUR J HUM GENET, V27, P422, DOI 10.1038/s41431-018-0301-5
   Blauw LL, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.002034
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Burgess S, 2017, GENET EPIDEMIOL, V41, P714, DOI 10.1002/gepi.22077
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Burgess S, 2015, AM J EPIDEMIOL, V181, P290, DOI 10.1093/aje/kwv017
   Burgess S, 2011, INT J EPIDEMIOL, V40, P755, DOI 10.1093/ije/dyr036
   Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489
   Collins R, 2016, LANCET, V388, P2532, DOI 10.1016/S0140-6736(16)31357-5
   Davies G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04362-x
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Evangelou E, 2018, NAT GENET, V50, P1412, DOI 10.1038/s41588-018-0205-x
   Ference BA, 2018, EUR HEART J, V39, P360, DOI 10.1093/eurheartj/ehx462
   Ference BA, 2017, JAMA-J AM MED ASSOC, V318, P947, DOI 10.1001/jama.2017.11467
   Ference BA, 2016, NEW ENGL J MED, V375, P2144, DOI 10.1056/NEJMoa1604304
   Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holmes MV, 2015, EUR HEART J, V36, P539, DOI 10.1093/eurheartj/eht571
   Hopkins PN, 2015, ATHEROSCLEROSIS, V243, P99, DOI 10.1016/j.atherosclerosis.2015.08.042
   HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
   Johns DG, 2012, DRUGS, V72, P491, DOI 10.2165/11599310-000000000-00000
   Joshi R, 2020, EUR J PREV CARDIOL, V27, P1617, DOI 10.1177/2047487319899621
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Kettunen J, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000572
   Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955
   Mahajan A, 2018, NAT GENET, V50, P559, DOI 10.1038/s41588-018-0084-1
   Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3
   Mohammadpour AH, 2013, CLIN PHARMACOKINET, V52, P615, DOI 10.1007/s40262-013-0071-8
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588-018-0302-x
   Mulick A. R., HIGH DENSITY LIPOPRO, DOI [10.1101/2020.03.02.19010173(2020, DOI 10.1101/2020.03.02.19010173(2020]
   Nielsen JB, 2018, NAT GENET, V50, P1234, DOI 10.1038/s41588-018-0171-3
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188
   Pott J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.001992
   Psaty BM, 2009, CIRC-CARDIOVASC GENE, V2, P73, DOI 10.1161/CIRCGENETICS.108.829747
   Schmidt AF, 2018, STAT METHODS MED RES, V27, P2413, DOI 10.1177/0962280216680652
   Schmidt AF, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011748.pub3
   Schmidt AF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16969-0
   Schmidt AF, 2018, HEART, V104, P1053, DOI 10.1136/heartjnl-2017-312858
   Schmidt AF, 2014, J CLIN EPIDEMIOL, V67, P821, DOI 10.1016/j.jclinepi.2014.02.008
   Shah S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13690-5
   Shah T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071345
   Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8
   Tall AR, 2018, CIRC RES, V122, P106, DOI 10.1161/CIRCRESAHA.117.311978
   Tikkanen E., METABOLIC BIOMARKERS, DOI [10.1101/2020.07.24.20158675(2020, DOI 10.1101/2020.07.24.20158675(2020]
   Vickers A J, 2001, BMC Med Res Methodol, V1, P6, DOI 10.1186/1471-2288-1-6
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   White J, 2016, JAMA CARDIOL, V1, P692, DOI 10.1001/jamacardio.2016.1884
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Williams DM, 2020, ANN NEUROL, V87, P30, DOI 10.1002/ana.25642
   Wuttke M, 2019, NAT GENET, V51, P957, DOI 10.1038/s41588-019-0407-x
NR 57
TC 11
Z9 11
U1 4
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 24
PY 2021
VL 12
IS 1
AR 5640
DI 10.1038/s41467-021-25703-3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UU7NX
UT WOS:000698984500009
PM 34561430
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Parmar, T
   Parmar, VM
   Perusek, L
   Georges, A
   Takahashi, M
   Crabb, JW
   Maeda, A
AF Parmar, Tanu
   Parmar, Vipul M.
   Perusek, Lindsay
   Georges, Anouk
   Takahashi, Masayo
   Crabb, John W.
   Maeda, Akiko
TI Lipocalin 2 Plays an Important Role in Regulating Inflammation in
   Retinal Degeneration
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID GELATINASE-ASSOCIATED LIPOCALIN; FACTOR-KAPPA-B; ISCHEMIA-REPERFUSION
   INJURY; PHOTORECEPTOR CELL-DAMAGE; PLURIPOTENT STEM-CELLS; MACULAR
   DEGENERATION; OXIDATIVE-STRESS; GENE-EXPRESSION; PIGMENT EPITHELIUM;
   RECEPTOR MEGALIN
AB It has become increasingly important to understand how retinal inflammation is regulated because inflammation plays a role in retinal degenerative diseases. Lipocalin 2 (LCN2), an acute stress response protein with multiple innate immune functions, is increased in ATP-binding cassette subfamily A member 4 (Abca4)(-/-) retinol dehydrogenase 8 (Rdh8)(-/-) double-knockout mice, an animal model for Stargardt disease and age-related macular degeneration (AMD). To examine roles of LCN2 in retinal inflammation and degeneration, Lcn2(-/-) Abca4(-/-) Rdh8(-/-) triple-knockout mice were generated. Exacerbated inflammation following light exposure was observed in Lcn2(-/-) Abca4(-/-) Rdh8(-/-) mice as compared with Abca4(-/-) Rdh8(-/-) mice, with upregulation of proinflammatory genes and microglial activation. RNA array analyses revealed an increase in immune response molecules such as Ccl8, Ccl2, and Cxcl10. To further probe a possible regulatory role for LCN2 in retinal inflammation, we examined the in vitro effects of LCN2 on NF-kB signaling in human retinal pigmented epithelial (RPE) cells differentiated from induced pluripotent stem cells derived from healthy donors. We found that LCN2 induced expression of antioxidant enzymes heme oxygenase 1 and superoxide dismutase 2 in these RPE cells and could inhibit the cytotoxic effects of H2O2 and LPS. ELISA revealed increased LCN2 levels in plasma of patients with Stargardt disease, retinitis pigmentosa, and age-related macular degeneration as compared with healthy controls. Finally, overexpression of LCN2 in RPE cells displayed protection from cell death. Overall these results suggest that LCN2 is involved in prosurvival responses during cell stress and plays an important role in regulating inflammation during retinal degeneration.
C1 [Parmar, Tanu; Parmar, Vipul M.; Perusek, Lindsay; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert,IP115,10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Georges, Anouk; Takahashi, Masayo; Maeda, Akiko] RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
   [Crabb, John W.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Maeda, Akiko] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; RIKEN; Cleveland Clinic Foundation;
   Case Western Reserve University
RP Maeda, A (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 2085 Adelbert,IP115,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM aam19@case.edu
FU National Institutes of Health [EY022658, EY11373]; Research to Prevent
   Blindness Foundation; Ohio Lions Eye Research Foundation; NATIONAL EYE
   INSTITUTE [R01EY022658, P30EY011373] Funding Source: NIH RePORTER
FX This work was supported by funding from National Institutes of Health
   Grants EY022658 and EY11373, the Research to Prevent Blindness
   Foundation, and the Ohio Lions Eye Research Foundation.
CR Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149
   Abella V, 2015, BIOMARKERS, V20, P565, DOI 10.3109/1354750X.2015.1123354
   Aigner F, 2007, AM J TRANSPLANT, V7, P779, DOI 10.1111/j.1600-6143.2006.01723.x
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Asimakopoulou A, 2017, DATA BRIEF, V13, P644, DOI 10.1016/j.dib.2017.06.048
   Asimakopoulou A, 2017, BBA-MOL BASIS DIS, V1863, P2093, DOI 10.1016/j.bbadis.2017.04.006
   Berard JL, 2012, GLIA, V60, P1145, DOI 10.1002/glia.22342
   Bolignano D, 2008, AM J KIDNEY DIS, V52, P595, DOI 10.1053/j.ajkd.2008.01.020
   Borkham-Kamphorst E, 2013, BBA-MOL BASIS DIS, V1832, P660, DOI 10.1016/j.bbadis.2013.01.014
   Borkham-Kamphorst E, 2011, LIVER INT, V31, P656, DOI 10.1111/j.1478-3231.2011.02495.x
   Bu DX, 2006, AM J PATHOL, V169, P2245, DOI 10.2353/ajpath.2006.050706
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chakraborty S, 2012, BBA-REV CANCER, V1826, P129, DOI 10.1016/j.bbcan.2012.03.008
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Chun BY, 2015, INVEST OPHTH VIS SCI, V56, P3691, DOI 10.1167/iovs.15-16851
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027
   Gasparini C, 2012, CURR PHARM DESIGN, V18, P5735, DOI 10.2174/138161212803530763
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guo H, 2014, MOL ENDOCRINOL, V28, P1616, DOI 10.1210/me.2014-1092
   Haase-Fielitz A, 2014, ANN CLIN BIOCHEM, V51, P335, DOI 10.1177/0004563214521795
   Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200
   Halabian R, 2013, CELL STRESS CHAPERON, V18, P785, DOI 10.1007/s12192-013-0430-2
   Hamzic N, 2013, J NEUROENDOCRINOL, V25, P271, DOI 10.1111/jne.12000
   Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031
   Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Kamoshita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103013
   Kang SS, 2018, MOL PSYCHIATR, V23, P344, DOI 10.1038/mp.2016.243
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Langelueddecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071586
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129
   Lee S, 2011, J BIOL CHEM, V286, P43855, DOI 10.1074/jbc.M111.299248
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   Mishra Jaya, 2005, Lancet, V365, P1231, DOI 10.1016/S0140-6736(05)74811-X
   Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056
   Nam Y, 2014, J BIOL CHEM, V289, P16773, DOI 10.1074/jbc.M113.542282
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Parmar T., 2016, INVEST OPHTHALMOL VI, V57
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Roudkenar MH, 2008, ARCH MED RES, V39, P560, DOI 10.1016/j.arcmed.2008.05.003
   Roudkenar MH, 2008, ARCH MED RES, V39, P402, DOI 10.1016/j.arcmed.2007.12.002
   Roudkenar MH, 2007, J RADIAT RES, V48, P39, DOI 10.1269/jrr.06057
   Roudkenar MH, 2011, FREE RADICAL RES, V45, P810, DOI 10.3109/10715762.2011.581279
   Roudkenar MH, 2009, EXP CELL RES, V315, P3140, DOI 10.1016/j.yexcr.2009.08.019
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Saha P, 2017, INFLAMM BOWEL DIS, V23, P1120, DOI 10.1097/MIB.0000000000001134
   Shashidharamurthy R, 2013, ARTHRITIS RHEUM-US, V65, P1064, DOI 10.1002/art.37840
   Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583
   Srinivasan G, 2012, J IMMUNOL, V189, P1911, DOI 10.4049/jimmunol.1200892
   Swiderski RE, 2007, INVEST OPHTH VIS SCI, V48, P3329, DOI 10.1167/iovs.06-1477
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Vazquez DE, 2015, INNATE IMMUN-LONDON, V21, P477, DOI 10.1177/1753425914548491
   Wang Y, 2007, CLIN CHEM, V53, P34, DOI 10.1373/clinchem.2006.075614
   Wunderlich KA, 2010, INVEST OPHTH VIS SCI, V51, P4809, DOI 10.1167/iovs.09-5073
   Xu MJ, 2015, HEPATOLOGY, V61, P692, DOI 10.1002/hep.27447
   Yamada Y, 2016, FREE RADICAL RES, V50, P414, DOI 10.3109/10715762.2015.1134795
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
   Zeng HY, 2008, MOL VIS, V14, P1075
   Zhang YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096997
   Zhao P, 2013, MOL METAB, V2, P161, DOI 10.1016/j.molmet.2013.04.003
NR 75
TC 33
Z9 34
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2018
VL 200
IS 9
BP 3128
EP 3141
DI 10.4049/jimmunol.1701573
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GD7TB
UT WOS:000430714600014
PM 29602770
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Feldman, TB
   Yakovleva, MA
   Arbukhanova, PM
   Borzenok, SA
   Kononikhin, AS
   Popov, IA
   Nikolaev, EN
   Ostrovsky, MA
AF Feldman, Tatiana B.
   Yakovleva, Marina A.
   Arbukhanova, Patimat M.
   Borzenok, Sergey A.
   Kononikhin, Alexey S.
   Popov, Igor A.
   Nikolaev, Evgeny N.
   Ostrovsky, Mikhail A.
TI Changes in spectral properties and composition of lipofuscin
   fluorophores from human-retinal-pigment epithelium with age and
   pathology
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Retinal pigment epithelium; Lipofuscin granule; Bisretinoid
   fluorophores; Fundus autofluorescence; High-performance liquid
   chromatography
ID RPE LIPOFUSCIN; FUNDUS AUTOFLUORESCENCE; A2E; PHOTOOXIDATION; OXIDATION;
   PRODUCTS; GRANULES; CELLS
AB Fundus autofluorescence mostly originates from bisretinoid fluorophores in lipofuscin granules, which accumulate in retinal-pigment-epithelium cells with age. The dynamics of accumulation, photo-oxidation, and photodegradation of bisretinoids during aging or in the presence of pathology have been insufficiently investigated. Changes in spectral properties and composition of human lipofuscin-granule fluorophores with age and pathology have now been investigated by a high-performance liquid chromatography method using spectrophotometric and fluorescent detectors connected in series. It was found that: (i) N-retinylidene-N-retinylethanolamine (A2E) fluorescence intensity is not predominant in the chloroform extract of human-cadaver-eye retinal pigment epithelium studied; bisretinoid photo-oxidation and photodegradation products have much higher fluorescent properties; (ii) the relative emission maximum in the fluorescence spectrum of suspended retinal-pigment-epithelium cells obtained from an individual human-cadaver eye without pathology is irrespective of donor age and falls within the range 575 +/- 15 nm; in two cadaver eyes with signs of age-related macular degeneration, emission maxima were shifted by 23-36 nm towards the shortwave region; and (iii) the ratio of bisretinoid photo-oxidation and photodegradation products to unoxidized bisretinoids in the chloroform extract of cadaver-eye retinal pigment epithelium increases with donor age, from 0.69 +/- 0.03 to 1.32 +/- 0.04. The differences in fluorescence properties between chloroform extracts obtained from cadaver eyes with and without signs of age-related macular degeneration could be used to increase the potential of fundus autofluorescence imaging as a noninvasive diagnostic method.
C1 [Feldman, Tatiana B.; Ostrovsky, Mikhail A.] Moscow MV Lomonosov State Univ, Fac Biol, Dept Mol Physiol, Moscow 119991, Russia.
   [Feldman, Tatiana B.; Yakovleva, Marina A.; Popov, Igor A.; Nikolaev, Evgeny N.; Ostrovsky, Mikhail A.] Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow 119334, Russia.
   [Arbukhanova, Patimat M.; Borzenok, Sergey A.] Sv Fyodorov Eye Microsurg Complex, Moscow 127486, Russia.
   [Kononikhin, Alexey S.; Nikolaev, Evgeny N.] Russian Acad Sci, Inst Energy Problems Chem Phys, Moscow 119334, Russia.
   [Kononikhin, Alexey S.; Popov, Igor A.; Nikolaev, Evgeny N.] Moscow Inst Phys & Technol, Dolgoprudnyi 141700, Moscow Region, Russia.
   [Nikolaev, Evgeny N.] Russian Acad Med Sci, Orekhovich Inst Biomed Chem, Moscow 119121, Russia.
C3 Lomonosov Moscow State University; Russian Academy of Sciences; Emanuel
   Institute of Biochemical Physics; Russian Academy of Sciences; N.N.
   Semenov Federal Research Centre for Chemical Physics, Russian Academy of
   Sciences; Moscow Institute of Physics & Technology; Russian Academy of
   Medical Sciences; Institute of Biomedical Chemistry
RP Feldman, TB (通讯作者)，Moscow MV Lomonosov State Univ, Fac Biol, Dept Mol Physiol, Leninskie Gory1, Moscow 119991, Russia.
EM feldmantb@mail.ru
RI Popov, Igor A/O-4615-2014; Borzenok, Sergey/ABF-9757-2021; Nikolaev,
   Eugene N/N-4498-2013; Kononikhin, Alexey/L-3171-2013
OI Popov, Igor A/0000-0002-5904-2470; Borzenok, Sergey/0000-0001-9160-6240;
   Nikolaev, Eugene N/0000-0001-6209-2068; 
FU Basic Research Program of the Russian Academy of Sciences; Russian
   Foundation for Basic Research [12-04-00844]; Russian Scientific Fund
   [14-24-00114]
FX The work was supported by the Basic Research Program of the Russian
   Academy of Sciences "Basic Science Applications to Medicine", the
   Russian Foundation for Basic Research (No. 12-04-00844). The part of
   research related to mass spectrometry measurements was supported by the
   Russian Scientific Fund (Grant 14-24-00114).
CR Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Feldman TB, 2010, RUSS CHEM B+, V59, P276, DOI 10.1007/s11172-010-0073-8
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Geng LJ, 1999, EXP EYE RES, V69, P539, DOI 10.1006/exer.1999.0735
   Holz F.G., 2007, ATLAS FUNDUS AUTOFLU, V1st ed.
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2010, VISION RES, V50, P729, DOI 10.1016/j.visres.2009.09.015
   Krogmeier JR, 2001, J MICROSC-OXFORD, V202, P386, DOI 10.1046/j.1365-2818.2001.00855.x
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schmitz-Valckenberg S, 2007, ATLAS FUNDUS AUTOFLU
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Sparrow JR, 2008, ADV EXP MED BIOL, V613, P393, DOI 10.1007/978-0-387-74904-4_46
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yakovleva MA, 2010, RUSS CHEM B+, V59, P2309, DOI 10.1007/s11172-010-0393-8
   Yakovleva M. A., 2006, Doklady Akademii Nauk, V409, P411
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
NR 32
TC 22
Z9 27
U1 0
U2 18
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD FEB
PY 2015
VL 407
IS 4
BP 1075
EP 1088
DI 10.1007/s00216-014-8353-z
PG 14
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AZ8AD
UT WOS:000348436100004
PM 25471291
DA 2022-11-30
ER

PT J
AU Liu, JH
   Wann, H
   Chen, MM
   Pan, WHT
   Chen, YC
   Liu, CM
   Yeh, MY
   Tsai, SK
   Young, MS
   Chuang, HY
   Chao, FP
   Chao, HM
AF Liu, Jorn-Hon
   Wann, Hsiung
   Chen, Mi-Mi
   Pan, Wynn H. T.
   Chen, Yei-Ching
   Liu, Chi-Ming
   Yeh, Ming-Yang
   Tsai, Shen-Kou
   Young, Mason Shing
   Chuang, Hui-Yen
   Chao, Fang-Ping
   Chao, Hsiao-Ming
TI Baicalein Significantly Protects Human Retinal Pigment Epithelium Cells
   Against H2O2-Induced Oxidative Stress by Scavenging Reactive Oxygen
   Species and Downregulating the Expression of Matrix Metalloproteinase-9
   and Vascular Endothelial Growth Factor
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; PLASMA-LEVELS;
   FLAVONOIDS; CULTURES; THERAPY; INJURY; H2O2
AB Purpose: Age-related macular degeneration is a leading cause of blindness in the elderly. At a later stage, neovascular or exudative age-related macular degeneration can lead to severe central vision loss that is related to aging-associated cumulative oxidative stress of the human retinal pigment epithelium (hRPE) cells. Early prevention with antioxidants is mandatory. The aim of this study was to determine whether and how baicalein can act as an antioxidant.
   Methods: The methods used included lactate dehydrogenase, 2',7'-dichloro-fluorescein diacetate, or enzyme-linked immunosorbent assay to measure cell viability, oxygen free radical levels, or the levels of vascular endothelial growth factor (VEGF)/matrix metalloproteinase-9 (MMP-9), respectively.
   Results: H2O2 dose-dependently reduced the cell viability of hRPE cells. This negative effect was dose-dependently (with a lower effect at 20 mu M) and significantly counteracted by pretreatment with baicalein (50 mu M). Treatment with H2O2 significantly stimulated the formation of oxygen free radicals. This increase was dose-dependently and significantly blunted by baicalein. Further, treatment with a sublethal dose of H2O2 was associated with an upregulation in the levels of VEGF and MMP-9. The increases in these proteins were also dose-dependently (with a lower effect at 20 mu M) and significantly (50 mu M) blunted by pretreatment with baicalein.
   Conclusion: This study supports an antioxidative role for baicalein whereby it protects hRPE cells against H2O2-induced oxidative stress by downregulating the levels of VEGF and MMP-9, which are increased by H2O2.
C1 [Liu, Jorn-Hon; Wann, Hsiung; Chen, Mi-Mi; Chen, Yei-Ching; Chuang, Hui-Yen; Chao, Fang-Ping; Chao, Hsiao-Ming] Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Liu, Jorn-Hon; Chao, Hsiao-Ming] Natl Yang Ming Univ, Dept Ophthalmol, Fac Med, Sch Med, Taipei 112, Taiwan.
   [Wann, Hsiung; Pan, Wynn H. T.; Chao, Hsiao-Ming] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan.
   [Liu, Chi-Ming] Cheng Hsin Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
C3 Cheng Hsin General Hospital; National Yang Ming Chiao Tung University;
   National Yang Ming Chiao Tung University; Cheng Hsin General Hospital
RP Chao, HM (通讯作者)，Cheng Hsin Gen Hosp, Dept Ophthalmol, 45 Cheng Hsin St,Beitou 112, Taipei, Taiwan.
EM ox_drchao@yahoo.ca
RI CHUANG, HUI-YEN/GVW-2101-2022
FU Cheng Hsin General Hospital (CHGH); Committee on Chinese Medicine and
   Pharmacy (CCMP); Taipei Veterans General Hospital (TPE-VGH) [CHGH98-77,
   CCMP97-RD-012, V96E2-012]; Department of Medical Research and Education
   in Cheng Hsin General Hospital; Department of Medical Research and
   Education in Taipei Veterans General Hospital
FX The authors thank Cheng Hsin General Hospital (CHGH), the Committee on
   Chinese Medicine and Pharmacy (CCMP), and Taipei Veterans General
   Hospital (TPE-VGH) for providing grants (CHGH98-77, CCMP97-RD-012, and
   V96E2-012, respectively) to carry out this study. The authors thank the
   Department of Medical Research and Education in both the Cheng Hsin
   General Hospital and the Taipei Veterans General Hospital for their
   generosity in providing the financial support and an access to the
   relevant facilities at the Core Laboratories. They also express their
   sincere gratitude to Professor Ralph Kirby at the Taipei National
   Yang-Ming University for professional revision.
CR Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2
   Chang WT, 2007, EUR J PHARMACOL, V566, P58, DOI 10.1016/j.ejphar.2007.03.037
   Chao HM, 2008, HUM EXP TOXICOL, V27, P327, DOI 10.1177/0960327108092294
   Chao HM, 2000, BRAIN RES, V877, P47, DOI 10.1016/S0006-8993(00)02592-0
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X
   Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Jung SH, 2008, NEUROCHEM INT, V53, P325, DOI 10.1016/j.neuint.2008.09.004
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaur D, 2004, AGEING RES REV, V3, P327, DOI 10.1016/j.arr.2004.01.003
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070
   Kuenz B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002559
   LEBEL CP, 1990, TOXICOL APPL PHARM, V104, P17, DOI 10.1016/0041-008X(90)90278-3
   LeVine SM, 1997, BRAIN RES, V760, P298, DOI 10.1016/S0006-8993(97)00470-8
   Liu Y, 2010, CHEM RES CHINESE U, V26, P249
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Nie DT, 2006, J BIOL CHEM, V281, P18601, DOI 10.1074/jbc.M601887200
   Patil AJ, 2009, TOXICOLOGY, V259, P69, DOI 10.1016/j.tox.2009.02.004
   Remacle J, 1992, EXS, V62, P99
   Schipper HM, 2004, AGEING RES REV, V3, P265, DOI 10.1016/j.arr.2004.02.001
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Spinale FG, 2007, PHYSIOL REV, V87, P1285, DOI 10.1152/physrev.00012.2007
   Takanashi T, 1997, INVEST OPHTH VIS SCI, V38, P2721
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274
   Wartenberg M, 2003, LAB INVEST, V83, P87, DOI 10.1097/01.LAB.0000049348.51663.2F
   Yang LP, 2009, INVEST OPHTH VIS SCI, V50, P2319, DOI 10.1167/iovs.08-2642
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 40
TC 18
Z9 20
U1 1
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2010
VL 26
IS 5
BP 421
EP 429
DI 10.1089/jop.2010.0063
PG 9
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 660LI
UT WOS:000282643800004
PM 20879805
DA 2022-11-30
ER

PT J
AU Lay, E
   Nutland, S
   Smith, JE
   Hiles, I
   Smith, RAG
   Seilly, DJ
   Buchberger, A
   Schwaeble, W
   Lachmann, PJ
AF Lay, E.
   Nutland, S.
   Smith, J. E.
   Hiles, I.
   Smith, R. A. G.
   Seilly, D. J.
   Buchberger, A.
   Schwaeble, W.
   Lachmann, P. J.
TI Complotype affects the extent of down-regulation by Factor I of the C3b
   feedback cycle in vitro
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE C3b feedback cycle; complotype; Factor I
ID COMPLEMENT ACTIVATION; FACTOR-H; MONOCLONAL-ANTIBODIES; SERUM;
   PHENOTYPES; COMPONENT; FRAGMENTS; PROTEINS; RISK; C-3
AB Sera from a large panel of normal subjects were typed for three common polymorphisms, one in C3 (R102G) and two in Factor H (V62I and Y402H), that influence predisposition to age-related macular degeneration and to some forms of kidney disease. Three groups of sera were tested; those that were homozygous for the three risk alleles; those that were heterozygous for all three; and those homozygous for the low-risk alleles. These groups vary in their response to the addition of exogenous Factor I when the alternative complement pathway is activated by zymosan. Both the reduction in the maximum amount of iC3b formed and the rate at which the iC3b is converted to C3dg are affected. For both reactions the at-risk complotype requires higher doses of Factor I to produce similar down-regulation. Because iC3b reacting with the complement receptor CR3 is a major mechanism by which complement activation gives rise to inflammation, the breakdown of iC3b to C3dg can be seen to have major significance for reducing complement-induced inflammation. These findings demonstrate for the first time that sera from subjects with different complement alleles behave as predicted in an in-vitro assay of the down-regulation of the alternative complement pathway by increasing the concentration of Factor I. These results support the hypothesis that exogenous Factor I may be a valuable therapeutic aid for down-regulating hyperactivity of the C3b feedback cycle, thereby providing a treatment for age-related macular degeneration and other inflammatory diseases of later life.
C1 [Lay, E.; Seilly, D. J.; Lachmann, P. J.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England.
   [Nutland, S.] Univ Cambridge, Cambridge Bioresource, Cambridge CB3 0ES, England.
   [Nutland, S.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
   [Smith, J. E.] GlaxoSmithKline R&D, Immunoinflammat Therapy Area, Stevenage, Herts, England.
   [Hiles, I.] GlaxoSmithKline R&D, Biopharm Discovery, Stevenage, Herts, England.
   [Smith, R. A. G.] Guys Hosp, Kings Coll London, MRC Ctr Transplantat, Prot Therapeut Lab, London SE1 9RT, England.
   [Buchberger, A.; Schwaeble, W.] Univ Leicester, Dept Infect, Leicester, Leics, England.
C3 University of Cambridge; University of Cambridge; University of
   Cambridge; GlaxoSmithKline; GlaxoSmithKline; Guy's & St Thomas' NHS
   Foundation Trust; University of London; King's College London;
   University of Leicester
RP Lachmann, PJ (通讯作者)，Univ Cambridge, Dept Vet Med, Madingley Rd, Cambridge CB3 0ES, England.
EM pjl1000@cam.ac.uk
RI Lachmann, P J/I-7968-2019
OI Lachmann, P J/0000-0003-2849-3524; Schwaeble,
   Wilhelm/0000-0001-8927-0864
FU GlaxoSmithKline; NIHR Biomedical Research Centre at Guy's, King's and St
   Thomas' NHS Trust; Medical Research Council [MR/J006742/1] Funding
   Source: researchfish; MRC [G0801952, G0501425, G0700859, G1000191]
   Funding Source: UKRI
FX We are grateful to Dr Yining Chen and Dr Nick Galwey for help with the
   statistics, Catherine Sparks for preparing recombinant Factor I, Sanja
   Ugrinovic for performing the assays for the antigenic concentrations of
   C3, Factor H and Factor B and to Claire Harris for discussions. Barbara
   King provided an invaluable contribution to the writing of the paper and
   the preparation of Tables and Figures. Financial support was provided by
   GlaxoSmithKline. Richard Smith is supported by the NIHR Biomedical
   Research Centre at Guy's, King's and St Thomas' NHS Trust.
CR ALPER CA, 1968, J CLIN INVEST, V47, P2181, DOI 10.1172/JCI105904
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Harrison RA, 1996, WEIRS HDB EXPT IMMUN, P1
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Lachmann PJ, 2010, J IMMUNOL METHODS, V352, P195, DOI 10.1016/j.jim.2009.11.003
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   LACHMANN PJ, 1980, IMMUNOLOGY, V41, P503
   LACHMANN PJ, 1982, J EXP MED, V156, P205, DOI 10.1084/jem.156.1.205
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   NYDEGGER UE, 1978, J IMMUNOL, V120, P1404
   Pickering MC, 2013, KIDNEY INT, V84, P1079, DOI 10.1038/ki.2013.377
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   ROSS GD, 1982, J IMMUNOL, V129, P2051
   Smith RAG, 2002, BIOCHEM SOC T, V30, P1037, DOI 10.1042/bst0301037
   Smith RAG, 2007, MOL IMMUNOL, V44, P3915, DOI 10.1016/j.molimm.2007.06.021
   SORENSEN H, 1975, HUM HERED, V25, P279, DOI 10.1159/000152736
   WALPORT M, 1987, CLIN EXP IMMUNOL, V69, P501
NR 20
TC 16
Z9 16
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD AUG
PY 2015
VL 181
IS 2
BP 314
EP 322
DI 10.1111/cei.12437
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CM9CL
UT WOS:000358003700013
PM 25124117
OA Green Published
DA 2022-11-30
ER

PT J
AU Pocrnich, CE
   Shao, Q
   Liu, H
   Feng, MM
   Harasym, S
   Savage, M
   Khimdas, S
   Laird, DW
   Hutnik, CML
AF Pocrnich, Cady E.
   Shao, Qing
   Liu, Hong
   Feng, Mary M.
   Harasym, Sarah
   Savage, Melissa
   Khimdas, Sarit
   Laird, Dale W.
   Hutnik, Cindy M. L.
TI The effect of connexin43 on the level of vascular endothelial growth
   factor in human retinal pigment epithelial cells
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Connexin43; Vascular endothelial growth factor; Retinal pigment
   epithelium; Age-related macular degeneration
ID JUNCTIONAL INTERCELLULAR COMMUNICATION; CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; RETROVIRAL DELIVERY; OXIDATIVE STRESS; IN-VIVO;
   VEGF-A; EXPRESSION; CHANNELS; DIFFERENTIATION
AB Connexins (Cx) are the basic units of gap junctions and contribute to cellular integrity by promoting intercellular communication. Disruption of the retinal pigment epithelial monolayer may be an early event in the pathogenesis of age-related macular degeneration, a condition in which vascular endothelial growth factor (VEGF) is known to be of importance. This study was designed to assess the effect of connexin43 (Cx43) expression and gap junctional intercellular communication (GJIC) on the expression and secretion of VEGF from the retinal pigment epithelium under normal cell culture and oxidative stress conditions.
   Stable cell lines of ARPE-19 were produced in which wild-type Cx43 was either over-expressed, down-regulated by targeted shRNA, or functionally inhibited by co-expression of a disease-linked dominant-negative mutant (G21R). Pharmacologic blockade of GJIC was accomplished with flufenamic acid. Oxidant challenge was performed with tert-butyl hydroperoxide (tBH). VEGF gene expression and secretion were assessed by real-time PCR and ELISA respectively.
   Over-expression of Cx43 in ARPE-19 cells reduced both gene expression and secretion of VEGF. Down-regulation of Cx43 increased gene expression and secretion of VEGF. Increased secretion of VEGF was also observed in ARPE-19 cells expressing a dominant-negative mutant of Cx43, and when GJIC was blocked. Over-expression of Cx43 reduced tBH-induced secretion of VEGF from ARPE-19 cells.
   These studies show that Cx43 protects against oxidative stress-induced VEGF secretion in ARPE-19 cells, and thus has important implications in understanding the pathogenesis of age-related macular degeneration.
C1 [Pocrnich, Cady E.; Liu, Hong; Feng, Mary M.; Harasym, Sarah; Savage, Melissa; Khimdas, Sarit; Hutnik, Cindy M. L.] Univ Western Ontario, Dept Ophthalmol, Ivey Eye Inst, St Josephs Hosp, London, ON N6A 4V2, Canada.
   [Pocrnich, Cady E.; Hutnik, Cindy M. L.] Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 5A5, Canada.
   [Shao, Qing; Laird, Dale W.] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 3K7, Canada.
C3 McGill University; Western University (University of Western Ontario);
   London Health Sciences Centre; Western University (University of Western
   Ontario); Western University (University of Western Ontario)
RP Hutnik, CML (通讯作者)，Univ Western Ontario, Dept Ophthalmol, Ivey Eye Inst, St Josephs Hosp, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM cindyh@sjhc.london.on.ca
RI Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015
OI Laird, Dale W/0000-0002-4568-3285; 
FU Canadian National Institute for the Blind (Baker Foundation); Pfizer;
   Pfizer, Canada
FX This research was sponsored by grants from Canadian National Institute
   for the Blind (Baker Foundation) and Pfizer. The authors have full
   control of all primary data, and we agree to allow Graefe's Archive for
   Clinical and Experimental Ophthalmology to review this data upon
   request.; The authors thank the Canadian National Institute for the
   Blind, Baker Foundation, for provision of funding. The authors also
   acknowledge an unrestricted grant from Pfizer, Canada.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0
   GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q
   Hutnik CML, 2008, INVEST OPHTH VIS SCI, V49, P800, DOI 10.1167/iovs.07-0717
   Ikeda Y, 2006, EXP EYE RES, V83, P1031, DOI 10.1016/j.exer.2006.05.007
   Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033
   Kannan R, 2006, MOL VIS, V12, P1649
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Laws MJ, 2008, DEVELOPMENT, V135, P2659, DOI 10.1242/dev.019810
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Malfait M, 2001, J MEMBRANE BIOL, V181, P31, DOI 10.1007/s0023200100082
   Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200
   McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Pimentel RC, 2002, CIRC RES, V90, P671, DOI 10.1161/01.RES.0000014823.75393.4D
   Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367
   Srinivas M, 2003, MOL PHARMACOL, V63, P1389, DOI 10.1124/mol.63.6.1389
   Suarez S, 2001, J CELL SCI, V114, P1229
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xue JL, 2010, CURR PROTOC MICROBIO, V19, p1D21
NR 28
TC 15
Z9 16
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2012
VL 250
IS 4
BP 515
EP 522
DI 10.1007/s00417-011-1871-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 916AR
UT WOS:000302069400007
PM 22138732
DA 2022-11-30
ER

PT J
AU Roybal, CN
   Hunsaker, LA
   Barbash, O
   Jagt, DLV
   Abcouwer, SF
AF Roybal, CN
   Hunsaker, LA
   Barbash, O
   Jagt, DLV
   Abcouwer, SF
TI The oxidative stressor arsenite activates vascular endothelial growth
   factor mRNA transcription by an ATF4-dependent mechanism
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; CHOROIDAL NEOVASCULAR MEMBRANES;
   ENDOPLASMIC-RETICULUM STRESS; FACTOR EXPRESSION; MACULAR DEGENERATION;
   MAMMALIAN-CELLS; SODIUM ARSENITE; HEME OXYGENASE; KINASE; ATF4
AB Aberrant retinal expression of vascular endothelial growth factor (VEGF) leading to neovascularization is a central feature of age-related macular degeneration and diabetic retinopathy, two leading causes of vision loss. Oxidative stress is suggested to occur in retinal tissue during age-related macular degeneration and diabetic retinopathy and is suspected in the mechanism of VEGF expression in these diseases. Arsenite, a thiol-reactive oxidative stressor, induces VEGF expression by a HIF-1 alpha-independent mechanism. Previously, we demonstrated that homocysteine, an endoplasmic reticulum stressor, increases VEGF transcription by a mechanism dependent upon activating transcription factor ATF4. Because ATF4 is expressed in response to oxidative stress, we hypothesized that ATF4 was also responsible for increased VEGF transcription in response to arsenite. We now show that arsenite increased steady state levels of VEGF mRNA and activated transcription from a VEGF promoter construct. Arsenite induced eIF2 alpha phosphorylation, resulting in increased ATF4 protein levels. Inactivation or loss of ATF4 greatly diminished the VEGF response to arsenite treatment. Overexpression of ATF4 was sufficient to activate the VEGF promoter, and arsenite cooperated with exogenous ATF4 to further activate the promoter. A complex containing ATF4 binds a DNA element at +1767 bp relative to the VEGF transcription start site, and DNA binding activity is increased by arsenite treatment. In addition, the ability of a thiol antioxidant, N-acetylcysteine, to inhibit the effect of arsenite on VEGF expression coincided with its ability to inhibit phosphorylation of eIF2 alpha and ATF4 protein expression. Thus, arsenite-induced up-regulation of VEGF gene transcription occurs by an ATF4-dependent mechanism.
C1 Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, Albuquerque, NM 87131 USA.
C3 University of New Mexico
RP Abcouwer, SF (通讯作者)，Univ New Mexico, Dept Biochem & Mol Biol, Sch Med, MSC08-4670,1, Albuquerque, NM 87131 USA.
EM sabcouwer@salud.unm.edu
OI Abcouwer, Steven F/0000-0003-2580-1288
FU NEI NIH HHS [EY13695, EY014535] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [F31EY014535, R03EY013695] Funding Source: NIH RePORTER
CR Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645
   Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995
   CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8
   DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9
   Duyndam MCA, 2003, J BIOL CHEM, V278, P6885, DOI 10.1074/jbc.M206320200
   Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200
   Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Goldstein M, 2004, EYE, V18, P460, DOI 10.1038/sj.eye.6700702
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200
   Ji C, 2004, WORLD J GASTROENTERO, V10, P1699
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829
   Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284
   KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Li WY, 1999, CELL MOL BIOL, V45, P59
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001
   Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   McEwen E, 2005, J BIOL CHEM, V280, P16925, DOI 10.1074/jbc.M412882200
   Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631
   Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391
   Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   SARDANA MK, 1981, PHARMACOLOGY, V23, P247, DOI 10.1159/000137557
   Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200
   Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101
   Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7
NR 36
TC 99
Z9 108
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 27
PY 2005
VL 280
IS 21
BP 20331
EP 20339
DI 10.1074/jbc.M411275200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 927ZX
UT WOS:000229242000023
PM 15788408
OA hybrid
DA 2022-11-30
ER

PT J
AU Chi, YT
   Yang, CH
   Cheng, CK
AF Chi, Yu-Tien
   Yang, Chang-Hao
   Cheng, Cheng-Kuo
TI Optical Coherence Tomography Angiography for Assessment of the
   3-Dimensional Structures of Polypoidal Choroidal Vasculopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; OCT ANGIOGRAPHY; NEOVASCULARIZATION SECONDARY;
   TYPE-3 NEOVASCULARIZATION; FEATURES
AB IMPORTANCE Investigating the quantitative 3-dimensional (3-D) anatomy of polypoidal complex is important for a better understanding of the pathogenesis of polypoidal choroidal vasculopathy (PCV).
   OBJECTIVE To quantitatively evaluate the 3-D characteristics of polypoidal structures, branching vascular networks (BVNs), and origin of PCV using optical coherence tomography angiography (OCTA) and multiple image systems.
   DESIGN, SETTING, AND PARTICIPANTS A prospective, observational study was conducted in 47 consecutive Taiwanese patients (47 eyes) from May 21, 2015, to April 30, 2017. All participants were scanned with the Optovue-RTVue-XR-Avanti OCTA system. Patients in whom PCV was identified on OCTA were examined to define characteristics and structures of the original spouting vessels (stalks) from the choroid, polypoidal structures, and BVNs on OCTA.
   MAIN OUTCOMES AND MEASURES Quantitative analysis of 3-D structures of the polypoidal complex.
   RESULTS Among the 47 patients, the mean (SD) patient age was 68.9 (8.0) years, and 28 (59.6%) men were included. Clear images of polypoidal structures could be detected in 17 eyes (36.2%, 22 polypoidal structures), BVNs in 26 eyes (55.3%, 26 tufts of BVNs), and stalks of origin from the choroid in 26 eyes (55.3%, 26 stalks) on the en face plane on OCTA. All polypoidal structures were found at a mean (SD) height of 45.3 (36.1) mu m above the retinal pigment epithelium (RPE) reference plane that was preset by the machine, while the BVNs were found at a mean (SD) depth of 28.6 (14.2) mu m below the RPE reference plane and the choroidal stalks at 80.4 (24.4) mu m below RPE reference plane. The mean (SD) thickness of polypoidal structures was 38.4 (15.5) mu m and of BVNs, 60.2 (25.0) mu m. The polypoidal structures were all above the Bruch membrane within the dome of the RPE detachment, the choroidal stalks were all in the choroid layer. The BVNs could be either above (up to 18 mu m), within, or below (up to 28 mu m) the Bruch membrane and were in proximity to the double layers of flattened RPE detachment.
   CONCLUSIONS AND RELEVANCE These results demonstrate a 3-D architecture of PCV that may be helpful for a better understanding of the anatomy, pathophysiology, and pathogenesis of PCV.
C1 [Chi, Yu-Tien; Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 11106, Taiwan.
   [Yang, Chang-Hao; Cheng, Cheng-Kuo] Natl Taiwan Univ, Dept Ophthalmol, Taipei, Taiwan.
   [Yang, Chang-Hao; Cheng, Cheng-Kuo] Natl Taiwan Univ, Sch Med, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Dept Ophthalmol, New Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; National Taiwan University;
   National Taiwan University; Fu Jen Catholic University; Fu Jen Catholic
   University
RP Cheng, CK (通讯作者)，Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei 11106, Taiwan.
EM ckcheng.md@gmail.com
RI Yang, Chang-Hao/AAR-3759-2021
OI YANG, CHANG-HAO/0000-0002-4328-8716
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Puliafito CA, 2014, OSLI RETINA, V45, P360, DOI 10.3928/23258160-20140925-01
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 34
TC 21
Z9 22
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2017
VL 135
IS 12
BP 1310
EP 1316
DI 10.1001/jamaophthalmol.2017.4360
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ0OO
UT WOS:000418056800009
PM 29049501
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wu, WK
   Georgiadis, A
   Copland, DA
   Liyanage, S
   Luhmann, UFO
   Robbie, SJ
   Liu, J
   Wu, J
   Bainbridge, JW
   Bates, DO
   Ali, RR
   Nicholson, LB
   Dick, AD
AF Wu, Wei-Kang
   Georgiadis, Anastasios
   Copland, David A.
   Liyanage, Sidath
   Luhmann, Ulrich F. O.
   Robbie, Scott J.
   Liu, Jian
   Wu, Jiahui
   Bainbridge, James W.
   Bates, David O.
   Ali, Robin R.
   Nicholson, Lindsay B.
   Dick, Andrew D.
TI IL-4 Regulates Specific Arg-1(+) Macrophage sFlt-1-Mediated Inhibition
   of Angiogenesis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; MURINE MACROPHAGES; HUMAN MONOCYTES; FACTOR VEGF;
   RETINAL NEOVASCULARIZATION; ALTERNATIVE ACTIVATION;
   RHEUMATOID-ARTHRITIS; DENDRITIC CELLS
AB One of the main drivers for neovascularization in age-related macular degeneration is activation of innate immunity in the presence of macrophages. Here, we demonstrate that T helper cell type 2 cytokines and, in particular, IL-4 condition human and murine monocyte phenotype toward Arg-1(+), and their subsequent behavior limits angiogenesis by increasing soluble fms-like tyrosine kinase 1 (sFlt-1) gene expression. We document that T helper cell type 2 cytokine-conditioned murine macrophages neutralize vascular endothelial growth factor-mediated endothelial cell proliferation (human umbilical vein endothelial cell and choroidal vasculature) in a sFlt-1 dependent manner. We demonstrate that in vivo intravitreal administration of IL-4 attenuates laser-induced choroidal neovascularization (L-CNV) due to specific IL-4 conditioning of macrophages. IL-4 induces the expression of sFlt-1 by resident CD11b(+) retinal microglia and infiltrating myeloid cells but not from retinal pigment epithelium. IL-4 induced suppression of L-CNV is not prevented when sFlt-1 expression is attenuated in retinal pigment epithelium. IL-4 mediated suppression of L-CNV was abrogated in IL-4R-deficient mice and in bone marrow chimeras reconstituted with myeloid cells that had undergone lentiviral-mediated shRNA silencing of sFlt-1, demonstrating the critical role of this cell population. Together, these data establish how IL-4 directly drives macrophage sFlt-1 production expressing an Arg-1(+) phenotype and support the therapeutic potential of targeted IL-4 conditioning within the tissue to regulate disease conditions such as neovascular age-related macular degeneration.
C1 [Wu, Wei-Kang; Nicholson, Lindsay B.; Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Copland, David A.; Liu, Jian; Wu, Jiahui; Nicholson, Lindsay B.; Dick, Andrew D.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
   [Georgiadis, Anastasios; Liyanage, Sidath; Luhmann, Ulrich F. O.; Robbie, Scott J.; Bainbridge, James W.; Ali, Robin R.; Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
   [Bates, David O.] Univ Nottingham, Sch Med, Queens Med Ctr, Div Canc & Stem Cells,Canc Biol, Nottingham, England.
   [Robbie, Scott J.; Bainbridge, James W.; Ali, Robin R.; Dick, Andrew D.] Moorfields Eye Hosp, Biomed Res Ctr, NIHR, London, England.
   [Robbie, Scott J.; Bainbridge, James W.; Ali, Robin R.; Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
C3 University of Bristol; University of Bristol; University of London;
   University College London; University of Nottingham; University of
   London; King's College London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London
RP Dick, AD (通讯作者)，Bristol Eye Hosp, Sch Clin Sci, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM a_dick@bristol.ac.uk
RI Copland, David/AAE-5334-2020; Copland, David/AAG-2368-2019; Georgiadis,
   Anastasios/G-8777-2012
OI Copland, David/0000-0002-2257-4270; Georgiadis,
   Anastasios/0000-0001-5079-3588; Bainbridge, James/0000-0003-1318-8201;
   Ali, Robin/0000-0003-3126-6517; Dick, Andrew/0000-0002-0742-3159;
   Luhmann, Ulrich F.O./0000-0002-1993-1951; Bates,
   David/0000-0003-4850-2360
FU National Eye Research Centre [PANM RJ5370]; Dunhill Medical Trust
   [R138/1109]; National Institute for Health Research (NIHR) Biomedical
   Research Center based at Moorfields Eye Hospital NHS Foundation Trust
   and University College London Institute of Ophthalmology; MRC
   [MR/K003003/1, MR/L012758/1] Funding Source: UKRI; Medical Research
   Council [MR/L012758/1, MR/K003003/1] Funding Source: researchfish;
   National Institute for Health Research [NIHR-RP-011-003,
   NF-SI-0513-10074] Funding Source: researchfish; Fight for Sight
   [1333/34] Funding Source: researchfish
FX Supported by the National Eye Research Centre grant PANM RJ5370, Dunhill
   Medical Trust grant R138/1109, and the National Institute for Health
   Research (NIHR) Biomedical Research Center based at Moorfields Eye
   Hospital NHS Foundation Trust and University College London Institute of
   Ophthalmology (A.D.D. and R.R.A.).
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Asosingh K, 2013, J IMMUNOL, V190, P3458, DOI 10.4049/jimmunol.1202095
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Ben Addi A, 2008, EUR J IMMUNOL, V38, P1610, DOI 10.1002/eji.200737781
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Di Marco GS, 2009, J AM SOC NEPHROL, V20, P2235, DOI 10.1681/ASN.2009010061
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fattahi MJ, 2012, PROSTAGLANDINS, V2012
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Fordham JB, 2012, SCI REP-UK, V2, DOI 10.1038/srep00512
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575
   Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795
   Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Horie S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03072
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kikuchi R, 2014, NAT MED, V20, P1464, DOI 10.1038/nm.3703
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kommineni VK, 2008, BIOCHEM BIOPH RES CO, V374, P479, DOI 10.1016/j.bbrc.2008.07.042
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Larsen H, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3934
   Lee MC, 2008, J LEUKOCYTE BIOL, V84, P835, DOI 10.1189/jlb.1007691
   Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Lu PR, 2012, INVEST OPHTH VIS SCI, V53, P3516, DOI 10.1167/iovs.10-5548
   Marrelli A, 2011, AUTOIMMUN REV, V10, P595, DOI 10.1016/j.autrev.2011.04.020
   Menzies FM, 2010, CLIN EXP IMMUNOL, V160, P369, DOI 10.1111/j.1365-2249.2009.04086.x
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mukutmoni M, 2001, PROSTAG LEUKOTR ESS, V65, P123, DOI 10.1054/plef.2001.0300
   Munder M, 1999, J IMMUNOL, V163, P3771
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   Nair MG, 2005, INFECT IMMUN, V73, P385, DOI 10.1128/IAI.73.1.385-394.2005
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Pujol BF, 2001, EUR J CELL BIOL, V80, P99, DOI 10.1078/0171-9335-00136
   Ramanathan M, 2007, MOL BIOL CELL, V18, P14, DOI 10.1091/mbc.E06-07-0596
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   Salmon-Ehr V, 2000, LAB INVEST, V80, P1337, DOI 10.1038/labinvest.3780141
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Singh TP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051752
   Su WH, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/413238
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tsutsui S, 2005, ONCOL REP, V14, P425
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang YS, 2011, CLIN EXP MED, V11, P113, DOI 10.1007/s10238-010-0112-7
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5
   Yang WG, 2001, CANCER RES, V61, P7840
   Yoo SA, 2005, J IMMUNOL, V174, P5846, DOI 10.4049/jimmunol.174.9.5846
   Zhang M, 2009, CURR EYE RES, V34, P401, DOI 10.1080/02713680902862971
NR 63
TC 27
Z9 29
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2015
VL 185
IS 8
BP 2324
EP 2335
DI 10.1016/j.ajpath.2015.04.013
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA CO3YD
UT WOS:000359096300022
PM 26079814
OA Bronze
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Schlichtenbrede, F
AF Jonas, J. B.
   Schlichtenbrede, F.
TI Visual acuity and intraocular pressure after high-dose intravitreal
   triamcinolone acetonide in selected ocular diseases
SO EYE
LA English
DT Review
DE intravitreal steroids; intravitreal triamcinolone; macular oedema;
   age-related macular degeneration; uveitis; intraocular pressure
ID CYSTOID MACULAR EDEMA; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; INJECTION; DEGENERATION; RECURRENCE
AB Purpose Within the last 5 years, intravitreal injections of triamcinolone acetonide have been for a wide variety of ocular diseases with intraocular oedema and neovascularization. With clinical experience accumulating, the question arises for which indication the side effects outweigh the therapeutic efficacy of intravitreal triamcinolone monotherapy.
   Scope Comparing different diseases, increase in visual acuity was lower in patients receiving intravitreal triamcinolone monotherapy for exudative age-related macular degeneration than in patients with diabetic macular oedema, branch retinal vein occlusion, central retinal vein occlusion, uveitis, and pseudophakic cystoid macular oedema. Rise in intraocular pressure was significantly higher in relatively young patients with uveitis than in any other patient group.
   Conclusions Improvement in vision after intravitreal triamcinolone monotherapy is highest in non-ischaemic diseases with an intraretinal macular oedema such as pseudophakic cystoid macular oedema; it is lower in partially ischaemic diseases with intraretinal macular oedema such as diabetic macular oedema or retinal vein occlusions; and it is lowest in diseases with a primarily subretinal location of the disease such as exudative age-related macular degeneration. For the latter diseases, intravitreal triamcinolone monotherapy is, therefore, no longer up-to-date, particularly with the upcoming intravitreal application of vascular endothelial growth factor blocking drugs. For diseases with intraretinal oedema, the rule of thumb may be that intravitreal triamcinolone increases vision as much as retinal ischaemia and tissue destruction by the underlying disease allow it. The rise in intraocular pressure is higher in relatively young patients with uveitis than in elderly patients with other reasons for macular oedema.
C1 [Jonas, J. B.; Schlichtenbrede, F.] Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chen SDM, 2004, BRIT J OPHTHALMOL, V88, P154, DOI 10.1136/bjo.88.1.154
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Degenring RF, 2003, ACTA OPHTHALMOL SCAN, V81, P399, DOI 10.1034/j.1600-0420.2003.00084.x
   Degenring RF, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Ip MS, 2002, ARCH OPHTHALMOL-CHIC, V120, P1217
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2005, ARCH OPHTHALMOL-CHIC, V123, P1338, DOI 10.1001/archopht.123.10.1338
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2005, EYE, V19, P65, DOI 10.1038/sj.eye.6701395
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Karacorlu M, 2005, EYE, V19, P382, DOI 10.1038/sj.eye.6701512
   Karacorlu M, 2003, ACTA OPHTHALMOL SCAN, V81, P648, DOI 10.1046/j.1395-3907.2003.0146.x
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   SANCHEZ JMB, 2001, ARCH SOC ESP OFTALMO, V76, P661
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P999, DOI 10.1136/bjo.2004.062596
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 46
TC 12
Z9 13
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2008
VL 22
IS 7
BP 869
EP 873
DI 10.1038/sj.eye.6702734
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 326XP
UT WOS:000257693200001
PM 17304257
OA Bronze
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Cheong, KX
   Ong, R
   Hamzah, H
   Yanagi, Y
   Wong, TY
   Chakravarthy, U
   Cheung, CMG
AF Teo, Kelvin Yi Chong
   Cheong, Kai Xiong
   Ong, Ricardo
   Hamzah, Haslina
   Yanagi, Yasuo
   Wong, Tien Yin
   Chakravarthy, Usha
   Cheung, Chui Ming Gemmy
TI Macular neovascularization in eyes with pachydrusen
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; AGE-RELATED MACULOPATHY; GEOGRAPHIC
   ATROPHY; 6-YEAR INCIDENCE; RISK-FACTORS; DEGENERATION; PROGRESSION;
   POPULATION; PROTOCOL; LESIONS
AB The natural history and clinical significance of pachydrusen is unclear. This study aims to compare the longitudinal changes of eyes with pachydrusen and soft drusen and progression to exudative macular neovascularisation (MNV). Patients with a diagnosis of MNV in one eye only and the fellow eye was selected as the study eye. Study eyes were required to have pachydrusen or soft drusen on fundus photographs and follow up of at least 2 years or until exudative MNV occurred. Systematic grading was performed at baseline and change in drusen area and onset of exudative MNV recorded over the period of follow up. A total of 75 eyes from 75 patients (29 with pachydrusen and 46 with soft drusen) were included. There was no difference in the rate of progression to exudative MNV in the soft and pachydrusen groups (13.3% versus 24.1%, p=0.38). Pachydrusen, as compared to soft drusen, was associated with polypoidal choroidal vasculopathy subtype (85.7% versus 16.7%, p < 0.01) and the location of exudation was co-localised with soft drusen but not with pachydrusen. There was a higher rate of increase in soft drusen area compared to pachydrusen area (27.7 +/- 31.9%/year versus 8.7 +/- 12.4%/year respectively, p < 0.01). We found no difference in the proportion of eyes that developed exudative MNV in this study however characterisation of drusen evolution patterns revealed a strong association with exudative MNV subtype.
C1 [Teo, Kelvin Yi Chong; Cheong, Kai Xiong; Ong, Ricardo; Hamzah, Haslina; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Teo, Kelvin Yi Chong; Cheong, Kai Xiong; Yanagi, Yasuo; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore 20 Coll Rd Discovery Tower, Singapore 169856, Singapore.
   [Teo, Kelvin Yi Chong] Univ Sydney, Camperdown, NSW 2006, Australia.
   [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Teo, Kelvin Yi Chong; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, 1E Kent Ridge,NUHS Tower Block,Level 7, Singapore 119228, Singapore.
   [Teo, Kelvin Yi Chong; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, 8 Coll Rd, Singapore 169857, Singapore.
   [Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; University of Sydney; Asahikawa Medical
   College; National University of Singapore; National University of
   Singapore; Queens University Belfast
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.; Cheung, CMG (通讯作者)，Singapore Eye Res Inst, Singapore 20 Coll Rd Discovery Tower, Singapore 169856, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, 1E Kent Ridge,NUHS Tower Block,Level 7, Singapore 119228, Singapore.; Cheung, CMG (通讯作者)，Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, 8 Coll Rd, Singapore 169857, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Yanagi, Yasuo/AAA-5441-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Teo, Kelvin/0000-0002-7458-7081
FU National Medical Research Council Large Collaborative Grant (TAAP)
   [NMRC/OFLCG/004/2018]
FX National Medical Research Council Large Collaborative Grant (TAAP)
   (NMRC/OFLCG/004/2018).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cornish EE, 2021, RETINA-J RET VIT DIS, V41, P118, DOI 10.1097/IAE.0000000000002798
   Cumberland PM, 2016, JAMA OPHTHALMOL, V134, P959, DOI 10.1001/jamaophthalmol.2016.1778
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Mao FF, 2019, INVEST OPHTH VIS SCI, V60, P4966, DOI 10.1167/iovs.19-27325
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sheth J, 2020, EYE, V34, P1501, DOI 10.1038/s41433-020-0886-0
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 41
TC 2
Z9 2
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 5
PY 2021
VL 11
IS 1
AR 7495
DI 10.1038/s41598-021-87083-4
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RJ7YA
UT WOS:000637816800020
PM 33820941
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Krezel, AK
   Hogg, R
   Lohfeld, L
   Chakravarthy, U
   Azuara-Blanco, A
AF Krezel, Aniela Krystyna
   Hogg, Ruth
   Lohfeld, Lynne
   Chakravarthy, Usha
   Azuara-Blanco, Augusto
TI Core outcomes for geographic atrophy trials
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; MACULAR DEGENERATION; SECONDARY; TOOL
AB Background/Aims Ongoing and recent clinical trials for geographic atrophy (GA) have used different outcomes. The goal of this study was to identify a core outcome set (COS) important for patients, clinicians and researchers, and to propose the use of COS in the design of future GA trials.
   Methods Five-component project including: Delphi method with patients and experts, focus groups and interviews with patients, relatives and workers supporting patients. Three hundred and one patients (301) with age-related macular degeneration participated in round 1 of a Delphi exercise. Most subjects had GA; 183 patients (61%) were females and the median (range) age was 77 (50-99) years. In round 2, of the 301 of the first round, 100 participants were randomly selected of whom 76 agreed to take part. In a parallel Delphi exercise, panellists comprised a mix of non-clinical scientists and clinicians (43 in the initial and 21 in the final round). In addition, interviews and focus groups consisting of patients (n=20), family members (n=4) and support workers (n=5) were undertaken.
   Results Core outcomes identified as important for age-related macular degeneration trials were the health of the outer retina, multimodal estimation of lesion size, reading speed, best corrected distance and near acuity, low luminance visual acuity, patient reported visual performance and safety.
   Conclusion This study identified a set of core outcomes that should be used in GA trials. The COS include patient-reported outcome measures, near visual acuity, reading speed and assessment of the outer retina.
C1 [Krezel, Aniela Krystyna; Hogg, Ruth; Chakravarthy, Usha; Azuara-Blanco, Augusto] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Krezel, Aniela Krystyna; Hogg, Ruth; Lohfeld, Lynne; Chakravarthy, Usha; Azuara-Blanco, Augusto] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Lohfeld, Lynne] Wenzhou Med Univ, Eye Hosp, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
C3 Queens University Belfast; Queens University Belfast; Wenzhou Medical
   University
RP Azuara-Blanco, A (通讯作者)，Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
EM a.azuara-blanco@qub.ac.uk
OI Lohfeld, Lynne/0000-0003-4711-7305; Hogg, Ruth/0000-0001-9413-2669;
   Azuara-Blanco, Augusto/0000-0002-4805-9322
CR Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]
   Chan AW, 2014, LANCET, V383, P257, DOI 10.1016/S0140-6736(13)62296-5
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Finger RP, 2014, INVEST OPHTH VIS SCI, V55, P8458, DOI 10.1167/iovs.14-14732
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Heneghan C, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1870-2
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hsu CC, 2007, RES EVALUAT, V7, P120
   Kotecha A, 2013, INVEST OPHTH VIS SCI, V54
   Krezel AK, 2015, EYE, V29, P1458, DOI 10.1038/eye.2015.132
   Krezel AK, 2015, BRIT J OPHTHALMOL, V99, P1560, DOI 10.1136/bjophthalmol-2014-306544
   Lindsley KB, 2018, JAMA OPHTHALMOL, V136, P1217, DOI 10.1001/jamaophthalmol.2018.3456
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Okoli C, 2004, INFORM MANAGE-AMSTER, V42, P15, DOI 10.1016/j.im.2003.11.002
   Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Saldanha IJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109400
   Sanderson T, 2010, ARTHRIT CARE RES, V62, P647, DOI 10.1002/acr.20151
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58
   Taylor DJ, 2018, GRAEF ARCH CLIN EXP, V256, P815, DOI 10.1007/s00417-017-3879-3
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Turk DC, 2008, PAIN, V137, P276, DOI 10.1016/j.pain.2007.09.002
   Waters AMI, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-168
   Williamson PR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1978-4
NR 28
TC 4
Z9 4
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2020
VL 104
IS 9
BP 1196
EP 1202
DI 10.1136/bjophthalmol-2019-314949
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PI3IA
UT WOS:000600986900004
PM 31848211
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hoang, QV
   Jung, JJ
   Mrejen, S
   Freund, KB
AF Hoang, Quan V.
   Jung, Jesse J.
   Mrejen, Sarah
   Freund, K. Bailey
TI INFLUENCE OF AXIAL LENGTH AND POSTINJECTION REFLUX ON SUSTAINED
   INTRAOCULAR PRESSURE ELEVATION AS A RESULT OF INTRAVITREAL ANTI-VASCULAR
   ENDOTHELIAL GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE axial; bevacizumab; injection; IOP; length; pressure; ranibizumab;
   reflux; transient; sustained
ID MACULAR DEGENERATION; RANIBIZUMAB LUCENTIS; BEVACIZUMAB; INJECTIONS;
   HYPERTENSION; PEGAPTANIB
AB Purpose: To assess an association of axial length (AL) or postinjection reflux with transient or sustained intraocular pressure (IOP) elevation in patients with neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor injections.
   Methods: One hundred and forty-seven eyes from 74 consecutive patients with neovascular age-related macular degeneration who presented to a single physician over a 2-month period had ALs measured by IOLMaster. Twenty-one patients had preinjection and immediate postinjection IOP measured and immediate reflux assessed.
   Results: Overall, 9.5% of eyes had been identified with sustained IOP elevation in our previous study. Axial length did not significantly differ between eyes that had (AL, 23.96 +/- 0.66 mm; n = 14) and had not experienced sustained IOP elevation (AL, 23.44 +/- 1.24 mm; n = 133; P = 0.12, t-test). By linear regression analysis, the relationship between experiencing sustained IOP elevation and AL was not statistically significant (R-2 = 0.0165; P = 0.121). The relationship between AL and immediate postinjection IOP elevation was also not statistically significant (R-2 = 0.0001; P = 0.97). Immediate postinjection IOP increase did differ between eyes without reflux (30.2 +/- 9.3 mmHg; n = 12) and those with reflux (1.1 +/- 7.2; n = 9; P < 0.001).
   Conclusion: Axial length does not seem to be a predictor of transient or sustained IOP elevation. Repeated trabecular meshwork trauma related to the absence or presence of reflux and immediate postinjection IOP elevation may be a contributing factor.
C1 [Hoang, Quan V.; Jung, Jesse J.; Mrejen, Sarah; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Hoang, Quan V.; Jung, Jesse J.; Mrejen, Sarah; Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Hoang, Quan V.; Jung, Jesse J.; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Hoang, Quan V.; Jung, Jesse J.; Freund, K. Bailey] NYU, Dept Ophthalmol, Med Ctr, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Columbia University; New
   York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Institute; Macula Foundation; Genentech; Regeneron; Bayer;
   NATIONAL EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Institute, and The Macula Foundation. Financial
   disclosure received from Genentech (Consultant, Research Support for K.
   B. F.), Regeneron (Consultant for K. B. F.), and Bayer (Consultant for
   K.B.F.).
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2013, J GLAUCOMA
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim GN, 2013, SEMIN OPHTHALMOL, V28, P61, DOI 10.3109/08820538.2012.754479
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P632, DOI 10.1007/s10384-011-0088-1
   Ladas JG, 2001, INVEST OPHTH VIS SCI, V42, P2584
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loukianou Eleni, 2011, International Ophthalmology, V31, P211, DOI 10.1007/s10792-010-9410-z
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 29
TC 13
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2014
VL 34
IS 3
BP 519
EP 524
DI 10.1097/IAE.0000000000000039
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DL
UT WOS:000336960100018
PM 24240557
DA 2022-11-30
ER

PT J
AU Wai, KM
   Vingopoulos, F
   Garg, I
   Kasetty, M
   Silverman, RF
   Katz, R
   Lains, I
   Miller, JW
   Husain, D
   Vavvas, DG
   Kim, LA
   Miller, JB
AF Wai, Karen M.
   Vingopoulos, Filippos
   Garg, Itika
   Kasetty, Megan
   Silverman, Rebecca F.
   Katz, Raviv
   Lains, Ines
   Miller, Joan W.
   Husain, Deeba
   Vavvas, Demetrios G.
   Kim, Leo A.
   Miller, John B.
TI Contrast sensitivity function in patients with macular disease and good
   visual acuity
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retina; macula; vision
ID QUALITY-OF-LIFE; DEGENERATION; RELIABILITY; VISION; PERFORMANCE; ADULTS
AB Introduction Contrast sensitivity function (CSF) may better estimate a patient's visual function compared with visual acuity (VA). Our study evaluates the quick CSF (qCSF) method to measure visual function in eyes with macular disease and good letter acuity. Methods Patients with maculopathies (retinal vein occlusion, macula-off retinal detachment, dry age-related macular degeneration and wet age-related macular degeneration) and good letter acuity (VA >= 20/30) were included. The qCSF method uses an intelligent algorithm to measure CSF across multiple spatial frequencies. All maculopathy eyes combined and individual macular disease groups were compared with healthy control eyes. Main outcomes included area under the log CSF (AULCSF) and six CS thresholds ranging from 1 cycle per degree (cpd) to 18 cpd. Results 151 eyes with maculopathy and 93 control eyes with VA >= 20/30 were included. The presence of a maculopathy was associated with significant reduction in AULCSF (beta: -0.174; p<0.001) and CS thresholds at all spatial frequencies except for 18 cpd (beta: -0.094 to -0.200 log CS, all p<0.01) compared with controls. Reductions in CS thresholds were most notable at low and intermediate spatial frequencies (1.5 cpd, 3 cpd and 6 cpd). Conclusion CSF measured with the qCSF active learning method was found to be significantly reduced in eyes affected by macular disease despite good VA compared with healthy control eyes. The qCSF method is a promising clinical tool to quantify subtle visual deficits that may otherwise go unrecognised by current testing methods.
C1 [Wai, Karen M.; Vingopoulos, Filippos; Garg, Itika; Katz, Raviv; Lains, Ines; Miller, Joan W.; Husain, Deeba; Vavvas, Demetrios G.; Kim, Leo A.; Miller, John B.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA.
   [Wai, Karen M.; Vingopoulos, Filippos; Garg, Itika; Kasetty, Megan; Silverman, Rebecca F.; Katz, Raviv; Lains, Ines; Miller, Joan W.; Husain, Deeba; Vavvas, Demetrios G.; Kim, Leo A.; Miller, John B.] Massachusetts Eye & Ear Infirm, Harvard Retinal Imaging Lab, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Massachusetts Eye & Ear Infirmary
RP Miller, JB (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA.
EM john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022; Garg, Itika/AIE-7779-2022
OI Garg, Itika/0000-0002-9537-8561; Miller, Joan/0000-0003-2046-3996; Wai,
   Karen/0000-0001-8980-2242
FU Lions International Equipment Fund; Massachusetts Lions Club [530125]
FX Lions International Equipment Fund and Massachusetts Lions Club (grant:
   #530125).
CR ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   BROWN B, 1981, AM J OPTOM PHYS OPT, V58, P218
   Buhren J, 2006, OPTOMETRY VISION SCI, V83, P290, DOI 10.1097/01.opx.0000216100.93302.2d
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Doran, 2004, BRIT J OPHTHALMOL
   Dorr M, 2015, CURR DIR BIOMED ENG, V1, P131
   ELLIOTT DB, 1993, INVEST OPHTH VIS SCI, V34, P108
   Freeman EE, 2005, OPTOMETRY VISION SCI, V82, P765, DOI 10.1097/01.opx.0000175008.88427.05
   Hou F, 2016, J VISION, V16, DOI 10.1167/16.6.18
   JINDRA LF, 1989, J CATARACT REFR SURG, V15, P141, DOI 10.1016/S0886-3350(89)80002-1
   Joltikov KA, 2017, INVEST OPHTH VIS SCI, V58, P277, DOI 10.1167/iovs.17-21863
   Kalia A, 2014, P NATL ACAD SCI USA, V111, P2035, DOI 10.1073/pnas.1311041111
   Kelly SA, 2012, OPTOMETRY VISION SCI, V89, P1172, DOI 10.1097/OPX.0b013e318264097b
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lesmes LA, 2010, J VISION, V10, DOI 10.1167/10.3.17
   Lin S, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.22
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Okamoto F, 2008, AM J OPHTHALMOL, V146, P85, DOI 10.1016/j.ajo.2008.02.011
   Owsley C, 2010, VISION RES, V50, P2348, DOI 10.1016/j.visres.2010.05.021
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Richman J, 2013, J CATARACT REFR SURG, V39, P1100, DOI 10.1016/j.jcrs.2013.05.001
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Rubin, 1989, OPHTHALMOL CLIN N AM, V2, P357
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   Savoie, 1973, PERCEPT PSYCHOPHYS
   Sia DIT, 2013, ACTA OPHTHALMOL, V91, P312, DOI 10.1111/j.1755-3768.2011.02379.x
   Silverman RF, 2020, OSLI RETINA, V51, P392, DOI 10.3928/23258160-20200702-04
   Stellmann J P, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315596184, DOI 10.1177/2055217315596184
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
   Thomas Merina, 2021, J Vitreoretin Dis, V5, P313, DOI 10.1177/2474126420961957
   Wang J, 2022, BRIT J OPHTHALMOL, V106, P241, DOI 10.1136/bjophthalmol-2020-317615
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Woods RL, 1995, CLIN EXP OPTOM, V78, P43, DOI [10.1111/j.1444-0938.1995.tb00787.x, DOI 10.1111/J.1444-0938.1995.TB00787.X]
NR 36
TC 7
Z9 7
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2022
VL 106
IS 6
BP 839
EP 844
DI 10.1136/bjophthalmol-2020-318494
EA FEB 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1M8DB
UT WOS:000726947700001
PM 33536229
DA 2022-11-30
ER

PT J
AU Cimarolli, VR
   Boerner, K
   Reinhardt, JP
   Horowitz, A
   Wahl, HW
   Schilling, O
   Brennan-Ing, M
AF Cimarolli, Verena R.
   Boerner, Kathrin
   Reinhardt, Joann P.
   Horowitz, Amy
   Wahl, Hans-Werner
   Schilling, Oliver
   Brennan-Ing, Mark
TI A population study of correlates of social participation in older adults
   with age-related vision loss
SO CLINICAL REHABILITATION
LA English
DT Article
DE Aging; social participation; visual impairment; disability; macular
   degeneration
ID MACULAR DEGENERATION; VISUAL IMPAIRMENT; DEPRESSION; DISABILITY; PEOPLE
AB Objective: To examine personal characteristics, disease-related impairment variables, activity limitations, and environmental factors as correlates of social participation in older adults with vision loss guided by the World Health Organization's International Classification of Functioning, Disability and Health Model.
   Design: Baseline data of a larger longitudinal study.
   Setting: Community-based vision rehabilitation agency.
   Subjects: A total of 364 older adults with significant vision impairment due to age-related macular degeneration.
   Main Measures: In-person interviews assessing social participation (i.e. frequency of social support contacts, social/leisure challenges faced due to vision loss, and of social support provided to others) and hypothesized correlates (e.g. visual acuity test, Functional Vision Screening Questionnaire, ratings of attachment to house and neighborhood, environmental modifications in home).
   Results: Regression analyses showed that indicators of physical, social, and mental functioning (e.g. better visual function, fewer difficulties with instrumental activities of daily living, fewer depressive symptoms) were positively related to social participation indicators (greater social contacts, less challenges in social/leisure domains, and providing more support to others). Environmental factors also emerged as independent correlates of social participation indicators when functional variables were controlled. That is, participants reporting higher attachment to their neighborhood and better income adequacy reported having more social contacts; and those implementing more environmental strategies were more likely to report greater challenges in social and leisure domains. Better income adequacy and living with more people were related to providing more social support to others.
   Conclusion: Environmental variables may play a role in the social participation of older adults with age-related macular degeneration.
C1 [Cimarolli, Verena R.; Reinhardt, Joann P.] Jewish Home Lifecare, Res Inst Aging, 120 West 106th St,PH, New York, NY 10025 USA.
   [Boerner, Kathrin] Univ Massachusetts Boston, Dept Gerontol, Boston, MA USA.
   [Reinhardt, Joann P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Horowitz, Amy] Fordham Univ, Grad Sch Social Serv, New York, NY 10023 USA.
   [Wahl, Hans-Werner; Schilling, Oliver] Heidelberg Univ, Dept Psychol Aging Res, Heidelberg, Germany.
   [Brennan-Ing, Mark] Ctr HIV & Aging, ACRIA, New York, NY USA.
   [Brennan-Ing, Mark] NYU, Coll Nursing, New York, NY USA.
C3 University of Massachusetts System; University of Massachusetts Boston;
   Icahn School of Medicine at Mount Sinai; Fordham University; Ruprecht
   Karls University Heidelberg; New York University
RP Cimarolli, VR (通讯作者)，Jewish Home Lifecare, Res Inst Aging, 120 West 106th St,PH, New York, NY 10025 USA.
EM vcimarolli@jewishhome.org
RI Boerner, Kathrin/M-1504-2019
OI Cimarolli, Verena/0000-0003-4551-3531
FU United States National Institute of Mental Health [R01 MH64437]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Study
   participants were drawn from a longitudinal study on coping with vision
   loss in late life, which was funded by the United States National
   Institute of Mental Health [R01 MH64437; A Horowitz, PI]. The study was
   conducted at Lighthouse International, New York, NY, USA.
CR Alma MA, 2011, DISABIL REHABIL, V33, P63, DOI 10.3109/09638288.2010.488711
   Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Boerner K, 2010, J GERONTOL B-PSYCHOL, V65, P22, DOI 10.1093/geronb/gbp098
   Casten R, 2013, OPHTHALMOLOGY AGEING, P207
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Desrosiers J, 2009, DISABIL REHABIL, V31, P1227, DOI 10.1080/09638280802532456
   Hayman KJ, 2007, OPTOMETRY VISION SCI, V84, P1024, DOI 10.1097/OPX.0b013e318157a6b1
   Hickson, 2005, INT J SPEECH-LANG PA, V7, P220, DOI [10.1080/14417040500337088, DOI 10.1080/14417040500337088]
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Law M, 2002, AM J OCCUP THER, V56, P640, DOI 10.5014/ajot.56.6.640
   Levasseur M, 2010, SOC SCI MED, V71, P2141, DOI 10.1016/j.socscimed.2010.09.041
   Liang J, 2001, PSYCHOL AGING, V16, P511, DOI 10.1037//0882-7974.16.3.511
   Lubben J., 2004, SOCIAL NETWORKS SOCI, P20
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Oswald Frank, 2005, Eur J Ageing, V2, P88, DOI 10.1007/s10433-005-0026-5
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pfeiffer E., 1975, MULTIDIMENSIONAL FUN
   Piskur B, 2014, CLIN REHABIL, V28, P211, DOI 10.1177/0269215513499029
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433
   Schilling OK, 2011, PSYCHOL AGING, V26, P203, DOI 10.1037/a0021127
   Stallinga HA, 2014, CLIN REHABIL, V28, P1225, DOI 10.1177/0269215514537092
   Theis KA, 2013, ARTHRIT CARE RES, V65, P1059, DOI 10.1002/acr.21977
   Wahl HW, 2012, GERONTOLOGIST, V52, P306, DOI 10.1093/geront/gnr154
   WAHL HW, 2000, LIGHTHOUSE HDB VISIO, P1069
   World Health Organization, 2001, INT CLASS FUNCT DIS
NR 31
TC 15
Z9 16
U1 4
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
EI 1477-0873
J9 CLIN REHABIL
JI Clin. Rehabil.
PD JAN
PY 2017
VL 31
IS 1
BP 115
EP 125
DI 10.1177/0269215515624479
PG 11
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA EF5XJ
UT WOS:000390402800012
PM 26817810
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Li, X
   Chen, XY
   Cai, ZL
   Zhang, ZR
   Tang, Y
   Chang, TC
   Chen, MS
   Zhang, MX
AF Zhang, Yun
   Li, Xun
   Chen, Xiaoye
   Cai, Zhaolun
   Zhang, Zirong
   Tang, You
   Chang, Tiancong
   Chen, Misha
   Zhang, Meixia
TI Combined therapy and antivascular endothelial growth factor
   monotherapies for polypoidal choroidal vasculopathy A protocol for the
   systematic review and network meta-analysis of efficacy and safety
SO MEDICINE
LA English
DT Review
DE antivascular endothelial growth factor monotherapy; combined therapy;
   network meta-analysis; photodynamic therapy; polypoidal choroidal
   vasculopathy
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; EXPRESSION
AB Background: Different antivascular endothelial growth factor (VEGF) monotherapy regimens and photodynamic therapy (PDT) combined with anti-VEGF therapy are available for patients with polypoidal choroidal vasculopathy (PCV). However, the comparative efficacy and safety of different anti-VEGF monotherapy regimens and combined therapy with PDT and anti-VEGF remains unknown. The aim of our study is to evaluate the efficacy and safety of anti-VEGF monotherapies and combined therapy in patients with PCV.
   Methods: We will systematically search PubMed. Embase, and the Cochrane library for eligible studies. The Cochrane Collaboration's tool for assessing the risk of bias in a randomized trial and the ROBINS-I tool will be used to assess the risk of bias in the included studies. The primary outcome is the mean change in best corrected visual acuity from baseline. The secondary outcomes are the mean change in central retinal thickness from baseline and the number of serious adverse events.
   Results: The result will generate a comprehensive suggestion for the treatment of PCV.
   Conclusion: The results of the network meta-analysis will be submitted in a peer-reviewed journal for publication.
   Ethics and dissemination: The study does not involve human subjects and requires no ethical approval or patient consent. The results of the network meta-analysis will be submitted in a peer-reviewed journal for publication and generate a comprehensive suggestion for the treatment of PCV.
C1 [Zhang, Yun; Li, Xun; Tang, You; Chang, Tiancong; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
   [Chen, Xiaoye] Sichuan Univ, West China Sch Med, Chengdu, Sichuan, Peoples R China.
   [Cai, Zhaolun] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China.
   [Zhang, Zirong] 2 Peoples Hosp Yunnan Prov, Dept Ophthalmol, Kunming, Yunnan, Peoples R China.
   [Chen, Misha] Sichuan Univ, West China Hosp, China Med Technol Transfer Ctr, Dept West, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
EM coretina@gmail.com
RI Cai, Zhaolun/Q-9930-2019; Zhang, meixia/AAH-6247-2019
OI Cai, Zhaolun/0000-0002-3706-6703; 
FU National Nature Science Foundation of China [81271019]; Sichuan
   Provincial Science and Technology Support Project [2015SZ0087]
FX This work is supported by the National Nature Science Foundation of
   China (no. 81271019) and the Sichuan Provincial Science and Technology
   Support Project (no. 2015SZ0087).
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Spaide RF, 1994, RETINA, V15, P100
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   van der Valk R, 2009, J CLIN EPIDEMIOL, V62, P1279, DOI 10.1016/j.jclinepi.2008.04.012
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 29
TC 1
Z9 2
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2018
VL 97
IS 51
AR e13775
DI 10.1097/MD.0000000000013775
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HI3GA
UT WOS:000456334600110
PM 30572531
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cheng, CY
   Wang, NL
   Wong, TY
   Congdon, N
   He, MG
   Wang, YX
   Braithwaite, T
   Casson, RJ
   Cicinelli, MV
   Das, A
   Flaxman, SR
   Jonas, JB
   Keeffe, JE
   Kempen, JH
   Leasher, J
   Limburg, H
   Naidoo, K
   Pesudovs, K
   Resnikoff, S
   Silvester, AJ
   Tahhan, N
   Taylor, HR
   Bourne, RRA
AF Cheng, Ching-Yu
   Wang, Ningli
   Wong, Tien Y.
   Congdon, Nathan
   He, Mingguang
   Wang, Ya Xing
   Braithwaite, Tasanee
   Casson, Robert J.
   Cicinelli, Maria Vittoria
   Das, Aditi
   Flaxman, Seth R.
   Jonas, Jost B.
   Keeffe, Jill Elizabeth
   Kempen, John H.
   Leasher, Janet
   Limburg, Hans
   Naidoo, Kovin
   Pesudovs, Konrad
   Resnikoff, Serge
   Silvester, Alexander J.
   Tahhan, Nina
   Taylor, Hugh R.
   Bourne, Rupert R. A.
CA Global Burden Dis Study
TI Prevalence and causes of vision loss in East Asia in 2015: magnitude,
   temporal trends and projections
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE global burden of disease study; vision loss expert group; vision loss;
   blindness; vision impairment; refractive error; cataract; glaucoma;
   macular degeneration; epidemiology
ID VISUAL IMPAIRMENT; GLOBAL PREVALENCE; CATARACT-SURGERY; BLINDNESS;
   POPULATION; GLAUCOMA; BURDEN; EPIDEMIOLOGY; RANIBIZUMAB; DISTANCE
AB Background
   To determine the prevalence and causes of blindness and vision impairment (VI) in East Asia in 2015 and to forecast the trend to 2020.
   Methods
   Through a systematic literature review and meta-analysis, we estimated prevalence of blindness (presenting visual acuity <3/60 in the better eye), moderate-to-severe vision impairment (MSVI; 3/60 <= presenting visual acuity <6/18), mild vision impairment (mild VI: 6/18 <= presenting visual acuity <6/12) and uncorrected presbyopia for 1990, 2010, 2015 and 2020. A total of 44 population-based studies were included.
   Results
   In 2015, age-standardised prevalence of blindness, MSVI, mild VI and uncorrected presbyopia was 0.37% (80% uncertainty interval (UI) 0.12%-0.68%), 3.06% (80% UI 1.35%-5.16%) and 2.65% (80% UI 0.92%-4.91%), 32.91% (80% UI 18.72%-48.47%), respectively, in East Asia. Cataract was the leading cause of blindness (43.6%), followed by uncorrected refractive error (12.9%), glaucoma, age-related macular degeneration, corneal diseases, trachoma and diabetic retinopathy (DR). The leading cause for MSVI was uncorrected refractive error, followed by cataract, age-related macular degeneration, glaucoma, corneal disease, trachoma and DR. The burden of VI due to uncorrected refractive error, cataracts, glaucoma and DR has continued to rise over the decades reported.
   Conclusions
   Addressing the public healthcare barriers for cataract and uncorrected refractive error can help eliminate almost 57% of all blindness cases in this region. Therefore, public healthcare efforts should be focused on effective screening and effective patient education, with access to high-quality healthcare.
C1 [Cheng, Ching-Yu; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Y.] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Wang, Ningli] Capital Med Univ, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Congdon, Nathan] Zhongshan Ophthalm Ctr, Prevent Ophthalmol, Zhongshan, Guangdong, Peoples R China.
   [Congdon, Nathan] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [He, Mingguang] Univ Melbourne, Ophthalmol Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Wang, Ya Xing] Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Braithwaite, Tasanee; Bourne, Rupert R. A.] Anglia Ruskin Univ, Sch Med, Vis & Eye Res Unit, Chelmsford, Essex, England.
   [Braithwaite, Tasanee] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Casson, Robert J.] Royal Adelaide Hosp, Ophthalmol, Adelaide, SA, Australia.
   [Cicinelli, Maria Vittoria] Univ Vita Salute, San Raffaele Hosp, Dept Ophthalmol, Milan, Italy.
   [Das, Aditi] Leeds Teaching Hosp NHS Trust, Ophthalm Publ Hlth, London, England.
   [Flaxman, Seth R.] Imperial Coll, Dept Math, London, England.
   [Flaxman, Seth R.] Imperial Coll, Data Sci Inst, London, England.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Seegartenklin Heidelberg, Mannheim, Germany.
   [Keeffe, Jill Elizabeth] LV Prasad Eye Inst, Hyderabad, Telangana, India.
   [Kempen, John H.] Univ Penn, Ophthalmol & Epidemiol, Philadelphia, PA 19104 USA.
   [Leasher, Janet] Nova Southeastern Univ, Coll Optometry, HPD, Davie, FL USA.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Naidoo, Kovin] African Vis Res Inst, Durban, South Africa.
   [Pesudovs, Konrad] Pesudovs, Glenelg, SA, Australia.
   [Resnikoff, Serge; Tahhan, Nina] Brien Holden Vis Inst, Sydney, NSW, Australia.
   [Silvester, Alexander J.] Royal Liverpool Univ Hosp, Ophthalmol, Liverpool, Merseyside, England.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat Hlth, Carlton, Vic, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Capital Medical University; Capital
   Medical University; Queens University Belfast; University of Melbourne;
   Capital Medical University; Anglia Ruskin University; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; Royal Adelaide Hospital; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Imperial College London;
   Imperial College London; Ruprecht Karls University Heidelberg; L. V.
   Prasad Eye Institute; University of Pennsylvania; Nova Southeastern
   University; Brien Holden Vision Institute; Royal Liverpool & Broadgreen
   University Hospitals NHS Trust; Royal Liverpool University Hospital;
   University of Liverpool; University of Melbourne
RP Bourne, RRA (通讯作者)，Sch Med, Vis & Eye Res Unit, Cambridge CB1 1PT, England.
EM rb@rupertbourne.co.uk
RI wang, YA XING/K-9671-2016; Cheng, Ching-Yu/Y-2229-2019; Wong, Tien
   Yin/AAC-9724-2020; cicinelli, maria vittoria/M-1611-2019; Tejedor,
   Jaime/G-7728-2015; He, Mingguang/AAY-5239-2020; Braithwaite,
   Tasanee/AAZ-1118-2020
OI wang, YA XING/0000-0003-2749-7793; Cheng, Ching-Yu/0000-0003-0655-885X;
   Wong, Tien Yin/0000-0002-8448-1264; cicinelli, maria
   vittoria/0000-0003-2938-0409; He, Mingguang/0000-0002-6912-2810;
   Braithwaite, Tasanee/0000-0002-3025-4066; Congdon,
   Nathan/0000-0001-9866-3416; Topouzis, Fotis/0000-0002-8966-537X;
   Pesudovs, Konrad/0000-0002-6322-9369; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Dreer, Laura/0000-0002-4728-5467; Kempen,
   John/0000-0002-2967-4792; Gazzard, Gus/0000-0003-1982-5005; Tejedor
   Fraile, Jaime/0000-0001-5507-5622; van Meurs, Joyce/0000-0001-6245-2123
FU Brien Holden Vision Institute; Ulverscroft Foundation (UK); Sight for
   Souls; institutional Research to Prevent Blindness Grant
FX This study was funded by the Brien Holden Vision Institute. The results
   in this paper are prepared independently of the final estimates of the
   Global Burden of Diseases, Injuries and Risk Factors study. NC is
   supported by the Ulverscroft Foundation (UK), JK is supported by an
   institutional Research to Prevent Blindness Grant and Sight for Souls.
CR Bank TW, 2015, RAPID AGING E ASIA P
   Bourne R, 2013, OPHTHAL EPIDEMIOL, V20, P33, DOI 10.3109/09286586.2012.741279
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CCCPC State Council, 2015, GUID OP DEEP SOE REF
   Chan EW, 2016, BRIT J OPHTHALMOL, V100, P78, DOI 10.1136/bjophthalmol-2014-306102
   Department of Economic and Social Affairs, 2015, POP DIV 2015
   Evans JR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005023.pub3
   Fenwick EK, 2016, JAMA OPHTHALMOL, V134, P1087, DOI 10.1001/jamaophthalmol.2016.2394
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gelman A, 2014, TEXTS STAT SCI, V3rd
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   IAPB Vision Atlas, 2017, GLOBAL VISION DATABA
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Ma XC, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5740
   Ministry of Education of the People's Republic of China, 2018, NAT PLAN COMPR PREV
   National Bureau of Statistics of China, STAT BAS MED INS SYS
   Ren Xue-tao, 2015, Chinese Medical Sciences Journal, V30, P1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabanayagam C, 2016, OPHTHAL EPIDEMIOL, V23, P209, DOI 10.1080/09286586.2016.1193618
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wolfs RCW, 2000, INVEST OPHTH VIS SCI, V41, P3309
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang GJ, 2014, LANCET INFECT DIS, V14, P881, DOI 10.1016/S1473-3099(14)70727-3
   Yang WY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22590
   Yi HM, 2015, AM J OPHTHALMOL, V160, P889, DOI 10.1016/j.ajo.2015.08.006
   Zhang MZ, 2011, OPHTHAL EPIDEMIOL, V18, P179, DOI 10.3109/09286586.2011.580884
   Zhao J L, 2018, Zhonghua Yan Ke Za Zhi, V54, P561, DOI 10.3760/cma.j.issn.0412-4081.2018.08.001
NR 37
TC 19
Z9 27
U1 2
U2 26
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2020
VL 104
IS 5
BP 616
EP 622
DI 10.1136/bjophthalmol-2018-313308
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2KF
UT WOS:000531384100005
PM 31462416
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Raisler, BJ
   Berns, KI
   Grant, MB
   Beliaev, D
   Hauswirth, WW
AF Raisler, BJ
   Berns, KI
   Grant, MB
   Beliaev, D
   Hauswirth, WW
TI Adeno-associated virus type-2 expression of pigmented epithelium-derived
   factor or Kringles 1-3 of angiostatin reduce retinal neovascularization
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; INDUCED RETINOPATHY;
   GENE-TRANSFER; TUMOR-GROWTH; VERTEPORFIN; INHIBITOR
AB Neovascular diseases of the retina include age-related macular degeneration and diabetic retinopathy, and together they comprise the leading causes of adult-onset blindness in developed countries. Current surgical, pharmaceutical, and laser therapies for age-related macular degeneration (AMD) rarely result in improved vision, do not significantly prevent neovascularization (NV), and often result in at least some vision loss. To address this therapeutic gap, we determined the efficacy of recombinant adeno-associated viral (rAAV) serotype-2-mediated expression of pigment epithelium-derived factor (PEDF) or Kringle domains 1-3 of angiostatin (K1K3) in reducing aberrant vessel formation in a mouse model of ischemia-induced retinal NV. Both PEDF and K1K3 are potent inhibitors of NV when injected directly, hence expression of these therapeutic factors from rAAV may provide long-term protection from neovascular eye disease. rAAV vectors expressing the therapeutic gene were injected into one eye of postnatal day 0 (PO) newborn mouse pups. Retinal NV was induced in P7 mice by exposure to elevated oxygen for 5 days followed by room air for another five days. Retinal NV was quantified by the number of vascular-endothelial-cell nuclei above the inner-limiting membrane in P17 eyes. The number of such vascular endothelial cell nuclei in eyes treated with rAAV-PEDF or rAAV-K1K3 was significantly reduced (both P < 0.0000002) compared with control eyes. Ocular protein levels detected by ELISA correlate well with the reduction in NV and confirm that expression of antineovascular agents from rAAV vectors may be a therapeutically useful treatment of retinal or choroidal neovascular disease.
C1 Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida
RP Hauswirth, WW (通讯作者)，Univ Florida, Dept Ophthalmol, Box 1002984, Gainesville, FL 32610 USA.
EM hauswrth@eye1.eye.ufl.edu
RI Beliaev, Denis/AAU-9545-2021
OI Beliaev, Denis/0000-0001-6954-4602
FU NEI NIH HHS [T32 EY007043, U10 EY013729, R01 EY011123, EY11123,
   T32EY07043, EY13729] Funding Source: Medline; NINDS NIH HHS [P01
   NS036302, NS36302] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY011123, U10EY013729, T32EY007043] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036302]
   Funding Source: NIH RePORTER
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.0.CO;2-F
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   Bennett J, 1997, INVEST OPHTH VIS SCI, V38, P2857
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Boulanger A, 2000, J BIOL CHEM, V275, P31274, DOI 10.1074/jbc.M003441200
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dogru M, 1999, JPN J OPHTHALMOL, V43, P217, DOI 10.1016/S0021-5155(99)00006-4
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P929
   Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743
   Kirsch M, 2000, J NEURO-ONCOL, V50, P173, DOI 10.1023/A:1006453428013
   Ladd BS, 2001, AM J OPHTHALMOL, V132, P659, DOI 10.1016/S0002-9394(01)01198-9
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lamkin J C, 1994, Semin Ophthalmol, V9, P10, DOI 10.3109/08820539409060253
   Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1
   Le D, 1994, Semin Ophthalmol, V9, P2, DOI 10.3109/08820539409060252
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lucas R, 1998, BLOOD, V92, P4730
   Luke C, 2001, BRIT J OPHTHALMOL, V85, P928, DOI 10.1136/bjo.85.8.928
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Meneses PI, 2001, GENE THER, V8, P646, DOI 10.1038/sj.gt.3301423
   Mino RP, 2001, INVEST OPHTH VIS SCI, V42, P3320
   Mokdad AH, 2001, DIABETES CARE, V24, P412, DOI 10.2337/diacare.24.2.412
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   MORI K, 2002, IN PRESS INVEST OPHT
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   Penn JS, 1996, MICROVASC RES, V51, P126, DOI 10.1006/mvre.1996.0014
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Smiddy WE, 1999, SURV OPHTHALMOL, V43, P491, DOI 10.1016/S0039-6257(99)00036-3
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384
   Spranger J, 2001, EXP CLIN ENDOCR DIAB, V109, pS438, DOI 10.1055/s-2001-18601
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 48
TC 106
Z9 127
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 25
PY 2002
VL 99
IS 13
BP 8909
EP 8914
DI 10.1073/pnas.122247299
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 567GZ
UT WOS:000176478200079
PM 12072560
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Grechenig, C
   Reiter, GS
   Riedl, S
   Arnold, J
   Guymer, R
   Gerendas, BS
   Bogunovic, H
   Schmidt-Erfurth, U
AF Grechenig, Christoph
   Reiter, Gregor S.
   Riedl, Sophie
   Arnold, Jennifer
   Guymer, Robyn
   Gerendas, Bianca S.
   Bogunovic, Hrvoje
   Schmidt-Erfurth, Ursula
TI IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A
   SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; artificial intelligence; fluid
   quantification; optical coherence tomography; subretinal fluid;
   treatment outcomes
ID PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; VISUAL-ACUITY;
   GEOGRAPHIC ATROPHY; RANIBIZUMAB; MORPHOLOGY; RELEVANT; THERAPY; RISK
AB Purpose: To investigate associations between residual subretinal fluid (rSRF) volumes, quantified using artificial intelligence and treatment outcomes in a subretinal fluid (SRF)-tolerant treat-and-extend (T&E) regimen in neovascular age-related macular degeneration.
   Methods: Patients enrolled in the prospective, multicenter FLUID study randomized in an SRF-tolerant T&E regimen were examined by spectral-domain optical coherence tomography and tested for best-corrected visual acuity (BCVA). Intraretinal fluid and SRF volumes were quantified using artificial intelligence tools. In total, 375 visits of 98 patients were divided into subgroups: extended intervals despite rSRF and extended intervals without fluid. Associations between BCVA change, SRF volume, subgroups, and treatment intervals were estimated using linear mixed models.
   Results: In extended intervals despite rSRF, increased SRF was associated with reduced BCVA at the next visit in the central 1 mm (-0.138 letters per nL; P = 0.014) and 6 mm (-0.024 letters per nL; P = 0.049). A negative association between increased interval and BCVA change was found for rSRF in 1 mm and 6 mm (-0.250 and -0.233 letter per week interval, respectively; both P<0.001). Extended intervals despite rSRF had significantly higher SRF volumes in the central 6 mm at the following visit (P = 0.002).
   Conclusion: Artificial intelligence-based analysis of extended visits despite rSRF demonstrated increasing SRF volumes associated with BCVA loss at the consecutive visit. This negative association contributes to the understanding of rSRF volumes on treatment outcomes in neovascular age-related macular degeneration.
C1 [Grechenig, Christoph; Reiter, Gregor S.; Riedl, Sophie; Gerendas, Bianca S.; Bogunovic, Hrvoje; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, Australia.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 Medical University of Vienna; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Reiter, Gregor/0000-0001-7661-4015
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Vogl WD, 2017, INVEST OPHTH VIS SCI, V58, P4173, DOI 10.1167/iovs.17-21878
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
NR 28
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2021
VL 41
IS 11
BP 2221
EP 2228
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB6BH
UT WOS:000756924700005
PM 33830960
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Smith, ND
   Crabb, DP
AF Taylor, Deanna J.
   Smith, Nicholas D.
   Crabb, David P.
TI Searching for Objects in Everyday Scenes: Measuring Performance in
   People With Dry Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; search; visual
   search
ID SEVERE VISUAL IMPAIRMENT; EYE-MOVEMENTS; GEOGRAPHIC ATROPHY; LOW-VISION;
   FOVEAL VISION; SCOTOMAS; REHABILITATION; CLASSIFICATION; POPULATION;
   GLAUCOMA
AB PURPOSE. Treatment success in clinical trials for AMD would ideally be aligned to measurable performance in visual tasks rather than imperceptible changes on clinical charts. We test the hypothesis that patients with dry AMD perform worse than visually healthy peers on computer-based surrogates of "real-world'' visual search tasks.
   METHODS. A prospective case-control study was conducted in which patients with dry AMD performed a computer-based "real-world'' visual search task. Participants searched for targets within images of everyday scenes while eye movements were recorded. Average search times across the images were recorded as a primary outcome measure. Comparisons were made against a 90% normative limit established in peers with healthy vision (controls). Eye movement parameters were examined as a secondary outcome measure.
   RESULTS. Thirty-one patients and 33 controls with median (interquartile range) age of 75 (70-79) and 71 (66-75) years and logMAR binocular visual acuity 0.2 (0.18-0.31) and -0.06 (-0.12 to 0), respectively, were examined. Four, 18, and 9 patients were categorized as having early, intermediate, and late AMD, respectively. Nineteen (61%) patients exceeded the 90% normative limits for average search time; this was statistically significant (Fisher's exact test, P < 0.0001). On average, patients made smaller saccades than controls (P < 0.001).
   CONCLUSIONS. People with dry AMD, certainly those with advanced disease, are likely to have measurable difficulties beyond those observed in visually healthy peers on "real-world'' search tasks. Further work might establish this type of task as a useful outcome measure for clinical trials.
C1 [Taylor, Deanna J.; Smith, Nicholas D.; Crabb, David P.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
C3 City University London
RP Crabb, DP (通讯作者)，City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM david.crabb.1@city.ac.uk
OI Crabb, David/0000-0001-8754-3902; Taylor, Deanna/0000-0001-8261-5225
FU Roche Products Ltd UK
FX Supported by part of an unrestricted investigator-initiated research
   grant from Roche Products Ltd UK.
CR BERTERA JH, 1988, INVEST OPHTH VIS SCI, V29, P470
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Coeckelbergh TRM, 2002, VISION RES, V42, P669, DOI 10.1016/S0042-6989(01)00297-8
   Cornelissen FW, 2005, OPTOMETRY VISION SCI, V82, P27
   Crabb DP, 2013, OPHTHALMOLOGY, V120, P1120, DOI 10.1016/j.ophtha.2012.11.043
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Dougherty BE, 2009, OPTOMETRY VISION SCI, V86, P955, DOI 10.1097/OPX.0b013e3181b180a6
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   FORD A, 1959, J OPT SOC AM, V49, P287, DOI 10.1364/JOSA.49.000287
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   Fuhr PS, 2007, OPTOMETRY VISION SCI, V84, P393, DOI 10.1097/OPX.0b013e31804f5afb
   Geringswald F, 2013, J VISION, V13, DOI 10.1167/13.3.28
   Geringswald F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00134
   Harvey H, 2014, VISION RES, V98, P54, DOI 10.1016/j.visres.2014.03.009
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hulleman J, 2017, BEHAV BRAIN SCI, V40, P1, DOI 10.1017/S0140525X15002794
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   MacKeben M, 2011, INVEST OPHTH VIS SCI, V52, P7603, DOI 10.1167/iovs.10-6728
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McGwin G, 1998, ACCIDENT ANAL PREV, V30, P781, DOI 10.1016/S0001-4575(98)00031-1
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   MURPHY KS, 1988, OPHTHAL PHYSL OPT, V8, P345, DOI 10.1111/j.1475-1313.1988.tb01065.x
   MURPHY KS, 1989, OPHTHAL PHYSL OPT, V9, P317, DOI 10.1111/j.1475-1313.1989.tb00915.x
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schoonjans F, 2011, EPIDEMIOLOGY, V22, P750, DOI 10.1097/EDE.0b013e318225c1de
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Smith ND, 2011, OPHTHAL PHYSL OPT, V31, P225, DOI 10.1111/j.1475-1313.2011.00836.x
   Smits N, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-4
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Thibaut M, 2016, J FR OPHTALMOL, V39, P82, DOI 10.1016/j.jfo.2015.08.010
   Van der Stigchel S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00579
NR 38
TC 14
Z9 14
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1887
EP 1892
DI 10.1167/iovs.16-21122
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000067
PM 28358960
OA Green Submitted, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Kim, SY
   Sadda, S
   Humayun, MS
   De Juan, E
   Melia, BM
   Green, WR
AF Kim, SY
   Sadda, S
   Humayun, MS
   De Juan, E
   Melia, BM
   Green, WR
TI Morphometric analysis of the macula in eyes with geographic atrophy due
   to age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (ARMD); ganglion cell layer (GCL);
   geographic atrophy (GA); inner nuclear layer (INL); morphometric
   analysis; outer nuclear layer (ONL); retinal pigment epithelium (RPE)
   cell
ID RETINAL-PIGMENT EPITHELIUM; PRESERVATION
AB Purpose: To evaluate the extent of neural cell death in eyes with geographic atrophy (GA).
   Methods: Ten eyes with GA and five age-matched control eyes were selected for morphometric analysis. The nuclei of the ganglion cell, inner nuclear, and outer nuclear layers were counted in contiguous 100-mum segments from 1,500 mum nasal to 1,500 mum temporal to the fovea.
   Results: The outer nuclear layer was most severely attenuated in eyes with GA, demonstrating a 76.9% reduction relative to control eyes (P < 0.0001). A significant loss of ganglion cells (by 30.7%) was also observed (P = 0.0008). There was no significant difference in the inner nuclear layer cells (P = 0.30). Among the GA eyes, the nuclei in all three layers were significantly reduced in segments in which the retinal pigment epithelium was completely absent (P less than or equal to 0.0003).
   Conclusion: Although the nuclei of the outer nuclear layer in eyes with GA were markedly attenuated, the nuclei of the inner nuclear layer were relatively preserved. There was also a significant reduction in ganglion cells in GA eyes, but considerable numbers remained even in the areas of complete retinal pigment epithelium atrophy. This finding suggests that therapies aimed at replacing outer nuclear function (such as neural retinal and retinal pigment epithelium transplantation or implantation of the intraocular retinal prosthesis) may be feasible for restoring vision in these patients.
C1 Johns Hopkins Univ Hosp, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
   Johns Hopkins Univ Hosp, Sch Med, Wilmer Biostat Ctr, Baltimore, MD 21287 USA.
   Johns Hopkins Univ Hosp, Sch Med, Dept Pathol, Baltimore, MD 21287 USA.
   Univ So Calif, Sch Med, Retina Inst, Los Angeles, CA USA.
   Univ So Calif, Sch Med, Doheny Eye Inst, Los Angeles, CA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Medicine; University of Southern California; Doheny Eye
   Institute; University of Southern California
RP Sadda, S (通讯作者)，Johns Hopkins Univ Hosp, Sch Med, Wilmer Ophthalmol Inst, Maumenee 215,600 N Wolfe St, Baltimore, MD 21287 USA.
EM ssadda@jhmi.edu
CR Adler R, 1999, MOL VIS, V5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DACEY DM, 1990, J COMP NEUROL, V301, P461, DOI 10.1002/cne.903010310
   del Cerro M, 2000, INVEST OPHTH VIS SCI, V41, P3142
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FISHER SK, 1991, INVEST OPHTH VIS SCI, V32, P1739
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P515
   Kim SY, 2001, INVEST OPHTH VIS SCI, V42, pS228
   KOBAYASHI A, 2001, INVEST OPHTH VIS SCI, V41, P3268
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Milam AH, 1995, DEGENERATIVE DISEASES OF THE RETINA, P275
   NEWMAN NM, 1987, BRIT J OPHTHALMOL, V71, P21, DOI 10.1136/bjo.71.1.21
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS, V1st ed., P3, DOI [10.1007/978-1-4419-0318-1_1, DOI 10.1007/0-387-22747-4_1]
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SNEDECOR GW, 1989, STAT METHODS, P142
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEILAND JD, 2000, GRAEFES ARCH CLIN EX, V238, P315
   WILLERSON D, 1978, BRIT J OPHTHALMOL, V62, P551, DOI 10.1136/bjo.62.8.551
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 29
TC 66
Z9 72
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2002
VL 22
IS 4
BP 464
EP 470
DI 10.1097/00006982-200208000-00011
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583XT
UT WOS:000177437200011
PM 12172114
DA 2022-11-30
ER

PT J
AU Told, R
   Palkovits, S
   Haslacher, H
   Frantal, S
   Schmidl, D
   Boltz, A
   Lasta, M
   Kaya, S
   Werkmeister, RM
   Garhofer, G
   Schmetterer, L
AF Told, Reinhard
   Palkovits, Stefan
   Haslacher, Helmuth
   Frantal, Sophie
   Schmidl, Doreen
   Boltz, Agnes
   Lasta, Michael
   Kaya, Semira
   Werkmeister, Rene M.
   Garhoefer, Gerhard
   Schmetterer, Leopold
TI Alterations of Choroidal Blood Flow Regulation in Young Healthy Subjects
   with Complement Factor H Polymorphism
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; HY402H GENE POLYMORPHISM; MACULAR DEGENERATION;
   ISOMETRIC-EXERCISE; MYOCARDIAL-INFARCTION; FOVEAL REGION; RISK-FACTORS;
   ACTIVATION; AMD; NEOVASCULARIZATION
AB A common polymorphism in the complement factor H gene (rs1061170, Y402H) is associated with a high risk of age-related macular degeneration (AMD). In the present study we hypothesized that healthy young subjects homozygous for the high-risk haplotype (CC) show abnormal choroidal blood flow (ChBF) regulation decades before potentially developing the disease. A total of 100 healthy young subjects were included in the present study, of which 4 subjects were excluded due to problems with genotyping or blood flow measurements. ChBF was measured continuously using laser Doppler flowmetry while the subjects performed isometric exercise (squatting) for 6 minutes. The increase in ChBF was less pronounced than the response in ocular perfusion pressure (OPP), indicating for some degree of choroidal blood flow regulation. Eighteen subjects were homozygous for C, 47 subjects were homozygous for T and 31 subjects were heterozygous (CT). The increase in OPP during isometric exercise was not different between groups. By contrast the increase in ChBF was more pronounced in subjects homozygous for the high risk C allele (p = 0.041). This was also evident from the pressure/flow relationship, where the increase in ChBF in homozygous C carriers started at lower OPPs as compared to the other groups. Our data indicate that the regulation of ChBF is abnormal in rs1061170 CC carriers. So far this polymorphism has been linked to age related macular degeneration (AMD) mainly via inflammatory pathways associated with the complement system dysfunction. Our results indicate that it could also be related to vascular factors that have been implicated in AMD pathogenesis.
C1 [Told, Reinhard; Palkovits, Stefan; Schmidl, Doreen; Boltz, Agnes; Lasta, Michael; Kaya, Semira; Garhoefer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Haslacher, Helmuth] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Told, Reinhard; Boltz, Agnes; Werkmeister, Rene M.; Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Frantal, Sophie] Med Univ Vienna, Ctr Med Stat Informat & Intelligence Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
RI H, Haslacher/D-4233-2013
OI H, Haslacher/0000-0003-4605-2503; Told, Reinhard/0000-0003-2046-7081;
   Schmidl, Doreen/0000-0001-5664-7768; Schmetterer,
   Leopold/0000-0002-7189-1707
FU Austrian Science Fund (FWF) [P 21406]
FX This study was supported by the Austrian Science Fund (FWF, project P
   21406). The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Boltz A, 2010, SPEKTRUM AUGENHEILKD, V24, P296, DOI 10.1007/s00717-010-0445-3
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen J, 2012, NAT MED, V18, P658, DOI 10.1038/nm.2761
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Fuchsjager-Mayrl G, 2003, INVEST OPHTH VIS SCI, V44, P728, DOI 10.1167/iovs.02-0372
   Geiser MH, 1999, KLIN MONATSBL AUGENH, V214, P285, DOI 10.1055/s-2008-1034795
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jylhava J, 2009, CLIN EXP IMMUNOL, V155, P53, DOI 10.1111/j.1365-2249.2008.03752.x
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Luksch A, 2003, INVEST OPHTH VIS SCI, V44, P734, DOI 10.1167/iovs.02-0177
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Polska E, 2003, MICROVASC RES, V65, P39, DOI 10.1016/S0026-2862(02)00010-9
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmidl D, 2011, EXP EYE RES, V93, P141, DOI 10.1016/j.exer.2010.09.002
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WOLZT M, 1995, BRIT J CLIN PHARMACO, V39, P347, DOI 10.1111/j.1365-2125.1995.tb04462.x
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 52
TC 14
Z9 15
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 15
PY 2013
VL 8
IS 4
AR e60424
DI 10.1371/journal.pone.0060424
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 125TD
UT WOS:000317563300005
PM 23596508
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wu, TH
   Tian, J
   Cutler, RG
   Telljohann, RS
   Bernlohr, DA
   Mattson, MP
   Handa, JT
AF Wu, Tinghuai
   Tian, Jane
   Cutler, Roy G.
   Telljohann, Richard S.
   Bernlohr, David A.
   Mattson, Mark P.
   Handa, James T.
TI Knockdown of FABP5 mRNA decreases cellular cholesterol levels and
   results in decreased apoB100 secretion and triglyceride accumulation in
   ARPE-19 cells
SO LABORATORY INVESTIGATION
LA English
DT Article
DE apoB; cholesterol; FABP5; RPE; siRNA; triglycerides
ID ACID-BINDING PROTEIN; LOW-DENSITY-LIPOPROTEIN; INHERITED RETINAL
   DYSTROPHY; PIGMENT EPITHELIAL-CELLS; FATTY-ACID; KNOCKOUT MICE; HEPG2
   CELLS; RAT-LIVER; RCS RAT; GENE
AB To maintain normal retinal function, retinal pigment epithelial (RPE) cells engulf photoreceptor outer segments (ROS) enriched in free fatty acids (FFAs). We have previously demonstrated fatty acid-binding protein 5 (FABP5) downregulation in the RPE/choroidal complex in a mouse model of aging and early age-related macular degeneration. FABPs are involved in intracellular transport of FFAs and their targeting to specific metabolic pathways. To elucidate the role of FABP5 in lipid metabolism, the production of the FABP5 protein in a human RPE cell line was inhibited using RNA interference technology. As a result, the levels of cholesterol and cholesterol ester were decreased by about 40%, whereas FFAs and triglycerides were increased by 18 and 67% after siRNA treatment, respectively. Some species of phospholipids were decreased in siRNA-treated cells. Cellular lipid droplets were evident and apoB secretion was decreased by 76% in these cells. Additionally, we discovered that ARPE-19 cells could synthesize and secrete Apolipoprotein B100 (apoB100), which may serve as a backbone structure for the formation of lipoprotein particles in these cells. Our results indicate that FABP5 mRNA knockdown results in the accumulation of cellular triglycerides, decreased cholesterol levels, and reduced secretion of apoB100 protein and lipoprotein-like particles. These observations indicated that FABP5 plays a critical role in lipid metabolism in RPE cells, suggesting that FABP5 downregulation in the RPE/choroid complex in vivo might contribute to aging and early age-related macular degeneration. Laboratory Investigation (2010) 90, 906-914; doi:10.1038/labinvest.2009.33; published online 11 May 2009
C1 [Wu, Tinghuai; Tian, Jane; Handa, James T.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Cutler, Roy G.; Telljohann, Richard S.; Mattson, Mark P.] Natl Inst Aging Intramural Res Program, Neurosci Lab, Baltimore, MD USA.
   [Bernlohr, David A.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); University of
   Minnesota System; University of Minnesota Twin Cities
RP Wu, TH (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
EM tingwu@jhmi.edu
RI Mattson, Mark P/F-6038-2012; Cutler, Roy G./L-5572-2013; Telljohann,
   Richard/ABF-1207-2021
FU NEI EY [14005]; AHAF Macular Degeneration Grant; Research to Prevent
   Blindness Clinician Scientist award; RPB grant; National Insitute on
   Aging [DK053189]; NATIONAL EYE INSTITUTE [R01EY014005, R01EY019904]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [R01DK053189, R56DK053189] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000317] Funding Source:
   NIH RePORTER
FX This work was supported by NEI EY 14005 (JTH), an AHAF Macular
   Degeneration Grant (JTH), a Research to Prevent Blindness Clinician
   Scientist award (JTH), an unrestricted RPB grant, the Intramural
   Research Program of the National Insitute on Aging, DK053189 (DAB), and
   gifts from Ric and Sandy Forsythe, The Kwok family the Merlau family,
   and Aleda Wright.
CR Atshaves BP, 2004, J BIOL CHEM, V279, P30954, DOI 10.1074/jbc.M313571200
   Avramoglu RK, 1995, J LIPID RES, V36, P2513
   Bisgaier CL, 1997, J LIPID RES, V38, P2502
   BOREN J, 1994, J BIOL CHEM, V269, P25879
   Coe NR, 1999, J LIPID RES, V40, P967
   Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6
   Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   FORTE TM, 1986, METHOD ENZYMOL, V128, P442
   FRANCONE OL, 1992, AM J PHYSIOL, V263, pE615, DOI 10.1152/ajpendo.1992.263.4.E615
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gibbons GF, 2003, PROG LIPID RES, V42, P479, DOI 10.1016/S0163-7827(03)00034-1
   Gilham D, 2005, MOL BIOL CELL, V16, P984, DOI 10.1091/mbc.e04-03-0224
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Hara H, 1999, J NUTR, V129, P942, DOI 10.1093/jn/129.5.942
   Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001
   Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Johnson MC, 2006, VET IMMUNOL IMMUNOP, V110, P357, DOI 10.1016/j.vetimm.2005.12.007
   Kang S, 2000, BBA-MOL CELL BIOL L, V1529, P223, DOI 10.1016/S1388-1981(00)00151-7
   KHAN B, 1989, BIOCHEM J, V258, P807, DOI 10.1042/bj2580807
   KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7
   Kingma PB, 1998, BIOCHEMISTRY-US, V37, P3250, DOI 10.1021/bi972520l
   KVILEKVAL K, 1994, J LIPID RES, V35, P1786
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Liao JF, 2005, J LIPID RES, V46, P597, DOI 10.1194/jlr.D400023-JLR200
   Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749
   Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   McMillian MK, 2001, IN VITRO MOL TOXICOL, V14, P177, DOI 10.1089/109793301753407948
   Moss EG, 2003, NAT CELL BIOL, V5, P771, DOI 10.1038/ncb0903-771
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Murphy EJ, 2004, J BIOL CHEM, V279, P34481, DOI 10.1074/jbc.M314263200
   Newberry EP, 2006, HEPATOLOGY, V44, P1191, DOI 10.1002/hep.21369
   Owada Y, 2002, MOL CELL BIOCHEM, V239, P83, DOI 10.1023/A:1020524621933
   Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193
   Simpson MA, 1999, MOL CELL BIOCHEM, V192, P33, DOI 10.1023/A:1006819715146
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Vassileva G, 2000, FASEB J, V14, P2040, DOI 10.1096/fj.99-0959com
   VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wu TH, 2003, BRAIN RES, V967, P19, DOI 10.1016/S0006-8993(02)04125-2
   Zhang YL, 2004, J BIOL CHEM, V279, P19362, DOI 10.1074/jbc.M400220200
   Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y
NR 46
TC 11
Z9 11
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JUN
PY 2010
VL 90
IS 6
BP 906
EP 914
DI 10.1038/labinvest.2009.33
PG 9
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 601UV
UT WOS:000278091300009
PM 19434059
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Lee, PP
   Feldman, ZW
   Ostermann, J
   Brown, DS
   Sloan, FA
AF Lee, PP
   Feldman, ZW
   Ostermann, J
   Brown, DS
   Sloan, FA
TI Longitudinal prevalence of major eye diseases
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; OPEN-ANGLE GLAUCOMA; AGE-RELATED MACULOPATHY; 10-YEAR
   FOLLOW-UP; DIABETIC-RETINOPATHY; 5-YEAR INCIDENCE; VISUAL-ACUITY; OCULAR
   DISEASE; POPULATION; MELLITUS
AB Objective: To describe the prevalence across time of 3 chronic eye diseases among a representative cohort of elderly subjects.
   Study Design: Longitudinal observation of Medicare claims.
   Population: A random sample of Medicare beneficiaries 65 years and older, nationally representative at baseline.
   Main Outcome Measures: Diagnosis of diabetic retinopathy, glaucoma, and age-related macular degeneration.
   Methods: Beneficiaries were followed from 1991 to 1999 unless mortality or enrollment in a health maintenance organization for 6 or more months in a year intervened. Claims data were analyzed for the presence of codes from the International Classification of Diseases, Ninth Revision, Clinical Modification, indicating 1 of the 3 conditions. Transitions between severity stages were also evaluated.
   Results: Of 20325 beneficiaries in 1991, 10476 were available for analysis in 1999. The prevalence of diabetes mellitus increased from 14.5% in 1991 to 25.6% by 1999, with diabetic retinopathy among persons with diabetes mellitus increasing from 6.9% to 17.4%. Primary open-angle glaucoma increased from 4.6% to 13.8%. The percentage of glaucoma suspects increased from 1.5% to 6.5%, as did the percentage of narrow-angle glaucoma (0.7%-2.7%). The prevalence of age-related macular degeneration increased from 5.0% to 27.1%. Overall, the proportion of subjects with at least 1 of these 3 diseases increased from 13.4% to 45.4%.
   Conclusions: The clinical diagnosis of major chronic eye diseases associated with aging increased dramatically in a longitudinal sample. At the end of 9 years, nearly half of the surviving Medicare beneficiaries had at least 1 of these diseases.
C1 Duke Univ, Ctr Hlth Policy Law & Management, Durham, NC 27708 USA.
   Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.
   Duke Univ, Dept Econ, Durham, NC 27708 USA.
C3 Duke University; Duke University; Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Ctr Hlth Policy Law & Management, Box 90253, Durham, NC 27708 USA.
RI Brown, Derek S/J-3035-2013; Ostermann, Jan/GQB-4743-2022
OI Brown, Derek S/0000-0001-9908-9882; Ostermann, Jan/0000-0002-8236-9500;
   Lee, Paul/0000-0002-3338-136X
FU NATIONAL INSTITUTE ON AGING [R01AG017473] Funding Source: NIH RePORTER;
   NIA NIH HHS [1R01-AG-17473] Funding Source: Medline
CR AGARDH E, 1994, DIABETIC MED, V11, P273, DOI 10.1111/j.1464-5491.1994.tb00271.x
   Blanchard JF, 1996, DIABETES CARE, V19, P807, DOI 10.2337/diacare.19.8.807
   Bohn RL, 2000, J GLAUCOMA, V9, P38
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   CHEN MS, 1995, INT J EPIDEMIOL, V24, P787, DOI 10.1093/ije/24.4.787
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Giansanti R, 1994, Diabetes Res, V25, P77
   Guillausseau PJ, 1998, DIABETIC MED, V15, P151, DOI 10.1002/(SICI)1096-9136(199802)15:2<151::AID-DIA527>3.3.CO;2-9
   Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518
   Hiller R, 1999, AM J OPHTHALMOL, V128, P440, DOI 10.1016/S0002-9394(99)00187-7
   Hirvela H, 1997, BRIT J OPHTHALMOL, V81, P214, DOI 10.1136/bjo.81.3.214
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1469, DOI 10.1001/archopht.1993.01090110027013
   JENSEN JE, 1984, ACTA OPHTHALMOL, V62, P203
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1487
   KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P58
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Lovestam-Adrian M, 2001, J DIABETES COMPLICAT, V15, P287, DOI 10.1016/S1056-8727(01)00167-2
   Maciejewski ML, 2001, HEALTH SERV RES, V35, P1245
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   MASON RP, 1989, OPHTHALMOLOGY, V96, P1363
   MIHARA T, 1983, Tohoku Journal of Experimental Medicine, V141, P661
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   MITCHELL RA, 1993, J EPIDEMIOL COMMUN H, V47, P42, DOI 10.1136/jech.47.1.42
   PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P179, DOI 10.1136/bjo.57.3.179
   PUGH JA, 1993, DIABETES CARE, V16, P889, DOI 10.2337/diacare.16.6.889
   Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   SCHAPPER.J, 1971, OPHTHALMOLOGICA, V162, P289, DOI 10.1159/000306295
   SLOAN FA, IN PRESS ARCH OPHTHA
   SORENSEN N, 1978, ACTA OPHTHALMOL, V56, P363
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   *US CENS BUR, 2002, NAT POP PROJ SUMM TA
   *US GAO, 1997, 97160 GAOHEHS
   Voutilainen-Kaunisto RM, 2001, J DIABETES COMPLICAT, V15, P24, DOI 10.1016/S1056-8727(00)00126-4
NR 45
TC 103
Z9 173
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2003
VL 121
IS 9
BP 1303
EP 1310
DI 10.1001/archopht.121.9.1303
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 721QT
UT WOS:000185327600011
PM 12963614
DA 2022-11-30
ER

PT J
AU Barchichat, I
   Thiel, M
   Job, O
   Schmid, M
AF Barchichat, Ilan
   Thiel, Michael
   Job, Oliver
   Schmid, Martin
TI Bilateral blindness after uneventful brolucizumab injection for macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Brolucizumab; Panuveitis; Perineural inflammation; Vasculitis; Bilateral
   blindness
ID INTRAVITREAL AFLIBERCEPT INJECTION; ANTIBODY FRAGMENT
AB Background: We report a very severe case of bilateral panuveitis and ischemic vasculitis with possible perineural inflammation, which followed bilateral intravitreal brolucizumab administration in a patient with neovascular age-related macular degeneration (nAMD).
   Case presentation: On December 11, 2020, a 81-year-old woman presented with severe bilateral loss of vision. Eight days earlier, she had received uneventful bilateral injection of brolucizumab, a novel anti-vascular endothelial growth factor (VEGF) single-chain variable region (scFv) recombinant protein drug, for treatment of neovascular age-related macular degeneration (nAMD).
   Slit-lamp examination revealed signs of a bilateral panocular vasculitis with ischemia. Scanning laser ophthalmoscopy of her left eye revealed marked vascular sheathing.
   T1 fat-saturated post-contrast images of the orbit revealed a higher-than-normal signal of the choroid, with localized choroidal detachment. Additionally, pathologic enhancement was visible around the optic nerve in the orbit, which was interpreted as vasculitis. Due to the severe bilateral panuveitis with vasculitis, an additional vitreous tap was obtained, which revealed elevated levels of interleukin six and interleukin ten.
   Conclusions: To our knowledge, this is the first documented case showing both panuveitis and ischemic vasculitis with possible perineural inflammation. We do not recommend performing bilateral brolucizumab injections until more data is available regarding the mechanism of brolucizumab-induced vasculitis. From a clinical point of view, we find it difficult to justify the use of brolucizumab when there are other well-known agents, such as ranibizumab and aflibercept, which have better safety profiles and comparable efficacy.
C1 [Barchichat, Ilan; Thiel, Michael; Job, Oliver; Schmid, Martin] Cantonal Hosp Lucerne, Dept Ophthalmol, Spitalstr, CH-6000 Luzern, Switzerland.
C3 Lucerne Cantonal Hospital
RP Barchichat, I (通讯作者)，Cantonal Hosp Lucerne, Dept Ophthalmol, Spitalstr, CH-6000 Luzern, Switzerland.
EM ilan.barchichat@luks.ch
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Borkar DS, 2018, AM J OPHTHALMOL, V194, P1, DOI 10.1016/j.ajo.2018.06.022
   Deshmukh D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205292
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gao XX, 2019, ACTA OPHTHALMOL, V97, pE938, DOI 10.1111/aos.14058
   Giocanti-Auregan A, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0317-y
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Kuriakose A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1298473
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Saam T, 2010, BRIT J RADIOL, V83, pE182, DOI 10.1259/bjr/74101656
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma A, 2022, OCUL IMMUNOL INFLAMM, V30, P1508, DOI 10.1080/09273948.2021.1897628
   Sharma A, 2021, EYE, V35, P1292, DOI 10.1038/s41433-020-01227-w
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Thiel MA, 2013, OPHTHALMOLOGY, V120, P1403, DOI 10.1016/j.ophtha.2012.12.015
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   World Health Organization, 2020, VIG DAT
NR 22
TC 0
Z9 0
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 16
PY 2022
VL 22
IS 1
AR 80
DI 10.1186/s12886-022-02305-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB4HW
UT WOS:000756806000001
PM 35172763
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DOSING AND EXPECTED ACUITY
   OUTCOME AT 1 YEAR
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; macular neovascularization; vascular
   endothelial growth factor
ID TREAT-AND-EXTEND; CHOROIDAL NEOVASCULARIZATION SECONDARY; OPTICAL
   COHERENCE TOMOGRAPHY; ANTI-VEGF TREATMENT; INTRAVITREAL AFLIBERCEPT
   INJECTION; RETINAL ANGIOMATOUS PROLIFERATION; RANIBIZUMAB VS.
   AFLIBERCEPT; DAILY CLINICAL-PRACTICE; REAL-LIFE EXPERIENCE; 2.0 MG
   RANIBIZUMAB
AB Purpose: To determine the dose-response characteristics of the antivascular endothelial growth factor agents ranibizumab and aflibercept in neovascular age-related macular degeneration using published randomized trials and observational series. Methods: Literature review of published series from 2006 to 2018 as determined from electronic searches of PubMed and the Cochrane Library. Data extracted included treatment strategy, frequency, and first year visual acuity response. Monthly or bimonthly treatment schedules were classified as Fixed, pro re nata studies as PRN, treat and extend as TE, and when no strategy was listed, as Variable. Results: Of 2062 citations retrieved, 96 were deemed eligible; these 96 citations provided 120 data points of dose frequency versus visual acuity change in Year 1 of treatment. The dose-response curve was nonlinear, but a log transform of the number of injections per year yielded a linear relationship defined by the expression, Letters of Improvement = -6.66 + 15.7*log (number of injections Year 1). After accounting for the number of injections neither the drug used (ranibizumab or aflibercept) nor the strategy used (Fixed, pro re nata, treat and extend, or Variable) were significant predictors of acuity change. As a group, studies using the pro re nata approach had the lowest number of injections and the worst acuity improvements as a treatment strategy. Conclusion: There seems to be a predictable, mathematically defined relationship between dose frequency and visual acuity change at 1 year in neovascular age-related macular degeneration. The performance of current treatment efforts, as suggested by reported series and Medicare claims data, seems to be substandard.
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，950 Third Ave, New York, NY 10022 USA.
EM rickspaide@gmail.com
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Barakat A, 2018, J FR OPHTALMOL, V41, P603, DOI 10.1016/j.jfo.2018.01.005
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burns PB, 2011, PLAST RECONSTR SURG, V128, P305, DOI 10.1097/PRS.0b013e318219c171
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Castro-Navarro V, 2017, Arch Soc Esp Oftalmol, V92, P112, DOI 10.1016/j.oftal.2016.09.005
   Castro-Navarro V, 2016, OPHTHALMOLOGICA, V236, P215, DOI 10.1159/000453281
   Cebeci Z, 2018, INT J OPHTHALMOL-CHI, V11, P267, DOI 10.18240/ijo.2018.02.15
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Figurska M, 2011, MED SCI MONITOR, V17, pCR485, DOI 10.12659/MSM.881934
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Galton F, 1907, NATURE, V75, P450, DOI 10.1038/075450a0
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Kestenbaum D., 2015, WEIGHTY ISSUE COW GU
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kucuk B, 2018, INT J OPHTHALMOL-CHI, V11, P645, DOI 10.18240/ijo.2018.04.18
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2018, AM J OPHTHALMOL, V191, pXLI, DOI 10.1016/j.ajo.2017.12.019
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Nghiem-Buffet S, 2017, RETINA-J RET VIT DIS, V37, P53, DOI 10.1097/IAE.0000000000001134
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Ozkaya Abdullah, 2013, ISRN Ophthalmol, V2013, P151027, DOI 10.1155/2013/151027
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Papavasileiou E, 2015, HELL J NUCL MED, V18, P29
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Providencia J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9276580
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Qi HJ, 2017, INT J OPHTHALMOL-CHI, V10, P91, DOI 10.18240/ijo.2017.01.15
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stein J, 2003, INVEST OPHTH VIS SCI, V44, pU695
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Takayama K, 2017, OPHTHALMOLOGICA, V237, P105, DOI 10.1159/000461785
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Wallis KF, 2014, STAT SCI, V29, P420, DOI 10.1214/14-STS468
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wang WJ, 2015, INT J OPHTHALMOL-CHI, V8, P138, DOI 10.3980/j.issn.2222-3959.2015.01.26
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Wu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101253
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
NR 146
TC 3
Z9 3
U1 5
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2021
VL 41
IS 6
BP 1153
EP 1163
DI 10.1097/IAE.0000000000003116
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2SL
UT WOS:000658826900004
PM 33464022
DA 2022-11-30
ER

PT J
AU Nielsen, MK
   Subhi, Y
   Molbech, CR
   Falk, MK
   Singh, A
   Nissen, MH
   Sorensen, TL
AF Nielsen, Marie Krogh
   Subhi, Yousif
   Molbech, Christopher R.
   Falk, Mads K.
   Singh, Amardeep
   Nissen, Mogens H.
   Sorensen, Torben L.
TI Patients with a fast progression profile in geographic atrophy have
   increased CD200 expression on circulating monocytes
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; CD200 membrane glycoprotein;
   geographic atrophy; microglia; monocytes
ID FUNDUS AUTOFLUORESCENCE PATTERNS; C-REACTIVE PROTEIN; MACULAR
   DEGENERATION; MICROGLIAL ACTIVATION; SUBRETINAL MICROGLIA; RETINAL
   DEGENERATION; AGE; COMPLEMENT; ACCUMULATION; MACROPHAGES
AB Importance Geographic atrophy (GA) is a progressing atrophy of the neuroretina with no treatment option. Background Age-related malfunction of retinal microglia amplifies response towards age-related tissue stress in age-related macular degeneration. Here, we investigated monocyte CD200 expression - the circulating middleman negotiating retinal microglial activity - in a poorly understood subtype of age-related macular degeneration. Design Prospective case-control study. Participants Forty-six patients with GA and 26 healthy controls were included. Methods All participants were subjected to a structured interview and detailed retinal examination. Controls were recruited from patient's spouses accompanying them in the clinic to match the groups best possibly. Participants had no history of immune disorders or cancer, and did not receive any immune-modulating medication. Patients did not have any history or sign of choroidal neovascularization in either eye. Fresh drawn blood was stained with monoclonal antibodies and prepared for flow cytometry to evaluate CD200 expression in monocytes and their functional subsets. Main Outcome Measures The percentage of CD200+ monocytes in patients and controls. Results We found that monocytes were more CD200 positive in patients with GA compared to healthy age-matched controls. Then, we explored the potential relationship between CD200 expression and important fundus autofluorescence patterns that predict disease progression. Patients with a high risk of progression (patients with high degree of hyperautofluorescence) had distinctly increased CD200 expression compared to other patients with GA. Conclusions and Relevance Our data reveals that abnormal monocytic CD200 expression is present in GA, and in particular among those identified as fast progressors.
C1 [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher R.; Falk, Mads K.; Singh, Amardeep; Sorensen, Torben L.] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher R.; Nissen, Mogens H.; Sorensen, Torben L.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Nissen, Mogens H.] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
   [Singh, Amardeep] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
C3 University of Copenhagen; University of Copenhagen; Lund University;
   Skane University Hospital
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM mrrm@regionsjaelland.dk
RI Subhi, Yousif/ABG-6330-2020; Singh, Amardeep/ABI-4544-2020
OI Subhi, Yousif/0000-0001-6620-5365; Krogh Nielsen,
   Marie/0000-0003-3804-7296
FU Velux Foundation; Fight for Sight Denmark; Region Zealand
FX The Velux Foundation, Fight for Sight Denmark and the Region Zealand
   funded this study. None of the funding bodies had any role in design,
   execution or interpretation of the research performed.
CR Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Buchanan JB, 2008, PSYCHONEUROENDOCRINO, V33, P755, DOI 10.1016/j.psyneuen.2008.02.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   Chen JJ, 2016, APMIS, V124, P406, DOI 10.1111/apm.12511
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Cox FF, 2012, BRAIN BEHAV IMMUN, V26, P789, DOI 10.1016/j.bbi.2011.10.004
   Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Du LL, 2017, MOL NEUROBIOL, V54, P1992, DOI 10.1007/s12035-016-9758-9
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hernangomez M, 2012, GLIA, V60, P1437, DOI 10.1002/glia.22366
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Hijioka K, 2008, BIOCHEM BIOPH RES CO, V374, P38, DOI 10.1016/j.bbrc.2008.06.080
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Koning N, 2010, J INNATE IMMUN, V2, P195, DOI 10.1159/000252803
   Krogh Nielsen M, 2017, IMMUN AGEING, V14, P18, DOI DOI 10.1186/s12979-017-0100-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo C, 2011, MOL VIS, V17, P1588
   Luo XG, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-9
   Lyons A, 2009, BRAIN BEHAV IMMUN, V23, P1020, DOI 10.1016/j.bbi.2009.05.060
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   MA WX, 2017, SCI REP UK, V7
   Rifai N, 2001, CLIN CHEM, V47, P28
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Song DL, 2017, MOL VIS, V23, P210
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Templeton SP, 2008, BRAIN PATHOL, V18, P40, DOI 10.1111/j.1750-3639.2007.00098.x
   Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6
   Xie X, 2017, J NEUROCHEM, V141, P222, DOI 10.1111/jnc.13972
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Zawada AM, 2011, BLOOD, V118, pE50, DOI 10.1182/blood-2011-01-326827
   Zhang S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-154
NR 58
TC 14
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2019
VL 47
IS 1
BP 69
EP 78
DI 10.1111/ceo.13362
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HL3KR
UT WOS:000458614400011
PM 30047199
DA 2022-11-30
ER

PT J
AU Annamalai, B
   Parsons, N
   Belhaj, M
   Brandon, C
   Potts, J
   Rohrer, B
AF Annamalai, Balasubramaniam
   Parsons, Nathaniel
   Belhaj, Marwa
   Brandon, Carlene
   Potts, Jay
   Rohrer, Barbel
TI Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor
   Reduces Choroidal Neovascularization in a Mouse Model
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE complement system; choroidal neovascularization; targeted alternative
   pathway inhibitor CR2-fH; encapsulated ARPE-19 cells
ID CILIARY NEUROTROPHIC FACTOR; FACTOR GENE POLYMORPHISMS; MACULAR
   DEGENERATION; ALTERNATIVE PATHWAY; OXIDATIVE STRESS; INTRAOCULAR
   IMPLANTS; TARGETED INHIBITOR; MEDIATED INJURY; ASSOCIATION; RISK
AB Purpose: Age-related macular degeneration (AMD) is a slowly progressing disease, and risk appears to be tied to an overactive complement system. We have previously demonstrated that mouse choroidal neovascularization (CNV) and smoke-induced ocular pathology can be reduced with an alternative pathway (AP) inhibitor fusion protein consisting of a complement receptor-2 fragment linked to the inhibitory domain of factor H (CR2-fH) when delivered systemically. Here we developed an experimental approach with genetically engineered encapsulated ARPE-19 cells to produce CR2-fH intravitreally.
   Methods: ARPE-19 cells were generated to stably express CR2 or CR2-fH, microencapsulated using sodium alginate, and injected intravitreally into 2-monthold C57BL/6J mice. CNV was induced using argon laser photocoagulation 4 weeks postinjection. Presence of capsules and progression of CNV was analyzed using optical coherence tomography. Bioavailability of CR2-fH was evaluated in retina sections by immunohistochemistry, and efficacy as an AP inhibitor by C3a ELISA.
   Results: Secretion of CR2-fH or CR2 from encapsulated ARPE-19 cells was confirmed. An efficacious concentration of CR2-fH capsules to reduce CNV was identified. Bioavailability studies showed that CR2-fH was present in capsules and retinas of injected mice, and reduced CNV-associated ocular C3a production.
   Conclusions: These findings indicate that the AP inhibitor CR2-fH, when generated intravitreally, can reduce CNV in mouse.
   Translational Relevance: Encapsulated ARPE-19 cells secreting CR2-fH or perhaps other antiangiogenic or prosurvival factors might be useful as a potential therapeutic tool to treat age-related macular degeneration.
C1 [Annamalai, Balasubramaniam; Parsons, Nathaniel; Brandon, Carlene; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Belhaj, Marwa; Potts, Jay] Univ South Carolina, Dept Cell Biol, Columbia, SC USA.
   [Rohrer, Barbel] Med Univ South Carolina, Div Res, Neurosci, Charleston, SC 29425 USA.
   [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA.
C3 Medical University of South Carolina; University of South Carolina
   System; University of South Carolina Columbia; Medical University of
   South Carolina; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Ralph H Johnson VA Medical Center
RP Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health (NIH) [R01EY019320]; Department of
   Veterans Affairs [I01 RX000444]; South Carolina SmartState Endowment
FX Supported by the National Institutes of Health (NIH) (R01EY019320) (BR),
   the Department of Veterans Affairs (I01 RX000444) (BR), and the South
   Carolina SmartState Endowment (BR). BR holds a patent that describes the
   CR2-fH technology. The remaining authors declare that they have no
   conflict of interest.
CR Alawieh A, 2016, IMMUNOL REV, V274, P270, DOI 10.1111/imr.12470
   An EY, 2008, MOL VIS, V14, P2292
   Atkinson C, 2010, J IMMUNOL, V185, P7007, DOI 10.4049/jimmunol.1001504
   Banda NK, 2009, J IMMUNOL, V183, P5928, DOI 10.4049/jimmunol.0901826
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Bulgu Y, 2014, INT J OPHTHALMOL-CHI, V7, P773, DOI [10.3980/j.issn.2222-3959.2014.05.06, 10.3980/j.issn.2222-3959.2014.06]
   Chew EY, 2015, AM J OPHTHALMOL, V159, P659, DOI 10.1016/j.ajo.2014.12.013
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Courtenay MD, 2014, INVEST OPHTH VIS SCI, V55, P4873, DOI 10.1167/iovs.14-14494
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Elvington A, 2012, J IMMUNOL, V189, P4640, DOI 10.4049/jimmunol.1201904
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Fridkis-Hareli M, 2011, BLOOD, V118, P4705, DOI 10.1182/blood-2011-06-359646
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gupta D, 2016, META GENE, V9, P249, DOI 10.1016/j.mgene.2016.07.011
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kaji H., 2017, ADV DRUG DELIV REV
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Liu MM, 2011, POSTGRAD MED J, V87, P487, DOI 10.1136/pgmj.2009.174912rep
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Moore K, 2013, MICROSC MICROANAL, V19, P213, DOI 10.1017/S143192761201389X
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Naidoo J, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/595410
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rohrer B, 2017, INVEST OPHTH VIS SCI, V58
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Schnabolk G, 2014, EXP EYE RES, V129, P18, DOI 10.1016/j.exer.2014.10.005
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sekine H, 2011, ARTHRITIS RHEUM-US, V63, P1076, DOI 10.1002/art.30222
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348
   Sun SH, 2011, AM J RESP CELL MOL, V45, P834, DOI 10.1165/rcmb.2010-0444OC
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Wong FSY, 2017, NEURAL REGEN RES, V12, P576, DOI 10.4103/1673-5374.205093
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 52
TC 10
Z9 10
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2018
VL 7
IS 2
AR 3
DI 10.1167/tvst.7.2.3
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1WI
UT WOS:000427367800003
PM 29576927
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kamga, H
   McCusker, J
   Yaffe, M
   Sewitch, M
   Sussman, T
   Strumpf, E
   Olivier, S
   Wittich, W
   Moghadaszadeh, S
   Freeman, EE
AF Kamga, Hortence
   McCusker, Jane
   Yaffe, Mark
   Sewitch, Maida
   Sussman, Tamara
   Strumpf, Erin
   Olivier, Sebastien
   Wittich, Walter
   Moghadaszadeh, Solmaz
   Freeman, Ellen E.
TI Self-care tools to treat depressive symptoms in patients with
   age-related eye disease: a randomized controlled clinical trial
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE depressive symptom; eye disease; self-care
ID GENERALIZED ANXIETY DISORDER; LIFE-SPACE MOBILITY; OLDER-ADULTS;
   MANAGEMENT; METAANALYSIS; EFFICACY; HEALTH
AB BackgroundDepression is very common in people with age-related eye disease. Our goal was to determine if self-care tools plus limited telephone support could reduce depressive symptoms in patients with age-related macular degeneration or diabetic retinopathy.
   DesignA single-blind randomized controlled clinical trial was conducted at Maisonneuve-Rosemont Hospital in Montreal, Canada.
   ParticipantsEighty participants were recruited.
   MethodsTo be eligible, participants must have had either late stage age-related macular degeneration or diabetic retinopathy, at least mild depressive symptoms, and visual acuity better than 20/200. Half were randomized to the intervention arm and half to delayed intervention/usual care. The intervention consisted of large print written and audio tools incorporating cognitive-behavioral principles plus three 10-minute telephone calls from a lay coach. Eight-week follow-up data were collected by telephone.
   Main Outcome MeasuresThe primary outcome was the 8-week change in depressive symptoms as measured by the Patient Health Questionnaire-9. Secondary outcomes included anxiety, life space and self-efficacy.
   ResultsThe baseline mean logMAR visual acuity was 0.37 (SD=0.20), and the baseline mean Patient Health Questionnaire-9 score was 9.5 (SD=3.9) indicating moderate depressive symptoms. After adjusting for baseline imbalances in visual acuity, the intervention reduced depressive symptoms by 2.1 points more than usual care (P=0.040). The intervention was not associated with the secondary outcomes (P>0.05).
   ConclusionsSelf-care tools plus telephone coaching led to a modest improvement in depressive symptoms in patients with age-related eye disease. Additional research on how to maximize their effect is necessary.
C1 [Kamga, Hortence; Olivier, Sebastien; Moghadaszadeh, Solmaz; Freeman, Ellen E.] Maisonneuve Rosemont Hosp, Montreal, PQ, Canada.
   [McCusker, Jane; Yaffe, Mark; Sewitch, Maida; Sussman, Tamara; Strumpf, Erin] McGill Univ, Montreal, PQ, Canada.
   [Olivier, Sebastien; Freeman, Ellen E.] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Wittich, Walter] Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
   [Freeman, Ellen E.] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.
C3 Universite de Montreal; McGill University; Universite de Montreal;
   Universite de Montreal; University of Ottawa
RP Freeman, EE (通讯作者)，Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.
EM eefreeman@gmail.com
RI Sussman, Tamara/AAD-6598-2021; Wittich, Walter/AAH-2145-2020
OI Sussman, Tamara/0000-0002-1226-6450; Wittich, Walter/0000-0003-2184-6139
FU Fonds de Recherche en Sante du Quebec; Vision Health Research Network;
   Antoine Turmel Foundation; Montreal, Canada
FX Fonds de Recherche en Sante du Quebec, Vision Health Research Network;
   Antoine Turmel Foundation; Montreal, Canada.
CR Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x
   Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299
   Bilsker D, 2005, ANTIDEPRESSANT SKILL
   Blazer DG, 2002, AGING MENT HEALTH, V6, P315, DOI 10.1080/1360786021000006938
   Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Burner Elizabeth, 2013, J Diabetes Sci Technol, V7, P111
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129
   CONSORT, TRANSP REP TRIALS 20
   Dezetter A, 2015, CAN J PSYCHIAT, V60, P284, DOI 10.1177/070674371506000607
   Dwight-Johnson M, 2000, J GEN INTERN MED, V15, P527, DOI 10.1046/j.1525-1497.2000.08035.x
   Gellatly J, 2007, PSYCHOL MED, V37, P1217, DOI 10.1017/S0033291707000062
   Hall J, 2016, AM J GERIAT PSYCHIAT, V24, P1063, DOI 10.1016/j.jagp.2016.06.006
   Holloway EE, 2015, AUST J PRIM HEALTH, V21, P169, DOI 10.1071/PY13085
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006
   Lu CY, 2012, EUR J CLIN PHARMACOL, V68, P65, DOI 10.1007/s00228-011-1087-3
   McCusker J, 2015, GEN HOSP PSYCHIAT, V37, P257, DOI 10.1016/j.genhosppsych.2015.03.007
   Moore M, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X649151
   Polku H, 2015, AGING MENT HEALTH, V19, P781, DOI 10.1080/13607863.2014.977768
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Rapaport MH, 2001, J CLIN PSYCHIAT, V62, P6
   Rees G, 2016, JAMA OPHTHALMOL, V134, P1007, DOI 10.1001/jamaophthalmol.2016.2213
   Rees G, 2015, PATIENT EDUC COUNS, V98, P174, DOI 10.1016/j.pec.2014.11.008
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   Rovner BW, 2015, J AM GERIATR SOC, V63, P1249, DOI 10.1111/jgs.13470
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Unutzer J, 2003, J AM GERIATR SOC, V51, P505, DOI 10.1046/j.1532-5415.2003.51159.x
   Venn S, 2013, SOC SCI MED, V79, P117, DOI 10.1016/j.socscimed.2012.09.037
   Williams GC, 1998, DIABETES CARE, V21, P1644, DOI 10.2337/diacare.21.10.1644
NR 33
TC 8
Z9 10
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY-JUN
PY 2017
VL 45
IS 4
BP 371
EP 378
DI 10.1111/ceo.12890
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EY0TK
UT WOS:000403671200007
PM 27928888
DA 2022-11-30
ER

PT J
AU Mennel, S
   Barbazetto, I
   Meyer, CH
   Peter, S
   Stur, M
AF Mennel, Stefan
   Barbazetto, Irene
   Meyer, Carsten H.
   Peter, Silvia
   Stur, Michael
TI Ocular photodynamic therapy - Standard applications and new indications
   (Part 1)
SO OPHTHALMOLOGICA
LA English
DT Review
DE ocular photodynamic therapy; macular degeneration; choroidal
   neovascularization, idiopathic; retinal,angiomatous proliferations;
   polypoidal choroidal vasculopathy; uveitis; angoid streaks; central
   serous chorioretinopathy; parafoveal telangiectasia;
   dystrophy,macular,fundus
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CENTRAL SEROUS
   CHORIORETINOPATHY; ANGIOID STREAKS; SUBRETINAL NEOVASCULARIZATION;
   INTRAVITREAL TRIAMCINOLONE; MACULAR DEGENERATION; PATHOLOGICAL MYOPIA;
   VERTEPORFIN THERAPY; NATURAL-HISTORY; HEMANGIOMA
AB Ocular photodynamic therapy ( PDT) was introduced as a novel treatment for neovascular forms of age- related macular degeneration and choroidal neovascularization ( CNV) secondary to pathologic myopia in the mid/ end 1990s. The current treatment recommendations are based on the results of two large, prospective, multicenter, randomized clinical trials ( Treatment of Age- Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Studies) and thousands of patients have been treated worldwide over the last years. Meanwhile, PDT has been performed in several other ocular pathologies with some remarkable results, however, with most reports being case reports and small case series without statistical significance. These extended applications include CNV secondary to choroiditis and retinochoroiditis, angioid streaks, central serous chorioretinopathy, retinal angiomatous proliferation, parafoveal telangiectasia or CNV associated with macular dystrophy and idiopathic CNV, as well as diseases without CNV, such as choroidal hemangioma, retinal hamartoma, choroidal melanoma, chronic central serous chorioretinopathy, angiomatous lesions secondary to systemic diseases, rubeosis iridis or neovascular glaucoma. To date, with the introduction of anti- VEGF therapy, the role of PDT will certainly change. However, it is reasonable to believe that it will maintain an important role in combination therapy due to its unique properties of selective vascular targeting. Therefore, it is essential for the ophthalmologist to be familiar with the extended applications and their modifications of treatment parameters. This review will summarize the standard and experimental applications of PDT based on our own results and the literature. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Marburg, Dept Ophthalmol, DE-35037 Marburg, Germany.
   Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   Columbia Presbyterian Med Ctr, ES Harkness Eye Inst, New York, NY USA.
   Acad Hosp Feldkirch, Dept Ophthalmol, Vienna, Austria.
   Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Philipps University Marburg; University of Bonn; Columbia University;
   NewYork-Presbyterian Hospital; Medical University of Vienna
RP Mennel, S (通讯作者)，Univ Marburg, Dept Ophthalmol, Robert Koch Str 4, DE-35037 Marburg, Germany.
EM stefan.mennel@lycos.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atebara NH, 2002, AM J OPHTHALMOL, V134, P788, DOI 10.1016/S0002-9394(02)01648-3
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Barbazetto IA, 2004, AM J OPHTHALMOL, V138, P183, DOI 10.1016/j.ajo.2004.04.007
   Barbazetto IA, 2003, AM J OPHTHALMOL, V135, P898, DOI 10.1016/S0002-9394(02)02222-5
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 2005, VERTEBPORFIN PHOTODY
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   CHARTERS L, 2006, OPHTHALMOLOGY T 0415, P48
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Conrath J, 2004, EYE, V18, P946, DOI 10.1038/sj.eye.6701357
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P399, DOI 10.1097/00006982-200406000-00010
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Giansanti F, 2005, RETINA-J RET VIT DIS, V25, P590, DOI 10.1097/00006982-200507000-00009
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta M, 2004, EYE, V18, P139, DOI 10.1038/sj.eye.6700597
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Harissi-Dagher M, 2005, AM J OPHTHALMOL, V139, P726, DOI 10.1016/j.ajo.2004.10.009
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Hershberger VS, 2003, OPHTHAL SURG LAS IM, V34, P318
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Hussain N, 2005, AM J OPHTHALMOL, V140, P333, DOI 10.1016/j.ajo.2005.02.027
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Karacorlu M, 2002, AM J OPHTHALMOL, V134, P360, DOI 10.1016/S0002-9394(02)01626-4
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Ladas ID, 2005, EUR J OPHTHALMOL, V15, P69, DOI 10.1177/112067210501500111
   Ladd BS, 2001, AM J OPHTHALMOL, V132, P659, DOI 10.1016/S0002-9394(01)01198-9
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Leslie T, 2005, BRIT J OPHTHALMOL, V89, P147, DOI 10.1136/bjo.2004.046623
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Mehta Hitendra B., 2005, Indian Journal of Ophthalmology, V53, P131
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Mennel S, 2006, ARCH OPHTHALMOL-CHIC, V124, P597, DOI 10.1001/archopht.124.4.597
   Mennel S, 2006, ACTA OPHTHALMOL SCAN, V84, P273, DOI 10.1111/j.1600-0420.2005.00519.x
   Mennel S, 2005, GRAEF ARCH CLIN EXP, V243, P68, DOI 10.1007/s00417-004-0964-1
   Mennel S, 2003, AM J OPHTHALMOL, V136, P580, DOI 10.1016/S0002-9394(03)00338-6
   Michels S, 2005, OPHTHALMOLOGY, V112, P2070, DOI 10.1016/j.ophtha.2005.06.034
   Michels S, 2004, OPHTHALMOLOGE, V101, P569, DOI 10.1007/s00347-003-0914-z
   Mimouni KF, 2003, AM J OPHTHALMOL, V135, P900, DOI 10.1016/S0002-9394(02)02224-9
   Muller VA, 2003, OPHTHALMIC RES, V35, P60, DOI 10.1159/000068195
   Muller-Velten R, 2003, OPHTHALMOLOGE, V100, P384, DOI 10.1007/s00347-002-0723-9
   Noske UM, 1998, OPHTHALMOLOGE, V95, P814, DOI 10.1007/s003470050358
   Parodi MB, 2006, AM J OPHTHALMOL, V141, P123, DOI 10.1016/j.ajo.2005.07.045
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P157, DOI 10.1016/j.ajo.2004.02.015
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P171, DOI 10.1097/00006982-200304000-00006
   Peiretti E, 2005, RETINA-J RET VIT DIS, V25, P377, DOI 10.1097/00006982-200504000-00024
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1155
   Rodriguez-Coleman H, 2004, ARCH OPHTHALMOL-CHIC, V122, P1085, DOI 10.1001/archopht.122.7.1085
   Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016/j.ophtha.2004.02.014
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P1256, DOI 10.1016/S0161-6420(02)01059-X
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Shaikh S, 2003, AM J OPHTHALMOL, V135, P1, DOI 10.1016/S0002-9394(02)01835-4
   Shanmugam Mahesh P., 2005, Indian Journal of Ophthalmology, V53, P61
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Slakter JS, 2003, INVEST OPHTH VIS SCI, V44, pU297
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Souied EH, 2005, AM J OPHTHALMOL, V140, P312
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   Taban M, 2004, CURR EYE RES, V28, P291, DOI 10.1076/ceyr.28.4.291.27829
   Tanaka Mayuko, 2003, Nippon Ganka Gakkai Zasshi, V107, P440
   *VER TRIAL STUD GR, IN PRESS ARCH OPHTHA
   Verbraak FD, 2003, GRAEF ARCH CLIN EXP, V241, P891, DOI 10.1007/s00417-003-0765-y
   Wachtlin J, 2005, OPHTHALMOLOGE, V102, P241, DOI 10.1007/s00347-004-1092-3
   Wachtlin J, 2004, OPHTHALMOLOGE, V101, P489, DOI 10.1007/s00347-004-0993-5
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
NR 88
TC 29
Z9 31
U1 1
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 4
BP 216
EP 226
DI 10.1159/000101922
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 181KE
UT WOS:000247434800001
PM 17579286
DA 2022-11-30
ER

PT J
AU Zhang, X
   Tohari, AM
   Marcheggiani, F
   Zhou, XZ
   Reilly, J
   Tiano, L
   Shu, XH
AF Zhang, Xun
   Tohari, Ali Mohammad
   Marcheggiani, Fabio
   Zhou, Xinzhi
   Reilly, James
   Tiano, Luca
   Shu, Xinhua
TI Therapeutic Potential of Co-enzyme Q10 in Retinal Diseases
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Co-enzyme Q10; oxidative stress; retina; age related macular
   degeneration; glaucoma; retinitis pigmentosa; diabetic retinopathy;
   protection
ID OPTIC-NERVE HEAD; GANGLION-CELL DEATH; OPEN-ANGLE GLAUCOMA; OXIDATIVE
   STRESS; MACULAR DEGENERATION; MOUSE MODEL; MITOCHONDRIAL ALTERATION;
   SUPEROXIDE-DISMUTASE; DIABETIC-RETINOPATHY; FREE-RADICALS
AB Background: Coenzyme Q10 (CoQ10) plays a critical role in mitochondrial oxidative phosphorylation by serving as an electron carrier in the respiratory electron transport chain. CoQ10 also functions as a lipid-soluble antioxidant by protecting lipids, proteins and DNA damaged by oxidative stress. CoQ10 deficiency has been associated with a number of human diseases in which CoQ10 supplementation therapy has been effective in slowing or reversing pathological changes. Oxidative stress is a major contributory factor in the process of retinal degeneration.
   Method: The related literature was reviewed through searching PubMed using keywords: CoQ10, CoQ10 and oxidative stress, CoQ10 and retinal degeneration. The functions of CoQ10 were summarized and its use in the treatment of age-related macular degeneration and glaucoma highlighted. The therapeutic potential of CoQ10 for other retinal diseases was also discussed.
   Results: CoQ10 has been applied in different types of neurodegeneration. CoQ10 is detectable in retina and declines with ageing. Early studies showed treatment of CoQ10 improved visual function in patients with age-related macular degeneration. In glaucomatous models, CoQ10 exposure protected ganglion cell death from environmental stress; in glaucoma patients, CoQ10 treatment demonstrated beneficial effects on function of inner retina and enhancement of visual cortical response. Since oxidative stress also plays a critical role in the pathogenesis of diabetic retinopathy and retinitis pigmentosa, CoQ10 is a therapeutic target for both conditions.
   Conclusion: A wide range of evidence supports a role of CoQ10 in retinal diseases through inhibiting production of reactive oxygen species and protecting neuroretinal cells from oxidative damage.
C1 [Zhang, Xun; Tohari, Ali Mohammad; Zhou, Xinzhi; Reilly, James; Shu, Xinhua] Glasgow Caledonian Univ, Dept Life Sci, Glasgow, Lanark, Scotland.
   [Marcheggiani, Fabio; Tiano, Luca] Polytech Univ Marche, Dept Dent & Clin Sci, Ancona, Italy.
C3 Glasgow Caledonian University; Marche Polytechnic University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Life Sci, Glasgow, Lanark, Scotland.; Tiano, L (通讯作者)，Polytech Univ Marche, Dept Dent & Clin Sci, Ancona, Italy.
EM I.tiano@univpm.it; Xinhua.Shu@gcu.ac.uk
RI Tiano, Luca/ABC-2341-2020
OI Tiano, Luca/0000-0002-7519-7106; ZHANG, XUN/0000-0003-0790-4291
FU Rosetrees Trust; Fight for Sight; Yorkhill Children's Hospital Charity;
   Visual Research Trust; Royal Society of Edinburgh; Rosetrees Trust
   [M160-F1] Funding Source: researchfish; Glasgow Children&quot;s Hospital
   Charity [YRSS/PSG/2014/06] Funding Source: researchfish; Fight for Sight
   [URP12, 1419/20] Funding Source: researchfish
FX Dr Shu's lab is supported by the Rosetrees Trust, the Fight for Sight,
   the Yorkhill Children's Hospital Charity and the Visual Research Trust.
   The Royal Society of Edinburgh funded Dr Luca Tiano's visit to Dr Shu's
   lab at GCU.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1
   Bramall AN, 2010, ANNU REV NEUROSCI, V33, P441, DOI 10.1146/annurev-neuro-060909-153227
   Chang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027218
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   CRANE FL, 1957, BIOCHIM BIOPHYS ACTA, V25, P220, DOI 10.1016/0006-3002(57)90457-2
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   El-Bab MF, 2012, CLIN OPHTHALMOL, V6, P269, DOI 10.2147/OPTH.S27363
   El-Bab MF, 2013, INT J GEN MED, V6, P799, DOI 10.2147/IJGM.S40665
   Erdurmus M, 2011, CURR EYE RES, V36, P713, DOI 10.3109/02713683.2011.584370
   Eshaq RS, 2014, REDOX BIOL, V2, P661, DOI 10.1016/j.redox.2014.04.006
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fato R, 2010, ACTA OPHTHALMOL, V88, pe150, DOI 10.1111/j.1755-3768.2009.01632.x
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5
   Garrido-Maraver J, 2014, MOL SYNDROMOL, V5, P187, DOI 10.1159/000360101
   Groneberg DA, 2005, INT J BIOCHEM CELL B, V37, P1208, DOI 10.1016/j.biocel.2004.11.017
   Gupta Madhur M, 2005, Indian J Physiol Pharmacol, V49, P187
   Hartnett ME, 2000, DIABETES CARE, V23, P234, DOI 10.2337/diacare.23.2.234
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8
   Hodgson JM, 2002, EUR J CLIN NUTR, V56, P1137, DOI 10.1038/sj.ejcn.1601464
   Hooper P, 2012, CAN J OPHTHALMOL, V47, P91, DOI 10.1016/j.jcjo.2012.01.022
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Iomdina EN, 2015, FRONT BIOSCI-LANDMRK, V20, P892, DOI 10.2741/4343
   Garcia-Medina JJ, 2011, EUR J OPHTHALMOL, V21, P637, DOI 10.5301/EJO.2010.6212
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Ko ML, 2005, FREE RADICAL BIO MED, V39, P365, DOI 10.1016/j.freeradbiomed.2005.03.025
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kowluru RA, 2006, INVEST OPHTH VIS SCI, V47, P1594, DOI 10.1167/iovs.05-1276
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Langsjoen H., 1994, Molecular Aspects of Medicine, V15, pS165, DOI 10.1016/0098-2997(94)90026-4
   Lee D, 2014, APOPTOSIS, V19, P603, DOI 10.1007/s10495-013-0956-x
   Lee D, 2014, INVEST OPHTH VIS SCI, V55, P993, DOI 10.1167/iovs.13-12564
   Levkovitch-Verbin H, 2015, PROG BRAIN RES, V220, P37, DOI 10.1016/bs.pbr.2015.05.005
   Li Y, 1999, INVEST OPHTH VIS SCI, V40, P1004
   Littarru GP, 2007, MOL BIOTECHNOL, V37, P31, DOI 10.1007/s12033-007-0052-y
   Littarru GP, 2005, CURR OPIN CLIN NUTR, V8, P641, DOI 10.1097/01.mco.0000171123.60665.16
   Lulli M, 2012, INVEST OPHTH VIS SCI, V53, P8295, DOI 10.1167/iovs.12-10374
   Lulli M, 2012, J RADIAT RES, V53, P695, DOI 10.1093/jrr/rrs025
   Malone PE, 2007, EXP EYE RES, V84, P444, DOI 10.1016/j.exer.2006.10.020
   Mancino R, 2011, MOL VIS, V17, P1298
   de la Camara CMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074223
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Muller A, 1997, EXP EYE RES, V64, P637, DOI 10.1006/exer.1996.0277
   Murakami Y, 2012, P NATL ACAD SCI USA, V109, P14598, DOI 10.1073/pnas.1206937109
   Nakajima Y, 2008, BRAIN RES, V1226, P226, DOI 10.1016/j.brainres.2008.06.026
   Nguyen CTO, 2008, INVEST OPHTH VIS SCI, V49, P3586, DOI 10.1167/iovs.08-1735
   Nguyen CTO, 2013, J GLAUCOMA, V22, P269, DOI 10.1097/IJG.0b013e318237cac7
   Noh YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.341
   Nucci C, 2007, INT REV NEUROBIOL, V82, P397, DOI 10.1016/S0074-7742(07)82022-8
   Oyster C. W., 1999, OPHTHAL PHYSL OPT, DOI [10.1046/j.1475-1313.2000.0052.x, DOI 10.1046/J.1475-1313.2000.0052.X]
   Parisi V, 2014, J GLAUCOMA, V23, P391, DOI 10.1097/IJG.0b013e318279b836
   Playford DA, 2003, ATHEROSCLEROSIS, V168, P169, DOI 10.1016/S0021-9150(02)00417-3
   Qu JF, 2011, BIOFACTORS, V37, P393, DOI 10.1002/biof.166
   Qu JF, 2009, INVEST OPHTH VIS SCI, V50, P1814, DOI 10.1167/iovs.08-2656
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Schmelzer C, 2008, BIOFACTORS, V32, P179, DOI 10.1002/biof.5520320121
   Schneider M, 2016, EXP EYE RES, V142, P49, DOI 10.1016/j.exer.2015.08.014
   Shotliff K, 2006, PRACT DIABETES INT, V23, P418, DOI [10.1002/pdi.1029, DOI 10.1002/PDI.1029, DOI 10.1002/PDI.1029]]
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Sucher NJ, 1997, VISION RES, V37, P3483, DOI 10.1016/S0042-6989(97)00047-3
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   Vlachantoni D, 2011, HUM MOL GENET, V20, P322, DOI 10.1093/hmg/ddq467
   Watts GF, 2002, DIABETOLOGIA, V45, P420, DOI 10.1007/s00125-001-0760-y
   Wax MB, 1998, ARCH OPHTHALMOL-CHIC, V116, P993, DOI 10.1001/archopht.116.8.993
   WHIKEHART DR, 2003, BIOCH EYE
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Yokoyama T, 2006, EXP EYE RES, V83, P602, DOI 10.1016/j.exer.2006.02.016
   Yu AL, 2008, INVEST OPHTH VIS SCI, V49, P5403, DOI 10.1167/iovs.07-1478
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
NR 82
TC 20
Z9 21
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2017
VL 24
IS 39
BP 4329
EP 4339
DI 10.2174/0929867324666170801100516
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA FQ5QS
UT WOS:000418416300002
PM 28762311
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Santulli, RJ
   Kinney, WA
   Ghosh, S
   DeCorte, BL
   Liu, L
   Tuman, RWA
   Zhou, Z
   Huebert, N
   Bursell, SE
   Clermont, AC
   Grant, MB
   Shaw, LC
   Mousa, SA
   Galemmo, RA
   Johnson, DL
   Maryanoff, BE
   Damiano, BP
AF Santulli, Rosemary J.
   Kinney, William A.
   Ghosh, Shyamali
   DeCorte, Bart L.
   Liu, Li
   Tuman, Robert W. A.
   Zhou, Zhao
   Huebert, Norman
   Bursell, Sven E.
   Clermont, Alan C.
   Grant, Maria B.
   Shaw, Lynn C.
   Mousa, Shaker A.
   Galemmo, Robert A., Jr.
   Johnson, Dana L.
   Maryanoff, Bruce E.
   Damiano, Bruce P.
TI Studies with an orally bioavailable alpha(v) integrin antagonist in
   animal models of ocular vasculopathy: Retinal neovascularization in mice
   and retinal vascular permeability in diabetic rats
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID ALPHA-V-INTEGRINS; IN-VIVO; CHOROIDAL NEOVASCULARIZATION;
   MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; PROLIFERATIVE RETINOPATHY;
   MACULAR DEGENERATION; VITRONECTIN RECEPTOR; ALPHA(V)BETA(3);
   ANGIOGENESIS
AB The alpha(v) integrins are key receptors involved in mediating cell migration and angiogenesis. In age-related macular degeneration (AMD) and diabetic retinopathy, angiogenesis plays a critical role in the loss of vision. These ocular vasculopathies might be treatable with a suitable alpha(v) antagonist, and an oral drug would offer a distinct advantage over current therapies. (3,S,beta,S)-1,2,3,4-Tetrahydro-beta-[[1-[1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl) propyl]-4-piperidinyl]methyl]-3-quinolinepropanoic acid (JNJ-26076713) is a potent, orally bioavailable, nonpeptide alpha(v) antagonist derived from the arginine-glycine-asparagine binding motif in the matrix protein ligands (e.g., vitronectin). This compound inhibits alpha(v)beta(3) and alpha(v)beta(5) binding to vitronectin in the low nanomolar range, it has excellent selectivity over integrins alpha(11b)beta(3) and alpha(5)beta(1), and it prevents adhesion to human, rat, and mouse endothelial cells. JNJ-26076713 blocks cell migration induced by vascular endothelial growth factor, fibroblast growth factor (FGF), and serum, and angiogenesis induced by FGF in the chick chorioallantoic membrane model. JNJ-26076713 is the first alpha(V) antagonist reported to inhibit retinal neovascularization in an oxygen-induced model of retinopathy of prematurity after oral administration. In diabetic rats, orally administered JNJ-26076713 markedly inhibits retinal vascular permeability, a key early event in diabetic macular edema and AMD. Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.
C1 [Santulli, Rosemary J.; Kinney, William A.; Ghosh, Shyamali; DeCorte, Bart L.; Liu, Li; Tuman, Robert W. A.; Zhou, Zhao; Huebert, Norman; Galemmo, Robert A., Jr.; Johnson, Dana L.; Maryanoff, Bruce E.; Damiano, Bruce P.] Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA 19477 USA.
   [Galemmo, Robert A., Jr.] Neuromed Pharmaceut, Vancouver, BC, Canada.
   [Grant, Maria B.; Shaw, Lynn C.] Univ Florida, Gainesville, FL USA.
   [Mousa, Shaker A.] Albany Coll Pharm, Pharmaceut Res Inst, Albany, NY USA.
   [Bursell, Sven E.; Clermont, Alan C.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
C3 Johnson & Johnson; Johnson & Johnson USA; State University System of
   Florida; University of Florida; Albany College of Pharmacy & Health
   Sciences; Harvard University; Joslin Diabetes Center, Inc.
RP Santulli, RJ (通讯作者)，Johnson & Johnson Pharmaceut Res & Dev, Welsh & McKean Rds, Spring House, PA 19477 USA.
EM rsantull@prdus.jnj.com
RI Mousa, Shaker A/A-7151-2017; Longo, Kenneth A/A-5631-2010
OI Mousa, Shaker A/0000-0002-9294-015X; 
CR Abiko T, 2003, DIABETES, V52, P829, DOI 10.2337/diabetes.52.3.829
   Bates RC, 2005, CELL CYCLE, V4, P1350, DOI 10.4161/cc.4.10.2053
   Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530
   Chavakis E, 2002, DIABETOLOGIA, V45, P262, DOI 10.1007/s00125-001-0727-z
   Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376
   Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Ghosh S, 2004, BIOORG MED CHEM LETT, V14, P5937, DOI 10.1016/j.bmcl.2004.08.067
   Grant MB, 2004, EXPERT OPIN INV DRUG, V13, P1275, DOI 10.1517/13543784.13.10.1275
   Hakkinen L, 2004, AM J PATHOL, V164, P229, DOI 10.1016/S0002-9440(10)63113-6
   Hodivala-Dilke KM, 2003, CELL TISSUE RES, V314, P131, DOI 10.1007/s00441-003-0774-5
   JENNIFER LWB, 2006, INVEST OPHTH VIS SCI, V47, P1600
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   KINNEY WA, 2008, IN PRESS J ORG CHEM
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023
   Lim EH, 2005, NANOMED-NANOTECHNOL, V1, P110, DOI 10.1016/j.nano.2005.03.008
   Ljubimov AV, 1996, J HISTOCHEM CYTOCHEM, V44, P1469, DOI 10.1177/44.12.8985139
   Luci DK, 2004, HETEROCYCLES, V62, P543
   Luna J, 1996, LAB INVEST, V75, P563
   Martin PL, 2005, CLIN CANCER RES, V11, P6959, DOI 10.1158/1078-0432.CCR-04-2623
   Miller WH, 2000, DRUG DISCOV TODAY, V5, P397, DOI 10.1016/S1359-6446(00)01545-2
   Mousa SA, 2003, MED RES REV, V23, P190, DOI 10.1002/med.10031
   Mousa SA, 2002, CURR OPIN CHEM BIOL, V6, P534, DOI 10.1016/S1367-5931(02)00350-2
   Murphy MG, 2005, J CLIN ENDOCR METAB, V90, P2022, DOI 10.1210/jc.2004-2126
   Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167
   Ribatti Domenico, 2000, Current Pharmaceutical Biotechnology, V1, P73, DOI 10.2174/1389201003379040
   Riecke B, 2001, HORM METAB RES, V33, P307, DOI 10.1055/s-2001-15279
   Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Speicher Matthew A, 2003, Expert Opin Emerg Drugs, V8, P239, DOI 10.1517/14728214.8.1.239
   Takagi H, 2002, JPN J OPHTHALMOL, V46, P270, DOI 10.1016/S0021-5155(02)00482-3
   Terai Y, 2001, J CELL PHYSIOL, V188, P394, DOI 10.1002/jcp.1122
   Trikha M, 2004, INT J CANCER, V110, P326, DOI 10.1002/ijc.20116
   Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849
   Wilder RL, 2002, ANN RHEUM DIS, V61, P96, DOI 10.1136/ard.61.suppl_2.ii96
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   Witmer AN, 2004, J HISTOCHEM CYTOCHEM, V52, P39, DOI 10.1177/002215540405200105
   Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yoon KC, 2005, GENE THER, V12, P617, DOI 10.1038/sj.gt.3302442
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang DH, 2007, INVEST NEW DRUG, V25, P49, DOI 10.1007/s10637-006-9013-8
NR 44
TC 37
Z9 56
U1 2
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAR
PY 2008
VL 324
IS 3
BP 894
EP 901
DI 10.1124/jpet.107.131656
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 266OH
UT WOS:000253445200002
PM 18083913
DA 2022-11-30
ER

PT J
AU Chen, Y
   Hu, Y
   Lu, K
   Flannery, JG
   Ma, JX
AF Chen, Ying
   Hu, Yang
   Lu, Kangmo
   Flannery, John G.
   Ma, Jian-xing
TI Very low density lipoprotein receptor, a negative regulator of the wnt
   signaling pathway and choroidal neovascularization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; FAMILIAL
   EXUDATIVE VITREORETINOPATHY; SUBRETINAL NEOVASCULARIZATION; VASCULAR
   DEVELOPMENT; CELL PROLIFERATION; FACTOR EXPRESSION; MOUSE MODEL; GENE;
   ANGIOGENESIS
AB Choroidal neovascularization (CNV) in age-related macular degeneration is a leading cause of blindness. Very low density lipoprotein receptor gene knock-out (Vldlr(-/-)) mice have been shown to develop subretinal neovascularization (NV) with an unknown mechanism. The present study showed that in Vldlr(-/-) mice, NV initiated in the choroid and progressed to penetrate the retinal pigment epithelium layer, proliferating in the subretinal space. This phenotype recapitulated what is seen in wet age-related macular degeneration, suggesting that this is a CNV model. The CNV correlated with overexpression of vascular endothelial growth factor in Vldlr(-/-) eyecups and was blocked by a neutralizing antibody against vascular endothelial growth factor receptor-2. The wnt co-receptor LRP5/6 expression was significantly up-regulated in Vldlr(-/-) eyecups compared with that in wild-type mice. Significantly, Vldlr(-/-) mice showed impaired phosphorylation of downstream effectors of the wnt signaling pathway, glycogen synthase kinase-3 beta (GSK-3 beta), and beta-catenin, concomitant with increased levels of free GSK-3 beta and beta-catenin, suggesting an increased activity of the wnt pathway. Down-regulation of VLDLR by small interference RNA resulted in up-regulation of LRP5/6 expression and activation of beta-catenin in cultured endothelial cells. Furthermore, Dickkopf-1, a specific inhibitor of the wnt pathway, effectively decreased vascular endothelial growth factor and beta-catenin levels in the retinal pigment epithelium of Vldlr(-/-) mice and in cells transfected with the VLDLR small interference RNA. These results suggest that VLDLR functions as a negative regulator of CNV, and this function is mediated through the wnt pathway.
C1 Univ Oklahoma, Hlth Sci Ctr, Dept Med, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   Univ Calif Berkeley, Helen Wills Neurosci Inst, Dept Mol & Cell Biol, Vis Sci & Neurosci Div, Berkeley, CA 94720 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of California System; University of California
   Berkeley
RP Ma, JX (通讯作者)，941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
EM jian-xing-ma@ouhsc.edu
OI Flannery, John/0000-0002-0720-8897
FU NATIONAL EYE INSTITUTE [R33EY015650, R01EY012231, R21EY015650] Funding
   Source: NIH RePORTER
CR BATTEY FD, 1994, J BIOL CHEM, V269, P23268
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965
   COGAN D G, 1963, Trans Ophthalmol Soc U K, V83, P465
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3
   Cursiefen C, 1997, KLIN MONATSBL AUGENH, V210, P341, DOI 10.1055/s-2008-1035072
   Dale TC, 1998, BIOCHEM J, V329, P209
   Easwaran V, 2003, CANCER RES, V63, P3145
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   JOKINEN EV, 1994, J BIOL CHEM, V269, P26411
   KAPUSTINA E. V., 1960, ARKH ANAT GISTOL I EMBRIOL, V39, P16
   Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081
   Kim KI, 2006, ARTERIOSCL THROM VAS, V26, P91, DOI 10.1161/01.ATV.0000193569.12490.4b
   Kondo H, 2003, BRIT J OPHTHALMOL, V87, P1291, DOI 10.1136/bjo.87.10.1291
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Masckauchan THN, 2006, PHYSIOLOGY, V21, P181, DOI 10.1152/physiol.00058.2005
   Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320
   Millar JBA, 2002, GENOME BIOL, V3
   Miller JW, 1997, AM J PATHOL, V151, P13
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nilsson L, 1999, J LIPID RES, V40, P913
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ojesina AI, 2004, J PEDIATR SURG, V39, P1446, DOI 10.1016/j.jpedsurg.2004.06.003
   Orlandini M, 2003, J BIOL CHEM, V278, P44650, DOI 10.1074/jbc.M304255200
   Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2
   Rehm HL, 2002, J NEUROSCI, V22, P4286, DOI 10.1523/JNEUROSCI.22-11-04286.2002
   Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   SAKAI J, 1994, J BIOL CHEM, V269, P2173
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tachikawa K, 2004, P NATL ACAD SCI USA, V101, P15225, DOI 10.1073/pnas.0406473101
   TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252
   Takahashi Sadao, 2004, J Atheroscler Thromb, V11, P200
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503
   Wu BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/iovs.03-1302
   Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Zhang XB, 2001, CANCER RES, V61, P6050
   2004, MORB MORTAL WKLY REP, V53, P1069
NR 54
TC 89
Z9 91
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 23
PY 2007
VL 282
IS 47
BP 34420
EP 34428
DI 10.1074/jbc.M611289200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 234FI
UT WOS:000251145700058
PM 17890782
OA hybrid
DA 2022-11-30
ER

PT J
AU Lavalette, S
   Raoul, W
   Houssier, M
   Camelo, S
   Levy, O
   Calippe, B
   Jonet, L
   Behar-Cohen, F
   Chemtob, S
   Guillonneau, X
   Combadiere, C
   Sennlaub, F
AF Lavalette, Sophie
   Raoul, William
   Houssier, Marianne
   Camelo, Serge
   Levy, Olivier
   Calippe, Bertrand
   Jonet, Laurent
   Behar-Cohen, Francine
   Chemtob, Sylvain
   Guillonneau, Xavier
   Combadiere, Christophe
   Sennlaub, Florian
TI Interleukin-1 beta Inhibition Prevents Choroidal Neovascularization and
   Does Not Exacerbate Photoreceptor Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RECEPTOR ANTAGONIST; MACULAR DEGENERATION; ENDOTHELIAL-CELLS;
   NEUTROPHILS; MICROGLIA; GROWTH; MICE; RAT; MICROPARTICLES; ANGIOGENESIS
AB The pro-inflammatory cytokine IL-1 beta has been shown to promote angiogenesis. It can have a neurotoxic or neuroprotective effect. Here, we have studied the expression of IL-1 beta in vivo and the effect of the IL-1 receptor antagonist on choroidal neovascularization (CNV) and retinal degeneration (RD). IL-1 beta expression significantly increased after laser injury (real time PCR) in C57BL/6 mice, in the C57BL/6 Cx3cr1(-/-) model of age-related macular degeneration (enzyme-linked immunoabsorbent assay), and in albino Wistar rats and albino BALB Cx3cr1(+/+) and Cx3cr1(-/-) mice (enzyme-linked immunoabsorbent assay) after light injury. IL-1 beta was localized to Ly6G-positive, Iba1-negative infiltrating neutrophils in laser-induced CNV as determined by IHC. IL-1 receptor antagonist treatment significantly inhibited CNV but did not affect Iba1-positive macrophage recruitment to the injury site. IL-1 beta significantly increased endothelial cell outgrowth in aortic ring assay independently of vascular endothelial growth factor, suggesting a direct effect of IL-1 beta on choroidal endothelial cell proliferation. Inhibition of IL-1 beta in light- and laser-induced RD models did not alter photoreceptor degeneration in Wistar rats, C57BL/6 mice, or RD-prone Cx3cr1(-/-) mice. Our results suggest that IL-1 beta inhibition might represent a valuable and safe alternative to Inhibition of vascular endothelial growth factor in the control of CNV in the context of concomitant photoreceptor degeneration as observed in age-related macular degeneration. (AmJ Pathol 2011, 178:2416-2423; DOI: 10.1016/j.ajpath.2011.01.013)
C1 [Sennlaub, Florian] Ctr Rech Cordeliers, INSERM, UMR S 872, Equipe 21, F-75006 Paris, France.
   [Lavalette, Sophie; Raoul, William; Houssier, Marianne; Camelo, Serge; Levy, Olivier; Calippe, Bertrand; Jonet, Laurent; Behar-Cohen, Francine; Guillonneau, Xavier; Sennlaub, Florian] Univ Paris 06, UMR S 872, Paris, France.
   [Lavalette, Sophie; Raoul, William; Houssier, Marianne; Camelo, Serge; Levy, Olivier; Calippe, Bertrand; Jonet, Laurent; Behar-Cohen, Francine; Guillonneau, Xavier; Sennlaub, Florian] Univ Paris 05, UMR S 872, Paris, France.
   [Behar-Cohen, Francine; Sennlaub, Florian] Hop Hotel Dieu, AP HP, Serv Ophtalmol, Paris, France.
   [Chemtob, Sylvain] CHU St Justine, Res Ctr, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ, Canada.
   [Chemtob, Sylvain] McGill Univ, Dept Pharm & Therapeut, Montreal, PQ, Canada.
   [Combadiere, Christophe] INSERM, U543, Lab Immunol Cellulaire, Paris, France.
   [Combadiere, Christophe] Univ Paris 06, UMR S 945, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; UDICE-French Research Universities; Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Universite de Montreal; Centre Hospitalier
   Universitaire Sainte-Justine; McGill University; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite
RP Sennlaub, F (通讯作者)，Ctr Rech Cordeliers, INSERM, UMR S 872, Equipe 21, 15 Rue Ecole Med, F-75006 Paris, France.
EM Florian.Sennlaub@inserm.fr
RI Guillonneau, xavier/E-3995-2017; Combadiere, Christophe/I-5639-2013;
   guillonneau, xavier/AAF-9495-2021; Sennlaub, Florian/F-2756-2017; Raoul,
   William/H-2118-2018
OI Guillonneau, xavier/0000-0001-7379-3935; Combadiere,
   Christophe/0000-0002-1755-4531; guillonneau, xavier/0000-0001-7379-3935;
   Sennlaub, Florian/0000-0003-4412-1341; Raoul,
   William/0000-0002-5040-3372; Houssier, Marianne/0000-0002-5329-4597;
   Camelo, Serge/0000-0001-8733-8503
FU INSERM, ANR "blanc" [AO5120DD]; European Grant "Innochem"
   [LSHB-CT-2005-518167]; ANR Maladies Neurologiques et Psychiatriques
   [ANR-08-MNPS-003]; ERC [ERC-2007 St.G. 210345]; Assistance
   Publique-Hopitaux de Paris
FX Supported by grants from INSERM, ANR "blanc" (AO5120DD), European Grant
   "Innochem" (LSHB-CT-2005-518167), ANR Maladies Neurologiques et
   Psychiatriques (ANR-08-MNPS-003) and ERC starting grant (ERC-2007 St.G.
   210345). F.S. is a recipient of a contract "Interface" from Assistance
   Publique-Hopitaux de Paris.
CR Banwell V, 2009, J STROKE CEREBROVASC, V18, P269, DOI 10.1016/j.jstrokecerebrovasdis.2008.11.009
   BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061
   BORASCHI D, 1991, BLOOD, V78, P1262
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Carmi Y, 2009, J IMMUNOL, V183, P4705, DOI 10.4049/jimmunol.0901511
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112
   Isoda K, 2004, ARTERIOSCL THROM VAS, V24, P1068, DOI 10.1161/01.ATV.0000127025.48140.a3
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Leroyer AS, 2008, J AM COLL CARDIOL, V52, P1302, DOI 10.1016/j.jacc.2008.07.032
   Leroyer AS, 2009, CIRCULATION, V119, P2808, DOI 10.1161/CIRCULATIONAHA.108.816710
   MALYAK M, 1994, J CLIN IMMUNOL, V14, P20, DOI 10.1007/BF01541172
   Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198
   Mountain DJH, 2008, LIFE SCI, V82, P1224, DOI 10.1016/j.lfs.2008.04.008
   Namekata K, 2009, NEUROSCI LETT, V465, P160, DOI 10.1016/j.neulet.2009.09.029
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2009, OCUL IMMUNOL INFLAMM, V17, P195, DOI 10.1080/09273940802710705
   Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Whiteley SJO, 2001, EXP EYE RES, V73, P557, DOI 10.1006/exer.2001.1066
   YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676
   Zhou JH, 2005, MOL VIS, V11, P414
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 32
TC 101
Z9 107
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2011
VL 178
IS 5
BP 2416
EP 2423
DI 10.1016/j.ajpath.2011.01.013
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 865JI
UT WOS:000298306800046
PM 21514452
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Vazquez, NP
   Harding, SP
   Heimann, H
   Czanner, G
   Knox, PC
AF Vazquez, Noelia Pitrelli
   Harding, Simon P.
   Heimann, Heinrich
   Czanner, Gabriela
   Knox, Paul C.
TI Radial shape discrimination testing for new-onset neovascular
   age-related macular degeneration in at-risk eyes
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; MONITORING-SYSTEM; VISUAL OUTCOMES;
   HYPERACUITY; RANIBIZUMAB; AMD; PREVALENCE; MANAGEMENT; VISION; DEVICE
AB We investigated the performance of the handheld radial shape discrimination (hRSD) test in detecting the development of neovascular AMD (nAMD) in a prospective, longitudinal, observational study. Patients diagnosed with unilateral nAMD, with no nAMD in the other eye (the study eye, SE), completed the hRSD test on consecutive, routine clinic visits up to a maximum of 12, or until they were diagnosed with nAMD in the SE based on slit-lamp biomicroscopy and spectral-domain OCT assessment, with fluorescein angiography confirmation. Masked grading was carried out to confirm the diagnosis of nAMD, and to ensure no cases of nAMD were missed. Receiver operating characteristics (ROC) analysis was used to explore the diagnostic performance of the hRSD test relative to clinical diagnosis. Data were available from 179 patients of whom 19 (10.6%; "converters") developed nAMD in the SE. The mean hRSD threshold at conversion was -0.47 (95% CI -0.38 to -0.55) logMAR compared to -0.53 (-0.50 to -0.57) logMAR in 160 non-converters. hRSD threshold in the converters began to decline 190 days before diagnosis of nAMD. The ROC curve demonstrated that at an hRSD cut-off of -0.60 logMAR, sensitivity was 0.79 (0.54-0.94) with a specificity of 0.54 (0.46-0.62); positive and negative predictive values were 0.16 and 0.96 respectively. We conclude that the hRSD test has moderate sensitivity for detecting the earliest stages of nAMD in the at-risk fellow eyes of patients with unilateral nAMD, compared to clinical diagnosis. Given its relative inexpensiveness, ease of use and the inherent connectivity of the platforms it can be presented on, it may have a role in early detection of nAMD in the population at large.
C1 [Vazquez, Noelia Pitrelli; Harding, Simon P.; Czanner, Gabriela; Knox, Paul C.] Univ Liverpool, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Vazquez, Noelia Pitrelli; Harding, Simon P.; Heimann, Heinrich] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Czanner, Gabriela] Liverpool John Moores Univ, Dept Appl Math, Liverpool, Merseyside, England.
C3 University of Liverpool; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool; Liverpool John Moores University
RP Knox, PC (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
EM pcknox@liv.ac.uk
RI Heimann, Heinrich/AAP-8747-2020; Knox, Paul/Q-1920-2019; Czanner,
   Gabriela/ABC-7569-2021
OI Heimann, Heinrich/0000-0002-3298-4644; Knox, Paul/0000-0002-2578-7335;
   Czanner, Gabriela/0000-0002-1157-2093; Pitrelli Vazquez,
   Noelia/0000-0002-9800-8419; Harding, Simon/0000-0003-4676-1158
FU Dunhill Medical Trust, London, UK [R283/0213]
FX This work was funded by a project grant from the Dunhill Medical Trust,
   London, UK (grant number: R283/0213) (PCK). The funder had no role in
   the design or conduct of this research, or in the preparation of this
   manuscript.
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Au A, 2011, CURR OPIN OPHTHALMOL, V22, P194, DOI 10.1097/ICU.0b013e3283459508
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1373/clinchem.2015.246280, 10.1148/radiol.2015151516]
   Buckle M, 2016, BRIT J OPHTHALMOL, V100, P240, DOI 10.1136/bjophthalmol-2014-306423
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Ku JY, 2017, INVEST OPHTH VIS SCI, V58
   Ku JY, 2016, PEERJ, V4, DOI 10.7717/peerj.2650
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061
   Loewenstein A, 2012, OPHTHALMIC RES, V48, P11, DOI 10.1159/000339842
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Pitrelli Vazquez Noelia, 2015, Br Ir Orthopt J, V12, P9
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Schneider EW, 2014, INVEST OPHTH VIS SCI, V55, P542, DOI 10.1167/iovs.13-13034
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stur M, 2010, OPHTHAL SURG LAS IM, V41, P598, DOI 10.3928/15428877-20100830-05
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2009, OPTOMETRY VISION SCI, V86, P695, DOI 10.1097/OPX.0b013e3181a7b0ff
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 36
TC 7
Z9 7
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2018
VL 13
IS 11
AR e0207342
DI 10.1371/journal.pone.0207342
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GZ5ZX
UT WOS:000449512300098
PM 30408127
OA Green Submitted, gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Hirata, FE
   de Vasconcellos, JPC
   Medina, FM
   Rim, PHH
   Fulco, EAM
   de Melo, MB
AF Hirata, Fabio Endo
   Cabral de Vasconcellos, Jose Paulo
   Medina, Flavio MacCord
   Hyun Rim, Priscila Hae
   Medeiros Fulco, Enzo Augusto
   de Melo, Monica Barbosa
TI Association of LOC387715/ARMS2 (rs10490924) Gene Polymorphism with
   Age-Related Macular Degeneration in the Brazilian Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE AMD; LOC387715/ARMS2; macular degeneration; polymorphism; rs10490924
ID COMPLEMENT FACTOR-H; CHROMOSOME 10Q26; SUSCEPTIBILITY; MACULOPATHY;
   DISEASES; HTRA1; RISK
AB Background: An association between LOC387715/ARMS2 (rs10490924) gene polymorphism and AMD has been reported. The aim of this study was to evaluate whether this polymorphism is associated with AMD in a Brazilian cohort.
   Materials and Methods: In total, 126 unrelated AMD patients (mean age 74.17 +/- 7.64) were compared with 86 healthy controls (mean age 71.82 +/- 7.12). Study subjects were classified according to the International ARM Epidemiological Study Group definition for early and late-stage AMD. LOC387715/ARMS2 rs10490924 polymorphism was evaluated through polymerase chain reaction and direct sequencing.
   Results: The T allele frequency was significantly higher in AMD patients than in controls (39.6% compared to 20.3%). The odds ratio (OR) for AMD was 2.05 (95% CI 1.13-3.71) for heterozygotes (TG) and 8.32 (95% CI 2.30-45.99) for homozygotes (TT).
   Conclusions: These results suggest that there is a contribution of the rs10490924 SNP of the LOC387715/ARMS2 gene to AMD susceptibility in this sample of the Brazilian population.
C1 [Hirata, Fabio Endo; Cabral de Vasconcellos, Jose Paulo; Medina, Flavio MacCord; Hyun Rim, Priscila Hae; Medeiros Fulco, Enzo Augusto] Univ Estadual Campinas, Fac Med Sci, Dept Ophthalmol, BR-13083875 Campinas, SP, Brazil.
   [de Melo, Monica Barbosa] Univ Estadual Campinas, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Mol Genet, BR-13083875 Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas
RP de Melo, MB (通讯作者)，Univ Estadual Campinas, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Mol Genet, POB 6010, BR-13083875 Campinas, SP, Brazil.
EM melomb@uol.com.br
RI Medina, Flavio/AFM-1303-2022
FU National Council of Technological and Scientific Development (CNPq)
   [472645/2008]
FX We thank the National Council of Technological and Scientific
   Development (CNPq) for the financial support [Grant #472645/2008].
CR Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2000, Community Eye Health, V13, P17
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Taleb A, 2009, CONDICOES SAUDE OCUL, P10
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tong Y, 2010, MOL VIS, V16, P1958
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
NR 26
TC 5
Z9 5
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2015
VL 36
IS 3
BP 224
EP 228
DI 10.3109/13816810.2013.867449
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA CR4UJ
UT WOS:000361334700004
PM 24372405
DA 2022-11-30
ER

PT J
AU Csaky, K
   Baffi, J
   Chan, CC
   Byrnes, GA
AF Csaky, K
   Baffi, J
   Chan, CC
   Byrnes, GA
TI Clinicopathologic correlation of progressive fibrovascular proliferation
   associated with occult choroidal neovascularization in age-related
   macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
C1 NEI, NIH, Bethesda, MD 20895 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Csaky, K (通讯作者)，NEI, NIH, Bldg 10,Room 10N119,9000 Rockville Pike, Bethesda, MD 20895 USA.
EM kcsaky@helix.nih.gov
FU NATIONAL EYE INSTITUTE [Z01EY000222, Z01EY000327, ZIAEY000222] Funding
   Source: NIH RePORTER
CR BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568
NR 5
TC 12
Z9 12
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2004
VL 122
IS 4
BP 650
EP 652
DI 10.1001/archopht.122.4.650
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812GT
UT WOS:000220828700027
PM 15078686
DA 2022-11-30
ER

PT J
AU Jarrard, P
AF Jarrard, Paula
TI Tailoring In-Home Lighting Preferences for Consumers With Age-Related
   Macular Degeneration: Using the LuxIQ Protocol
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
DE lighting assessment; age-related macular degeneration; LuxIQ; low vision
ID OCCUPATIONAL-THERAPY INTERVENTIONS; OLDER-ADULTS; LOW-VISION; IMPROVE
C1 [Jarrard, Paula] Indiana State Univ, Indiana Univ, Occupat Therapy Program, Sch Optometry, Terre Haute, IN 47809 USA.
C3 Indiana State University; Indiana University System
RP Jarrard, P (通讯作者)，Indiana State Univ, Occupat Therapy Program, 567 N 5TH ST, Terre Haute, IN 47809 USA.
EM paula.Jarrard@indstate.edu
FU Family & Social Services Administration of Indiana, Older Independent
   Blind and Visually Impaired Grant
FX The author would like to acknowledge consumers at the Wabash Valley
   Independent Living and Learning Center, Terre Haute, Indiana, for their
   participation. Support was provided by the Family & Social Services
   Administration of Indiana, Older Independent Blind and Visually Impaired
   Grant. The Indiana State University Institutional Review Board approved
   this study's work with human subjects.
CR Barstow B., 2015, WORKSH PRES AOTA ANN
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   Jasper Ridge Inc., 2020, LUXIQ LIGHT EX SYST
   Law M., 2000, CANADIAN OCCUPATIONA, V5th
   Liu CJ, 2013, AM J OCCUP THER, V67, P279, DOI 10.5014/ajot.2013.005512
   National Eye Institute, 2019, AGE RELATED MACULAR
   Perlmutter M., 2013, HOME ENV LIGHTING AS
   Perlmutter M., 2015, LUXIQ PROTOCOL USE H
   Rotruck J., 2015, LOW VISION PATIENTS
   Sanders M, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.72S1-PO1008
   Smallfield S, 2013, AM J OCCUP THER, V67, P288, DOI 10.5014/ajot.2013.004929
   Succar T., 2015, VISABILITY, V9, P6
NR 13
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JAN
PY 2022
VL 116
IS 1
BP 110
EP 113
DI 10.1177/0145482X211072553
PG 4
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA ZX0DH
UT WOS:000771572100012
DA 2022-11-30
ER

PT J
AU Sadigh, S
   Cideciyan, AV
   Sumaroka, A
   Huang, WC
   Luo, XD
   Swider, M
   Steinberg, JD
   Stambolian, D
   Jacobson, SG
AF Sadigh, Sam
   Cideciyan, Artur V.
   Sumaroka, Alexander
   Huang, Wei Chieh
   Luo, Xunda
   Swider, Malgorzata
   Steinberg, Janet D.
   Stambolian, Dwight
   Jacobson, Samuel G.
TI Abnormal Thickening as well as Thinning of the Photoreceptor Layer in
   Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FIBROBLAST-GROWTH-FACTOR;
   RETINITIS-PIGMENTOSA; RETINAL SENSITIVITY; SOFT DRUSEN; DISEASE;
   MICROPERIMETRY; SUSCEPTIBILITY; PROGRESSION; EXPRESSION
AB PURPOSE. To investigate the relationship between photoreceptor layers overlying and adjacent to large drusen in intermediate nonneovascular AMD.
   METHODS. Patients with AMD (n = 41; aged 53-83 years) and elderly control subjects without eye disease (n = 10; aged 51-79 years) were studied with spectral-domain optical coherence tomography. Characteristics of large drusen (>= 125 mu m) were measured and the thickness of photoreceptor laminae overlying drusen and in retinal regions neighboring the drusen were quantified.
   RESULTS. There were 750 large drusen in 63 intermediate AMD eyes studied. The width of the drusen sampled averaged 352 mu m (SD = 153) and the height averaged 78 mu m (SD = 31). There was significant reduction of the photoreceptor outer nuclear layer (ONL) thickness overlying 92% of the drusen. The thickness of the layer corresponding to photoreceptor inner and outer segments above drusen was also reduced, and the reduction was proportional to ONL thickness. In a substantial fraction (similar to 20%) of normally laminated paradrusen locations sampled within similar to 300 mu m of peak drusen height, ONL thickness was significantly increased compared with age and retinal location-matched normal values. Topographical analyses of the macula showed ONL thickening occurring in paradrusen regions as well as retinal locations distant from drusen.
   CONCLUSIONS. Reductions in the photoreceptor laminae overlying drusen were detectable and this is consistent with histological studies revealing neuronal degeneration in AMD. ONL thickening in some macular areas of AMD eyes has not been previously reported and may be an early phenotypic marker for photoreceptor stress, as it has been speculated to be in hereditary retinal degenerations. (Invest Ophthalmol Vis Sci. 2013;54:1603-1612) DOI:10.1167/iovs.12-11286
C1 [Sadigh, Sam; Cideciyan, Artur V.; Sumaroka, Alexander; Huang, Wei Chieh; Luo, Xunda; Swider, Malgorzata; Steinberg, Janet D.; Jacobson, Samuel G.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Stambolian, Dwight] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Stambolian, Dwight] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine
RP Cideciyan, AV (通讯作者)，Univ Penn, Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM cideciya@mail.med.upenn.edu
RI Cideciyan, Artur V/A-1075-2007; Luo, Xunda/K-6692-2013
OI Cideciyan, Artur V/0000-0002-2018-0905; Jacobson,
   Samuel/0000-0003-2122-169X
FU Pennsylvania Department of Health; Macula Vision Research Foundation;
   Beckman Initiative for Macular Research; Foundation Fighting Blindness
FX Supported by a grant from the Pennsylvania Department of Health to the
   University of Pennsylvania, Macula Vision Research Foundation, the
   Beckman Initiative for Macular Research, and the Foundation Fighting
   Blindness. AVC is a Research to Prevent Blindness Senior Scientific
   Investigator.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P4759, DOI 10.1167/iovs.07-0453
   Beltran WA, 2007, EXP EYE RES, V84, P753, DOI 10.1016/j.exer.2006.12.019
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P3985, DOI 10.1167/iovs.08-3364
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Carroll J, 2009, P NATL ACAD SCI USA, V106, P20948, DOI 10.1073/pnas.0910128106
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Cideciyan AV, 2011, HUM MOL GENET, V20, P1411, DOI 10.1093/hmg/ddr022
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Jacobson SG, 2007, P NATL ACAD SCI USA, V104, P15123, DOI 10.1073/pnas.0706367104
   Jacobson SG, 2013, HUM MOL GENET, V22, P168, DOI 10.1093/hmg/dds421
   Jacobson SG, 2011, INVEST OPHTH VIS SCI, V52, P7924, DOI 10.1167/iovs.11-8313
   Jacobson SG, 2010, NEW ENGL J MED, V363, P1669, DOI 10.1056/NEJMcibr1007685
   Jacobson SG, 2003, HUM MOL GENET, V12, P1073, DOI 10.1093/hmg/ddg117
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Peet JA, 2007, INVEST OPHTH VIS SCI, V48, P4002, DOI 10.1167/iovs.06-1388
   Rangaswamy NV, 2010, INVEST OPHTH VIS SCI, V51, P4213, DOI 10.1167/iovs.09-4945
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Sung KR, 2009, OPHTHALMOLOGY, V116, P1119, DOI 10.1016/j.ophtha.2009.01.004
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tackenberg MA, 2009, MOL VIS, V15, P1886
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   WEN R, 1995, J NEUROSCI, V15, P7377
   Xiao M, 1998, INVEST OPHTH VIS SCI, V39, P618
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 63
TC 63
Z9 63
U1 2
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 1603
EP 1612
DI 10.1167/iovs.12-11286
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400004
PM 23361506
DA 2022-11-30
ER

PT J
AU Zhang, D
   Robinson, K
   Washington, I
AF Zhang, Dan
   Robinson, Kiera
   Washington, Ilyas
TI C20D(3)-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes
   in a Mouse Model
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE Stargardt disease; AMD; vitamin A
ID QUANTITATIVE FUNDUS AUTOFLUORESCENCE; MACULAR-DEGENERATION; A2E;
   LIPOFUSCIN; LIGHT; MICE; SUPEROXIDATION; RETINOPATHY; BLINDNESS
AB Purpose: This study aimed to evaluate the contribution of vitamin A dimerization to retinal pigment epithelium (RPE) atrophic changes. Leading causes of irreversible blindness, including Stargardt disease and age-related macular degeneration (AMD), occur as a result of atrophic changes in RPE. The cause of the RPE atrophic changes is not apparent. During the vitamin A cycle, vitamin A dimerizes, leading to vitamin A cycle byproducts, such as vitamin A dimers, in the RPE.
   Methods: To study the consequence of vitamin A dimerization to RPE atrophic changes, we used a rodent model with accelerated vitamin A dimerization, Abca4(-/-)/Rdh8(-/-) mice, and the vitamin A analog C20D(3)-vitamin A to selectively ameliorate the accelerated rate of vitamin A dimerization.
   Results: We show that ameliorating the rate of vitamin A dimerization with C20D(3)-vitamin A mitigates pathological changes observed in the prodromal phase of the most prevalent retinal degenerative diseases, including fundus autofluorescence changes, dark adaptation delays, and signature RPE atrophic changes.
   Conclusions: Data demonstrate that the dimerization of vitamin A during the vitamin A cycle is sufficient alone to cause the prerequisite RPE atrophic changes thought to be responsible for the leading causes of irreversible blindness and that correcting the dimerization rate with C20D(3)-vitamin A may be sufficient to prevent the RPE atrophic changes.
   Translational Relevance: Preventing the dimerization of vitamin A with the vitamin A analog C20D(3)-vitamin A may be sufficient to alter the clinical course of the most prevalent forms of blindness, including Stargardt disease and age-related macular degeneration (AMD).
C1 [Zhang, Dan; Robinson, Kiera; Washington, Ilyas] Columbia Univ, Med Ctr, Ophthalmol, New York, NY USA.
   [Washington, Ilyas] BiOOrg3 14, Buffalo, WY 82834 USA.
C3 Columbia University
RP Washington, I (通讯作者)，BiOOrg3 14, Buffalo, WY 82834 USA.
EM publications@bioorg314.com
OI W, I/0000-0002-2238-7918
FU US National Institutes of Health, National Eye Institute [1R01EY021207];
   Research to Prevent Blindness (RPB) Inc., New York, NY; BrightFocus
   Foundation, Clarksburg, MD
FX Supported by the US National Institutes of Health, National Eye
   Institute (grant number 1R01EY021207) , Research to Prevent Blindness
   (RPB) Inc., New York, NY, and The BrightFocus Foundation, Clarksburg,
   MD.
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bertolotto M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741538
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird A, 2021, BRIT J OPHTHALMOL, V105, P1469, DOI 10.1136/bjophthalmol-2020-317447
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hu JN, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101787
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Lem J, 2004, TRENDS MOL MED, V10, P150, DOI 10.1016/j.molmed.2004.02.009
   Liu Qiangni, 2019, Cell Physiol Biochem, V53, P400, DOI 10.33594/000000146
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Meyer A, 1877, GRAEFES ARCH OPHTHAL, V23, P159
   Mihai DM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.314
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Penn J, 2015, DIS MODEL MECH, V8, P131, DOI 10.1242/dmm.017194
   Piccardi M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102461
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Washington I, 2005, ANGEW CHEM INT EDIT, V44, P7097, DOI 10.1002/anie.200501346
   Washington I, 2007, PHOTOCH PHOTOBIO SCI, V6, P775, DOI 10.1039/b618104j
   Washington I, 2006, PHOTOCHEM PHOTOBIOL, V82, P1394, DOI 10.1562/2006-02-28-RA-828
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang D, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101074
NR 51
TC 0
Z9 0
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 8
DI 10.1167/tvst.10.14.8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XN8FY
UT WOS:000729735200001
PM 34878528
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, SY
   Chhabra, R
AF Liu, Siyin
   Chhabra, Ramandeep
TI Comparison of 3-year outcomes of photodynamic therapy combined with
   intravitreal ranibizumab or aflibercept for polypoidal choroidal
   vasculopathy in a European cohort
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Ranibizumab; Aflibercept;
   Photodynamic therapy; Switching
ID MACULAR DEGENERATION; VERTEPORFIN; COMBINATION; EVEREST; LAPTOP; TRIAL
AB Purpose Combined use of photodynamic therapy (PDT) with intravitreal anti-vascular endothelial growth factors (anti-VEGF) agents, such as ranibizumab (IVR) or aflibercept (IVA), has been shown to be effective for treating polypoidal choroidal vasculopathy (PCV). However, it is currently not well established which anti-VEGF agent provides superior outcomes for performing combination therapy. The present study compares the visual outcomes and re-treatment burden of combination therapy of PDT with either IVR or IVA in a European cohort of patients with PCV.
   Methods A retrospective analysis was done on PCV patients who had received combination therapy of PDT with either IVR or IVA. The demographic characteristics, visual outcome, and anti-VEGF re-treatment exposures were analysed and compared.
   Results A total of forty-four eyes (n = 11 male, 25%) were included in the analysis: 7 patients received IVR, 19 started with IVR but switched to IVA (IVS), and 18 received IVA, in combination with PDT. The BCVA improved in all three groups at 6-, 12-, 18-, 24-, 30-, and 36-month follow-ups after PDT, although the improvement was not statistically significant in the IVR group. The number of intravitreal anti-VEGF injections required/year after PDT was significantly fewer than before PDT. Significantly less eyes in the IVS group attained a good visual acuity of more than 70 ETDRS letters at the final visit.
   Conclusion Both IVR and IVA combined with PDT were effective treatments for the European cohort of patients with PCV. In eyes refractory to IVR, performing PDT promptly may be more beneficial than switching to IVA.
C1 [Liu, Siyin; Chhabra, Ramandeep] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Liu, Siyin; Chhabra, Ramandeep] Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Chhabra, Ramandeep] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester
RP Liu, SY (通讯作者)，Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.; Liu, SY (通讯作者)，Univ Manchester, Sch Biol Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
EM siyin.liu@mft.nhs.uk
CR [Anonymous], NEW PHASE 3 DATA SHO
   [Anonymous], ROYAL COLL OPHTHALMO
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   CZARSKA-THORLEY D, 2021, VISUDYNE VERTEPORFIN
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Ito A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235213
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kim JH, 2020, GRAEF ARCH CLIN EXP, V258, P1677, DOI 10.1007/s00417-020-04710-y
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Liu SY, 2022, EYE, V36, P1934, DOI 10.1038/s41433-021-01773-x
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Weng HY, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11031194
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 44
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2022
VL 260
IS 11
BP 3533
EP 3542
DI 10.1007/s00417-022-05724-4
EA JUN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5L3BJ
UT WOS:000808417300001
PM 35678837
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Winkler, TW
   Brandl, C
   Grassmann, F
   Gorski, M
   Stark, K
   Loss, J
   Weber, BHF
   Heid, IM
AF Winkler, Thomas W.
   Brandl, Caroline
   Grassmann, Felix
   Gorski, Mathias
   Stark, Klaus
   Loss, Julika
   Weber, Bernhard H. F.
   Heid, Iris M.
CA Int Agerelated Macular Degeneratio
TI Investigating the modulation of genetic effects on late AMD by age and
   sex: Lessons learned and two additional loci
SO PLOS ONE
LA English
DT Article
ID RETINALDEHYDE-BINDING PROTEIN; RETINITIS PUNCTATA ALBESCENS; GENOME-WIDE
   ASSOCIATION; BEAVER DAM EYE; MACULAR DEGENERATION; ENVIRONMENT
   INTERACTION; BOTHNIA DYSTROPHY; RISK-FACTORS; RLBP1 GENE; CFH GENE
AB Late-stage age-related macular degeneration (AMD) is the leading cause of visual impairment in the elderly with a complex etiology.The most important non-modifiable risk factors for onset and progression of late AMD are age and genetic risk factors, however, little is known about the interplay between genetics and age or sex. Here, we conducted a large-scale age-and sex-stratified genome-wide association study (GWAS) using 1000 Genomes imputed genome-wide and ExomeChip data (>12 million variants). The data were established by the International Age-related Macular Degeneration Genomics Consortium (IAMDGC) from 16,144 late AMD cases and 17,832 controls. Our systematic search for interaction effects yielded significantly stronger effects among younger individuals at two known AMD loci (near CFH and ARMS2/HTRA1). Accounting for age and gene-age interaction using a joint test identified two additional AMD loci compared to the previous main effect scan. One of these two is a novel AMD GWAS locus, near the retinal clusterin-like protein (CLUL1) gene, and the other, near the retinaldehyde binding protein 1 (RLBP1), was recently identified in a joint analysis of nuclear and mitochondrial variants. Despite considerable power in our data, neither sex-dependent effects nor effects with opposite directions between younger and older individuals were observed. This is the first genome-wide interaction study to incorporate age, sex and their interaction with genetic effects for late AMD. Results diminish the potential for a role of sex in the etiology of late AMD yet highlight the importance and existence of age-dependent genetic effects.
C1 [Winkler, Thomas W.; Brandl, Caroline; Gorski, Mathias; Stark, Klaus; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Loss, Julika] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Regensburg
RP Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
EM iris.heid@klinik.uni-regensburg.de
RI Stark, Klaus/L-7367-2013
OI Stark, Klaus/0000-0002-7832-1942; Winkler, Thomas/0000-0003-0292-5421;
   Brandl, Caroline/0000-0001-8223-6137; Grassmann,
   Felix/0000-0003-1390-7528
FU German Federal Ministry of Education and Research [BMBF 01ER1206, BMBF
   01ER1507, BMBF 01GP1308]
FX The authors gratefully acknowledge the excellent International
   Age-related Macular Degeneration Genomics Consortium (IAMDGC),
   (http://amdgeneticsorg/). This analyses are supported by grants from the
   German Federal Ministry of Education and Research (BMBF 01ER1206, BMBF
   01ER1507 to IMH, and BMBF 01GP1308) to JL. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aguet F, 2016, COLD SPRING HARBOR L
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Aschard H, 2010, HUM HERED, V70, P292, DOI 10.1159/000323318
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Brandl C, 2015, J CLIN MED, V4, P282, DOI 10.3390/jcm4020282
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Daiger S, 1998, INVEST OPHTHALMOLVIS, V39, P295
   Eichers ER, 2002, AM J HUM GENET, V70, P955, DOI 10.1086/339688
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   He XQ, 2009, P NATL ACAD SCI USA, V106, P18545, DOI 10.1073/pnas.0907454106
   Hipp S, 2015, ACTA OPHTHALMOL, V93, pE281, DOI 10.1111/aos.12573
   Katsanis N, 2001, CLIN GENET, V59, P424, DOI 10.1034/j.1399-0004.2001.590607.x
   Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sturgill GM, 2006, OPHTHALMIC GENET, V27, P151, DOI 10.1080/13816810600976871
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   Sung YJ, 2016, GENET EPIDEMIOL, V40, P404, DOI 10.1002/gepi.21978
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Winkler TW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181038
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang Q, 2003, INVEST OPHTH VIS SCI, V44, P4542, DOI 10.1167/iovs.02-1202
   Zhang Q, 2000, GENE, V243, P151, DOI 10.1016/S0378-1119(99)00542-9
NR 46
TC 14
Z9 14
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2018
VL 13
IS 3
AR e0194321
DI 10.1371/journal.pone.0194321
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FY9MC
UT WOS:000427189300053
PM 29529059
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Okemefuna, AI
   Nan, R
   Miller, A
   Gor, J
   Perkins, SJ
AF Okemefuna, Azubuike I.
   Nan, Ruodan
   Miller, Ami
   Gor, Jayesh
   Perkins, Stephen J.
TI Complement Factor H Binds at Two Independent Sites to C-reactive Protein
   in Acute Phase Concentrations
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID REGULATOR FACTOR-H; SEDIMENTATION-VELOCITY; X-RAY; SCATTERING DATA;
   FACTOR-I; POLYMORPHISM; ACTIVATION; NEUTRON; ULTRACENTRIFUGATION;
   DISTRIBUTIONS
AB Factor H (FH) regulates the activation of C3b in the alternative complement pathway, both in serum and at host cell surfaces. It is composed of 20 short complement regulator (SCR) domains. The Y402H polymorphism in FH is a risk factor for age-related macular degeneration. C-reactive protein (CRP) is an acute phase protein that binds Ca2+. We established the FH-CRP interaction using improved analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and synchrotron x-ray scattering methods. Physiological FH and CRP concentrations were used in 137 mM NaCl and 2 mM Ca2+, in which the occurrence of denatured CRP was avoided. In solution, AUC revealed FH-CRP binding. The FH-CRP interaction inhibited the formation of higher FH oligomers, indicating that CRP blocked FH dimerization sites at both SCR-6/8 and SCR-16/20. SPR confirmed the FH-CRP interaction and its NaCl concentration dependence upon using either immobilized FH or CRP. The SCR-1/5 fragment of FH did not bind to CRP. In order of increasing affinity, SCR-16/20, SCR-6/8 (His-402), and SCR-6/8 (Tyr-402) fragments bound to CRP. X-ray scattering showed that FH became more compact when binding to CRP, which is consistent with CRP binding at two different FH sites. We concluded that FH and CRP bind at elevated acute phase concentrations of CRP in physiological buffer. The SCR-16/20 site is novel and indicates the importance of the FH-CRP interaction for both age-related macular degeneration and atypical hemolytic uremic syndrome.
C1 [Okemefuna, Azubuike I.; Nan, Ruodan; Miller, Ami; Gor, Jayesh; Perkins, Stephen J.] UCL, Dept Biol Mol & Struct, London WC1E 6BT, England.
C3 University of London; University College London
RP Perkins, SJ (通讯作者)，UCL, Dept Biol Mol & Struct, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
FU BBSRC [BB/E013104/1] Funding Source: UKRI; MRC [G0801724] Funding
   Source: UKRI; Biotechnology and Biological Sciences Research Council
   [BB/E013104/1] Funding Source: Medline; Medical Research Council
   [G0801724] Funding Source: Medline
CR Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Blizniukov OP, 2003, MOL BIOL+, V37, P912, DOI 10.1023/B:MBIL.0000008361.22136.c8
   Bonner A, 2007, J BIOL CHEM, V282, P16969, DOI 10.1074/jbc.M701281200
   Bonner A, 2009, J BIOL CHEM, V284, P5077, DOI 10.1074/jbc.M807529200
   Brown PH, 2006, BIOPHYS J, V90, P4651, DOI 10.1529/biophysj.106.081372
   Christopeit T, 2009, ANAL BIOCHEM, V391, P39, DOI 10.1016/j.ab.2009.04.037
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584
   DEBEER FC, 1982, J IMMUNOL METHODS, V50, P17, DOI 10.1016/0022-1759(82)90300-3
   FARRIES TC, 1990, COMPLEMENT INFLAMMAT, V7, P30, DOI 10.1159/000463124
   Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008
   Gilbert HE, 2005, J MOL BIOL, V346, P859, DOI 10.1016/j.jmb.2004.12.006
   Glatter O., 1982, SMALL ANGLE X RAY SC
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hurwitz S, 1996, CRIT REV BIOCHEM MOL, V31, P41, DOI 10.3109/10409239609110575
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   KAPLAN MH, 1974, J IMMUNOL, V112, P2135
   KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li KY, 2008, J MOL BIOL, V384, P137, DOI 10.1016/j.jmb.2008.08.084
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8
   NELSON SR, 1991, CLIN CHIM ACTA, V200, P191, DOI 10.1016/0009-8981(91)90090-Y
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1041, DOI 10.1074/jbc.M109.044495
   Okemefuna AI, 2009, J MOL BIOL, V391, P119, DOI 10.1016/j.jmb.2009.06.013
   Okemefuna AI, 2009, J MOL BIOL, V391, P98, DOI 10.1016/j.jmb.2009.06.010
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x
   PERKINS SJ, 1985, EUR J BIOCHEM, V147, P525
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   PERKINS SJ, 1986, PROTIDES BIOL FLUIDS, V34, P323
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X
   Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Tanious FA, 2008, METHOD CELL BIOL, V84, P53, DOI 10.1016/S009911-679X(07)84003-9
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
NR 57
TC 96
Z9 97
U1 0
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 8
PY 2010
VL 285
IS 2
BP 1053
EP 1065
DI 10.1074/jbc.M109.044529
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 539MH
UT WOS:000273258200026
PM 19850925
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Pahl, L
   Spangenberg, A
   Schubert, S
   Schonmann, U
   Schmidtke, J
   Stuhrmann, M
AF Pahl, Lisa
   Spangenberg, Astrid
   Schubert, Stephanie
   Schoenmann, Uwe
   Schmidtke, Joerg
   Stuhrmann, Manfred
TI Characterization of the 10q26-orthologue in rhesus monkeys corroborates
   a functional connection between ARMS2 and HTRA1
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; HTRA1; ARMS2; rhesus monkey; linkage
   disequilibrium; association study
ID MACULAR DEGENERATION; SUSCEPTIBILITY GENES; CHROMOSOME 10Q26;
   MACACA-MULATTA; MESSENGER-RNA; AGE; DRUSEN; ASSOCIATION; MACULOPATHY;
   LOC387715
AB Age-related macular degeneration, which is the leading cause of blindness in industrialized countries, is a multifactorial, degenerative disorder of the macula with strong heritability. For age-related macular degeneration in humans, the genes ARMS2 and HTRA1 in the region 10q26 are both promising candidates for being involved in pathogenesis. However, the associated variants are located in a region of strong linkage disequilibrium and so far, the identification of the causative gene in humans was not yet possible. This dilemma might be solved using an appropriate model organism. Rhesus monkeys suffer from drusen, a major hallmark of age-related macular degeneration, and the drusen-phenotype shares susceptibility factors with human macular degeneration. Thus, the rhesus monkey represents a natural animal model to uncover genetic factors leading to macular degeneration. Moreover, the existence of genetically homogenous cohorts offers an excellent opportunity to determine risk factors. However, the 10q26-orthologue genomic region in rhesus monkeys is not characterized in detail so far. Therefore, the aim of this study is to analyze the rhesus linkage disequilibrium structure and to investigate whether variants in ARMS2 or HTRA1 are associated with the drusen-phenotype as well. We sequenced parts of a 20 kb region around ARMS2 and HTRA1 in a genetically homogeneous cohort of 91 rhesus monkeys descending from the CPRC rhesus cohort on Cayo Santiago and currently housed in the German Primate Centre in Gottingen. Within this group, ophthalmoscopic examinations revealed a naturally high drusen prevalence of about 47% in monkeys >5 years. We detected 56 genetic variants within and around ARMS2 and HTRA1 and, as one deviates from Hardy-Weinberg-Equilibrium, 55 polymorphisms were used to generate a linkage disequilibrium-Plot and to perform association studies. We observed strong linkage disequilibrium between the markers and were able to define two haplotype blocks. One of these blocks spanned the whole ARMS2 locus and the 5 part of HTRA1 almost perfectly resembling the situation found in humans. Tests for association revealed a variant in the promoter region of HTRA1 and two variants in the 5'-UTR of ARMS2 to be associated with drusen. The strong linkage disequilibrium inhibits as in humans a determination of the risk gene using statistical methods only. However, the conserved linkage disequilibrium structure in humans and macaques goes in line with the recently emerged dual causality model proposing that ARMS2 and HTRA1 are functionally connected and that both genes contribute to the disease pathology. Moreover, the characterization of the 10q26-orthologue genomic region of the rhesus monkey provides a basis for now needed functional investigations in a well-characterized model organism. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Pahl, Lisa; Schubert, Stephanie; Schmidtke, Joerg; Stuhrmann, Manfred] Hannover Med Sch, Inst Human Genet, D-30625 Hannover, Germany.
   [Schoenmann, Uwe] German Primate Ctr, Gottingen, Germany.
C3 Hannover Medical School; Deutsches Primatenzentrum (DPZ)
RP Pahl, L (通讯作者)，Hannover Med Sch, Inst Human Genet, OE 6300,Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM pahl.lisa@mh-hannover.de
OI Schubert, Stephanie/0000-0001-8634-7299
FU Studienstiftung des deutschen Volkes
FX This work was supported by a grant of the Studienstiftung des deutschen
   Volkes to L.P. We thank Abbott Germany for allocating a fundus camera.
   We thank Dr. Lars G. Fritsche (Institute of Human Genetics, University
   of Regensburg) for providing statistical advice and for critically
   reading the manuscript. We thank Prof. Dr. Bernhard Weber (Institute of
   Human Genetics, University of Regensburg) for his help with primer
   selection and his generosity for providing substantial genomic sequence
   data of the ARMS2/HTRA1 locus of the Rhesus monkey.
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2010, MOL VIS, V16, P1317
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUMAN GENETICS, V81
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Singh KK, 2005, EXP EYE RES, V81, P401, DOI 10.1016/j.exer.2005.02.011
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 26
TC 11
Z9 11
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2012
VL 98
BP 75
EP 78
DI 10.1016/j.exer.2012.03.007
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 944DG
UT WOS:000304178000011
PM 22465519
DA 2022-11-30
ER

PT J
AU Chen, E
   Kaiser, RS
   Vander, JF
AF Chen, Eric
   Kaiser, Richard S.
   Vander, James F.
TI Intravitreal bevacizumab for refractory pigment epithelial detachment
   with occult choroidal neovascularization in age-related macular
   degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; intravitreal; pigment epithelial detachment;
   vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR
AB Purpose: New medications targeting vascular endothelial growth factor show promise in the treatment of wet macular degeneration. This study describes the clinical response and optical coherence tomography (OCT) findings for patients with refractory pigment epithelial detachment (PED) and occult choroidal neovascular membranes (CNVMs) who were treated with intravitreal bevacizumab.
   Methods: A retrospective analysis of data for 10 patients with fibrovascular PEDs, initially treated with intravitreal pegaptanib, thermal laser, or photodynamic therapy with or without triamcinolone acetonide administration, was performed. All patients were refractory to previous treatment. They received monthly injections of bevacizumab and were followed by clinical examination, angiography, and OCT.
   Results: Nine of 10 patients had stable or improved vision. Angiogram findings showed resolution of leakage from CNVMs. OCT demonstrated resolution of the subretinal or intraretinal fluid but persistence of the PED itself. Vision improvement was correlated with OCT changes.
   Conclusion: Intravitreal bevacizumab may be a viable option in treating patients with fibrovascular PEDs. OCT findings suggest that visual improvement is secondary to resolution of subretinal and intraretinal edema without resolution of the PED.
C1 Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Kaiser, RS (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM KaiserRick@aol.com
OI Chen, Eric/0000-0003-0760-925X
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, INVEST OPHTHALMOL VI, V47
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 12
TC 48
Z9 52
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2007
VL 27
IS 4
BP 445
EP 450
DI 10.1097/01.iae.0000249574.89437.40
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 171AA
UT WOS:000246706100007
PM 17420696
DA 2022-11-30
ER

PT J
AU Klein, R
   Lee, KE
   Gangnon, RE
   Klein, BEK
AF Klein, Ronald
   Lee, Kristine E.
   Gangnon, Ronald E.
   Klein, Barbara E. K.
TI Incidence of Visual Impairment Over a 20-Year Period The Beaver Dam Eye
   Study
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; UNITED-STATES; MACULAR
   DEGENERATION; SOCIOECONOMIC-STATUS; POPULATION; PREVALENCE; ACUITY;
   BLINDNESS; AMERICANS
AB Purpose: To describe visual impairment (VI) over a 20-year period and its associations with age-related eye diseases and socioeconomic factors in the Beaver Dam Eye Study.
   Design: Population-based cohort study.
   Participants: Four thousand nine hundred twenty-six persons 43 to 86 years of age participated in the baseline examination phase from 1988 through 1990, and 3721, 2962, 2375, and 1913 persons participated in follow-up examinations each spaced 5 years apart from 1993 through 1995, 1998 through 2000, 2003 through 2005, and 2008 through 2010, respectively.
   Methods: Best-corrected visual acuity after refraction, assessed by the Early Treatment Diabetic Retinopathy Study protocol.
   Main Outcome Measures: Incidence of VI, defined as best-corrected visual acuity of poorer than 20/40 in the better eye in persons with one or both eyes 20/40 or better at the beginning of a 5-year interval, and incidence of severe VI, defined as best-corrected visual acuity of 20/200 or worse in the better eye in persons with one or both eyes better than 20/200 at the beginning of a 5-year interval.
   Results: Overall incidence of VI between examinations (5-year interval) was 1.4% (varying from 0.1% in persons 50-54 years of age to 14.6% in those 85 years of age and older), whereas for severe VI it was 0.4% (varying from 0.0% in persons 50-54 years of age to 6.9% in those >= 85 years of age). The incidence of VI decreased for each period after adjustment for age, from the first 5-year interval between examinations (1988-1990 to 1993-1995) to the fourth and most recent 5-year interval (2003-2005 to 2008-2010; odds ratio fourth interval vs. first interval, 0.53; 95% confidence interval, 0.32-0.87; P = 0.01). This period effect was no longer significant after adjustment for age-related macular degeneration. Age-related macular degeneration remained the leading cause of incident severe VI (54% of eyes with incident severe VI, which was as low as 40% and as high as 57% for specific visits), with no evidence of a trend across visits. The overall frequency of VI correctable with new refraction was 38% of all eyes with VI.
   Conclusions: These data provide population-based estimates that show a high (15%) 5-year incidence of VI in persons 85 years of age and older. Age-related macular degeneration remained the leading cause of severe VI in this population over the 20 years of the study. (C) 2013 by the American Academy of Ophthalmology.
C1 [Klein, Ronald; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 North Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Gangnon, Ronald/0000-0003-2587-6714; Klein, Ronald/0000-0002-4428-6237
FU National Institutes of Health, Bethesda, Maryland [EY06594]; Research to
   Prevent Blindness, Inc., New York, New York; National Eye Institute;
   NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant no.: EY06594 [B. E. K. K., R. K.]; and by Research to Prevent
   Blindness, Inc., New York, New York (R. K., B. E. K. K., Senior
   Scientific Investigator Awards). The National Eye Institute provided
   funding for the entire study, including collection and analyses of data;
   Research to Prevent Blindness provided additional support for data
   analyses. Neither funding organization had a role in the design or
   conduct of this research. The content is solely the responsibility of
   the authors and does not necessarily reflect the official views of the
   National Eye Institute or the National Institutes of Health.
CR [Anonymous], 1985, NTIS PUB, P101
   CAMPBELL JA, 1988, P SURV RES METH SECT, P549
   Chiang A, 2011, CURR OPIN OPHTHALMOL, V22, P199, DOI 10.1097/ICU.0b013e32834597d9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Dandona R, 2001, BRIT J OPHTHALMOL, V85, P1484, DOI 10.1136/bjo.85.12.1484
   Foran S, 2002, AM J OPHTHALMOL, V134, P712, DOI 10.1016/S0002-9394(02)01673-2
   Hennis AJ, 2009, OPHTHALMOLOGY, V116, P1461, DOI 10.1016/j.ophtha.2009.02.017
   Klein BE, 1991, NTIS PUBLICATION, P74
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2010, DIABETES, V59, P1853, DOI 10.2337/db09-1904
   Lee DJ, 2009, OPHTHAL EPIDEMIOL, V16, P42, DOI 10.1080/09286580802624434
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nucci C, 2005, EYE, V19, P175, DOI 10.1038/sj.eye.6701444
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   United States Census Bureau, 2008 NAT POP PROJ SU
   US Social Security Administration, 2007, PER LIF TABL
   Varma R, 2008, INVEST OPHTH VIS SCI, V49, P5264, DOI 10.1167/iovs.08-1814
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
NR 29
TC 56
Z9 56
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2013
VL 120
IS 6
BP 1210
EP 1219
DI 10.1016/j.ophtha.2012.11.041
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 167RJ
UT WOS:000320650700026
PM 23466270
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Maynard, ML
   Zele, AJ
   Kwan, AS
   Feigl, B
AF Maynard, Michelle L.
   Zele, Andrew J.
   Kwan, Anthony S.
   Feigl, Beatrix
TI Intrinsically Photosensitive Retinal Ganglion Cell Function, Sleep
   Efficiency and Depression in Advanced Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE intrinsically photosensitive retinal ganglion cells (ipRGCs); pupil
   light reflex; post-illumination pupil response; sleep; depression
ID ILLUMINATION PUPIL RESPONSE; LIGHT REFLEX; QUALITY INDEX; CIRCADIAN
   PHOTOENTRAINMENT; CATARACT-SURGERY; MELANOPSIN; IMPACT; ROD; SYMPTOMS;
   CONE
AB PURPOSE. Melanopsin expressing intrinsically photosensitive retinal ganglion cells (ipRGC) input to multiple brain regions including those for pupil control, circadian rhythms, sleep and mood regulation. Here we measured ipRGC function and its relationship to sleep quality and depression in patients with advanced AMD.
   METHODS. The melanopsin-mediated post-illumination pupil response (PIPR) was measured in 53 patients with advanced AMD (age 78.8 +/- 8.8 years) and in 20 healthy controls (age 72.5 +/- 3.3 years). Sleep quality and efficiency was assessed using the Pittsburgh Sleep Quality Index (PSQI). Risk of depression was determined using the Center for Epidemiologic Studies Depression questionnaire.
   RESULTS. The group with AMD showed significantly reduced pupil constrictions (P = 0.039); PIPR amplitudes (P = 0.003); global sleep scores (P = 0.01); and higher levels of depression (P < 0.001) than the control group. There was a significant correlation between the PIPR amplitude and global sleep score in the AMD group (P = 0.01). The amplitude of PIPR significantly correlated with sleep efficiency (P = 0.008; regression, P = 0.01, R-2 = 0.13), but not sleep quality (P = 0.23) in the AMD group. There was no correlation between PIPR and depression scores.
   CONCLUSIONS. Intrinsically photosensitive RGC dysfunction in advanced AMD contributes to the observed reduction in sleep efficiency. The correlation between the melanopsin-mediated PIPR and sleep may indicate reduced photic input to the suprachiasmatic nucleus and ventrolateral preoptic area due to ipRGC dysfunction in AMD.
C1 [Maynard, Michelle L.; Zele, Andrew J.; Feigl, Beatrix] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Med Retina & Visual Sci Labs, Brisbane, Qld, Australia.
   [Maynard, Michelle L.; Feigl, Beatrix] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry & Vis Sci, Brisbane, Qld, Australia.
   [Kwan, Anthony S.; Feigl, Beatrix] Queensland Eye Inst, South Brisbane, Australia.
   [Kwan, Anthony S.] Univ Queensland, Fac Hlth & Behav Sci, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Queensland
   Eye Institute; University of Queensland
RP Feigl, B (通讯作者)，Queensland Univ Technol, 60 Musk Ave, Brisbane, Qld 4059, Australia.
EM b.feigl@qut.edu.au
RI Kwan, Shiu Lun Anthony/B-1052-2012
OI Zele, Andrew/0000-0003-0291-9929; Feigl, Beatrix/0000-0001-7198-7373
FU Australian Research Council [ARC-DP140100333]; IHBI Vision and Eye
   Program Grant
FX Supported by Australian Research Council Discovery Projects
   (ARC-DP140100333: AJZ, BF), and an IHBI Vision and Eye Program Grant
   (BF, AJZ). The authors alone are responsible for the content and writing
   of the paper.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Adhikari P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161175
   Adhikari P, 2015, SCI REP-UK, V5, DOI 10.1038/srep17610
   Adhikari P, 2015, INVEST OPHTH VIS SCI, V56, P3838, DOI 10.1167/iovs.14-16233
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alexander I, 2014, INVEST OPHTH VIS SCI, V55, P4999, DOI 10.1167/iovs.14-14054
   Altimus CM, 2008, P NATL ACAD SCI USA, V105, P19998, DOI 10.1073/pnas.0808312105
   Altimus CM, 2010, NAT NEUROSCI, V13, P1107, DOI 10.1038/nn.2617
   Ancoli-Israel S, 2006, AM J GERIAT PSYCHIAT, V14, P95, DOI 10.1097/01.JGP.0000196627.12010.d1
   Ayaki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep25699
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brondsted AE, 2015, OPHTHALMOLOGY, V122, P2115, DOI 10.1016/j.ophtha.2015.06.033
   Bunney WE, 2000, NEUROPSYCHOPHARMACOL, V22, P335, DOI 10.1016/S0893-133X(99)00145-1
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chen SK, 2011, NATURE, V476, P92, DOI 10.1038/nature10206
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cole JC, 2006, SLEEP, V29, P112, DOI 10.1093/sleep/29.1.112
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387
   Ecker JL, 2010, NEURON, V67, P49, DOI 10.1016/j.neuron.2010.05.023
   Feigl B, 2014, OPTOMETRY VISION SCI, V91, P894, DOI 10.1097/OPX.0000000000000284
   Feigl B, 2012, ACTA OPHTHALMOL, V90, pe230, DOI 10.1111/j.1755-3768.2011.02226.x
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P4362, DOI 10.1167/iovs.10-7069
   Fernandez DC, 2016, P NATL ACAD SCI USA, V113, P6047, DOI 10.1073/pnas.1523629113
   Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gamlin PDR, 2007, VISION RES, V47, P946, DOI 10.1016/j.visres.2006.12.015
   Gooley JJ, 2003, J NEUROSCI, V23, P7093, DOI 10.1523/JNEUROSCI.23-18-07093.2003
   Gracitelli CPB, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5317371
   Gracitelli CPB, 2015, OPHTHALMOLOGY, V122, P1139, DOI 10.1016/j.ophtha.2015.02.030
   Gracitelli CPB, 2014, INVEST OPHTH VIS SCI, V55, P7997, DOI 10.1167/iovs.14-15146
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   Herbst K, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-4
   HOCH CC, 1994, SLEEP, V17, P489, DOI 10.1093/sleep/17.6.489
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Jusuf PR, 2007, EUR J NEUROSCI, V26, P2906, DOI 10.1111/j.1460-9568.2007.05924.x
   Kankipati L, 2011, INVEST OPHTH VIS SCI, V52, P2287, DOI 10.1167/iovs.10-6023
   Kankipati L, 2010, INVEST OPHTH VIS SCI, V51, P2764, DOI 10.1167/iovs.09-4717
   Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033
   KASPER S, 1989, ARCH GEN PSYCHIAT, V46, P823
   Kawasaki A, 2007, J NEURO-OPHTHALMOL, V27, P195, DOI 10.1097/WNO.0b013e31814b1df9
   Keenan TD, 2016, BR J OPHTHALMOL
   Kessel L, 2010, J CATARACT REFR SURG, V36, P308, DOI 10.1016/j.jcrs.2009.08.035
   Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706
   Kostic C, 2016, INVEST OPHTH VIS SCI, V57, P2501, DOI 10.1167/iovs.16-19150
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LeGates TA, 2012, NATURE, V491, P594, DOI 10.1038/nature11673
   Liao HW, 2016, J COMP NEUROL, V524, P2845, DOI 10.1002/cne.23995
   Magee CA, 2008, SLEEP BIOL RHYTHMS, V6, P222, DOI 10.1111/j.1479-8425.2008.00371.x
   MANT A, 1988, COMMUNITY HEALTH ST, V12, P192
   Markwell EL, 2010, CLIN EXP OPTOM, V93, P137, DOI 10.1111/j.1444-0938.2010.00479.x
   Maynard ML, 2015, INVEST OPHTH VIS SCI, V56, P6906, DOI 10.1167/iovs.15-17357
   McDougal DH, 2010, VISION RES, V50, P72, DOI 10.1016/j.visres.2009.10.012
   Mersch PPA, 2004, J AFFECT DISORDERS, V80, P209, DOI 10.1016/S0165-0327(03)00114-9
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Munch M, 2012, INVEST OPHTH VIS SCI, V53, P4546, DOI 10.1167/iovs.12-9494
   Park JC, 2011, INVEST OPHTH VIS SCI, V52, P6624, DOI 10.1167/iovs.11-7586
   Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288
   Perez-Leon JA, 2006, EUR J NEUROSCI, V24, P1117, DOI 10.1111/j.1460-9568.2006.04999.x
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Roecklein K, 2013, PSYCHIAT RES, V210, P150, DOI 10.1016/j.psychres.2013.05.023
   Roecklein KA, 2009, J AFFECT DISORDERS, V114, P279, DOI 10.1016/j.jad.2008.08.005
   Rosenthal NE., 1987, PSYCHOBIOLOGY BULIMI, P205
   Schmidt TM, 2011, TRENDS NEUROSCI, V34, P572, DOI 10.1016/j.tins.2011.07.001
   Stanley N, 2005, EUR UROL SUPPL, V3, P17, DOI 10.1016/S1569-9056(05)80003-X
   Thompson S, 2011, INVEST OPHTH VIS SCI, V52, P618, DOI 10.1167/iovs.10-6146
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Wang HZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062841
   Zele AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017860
NR 74
TC 31
Z9 32
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20659
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EO8LC
UT WOS:000396939600035
PM 28535270
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nakano-Okuno, M
   Borah, BR
   Nakano, I
AF Nakano-Okuno, Mariko
   Borah, B. Rashmi
   Nakano, Ichiro
TI Ethics of iPSC-Based Clinical Research for Age-Related Macular
   Degeneration: Patient-Centered Risk-Benefit Analysis
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Human subject research; Induced pluripotent stem cells (iPSCs);
   Age-related macular degeneration (AMD); Patient-centered risk-benefit
   analysis; Tumorigenicity; Therapeutic misconception/misestimation
ID PLURIPOTENT STEM-CELLS; SOMATIC-CELLS; IN-VITRO; TUMORIGENICITY;
   GENERATION
AB The opportunity to undergo an induced pluripotent stem cell-based autologous transplant can strike patients as a chance for a cure from a debilitating condition with few options for respite. However, when clinical studies of this caliber present themselves, patients and researchers, each with their own set of motives, may find it difficult to take a balanced approach to evaluating them. We present a patient-centered risk-benefit analysis of the iPSC-based clinical research currently underway in Japan, including a survey of in vitro and in vivo tests that support this project, an in-depth discussion of risks, and further elucidation of considerations patients may wish to consider. The arguments presented will assist patients in undertaking a more informed decision-making process.
C1 [Nakano-Okuno, Mariko] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA.
   [Nakano-Okuno, Mariko; Borah, B. Rashmi] Ohio State Univ, Wexner Med Ctr, Ctr Bioeth & Med Humanities, Columbus, OH 43210 USA.
   [Nakano, Ichiro] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Nakano, Ichiro] Ohio State Univ, James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University System of Ohio; Ohio State
   University; James Cancer Hospital & Solove Research Institute;
   University System of Ohio; Ohio State University
RP Nakano-Okuno, M (通讯作者)，Ohio State Univ, Coll Med, Dept Internal Med, B054 Graves Hall,333 10th Ave, Columbus, OH 43210 USA.
EM nakano.9@osu.edu
RI Nakano, Ichiro/AAR-9562-2020; Nakano, Ichiro/F-2076-2014
OI Nakano, Ichiro/0000-0002-0916-3207; Nakano, Ichiro/0000-0002-6734-3468;
   Nakano-Okuno, Mariko/0000-0002-2465-3212
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Dressel R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002622
   Frappier L, 2012, VIRUSES-BASEL, V4, P1537, DOI 10.3390/v4091537
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Graham-Rowe D., 2008, NATURE, DOI [10.1038/news.2008.1088, DOI 10.1038/NEWS.2008.1088]
   Griscelli F, 2012, AM J PATHOL, V180, P2084, DOI 10.1016/j.ajpath.2012.01.011
   Habets MGJL, 2014, REGEN MED, V9, P1, DOI [10.2217/RME.13.83, 10.2217/rme.13.83]
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Horng Sam, 2003, IRB, V25, P11, DOI 10.2307/3564408
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Hyun I, 2008, CELL STEM CELL, V3, P607, DOI 10.1016/j.stem.2008.11.009
   International Society for Stem Cell Research, 2008, GUIDELINES FOR THE C
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Kingsman SM, 2005, GENE THER, V12, P3, DOI 10.1038/sj.gt.3302417
   Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Montserrat N, 2013, CELL STEM CELL, V13, P341, DOI 10.1016/j.stem.2013.06.019
   Obokata H, 2014, NATURE, V505, P641, DOI 10.1038/nature12968
   Okita K, 2011, PHILOS T R SOC B, V366, P2198, DOI 10.1098/rstb.2011.0016
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Review Panel on Human Stem Cell Clinical Research the Health Science Council in the Japan Ministry of Health Labor and Welfare, 2013, ON OPINIONS CONCERNI
   RIKEN and Foundation for Biomedical Research and Innovation, 2013, PILOT SAFETY STUDY O
   RIKEN Institute of Biomedical Research and Innovation Hospital and Kobe City Medical Center General Hospital, 2013, INFORMED CONSENT DOC
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Solomon MZ, 2013, HASTINGS CENT REP, V43, pS2, DOI 10.1002/hast.132
   Sommer CA, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt26
   Steinemann D, 2013, AM J STEM CELLS, V2, P39
   The Japan Ministry of Health Labor and Welfare, 2008, ETHICAL GUIDELINE FO
   U.S. Department of Health Education and Welfare, 1979, OPRR REPORTS
   Yamanaka S, 2012, CELL STEM CELL, V10, P678, DOI 10.1016/j.stem.2012.05.005
   Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001
NR 36
TC 15
Z9 15
U1 1
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD DEC
PY 2014
VL 10
IS 6
BP 743
EP 752
DI 10.1007/s12015-014-9536-x
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AT3XQ
UT WOS:000344868600001
PM 24974102
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Marsiglia, M
   Boddu, S
   Bearelly, S
   Xu, LN
   Breaux, BE
   Freund, KB
   Yannuzzi, LA
   Smith, RT
AF Marsiglia, Marcela
   Boddu, Sucharita
   Bearelly, Srilaxmi
   Xu, Luna
   Breaux, Barry E., Jr.
   Freund, K. Bailey
   Yannuzzi, Lawrence A.
   Smith, R. Theodore
TI Association Between Geographic Atrophy Progression and Reticular
   Pseudodrusen in Eyes With Dry Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; age-related macular degeneration; reticular macular
   disease; reticular pseudodrusen; subretinal drusenoid deposits;
   autofluorescence; infrared
ID SUBRETINAL DRUSENOID DEPOSITS; FUNDUS AUTOFLUORESCENCE; INTERACTIVE
   SEGMENTATION; HIGH-RISK; DISEASE; EPIDEMIOLOGY; IMAGES; REGISTRATION;
   MACULOPATHY; CIRCULATION
AB PURPOSE. To evaluate geographic atrophy (GA) progression in eyes with dry AMD and to determine factors related to GA expansion, notably reticular pseudodrusen (RPD), also known as subretinal drusenoid deposits (SDD) or reticular macular disease (RMD).
   METHODS. This was a retrospective cohort study of patients with dry AMD who were diagnosed with GA in at least one eye and were imaged with sequential fundus autofluorescence (FAF) and/or near infrared reflectance (NIR-R) imaging. Images were analyzed for the presence of GA within the macular region. Geographic atrophy progression was measured in the fields of a modified Wisconsin grid and spatially correlated with RPD. Factors also evaluated for association with GA progression included initial GA size and pattern.
   RESULTS. The study sample included 126 eyes of 92 patients, with an average follow up of 20.4 months (SD = 11.7). At baseline, 93.6% of eyes had RPD, and the average GA area was 2.8 mm(2) (SD = 2.9). The average GA progression rate was 0.8 mm(2)/y (SD = 0.6), with a statistically significant difference between the unilobular and multilobular phenotype groups (0.3 mm(2)/y vs. 0.9 mm(2)/y, P = 0.02). Patients in the lower 50th percentile of initial GA area had a lower progression rate than patients in the upper 50th percentile (0.6 mm(2)/y vs. 1.1 mm(2)/y, P < 0.001). Geographic atrophy progression was more frequent in fields with RPD than in those without RPD (74.2% vs. 41.7%, P < 0.001).
   CONCLUSIONS. The high correlation between the presence of RPD (also known as SDD or RMD) and the presence of GA, and the expansion of GA into areas with these lesions suggest that they are an early manifestation of the process leading to GA.
C1 [Marsiglia, Marcela; Boddu, Sucharita; Freund, K. Bailey; Yannuzzi, Lawrence A.; Smith, R. Theodore] NYU, Dept Ophthalmol, Langone Med Ctr, New York, NY 10016 USA.
   [Marsiglia, Marcela; Bearelly, Srilaxmi; Freund, K. Bailey] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Marsiglia, Marcela; Freund, K. Bailey; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Marsiglia, Marcela; Freund, K. Bailey; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Xu, Luna; Breaux, Barry E., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
C3 New York University; NYU Langone Medical Center; Columbia University;
   Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Columbia University
RP Smith, RT (通讯作者)，NYU, Dept Ophthalmol, Langone Med Ctr, 462 1st Ave NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI ; Freund, K. Bailey/V-7488-2018
OI smith, theodore/0000-0002-1693-943X; Freund, K.
   Bailey/0000-0002-7888-9773
FU Robert Burch III Scholars Fund, Columbia University, New York, New York;
   National Institutes of Health/National Eye Institutes [R01 EY015520];
   Research to Prevent Blindness; Foundation Fighting Blindness; Macula
   Foundation, Inc.; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source:
   NIH RePORTER
FX Supported by grants from the Robert Burch III Scholars Fund, Columbia
   University, New York, New York (SBe), National Institutes of
   Health/National Eye Institutes Grant R01 EY015520 (RTS), unrestricted
   funds from Research to Prevent Blindness (RTS), an individual
   investigator research award from the Foundation Fighting Blindness
   (RTS), and The Macula Foundation, Inc. (LAY and KBF).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Chen J, 2008, IEEE ENG MED BIO, P2242, DOI 10.1109/IEMBS.2008.4649642
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   FOOS RY, 1982, ARCH OPHTHALMOL-CHIC, V100, P1492, DOI 10.1001/archopht.1982.01030040470020
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P161, DOI 10.1007/BF00127645
   HAYREH SS, 1981, OPHTHALMOLOGICA, V183, P11
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lee N, 2009, IFMBE PROC, V25, P227, DOI 10.1007/978-3-642-03891-4_61
   Lee N, 2008, CONF REC ASILOMAR C, P655, DOI 10.1109/ACSSC.2008.5074488
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Martillo MA, 2012, MED HYPOTHESIS DISCO, V1, P37
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2007, MOL VIS, V13, P196
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 45
TC 121
Z9 123
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2013
VL 54
IS 12
BP 7362
EP 7369
DI 10.1167/iovs.12-11073
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265KH
UT WOS:000327949700025
PM 24114542
OA Green Published
DA 2022-11-30
ER

PT J
AU Saleh, R
   Karpe, A
   Zinkernagel, MS
   Munk, MR
AF Saleh, Rafidah
   Karpe, Aashraya
   Zinkernagel, Martin S.
   Munk, Marion R.
TI Inner retinal layer change in glaucoma patients receiving anti-VEGF for
   neovascular age related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Retinal nerve fiber layer thickness; Ganglion cell layer thickness;
   Anti-VEGF; Wet AMD; Glaucoma; Exudative age-related macular
   degeneration; Intraocular pressure; Ocular hypertension; Visual fields;
   Retinal layer segmentation
ID ENDOTHELIAL GROWTH-FACTOR; GANGLION-CELL COMPLEX; INTRAOCULAR-PRESSURE;
   PLEXIFORM LAYER; SUSTAINED ELEVATION; NERVE; THICKNESS; RANIBIZUMAB;
   SEGMENTATION; INJECTIONS
AB The purpose was to evaluate the effects of long-term anti-VEGF treatment on the retinal nerve fiber layer (RNFL) and retinal ganglion cell layer (RGCL) thickness for patients with neovascular AMD and glaucoma.
   Medical records of respective patients who had received more than 15 anti-VEGF injections were reviewed. Initial and latest SD-OCT macular scans were segmented and changes of the RNFL and RGCL thickness at the four outer ETDRS quadrants were evaluated. Secondary outcome measures included changes of visual field parameters seen in automated perimetry.
   Sixteen patients were included (mean age 78 +/- 6 years). The mean total number of anti-VEGF injections was 39 +/- 16. The mean treatment duration was 6.1 +/- 2.1 years. The mean IOP decreased from 18 +/- 5 mmHg at baseline to 15 +/- 5 mmHg at the last visit (p = 0.026). The mean RNFL thickness volume of the outer ETDRS quadrants (0.98 +/- 0.18 mm(3) to 0.97 +/- 0.18 mm(3) p = 0.61) and its average thickness (37.9 +/- 7.3 mu m to 37.2 +/- 7.4 mu m, p = 0.6) did not significantly change. However, the average RGCL thickness decreased significantly from 0.86 +/- 0.12 mm(3) to 0.79 +/- 0.11 mm(3) (p = 0.01), and from 27.7 +/- 4.2 to 25.9 +/- 3.7 mu m (p = 0.01). Number of injections correlated with the RGCL change (r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and absolute scotomata did not significantly change with p-values of 0.28, 0.21 and 0.07, respectively.
   Patients under long term treatment with anti-VEGF and concurrent glaucoma show significant decrease in macular RGLC volume. However, this decrease is comparable to reported RGCL decrease in patients under anti-VEGF treatment without underlying glaucoma and suggests that glaucoma patients may not be at a higher risk for losing macular RNFL and RGCL, at least if adequate control of intraocular pressure is maintained.
C1 [Saleh, Rafidah; Karpe, Aashraya; Zinkernagel, Martin S.; Munk, Marion R.] Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Saleh, Rafidah; Karpe, Aashraya; Zinkernagel, Martin S.; Munk, Marion R.] Univ Bern, Bern, Switzerland.
   [Zinkernagel, Martin S.] Univ Hosp Bern, Dept Clin Res, Bern, Switzerland.
   [Zinkernagel, Martin S.; Munk, Marion R.] Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern Photog Reading Ctr, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern
RP Munk, MR (通讯作者)，Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.; Munk, MR (通讯作者)，Univ Bern, Bern, Switzerland.; Munk, MR (通讯作者)，Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern Photog Reading Ctr, Bern, Switzerland.
EM marion_munk@hotmail.com
OI Zinkernagel, Martin S./0000-0003-3447-2359; Saleh,
   Rafidah/0000-0003-2156-4043
FU Bayer
FX No funding was received for this research. Martin S Zinkernagel is a
   stock holder and a consultant for Novartis and a consultant for Bayer.
   Marion R Munk is a consultant for Novartis and Bayer and received travel
   grants from Bayer. The remaining authors certify that they have no
   affiliations with or involvement in any organization or entity with any
   financial interest (such as honoraria; educational grants; participation
   in speakers' bureaus; membership, employment, consultancies, stock
   ownership, or other equity interest; and expert testimony or
   patent-licensing arrangements), or non-financial interest (such as
   personal or professional relationships, affiliations, knowledge or
   beliefs) in the subject matter or materials discussed in this
   manuscript.
CR AIRAKSINEN PJ, 1984, AM J OPHTHALMOL, V98, P566, DOI 10.1016/0002-9394(84)90242-3
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bressler SB, 2015, JAMA OPHTHALMOL, V133, P589, DOI 10.1001/jamaophthalmol.2015.186
   Budenz DL, 2007, OPHTHALMOLOGY, V114, P1046, DOI 10.1016/j.ophtha.2006.08.046
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Garas A, 2013, J GLAUCOMA, V22, P195, DOI 10.1097/IJG.0b013e31824083e6
   Girkin CA, 2011, OPHTHALMOLOGY, V118, P2403, DOI 10.1016/j.ophtha.2011.06.013
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Griffith JF, 2015, CLIN OPHTHALMOL, V9, P1275, DOI 10.2147/OPTH.S85851
   Harwerth RS, 2008, INVEST OPHTH VIS SCI, V49, P4437, DOI 10.1167/iovs.08-1753
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Katayama BYNY, 2014, J GLAUCOMA, V23, P461, DOI 10.1097/IJG.0b013e3182948476
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim NR, 2010, INVEST OPHTH VIS SCI, V51, P4646, DOI 10.1167/iovs.09-5053
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shin HY, 2013, INVEST OPHTH VIS SCI, V54, P7344, DOI 10.1167/iovs.13-12667
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P77, DOI 10.1001/archopht.1991.01080010079037
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Yuda K, 2010, GRAEF ARCH CLIN EXP, V248, P353, DOI 10.1007/s00417-009-1222-3
   Zeimer R, 1998, OPHTHALMOLOGY, V105, P224, DOI 10.1016/S0161-6420(98)92743-9
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 37
TC 17
Z9 18
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2017
VL 255
IS 4
BP 817
EP 824
DI 10.1007/s00417-017-3590-4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ER5DE
UT WOS:000398820800022
PM 28127658
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Hanout, M
   Horan, N
   Do, DV
AF Hanout, Mostafa
   Horan, Nicholas
   Do, Diana V.
TI Introduction to microperimetry and its use in analysis of geographic
   atrophy in age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE fixation; geographic atrophy; microperimetry; preferred retinal locus;
   retinal sensitivity
ID TEST-RETEST VARIABILITY; FUNDUS PERIMETRY; RETINAL SENSITIVITY;
   VISUAL-ACUITY; LASER PHOTOCOAGULATION; NIDEK MP1; FIXATION; EYES;
   PROGRESSION; THICKNESS
AB Purpose of review
   This article discusses recent advances in the fundus-guided perimetry (microperimetry) and its utilization in evaluation and monitoring of patients with geographic atrophy.
   Recent findings
   Although best-corrected visual acuity has been gold standard in clinical practice for decades, it does not provide an entire assessment of visual function that determines daily activity and quality of life of a patient. Furthermore, psychophysical tests, including low-luminance visual acuity, reading speed, and contrast sensitivity, cannot be used to quantify retinal sensitivity or detect pattern of retinal dysfunction. Microperimetry provides a true evaluation of visual function by offering fundus-controlled testing through eye-tracking technology that allows for structural and functional correlation and test-retest reliability for the same test point. Furthermore, it enables precise assessment of location and stability of fixation. Recent research has shown microperimetry to be more representative of the macular function in macular diseases.
   Summary
   Microperimetry is currently the clinical investigation of choice to assess residual visual functions and functional vision in macular degenerative diseases, especially geographic atrophy. There is an increasing popularity to employ microperimetry in clinical trials investigating new treatments for geographic atrophy, as well as other macular degenerative diseases, as a reliable functional outcome measure.
C1 [Hanout, Mostafa; Horan, Nicholas; Do, Diana V.] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center
RP Do, DV (通讯作者)，Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, 985540 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM diana.do@unmc.edu
RI Hanout, Mostafa/Q-6840-2017
OI Hanout, Mostafa/0000-0001-7829-9776
FU Genentech; Regeneron
FX D.V.D. has received research funding from Genentech and Regeneron.
CR ACOSTA F, 1991, OPHTHALMOLOGY, V98, P1820
   Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Chen FK, 2011, OPTOMETRY VISION SCI, V88, P742, DOI 10.1097/OPX.0b013e3182167641
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Chew EY, 2014, AM J OPHTHALMOL, V14, P00819
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   ENOCH JM, 1982, AM J OPTOM PHYS OPT, V59, P952
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hatef E, 2014, EYE, V28, P1239, DOI 10.1038/eye.2014.182
   Hatef E, 2011, AM J OPHTHALMOL, V152, P400, DOI 10.1016/j.ajo.2011.02.024
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P84, DOI 10.1136/bjo.2007.124016
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liu HT, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.5.3
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P347, DOI 10.1016/j.jcjo.2013.07.010
   Markowitz SN, 2011, OPHTHALMOLOGY, V118, P2528, DOI 10.1016/j.ophtha.2011.08.006
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2006, Arch Soc Esp Oftalmol, V81, P183
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Ozdemir H, 2008, EYE, V22, P204, DOI 10.1038/sj.eye.6702563
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Parravano M, 2013, DOC OPHTHALMOL, V127, P217, DOI 10.1007/s10633-013-9404-z
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Richter-Mueksch S, 2007, AM J OPHTHALMOL, V144, P23, DOI 10.1016/j.ajo.2007.03.045
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   Rohrschneider K, 1997, OPHTHALMOLOGE, V94, P624, DOI 10.1007/s003470050171
   Rohrschneider K, 2000, AM J OPHTHALMOL, V129, P27, DOI 10.1016/S0002-9394(99)00270-6
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Sabates NR, 1996, RETINA-J RET VIT DIS, V16, P296, DOI 10.1097/00006982-199616040-00004
   Sauer CG, 1997, J MED GENET, V34, P961, DOI 10.1136/jmg.34.12.961
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Seiple W, 2012, OPTOMETRY VISION SCI, V89, P1182, DOI 10.1097/OPX.0b013e3182640c83
   Sepah YJ, 2012, J OPHTHALMIC INFLAMM, V2, P65, DOI 10.1007/s12348-011-0052-8
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Shulman M, 2013, OPHTHAL SURG LAS IM, V44, P577, DOI 10.3928/23258160-20131105-07
   Springer C, 2008, INVESTIG OPHTHALMOL, V49, P3900
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yohannan J, 2013, OPHTHALMOLOGY, V120, P1254, DOI 10.1016/j.ophtha.2012.12.003
NR 57
TC 28
Z9 30
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2015
VL 26
IS 3
BP 149
EP 156
DI 10.1097/ICU.0000000000000153
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF1RV
UT WOS:000352326200002
PM 25784112
DA 2022-11-30
ER

PT J
AU Hussain, AA
   Starita, C
   Hodgetts, A
   Marshall, J
AF Hussain, A. A.
   Starita, C.
   Hodgetts, A.
   Marshall, J.
TI Macromolecular diffusion characteristics of ageing human Bruch's
   membrane: Implications for age-related macular degeneration (AMD)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Bruch's membrane; macular degeneration; ageing; diffusion
ID DARK-ADAPTATION; PIGMENT EPITHELIUM; AMINO-ACIDS; TRANSPORT;
   PERMEABILITY; TAURINE; RAT; CHORIOCAPILLARIS; ACCUMULATION; CHOLESTEROL
AB Macromolecular species such as retinal binding protein, transferrin, ceruloplasmin, etc., released by the fenestrated choroidal capillaries must diffuse across Bruch's membrane for interaction with the basal membranes of the retinal pigment epithelium (RPE) for delivery of essential metabolites to the neural retina. The patency of this pathway through ageing Bruch's was examined by quantifying the diffusional flux of a 21.2 kDa fluorescein-isothiocyanate labelled dextran. Dextran flux measurements across Bruch's membrane from the macular region of the human fundus showed a highly significant decrease (p < 0.001) with ageing of donor such that diffusional transport in the ninth decade was about 6.5% of that in the first decade of life. Peripheral regions also showed a highly significant decline (p < 0.001) but ageing changes were considerably slowed in comparison to the macula with diffusional rates in the ninth decade being about 44% of that in the first decade. Peripheral samples from AMD donors displayed diffusional rates that were lower than the control population. The age-related decline in macromolecular diffusion across Bruch's membrane suggests that in the elderly, the patency of the conducting pathways may be compromised and in the more advanced ageing of Bruch's associated with AMD, the metabolic trafficking of carrier proteins may be severely impaired. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Hussain, A. A.; Starita, C.; Hodgetts, A.; Marshall, J.] St Thomas Hosp, Dept Ophthalmol, Kings Coll London, Rayne Inst, London SE1 7EH, England.
C3 Guy's & St Thomas' NHS Foundation Trust; University of London; King's
   College London
RP Hussain, AA (通讯作者)，St Thomas Hosp, Dept Ophthalmol, Kings Coll London, Rayne Inst, Lambeth Palace Rd, London SE1 7EH, England.
EM alyhussain@aol.com
RI Hodgetts, Andrea/E-8027-2011
OI Hodgetts, Andrea/0000-0002-1623-7710
FU Guide Dogs for the Blind Association, UK; Fight for Sight, UK
FX This work was generously supported by the Guide Dogs for the Blind
   Association, UK and Fight for Sight, UK.
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   AMU TC, 1982, BIOPHYS CHEM, V16, P269, DOI 10.1016/0301-4622(82)87031-2
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Ban Y, 2000, AM J PHYSIOL-CELL PH, V279, pC744, DOI 10.1152/ajpcell.2000.279.3.C744
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gribbon P, 1998, BIOPHYS J, V75, P1032, DOI 10.1016/S0006-3495(98)77592-7
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HO CH, 1998, COMP BIOCH PHYSL, V121, P441
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kundaiker S, 1996, J PHYSIOL-LONDON, V492, P505, DOI 10.1113/jphysiol.1996.sp021325
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703
   Militante J, 2004, NEUROCHEM RES, V29, P151, DOI 10.1023/B:NERE.0000010444.97959.1b
   MILLER S, 1976, EXP EYE RES, V23, P177, DOI 10.1016/0014-4835(76)90201-3
   MIYAMOTO Y, 1994, INVEST OPHTH VIS SCI, V35, P3589
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   OLIVER JD, 1992, J AM SOC NEPHROL, V3, P214
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAPPENHEIMER JR, 1951, AM J PHYSIOL, V167, P13, DOI 10.1152/ajplegacy.1951.167.1.13
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAUTLER EL, 1986, EXP EYE RES, V43, P207, DOI 10.1016/S0014-4835(86)80088-4
   PINO RM, 1983, J HISTOCHEM CYTOCHEM, V31, P411, DOI 10.1177/31.3.6827079
   PINO RM, 1981, J HISTOCHEM CYTOCHEM, V29, P281, DOI 10.1177/29.2.7252121
   Pluen A, 1999, BIOPHYS J, V77, P542, DOI 10.1016/S0006-3495(99)76911-0
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   REFOJO MF, 1982, INVEST OPHTH VIS SCI, V22, P129
   REFOJO MF, 1979, J POLYM SCI POL SYM, P227
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Sarks SH, 1976, BR J OPHTHALMOL, V251, P4062
   SCHMIDT M, 1981, MACROMOLECULES, V14, P210, DOI 10.1021/ma50002a045
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Williams JC, 1998, BIOPHYS J, V75, P493, DOI 10.1016/S0006-3495(98)77538-1
   WINKLER BS, 1983, BIOCH EYE, P227
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
   [No title captured]
NR 55
TC 68
Z9 69
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2010
VL 90
IS 6
BP 703
EP 710
DI 10.1016/j.exer.2010.02.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 602UR
UT WOS:000278164900007
PM 20206163
DA 2022-11-30
ER

PT J
AU Madeira, C
   Godinho, G
   Vilares-Morgado, R
   Beato, J
   Pinheiro-Costa, J
   Carneiro, A
   Falcao-Reis, F
   Falcao, M
AF Madeira, Carolina
   Godinho, Goncalo
   Vilares-Morgado, Rodrigo
   Beato, Joao
   Pinheiro-Costa, Joao
   Carneiro, Angela
   Falcao-Reis, Fernando
   Falcao, Manuel
TI Long-term progression of geographic atrophy in age-related macular
   degeneration does the phakic status matter?
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Cataract surgery; Fundus autofluorescence; Geographic atrophy;
   Phacoemulsification; Phakic; Progression; Pseudophakic
ID CATARACT-SURGERY; FUNDUS AUTOFLUORESCENCE; EYE DISEASE; BEAVER DAM;
   MACULOPATHY; RISK; SECONDARY; ASSOCIATION; LENS
AB Purpose To assess the long-term risk of geographic atrophy (GA) progression after cataract surgery.
   Methods Subjects with GA secondary to AMD followed for at least 1 year with fundus autofluorescence imaging and with at least two visits at our centre were included. Patients with wet AMD, disciform scar, past history of intravitreal injections or laser treatment, other maculopathies and with poor quality images were excluded. GA area at baseline and at follow-up visit was measured. Three study groups were defined according to their phakic status: (A) pseudophakia, (B) phakic and (C) phacoemulsification surgery performed during the study. Differences of GA area progression were compared between these study groups. In addition, comparison between GA progression rate in group (C) before and after the surgery was performed. The enlargement rate (ER) was calculated for lesion size after transforming the measurements to the square-root scale.
   Results A total of 92 eyes of 92 patients were enrolled. Median follow-up time was 4 [1-10] years. Regarding the eye's phakic status, 29 (31.5%) were pseudophakic and 63 (68.5%) were phakic; of these, 22 underwent phacoemulsification during the study. Overall, the median baseline and follow-up area of GA were 1.42 [0.04-32.10] mm(2) and 6.48 [0.25-47.40] mm(2), respectively. The ER was similar between phakic and pseudophakic eyes (0.18 [0.01-1.03] vs 0.15 [0.01-0.65] mm/year, p = 0.62). In patients that underwent cataract surgery during the study, the GA ER remained stable (0.13 [0.01-0.92] vs 0.14 [0.01-0.63] mm/year, p = 0.43).
   Conclusion These results suggest that cataract surgery does not increase the risk of pre-existing GA progression. Therefore, cataract surgery seems safe and a potential therapeutic weapon to improve visual acuity and consequently quality of life in GA patients.
C1 [Madeira, Carolina; Godinho, Goncalo; Vilares-Morgado, Rodrigo; Beato, Joao; Pinheiro-Costa, Joao; Carneiro, Angela; Falcao-Reis, Fernando; Falcao, Manuel] Ctr Hosp & Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
   [Vilares-Morgado, Rodrigo] Univ Porto, Fac Med, Porto, Portugal.
   [Beato, Joao; Pinheiro-Costa, Joao; Carneiro, Angela; Falcao-Reis, Fernando; Falcao, Manuel] Univ Porto, Fac Med, Dept Surg & Physiol, Porto, Portugal.
C3 Universidade do Porto; Universidade do Porto
RP Madeira, C (通讯作者)，Ctr Hosp & Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
EM tania.carolina.madeira@gmail.com
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Artigas JM, 2012, INVEST OPHTH VIS SCI, V53, P4076, DOI 10.1167/iovs.12-9471
   Artigas JM, 2011, OPHTHALMOLOGY, V118, P3, DOI 10.1016/j.ophtha.2010.06.023
   Augustin AJ, 2010, KLIN MONATSBL AUGENH, V227, P617, DOI 10.1055/s-0029-1245524
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chaikitmongkol V, 2016, CURR OPIN OPHTHALMOL, V27, P217, DOI 10.1097/ICU.0000000000000259
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Eter N, 2005, KLIN MONATSBL AUGENH, V222, P409, DOI 10.1055/s-2005-858079
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Sastre-Ibanez M, 2018, Arch Soc Esp Oftalmol (Engl Ed), V93, P22, DOI 10.1016/j.oftal.2017.07.004
   Schachar IH, 2013, JAMA OPHTHALMOL, V131, P1009, DOI 10.1001/jamaophthalmol.2013.4014
   Varma R, 2012, INVEST OPHTH VIS SCI, V53, P2294
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 30
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3711
EP 3719
DI 10.1007/s00417-021-05255-4
EA JUN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000665818900001
PM 34169351
DA 2022-11-30
ER

PT J
AU Liu, SC
   Wu, MX
   Zhang, BW
   Xiong, XJ
   Wang, H
   Zhou, XY
AF Liu, Shengchun
   Wu, Mingxing
   Zhang, Bianwen
   Xiong, Xiaojing
   Wang, Hao
   Zhou, Xiyuan
TI Analysis of genetic polymorphisms for age-related macular degeneration
   (AMD) in Chinese Tujia ethnic minority group
SO BMC MEDICAL GENETICS
LA English
DT Article
DE Age-related macular degeneration; Single nucleotide polymorphism;
   Chinese Tujia ethnic minority group
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; RISK ALLELES;
   CFH; ARMS2; COHORT; VEGFA
AB BackgroundAge-related macular degeneration (AMD) can cause vision loss or blindness in elderly. The associations between single nucleotide polymorphism (SNP) and AMD in Chinese Tujia ethnic minority group are still unclear.MethodsA total of 2122 Tujia volunteers were recruited and 197 of them were diagnosed with AMD (either dry or wet type).Then the blood specimens of these 197 AMD patients and 404 controls from the remaining 1925 normal Tujia volunteers were collected to detect the frequencies of 39 chosen SNPs. The Bonferroni method was used to correct the P values from the Fisher's exact test.ResultsThe mean age of the 197 AMD patients(113 males and 84 females) was 68.4197years old. No significant differences in allelic and genotypic frequencies were found for all the 39 SNPs between the patients and controls. However, weak correlations between 10 SNPs (CFH rs1329428 TT genotype, CFH rs3753394 CC genotype and T allele, CFH rs1410996 AA genotype, CFH rs800292 AA genotype, CFH rs800292 A allele, VEGF rs833061 TT genotype and C allele, VEGF rs2010963 CG genotype, VEGFR2 rs1531289 TT genotype, ARMS2 rs10490924 TT genotype, KCTD10 rs238104 GC genotype, rs1531289 T allele and ARMS2 rs10490924 T allele) and AMD were shown.ConclusionsThe effects of 39 SNPs have found no associations with the morbidity of AMD in Chinese Tujia ethnic minority group.
C1 [Liu, Shengchun; Wu, Mingxing; Zhang, Bianwen; Xiong, Xiaojing; Wang, Hao; Zhou, Xiyuan] Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, 74 Linjiang Rd, Chongqing 400010, Peoples R China.
   [Liu, Shengchun] Chongqing Key Lab Ophthalmol, Chongqing 400010, Peoples R China.
   [Liu, Shengchun] Chongqing Eye Inst, Chongqing 400010, Peoples R China.
C3 Chongqing Medical University
RP Zhou, XY (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, 74 Linjiang Rd, Chongqing 400010, Peoples R China.
EM zhouxiyuan2002@163.com
FU Epidemiological investigation of Han and Tujia AMD in Southwest China
   [cstc2015shmszx120058]
FX This study was supported by Epidemiological investigation of Han and
   Tujia AMD in Southwest China and study of related gene
   polymorphisms(cstc2015shmszx120058). The funding body was mainly used in
   the specimens collection and data analysis.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Borgiani P, 2017, EYE LOND, V32, P446, DOI DOI 10.1038/eye.2017.192
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Dong Y, 2015, INT J OPHTHALMOL-CHI, V8, P385, DOI 10.3980/j.issn.2222-3959.2015.02.31
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Huang Y, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1274960
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Ruamviboonsuk P, 2017, J HUM GENET, V62, P957, DOI 10.1038/jhg.2017.72
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Velazquez-Villoria A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162296
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Xiang W, 2016, OPHTHALMIC GENET, V37, P388, DOI 10.3109/13816810.2015.1107597
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang YR, 2014, LEGAL MED-TOKYO, V16, P173, DOI 10.1016/j.legalmed.2014.01.010
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
   Zhou TQ, 2015, GENET MOL RES, V14, P17432, DOI 10.4238/2015.December.21.13
   Zhuang WJ, 2014, OPHTHALMIC GENET, V35, P156, DOI 10.3109/13816810.2014.921314
NR 36
TC 8
Z9 8
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JAN 29
PY 2019
VL 20
AR 25
DI 10.1186/s12881-019-0756-4
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HJ3YZ
UT WOS:000457111500001
PM 30696427
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Szemraj, M
   Oszajca, K
   Szemraj, J
   Jurowski, P
AF Szemraj, Maciej
   Oszajca, Katarzyna
   Szemraj, Janusz
   Jurowski, Piotr
TI MicroRNA Expression Analysis in Serum of Patients with Congenital
   Hemochromatosis and Age-Related Macular Degeneration (AMD)
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Iron Metabolism Disorders; Macular Degeneration; Transcriptome
ID OCULAR NEOVASCULARIZATION; OXIDATIVE STRESS; IRON; DISEASE;
   PROLIFERATION; MIRNAS; DAMAGE; CELLS
AB Background: Congenital hemochromatosis is a disorder caused by mutations of genes involved in iron metabolism, leading to increased levels of iron concentration in tissues and serum. High concentrations of iron can lead to the development of AMD. The aim of this study was to analyze circulating miRNAs in the serum of congenital hemochromatosis patients with AMD and their correlation with the expression of genes involved in iron metabolism.
   Material/Methods: Peripheral blood monolayer cells and serum were obtained from patients with congenital hemochromatosis, congenital hemochromatosis and AMD, AMD patients without congenital hemochromatosis, and healthy controls. Serum miRNAs expressions were analyzed by RT-PCR (qRT-PCR) using TaqMan MicroRNA probes, and proteins levels were measured by ELSA kits. Gene polymorphisms in TF and TFRC genes were determined using the TaqMan discrimination assay.
   Results: Statistical analysis of the miRNAs expressions selected for further study the miR-31, miR-133a, miR-141, miR-145, miR-149, and miR-182, which are involved in the posttranscriptional expression of iron-related genes: TF, TFRI, DMT1, FTL, and FPN1. It was discovered that the observed changes in the expressions of the miRNAs was correlated with the level of protein in the serum of the analyzed genes. There were no statistically significant differences in the distribution of genotype and allele frequencies in TF and TFRC genes between analyzed groups of patients.
   Conclusions: The differences studied in the miRNA serum profile, in conjunction with the changes in the analyzed protein levels, may be useful in the early detection of congenital hemochromatosis in patients who may develop AMD disease.
C1 [Szemraj, Maciej; Jurowski, Piotr] Med Univ Lodz, Dept Eye Dis, Lodz, Poland.
   [Oszajca, Katarzyna; Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz
RP Szemraj, J (通讯作者)，Med Univ Lodz, Dept Med Biochem, Lodz, Poland.
EM janusz.szemraj@umed.lodz.pl
RI ; Oszajca, Katarzyna/S-9288-2016
OI Jurowski, Piotr/0000-0003-1471-8577; Oszajca,
   Katarzyna/0000-0002-7070-8720
FU National Center of Science [NN 402 591340]
FX This work was supported by grant NN 402 591340 from the National Center
   of Science
CR Adams PC, 2007, LANCET, V370, P1855, DOI 10.1016/S0140-6736(07)61782-6
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Bacon BR, 1992, NETFIRMS, P45
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BURKE JM, 1981, INVEST OPHTH VIS SCI, V20, P582
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   CZEPIEL J, 2003, NEW CLIN, V10, P65
   Derc K, 2001, GASTROENTEROL POL, V8, P181
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Ertekin S, 2014, MOL VIS, V20, P1057
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   de Almeida LNF, 2009, ARQ BRAS OFTALMOL, V72, P567, DOI 10.1590/S0004-27492009000400027
   Galecka E, 2016, PHARMACOL REP, V68, P913, DOI 10.1016/j.pharep.2016.04.019
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hartleb M, 1999, HEPATOLOGIA POLAND, V6, P141
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Xiao CX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030343
   Zhao JJ, 2009, CHILD NERV SYST, V25, P13, DOI 10.1007/s00381-008-0701-x
NR 34
TC 8
Z9 8
U1 0
U2 3
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD AUG 22
PY 2017
VL 23
DI 10.12659/MSM.902366
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FF8GY
UT WOS:000409256000001
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Zanzottera, EC
   Messinger, JD
   Ach, T
   Smith, RT
   Curcio, CA
AF Zanzottera, Emma C.
   Messinger, Jeffrey D.
   Ach, Thomas
   Smith, R. Theodore
   Curcio, Christine A.
TI Subducted and Melanotic Cells in Advanced Age-Related Macular
   Degeneration Are Derived From Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   melanosomes; lipofuscin; histology; apoptosis; migration;
   transdifferentiation; basal laminar deposits
ID GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; MESENCHYMAL
   TRANSITION; RETINITIS-PIGMENTOSA; HUMAN EYES; AUTOFLUORESCENCE;
   ACCUMULATION; INVOLVEMENT; MICROGLIA; FEATURES
AB PURPOSE. To describe, illustrate, and account for two cell types plausibly derived from RPE in geographic atrophy (GA) and choroidal neovascularization (CNV) of AMD, using melano-somes, lipofuscin, and basal laminar deposit (BLamD) as anatomical markers.
   METHODS. Human donor eyes with GA (n = 13) or CNV (n = 39) were histologically processed, photodocumented, and analyzed for frequencies of occurrence. We defined RPE as cells containing spindle-shaped melanosomes and RPE lipofuscin, internal to basal lamina or BLamD, if present, or Bruch's membrane if not, and RPE-derived cells as those plausibly derived from RPE and not attached to basal lamina or BLamD.
   RESULTS. 'Subducted' cells contain RPE melanosomes and localize to the sub-RPE space, on Bruch's membrane. Credible transitional forms from RPE cells were seen. Grades of RPE overlying 'Subducted' cells were 'Atrophic with BLamD' (32.2% vs. 37.0% of 'Subducted,' for GA and CNV eyes, respectively), 'Dissociated' (22.0% vs. 21.7%), 'Nonuniform' (22.0% vs. 23.9%), and 'Sloughed' RPE (10.2% vs. 4.3%). Found exclusively in CNV scars, 'Melanotic' cells containing spherical melanosomes were adjacent to 'Entombed' RPE with spindle-shaped and spherical melanosomes. Of subretinal 'Melanotic' cells, 40.0% associated with 'Atrophy with BLamD,' 36.8% with 'Atrophy without BLamD,' and 20.6% with 'Entombed.'
   CONCLUSIONS. 'Dissociated' RPE within atrophic areas may be the source of 'Subducted' cells. 'Entombed' RPE within fibrovascular and fibrocellular scars may be the source of 'Melanotic' cells. An imaging correlate for 'Subducted' cells awaits discovery; 'Melanotic' cells appear gray-black in the CNV fundus. Results provide a basis for future molecular phenotyping studies.
C1 [Zanzottera, Emma C.; Messinger, Jeffrey D.; Ach, Thomas; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Zanzottera, Emma C.] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Ach, Thomas] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Smith, R. Theodore] NYU, Dept Ophthalmol, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Milan; Luigi Sacco Hospital; University of Wurzburg; New
   York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, EyeSight Fdn, Sch Med, Dept Ophthalmol,Alabama Vis Res Labs, 1670 Univ Blvd,Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Ach, Thomas/AAE-7870-2021
OI Ach, Thomas/0000-0001-6583-8283
FU National Eye Institute [EY06109, R01 EY015520, R01 EY 021470];
   University of Milan; DFG (German Research Foundation) [AC265/1-1,
   AC265/2-1]; International Retinal Research Foundation, National Eye
   Institute [P30 EY003039]; Arnold and Mabel Beckman Initiative for
   Macular Research; Edward N. and Della L. Thome Memorial Foundation;
   NATIONAL EYE INSTITUTE [R01EY021470, R01EY006109, R01EY015520] Funding
   Source: NIH RePORTER
FX Supported by National Eye Institute Grants EY06109 (CAC), R01 EY015520
   (RTS), and R01 EY 021470 (RTS), with institutional support from the
   EyeSight Foundation of Alabama and Research to Prevent Blindness, Inc.
   (CAC). Also supported by University of Milan (ECZ) and DFG (German
   Research Foundation) Grants AC265/1-1 and AC265/2-1 (TA). Acquisition of
   donor eyes was supported by International Retinal Research Foundation,
   National Eye Institute P30 EY003039, and the Arnold and Mabel Beckman
   Initiative for Macular Research. Creation of Project MACULA was
   additionally supported from the Edward N. and Della L. Thome Memorial
   Foundation.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Curcio CA, 2005, VISION RES, V45, P3496, DOI 10.1016/j.visres.2005.07.038
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feist RM, 2014, GRAEF ARCH CLIN EXP, V252, P347, DOI 10.1007/s00417-013-2531-0
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   LLOYD WC, 1990, OPHTHALMOLOGY, V97, P1052
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   REGILLO CD, 1993, OPHTHALMOLOGY, V100, P400
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schaal KB, 2015, RETINA
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shen Chia-Ning, 2004, Organogenesis, V1, P36
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 51
TC 67
Z9 67
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2015
VL 56
IS 5
BP 3269
EP 3278
DI 10.1167/iovs.15-16432
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK7UJ
UT WOS:000356439200061
PM 26024109
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, JY
   Lee, DH
   Lee, JY
   Yoon, YH
AF Lee, Jin Young
   Lee, Dong Hoon
   Lee, Joo Yong
   Yoon, Young Hee
TI Correlation Between Subfoveal Choroidal Thickness and the Severity or
   Progression of Nonexudative Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE subfoveal choroidal thickness; nonexudative age-related macular
   degeneration; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE PATTERNS;
   GEOGRAPHIC ATROPHY; BLOOD-FLOW; DISEASE; DRUSEN; VOLUME; AMD; EYE
AB PURPOSE. To investigate the correlation between subfoveal choroidal thickness (SFChT) and the severity or progression of nonexudative AMD.
   METHODS. One hundred seventy-six eyes of 114 patients with nonexudative AMD were included in this study. These eyes were divided into stages I through IV, based on the Age-Related Eye Disease Study (AREDS) classification of fundus findings. Using enhanced depth imaging from spectralis domain optical coherence tomography (SD-OCT), the central retinal thickness (CRT), SFChT, and parafoveal choroidal thickness (PFChT) were measured. The area of geographic atrophy (GA) was measured from fundus autofluorescence (FAF) images, and the progression of GA was calculated using RegionFinder software.
   RESULTS. The age-adjusted SFChT levels were lower at later stages of nonexudative AMD. These measurements were as follows: 266.68 +/- 12.60 (stage I: 28 eyes), 263.34 +/- 9.87 (stage II: 48 eyes), 200.55 +/- 8.83 (stage III: 71 eyes), and 188.34 +/- 13.72 (stage IV: 29 eyes) (P = 0.0028). The age-adjusted SFChT was also negatively correlated with the best corrected visual acuity (BCVA) (estimate, -0.001; P = 0.0006). Among 16 eyes with GA at baseline, SFChT showed a negative correlation with the baseline area of GA (r = 0.5521, P = 0.0133). In addition, GA progressed more rapidly during the mean follow up of 22.19 +/- 9.08 months when the SFChT was lower at baseline (r = 0.5658, P = 0.0112).
   CONCLUSIONS. Subfoveal choroidal thickness is closely related to the BCVA, the severity of nonexudative AMD, as well as the rate of GA progression. Subfoveal choroidal thickness may be a predictor of disease progression in GA cases.
C1 [Lee, Jin Young; Lee, Dong Hoon; Lee, Joo Yong; Yoon, Young Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul 138736, South Korea.
C3 University of Ulsan; Asan Medical Center
RP Yoon, YH (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 88 Olymp Ro,43 Gil, Seoul 138736, South Korea.
EM yhyoon@amc.seoul.kr
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P112, DOI 10.1016/j.ajo.2010.07.004
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
NR 25
TC 73
Z9 74
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2013
VL 54
IS 12
BP 7812
EP 7818
DI 10.1167/iovs.13-12284
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265KH
UT WOS:000327949700079
PM 24204054
DA 2022-11-30
ER

PT J
AU Eandi, CM
   Ciardella, A
   Parravano, M
   Missiroli, F
   Alovisi, C
   Veronese, C
   Morara, MC
   Grossi, M
   Virgili, G
   Ricci, F
AF Eandi, Chiara M.
   Ciardella, Antonio
   Parravano, Mariacristina
   Missiroli, Filippo
   Alovisi, Camilla
   Veronese, Chiara
   Morara, Maria C.
   Grossi, Massimo
   Virgili, Gianni
   Ricci, Federico
TI Indocyanine Green Angiography and Optical Coherence Tomography
   Angiography of Choroidal Neovascularization in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE indocyanine green angiography; choroidal neovascularization; optical
   coherence tomography; retina
ID FLUORESCEIN ANGIOGRAPHY; SPECTRAL-DOMAIN; FEATURES; THERAPY
AB PURPOSE. To compare the capability of indocyanine green angiography (ICGA) and optical coherence tomography angiography (OCTA) in detecting choroidal neovascularization (CNV).
   METHODS. In this prospective study, patients with CNV detected with fluorescein angiography (FA) underwent ICGA and OCTA, spectral domain OCT (SD-OCT), and infrared or fundus color photographs. CNV lesions were outlined on ICGA and OCTA images, and the composition and size of the CNV was documented.
   RESULTS. One hundred eighty-two eyes were included. With ICGA, well-defined lesions were observed in 37.9%, partly defined in 44.5%, and undefined in 17% of eyes. On OCTA, welldefined, partly defined, and undefined vessels were observed in 53.8%, 27.5%, and 18.7% of eyes, respectively. There was a good correlation between CNV size measured with the two instruments (r = 0.84). However, OCTA underestimated CNV area by about 4.5% (slope coefficient with linear regression: 0.55, 95% confidence interval [CI]: 0.46 to 0.65; intercept: 0.27, 95% CI: -0.2 to 0.56). On ICGA, CNV composition was capillary in 28%, mature in 14.3%, and mixed (capillary and major neovascular complex) in 57.7% of eyes. Similarly, OCTA revealed capillary, mature, and mixed CNV in 28.9%, 15.9%, and 55.5% of eyes, respectively.
   CONCLUSIONS. OCTA provides the clinician the ability to perform precise structural and vascular assessment of CNV noninvasively. Our study is, to our knowledge, the largest OCTA analysis to date of CNV secondary to neovascular AMD analyzed simultaneously by ICGA and OCTA.
C1 [Eandi, Chiara M.; Alovisi, Camilla] Univ Torino, Eye Clin, Dept Surg Sci, Via Juvarra 19, I-10122 Turin, Italy.
   [Ciardella, Antonio; Alovisi, Camilla; Veronese, Chiara] Univ Bologna, Azienda Osped, Unita Operat Oftalmol Ciardella, Policlin S Orsola Malpighi, Bologna, Italy.
   [Parravano, Mariacristina] IRCCS Fdn GB Bietti, Rome, Italy.
   [Missiroli, Filippo; Grossi, Massimo; Ricci, Federico] Univ Tor Vergata, Dept Surg & Expt Med, Rome, Italy.
   [Virgili, Gianni] Univ Florence, Dept Translat Surg & Med, Florence, Italy.
C3 University of Turin; IRCCS Azienda Ospedaliero-Universitaria di Bologna;
   University of Bologna; IRCCS - Fondazione "G.B. Bietti" per lo Studio e
   la Ricerca in Oftalmologia; University of Rome Tor Vergata; University
   of Florence
RP Eandi, CM (通讯作者)，Univ Torino, Eye Clin, Dept Surg Sci, Via Juvarra 19, I-10122 Turin, Italy.
EM ceandi@gmail.com
RI ricci, federico/AAC-3836-2020; Virgili, Gianni/P-6607-2014
OI ricci, federico/0000-0002-4224-9280; Virgili, Gianni/0000-0002-9960-2989
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Gass J.D., 1967, AM J OPHTHALMOL, V63, pS1
   Guyer D, 2001, RETINA-J RET VIT DIS, V3, P943
   HYVARINEN L, 1980, ACTA OPHTHALMOL, V58, P528
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Ryan SJ, 2013, RETINA, P1150
   Schneider U, 1996, GER J OPHTHALMOL, V5, P6
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wolf S, 1996, GER J OPHTHALMOL, V5, P251
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 33
TC 18
Z9 18
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2017
VL 58
IS 9
BP 3690
EP 3696
DI 10.1167/iovs.17-21941
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1WU
UT WOS:000410931200049
PM 28738134
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ramsey, DJ
   Sunness, JS
   Malviya, P
   Applegate, C
   Hager, GD
   Handa, JT
AF Ramsey, David J.
   Sunness, Janet S.
   Malviya, Poorva
   Applegate, Carol
   Hager, Gregory D.
   Handa, James T.
TI AUTOMATED IMAGE ALIGNMENT AND SEGMENTATION TO FOLLOW PROGRESSION OF
   GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; automated image segmentation; fundus
   autofluorescence; geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE; DIABETIC-RETINOPATHY; DISEASE PROGRESSION;
   UNITED-STATES; EYE DISEASE; QUANTIFICATION; IDENTIFICATION; PHOTOGRAPHS
AB Purpose: To develop a computer-based image segmentation method for standardizing the quantification of geographic atrophy (GA).
   Methods: The authors present an automated image segmentation method based on the fuzzy c-means clustering algorithm for the detection of GA lesions. The method is evaluated by comparing computerized segmentation against outlines of GA drawn by an expert grader for a longitudinal series of fundus autofluorescence images with paired 30 color fundus photographs for 10 patients.
   Results: The automated segmentation method showed excellent agreement with an expert grader for fundus autofluorescence images, achieving a performance level of 94 +/- 5% sensitivity and 98 +/- 2% specificity on a per-pixel basis for the detection of GA area, but performed less well on color fundus photographs with a sensitivity of 47 +/- 26% and specificity of 98 +/- 2%. The segmentation algorithm identified 75 +/- 16% of the GA border correctly in fundus autofluorescence images compared with just 42 +/- 25% for color fundus photographs.
   Conclusion: The results of this study demonstrate a promising computerized segmentation method that may enhance the reproducibility of GA measurement and provide an objective strategy to assist an expert in the grading of images.
C1 [Ramsey, David J.; Handa, James T.] Johns Hopkins Univ, Wilmer Eye Inst, Johns Hopkins Sch Med, Baltimore, MD 21218 USA.
   [Sunness, Janet S.; Applegate, Carol] Greater Baltimore Med Ctr, Hoover Rehabil Low Vis Serv, Baltimore, MD USA.
   [Malviya, Poorva; Hager, Gregory D.] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Greater Baltimore
   Medical Center; Johns Hopkins University
RP Handa, JT (通讯作者)，Room 3015,Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
RI Ramsey, David/AAW-2081-2021
OI Ramsey, David/0000-0002-5504-812X; Sunness, Janet/0000-0001-8823-0780
FU National Institutes of Health [EY08552 JSS]; Research to Prevent
   Blindness (Wilmer); Johns Hopkins Internal funds; NATIONAL EYE INSTITUTE
   [R01EY008552] Funding Source: NIH RePORTER
FX Supported in part by the National Institutes of Health (EY08552 JSS),
   Research to Prevent Blindness (Wilmer), and Johns Hopkins Internal
   funds.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Arnedo A, 2000, EUR PHYS J B, V15, P567, DOI 10.1007/s100510051161
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Bezdek JC, 1981, INT J SYST MEAS DECI, V1-2, P13
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Chakravarthy U, 2007, INVEST OPHTH VIS SCI, V48, P349, DOI 10.1167/iovs.06-0493
   Chen WJ, 2006, ACAD RADIOL, V13, P63, DOI 10.1016/j.acra.2005.08.035
   Chutatape Opas, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4440
   Devisetti K, 2011, IEEE ENG MED BIO, P3958, DOI 10.1109/IEMBS.2011.6090983
   Dunn J. C., 1974, Journal of Cybernetics, V4, P95
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HEIJL A, 1989, INVEST OPHTH VIS SCI, V30, P2376
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hsu W, 2001, PROC CVPR IEEE, P246
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Leandro JJG, 2001, SIBGRAPI 01 FLORIANO, P84
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Mansouri K, 2013, ACTA OPHTHALMOL, V91, pE379, DOI 10.1111/aos.12057
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Multicenter A, PROOF CONCEPT STUDY
   Osareh A, 2003, BRIT J OPHTHALMOL, V87, P1220, DOI 10.1136/bjo.87.10.1220
   Osareh A, 2009, IEEE T INF TECHNOL B, V13, P535, DOI 10.1109/TITB.2008.2007493
   Ramsey DJ, 2011, ASS RES VISION OPHTH
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Usher D, 2004, DIABETIC MED, V21, P84, DOI 10.1046/j.1464-5491.2003.01085.x
   Walter T, 2002, LECT NOTES COMPUT SC, V2526, P210
   Wang H, 2000, PROC CVPR IEEE, P181
   You QS, 2010, BRIT J OPHTHALMOL, V94, P575, DOI 10.1136/bjo.2009.165720
NR 45
TC 30
Z9 31
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2014
VL 34
IS 7
BP 1296
EP 1307
DI 10.1097/IAE.0000000000000069
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK9UG
UT WOS:000338772600006
PM 24398699
DA 2022-11-30
ER

PT J
AU Xue, W
   Li, JJ
   Zou, YL
   Zou, B
   Wei, L
AF Xue, Wei
   Li, Jing Jing
   Zou, Yanli
   Zou, Bin
   Wei, Lai
TI Microbiota and Ocular Diseases
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Review
DE gut microbiome; gut-eye axis; ophthalmic diseases; multiomics; microbial
   therapeutics
ID HELICOBACTER-PYLORI INFECTION; ACUTE ANTERIOR UVEITIS; GUT MICROBIOTA;
   INTESTINAL MICROBIOTA; SURFACE MICROBIOME; SJOGRENS-SYNDROME;
   OPEN-ANGLE; QUANTITATIVE METAPROTEOMICS; BLOOD MICROBIOME; MEIBOMIAN
   GLAND
AB Recent advances have identified significant associations between the composition and function of the gut microbiota and various disorders in organ systems other than the digestive tract. Utilizing next-generation sequencing and multiomics approaches, the microbial community that possibly impacts ocular disease has been identified. This review provides an overview of the literature on approaches to microbiota analysis and the roles of commensal microbes in ophthalmic diseases, including autoimmune uveitis, age-related macular degeneration, glaucoma, and other ocular disorders. In addition, this review discusses the hypothesis of the "gut-eye axis" and evaluates the therapeutic potential of targeting commensal microbiota to alleviate ocular inflammation.
C1 [Xue, Wei; Li, Jing Jing; Zou, Yanli; Zou, Bin; Wei, Lai] Sun Yat Sen Univ, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Zou, Yanli] Southern Med Univ, Affiliated Foshan Hosp, Dept Ophthalmol, Foshan, Peoples R China.
C3 Sun Yat Sen University; Southern Medical University - China
RP Wei, L (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
EM weil9@mail.sysu.edu.cn
CR Abu-Ali GS, 2018, NAT MICROBIOL, V3, P356, DOI 10.1038/s41564-017-0084-4
   Al-Mujaini Abdullah, 2009, Sultan Qaboos Univ Med J, V9, P184
   Almeida A, 2019, NATURE, V568, P499, DOI 10.1038/s41586-019-0965-1
   Anderson MS, 2005, IMMUNITY, V23, P227, DOI 10.1016/j.immuni.2005.07.005
   Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   Andersson J, 2021, OCUL SURF, V19, P210, DOI 10.1016/j.jtos.2020.09.003
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Angelucci F, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1494-4
   Aron-Wisnewsky J, 2016, NAT REV NEPHROL, V12, P169, DOI 10.1038/nrneph.2015.191
   Arrieta MC, 2016, CELL HOST MICROBE, V19, P575, DOI 10.1016/j.chom.2016.04.014
   Asquith MJ, 2016, ARTHRITIS RHEUMATOL, V68, P2151, DOI 10.1002/art.39681
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469
   Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2
   Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468
   Baggia S, 1997, J INVEST MED, V45, P295
   Baim AD, 2019, EXP BIOL MED, V244, P419, DOI 10.1177/1535370218813616
   Berer K, 2017, P NATL ACAD SCI USA, V114, P10719, DOI 10.1073/pnas.1711233114
   Bernstein Charles N, 2017, Inflamm Intest Dis, V2, P116, DOI 10.1159/000481401
   Berthelot JM, 2015, JOINT BONE SPINE, V82, P8, DOI 10.1016/j.jbspin.2014.07.011
   Bodis G, 2018, METHODS MOL BIOL, V1802, P11, DOI 10.1007/978-1-4939-8546-3_2
   Both T, 2017, INT J MED SCI, V14, P191, DOI 10.7150/ijms.17718
   Burucoa C, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12403
   Caputi V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061689
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Cavuoto KM, 2018, CLIN OPHTHALMOL, V12, P1189, DOI 10.2147/OPTH.S166547
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chang JH, 2007, INVEST OPHTH VIS SCI, V48, P1711, DOI 10.1167/iovs.06-0807
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Cheng K, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0375-2
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chibbar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102375
   Chisari G, 2017, CURR CLIN PHARMACOL, V12, P99, DOI 10.2174/1574884712666170704145046
   Chmiela M, 2006, HELICOBACTER, V11, P21, DOI 10.1111/j.1478-405X.2006.00422.x
   Choi SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.42
   Chowdhury Shankar R, 2007, BMC Genomics, V8, P215, DOI 10.1186/1471-2164-8-215
   Clarridge JE, 2004, CLIN MICROBIOL REV, V17, P840, DOI 10.1128/CMR.17.4.840-862.2004
   Coker OO, 2020, GASTROENTEROLOGY, V159, P1459, DOI 10.1053/j.gastro.2020.06.042
   Colmegna I, 2004, CLIN MICROBIOL REV, V17, P348, DOI 10.1128/CMR.17.2.348-369.2004
   Commisso M, 2013, COMPUT STRUCT BIOTEC, V4, DOI 10.5936/csbj.201301007
   Cone RE, 2009, OPHTHALMOL EYE DIS, V1, P33
   Cryan JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/physrev.00018.2018
   Daliri EBM, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020300
   Daliri EBM, 2020, BIOSCI MICROB FOOD H, V39, P199, DOI 10.12938/bmfh.2020-001
   Daliri EBM, 2017, CRIT REV FOOD SCI, V57, P3565, DOI 10.1080/10408398.2016.1220913
   Damgaard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120826
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   de Paiva CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23561
   Deng YH, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00245-6
   Dennis-Wall JC, 2017, AM J CLIN NUTR, V105, P758, DOI 10.3945/ajcn.116.140012
   Deshpande N, 2008, J GLAUCOMA, V17, P605, DOI 10.1097/IJG.0b013e318166f00b
   Dong XJ, 2019, INVEST OPHTH VIS SCI, V60, P4774, DOI 10.1167/iovs.19-27719
   Dong X, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1590
   Drago L, 2016, EUR J GASTROEN HEPAT, V28, P532, DOI 10.1097/MEG.0000000000000581
   Dzidic Majda, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6030056
   Easterly CW, 2019, MOL CELL PROTEOMICS, V18, pS82, DOI 10.1074/mcp.RA118.001240
   Eguchi H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009310
   Eguchi H, 2017, CORNEA, V36, pS46, DOI 10.1097/ico.0000000000001338
   Eisenstein EM, 2009, PEDIATR RES, V65, p26R, DOI 10.1203/PDR.0b013e31819e76c7
   Emerson JB, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0285-3
   Ericsson AC, 2015, ILAR J, V56, P205, DOI 10.1093/ilar/ilv021
   Fernandez-Rubio ME, 2010, EYE, V24, P825, DOI 10.1038/eye.2009.218
   Flemming A, 2018, NAT REV IMMUNOL, V18, P603, DOI 10.1038/s41577-018-0063-x
   Forrester JV, 2013, INT REV IMMUNOL, V32, P76, DOI 10.3109/08830185.2012.747524
   Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
   Franzosa EA, 2014, P NATL ACAD SCI USA, V111, pE2329, DOI 10.1073/pnas.1319284111
   Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020
   Galloway PH, 2003, OPHTHALMOLOGY, V110, P922, DOI 10.1016/S0161-6420(03)00093-9
   Gavin PG, 2018, DIABETES CARE, V41, P2178, DOI 10.2337/dc18-0777
   Geyer O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102535
   Ghaisas S, 2016, PHARMACOL THERAPEUT, V158, P52, DOI 10.1016/j.pharmthera.2015.11.012
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   Gorkiewicz G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055817
   Graham JE, 2007, INVEST OPHTH VIS SCI, V48, P5616, DOI 10.1167/iovs.07-0588
   Granata I, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111811
   Gray DHD, 2007, P NATL ACAD SCI USA, V104, P18193, DOI 10.1073/pnas.0709160104
   Graziani F, 2016, J APPL MICROBIOL, V120, P1403, DOI 10.1111/jam.13095
   Gregory AC, 2020, CELL HOST MICROBE, V28, P724, DOI 10.1016/j.chom.2020.08.003
   Greiling TM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan2306
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Guo JG, 2014, GRAEF ARCH CLIN EXP, V252, P925, DOI 10.1007/s00417-014-2619-1
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hasegawa Y, 2004, J NEUROSCI, V24, P6826, DOI 10.1523/JNEUROSCI.1856-04.2004
   Heintz-Buschart A, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.180
   Henke MT, 2019, P NATL ACAD SCI USA, V116, P12672, DOI 10.1073/pnas.1904099116
   HOEKZEMA R, 1992, INVEST OPHTH VIS SCI, V33, P532
   Horai R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00232
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Horai R, 2013, J AUTOIMMUN, V44, P21, DOI 10.1016/j.jaut.2013.06.003
   Hori Y, 2008, AM J OPHTHALMOL, V146, P729, DOI 10.1016/j.ajo.2008.06.003
   Hornef MW, 2016, GUT, V65, P365, DOI 10.1136/gutjnl-2015-310027
   Hsu BB, 2019, CELL HOST MICROBE, V25, P803, DOI 10.1016/j.chom.2019.05.001
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Huang Y, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.04.008
   Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234
   Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jagtap PD, 2015, PROTEOMICS, V15, P3553, DOI 10.1002/pmic.201500074
   Jangi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12015
   Janowitz C, 2019, INVEST OPHTH VIS SCI, V60, P420, DOI 10.1167/iovs.18-24813
   Jia YY, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00208-18
   Jiang XD, 2018, INFECT DRUG RESIST, V11, P1729, DOI 10.2147/IDR.S162135
   Jiang Y, 2016, MICROBIOME, V4, DOI 10.1186/s40168-015-0146-x
   Jin Ping, 2003, J Transl Med, V1, P8, DOI 10.1186/1479-5876-1-8
   Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430
   Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198
   Kell Douglas, 2015, F1000Res, V4, P179, DOI 10.12688/f1000research.6709.2
   Khan MA, 2008, JCR-J CLIN RHEUMATOL, V14, P50, DOI 10.1097/RHU.0b013e3181637a38
   Kho ZY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01835
   Kim J, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111166
   Klenkler B, 2004, EXP EYE RES, V79, P677, DOI 10.1016/j.exer.2004.07.008
   Knop Erich, 2007, Chem Immunol Allergy, V92, P36, DOI 10.1159/000099252
   Korobelnik JF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0035-x
   Kountouras J, 2001, OPHTHALMOLOGY, V108, P599, DOI 10.1016/S0161-6420(00)00598-4
   Kugadas A, 2017, INVEST OPHTH VIS SCI, V58, P4593, DOI 10.1167/iovs.17-22119
   Kugadas A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005855
   Kuklinski E, 2017, CLIN IMMUNOL, V182, P55, DOI 10.1016/j.clim.2017.04.017
   Kurtz S, 2008, J GLAUCOMA, V17, P223, DOI 10.1097/IJG.0b013e31815a34ac
   Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9
   Lee SH, 2012, INVEST OPHTH VIS SCI, V53, P5585, DOI 10.1167/iovs.12-9922
   Li JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609765
   Liang ST, 2000, J BACTERIOL, V182, P3037, DOI 10.1128/JB.182.11.3037-3044.2000
   Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Lobato RD, 2008, NEUROCIRUGIA, V19, P456
   Long SP, 2020, NPJ BIOFILMS MICROME, V6, DOI 10.1038/s41522-020-0123-4
   Lorenzon R, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021037
   Lu Louise J., 2016, Yale Journal of Biology and Medicine, V89, P325
   Luissint AC, 2016, GASTROENTEROLOGY, V151, P616, DOI 10.1053/j.gastro.2016.07.008
   Lusthaus J, 2019, MED J AUSTRALIA, V210, P180, DOI 10.5694/mja2.50020
   Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400
   Maurice CF, 2013, CELL, V152, P39, DOI 10.1016/j.cell.2012.10.052
   Mayers MD, 2017, J PROTEOME RES, V16, P1014, DOI 10.1021/acs.jproteome.6b00938
   Mendez R, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01348-7
   Mesuere B, 2016, BIOINFORMATICS, V32, P1746, DOI 10.1093/bioinformatics/btw039
   Miedzybrodzki R, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3612015
   Miller D, 2009, CURR OPIN ALLERGY CL, V9, P466, DOI 10.1097/ACI.0b013e3283303e1b
   Miyazaki D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69554-2
   Moon J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229029
   Morais LH, 2021, NAT REV MICROBIOL, V19, P241, DOI 10.1038/s41579-020-00460-0
   Morita Y, 2018, AGING-US, V10, P2723, DOI 10.18632/aging.101583
   Mshangila B, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-71
   Muth T, 2018, ANAL CHEM, V90, P685, DOI 10.1021/acs.analchem.7b03544
   Nadeem U., 2020, HIGH THROUGHPUT RNA, V3, P34
   Nagpal R, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102950
   Nakamura YK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12163-3
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Napolitano P, 2021, ANN MED, V53, P750, DOI 10.1080/07853890.2021.1925150
   Negata N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40182-9
   Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189
   Noack M, 2014, AUTOIMMUN REV, V13, P668, DOI 10.1016/j.autrev.2013.12.004
   O'Keeffe KM, 2015, INFECT IMMUN, V83, P3445, DOI 10.1128/IAI.00358-15
   Olivares M, 2015, GUT, V64, P406, DOI 10.1136/gutjnl-2014-306931
   Olson JA, 1996, OCUL IMMUNOL INFLAMM, V4, P91, DOI 10.3109/09273949609079638
   Ozkan J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10494-9
   Paisse S, 2016, TRANSFUSION, V56, P1138, DOI 10.1111/trf.13477
   Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001
   Peng B, 2015, PROTEIN CELL, V6, P628, DOI 10.1007/s13238-015-0185-x
   Pianta A, 2017, J CLIN INVEST, V127, P2946, DOI 10.1172/JCI93450
   Pickering H, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00297
   Pinna A, 2005, OPHTHALMOLOGY, V112, P883, DOI 10.1016/j.ophtha.2004.12.024
   Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1
   Potgieter M, 2015, FEMS MICROBIOL REV, V39, P567, DOI 10.1093/femsre/fuv013
   Proekt I, 2017, CURR OPIN IMMUNOL, V49, P71, DOI 10.1016/j.coi.2017.10.003
   Proekt I, 2016, J CLIN INVEST, V126, P3758, DOI 10.1172/JCI84440
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rajilic-Stojanovic M, 2015, AM J GASTROENTEROL, V110, P278, DOI 10.1038/ajg.2014.427
   Rakover IS, 2010, J NEUROIMMUNOL, V225, P68, DOI 10.1016/j.jneuroim.2010.04.014
   Rausch P, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0743-1
   Riviere A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00979
   Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012
   Rolig AS, 2018, ELIFE, V7, DOI 10.7554/eLife.37172
   Rosenbaum JT, 2018, NAT REV RHEUMATOL, V14, P704, DOI 10.1038/s41584-018-0097-2
   ROSENBAUM JT, 1989, J RHEUMATOL, V16, P792
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Santa Cruz C, 1998, OPHTHALMIC SURG LAS, V29, P803
   Santos TMA, 2011, AM J VET RES, V72, P1079, DOI 10.2460/ajvr.72.8.1079
   SAVAGE DC, 1981, APPL ENVIRON MICROB, V42, P996, DOI 10.1128/AEM.42.6.996-1001.1981
   Schabereiter-Gurtner C, 2001, INVEST OPHTH VIS SCI, V42, P1164
   Scher JU, 2016, ARTHRITIS RHEUMATOL, V68, P35, DOI 10.1002/art.39259
   Schierwagen R, 2019, GUT, V68, P578, DOI 10.1136/gutjnl-2018-316227
   Schloss PD, 2004, MICROBIOL MOL BIOL R, V68, P686, DOI 10.1128/MMBR.68.4.686-691.2004
   Schuster AK, 2020, DTSCH ARZTEBL INT, V117, P225, DOI 10.3238/arztebl.2020.0225
   Schweppe DK, 2015, CHEM BIOL, V22, P1521, DOI 10.1016/j.chembiol.2015.09.015
   Shakya M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00904
   Sheehan D, 2015, J GASTROENTEROL, V50, P495, DOI 10.1007/s00535-015-1064-1
   Shi ZQ, 2018, J CONTROL RELEASE, V270, P14, DOI 10.1016/j.jconrel.2017.11.028
   Shobar RM, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2015.54
   Singh PK, 2014, ANTIMICROB AGENTS CH, V58, P4621, DOI 10.1128/AAC.00126-14
   Skrzypecki J, 2021, INT OPHTHALMOL, V41, P341, DOI 10.1007/s10792-020-01587-y
   Skrzypecki J, 2018, J GLAUCOMA, V27, P823, DOI 10.1097/IJG.0000000000001025
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   St Leger AJ, 2017, IMMUNITY, V47, P148, DOI 10.1016/j.immuni.2017.06.014
   Stapleton F, 2007, AM J OPHTHALMOL, V144, P690, DOI 10.1016/j.ajo.2007.06.037
   Stein-Streilein J, 2008, TRENDS IMMUNOL, V29, P548, DOI 10.1016/j.it.2008.08.002
   Sun MM, 2017, J GASTROENTEROL, V52, P1, DOI 10.1007/s00535-016-1242-9
   Sun NN, 2021, BRAIN BEHAV IMMUN, V92, P102, DOI 10.1016/j.bbi.2020.11.032
   Szymula A, 2014, CLIN IMMUNOL, V152, P1, DOI 10.1016/j.clim.2014.02.004
   Tadayoni Ramin, 2014, J Ophthalmic Vis Res, V9, P405, DOI 10.4103/2008-322X.150799
   Tai NW, 2015, REV ENDOCR METAB DIS, V16, P55, DOI 10.1007/s11154-015-9309-0
   TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359
   Todokoro D, 2018, JPN J OPHTHALMOL, V62, P699, DOI 10.1007/s10384-018-0630-5
   Trujillo-Vargas CM, 2020, OCUL SURF, V18, P335, DOI 10.1016/j.jtos.2019.10.006
   Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322
   Vercelli D, 2021, CURR OPIN IMMUNOL, V72, P247, DOI 10.1016/j.coi.2021.06.002
   Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201
   Vignoli A, 2019, ANGEW CHEM INT EDIT, V58, P968, DOI 10.1002/anie.201804736
   Viladomiu M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf9655
   WAKEFIELD D, 1991, SURV OPHTHALMOL, V36, P223, DOI 10.1016/0039-6257(91)90005-Z
   Walter J, 2020, CELL, V180, P221, DOI 10.1016/j.cell.2019.12.025
   Wang CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020565
   Wang JF, 2016, ENVIRON MICROBIOL, V18, P2143, DOI 10.1111/1462-2920.12923
   Weinbauer MG, 2004, FEMS MICROBIOL REV, V28, P127, DOI 10.1016/j.femsre.2003.08.001
   Weinstein JE, 2018, CURR OPIN OPHTHALMOL, V29, P267, DOI 10.1097/ICU.0000000000000466
   Wen XF, 2017, INVEST OPHTH VIS SCI, V58, P6030, DOI 10.1167/iovs.17-22957
   Wu TG, 2003, CURR EYE RES, V26, P33, DOI 10.1076/ceyr.26.1.33.14253
   Xiong WL, 2015, J PROTEOME RES, V14, P133, DOI 10.1021/pr500936p
   Yamazaki T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145091
   Yanagisawa N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103241
   Yang PZ, 2018, BRIT J OPHTHALMOL, V102, P215, DOI 10.1136/bjophthalmol-2016-309499
   Ye Z, 2020, GUT MICROBES, V11, P539, DOI 10.1080/19490976.2019.1700754
   Ye Z, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0520-6
   Yuan F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094616
   Zaidi TS, 2018, INVEST OPHTH VIS SCI, V59, P2512, DOI 10.1167/iovs.18-23795
   Zeng H, 2015, TRENDS IMMUNOL, V36, P3, DOI 10.1016/j.it.2014.08.003
   Zeng J, 2015, INVEST OPHTH VIS SCI, V56, P5238, DOI 10.1167/iovs.15-17059
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang X, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0767-6
   Zhang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05357-4
   Zhang Y, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113856
   Zhao FX, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.22
   Zhou JH, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114108
   Zhou Y, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0099-x
   Zilliox MJ, 2020, OCUL SURF, V18, P706, DOI 10.1016/j.jtos.2020.07.007
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.8
NR 239
TC 5
Z9 5
U1 12
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD OCT 21
PY 2021
VL 11
AR 759333
DI 10.3389/fcimb.2021.759333
PG 17
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology
GA WU6DT
UT WOS:000716634800001
PM 34746029
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Auricchio, A
   Behling, KC
   Maguire, AM
   O'Connor, EE
   Bennett, J
   Wilson, JM
   Tolentino, MJ
AF Auricchio, A
   Behling, KC
   Maguire, AM
   O'Connor, EE
   Bennett, J
   Wilson, JM
   Tolentino, MJ
TI Inhibition of retinal neovascularization by intraocular viral-mediated
   delivery of anti-angiogenic agents
SO MOLECULAR THERAPY
LA English
DT Article
DE retina; diabetic retinopathy; PEDF; endostatin; TIMP3; AAV
ID EPITHELIUM-DERIVED FACTOR; TISSUE INHIBITOR; CHOROIDAL
   NEOVASCULARIZATION; GENE-THERAPY; INDUCED RETINOPATHY; VECTORS;
   METALLOPROTEINASES; EXPRESSION; ENDOSTATIN; FAMILY
AB Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes of severe visual loss in the developed world. Gene transfer to the eye using adeno-associated viral (AAV) vectors is a promising new treatment for inherited and acquired ocular diseases. We used an AAV vector with rapid onset and high levels of gene expression in the retina to deliver three anti-angiogenic factors (pigment epithelium-derived factor, tissue inhibitor of metalloproteinase-3, and endostatin) to the eyes of mice in a mouse model of retinopathy of prematurity. All three vectors inhibited ischemia-induced neovascularization.
C1 Univ Penn, Philadelphia, PA 19104 USA.
   Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   Wistar Inst Anat & Biol, Dept Med & Cellular Engn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine; The Wistar Institute
RP Tolentino, MJ (通讯作者)，Univ Penn, Philadelphia, PA 19104 USA.
RI Wilson, James M/F-9220-2011; AURICCHIO, Alberto/AHE-7979-2022
OI Wilson, James M/0000-0002-9630-3131; AURICCHIO,
   Alberto/0000-0002-0832-2472; Behling, Kathryn/0000-0002-6188-2452
FU NEI NIH HHS [T32-EY-07035, R01-EY12156, K08 EY 13410-01, R01-EY10820]
   Funding Source: Medline; NIDDK NIH HHS [P30 DK47757-09] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [T32EY007035, R01EY012156, R01EY010820,
   K08EY013410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source:
   NIH RePORTER
CR AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Bennett J, 1997, INVEST OPHTH VIS SCI, V38, P2857
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Clackson T, 2000, GENE THER, V7, P120, DOI 10.1038/sj.gt.3301120
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Karakousis PC, 2001, MOL VIS, V7, P154
   Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   STRICKLIN GP, 1986, COLLAGEN REL RES, V6, P219
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
NR 24
TC 126
Z9 145
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD OCT
PY 2002
VL 6
IS 4
BP 490
EP 494
DI 10.1006/mthe.2002.0702
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 601WR
UT WOS:000178472200010
PM 12377190
OA hybrid
DA 2022-11-30
ER

PT J
AU Vilkeviciute, A
   Cebatoriene, D
   Kriauciuniene, L
   Liutkeviciene, R
AF Vilkeviciute, Alvita
   Cebatoriene, Dzastina
   Kriauciuniene, Loresa
   Liutkeviciene, Rasa
TI VEGFA Haplotype and VEGF-A and VEGF-R2 Protein Associations with
   Exudative Age-Related Macular Degeneration
SO CELLS
LA English
DT Article
DE age-related macular degeneration; VEGFA; haplotype; serum concentration;
   rs1570360; rs699947; rs3025033; rs2146323
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR GENE POLYMORPHISMS; SERUM-LEVELS;
   INTRAVITREAL RANIBIZUMAB; TREATMENT RESPONSE; PLASMA-LEVELS; CFH;
   SUSCEPTIBILITY; BEVACIZUMAB; PREVALENCE
AB Our study aimed to reveal the associations between VEGFA SNPs (rs1570360, rs699947, rs3025033, and rs2146323), their haplotypes, VEGF-A and VEGF-R2 serum concentrations, and early and exudative AMD. A total of 339 subjects with early AMD and 419 with exudative AMD groups, and 374 healthy subjects, were genotyped for four VEGFA SNPs (rs1570360, rs699947, rs3025033, and rs2146323). VEGF-A and VEGFR-2 serum concentrations were measured in exudative AMD and controls. The results revealed that rs3025033 G allele was significantly associated with lower odds of exudative AMD under the dominant model (OR = 0.67; 95% CI: 0.49-0.80; p = 0.0088) and additive (OR = 0.7; 95% CI: 0.54-0.90; p = 0.0058) models after Bonferroni correction. In the female group, rs3025033 AG genotype was associated with exudative AMD under the codominant model (OR = 0.57; 95% CI: 0.37-0.87; p = 0.009) and G allele under the dominant (OR = 0.55; 95% CI: 0.37-0.82; p = 0.0032) and additive models (OR = 0.60; 95% CI: 0.42-0.84; p = 0.0028). Haplotype analysis revealed that individuals carrying rs1570360, rs699947, rs3025033, and rs2146323 haplotype A-A-G-A had decreased risk of exudative AMD (OR = 0.46, 95% CI: 0.23-0.90; p = 0.023). The VEGF-A and VEGF-R2 serum concentrations did not differ between study groups; we found that patients with exudative AMD carrying at least one C allele at rs699947 have statistically significantly higher VEGF-A serum concentrations compared to AA genotype carriers (485.95 (945.93) vs. 194.97 (-), respectively, p = 0.046). In conclusion, we found that VEGFA rs3025033 and haplotype rs1570360A-rs699947A-rs3025033G- rs2146323A play a protective role for exudative AMD in the Caucasian population. Furthermore, rs699947 is associated with elevated VEGF-A serum concentrations in exudative AMD.
C1 [Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu St 2, LT-50161 Kaunas, Lithuania.
   [Cebatoriene, Dzastina] Lithuanian Univ Hlth Sci, Med Acad, A Mickeviciaus St 9, LT-44307 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Vilkeviciute, A (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu St 2, LT-50161 Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt; dzastina.cebatoriene@lsmu.lt;
   loresa.kriauciuniene@lsmuni.lt; rasa.liutkeviciene@lsmuni.lt
OI Vilkeviciute, Alvita/0000-0002-0427-5568
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambreen F, 2015, MOL VIS, V21, P985
   Battu P, 2021, CURR NEUROVASC RES, V18, P181, DOI 10.2174/1567202618666210531130711
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Bulgu Y, 2014, INT J OPHTHALMOL-CHI, V7, P773, DOI [10.3980/j.issn.2222-3959.2014.05.06, 10.3980/j.issn.2222-3959.2014.06]
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Courtenay MD, 2014, INVEST OPHTH VIS SCI, V55, P4873, DOI 10.1167/iovs.14-14494
   Cruz-Gonzalez F, 2016, Arch Soc Esp Oftalmol, V91, P177, DOI 10.1016/j.oftal.2015.12.016
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Cruz-Gonzalez F, 2013, CURR EYE RES, V38, P1274, DOI 10.3109/02713683.2013.819926
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Green W.R., 1978, T AM OPHTHAL SOC, V75, P180, DOI [10.1097/00006982-200507001-00005, DOI 10.1097/00006982-200507001-00005]
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Habibi I, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-15
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Huang C, 2013, MOL VIS, V19, P1211
   Gonalves FTI, 2015, ARQ BRAS OFTALMOL, V78, P290, DOI 10.5935/0004-2749.20150077
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Leone JP, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01372-w
   Li HH, 2022, EUR J OPHTHALMOL, V32, P2726, DOI 10.1177/11206721211058000
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu YY, 2019, INT J OPHTHALMOL-CHI, V12, P457, DOI 10.18240/ijo.2019.03.17
   Liukkonen MPK, 2022, ACTA OPHTHALMOL, V100, pE1153, DOI 10.1111/aos.15051
   Liutkeviciene R, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9602949
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Ornek N, 2016, INT J OPHTHALMOL-CHI, V9, P556, DOI 10.18240/ijo.2016.04.13
   Papachristos A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113753
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Sharma K, 2015, ANN NEUROSCI, V22, P232, DOI 10.5214/ans.0972.7531.220408
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Song YX, 2019, GENE, V698, P186, DOI 10.1016/j.gene.2019.02.070
   Song YX, 2018, GENE, V679, P241, DOI 10.1016/j.gene.2018.09.005
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Tsuchihashi T, 2014, CLIN OPHTHALMOL, V8, P2471, DOI 10.2147/OPTH.S71305
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tu JW, 2014, MED SCI MONITOR, V20, P2520, DOI 10.12659/MSM.891394
   Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091
   Vilkeviciute A, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6622934
   Vilkeviciute A, 2020, IN VIVO, V34, P2443, DOI 10.21873/invivo.12059
   Vural E, 2021, OPHTHALMOLOGICA, V244, P102, DOI 10.1159/000513050
   Wilkinson P.C., 2006, RETINA-J RET VIT DIS, V3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 65
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAR
PY 2022
VL 11
IS 6
AR 996
DI 10.3390/cells11060996
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0E9CS
UT WOS:000776970900001
PM 35326447
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shimizu, H
   Yamada, K
   Suzumura, A
   Kataoka, K
   Takayama, K
   Sugimoto, M
   Terasaki, H
   Kaneko, H
AF Shimizu, Hideyuki
   Yamada, Kazuhisa
   Suzumura, Ayana
   Kataoka, Keiko
   Takayama, Kei
   Sugimoto, Masataka
   Terasaki, Hiroko
   Kaneko, Hiroki
TI Caveolin-1 Promotes Cellular Senescence in Exchange for Blocking
   Subretinal Fibrosis in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE caveolin-1; age-related macular degeneration; subretinal fibrosis;
   epithelial-mesenchymal transition; cellular senescence
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; NEOVASCULARIZATION;
   RANIBIZUMAB; GROWTH
AB PURPOSE. To determine whether caveolin-1 (i) prevents epithelial-mesenchymal transition in the RPE and laser-induced subretinal fibrosis and (ii) promotes or inhibits cellular senescence in the RPE.
   METHODS. We examined laser-induced subretinal fibrosis and RPE cell contraction in wild-type and Caveolin-1 knockout (Cav-1(-/-)) mice treated with or without cavtratin, a cell-permeable peptide of caveolin-1. The senescence marker p16(INK4a) was measured in RPE tissues from patients with geographic atrophy and aged mice, laser-induced subretinal fibrosis, and primary human RPE cells. Human RPE was examined by TUNEL staining, reactive oxygen species generation, cell viability, and senescence-associated beta-galactosidase staining.
   RESULTS. The volume of subretinal fibrosis was significantly smaller in cavtratin-injected eyes from wild-type mice than in control eyes from wild-type, P = 0.0062, and Cav-1(-/-) mice, P = 0.0095. Cavtratin treatment produced significant improvements in primary RPE cell contraction in wild-type, P = 0.04, and Cav-1(-/-) mice, P = 0.01. p16(INK4a) expression in the RPE was higher in patients with than without geographic atrophy. p16(INK4a) was expressed in 18-month-old but not 2-month-old wild-type mouse eyes. p16(INK4a) and collagen type I antibodies showed co-localization in subretinal fibrosis. Cavtratin did not affect RPE cell apoptosis or reactive oxygen species generation, but decreased cell viability and increased senescence-associated beta-galactosidase-positive cells.
   CONCLUSIONS. Enhanced expression of caveolin-1 successfully blocked epithelial-mesenchymal transition of RPE and the reduction of subretinal fibrosis in mice. Nevertheless, in exchange for blocking subretinal fibrosis, caveolin-1 promotes RPE cellular senescence and might affect the progression of geographic atrophy in AMD.
C1 [Shimizu, Hideyuki; Yamada, Kazuhisa; Suzumura, Ayana; Kataoka, Keiko; Terasaki, Hiroko; Kaneko, Hiroki] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi, Japan.
   [Takayama, Kei] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Sugimoto, Masataka] Natl Ctr Geriatr & Gerontol, Dept Mech Aging, Obu, Aichi, Japan.
   [Terasaki, Hiroko] Nagoya Univ, Inst Innovat Future Soc, Nagoya, Aichi, Japan.
C3 Nagoya University; National Defense Medical College - Japan; National
   Center for Geriatrics & Gerontology; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465
FU JSPS KAKENHI [19K09988]; Eye Research Foundation for the Aged (ERFA);
   Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen
   Pharmaceutical's Founder; Bayer Retina Award Foundation; Ichihara
   International Scholarship Foundation
FX Supported by Grants-in-Aid for Scientific Research (C) (H.K., 19K09988)
   from JSPS KAKENHI (http://www.jsps.go.jp/), the Eye Research Foundation
   for the Aged (ERFA, H.K.), the Charitable Trust Fund for Ophthalmic
   Research in Commemoration of Santen Pharmaceutical's Founder (H.K.), and
   the Bayer Retina Award Foundation (H.K.), and Ichihara International
   Scholarship Foundation (H.K.).
CR Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bailey KM, 2008, J BIOL CHEM, V283, P13714, DOI 10.1074/jbc.M709329200
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hashimoto M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87732
   Ijima R, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.6
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jiang YD, 2017, P NATL ACAD SCI USA, V114, P10737, DOI 10.1073/pnas.1706394114
   Kaneko H, 2014, BRIT J PHARMACOL, V171, P3754, DOI 10.1111/bph.12737
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0
   Nagasaka Y, 2017, INVEST OPHTH VIS SCI, V58, P221, DOI 10.1167/iovs.16-20513
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Perdue N, 2006, EXP EYE RES, V83, P1154, DOI 10.1016/j.exer.2006.06.007
   Qin G, 2015, ONCOTARGET, V6, P41794, DOI 10.18632/oncotarget.5993
   Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529
   Wang XM, 2006, J EXP MED, V203, P2895, DOI 10.1084/jem.20061536
   Yamada K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.1
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 32
TC 5
Z9 5
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2020
VL 61
IS 11
AR 21
DI 10.1167/iovs.61.11.21
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NV9SF
UT WOS:000574650900014
PM 32926104
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yoo, TK
   Kim, SH
   Kwak, J
   Kim, HK
   Rim, TH
AF Yoo, Tae Keun
   Kim, Soo Han
   Kwak, Jiyong
   Kim, Hong Kyu
   Rim, Tyler Hyungtaek
TI Association Between Osteoporosis and Age-Related Macular Degeneration:
   The Korea National Health and Nutrition Examination Survey
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; osteoporosis; postmenopausal women;
   bone mineral density
ID BONE-MINERAL DENSITY; VITAMIN-D STATUS; POSTMENOPAUSAL WOMEN; HORMONE
   REPLACEMENT; METABOLIC SYNDROME; RISK; ESTROGEN; CALCIFICATION;
   PATHOGENESIS; MACULOPATHY
AB PURPOSE. Previous studies have reported a possible link between low bone mineral density and AMD. The aim of the present study was to investigate the association between osteoporosis and AMD in a South Korean cohort.
   METHODS. This cross-sectional, nationwide study included 3496 women and 2789 men who had participated in the Korean National Health and Nutrition Examination Survey from 2008 to 2011. All retinal photographs were graded using an international classification and grading system. Osteoporosis was assessed using dual-energy x-ray absorptiometry. Multivariate logistic regression analysis was performed to examine the relationship between osteoporosis and AMD after adjustment for potential confounders, including age, the body mass index, dietary calcium intake, and the serum vitamin D level. The odds ratios (OR) for other aging-related eye diseases, including cataract, open-angle glaucoma, and diabetic retinopathy, were analyzed in accordance with the presence of osteoporosis.
   RESULTS. Multivariate regression analysis revealed that osteoporosis was significantly associated with all types of AMD (early and late: OR, 1.31; P = 0.017) and early AMD (OR, 1.36; P = 0.007) in women. Late AMD was not associated with osteoporosis (OR, 0.84; P = 0.670). In men, osteoporosis was not associated with any type of AMD. In women, the status of osteoporosis in the femoral neck showed a linear relationship with AMD (P = 0.004). Although osteoporosis was associated with AMD in women, it showed no association with other age-related eye diseases; this suggested a disease-specific association.
   CONCLUSIONS. Our findings suggest that osteoporosis plays a role in AMD development in postmenopausal women.
C1 [Yoo, Tae Keun; Kwak, Jiyong; Rim, Tyler Hyungtaek] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 50-1 Yonsei Ro, Seoul 03722, South Korea.
   [Kim, Soo Han] Yonsei Univ, Wonju Coll Med, Dept Ophthalmol, Wonju, South Korea.
   [Kim, Hong Kyu] Dankook Univ, Dankook Univ Hosp, Coll Med, Dept Ophthalmol, Cheonan, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Dankook University; Dankook University Hospital
RP Rim, TH (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 50-1 Yonsei Ro, Seoul 03722, South Korea.
EM awaitingyourfeedback@gmail.com
RI Yoo, Tae Keun/Q-3620-2019
OI Yoo, Tae Keun/0000-0003-0890-8614; Kwak, Jay Jiyong/0000-0002-7738-9136
FU faculty research grant from Yonsei University College of Medicine for
   2017 [6-2017-0089]
FX Supported by a faculty research grant from Yonsei University College of
   Medicine for 2017 (6-2017-0089; Yonsei University, Seoul, South Korea).
CR AARON J E, 1989, Clinical Rheumatology, V8, P84, DOI 10.1007/BF02207240
   Abdelhafiz AH, 2003, AGE AGEING, V32, P26, DOI 10.1093/ageing/32.1.26
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140-6736(02)08827-X
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   GALLAGHER JC, 1980, J CLIN ENDOCR METAB, V51, P1359, DOI 10.1210/jcem-51-6-1359
   Hjortnaes J, 2010, EUR HEART J, V31, P1975, DOI 10.1093/eurheartj/ehq237
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Jiang XZ, 2016, MATURITAS, V83, P59, DOI 10.1016/j.maturitas.2015.09.009
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198-003-1490-4
   Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kajikawa M, 2017, CIRC J, V81, P862, DOI 10.1253/circj.CJ-16-1236
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kang MJ, 2016, J KOR OPHTHALMOL SOC, V57, P1451, DOI 10.3341/jkos.2016.57.9.1451
   Kim MK, 2017, OSTEOPOROSIS INT, V28, P299, DOI 10.1007/s00198-016-3717-1
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Li P, 2015, CLIN INVEST MED, V38, P123
   Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Matsuzaki M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132239
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Oh K, 2007, EPIDEMIOL HEALTH, V29, P139
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Paccou J, 2015, OSTEOPOROSIS INT, V26, P1893, DOI 10.1007/s00198-015-3132-z
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Sundh D, 2016, J INTERN MED, V280, P496, DOI 10.1111/joim.12514
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wu CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171667
   Yoo TK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166331
   Yoo TK, 2014, PUBLIC HEALTH NUTR, V17, P833, DOI 10.1017/S1368980013003492
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140-6736(10)60320-0
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198-016-3769-2
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 52
TC 6
Z9 6
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD132
EP AMD142
DI 10.1167/iovs.18-24059
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR8YP
UT WOS:000443024700003
PM 30372730
OA gold
DA 2022-11-30
ER

PT J
AU Carresi, C
   Cruciani, F
   Paolucci, F
   Curto, T
   Mazzeo, L
   Cuozzo, G
   Moramarco, A
   Gharbiya, M
AF Carresi, C.
   Cruciani, F.
   Paolucci, F.
   Curto, T.
   Mazzeo, L.
   Cuozzo, G.
   Moramarco, A.
   Gharbiya, M.
TI Montelparo Study: Risk factors for Age-Related Macular Degeneration in a
   little rural community in Italy
SO CLINICA TERAPEUTICA
LA English
DT Article
DE age related macular degeneration; epidemiology; ophthalmic health; risk
   factors; rural community
C1 [Carresi, C.] Univ Roma La Sapienza, Dept Ophthalmol, Policlin Umberto I, I-00161 Rome, Italy.
   Int Agcy Prevent Blindness, Italian Branch, Rome, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome
RP Carresi, C (通讯作者)，Univ Roma La Sapienza, Dept Ophthalmol, Policlin Umberto I, I-00161 Rome, Italy.
EM claudiocarresi@tiscali.it
RI Gharbiya, Magda/AAS-1182-2021; Moramarco, Antonietta/ABC-7729-2021
OI Gharbiya, Magda/0000-0002-4991-9689; MORAMARCO,
   Antonietta/0000-0001-9516-438X
NR 0
TC 6
Z9 6
U1 0
U2 1
PU SOC EDITRICE UNIV
PI ROME
PA VIA G B MORGAGNI 1, ROME, 10061, ITALY
SN 0009-9074
J9 CLIN TER
JI Clin. Ter.
PD MAY-JUN
PY 2009
VL 160
IS 3
PG 1
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 469MD
UT WOS:000267902400014
PM 19756317
DA 2022-11-30
ER

PT J
AU Warren, M
AF Warren, Mary
TI Memory Loss, Dementia, and Stroke: Implications for Rehabilitation of
   Older Adults with Age-Related Macular Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID RISK-FACTORS; NEGLECT
C1 Univ Alabama Birmingham, Dept Occupat Therapy, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Warren, M (通讯作者)，Univ Alabama Birmingham, Dept Occupat Therapy, 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM warrenm@uab.edu
CR Ardila A, 2007, ARCH CLIN NEUROPSYCH, V22, P1003, DOI 10.1016/j.acn.2007.08.004
   Atkinson R. C., 1968, PSYCHOL LEARN MOTIV, V2, P89, DOI [DOI 10.1016/S0079-7421(08)60422-3, 10.1016/S0079-7421(08)60422-3]
   Behrmann M, 2002, PHYSIOL BEHAV, V77, P613, DOI 10.1016/S0031-9384(02)00896-X
   Bozeat S, 2000, J NEUROL NEUROSUR PS, V69, P178, DOI 10.1136/jnnp.69.2.178
   CARMANMERRIFIEL.C, 2005, INT C SERIES, V1282, P55
   *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P3
   Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011
   CLARKE G, 2005, INT C SERIES, V1252, P365
   Crews JE, 2006, J VISUAL IMPAIR BLIN, V100, P824
   Czernuszenko A, 2007, NEUROL NEUROCHIR POL, V41, P28
   Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5
   Gazzaley A, 2007, NEUROPSYCHOLOGY, V21, P532, DOI 10.1037/0894-4105.21.5.532
   GILLEN G, 1998, STROKE REHABILITATIO
   Gillen R, 2005, ARCH PHYS MED REHAB, V86, P763, DOI 10.1016/j.apmr.2004.10.029
   Jones SA, 2006, AGE AGEING, V35, P560, DOI 10.1093/ageing/afl074
   Kelley BJ, 2007, NEUROL CLIN, V25, P577, DOI 10.1016/j.ncl.2007.03.008
   Kerkhoff G, 2001, PROG NEUROBIOL, V63, P1, DOI 10.1016/S0301-0082(00)00028-9
   Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691
   KERKHOFF G, 1999, RESTORATIVE NEUROL N, V15, P235
   Levy L, 2005, COGNITION OCCUPATION, P327
   LEVY LL, 2001, OT PRACTICE, V5, pCE1
   Pambakian ALM, 1997, BRIT J OPHTHALMOL, V81, P324, DOI 10.1136/bjo.81.4.324
   Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa
   Plassman BL, 2007, NEUROEPIDEMIOLOGY, V29, P125, DOI 10.1159/000109998
   Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372
   Ringman JM, 2004, NEUROLOGY, V63, P468, DOI 10.1212/01.WNL.0000133011.10689.CE
   Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918
   Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005
   Teri L, 1997, WESTERN J MED, V167, P269
   Vinkers DJ, 2005, NEUROLOGY, V65, P107, DOI 10.1212/01.wnl.0000167544.54228.95
   Wainapel S. F., 2001, ISSUES LOW VISION RE, P55
   Ward L, 2007, GERONTOLOGY, V53, P362, DOI 10.1159/000104787
   Xie JP, 2006, STROKE, V37, P2567, DOI 10.1161/01.STR.0000240506.34616.10
   Yelnik AP, 2006, GAIT POSTURE, V24, P262, DOI 10.1016/j.gaitpost.2005.09.007
NR 34
TC 2
Z9 2
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD OCT
PY 2008
VL 102
IS 10
SI SI
BP 611
EP 615
DI 10.1177/0145482X0810201005
PG 5
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 365YI
UT WOS:000260445400005
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Sahel, JA
   Danis, R
   Fleckenstein, M
   Jaffe, GJ
   Wolf, S
   Pruente, C
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Sahel, Jose-Alain
   Danis, Ronald
   Fleckenstein, Monika
   Jaffe, Glenn J.
   Wolf, Sebastian
   Pruente, Christian
   Holz, Frank G.
TI Natural History of Geographic Atrophy Progression Secondary to
   Age-Related Macular Degeneration (Geographic Atrophy Progression Study)
SO OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE PATTERNS; VISUAL-ACUITY; ENLARGEMENT; TRIALS;
   EYE
AB Purpose: The Geographic Atrophy Progression (GAP) study was designed to assess the rate of geographic atrophy (GA) progression and to identify prognostic factors by measuring the enlargement of the atrophic lesions using fundus autofluorescence (FAF) and color fundus photography (CFP).
   Design: Prospective, multicenter, noninterventional natural history study.
   Participants: A total of 603 participants were enrolled in the study; 413 of those had gradable lesion data from FAF or CFP, and 321 had gradable lesion data from both FAF and CFP.
   Methods: Atrophic lesion areas were measured by FAF and CFP to assess lesion progression over time. Lesion size assessments and best-corrected visual acuity (BCVA) were conducted at screening/baseline (day 0) and at 3 follow-up visits: month 6, month 12, and month 18 (or early exit).
   Main Outcome Measures: The GA lesion progression rate in disease subgroups and mean change from baseline visual acuity.
   Results: Mean (standard error) lesion size changes from baseline, determined by FAF and CFP, respectively, were 0.88 (0.1) and 0.78 (0.1) mm(2) at 6 months, 1.85 (0.1) and 1.57 (0.1) mm(2) at 12 months, and 3.14 (0.4) and 3.17 (0.5) mm(2) at 18 months. The mean change in lesion size from baseline to month 12 was significantly greater in participants who had eyes with multifocal atrophic spots compared with those with unifocal spots (P < 0.001) and those with extrafoveal lesions compared with those with foveal lesions (P = 0.001). The mean (standard deviation) decrease in visual acuity was 6.2 +/- 15.6 letters for patients with image data available. Atrophic lesions with a diffuse (mean 0.95 mm(2)) or banded (mean 1.01 mm(2)) FAF pattern grew more rapidly by month 6 compared with those with the "none" (mean, 0.13 mm(2)) and focal (mean, 0.36 mm(2)) FAF patterns.
   Conclusions: Although differences were observed in mean lesion size measurements using FAF imaging compared with CFP, the measurements were highly correlated with one another. Significant differences were found in lesion progression rates in participants stratified by hyperfluorescence pattern subtype. This large GA natural history study provides a strong foundation for future clinical trials. (C) 2016 by the American Academy of Ophthalmology.
C1 [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Sahel, Jose-Alain] Univ Paris 06, Paris, France.
   [Sahel, Jose-Alain] Inst Vis, Paris, France.
   [Danis, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Wolf, Sebastian] Univ Bern, Inselspital, Univ Hosp Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Pruente, Christian] Kantonsspital Baselland, Dept Ophthalmol, Liestal, Switzerland.
   [Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
C3 University of Bonn; UDICE-French Research Universities; Sorbonne
   Universite; UDICE-French Research Universities; Sorbonne Universite;
   University of Wisconsin System; University of Wisconsin Madison; Duke
   University; University of Bern; University Hospital of Bern;
   Kantonsspital Baselland; University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Wolf, Sebastian/B-8782-2008; Mitchell, Paul/P-1498-2014; Sahel,
   Jose-Alain/F-3172-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Sahel,
   Jose-Alain/0000-0002-4831-1153; Fleckenstein, Monika/0000-0001-8321-8037
CR Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Khan M., 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/608390
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 23
TC 108
Z9 108
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 361
EP 368
DI 10.1016/j.ophtha.2015.09.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2TK
UT WOS:000368362200029
PM 26545317
DA 2022-11-30
ER

PT J
AU Synowiec, E
   Pogorzelska, M
   Blasiak, J
   Szaflik, J
   Szaflik, JP
AF Synowiec, Ewelina
   Pogorzelska, Magdalena
   Blasiak, Janusz
   Szaflik, Jerzy
   Szaflik, Jacek Pawel
TI Genetic polymorphism of the iron-regulatory protein-1 and -2 genes in
   age-related macular degeneration
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Age-related macular degeneration; AMD; IRP-1 and-2; Gene polymorphism;
   Iron; Oxidative stress; Reactive oxygen species; Iron-regulatory
   proteins
ID OXIDATIVE STRESS; FAMILIAL AGGREGATION; MOLECULAR CONTROL; POTENTIAL
   FACTOR; MESSENGER-RNA; RISK-FACTORS; POPULATION; DAMAGE; HOMEOSTASIS;
   METABOLISM
AB Iron can be involved in the pathogenesis of AMD through the oxidative stress because it may catalyze the Haber-Weiss and Fenton reactions converting hydrogen peroxide to free radicals, which can induce cellular damage. We hypothesized that genetic polymorphism in genes related to iron metabolism may predispose individuals to the development of AMD and therefore we checked for an association between the g.32373708 G > A polymorphism (rs867469) of the IRP1 gene and the g.49520870 G > A (rs17483548) polymorphism of the IRP2 gene and AMD risk as well as the modulation of this association by some environmental and life-style factors. Genotypes were determined in DNA from blood of 269 AMD patients and 116 controls by the allele-specific oligonucleotide-restriction fragment length polymorphism and the polymerase chain reaction-restriction fragment length polymorphism. An association between AMD, dry and wet forms of AMD and the G/G genotype of the g.32373708 G > A-IRP1 polymorphism was found (OR 3.40, 4.15, and 2.75). On the other hand, the G/A genotype reduced the risk of AMD as well as its dry or wet form (OR 0.23, 0.21, 0.26). Moreover, the G allele of the g.49520870 G > A-IRP2 polymorphism increased the risk of the dry form of the disease (OR 1.51) and the A/A genotype and the A allele decreased such risk (OR 0.43 and 0.66). Our data suggest that the g.32373708 G > A-IRP1 and g.49520870 G > A-IRP2 polymorphisms may be associated with increased risk for AMD.
C1 [Blasiak, Janusz; Szaflik, Jerzy; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Blasiak, Janusz; Szaflik, Jerzy; Szaflik, Jacek Pawel] Samodzielny Publ Klini Szpital Okulistyczny, PL-03710 Warsaw, Poland.
   [Synowiec, Ewelina; Pogorzelska, Magdalena; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 Medical University of Warsaw; University of Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Synowiec, Ewelina/0000-0002-0730-4491; Blasiak,
   Janusz/0000-0001-9539-9584; Szaflik, Jerzy/0000-0002-7601-1326
FU Ministry of Science and Higher Education [N N402 248336]
FX This study was supported by the Grant number N N402 248336 of Ministry
   of Science and Higher Education.
CR Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Galy B, 2008, CELL METAB, V7, P79, DOI 10.1016/j.cmet.2007.10.006
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Goforth JB, 2010, RNA, V16, P154, DOI 10.1261/rna.1857210
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443
   Langaee T, 2010, CONCEPTS PHARMACOGEN, P29
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Madsen E, 2007, ANNU REV NEUROSCI, V30, P317, DOI 10.1146/annurev.neuro.30.051606.094232
   McCall MR, 1999, FREE RADICAL BIO MED, V26, P1034, DOI 10.1016/S0891-5849(98)00302-5
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Moos T, 2004, ANN NY ACAD SCI, V1012, P14, DOI 10.1196/annals.1306.002
   Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521
   [National Eye Institute US National Institutes of Health], FACTS AG REL MAC DEG
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Smith SR, 2006, BLOOD CELL MOL DIS, V36, P283, DOI 10.1016/j.bcmd.2005.12.006
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Viatte L, 2009, J MOL MED, V87, P913, DOI 10.1007/s00109-009-0494-8
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Volz K, 2008, CURR OPIN STRUC BIOL, V18, P106, DOI 10.1016/j.sbi.2007.12.010
   Wang ZJ, 1998, INVEST OPHTH VIS SCI, V39, P631
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   World Health Organization (WHO), PRIOR EY DIS
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
NR 62
TC 14
Z9 14
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2012
VL 39
IS 6
BP 7077
EP 7087
DI 10.1007/s11033-012-1539-6
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 933HQ
UT WOS:000303351900080
PM 22331484
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Kaye, RA
   Patasova, K
   Patel, PJ
   Hysi, P
   Lotery, AJ
AF Kaye, Rebecca A.
   Patasova, Karina
   Patel, Praveen J.
   Hysi, Pirro
   Lotery, Andrew J.
CA UK Biobank Eye & Vision Consortium
TI Macular thickness varies with age-related macular degeneration genetic
   risk variants in the UK Biobank cohort
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RACIAL-DIFFERENCES; OCT IMAGES;
   ASSOCIATIONS; PREVALENCE; ARMS2; SEGMENTATION; LOC387715; RARE; CFH
AB To evaluate the influence AMD risk genomic variants have on macular thickness in the normal population. UK Biobank participants with no significant ocular history were included using the UK Biobank Resource (project 2112). Spectral-domain optical coherence tomography (SD-OCT) images were taken and segmented to define retinal layers. The influence of AMD risk single-nucleotide polymorphisms (SNP) on retinal layer thickness was analysed. AMD risk associated SNPs were strongly associated with outer-retinal layer thickness. The inner-segment outer segment (ISOS)-retinal pigment epithelium (RPE) thickness measurement, representing photoreceptor outer segments was most significantly associated with the cumulative polygenic risk score, composed of 33 AMD-associated variants, resulting in a decreased thickness (p = 1.37 x 10(-67)). Gene-gene interactions involving the NPLOC4-TSPAN10 SNP rs6565597 were associated with significant changes in outer retinal thickness. Thickness of outer retinal layers is highly associated with the presence of risk AMD SNPs. Specifically, the ISOS-RPE measurement. Changes to ISOS-RPE thickness are seen in clinically normal individuals with AMD risk SNPs suggesting structural changes occur at the macula prior to the onset of disease symptoms or overt clinical signs.
C1 [Kaye, Rebecca A.; Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
   [Patasova, Karina; Hysi, Pirro] Kings Coll London, Sch Med, Dept Twin Res & Genet Epidemiol, London, England.
   [Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, UCL Inst Ophthalmol, London, England.
   [Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Patel, Praveen J.] Moorfields Eye Hosp, London, England.
C3 University of Southampton; University of London; King's College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Kaye, Rebecca/0000-0002-1504-3201; Lotery, Andrew/0000-0001-5541-4305
FU Wellcome Trust grant [210572/Z/18/Z]; Fight for Sight studentship
FX The funding was provided by a Wellcome Trust grant [210572/Z/18/Z]
   supporting R.K. and a Fight for Sight studentship supporting K.P.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Allen N, 2012, HEALTH POLICY TECHN, V1, P123, DOI 10.1016/j.hlpt.2012.07.003
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Burgess S, 2017, STAT METHODS MED RES, V26, P2333, DOI 10.1177/0962280215597579
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chan MPY, 2016, OPHTHALMOLOGY, V123, P771, DOI 10.1016/j.ophtha.2015.11.031
   Chua SYL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55484-1
   Chua SYL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025077
   Ctori I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169520
   Cumberland PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139780
   Dornier E, 2012, J CELL BIOL, V199, P481, DOI 10.1083/jcb.201201133
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hannah Currant PH., 2020, GENETIC VARIATION AF, V52, P5105
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kamoshita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103013
   Keane PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164095
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Morgan MD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07691-z
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Nagai N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051347
   Oeverhaus M, 2017, OPHTHALMOLOGICA, V238, P6, DOI 10.1159/000468949
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Patel PJ, 2016, OPHTHALMOLOGY, V123, P829, DOI 10.1016/j.ophtha.2015.11.009
   Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570
   Plotnikov D, 2019, HUM GENET, V138, P723, DOI 10.1007/s00439-019-02022-8
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick T, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.17
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shah RL, 2018, HUM GENET, V137, P881, DOI 10.1007/s00439-018-1942-8
   Simcoe M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd1239
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Tao LW, 2016, CLIN EXP OPHTHALMOL, V44, P422, DOI 10.1111/ceo.12685
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wistow G, 2002, MOL VIS, V8, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Zheng Jie, 2017, Curr Epidemiol Rep, V4, P330, DOI 10.1007/s40471-017-0128-6
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 50
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 1
PY 2021
VL 11
IS 1
AR 23255
DI 10.1038/s41598-021-02631-2
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XG9VW
UT WOS:000725094400030
PM 34853365
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Leisy, HB
   Rastogi, A
   Guevara, G
   Ahmad, M
   Smith, RT
AF Leisy, H. B.
   Rastogi, A.
   Guevara, G.
   Ahmad, M.
   Smith, R. T.
TI The association of geographic atrophy and decreased renal function in
   patients with age-related macular degeneration
SO EYE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; OPTICAL COHERENCE TOMOGRAPHY;
   BLUE-MOUNTAINS-EYE; CHOROIDAL THICKNESS; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; HYPERTENSION; HEMODIALYSIS; PATHOGENESIS; PROGRESSION
AB Purpose The purpose of the study was to investigate the association between area and presence of geographic atrophy (GA) and renal function, as measured by glomerular filtration rate (GFR).
   Patients and methods We retrospectively identified patients aged 50-90 years who were assigned an ICD-9 diagnosis code for age-related macular generation (AMD) between January 2012 and January 2016. Patients met inclusion criteria if they had at least one macular spectral domain optical coherence tomography volume scan, one provider note, and one GFR value in the electronic medical record. Images were evaluated for the presence of GA, area of GA, drusen, and subretinal drusenoid deposits (SDD) and for subfoveal choroidal thickness (CTh) by standard criteria. Imaging findings were correlated with the most recent GFR from the patient's chart.
   Results We identified 107 patients who met our inclusion criteria (mean age= 74 years, range 50-90 years). Overall, we found a significant correlation between the presence of GA and reduced GFR (P= 0.002), which was maintained even after accounting for age and other confounders. No association between GFR and GA area was found. CTh was significantly lower in patients with GA (P= 0.038) and those with decreased GFR (P= 0.004). Within the SDD-positive population, GA was associated with reduced GFR (P= 0.007) but only trended toward significance after controlling for age.
   Conclusion Our study findings demonstrate an association between impaired renal function and the presence, but not area, of GA within an AMD population. These findings may shed light on common pathogenic mechanisms for these two diseases.
C1 [Leisy, H. B.; Rastogi, A.; Guevara, G.; Ahmad, M.; Smith, R. T.] NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
C3 New York University
RP Leisy, HB (通讯作者)，NYU, Sch Med, Dept Ophthalmol, 462 First Ave NBV 5N18, New York, NY 10016 USA.
EM hbleisy@gmail.com
RI Mitchell, Paul/P-1498-2014
OI smith, theodore/0000-0002-1693-943X
FU Research to Prevent Blindness (New York); NATIONAL EYE INSTITUTE
   [R01EY015520] Funding Source: NIH RePORTER
FX The research was supported by unrestricted funds from Research to
   Prevent Blindness (New York) to the Department of Ophthalmology, New
   York University School of Medicine. The funding organization had no role
   in the design or conduct of this research.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Chong EW, 2014, OPTOMETRY VISION SCI, V91, P860, DOI 10.1097/OPX.0000000000000288
   DAVIES DF, 1950, J CLIN INVEST, V29, P496, DOI 10.1172/JCI102286
   Elsayed EF, 2007, ARCH INTERN MED, V167, P1130, DOI 10.1001/archinte.167.11.1130
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gok M, 2015, INDIAN J OPHTHALMOL, V63, P239, DOI 10.4103/0301-4738.156928
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ishibazawa A, 2015, INVEST OPHTH VIS SCI, V56, P6534, DOI 10.1167/iovs.15-16719
   Jocic JD, 2015, INT UROL NEPHROL, V47, P1693, DOI 10.1007/s11255-015-1078-x
   Jung JW, 2014, BRIT J OPHTHALMOL, V98, P207, DOI 10.1136/bjophthalmol-2013-303645
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Tan CSH, 2014, INT OPHTHALMOL, V34, P735, DOI 10.1007/s10792-014-9918-8
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan K, SURV OPHTHALMOL, V61, P566
   Taniguchi H, 2015, OPHTHALMOLOGICA, V233, P128, DOI 10.1159/000371716
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong CW, 2014, KIDNEY INT, V85, P1290, DOI 10.1038/ki.2013.491
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 37
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 62
EP 67
DI 10.1038/eye.2016.261
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700006
PM 27834969
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, Peter K.
TI STRATEGIES FOR INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macula;
   vascular endothelial growth factor
ID MACULAR DEGENERATION; NEOVASCULARIZATION
AB Clinical trials increasingly support the premise that inhibition of vascular endothelial growth factor is a viable but insufficient target for long-term control of age-related macular degeneration (AMD). Additional biologic therapies targeted at very specific steps in the proliferative signaling pathway are being actively sought as alternatives or adjunctive strategies for the treatment of AMD. This rapidly advancing area of drug development is particularly encouraging because of the growing appreciation for the redundancies and interrelationships between the molecular events. The complexity of this signaling pathway supports the development of combination treatments for optimal control of biologic functions. RETINA 29:S12-S14, 2009
C1 Cleveland Clin, Cole Eye Inst, Vitreoretinal Dept, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, Vitreoretinal Dept, 9500 Euclid Ave,Desk I3, Cleveland, OH 44106 USA.
EM pkkaiser@aol.com
CR Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001
   HEIER J, 2007, RET SOC ANN M SEPT B
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 8
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S12
EP S14
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700005
DA 2022-11-30
ER

PT J
AU Han, SY
   Bae, JH
   Oh, J
   Yu, HG
   Song, SJ
AF Han, So Young
   Bae, Jeong Hun
   Oh, Jaeryung
   Yu, Hyeong Gon
   Song, Su Jeong
TI Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from
   Age-Related Macular Degeneration with Combined Severe Diabetic
   Retinopathy
SO DIABETES & METABOLISM JOURNAL
LA English
DT Article
DE Choroidal neovascularization; Diabetic retinopathy; Macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT;
   VERTEPORFIN; PREVALENCE
AB Background: To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from agerelated macular degeneration (AMD) with combined severe diabetic retinopathy (DR).
   Methods: This retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT).
   Results: The mean follow-up time was 16.7 +/- 14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21 +/- 0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0 +/- 0.6 logMAR (P=0.107), 0.95 +/- 0.62 logMAR (P=0.044), 1.10 +/- 0.68 logMAR (P=0.296), and 1.13 +/- 0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9 +/- 134.6 mu m at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8 +/- 172.1 (P=0.864), 346.2 +/- 246.2 (P=0.857), 342 +/- 194.1 (P=0.551), and 294.2 +/- 108.3 mu m (P=0.621), respectively.
   Conclusion: Intravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.
C1 [Han, So Young] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul, South Korea.
   [Bae, Jeong Hun; Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Kangbuk Samsung Hosp, 29 Saemunan Ro, Seoul 110746, South Korea.
   [Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, Seoul 136705, South Korea.
   [Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Korea University; Korea
   University Medicine (KU Medicine); Seoul National University (SNU)
RP Song, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Kangbuk Samsung Hosp, 29 Saemunan Ro, Seoul 110746, South Korea.
EM ssjeye@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Yu, Hyeong Gon/0000-0002-1795-202X
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CALDWELL RB, 1986, INVEST OPHTH VIS SCI, V27, P1691
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladd BS, 2001, AM J OPHTHALMOL, V132, P659, DOI 10.1016/S0002-9394(01)01198-9
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Yoshikawa T, 2011, JPN J OPHTHALMOL, V55, P235, DOI 10.1007/s10384-011-0010-x
NR 20
TC 1
Z9 2
U1 0
U2 1
PU KOREAN DIABETES ASSOC
PI SEOUL
PA 101-2104, LOTTE CASTLE PRES, 109 MAPO-DAERO, MAPO-GU, SEOUL, 04146,
   SOUTH KOREA
SN 2233-6079
EI 2233-6087
J9 DIABETES METAB J
JI Diabetes Metab. J.
PD FEB
PY 2015
VL 39
IS 1
BP 46
EP 50
DI 10.4093/dmj.2015.39.1.46
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA DA7QX
UT WOS:000368000300007
PM 25729712
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Querques, G
   Kamami-Levy, C
   Blanco-Garavito, R
   Georges, A
   Pedinielli, A
   Capuano, V
   Poulon, F
   Souied, EH
AF Querques, Giuseppe
   Kamami-Levy, Cynthia
   Blanco-Garavito, Rocio
   Georges, Anouk
   Pedinielli, Alexandre
   Capuano, Vittorio
   Poulon, Fanny
   Souied, Eric H.
TI Appearance of medium-large drusen and reticular pseudodrusen on adaptive
   optics in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; EYES;
   PROGRESSION; IMPACT
AB Purpose To investigate the appearance of medium-large drusen and reticular pseudodrusen on adaptive optics (AO).
   Methods In 14 consecutive patients, AO infrared (IR) images were overlaid with confocal scanning-laser-ophthalmoscope IR reflectance images and IR-referenced spectral-domain optical coherence tomography.
   Results In eight eyes of six patients, a total of 19 images of medium-large drusen were investigated by AO imaging. En face AO revealed medium-large drusen as highly hyper-reflective round/oval lesions, always centred and/or surrounded by a continuous/discontinuous hyporeflectivity. Cone photoreceptors were detected overlying drusen, appearing either as continuous 'bright' hyper-reflective dots over a 'dark' hyporeflective background, or as continuous 'dark' hyporeflective dots over a 'bright' hyper-reflective background. In eight eyes from eight patients, a total of 14 images of pseudodrusen were investigated by AO imaging. En face AO revealed reticular pseudodrusen as isoreflective lesions, always surrounded by a continuous/discontinuous hyporeflectivity. Cone photoreceptors were detected overlying pseudodrusen as 'bright' hyperreflective dots over either a hyporeflective or isoreflective background. No 'dark' hyporeflective dots were detected in eyes with reticular pseudodrusen only. Cone photoreceptors were counted on the border of the drusen and pseudodrusen, respectively, and in a visibly healthy zone in its absolute vicinity. A similar decrease in cone appearance was observed for drusen and pseudodrusen (15.7% vs 16.2%).
   Conclusions AO allows differences in reflectivity between medium-large drusen and reticular pseudodrusen to be appreciated. The cone mosaics may be detected as continuous 'bright' hyper-reflective dots overlying/on the border of drusen and pseudodrusen deposits, and possibly as continuous 'dark' hyporeflective dots overlying drusen only.
C1 [Querques, Giuseppe; Kamami-Levy, Cynthia; Blanco-Garavito, Rocio; Georges, Anouk; Pedinielli, Alexandre; Capuano, Vittorio; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Poulon, Fanny] Inst Opt Grad Sch, Palaiseau, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Kamami-Levy, Cynthia/0000-0002-5770-5269; Querques,
   Giuseppe/0000-0002-3292-9581
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Hofer H, 2001, OPT EXPRESS, V8, P631, DOI 10.1364/OE.8.000631
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, ACTA OPHTHALMOL, V90, pE327, DOI 10.1111/j.1755-3768.2011.02228.x
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 30
TC 21
Z9 21
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2014
VL 98
IS 11
BP 1522
EP 1527
DI 10.1136/bjophthalmol-2014-305455
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS3FR
UT WOS:000344163200011
PM 24985725
DA 2022-11-30
ER

PT J
AU Mo, FM
   Proia, AD
   Johnson, WH
   Cyr, D
   Lashkari, K
AF Mo, Fong Ming
   Proia, Alan D.
   Johnson, Walter H.
   Cyr, Desiree
   Lashkari, Kameran
TI Interferon gamma-Inducible Protein-10 (IP-10) and Eotaxin as Biomarkers
   in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR3; EOSINOPHIL CHEMOATTRACTANT; CULTURED RPE;
   MURINE MODEL; IN-VITRO; T-CELLS; EXPRESSION; INFLAMMATION; CXCL10;
   DRUSEN
AB PURPOSE. To analyze serum cytokine levels in subjects with different stages of AMD and to study the expression of salient cytokines in postmortem eyes with AMD.
   METHODS. A suspension array system was used to analyze sera (n = 18 to 20/group) from control subjects and those with early AMD (AREDS stage 1), intermediate dry AMD (AREDS stage 3), advanced AMD with geographic atrophy (GA), or neovascular AMD (CNV). Postmortem eyes with AMD or control eyes were examined immunohistochemically for expression of IP-10 and eotaxin (n = 4 to 8/group).
   RESULTS. Serum eotaxin and IP-10 levels were significantly elevated in all stages of AMD, except for eotaxin levels in neovascular AMD (P < 0.07). The peak of serum IP-10 concentration was at intermediate dry AMD. In donor eyes, IP-10 and eotaxin expressions were increased in the RPE of eyes with early AMD, GA, and CNV. Eotaxin accumulated within the layer of basal linear/laminar deposits in all stages of AMD, while IP-10 was mainly in eyes with GA and CNV. IP-10 was abundant in the connective tissue matrix associated with CNV, and eotaxin was usually present but more focally and with less intense staining. Both IP-10 and eotaxin were expressed by neovascular endothelial cells. Both IP-10 and eotaxin were expressed in the neurosensory retina, but there was no detectable difference in staining between eyes with or without AMD.
   CONCLUSIONS. IP-10 and eotaxin may be early biomarkers in AMD. The authors hypothesize that the relative balance between levels of IP-10 and eotaxin is critical in regulating the neovascular response. (Invest Ophthalmol Vis Sci. 2010; 51: 4226-4236) DOI:10.1167/iovs.09-3910
C1 [Mo, Fong Ming; Cyr, Desiree; Lashkari, Kameran] Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Mo, Fong Ming; Lashkari, Kameran] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Proia, Alan D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
   [Johnson, Walter H.] Suffolk Univ, Dept Phys, Boston, MA 02114 USA.
   [Johnson, Walter H.] Suffolk Univ, Sagan Res Lab, Boston, MA 02114 USA.
C3 Harvard University; Schepens Eye Research Institute; Harvard University;
   Harvard Medical School; Duke University; Suffolk University; Suffolk
   University
RP Lashkari, K (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM kameran.lashkari@schepens.harvard.edu
OI Lashkari, Kameran/0000-0003-3855-0246
FU Novartis Institute for Biomedical Research, Cambridge, MA; Schepens Eye
   Research Institute
FX Supported in part by a grant from the Novartis Institute for Biomedical
   Research, Cambridge, MA, and in part by the Stone Scholar Fund, Schepens
   Eye Research Institute.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   An EY, 2008, MOL VIS, V14, P2292
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873
   Bartels J, 1996, BIOCHEM BIOPH RES CO, V225, P1045, DOI 10.1006/bbrc.1996.1292
   Boulday G, 2006, J IMMUNOL, V176, P3098, DOI 10.4049/jimmunol.176.5.3098
   Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105
   Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200
   Christen U, 2004, AUTOIMMUNITY, V37, P273, DOI 10.1080/08916930410001713124
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Elner SG, 2006, EXP EYE RES, V83, P374, DOI 10.1016/j.exer.2006.01.013
   Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jain V, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-83
   Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002
   JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881
   Kawamura A, 2003, CIRC J, V67, P851, DOI 10.1253/circj.67.851
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lazzeri E, 2005, TRANSPLANTATION, V79, P1215, DOI 10.1097/01.TP.0000160759.85080.2E
   Lazzeri E., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P109, DOI 10.2174/1568008053174723
   Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946
   Liu LP, 2005, CURR TOP DEV BIOL, V68, P149, DOI 10.1016/S0070-2153(05)68006-4
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   MENDENHALL S, 1995, STAT ENG SCI, P937
   Miles EA, 2008, ATHEROSCLEROSIS, V196, P298, DOI 10.1016/j.atherosclerosis.2006.11.002
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456
   Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173
   Romagnani P, 1999, J AM SOC NEPHROL, V10, P2518
   Romagnani P, 2002, AM J PATHOL, V161, P195, DOI 10.1016/S0002-9440(10)64171-5
   Romagnani P, 2002, J AM SOC NEPHROL, V13, P53, DOI 10.1681/ASN.V13153
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631
   Rotondi M, 2004, AM J TRANSPLANT, V4, P1466, DOI 10.1111/j.1600-6143.2004.00525.x
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shigihara T, 2005, J IMMUNOL, V175, P8401, DOI 10.4049/jimmunol.175.12.8401
   Sorensen TL, 2004, CURR NEUROVASC RES, V1, P183, DOI 10.2174/1567202043480143
   Sorensen TL, 2001, EUR J NEUROL, V8, P665, DOI 10.1046/j.1468-1331.2001.00327.x
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Tager AM, 2004, AM J RESP CELL MOL, V31, P395, DOI 10.1165/rcmb.2004-0175OC
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tang NLS, 2005, CLIN CHEM, V51, P2333, DOI 10.1373/clinchem.2005.054460
   Tateno H, 2004, RESP MED, V98, P782, DOI 10.1016/j.rmed.2004.01.005
   Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280
   Wada T, 1999, NEPHROL DIAL TRANSPL, V14, P76, DOI 10.1093/ndt/14.1.76
   Whiteley W, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000145
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 66
TC 69
Z9 80
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4226
EP 4236
DI 10.1167/iovs.09-3910
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100056
PM 20220052
DA 2022-11-30
ER

PT J
AU Liu, HT
   Liu, HH
   Prokosch, V
AF Liu, Hongtao
   Liu, Hanhan
   Prokosch, Verena
TI The Relationship between Mitochondria and Neurodegeration in the Eye: A
   Review
SO APPLIED SCIENCES-BASEL
LA English
DT Review
DE mitochondrial; ROS; neurodegeneration; glaucoma
ID RETINAL GANGLION-CELLS; TRABECULAR MESHWORK CELLS; OPTIC-NERVE HEAD;
   TRIGGERS OPA1 RELEASE; OXIDATIVE STRESS; DNA MUTATIONS; INORGANIC
   POLYPHOSPHATE; OCULAR HYPERTENSION; EXPERIMENTAL-MODEL; NEURITE
   OUTGROWTH
AB Mitochondria are the energy factories of cells. Mitochondrial dysfunction directly affects the function and morphology of cells. In recent years, growing evidence has shown that mitochondrial dysfunction plays an important role in neurodegenerative diseases. In the eye, some age-related diseases are considered to be neurodegenerative diseases, such as primary open-angle glaucoma (POAG) and age-related macular degeneration (AMD). Here, we review the mechanisms of mitochondrial damage, post-injury repair, and the roles of mitochondria in various tissues of the eye. In the following sections, the potential for treating glaucoma by reducing mitochondrial damage and promoting post-injury repair is also discussed.
C1 [Liu, Hongtao; Liu, Hanhan; Prokosch, Verena] Univ Cologne, Dept Ophthalmol, Fac Med, Univ Hosp Cologne, D-50937 Cologne, Germany.
C3 University of Cologne
RP Prokosch, V (通讯作者)，Univ Cologne, Dept Ophthalmol, Fac Med, Univ Hosp Cologne, D-50937 Cologne, Germany.
EM hliu6@smail.uni-koeln.de; hanhan.liu@uk-koeln.de;
   verena.prokosch-willing@uk-koeln.de
FU Deutsche Forschungsgemeinschaft (DFG) [PR1569-1-1]
FX This research was funded by Deutsche Forschungsgemeinschaft (DFG), grant
   number PR1569-1-1.
CR Abrahan Carolina, 2016, Adv Exp Med Biol, V854, pE1, DOI 10.1007/978-3-319-17121-0_107
   Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P2533, DOI 10.1167/iovs.05-1639
   Agrawal SA, 2017, HUM MOL GENET, V26, P2667, DOI 10.1093/hmg/ddx149
   Albalawi F, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00227
   Almasieh M, 2011, J NEUROCHEM, V118, P1075, DOI 10.1111/j.1471-4159.2011.07382.x
   Amankwa CE, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10040575
   Ammar DA, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.1.4
   Amodeo GF, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0042-3
   Annesley SJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070680
   BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9
   Banerjee D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070760
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695
   Bell K, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0044-9
   Bradshaw PC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030504
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Cadenas S, 2018, BBA-BIOENERGETICS, V1859, P940, DOI 10.1016/j.bbabio.2018.05.019
   Capasso M, 2005, J ALZHEIMERS DIS, V8, P93
   Castro CM, 2020, FASEB J, V34, P5027, DOI 10.1096/fj.201902459R
   Chan ASY, 2012, INVEST OPHTH VIS SCI, V53, P704, DOI 10.1167/iovs.11-7408
   Chaphalkar RM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60558-6
   Cheng HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108090
   Chhunchha B, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.60
   Choi SH, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101703
   Chouchani ET, 2013, NAT MED, V19, P753, DOI 10.1038/nm.3212
   Chowdhury UR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179345
   Chowdhury UR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141783
   Coughlin L, 2015, INVEST OPHTH VIS SCI, V56, P1437, DOI 10.1167/iovs.14-16126
   Cozzolino M, 2009, ANTIOXID REDOX SIGN, V11, P1547, DOI 10.1089/ARS.2009.2545
   D'Amico D, 2019, MOL CELL, V73, P775, DOI 10.1016/j.molcel.2018.11.034
   Dai Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0146-9
   Dai Y, 2011, INVEST OPHTH VIS SCI, V52, P2468, DOI 10.1167/iovs.10-5873
   DeBalsi KL, 2017, AGEING RES REV, V33, P89, DOI 10.1016/j.arr.2016.04.006
   Di Carlo M, 2012, FREE RADICAL RES, V46, P1327, DOI 10.3109/10715762.2012.714466
   Divakaruni AS, 2020, TRENDS MOL MED, V26, P3, DOI [10.1016/j.molmed.2019.11.007, 10.1016/j.molmad.2019.11.007]
   Dong LD, 2018, MOL MED REP, V17, P2289, DOI 10.3892/mmr.2017.8137
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Feng Y, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050671
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200
   Fivenson EM, 2017, NEUROCHEM INT, V109, P202, DOI 10.1016/j.neuint.2017.02.007
   Fu ZJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041503
   Gericke A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9736047
   Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011
   Gong WF, 2019, CELL CYCLE, V18, P1549, DOI 10.1080/15384101.2019.1612697
   Gonzalez-Polo RA, 2013, BRIT J PHARMACOL, V168, P60, DOI 10.1111/j.1476-5381.2012.02203.x
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Guo Y, 2011, INVEST OPHTH VIS SCI, V52, P1460, DOI 10.1167/iovs.10-5930
   Ham PB, 2017, PROG NEUROBIOL, V157, P92, DOI 10.1016/j.pneurobio.2016.06.006
   Harun-Or-Rashid M, 2020, NEUROBIOL DIS, V141, DOI 10.1016/j.nbd.2020.104944
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P4912, DOI 10.1167/iovs.08-2192
   He Y, 2009, MOL VIS, V15, P815
   Hebert SL, 2010, MECH AGEING DEV, V131, P451, DOI 10.1016/j.mad.2010.03.007
   Hill S, 2014, REDOX BIOL, V2, P936, DOI 10.1016/j.redox.2014.07.005
   Hong S, 2014, MOL VIS, V20, P1456
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Ikonne EU, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04408
   Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331
   Ivankovic D, 2016, J NEUROCHEM, V136, P388, DOI 10.1111/jnc.13412
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Jacobson KA, 2016, J OCUL PHARMACOL TH, V32, P534, DOI 10.1089/jop.2016.0090
   Jaiswal M, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002197
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Jang JY, 2018, J CLIN INVEST, V128, P3662, DOI 10.1172/JCI120842
   Jiang WM, 2016, AM J TRANSL RES, V8, P799
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Ju WK, 2008, INVEST OPHTH VIS SCI, V49, P4903, DOI 10.1167/iovs.07-1661
   Ju WK, 2010, MOL VIS, V16, P1331
   Ju WK, 2008, MOL VIS, V14, P2629
   Ju WK, 2009, INVEST OPHTH VIS SCI, V50, P707, DOI 10.1167/iovs.08-2499
   Kamel K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.4
   Kanamori A, 2010, J NEUROCHEM, V114, P488, DOI 10.1111/j.1471-4159.2010.06781.x
   Kauppila TES, 2017, CELL METAB, V25, P57, DOI 10.1016/j.cmet.2016.09.017
   Khawaja AP, 2018, NAT GENET, V50, P778, DOI 10.1038/s41588-018-0126-8
   Kim HT, 2016, BMB REP, V49, P69, DOI 10.5483/BMBRep.2016.49.2.006
   Kim HT, 2015, CELL REP, V13, P990, DOI 10.1016/j.celrep.2015.09.075
   Kim KY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.180
   Kim SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.80
   Kimball EC, 2018, EXP EYE RES, V172, P78, DOI 10.1016/j.exer.2018.04.001
   Kimball EC, 2017, EXP EYE RES, V160, P106, DOI 10.1016/j.exer.2017.04.003
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Kiyama T, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0287-z
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P44879, DOI 10.18632/oncotarget.9821
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Lee S, 2012, INVEST OPHTH VIS SCI, V53, P2431, DOI 10.1167/iovs.12-9596
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Lenaers G, 2009, INT J BIOCHEM CELL B, V41, P1866, DOI 10.1016/j.biocel.2009.04.013
   Li A, 2012, J CELL PHYSIOL, V227, P172, DOI 10.1002/jcp.22715
   Li LP, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00403-4
   Li L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00347
   Li PP, 2021, MOLECULES, V26, DOI 10.3390/molecules26092411
   Li XY, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/678123
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Lin YZ, 2010, INVEST OPHTH VIS SCI, V51, P6483, DOI 10.1167/iovs.10-5410
   Liu HH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073689
   Lopez-Gonzalez R, 2016, NEURON, V92, P383, DOI 10.1016/j.neuron.2016.09.015
   Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69
   Maddineni P, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00400-9
   Manzar H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239299
   Marshall J, 2015, J BIOL CHEM, V290, P22030, DOI 10.1074/jbc.M115.662791
   McElnea EM, 2011, MOL VIS, V17, P1182
   McElnea EM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-153
   Nakano N, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00096
   Narayanan SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022460
   Navneet S, 2019, EXP EYE RES, V178, P228, DOI 10.1016/j.exer.2018.03.022
   Niittykoski M, 2010, INVEST OPHTH VIS SCI, V51, P6387, DOI 10.1167/iovs.09-3816
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Noh YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.341
   Nucci C, 2013, MOL VIS, V19, P1841
   Ozkan EB, 2013, INDIAN J OPHTHALMOL, V61, P329, DOI 10.4103/0301-4738.109518
   Park JS, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0829-3
   Perkins GA, 2012, MOL VIS, V18, P3029
   Picca A, 2018, NAT REV CARDIOL, V15, P543, DOI 10.1038/s41569-018-0059-z
   Plana-Bonamaiso A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2255-0
   Ploumi C, 2017, FEBS J, V284, P183, DOI 10.1111/febs.13820
   Prunty MC, 2015, INVEST OPHTH VIS SCI, V56, P5862, DOI 10.1167/iovs.15-16810
   Quillen S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238104
   Rao VR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.4
   Sacca Sergio Claudio, 2019, Subcell Biochem, V91, P393, DOI 10.1007/978-981-13-3681-2_14
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Shim MS, 2018, BIOCHEM BIOPH RES CO, V503, P2690, DOI 10.1016/j.bbrc.2018.08.025
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Solesio ME, 2016, BBA-GEN SUBJECTS, V1860, P1317, DOI 10.1016/j.bbagen.2016.03.020
   Solesio ME, 2020, CELL CALCIUM, V86, DOI 10.1016/j.ceca.2019.102127
   Solesio ME, 2016, BIOCHEM SOC T, V44, P7, DOI 10.1042/BST20150206
   Solesio ME, 2012, TOXICOL SCI, V129, P411, DOI 10.1093/toxsci/kfs218
   Stahon KE, 2016, J NEUROSCI, V36, P9990, DOI 10.1523/JNEUROSCI.1316-16.2016
   Stiemke AB, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00031
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   Sundaresan P, 2015, GENET MED, V17, P279, DOI 10.1038/gim.2014.121
   Tabak S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052421
   Taguchi M, 2016, J NEUROCHEM, V136, P741, DOI 10.1111/jnc.13427
   Talla V, 2014, INVEST OPHTH VIS SCI, V55, P5214, DOI 10.1167/iovs.14-14688
   Talla V, 2013, MOL THER, V21, P1876, DOI 10.1038/mt.2013.104
   Tan DQ, 2018, ANTIOXID REDOX SIGN, V29, P149, DOI 10.1089/ars.2017.7273
   Tanwar M, 2010, MOL VIS, V16, P518
   Tribble JR, 2019, BRAIN COMMUN, V1, DOI 10.1093/braincomms/fcz035
   Tulsawani R, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-125
   Van Bergen NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140919
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wang C, 2019, CELL CYCLE, V18, P932, DOI 10.1080/15384101.2019.1593645
   Wang J, 2015, FREE RADICAL BIO MED, V86, P25, DOI 10.1016/j.freeradbiomed.2015.04.009
   Wei T, 2015, EXP THER MED, V9, P476, DOI 10.3892/etm.2014.2084
   Wei X, 2011, AM J PATHOL, V179, P2788, DOI 10.1016/j.ajpath.2011.08.015
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   Willmes C, 2020, TRENDS MOL MED, V26, P1, DOI 10.1016/j.molmed.2019.10.006
   Wu JH, 2015, NEUROBIOL DIS, V74, P167, DOI 10.1016/j.nbd.2014.11.014
   Xie WK, 2018, EXP EYE RES, V177, P181, DOI 10.1016/j.exer.2018.08.003
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang YX, 2012, MOL VIS, V18, P2127
   Ying Y, 2021, AGING-US, V13, P8628, DOI 10.18632/aging.202677
   You ZP, 2018, EXP THER MED, V15, P4379, DOI 10.3892/etm.2018.5961
   Yu C, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0265-7
   Zhao J, 2019, EUR REV MED PHARMACO, V23, P3173, DOI 10.26355/eurrev_201904_17675
   Zhu XL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01006
   Zhu Y, 2018, INVEST OPHTH VIS SCI, V59, P3984, DOI 10.1167/iovs.18-23885
NR 159
TC 2
Z9 2
U1 2
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD AUG
PY 2021
VL 11
IS 16
AR 7385
DI 10.3390/app11167385
PG 16
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA UF6EO
UT WOS:000688665200001
OA gold
DA 2022-11-30
ER

PT J
AU Dhirachaikulpanich, D
   Li, X
   Porter, LF
   Paraoan, L
AF Dhirachaikulpanich, Dhanach
   Li, Xin
   Porter, Louise F.
   Paraoan, Luminita
TI Integrated Microarray and RNAseq Transcriptomic Analysis of Retinal
   Pigment Epithelium/Choroid in Age-Related Macular Degeneration
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   neurodegeneration; transcriptome; neuroactive ligand-receptor;
   extracellular matrix
ID GENE-SET ANALYSIS; 10-YEAR INCIDENCE; TENASCIN-C; EXPRESSION;
   METAANALYSIS; WEBGESTALT; CELLS; CHORIOCAPILLARIS; PHOSPHORYLATION;
   IDENTIFICATION
AB We report for the first time an integrated transcriptomic analysis of RPE/choroid dysfunction in AMD (mixed stages) based on combining data from publicly available microarray (GSE29801) and RNAseq (GSE135092) datasets aimed at increasing the ability and power of detection of differentially expressed genes and AMD-associated pathways. The analysis approach employed an integrating quantitative method designed to eliminate bias among different transcriptomic studies. The analysis highlighted 764 meta-genes (366 downregulated and 398 upregulated) in macular AMD RPE/choroid and 445 meta-genes (244 downregulated and 201 upregulated) in non-macular AMD RPE/choroid. Of these, 731 genes were newly detected as differentially expressed (DE) genes in macular AMD RPE/choroid and 434 genes in non-macular AMD RPE/choroid compared with controls. Over-representation analysis of KEGG pathways associated with these DE genes mapped revealed two most significantly associated biological processes in macular RPE/choroid in AMD, namely the neuroactive ligand-receptor interaction pathway (represented by 30 DE genes) and the extracellular matrix-receptor interaction signaling pathway (represented by 12 DE genes). Furthermore, protein-protein interaction (PPI) network identified two central hub genes involved in the control of cell proliferation/differentiation processes,HDAC1andCDK1. Overall, the analysis provided novel insights for broadening the exploration of AMD pathogenesis by extending the number of molecular determinants and functional pathways that underpin AMD-associated RPE/choroid dysfunction.
C1 [Dhirachaikulpanich, Dhanach; Li, Xin; Porter, Louise F.; Paraoan, Luminita] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Dhirachaikulpanich, Dhanach] Mahidol Univ, Siriraj Hosp, Fac Med, Bangkok, Thailand.
C3 University of Liverpool; Mahidol University
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
EM lparaoan@liverpool.ac.uk
RI Porter, Louise/GQP-6108-2022; Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Dhirachaikulpanich,
   Dhanach/0000-0003-2234-1837; Porter, Louise/0000-0002-7406-0319
FU Liverpool-Mahidol Partnership Scholarship; Liverpool-China Scholarship
   Council Partnership Scholarship; NIHR; Academy of Medical Sciences
   [SGL019\ 1076]
FX DD was a recipient of a Liverpool-Mahidol Partnership Scholarship. XL
   was the recipient of a Liverpool-China Scholarship Council Partnership
   Scholarship. LFP was a clinical lecturer funded by NIHR and the Academy
   of Medical Sciences (SGL019\ 1076).
CR Alimadadi A, 2020, GENES-BASEL, V11, DOI 10.3390/genes11010060
   Anderson KW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126592
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ashikawa Y, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00266
   Badr MT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213470
   Barrie ES, 2017, HUM MUTAT, V38, P112, DOI 10.1002/humu.23135
   Biernacka JM, 2013, INT J NEUROPSYCHOPH, V16, P271, DOI 10.1017/S1461145712000375
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Brown LA, 2017, NUCLEIC ACIDS RES, V45, P9860, DOI 10.1093/nar/gkx714
   Conti-Fine BM, 2000, EUR J PHARMACOL, V393, P279, DOI 10.1016/S0014-2999(00)00036-4
   de Magalhaes JP, 2009, BIOINFORMATICS, V25, P875, DOI 10.1093/bioinformatics/btp073
   Fisher R. A, 1992, BREAKTHROUGHS STAT, P66, DOI 10.1007/978-1-4612-4380-9_6
   Goder A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03096-0
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Gorska E, 2010, EUR J MED RES, V15, P50
   Hamza TH, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002237
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hardy J, 2010, NEURON, V68, P201, DOI 10.1016/j.neuron.2010.10.014
   Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Ji XM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05074-y
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137432
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Ma TZ, 2017, J COMPUT BIOL, V24, P647, DOI 10.1089/cmb.2017.0056
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   Noh SJ, 2008, INVEST OPHTH VIS SCI, V49, P4753, DOI 10.1167/iovs.08-2166
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reinhard J, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00030
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   SCHULTZ R, 2018, INVEST OPHTH VIS SCI, V59, pNIL_0242
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su LN, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00633
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tang JH, 2013, CLIN SCI, V124, P651, DOI 10.1042/CS20120504
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Tseng GC, 2012, NUCLEIC ACIDS RES, V40, P3785, DOI 10.1093/nar/gkr1265
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang, 2018, BMC SYST BIOL, V12
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wauman J, 2017, FRONT ENDOCRINOL, V8, P1, DOI 10.3389/fendo.2017.00030
   Wen Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153329
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Xia JG, 2015, NAT PROTOC, V10, P823, DOI 10.1038/nprot.2015.052
   Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443
   Yang F, 2018, VITAM HORM, V106, P333, DOI 10.1016/bs.vh.2017.05.001
   Yoo SS, 2014, LUNG CANCER, V86, P85, DOI 10.1016/j.lungcan.2014.08.002
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhou GY, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004624
NR 71
TC 6
Z9 6
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 21
PY 2020
VL 8
AR 808
DI 10.3389/fcell.2020.00808
PG 10
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA NN1AW
UT WOS:000568522900001
PM 32984320
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Csaky, K
   Ferris, F
   Chew, EY
   Nair, P
   Cheetham, JK
   Duncan, JL
AF Csaky, Karl
   Ferris, Frederick, III
   Chew, Emily Y.
   Nair, Prashant
   Cheetham, Janet K.
   Duncan, Jacque L.
TI Report From the NEI/FDA Endpoints Workshop on Age-Related Macular
   Degeneration and Inherited Retinal Diseases
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY; MICROPERIMETRY
C1 [Csaky, Karl] Retina Fdn Southwest, Dallas, TX USA.
   [Ferris, Frederick, III; Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Cheetham, Janet K.] Fdn Fighting Blindness, Columbia, MD USA.
   [Duncan, Jacque L.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
C3 Retina Foundation of the Southwest; National Institutes of Health (NIH)
   - USA; NIH National Eye Institute (NEI); University of California
   System; University of California San Francisco
RP Duncan, JL (通讯作者)，Univ Calif San Francisco, 10 Koret Way,K113, San Francisco, CA 94143 USA.
EM jacque.duncan@ucsf.edu
OI Ferris, Frederick/0000-0002-4933-0639
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Birch DG, 2015, OPHTHALMOLOGY, V122, P833, DOI 10.1016/j.ophtha.2014.11.005
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lappi O, 2015, J EYE MOVEMENT RES, V8
   Ratnam K, 2013, INVEST OPHTH VIS SCI, V54, P5836, DOI 10.1167/iovs.13-12557
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   U. S. Food and Drug Administration, CLIN OUTC ASS QUAL P
   U. S. Food and Drug Administration, GUID IND FDA STAFF I
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Weleber RG, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.14
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zayit-Soudry S, 2015, INVEST OPHTH VIS SCI, V56, P6179, DOI 10.1167/iovs.15-17010
NR 17
TC 79
Z9 79
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2017
VL 58
IS 9
BP 3456
EP 3463
DI 10.1167/iovs.17-22339
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1WU
UT WOS:000410931200020
PM 28702674
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Guymer, R
   Cipriani, T
   Rittenhouse, KD
   Lim, L
   Robman, LD
   Li, WL
   Wang, WL
   Deng, SB
   Banerjee, P
AF Guymer, Robyn
   Cipriani, Tania
   Rittenhouse, Kay D.
   Lim, Lyndell
   Robman, Liubov D.
   Li, Wenlin
   Wang, Wenlian
   Deng, Shibing
   Banerjee, Poulabi
TI Plasma levels of amyloid beta and other proinflammatory mediators in
   patients with age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Amyloid beta; Inflammatory
   mediators
ID C-REACTIVE PROTEIN; FACTOR-H POLYMORPHISM; ALZHEIMERS-DISEASE; DRUSEN;
   RISK; ASSOCIATION; INFLAMMATION; DEPOSITS; COMMON; GENE
AB To investigate the plasma levels of amyloid beta (A beta) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity.
   Plasma samples were obtained from AMD subjects at various stages of disease-early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)-and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (A beta isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables.
   Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of II2 isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma A beta 1-42 levels, and its ratio with A beta 1-40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for II2 isotypes, the ROC curve showed a moderate prediction (AUC = - similar to 0.78) of AMD vs control using the A beta 1-42 isotype.
   Plasma A beta 1-42 may have utility as a systemic biomarker for AMD.
C1 [Guymer, Robyn; Cipriani, Tania; Lim, Lyndell; Robman, Liubov D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
   [Li, Wenlin; Wang, Wenlian; Deng, Shibing] Pfizer Inc, Sci Ctr 10777, San Diego, CA 92121 USA.
   [Rittenhouse, Kay D.] Bayer Healthcare, Whippany, NJ 07981 USA.
   [Banerjee, Poulabi] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Pfizer; Bayer AG; Bayer Healthcare
   Pharmaceuticals; Regeneron
RP Guymer, R (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rh.guymer@unimelb.edu.au
OI Lim, Lyndell/0000-0003-2491-685X; Guymer, Robyn/0000-0002-9441-4356
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Bibl M, 2012, ELECTROPHORESIS, V33, P445, DOI 10.1002/elps.201100455
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Dentchev T, 2003, MOL VIS, V9, P184
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ertekin-Taner N, 2008, NEUROLOGY, V70, P596, DOI 10.1212/01.wnl.0000278386.00035.21
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2009, NEUROLOGY, V73, P847, DOI 10.1212/WNL.0b013e3181b78448
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mayeux R, 2003, NEUROLOGY, V61, P1185, DOI 10.1212/01.WNL.0000091890.32140.8F
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tzekov R, 2014, SURV OPHTHALMOL, V59, P414, DOI 10.1016/j.survophthal.2013.10.002
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 45
TC 13
Z9 13
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 253
IS 8
BP 1347
EP 1354
DI 10.1007/s00417-015-2970-x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9AA
UT WOS:000358736700019
PM 25744331
DA 2022-11-30
ER

PT J
AU Smailhodzic, D
   Fleckenstein, M
   Theelen, T
   Boon, CJF
   van Huet, RAC
   de Ven, JPHV
   Den Hollander, AI
   Schmitz-Valckenberg, S
   Hoyng, CB
   Weber, BHF
   Holz, FG
   Klevering, BJ
AF Smailhodzic, Dzenita
   Fleckenstein, Monika
   Theelen, Thomas
   Boon, Camiel J. F.
   van Huet, Ramon A. C.
   de Ven, Johannes P. H. van
   Den Hollander, Anneke I.
   Schmitz-Valckenberg, Steffen
   Hoyng, Carel B.
   Weber, Bernhard H. F.
   Holz, Frank G.
   Klevering, B. Jeroen
TI Central Areolar Choroidal Dystrophy (CACD) and Age-Related Macular
   Degeneration (AMD): Differentiating Characteristics in Multimodal
   Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; BASAL LINEAR DEPOSIT; FUNDUS
   AUTOFLUORESCENCE PATTERNS; PERIPHERIN/RDS GENE; GEOGRAPHIC ATROPHY;
   RETINAL DEGENERATION; RDS/PERIPHERIN GENE; HIGH-RESOLUTION; POINT
   MUTATION; MACULOPATHY
AB PURPOSE. Late-onset central areolar choroidal dystrophy (CACD) may easily be confused with geographic atrophy (GA) in AMD. To detect discerning features, the morphologic changes in CACD patients and in AMD patients were assessed with confocal scanning laser ophthalmoscopy (cSLO), fundus autofluorescence (FAF), and spectral-domain optical coherence tomography (SD-OCT).
   METHODS. A total of 30 CACD patients with identified PRPH2 gene mutations were analyzed and compared to 19 patients with early AMD and 13 patients with AMD-associated GA. The presence of drusen and pigment clumping was determined with color fundus photography. High-resolution in vivo imaging was performed with cSLO and SD-OCT. FAF images and SD-OCT volume scans were analyzed in each study eye.
   RESULTS. On FAF, a speckled FAF pattern occurred significantly more often in CACD (85%) than in early AMD (5.6%; P < 0.0001). There was a significantly higher frequency of sub-RPE deposits in eyes with AMD than in eyes with CACD (36.8% versus 2.1% of scans, P = 0.0019). Reticular drusen could be visualized by SD-OCT and FAF imaging in 52.6% of the eyes with early AMD and in 100% of the eyes with GA, whereas this drusen phenotype did not manifest in eyes with CACD.
   CONCLUSIONS. Although outer retinal atrophy is the clinically common feature in advanced CACD as well as GA, there are microstructural alterations on high-resolution SD-OCT and FAF imaging that allow for the differentiation between CACD and AMD. The findings may help to identify patients in whom a diagnostic PRPH2 screening is warranted. (ClinicalTrials. gov number, NCT00393692.) (Invest Ophthalmol Vis Sci. 2011;52:8908-8918) DOI:10.1167/iovs.11-7926
C1 [Smailhodzic, Dzenita; Theelen, Thomas; Boon, Camiel J. F.; van Huet, Ramon A. C.; de Ven, Johannes P. H. van; Den Hollander, Anneke I.; Hoyng, Carel B.; Klevering, B. Jeroen] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, NL-6526 EX Nijmegen, Netherlands.
   [Den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, NL-6526 EX Nijmegen, Netherlands.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Grade Reading Ctr, D-5300 Bonn, Germany.
   [Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Bonn; University of Regensburg
RP Smailhodzic, D (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Philips van Leydenlaan 15, NL-6526 EX Nijmegen, Netherlands.
EM d.smailhodzic@ohk.umcn.nl
RI Klevering, B.J./L-4434-2015; Hollander, Anneke den/N-4911-2014; van
   Huet, Ramon AC/A-4652-2016; Hoyng, C.B./H-8050-2014; Theelen,
   Thomas/A-3192-2012; Boon, CJF/P-7534-2014
OI van Huet, Ramon AC/0000-0003-2786-3511; Theelen,
   Thomas/0000-0001-9067-1171; Fleckenstein, Monika/0000-0001-8321-8037;
   Weber, Bernhard H.F./0000-0002-8808-7723; Boon, CJF/0000-0002-6737-7932
FU Netherlands Organisation for Scientific Research [016.096.309]; MD
   fonds; Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting
   Researchfonds Oogheelkunde; Stichting Nederlands Oogheelkundig
   Onderzoek; Stichting Blindenhulp; Gelderse Blindenstichting; DFG (German
   Research Council) [Ho1926/3-1, WE 1259/19-2, BONFOR 0-137-0012]
FX Supported by The Netherlands Organisation for Scientific Research Grant
   016.096.309; the MD fonds; Oogfonds; Landelijke Stichting voor Blinden
   en Slechtzienden; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid; Stichting Researchfonds Oogheelkunde; Stichting Nederlands
   Oogheelkundig Onderzoek; Stichting Blindenhulp; and the Gelderse
   Blindenstichting; and DFG (German Research Council) Grants Ho1926/3-1,
   WE 1259/19-2, and BONFOR 0-137-0012 (MF). The sponsor or funding
   organization had no role in the design or conduct of this research.
CR ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659
   ASHTON N, 1953, BRIT J OPHTHALMOL, V37, P140, DOI 10.1136/bjo.37.3.140
   Baird PN, 2007, CLIN EXP OPHTHALMOL, V35, P194, DOI 10.1111/j.1442-9071.2007.01477.x
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Downes SM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1373, DOI 10.1001/archopht.117.10.1373
   Duncan JL, 2011, INVEST OPHTH VIS SCI, V52, P1557, DOI 10.1167/iovs.10-6549
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farjo R, 2007, J COMP NEUROL, V504, P619, DOI 10.1002/cne.21476
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gamundi MJ, 2007, MOL VIS, V13, P1031
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hoyng CB, 1996, AM J OPHTHALMOL, V121, P623, DOI 10.1016/S0002-9394(14)70627-0
   Hoyng CB, 1996, GRAEF ARCH CLIN EXP, V234, P87, DOI 10.1007/BF00695246
   Hughes AE, 1998, J MED GENET, V35, P770, DOI 10.1136/jmg.35.9.770
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Joffe L, 2003, RETINA-J RET VIT DIS, V23, P530, DOI 10.1097/00006982-200308000-00014
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   Kohl S, 1997, J MED GENET, V34, P620, DOI 10.1136/jmg.34.8.620
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   Papermaster DS, 2002, INVEST OPHTH VIS SCI, V43, P1300
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   REIG C, 1995, OPHTHALMIC GENET, V16, P39, DOI 10.3109/13816819509056911
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Trujillo M J, 1998, Hum Mutat, V12, P70, DOI 10.1002/(SICI)1098-1004(1998)12:1<70::AID-HUMU11>3.0.CO;2-M
   USUKURA J, 1987, EXP EYE RES, V45, P501, DOI 10.1016/S0014-4835(87)80061-1
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WROBLEWSKI JJ, 1994, OPHTHALMOLOGY, V101, P12
   Yanagihashi S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1458, DOI 10.1001/archopht.121.10.1458
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 62
TC 46
Z9 46
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 8908
EP 8918
DI 10.1167/iovs.11-7926
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400021
PM 22003107
OA Green Published
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Delyfer, MN
   Rougier, MB
   Amouyel, P
   Colin, J
   Le Goff, M
   Malet, F
   Dartigues, JF
   Lambert, JC
   Korobelnik, JF
AF Delcourt, Cecile
   Delyfer, Marie-Noelle
   Rougier, Marie-Benedicte
   Amouyel, Philippe
   Colin, Joseph
   Le Goff, Melanie
   Malet, Florence
   Dartigues, Jean-Francois
   Lambert, Jean-Charles
   Korobelnik, Jean-Francois
TI Associations of Complement Factor H and Smoking with Early Age-Related
   Macular Degeneration: The ALIENOR Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; NONMYDRIATIC DIGITAL CAMERA; BEAVER DAM EYE; 10-YEAR
   INCIDENCE; RISK-FACTORS; CHOROIDAL NEOVASCULARIZATION; 5-YEAR INCIDENCE;
   SEVERITY SCALE; MACULOPATHY; DRUSEN
AB PURPOSE. To assess the associations of complement factor H (CFH) Y402H polymorphism and smoking with specific features of early AMD (type, location, and area).
   METHODS. The ALIENOR study is a population-based study of age-related eye diseases in 963 residents of Bordeaux (France), aged 73 years or more. AMD features were graded from non-mydriatic color retinal photographs. CFH Y402H was genotyped by using DNA extracted from blood. Statistical analyses included 796 subjects with complete data.
   RESULTS. CFH CC genotype was strongly associated with late neovascular AMD (OR, 6.0; 95% confidence interval [CI], 1.5-23.5) but not with late atrophic AMD (OR, 0.9; 95% CI, 0.2-4.3). Among early characteristics, it was associated with central soft drusen (within 500 mu m of the fovea), whether of intermediate (63-125 mu m; OR, 2.7; 95% CI, 1.5-4.8), or large (>125 mu m; OR, 5.9; 95% CI, 2.2-15.7) size, but not with pericentral soft drusen (500-3000 mu m from the fovea). It was also strongly associated with a large central area of soft drusen (OR, 5.7; 95% CI, 1.7-19.2). Similarly, heavy smoking (>20 pack-years) was strongly associated with central large drusen (OR, 3.9; 95% CI, 1.6-9.6) and a large central area of drusen (OR, 3.5; 95% CI, 1.2-10.0), but not with pericentral soft drusen. By contrast, both CFH CC and smoking tended to be more strongly associated with pericentral pigmentary abnormalities.
   CONCLUSIONS. Location of abnormalities, together with type and area, may prove useful for the identification of subjects at high risk for late AMD. (Invest Ophthalmol Vis Sci. 2011;52:5955-5962) DOI: 10.1167/iovs.10-6235
C1 [Delcourt, Cecile; Delyfer, Marie-Noelle; Le Goff, Melanie; Dartigues, Jean-Francois; Korobelnik, Jean-Francois] Univ Bordeaux Segalen, INSERM, U897, F-33076 Bordeaux, France.
   [Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Colin, Joseph; Malet, Florence; Korobelnik, Jean-Francois] CHU Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Amouyel, Philippe; Lambert, Jean-Charles] INSERM, U744, F-59045 Lille, France.
   [Amouyel, Philippe; Lambert, Jean-Charles] Inst Pasteur, F-59019 Lille, France.
   [Amouyel, Philippe; Lambert, Jean-Charles] Univ Lille Nord France, Lille, France.
   [Amouyel, Philippe] Ctr Hosp Reg Univ Lille, Lille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille - ISITE; Universite de
   Lille; Universite de Lille - ISITE; CHU Lille
RP Delcourt, C (通讯作者)，Univ Bordeaux Segalen, INSERM, U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@isped.u-bordeaux2.fr
RI lambert, jean-charles/F-8787-2013; Delyfer, Marie-Noelle/T-3304-2019; LE
   GOFF, Mélanie/A-3541-2016; KOROBELNIK, Jean-Francois/A-5448-2016;
   Lambert, jean-charles/A-9553-2014; Delcourt, Cecile/I-2627-2013;
   DARTIGUES, Jean François/T-4513-2019
OI lambert, jean-charles/0000-0003-0829-7817; Lambert,
   jean-charles/0000-0003-0829-7817; Delcourt, Cecile/0000-0002-2099-0481;
   Amouyel, Philippe/0000-0001-9088-234X
FU Laboratoires Thea; Clermont-Ferrand, France
FX Supported by Laboratoires Thea, Clermont-Ferrand, France. The sponsor
   participated in the design of the study, but not in the collection,
   management, statistical analysis, and interpretation of the data or in
   the preparation, review, and approval of the present manuscript.
CR [Anonymous], 2003, NEUROEPIDEMIOLOGY, V22, P316
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Souied EH, 2005, MOL VIS, V11, P1135
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
NR 48
TC 37
Z9 37
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 5955
EP 5962
DI 10.1167/iovs.10-6235
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800QC
UT WOS:000293377400122
PM 21642625
DA 2022-11-30
ER

PT J
AU Jones, RPO
   Ridley, C
   Jowitt, TA
   Wang, MC
   Howard, M
   Bobola, N
   Wang, T
   Bishop, PN
   Kielty, CM
   Baldock, C
   Lotery, AJ
   Trump, D
AF Jones, Richard P. O.
   Ridley, Caroline
   Jowitt, Thomas A.
   Wang, Ming-Chuan
   Howard, Marjorie
   Bobola, Nicoletta
   Wang, Tao
   Bishop, Paul N.
   Kielty, Cay M.
   Baldock, Clair
   Lotery, Andrew J.
   Trump, Dorothy
TI Structural Effects of Fibulin 5 Missense Mutations Associated with
   Age-Related Macular Degeneration and Cutis Laxa
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; ELASTIC FIBER FORMATION; CIGARETTE-SMOKING; GENE;
   POLYMORPHISM; RISK
AB PURPOSE. AMD has a complex etiology with environmental and genetic risk factors. Ten fibulin 5 sequence variants have been associated with AMD and two other fibulin 5 mutations cause autosomal-recessive cutis laxa. Fibulin 5 is a 52-kDa calcium-binding epidermal growth factor (cbEGF)-rich extracellular matrix protein that is essential for the formation of elastic tissues. Biophysical techniques were used to detect structural changes in the fibulin 5 mutants and to determine whether changes are predictive of pathogenicity.
   METHODS. Native PAGE, nonreduced SDS-PAGE, size-exclusion column multiangle laser light scattering, sedimentation velocity, and circular dichroism (CD) were used to investigate the mobility, hydrodynamic radii, folding, and oligomeric states of the fibulin 5 mutants in the absence and presence of Ca2+.
   RESULTS. CD showed that all mutants are folded, although perturbations to secondary structure contents were detected. Both cutis laxa mutants increased dimerization. Most other mutants slightly increased self-association in the absence of Ca2+ but this was also demonstrated by G202R, a polymorphism detected in a control individual. The AMD-associated mutant G412E showed lower-than-expected mobility during native-PAGE, the largest hydrodynamic radius for the monomer form and the highest levels of aggregation in both the absence and presence of Ca2+
   CONCLUSIONS. The results identified structural differences for the disease-causing cutis laxa mutants and for one AMD variant (G412E), suggesting that this may also be pathogenic. Although the other AMD-associated mutants showed no gross structural differences, they cannot be excluded as pathogenic by differences outside the scope of this study-for example, disruption of heterointeractions. (Invest Ophthalmol Vis Sci. 2010;51:2356-2362) DOI: 10.1167/iovs.09-4620
C1 [Jones, Richard P. O.; Wang, Tao; Bishop, Paul N.; Trump, Dorothy] Univ Manchester, Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester M13 9WL, Lancs, England.
   [Ridley, Caroline; Jowitt, Thomas A.; Wang, Ming-Chuan; Howard, Marjorie; Bishop, Paul N.; Kielty, Cay M.; Baldock, Clair] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9WL, Lancs, England.
   [Bobola, Nicoletta] Univ Manchester, Fac Med & Human Sci, Sch Dent, Manchester M13 9WL, Lancs, England.
   [Lotery, Andrew J.] Univ Southampton, Clin Neurosci Div, Southampton, Hants, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; University of Southampton
RP Trump, D (通讯作者)，Univ Manchester, Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, Oxford Rd, Manchester M13 9WL, Lancs, England.
EM rpojones@yahoo.co.uk; dorothy.trump@manchester.ac.uk
OI Ridley, Caroline/0000-0002-5483-0320; Bishop, Paul/0000-0001-7937-7932;
   Jowitt, Thomas/0000-0002-4045-0933; Lotery, Andrew/0000-0001-5541-4305;
   Baldock, Clair/0000-0003-3497-1959
FU Wellcome Trust [123364, 072291]; VIP award; National Institutes of
   Health Research (NIHR) Manchester Biomedical Research Centre; MRC
   [G0801787] Funding Source: UKRI; Medical Research Council [G0801787]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0507-10094] Funding Source: researchfish
FX Supported by Wellcome Trust Grants 123364 (DT, AJL, PNB CMK, RPOJ, CR),
   072291 (CB, MCW) and VIP award (NB, RPOJ & DT); and the National
   Institutes of Health Research (NIHR) Manchester Biomedical Research
   Centre.
CR Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Choudhury R, 2009, J BIOL CHEM, V284, P24553, DOI 10.1074/jbc.M109.019364
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   DIXON WJ, 1983, INTRO STAT ANAL, P44
   Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elahi E, 2006, J INVEST DERMATOL, V126, P1506, DOI 10.1038/sj.jid.5700247
   FISCHER J, 2004, 3 EUR S ELAST MANCH
   Freeman LJ, 2005, BIOCHEM J, V388, P1, DOI 10.1042/BJ20050368
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayes D., 1995, PROGRAM SEDNTERP SED
   Hu QR, 2006, HUM MOL GENET, V15, P3379, DOI 10.1093/hmg/ddl414
   Hu QR, 2006, J INVEST DERMATOL, V126, P283, DOI 10.1038/sj.jid.5700047
   Jones DT, 1999, PROTEINS, P104
   Jones RPO, 2009, J BIOL CHEM, V284, P25938, DOI 10.1074/jbc.M109.011627
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Lomas AC, 2007, BIOCHEM J, V405, P417, DOI 10.1042/BJ20070400
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   MATHEWS CK, 1990, BIOCHEMISTRY-US, P1129
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
NR 35
TC 21
Z9 24
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2010
VL 51
IS 5
BP 2356
EP 2362
DI 10.1167/iovs.09-4620
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589UU
UT WOS:000277180500011
PM 20007835
OA Green Published
DA 2022-11-30
ER

PT J
AU Beatty, S
   van Kuijk, FJGM
   Chakravarthy, U
AF Beatty, Stephen
   van Kuijk, Frederik J. G. M.
   Chakravarthy, Usha
TI Macular pigment and age-related macular degeneration: Longitudinal data
   and better techniques of measurement are needed
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID IN-VIVO METHODS; OPTICAL-DENSITY; SERUM CONCENTRATIONS;
   RAMAN-SPECTROSCOPY; ZEAXANTHIN; LUTEIN; AUTOFLUORESCENCE; CAROTENOIDS;
   SUPPLEMENTATION; VALIDITY
C1 [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Ctr Ophthalmol & Vis Sci, Royal Grp Hosp, Belfast BT12 6BA, Antrim, North Ireland.
   [Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [van Kuijk, Frederik J. G. M.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX USA.
C3 Queens University Belfast; South East Technological University (SETU);
   University of Texas System; University of Texas Medical Branch Galveston
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Ctr Ophthalmol & Vis Sci, Royal Grp Hosp, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Ermakov I, 2004, J BIOMED OPT, V9, P139, DOI 10.1117/1.1627776
   Gellermann W, 2006, OPTOMETRY VISION SCI, V83, P254, DOI 10.1097/01.opx.0000214591.07685.93
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hogg RE, 2007, BRIT J OPHTHALMOL, V91, P485, DOI 10.1136/bjo.2006.090936
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Robson AG, 2005, PERCEPTION, V34, P1029, DOI 10.1068/p5196
   RUDDOCK K. H., 1965, VISION RES, V5, P47, DOI 10.1016/0042-6989(65)90074-X
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   TOYADA Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
NR 29
TC 27
Z9 28
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2008
VL 49
IS 3
BP 843
EP 845
DI 10.1167/iovs.07-1276
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 271TZ
UT WOS:000253812900001
PM 18326700
DA 2022-11-30
ER

PT J
AU Ratay, ML
   Bellotti, E
   Gottardi, R
   Little, SR
AF Ratay, Michelle L.
   Bellotti, Elena
   Gottardi, Riccardo
   Little, Steven R.
TI Modern Therapeutic Approaches for Noninfectious Ocular Diseases
   Involving Inflammation
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Review
DE age-related macular degeneration; drug delivery; dry eye disease;
   therapeutics; uveitis
ID DRY EYE DISEASE; DRUG-DELIVERY SYSTEMS; REGULATORY T-CELLS; MEIBOMIAN
   GLAND DYSFUNCTION; LOW-DOSE CYCLOSPORINE; EMBRYONIC STEM-CELLS;
   LONG-TERM EFFICACY; MACULAR DEGENERATION; MYCOPHENOLATE-MOFETIL;
   FLUOCINOLONE ACETONIDE
AB Dry eye disease, age-related macular degeneration, and uveitis are ocular diseases that significantly affect the quality of life of millions of people each year. In these diseases, the action of chemokines, proinflammatory cytokines, and immune cells drives a local inflammatory response that results in ocular tissue damage. Multiple therapeutic strategies are developed to either address the symptoms or abate the underlying cause of these diseases. Herein, the challenges to deliver drugs to the relevant location in the eye for each of these diseases are reviewed along with current and innovative therapeutic approaches that attempt to restore homeostasis within the ocular microenvironment.
C1 [Ratay, Michelle L.] Univ Pittsburgh, Dept Bioengn, 427 Benedum Hall 3700 OHara St, Pittsburgh, PA 15261 USA.
   [Bellotti, Elena] Univ Pittsburgh, Dept Chem Engn, 427 Benedum Hall 3700 OHara St, Pittsburgh, PA 15261 USA.
   [Gottardi, Riccardo] Ri MED Fdn, Dept Orthoped Surg, Dept Chem Engn, 427 Benedum Hall 3700 OHara St, Pittsburgh, PA 15261 USA.
   [Little, Steven R.] McGowan Inst Regenerat Med, Dept Pharmaceut Sci, Dept Immunol, Dept Chem Engn,Dept Bioengn,Dept Ophthalmol, 940 Benedum Hall 3700 OHara St, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Little, SR (通讯作者)，McGowan Inst Regenerat Med, Dept Pharmaceut Sci, Dept Immunol, Dept Chem Engn,Dept Bioengn,Dept Ophthalmol, 940 Benedum Hall 3700 OHara St, Pittsburgh, PA 15261 USA.
EM srlittle@pitt.edu
RI Gottardi, Riccardo/AAA-5047-2019
OI Gottardi, Riccardo/0000-0001-8040-5531; Bellotti,
   Elena/0000-0002-4291-6530
FU National Center for Advancing Translational Sciences of the National
   Institutes of Health [TL1TR000145]; Wallace H. Coulter Foundation;
   Camille and Henry Dreyfus Foundation [NIH-R01EY024039, P30 EY008098,];
   Ri.MED Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [TL1TR000145] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY024039] Funding Source: NIH RePORTER
FX M.L.R. and E.B. contributed equally to this work. Research reported in
   this publication was supported by the National Center for Advancing
   Translational Sciences of the National Institutes of Health under Award
   Number TL1TR000145, the Wallace H. Coulter Foundation (Translational
   Research Award to S.R.L.), the Camille and Henry Dreyfus Foundation
   (Camille Dreyfus Teacher Scholar Award to S.R.L.), NIH-R01EY024039, P30
   EY008098, and the Ri.MED Foundation (to R.G.). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Abud TB, 2016, OPHTHALMOLOGY, V123, P1449, DOI 10.1016/j.ophtha.2016.02.044
   Acharya AP, 2013, BIOMATERIALS, V34, P3422, DOI 10.1016/j.biomaterials.2013.01.032
   Acharya NR, 2013, JAMA OPHTHALMOL, V131, P1405, DOI 10.1001/jamaophthalmol.2013.4237
   Agarwal RK, 2004, METH MOLEC MED, V102, P395
   ALKHATIB SQ, 2002, INVEST OPHTHALMOL VI, V43
   Allison AC, 2005, LUPUS, V14, pS2, DOI 10.1191/0961203305lu2109oa
   Anderson JM, 2012, ADV DRUG DELIVER REV, V64, P72, DOI 10.1016/j.addr.2012.09.004
   Andres-Guerrero V, 2015, J CONTROL RELEASE, V211, P105, DOI 10.1016/j.jconrel.2015.05.279
   Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152
   Araujo J, 2009, NANOMED-NANOTECHNOL, V5, P394, DOI 10.1016/j.nano.2009.02.003
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bagnis CI, 2002, J AM SOC NEPHROL, V13, P2962, DOI 10.1097/01.ASN.0000034945.61533.26
   Baluna R, 1997, IMMUNOPHARMACOLOGY, V37, P117, DOI 10.1016/S0162-3109(97)00041-6
   Baranowski P, 2014, SCI WORLD J, DOI 10.1155/2014/861904
   Barnes PJ, 2006, EUR J PHARMACOL, V533, P2, DOI 10.1016/j.ejphar.2005.12.052
   Barry RJ, 2014, CLIN OPHTHALMOL, V8, P1891, DOI 10.2147/OPTH.S47778
   Baudouin C, 2013, OCUL SURF, V11, P246, DOI 10.1016/j.jtos.2013.07.003
   Becker MD, 2000, OCUL IMMUNOL INFLAMM, V8, P93, DOI 10.1076/0927-3948(200006)8:2;1-0;FT093
   Bertram JP, 2009, ACTA BIOMATER, V5, P2860, DOI 10.1016/j.actbio.2009.04.012
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Blackie CA, 2016, CLIN OPHTHALMOL, V10, P1385, DOI 10.2147/OPTH.S109663
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Boyer DS, 1999, AM J OPHTHALMOL, V127, P349, DOI 10.1016/S0002-9394(98)00176-7
   Braun J, 2003, ARTHRITIS RHEUM-US, V48, P2224, DOI 10.1002/art.11104
   Brewitt H, 2001, SURV OPHTHALMOL, V45, pS199, DOI 10.1016/S0039-6257(00)00202-2
   Bron AJ, 2015, PROG RETIN EYE RES, V44, P36, DOI 10.1016/j.preteyeres.2014.10.001
   Busch M, 2013, INVEST OPHTH VIS SCI, V54, P39, DOI 10.1167/iovs.12-10138
   Calvo P., 2014, BR J OPHTHALMOL, P1
   Campochiaro P. A., 2016, GENE THER, V28, P99, DOI [10.1089/hum.2016.11727710144, DOI 10.1089/HUM.2016.11727710144]
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Caspi RR, 2011, INVEST OPHTH VIS SCI, V52, P1873, DOI 10.1167/iovs.10-6909
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CHANAUD NP, 1995, EXP EYE RES, V61, P429, DOI 10.1016/S0014-4835(05)80138-1
   Chang E., 2013, J CLIN EXP OPHTHAMOL, V2, P1
   Chauhan SK, 2009, J IMMUNOL, V182, P1247, DOI 10.4049/jimmunol.182.3.1247
   Chen JJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/658925
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Chen W, 2013, INVEST OPHTH VIS SCI, V54, P6287, DOI 10.1167/iovs.13-12081
   Chen Y, 2014, MUCOSAL IMMUNOL, V7, P38, DOI 10.1038/mi.2013.20
   Chen Y., 2014, EUROPEAN J PHARM BIO, V95, P378
   Cholkar K., 2014, RECENT PAT NANOMED, V2, P82
   Cholkar K, 2013, J OCUL PHARMACOL TH, V29, P106, DOI 10.1089/jop.2012.0200
   Christodoulou MI, 2008, AM J PATHOL, V173, P1389, DOI 10.2353/ajpath.2008.080246
   Clouzeau C, 2012, MOL VIS, V18, P851
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cordero-Coma M, 2015, SURV OPHTHALMOL, V60, P575, DOI 10.1016/j.survophthal.2015.06.004
   Cox CA, 2010, OPHTHALMOLOGY, V117, P1782, DOI 10.1016/j.ophtha.2010.01.037
   Cunha-Vaz J., 2016, PHARM OCULAR THERAPE, P37, DOI [10.1007/978-3-319-25498-2_3, DOI 10.1007/978-3-319-25498-2_3]
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   De Paiva CS, 2006, EXP EYE RES, V83, P526, DOI 10.1016/j.exer.2006.02.004
   de Smet MD, 2011, PROG RETIN EYE RES, V30, P452, DOI 10.1016/j.preteyeres.2011.06.005
   de Wert G, 2003, HUM REPROD, V18, P672, DOI 10.1093/humrep/DEG143
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Dick AD, 2013, OPHTHALMOLOGY, V120, P777, DOI 10.1016/j.ophtha.2012.09.040
   Dinarello CA, 2013, SEMIN IMMUNOL, V25, P469, DOI 10.1016/j.smim.2013.10.008
   Doycheva D, 2011, GRAEF ARCH CLIN EXP, V249, P1235, DOI 10.1007/s00417-011-1731-8
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Duivenvoorden WCM, 2002, CANCER RES, V62, P1588
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   El Annan J, 2009, INVEST OPHTH VIS SCI, V50, P3802, DOI 10.1167/iovs.08-2417
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Fang IM, 2005, J OCUL PHARMACOL TH, V21, P420, DOI 10.1089/jop.2005.21.420
   Fangueiro JF, 2016, CURR PHARM DESIGN, V22, P1135, DOI 10.2174/1381612822666151216145900
   Fedorchak MV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09379-8
   Fedorchak MV, 2014, EXP EYE RES, V125, P210, DOI 10.1016/j.exer.2014.06.013
   Fields M, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5040044
   Fisher JD, 2015, CLIN IMMUNOL, V160, P24, DOI 10.1016/j.clim.2015.04.013
   Friedman NJ, 2010, CURR OPIN OPHTHALMOL, V21, P310, DOI 10.1097/ICU.0b013e32833a8c15
   Gangaputra S, 2009, OPHTHALMOLOGY, V116, P2188, DOI 10.1016/j.ophtha.2009.04.020
   Gasparin F, 2012, ARQ BRAS OFTALMOL, V75, P143, DOI 10.1590/S0004-27492012000200016
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gayton JL, 2009, CLIN OPHTHALMOL, V3, P405
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Glowacki AJ, 2015, ANN BIOMED ENG, V43, P593, DOI 10.1007/s10439-014-1125-2
   Glowacki AJ, 2013, P NATL ACAD SCI USA, V110, P18525, DOI 10.1073/pnas.1302829110
   Gooch Nathan, 2012, Pharmaceutics, V4, P197, DOI 10.3390/pharmaceutics4010197
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Gower NJD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0188-2
   Goyal S, 2009, ARCH OPHTHALMOL-CHIC, V127, P882, DOI 10.1001/archophthalmol.2009.125
   Gulsen D, 2004, INVEST OPHTH VIS SCI, V45, P2342, DOI 10.1167/iovs.03-0959
   Gupta C, 2011, J CONTROL RELEASE, V150, P70, DOI 10.1016/j.jconrel.2010.11.009
   Guzman-Aranguez A., 2015, EYE CONTACT LENS, V42, P1
   Hale S, 2006, CYTOKINE, V33, P231, DOI 10.1016/j.cyto.2005.12.012
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   He Y, 2006, J OCUL PHARMACOL TH, V22, P121, DOI 10.1089/jop.2006.22.121
   He Y, 2006, INVEST OPHTH VIS SCI, V47, P3983, DOI 10.1167/iovs.05-1373
   Hessen Michelle, 2014, J Ophthalmic Vis Res, V9, P240
   Hogan AC, 2007, OPHTHALMOLOGY, V114, P1000, DOI 10.1016/j.ophtha.2007.01.026
   Hostettler KE, 2012, RESPIRATION, V83, P218, DOI 10.1159/000328738
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107
   Hunter RS, 2011, CLIN OPHTHALMOL, V5, P1613, DOI 10.2147/OPTH.S17419
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jehangir N, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9312340
   Jhunjhunwala S, 2012, ADV MATER, V24, P4735, DOI 10.1002/adma.201202513
   Junemann A.G.M., 2016, OPHTHALMOL J, V1, P29, DOI [10.5603/OJ.2016.0005, DOI 10.5603/OJ.2016.0005]
   Jung HJ, 2013, J CONTROL RELEASE, V165, P82, DOI 10.1016/j.jconrel.2012.10.010
   Kabat A. G., 2012, REV OPTOM, P109
   Kacmaz RO, 2010, OPHTHALMOLOGY, V117, P576, DOI 10.1016/j.ophtha.2009.08.010
   Kamaleddin MA, 2017, NANOMED-NANOTECHNOL, V13, P1459, DOI 10.1016/j.nano.2017.02.007
   Kang H, 2016, INT J NANOMED, V11, P2921, DOI 10.2147/IJN.S107569
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kenawy N, 2011, GRAEF ARCH CLIN EXP, V249, P297, DOI 10.1007/s00417-010-1523-6
   Kersey JP, 2006, EYE, V20, P407, DOI 10.1038/sj.eye.6701895
   Kim Jane S, 2015, Int Ophthalmol Clin, V55, P79, DOI 10.1097/IIO.0000000000000070
   Kim J, 2008, BIOMATERIALS, V29, P2259, DOI 10.1016/j.biomaterials.2008.01.030
   Kim J, 2010, J CONTROL RELEASE, V148, P110, DOI 10.1016/j.jconrel.2010.07.119
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim Y.-H., 2016, BIOCHEM BIOPH RES CO, V482, P1148
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kitahara K, 2007, CURR OPIN RHEUMATOL, V19, P238, DOI 10.1097/BOR.0b013e328099af80
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Krauss AH, 2015, INVEST OPHTH VIS SCI, V56, P5888, DOI 10.1167/iovs.15-17249
   Kruh JN, 2014, OPHTHALMOLOGY, V121, P358, DOI 10.1016/j.ophtha.2013.07.019
   Kulkarni P, 2001, J OCUL PHARMACOL TH, V17, P181, DOI 10.1089/10807680151125537
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kuno N, 2011, POLYMERS-BASEL, V3, P193, DOI 10.3390/polym3010193
   Lallemand F, 2003, EUR J PHARM BIOPHARM, V56, P307, DOI 10.1016/S0939-6411(03)00138-3
   Lane SS, 2012, CORNEA, V31, P396, DOI 10.1097/ICO.0b013e318239aaea
   Larson T, 2011, EXPERT OPIN EMERG DR, V16, P309, DOI 10.1517/14728214.2011.537824
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lee DJ, 2015, J FUNCT BIOMATER, V6, P650, DOI 10.3390/jfb6030650
   Lee J, 2016, DRUG METAB DISPOS, V44, P1675, DOI 10.1124/dmd.116.069369
   Lee MJ, 2015, MOL THER, V23, P139, DOI 10.1038/mt.2014.159
   Lee RWJ, 2012, OPHTHALMOLOGY, V119, P1223, DOI 10.1016/j.ophtha.2011.12.030
   Lee Sun Ho, 2012, Korean J Ophthalmol, V26, P21, DOI 10.3341/kjo.2012.26.1.21
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lemp MA, 2008, AM J OPHTHALMOL, V146, P350, DOI 10.1016/j.ajo.2008.05.016
   Lemp MA, 2007, OCUL SURF, V5, P75
   Letko E, 2015, OPHTHALMOLOGY, V122, P939, DOI 10.1016/j.ophtha.2014.12.033
   Li DQ, 2004, INVEST OPHTH VIS SCI, V45, P4302, DOI 10.1167/iovs.04-0299
   Lim A, 2015, TRENDS MOL MED, V21, P736, DOI 10.1016/j.molmed.2015.10.001
   Lin Phoebe, 2015, Curr Ophthalmol Rep, V3, P170
   Lin P, 2014, OPHTHALMOLOGY, V121, P365, DOI 10.1016/j.ophtha.2013.08.029
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Maulvi F.A., 2016, DRUG DELIV, V7544, P1
   Maulvi FA, 2017, ACTA BIOMATER, V53, P211, DOI 10.1016/j.actbio.2017.01.063
   Maya JR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/310329
   Merida S, 2015, INT J MOL SCI, V16, P18778, DOI 10.3390/ijms160818778
   Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003
   Mohammad DA, 2007, ANN PHARMACOTHER, V41, P449, DOI 10.1345/aph.1H540
   Moinard-Checot D, 2008, J COLLOID INTERF SCI, V317, P458, DOI 10.1016/j.jcis.2007.09.081
   Molokhia SA, 2013, J OCUL PHARMACOL TH, V29, P92, DOI 10.1089/jop.2012.0241
   Moore CP, 2001, INVEST OPHTH VIS SCI, V42, P653
   Morrison PWJ, 2014, THER DELIV, V5, P1297, DOI [10.4155/tde.14.75, 10.4155/TDE.14.75]
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Mullen JC, 2007, J HEART LUNG TRANSPL, V26, P504, DOI 10.1016/j.healun.2007.01.032
   Mullen JC, 2014, TRANSPLANT RES, V3, DOI 10.1186/2047-1440-3-14
   Murphy CC, 2005, ARCH OPHTHALMOL-CHIC, V123, P634, DOI 10.1001/archopht.123.5.634
   MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38
   Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983
   Nelson JD, 2000, ADV THER, V17, P84, DOI 10.1007/BF02854841
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Niederkorn JY, 2006, J IMMUNOL, V176, P3950, DOI 10.4049/jimmunol.176.7.3950
   Nussenblatt RB, 2005, OPHTHALMOLOGY, V112, P764, DOI 10.1016/j.ophtha.2004.12.034
   Nussenblatt RB, 2003, J AUTOIMMUN, V21, P283, DOI 10.1016/S0896-8411(03)00113-6
   Okanobo A, 2012, AM J OPHTHALMOL, V154, P63, DOI 10.1016/j.ajo.2012.01.034
   Palareti G, 2016, INT J LAB HEMATOL, V38, P42, DOI 10.1111/ijlh.12426
   Pan Q, 2015, J CONTROL RELEASE, V201, P32, DOI 10.1016/j.jconrel.2015.01.009
   Papaliodis GN, 2003, OPHTHALMOLOGY, V110, P786, DOI 10.1016/S0161-6420(02)01932-2
   Papotto PH, 2014, AUTOIMMUN REV, V13, P909, DOI 10.1016/j.autrev.2014.05.003
   Pasadhika S, 2014, BIOL-TARGETS THER, V8, P67, DOI 10.2147/BTT.S41477
   Patel DD, 2013, ANN RHEUM DIS, V72, P116, DOI 10.1136/annrheumdis-2012-202371
   Peng CC, 2011, J CONTROL RELEASE, V154, P267, DOI 10.1016/j.jconrel.2011.06.028
   Peng CC, 2010, BIOMATERIALS, V31, P4032, DOI 10.1016/j.biomaterials.2010.01.113
   Perez VL, 2016, OCUL SURF, V14, P207, DOI 10.1016/j.jtos.2016.01.001
   Perry D. E., 2004, CURR OPIN OPHTHAMOL, V15, P299
   Perry HD, 2008, ARCH OPHTHALMOL-CHIC, V126, P1046, DOI 10.1001/archopht.126.8.1046
   Peter C. S., 2010, ADV EXP MED BIOL, V703, P9
   Peters T, 2017, BIOMATERIALS, V124, P157, DOI 10.1016/j.biomaterials.2017.02.006
   Pflugfelder SC, 2000, CORNEA, V19, P644, DOI 10.1097/00003226-200009000-00009
   Pflugfelder SC, 2017, J OCUL PHARMACOL TH, V33, P5, DOI 10.1089/jop.2016.0105
   Nguyen QD, 2016, OPHTHALMOLOGY, V123, P2413, DOI 10.1016/j.ophtha.2016.07.029
   Ramazani F, 2015, EUR J PHARM BIOPHARM, V95, P368, DOI 10.1016/j.ejpb.2015.02.011
   Rasaiah SB, 2000, CLIN TRANSPLANT, V14, P409, DOI 10.1034/j.1399-0012.2000.14040902.x
   Rashid S, 2008, ARCH OPHTHALMOL-CHIC, V126, P219, DOI 10.1001/archophthalmol.2007.61
   Ratay ML, 2017, J CONTROL RELEASE, V258, P208, DOI 10.1016/j.jconrel.2017.05.007
   Reinisch W, 2012, J CROHNS COLITIS, V6, P248, DOI 10.1016/j.crohns.2011.11.001
   Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006
   Roberts CW, 2007, CORNEA, V26, P805, DOI 10.1097/ICO.0b013e318074e460
   Rolando M, 2001, SURV OPHTHALMOL, V45, pS203, DOI 10.1016/S0039-6257(00)00203-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothstein SN, 2008, J MATER CHEM, V18, P1873, DOI 10.1039/b718277e
   Rothstein SN, 2011, J MATER CHEM, V21, P29, DOI 10.1039/c0jm01668c
   Rothstein SN, 2009, BIOMATERIALS, V30, P1657, DOI 10.1016/j.biomaterials.2008.12.002
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Sakoda Y, 2016, J IMMUNOL, V196, P2947, DOI 10.4049/jimmunol.1501742
   Salama HA, 2017, AAPS PHARMSCITECH, V18, P2517, DOI 10.1208/s12249-017-0710-8
   Samson CM, 2001, OPHTHALMOLOGY, V108, P1134, DOI 10.1016/S0161-6420(01)00576-0
   Schopf LR, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.11
   Schultz CL, 2009, CLIN EXP OPTOM, V92, P343, DOI 10.1111/j.1444-0938.2009.00370.x
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartzman S, 2016, BEST PRACT RES CL RH, V30, P304, DOI 10.1016/j.berh.2016.07.005
   Sen ES, 2015, NAT REV RHEUMATOL, V11, P338, DOI 10.1038/nrrheum.2015.20
   Servat JJ, 2012, EXPERT OPIN BIOL TH, V12, P311, DOI 10.1517/14712598.2012.658366
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Shapiro A., 2016, RETINA TODAY, V1
   Sheppard JD, 2014, OPHTHALMOLOGY, V121, P475, DOI 10.1016/j.ophtha.2013.09.015
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Siemasko K. F., 2008, INVEST OPHTH VIS SCI, P5434
   Siepmann K, 2006, GRAEF ARCH CLIN EXP, V244, P788, DOI 10.1007/s00417-005-0066-8
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Sloper CML, 1999, OPHTHALMOLOGY, V106, P723, DOI 10.1016/S0161-6420(99)90156-2
   Smith JR, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.2
   Sobrin L, 2008, OPHTHALMOLOGY, V115, P1416, DOI 10.1016/j.ophtha.2007.12.011
   Sodha S, 2011, J BIOMAT SCI-POLYM E, V22, P443, DOI 10.1163/092050610X487738
   Srivastava A, 2010, CLIN CHIM ACTA, V411, P1165, DOI 10.1016/j.cca.2010.04.017
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stechmiller J, 2010, BIOL RES NURS, V11, P336, DOI 10.1177/1099800409346333
   Stein-Streilein J, 2007, J LEUKOCYTE BIOL, V81, P593, DOI 10.1189/jlb.0606383
   Stern ME, 2010, MUCOSAL IMMUNOL, V3, P425, DOI 10.1038/mi.2010.26
   Stern ME, 2004, EXP EYE RES, V78, P409, DOI 10.1016/j.exer.2003.09.003
   Stern ME, 2013, INT REV IMMUNOL, V32, P19, DOI 10.3109/08830185.2012.748052
   Stevenson D, 2000, OPHTHALMOLOGY, V107, P967, DOI 10.1016/S0161-6420(00)00035-X
   Stevenson W, 2012, ARCH OPHTHALMOL-CHIC, V130, P90, DOI 10.1001/archophthalmol.2011.364
   Stewart J. M., 2017, ADV DRUG DELIVERY RE, P1
   Strober B, 2017, J AM ACAD DERMATOL, V76, P655, DOI 10.1016/j.jaad.2016.11.043
   Sukumaran S., 2012, ISRN RHEUMATOL, V2012
   T. C. R. Group, 2011, NEW ENGL J MED, V364, P1897
   Tai MC, 2002, CORNEA, V21, P135, DOI 10.1097/00003226-200203000-00001
   Takase H, 2006, INVEST OPHTH VIS SCI, V47, P1557, DOI 10.1167/iovs.05-0836
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Thode AR, 2015, DRUGS, V75, P1177, DOI 10.1007/s40265-015-0432-8
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Thorne JE, 2005, OPHTHALMOLOGY, V112, P1472, DOI 10.1016/j.ophtha.2005.02.020
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tong L, 2016, OCUL SURF, V14, P233, DOI 10.1016/j.jtos.2015.12.004
   Trittibach P, 2008, GENE THER, V15, P1478, DOI 10.1038/gt.2008.109
   Trounson A, 2016, NAT REV MOL CELL BIO, V17, P194, DOI 10.1038/nrm.2016.10
   Tugal-Tutkun I, 2005, ARTHRITIS RHEUM-US, V52, P2478, DOI 10.1002/art.21231
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304
   Vitale AT, 1996, OPHTHALMOLOGY, V103, P365
   Vlad G, 2007, TRANSPL IMMUNOL, V18, P13, DOI 10.1016/j.trim.2007.03.001
   Wang CY, 2014, EXP EYE RES, V129, P74, DOI 10.1016/j.exer.2014.11.002
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YN, 2011, BIOMATERIALS, V32, P4903, DOI 10.1016/j.biomaterials.2011.03.027
   Wei Y, 2014, EYE CONTACT LENS, V40, P248, DOI 10.1097/ICL.0000000000000042
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
   Wolska E, 2013, INT J PHARMACEUT, V441, P449, DOI 10.1016/j.ijpharm.2012.11.009
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yadav M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00232
   Yagci A, 2014, INT OPHTHALMOL, V34, P1291, DOI 10.1007/s10792-014-9969-x
   Yang M, 2016, DRUG DELIV, V23, P3538, DOI 10.1080/10717544.2016.1204570
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yellepeddi VK, 2015, DRUG DISCOV TODAY, V20, P884, DOI 10.1016/j.drudis.2015.01.013
   Yoshida EM, 2005, LIVER TRANSPLANT, V11, P1064, DOI 10.1002/lt.20490
   You CY, 2017, CLIN OPHTHALMOL, V11, P257, DOI 10.2147/OPTH.S121734
   Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363
   Zhang Z, 2014, INVEST OPHTH VIS SCI, V55, P2963, DOI 10.1167/iovs.13-13577
   Zhao Y, 2016, EYE CONTACT LENS, V42, P339, DOI 10.1097/ICL.0000000000000228
   Zulian F, 2010, ARTHRIT CARE RES, V62, P821, DOI 10.1002/acr.20115
NR 268
TC 9
Z9 9
U1 1
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD DEC 6
PY 2017
VL 6
IS 23
AR 1700733
DI 10.1002/adhm.201700733
PG 23
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Science & Technology - Other Topics; Materials Science
GA FP3UL
UT WOS:000417543400001
PM 29034584
OA Green Accepted
DA 2022-11-30
ER

PT J
AU de Cordoba, SR
   de Jorge, EG
AF de Cordoba, S. Rodriguez
   de Jorge, E. Goicoechea
TI Translational mini-review series on complement factor H: Genetics and
   disease associations of human complement factor H
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Review
DE age-related macular degeneration (AMD); factor H; haemolytic-uraemic
   syndrome (HUS); membranoproliferative glomerulonephritis type II
   (MPGN2); RCA
ID HEMOLYTIC-UREMIC SYNDROME; C-REACTIVE PROTEIN; GLOMERULONEPHRITIS
   TYPE-II; MEMBRANE COFACTOR PROTEIN; HEPARIN-BINDING DOMAIN; SHORT
   CONSENSUS REPEAT; DENSE DEPOSIT DISEASE; MEMBRANOPROLIFERATIVE
   GLOMERULONEPHRITIS; MACULAR DEGENERATION; ALTERNATIVE PATHWAY
AB Factor H is an abundant plasma glycoprotein that plays a critical role in the regulation of the complement system in plasma and in the protection of host cells and tissues from damage by complement activation. Several recent studies have described the association of genetic variations of the complement factor H gene (CFH) with atypical haemolytic uraemic syndrome (aHUS), age-related macular degeneration (AMD) and membranoproliferative glomerulonephritis (MPGN). This review summarizes our current knowledge of CFH genetics and examines the CFH genotype-phenotype correlations that are helping to understand the molecular basis underlying these renal and ocular pathologies.
C1 Ctr Invest Biol, Ctr Invest Biomed, Red Enfermed Raras, Madrid, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo
   Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de
   Investigaciones Biologicas (CIB)
RP de Cordoba, SR (通讯作者)，Ctr Invest Biol, Ramiro Maeztu 9, E-28040 Madrid, Spain.
EM SRdeCordoba@cib.csic.es
RI de Cordoba, Santiago Rodriguez/K-6727-2014; de Jorge, Elena
   Goicoechea/L-4580-2016; Mohammed, Imran/J-8271-2012
OI de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; de Jorge, Elena
   Goicoechea/0000-0002-4978-2483; Mohammed, Imran/0000-0002-8412-0768
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Atkinson JP, 2005, ANN NY ACAD SCI, V1056, P144, DOI 10.1196/annals.1352.032
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Dragon-Dureya MA, 2007, MOL IMMUNOL, V44, P3922, DOI 10.1016/j.molimm.2007.06.036
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2006, MOL IMMUNOL, V43, P1769, DOI 10.1016/j.molimm.2005.11.008
   Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Fernandez-Alonso C, 2007, MOL IMMUNOL, V44, P3982, DOI 10.1016/j.molimm.2007.06.191
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Fremeaux-Bacchi V, 2007, MOL IMMUNOL, V44, P172, DOI 10.1016/j.molimm.2006.07.061
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2007, MOL IMMUNOL, V44, P3983, DOI 10.1016/j.molimm.2007.06.194
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   JOZSI M, 2007, MOL IMMUNOL, V44, P3024
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   KAPLAN MH, 1974, J IMMUNOL, V112, P2135
   Kavanagh D, 2005, J AM SOC NEPHROL, V16, P2150, DOI 10.1681/ASN.2005010103
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   KUTTNERKONDO L, 2007, MOL IMMUNOL, V44, P201
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Law SKA, 1995, COMPLEMENT
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2007, MOL IMMUNOL, V44, P3919, DOI 10.1016/j.molimm.2007.06.031
   McRae JL, 2002, GENETICA, V114, P157, DOI 10.1023/A:1015114512924
   McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200
   MISASI R, 1989, EUR J IMMUNOL, V19, P1765, DOI 10.1002/eji.1830190936
   MOLD C, 1984, J IMMUNOL, V133, P882
   MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2005, J AM SOC NEPHROL, V16, P1035, DOI 10.1681/ASN.2004100861
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   Ohali M, 1998, PEDIATR NEPHROL, V12, P619, DOI 10.1007/s004670050515
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1983, J IMMUNOL, V131, P1930
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rougier N, 1998, J AM SOC NEPHROL, V9, P2318
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Scholl HPN, 2007, MOL VIS, V13, P196
   SCHREIBER RD, 1978, P NATL ACAD SCI USA, V75, P3948, DOI 10.1073/pnas.75.8.3948
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110
   Tortajada A, 2007, MOL IMMUNOL, V44, P3925, DOI 10.1016/j.molimm.2007.06.042
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
   ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4
NR 108
TC 216
Z9 231
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 2008
VL 151
IS 1
BP 1
EP 13
DI 10.1111/j.1365-2249.2007.03574.x
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 238FH
UT WOS:000251432200001
PM 18081690
OA Green Published
DA 2022-11-30
ER

PT J
AU Raimondi, R
   Zollet, P
   De Rosa, FP
   Tsoutsanis, P
   Stravalaci, M
   Paulis, M
   Inforzato, A
   Romano, MR
AF Raimondi, Raffaele
   Zollet, Piero
   De Rosa, Francesco Paolo
   Tsoutsanis, Panagiotis
   Stravalaci, Matteo
   Paulis, Marianna
   Inforzato, Antonio
   Romano, Mario R.
TI Where Are We with RPE Replacement Therapy? A Translational Review from
   the Ophthalmologist Perspective
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinal pigmented epithelium; replacement; induced pluripotent stem
   cells; embryonic stem cells; age related macular degeneration; Stargardt
   disease
ID RETINAL-PIGMENT EPITHELIUM; PLURIPOTENT STEM-CELLS; MACULAR
   DEGENERATION; OXIDATIVE STRESS; DIRECTED DIFFERENTIATION; INFLAMMATION;
   RENEWAL; MODELS; SAFETY; LINES
AB The retinal pigmented epithelium (RPE) plays a pivotal role in retinal homeostasis. It is therefore an interesting target to fill the unmet medical need of different retinal diseases, including age-related macular degeneration and Stargardt disease. RPE replacement therapy may use different cellular sources: induced pluripotent stem cells or embryonic stem cells. Cells can be transferred as suspension on a patch with different surgical approaches. Results are promising although based on very limited samples. In this review, we summarize the current progress of RPE replacement and provide a comparative assessment of different published approaches which may become standard of care in the future.
C1 [Raimondi, Raffaele; Zollet, Piero; Stravalaci, Matteo; Paulis, Marianna; Inforzato, Antonio] IRCCS Humanitas Res Hosp, Via Manzoni 56, I-20089 Rozzano, Italy.
   [Raimondi, Raffaele; Zollet, Piero; De Rosa, Francesco Paolo; Tsoutsanis, Panagiotis; Stravalaci, Matteo; Inforzato, Antonio; Romano, Mario R.] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Pieve Emanuele, Italy.
   [Paulis, Marianna] Natl Res Council Italy, UOS Milan, Inst Genet & Biomed Res IRGB, I-20138 Milan, Italy.
   [Romano, Mario R.] Ctr Eye, Humanitas Gavazzeni Castelli, I-24128 Bergamo, Italy.
C3 Humanitas University; Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Ricerca Genetica e Biomedica (IRGB-CNR)
RP Raimondi, R (通讯作者)，IRCCS Humanitas Res Hosp, Via Manzoni 56, I-20089 Rozzano, Italy.; Raimondi, R (通讯作者)，Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Pieve Emanuele, Italy.
EM raffor9@gmail.com; piero.zollet@humanitas.it;
   derosafrancescopaolo@gmail.com; tpanos02@gmail.com;
   Matteo.stravalaci@humanitasresearch.it;
   marianna.paulis@humanitasresearch.it;
   antonio.inforzato@humanitasresearch.it; mario.romano@hunimed.eu
RI Paulis, Marianna/R-8113-2018; Inforzato, Antonio/ABG-4513-2020;
   Stravalaci, Matteo/AAB-8963-2019
OI Paulis, Marianna/0000-0001-7803-9982; Inforzato,
   Antonio/0000-0001-8110-0027; Stravalaci, Matteo/0000-0002-5636-4204;
   Zollet, Piero/0000-0002-5892-7533; De Rosa, Francesco
   Paolo/0000-0002-1631-1634
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults with Retinitis Pigmentosa
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Smet MD, 2018, INVEST OPHTH VIS SCI, V59, P311, DOI 10.1167/iovs.17-22233
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Jia JL, 2012, CELL, V151, P576, DOI 10.1016/j.cell.2012.09.023
   Kramer J, 2019, ADV EXP MED BIOL, V1186, P99, DOI 10.1007/978-3-030-28471-8_4
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li SY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13100
   Limnios IJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02316-7
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Michelet F, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1568-3
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   O'Neill HC, 2020, CURR STEM CELL RES T, V15, P89, DOI 10.2174/1574888X15666191218094020
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Reyes AP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15326-5
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma A, 2021, BIOL-TARGETS THER, V15, P299, DOI 10.2147/BTT.S290331
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shenfield F, 2005, LANCET, V365, P2071, DOI 10.1016/S0140-6736(05)66555-5
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2016, EUR J PHARMACOL, V787, P84, DOI 10.1016/j.ejphar.2016.03.066
   Sugino IK, 2014, DEV OPHTHALMOL, V53, P133, DOI 10.1159/000358531
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sung Y, 2021, BRIT J OPHTHALMOL, V105, P829, DOI 10.1136/bjophthalmol-2020-316225
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P139, DOI 10.1007/978-3-319-95046-4_27
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
NR 52
TC 2
Z9 2
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 2
AR 682
DI 10.3390/ijms23020682
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YN0KM
UT WOS:000746956600001
PM 35054869
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, XR
   Li, SH
   Tang, Y
   Guo, YZ
   Gao, S
AF Zhang, Xinru
   Li, Shuhan
   Tang, Yue
   Guo, Yuzun
   Gao, Shuai
TI Intractable Ocular Diseases and Treatment Progress
SO AAPS PHARMSCITECH
LA English
DT Review
DE ocular barriers; intractable ocular diseases; drug delivery systems;
   siRNA
ID DRUG-DELIVERY; DRY EYE; IN-VIVO; MACULAR DEGENERATION; CONTACT-LENSES;
   PATHOPHYSIOLOGY; BARRIER; CLASSIFICATION; TRANSPORTERS; NANOEMULSION
AB In recent years, with the aging of the population and the frequent use of electronic devices, many eye diseases have shown a linear upward trend, such as dry eye disease, glaucoma, cataract, age-related macular degeneration, and diabetic retinopathy. These diseases are often chronic and difficult to cure. Based on the structure and barrier of the human eye, this review describes the pathogenesis and treatments of several intractable eye diseases and summarizes the advanced ocular drug delivery systems to provide new treatment ideas for these diseases. Finally, we also look forward to the prospect of RNAi therapy in the treatment of eye diseases.
C1 [Zhang, Xinru; Li, Shuhan; Tang, Yue] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China.
   [Zhang, Xinru; Li, Shuhan; Tang, Yue; Guo, Yuzun; Gao, Shuai] China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China.
C3 Guizhou Medical University; China Pharmaceutical University
RP Tang, Y (通讯作者)，Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China.; Tang, Y (通讯作者)，China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China.
EM tangyue@cpu.edu.cn
RI zhang, xinru/GZK-8155-2022
FU Open Project of State Key Laboratory of Functions and Applications of
   Medicinal Plants of Guizhou Medicinal University [FAMP201805K]; Guizhou
   Science and Technology Platform Talents [[2017]5101]
FX This work was funded by the Open Project of State Key Laboratory of
   Functions and Applications of Medicinal Plants of Guizhou Medicinal
   University (FAMP201805K) and Guizhou Science and Technology Platform
   Talents ([2017]5101).
CR Agrahari V, 2017, EXPERT OPIN DRUG DEL, V14, P1145, DOI 10.1080/17425247.2017.1272569
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], 2018, INT J MOL SCI
   Asbell PA, 2005, LANCET, V365, P599
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Barbosa FL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050978
   Boote C, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100773
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bron AJ, 2017, OCUL SURF, V15, P438, DOI 10.1016/j.jtos.2017.05.011
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Cabrera FJ, 2019, DRUG DISCOV TODAY, V24, P1679, DOI 10.1016/j.drudis.2019.05.035
   Casson RJ, 2012, CLIN EXP OPHTHALMOL, V40, P341, DOI 10.1111/j.1442-9071.2012.02773.x
   Chen J, 2018, AAPS PHARMSCITECH, V19, P3670, DOI 10.1208/s12249-018-1183-0
   Clayton JA, 2018, NEW ENGL J MED, V378, P2212, DOI 10.1056/NEJMra1407936
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   da Silva GR, 2010, BRAZ J PHARM SCI, V46, P585, DOI 10.1590/S1984-82502010000300024
   Fernandez-Martinez L, 2011, EUR J HUM GENET, V19, P445, DOI 10.1038/ejhg.2010.217
   Garhwal R, 2012, INVEST OPHTH VIS SCI, V53, P1341, DOI 10.1167/iovs.11-8215
   Gaudana R, 2009, RECENT PERSPECTIVES, V26
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gote V, 2019, J PHARMACOL EXP THER, V370, P602, DOI 10.1124/jpet.119.256933
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Habot-Wilner Z, 2019, ACTA OPHTHALMOL, V97, P460, DOI 10.1111/aos.14042
   Hagigit T, 2012, J CONTROL RELEASE, V160, P225, DOI 10.1016/j.jconrel.2011.11.022
   Hirai K, 2012, CLIN OPHTHALMOL, V6, P133, DOI 10.2147/OPTH.S28886
   Huang H, 2018, ADV DRUG DELIVER REV, V126, P96, DOI 10.1016/j.addr.2017.09.008
   Huang XN, 2019, DRUG DISCOV TODAY, V24, P1510, DOI 10.1016/j.drudis.2019.05.005
   Imperiale JC, 2018, J CONTROL RELEASE, V285, P106, DOI 10.1016/j.jconrel.2018.06.031
   Jumelle C, 2020, J CONTROL RELEASE, V321, P1, DOI 10.1016/j.jconrel.2020.01.057
   Juuti-Uusitalo K., 2012, PLOS ONE, V7, P1
   KANCLERZ P, 2020, SURV OPHTHALMOL
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kuo YK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081227
   Lajunen T, 2016, J CONTROL RELEASE, V244, P157, DOI 10.1016/j.jconrel.2016.08.024
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Loftsson T, 2017, INT J PHARMACEUT, V531, P413, DOI 10.1016/j.ijpharm.2017.04.010
   Luschmann C, 2013, INT J PHARMACEUT, V455, P331, DOI 10.1016/j.ijpharm.2013.07.002
   Lusthaus J, 2019, MED J AUSTRALIA, V210, P180, DOI 10.5694/mja2.50020
   Madni A, 2017, INT J PHARMACEUT, V530, P326, DOI 10.1016/j.ijpharm.2017.07.065
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Maulvi FA, 2017, INT J PHARMACEUT, V524, P193, DOI 10.1016/j.ijpharm.2017.03.083
   Maulvi FA, 2016, J CONTROL RELEASE, V226, P47, DOI 10.1016/j.jconrel.2016.02.012
   Messmer EM, 2015, DTSCH ARZTEBL INT, V112, P71, DOI 10.3238/arztebl.2015.0071
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nie Y., 2009, BIOSCI HYPOTHESES, V2, P223, DOI [DOI 10.1016/J.BIHY.2009.04.003, 10.1016/j.bihy.2009.04.003]
   Noda K, 2013, INFLAMM REGEN, V33, P230
   Novack GD, 2017, OCUL SURF, V15, P629, DOI 10.1016/j.jtos.2017.05.009
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Neil EC, 2019, CURR OPIN OPHTHALMOL, V30, P166, DOI 10.1097/ICU.0000000000000569
   Occhiutto Marcelo L, 2012, Pharmaceutics, V4, P252, DOI 10.3390/pharmaceutics4020252
   Ozcan G, 2015, ADV DRUG DELIVER REV, V87, P108, DOI 10.1016/j.addr.2015.01.007
   Paradiso P, 2017, J BIOMED MATER RES B, V105, P1799, DOI 10.1002/jbm.b.33715
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Platania CBM, 2019, BIOCHEM PHARMACOL, V168, P249, DOI 10.1016/j.bcp.2019.07.010
   Qiu WQ, 2013, RHEUMATOL INT, V33, P2543, DOI 10.1007/s00296-013-2769-1
   Rafiei F, 2020, INT OPHTHALMOL, V40, P2385, DOI 10.1007/s10792-020-01391-8
   Rhee MK, 2017, OPHTHALMOLOGY, V124, pS14, DOI 10.1016/j.ophtha.2017.08.029
   Rodriguez ML, 2019, OXID MED CELL LONGEV, V2019, P1
   Saw PE, 2020, SCI CHINA LIFE SCI, V63, P485, DOI 10.1007/s11427-018-9438-y
   Schaal S, 2007, EXP EYE RES, V84, P561, DOI 10.1016/j.exer.2006.11.010
   Singh Y, 2017, J CONTROL RELEASE, V252, P28, DOI 10.1016/j.jconrel.2017.03.008
   Souto EB, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11090460
   Srinivasarao DA, 2018, WIRES NANOMED NANOBI, P1
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Tamm E., 2010, ENCY EYE, P179, DOI [10.1016/B978-0-12-374203-2.00085-3, DOI 10.1016/B978-0-12-374203-2.00085-3]
   Tatke A, 2018, AAPS PHARMSCITECH, V19, P1662, DOI 10.1208/s12249-018-0979-2
   Thrimawithana TR, 2018, ADV DRUG DELIVER REV, V126, P185, DOI 10.1016/j.addr.2018.03.009
   Thulasi P, 2017, OPHTHALMOLOGY, V124, pS27, DOI 10.1016/j.ophtha.2017.07.022
   Tomi M, 2010, EXPERT OPIN DRUG MET, V6, P1111, DOI 10.1517/17425255.2010.486401
   Trichonas G, 2014, CURR ISSUES AGE RELA, P7
   van Oterendorp C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038820
   Velagaleti PR, 2013, METHODS PHARM TOXICO, P33
   Veritti D, 2020, EXPERT OPIN PHARMACO, V21, P773, DOI 10.1080/14656566.2020.1736557
   Wang S, 2019, OXIDATIVE MED CELL L, V2019
   WATSKY MA, 1988, CURR EYE RES, V7, P483, DOI 10.3109/02713688809031801
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wen H, 2013, J PHARM SCI-US, V102, P892, DOI 10.1002/jps.23387
   Whitehead M, 2018, EXPERT OPIN BIOL TH, V18, P1257, DOI 10.1080/14712598.2018.1545836
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Wu L, 2013, WORLD J DIABETES, V4, P290, DOI 10.4239/wjd.v4.i6.290
   Xiao S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-019-1541-1
   Yang J, 2017, NANOMED-NANOTECHNOL, V13, P1147, DOI 10.1016/j.nano.2016.12.021
   Yellepeddi VK, 2015, DRUG DISCOV TODAY, V20, P884, DOI 10.1016/j.drudis.2015.01.013
   Zhang J, 2016, DRUG DEV IND PHARM, V42, P546, DOI 10.3109/03639045.2015.1088867
   Zhang Li, 2011, Zhonghua Yan Ke Za Zhi, V47, P105
NR 92
TC 2
Z9 2
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD AUG 14
PY 2020
VL 21
IS 6
AR 236
DI 10.1208/s12249-020-01774-1
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NF7XL
UT WOS:000563507500002
PM 32803351
DA 2022-11-30
ER

PT J
AU Nagpal, M
   Khandelwal, J
   Juneja, R
   Mehrotra, N
AF Nagpal, Manish
   Khandelwal, Jayesh
   Juneja, Rakesh
   Mehrotra, Navneet
TI Correlation of optical coherence tomography angiography and
   microperimetry (MP3) features in wet age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; anti-VEGF; microperimetry; neovascular
   network; optical coherence tomography angiography; retinal sensitivity
ID RETINAL SENSITIVITY
AB Purpose: To evaluate and correlate the functional treatment response using microperimetry (MP3) with the morphological findings on optical coherence tomography angiography (OCTA) in wet AMD pre-and post-treatment with anti-vascular endothelial growth factor (VEGF). This was a single-centre prospective, interventional study. Methods: Patients with wet AMD were treated with 3 injections of intravitreal anti-VEGF at monthly intervals for 3 months and followed at 1, 2, 3, and 6 months postinjection. Using " overlay" features, morphologic characteristics of OCTA at the site of choroidal neovascular membrane (CNVM) lesion were analyzed and correlated functionally with MP3. Data were collected including visual acuity at presentation and follow-up with multimodal imaging features, treatment details, complications (if any), and treatment given for that complication. Descriptive observational analysis and paired t-test was used to compare the appearance of the neovascular network on OCTA imaging with retinal sensitivity on MP3. Results: OCTA in the pretreatment phase revealed CNVM as an abnormal vascular network arising from the choroid and invading the subretinal space. On MP3, decreased retinal sensitivity was observed corresponding to the area of CNVM. Post-treatment, OCTA revealed reduction in abnormal vascular network in 51 (91.07%) eyes that correlated with increased retinal sensitivity at the corresponding area on MP3. Statistical analysis showed baseline mean retinal sensitivity at the site of CNVM as 320.07 dB, which improved to 521.53 and 730.20 dB at 1 and 3 months postinjection follow-up, respectively. Conclusion: Combining the findings of OCTA and MP3 using " overlay" features gives us precise information of structure-function correlation at presentation and also in response to treatment. It also helps to improve patient's compliance, confidence to treatment, and their understanding of the disease process as well.
C1 [Nagpal, Manish; Khandelwal, Jayesh; Juneja, Rakesh; Mehrotra, Navneet] Retina Fdn, Dept Retina & Vitreous, Near Shahibag Underbridge, Ahmadabad, Gujarat, India.
RP Nagpal, M (通讯作者)，Retina Fdn, Dept Retina & Vitreous, Near Shahibag Underbridge, Ahmadabad, Gujarat, India.
EM drmanishnagpal@yahoo.com
RI MEHROTRA, NAVNEET/AAJ-6709-2020
CR Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Balasubramanian S, 2018, BRIT J OPHTHALMOL, V102, P109, DOI 10.1136/bjophthalmol-2017-310258
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Juneja R, 2018, AIOS 2018, V1, pFP472
   Juneja R, 2017, APVRS 2017, pEX1
   Mehrotra N, 2017, VRSI 2017, pPP73
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Querques G, 2008, J FR OPHTALMOL, V31, P515, DOI 10.1016/S0181-5512(08)72469-0
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
NR 13
TC 4
Z9 4
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2018
VL 66
IS 12
BP 1790
EP 1795
DI 10.4103/ijo.IJO_866_18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB0BS
UT WOS:000450676000021
PM 30451180
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Takahashi, VKL
   Takiuti, JT
   Jauregui, R
   Tsang, SH
AF Takahashi, Vitor K. L.
   Takiuti, Julia T.
   Jauregui, Ruben
   Tsang, Stephen H.
TI Gene therapy in inherited retinal degenerative diseases, a review
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Adeno-associated virus; gene therapy; inherited retinal diseases
ID LEBER CONGENITAL AMAUROSIS; BETA-SUBUNIT; RETINITIS-PIGMENTOSA;
   USHER-SYNDROME; ROD PHOSPHODIESTERASE; NONSENSE MUTATION; PRECLINICAL
   MODEL; RPE65 MUTATIONS; VISUAL FUNCTION; ANIMAL-MODELS
AB Hereditary diseases of the retina represent a group of diseases with several heterogeneous mutations that have the common end result of progressive photoreceptor death leading to blindness. Retinal degenerations encompass multifactorial diseases such as age-related macular degeneration, Leber congenital amaurosis, Stargardt disease, and retinitis pigmentosa. Although there is currently no cure for degenerative retinal diseases, ophthalmology has been at the forefront of the development of gene therapy, which offers hope for the treatment of these conditions. This article will explore an overview of the clinical trials of gene supplementation therapy for retinal diseases that are underway or planned for the near future.
C1 [Takahashi, Vitor K. L.; Takiuti, Julia T.; Jauregui, Ruben; Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Takahashi, Vitor K. L.; Takiuti, Julia T.; Jauregui, Ruben; Tsang, Stephen H.] Columbia Univ, Inst Human Nutr, Jonas Childrens Vis Care & Bernard, Dept Ophthalmol,Columbia Stem Cell Initiat, New York, NY USA.
   [Takahashi, Vitor K. L.; Takiuti, Julia T.; Jauregui, Ruben; Tsang, Stephen H.] Columbia Univ, Inst Human Nutr, Jonas Childrens Vis Care & Bernard, Dept Pathol & Cell Biol,Columbia Stem Cell Initia, New York, NY USA.
   [Takahashi, Vitor K. L.; Takiuti, Julia T.; Jauregui, Ruben; Tsang, Stephen H.] Columbia Univ, Bernard & Shirlee Brown Glaucoma Lab, New York, NY USA.
   [Takahashi, Vitor K. L.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Takiuti, Julia T.] Univ Sao Paulo, Med Sch, Div Ophthalmol, Sao Paulo, Brazil.
   [Jauregui, Ruben] Weill Cornell Med Coll, New York, NY USA.
   [Tsang, Stephen H.] Columbia Univ, Coll Phys & Surg, Inst Human Nutr, Dept Pathol & Cell Biol Stem Cell Initiat CSCI, New York, NY USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Universidade Federal de Sao Paulo (UNIFESP); Universidade de
   Sao Paulo; Cornell University; Columbia University
RP Tsang, SH (通讯作者)，Columbia Univ, Med Ctr, 635 West 165th St,Box 212, New York, NY 10032 USA.
EM sht2@cumc.columbia.edu
RI Cote, Rick H/G-3363-2013
OI Cote, Rick H/0000-0002-1573-6526; Jauregui, Ruben/0000-0002-2367-7298
FU National Institute of Health [5P30EY019007, R01EY018213, R01EY024698,
   R01EY026682, R21AG050437]; National Cancer Institute Core
   [5P30CA013696]; Research to Prevent Blindness (RPB) Physician-Scientist
   Award; RPB, New York, NY, USA; Tistou and Charlotte Kerstan Foundation;
   Schneeweiss Stem Cell Fund, New York State [C029572]; Foundation
   Fighting Blindness New York Regional Research Center Grant
   [C-NY05-0705-0312]; Crowley Family Fund; Gebroe Family Foundation
FX The Jonas Children's Vision Care is supported by the National Institute
   of Health [5P30EY019007, R01EY018213, R01EY024698, R01EY026682,
   R21AG050437], National Cancer Institute Core [5P30CA013696], the
   Research to Prevent Blindness (RPB) Physician-Scientist Award,
   unrestricted funds from RPB, New York, NY, USA. S.H.T. is a member of
   the RD-CURE Consortium and is supported by the Tistou and Charlotte
   Kerstan Foundation, the Schneeweiss Stem Cell Fund, New York State
   [C029572], the Foundation Fighting Blindness New York Regional Research
   Center Grant [C-NY05-0705-0312], the Crowley Family Fund, and the Gebroe
   Family Foundation.
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Arland V, 2003, VISION RES, V43, P919, DOI 10.1016/S0042-6989(02)00389-9
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   BIRD AC, 1975, BRIT J OPHTHALMOL, V59, P177, DOI 10.1136/bjo.59.4.177
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   Byrne LC, 2014, GENE THER, V21, P585, DOI 10.1038/gt.2014.31
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Chung DC, 2009, J AAPOS, V13, P587, DOI 10.1016/j.jaapos.2009.10.004
   Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   Davis RJ, 2008, INVEST OPHTH VIS SCI, V49, P5067, DOI 10.1167/iovs.07-1422
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Deng WT, 2015, HUM GENE THER, V26, P593, DOI 10.1089/hum.2015.035
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Fauser S, 2002, SURV OPHTHALMOL, V47, P357, DOI 10.1016/S0039-6257(02)00314-4
   Fishman GA, 2010, OPHTHALMIC GENET, V31, P183, DOI 10.3109/13816810.2010.499887
   FLOTTE TR, 1995, GENE THER, V2, P357
   Fulton AB, 1996, ARCH OPHTHALMOL-CHIC, V114, P698, DOI 10.1001/archopht.1996.01100130690009
   Gakovic M, 2011, HUM MOL GENET, V20, P4840, DOI 10.1093/hmg/ddr423
   George NDL, 1996, ARCH OPHTHALMOL-CHIC, V114, P274, DOI 10.1001/archopht.1996.01100130270007
   Gorbatyuk M, 2007, VISION RES, V47, P1202, DOI 10.1016/j.visres.2006.11.026
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Han ZC, 2011, INVEST OPHTH VIS SCI, V52, P3051, DOI 10.1167/iovs.10-6916
   Hart AW, 2005, INVEST OPHTH VIS SCI, V46, P3443, DOI 10.1167/iovs.05-0254
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hashimoto T, 2007, GENE THER, V14, P584, DOI 10.1038/sj.gt.3302897
   Heon E, 2016, INVEST OPHTH VIS SCI, V57, pOCT377, DOI 10.1167/iovs.15-18421
   Huttl S, 2005, J NEUROSCI, V25, P130, DOI 10.1523/JNEUROSCI.3764-04.2005
   Ionita MA, 2007, EXP EYE RES, V84, P1, DOI 10.1016/j.exer.2005.12.012
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102
   Jauregui R, 2018, ASIA-PAC J OPHTHALMO, V7, P183, DOI 10.22608/APO.201851
   Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002
   KEELER C, 1966, J HERED, V57, P47, DOI 10.1093/oxfordjournals.jhered.a107462
   Koch S, 2012, HUM MOL GENET, V21, P4486, DOI 10.1093/hmg/dds290
   Kohl S, 2013, EUR J HUM GENET, V21, DOI 10.1038/ejhg.2013.44
   Kohl S, 2012, AM J HUM GENET, V91, P527, DOI 10.1016/j.ajhg.2012.07.006
   Komaromy AM, 2010, HUM MOL GENET, V19, P2581, DOI 10.1093/hmg/ddq136
   Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3
   Lin Michael K, 2015, Retin Physician, V12, P52
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Mao HY, 2011, HUM GENE THER, V22, P567, DOI 10.1089/hum.2010.140
   Mathur P, 2015, BBA-MOL BASIS DIS, V1852, P406, DOI 10.1016/j.bbadis.2014.11.020
   MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Mowat FM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00342
   Mueller C, 2008, GENE THER, V15, P858, DOI 10.1038/gt.2008.68
   Ou JX, 2015, J CLIN INVEST, V125, P2891, DOI 10.1172/JCI81380
   Pang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035250
   Parker MA, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.5.10
   Petersen-Jones SM, 2018, J CLIN INVEST, V128, P190, DOI 10.1172/JCI95161
   Petersen-Jones SM, 1999, INVEST OPHTH VIS SCI, V40, P1637
   Petit L, 2012, MOL THER, V20, P2019, DOI 10.1038/mt.2012.134
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Saito Y, 2008, CLIN OPHTHALMOL, V2, P821
   Sakamoto K, 2009, HUM MOL GENET, V18, P178, DOI 10.1093/hmg/ddn327
   SANKILA EM, 1992, NAT GENET, V1, P109, DOI 10.1038/ng0592-109
   SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9
   Seitz IP, 2017, INVEST OPHTH VIS SCI, V58, P5784, DOI 10.1167/iovs.17-22473
   Sikkink SK, 2007, J MED GENET, V44, P225, DOI 10.1136/jmg.2006.047340
   Sonoda KH, 2005, IMMUNOLOGY, V116, P390, DOI 10.1111/j.1365-2567.2005.02239.x
   Stieger K, 2009, ILAR J, V50, P206, DOI 10.1093/ilar.50.2.206
   SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968
   Testa F, 2017, RETINA-J RET VIT DIS, V37, P1581, DOI 10.1097/IAE.0000000000001389
   Thiadens AAHJ, 2009, OPHTHALMOLOGY, V116, P1984, DOI 10.1016/j.ophtha.2009.03.053
   Tolmachova T, 2013, J MOL MED, V91, P825, DOI 10.1007/s00109-013-1006-4
   Tsang SH, 2007, ARCH OPHTHALMOL-CHIC, V125, P259, DOI 10.1001/archopht.125.2.259
   VANDENHURK JAJM, 1992, AM J HUM GENET, V50, P1195
   Vasireddy V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129982
   Wang H, 2009, AM J HUM GENET, V84, P380, DOI 10.1016/j.ajhg.2009.02.005
   Wert KJ, 2014, HUM MOL GENET, V23, P514, DOI 10.1093/hmg/ddt452
   Wert KJ, 2013, HUM MOL GENET, V22, P558, DOI 10.1093/hmg/dds466
   Winkler PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072229
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Zeng Y, 2016, INVEST OPHTH VIS SCI, V57, pOCT277, DOI 10.1167/iovs.15-18920
   Zhang QJ, 2016, ASIA-PAC J OPHTHALMO, V5, P265, DOI 10.1097/APO.0000000000000227
   Zou JH, 2011, INVEST OPHTH VIS SCI, V52, P2343, DOI 10.1167/iovs.10-6141
NR 87
TC 39
Z9 44
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 5
BP 560
EP 568
DI 10.1080/13816810.2018.1495745
PG 9
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA HC8KO
UT WOS:000452051900002
PM 30040511
DA 2022-11-30
ER

PT J
AU Yao, AN
   van Wijngaarden, P
AF Yao, Anthony
   van Wijngaarden, Peter
TI Metabolic pathways in context:mTORsignalling in the retina and optic
   nerve - A review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE metabolism; mTOR; optic nerve; retina
ID MACULAR DEGENERATION; PIGMENT EPITHELIUM; SUBCONJUNCTIVAL SIROLIMUS;
   INTRAVITREAL SIROLIMUS; GEOGRAPHIC ATROPHY; AXON REGENERATION; SIRNA
   PF-04523655; MAMMALIAN TARGET; GENE-EXPRESSION; RAPAMYCIN MTOR
AB The mechanistic target of rapamycin (mTOR) signalling network plays a key role in growth and development, autophagy, metabolism, inflammation as well as ageing, and it is therefore important in ocular health and disease. mTOR dysregulation has been identified in a range of conditions, including age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, traumatic optic neuropathy and glaucoma. Experimental modulation of the pathway has contributed to the understanding of these diseases and offers the potential for new avenues of therapy. This review discusses the mTOR pathway and its role in health and in diseases of the retina and optic nerve.
C1 [Yao, Anthony; van Wijngaarden, Peter] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic, Australia.
   [van Wijngaarden, Peter] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP van Wijngaarden, P (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic, Australia.
EM peterv@unimelb.edu.au
OI Yao, Anthony/0000-0003-3838-8795; van Wijngaarden,
   Peter/0000-0002-8800-7834
CR Agarwal A, 2016, DEV OPHTHALMOL, V55, P276, DOI 10.1159/000438951
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Avet-Rochex A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004624
   Bauer TM, 2015, PHARMACOL THERAPEUT, V146, P53, DOI 10.1016/j.pharmthera.2014.09.006
   Berry M, 2016, NEUROBIOL DIS, V85, P99, DOI 10.1016/j.nbd.2015.10.002
   Bonet-Ponce L, 2015, BBA-MOL BASIS DIS, V1852, P1400, DOI 10.1016/j.bbadis.2015.03.006
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Bracha P, 2017, INVEST OPHTH VIS SCI, V58
   Cabahug VLO, 2019, CLIN OPHTHALMOL, V13, P649, DOI 10.2147/OPTH.S198401
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Choi JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04774-9
   Chung SH, 2013, INVEST OPHTH VIS SCI, V54, P6578, DOI 10.1167/iovs.13-12311
   Coughlin BA, 2017, VISION RES, V139, P93, DOI 10.1016/j.visres.2017.03.013
   Crino PB, 2016, NAT REV NEUROL, V12, P379, DOI 10.1038/nrneurol.2016.81
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   Duan X, 2015, NEURON, V85, P1244, DOI 10.1016/j.neuron.2015.02.017
   Dugel PU, 2012, OPHTHALMOLOGY, V119, P124, DOI 10.1016/j.ophtha.2011.07.034
   El Hiani Y, 2019, BIOCHEM CELL BIOL, V97, P58, DOI 10.1139/bcb-2018-0004
   Elmenier FM, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111718
   Fernandes R., 2016, MOL MED MTOR, P379
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   He JN, 2019, MOL NEUROBIOL, V56, P6586, DOI 10.1007/s12035-019-1559-5
   Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1
   Johnson SC, 2015, INTERD T GERONT GERI, V40, P107, DOI 10.1159/000364974
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1
   Kim J, 2016, AMINO ACIDS, V48, P915, DOI 10.1007/s00726-016-2171-x
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Koch JC, 2016, EXP EYE RES, V144, P81, DOI 10.1016/j.exer.2015.08.016
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Krishnadev N, 2011, GRAEF ARCH CLIN EXP, V249, P1627, DOI 10.1007/s00417-011-1694-9
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lascaratos G, 2017, MITOCHONDRION, V36, P96, DOI 10.1016/j.mito.2017.05.003
   Leibinger M, 2012, NEUROBIOL DIS, V46, P314, DOI 10.1016/j.nbd.2012.01.004
   Levkovitch-Verbin H, 2004, EYE, V18, P1066, DOI 10.1038/sj.eye.6701576
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Lin B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1198-1
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   de Faria JML, 2016, INVEST OPHTH VIS SCI, V57, P4356, DOI 10.1167/iovs.16-19197
   Ma J, 2016, INVEST OPHTH VIS SCI, V57, P3138, DOI 10.1167/iovs.15-18795
   Ma S, 2015, EXP EYE RES, V135, P1, DOI 10.1016/j.exer.2015.04.006
   Maiese K, 2016, BRIT J CLIN PHARMACO, V82, P1245, DOI 10.1111/bcp.12804
   Malagelada C, 2011, J NEUROSCI, V31, P3186, DOI 10.1523/JNEUROSCI.4011-10.2011
   Maturi R, 2017, 35 ANN M AM SOC RET
   McDougald DS, 2019, MOL THER, V27, P1313, DOI 10.1016/j.ymthe.2019.04.009
   Morgan-Warren PJ, 2016, INVEST OPHTH VIS SCI, V57, P429, DOI 10.1167/iovs.15-17511
   Morquette B, 2015, CELL DEATH DIFFER, V22, P612, DOI 10.1038/cdd.2014.149
   Myers DR, 2019, IMMUNOL REV, V291, P134, DOI 10.1111/imr.12796
   Nakahara T, 2017, BIOL PHARM BULL, V40, P2045, DOI 10.1248/bpb.b17-00475
   Ng SK, 2015, CLIN EXP OPHTHALMOL, V43, P367, DOI 10.1111/ceo.12462
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Park HYL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30165-7
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Patil RA, 2017, RIVER SEDIMENTATION, P259
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Porter K, 2015, BBA-MOL BASIS DIS, V1852, P379, DOI 10.1016/j.bbadis.2014.11.021
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Nguyen QD, 2018, OPHTHALMOLOGY, V125, P1984, DOI 10.1016/j.ophtha.2018.06.015
   Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rittenhouse KD, 2014, INVEST OPHTH VIS SCI, V55, P1232, DOI 10.1167/iovs.13-13449
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Sabatini DM, 2017, P NATL ACAD SCI USA, V114, P11818, DOI 10.1073/pnas.1716173114
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719
   Sun F, 2011, NATURE, V480, P372, DOI 10.1038/nature10594
   Teotia P, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.178012
   Thierry M, 2015, EXP EYE RES, V135, P37, DOI 10.1016/j.exer.2015.04.012
   Trinh XB, 2009, BRIT J CANCER, V100, P971, DOI 10.1038/sj.bjc.6604921
   Venkatesh A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.182
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Watve MG, 2001, ARCH MICROBIOL, V176, P386, DOI 10.1007/s002030100345
   Wei J, 2016, CELL PHYSIOL BIOCHEM, V40, P1570, DOI 10.1159/000453207
   Whitehead M, 2018, EXPERT OPIN BIOL TH, V18, P1257, DOI 10.1080/14712598.2018.1545836
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yagasaki R, 2014, EXP EYE RES, V129, P127, DOI 10.1016/j.exer.2014.11.005
   Yang JY, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0380-0
   Yoshida T, 2010, NAT MED, V16, P767, DOI 10.1038/nm.2157
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Zarbin MA, 2012, OXID STRESS APPL BAS, P1, DOI 10.1007/978-1-61779-606-7_1
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang LJ, 2016, HUM MOL GENET, V25, P4244, DOI 10.1093/hmg/ddw256
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou JZ, 2021, ARCH PHYSIOL BIOCHEM, V127, P44, DOI 10.1080/13813455.2019.1609996
NR 96
TC 12
Z9 12
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2020
VL 48
IS 8
SI SI
BP 1072
EP 1084
DI 10.1111/ceo.13819
EA AUG 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OU0GL
UT WOS:000559913100001
PM 32639081
OA Green Published
DA 2022-11-30
ER

PT J
AU Ludwig, CA
   Leng, T
AF Ludwig, Cassie A.
   Leng, Theodore
TI Retinotomy Closure Following Subretinal Stem Cell Transplant With a
   30-Gauge Needle
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PRESUMED OCULAR HISTOPLASMOSIS; MACULAR DEGENERATION; SUBMACULAR
   SURGERY; SURGICAL REMOVAL; NEOVASCULARIZATION; DRAINAGE; FLUID; HOLE
AB The authors report two cases of posterior retinotomy closure following subretinal stem cell transplantation for age-related macular degeneration with a 30-gauge needle - a larger bore needle than those used in prior studies. Partial retinotomy closure was seen on optical coherence tomography within 24 hours in one patient, whereas complete closure occurred by the 5-month and 1-year follow-up visits. A trace retinal hemorrhage occurred in one case, with resolution by 12 weeks. These findings demonstrate the likelihood of uncomplicated, spontaneous retinotomy closure following subretinal stem cell transplantation with a 30-gauge needle.
C1 [Ludwig, Cassie A.; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Ludwig, Cassie A/0000-0002-9586-3735; Leng, Theodore/0000-0002-8461-3562
FU TL1 component of the Stanford Clinical and Translational Science Award
   [NIH TL1 TR 001084]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [TL1TR001084] Funding Source: NIH RePORTER
FX Supported by Cassie A. Ludwig from the TL1 component of the Stanford
   Clinical and Translational Science Award to Spectrum (NIH TL1 TR
   001084).
CR AYLWARD GW, 1995, BRIT J OPHTHALMOL, V79, P724, DOI 10.1136/bjo.79.8.724
   Bennett J., 2013, RETINA, P652
   Cooper BA, 2000, AM J OPHTHALMOL, V130, P838, DOI 10.1016/S0002-9394(00)00638-3
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Ezra E, 2004, ARCH OPHTHALMOL-CHIC, V122, P224, DOI 10.1001/archopht.122.2.224
   GREVE MDJ, 1995, OPHTHALMIC SURG LAS, V26, P330
   Holekamp NM, 1997, OPHTHALMOLOGY, V104, P22, DOI 10.1016/S0161-6420(97)30367-4
   Holekamp NM, 1999, RETINA VITREOUS MACU, P131
   Kang SW, 2003, BRIT J OPHTHALMOL, V87, P1015, DOI 10.1136/bjo.87.8.1015
   MCDONALD HR, 1989, OPHTHALMOLOGY, V96, P358, DOI 10.1016/S0161-6420(89)32902-2
   RAYMOND GL, 1993, BRIT J OPHTHALMOL, V77, P428, DOI 10.1136/bjo.77.7.428
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   THOMAS MA, 1994, RETINA-J RET VIT DIS, V14, P84, DOI 10.1097/00006982-199401000-00019
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
NR 16
TC 2
Z9 2
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2016
VL 47
IS 9
BP 869
EP 873
DI 10.3928/23258160-20160901-12
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3HM
UT WOS:000393103200012
PM 27631485
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Zhou, B
AF Wykoff, Charles C.
   Zhou, Brenda
TI Innovation in Neovascular Age-Related Macular Degeneration:
   Consideration of Brolucizumab, Abicipar, and the Port Delivery System
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID 2.0 MG; RANIBIZUMAB; AFLIBERCEPT; EFFICACY; THERAPY; GROWTH; SAFETY
C1 [Wykoff, Charles C.; Zhou, Brenda] Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
RP Wykoff, CC (通讯作者)，Retina Consultants Houston, 6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com; brenda.zhou@houstonretina.com
OI Zhou, Brenda/0000-0002-9532-0570
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 2018, EST FUND VAR RES CON
   Awh CC, 2018, AM SOC RET SPEC 2018
   Bains U, 2018, SEMIN OPHTHALMOL, V33, P1, DOI 10.1080/08820538.2017.1353805
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2017, AM AC OPHTH 2017 ANN
   Dugel PU, 2018, AM AC OPHTH 2018 ANN
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Harrison L, 2018, MEDSCAPE
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Khurana R., 2018, AM AC OPHTH 2018 ANN
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liang H, 2018, ASS RES VIS OPHTH 20
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P794, DOI 10.1016/j.ophtha.2018.02.027
   Rosenfeld PJ, 2005, AM AC OPHTH 109 ANN
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   SINGERMAN LJ, 2015, INVEST OPHTH VIS SCI, V56
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yu Y, 2018, ASS RES VIS OPHTH 20
NR 35
TC 5
Z9 5
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD DEC
PY 2018
VL 49
IS 12
BP 913
EP 917
DI 10.3928/23258160-20181203-01
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HH7QQ
UT WOS:000455925900012
PM 30566697
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI First workshop on Cell Transplantation in Age-Related Macular
   Degeneration - 11-14 September, Cologne, Germany - Abstracts
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2004
VL 242
IS 1
BP 51
EP 64
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766PU
UT WOS:000188385400010
DA 2022-11-30
ER

PT J
AU Dausse, E
   Gomes, SD
   Toulme, JJ
AF Dausse, Eric
   Gomes, Sonia Da Rocha
   Toulme, Jean-Jacques
TI Aptamers: a new class of oligonucleotides in the drug discovery
   pipeline?
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; DNA-POLYMERASE; RNA MOLECULES;
   TUMOR-CELLS; SELECTION; DELIVERY; THERAPEUTICS; ANTISENSE; INHIBIT
AB Aptamers are oligonucleotides identified in a randomly synthesized library containing up to 1015 different molecules that fold into defined three-dimensional structures. Following their selection for predetermined properties at the end of an iterative process known as SELEX (Systematic Evolution of Ligands by Exponential enrichment) they can be chemically modified in order to provide them with additional properties. These molecules display both high affinity and specificity for their target. Aptamers constitute promising molecules for therapeutic applications as exemplified by pegaptanib, an aptamer-derived anti-VEGF compound shown to be effective in treating age-related macular degeneration.
C1 [Dausse, Eric; Toulme, Jean-Jacques] INSERM, U869, F-33076 Bordeaux, France.
   [Dausse, Eric; Toulme, Jean-Jacques] Univ Bordeaux, IECB, Bordeaux, France.
   [Gomes, Sonia Da Rocha] Novaptech, European Inst Chem & Biol, F-33607 Pessac, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux
RP Toulme, JJ (通讯作者)，INSERM, U869, F-33076 Bordeaux, France.
EM jean-jacques.toulme@inserm.fr
OI Toulme, Jean-jacques/0000-0002-8432-5034
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Bagalkot V, 2006, ANGEW CHEM INT EDIT, V45, P8149, DOI 10.1002/anie.200602251
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Berezovski M, 2006, J AM CHEM SOC, V128, P1410, DOI 10.1021/ja056943j
   Blank M, 2005, CURR OPIN CHEM BIOL, V9, P336, DOI 10.1016/j.cbpa.2005.06.011
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Charlton J, 1997, BIOCHEMISTRY-US, V36, P3018, DOI 10.1021/bi962669h
   Chekulaeva M, 2009, CURR OPIN CELL BIOL, V21, P452, DOI 10.1016/j.ceb.2009.04.009
   Chelliserrykattil J, 2004, NAT BIOTECHNOL, V22, P1155, DOI 10.1038/nbt1001
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Chu TC, 2006, CANCER RES, V66, P5989, DOI 10.1158/0008-5472.CAN-05-4583
   Cox JC, 1998, BIOTECHNOL PROGR, V14, P845, DOI 10.1021/bp980097h
   Di Primo C, 2007, FEBS LETT, V581, P771, DOI 10.1016/j.febslet.2007.01.047
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   Eckstein F, 2007, EXPERT OPIN BIOL TH, V7, P1021, DOI 10.1517/14712598.7.7.1021
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Geary RS, 2002, CLIN PHARMACOKINET, V41, P255, DOI 10.2165/00003088-200241040-00002
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   Gomes SD, 2004, BIOCHEM BIOPH RES CO, V322, P820, DOI 10.1016/j.bbrc.2004.07.185
   Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2
   Helmling S, 2004, P NATL ACAD SCI USA, V101, P13174, DOI 10.1073/pnas.0404175101
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   James W, 2007, J GEN VIROL, V88, P351, DOI 10.1099/vir.0.82442-0
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kaur G, 2008, EXPERT OPIN INV DRUG, V17, P43, DOI 10.1517/13543784.17.1.43
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kim Y, 2008, P NATL ACAD SCI USA, V105, P5664, DOI 10.1073/pnas.0711803105
   Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006
   Lupold SE, 2002, CANCER RES, V62, P4029
   Mayer G, 2009, ANGEW CHEM INT EDIT, V48, P2672, DOI 10.1002/anie.200804643
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Muller J, 2008, J THROMB HAEMOST, V6, P2105, DOI 10.1111/j.1538-7836.2008.03162.x
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963
   Shi H, 1999, P NATL ACAD SCI USA, V96, P10033, DOI 10.1073/pnas.96.18.10033
   Strobel SA, 2007, CURR OPIN CHEM BIOL, V11, P636, DOI 10.1016/j.cbpa.2007.09.010
   Tarhini Ahmad A, 2007, Future Oncol, V3, P263, DOI 10.2217/14796694.3.3.263
   Toulme JJ, 2004, FEBS LETT, V567, P55, DOI 10.1016/j.febslet.2004.03.111
   Toulme JJ, 2001, NAT BIOTECHNOL, V19, P17, DOI 10.1038/83451
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Umehara T, 2005, J BIOCHEM, V137, P339, DOI 10.1093/jb/mvi042
   Veedu RN, 2009, ORG BIOMOL CHEM, V7, P1404, DOI 10.1039/b819946a
   Vento MT, 2008, MOL CANCER THER, V7, P3381, DOI 10.1158/1535-7163.MCT-08-0580
   Werner A, 2009, RNA BIOL, V6, P43, DOI 10.4161/rna.6.1.7568
   Wilson C, 2006, CURR OPIN CHEM BIOL, V10, P607, DOI 10.1016/j.cbpa.2006.10.001
   Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399
   Yan AC, 2009, RNA BIOL, V6, P316, DOI 10.4161/rna.6.3.8808
NR 51
TC 53
Z9 58
U1 0
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD OCT
PY 2009
VL 9
IS 5
BP 602
EP 607
DI 10.1016/j.coph.2009.07.006
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 507YA
UT WOS:000270890700012
PM 19717337
DA 2022-11-30
ER

PT J
AU Bhisitkul, RB
AF Bhisitkul, R. B.
TI Vascular endothelial growth factor biology: clinical implications for
   ocular treatments
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COHERENCE TOMOGRAPHY FINDINGS; METASTATIC COLORECTAL-CANCER;
   RETINAL-PIGMENT EPITHELIUM; HEPARIN-BINDING DOMAIN; MACULAR
   DEGENERATION; INTRAVITREAL INJECTION; VEIN OCCLUSION; VEGF ISOFORMS;
   TUMOR-CELLS; CHOROIDAL NEOVASCULARIZATION
AB Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.
C1 Univ Calif San Francisco, Beckman Vis Ctr, Dept Ophthalmol, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco
RP Bhisitkul, RB (通讯作者)，Univ Calif San Francisco, Beckman Vis Ctr, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA.
EM BhisitkulR@vision.ucsf.edu
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akiyama H, 2005, MOL PHARMACOL, V68, P1543, DOI 10.1124/mol.105.015628
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bauer SM, 2005, J VASC SURG, V41, P699, DOI 10.1016/j.jvs.2005.01.015
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Demir R, 2006, PLACENTA, V27, P535, DOI 10.1016/j.placenta.2005.05.011
   Ding XM, 2005, CHINESE MED J-PEKING, V118, P1644
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gordon JD, 1996, J CLIN ENDOCR METAB, V81, P353, DOI 10.1210/jc.81.1.353
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAUGHNEY PC, 2005, 2005 ARVO ANN M FORT, P1
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin AC, 2004, INVEST OPHTH VIS SCI, V45, P3387, DOI 10.1167/iovs.04-0349
   McColm J, 2004, MOL VIS, V10, P512
   Meeson AP, 1999, DEVELOPMENT, V126, P1407
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Murata T, 1996, LAB INVEST, V74, P68
   Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Zhang HT, 2000, BRIT J CANCER, V83, P63
NR 73
TC 131
Z9 149
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2006
VL 90
IS 12
BP 1542
EP 1547
DI 10.1136/bjo.2006.098426
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 106WX
UT WOS:000242133800024
PM 17114590
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Masket, S
   Ceran, BB
AF Masket, Samuel
   Ceran, Basak Bostanci
TI Atypical case of ocular hemosiderosis: Leopard cataract
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
AB We present an interventional case report of an 83-year-old woman who developed ocular hemosiderosis secondary to massive retinal and intravitreal bleeding associated with a choroidal neovascular membrane as a result of age-related macular degeneration. Anterior segment manifestations included low-grade inflammation, posterior synechiae, reversible hyperchromic heterochromia, and a mature cataract with "leopard spots." The longstanding vitreous hemorrhage was thought to be the etiology of these findings. At the request of the vitreoretinal surgeon, cataract surgery was performed to provide visualization of the posterior segment. However, the patient's visual potential was limited by her underlying retinal pathology.
C1 [Masket, Samuel] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Masket, S (通讯作者)，Suite 911,2080 Century Pk E, Los Angeles, CA 90067 USA.
EM avcmasket@aol.com
RI Ceran, Basak Bostanci/Y-9324-2019
OI Bostanci, Basak/0000-0001-5483-2767
CR He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HOGAN MJ, 1962, OPHTHALMIC PATHOLOGY, P159
   Pollack A, 1998, ARCH OPHTHALMOL-CHIC, V116, P678
   Welch R B, 1975, Trans Am Ophthalmol Soc, V73, P187
   WELCH RB, 1975, T AM OPHTHAL SOC, V73, P199
   YANOFF M, 2009, OCULAR PATHOLOGY, V24, P148
NR 6
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD OCT
PY 2011
VL 37
IS 10
BP 1902
EP 1904
DI 10.1016/j.jcrs.2011.07.024
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 830MB
UT WOS:000295660000025
PM 21803538
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Cunefare, D
   Chiu, E
   Luu, CD
   Ayton, LN
   Toth, CA
   Farsiu, S
   Guymer, RH
AF Wu, Zhichao
   Cunefare, David
   Chiu, Elizabeth
   Luu, Chi D.
   Ayton, Lauren N.
   Toth, Cynthia A.
   Farsiu, Sina
   Guymer, Robyn H.
TI Longitudinal Associations Between Microstructural Changes and
   Microperimetry in the Early Stages of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; microperimetry; optical coherence
   tomography; longitudinal
ID OPTICAL COHERENCE TOMOGRAPHY; NASCENT GEOGRAPHIC ATROPHY;
   DRUSEN-ASSOCIATED ATROPHY; SD-OCT; FUNDUS AUTOFLUORESCENCE; AUTOMATIC
   SEGMENTATION; HYPERREFLECTIVE FOCI; INTERMEDIATE AMD; NATURAL-HISTORY;
   IMAGES
AB PURPOSE. To determine whether longitudinal changes in mesopic visual function on microperimetry occurred independent of its associations with microstructural parameters on spectral-domain optical coherence tomography (SD-OCT) in the early stages of AMD.
   METHODS. Forty-one AMD eyes underwent microperimetry testing and SD-OCT scans over a 12-month period at 6-month intervals. Microstructural parameters analyzed include the retinal pigment epithelium-drusen complex (RPEDC) layer thickness, number of hyperreflective foci (HF) and their inner retinal migration (represented by a weighted axial distribution score; AxD), and the number of atrophic areas.
   RESULTS. Microperimetric sensitivity was 0.29 dB (95% confidence interval [CI] = -0.38 to -0.20 dB, P < 0.001) and 0.13 dB (95% CI = -0.22 to -0.03 dB, P = 0.008) lower in each sector for every 10-mu m higher RPEDC layer thickness and 1-HF present, but was not associated with the AxD score or the number of atrophic areas present (P <= 0.464). However, each 10-mu m greater RPEDC layer thickness and 1-HF present was not independently associated with a further decline in sensitivity (-0.08 dB/year, 95% CI = -0.24 to 0.07 dB/year, P = 0.288 and 0.09 dB/year, 95% CI = -0.06 to 0.24 dB/year, P = 0.242, respectively) over time when accounting for the association between RPEDC layer thickness and number of HF with microperimetric sensitivity.
   CONCLUSIONS. Longitudinal changes in mesopic visual function measured on microperimetry paralleled changes in the microstructural changes over a 12-month time frame, without any changes occurring independent of the associations between structure and function alone.
C1 [Wu, Zhichao; Luu, Chi D.; Ayton, Lauren N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Cunefare, David; Chiu, Elizabeth; Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Duke University; Duke University
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Toth, Cynthia/L-5534-2019; Ayton, Lauren/AAV-2977-2021
OI Toth, Cynthia/0000-0002-2324-0854; Ayton, Lauren/0000-0001-9907-084X;
   Guymer, Robyn/0000-0002-9441-4356; Luu, Chi/0000-0002-7604-7097; Farsiu,
   Sina/0000-0003-4872-2902
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E
   de Amorim GFC, 2014, OSLI RETINA, V45, P1
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   FELDMAN HA, 1988, J APPL PHYSIOL, V64, P1721, DOI 10.1152/jappl.1988.64.4.1721
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gonzalez R. C., 2008, DIGITAL IMAGE PROCES
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7595, DOI 10.1167/iovs.13-11762
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Wu ZC, 2015, OPHTHALMOLOGY, V122, pE53, DOI 10.1016/j.ophtha.2015.03.011
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 38
TC 34
Z9 34
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 8
BP 3714
EP 3722
DI 10.1167/iovs.15-18294
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT8GW
UT WOS:000381729000020
PM 27415789
OA gold
DA 2022-11-30
ER

PT J
AU Coscas, F
   Puche, N
   Coscas, G
   Srour, M
   Francais, C
   Glacet-Bernard, A
   Querques, G
   Souied, EH
AF Coscas, Florence
   Puche, Nathalie
   Coscas, Gabriel
   Srour, Mayer
   Francais, Catherine
   Glacet-Bernard, Agnes
   Querques, Giuseppe
   Souied, Eric H.
TI Comparison of Macular Choroidal Thickness in Adult Onset Foveomacular
   Vitelliform Dystrophy and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE adult onset foveomacular vitelliform dystrophy; age-related macular
   degeneration (AMD); choroidal neovascularization (CNV); choroidal
   thickness; enhanced depth imaging (EDI); optical coherence tomography
   (OCT); pigment epithelial detachment (PED)
ID OPTICAL COHERENCE TOMOGRAPHY; AXIAL LENGTH; FEATURES; EYES
AB PURPOSE. To compare macular choroidal thickness (MCT) in eyes with adult onset foveomacular vitelliform dystrophy (AOFVD) and eyes with AMD.
   METHODS. Five groups of 38 eyes each were included in a prospective, observational, comparative study: AOFVD eyes with fluid accumulation; AOFVD fellow eyes without fluid (early stage); advanced exudative (wet) AMD; advanced dry AMD; and healthy normal eyes. All study eyes underwent a comprehensive ophthalmologic examination. Macular choroidal thickness was measured using enhanced depth imaging optical coherence tomography (EDI-OCT).
   RESULTS. Subfoveal choroidal thickness (SFCT) in AOFVD with subretinal fluid (325.66 +/- 85.98 mu m) was significantly (P < 0.001) thicker compared with that in exudative AMD (158.55 +/- 57.87 mu m) and in dry AMD (157.53 +/- 67.08 mu m). Also, in AOFVD, the choroid was significantly (P = 0.001) thicker than that in the normal group (255.87 +/- 87.46 mu m). However, in AOFVD, there was no significant difference (P = 0.69) between the SFCT in the study eye and in the fellow eye (317.66 +/- 90.04 mu m). The choroidal thickness at each of the other 12 measured points showed similar results.
   CONCLUSIONS. This study demonstrates choroidal thickening in AOFVD in contrast with the choroidal thinning observed in advanced AMD. These findings suggest that the pathogenic mechanisms in AOFVD are different from those in exudative AMD. Choroidal thickness measurement could help differentiate the challenging diagnosis between exudative AMD and the advanced stage of AOFVD (with fluid accumulation but without choroidal neovascularization).
C1 [Coscas, Florence; Puche, Nathalie; Coscas, Gabriel; Srour, Mayer; Glacet-Bernard, Agnes; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Coscas, Florence; Coscas, Gabriel; Francais, Catherine] Ctr Odeon, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Coscas, F (通讯作者)，Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM coscas@gmail.com
OI GLACET-BERNARD, AGNES/0000-0002-2251-9124; Querques,
   Giuseppe/0000-0002-3292-9581
CR Benhamou N, 2003, AM J OPHTHALMOL, V135, P362, DOI 10.1016/S0002-9394(02)01946-3
   Best F., 1905, Z AUGENHEILKD, V13, P199, DOI [DOI 10.1159/000290318, 10.1159/000290318]
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2012, EUR J OPHTHALMOL, V22, P992, DOI 10.5301/ejo.5000189
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GLACETBERNARD A, 1990, J FR OPHTALMOL, V13, P407
   Hata M, 2012, JPN J OPHTHALMOL, V56, P564, DOI 10.1007/s10384-012-0173-0
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P958
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Men G, 2004, AM J OPHTHALMOL, V137, P963, DOI 10.1016/j.ajo.2003.11.014
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   PATRINELY JR, 1985, OPHTHALMOLOGY, V92, P1712
   Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075
   Querques G, 2008, AM J OPHTHALMOL, V146, P501, DOI 10.1016/j.ajo.2008.05.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   Shin Joong Won, 2012, Korean J Ophthalmol, V26, P255, DOI 10.3341/kjo.2012.26.4.255
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong Ian Y, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS75, DOI 10.3928/15428877-20110627-07
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
NR 36
TC 34
Z9 44
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 64
EP 69
DI 10.1167/iovs.13-12931
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200007
PM 24282233
DA 2022-11-30
ER

PT J
AU Bhisitkul, RB
   Desai, SJ
   Boyer, DS
   Sadda, SR
   Zhang, K
AF Bhisitkul, Robert B.
   Desai, Shilpa J.
   Boyer, David S.
   Sadda, SriniVas R.
   Zhang, Kang
TI Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD
   Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study)
SO OPHTHALMOLOGY
LA English
DT Article
ID DEGENERATION TREATMENTS TRIALS; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; THERAPY; GROWTH; VERTEPORFIN;
   RISK; VEGF
AB Purpose: To compare study and fellow eyes in subjects with age-related macular degeneration (AMD) for 7-year outcomes arising from contrasting treatment histories and disease statuses.
   Design: Multicenter cohort study, predetermined secondary analysis.
   Participants: A total of 65 participants from the ranibizumab-treatment arms of the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR), Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab In the Treatment of Neovascular AMD (MARINA), and Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (HORIZON) trials, recruited for an update evaluation from 14 study sites.
   Methods: Seven-year visual outcomes and retinal imaging data were compared with the ANCHOR, MARINA, and HORIZON databases. Under the ANCHOR and MARINA protocols, study eyes had received monthly ranibizumab injections for the initial 2 years, during which fellow eyes were prohibited from antievascular endothelial growth factor (VEGF) treatments.
   Main Outcome Measures: Percentage of subjects with study eye vision better than fellow eye, vision change from baseline to year 7, and mean area of macular atrophy (MA) were predetermined secondary end points.
   Results: Fellow eyes with exudative AMD had received a mean 7.3 total injections of anti-VEGF agents in the mean 3.4 years off-study. For the 35% of subjects with exudative AMD in both eyes at baseline, within-patient comparisons at year 7 showed better vision in the study eye in 82%, with better mean final vision in study eyes (54.7 vs. 27.3 letters in fellow eyes, P < 0.001). Also in this subgroup, study eyes, which had received 2 years of high-frequency ranibizumab, had less severe MA than the respective fellow eye at year 7 in 88% of patients (mean area +/- standard deviation 2.8 +/- 2.2 mm(2) vs. 5.8 +/- 2.5 mm(2) in the fellow eyes, P = 0.0013). Final fellow eye vision outcome was significantly correlated with MA severity (coefficient -6.95, P < 0.001), and patients' inter-eye vision difference corresponded to the degree of MA asymmetry.
   Conclusions: Exudative fellow eyes remained at risk for further vision decline in later years under management with low-frequency anti-VEGF therapy. In patients with bilateral exudative AMD at baseline, final vision at year 7 was significantly better in study eyes than in fellow eyes, and MA was less severe. Macular atrophy area correlated with final visual outcomes, determined inter-eye vision differences, and was not attributable to high-frequency ranibizumab therapy. (C) 2016 by the American Academy of Ophthalmology.
C1 [Bhisitkul, Robert B.; Desai, Shilpa J.] Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA.
   [Boyer, David S.] Retina Vitreous Associates, Los Angeles, CA USA.
   [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Francisco;
   Retina Vitreous Associates Medical Group; Doheny Eye Institute;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California San Diego
RP Bhisitkul, RB (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA.
EM Robert.Bhisitkul@ucsf.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Genentech; GlaxoSmithKline; Envision Inc (Genentech); Alcon; Allergan;
   Ophthotech; Regeneron; Zeiss; Optovue; NATIONAL EYE INSTITUTE
   [P30EY002162] Funding Source: NIH RePORTER; Veterans Affairs
   [I01BX001898] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): R.B.B.: Scientific
   Advisory Board - Genentech, Santen, Aerie Pharmaceuticals, Allergan,
   Bausch & Lomb; Grants/grants pending - Genentech, GlaxoSmithKline;
   Patents planned, pending, or issued from Zordera Medical.; S.J.D.:
   Support - Envision Inc (funded by Genentech).; D.B.: Consultant - Alcon,
   Allergan, Allegro, Bayer, Neurotech, Novartis, Ophthotech; Grants/grants
   pending - Alcon, Allergan, Ophthotech, Regeneron; Receives payment -
   lectures from Regeneron.; S.R.S.: Consultant - Heidelberg Engineering,
   Allergan; Patents planned, pending, or issued from Topcon Systems; Funds
   - Zeiss, Optovue.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
NR 22
TC 54
Z9 55
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1269
EP 1277
DI 10.1016/j.ophtha.2016.01.033
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400023
PM 26996339
DA 2022-11-30
ER

PT J
AU Perdicchi, A
   Peluso, G
   Iacovello, D
   Balestrieri, M
   Delle Fave, M
   Abdolrahimzadeh, S
   Scuderi, GL
   Fenicia, V
   Recupero, SM
AF Perdicchi, Andrea
   Peluso, Giacomo
   Iacovello, Daniela
   Balestrieri, Marco
   Delle Fave, Martina
   Abdolrahimzadeh, Solmaz
   Scuderi, Gian Luca
   Fenicia, Vito
   Recupero, Santi Maria
TI Ganglion Cell Complex Evaluation in Exudative Age-Related Macular
   Degeneration after Repeated Intravitreal Injections of Ranibizumab
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB; VEGF; SAFETY
AB Purpose. To detect the effects of intravitreal ranibizumab injections on GCC in patients with wet AMD. Methods. 32 wet AMD eyes were selected and submitted at three ranibizumab injections. RTVue-OCT GCC and MM5 protocol were performed before treatment and twenty days after each injection. Results. At baseline mean GCC thickness was 93.9 +/- 18.5 mu m. Twenty days after each intravitreal injection it was, respectively, 85.8 +/- 10.1, 86.5 +/- 9.3, and 91.1 +/- 11.5 mu m, without statistical significance. A significant improvement in visual acuity (P = 0.031) and a reduction of mean foveal (P = 0.001) and macular thickness (P = 0.001) were observed. Conclusion. The clinical results confirm therapeutic efficacy of intravitreal injections of ranibizumab in wet AMD. A contemporary not statistically significant reduction of GCC thickness suggests that the loading phase of ranibizumab does not have any toxic effects on ganglion cell complex.
C1 [Perdicchi, Andrea; Peluso, Giacomo; Iacovello, Daniela; Balestrieri, Marco; Delle Fave, Martina; Scuderi, Gian Luca; Fenicia, Vito; Recupero, Santi Maria] Univ Roma La Sapienza, St Andrea Hosp, Fac Med & Psychol, NESMOS Dept,Ophthalmol Unit, I-00189 Rome, Italy.
   [Abdolrahimzadeh, Solmaz] Univ Roma La Sapienza, Azienda Policlin Umberto I, Ophthalmol Unit, I-00189 Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza
   University Rome; University Hospital Sapienza Rome
RP Peluso, G (通讯作者)，Univ Roma La Sapienza, St Andrea Hosp, Fac Med & Psychol, NESMOS Dept,Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
EM peluso.doc@gmail.com
RI Scuderi, Gianluca/R-5769-2016
OI Scuderi, Gianluca/0000-0003-0744-0722
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ciarnella A, 2012, CASE REP OPHTHALM, V3, P298, DOI 10.1159/000342848
   Fenicia V., 2014, EYE
   Fenicia V, 2013, CASE REP OPHTHALM, V4, P64, DOI 10.1159/000354066
   FLAMMER J, 1986, GRAEF ARCH CLIN EXP, V224, P389, DOI 10.1007/BF02173350
   Frenkel REP, 2007, AM J OPHTHALMOL, V143, P1034, DOI 10.1016/j.ajo.2007.01.052
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lambiase A, 2014, DRUG TODAY, V50, P239, DOI [10.1358/dot.2014.050.03.2103755, 10.1358/dot.2014.50.3.2103755]
   Lumbroso B., 2004, GUIDA PRATICA ALLINT
   MAFFEI L, 1981, SCIENCE, V211, P953, DOI 10.1126/science.7466369
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scuderi GL, 2011, EUR J OPHTHALMOL, V21, P251, DOI 10.5301/EJO.2010.3712
   SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Vavvas Demetrios, 2006, Ophthalmol Clin North Am, V19, P353
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
NR 30
TC 5
Z9 6
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 268796
DI 10.1155/2015/268796
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CL1DB
UT WOS:000356681600001
PM 26167478
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Obeid, A
   Talcott, KE
   Ali, FS
   Gao, XX
   Sioufi, K
   Wibbelsman, TD
   Ho, AC
AF Obeid, Anthony
   Talcott, Katherine E.
   Ali, Ferhina S.
   Gao, Xinxiao
   Sioufi, Kareem
   Wibbelsman, Turner D.
   Ho, Allen C.
TI Macular Hole Following Subretinal Tissue Plasminogen Activator for
   Submacular Hemorrhage Secondary to Neovascular AMD
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID DISPLACEMENT; MANAGEMENT
AB A full-thickness macular hole (FTMH) is a rare sequoia to submacular hemorrhage. Herein, the authors report a case of an 80-year-old man actively being treated for neovascular age-related macular degeneration who presented with sudden vision loss in the right eye. Examination with optical coherence tomography (OCT) imaging revealed submacular hemorrhage. The patient underwent vitrectomy with subretinal tissue plasminogen activator (tPA) with no intraoperative complications. Dilated fundus examination and OCT imaging revealed a FTMH at postop week 1. Possible causes for MH development include the submacular hemorrhage itself and subretinal administration of the tPA infusion.
C1 [Obeid, Anthony; Talcott, Katherine E.; Ali, Ferhina S.; Gao, Xinxiao; Sioufi, Kareem; Wibbelsman, Turner D.; Ho, Allen C.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA USA.
C3 Jefferson University
RP Ho, AC (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM acho@midatlanticretina.com
RI Sioufi, Kareem/AAA-2281-2021
OI Sioufi, Kareem/0000-0001-6944-4126; Ho, Allen/0000-0003-3921-608X
CR Bakri SJ, 2007, GRAEF ARCH CLIN EXP, V245, P609, DOI 10.1007/s00417-006-0349-8
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Colucciello M, 2000, RETINA-J RET VIT DIS, V20, P94, DOI 10.1097/00006982-200001000-00018
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Mitamura Y, 2002, RETINA-J RET VIT DIS, V22, P113, DOI 10.1097/00006982-200202000-00023
   Tashimo A, 2003, AM J OPHTHALMOL, V135, P487, DOI 10.1016/S0002-9394(02)02084-6
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Wan Michael J, 2009, Retin Cases Brief Rep, V3, P86, DOI 10.1097/ICB.0b013e31815f3cd2
NR 8
TC 1
Z9 1
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2019
VL 50
IS 9
BP 257
EP 259
DI 10.3928/23258160-20190905-18
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA JC5LI
UT WOS:000489323500006
PM 31589767
DA 2022-11-30
ER

PT J
AU Schmetterer, L
   Garhofer, G
AF Schmetterer, Leopold
   Garhofer, Gerhard
TI How can blood flow be measured?
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE blue field entoptic technique; color Doppler imaging; laser Doppler
   velocimetry; laser speckle technique; ocular blood flow; pulsatile
   ocular blood flow; retinal vessel diameters
ID OPTICAL COHERENCE TOMOGRAPHY; LASER-DOPPLER FLOWMETRY; REAL-TIME
   MEASUREMENT; RETINAL-VESSELS; ABSOLUTE MEASUREMENT; SPECKLE PHENOMENON;
   FUNDUS PULSATIONS; NERVE HEAD; FLUORESCEIN; CIRCULATION
AB Since vascular impairment has been hypothesized to play a role in several ocular diseases including glaucoma, diabetic retinopathy and age-related macular degeneration, the non-invasive assessment of ocular blood flow has received more and more attention. Despite the many advances that have been made in the last 30 years, there is still no gold standard for the evaluation of blood flow in humans available and sophisticated and expensive equipment is required. This article aims to review the different techniques available today for the assessment of ocular blood flow Furthermore the advantages and the possible limitations of the techniques are discussed.
C1 [Schmetterer, Leopold; Garhofer, Gerhard] Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Univ Vienna, Dept Biomed Engn & Phys, Vienna, Austria.
C3 University of Vienna; University of Vienna
RP Schmetterer, L (通讯作者)，Univ Vienna, Dept Clin Pharmacol, Waehringer Guertel 18, Vienna, Austria.
OI Schmetterer, Leopold/0000-0002-7189-1707
CR Arend O, 1999, SURV OPHTHALMOL, V44, pS3, DOI 10.1016/S0039-6257(99)00088-0
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   Blum M, 1999, GRAEF ARCH CLIN EXP, V237, P296, DOI 10.1007/s004170050236
   BONNER R, 1990, DEV CARDIOVASC MED, P17
   BRIERS JD, 1982, INVEST OPHTH VIS SCI, V22, P255
   CHEN HC, 1994, EYE, V8, P97, DOI 10.1038/eye.1994.19
   Dumskyj MJ, 1996, CURR EYE RES, V15, P625, DOI 10.3109/02713689609008902
   FEKE GT, 1987, IEEE T BIO-MED ENG, V34, P673, DOI 10.1109/TBME.1987.325992
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Fuchsjager-Mayrl G, 2002, INVEST OPHTH VIS SCI, V43, P1520
   Guan K, 2003, MICROVASC RES, V65, P145, DOI 10.1016/S0026-2862(03)00007-4
   Gugleta K, 2002, INVEST OPHTH VIS SCI, V43, P723
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   KOHNER EM, 1976, DIABETES, V25, P839
   LANGHAM ME, 1989, ACTA OPHTHALMOL, V67, P9
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Michelson G, 1996, J GLAUCOMA, V5, P99
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   Polak K, 2000, BRIT J OPHTHALMOL, V84, P1285, DOI 10.1136/bjo.84.11.1285
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   Polska E, 2001, AM J PHYSIOL-HEART C, V280, pH1442, DOI 10.1152/ajpheart.2001.280.4.H1442
   PREUSSNER PR, 1983, GRAEF ARCH CLIN EXP, V221, P110, DOI 10.1007/BF02133848
   RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117
   RIVA CE, 1985, INVEST OPHTH VIS SCI, V26, P1124
   RIVA CE, 1979, APPL OPTICS, V18, P2301, DOI 10.1364/AO.18.002301
   RIVA CE, 1980, J OPT SOC AM, V70, P1234, DOI 10.1364/JOSA.70.001234
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   SCHEIDER A, 1993, AM J OPHTHALMOL, V115, P50, DOI 10.1016/S0002-9394(14)73524-X
   Schmetterer L, 1996, BRIT J OPHTHALMOL, V80, P217, DOI 10.1136/bjo.80.3.217
   SCHMETTERER LF, 1995, OPT ENG, V34, P711, DOI 10.1117/12.193292
   SILVER DM, 1989, ACTA OPHTHALMOL, V67, P25
   Strenn K, 1997, BRIT J OPHTHALMOL, V81, P360, DOI 10.1136/bjo.81.5.360
   Tamaki Y, 1997, JPN J OPHTHALMOL, V41, P49, DOI 10.1016/S0021-5155(96)00008-1
   TAMAKI Y, 1995, EXP EYE RES, V60, P373, DOI 10.1016/S0014-4835(05)80094-6
   TANAKA T, 1991, OPHTHALMOLOGY, V98, P1824
   TAYLOR KJW, 1990, RADIOLOGY, V174, P297, DOI 10.1148/radiology.174.2.2404309
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   WOLF S, 1991, OPHTHALMOLOGY, V98, P996
   WOLF S, 1989, GRAEF ARCH CLIN EXP, V227, P145, DOI 10.1007/BF02169788
   Yazdanfar S, 2000, OPT LETT, V25, P1448, DOI 10.1364/OL.25.001448
   Yazdanfar S, 2003, ARCH OPHTHALMOL-CHIC, V121, P235
NR 44
TC 62
Z9 62
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV
PY 2007
VL 52
SU 2
BP S134
EP S138
DI 10.1016/j.survophthal.2007.08.008
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 240TS
UT WOS:000251610900008
PM 17998038
DA 2022-11-30
ER

PT J
AU Le Fur, I
   Laumet, G
   Richard, F
   Fievet, N
   Berr, C
   Rouaud, O
   Delcourt, C
   Amouyel, P
   Lambert, JC
AF Le Fur, Isabelle
   Laumet, Geoffroy
   Richard, Florence
   Fievet, Nathalie
   Berr, Claudine
   Rouaud, Olivier
   Delcourt, Cecile
   Amouyel, Philippe
   Lambert, Jean-Charles
TI Association study of the CFH Y402H polymorphism with Alzheimer's disease
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE CFH; Alzheimer; Polymorphism; Prospective study; Cross-sectional study
ID MACULAR DEGENERATION; METAANALYSIS
AB Several reports indicated that Alzheimer's disease (AD) and age-related macular degeneration (AMD) may share similar genetic and pathological features. We postulated that the functional Y402H polymorphism within the CFH gene and unambiguously recognised as a major genetic determinant of AMD, may also be a risk factor of AD. We analysed the association of this polymorphism with the AD risk in both prospective and cross-sectional studies. We were not able to detect such an association whatever the studied population, suggesting that the CFH gene is not a genetic determinant of AD. (C) 2008 Published by Elsevier Inc.
C1 [Le Fur, Isabelle; Laumet, Geoffroy; Richard, Florence; Fievet, Nathalie; Amouyel, Philippe; Lambert, Jean-Charles] Univ Lille 2, INSERM, U744, Inst Pasteur, F-59019 Lille, France.
   [Berr, Claudine] Univ Montpellier 1, INSERM, U888, Montpellier, France.
   [Rouaud, Olivier] Hop Gen, Ctr Hosp Univ, Serv Neurol, Dijon, France.
   [Delcourt, Cecile] Univ Victor Segalen, INSERM, U593, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); Le
   Reseau International des Instituts Pasteur (RIIP); Universite de Lille -
   ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; CHU Dijon Bourgogne; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux
RP Lambert, JC (通讯作者)，Univ Lille 2, INSERM, U744, Inst Pasteur, BP 245,1 Rue Prof Calmette, F-59019 Lille, France.
EM jean-charles.lambert@pasteur-lille.fr
RI Laumet, Geoffroy/O-7480-2019; berr, Claudine/D-5238-2014; Lambert,
   jean-charles/A-9553-2014; lambert, jean-charles/F-8787-2013; Delcourt,
   Cecile/I-2627-2013
OI berr, Claudine/0000-0001-5254-7655; Lambert,
   jean-charles/0000-0003-0829-7817; lambert,
   jean-charles/0000-0003-0829-7817; Delcourt, Cecile/0000-0002-2099-0481;
   Amouyel, Philippe/0000-0001-9088-234X; Rouaud,
   Olivier/0000-0001-9767-8421
CR Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Hye A, 2006, BRAIN, V129, P3042, DOI 10.1093/brain/awl279
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
NR 7
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JAN
PY 2010
VL 31
IS 1
BP 165
EP 166
DI 10.1016/j.neurobiolaging.2008.03.003
PG 2
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 525KA
UT WOS:000272213500018
PM 18433936
DA 2022-11-30
ER

PT J
AU Li, KKW
   Wong, D
AF Li, Kenneth K. W.
   Wong, David
TI Avoiding retinal slippage during macular translocation surgery with 360
   retinotomy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE retinal slippage; perfluorocarbon air exchange; perfluorocarbon fluid;
   silicone oil; macular translocation surgery
ID PERFLUOROCARBON LIQUIDS; SURGICAL TECHNIQUES; SILICONE OIL; MANAGEMENT;
   PERFLUORODECALIN; DETACHMENTS; TEARS
AB Purpose To describe a surgical technique to avoid retinal slippage.
   Method An audit was carried out on a consecutive series of 75 consecutive cases of macular translocation for age-related macular degeneration (MT360). We encountered two cases of slippage, which led to a change in technique.
   Result No further cases of slippage were encountered. We were able to perform an exchange of perfluorocarbon liquid with air or directly with silicone oil.
   Discussion Retinal slippage is caused by the presence of aqueous in the infusion tubing. Meticulous removal of all aqueous from the infusion system and vitreous cavity can eliminate this complication.
C1 [Li, Kenneth K. W.; Wong, David] Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Pokfulam, Hong Kong, Peoples R China.
   [Wong, David] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
C3 University of Hong Kong; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool
RP Li, KKW (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Pokfulam, Hong Kong, Peoples R China.
EM kennethli@rcsed.ac.uk
RI Wong, David/C-4440-2009; Wong, Sai Hung David/D-8482-2015; Li,
   Kenneth/M-4140-2017
OI Li, Kenneth/0000-0001-9440-8063
CR CHANG S, 1989, ARCH OPHTHALMOL-CHIC, V107, P761, DOI 10.1001/archopht.1989.01070010779046
   CHANG S, 1989, OPHTHALMOLOGY, V96, P785
   CHANG S, 1987, AM J OPHTHALMOL, V103, P38, DOI 10.1016/S0002-9394(14)74166-2
   CHANG S, 1988, AM J OPHTHALMOL, V106, P668, DOI 10.1016/0002-9394(88)90698-8
   COMARATTA MR, 1991, CURR OPIN OPHTHALMOL, V2, P291
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   MATHIS A, 1992, RETINA-J RET VIT DIS, V12, pS7, DOI 10.1097/00006982-199212031-00003
   Meffert S, 1999, CAN J OPHTHALMOL, V34, P272
   PETERSEN J, 1987, GRAEF ARCH CLIN EXP, V225, P452, DOI 10.1007/BF02334175
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Wong D, 1998, GRAEF ARCH CLIN EXP, V236, P234, DOI 10.1007/s004170050070
   Wong D, 2000, BRIT J OPHTHALMOL, V84, P352, DOI 10.1136/bjo.84.4.352
NR 12
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2008
VL 246
IS 5
BP 649
EP 651
DI 10.1007/s00417-007-0677-3
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 285JO
UT WOS:000254773300004
PM 18004588
DA 2022-11-30
ER

PT J
AU Mucke, HAM
AF Mucke, Hermann A. M.
TI New ocular therapeutics: A view from the patenting perspective
SO IDRUGS
LA English
DT Article
DE age-related macular degeneration; glaucoma; intellectual property;
   ophthalmology; siRNA
AB This feature article provides an overview of the newest therapeutic developments for ocular diseases, based on patents and patent applications that were published in the 12-month period from November 2005 to October 2006. In contrast to peer-reviewed literature covering breakthroughs in basic science research, the patenting perspective discloses the intentions of the pharmaceutical industry for imminent drug development. Selected documents describing drug delivery, dry eye syndrome, ocular infections and lesions, glaucoma and age-related macular degeneration are discussed. The role of RNA interference, which is of particular interest in ophthalmology research, is also highlighted.
C1 HM Pharma Consultancy, A-1160 Vienna, Austria.
RP Mucke, HAM (通讯作者)，HM Pharma Consultancy, Enenkelstr 28-32, A-1160 Vienna, Austria.
EM h.mucke@hmpharmacon.com
OI Mucke, Hermann/0000-0002-1491-6250
CR Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferrer E, 2006, DRUG NEWS PERSPECT, V19, P151, DOI 10.1358/dnp.2006.19.3.985929
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Paulsen F, 2006, INT REV CYTOL, V249, P229, DOI 10.1016/S0074-7696(06)49005-7
   Schallhorn SC, 2006, AM J OPHTHALMOL, V141, P733, DOI 10.1016/j.ajo.2005.11.036
   Tolentino Michael, 2006, Ophthalmol Clin North Am, V19, P393
NR 8
TC 2
Z9 4
U1 0
U2 1
PU THOMSON SCIENTIFIC
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND STREET, LONDON, W1T 4JE, ENGLAND
SN 1369-7056
J9 IDRUGS
JI IDrugs
PD JAN
PY 2007
VL 10
IS 1
BP 37
EP 41
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 178US
UT WOS:000247246200013
PM 17187313
DA 2022-11-30
ER

PT J
AU Qian, CX
   Young, LH
AF Qian, Cynthia X.
   Young, Lucy H.
TI The Impact of Cataract Surgery on AMD Development and Progression
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; blue-blocking intraocular lens;
   cataract; cataract surgery; pseudophakia
ID AGE-RELATED MACULOPATHY; FILTERING INTRAOCULAR LENSES; BLUE MOUNTAINS
   EYE; QUALITY-OF-LIFE; BEAVER DAM EYE; MACULAR DEGENERATION;
   RISK-FACTORS; INTRAVITREAL BEVACIZUMAB; 10-YEAR INCIDENCE; VISUAL-ACUITY
AB Age-related macular degeneration (AMD) and cataract are two leading causes of visual impairment worldwide which often occur concurrently in the same patient. With more than 1.6 million cataract operations performed per year in the United States, many of which occur in the nearly 1.75 million individuals diagnosed with AMD, there is ample incentive to further explore the interaction between these two conditions. Notably, the role of cataract surgery on AMD development and progression is of particular interest. This review summarizes the major findings from literature focusing on the effect of cataract surgery on AMD.
C1 [Qian, Cynthia X.; Young, Lucy H.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Young, LH (通讯作者)，Harvard Univ, Sch Med, Retina Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM lucy_young@meei.harvard.edu
OI Young, Lucy/0000-0001-8634-7512
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Banta James T, 2012, Int Ophthalmol Clin, V52, P73, DOI 10.1097/IIO.0b013e31824b3ed3
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Grixti A, 2014, ISRN OPHTHALMOLOGY, V2014, P6
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein BEK, 2009, ARCH OPHTHALMOL-CHIC, V127, P1528, DOI 10.1001/archophthalmol.2009.258
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lai E, 2014, CURR OPIN OPHTHALMOL, V25, P35, DOI 10.1097/ICU.0000000000000016
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Patel JI, 2007, CURR OPIN OPHTHALMOL, V18, P9, DOI 10.1097/ICU.0b013e3280112a0f
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rosen ES, 2014, J CATARACT REFR SURG, V40, P173, DOI 10.1016/j.jcrs.2013.11.022
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   West Emily S., 2005, International Ophthalmology Clinics, V45, P41
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P1337, DOI 10.1136/bjo.84.12.1337
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 59
TC 11
Z9 11
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2014
VL 29
IS 5-6
SI SI
BP 301
EP 311
DI 10.3109/08820538.2014.962166
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS0ZW
UT WOS:000344006400005
PM 25325855
DA 2022-11-30
ER

PT J
AU Patasius, M
   Marozas, V
   Jegelevicius, D
   Lukosevicius, A
   Speckauskas, M
AF Patasius, M.
   Marozas, V.
   Jegelevicius, D.
   Lukosevicius, A.
   Speckauskas, M.
TI Modification of Method for Drusen Detection in Eye Fundus Images
SO ELEKTRONIKA IR ELEKTROTECHNIKA
LA English
DT Article
ID AUTOMATED DETECTION
AB Drusen are white or yellow spots in eye fundus that consist of extracellular material They are a sign of age-related macular degeneration (AM D) - the main cause of blindness in the developed countries and a third main cause of blindness in the whole world Previously a drusen detection method based on optimized colour combinations has been proposed, but it has only been investigated empirically Thus here this method is investigated using one-dimensional and two-dimensional models of drusen, its properties are found and improvements suggested III 8, bib1 9, tabl 1 (in English, abstracts in English, Russian and Lithuanian).
C1 [Patasius, M.; Marozas, V.; Jegelevicius, D.; Lukosevicius, A.] Kaunas Univ Technol, LT-51369 Kaunas, Lithuania.
   [Speckauskas, M.] Kaunas Univ Med, LT-50009 Kaunas, Lithuania.
C3 Kaunas University of Technology; Lithuanian University of Health
   Sciences
RP Patasius, M (通讯作者)，Kaunas Univ Technol, Studentu Str 65, LT-51369 Kaunas, Lithuania.
RI Jegelevičius, Darius/AAE-7611-2022; Jegelevičius, Darius/P-5535-2018;
   Patašius, Martynas/AAP-3023-2020; Marozas, Vaidotas/T-4499-2017;
   Lukoševičius, Arūnas/AAO-3779-2020
OI Jegelevičius, Darius/0000-0002-5999-7744; Jegelevičius,
   Darius/0000-0002-5999-7744; Patašius, Martynas/0000-0002-2537-7934;
   Marozas, Vaidotas/0000-0002-6879-5845; Lukoševičius,
   Arūnas/0000-0002-9268-5347
FU EU [FP-201119]; NICDIT under EUROSTARS programme [E!4297]
FX The work was partially supported by EU project SM-BIO-POWER (grant
   agreement FP-201119) and project E!4297 NICDIT under EUROSTARS programme
CR Checco P, 2006, IEEE INT SYMP CIRC S, P2181
   Grisan E, 2008, 4th European Conference of the International Federation for Medical and Biological Engineering - ECIFMBE 2008, P472
   LAPTIK R, 2007, ELEKTRON ELEKTROTECH, V8, P13
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Patasius M, 2009, ELEKTRON ELEKTROTECH, P53
   Patasius M., 2009, BIOM ENG P INT C KAU, P160
   SANCHEZ CI, 2009, MEDICAL IMAGING 2009
   SERACKIS A, 2008, ELEKTRON ELEKTROTECH, V1, P83
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
NR 9
TC 2
Z9 2
U1 0
U2 3
PU KAUNAS UNIV TECHNOLOGY
PI KAUNAS
PA KAUNAS UNIV TECHNOL, DEPT ELECTRONICS ENGINEERING, STUDENTU STR 50,
   KAUNAS, LT-51368, LITHUANIA
SN 1392-1215
J9 ELEKTRON ELEKTROTECH
JI Elektron. Elektrotech.
PY 2010
IS 5
BP 115
EP 118
PG 4
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 599JI
UT WOS:000277907400026
DA 2022-11-30
ER

PT J
AU Garg, AK
   Knight, D
   Lando, L
   Chao, DL
AF Garg, Anupam K.
   Knight, Darren
   Lando, Leonardo
   Chao, Daniel L.
TI Advances in Retinal Oximetry
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Review
DE retinal oximetry; retina; imaging; oxygen saturation; oxygenation
AB Similar to other organs, the retina relies on tightly regulated perfusion and oxygenation. Previous studies have demonstrated that retinal blood flow is affected in a variety of eye and systemic diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. Although measurement of peripheral oxygen saturation has become a standard clinical measurement through the development of pulse oximetry, developing a noninvasive technique to measure retinal oxygen saturation has proven challenging, and retinal oximetry technology currently remains inadequate for reliable clinical use. Here, we review current strategies and approaches, as well as several newer technologies in development, and discuss the future of retinal oximetry.
C1 [Garg, Anupam K.; Knight, Darren; Lando, Leonardo; Chao, Daniel L.] Univ Calif San Diego, Shiley Eye Inst, Viterbi Family Dept Ophthalmol, La Jolla, CA USA.
   [Garg, Anupam K.; Chao, Daniel L.] Univ Calif San Diego, Sch Med, La Jolla, CA USA.
   [Chao, Daniel L.] Janssen Res & Dev, Raritan, NJ USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Johnson & Johnson; Janssen Pharmaceuticals
RP Chao, DL (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM daniel.chao3@gmail.com
CR Beach J, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.5.2
   Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   Bek T, 2019, BRIT J OPHTHALMOL, V103, P1167, DOI 10.1136/bjophthalmol-2018-312764
   Bek T, 2016, INVEST OPHTH VIS SCI, V57, P5429, DOI 10.1167/iovs.16-20305
   Blair NP, 2017, INVEST OPHTH VIS SCI, V58, P5556, DOI 10.1167/iovs.17-21934
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Chan ED, 2013, RESP MED, V107, P789, DOI 10.1016/j.rmed.2013.02.004
   Chen H, 2017, ACTA OPHTHALMOL, V95, pE436, DOI 10.1111/aos.13332
   Chen SY, 2017, BIOMED OPT EXPRESS, V8, P1415, DOI 10.1364/BOE.8.001415
   Chen SY, 2015, BIOMED OPT EXPRESS, V6, P2840, DOI 10.1364/BOE.6.002840
   Choi W, 2018, BIOMED ENG LETT, V8, P139, DOI 10.1007/s13534-018-0062-7
   Chong SP, 2017, BIOMED OPT EXPRESS, V8, P323, DOI 10.1364/BOE.8.000323
   Christoffersen NLB, 1999, OPHTHALMOLOGY, V106, P2054, DOI 10.1016/S0161-6420(99)90483-9
   Cohen D, 1999, C P LAS EL OPT SON A, P220
   de la Zerda A, 2010, OPT LETT, V35, P270, DOI 10.1364/OL.35.000270
   DELORI FC, 1988, APPL OPTICS, V27, P1113, DOI 10.1364/AO.27.001113
   DePaoli DT, 2019, SCIREP, V9, P1
   Desjardins M, 2016, EXP EYE RES, V146, P330, DOI 10.1016/j.exer.2016.04.001
   Drewes J, 1999, PROC SPIE, V3591, P114, DOI 10.1117/12.350607
   Dwight Jason G, 2016, Int Ophthalmol Clin, V56, P25, DOI 10.1097/IIO.0000000000000139
   Einarsdottir AB, 2018, ACTA OPHTHALMOL, V96, P528, DOI 10.1111/aos.13682
   Einarsdottir AB, 2016, J ALZHEIMERS DIS, V49, P79, DOI 10.3233/JAD-150457
   Eliasdottir TS, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13932
   Eliasdottir TS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174026
   Eysteinsson T, 2014, ACTA OPHTHALMOL, V92, P449, DOI 10.1111/aos.12359
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Flammer J, 2007, SURV OPHTHALMOL, V52, pS162, DOI 10.1016/j.survophthal.2007.08.012
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Garhofer G, 2010, ACTA OPHTHALMOL, V88, P717, DOI 10.1111/j.1755-3768.2009.01587.x
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Geirsdottir A, 2012, INVEST OPHTH VIS SCI, V53, P5433, DOI 10.1167/iovs.12-9912
   Hafner J, 2017, INVEST OPHTH VIS SCI, V58, P5541, DOI 10.1167/iovs.17-22523
   Hammer M, 2009, GRAEF ARCH CLIN EXP, V247, P1025, DOI 10.1007/s00417-009-1078-6
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Hardarson SH, 2012, ACTA OPHTHALMOL, V90, P466, DOI 10.1111/j.1755-3768.2011.02109.x
   Hardarson SH, 2012, BRIT J OPHTHALMOL, V96, P560, DOI 10.1136/bjophthalmol-2011-300640
   Hardarson SH, 2010, AM J OPHTHALMOL, V150, P871, DOI 10.1016/j.ajo.2010.06.020
   Hardarson SH, 2009, INVEST OPHTH VIS SCI, V50, P5247, DOI 10.1167/iovs.08-3117
   Hariri A, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.3.036005
   Heitmar R, 2012, GRAEF ARCH CLIN EXP, V250, P1429, DOI 10.1007/s00417-012-1980-1
   Hennen SN, 2015, EXP EYE RES, V138, P153, DOI 10.1016/j.exer.2015.05.022
   HICKAM J B, 1959, Trans Am Clin Climatol Assoc, V71, P34
   HICKAM JB, 1966, CIRCULATION, V33, P302, DOI 10.1161/01.CIR.33.2.302
   HICKAM JB, 1963, CIRCULATION, V27, P375, DOI 10.1161/01.CIR.27.3.375
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jakobsen DB, 2019, ACTA OPHTHALMOL, V97, P525, DOI 10.1111/aos.13996
   Jani PD, 2014, RETINA-J RET VIT DIS, V34, P394, DOI 10.1097/IAE.0b013e3182979e7b
   Jeppesen SK, 2019, CURR EYE RES, V44, P46, DOI 10.1080/02713683.2018.1524015
   Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967
   Jorgensen C, 2014, INVEST OPHTH VIS SCI, V55, P5365, DOI 10.1167/iovs.14-14811
   Jorgensen CM, 2014, ACTA OPHTHALMOL, V92, P34, DOI 10.1111/aos.12283
   Kaluzny J, 2017, CURR EYE RES, V42, P629, DOI 10.1080/02713683.2016.1221976
   Kashani AH, 2014, RETINA-J RET VIT DIS, V34, P1854, DOI 10.1097/IAE.0000000000000146
   Kim SK, 2011, IEEE T MED IMAGING, V30, P1577, DOI 10.1109/TMI.2011.2140329
   Kristjansdottir JV, 2013, INVEST OPHTH VIS SCI, V54, P3234, DOI 10.1167/iovs.12-10507
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Laufer J, 2005, PHYS MED BIOL, V50, P4409, DOI 10.1088/0031-9155/50/18/011
   Li ZX, 2019, ACTA OPHTHALMOL, V97, P296, DOI 10.1111/aos.14066
   Liu T, 2013, CURR EYE RES, V38, P1229, DOI 10.3109/02713683.2013.815219
   Liu WZ, 2016, PHOTOACOUSTICS, V4, P112, DOI 10.1016/j.pacs.2016.05.001
   Liu WZ, 2014, PHOTOACOUSTICS, V2, P81, DOI 10.1016/j.pacs.2014.04.003
   Liu WZ, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.6.066003
   Liu X, 2017, ACTA OPHTHALMOL, V95, pE54, DOI 10.1111/aos.13167
   Long CD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8232468
   Lu GL, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.1.010901
   Man REK, 2013, ACTA OPHTHALMOL, V91, pE590, DOI 10.1111/aos.12173
   Man REK, 2014, INVEST OPHTH VIS SCI, V55, P1763, DOI 10.1167/iovs.13-13320
   Mohan A, 2016, CURR EYE RES, V41, P1223, DOI 10.3109/02713683.2015.1104361
   Mohan A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126179
   Moore D, 2008, CLIN OPHTHALMOL, V2, P849
   Mordant DJ, 2014, EYE, V28, P1190, DOI 10.1038/eye.2014.169
   Mordant DJ, 2011, EYE, V25, P309, DOI 10.1038/eye.2010.222
   Nakano Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159650
   Narasimha-Iyer H, 2008, IEEE T INF TECHNOL B, V12, P406, DOI 10.1109/TITB.2007.897782
   Nicholson L, 2019, INVEST OPHTH VIS SCI, V60, P2083, DOI 10.1167/iovs.18-24917
   Nitta E, 2017, ACTA OPHTHALMOL, V95, pE350, DOI 10.1111/aos.13274
   Olafsdottir OB, 2014, BRIT J OPHTHALMOL, V98, P329, DOI 10.1136/bjophthalmol-2013-303162
   Olafsdottir OB, 2011, INVEST OPHTH VIS SCI, V52, P6409, DOI 10.1167/iovs.10-6985
   Palkovits S, 2014, INVEST OPHTH VIS SCI, V55, P4707, DOI 10.1167/iovs.14-14593
   Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621
   Patel SR, 2013, EXP EYE RES, V116, P185, DOI 10.1016/j.exer.2013.09.004
   Patel SR, 2013, INVEST OPHTH VIS SCI, V54, P5163, DOI 10.1167/iovs.13-12124
   PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678
   Pi SH, 2020, P NATL ACAD SCI USA, V117, P11658, DOI 10.1073/pnas.1918546117
   Pi SH, 2018, BIOMED OPT EXPRESS, V9, P2056, DOI 10.1364/BOE.9.002056
   Povazay B, 2002, PROC SPIE, V4619, P90, DOI 10.1117/12.470466
   Rodriguez DA, 2016, INVEST OPHTH VIS SCI, V57, P6474, DOI 10.1167/iovs.16-20138
   Rose K, 2018, ACTA OPHTHALMOL, V96, pE727, DOI 10.1111/aos.13797
   Schweitzer D, 1999, IEEE T BIO-MED ENG, V46, P1454, DOI 10.1109/10.804573
   Shah RS, 2016, INVEST OPHTH VIS SCI, V57, pOCT86, DOI 10.1167/iovs.15-18891
   Shahidi AM, 2013, EXP EYE RES, V113, P143, DOI 10.1016/j.exer.2013.06.001
   Shahidi AM, 2017, CURR EYE RES, V42, P557, DOI 10.1080/02713683.2016.1217544
   Shu X, 2019, QUANT IMAG MED SURG, V9, P769, DOI 10.21037/qims.2019.05.01
   Sinova I, 2018, AM J OPHTHALMOL, V188, P74, DOI 10.1016/j.ajo.2018.01.015
   Song W, 2014, SCI REP-UK, V4, DOI 10.1038/srep06525
   Song WY, 2020, BIOMED OPT EXPRESS, V11, P4037, DOI 10.1364/BOE.395843
   Svrcinova T, 2018, ACTA OPHTHALMOL, V96, pE309, DOI 10.1111/aos.13571
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Tayyari F, 2015, INVEST OPHTH VIS SCI, V56, P6796, DOI 10.1167/iovs.15-17481
   Told R, 2018, ACTA OPHTHALMOL, V96, pE614, DOI 10.1111/aos.13719
   Turksever C, 2015, ACTA OPHTHALMOL, V93, pE439, DOI 10.1111/aos.12598
   Vandewalle E, 2014, ACTA OPHTHALMOL, V92, P105, DOI 10.1111/aos.12011
   Vasefi F, 2016, IMAGING IN DERMATOLOGY, P187, DOI 10.1016/B978-0-12-802838-4.00016-9
   Vehmeijer W, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.19
   Waizel M, 2018, ACTA OPHTHALMOL, V96, pE828, DOI 10.1111/aos.13726
   Wang LHV, 2012, SCIENCE, V335, P1458, DOI 10.1126/science.1216210
   Whitehead M, 2018, EXPERT OPIN BIOL TH, V18, P1257, DOI 10.1080/14712598.2018.1545836
   Willerslev A, 2017, ACTA OPHTHALMOL, V95, P146, DOI 10.1111/aos.13249
   Yang JY, 2017, INT J OPHTHALMOL-CHI, V10, P267, DOI 10.18240/ijo.2017.02.14
   Yang W, 2016, ACTA OPHTHALMOL, V94, P373, DOI 10.1111/aos.12943
   Yang XN, 2017, OPHTHAL PLAST RECONS, V33, P459, DOI 10.1097/IOP.0000000000000826
   Yao JJ, 2013, LASER PHOTONICS REV, V7, P758, DOI 10.1002/lpor.201200060
   Yap ZL, 2018, CLIN OPHTHALMOL, V12, P79, DOI 10.2147/OPTH.S128459
   Yi J, 2015, BIOMED OPT EXPRESS, V6, P3701, DOI 10.1364/BOE.6.003701
   Yi J, 2013, OPT LETT, V38, P1796, DOI 10.1364/OL.38.001796
   Yip W, 2014, INVEST OPHTH VIS SCI, V55, P7104, DOI 10.1167/iovs.13-13854
   YOSHIDA A, 1983, ARCH OPHTHALMOL-CHIC, V101, P225
   Zhang HF, 2006, NAT BIOTECHNOL, V24, P848, DOI 10.1038/nbt1220
   Zhang TW, 2019, BIOMED OPT EXPRESS, V10, P2918, DOI 10.1364/BOE.10.002918
   Zheng QS, 2015, OPHTHAL PHYSL OPT, V35, P562, DOI 10.1111/opo.12223
   Zijlstra W. G., 2000, VISIBLE NEAR INFRARE
   Zong Y, 2016, GRAEF ARCH CLIN EXP, V254, P243, DOI 10.1007/s00417-015-3039-6
NR 124
TC 8
Z9 8
U1 4
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.5
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2VZ
UT WOS:000635403100005
PM 34003890
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Baker, D
   Akpenyi, O
   Shahzad, H
   Mellington, F
AF Baker, Diya
   Akpenyi, Onyinye
   Shahzad, Haris
   Mellington, Faye
TI Patients' perceptions of visual impairment associated with smoking: A
   cross-sectional study of a United Kingdom tertiary eye centre
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Preventive medicine; screening; socioeconomics and education in
   medicine; ophthalmology; lens; cataract; age-related macular
   degeneration; retina; thyroid eye disease; orbital disease; retinopathy
   of prematurity; diabetic retinopathy; uveitis
ID BLINDNESS
AB Smoking is a well-established risk factor for several eye disorders including cataracts and age-related macular degeneration. While many individuals are informed of the various adverse health effects, there is limited research into patients' awareness of the relationship between smoking and eye disease and the potential impact this might have on reducing smoking behaviour. Our findings document the low level of awareness of the risk of blindness from smoking at a tertiary eye unit in the United Kingdom and highlight the need for increased involvement from eye care professionals, alongside health campaigns to educate the public of this consequence of smoking.
C1 [Baker, Diya] Univ Cambridge, Inst Continuing Educ, Madingley Hall, Cambridge, England.
   [Baker, Diya; Akpenyi, Onyinye; Mellington, Faye] Birmingham Midland Eye Ctr, Birmingham, W Midlands, England.
   [Shahzad, Haris] Univ Birmingham, Coll Med & Dent Sci, Birmingham B15 2TT, Edgbaston, England.
C3 University of Cambridge; University of Birmingham
RP Shahzad, H (通讯作者)，Univ Birmingham, Coll Med & Dent Sci, Birmingham B15 2TT, Edgbaston, England.
EM hshahzad98@gmail.com
OI Shahzad, Haris/0000-0002-9165-3095
CR Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   Carroll T, 2003, TOB CONTROL, V12, P40
   Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1928, DOI 10.1016/j.ophtha.2009.03.006
   Kennedy RD, 2011, OPTOMETRY, V82, P310, DOI 10.1016/j.optm.2010.10.014
   WHO Regional Office for Europe, 2019, TRENDS REP 2019
NR 5
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP NP283
EP NP285
AR 11206721211020647
DI 10.1177/11206721211020647
EA MAY 2021
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678539900001
PM 34053334
OA hybrid, Green Published
DA 2022-11-30
ER

PT S
AU Schlingemann, RO
   Witmer, AN
AF Schlingemann, R. O.
   Witmer, A. N.
BE Verhaagen, J
   Hol, EM
   Huitenga, I
   Wijnholds, J
   Bergen, AB
   Boer, GJ
   Swaab, DF
TI Treatment of retinal diseases with VEGF antagonists
SO NEUROTHERAPY: PROGRESS IN RESTORATIVE NEUROSCIENCE AND NEUROLOGY
SE Progress in Brain Research
LA English
DT Review
CT 25th International Summer School of Brain Research
CY AUG 25-28, 2008
CL Royal Netherlands Acad Arts & Sci (KNAW), Amsterdam, NETHERLANDS
SP Netherlands Inst Neurosci (NIN), Abcam, Alzheimer Nederland, Amsterdam Mol Therapeut (AMT), Appl Biosyst, Bio-Connect BV, Boehringer Ingelheim, Bristol-Myers Squibb BV, Corning, Curatis Pharma GmbH, Eurogentec BV, Elsevier Sci Publishers, Genzyme Europe BV, GlaxoSmithKline, Grad Sch Neurosci Amsterdam (ONWA), Hersenstichting Nederland, Invitrogen, Leica Microsyst BV, Landelijke Stichting Blinden Slechtzienden (LSBS), Merck Res Labs, ZonMw, Solvay Pharmaceut BV, Stichting Blindenhulp, Stichting Blinden-penning, Stichting Glaucoomfonds, Stichting MD Fonds, Stichting MS Res, Stichting Van den Houtenfonds, Tebu-Bio, Uitgeverij Nieuwezijds, Zeiss
HO Royal Netherlands Acad Arts & Sci (KNAW)
DE vascular endothelial growth factor; angiogenesis; neovascularization;
   diabetic retinopathy; age-related macular degeneration; therapy
ID ENDOTHELIAL-GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY;
   INTRAVITREAL BEVACIZUMAB AVASTIN; METASTATIC COLORECTAL-CANCER;
   VASCULAR-PERMEABILITY FACTOR; MACULAR DEGENERATION; IRIS
   NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION; NONHUMAN PRIMATE;
   CAPILLARY NONPERFUSION
AB Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the most prevalent causes of blindness in the Western world. The pathogenesis of neovascularization and vascular leakage, both hallmarks of these diseases, appears to have one common denominator: vascular endothelial growth factor (VEGF). Since the recent introduction of anti-VEGF therapy, intravitreal injections with these agents have become standard care in neovascular AMD, and have been found to be a valuable additional treatment strategy in several other vascular retinal diseases. This review provides an overview of the history of anti-VEGF treatment in the eye, its rationale, its efficacy, and its potential drawbacks.
C1 [Schlingemann, R. O.; Witmer, A. N.] Univ Amsterdam, Acad Med Ctr, Med Retina Unit, NL-1105 AZ Amsterdam, Netherlands.
   [Schlingemann, R. O.; Witmer, A. N.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam
RP Schlingemann, RO (通讯作者)，Univ Amsterdam, Acad Med Ctr, Med Retina Unit, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM r.schlingemann@amc.uva.nl
RI Verhaagen, Joost/G-4773-2012
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Batioglu Figen, 2008, International Ophthalmology, V28, P59, DOI 10.1007/s10792-007-9105-2
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro P. A., 2006, INVEST OPHTHALMOL, V47, P5443
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Crabbe MJC, 1998, PROG RETIN EYE RES, V17, P313, DOI 10.1016/S1350-9462(97)00013-X
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453
   Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Folkman J, 1997, EXS, V79, P1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grosskreutz CL, 1999, MICROVASC RES, V58, P128, DOI 10.1006/mvre.1999.2171
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Hofman P, 2001, OPHTHALMIC RES, V33, P156, DOI 10.1159/000055663
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649
   Jiang Y., 2008, ACTA OPHTHA IN PRESS
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   LANDERS MB, 1982, RETINA-J RET VIT DIS, V2, P167, DOI 10.1097/00006982-198200230-00007
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lee E., 2008, INVEST OPHTHALMOL, V49, P3494
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyamoto K, 1997, MICROVASC RES, V54, P43, DOI 10.1006/mvre.1997.2018
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ola MS, 2006, AM J PHYSIOL-ENDOC M, V290, pE1057, DOI 10.1152/ajpendo.00323.2005
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Paques M, 2000, CURR EYE RES, V21, P560, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT560
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Shinoda K, 1999, BRIT J OPHTHALMOL, V83, P834, DOI 10.1136/bjo.83.7.834
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Stalmans I, 2005, Verh K Acad Geneeskd Belg, V67, P229
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   Witmer AN, 2004, J HISTOCHEM CYTOCHEM, V52, P39, DOI 10.1177/002215540405200105
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 95
TC 38
Z9 41
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0079-6123
BN 978-0-12-374511-8
J9 PROG BRAIN RES
JI Prog. Brain Res.
PY 2009
VL 175
BP 253
EP 267
DI 10.1016/S0079-6123(09)17517-9
PG 15
WC Clinical Neurology; Neurosciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA BDJ56
UT WOS:000313549600018
PM 19660661
DA 2022-11-30
ER

PT J
AU Chhablani, J
   Barteselli, G
AF Chhablani, Jay
   Barteselli, Giulio
TI Clinical applications of choroidal imaging technologies
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroid; enhanced depth imaging technique; swept source optical
   coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; KOYANAGI-HARADA DISEASE; MACULAR
   DEGENERATION; SWEPT-SOURCE; OCULAR TOXOPLASMOSIS; GLOBAL REASSESSMENT;
   MEMORIAL-LECTURE; VASCULAR LAYERS; HEALTHY EYES; THICKNESS
AB Choroid supplies the major blood supply to the eye, especially the outer retinal structures. Its understanding has significantly improved with the advent of advanced imaging modalities such as enhanced depth imaging technique and the newer swept source optical coherence tomography. Recent literature reports the findings of choroidal changes, quantitative as well as qualitative, in various chorioretinal disorders. This review article describes applications of choroidal imaging in the management of common diseases such as age-related macular degeneration, high myopia, central serous chorioretinopathy, chorioretinal inflammatory diseases, and tumors. This article briefly discusses future directions in choroidal imaging including angiography.
C1 [Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Vitreous Ctr, Hyderabad 500034, Telangana, India.
   [Barteselli, Giulio] Genentech Inc, San Francisco, CA 94080 USA.
C3 L. V. Prasad Eye Institute; Roche Holding; Genentech
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Vitreous Ctr, Kallam Anji Reddy Campus,LV Prasad Marg, Hyderabad 500034, Telangana, India.
EM jay.chhablani@gmail.com
OI Barteselli, Giulio/0000-0003-0533-1135
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Adhi M, 2013, OSLI RETINA, V44, P252, DOI 10.3928/23258160-20130503-08
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Arevalo JF, 2000, OPHTHALMOLOGY, V107, P344, DOI 10.1016/S0161-6420(99)00051-2
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Ayton LN, 2013, CLIN EXP OPHTHALMOL, V41, P396, DOI 10.1111/j.1442-9071.2012.02867.x
   Barteselli Giulio, 2014, Retina, V34, P880, DOI 10.1097/IAE.0000000000000015
   Barteselli G, 2013, AM J OPHTHALMOL, V155, P727, DOI 10.1016/j.ajo.2012.10.019
   Barteselli G, 2013, RETINA-J RET VIT DIS, V33, P247, DOI 10.1097/IAE.0b013e31826f5252
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Bonfioli Adriana A, 2005, Semin Ophthalmol, V20, P129, DOI 10.1080/08820530500231961
   Chhablani J, 2014, INDIAN J OPHTHALMOL, V62, P1060, DOI 10.4103/0301-4738.146711
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   da Silva FT, 2013, BRIT J OPHTHALMOL, V97, P70, DOI 10.1136/bjophthalmol-2012-302089
   Dhoot DS, 2013, BRIT J OPHTHALMOL, V97, P66, DOI 10.1136/bjophthalmol-2012-301917
   Elagouz M, 2010, SURV OPHTHALMOL, V55, P134, DOI 10.1016/j.survophthal.2009.05.003
   Esmaeelpour M, 2012, INVEST OPHTH VIS SCI, V53, P6803, DOI 10.1167/iovs.12-10314
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Fardeau C, 1999, OPHTHALMOLOGY, V106, P1928, DOI 10.1016/S0161-6420(99)90403-7
   Fryczkowski A W, 1988, Klin Oczna, V90, P145
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Goldenberg D, 2013, GRAEF ARCH CLIN EXP, V251, P2037, DOI 10.1007/s00417-013-2334-3
   Harada T, 2011, CLIN OPHTHALMOL, V5, P1599, DOI 10.2147/OPTH.S26324
   HECKENLIVELY JR, 1988, AM J OPHTHALMOL, V105, P504, DOI 10.1016/0002-9394(88)90242-5
   Herbort CP, 2012, KLIN MONATSBL AUGENH, V229, P306, DOI 10.1055/s-0031-1299394
   Holland GN, 2004, AM J OPHTHALMOL, V137, P1, DOI 10.1016/j.ajo.2003.10.032
   Holland GN, 2003, AM J OPHTHALMOL, V136, P973, DOI 10.1016/j.ajo.2003.09.040
   Invernizzi A, 2015, RETINA-J RET VIT DIS, V35, P525, DOI 10.1097/IAE.0000000000000312
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim JT, 2013, INVEST OPHTH VIS SCI, V54, P3378, DOI 10.1167/iovs.12-11503
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1921, DOI 10.1097/IAE.0b013e31822bf6b1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Modi YS, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-58
   Nakai K, 2012, GRAEF ARCH CLIN EXP, V250, P1089, DOI 10.1007/s00417-011-1910-7
   Nakayama M, 2012, RETINA-J RET VIT DIS, V32, P2061, DOI 10.1097/IAE.0b013e318256205a
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Rayess N, 2015, AM J OPHTHALMOL, V159, P85, DOI 10.1016/j.ajo.2014.09.033
   RYAN SJ, 1980, AM J OPHTHALMOL, V89, P31, DOI 10.1016/0002-9394(80)90226-3
   Sakata VM, 2014, J OPHTHALMIC INFLAMM, V4, DOI 10.1186/1869-5760-4-6
   Shields CL, 2014, RETINA-J RET VIT DIS, V34, P1495, DOI 10.1097/IAE.0000000000000288
   Shields CL, 2014, RETINA-J RET VIT DIS, V34, P1347, DOI 10.1097/IAE.0000000000000145
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Spaide RF, 2012, RETINA-J RET VIT DIS, V32, P1037, DOI 10.1097/IAE.0b013e318242b9c0
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   SPALTON DJ, 1981, BRIT J OPHTHALMOL, V65, P348, DOI 10.1136/bjo.65.5.348
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Torres VLL, 2011, AM J OPHTHALMOL, V151, P586, DOI 10.1016/j.ajo.2010.09.028
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Wilke R, 2011, INVEST OPHTH VIS SCI, V52, P5995, DOI 10.1167/iovs.10-6946
   Wu Chan, 2011, Chinese Medical Sciences Journal, V26, P231
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   Zhu Y, 2015, RETINA-J RET VIT DIS, V35, P695, DOI 10.1097/IAE.0000000000000381
NR 68
TC 14
Z9 14
U1 0
U2 8
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2015
VL 63
IS 5
BP 384
EP 390
DI 10.4103/0301-4738.159861
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5OC
UT WOS:000357736600005
PM 26139797
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Walker, DP
   Vollmer-Snarr, HR
   Eberting, CLD
AF Walker, Daniel P.
   Vollmer-Snarr, Heidi R.
   Eberting, Cheryl Lee D.
TI Ocular hazards of blue-light therapy in dermatology
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Review
DE age-related macular degeneration; blue light; blue-light phototherapy;
   photodynamic therapy; phototherapy; retinopathy
ID AGE-RELATED MACULOPATHY; DELTA-AMINOLEVULINIC-ACID; PIGMENT
   EPITHELIAL-CELLS; BLOCKING INTRAOCULAR LENSES; PHOTODYNAMIC THERAPY;
   MACULAR DEGENERATION; RISK-FACTORS; 5-AMINOLEVULINIC ACID; ACTINIC
   KERATOSES; INDUCED DAMAGE
AB Blue-light phototherapy has become important in the treatment of many dermatologic conditions and as a result continue to be developed. Although blue-light therapy is successful, research shows that excessive ocular blue-light exposure may contribute to age-related macular degeneration and other vision problems. As blue-light therapy becomes increasingly more popular for clinical and at-home use, patients and operators of blue-light devices should be aware of its associated ocular hazards. Protective eyewear should be carefully selected and implemented with each therapy session to guard against the development of retinal disease. (J Am Acad Dermatol 2012;66:130-5.)
C1 [Walker, Daniel P.] Univ Texas SW Med Ctr, Dallas, TX USA.
   [Vollmer-Snarr, Heidi R.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.
   [Eberting, Cheryl Lee D.] Alpine Dermatol PC, Alpine, UT 84004 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; Brigham Young University
RP Eberting, CLD (通讯作者)，Alpine Dermatol PC, 144 S Main St,Suite 100, Alpine, UT 84004 USA.
EM alpinedermatology@gmail.com
OI Vollmer-Snarr, Heidi/0000-0002-7312-4907
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   ANDLEY UP, 1990, PHOTODERMATOL PHOTO, V7, P98
   [Anonymous], 1997, HEALTH PHYS, V73, P539
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   BERNINGER TA, 1989, ARCH OPHTHALMOL-CHIC, V107, P1453, DOI 10.1001/archopht.1989.01070020527032
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BRADNAM MS, 1995, OPHTHALMOLOGY, V102, P799, DOI 10.1016/S0161-6420(95)30954-2
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Bryld LE, 2007, J EUR ACAD DERMATOL, V21, P1199, DOI 10.1111/j.1468-3083.2007.02219.x
   Busch EM, 1999, VISION RES, V39, P1233, DOI 10.1016/S0042-6989(98)00233-8
   Council on Dental Materials Instruments and Equipment, 1986, J AM DENT ASSOC, p[112, 533]
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Dijkstra AT, 2001, J EUR ACAD DERMATOL, V15, P550, DOI 10.1046/j.1468-3083.2001.00333.x
   FIJAN S, 1995, BRIT J DERMATOL, V133, P282, DOI 10.1111/j.1365-2133.1995.tb02630.x
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gilbert DJ, 2007, DERMATOL CLIN, V25, P111, DOI 10.1016/j.det.2006.09.012
   Glickman G, 2006, BIOL PSYCHIAT, V59, P502, DOI 10.1016/j.biopsych.2005.07.006
   Goldman Mitchel, 2003, J Cosmet Laser Ther, V5, P107, DOI 10.1080/14769170310001267
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   HAM WTJ, 1986, INVOLVEMENT RETINAL
   Hammer M, 2006, MOL VIS, V12, P1348
   Hanifin John P., 2007, Journal of Physiological Anthropology, V26, P87, DOI 10.2114/jpa2.26.87
   Hankins MW, 2008, TRENDS NEUROSCI, V31, P27, DOI 10.1016/j.tins.2007.11.002
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Horn M, 2003, BRIT J DERMATOL, V149, P1242, DOI 10.1111/j.1365-2133.2003.05600.x
   Hui S, 2009, PHOTOCHEM PHOTOBIOL, V85, P966, DOI 10.1111/j.1751-1097.2008.00506.x
   Itkin A, 2004, DERMATOL SURG, V30, P1054, DOI 10.1111/j.1524-4725.2004.30317.x
   Jeffes EW, 1997, ARCH DERMATOL, V133, P727, DOI 10.1001/archderm.133.6.727
   Kawada A, 2002, J DERMATOL SCI, V30, P129, DOI 10.1016/S0923-1811(02)00068-3
   KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   LAWWILL T, 1977, DOC OPHTHALMOL, V44, P379
   Lee C, 2006, CHRONOBIOL INT, V23, P859, DOI 10.1080/07420520600827160
   MacCormack MA, 2008, SEMIN CUTAN MED SURG, V27, P52, DOI 10.1016/j.sder.2007.12.001
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   Mainster MA, 2007, CATARACT SURG
   Mainster MA, 2009, AM J OPHTHALMOL, V147, P8, DOI 10.1016/j.ajo.2008.08.020
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Nestor Mark S, 2006, J Drugs Dermatol, V5, P140
   Nybaek H, 2005, DERMATOLOGY, V211, P135, DOI 10.1159/000086443
   Richey DF, 2007, DERMATOL CLIN, V25, P59, DOI 10.1016/j.det.2006.09.001
   Sasseville A, 2006, J PINEAL RES, V41, P73, DOI 10.1111/j.1600-079X.2006.00332.x
   Schroeter CA, 2005, DERMATOL SURG, V31, P71, DOI 10.1097/00042728-200501000-00013
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SIMONS K, 1993, ARCH OPHTHALMOL-CHIC, V111, P297, DOI 10.1001/archopht.1993.01090030015002
   Sliney DH, 2002, INT J TOXICOL, V21, P501, DOI 10.1080/10915810290169927
   SLINEY DH, 1994, INT LIGHT CONTR ENV, P183
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soler AM, 1999, ACTA DERM-VENEREOL, V79, P204
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Szeimies RM, 1996, DERMATOLOGY, V192, P246, DOI 10.1159/000246376
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Touma D, 2004, ARCH DERMATOL, V140, P33, DOI 10.1001/archderm.140.1.33
   TSO MOM, 1979, INVEST OPHTH VIS SCI, V18, P447
   Tzung TY, 2004, PHOTODERMATOL PHOTO, V20, P266, DOI 10.1111/j.1600-0781.2004.00109.x
   Van Someren EJW, 2002, PROG BRAIN RES, V138, P205, DOI 10.1016/S0079-6123(02)38080-4
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zeitouni NC, 2003, MOL IMMUNOL, V39, P1133, DOI 10.1016/S0161-5890(03)00083-X
NR 74
TC 11
Z9 12
U1 6
U2 28
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JAN
PY 2012
VL 66
IS 1
BP 130
EP 135
DI 10.1016/j.jaad.2010.11.040
PG 6
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 871BH
UT WOS:000298712100018
PM 21536341
OA Bronze
DA 2022-11-30
ER

PT J
AU Anderson, OA
   Bainbridge, JWB
   Shima, DT
AF Anderson, Owen A.
   Bainbridge, James W. B.
   Shima, David T.
TI Delivery of anti-angiogenic molecular therapies for retinal disease
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID EPITHELIUM-DERIVED FACTOR; INHIBITS CHOROIDAL NEOVASCULARIZATION; LEBERS
   CONGENITAL AMAUROSIS; DRUG-DELIVERY; MACULAR DEGENERATION;
   GENE-TRANSFER; CYTOMEGALOVIRUS RETINITIS; POSTERIOR SEGMENT; INTRAOCULAR
   IMPLANTS; GANCICLOVIR IMPLANT
AB Angiogenic diseases of the retina are the leading cause of blindness in the developed world. The development of anti-angiogenic molecular therapies has transformed the prognosis of these conditions, especially age-related macular degeneration. With these new treatments comes the new challenge of delivering an effective dosage to the retina, over a prolonged period of time and in a safe and cost-effective manner. A range of new anti-angiogenics are on the horizon, offering new and varied modes of drug delivery. In addition, a range of new sustained-release drug delivery technologies are being developed.
C1 [Anderson, Owen A.; Bainbridge, James W. B.; Shima, David T.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London
RP Anderson, OA (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM o.anderson@ucl.ac.uk
OI Bainbridge, James/0000-0003-1318-8201
CR Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Anderson OA, 2008, INVEST OPHTH VIS SCI, V49, P4041, DOI 10.1167/iovs.07-1660
   Auricchio A, 2002, MOL THER, V6, P238, DOI 10.1006/mthe.2002.0660
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bainbridge JWB, 2003, GENE THER, V10, P1049, DOI 10.1038/sj.gt.3301945
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bejjani R, 2005, MOL VIS, V11, P124
   BILL A, 1964, EXP EYE RES, V3, P179, DOI 10.1016/S0014-4835(64)80033-6
   Bochot A, 1998, J DRUG TARGET, V6, P309, DOI 10.3109/10611869808996838
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   de Carvalho RAP, 2006, INVEST OPHTH VIS SCI, V47, P4532, DOI 10.1167/iovs.06-0030
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Dunn JP, 2004, RETINA-J RET VIT DIS, V24, P41, DOI 10.1097/00006982-200402000-00007
   Eljarrat-Binstock E, 2008, J CONTROL RELEASE, V126, P156, DOI 10.1016/j.jconrel.2007.11.016
   FITZGERALD P, 1987, J PHARM PHARMACOL, V39, P487, DOI 10.1111/j.2042-7158.1987.tb03428.x
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gilger BC, 2006, INVEST OPHTH VIS SCI, V47, P2596, DOI 10.1167/iovs.05-1540
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Halhal M, 2004, EXP EYE RES, V78, P751, DOI 10.1016/j.exer.2003.10.017
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hoane MR, 2000, EXP NEUROL, V162, P189, DOI 10.1006/exnr.2000.7311
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hori Y, 1996, BRIT J PHARMACOL, V118, P1584, DOI 10.1111/j.1476-5381.1996.tb15578.x
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   KIMURA H, 2006, INTRAOCULAR DRUG DEL, P175
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Kunou N, 2000, J CONTROL RELEASE, V68, P263, DOI 10.1016/S0168-3659(00)00267-4
   Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   LAVINSKY D, 2008, INVEST OPHTHALMOL VI, V49
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   Li H, 2006, EXP EYE RES, V83, P824, DOI 10.1016/j.exer.2006.04.014
   Liu WG, 1998, ANTIMICROB AGENTS CH, V42, P1417, DOI 10.1128/AAC.42.6.1417
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   Pearson P, 2006, INVEST OPHTH VIS SCI, V47, P5442
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Prausnitz MR, 1998, J PHARM SCI, V87, P1479, DOI 10.1021/js9802594
   Presta LG, 1997, CANCER RES, V57, P4593
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691
   Riely G, 2007, CLIN CANCER RES, V13, p4623S, DOI 10.1158/1078-0432.CCR-07-0544
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   *ROYAL COLL OPHTH, 2008, GUID RAN CLIN GUID C
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Sanftner LHM, 2001, MOL THER, V3, P688, DOI 10.1006/mthe.2001.0308
   Schmidt PG, 2007, EXPERT OPIN BIOL TH, V7, P1427, DOI 10.1517/14712598.7.9.1427
   Shane TS, 2003, AM J OPHTHALMOL, V136, P649, DOI 10.1016/S0002-9394(03)00333-7
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Steinkuller PG, 1999, J AAPOS, V3, P26, DOI 10.1016/S1091-8531(99)70091-1
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126
   Vandervoort J, 2007, NANOMEDICINE-UK, V2, P11, DOI 10.2217/17435889.2.1.11
   Voigt M, 2002, BIOCHEM BIOPH RES CO, V295, P336, DOI 10.1016/S0006-291X(02)00656-3
   WANG W, 1991, CURR EYE RES, V10, P571, DOI 10.3109/02713689109001766
NR 78
TC 24
Z9 28
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD APR
PY 2010
VL 15
IS 7-8
SI SI
BP 272
EP 282
DI 10.1016/j.drudis.2010.02.004
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 586FK
UT WOS:000276888300005
PM 20184967
DA 2022-11-30
ER

PT J
AU Wang, J
   Shi, X
   Bo, QY
   Wang, H
   Wei, F
   Liu, J
   Wang, H
   Zhang, LW
   Qi, Y
   Li, Z
   Chen, QX
   Sun, XD
AF Wang, Jing
   Shi, Xiang
   Bo, Qiyu
   Wang, Hong
   Wei, Fang
   Liu, Jun
   Wang, Hao
   Zhang, Liuwei
   Qi, Yan
   Li, Zhen
   Chen, Qixian
   Sun, Xiaodong
TI Original Research Paper Synthetic anti-angiogenic genomic therapeutics
   for treatment of neovascular age-related macular degeneration
SO ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; Anti-angiogenesis; Gene therapy;
   Polymer; Vascular endothelial growth factor
ID CHOROIDAL NEOVASCULARIZATION; GENE-THERAPY; BEVACIZUMAB; RANIBIZUMAB;
   INHIBITION
AB In light of the intriguing potential of anti-angiogenic approach in suppressing choroidal neovascularization, we attempted to elaborate synthetic gene delivery systems encapsulating anti-angiogenic plasmid DNA as alternatives of clinical antibody-based therapeutics. Herein, block copolymer of cyclic Arg-Gly-Asp-poly(ethylene glycol)poly(lysine-thiol) [RGD-PEG-PLys(thiol)] with multifunctional components was tailored in manufacture of core-shell DNA delivery nanoparticulates. Note that the polycationic PLys segments were electrostatically complexed with anionic plasmid DNA into nanoscaled core, and the tethered biocompatible PEG segments presented as the spatial shell (minimizing non-specific reactions in biological milieu). Furthermore, the aforementioned self-assembly was introduced with redox-responsive disulfide crosslinking due to the thiol coupling. Hence, reversible stabilities, namely stable in extracellular milieu but susceptible to disassemble for liberation of the DNA payloads in intracellular reducing microenvironment, were verified to facilitate transcellular gene transportation. In addition, RGD was installed onto the surface of the proposed self-assemblies with aim of targeted accumulation and internalization into angiogenic endothelial cells given that RGD receptors were specifically overexpressed on their cytomembrane surface. The proposed anti-angiogenic DNA therapeutics were validated to exert efficient expression of anti-angiogenic proteins in endothelial cells and elicit potent inhibition of ocular neovasculature post intravitreous administration. Hence, the present study approved the potential of gene therapy in treatment of choroidal neovascularization. In light of sustainable gene expression properties of DNA therapeutics, our proposed synthetic gene delivery system inspired prosperous potentials in long-term treatment of choroidal neovascularization, which should be emphasized to develop further towards clinical translations. (C) 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V.
C1 [Wang, Jing; Shi, Xiang; Bo, Qiyu; Wang, Hong; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai 200080, Peoples R China.
   [Wei, Fang; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Ocular Fundus Dis, Sch Med, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Sch Med, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Natl Clin Res Ctr Eye Dis, Sch Med, Shanghai 200080, Peoples R China.
   [Liu, Jun] Ningbo Hygeia Med Technol Co Ltd, Ningbo 315201, Peoples R China.
   [Wang, Hao; Zhang, Liuwei; Chen, Qixian] Dalian Univ Technol, Sch Bioengn, Dalian 116024, Peoples R China.
   [Qi, Yan; Li, Zhen] Dalian Med Univ, Coll Pharm, Dalian 116044, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Dalian University
   of Technology; Dalian Medical University
RP Chen, QX (通讯作者)，Dalian Univ Technol, Sch Bioengn, Dalian 116024, Peoples R China.
EM qixian@dlut.edu.cn; xdsun@sjtu.edu.cn
OI Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [81900869, 81730026,
   81802482]; National Key RD Program [2019YFC0840607, 2017YFA0105301];
   Science and Technology Commission of Shanghai Municipality [17411953000,
   19495800700]; Shanghai Sailing Program [19YF1439500]; Talent Project of
   Revitalizing Liaoning [XLYC1807184]; Dalian Science&Technology
   Innovation Fund [2020JJ26SN050]
FX This research was funded by National Natural Science Foundation of China
   (81900869, 81730026, 81802482), National Key R&D Program
   (2019YFC0840607, 2017YFA0105301), Science and Technology Commission of
   Shanghai Municipality (17411953000, 19495800700), Shanghai Sailing
   Program (19YF1439500), Talent Project of Revitalizing Liaoning
   (XLYC1807184), and Dalian Science&Technology Innovation Fund
   (2020JJ26SN050).
CR Alharbi NK, 2016, VACCINE, V34, P49, DOI 10.1016/j.vaccine.2015.11.028
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Aya I, 2011, PLOS ONE, V6
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cabral H, 2018, CHEM REV, V118, P6844, DOI 10.1021/acs.chemrev.8b00199
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Endo T, 2012, DRUG DELIV TRANSL RE, V2, P398, DOI 10.1007/s13346-012-0091-1
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Hutton-Smith LA, 2018, MOL PHARMACEUT, V15, P2770, DOI 10.1021/acs.molpharmaceut.8b00280
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Ma CY, 2016, BIOCONJUGATE CHEM, V27, P1005, DOI 10.1021/acs.bioconjchem.6b00048
   Maier M, 2008, KLIN MONATSBL AUGENH, V225, P818, DOI 10.1055/s-2008-1027638
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Michaelsen SR, 2018, NEURO-ONCOLOGY, V20, P1462, DOI 10.1093/neuonc/noy103
   Osada K, 2010, J AM CHEM SOC, V132, P12343, DOI 10.1021/ja102739b
   Qu Y, 2019, J CONTROL RELEASE, V296, P93, DOI 10.1016/j.jconrel.2019.01.016
   Reid CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29726-7
   RUSSO A, 1986, CANCER RES, V46, P2845
   Schechet S, 2018, OSLI RETINA, V49, P80, DOI 10.3928/23258160-20180129-01
   Takeda KM, 2017, BIOMACROMOLECULES, V18, P36, DOI 10.1021/acs.biomac.6b01247
   Tockary TA, 2016, SMALL, V12, P1193, DOI 10.1002/smll.201501815
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yan ZZ, 2018, MOL VIS, V24, P83
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 28
TC 0
Z9 0
U1 2
U2 9
PU SHENYANG PHARMACEUTICAL UNIV
PI SHENYANG
PA SHENYANG PHARMACEUTICAL UNIV, NO 103, WENHUA RD, SHENYANG, 110016,
   PEOPLES R CHINA
SN 1818-0876
J9 ASIAN J PHARM SCI
JI Asian J. Pharm. Sci.
PD SEP
PY 2021
VL 16
IS 5
BP 623
EP 632
DI 10.1016/j.ajps.2021.04.001
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XA8WD
UT WOS:000720919900008
PM 34849167
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Alhamzawi, R
   Yu, KM
AF Alhamzawi, Rahim
   Yu, Keming
TI Bayesian Lasso-mixed quantile regression
SO JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION
LA English
DT Article
DE asymmetric Laplace distribution; Gibbs sampler; random effects;
   longitudinal data; quantile regression
ID SELECTION
AB In this paper, we discuss the regularization in linear-mixed quantile regression. A hierarchical Bayesian model is used to shrink the fixed and random effects towards the common population values by introducing an l(1) penalty in the mixed quantile regression check function. A Gibbs sampler is developed to simulate the parameters from the posterior distributions. Through simulation studies and analysis of an age-related macular degeneration (ARMD) data, we assess the performance of the proposed method. The simulation studies and the ARMD data analysis indicate that the proposed method performs well in comparison with the other approaches.
C1 [Alhamzawi, Rahim; Yu, Keming] Brunel Univ, Dept Math Sci, Uxbridge UB8 3PH, Middx, England.
C3 Brunel University
RP Alhamzawi, R (通讯作者)，Brunel Univ, Dept Math Sci, Uxbridge UB8 3PH, Middx, England.
EM rahim.al-hamzawi@brunel.ac.uk
RI Alhamzawi, Rahim/F-3390-2014
OI Alhamzawi, Rahim/0000-0003-1912-9579
CR Adler D, 2005, VIOPLOT VIOLIN PLOT
   Akaike H., 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15
   Alhamzawi R., 2012, COMPUT STAT IN PRESS
   Alhamzawi R, 2012, STAT MODEL, V12, P279, DOI 10.1177/1471082X1101200304
   ANDREWS DF, 1974, J ROY STAT SOC B MET, V36, P99
   Bob W., 2009, SUPPDISTS SUPPLEMENT
   Bondell HD, 2010, BIOMETRICS, V66, P1069, DOI 10.1111/j.1541-0420.2010.01391.x
   Bradic J, 2011, J R STAT SOC B, V73, P325, DOI 10.1111/j.1467-9868.2010.00764.x
   Chaili P.X., 2008, THESIS U MANCHESTER
   Chen Z, 2003, BIOMETRICS, V59, P762, DOI 10.1111/j.0006-341X.2003.00089.x
   Chhikara RS., 1989, INVERSE GAUSSIAN DIS
   Ibrahim JG, 2011, BIOMETRICS, V67, P495, DOI 10.1111/j.1541-0420.2010.01463.x
   Kinney SK, 2007, BIOMETRICS, V63, P690, DOI 10.1111/j.1541-0420.2007.00771.x
   KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643
   Koenker R, 1999, J AM STAT ASSOC, V94, P1296, DOI 10.2307/2669943
   Koenker R., 2012, QUANTREG QUANTILE RE
   Koenker R., 2005, QUANTILE REGRESSION, DOI DOI 10.1017/CBO9780511754098
   Kozumi H, 2011, J STAT COMPUT SIM, V81, P1565, DOI 10.1080/00949655.2010.496117
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Li Q, 2010, BAYESIAN ANAL, V5, P151, DOI 10.1214/10-BA506
   Li YJ, 2008, J COMPUT GRAPH STAT, V17, P163, DOI 10.1198/106186008X289155
   Luo YX, 2012, J STAT COMPUT SIM, V82, P1635, DOI 10.1080/00949655.2011.590488
   Park T, 2008, J AM STAT ASSOC, V103, P681, DOI 10.1198/016214508000000337
   Reed C, 2009, PARTIALLY COLLAPSED
   Saville BR, 2009, BIOMETRICS, V65, P369, DOI 10.1111/j.1541-0420.2008.01107.x
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Wu YC, 2009, STAT SINICA, V19, P801
   Yu KM, 2003, J ROY STAT SOC D-STA, V52, P331, DOI 10.1111/1467-9884.00363
   Yu KM, 2001, STAT PROBABIL LETT, V54, P437, DOI 10.1016/S0167-7152(01)00124-9
   Zou H, 2008, ANN STAT, V36, P1108, DOI 10.1214/07-AOS507
NR 30
TC 15
Z9 16
U1 0
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0094-9655
EI 1563-5163
J9 J STAT COMPUT SIM
JI J. Stat. Comput. Simul.
PY 2014
VL 84
IS 4
BP 868
EP 880
DI 10.1080/00949655.2012.731689
PG 13
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematics
GA AI4KM
UT WOS:000336834100011
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Johnson, T
   Rovner, B
   Haller, J
AF Johnson, T.
   Rovner, B.
   Haller, J.
TI Suicide and Visual Loss: A Case Report Reflecting the Need for
   Recognition and Management in Ophthalmological Settings
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; blindness; depressive symptoms;
   suicide; suicidal ideation
ID QUALITY-OF-LIFE; DIMINISHED PERCEPTION; DEPRESSIVE SYMPTOMS; VISION;
   IMPAIRMENT; DISEASE; LIGHT
AB In the United States, 5.5 million people over the age of 40 meet criteria for visual impairment (VI). They often suffer significant psychosocial and health consequences, including reduced quality of life and depression, which can be persistent and difficult to treat. Additionally, VI may increase the risk of suicide. We report a case of a patient with age-related macular degeneration (ARMD) and suicidal ideation. While this link is reasonable, there are no prior cases of suicidality among patients with ARMD. Moreover, the literature is silent regarding proper approaches to diagnosing and managing suicidality among patients with VI, especially ARMD.
C1 [Johnson, T.; Haller, J.] Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA.
   [Rovner, B.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Johnson, T (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, 840 Walnut St, Philadelphia, PA 19107 USA.
EM timothyvjohnson@gmail.com
CR Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bookwala J, 2011, GERONTOLOGIST, V51, P798, DOI 10.1093/geront/gnr051
   Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Burack-Weiss A, 1992, AGEING EYE LOW VISIO
   CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Friberg TR, 2008, J AFFECT DISORDERS, V108, P235, DOI 10.1016/j.jad.2007.10.021
   Friberg TR, 2000, J AFFECT DISORDERS, V61, P113, DOI 10.1016/S0165-0327(99)00194-9
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Kupfer C, 2000, OPHTHALMOLOGY, V107, P229, DOI 10.1016/S0161-6420(99)00094-9
   Lam BL, 2008, ARCH OPHTHALMOL-CHIC, V126, P975, DOI DOI 10.1001/ARCH0PHT.126.7.975
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Rosenberg EA, 2008, AM FAM PHYSICIAN, V77, P1431
   Tasman W, 2004, ARCH OPHTHALMOL-CHIC, V122, P648, DOI 10.1001/archopht.122.4.648
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   World Health Organization, INT STAT CLASS DIS R, V10
NR 20
TC 7
Z9 7
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JUL
PY 2014
VL 29
IS 4
BP 202
EP 204
DI 10.3109/08820538.2013.821500
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AI7BM
UT WOS:000337035200007
PM 24702438
DA 2022-11-30
ER

PT J
AU Ramsden, CM
   Powner, MB
   Carr, AJF
   Smart, MJK
   da Cruz, L
   Coffey, PJ
AF Ramsden, Conor M.
   Powner, Michael B.
   Carr, Amanda-Jayne F.
   Smart, Matthew J. K.
   da Cruz, Lyndon
   Coffey, Peter J.
TI Stem cells in retinal regeneration: past, present and future
SO DEVELOPMENT
LA English
DT Review
DE Age-related macular degeneration; Retinitis pigmentosa; Stargardt's
   disease; Stem cells; Clinical trials
ID PIGMENT EPITHELIUM; INDUCED PLURIPOTENT; MACULAR DEGENERATION; IN-VITRO;
   DIRECTED DIFFERENTIATION; BRUCHS MEMBRANE; RODENT MODEL;
   TRANSPLANTATION; RPE; RESCUE
AB Stem cell therapy for retinal disease is under way, and several clinical trials are currently recruiting. These trials use human embryonic, foetal and umbilical cord tissue-derived stem cells and bone marrow-derived stem cells to treat visual disorders such as age-related macular degeneration, Stargardt's disease and retinitis pigmentosa. Over a decade of analysing the developmental cues involved in retinal generation and stem cell biology, coupled with extensive surgical research, have yielded differing cellular approaches to tackle these retinopathies. Here, we review these various stem cell-based approaches for treating retinal diseases and discuss future directions and challenges for the field.
C1 [Ramsden, Conor M.; Powner, Michael B.; Carr, Amanda-Jayne F.; Smart, Matthew J. K.; da Cruz, Lyndon; Coffey, Peter J.] UCL, Inst Ophthalmol, Div ORBIT, London Project Cure Blindness, London EC1V 9EL, England.
   [Ramsden, Conor M.; da Cruz, Lyndon] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.
   [Ramsden, Conor M.; da Cruz, Lyndon] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Coffey, Peter J.] Univ Calif Santa Barbara, NRI, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of
   California System; University of California Santa Barbara
RP Coffey, PJ (通讯作者)，UCL, Inst Ophthalmol, Div ORBIT, London Project Cure Blindness, 11-43 Bath St, London EC1V 9EL, England.
EM p.coffey@ucl.ac.uk
RI Powner, Michael/CAG-7455-2022; Carr, Amanda/ABG-6282-2020
OI Carr, Amanda/0000-0002-5469-0030; Powner, Michael/0000-0003-4913-1004;
   Coffey, Peter/0000-0002-5427-2939
FU London Project to Cure Blindness; Medical Research Council (MRC) UK;
   California Institute of Regenerative Medicine (CIRM); Fight for Sight
   UK; Lincy Foundation; Macular Society; National Institute for Health
   Research (NIHR) Biomedical Research Centre based at Moorfields Eye
   Hospital National Health Service (NHS) Foundation Trust; University
   College London Institute of Ophthalmology; MRC [G1000730, G0300288]
   Funding Source: UKRI; Medical Research Council [G1000730, G0300288]
   Funding Source: researchfish
FX This work was supported by funding from The London Project to Cure
   Blindness; the Medical Research Council (MRC) UK; the California
   Institute of Regenerative Medicine (CIRM); Fight for Sight UK; The Lincy
   Foundation; the Macular Society; and the National Institute for Health
   Research (NIHR) Biomedical Research Centre based at Moorfields Eye
   Hospital National Health Service (NHS) Foundation Trust and University
   College London Institute of Ophthalmology. The views expressed are those
   of the author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health. Deposited in PMC for release after 12 months.
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL, V119, P1417
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Garita-Hernandez M, 2013, STEM CELLS, V31, P966, DOI 10.1002/stem.1339
   Giansanti F., 2009, COCHRANE DB SYST REV, V4
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kumar A., 2012, WORLD J RETINA VIT, V2, P5
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Larijani Bagher, 2012, Acta Med Iran, V50, P79
   Li M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-100
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pappa KI, 2009, REGEN MED, V4, P423, DOI 10.2217/RME.09.12
   Park SS, 2012, INVEST OPHTH VIS SCI, V53, P986, DOI 10.1167/iovs.11-8833
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singhal S, 2012, STEM CELL TRANSL MED, V1, P188, DOI 10.5966/sctm.2011-0005
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Yang ZL, 2008, J CLIN INVEST, V118, P2908, DOI 10.1172/JCI35891
   Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang K., 2001, NAT GENET, V27, P151
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zimmermann A, 2012, STEM CELLS DEV, V21, P2364, DOI 10.1089/scd.2012.0088
NR 86
TC 186
Z9 197
U1 2
U2 102
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD JUN 15
PY 2013
VL 140
IS 12
BP 2576
EP 2585
DI 10.1242/dev.092270
PG 10
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA 154EY
UT WOS:000319655800016
PM 23715550
OA Green Published
DA 2022-11-30
ER

PT J
AU Boulton, M
   Rozanowska, M
   Wess, T
AF Boulton, M
   Rozanowska, M
   Wess, T
TI Ageing of the retinal pigment epithelium: implications for
   transplantation
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
ID HUMAN OCULAR LIPOFUSCIN; LIGHT-INDUCED DAMAGE; HUMAN RPE CELLS; AGE
   PIGMENT; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE; PHOTORECEPTOR
   LOSS; GENE-THERAPY; VITAMIN-E; MELANIN
AB This review will discuss some of the implications for using cells from aged donors for retinal pigment epithelium (RPE) transplantation. It will consider age-related changes in the structure and function of RPE cells and the accumulation of potentially damaging photoreactive constituents. The review will focus on the role of the ocular pigments lipofuscin and melanin in respect to age-related changes in composition, photoreactivity and potential role in retinal ageing and age-related macular degeneration. The article concludes by considering the suitability of senescent RPE cells for transplantation and whether such cells can be rejuvenated.
C1 Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, S Glam, Wales.
C3 Cardiff University
RP Boulton, M (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, S Glam, Wales.
EM boultonm@cf.ac.uk
RI Rozanowska, Malgorzata B/B-7860-2014; Rozanowska,
   Malgorzata/AAD-4806-2021
OI Rozanowska, Malgorzata B/0000-0003-2913-8954; Rozanowska,
   Malgorzata/0000-0003-2913-8954
CR Abe T, 1996, EXP EYE RES, V63, P201, DOI 10.1006/exer.1996.0109
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   BOULTON M, 2004, IN PRESS MACULA
   BRIZZEE KR, 1981, AGE PIGMENTS, P101
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cantrell A, 2001, J PHOTOCH PHOTOBIO B, V64, P162, DOI 10.1016/S1011-1344(01)00224-X
   Clancy CMR, 2000, J PHYS CHEM B, V104, P12098, DOI 10.1021/jp0030544
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Dayhaw-Barker P, 2001, INVEST OPHTH VIS SCI, V42, pS755
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GAILLARD ER, 2003, INV OPHTH VIS SCI AB, V377
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Haralampus-Grynaviski NM, 2001, PHOTOCHEM PHOTOBIOL, V74, P364, DOI 10.1562/0031-8655(2001)074<0364:PTSDOT>2.0.CO;2
   Hjelmeland LM, 1999, INVEST OPHTH VIS SCI, V40, P1
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOLZ FG, 1999, INVEST OPHTH VIS SCI, V41, P2303
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Krogmeier JR, 2001, J MICROSC-OXFORD, V202, P386, DOI 10.1046/j.1365-2818.2001.00855.x
   Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177
   Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   MAHAFFY H, 2003, INVEST OPHTHALMOL VI
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Narfstrom K, 2003, J HERED, V94, P31, DOI 10.1093/jhered/esg015
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Pawlak A, 2002, ARCH BIOCHEM BIOPHYS, V403, P59, DOI 10.1016/S0003-9861(02)00260-6
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   ROZANOWSKA M, 2004, INV OPHTH VIS SCI AB, V678
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Simovich M J, 2001, Hum Mutat, V18, P164, DOI 10.1002/humu.1168
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   SOHAL RS, 1981, AGE PIGMENTS
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Thompson DA, 2002, AM J HUM GENET, V70, P224, DOI 10.1086/338455
   Wang Q, 2001, Ophthalmic Genet, V22, P133, DOI 10.1076/opge.22.3.133.2224
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
NR 83
TC 47
Z9 47
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2004
VL 242
IS 1
BP 76
EP 84
DI 10.1007/s00417-003-0812-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766PU
UT WOS:000188385400013
PM 14663593
DA 2022-11-30
ER

PT J
AU McNabb, RP
   Tian, J
   Farsiu, S
   Izatt, JA
   Lad, EM
   Kuo, AN
AF McNabb, Ryan P.
   Tian, James
   Farsiu, Sina
   Izatt, Joseph A.
   Lad, Eleonora M.
   Kuo, Anthony N.
TI Retinal imaging in human autopsy eyes using a custom optical coherence
   tomography periscope
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID MACULAR DEGENERATION; SDOCT; MICROSCOPY; IMAGES; WIDE
AB Age-related macular degeneration (AMD) is a major cause of vision loss in the elderly. To better study the pathobiology of AMD, postmortem eyes offer an excellent opportunity to correlate optical coherence tomography (OCT) imaging characteristics with histopathology. However, postmortem eyes from autopsy present challenges to standard OCT imaging including opaque anterior segment structures and standard of care autopsy processing resulting in oblique views to the macula. To overcome these challenges, we report a custom periscope attached by a standard mount to an OCT sample arm and demonstrate high quality macular OCT acquisitions in autopsy-processed eyes. (C) 2017 Optical Society of America
C1 [McNabb, Ryan P.; Tian, James; Farsiu, Sina; Izatt, Joseph A.; Lad, Eleonora M.; Kuo, Anthony N.] Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27705 USA.
   [Farsiu, Sina; Izatt, Joseph A.; Kuo, Anthony N.] Duke Univ, Dept Biomed Engn, 101 Sci Dr, Durham, NC 27708 USA.
C3 Duke University; Duke University
RP McNabb, RP (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27705 USA.
EM ryan.mcnabb@dm.duke.edu
RI Izatt, Joseph/C-9067-2014
OI Izatt, Joseph/0000-0003-1993-2249; Farsiu, Sina/0000-0003-4872-2902
FU National Institutes of Health [R01-EY024312, R21-EY025427, R01-EY023039,
   5K12-EY016333-08]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY023039, K12EY016333, K23EY026988, P30EY005722, R01EY024312,
   R21EY025428] Funding Source: NIH RePORTER
FX We acknowledge support from the National Institutes of Health
   (R01-EY024312, R21-EY025427, R01-EY023039, 5K12-EY016333-08) and
   Research to Prevent Blindness Ernest & Elizabeth Althouse Special
   Scholar Award.
CR Ahsen OO, 2013, OPT EXPRESS, V21, P18021, DOI 10.1364/OE.21.018021
   American Academy of Ophthalmology, 2015, AG REL MAC DEG PREF
   Bagheri N, 2012, ADV EXP MED BIOL, V723, P479, DOI 10.1007/978-1-4614-0631-0_60
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Izatt JA, 2008, BIOL MED PHYS BIOMED, P47, DOI 10.1007/978-3-540-77550-8_2
   IZATT JA, 1994, OPT LETT, V19, P590, DOI 10.1364/OL.19.000590
   McNabb R. P., 2017, DMLS PERISCOPE STL
   McNabb RP, 2016, BRIT J OPHTHALMOL, V100, P1377, DOI 10.1136/bjophthalmol-2015-307480
   McNabb RP, 2012, BIOMED OPT EXPRESS, V3, P2050, DOI 10.1364/BOE.3.002050
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
NR 17
TC 2
Z9 2
U1 0
U2 2
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD SEP 1
PY 2017
VL 8
IS 9
BP 4152
EP 4159
DI 10.1364/BOE.8.004152
PG 8
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FF5IS
UT WOS:000409020600019
PM 28966854
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, JQ
   Deng, H
   Xie, J
   Liu, X
   Zhang, Y
   Huang, NY
   Gu, Y
AF Zhao, Jingquan
   Deng, Hong
   Xie, Jie
   Liu, Xin
   Zhang, Yang
   Huang, Naiyan
   Gu, Ying
TI Towards Characteristics of Photodynamic Drugs Specifically Aimed at
   Microvascular Diseases
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Photodynamic therapy (PDT); Photosensitizers; Solid tumor; Microvascular
   disease; Target-related characteristic drug; Drug delivery; Biological
   activity; Drug preparation
ID HYPOCRELLIN-B; MACULAR DEGENERATION; SINGLET OXYGEN; ANTICANCER AGENTS;
   THERAPY; ESR; TUMOR; PHOTOSENSITIZATION; PERYLENEQUINONES;
   PHOTOGENERATION
AB Photodynamic therapy (PDT) is a versatile methodology to treat various diseases but the drugs (photosensitizers) specifically aimed at individual character of diseases are urgently needed. Among those, the perilenoquinoid photosensitizers were thought of low PDT effectiveness to solid tumors due to low absorption on the "photodynamic window" but may be specially suitable for PDT to some microvascular diseases, such as age-related macular degeneration (AMD) and port wine stains (PWS), as well as other superficial diseases. Two strategies were discussed to convert the photosensitizers into clinically acceptable drugs in consideration of the drug-delivery and biological activity.
C1 [Zhao, Jingquan; Deng, Hong; Xie, Jie; Liu, Xin; Zhang, Yang] Chinese Acad Sci, Inst Chem, Key Lab Photochem, BNLMS, Beijing 100190, Peoples R China.
   [Huang, Naiyan; Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Chemistry, CAS; Chinese
   People's Liberation Army General Hospital
RP Zhao, JQ (通讯作者)，Chinese Acad Sci, Inst Chem, Key Lab Photochem, BNLMS, 2,1st N St, Beijing 100190, Peoples R China.
EM zhaojq@iccas.ac.cn; guyinglaser@sina.com
RI zhao, jing/B-3868-2019
FU National Natural Science Foundation of China [20872144]
FX Project supported by the National Natural Science Foundation of China
   (No. 20872144).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barclay LRC, 2003, PHOTOCHEM PHOTOBIOL, V78, P248, DOI 10.1562/0031-8655(2003)078<0248:PIOSBB>2.0.CO;2
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   BERGH H, 2001, SEMINARS OPHTHALMOLO, V16, P181
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P198
   CHRISTOPHE H, 1997, PHOTOCHEM PHOTOBIOL, V65, P818
   Dewhirst MW, 2007, CLIN CANCER RES, V13, P375, DOI 10.1158/1078-0432.CCR-06-2629
   DIWU ZJ, 1992, J PHOTOCH PHOTOBIO A, V64, P273, DOI 10.1016/1010-6030(92)85002-C
   Diwu ZJJ, 1996, FREE RADICAL BIO MED, V20, P589, DOI 10.1016/0891-5849(95)02061-6
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   ERIN M, 2008, ANGEW CHEM INT EDIT, V47, P6877
   Estey EP, 1996, CANCER CHEMOTH PHARM, V37, P343, DOI 10.1007/s002800050395
   Flors C, 2006, J EXP BOT, V57, P1725, DOI 10.1093/jxb/erj181
   Grossweiner L. I., 2005, SCI PHOTOTHERAPY INT, P1
   He YY, 1998, J PHOTOCH PHOTOBIO B, V44, P45, DOI 10.1016/S1011-1344(98)00116-X
   He YY, 1998, TETRAHEDRON LETT, V39, P5069, DOI 10.1016/S0040-4039(98)00928-9
   He YY, 1998, J PHOTOCH PHOTOBIO A, V115, P213, DOI 10.1016/S1010-6030(98)00273-1
   He YY, 1999, BBA-GEN SUBJECTS, V1472, P232, DOI 10.1016/S0304-4165(99)00126-9
   He YY, 1999, DYES PIGMENTS, V44, P63, DOI 10.1016/S0143-7208(99)00074-1
   HU YZ, 1993, J PHOTOCH PHOTOBIO B, V17, P195, DOI 10.1016/1011-1344(93)80013-Y
   Hudson JB, 1997, PHOTOCHEM PHOTOBIOL, V65, P352, DOI 10.1111/j.1751-1097.1997.tb08570.x
   Immordino ML, 2006, INT J NANOMED, V1, P297
   JAIN RK, 2008, ANGIOGENESIS INTEGRA, P267
   Kaihong Z., 1989, CHINESE J ORG CHEM, V9, P252
   Kanda S, 2007, INT J MOL MED, V20, P113
   Khoobehi B, 2002, OPHTHALMIC SURG LAS, V33, P207
   LI C, 2005, Patent No. 200510010612
   Li C, 2006, CHINESE SCI BULL, V51, P1050, DOI 10.1007/s11434-006-1050-3
   Li L, 2000, BBA-GEN SUBJECTS, V1523, P6, DOI 10.1016/S0304-4165(00)00081-7
   Liu F. G., 2005, CHIN J CLIN REHABILI, V9, P254
   [刘慧龙 Liu Huilong], 2003, [中国激光医学杂志, Chinese Journal of Laser Medicine and Surgery], V12, P151
   LIU X, 2008, THESIS CHINESE ACAD
   Liu X, 2009, CHINESE SCI BULL, V54, P2045, DOI 10.1007/s11434-009-0036-3
   Liu X, 2009, J PHOTOCH PHOTOBIO B, V94, P171, DOI 10.1016/j.jphotobiol.2008.11.008
   Liu YX, 2005, J HIGH ENERGY PHYS
   Lu ZB, 2006, FREE RADICAL BIO MED, V41, P1590, DOI 10.1016/j.freeradbiomed.2006.08.021
   Ma JH, 2001, PHOTOCHEM PHOTOBIOL, V74, P143, DOI 10.1562/0031-8655(2001)074<0143:EOSMOP>2.0.CO;2
   Ma L, 2003, WORLD J GASTROENTERO, V9, P485, DOI 10.3748/wjg.v9.i3.485
   Miller GG, 1997, PHOTOCHEM PHOTOBIOL, V65, P714, DOI 10.1111/j.1751-1097.1997.tb01915.x
   MIN W, 1997, DYES PIGMENTS, V35, P297
   Nielsen KP, 2005, PHOTOCHEM PHOTOBIOL, V81, P1190, DOI 10.1562/2005-04-06-RA-478
   Ou ZZ, 2002, NEW J CHEM, V26, P1130, DOI 10.1039/b202439j
   Rajkumar SV, 2002, J HEMATOTH STEM CELL, V11, P33, DOI 10.1089/152581602753448522
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   SHOPOVA M, 1992, J PHOTOCH PHOTOBIO B, V16, P83, DOI 10.1016/1011-1344(92)85155-N
   Smirnov A, 1999, J AM CHEM SOC, V121, P7979, DOI 10.1021/ja9906002
   Song LM, 2007, PHOTOCH PHOTOBIO SCI, V6, P683, DOI 10.1039/b618678e
   Song LM, 2006, BBA-GEN SUBJECTS, V1760, P333, DOI 10.1016/j.bbagen.2006.01.001
   Song YH, 1999, FREE RADICAL RES, V31, P477, DOI 10.1080/10715769900301041
   Song YZ, 1999, BBA-GEN SUBJECTS, V1472, P307, DOI 10.1016/S0304-4165(99)00137-3
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Torchilin V., 2003, LIPOSOMES PRACTICAL
   Wang L, 2007, SPECTROSC SPECT ANAL, V27, P1788
   Wang ZJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P773, DOI 10.1562/0031-8655(1999)070<0773:PTDAPT>2.3.CO;2
   Weng M, 1997, J CHEM SOC FARADAY T, V93, P3491, DOI 10.1039/a700842b
   Wu T, 2000, ANTI-CANCER DRUG DES, V15, P287
   WU ZD, 1990, PHOTOCHEM PHOTOBIOL, V52, P609
   Xu SJ, 2004, BIOORG MED CHEM LETT, V14, P1499, DOI 10.1016/j.bmcl.2004.01.003
   Xu SJ, 2003, J PHOTOCH PHOTOBIO B, V72, P61, DOI 10.1016/j.jphotobiol.2003.09.001
   Xu SJ, 2003, J ORG CHEM, V68, P2048, DOI 10.1021/jo026554x
   Young AE, 1988, VASCULAR BIRTHMARKS, P24
   Zhang H, 2003, CHINESE J ELECTRON, V12, P75
   Zhao BZ, 2006, BIOORGAN MED CHEM, V14, P2428, DOI 10.1016/j.bmc.2005.11.022
   Zhao BZ, 2005, BBA-GEN SUBJECTS, V1722, P124, DOI 10.1016/j.bbagen.2004.12.009
   Zhao BZ, 2004, BBA-GEN SUBJECTS, V1670, P113, DOI 10.1016/j.bbagen.2003.10.018
   ZHAO JQ, 2008, Patent No. 2008101012180
   ZHAO JQ, 2003, Patent No. 20031481477
   ZHAO JQ, 2006, Patent No. 2006100016772
   ZHAO JQ, 2007, Patent No. 2007101207273
   Zhao YW, 2004, NEW J CHEM, V28, P484, DOI 10.1039/b311023k
   Zhao YW, 2004, DYES PIGMENTS, V63, P175, DOI 10.1016/j.dyepig.2004.02.010
   Zhao YW, 2003, NEW J CHEM, V27, P880, DOI 10.1039/b211388k
NR 74
TC 5
Z9 9
U1 1
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD APR
PY 2010
VL 10
IS 4
BP 332
EP 341
DI 10.2174/138955710791330963
PG 10
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 599BX
UT WOS:000277886300006
PM 20105128
DA 2022-11-30
ER

PT J
AU Ng, EWM
   Shima, DT
   Calias, P
   Cunningham, ET
   Guyer, DR
   Adamis, AP
AF Ng, EWM
   Shima, DT
   Calias, P
   Cunningham, ET
   Guyer, DR
   Adamis, AP
TI Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   DIABETIC MACULAR EDEMA; NUCLEIC-ACID APTAMERS; IN-VIVO; PERMEABILITY
   FACTOR; NONHUMAN PRIMATE; RETINAL NEOVASCULARIZATION; IRIS
   NEOVASCULARIZATION; RECEPTOR-BINDING
AB Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, the VEGF isoform primarily responsible for pathological ocular neovascularization and vascular permeability. After nearly a decade of preclinical development to optimize and characterize its biological effects, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Pegaptanib therefore has the notable distinction of being the first aptamer therapeutic approved for use in humans, paving the way for future aptamer applications.
C1 Eyetech Pharmaceut Inc, New York, NY 10036 USA.
RP Ng, EWM (通讯作者)，Eyetech Pharmaceut Inc, 3 Times Sq,12th Floor, New York, NY 10036 USA.
EM Tony.Adamis@eyetech.com
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], [No title captured]
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Balasubramaniam V, 2003, AM J PHYSIOL-LUNG C, V284, pL826, DOI 10.1152/ajplung.00199.2002
   Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Blind M, 1999, P NATL ACAD SCI USA, V96, P3606, DOI 10.1073/pnas.96.7.3606
   Breaker RR, 2004, NATURE, V432, P838, DOI 10.1038/nature03195
   Buerger C, 2003, J CANCER RES CLIN, V129, P669, DOI 10.1007/s00432-003-0489-8
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Crawford Margaret, 2003, Briefings in Functional Genomics & Proteomics, V2, P72, DOI 10.1093/bfgp/2.1.72
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico D. J., 2005, INVEST OPHTH VIS SCI, V46, P2309
   DAMICO DJ, IN PRESS OPHTHALMOLO
   DESMIDT PC, 1991, NUCLEIC ACIDS RES, V19, P4695, DOI 10.1093/nar/19.17.4695
   DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   EATON B, 2005, CURR OPIN CHEM BIOL, V1, P10
   Eaton BE, 1995, CHEM BIOL, V346, P818
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   *EU STUD GROUP, 2002, RETINA, V22, P143
   Eulberg D, 2003, CHEMBIOCHEM, V4, P979, DOI 10.1002/cbic.200300663
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Hendry Philip, 2004, BMC Chemical Biology, V4, P1, DOI 10.1186/1472-6769-4-1
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jason TLH, 2004, TOXICOL APPL PHARM, V201, P66, DOI 10.1016/j.taap.2004.04.017
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   LEE JH, P NATL ACAD SCI US
   LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   MAYOR G, 2003, DRUGPLUS INT     NOV
   Michaud M, 2003, J AM CHEM SOC, V125, P8672, DOI 10.1021/ja034483t
   Miele E, 2004, J PEDIATR GASTR NUTR, V38, P502, DOI 10.1097/00005176-200405000-00008
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   NIJMJEE SM, 2005, ANNU REV MED, V56, P555
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909
   Peracchi A, 2004, REV MED VIROL, V14, P47, DOI 10.1002/rmv.415
   PEYMAN GA, 1995, ADV DRUG DELIVER REV, V16, P107, DOI 10.1016/0169-409X(95)00018-3
   PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richards J, 1999, CANCER RES, V59, P2096
   Rimmele M, 2003, CHEMBIOCHEM, V4, P963, DOI 10.1002/cbic.200300648
   Roberts WG, 1997, CANCER RES, V57, P765
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIMA DT, 2004, INVEST OPHTHALMOL VI, V45
   Shuler RK, 2004, J OCUL PHARMACOL TH, V20, P159, DOI 10.1089/108076804773710830
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ulrich H, 2004, CYTOM PART A, V59A, P220, DOI 10.1002/cyto.a.20056
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325
   Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399
   Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200
NR 98
TC 1028
Z9 1113
U1 24
U2 437
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD FEB
PY 2006
VL 5
IS 2
BP 123
EP 132
DI 10.1038/nrd1955
PG 10
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 008VD
UT WOS:000235067900025
PM 16518379
DA 2022-11-30
ER

PT J
AU Newman, A
   Andrew, N
   Casson, R
AF Newman, Alexander
   Andrew, Nicholas
   Casson, Robert
TI Review of the association between retinal microvascular characteristics
   and eye disease
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE arteriole; retinal imaging; retinal vessel diameter; vascular disease;
   venule
ID OPEN-ANGLE GLAUCOMA; CARDIOVASCULAR RISK-FACTORS; AGE-RELATED
   MACULOPATHY; ISCHEMIC OPTIC NEUROPATHY; POOLED DATA-ANALYSIS; GENERAL
   JAPANESE POPULATION; VASCULAR FRACTAL DIMENSION; DIABETIC MACULAR EDEMA;
   CORONARY-HEART-DISEASE; OCULAR BLOOD-FLOW
AB Computerized retinal imaging technologies enable the static and dynamic measurement of a range of retinal microvascular parameters. Large population-based studies have reported associations between these microvascular indices and various ophthalmic diseases including diabetes, age-related macular degeneration, retinal artery embolism, retinal vein occlusion, glaucoma and non-glaucomatous optic neuropathies. Increasingly, sophisticated imaging and analysis techniques have the potential to provide relevant clinical information regarding disease risk and progression; however, further studies are required to verify associations and strengthen the predictive power of these techniques. We summarize the current state of knowledge regarding retinal microvascular characteristics and eye disease.
C1 [Newman, Alexander] Gold Coast Univ Hosp, Dept Ophthalmol, Level 1, Southport, Qld 4215, Australia.
   [Newman, Alexander] Griffith Univ, Sch Med, Gold Coast, Qld, Australia.
   [Andrew, Nicholas; Casson, Robert] Univ Adelaide, South Australian Inst Ophthalmol, Adelaide, SA, Australia.
C3 Gold Coast University Hospital; Griffith University; University of
   Adelaide
RP Newman, A (通讯作者)，Gold Coast Univ Hosp, Dept Ophthalmol, Level 1, Southport, Qld 4215, Australia.
EM ar.newman@hotmail.com
CR Amerasinghe N, 2008, INVEST OPHTH VIS SCI, V49, P5397, DOI 10.1167/iovs.08-2142
   Arakawa S, 2011, INVEST OPHTH VIS SCI, V52, P5905, DOI 10.1167/iovs.11-7775
   Arend O, 1998, ACTA OPHTHALMOL SCAN, V76, P43, DOI 10.1034/j.1600-0420.1998.760108.x
   Arend O, 2002, BRIT J OPHTHALMOL, V86, P429, DOI 10.1136/bjo.86.4.429
   Arnarsson A, 2000, INVEST OPHTH VIS SCI, V41, P877
   Arnold AC, 2003, J NEURO-OPHTHALMOL, V23, P157, DOI 10.1097/00041327-200306000-00012
   Bek T, 2008, GRAEF ARCH CLIN EXP, V246, P763, DOI 10.1007/s00417-008-0766-y
   Berndt-Zipfel C, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-59
   Bertelsen M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7885
   Boillot A, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052708, 10.1371/journal.pone.0064417]
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Callizo J, 2015, OPHTHALMOLOGY, V122, P1881, DOI 10.1016/j.ophtha.2015.05.044
   Catita J, 2015, EXP EYE RES, V135, P14, DOI 10.1016/j.exer.2015.03.019
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang M, 2011, AM J OPHTHALMOL, V151, P100, DOI 10.1016/j.ajo.2010.07.025
   Chester AH, 1998, CARDIOVASC RES, V38, P814, DOI 10.1016/S0008-6363(98)00054-6
   Cheung CY, 2012, AM J OPHTHALMOL, V154, P663, DOI 10.1016/j.ajo.2012.04.016
   Cheung CY, 2011, J HYPERTENS, V29, P1380, DOI 10.1097/HJH.0b013e328347266c
   Cheung CYL, 2013, STROKE, V44, P2402, DOI 10.1161/STROKEAHA.113.001738
   Cheung CY, 2015, DIABETOLOGIA, V58, P871, DOI 10.1007/s00125-015-3511-1
   Cheung N, 2009, DIABETES CARE, V32, P106, DOI 10.2337/dc08-1233
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P4297, DOI 10.1167/iovs.08-1826
   Cheung N, 2008, AM J OPHTHALMOL, V146, P620, DOI 10.1016/j.ajo.2008.05.033
   Cheung N, 2008, DIABETES CARE, V31, P1842, DOI 10.2337/dc08-0189
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P2403, DOI 10.1167/iovs.07-1313
   Cheung N, 2007, INVEST OPHTH VIS SCI, V48, P4945, DOI 10.1167/iovs.07-0472
   Cheung N, 2012, ARCH OPHTHALMOL-CHIC, V130, P783, DOI 10.1001/archophthalmol.2012.727
   Chew SKH, 2012, CURR HYPERTENS REP, V14, P144, DOI 10.1007/s11906-012-0252-0
   Chin YC, 2014, OPHTHAL EPIDEMIOL, V21, P224, DOI 10.3109/09286586.2014.926941
   Collignon NJM, 1997, INT OPHTHALMOL, V21, P199, DOI 10.1023/A:1005918922700
   Corvi F, 2015, RETINA-J RET VIT DIS, V35, P2052, DOI 10.1097/IAE.0000000000000584
   Cosatto VF, 2010, CURR EYE RES, V35, P850, DOI 10.3109/02713683.2010.490628
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Cugati S, 2006, STROKE, V37, P908, DOI 10.1161/01.STR.0000204118.87477.46
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   Dahlof B, 1992, Blood Press, V1, P35, DOI 10.3109/08037059209065122
   de Haseth K, 2007, AM J OPHTHALMOL, V143, P1040, DOI 10.1016/j.ajo.2007.01.032
   de Voogd S, 2006, OPHTHALMOLOGY, V113, P1827, DOI 10.1016/j.ophtha.2006.03.063
   de Voogd S, 2006, INVEST OPHTH VIS SCI, V47, P3772, DOI 10.1167/iovs.05-1278
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delles C, 2004, STROKE, V35, P1289, DOI 10.1161/01.STR.0000126597.11534.3b
   Di Capua M, 2010, J THROMB THROMBOLYS, V30, P16, DOI 10.1007/s11239-009-0388-1
   Dielemans I, 1996, OPHTHALMOLOGY, V103, P1271, DOI 10.1016/S0161-6420(96)30511-3
   Ding J, 2014, J HYPERTENS, V32, P207, DOI 10.1097/HJH.0b013e32836586f4
   Ding J, 2012, CLIN EXP OPTOM, V95, P290, DOI 10.1111/j.1444-0938.2012.00725.x
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doubal FN, 2009, J NEUROL NEUROSUR PS, V80, P158, DOI 10.1136/jnnp.2008.153460
   ELMAN MJ, 1990, OPHTHALMOLOGY, V97, P1543
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Flammer J, 2007, SURV OPHTHALMOL, V52, pS162, DOI 10.1016/j.survophthal.2007.08.012
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FRISEN L, 1984, OPHTHALMOLOGY, V91, P1342
   Giambene B, 2009, GRAEF ARCH CLIN EXP, V247, P693, DOI 10.1007/s00417-008-0981-6
   GOTO I, 1975, STROKE, V6, P263, DOI 10.1161/01.STR.6.3.263
   GOTTFREDSDOTTIR MS, 1993, AM J OPHTHALMOL, V115, P64, DOI 10.1016/S0002-9394(14)73526-3
   Grauslund J, 2009, DIABETOLOGIA, V52, P2213, DOI 10.1007/s00125-009-1459-8
   Grosso A, 2005, BRIT J OPHTHALMOL, V89, P1646, DOI 10.1136/bjo.2005.072546
   GRUNWALD JE, 1986, INVEST OPHTH VIS SCI, V27, P1713
   GRUNWALD JE, 1986, OPHTHALMOLOGY, V93, P590
   GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P1853
   GRUNWALD JE, 1991, INVEST OPHTH VIS SCI, V32, P39
   GRUNWALD JE, 1990, INVEST OPHTH VIS SCI, V31, P521
   GUPTA A, 1994, EYE, V8, P668, DOI 10.1038/eye.1994.165
   Hall JK, 2001, AM J OPHTHALMOL, V132, P855, DOI 10.1016/S0002-9394(01)01200-4
   Hamid Sadaf, 2008, J Pak Med Assoc, V58, P233
   Hanssen H, 2011, ATHEROSCLEROSIS, V216, P433, DOI 10.1016/j.atherosclerosis.2011.02.009
   Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1928, DOI 10.1016/j.ophtha.2009.03.006
   Hayreh SS, 1999, SURV OPHTHALMOL, V43, pS27, DOI 10.1016/S0039-6257(99)00018-1
   Hayreh SS, 2001, AM J OPHTHALMOL, V131, P61, DOI 10.1016/S0002-9394(00)00709-1
   HAYREH SS, 1990, EYE, V4, P25, DOI 10.1038/eye.1990.4
   Ho JD, 2009, STROKE, V40, P2685, DOI 10.1161/STROKEAHA.109.554642
   Hoehn R, 2013, OPHTHALMOLOGY, V120, P961, DOI 10.1016/j.ophtha.2012.10.031
   Hoki SL, 2008, AM J OPHTHALMOL, V145, P143, DOI 10.1016/j.ajo.2007.08.030
   Howard KP, 2014, JAMA OPHTHALMOL, V132, P23, DOI 10.1001/jamaophthalmol.2013.6326
   Hu CC, 2009, BRIT J OPHTHALMOL, V93, P717, DOI 10.1136/bjo.2008.151605
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hughes AD, 2008, J HYPERTENS, V26, P1703, DOI 10.1097/HJH.0b013e328304b072
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2013, OPHTHALMOLOGICA, V229, P125, DOI 10.1159/000342158
   Ikram MK, 2013, DIABETES CARE, V36, P750, DOI 10.2337/dc12-1554
   Ikram MK, 2005, INVEST OPHTH VIS SCI, V46, P1182, DOI 10.1167/iovs.04-1459
   Ikram MK, 2005, OPHTHALMOLOGY, V112, P548, DOI 10.1016/j.ophtha.2004.10.038
   Ikram MK, 2004, INVEST OPHTH VIS SCI, V45, P2129, DOI 10.1167/iovs.03-1390
   Im JC, 2016, GRAEF ARCH CLIN EXP, V254, P1267, DOI 10.1007/s00417-015-3175-z
   J-d H, 2009, AM J OPHTHALMOL, V147
   Janssen MCH, 2005, THROMB HAEMOSTASIS, V93, P1021, DOI 10.1160/TH04-11-0768
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1599
   JONAS JB, 1993, INVEST OPHTH VIS SCI, V34, P2260
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1604
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kaufman PL, 2011, ADLERS PHYSL EYE
   Kawasaki R, 2008, BRIT J OPHTHALMOL, V92, P161, DOI 10.1136/bjo.2007.127449
   Kee AR, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12327
   Keel S, 2014, ASIA-PAC J OPHTHALMO, V3, P164, DOI 10.1097/APO.0000000000000053
   Kifley A, 2007, AM J OPHTHALMOL, V143, P1024, DOI 10.1016/j.ajo.2007.01.034
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   Klein R, 2006, ARCH OPHTHALMOL-CHIC, V124, P87, DOI 10.1001/archopht.124.1.87
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1446, DOI 10.1001/archopht.121.10.1446
   Klein R, 2003, OPHTHALMOLOGY, V110, P2118, DOI 10.1016/S0161-6420(03)00863-7
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1063
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644
   Klein R, 2007, AM J OPHTHALMOL, V143
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P513, DOI 10.1001/archopht.126.4.513
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2006, OPHTHALMOLOGY, V113, P1488, DOI 10.1016/j.ophtha.2006.03.028
   Klein R, 2012, ARCH OPHTHALMOL-CHIC, V130, P749, DOI 10.1001/archophthalmol.2011.2560
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Koh V, 2016, OPHTHAL EPIDEMIOL, V23, P6, DOI 10.3109/09286586.2015.1082604
   Kolar P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/724780
   Kolodjaschna J, 2004, AM J PHYSIOL-HEART C, V287, pH691, DOI 10.1152/ajpheart.01240.2003
   Kothy P, 2001, Acta Physiol Hung, V88, P281, DOI 10.1556/APhysiol.88.2001.3-4.10
   Kremmer S, 2014, OPEN OPHTHALMOL J, V8, P60, DOI 10.2174/1874364101408010060
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Kwa VIH, 2006, LANCET NEUROL, V5, P108, DOI 10.1016/S1474-4422(06)70332-5
   Lam A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1494, DOI 10.1001/archopht.120.11.1494
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Lee AJ, 2006, OPHTHALMOLOGY, V113, P1069, DOI 10.1016/j.ophtha.2006.02.062
   Lee KE, 2007, INVEST OPHTH VIS SCI, V48, P63, DOI 10.1167/iovs.05-1203
   Lee S B, 1998, Korean J Ophthalmol, V12, P51
   Leske MC, 2008, OPHTHALMOLOGY, V115, P85, DOI 10.1016/j.ophtha.2007.03.017
   Leung M, 1997, EYE, V11, P371, DOI 10.1038/eye.1997.78
   Li LJ, 2016, J PHYSIOL-LONDON, V594, P2175, DOI 10.1113/JP270947
   Li LJ, 2013, ACTA PAEDIATR, V102, P941, DOI 10.1111/apa.12294
   Liew Gerald, 2007, Arq Bras Endocrinol Metab, V51, P352, DOI 10.1590/S0004-27302007000200027
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Liew G, 2011, REV ESP CARDIOL, V64, P515, DOI [10.1016/j.recesp.2011.02.014, 10.1016/j.rec.2011.02.017]
   Lim LL, 2008, BRIT J OPHTHALMOL, V92, P1316, DOI 10.1136/bjo.2008.140640
   Lim LS, 2009, AM J OPHTHALMOL, V148, P368, DOI 10.1016/j.ajo.2009.04.006
   Lim M, 2013, MICROCIRCULATION, V20, P257, DOI 10.1111/micc.12026
   Lin HC, 2010, OPHTHALMOLOGY, V117, P2088, DOI 10.1016/j.ophtha.2010.03.003
   Lundberg K, 2013, RETINA-J RET VIT DIS, V33, P2089, DOI 10.1097/IAE.0b013e3182891dda
   Maar N, 2004, ARCH OPHTHALMOL-CHIC, V122, P987, DOI 10.1001/archopht.122.7.987
   Mandecka A, 2007, DIABETES CARE, V30, P3048, DOI 10.2337/dc07-0927
   MANSOUR AM, 1992, OPHTHALMOLOGICA, V204, P199, DOI 10.1159/000310294
   Martin SC, 2002, BRIT J OPHTHALMOL, V86, P774, DOI 10.1136/bjo.86.7.774
   MARTIN XD, 1989, GRAEF ARCH CLIN EXP, V227, P526, DOI 10.1007/BF02169445
   Mathews Michaela Kunz, 2005, Curr Opin Ophthalmol, V16, P341, DOI 10.1097/01.icu.0000188361.52166.93
   McClintic BR, 2010, AM J MED, V123, DOI 10.1016/j.amjmed.2009.05.030
   McGeechan K, 2008, ARCH INTERN MED, V168, P2304, DOI 10.1001/archinte.168.21.2304
   McGeechan K, 2009, AM J EPIDEMIOL, V170, P1323, DOI 10.1093/aje/kwp306
   McGeechan K, 2009, ANN INTERN MED, V151, P404, DOI 10.7326/0003-4819-151-6-200909150-00005
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Mitchell P, 1997, STROKE, V28, P63, DOI 10.1161/01.STR.28.1.63
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Mitchell P, 2005, OPHTHALMOLOGY, V112, P245, DOI 10.1016/j.ophtha.2004.08.015
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Moore D, 2008, CLIN OPHTHALMOL, V2, P849
   Moradi A, 2014, EYE, V28, P1315, DOI 10.1038/eye.2014.186
   Moss HE, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0561-1
   Newman AR, 2017, CLIN EXP OPHTHALMOL, V45, P33, DOI 10.1111/ceo.12773
   Nguyen TT, 2008, DIABETES, V57, P536, DOI 10.2337/db07-1376
   Nguyen TT, 2006, TRENDS ENDOCRIN MET, V17, P262, DOI 10.1016/j.tem.2006.07.006
   Nguyen TT, 2009, INVEST OPHTH VIS SCI, V50, P5609, DOI 10.1167/iovs.09-3442
   Nguyen TT, 2009, CURR DIABETES REP, V9, P277, DOI 10.1007/s11892-009-0043-4
   Nguyen TT, 2008, DIABETES CARE, V31, P544, DOI 10.2337/dc07-1528
   Nguyen TT, 2007, DIABETES CARE, V30, P2708, DOI 10.2337/dc07-0732
   O'Mahoney PRA, 2008, ARCH OPHTHALMOL-CHIC, V126, P692, DOI 10.1001/archopht.126.5.692
   Oyster CW., 1999, HUMAN EYE STRUCTURE
   Pache M, 2006, SURV OPHTHALMOL, V51, P179, DOI 10.1016/j.survophthal.2006.02.008
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Papastathopoulos KI, 1999, BRIT J OPHTHALMOL, V83, P285, DOI 10.1136/bjo.83.3.285
   Papastathopoulos KI, 1998, BRIT J OPHTHALMOL, V82, P48, DOI 10.1136/bjo.82.1.48
   PAPASTATHOPOULOS KI, 1995, OPHTHALMOLOGY, V102, P1706
   Park J, 2016, INT J OPHTHALMOL-CHI, V9, P999, DOI 10.18240/ijo.2016.07.11
   Patton N, 2005, J ANAT, V206, P319, DOI 10.1111/j.1469-7580.2005.00395.x
   Pomeranz HD, 2004, J LAB CLIN MED, V143, P141, DOI 10.1016/j.lab.2003.12.010
   RADER J, 1994, AM J OPHTHALMOL, V117, P72, DOI 10.1016/S0002-9394(14)73017-X
   Rankin SJA, 1996, J GLAUCOMA, V5, P22
   Rim TH, 2015, OPHTHALMOLOGY, V122, P1187, DOI 10.1016/j.ophtha.2015.01.020
   Rogers SL, 2008, DIABETES CARE, V31, P761, DOI 10.2337/dc07-1622
   Roy MS, 2011, ARCH OPHTHALMOL-CHIC, V129, P8, DOI 10.1001/archophthalmol.2010.340
   Rudkin AK, 2010, EYE, V24, P678, DOI 10.1038/eye.2009.142
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Salim S, 2010, SURV OPHTHALMOL, V55, P64, DOI 10.1016/j.survophthal.2009.03.006
   Salomon O, 1999, OPHTHALMOLOGY, V106, P739, DOI 10.1016/S0161-6420(99)90159-8
   Samarawickrama C, 2009, INVEST OPHTH VIS SCI, V50, P5619, DOI 10.1167/iovs.09-3878
   Sasaki M, 2013, ACTA OPHTHALMOL, V91, pE418, DOI 10.1111/aos.12114
   Schwartz B, 1995, ACTA OPHTHALMOL SCAN, V73, P41
   Schwartz B, 1994, Surv Ophthalmol, V38 Suppl, pS23, DOI 10.1016/0039-6257(94)90044-2
   Serre K, 2012, MICROCIRCULATION, V19, P29, DOI 10.1111/j.1549-8719.2011.00121.x
   Shankar A, 2011, MICROCIRCULATION, V18, P655, DOI 10.1111/j.1549-8719.2011.00134.x
   Skalicky S.E., 2016, OCULAR VISUAL PHYSL
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snell R, 1998, CLIN ANATOMY EYE, V2
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Stem MS, 2013, OPHTHALMOLOGY, V120, P362, DOI 10.1016/j.ophtha.2012.07.080
   Strachan MWJ, 2005, NEW ENGL J MED, V352, pE17, DOI 10.1056/NEJMicm030575
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   TALKS SJ, 1995, EYE, V9, P85, DOI 10.1038/eye.1995.13
   Tamai K, 2002, EXP EYE RES, V75, P69, DOI 10.1006/exer.2002.1178
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tatlipinar S, 2012, CLIN EXP OPTOM, V95, P94, DOI 10.1111/j.1444-0938.2011.00662.x
   Tedeschi-Reiner E, 2005, AM J CARDIOL, V96, P1107, DOI 10.1016/j.amjcard.2005.05.070
   Tezel G, 1996, OPHTHALMOLOGY, V103, P2105, DOI 10.1016/S0161-6420(96)30382-5
   Thom S, 2009, HYPERTENSION, V54, P405, DOI 10.1161/HYPERTENSIONAHA.109.133819
   TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48
   Tilma KK, 2012, ACTA OPHTHALMOL, V90, P750, DOI 10.1111/j.1755-3768.2011.02185.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   Van Hecke MV, 2006, CLIN SCI, V110, P597, DOI 10.1042/CS20050270
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vinten M, 2007, ACTA OPHTHALMOL SCAN, V85, P21, DOI 10.1111/j.1600-0420.2006.00806.x
   Wang JJ, 2006, OBESITY, V14, P206, DOI 10.1038/oby.2006.27
   Wang JJ, 2007, EUR HEART J, V28, P1984, DOI 10.1093/eurheartj/ehm221
   Wang JJ, 2006, STROKE, V37, P1833, DOI 10.1161/01.STR.0000226929.23297.75
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wang SA, 2007, CLIN EXP OPHTHALMOL, V35, P800, DOI 10.1111/j.1442-9071.2007.01627.x
   Wickremasinghe SS, 2008, INVEST OPHTH VIS SCI, V49, P4707, DOI 10.1167/iovs.08-1678
   Wickremasinghe SS, 2012, INVEST OPHTH VIS SCI, V53, P37, DOI 10.1167/iovs.11-7689
   WILSON CA, 1988, AM J OPHTHALMOL, V106, P131
   Wolf S, 1998, BRIT J OPHTHALMOL, V82, P892, DOI 10.1136/bjo.82.8.892
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Wong TY, 2011, ARCH OPHTHALMOL-CHIC, V129, P95, DOI 10.1001/archophthalmol.2010.347
   Wong Tien Yin, 2002, Curr Opin Ophthalmol, V13, P142, DOI 10.1097/00055735-200206000-00002
   Wong TY, 2005, BRIT MED BULL, V73-74, P57, DOI 10.1093/bmb/ldh050
   Wong TY, 2005, ARCH INTERN MED, V165, P1060, DOI 10.1001/archinte.165.9.1060
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2005, AM J OPHTHALMOL, V139, P373, DOI 10.1016/j.ajo.2004.08.008
   Wong TY, 2004, INVEST OPHTH VIS SCI, V45, P2949, DOI 10.1167/iovs.04-0069
   Wong TY, 2004, LANCET NEUROL, V3, P179, DOI 10.1016/S1474-4422(04)00682-9
   Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P2528, DOI 10.1001/jama.287.19.2528
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Xu L, 2007, AM J OPHTHALMOL, V144, P972, DOI 10.1016/j.ajo.2007.07.015
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yanagi M, 2014, INVEST OPHTH VIS SCI, V55, P405, DOI 10.1167/iovs.13-12512
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   Yasuda M, 2010, INVEST OPHTH VIS SCI, V51, P3205, DOI 10.1167/iovs.09-4453
   Yau JWY, 2008, INTERN MED J, V38, P904, DOI 10.1111/j.1445-5994.2008.01720.x
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Youm DJ, 2012, CURR EYE RES, V37, P334, DOI 10.3109/02713683.2011.629070
   ZHAO JL, 1993, OPHTHALMOLOGY, V100, P423
   Zheng YF, 2009, INVEST OPHTH VIS SCI, V50, P4091, DOI 10.1167/iovs.09-3444
   Zhou JQ, 2013, OPHTHALMOLOGY, V120, P803, DOI 10.1016/j.ophtha.2012.09.033
NR 257
TC 16
Z9 17
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2018
VL 46
IS 5
BP 531
EP 552
DI 10.1111/ceo.13119
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM8QJ
UT WOS:000438497300011
PM 29193621
OA Green Published
DA 2022-11-30
ER

PT J
AU Sarkar, B
   Siddiqui, Z
   Kim, KK
   Nguyen, PK
   Reyes, X
   McGill, TJ
   Kumar, VA
AF Sarkar, Biplab
   Siddiqui, Zain
   Kim, Ka Kyung
   Nguyen, Peter K.
   Reyes, Xavier
   McGill, Trevor J.
   Kumar, Vivek A.
TI Implantable anti-angiogenic scaffolds for treatment of neovascular
   ocular pathologies
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Review
DE Pathological neovascularization; Age-related macular degeneration;
   Diabetic retinopathy; Self-assembly; Hydrogel; Peptide nanofibers;
   Anti-angiogenic materials
ID DIABETIC MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL
   BEVACIZUMAB AVASTIN; MULTIDOMAIN PEPTIDE NANOFIBERS; HUMAN PLASMINOGEN;
   DEFERRED LASER; VISUAL-ACUITY; HIGH GLUCOSE; RETINOPATHY; DEGENERATION
AB The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes.
   Graphical abstract Development of materials for long-term intravitreal delivery for management of posterior segment diseases
C1 [Sarkar, Biplab; Siddiqui, Zain; Kim, Ka Kyung; Nguyen, Peter K.; Reyes, Xavier; Kumar, Vivek A.] New Jersey Inst Technol, Dept Biomed Engn, 138 Warren St LSEB 316, Newark, NJ 07102 USA.
   [McGill, Trevor J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Kumar, Vivek A.] New Jersey Inst Technol, Dept Chem & Mat Engn, Newark, NJ 07102 USA.
   [Kumar, Vivek A.] Rutgers Sch Dent Med, Dept Restorat Dent, Newark, NJ USA.
C3 New Jersey Institute of Technology; Oregon Health & Science University;
   New Jersey Institute of Technology; Rutgers State University New
   Brunswick; Rutgers State University Medical Center
RP Kumar, VA (通讯作者)，New Jersey Inst Technol, Dept Biomed Engn, 138 Warren St LSEB 316, Newark, NJ 07102 USA.; Kumar, VA (通讯作者)，New Jersey Inst Technol, Dept Chem & Mat Engn, Newark, NJ 07102 USA.; Kumar, VA (通讯作者)，Rutgers Sch Dent Med, Dept Restorat Dent, Newark, NJ USA.
EM vak@njit.edu
RI Sarkar, Biplab/AAA-9297-2020
OI Sarkar, Biplab/0000-0002-9298-2392; Kumar, Vivek/0000-0001-7536-9281
FU NIH [R15 EY029504]; NSF [IIP 1903617]; NJIT Undergraduate Research and
   Innovation (URI) Program; NJIT Startup funds
FX This work was supported by grant NIH R15 EY029504, NSF IIP 1903617, the
   NJIT Undergraduate Research and Innovation (URI) Program, and NJIT
   Startup funds (to V.A.K.).
CR ABBASI J, 2018, JAMA-J AM MED ASSOC, V319, P2263, DOI DOI 10.1001/JAMA.2018.7447
   Adamiec-Mroczek J, 2010, CYTOKINE, V49, P269, DOI 10.1016/j.cyto.2009.11.004
   Aghdam SY, 2013, BIOCHEM BIOPH RES CO, V432, P339, DOI 10.1016/j.bbrc.2013.01.101
   [Anonymous], 1982, SPRINGERLINK ONL SER, pv
   [Anonymous], NAT BIOTECHNOL
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Aulisa L, 2009, BIOMACROMOLECULES, V10, P2694, DOI 10.1021/bm900634x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Bell BA, 2016, EXP EYE RES, V153, P65, DOI 10.1016/j.exer.2016.10.001
   Bell BA, 2014, EXP EYE RES, V129, P107, DOI 10.1016/j.exer.2014.10.018
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bhise NS, 2011, EXPERT OPIN DRUG DEL, V8, P485, DOI 10.1517/17425247.2011.558082
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Byrne LC., 2017, SCI TRANSL MED, V9
   Cai X, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3789217
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cheung CYL, 2014, ALZHEIMERS DEMENT, V10, P135, DOI 10.1016/j.jalz.2013.06.009
   Chrzanowska M, 2018, INT J OPHTHALMOL-CHI, V11, P1856, DOI 10.18240/ijo.2018.11.19
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426
   Dhoot DS, 2013, BRIT J OPHTHALMOL, V97, P66, DOI 10.1136/bjophthalmol-2012-301917
   Dixelius J, 2006, CANCER RES, V66, P2089, DOI 10.1158/0008-5472.CAN-05-2217
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Dong H, 2007, J AM CHEM SOC, V129, P12468, DOI 10.1021/ja072536r
   Dowler JGF, 2003, J ROY SOC MED, V96, P277, DOI 10.1258/jrsm.96.6.277
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2015, CLIN OPHTHALMOL, V9, P1321, DOI 10.2147/OPTH.S79948
   Edmond M, 2016, INVEST OPHTH VIS SCI, V57, pOCT184, DOI 10.1167/iovs.15-18883
   Ehlers JP, 2015, OSLI RETINA, V46, P327, DOI 10.3928/23258160-20150323-05
   Ehlers JP, 2013, RETINA-J RET VIT DIS, V33, P1172, DOI 10.1097/IAE.0b013e31827b6565
   Elman MJ, 2015, OPHTHALMOLOGY, V122, P375, DOI 10.1016/j.ophtha.2014.08.047
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Feenstra Derrick J, 2013, J Clin Exp Ophthalmol, V4, P298
   Feke Gilbert T, 2015, Alzheimers Dement (Amst), V1, P144, DOI 10.1016/j.dadm.2015.01.004
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fong DS, 2007, RETINA-J RET VIT DIS, V27, P816, DOI 10.1097/IAE.0b013e318042d32c
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gonzalez VH, 2009, BRIT J OPHTHALMOL, V93, P1474, DOI 10.1136/bjo.2008.155663
   Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hitscherich P, 2018, J BIOMED NANOTECHNOL, V14, P802, DOI 10.1166/jbn.2018.2583
   Holmes D, 2018, NATURE, V561, pS1, DOI 10.1038/d41586-018-06110-z
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonas Jost B, 2007, Dev Ophthalmol, V39, P96, DOI 10.1159/000098502
   Kadlubowska J, 2016, CURR NEUROPHARMACOL, V14, P831, DOI 10.2174/1570159X14666160614095559
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Khayat M, 2017, INVESTIG OPTHALMOL V, V58
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kumar VA, 2016, BIOMATERIALS, V98, P113, DOI 10.1016/j.biomaterials.2016.04.032
   Kumar VA, 2015, J AM CHEM SOC, V137, P4823, DOI 10.1021/jacs.5b01549
   Kumar VA, 2015, BIOMATERIALS, V52, P71, DOI 10.1016/j.biomaterials.2015.01.079
   Kumar VA, 2015, ACS NANO, V9, P860, DOI 10.1021/nn506544b
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lang GE, 2012, OPHTHALMOLOGICA, V227, P21, DOI 10.1159/000337156
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Leach DG, 2018, BIOMATERIALS, V163, P67, DOI 10.1016/j.biomaterials.2018.01.035
   Li IC, 2016, BIOMACROMOLECULES, V17, P2087, DOI 10.1021/acs.biomac.6b00309
   Li R, 2017, BIOMATERIALS, V145, P33, DOI 10.1016/j.biomaterials.2017.08.031
   MacLaren RE, 2016, OPHTHALMOLOGY, V123, pS98, DOI 10.1016/j.ophtha.2016.06.041
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   Moore AN, 2018, BIOMATERIALS, V161, P154, DOI 10.1016/j.biomaterials.2018.01.033
   Moore AN, 2017, ACCOUNTS CHEM RES, V50, P714, DOI 10.1021/acs.accounts.6b00553
   Mukherjee N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185242
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen PK, 2018, ACS APPL BIO MATER, V1, P865, DOI 10.1021/acsabm.8b00283
   Nguyen PK, 2018, ACS OMEGA, V3, P5980, DOI 10.1021/acsomega.8b00347
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   Ogura Y., 2019, OPHTHALMOLOGY
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olivares AM, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0913-0
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petropoulos IK, 2007, NEW ENGL J MED, V356, P1979, DOI 10.1056/NEJMicm062788
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Pocock SJ, 2016, NEW ENGL J MED, V375, P861, DOI 10.1056/NEJMra1510064
   Ponce ML, 2003, CANCER RES, V63, P5060
   Querques G, 2009, RETINA-J RET VIT DIS, V29, P121, DOI 10.1097/IAE.0b013e31818baa03
   Rachitskaya AV, 2017, OPHTHALMOL RETINA, V1, P420, DOI 10.1016/j.oret.2017.01.005
   Rachitskaya AV, 2017, BRIT J OPHTHALMOL, V101, P445, DOI 10.1136/bjophthalmol-2016-308551
   Rachitskaya AV, 2016, OSLI RETINA, V47, P999, DOI 10.3928/23258160-20161031-03
   Reichle Michelle L, 2005, Optometry, V76, P450, DOI 10.1016/j.optm.2005.06.013
   Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241
   Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   Roth Bryan M, 2012, Ophthalmic Surg Lasers Imaging, V43, pS142, DOI 10.3928/15428877-20121001-05
   Samiy Nasrollah, 2014, J Ophthalmic Vis Res, V9, P506, DOI 10.4103/2008-322X.150831
   Sarkar B, 2019, ACS BIOMATER SCI ENG, DOI [10.1021/acsbiomaterials.1029b00967, DOI 10.1021/ACSBIOMATERIALS.1029B00967]
   Sarkar B, 2018, BIOMACROMOLECULES, V19, P3597, DOI 10.1021/acs.biomac.8b01137
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Sharma R, 2019, SCI TRANSL MED, V11
   Silva JM, 2017, J VITREORETINAL DIS, V1, P298, DOI [10.1177/2474126417721560, DOI 10.1177/2474126417721560]
   Silva PS, 2009, SEMIN OPHTHALMOL, V24, P93, DOI 10.1080/08820530902800355
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Singh RP, 2017, BRIT J OPHTHALMOL, V101, P1340, DOI 10.1136/bjophthalmol-2016-309747
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Smithwick Elizabeth, 2017, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V16, P33, DOI 10.2174/1871523016666170502115816
   Snyder Peter J, 2016, Alzheimers Dement (Amst), V4, P169
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stem MS, 2013, CURR MED CHEM, V20, P3241, DOI 10.2174/09298673113209990027
   Takamura Y, 2018, BR J OPHTHALMOL
   Tarr Joanna M, 2013, ISRN Ophthalmol, V2013, P343560, DOI 10.1155/2013/343560
   Thakur A, 2011, MICROVASC RES, V82, P346, DOI 10.1016/j.mvr.2011.09.001
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Viets K, 2016, TRENDS GENET, V32, P638, DOI 10.1016/j.tig.2016.07.004
   Wai KM, 2017, BRIT J OPHTHALMOL, V101, P574, DOI 10.1136/bjophthalmol-2016-308727
   Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642
   Webber MJ, 2011, P NATL ACAD SCI USA, V108, P13438, DOI 10.1073/pnas.1016546108
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Xu D, 2013, INVEST OPHTH VIS SCI, V54, P163, DOI 10.1167/iovs.12-10246
   Xu HZ, 2011, INVEST OPHTH VIS SCI, V52, P2160, DOI 10.1167/iovs.10-6518
   Yaqoob Zahid, 2005, Biotechniques, V39, pS6, DOI 10.2144/000112090
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yi ZF, 2009, INT J CANCER, V124, P843, DOI 10.1002/ijc.24027
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
   Yuan A., 2011, Clinical Investigation, V1, P1445
   YUAN A, 2014, INVEST OPHTH VIS SCI, V55
   Yuan A, 2011, J CLIN EXP OPHTHALMO, V02
   Yuan A, 2014, INT J OPHTHALMOL-CHI, V7, P86, DOI 10.3980/j.issn.2222-3959.2014.01.15
   Yuan A, 2012, RETINA-J RET VIT DIS, V32, P1994, DOI 10.1097/IAE.0b013e3182695a5b
   Yuan Alex, 2010, Ophthalmic Surg Lasers Imaging, V41 Online, pe1, DOI 10.3928/15428877-20101025-10
   Zhang SX, 2005, CURR EYE RES, V30, P681, DOI 10.1080/02713680590934102
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 137
TC 2
Z9 2
U1 0
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD OCT
PY 2020
VL 10
IS 5
BP 1191
EP 1202
DI 10.1007/s13346-020-00753-0
EA MAR 2020
PG 12
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA NG2VV
UT WOS:000522573500001
PM 32232681
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jeong, HC
   Cho, SJ
   Lee, MO
   Cha, HJ
AF Jeong, Ho-Chang
   Cho, Seung-Ju
   Lee, Mi-Ok
   Cha, Hyuk-Jin
TI Technical approaches to induce selective cell death of pluripotent stem
   cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Teratoma; Human pluripotent stem cells; Selective cell death; Apoptosis;
   Safe stem cell therapy
ID RESIDUAL UNDIFFERENTIATED CELLS; RETINAL-PIGMENT EPITHELIUM; CASPASE-9
   SAFETY SWITCH; TERATOMA FORMATION; DNA-DAMAGE; SUICIDE GENE; IPS CELLS;
   PROBE; DIFFERENTIATION; PURIFICATION
AB Despite the recent promising results of clinical trials using human pluripotent stem cell (hPSC)-based cell therapies for age-related macular degeneration (AMD), the risk of teratoma formation resulting from residual undifferentiated hPSCs remains a serious and critical hurdle for broader clinical implementation. To mitigate the tumorigenic risk of hPSC-based cell therapy, a variety of approaches have been examined to ablate the undifferentiated hPSCs based on the unique molecular properties of hPSCs. In the present review, we offer a brief overview of recent attempts at selective elimination of undifferentiated hPSCs to decrease the risk of teratoma formation in hPSC-based cell therapy.
C1 [Jeong, Ho-Chang; Cho, Seung-Ju; Cha, Hyuk-Jin] Sogang Univ, Dept Life Sci, Coll Nat Sci, 1 Sinsu Dong, Seoul 121742, South Korea.
   [Lee, Mi-Ok] KRIBB, Stem Cell Res Ctr, Daejeon 305806, South Korea.
C3 Sogang University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB)
RP Cha, HJ (通讯作者)，Sogang Univ, Dept Life Sci, Coll Nat Sci, 1 Sinsu Dong, Seoul 121742, South Korea.
EM hjcha@sogang.ac.kr
RI Cha, Hyuk-Jin/AAB-8508-2020; Jeong, Hochang/C-9070-2019
OI Cha, Hyuk-Jin/0000-0001-9277-2662; Jeong, Hochang/0000-0002-5379-8314
FU National Research Foundation of Korea (NRF) grant - Korea government
   (MSIP) [2011-0030043, 2009-0093822, 2017R1A2A2A05000766]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIP) (Nos. 2011-0030043,
   2009-0093822 and 2017R1A2A2A05000766).
CR Alper J, 2009, NAT BIOTECHNOL, V27, P213, DOI 10.1038/nbt0309-213a
   Ando M, 2015, STEM CELL REP, V5, P597, DOI 10.1016/j.stemcr.2015.07.011
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Bagnaninchi PO, 2011, P NATL ACAD SCI USA, V108, P6462, DOI 10.1073/pnas.1018260108
   Baker M, 2011, NATURE, V479, P459, DOI 10.1038/479459a
   Ban K, 2015, STEM CELL REP, V5, P1239, DOI 10.1016/j.stemcr.2015.10.021
   Bedel A, 2017, STEM CELL TRANSL MED, V6, P382, DOI 10.5966/sctm.2016-0201
   Ben-David U, 2015, STEM CELLS, V33, P1013, DOI 10.1002/stem.1888
   Ben-David U, 2014, NAT PROTOC, V9, P729, DOI 10.1038/nprot.2014.050
   Ben-David U, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2992
   Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015
   Bieberich E, 2004, J CELL BIOL, V167, P723, DOI 10.1083/jcb.200405144
   Bizy A, 2013, STEM CELL RES, V11, P1335, DOI 10.1016/j.scr.2013.09.003
   Blum B, 2009, NAT BIOTECHNOL, V27, P281, DOI 10.1038/nbt.1527
   Bulina ME, 2006, NAT BIOTECHNOL, V24, P95, DOI 10.1038/nbt1175
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cheng FY, 2012, BIOMATERIALS, V33, P3195, DOI 10.1016/j.biomaterials.2012.01.023
   Cho S-J, 2016, ACS CENTRAL SCI, V3, P272
   Cho SJ, 2015, STEM CELL REP, V5, P1067, DOI 10.1016/j.stemcr.2015.10.004
   Choi HS, 2008, CELL TISSUE RES, V333, P197, DOI 10.1007/s00441-008-0632-6
   Choi WS, 2013, ANTIVIR THER, V18, P813, DOI 10.3851/IMP2556
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576
   Cunningham JJ, 2012, NAT BIOTECHNOL, V30, P849, DOI 10.1038/nbt.2329
   Dabir DV, 2013, DEV CELL, V25, P81, DOI 10.1016/j.devcel.2013.03.006
   Desmarais JA, 2012, STEM CELLS, V30, P1385, DOI 10.1002/stem.1117
   Dumitru R, 2012, MOL CELL, V46, P573, DOI 10.1016/j.molcel.2012.04.002
   Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB
   Filion TM, 2009, J CELL PHYSIOL, V220, P586, DOI 10.1002/jcp.21735
   Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426
   Fong CY, 2009, STEM CELL REV REP, V5, P72, DOI 10.1007/s12015-009-9054-4
   Fujikawa T, 2005, AM J PATHOL, V166, P1781, DOI 10.1016/S0002-9440(10)62488-1
   Han JJ, 2016, BIOMATERIALS, V105, P66, DOI 10.1016/j.biomaterials.2016.07.033
   Hara A, 2008, STEM CELLS DEV, V17, P619, DOI 10.1089/scd.2007.0235
   Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231
   Heslop JA, 2015, STEM CELL TRANSL MED, V4, P389, DOI 10.5966/sctm.2014-0110
   Hirata N, 2014, CELL REP, V6, P1165, DOI 10.1016/j.celrep.2014.02.006
   Hong YL, 2004, P NATL ACAD SCI USA, V101, P14443, DOI 10.1073/pnas.0401346101
   Hotta A, 2009, NAT METHODS, V6, P370, DOI [10.1038/nmeth.1325, 10.1038/NMETH.1325]
   Huskey NE, 2015, STEM CELL REP, V4, P374, DOI 10.1016/j.stemcr.2015.01.019
   Im CN, 2010, ANGEW CHEM INT EDIT, V49, P7497, DOI 10.1002/anie.201002463
   Janoly-Dumenil Audrey, 2009, Antiviral Chemistry & Chemotherapy, V19, P257
   Jha R, 2015, BIOMATERIALS, V50, P176, DOI 10.1016/j.biomaterials.2015.01.043
   Kang NY, 2011, NAT PROTOC, V6, P1044, DOI 10.1038/nprot.2011.350
   Kim KT, 2017, J DERMATOL SCI, V86, P123, DOI 10.1016/j.jdermsci.2017.01.011
   Kim S, 2016, ONCOTARGET
   Kimbrel EA, 2015, NAT REV DRUG DISCOV, V14, P681, DOI 10.1038/nrd4738
   King FW, 2011, STEM CELLS DEV, V20, P475, DOI 10.1089/scd.2010.0219
   Knoepfler PS, 2009, STEM CELLS, V27, P1050, DOI 10.1002/stem.37
   Kolle G, 2009, STEM CELLS, V27, P2446, DOI 10.1002/stem.182
   Kotini AG, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2015.57
   Kuo TF, 2014, J AM CHEM SOC, V136, P9798, DOI 10.1021/ja501795c
   Kuroda T, 2015, REGEN THER, V2, P17, DOI 10.1016/j.reth.2015.08.001
   Kuroda T, 2014, METHODS MOL BIOL, V1210, P183, DOI 10.1007/978-1-4939-1435-7_14
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   Lebkowski Jane, 2011, Regen Med, V6, P11, DOI 10.2217/rme.11.77
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Lee AS, 2009, CELL CYCLE, V8, P2608, DOI 10.4161/cc.8.16.9353
   Lee MO, 2013, P NATL ACAD SCI USA, V110, pE3281, DOI 10.1073/pnas.1303669110
   Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395
   Lin CP, 1999, IEEE J SEL TOP QUANT, V5, P963, DOI 10.1109/2944.796318
   Liu JC, 2014, TRENDS CELL BIOL, V24, P268, DOI 10.1016/j.tcb.2014.03.002
   Liu JC, 2013, CELL STEM CELL, V13, P483, DOI 10.1016/j.stem.2013.07.018
   Malecki M, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt462
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Miki K, 2015, CELL STEM CELL, V16, P699, DOI 10.1016/j.stem.2015.04.005
   Moon J, 2013, CELL TRANSPLANT, V22, P1263, DOI 10.3727/096368912X657242
   Onuma Y, 2013, BIOCHEM BIOPH RES CO, V431, P524, DOI 10.1016/j.bbrc.2013.01.025
   Ou W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081131
   Parr CJC, 2016, SCI REP-UK, V6, DOI 10.1038/srep32532
   Richards MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103548
   Rodrigues GMC, 2015, BIOTECHNOL J, V10, P1103, DOI 10.1002/biot.201400535
   Rong ZL, 2012, J BIOL CHEM, V287, P32338, DOI 10.1074/jbc.M112.383810
   Schuldiner M, 2003, STEM CELLS, V21, P257, DOI 10.1634/stemcells.21-3-257
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Smith AJ, 2012, STEM CELL TRANSL MED, V1, P709, DOI 10.5966/sctm.2012-0066
   Straathof KC, 2005, BLOOD, V105, P4247, DOI 10.1182/blood-2004-11-4564
   Strauss S, 2010, NAT BIOTECHNOL, V28, P989, DOI 10.1038/nbt1010-989
   Tachibana M, 2013, CELL, V153, P1228, DOI 10.1016/j.cell.2013.05.006
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947
   Tateno H, 2015, STEM CELL REP, V4, P811, DOI 10.1016/j.stemcr.2015.02.016
   Tateno H, 2014, METHODS MOL BIOL, V1200, P313, DOI 10.1007/978-1-4939-1292-6_26
   Tateno H, 2014, SCI REP-UK, V4, DOI 10.1038/srep04069
   Tateno H, 2013, STEM CELL TRANSL MED, V2, P265, DOI 10.5966/sctm.2012-0154
   Tateno H, 2011, J BIOL CHEM, V286, P20345, DOI 10.1074/jbc.M111.231274
   Terstegge S, 2010, STEM CELL REV REP, V6, P260, DOI 10.1007/s12015-010-9114-9
   TeSlaa T, 2016, SEMIN CELL DEV BIOL, V52, P76, DOI 10.1016/j.semcdb.2016.01.027
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tohyama S, 2016, CELL METAB, V23, P663, DOI 10.1016/j.cmet.2016.03.001
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Vazquez-Martin A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00964
   Weissbein U, 2014, J CELL BIOL, V204, P153, DOI 10.1083/jcb.201310135
   Wile BM, 2014, NAT PROTOC, V9, P2411, DOI 10.1038/nprot.2014.154
   Winter GE, 2014, NAT CHEM BIOL, V10, P768, DOI [10.1038/NCHEMBIO.1590, 10.1038/nchembio.1590]
   Wu CF, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.53
   Yagyu S, 2015, MOL THER, V23, P1475, DOI 10.1038/mt.2015.100
   Yamanaka K, 2011, CLIN CANCER RES, V17, P5423, DOI 10.1158/1078-0432.CCR-10-3410
   Yea CH, 2016, BIOMATERIALS, V75, P250, DOI 10.1016/j.biomaterials.2015.10.038
   Zhang L, 2014, CELL CYCLE, V13, P762, DOI 10.4161/cc.27677
NR 100
TC 18
Z9 19
U1 0
U2 15
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUL
PY 2017
VL 74
IS 14
BP 2601
EP 2611
DI 10.1007/s00018-017-2486-0
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EY3QF
UT WOS:000403887100007
PM 28246701
DA 2022-11-30
ER

PT J
AU Bocci, V
   Valacchi, G
AF Bocci, Velio
   Valacchi, Giuseppe
TI Nrf2 activation as target to implement therapeutic treatments
SO FRONTIERS IN CHEMISTRY
LA English
DT Review
DE oxidative stress; antioxidants; pathologies; calorie restriction; ozone
ID CALORIE RESTRICTION; OXIDATIVE STRESS; OZONE THERAPY; CELL-SURVIVAL;
   LIFE-SPAN; ANTIOXIDANT; MECHANISMS; PATHWAY; EXPRESSION; BLOOD
AB A chronic increase of oxidative stress is typical of serious pathologies such as myocardial infarction, stroke, chronic limb ischemia, chronic obstructive pulmonary disease (CORD), type II-diabetes, age-related macular degeneration leads to an epic increase of morbidity and mortality in all countries of the world. The initial inflammation followed by an excessive release of reactive oxygen species (ROS) implies a diffused cellular injury that needs to be corrected by an inducible expression of the innate detoxifying and antioxidant system. The transcription factor Nrf2, when properly activated, is able to restore a redox homeostasis and possibly improve human health.
C1 [Bocci, Velio] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
   [Valacchi, Giuseppe] Univ Ferrara, Dept Life Sci & Biotechnol, Via Borsari 46, I-44121 Ferrara, Italy.
C3 University of Siena; University of Ferrara
RP Valacchi, G (通讯作者)，Univ Ferrara, Dept Life Sci & Biotechnol, Via Borsari 46, I-44121 Ferrara, Italy.
EM giuseppe.valacchi@unife.it
CR Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006
   ALARY J, 1995, CHEM RES TOXICOL, V8, P34, DOI 10.1021/tx00043a004
   Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0
   Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033
   Barbano R, 2013, EPIGENETICS-US, V8, P105, DOI 10.4161/epi.23319
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bocci, 2014, AM J CLIN EXP MED, V2, P9, DOI DOI 10.11648/J.AJCEM.20140202.11
   Bocci V, 2013, CURR MED CHEM, V20, P3397, DOI 10.2174/0929867311320270005
   Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Bocci V, 2011, AM J CARDIOVASC DRUG, V11, P73, DOI 10.2165/11539890-000000000-00000
   Bocci V, 2006, J BIOCHEM MOL TOXIC, V20, P133, DOI 10.1002/jbt.20124
   Bocci V, 2009, CURR DRUG THER, V4, P159, DOI 10.2174/157488509789055045
   Bocci Velio, 2010, Curr Aging Sci, V3, P177
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   Bocci VA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-66
   Calabrese EJ, 2013, CRIT REV TOXICOL, V43, P580, DOI 10.3109/10408444.2013.808172
   Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   de Lemos ET, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/741545
   Di Paolo N, 2005, INT J ARTIF ORGANS, V28, P1039, DOI 10.1177/039139880502801012
   Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JCI200317863
   Finley JW, 2005, J NUTR, V135, P1236, DOI 10.1093/jn/135.5.1236
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   Fontana L, 2008, EUR J CARDIOV PREV R, V15, P3, DOI 10.1097/HJR.0b013e3282f17bd4
   Fontana L, 2009, CURR OPIN GASTROEN, V25, P144, DOI 10.1097/MOG.0b013e32831ef1ba
   Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041
   Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006
   Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0
   Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Hanada N, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-66
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266
   Kanfi Y, 2008, FEBS LETT, V582, P543, DOI 10.1016/j.febslet.2008.06.005
   Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815
   Kang C, 2009, FREE RADICAL BIO MED, V47, P1394, DOI 10.1016/j.freeradbiomed.2009.08.007
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653
   KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W
   Lau A, 2013, ANTIOXID REDOX SIGN, V18, P91, DOI 10.1089/ars.2012.4754
   Laurent A, 1999, CHEM RES TOXICOL, V12, P887, DOI 10.1021/tx9900425
   Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7
   Li L, 2009, EYE, V23, P1464, DOI 10.1038/eye.2008.281
   Little JP, 2010, AM J PHYSIOL-REG I, V298, pR912, DOI 10.1152/ajpregu.00409.2009
   Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015
   Maines MD, 1996, UROLOGY, V47, P727, DOI 10.1016/S0090-4295(96)00010-6
   Mendiratta S, 1998, FREE RADICAL BIO MED, V24, P789, DOI 10.1016/S0891-5849(97)00351-1
   MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Muscarella LA, 2011, EPIGENETICS-US, V6, P317, DOI 10.4161/epi.6.3.14408
   Muthusamy VR, 2012, FREE RADICAL BIO MED, V52, P366, DOI 10.1016/j.freeradbiomed.2011.10.440
   Nakao A, 2009, J CLIN BIOCHEM NUTR, V44, P1, DOI 10.3164/jcbn.08-193R
   No Jae Hong, 2014, J Cancer Prev, V19, P111, DOI 10.15430/JCP.2014.19.2.111
   Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577
   Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428
   Pecorelli A, 2013, TOXICOL APPL PHARM, V267, P30, DOI 10.1016/j.taap.2012.12.001
   PRYOR WA, 1995, FREE RADICAL BIO MED, V19, P935, DOI 10.1016/0891-5849(95)02033-7
   Sack MN, 2012, J MOL CELL CARDIOL, V52, P520, DOI 10.1016/j.yjmcc.2011.11.004
   Sagai M, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-29
   Soejima Y, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-9
   Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005
   Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2
   Travagli V, 2007, INT J BIOL MACROMOL, V41, P504, DOI 10.1016/j.ijbiomac.2007.06.010
   Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369
   Valacchi G, 2000, MEDIAT INFLAMM, V9, P271, DOI 10.1080/09629350020027573
   Valacchi G, 1999, MEDIAT INFLAMM, V8, P205, DOI 10.1080/09629359990360
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Xu JJ, 2014, J NEUROTRAUM, V31, P1343, DOI 10.1089/neu.2013.3222
   Yang CM, 2012, J AGR FOOD CHEM, V60, P1576, DOI 10.1021/jf204451n
   Yang YC, 2011, FREE RADICAL BIO MED, V51, P2073, DOI 10.1016/j.freeradbiomed.2011.09.007
   Zhang DD, 2010, ANTIOXID REDOX SIGN, V13, P1623, DOI 10.1089/ars.2010.3301
NR 72
TC 73
Z9 78
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD FEB 2
PY 2015
VL 3
AR 4
DI 10.3389/fchem.2015.00004
PG 6
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DI1VI
UT WOS:000373284100001
PM 25699252
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Andric, M
   Dixit, S
   Robaei, D
   Watchorn, R
   Verma, N
AF Andric, Marko
   Dixit, Shreya
   Robaei, Dana
   Watchorn, Rosemary
   Verma, Nitin
TI A case of subacute cutaneous lupus erythematosus as a result of
   ranibizumab (Lucentis) treatment
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Drug reaction; drug-induced; ranibizumab; subacute cutaneous lupus
   erythematosus
AB Cutaneous lupus erythematosus is a previously undiagnosed side-effect of ranibizumab. Here, we present a case of an 82-year-old female Caucasian patient with wet age-related macular degeneration. Following a single intraocular injection of Lucentis (ranibizumab), she developed a subacute cutaneous lupus erythematosus which, with treatment, took nearly 12 months to resolve. This shows that cutaneous lupus erythematosus is a potential side-effect of many medications, including ranibizumab, as in our case and, in an aging population where polypharmacy is a growing reality, clinicians should be aware of how to diagnose and best manage such cases.
C1 [Andric, Marko; Dixit, Shreya; Robaei, Dana; Watchorn, Rosemary; Verma, Nitin] Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas, Australia.
C3 Royal Hobart Hospital
RP Andric, M (通讯作者)，404-300 Pacific Hwy, Crows Nest, NSW 2065, Australia.
EM markoandric84@gmail.com
RI Robaei, Dana/ABC-4608-2020
OI Robaei, Dana/0000-0003-3307-6784
CR Fenniche S, 2005, SKIN PHARMACOL PHYSI, V18, P230, DOI 10.1159/000086668
   Kuhn A, 2008, LUPUS, V17, P389, DOI 10.1177/0961203308090019
   LEHMANN P, 1990, J AM ACAD DERMATOL, V22, P181, DOI 10.1016/0190-9622(90)70020-I
   Lyon CC, 1998, ACTA DERM-VENEREOL, V78, P57
   McCauliffe DP, 1998, LANCET, V351, P1527, DOI 10.1016/S0140-6736(05)61117-8
   Popovic K, 2007, ARTHRITIS RHEUM, V56, P255, DOI 10.1002/art.22286
   REED BR, 1985, ANN INTERN MED, V103, P49, DOI 10.7326/0003-4819-103-1-49
   Romiti N, 2004, AN BRAS DERMATOL, V79, P353
   SONTHEIMER RD, 1989, MED CLIN N AM, V73, P1073, DOI 10.1016/S0025-7125(16)30620-4
   Sontheimer RD, 2009, ARCH DERMATOL RES, V301, P65, DOI 10.1007/s00403-008-0890-x
NR 10
TC 4
Z9 4
U1 0
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2013
VL 61
IS 12
BP 752
EP 754
DI 10.4103/0301-4738.121133
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA1NG
UT WOS:000330862400013
PM 24212210
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fan, NW
   Lau, LI
   Chen, SJ
   Yang, CS
   Lee, FL
AF Fan, Nai-Wen
   Lau, Ling-Ing
   Chen, Shih-Jen
   Yang, Chang-Sue
   Lee, Fenq-Lih
TI Comparison of the effect of reduced-fluence photodynamic therapy with
   intravitreal bevacizumab and standard-fluence alone for polypoidal
   choroidal vasculopathy
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE combination therapy; intravitreal bevacizumab; photodynamic therapy;
   polypoidal choroidal vasculopathy; reduced-fluence photodynamic therapy
ID VERTEPORFIN; RANIBIZUMAB; NEOVASCULARIZATION; COMBINATION; EFFICACY
AB Background: Photodynamic therapy (PDT) has previously been reported to be effective in treating polypoidal choroidal vasculopathy (PCV), with satisfactory polyp regression. However, the optimum treatment protocol remains controversial. This study compared the effect of reduced-fluence PDT combined with intravitreal bevacizumab (rPDT/IVB) and standard-fiuence PDT (sPDT) alone for treating symptomatic PCV in Chinese patients.
   Methods: A retrospective review was carried out of the medical records of patients with PCV who were treated with rPDT/IVB (14 eyes of 13 patients) or sPDT (12 eyes of 12 patients) with at least 6 months of follow-up.
   Results: The mean best-corrected visual acuity of the rPDT/IVB group improved significantly at the 6-month follow-up (p = 0.041). Only one eye (7.1%) in the rPDT/IVB group showed a decrease in visual acuity, compared with four eyes (33.3%) in the sPDT group. A total of 40.0% of eyes in the sPDT group showed increased lipid exudate at follow-up 1 month after treatment, whereas no increase in lipid exudate was observed in the rPDT/IVB group (p = 0.015). The mean maximum area of post-treatment hemorrhage in the rPDT/IVB group was smaller than that in the sPDT group (2.57 +/- 2.74 mm(2) vs. 12.69 +/- 10.28 mm(2), p = 0.042).
   Conclusion: Combination therapy with rPDT/IVB for patients with PCV showed encouraging results in vision improvement, a lower decrease in visual acuity, significantly less post-treatment lipid exudate and a smaller area of post-treatment hemorrhage at the 6-month follow-up than patients treated with sPDT. Copyright (c) 2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
C1 [Fan, Nai-Wen; Lau, Ling-Ing; Chen, Shih-Jen; Yang, Chang-Sue; Lee, Fenq-Lih] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Lau, Ling-Ing; Chen, Shih-Jen; Yang, Chang-Sue; Lee, Fenq-Lih] Natl Yang Ming Univ, Sch Med, Div Ophthalmol, Taipei 112, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University
RP Lau, LI (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM leliew@vghtpe.gov.tw
RI Fan, Nai-Wen/ACB-0737-2022
OI Lau, Ling-Ing/0000-0001-6956-1496
FU Taipei Veterans General Hospital, Taipei, Taiwan [V98A-101]
FX This work was supported by grant V98A-101 from Taipei Veterans General
   Hospital, Taipei, Taiwan.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fukushima Y, 2007, JPN J OPHTHALMOL, V51, P307, DOI 10.1007/s10384-007-0444-3
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
NR 35
TC 10
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD FEB
PY 2014
VL 77
IS 2
BP 101
EP 107
DI 10.1016/j.jcma.2013.10.012
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AC2SC
UT WOS:000332353300009
PM 24332412
OA Bronze
DA 2022-11-30
ER

PT J
AU Guo, JL
   Qiu, XX
   Tang, WY
   Xu, GZ
   Moyers, MF
   Ren, W
   Xing, Y
   Gao, J
   Sun, JY
   Lu, JD
   Kong, L
   Liu, W
AF Guo, Jingli
   Qiu, Xianxin
   Tang, Wenyi
   Xu, Gezhi
   Moyers, Michael F.
   Ren, Wei
   Xing, Ying
   Gao, Jin
   Sun, Jiayao
   Lu, Jiade
   Kong, Lin
   Liu, Wei
TI One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with
   Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal
   Vasculopathy: A Pilot Study
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Intravitreal conbercept; Polypoidal choroidal vasculopathy; Proton-beam
   irradiation; Recurrent; Refractory
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; STEREOTACTIC
   RADIOTHERAPY; RANIBIZUMAB MONOTHERAPY; RADIATION-THERAPY; PHASE I/II;
   AFLIBERCEPT; NEOVASCULARIZATION; COMBINATION; EVEREST
AB Introduction To investigate the efficacy and safety of proton-beam irradiation (PBI) combined with intravitreal conbercept (IVC) injection for refractory or recurrent polypoidal choroidal vasculopathy (PCV). Methods A prospective interventional clinical trial included 12 patients with refractory PCV (defined as persistent exudation or fluid after six consecutive injections at monthly intervals and/or photodynamic therapy) or recurrent PCV (defined as new exudative signs after six monthly injections and/or photodynamic therapy) treated between January 2019 and September 2020. Every patient underwent single PBI (14 GyE) with concomitant IVC (0.5 mg) within 1 week and further doses of IVC were administered pro re nata. Results By the 12-month follow-up, the subretinal fluid was completely absorbed in 9 eyes (81.8%). The angiographic regression and closure rates of the polyps were 60% (12/20) and 90% (18/20), respectively. The mean number of IVC injections was 3.1 +/- 1.37. The mean BCVA improved by 20 letters (P = 0.006). The mean central macular thickness (CMT) decreased from 476.50 +/- 123.63 mu m to 317.70 +/- 89.34 mu m (P = 0.004). The areas of branching vascular networks and polyps decreased by 37.2% and 72.3%, respectively. Radiation retinopathy was observed in five eyes, but no systemic adverse events were observed. Conclusion PBI combined with IVC appears to promote polyp regression and closure, reduce CMT, and improve BCVA, with a favorable safety profile, after 12 months. Therefore, PBI may be a useful adjuvant therapy for patients with refractory or recurrent PCV.
C1 [Guo, Jingli; Tang, Wenyi; Xu, Gezhi; Liu, Wei] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
   [Guo, Jingli; Tang, Wenyi; Xu, Gezhi; Liu, Wei] Fudan Univ, NHC Key Lab Myopia, Shanghai, Peoples R China.
   [Guo, Jingli; Tang, Wenyi; Xu, Gezhi; Liu, Wei] Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
   [Qiu, Xianxin; Moyers, Michael F.; Gao, Jin; Sun, Jiayao; Lu, Jiade] Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Shanghai, Peoples R China.
   [Qiu, Xianxin; Moyers, Michael F.; Xing, Ying; Gao, Jin; Sun, Jiayao; Lu, Jiade; Kong, Lin] Fudan Univ, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Canc Hosp, Shanghai 201321, Peoples R China.
   [Ren, Wei] Natl Canc Ctr Singapore, Dept Radiat Oncol, Singapore, Singapore.
   [Xing, Ying] Shanghai Proton & Heavy Ion Ctr, Dept Med Phys, Shanghai, Peoples R China.
   [Kong, Lin] Shanghai Engn Res Ctr Proton & Heavy Ion Radiat T, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; National Cancer
   Centre Singapore (NCCS)
RP Liu, W (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.; Kong, L (通讯作者)，Fudan Univ, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Canc Hosp, Shanghai 201321, Peoples R China.
EM 18553522773@163.com; lin.kong@sphic.com; Bfgf2020@163.com
RI liu, wei/GYJ-4893-2022
OI Lu, Jiade J/0000-0001-7163-9539
FU Clinical Research Plan of Shanghai Hospital Development Center
   [SHDC2020CR2041B]; Science and Technology Commission of Shanghai
   Municipality [20Y11911100]
FX This study, including the journal's Rapid Service Fees, was supported by
   Clinical Research Plan of Shanghai Hospital Development Center
   (SHDC2020CR2041B), Science and Technology Commission of Shanghai
   Municipality (20Y11911100).
CR Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Chen L, 2014, BRIT J OPHTHALMOL, V98, P1212, DOI 10.1136/bjophthalmol-2013-304761
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Introini U, 2015, OPHTHALMOLOGICA, V233, P82, DOI 10.1159/000368561
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Osmanovic S, 2017, OPHTHALMOL RETINA, V1, P217, DOI 10.1016/j.oret.2016.11.003
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 33
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD FEB
PY 2022
VL 11
IS 1
BP 187
EP 199
DI 10.1007/s40123-021-00409-3
EA NOV 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YJ5MU
UT WOS:000718081200001
PM 34773572
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Qi, HJ
   Jin, EZ
   Zhao, MW
AF Qi, Hui-Jun
   Jin, En-Zhong
   Zhao, Ming-Wei
TI One-year outcomes of intravitreal conbercept combined rescue therapy for
   polypoidal choroidal vasculopathy in a Chinese population: a real-life
   clinical data
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE conbercept; anti-vascular endothelial growth factor; polypoidal
   choroidal vasculopathy; intravitreal injection; laser photocoagulation;
   photodynamic therapy
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; PIGMENT-EPITHELIUM; RANIBIZUMAB
   INJECTIONS; FOLLOW-UP; VERTEPORFIN; AFLIBERCEPT; BEVACIZUMAB
AB AIM: To evaluate the real-life clinical outcomes of intravitreal injection of conbercept combined rescue therapy for polypoidal choroidal vasculopathy (PCV).
   METHODS: This was an open label, single center, and interventional study. All enrolled patients were treated initially with three consecutive monthly intravitreal conbercept injections (0.5 mg). Additional conbercept injections were administered upon substantial polyp regression with improved visual acuity (VA). Eyes with partial or no polyp regression and poor VA were rescue treated with photodynamic therapy (PDT) for subfoveal polyps or thermal laser photocoagulation for extrafoveal polyps. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and polyp regression were observed as primary outcomes. Side effects were also collected during the follow-up period.
   RESULTS: A total of 56 eyes (56 patients) with PCV were included. BCVA increased significantly from the baseline of 43.52 +/- 24.21 letters to 55.88 +/- 21.94 letters (P<0.001) at 12mo, while CFT decreased significantly from 457.41 +/- 207.86 mu m to 247.98 +/- 127.08 mu m (P<0.001). All patients showed polyp regression. Twenty-three eyes achieved complete polyp regression after the three initial injections, which increased to 44 eyes at 12mo. Seventeen eyes underwent rescue therapy, among which 2 eyes treated with PDT and 15 eyes treated with laser photocoagulation. A mean of 4.30 +/- 1.43 injections were given per eye. No intraocular inflammation, retinal or vitreous hemorrhage, or systemic complication occurred.
   CONCLUSION: Conbercept is an effective and safe option for the treatment of PCV in Chinese population. The treatment regimen of three initial conbercept injections followed by additional injections or rescue therapies is efficacious for treating PCV.
C1 [Qi, Hui-Jun; Jin, En-Zhong; Zhao, Ming-Wei] Peking Univ, Peoples Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Dept Ophthalmol,Ophthalmol & Optometry Ctr, Xizhimen South St 11, Beijing 100044, Peoples R China.
C3 Peking University
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Dept Ophthalmol,Ophthalmol & Optometry Ctr, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM zhaomingwei64@163.com
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chhablani JK, 2014, INDIAN J OPHTHALMOL, V62, P97, DOI 10.4103/0301-4738.126197
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2012, ASIA-PAC J OPHTHALMO, V1, P97, DOI 10.1097/APO.0b013e31823e5a95
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee Y-A, 2012, TAIWAN J OPHTHALMOL, V2, P64
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F., 2007, OPHTHALMOLOGY CHINA, V16, P373
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 55
TC 5
Z9 6
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2019
VL 12
IS 1
BP 51
EP 57
DI 10.18240/ijo.2019.01.08
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HH4EY
UT WOS:000455675300008
PM 30662840
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Rouvas, A
   Gouliopoulos, NS
   Moschos, MM
   Theodossiadis, P
AF Rouvas, Alexandros
   Gouliopoulos, Nikolaos S.
   Moschos, Marilita M.
   Theodossiadis, Panagiotis
TI Optic disk melanocytoma associated with polypoidal choroidal
   vasculopathy lesions, after combination treatment of photodynamic
   therapy and intavitreal aflibercept (Eylea), a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Optic disc melanocytoma; Aflibercept;
   Photodynamic therapy
ID MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; VERTEPORFIN
AB BackgroundWe report a rare case of a woman with optic disk melanocytoma (ODMC) in conjunction with polypoidal choroidal vasculopathy (PCV). We also present, for the first time in literature, the clinical and morphological outcomes of the applied treatment, consisting of a session of photodynamic therapy (PDT) and three monthly intravitreal aflibercept injections.Case presentationAn 83-year-old Greek woman, complaining for visual decline at her left eye, referred to our department and was diagnosed with ODMC associated with PCV. At presentation, best corrected visual acuity (BCVA) was 2/10, fundus examination revealed a pigmented lesion covering partially the optic nerve head and extending into the peripapillary choroid and retina, while hard exudates were observed temporal to it. Blocked hypofluorescence in the area covered by the lesion and diffuse hyperfluorescence at its temporal rim were shown by fluorescein angiography (FA). Indocyanine green angiography (ICGA) identified 3 hyperfluorescent polypoidal lesions arising from the choroidal vasculature. Optical coherence tomography (OCT) revealed subretinal fluid and retinal pigment epithelium detachment (RPE) at the region corresponding to polyps. The treatment included a PDT session combined with 3 monthly intravitreal aflibercept injections. Three months since the treatment initiation, new BCVA was 5/10, ICGA demonstrated total polyps occlusion, while OCT detected RPE detachment without subretinal fluid. Ten months later, ODMC was stable, BCVA rose to 7/10, no polyps were present, and total resolution of RPE detachment was achieved.ConclusionsThis is the first case report of PCV coexisting with ODMC, presenting both ICGA and OCT findings, and the applied treatment and its outcomes. Furthermore, we demonstrated that PDT combined with intravitreal aflibercept injections seems to be a promising treatment for PCV.
C1 [Rouvas, Alexandros; Gouliopoulos, Nikolaos S.; Theodossiadis, Panagiotis] Univ Athens, Sch Med, Attikon Gen Hosp Athens, Dept Ophthalmol 2, 1 Rimini Str, Athens 12462, Greece.
   [Moschos, Marilita M.] Univ Athens, Sch Med, G Genimmatas Gen Hosp Athens, Dept Ophthalmol 1, 154 Mesog Ave, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   University Hospital Attikon; Athens Medical School; National &
   Kapodistrian University of Athens
RP Rouvas, A (通讯作者)，Univ Athens, Sch Med, Attikon Gen Hosp Athens, Dept Ophthalmol 2, 1 Rimini Str, Athens 12462, Greece.
EM alexander.rouvas@gmail.com
RI Gouliopoulos, Nikolaos/AAV-8128-2021
OI Gouliopoulos, Nikolaos/0000-0002-4154-1597
CR Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chalam KV, 2006, EUR J OPHTHALMOL, V16, P776, DOI 10.1177/112067210601600523
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   GARCIAARUMI J, 1994, RETINA-J RET VIT DIS, V14, P173, DOI 10.1097/00006982-199414020-00012
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lee E, 2015, ASIA-PAC J OPHTHALMO, V4, P273, DOI 10.1097/APO.0000000000000096
   Liu K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09424
   Mitchell P, 2017, INTRAVITREAL AFLIBER
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Nicolas El-Haddad M, 2002, ARCH SOC ESP OFTALMO, V77, P455
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas A, 2019, INT OPHTHALMOL, V39, P431, DOI 10.1007/s10792-018-0833-2
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shields JA, 2004, OPHTHALMOLOGY, V111, P1739, DOI 10.1016/j.ophtha.2004.02.016
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zimmerman LE., 1962, INT OPHTHALMOL CLIN, V2, P431
NR 24
TC 2
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD OCT 12
PY 2018
VL 18
AR 267
DI 10.1186/s12886-018-0927-7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW7YR
UT WOS:000447189700001
PM 30309335
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chan, WM
   Liu, DTL
   Lai, TYY
   Li, HT
   Tong, JP
   Lam, DSC
AF Chan, WM
   Liu, DTL
   Lai, TYY
   Li, HT
   Tong, JP
   Lam, DSC
TI Extensive submacular haemorrhage in polypoidal choroidal vasculopathy
   managed by sequential gas displacement and photodynamic therapy: a pilot
   study of one-year follow up
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE gas displacement; photodynamic therapy; polypoidal choroical
   vasculopathy; submacular haemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; MACULAR DEGENERATION; NATURAL-HISTORY; VERTEPORFIN; SERIES
AB Background: Polypoidal choroidal vasculopathy (PCV) with peculiar vascular lesions presents frequently as recurrent submacular haemorrhage. The best treatment is still not certain. It is the authors' objective to evaluate the 1-year safety and efficacy of photodynamic therapy (PDT) using verteporfin for persistent macular PCV after pneumatic displacement of the massive submacular haemorrhage with intravitreal perfluoropropare (C3F8).
   Methods: A prospective, non-comparative, interventional case series on patients with extensive and thick submacular haemorrhage secondary to PCV, which was displaced pneumatically with intravitreal pure 0.4 ml C3F8. Fluorescein angiography and indocyanine green angiography were repeated 1-2 weeks later to delineate any persistent active leaking polypoidal lesions, which were then treated with PDT Retreatment might be considered in each follow up at every 3 months.
   Results: Six eyes of six patients with the mean age of 53.6 years had been recruited and completed 1-year follow up. The mean baseline Snellen equivalent best-corrected visual acuity (BCVA) was 6/92 and the mean final BCVA at 1 year was 6/17.The mean improvement in logMAR BCVA after the sequential treatments was seven lines (range +3 to + 19 lines) (Wilcoxon signed-ranks test, P = 0.03). All patients had at least moderate visual gains. No patient suffered serious complications from PDT.
   Conclusions: This first report on combined treatment with intravitreal gas injection and sequential PDT on PCV seems to be a well-tolerated option. Further comparative studies with larger sample size and longer follow up are warranted.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   Zhejiang Univ, Zheyi Eye Ctr, Affiliated Hosp Med Coll 1, Hangzhou 310027, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Zhejiang University
RP Chan, WM (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2004, AM J OPHTHALMOL, V137, P574, DOI 10.1016/j.ajo.2003.08.044
   Chaudhry NA, 1999, OPHTHALMIC SURG LAS, V30, P670
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Sato T, 2001, INVEST OPHTH VIS SCI, V42, pS800
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YAZAWA M, 2001, INVEST OPHTH VIS SCI, V42, pS824
NR 28
TC 25
Z9 27
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2005
VL 33
IS 6
BP 611
EP 618
DI 10.1111/j.1442-9071.2005.01105.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 002ZT
UT WOS:000234652100015
PM 16402954
DA 2022-11-30
ER

PT J
AU Cheng, Y
   Shi, X
   Qu, JF
   Zhao, MW
   Li, XX
AF Cheng, Yong
   Shi, Xuan
   Qu, Jin-Feng
   Zhao, Ming-Wei
   Li, Xiao-Xin
TI Comparison of the 1-year Outcomes of Conbercept Therapy between Two
   Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Angiographic Subtypes; Anti-vascular Endothelial Growth Factor;
   Conbercept; Polypoidal Choroidal Vasculopathy
ID INTRAVITREAL RANIBIZUMAB TREATMENT; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; CLINICAL CHARACTERISTICS;
   VERTEPORFIN; BEVACIZUMAB; EFFICACY; CLASSIFICATION; IPCV
AB Background: Polypoidal choroidal vasculopathy (PCV) is characterized by the presence of polyps with or without a branching vascular network and more prevalent among Asians. The aim of this study was to compare the outcomes of conbercept therapy between two different angiographic subtypes of PCV.
   Methods: Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In Type 1, both feeder and draining vessels are visible on ICGA and network vessels are numerous. In Type 2, neither feeder nor draining vessels are detectable, and the number of network vessels is small. The patients were treated with intravitreal conbercept (IVC) for 3 months. Additional IVC was given at subsequent monthly visits, if needed. The patients were followed up for 12 months, and changes in mean best-corrected visual acuity (BCVA), central retinal thickness (CRT), subretinal fluid (SRF) thickness, pigmented epithelial detachment (PED), hemorrhage, and number of polypoidal lesions were evaluated.
   Results: The mean BCVA in Type 2 PCV (15.92 +/- 9.76 letters) achieved a significantly greater improvement than that in the Type 1 (14.10 +/- 9.07 letters) at month 12 (t = 2.37, P < 0.01). Moreover, the mean CRT decrease was numerically greater in Type 2 (120.44 +/- 73.81 mu m) compared with Type 1 (106.48 +/- 72.33 mu m) at month 6 (t = 4.31, P < 0.01), and greater in Type 2 (130.21 +/- 76.28 mu m) compared with Type 1 (111.67 +/- 79.57 mu m) at month 9 (t = 1.87, P < 0.01). There was no significant difference between the two types for the decrease in SRF thickness, PED height, and regression of polyps from month 3 to 12 (t = 2.97, P > 0.05).
   Conclusion: Classification systems for PCV will show differences in presentation, natural history, or response to anti- vascular endothelial growth factor treatment and might, therefore, provide a new key to the choice of treatment for the disease.
C1 [Cheng, Yong; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Li, Xiao-Xin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Cheng, Yong; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Li, Xiao-Xin] Minist Educ, Key Lab Vision Loss & Restorat, 11 Xizhimen South Ave, Beijing 100044, Peoples R China.
   [Cheng, Yong; Shi, Xuan; Qu, Jin-Feng; Zhao, Ming-Wei; Li, Xiao-Xin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100044, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.; Li, XX (通讯作者)，Minist Educ, Key Lab Vision Loss & Restorat, 11 Xizhimen South Ave, Beijing 100044, Peoples R China.
EM drlixiaoxin@163.com
FU Capital Health Research and Development of Special [2014-3-4086]
FX This study was supported by a grant from the Capital Health Research and
   Development of Special (No. 2014-3-4086).
CR BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Chhablani JK, 2013, INDIAN J OPHTHALMOL, V61, P136, DOI 10.4103/0301-4738.109390
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Fernandez M, 2012, CASE REP MED, V2012, DOI 10.1155/2012/897097
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giovannini A, 1999, DOC OPHTHALMOL, V97, P367, DOI 10.1023/A:1002102630242
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hata Masayuki, 2012, Nippon Ganka Gakkai Zasshi, V116, P937
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Shechtman D, 2004, OPTOMETRY VISION SCI, V81, P491, DOI 10.1097/00006324-200407000-00009
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamagishi T, 2014, BRIT J OPHTHALMOL, V98, P780, DOI 10.1136/bjophthalmol-2013-303739
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 51
TC 9
Z9 10
U1 0
U2 8
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD NOV 5
PY 2016
VL 129
IS 21
BP 2610
EP 2616
DI 10.4103/0366-6999.192779
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EB0MH
UT WOS:000387037400015
PM 27779169
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Matsuo, T
   Uchida, T
   Sakurai, J
   Yamashita, K
   Matsuo, C
   Araki, T
   Yamashita, Y
   Kamikawa, K
AF Matsuo, Toshihiko
   Uchida, Tetsuya
   Sakurai, Jun
   Yamashita, Koichiro
   Matsuo, Chie
   Araki, Tomoaki
   Yamashita, Yusuke
   Kamikawa, Kunihisa
TI Visual Evoked Potential Recovery by Subretinal Implantation of
   Photoelectric Dye-Coupled Thin Film Retinal Prosthesis in Monkey Eyes
   With Macular Degeneration
SO ARTIFICIAL ORGANS
LA English
DT Article
DE Dye-coupled thin film retinal prosthesis; Photoelectric dye; Monkey;
   Vitreous surgery; Macular degeneration; Visual evoked potential
ID SAFETY; TRIAL
AB Retinal prosthesis or artificial retina is a promising modality of treatment for outer retinal degeneration, caused by primary and secondary loss of photoreceptor cells, in hereditary retinal dystrophy and age-related macular degeneration, respectively. Okayama University-type retinal prosthesis (OUReP) is a photoelectric dye-coupled polyethylene film which generates electric potential in response to light and stimulates nearby neurons. The dyecoupled films were implanted by vitreous surgery in the subretinal space of monkey eyes with macular degeneration which had been induced by cobalt chloride injection from the scleral side. A pilot 1-month observation study involved 6 monkeys and a pivotal 6-month observation study involved 8 monkeys. Of 8 monkeys in 6-month group, 3 monkeys underwent dye-coupled film removal at 5 months and were observed further for 1 month. The amplitude of visual evoked potential which had been reduced by macular degeneration did recover at 1 month after film implantation and maintained the level at 6 months. Optical coherence tomography showed no retinal detachment, and full-field electroretinograms maintained a-wave and b-wave amplitudes, indicative of no retinal toxicity. Pathological examinations after 6-month implantation showed structural integrity of the inner retinal layer in close apposition to dye-coupled films. The implanted films which were removed by vitrectomy 5 months later showed light-evoked surface electric potentials by scanning Kelvin probe measurement. The photoelectric dye-coupled film (OUReP), which serves as a light-receiver and a displacement current generator in the subretinal space of the eye, has a potential for recovering vision in diseases with photoreceptor cell loss, such as retinitis pigmentosa and age-related macular degeneration.
C1 [Matsuo, Toshihiko] Okayama Univ, Med Sch, Dept Ophthalmol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
   [Matsuo, Toshihiko] Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
   [Uchida, Tetsuya; Yamashita, Koichiro] Okayama Univ, Fac Engn, Polymer Mat Sci, Okayama, Japan.
   [Uchida, Tetsuya; Yamashita, Koichiro] Grad Sch Nat Sci & Technol, Okayama, Japan.
   [Sakurai, Jun; Kamikawa, Kunihisa] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan.
   [Araki, Tomoaki; Yamashita, Yusuke] Shin Nippon Biomed Labs Ltd, Kagoshima, Japan.
   [Matsuo, Toshihiko] Grad Sch Interdisciplinary Sci & Engn Hlth Syst, Okayama, Japan.
C3 Okayama University; Okayama University; Okayama University; Shin Nippon
   Biomedical Laboratories Ltd.
RP Matsuo, T (通讯作者)，Okayama Univ, Med Sch, Dept Ophthalmol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.; Matsuo, T (通讯作者)，Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama 7008558, Japan.; Matsuo, T (通讯作者)，Grad Sch Interdisciplinary Sci & Engn Hlth Syst, Okayama, Japan.
EM matsuot@cc.okayama-u.ac.jp
RI Uchida, Tetsuya/B-2114-2011
OI Uchida, Tetsuya/0000-0002-7972-3054
FU Japan Agency for Medical Research and Development (AMED)
FX We thank the staff at Shin Nippon Biomedical Laboratories, Ltd.,
   Kagoshima City, Japan, for helping us conduct experiments in monkeys. We
   also thank Dr. Toshinori Furukawa at Kurashiki University of Science and
   the Arts, Dr. Shigiko Takei and Dr. Daisuke Ido at Ina Research, Inc.,
   for their advice on surgeries. This study was supported by a grant
   (Seeds C 2016) for the Translational Research Network Program from the
   Japan Agency for Medical Research and Development (AMED).
CR Alamusi, 2017, J ARTIF ORGANS, V20, P158, DOI 10.1007/s10047-016-0943-4
   Alamusi, 2015, J ARTIF ORGANS, V18, P264, DOI 10.1007/s10047-015-0825-1
   Alamusi, 2013, J ARTIF ORGANS, V16, P343, DOI 10.1007/s10047-013-0697-1
   Chuang AT, 2014, BRIT J OPHTHALMOL, V98, P852, DOI 10.1136/bjophthalmol-2013-303708
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   Ghezzi D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00290
   Huang F, 2015, ACTA BIOMATER, V12, P42, DOI 10.1016/j.actbio.2014.10.023
   Humayun MS, 2016, OPHTHALMOLOGY, V123, pS89, DOI 10.1016/j.ophtha.2016.06.044
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Kelly SK, 2011, IEEE T BIO-MED ENG, V58, P3197, DOI 10.1109/TBME.2011.2165713
   Liu SH, 2017, J OCUL PHARMACOL TH, V33, P149, DOI 10.1089/jop.2016.0093
   Loewenstein JI, 2004, ARCH OPHTHALMOL-CHIC, V122, P587, DOI 10.1001/archopht.122.4.587
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Matsuo T, 2003, ACTA MED OKAYAMA, V57, P257
   Matsuo T., 2014, SPRINGERPLUS, V3, P301
   Matsuo T, 2007, BRIT J OPHTHALMOL, V91, P888, DOI 10.1136/bjo.2007.114538
   Matsuo T, 2018, J VET MED SCI, V80, P247, DOI 10.1292/jvms.17-0422
   Matsuo T, 2017, J VET MED SCI, V79, P1939, DOI 10.1292/jvms.17-0450
   Matsuo T, 2009, J ARTIF ORGANS, V12, P213, DOI 10.1007/s10047-009-0471-6
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   Okamoto K, 2008, J ARTIF ORGANS, V11, P45, DOI 10.1007/s10047-008-0403-x
   Roux S, 2016, ELIFE, V5, DOI 10.7554/eLife.12687
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Suga S, 2006, United States Patent, Patent No. [US 7,101,533 B2, 7101533]
   Tamaki M, 2011, J ARTIF ORGANS, V14, P140, DOI 10.1007/s10047-011-0557-9
   Tamaki T, 2008, J ARTIF ORGANS, V11, P38, DOI 10.1007/s10047-007-0398-8
   Uchida T., 2005, MEM FAC ENG OKAYAMA, V39, P16, DOI [10.18926/14136, DOI 10.18926/14136]
   Uji A, 2005, ARTIF ORGANS, V29, P53, DOI 10.1111/j.1525-1594.2004.29010.x
   Uji A, 2006, ARTIF ORGANS, V30, P695, DOI 10.1111/j.1525-1594.2006.00286.x
NR 31
TC 11
Z9 11
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD AUG
PY 2018
VL 42
IS 8
SI SI
BP E186
EP E203
DI 10.1111/aor.13120
PG 18
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Transplantation
GA GS3TU
UT WOS:000443546000003
PM 29633282
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Smith, RT
   Sohrab, MA
   Busuioc, M
   Barile, G
AF Smith, R. Theodore
   Sohrab, Mahsa A.
   Busuioc, Mihai
   Barile, Gaetano
TI Reticular Macular Disease
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; AUTOFLUORESCENCE CHARACTERISTICS; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; GRADING SYSTEM; HIGH-RISK;
   DRUSEN; DEGENERATION; RECONSTRUCTION; PSEUDODRUSEN
AB PURPOSE: To present a unified description of reticular macular disease (RMD), a common clinical entity that includes reticular pseudodrusen (RPD) and confers high-risk of progression to advanced age-related macular degeneration.
   DESIGN: Population-based, retrospective, cross-sectional study. Forty-two patients with reticular findings in at least one imaging method, of whom 21 were followed up.
   METHODS: RMD was defined as RPD in color or red-free photography, in a reticular pattern on scanning laser ophthalmoscope imaging (autofluorescence scans, infrared photographs, or indocyanine green angiography), or both. Color and red-free images were contrast-enhanced, and color photographs were examined in green and blue channels. Image registration in different methods allowed comparison of areas involved and assessment of lesion colocalization.
   RESULTS: RMD generally was present in both photography and scanning laser ophthalmoscope imaging. When present in two image methods, areas of RMD either largely overlapped or one fell within the other. Individual lesions had high spatial correspondence. Serial imaging showed faded to absent findings in eyes in which choroidal neovascularization developed.
   CONCLUSIONS: RMD is a single disease entity with stereotypical presentations in multiple imaging methods, of which RPD is one. Autofluorescence, infrared imaging, and indocyanine green angiography suggest that it involves the retinal pigment epithelium and choriocapillaris, whereas photographic patterns implicate the inner choroid. Infrared imaging, unlike other methods, can demonstrate RMD in the central macula. RMD is associated with progression to advanced age-related macular degeneration, perhaps on an inflammatory basis. RI M deserves wider recognition among clinicians caring for elderly patients. (Am J Oph, thalmol 2009;148:733-743. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Smith, R. Theodore] Columbia Univ, Inst Eye, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University
RP Smith, RT (通讯作者)，Columbia Univ, Inst Eye, Dept Ophthalmol, 635 W 165 St, New York, NY 10032 USA.
EM rts1@columbia.edu
OI smith, theodore/0000-0002-1693-943X
FU NEW YORK COMMUNITY TRUST, NEW YORK, NEW YORK [R01 EY015520]; National
   Eye Institute, Bethesda, Maryland; NATIONAL EYE INSTITUTE [R01EY015520]
   Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY GRANTS FROM THE NEW YORK COMMUNITY TRUST,
   NEW YORK, NEW YORK; GRANT NO. R01 EY015520 from the National Eye
   Institute, Bethesda, Maryland; and unrestricted funds from Research to
   Prevent Blindness Inc, New York, New York. The authors indicate no
   financial conflict of interest. Involved in design and Conduct of study
   (R.T.S., M.A.S., M.B., G.B.); collection, management, analysis, and
   interpretation of data (R.T.S., M.A.S., M.B., G.B.); and preparation,
   review, or approval of the manuscript (R.T.S., M.A.S., M.B., G.B.). The
   Macular Genetics Study at Columbia University was approved by the
   Institutional Review Board of Columbia University and adhered to the
   tenets the Declaration of Helsinki.
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2005, INVEST OPHTH VIS SCI, V46, P2940, DOI 10.1167/iovs.04-0778
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
NR 15
TC 142
Z9 148
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2009
VL 148
IS 5
BP 733
EP 743
DI 10.1016/j.ajo.2009.06.028
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518DA
UT WOS:000271669300015
PM 19878758
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pelletier, AL
   Rojas-Roldan, L
   Coffin, J
AF Pelletier, Allen L.
   Rojas-Roldan, Ledy
   Coffin, Janis
TI Vision Loss in Older Adults
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID 10-YEAR FOLLOW-UP; MACULAR DEGENERATION; EYE DISEASE; PROGRESSION;
   RETINOPATHY; CATARACT; LUTEIN/ZEAXANTHIN; PERSPECTIVES; BEVACIZUMAB;
   FENOFIBRATE
AB Vision loss affects 37 million Americans older than 50 years and one in four who are older than 80 years. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in adults older than 65 years. However, family physicians play a critical role in identifying persons who are at risk of vision loss, counseling patients, and referring patients for disease-specific treatment. The conditions that cause most cases of vision loss in older patients are age-related macular degeneration, glaucoma, ocular complications of diabetes mellitus, and age-related cataracts. Vitamin supplements can delay the progression of age-related macular degeneration. Intravitreal injection of a vascular endothelial growth factor inhibitor can preserve vision in the neovascular form of macular degeneration. Medicated eye drops reduce intraocular pressure and can delay the progression of vision loss in patients with glincoma, but adherence to treatment is poor. Laser trabeculoplasty also lowers intraocular pressure and preserves vision in patients with primary open-angle glaucoma, but long-term studies are needed to identify who is most likely to benefit from surgery. Tight glycemic control in adults with diabetes slows the progression of diabetic retinopathy, but must be balanced against the risks of hypoglycemia and death in older adults. Fenofibrate also slows progression of diabetic retinopathy. Panretinal photocoagulation is the mainstay of treatment for diabetic retinopathy, whereas vascular endothelial growth factor inhibitors slow vision loss resulting from diabetic macular edema. Preoperative testing before cataract surgery does not improve outcomes and is not recommended. Copyright (C) 2016 American Academy of Family Physicians.
C1 [Pelletier, Allen L.; Rojas-Roldan, Ledy; Coffin, Janis] Augusta Univ, Med Coll Georgia, Dept Family Med, Augusta, GA USA.
C3 University System of Georgia; Augusta University
RP Pelletier, AL (通讯作者)，Med Coll Georgia, HB 4020, Augusta, GA 30912 USA.
EM apelletier@augusta.edu
CR AAO, 2021, AM ACAD OPHTHALMOL
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cardarelli WJ, 2013, AM J MANAG CARE, V19, pS85
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, NEW ENGL J MED, V367, P2458
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2011, NEW ENGL J MED, V364, P190
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Courtney-Long EA, 2015, MMWR-MORBID MORTAL W, V64, P777, DOI 10.15585/mmwr.MM6429a2
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Evans JR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011234.pub2
   Galor A, 2011, CURR OPIN OPHTHALMOL, V22, P477, DOI 10.1097/ICU.0b013e32834bbe7a
   Gerstein HC, 2011, NEW ENGL J MED, V364, P818, DOI 10.1056/NEJMoa1006524
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gordon Josette E, 2002, J Fam Pract, V51, P105
   Grover D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005656.pub2
   Haddrill M., LUCENTIS VS AVASTIN
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Martinez-Zapata MJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008721.pub2
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keay L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007293.pub3
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kirkman MS, 2012, DIABETES CARE, V35, P2650, DOI 10.2337/dc12-1801
   Lum F, 2016, OPHTHALMOLOGY, V123, P928, DOI [10.1016/j.ophtha.2016.01.024, 10.1016/j.ophtha.2015.10.047]
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Neel ST, 2014, JAMA OPHTHALMOL, V132, P1282, DOI 10.1001/jamaophthalmol.2014.2074
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Pelletier AL, 2009, AM FAM PHYSICIAN, V79, P963
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Riaz Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001323.pub2
   Roberts JE, 2011, EYE CONTACT LENS, V37, P246, DOI 10.1097/ICL.0b013e31821cbcc9
   Samples JR, 2011, OPHTHALMOLOGY, V118, P2296, DOI 10.1016/j.ophtha.2011.04.037
   Schwartz GR, 2008, SURV OPHTHALMOL, V53, pS57, DOI 10.1016/j.survophthal.2008.08.002
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P908, DOI 10.1001/jama.2016.0763
   Social Security Administration, 2016, YOUR BLIND HAV LOW V
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   U.S. Preventive Services Task Force, 2013, GLAUC SCREEN FIN REC
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Waterman H, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006132.pub3
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
NR 52
TC 37
Z9 38
U1 0
U2 10
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD AUG 1
PY 2016
VL 94
IS 3
BP 219
EP 226
PG 8
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DS8WR
UT WOS:000381064200010
PM 27479624
DA 2022-11-30
ER

PT J
AU Mori, R
   Tanaka, K
   Yuzawa, M
AF Mori, Ryusaburo
   Tanaka, Koji
   Yuzawa, Mitsuko
TI Factors predicting 2-year treatment results of ranibizumab therapy for
   polypoidal choroidal vasculopathy in eyes with good baseline visual
   acuity
SO MEDICINE
LA English
DT Article
DE good baseline visual acuity; polypoidal choroidal vasculopathy;
   ranibizumab
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; VASCULAR
   HYPERPERMEABILITY; PROGNOSTIC-FACTORS; OUTCOMES
AB This study aimed to explore predictors of long-term stabilization of polypoidal choroidal vasculopathy (PCV) lesions and vision in response to injection of intravitreal ranibizumab (IVR). The treated eyes had a baseline best corrected visual acuity (BCVA) of at least 0.6 (logarithm of the minimal angle of resolution (logMAR) 0.22).
   We treated 45 eyes showing BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0), with IVR for 3 consecutive months. All eyes were confirmed to have subfoveal PCV prior to starting this treatment regimen. Additional IVR was administered at the subsequent monthly visits, if necessitated by evidence of persistent PCV, for up to 23 months after the first ranibizumab injection. The subjects were then carefully followed-up for 24 months, allowing detailed retrospective evaluation of changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and polypoidal lesion numbers. The relationships between retreatment and each of the baseline characteristics and SRD development during follow-up were analyzed.
   The mean logMAR BCVAs were 0.111 +/- 0.076, 0.068 +/- 0.206 (P=.0033) and 0.115 +/- 0.265 (P=.27) at baseline and at 12 and 24 months, respectively. At 24 months, 87% of eyes had BCVA of 20/40 or better. Not requiring retreatment between 12 and 23 months was found to be significantly associated with the absence of retinal pigment epithelial detachment (RPED) at baseline (odds ratio: 0.262 (95% confidence interval (CI): 0.073-0.946). The rates of retreatment from 12 to 23 months were significantly higher in eyes with SRD at 6 and 12 months than in those without SRD (P=.004 and P<.001).
   In conclusion, during 24 months of antivascular endothelial growth factor (VEGF) therapy using ranibizumab for PCV, BCVA was maintained in those with good visual acuity at baseline. Comprehensive analyses revealed RPED at baseline and SRD development during follow-up to correlate significantly with the need for retreatment between 12 and 23 months. Our observations might facilitate tailoring treatments to individual PCV patients.
C1 [Mori, Ryusaburo; Tanaka, Koji; Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.
C3 Nihon University
RP Mori, R (通讯作者)，Nihon Univ Hosp, Dept Ophthalmol, Chiyoda Ku, 1-6 Kanda Surugadai, Tokyo 1018309, Japan.
EM mori.ryusaburo@gmail.com
RI Tanaka, Koji/H-3119-2019
OI Tanaka, Koji/0000-0003-3323-4148
FU Novartis Pharma K.K. ( Tokyo, Japan)
FX This work was partially supported by Novartis Pharma K.K. ( Tokyo,
   Japan). Although Novartis Pharma K.K. and Novartis AG were invited to
   comment on the research plan and this manuscript during the review
   process, neither any role (responsibility) in either the design or the
   conduct of this research. Changes in response to the comments received
   were made by the authors, solely on the basis of scientific and
   editorial merit.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kato A, 2015, OPHTHALMOLOGICA, V233, P27, DOI 10.1159/000368249
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nishimura T, 2015, GRAEF ARCH CLIN EXP, V253, P1201, DOI 10.1007/s00417-014-2779-z
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 18
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN
PY 2018
VL 97
IS 25
AR e11188
DI 10.1097/MD.0000000000011188
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GN9SF
UT WOS:000439547300069
PM 29924037
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Chang, TS
   Fine, JT
   Dolan, CM
   Ward, J
AF Bressler, Neil M.
   Chang, Tom S.
   Fine, Jennifer T.
   Dolan, Chantal M.
   Ward, James
CA Anti-VEGF Antibody Treatment Pred
TI Improved Vision-Related Function After Ranibizumab vs Photodynamic
   Therapy A Randomized Clinical Trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; RESPONSIVENESS; SURGERY;
   ACUITY
AB Objective: To compare patient-reported visual function in those with neovascular age-related macular degeneration treated with ranibizumab or verteporfin photodynamic therapy (PDT).
   Design: Multicenter, double-masked, phase 3 trial (ANCHOR). Participants were randomized in a 1:1:1 ratio to receive 0.3 or 0.5 mg of intravitreal ranibizumab plus sham verteporfin or sham injections plus active verteporfin monthly. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered at baseline and 1, 2, 3, 6, 9, 12, 18, and 24 months.
   Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 months.
   Results:At 12 months, patients treated with ranibizumab (0.3 mg [n = 137] or 0.5 mg [n = 139]) had mean improvements in NEI VFQ-25 composite scores of 5.9 (95% confidence interval [CI], 3.6 to 8.3) and 8.1 (95% CI, 5.3 to 10.8) points, respectively; patients treated with PDT (n = 142) had a mean improvement of 2.2 points (95% CI,-0.3 to 4.7; vs 0.5 mg of ranibizumab, P < .001; vs 0.3 mg of ranibizumab, P = .003). At each dose through 24 months, patients treated with ranibizumab were more likely to improve in most subscales, including the pre-specified subscales (near activities, distance activities, and vision-specific dependency).
   Conclusions: Patients treated with ranibizumab were more likely to report clinically meaningful improvements in visual function through 24 months compared with those treated with verteporfin PDT.
   Application to Clinical Practice: Ranibizumab treatment in neovascular age-related macular degeneration can improve patient-reported visual function.
   Trial Registration: clinicaltrials.gov Identifier:NCT00061594
C1 [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol,Retina Div, Baltimore, MD 21205 USA.
   [Chang, Tom S.] Retina Inst Calif, Pasadena, CA USA.
   [Fine, Jennifer T.; Dolan, Chantal M.; Ward, James] Genentech Inc, San Francisco, CA 94080 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Roche Holding;
   Genentech
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol,Retina Div, 550 N Broadway,Ste 115, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
FU Genentech Inc; Novartis Pharma AG; Johns Hopkins University (JHU);
   Genentech for clinical and scientific consultation
FX This study was supported by Genentech Inc and Novartis Pharma AG. Dr
   Bressler's employer, the Johns Hopkins University (JHU), but not Dr
   Bressler, receives funding as principal investigator from Allergan,
   Bausch & Lomb, Carl Zeiss Meditec, Genentech, Jerini, Notal Vision,
   Novartis, Othera, QLT, Regeneron, and Steba Pharmaceuticals for
   sponsored projects by the Department of Ophthalmology for Dr Bressler's
   efforts. Dr Bressler receives salary support for these sponsored
   projects; the terms of these projects are negotiated and administered by
   JHU's Office of Research Administration. Under JHU's policy, support for
   the costs of research, administered by the institution, does not
   constitute a conflict of interest. In addition, Dr Bressler's spouse is
   a paid consultant for Notal Vision and Oxigene. The terms of these
   arrangements are being managed by JHU in accordance with its conflict of
   interest policies. Dr Chang receives funding from Genentech for clinical
   and scientific consultation. Dr Fine is a Genentech employee. Drs Dolan
   and Ward are paid consultants for Genentech. The design and conduct of
   the study as well as the data collection, management, and analysis were
   supported by Genentech Inc and Novartis Pharma AG. Medical writing
   assistance for this manuscript was provided by Genentech Inc.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59
NR 24
TC 74
Z9 77
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2009
VL 127
IS 1
BP 13
EP 21
DI 10.1001/archophthalmol.2008.562
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 393UN
UT WOS:000262399000001
PM 19139332
DA 2022-11-30
ER

PT J
AU Chiang, A
   Chang, LK
   Yu, F
   Sarraf, D
AF Chiang, Allen
   Chang, Louis K.
   Yu, Fei
   Sarraf, David
TI PREDICTORS OF ANTI-VEGF-ASSOCIATED RETINAL PIGMENT EPITHELIAL TEAR USING
   FA AND OCT ANALYSIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal pigment epithelial tear; RPE tear; pigment epithelial
   detachment; PED; age related macular degeneration; AMD; complications;
   risk factors; optical coherence tomography; fluorescein angiography
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; INTRAVITREAL BEVACIZUMAB
   INJECTION; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; AVASTIN;
   RANIBIZUMAB; VERTEPORFIN; RIP
AB Purpose: To identify fluorescein angiography and optical coherence tomography (OCT) predictors for retinal pigment epithelial (RPE) tear in eyes with pigment epithelium detachment (PED) associated with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor (VEGF) modulating therapy.
   Design: Retrospective comparative case series.
   Methods: In a single institutional center, 60 consecutive patients with PED and neovascular age-related macular degeneration treated with VEGF modulating therapy (either pegaptanib, bevacizumab, or ranibizumab) for more than a 27-month period were included in the study. Fluorescein angiography (FA) and OCT imaging was performed before and after anti-VEGF therapy. Formal statistical analysis comparing the tear group to the nontear group was performed to identify high-risk features for RPE tear.
   Results: RPE tear rate for eyes with vascularized PED receiving anti-VEGF therapy was 17% (10/60). There were highly statistically significant differences in the median PED size on fluorescein angiography (greatest linear diameter) (3.2 mm versus 1.8 mm, respectively; P < 0.001) and in the median maximum PED height on OCT (394 mu m versus 149 Am, respectively; P = 0.001) between the tear group and nontear group. There was also a significant difference in terms of the presence of subretinal fluid on OCT between the two groups (87.5% versus 39%, respectively; P = 0.019).
   Conclusion: Large PED basal diameter and vertical height are correlated with an increased risk of developing an RPE tear after anti-VEGF therapy. Patients with large vascularized PED by fluorescein angiography and/or OCT analysis should be alerted of the risk for vision loss due to RPE tear after anti-VEGF therapy. RETINA 28:1265-1269, 2008
C1 [Chiang, Allen; Chang, Louis K.; Yu, Fei; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
FU RPB
FX Supported by an RPB grant to Dr. David Sarraf.
CR Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   CHUANG LK, 2007, RETINA, V27, P523
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   DECKER WL, 1983, OPHTHALMOLOGY, V5, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 23
TC 86
Z9 90
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2008
VL 28
IS 9
BP 1265
EP 1269
DI 10.1097/IAE.0b013e31817d5d03
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366IM
UT WOS:000260474200014
PM 18628724
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kang, SW
   Ha, HS
   Kim, SJ
   Kim, JR
AF Kim, Jae Hui
   Kang, Se Woong
   Ha, Hyo Shin
   Kim, Sang Jin
   Kim, Jae Ryung
TI Overestimation of subfoveal choroidal thickness by measurement based on
   horizontally compressed optical coherence tomography images
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Overestimation; Optical coherence tomography;
   Horizontally compressed; 1:1 pixel; 1:1 micron
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION; VASCULOPATHY
AB To measure the difference in subfoveal choroidal thickness between 1:1 pixel (horizontally compressed) images and 1:1 micron images in age-related macular degeneration.
   This study included 122 eyes from 122 patients diagnosed with age-related macular degeneration. Choroidal thickness was measured using enhanced-depth imaging optical coherence tomography. The measurement line was drawn as a perpendicular line between Bruch's membrane and the chorio-scleral interface. The thickness was compared between measurements based on a 1:1 pixel image and a 1:1 micron image. Eyes with a straight vertical measurement line and oblique measurement line were classified into vertical measurement group and oblique measurement group, respectively. Intra-group comparisons of subfoveal choroidal thickness measurements based on the 1:1 pixel images and the 1:1 micron images were performed for the two groups.
   The mean subfoveal choroidal thicknesses measured on the 1:1 pixel images and the 1:1 micron images were 232.3 +/- 106.4 mu m and 228.9 +/- 108.1 mu m, respectively (p = 0.003). In the vertical measurement group (86 eyes), the mean subfoveal choroidal thickness was 226.3 +/- 109.9 mu m and 225.4 +/- 112.0 mu m, respectively (p = 0.423). In the oblique measurement group (36 eyes), the thickness was 246.5 +/- 97.3 mu m and 237.5 +/- 98.9 mu m, respectively (p < 0.001).
   Significant overestimation of the subfoveal choroidal thickness was noted when it was measured on a 1:1 pixel image. This finding suggests that the measurement of choroidal thickness should be performed based on a 1:1 micron image, especially if the measurement line is not vertical.
C1 [Kim, Jae Hui; Kang, Se Woong; Ha, Hyo Shin; Kim, Sang Jin; Kim, Jae Ryung] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul 135710, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
RI Kim, Jaeryung/AAB-6693-2022; Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690; Kim, Jaeryung/0000-0002-8003-5849
CR Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
NR 16
TC 16
Z9 19
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2013
VL 251
IS 4
BP 1091
EP 1096
DI 10.1007/s00417-012-2147-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114RD
UT WOS:000316759000006
PM 22948949
DA 2022-11-30
ER

PT J
AU Austin, BA
   Liu, BY
   Li, ZQ
   Nussenblatt, RB
AF Austin, Bobbie Ann
   Liu, Baoying
   Li, Zhuqing
   Nussenblatt, Robert B.
TI Biologically Active Fibronectin Fragments Stimulate Release of MCP-1 and
   Catabolic Cytokines from Murine Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; HTRA1 PROMOTER POLYMORPHISM; COMPLEMENT
   FACTOR-H; MACULAR DEGENERATION; MATRIX METALLOPROTEINASES; BRUCHS
   MEMBRANE; RHEUMATOID-ARTHRITIS; JAPANESE POPULATION; DRUSEN FORMATION;
   SYNOVIAL-FLUID
AB PURPOSE. High-temperature requirement serine protease (HTRA1) was identified as a candidate age-related macular degeneration gene in multiple genetic studies in humans. To date, no functional studies have shown a mechanism for HTRA1 to instigate ocular tissue abnormalities. In the present study, the authors focused on a substrate of HTRA1, fibronectin, because fibronectin fragments (Fnfs) stimulate biochemical events in other age-related degenerative diseases that are analogous to changes associated with age-related macular degeneration (AMD). The purpose of the study was to determine whether Fnfs stimulate the release of proinflammatory and catabolic cytokines from murine retinal pigment epithelium (RPE).
   METHODS. Fibronectin was purified from murine serum by gelatin cross-linked agarose chromatography and subsequently was enzymatically digested with alpha-chymotrypsin. The bioactivity of Fnfs was verified by measuring levels of IL-6 and TNF-alpha in Fnf-exposed murine splenocytes. To analyze the effect of Fnfs on RPE, cytokine and chemokine levels in RPE culture supernatants were assayed by ELISA.
   RESULTS. IL-6 and TNF-alpha proinflammatory cytokines were released from primary murine splenocytes in proportion to the dose and length of Fnf treatment, indicating that alpha-chymotryptic digests of fibronectin are biologically active. Fnf treatment of murine RPE cells stimulated the release of microgram and nanogram levels of IL-6, MMP-3, MMP-9, and MCP-1, whereas only picogram levels were detected in untreated cells.
   CONCLUSIONS. Fnfs stimulate the release of proinflammatory cytokines, matrix metalloproteinases, and monocyte chemoattractant protein from murine RPE cells. This observation indicated that Fnfs could contribute to ocular abnormalities by promoting inflammation, catabolism, and monocyte chemo-attraction. (Invest Ophthalmol Vis Sci. 2009; 50: 2896-2902) DOI: 10.1167/iovs.08-2495
C1 [Austin, Bobbie Ann; Liu, Baoying; Li, Zhuqing; Nussenblatt, Robert B.] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Nussenblatt, RB (通讯作者)，NEI, NIH, 10 Ctr Dr,Bldg 10-10N113, Bethesda, MD 20892 USA.
EM drbob@nei.nih.gov
FU National Eye Institute Intramural Research Training Award; NATIONAL EYE
   INSTITUTE [ZIAEY000464, ZIAEY000439, Z01EY000439] Funding Source: NIH
   RePORTER
FX Supported by a National Eye Institute Intramural Research Training
   Award.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8
   BOK D, 1993, J CELL SCI, P189
   Cameron DJ, 2008, ADV EXP MED BIOL, V613, P253, DOI 10.1007/978-0-387-74904-4_29
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Homandberg GA, 1996, ARCH BIOCHEM BIOPHYS, V334, P325, DOI 10.1006/abbi.1996.0461
   Homandberg GA, 1998, J ORTHOPAED RES, V16, P237, DOI 10.1002/jor.1100160211
   Homandberg GA, 1997, BIOCHEM J, V321, P751, DOI 10.1042/bj3210751
   Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kong WY, 2004, J BIOL CHEM, V279, P55334, DOI 10.1074/jbc.M410804200
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Parier V, 2008, REV MED INTERNE, V29, P215, DOI 10.1016/j.revmed.2007.08.021
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peters JH, 2003, ARTHRITIS RES THER, V5, pR329, DOI 10.1186/ar1001
   Plantner JJ, 1998, CURR EYE RES, V17, P132, DOI 10.1076/ceyr.17.2.132.5610
   Przybysz M, 2007, RHEUMATOLOGY, V46, P1071, DOI 10.1093/rheumatology/kem067
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756
   Scholl HPN, 2007, MOL VIS, V13, P196
   Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Weger M, 2007, MOL VIS, V13, P1274
   XIE DL, 1992, J RHEUMATOL, V19, P1448
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yasuda T, 2003, LAB INVEST, V83, P153, DOI 10.1097/01.LAB.0000056999.08437.B2
   Yasuda T, 2002, ARTHRITIS RHEUM, V46, P138, DOI 10.1002/1529-0131(200201)46:1<138::AID-ART10051>3.0.CO;2-K
   Yoshida T, 2007, MOL VIS, V13, P545
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zeng Jun, 2004, Yan Ke Xue Bao, V20, P191
NR 77
TC 33
Z9 36
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2896
EP 2902
DI 10.1167/iovs.08-2495
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450ME
UT WOS:000266403800049
PM 19151387
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Hayreh, SS
   Martus, P
AF Jonas, JB
   Hayreh, SS
   Martus, P
TI Influence of arterial hypertension and diet-induced atherosclerosis on
   macular drusen
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; CHOROIDAL PERFUSION ABNORMALITY; SYSTEMIC
   VASCULAR-DISEASE; BLUE-MOUNTAINS EYE; RHESUS-MONKEYS; MALIGNANT
   HYPERTENSION; FUNDUS LESIONS; CIGARETTE-SMOKING; OPTIC-NERVE; BLOOD-FLOW
AB Purpose: To evaluate whether development of macular drusen is influenced by experimentally induced chronic arterial hypertension and atherosclerosis. Methods: The prospective experimental study included 93 eyes of 51 elderly rhesus monkeys. The total study group was divided into groups with experimental arterial hypertension. (n=22), diet-induced atherosclerosis (n=10), or both arterial hypertension and atherosclerosis (n=29) and a control group without arterial hypertension or atherosclerosis (n=32). Using color wide-angle fundus photographs taken at the beginning and the end of the study, age-related macular degeneration was graded by counting the number and estimating the mean size of drusen in the macular region. Results: In the monkeys with arterial hypertension, the count and area of the macular drusen and the change in number and size of macular drusen during the follow-up period were significantly (P<0.05) higher than in the monkeys of the control group. Correspondingly, the count and size of macular drusen were significantly (P<0.05) correlated with the duration of arterial hypertension. In contrast, monkeys with only atherosclerosis did not vary significantly (P>0.10) from monkeys of the control group in number and size of drusen. The macular drusen parameters were statistically (P>0.20) independent of the duration of atherosclerosis. Similarly, the atherosclerotic monkeys and the monkeys of the control group did not vary significantly (P>0.30) in the change of the macular drusen parameters during the follow-up period. Conclusions Development of macular drusen as part of age-related macular degeneration in rhesus monkeys may be associated with experimentally induced arterial hypertension. It does not seem to be influenced by diet-induced atherosclerosis.
C1 Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
   Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
   Univ Iowa, Coll Med, Dept Vis Sci, Iowa City, IA 52242 USA.
   Free Univ Berlin, Benjamin Franklin Sch Med, Inst Med Informat Biostat & Epidemiol, D-1000 Berlin, Germany.
C3 University of Iowa; Ruprecht Karls University Heidelberg; University of
   Iowa; Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Hayreh, SS (通讯作者)，Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
RI Hayreh, Sohan Singh/AFU-1623-2022
OI Hayreh, Sohan/0000-0002-0709-886X
FU NEI NIH HHS [EY-1576] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY001576] Funding Source: NIH RePORTER
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 1998, AM J OPHTHALMOL, V126, P153
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P617
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P161, DOI 10.1007/BF00127645
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P1383
   Hayreh SS, 1998, INVEST OPHTH VIS SCI, V39, P2296
   Hayreh SS, 1997, ARCH OPHTHALMOL-CHIC, V115, P220, DOI 10.1001/archopht.1997.01100150222012
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P45
   Hayreh SS, 2000, OPHTHALMOLOGY, V107, P1009, DOI 10.1016/S0161-6420(00)00074-9
   HAYREH SS, 1989, OPHTHALMOLOGICA, V198, P230, DOI 10.1159/000310001
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Jonas JB, 2000, INVEST OPHTH VIS SCI, V41, P2972
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   KISHI S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1189, DOI 10.1001/archopht.1985.01050080101029
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLIFFEN M, 1995, LAB INVEST, V73, P267
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   *TEDC CS GROUP, 1992, ARCH OPHTHALMOL-CHIC, V111, P1701
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   ULSHAFER RJ, 1987, RETINA-J RET VIT DIS, V7, P198, DOI 10.1097/00006982-198700730-00011
   Verhoeff FH, 1937, ARCH OPHTHALMOL-CHIC, V18, P561
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 42
TC 10
Z9 10
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2003
VL 241
IS 2
BP 125
EP 134
DI 10.1007/s00417-002-0615-3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 655XU
UT WOS:000181578600010
PM 12605267
DA 2022-11-30
ER

PT J
AU Finger, RP
   Porz, G
   Fleckenstein, M
   Issa, PC
   Lechtenfeld, W
   Brohlburg, D
   Scholl, HPN
   Holz, FG
AF Finger, Robert P.
   Porz, Gabriele
   Fleckenstein, Monika
   Issa, Peter Charbel
   Lechtenfeld, Werner
   Brohlburg, Daniela
   Scholl, Hendrik P. N.
   Holz, Frank G.
TI THE RETINA HOTLINE Eighteen-Month Results From a Telephone Hotline for
   Patients With Retinal Diseases
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE telephone hotline; medical retina; age-related macular degeneration
   (AMD); self-reported retinal disease; psychosocial support; medical
   triage; health services evaluation
ID CONSULTATION; BLINDNESS; SAFETY; TRIAGE; CARE
AB Purpose: The purpose of this study was to establish and evaluate a nationwide telephone counseling for patients with retinal diseases hotline in Germany against the background of an increasing demand for information and counseling in the field of retina services as a result of current demographic trends.
   Methods: The telephone Retina Hotline was installed, advertised, and run for 1.5 years at the Department of Ophthalmology, University of Bonn, and open to callers from the whole of Germany. The hotline was staffed by ophthalmologists. Calls were handled according to standard flow charts and counsel given adhered to a list of standardized answers as appropriate in the individual case. All calls were documented in an online database, which was subsequently analyzed and used for evaluation.
   Results: A total of 1,384 calls were documented leading to an average of 7.6 calls per afternoon. The average length of calls was 8.5 minutes. The majority of callers were female patients (63%) who had age-related macular degeneration. Only 17% of callers were relatives. Most callers (59%) were >60 years of age. The majority of questions were related to therapeutic options for dry or neovascular age-related macular degeneration as well as various forms of retinitis pigmentosa (45%).
   Conclusion: A service such as the Retina Hotline seems necessary and well justified against the background of need for information and support documented. However, on the basis of an adequate computer program and a standard catalog of answers or flow charts, it may not need to be staffed by ophthalmologists, but well-trained nonmedical staff may be sufficient. RETINA 30: 635-639, 2010
C1 [Finger, Robert P.; Porz, Gabriele; Fleckenstein, Monika; Issa, Peter Charbel; Scholl, Hendrik P. N.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Lechtenfeld, Werner; Brohlburg, Daniela] Proretina Deutschland eV, Aachen, Germany.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Bonn; Johns Hopkins University; Johns Hopkins Medicine
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Issa, Peter Charbel/E-8935-2018; Issa, Peter Charbel/F-9603-2011; Issa,
   Peter Charbel/O-2580-2019
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Finger, Robert P/0000-0003-4253-7597;
   Fleckenstein, Monika/0000-0001-8321-8037
FU Pro Retina, the German patient association for patients with retinal
   diseases
FX Supported by Pro Retina, the German patient association for patients
   with retinal diseases.
CR Boter H, 2000, J CLIN NURS, V9, P199, DOI 10.1046/j.1365-2702.2000.00356.x
   Bunn F, 2005, BRIT J GEN PRACT, V55, P956
   Dale J, 1998, Nurs Stand, V12, P41
   Finger RP, 2007, OPHTHALMOLOGE, V104, P839, DOI 10.1007/s00347-007-1600-3
   Finger RP, 2007, OPHTHALMOLOGE, V104, P838, DOI 10.1007/s00347-007-1612-z
   Finger Robert P, 2007, Pharm Unserer Zeit, V36, P424, DOI 10.1002/pauz.200700237
   Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054
   Marsden J, 2000, J ADV NURS, V31, P401, DOI 10.1046/j.1365-2648.2000.01285.x
   Pettinari CJ, 2001, J ADV NURS, V36, P668, DOI 10.1046/j.1365-2648.2001.02031.x
   Rendell J, 1999, Insight, V24, P112, DOI 10.1016/S1060-135X(99)90019-2
NR 10
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2010
VL 30
IS 4
BP 635
EP 639
DI 10.1097/IAE.0b013e3181cbda20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 608AE
UT WOS:000278548900014
PM 20394113
DA 2022-11-30
ER

PT J
AU Tang, K
   Si, JK
   Guo, DD
   Cui, Y
   Du, YX
   Pan, XM
   Bi, HS
AF Tang, Kai
   Si, Jun-Kang
   Guo, Da-Dong
   Cui, Yan
   Du, Yu-Xiang
   Pan, Xue-Mei
   Bi, Hong-Sheng
TI Ranibizumab alone or in combination with photodynamic therapy vs
   photodynamic therapy for polypoidal choroidal vasculopathy: a systematic
   review and Meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE photodynamic therapy; ranibizumab; combination treatment; monotherapy;
   polypoidal choroidal vasculopathy; Meta-analysis; systematic review
ID ENDOTHELIAL GROWTH-FACTOR; COMBINED INTRAVITREAL RANIBIZUMAB;
   EPITHELIUM-DERIVED FACTOR; MACULAR DEGENERATION; FOLLOW-UP; VERTEPORFIN;
   BEVACIZUMAB; MONOTHERAPY; INJECTIONS; RECURRENT
AB AIM: To compare the efficacy of intravitreal ranibizumab (IVR) alone or in combination with photodynamic therapy (PDT) vs PDT in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
   METHODS: A systematic search of a wide range of databases (including PubMed, EMBASE, Cochrane Library and Web of Science) was searched to identify relevant studies. Both randomized controlled trials (RCTs) and non -RCT studies were included. Methodological quality of included literatures was evaluated according to the Newcastle -Ottawa Scale. RevMan 5.2.7 software was used to do the Meta-analysis.
   RESULTS: Three RCTs and 6 retrospective studies were included. The results showed that PDT monotherapy had a significantly higher proportion in patients who achieved complete regression of polyps than IVR monotherapy at months 3, 6, and 12 (All 0.01), respectively. However, IVR had a tendency to be more effective in improving vision on the basis of RCTs. The proportion of patients who gained complete regression of polyps revealed that there was no significant difference between the combination treatment and PDT monotherapy. The mean change of best - corrected visual acuity (BCVA) from baseline showed that the combination treatment had significant superiority in improving vision vs PDT monotherapy at months 3, 6 and 24 (All P<0.05), respectively. In the mean time, this comparison result was also significant at month 12 (P< 0.01) after removal of a heterogeneous study.
   CONCLUSION: IVR has non -inferiority compare with PDT either in stabilizing or in improving vision, although it can hardly promote the regression of polyps. The combination treatment of PDT and IVR can exert a synergistic effect on regressing polyps and on maintaining or improving visual acuity. Thus, it can be the first-line therapy for PCV.
C1 [Tang, Kai; Si, Jun-Kang; Du, Yu-Xiang; Pan, Xue-Mei; Bi, Hong-Sheng] Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Jinan 250002, Shandong, Peoples R China.
   [Tang, Kai; Si, Jun-Kang; Du, Yu-Xiang] Shandong Univ Tradit Chinese Med, Dept Ophthalmol, Jinan 250002, Shandong, Peoples R China.
   [Guo, Da-Dong; Cui, Yan; Bi, Hong-Sheng] Shandong Univ Tradit Chinese Med, Inst Eye, Jinan 250002, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Shandong University of Traditional
   Chinese Medicine
RP Bi, HS (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, 48 Yingxiongshan Rd, Jinan 250002, Shandong, Peoples R China.
EM hongshengbi123@163.com
OI Tang, Kai/0000-0001-6897-5857; Si, Junkang/0000-0003-3801-5868
FU National Natural Science Foundation of China [81373826, 81100658];
   Development Project of Science and Technology of Traditional Chinese
   Medicine of Shandong Province [2013ZDZK-083]; Development Project of
   Medicine and Health Science Technology of Shandong Province [2013WS0251]
FX Supported by the National Natural Science Foundation of China
   (No.81373826, No.81100658); Development Project of Science and
   Technology of Traditional Chinese Medicine of Shandong Province (No.
   2013ZDZK-083); Development Project of Medicine and Health Science
   Technology of Shandong Province (No. 2013WS0251).
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Fernandez M, 2012, CASE REP MED, V2012, DOI 10.1155/2012/897097
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Imasawa M, 2011, JPN J OPHTHALMOL, V55, P241, DOI 10.1007/s10384-011-0006-6
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori R, 2013, JPN J OPHTHALMOL, V57, P365, DOI 10.1007/s10384-013-0245-9
   Nemoto R, 2012, CLIN OPHTHALMOL, V6, P1633, DOI 10.2147/OPTH.S37252
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Saito M, 2013, EYE, V27, P931, DOI 10.1038/eye.2013.114
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 48
TC 20
Z9 20
U1 0
U2 17
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT
PY 2015
VL 8
IS 5
BP 1056
EP 1066
DI 10.3980/j.issn.2222-3959.2015.05.36
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS1WD
UT WOS:000361858600036
PM 26558226
DA 2022-11-30
ER

PT J
AU Ayalasomayajula, SP
   Kompella, UB
AF Ayalasomayajula, SP
   Kompella, UB
TI Induction of vascular endothelial growth factor by 4-hydroxynonenal and
   its prevention by glutathione precursors in retinal pigment epithelial
   cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE ARPE-19 cell; GSH precursor; 4-hydroxynonenal; oxidative stress; VEGF
   (vascular endothelial growth factor)
ID EXPRESSION IN-VITRO; MACULAR DEGENERATION; LIPID-PEROXIDATION;
   DIABETIC-RETINOPATHY; EXTRACELLULAR-MATRIX; OXIDATIVE STRESS; FACTOR
   SECRETION; RAT RETINA; PRODUCT; ACTIVATION
AB Although 4-hydroxynonenal, a highly reactive lipid peroxidation product, is implicated in several age-related disorders such as Alzheimer's and Parkinson's diseases, its role in age-related macular degeneration is not known. The purpose of this study was to determine whether 4-hydroxynonenal increases vascular endothelial growth factor (VEGF) expression in human retinal pigment epithelial cells (ARPE-19), a source of VEGF in choroidal neovascularization observed in age-related macular degeneration. In addition, it was the purpose of this study to assess whether glutathione (GSH) and GSH precursors can inhibit the effects of 4-hydroxynonenal. At 1 muM, 4-hydroxynonenal did not alter cell viability, but elevated VEGF secretion and mRNA expression by 35% (p < 0.05) and 1.9-fold (p < 0.05), respectively. However, at concentrations 5 muM and above, 4-hydroxynonenal reduced VEGF secretion as well as cell viability. At 1 and 10 muM, 4-hydroxynonenal did not induce apoptosis in ARPE-19 cells. 4-Hydroxynonenal (1 muM) reduced intracellular GSH by 25% (p < 0.05) and increased oxidative stress by 50% (p < 0.05). GSH precursor pretreatment for 1 h, which increased intracellular GSH levels by 50% (p < 0.05), as well as GSH co-treatment, inhibited the VEGF-inductive and cytotoxic effects of 4-hydroxynonenal. Thus, 4-hydroxynonenal (1 muM) induces VEGF expression and secretion in ARPE-19 cells. This effect is likely due to GSH depletion and an associated increase in intracellular oxidative stress, resulting in increased VEGF mRNA levels. 4-Hydroxynonenal-mediated VEGF secretion as well as cytotoxicity can be reversed with GSH precursor pretreatment or GSH co-treatment. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Kompella, UB (通讯作者)，Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, 600 S 42nd St, Omaha, NE 68198 USA.
OI Ayalasomayajula, Surya/0000-0002-5917-9397
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Aukunuru JV, 2001, PHARM RES-DORDR, V18, P565, DOI 10.1023/A:1011060705599
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boon PJM, 1999, TOXICOL APPL PHARM, V159, P214, DOI 10.1006/taap.1999.8742
   Brown NS, 2000, CANCER RES, V60, P6298
   Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x
   CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253
   CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dygas A, 1998, ACTA BIOCHIM POL, V45, P59, DOI 10.18388/abp.1998_4318
   ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Grimshaw MJ, 2001, OSTEOARTHR CARTILAGE, V9, P357, DOI 10.1053/joca.2000.0396
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Husain D., 1997, Investigative Ophthalmology and Visual Science, V38, pS501
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5
   Mangipudy RS, 1999, MOL CELL BIOCHEM, V200, P51, DOI 10.1023/A:1006985700851
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   NISHIKAWA A, 1992, LIPIDS, V27, P54, DOI 10.1007/BF02537060
   Obrosova IG, 2000, EUR J PHARMACOL, V398, P139, DOI 10.1016/S0014-2999(00)00286-7
   OHIA SE, 1994, RES COMMUN MOL PATH, V85, P21
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413
   Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SRIVASTAVA SK, 1994, EXP EYE RES, V59, P151, DOI 10.1006/exer.1994.1093
   Toti P., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P363
   Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234
   VanderJagt DL, 1997, BIOCHEM PHARMACOL, V53, P1133, DOI 10.1016/S0006-2952(97)00090-7
   VANKUIJK FJG, 1988, THESIS U NIJMEGEN NE
   Verdejo C, 1999, EYE, V13, P183, DOI 10.1038/eye.1999.48
   Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   ZHAO M, 1996, CHUNG HUA YEN KO TSA, V32, P230
NR 56
TC 46
Z9 47
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 9
PY 2002
VL 449
IS 3
BP 213
EP 220
AR PII S0014-2999(02)02043-5
DI 10.1016/S0014-2999(02)02043-5
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 588AZ
UT WOS:000177679400003
PM 12167462
DA 2022-11-30
ER

PT J
AU Zhou, JZ
   Chen, FH
   Yan, AM
   Xia, XB
AF Zhou, Jinzi
   Chen, Fenghua
   Yan, Aimin
   Xia, Xiaobo
TI Overexpression of HTRA1 increases the proliferation and migration of
   retinal pigment epithelium cells
SO ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE proliferation; migration; HtrA1; AMD; RPE
ID MACULAR DEGENERATION; SERINE-PROTEASE; SUSCEPTIBILITY; IMPAIR; NLRP3
AB Background. Age-related macular degeneration (AMD) mainly affects the central region of retina and has many late-stage manifestations. Objectives. Age-related macular degeneration is a leading cause of irreversible blindness in older people. The main feature of AMD is retinal pigment epithelium (RPE) degeneration. In this study, we aimed to explore the influence of HTRA1 expression on the proliferation and migration of RPE cells. Materials and methods. Human ARPE-19 cells were transfected with an HTRA1 overexpression lentivirus or HTRA1 siRNA to silence HtrA1 expression. Quantitave reverse-transcription polymerase chain reaction (qRTPCR) and western blotting were used to verify the relative level of HTRA1 mRNA and expression of HTRA1 protein of transfected human ARPE-19 cells. The MTT clone formation and transwell assays were used to confirm the effect of HTRA1 expression on the proliferation, colony forming ability and migration of ARPE-19 cells. Results. The proliferation capacity (shown as optical density value) of ARPE-19 cells in the HTRA1-overexpressing group at culture times of 24 h and 48 h were 0.595 +/- 0.032 and 0.867 +/- 0.037 respectively, which were much higher than in the mock group. However, the proliferative capacity of cells in the HTRA1-silenced group decreased with increasing time of culture, compared with the mock group. The number of cloned and migrating cells in the HTRA1-overexpressing group were much higher than in the mock group, whereas the numbers in the HTRA1-silenced group were significantly lower. Conclusions. Overexpression of HTRA1 promotes proliferation and migration of RPE cells, which can help maintain the function of sensory neurons in the retina. Therefore, HTRA1 may be a suitable target for AMD treatments.
C1 [Zhou, Jinzi; Chen, Fenghua; Yan, Aimin] First Peoples Hosp Guiyang, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
   [Xia, Xiaobo] Cent South Univ, Dept Ophthalmol, Xiangya Hosp, Changsha, Hunan, Peoples R China.
C3 Central South University
RP Zhou, JZ (通讯作者)，First Peoples Hosp Guiyang, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
EM zjinzh1109@163.com
FU Natural Science Foundation of Tianjin [16JCQNJC12700]; National Natural
   Science Foundation of China [81500745]
FX Natural Science Foundation of Tianjin (grant No. 16JCQNJC12700) and the
   National Natural Science Foundation of China (grant No.81500745) .
CR Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kramer N, 2013, MUTAT RES-REV MUTAT, V752, P10, DOI 10.1016/j.mrrev.2012.08.001
   Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Streichan SJ, 2014, P NATL ACAD SCI USA, V111, P5586, DOI 10.1073/pnas.1323016111
   Stroka KM, 2014, CELL, V157, P611, DOI 10.1016/j.cell.2014.02.052
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Yang CH., 2014, TAIWAN J OPHTHALMOL, V4, P1, DOI [10.1016/j. tjo.2014.01.002, DOI 10.1016/J.TJO.2014.01.002]
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
NR 24
TC 1
Z9 1
U1 2
U2 7
PU WROCLAW MEDICAL UNIV
PI WROCLAW
PA UL K MARCINKOWSKIEGO 2-6, WROCLAW, 50-368, POLAND
SN 1899-5276
EI 2451-2680
J9 ADV CLIN EXP MED
JI Adv. Clin. Exp. Med.
PD AUG
PY 2021
VL 30
IS 8
BP 859
EP 864
DI 10.17219/acem/135939
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA UJ8VQ
UT WOS:000691557700011
PM 34310874
OA gold
DA 2022-11-30
ER

PT J
AU Park, SS
   Bauer, G
   Abedi, M
   Pontow, S
   Panorgias, A
   Jonnal, R
   Zawadzki, RJ
   Werner, JS
   Nolta, J
AF Park, Susanna S.
   Bauer, Gerhard
   Abedi, Mehrdad
   Pontow, Suzanne
   Panorgias, Athanasios
   Jonnal, Ravi
   Zawadzki, Robert J.
   Werner, John S.
   Nolta, Jan
TI Intravitreal Autologous Bone Marrow CD34+Cell Therapy for Ischemic and
   Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial
   Findings
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE stem cells; retinal degeneration; retinal imaging; retinal vein
   occlusion; OCT
ID ENDOTHELIAL PROGENITOR CELLS; STEM-CELL; MACULAR DEGENERATION;
   TRANSPLANTATION; REGENERATION
AB PURPOSE. Because human bone marrow (BM) CD34+ stem cells home into damaged tissue and may play an important role in tissue repair, this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD34+ BM cells as potential therapy for ischemic or degenerative retinal conditions.
   METHODS. This prospective study enrolled six subjects (six eyes) with irreversible vision loss from retinal vascular occlusion, hereditary or nonexudative age-related macular degeneration, or retinitis pigmentosa. CD34+ cells were isolated under Good Manufacturing Practice conditions from the mononuclear cellular fraction of the BM aspirate using a CliniMACs magnetic cell sorter. After intravitreal CD34+ cell injection, serial ophthalmic examinations, microperimetry/perimetry, fluorescein angiography, electroretinography (ERG), optical coherence tomography (OCT), and adaptive optics OCT were performed during the 6-month follow-up.
   RESULTS. A mean of 3.4 million (range, 1-7 million) CD34+ cells were isolated and injected per eye. The therapy was well tolerated with no intraocular inflammation or hyperproliferation. Best-corrected visual acuity and full-field ERG showed no worsening after 6 months. Clinical examination also showed no worsening during follow-up except among age-related macular degeneration subjects in whom mild progression of geographic atrophy was noted in both the study eye and contralateral eye at 6-month follow-up, concurrent with some possible decline on multifocal ERG and microperimetry. Cellular in vivo imaging using adaptive optics OCT showed changes suggestive of new cellular incorporation into the macula of the hereditary macular degeneration study eye.
   CONCLUSIONS. Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration.
C1 [Park, Susanna S.; Panorgias, Athanasios; Jonnal, Ravi; Zawadzki, Robert J.; Werner, John S.] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Bauer, Gerhard; Pontow, Suzanne; Nolta, Jan] Univ Calif Davis, Sch Med, Inst Regenerat Cures, Sacramento, CA 95817 USA.
   [Abedi, Mehrdad] Univ Calif Davis, Ctr Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis
RP Park, SS (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.edu
RI Zawadzki, Robert/E-7534-2011; Abedi, Mehrdad/ABC-3565-2021; Zawadzki,
   Robert J./S-3236-2019
OI Zawadzki, Robert/0000-0002-9574-156X; Zawadzki, Robert
   J./0000-0002-9574-156X; Panorgias, Athanasios/0000-0002-5024-835X;
   Nolta, Jan/0000-0003-4576-8542
FU Foundation Fighting Blindness [CD-CDBT 0808-0471-UCD]; National Eye
   Institute [NIH EY024239]; Research to Prevent Blindness; UC-Davis Retina
   Research Fund; California Institute for Regenerative Medicine (CIRM);
   CIRM [FA-00611]; NATIONAL EYE INSTITUTE [R01EY024239, P30EY012576]
   Funding Source: NIH RePORTER
FX Supported by Foundation Fighting Blindness Grant CD-CDBT 0808-0471-UCD
   (JN), National Eye Institute Grant NIH EY024239 (JSW), a Research to
   Prevent Blindness unrestricted departmental grant, and the UC-Davis
   Retina Research Fund (SSP). JN and GB are partially supported by the
   California Institute for Regenerative Medicine (CIRM). The UC-Davis GMP
   facility was built with funds from CIRM Major Facilities Grant FA-00611.
CR Booth C, 2013, CLIN EXP IMMUNOL, V172, P139, DOI 10.1111/cei.12004
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Caballero S, 2007, DIABETES, V56, P960, DOI 10.2337/db06-1254
   Calzi SL, 2009, MICROVASC RES, V78, P132, DOI 10.1016/j.mvr.2009.03.007
   Chang KH, 2007, P NATL ACAD SCI USA, V104, P10595, DOI 10.1073/pnas.0702072104
   Cyranoski D, 2013, NAT BIOTECHNOL, V31, P272, DOI 10.1038/nbt0413-272c
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Jakob Philipp, 2013, Curr Heart Fail Rep, V10, P165, DOI 10.1007/s11897-013-0134-z
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Kuroda R, 2014, TISSUE ENG PART B-RE, V20, P190, DOI [10.1089/ten.teb.2013.0511, 10.1089/ten.TEB.2013.0511]
   Lin CS, 2013, STEM CELLS DEV, V22, P1018, DOI 10.1089/scd.2012.0504
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Masuda H, 2013, TRENDS CARDIOVAS MED, V23, P99, DOI 10.1016/j.tcm.2012.09.007
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Park SS, 2012, INVEST OPHTH VIS SCI, V53, P986, DOI 10.1167/iovs.11-8833
   Patel AN, 2005, J THORAC CARDIOV SUR, V130, P1631, DOI 10.1016/j.jtcvs.2005.07.056
   Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Schmeisser A, 2002, J HEMATOTH STEM CELL, V11, P69, DOI 10.1089/152581602753448540
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Vrtovec B, 2013, CLIN PHARMACOL THER, V94, P452, DOI 10.1038/clpt.2013.134
   Yanuzzi LA, 2010, THE RETINAL ATLAS, P63
   Zawadzki RJ, 2009, OPT EXPRESS, V17, P4084, DOI 10.1364/OE.17.004084
   Zhang QH, 2007, CHINESE MED J-PEKING, V120, P2297, DOI 10.1097/00029330-200712020-00027
NR 30
TC 103
Z9 110
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2015
VL 56
IS 1
BP 81
EP 89
DI 10.1167/iovs.14-15415
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE0TQ
UT WOS:000351519800009
PM 25491299
OA Green Published
DA 2022-11-30
ER

PT J
AU Ruck, A
   Bohmler, A
   Steiner, R
AF Rueck, Angelika
   Boehmler, Andrea
   Steiner, Rudolf
TI PDT with TOOKAD (R) studied in the chorioallantoic membrane of
   fertilized eggs
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Photodynamic therapy; Vascular effects; CAM model; WST09; AMD
AB Background: The potential application of TOOKAD (R) PDT for the treatment of blood vessels was investigated. TOOKAD (R) (WST09), a novel palladium-bacteriopheophorbide absorbs light in the near IR with a high quantum yield of intersystem crossing. Our study assessed the efficacy of this drug in inducing vascular damage with a view to its possible use in the treatment of age-related macular degeneration.
   Methods: Vascular damage of TOOKAD (R) -PDT was studied in neovessels of the chorioallantoic membrane of fertilized eggs. Pharmacokinetic investigations were done by video microscopy and laser scanning microscopy. To induce damage vessels were irradiated with 763 nm light from a diode laser.
   Results: TOOKAD (R) was accumulated in the vessels in the first minutes following injection. TOOKAD (R) fluorescence was seen predominantly in the lumen and not in the vascular endothelial layer. Although fluorescence was very weak it could be attributed to TOOKAD (R) from the fluorescence spectrum in the circulation. Damage assessment was done 24 h after application of 763 nm light. No significant difference in the degree of damage was observed with different short drug-light intervals (1-10 min), but damage increased with the light energy dose. Closure of smaller vessels and vanished capillaries could be achieved by irradiation with 5 J/cm(2) and a TOOKAD (R) dose of 33 mu g/embryo, corresponding to a phototoxic efficacy of 0.0062.
   Conclusions: From the results discussed in this work, TOOKAD (R) could be a potential drug for the PDT of age-related macular degeneration in which the growth of new vessels in the choroids can lead to loss of vision. (C) 2005 Elsevier B.V. All rights reserved.
C1 [Rueck, Angelika; Boehmler, Andrea; Steiner, Rudolf] Inst Laser Technol Med & Metrol, D-89081 Ulm, Germany.
RP Ruck, A (通讯作者)，Inst Laser Technol Med & Metrol, Helmholtzstr 12, D-89081 Ulm, Germany.
EM angelika.rueck@ilm.uni-ulm.de
FU Negma-Lerads Laboratories, Magny-les-Hameaux, France
FX The authors thank Dr. Pierre-Herve Brun for fruitful discussions
   concerning this study. We gratefully acknowledge Dr. Debra Kelleher for
   carefully reading this paper. This work was financially supported by
   Negma-Lerads Laboratories, Magny-les-Hameaux, France.
CR Borle F, 2003, BRIT J CANCER, V89, P2320, DOI 10.1038/sj.bjc.6601428
   Borle F, 2003, PHOTOCHEM PHOTOBIOL, V78, P377, DOI 10.1562/0031-8655(2003)078<0377:EOTPTF>2.0.CO;2
   Bourre L, 2002, J PHOTOCH PHOTOBIO B, V67, P23, DOI 10.1016/S1011-1344(02)00279-8
   Brown S B, 2001, Expert Opin Pharmacother, V2, P351
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chen Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P438, DOI 10.1562/0031-8655(2002)076<0438:PSINCP>2.0.CO;2
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   GOTTFRIED V, 1991, INT J RADIAT BIOL, V60, P349, DOI 10.1080/09553009114552121
   Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940
   Hammer-Wilson MJ, 1999, J PHOTOCH PHOTOBIO B, V53, P44, DOI 10.1016/S1011-1344(99)00124-4
   Hornung R, 1999, J PHOTOCH PHOTOBIO B, V49, P41, DOI 10.1016/S1011-1344(99)00014-7
   Hunt DWC, 2003, IDRUGS, V6, P464
   Kelleher DK, 2004, INT J ONCOL, V24, P1505
   Koudinova NV, 2003, INT J CANCER, V104, P782, DOI 10.1002/ijc.11002
   Kress M, 2003, J BIOMED OPT, V8, P26, DOI 10.1117/1.1528595
   Kunzi-Rapp K, 1999, ARCH DERMATOL RES, V291, P290, DOI 10.1007/s004030050410
   Kusserow C, 2003, OPHTHALMOLOGE, V100, P197, DOI 10.1007/s00347-002-0673-2
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   Malik E, 2000, HUM REPROD, V15, P584, DOI 10.1093/humrep/15.3.584
   Messmer KJ, 2001, ANN PHARMACOTHER, V35, P1593
   NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003
   Obana A, 2001, INVEST OPHTH VIS SCI, V42, P2639
   Pandey RK, 1997, J MED CHEM, V40, P2770, DOI 10.1021/jm9702894
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Ribatti D, 2001, ANAT RECORD, V264, P317, DOI 10.1002/ar.10021
   Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256
   RUCK A, 1992, J PHOTOCH PHOTOBIO B, V12, P403, DOI 10.1016/1011-1344(92)85044-U
   Samkoe KS, 2003, J BIOMED OPT, V8, P410, DOI 10.1117/1.1577117
   Schlatter P, 1997, MICROVASC RES, V54, P65, DOI 10.1006/mvre.1997.2022
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Strauss WSL, 1997, J PHOTOCH PHOTOBIO B, V39, P176, DOI 10.1016/S1011-1344(97)00002-X
   Teuchner K, 1997, J LUMIN, V72-4, P612, DOI 10.1016/S0022-2313(96)00411-5
   Tremblay A, 2003, PHOTOCHEM PHOTOBIOL, V78, P124, DOI 10.1562/0031-8655(2003)078<0124:EPOWTA>2.0.CO;2
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 38
TC 22
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2005
VL 2
IS 1
BP 79
EP 90
DI 10.1016/S1572-1000(05)00006-2
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA V27CH
UT WOS:000208590800009
PM 25048560
DA 2022-11-30
ER

PT J
AU Penha, FM
   Rosenfeld, PJ
   Gregori, G
   Falcao, M
   Yehoshua, Z
   Wang, F
   Feuer, WJ
AF Penha, Fernando M.
   Rosenfeld, Philip J.
   Gregori, Giovanni
   Falcao, Manuel
   Yehoshua, Zohar
   Wang, Fenghua
   Feuer, William J.
TI Quantitative Imaging of Retinal Pigment Epithelial Detachments Using
   Spectral-Domain Optical Coherence Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; ANGIOGRAPHY
AB PURPOSE: To evaluate the reproducibility of area and volume measurements of retinal pigment epithelium detachments (PEDs) in eyes of patients with age-related macular degeneration using spectral-domain optical coherence tomography imaging and a novel automated, quantitative algorithm.
   DESIGN: Prospective study to evaluate a diagnostic technology.
   METHODS: Patients with PEDs associated with age-related macular degeneration underwent spectral-domain optical coherence tomography imaging. Each eye was imaged 5 times, and each scan consisted of a raster pattern comprising 40 000 uniformly spaced A-scans organized as a 200 x 200 A-scan array. Each raster scan covered a retinal area of 6 x 6 mm encompassing the entire PED. A novel algorithm was used to create PED maps that permitted both qualitative and quantitative assessment of PED area and volume. Test retest standard deviations of PED area and volume measurements were calculated for each eye.
   RESULTS: Sixty-three eyes of 58 patients were enrolled in this study. The qualitative appearance and the quantitative measurements of PED area and volume were highly reproducible over the 5 different datasets obtained from each eye. The intraclass correlation coefficient was more than 0.99 for both area and volume measurements obtained using the entire dataset.
   CONCLUSIONS: A novel algorithm for the qualitative and quantitative assessment of PEDs imaged using spectral-domain optical coherence tomography was shown to be highly reproducible. The ability to measure PED area and volume reliably represents a novel strategy for following disease progression, especially when assessing the response of vascularized PEDs to antiangiogenic therapy. (Am J Ophthalmol 2012;153:515-523. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Penha, Fernando M.; Rosenfeld, Philip J.; Gregori, Giovanni; Falcao, Manuel; Yehoshua, Zohar; Wang, Fenghua; Feuer, William J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Falcao/AAQ-8509-2020; Penha, Fernando M/G-1784-2012
OI Falcao/0000-0003-4718-0910; 
FU CARL ZEISS MEDITEC, INC, DUBLIN, CALIFORNIA, USA; Research to Prevent
   Blindness, Inc, New York, New York, USA; Core Center from the National
   Eye Institute, National Institutes of Health, Bethesda, Maryland, USA
   [P30 EY014801]; Jerome A. Yavitz Charitable Foundation, Miami, Florida;
   Macula Vision Research Foundation, West Conshohocken, Pennsylvania; Feig
   Family Foundation, Palm Beach Gardens, Florida; Gemcon Family
   Foundation, Palm Beach, Florida; Carl and Lily Pforzheimer Foundation,
   New York, New York; Emma Clyde Hodge Memorial Foundation Pittsburgh,
   Pennsylvania; Department of Defense, Washington, DC, USA
   [W81XWH-09-0675]; Carl Zeiss Meditec, Inc.; Shanghai Pujiang Project
   [2010-00049]; Chinese National "863" Project [2008AA030118]; Chinese
   National "973" Project [2011CB707500]; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY A GRANT FROM CARL ZEISS
   MEDITEC, INC, DUBLIN, CALIFORNIA, USA; AN unrestricted grant from
   Research to Prevent Blindness, Inc, New York, New York, USA; Core Center
   Grant P30 EY014801 to the University of Miami from the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland, USA; the
   Jerome A. Yavitz Charitable Foundation, Miami, Florida; the Macula
   Vision Research Foundation, West Conshohocken, Pennsylvania; the Feig
   Family Foundation, Palm Beach Gardens, Florida; the Gemcon Family
   Foundation, Palm Beach, Florida; the Carl and Lily Pforzheimer
   Foundation, New York, New York; and the Emma Clyde Hodge Memorial
   Foundation Pittsburgh, Pennsylvania. Giovanni Gregori also receives
   support from grant W81XWH-09-0675 from the Department of Defense,
   Washington, DC, USA. Drs Penha, Rosenfeld, Oregon, Falcao, Yehoshua, and
   Wang received research support from Carl Zeiss Meditec, Inc. Dr Gregori
   co-owns a patent that is licensed to Carl Zeiss Meditec, Inc. Dr
   Rosenfeld has received honoraria for lectures from Carl Zeiss Meditec,
   Inc. Dr Wang received additional support from the Shanghai Pujiang
   Project (2010-00049), the Chinese National "863" Project (2008AA030118),
   and the Chinese National "973" Project (2011CB707500). Dr Feuer has no
   financial or proprietary interest in the materials presented herein.
   Involved in Design of study (F.M.P., P.J.R., G.G., M.F., Z.Y., F.W.);
   Conduct of study (F.M.P., P.J.R., G.G., M.F., Z.Y., F.W.); Analysis and
   interpretation of data (F.M.P., P.J.R., G.G., M.F., Z.Y., W.J.F.); and
   Preparation and review of manuscript (F.M.P., P.J.R., G.G., M.F., Z.Y.,
   F.W., W.J.F.). This prospective study was approved by the Institutional
   Review Board of the University of Miami Miller School of Medicine and
   was compliant with the Health Insurance Portability and Accountability
   Act of 1996.
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P890, DOI 10.1136/bjo.87.7.890
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   FREDERICK AR, 1993, RETINA-J RET VIT DIS, V13, P3, DOI 10.1097/00006982-199313010-00002
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   NARASIMHAIYER H, 2006, C P IEEE ENG MED BIO, V1, P4714
   SAITO J, 1995, EYE, V9, P70, DOI 10.1038/eye.1995.11
   Sickenberg M, 1999, GRAEF ARCH CLIN EXP, V237, P353, DOI 10.1007/s004170050244
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   Strauss RW, 2007, OPHTHALMIC RES, V39, P98, DOI 10.1159/000099245
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Tsai CL, 2008, IEEE T INF TECHNOL B, V12, P480, DOI 10.1109/TITB.2007.908790
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   2002, RETINA, V22, P6
NR 22
TC 35
Z9 36
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2012
VL 153
IS 3
BP 515
EP 523
DI 10.1016/j.ajo.2011.08.031
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907CB
UT WOS:000301394300017
PM 22030354
DA 2022-11-30
ER

PT J
AU Radu, RA
   Hu, J
   Yuan, Q
   Welch, DL
   Makshanoff, J
   Lloyd, M
   McMullen, S
   Travis, GH
   Bok, D
AF Radu, Roxana A.
   Hu, Jane
   Yuan, Quan
   Welch, Darcy L.
   Makshanoff, Jacob
   Lloyd, Marcia
   McMullen, Stephen
   Travis, Gabriel H.
   Bok, Dean
TI Complement System Dysregulation and Inflammation in the Retinal Pigment
   Epithelium of a Mouse Model for Stargardt Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; OXIDATIVE DAMAGE;
   HUMAN-DISEASE; RIM PROTEIN; LIPOFUSCIN; A2E; ABCR; RISK; GENE
AB Accumulation of vitamin A-derived lipofuscin fluorophores in the retinal pigment epithelium (RPE) is a pathologic feature of recessive Stargardt macular dystrophy, a blinding disease caused by dysfunction or loss of the ABCA4 transporter in rods and cones. Age-related macular degeneration, a prevalent blinding disease of the elderly, is strongly associated with mutations in the genes for complement regulatory proteins (CRP), causing chronic inflammation of the RPE. Here we explore the possible relationship between lipofuscin accumulation and complement activation in vivo. Using the abca4(-/-) mouse model for recessive Stargardt, we investigated the role of lipofuscin fluorophores (A2E-lipofuscin) on oxidative stress and complement activation. We observed higher expression of oxidative-stress genes and elevated products of lipid peroxidation in eyes from abca4(-/-) versus wild-type mice. We also observed higher levels of complement-activation products in abca4(-/-) RPE cells. Unexpectedly, expression of multiple CRPs, which protect cells from attack by the complement system, were lower in abca4(-/-) versus wildtype RPE. To test whether acute exposure of healthy RPE cells to A2E-lipofuscin affects oxidative stress and expression of CRPs, we fed cultured fetal-derived human RPE cells with rod outer segments from wild-type or abca4(-/-) retinas. In contrast to RPE cells in abca4(-/-) mice, human RPE cells exposed to abca4(-/-) rod outer segments adaptively increased expression of both oxidative-stress and CRP genes. These results suggest that A2E accumulation causes oxidative stress, complement activation, and down-regulation of protective CRP in the Stargardt mouse model. Thus, Stargardt disease and age-related macular degeneration may both be caused by chronic inflammation of the RPE.
C1 [Radu, Roxana A.; Hu, Jane; Yuan, Quan; Welch, Darcy L.; Makshanoff, Jacob; Lloyd, Marcia; McMullen, Stephen; Travis, Gabriel H.; Bok, Dean] Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Travis, Gabriel H.] Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Bok, Dean] Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA.
   [Bok, Dean] Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA
RP Radu, RA (通讯作者)，Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM radu@jsei.ucla.edu
RI Radu, Roxana A./K-8924-2019; yuan, quan/GZM-5597-2022; Travis, Gabriel
   Harvey/AIF-1062-2022
OI Travis, Gabriel Harvey/0000-0003-4020-9493; Radu,
   Roxana/0000-0002-5064-6403
FU National Institutes of Health [EY00331, R24 EY017404]; American Health
   Assistance Foundation; Macula Vision Research Foundation; Foundation
   Fighting Blindness; NATIONAL EYE INSTITUTE [P30EY000331, R01EY011713,
   R24EY017404] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY00331 (NEI; to D. B.) and R24 EY017404. This work was
   also supported by grants from the American Health Assistance Foundation
   (to R. A. R.), the Macula Vision Research Foundation (to D. B. and G. H.
   T.), and the Foundation Fighting Blindness (to D. B. and G. H. T.).
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bither P P, 1988, J Am Optom Assoc, V59, P106
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu J, 2001, MOL VIS, V7, P14
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurth I, 2007, MOL CELL BIOL, V27, P1370, DOI 10.1128/MCB.01486-06
   LI B, 1993, J IMMUNOL, V151, P4295
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG B, 1991, PATHOLOGY, V23, P118, DOI 10.3109/00313029109060809
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 51
TC 108
Z9 112
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 27
PY 2011
VL 286
IS 21
BP 18593
EP 18601
DI 10.1074/jbc.M110.191866
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 766ME
UT WOS:000290785700031
PM 21464132
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, MG
   Bakri, SJ
   Pershing, S
AF Zhou, Maggie
   Bakri, Sophie J.
   Pershing, Suzann
TI Risk factors for incident central serous retinopathy: case-control
   analysis of a US national managed care population
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE epidemiology; ophthalmology; central serous retinopathy
ID CHORIORETINOPATHY; CAPILLARY
AB Aim To evaluate clinical comorbidities and steroid use as risk factors for central serous retinopathy (CSR). Methods Using national insurance databases, we conducted a case-control study of beneficiaries with an incident diagnosis of CSR between 2007 and 2015 (n=35 492) and randomly selected controls matched on age-based and sex-based propensity scores (n=1 77 460). Results The mean age (SD) of cases was 49.1 (12.2) years, and the majority (69.2%) were male. Cases were more likely to have received steroids in the past year (OR 1.14, 95% CI 1.09 to 1.19, p<0.001) and to have comorbid Cushing's syndrome (OR 2.19, 95% CI 1.33 to 3.59, p=0.002), age-related macular degeneration (OR 5.24, 95% CI 5.00 to 5.49, p<0.001), diabetic macular oedema (OR 2.05, 95% CI 1.71 to 2.47, p<0.001) and diabetes mellitus (OR 1.44, 95% CI 1.33 to 1.56, p<0.001). Glaucoma was associated with lower odds of CSR (OR 0.54, 95% CI 0.51 to 0.56, p<0.001). Patients with other previously hypothesised risk factors (including essential hypertension, pregnancy, other autoimmune disease, sleep disorders, Helicobacter pylori infection and gastro-oesophageal reflux disease) had lower odds of CSR. Conclusions Male middle-aged patients with recent steroid exposure were significantly more likely to develop CSR. Other risk factors include diabetes mellitus, diabetic macular oedema and age-related macular degeneration. Other previously hypothesised risk factors did not appear to confer increased risk. More research is needed to confirm and examine underlying pathophysiology.
C1 [Zhou, Maggie; Pershing, Suzann] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Bakri, Sophie J.] Mayo Clin, Ophthalmol, Rochester, MN USA.
   [Pershing, Suzann] VA Palo Alto Hlth Care Syst, Ophthalmol, Palo Alto, CA USA.
C3 Stanford University; Mayo Clinic; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); VA Palo Alto Health Care System
RP Pershing, S (通讯作者)，Stanford Univ, Sch Med, Stanford, CA 94305 USA.
EM pershing@stanford.edu
RI zhou, Maggie/GWQ-6970-2022
OI Zhou, Maggie/0000-0001-5308-0014
FU National Institutes of Health, National Center for Advancing
   Translational Science Clinical and Translational Science Award [UL1
   TR001085]
FX Data for this project were accessed using the Stanford Center for
   Population Health Sciences Data Core. The PHS Data Core is supported by
   a National Institutes of Health, National Center for Advancing
   Translational Science Clinical and Translational Science Award (UL1
   TR001085) and by an internal Stanford funding.
CR Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Bearelly S, 2008, ARCH OPHTHALMOL-CHIC, V126, P986, DOI 10.1001/archopht.126.7.986
   Brodie FL, 2015, RETINA-J RET VIT DIS, V35, P238, DOI 10.1097/IAE.0000000000000326
   Chang YS, 2016, RETINA-J RET VIT DIS, V36, P798, DOI 10.1097/IAE.0000000000000796
   Chang YS, 2015, INVEST OPHTH VIS SCI, V56, P4083, DOI 10.1167/iovs.14-16360
   Chatziralli I, 2017, CURR EYE RES, V42, P1069, DOI 10.1080/02713683.2016.1276196
   Chen SN, 2015, RETINA-J RET VIT DIS, V35, P231, DOI 10.1097/IAE.0000000000000278
   Daruich A, 2017, DEV OPHTHALMOL, V58, P27, DOI 10.1159/000455267
   Eom Youngsub, 2012, Korean J Ophthalmol, V26, P260, DOI 10.3341/kjo.2012.26.4.260
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2010, RETINA-J RET VIT DIS, V30, P267, DOI 10.1097/IAE.0b013e3181c2e0f4
   Jain AK, 2010, GRAEF ARCH CLIN EXP, V248, P1037, DOI 10.1007/s00417-009-1257-5
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Lam A, 2005, CURR EYE RES, V30, P221, DOI 10.1080/02713680490908760
   Latkany Paul, 2010, J Ocul Biol Dis Infor, V3, P30, DOI 10.1007/s12177-010-9052-4
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Liu B, 2016, RETINA-J RET VIT DIS, V36, P9, DOI 10.1097/IAE.0000000000000837
   Mansuetta CC, 2004, AM J OPHTHALMOL, V137, P1096, DOI 10.1016/j.ajo.2004.01.054
   Nicholson BP, 2018, SURV OPHTHALMOL, V63, P1, DOI 10.1016/j.survophthal.2017.06.008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Rim TH, 2018, JAMA OPHTHALMOL, V136, P1164, DOI 10.1001/jamaophthalmol.2018.3293
   VIBERTI GC, 1983, AM J MED, V75, P81, DOI 10.1016/0002-9343(83)90257-7
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
NR 28
TC 5
Z9 5
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2019
VL 103
IS 12
BP 1784
EP 1788
DI 10.1136/bjophthalmol-2018-313050
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JT7FH
UT WOS:000501150600017
PM 30872284
DA 2022-11-30
ER

PT J
AU Stewart, MW
AF Stewart, Michael W.
TI The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in
   Ophthalmology
SO MAYO CLINIC PROCEEDINGS
LA English
DT Review
ID COHERENCE TOMOGRAPHY FINDINGS; RETINA STUDY-GROUP; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; MICROVASCULAR PERMEABILITY;
   DIABETIC-RETINOPATHY; CELLS SECRETE; FACTOR VEGF; RANIBIZUMAB; INJECTION
AB Vascular endothelial growth factor (VEGF) plays an important role in both physiologic and pathologic angiogenesis and contributes to increased permeability across both the blood-retinal and blood-brain barriers. After 2 decades of extensive research into the VEGF families and receptors, specific molecules have been targeted for drug development, and several medications have received US Food and Drug Administration approval. Bevacizumab, a full-length antibody against VEGF approved for the intravenous treatment of advanced carcinomas, has been used extensively in ophthalmology for exudative age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and other chorioretinal vascular disorders. Pegaptanib and ranibizumab have been developed specifically for intraocular use, whereas the soon-to-be-introduced aflibercept (VEGF Trap-Eye) is moving through clinical trials for both intraocular and systemic use. Although these drugs exhibit excellent safety profiles, ocular and systemic complications, particularly thromboembolic events, remain a concern in patients receiving therapy. Patients experiencing adverse events that may be related to VEGF suppression should be carefully evaluated by both the ophthalmologist and the medical physician to reassess the need for intraocular therapy and explore the feasibility of changing medications. For this review a search of Pub Med from January 1, 1985 through April 15, 2011, was performed using the following terms (or combination of terms): vascular endothelial growth factors, VEGF, age-related macular degeneration, diabetic retinopathy, retina vein occlusions, retinopathy of prematurity, intravitreal injections, bevacizumab, ranibizumab, and VEGF Trap. Studies were limited to those published in English. Other articles were identified from bibliographies of retrieved articles and archives of the author. (C) 2012 Mayo Foundation for Medical Education and Research Mayo Clin Proc. 2012:87(1):77-88
C1 Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic
RP Stewart, MW (通讯作者)，Mayo Clin, Dept Ophthalmol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM stewart.michael@mayo.edu
FU Regeneron; Bayer
FX Dr Stewart has received research support from Regeneron and Bayer. He
   has served on an Advisory Board for Regeneron.
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Figueroa MS, 2010, BRIT J OPHTHALMOL, V94, P1052, DOI 10.1136/bjo.2009.173732
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalil RAK, 2010, REV BRAS CIR CARDIOV, V25, P311, DOI 10.1590/S0102-76382010000300006
   Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P513, DOI 10.1001/archopht.126.4.513
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Li WY, 1997, CHINESE MED J-PEKING, V110, P659
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mahajan VB, 2011, RETINA-J RET VIT DIS, V31, P31, DOI 10.1097/IAE.0b013e3181ed8c80
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   Rehak M, 2010, J THROMB HAEMOST, V8, P1886, DOI 10.1111/j.1538-7836.2010.03909.x
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Russell DA, 2008, BRIT J SURG, V95, P576, DOI 10.1002/bjs.6100
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Tziros C, 2006, CURR DRUG TARGETS, V7, P1243, DOI 10.2174/138945006778559111
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wen Y, 1998, J BIOL CHEM, V273, P2090, DOI 10.1074/jbc.273.4.2090
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu L, 2009, RETINA-J RET VIT DIS, V29, P1396, DOI 10.1097/IAE.0b013e3181bcef53
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yazdani S, 2009, J GLAUCOMA, V18, P632, DOI 10.1097/IJG.0b013e3181997211
NR 88
TC 124
Z9 138
U1 0
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD JAN
PY 2012
VL 87
IS 1
BP 77
EP 88
DI 10.1016/j.mayocp.2011.10.001
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 883XD
UT WOS:000299667300012
PM 22212972
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU He, SK
   Ouyang, S
   Li, XH
   Ma, BY
AF He, Shikun
   Ouyang, Sha
   Li, Xiaohua
   Ma, Binyun
TI Inhibition of laser induced rats choroidal neovascularization by
   intravitreous injection of sEphB4-HSA
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Choroidal neovascularization (CNV); soluble EpHB4 (sEphB4); VEGF-R2;
   fibronectin (FN)
ID ENDOTHELIAL-CELL FUNCTION; ANGIOGENESIS; EXPRESSION; RECEPTORS;
   BEVACIZUMAB; CYTOKINES; EPHRINB2; ROLES
AB Background: Choroidal neovascularization (CNV) is a leading cause of central vision loss complicated with age-related macular degeneration. Although intravitreal anti-VEGF therapy is widely used in wet age-related macular degeneration, optimal treatment regimens for the disease are still under investigation. EphrinB2 and EphB4 regulate angiogenesis, and interruption of EphB4/ephrinB2 has been demonstrated to inhibit angiogenesis. In the current study, we studied the effects of soluble EphB4 (sEphB4) on laser induced CNV in a rat model by intravitreous injection and the underlying mechanism.
   Methods: Male rats (Brown-Norway) were used in the study. CNV was induced by laser and the sEphB4 was injected intravitreous after laser at days 3 and 7. The CNV lesions were evaluated by three methods: fluorescein angiography (FA) in vivo, CNV volume by confocal analysis of choroidal flat-mounts and H&E staining. The expression of fibronectin (FN), VEGFR-2, phospho-VEGFR-2 (pVEGFR-2), the double labeling of EphB4 with FN was analyzed by immunofluorescence. The interaction of FN with EphB4 and the effects of intraocular injection of sEphB4 on the inhibition of pVEGFR-2 were determined by western blot.
   Results: The FA leakage and CNV volume were significantly inhibited by the injection of the sEphB4. Further, histology analysis showed that CNV lesion was significantly smaller in the rats with sEphB4 injection than rats with placebo application. The expressions of pVEGFR-2 and FN in the CNV lesions were reduced compared with controls.
   Conclusions: Our study suggests that the inhibition of CNV by sEphB4 may be through suppression of VEGFR-2 phosphorylation and the expression of FN. sEphB4 may be a new potential therapeutic strategy of CNV.
C1 [He, Shikun; Ouyang, Sha] Univ Southern Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [He, Shikun; Ouyang, Sha] Univ Southern Calif, USC Roski Eye Inst, Keck Sch Med, 1450 San Pablo St,4400, Los Angeles, CA 90033 USA.
   [Ouyang, Sha] Cent South Univ, Xiangya Hosp 3, Dept Ophthalmol, Changsha, Peoples R China.
   [Li, Xiaohua] Henan Prov Peoples Hosp, Dept Ophthalmol, Zhengzhou, Peoples R China.
   [Li, Xiaohua] Henan Eye Hosp, Dept Ophthalmol, Zhengzhou, Peoples R China.
   [Ma, Binyun] Univ Southern Calif, Dept Med, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   Central South University; Zhengzhou University; University of Southern
   California
RP He, SK (通讯作者)，Univ Southern Calif, USC Roski Eye Inst, Keck Sch Med, 1450 San Pablo St,4400, Los Angeles, CA 90033 USA.; Ma, BY (通讯作者)，Univ Southern Calif, Dept Med, Keck Sch Med, Los Angeles, CA 90033 USA.
EM shikunhe@usc.edu; binyunma@usc.edu
CR Abengozar MA, 2012, BLOOD, V119, P4565, DOI 10.1182/blood-2011-09-380006
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Brar M, 2010, BRIT J OPHTHALMOL, V94, P1668, DOI 10.1136/bjo.2010.182881
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   Chen YN, 2019, SEMIN CANCER BIOL, V56, P37, DOI 10.1016/j.semcancer.2017.10.002
   COURTOY PJ, 1983, J ULTRA MOL STRUCT R, V83, P258, DOI 10.1016/S0022-5320(83)90133-8
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Du EM, 2020, MOL BIOL REP, V47, P4681, DOI 10.1007/s11033-020-05470-y
   Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   He SK, 2010, INVEST OPHTH VIS SCI, V51, P543, DOI 10.1167/iovs.09-3475
   He SK, 2005, INVEST OPHTH VIS SCI, V46, P4772, DOI 10.1167/iovs.05-0502
   Hielscher A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147600
   Hollanders K, 2015, CURR EYE RES, V40, P611, DOI 10.3109/02713683.2014.943910
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Li X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095004, 10.1371/journal.pone.0089856, 10.1371/journal.pone.0110546, 10.1371/journal.pone.0099697, 10.1371/journal.pone.0098139]
   Liu ZG, 2014, J CANCER RES CLIN, V140, P525, DOI 10.1007/s00432-013-1534-x
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Salvucci O, 2012, ADV CANCER RES, V114, P21, DOI 10.1016/B978-0-12-386503-8.00002-8
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shi S, 2012, J PHARM SCI-US, V101, P1969, DOI 10.1002/jps.23096
   Swift MR, 2009, CIRC RES, V104, P576, DOI 10.1161/CIRCRESAHA.108.188805
   Tanemura M, 2004, MOL VIS, V10, P923
   Turgut B, 2013, J OPHTHALMIC PATHOL, V2, P1
   Uhl C, 2018, ANGIOGENESIS, V21, P873, DOI 10.1007/s10456-018-9633-6
   Umeda N, 2004, AM J OPHTHALMOL, V138, P270, DOI 10.1016/j.ajo.2004.04.006
   Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515
NR 36
TC 2
Z9 2
U1 0
U2 1
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JAN
PY 2021
VL 9
IS 1
AR 18
DI 10.21037/atm-20-3810
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA QG9EM
UT WOS:000617882600006
PM 33553311
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Flores, R
   Carneiro, A
   Serra, J
   Gouveia, N
   Pereira, T
   Mendes, JM
   Coelho, PS
   Tenreiro, S
   Seabra, MC
AF Flores, Rita
   Carneiro, Angela
   Serra, Joana
   Gouveia, Nelia
   Pereira, Telmo
   Mendes, Jorge M.
   Coelho, Pedro S.
   Tenreiro, Sandra
   Seabra, Miguel C.
TI CORRELATION STUDY BETWEEN DRUSEN MORPHOLOGY AND FUNDUS AUTOFLUORESCENCE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; color fundus photography; drusen; drusen morphology; fundus
   autofluorescence; intermediate AMD; nonexudative AMD; optical coherence
   tomography
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; LIPOFUSCIN; EYES; DEPOSITS
AB Purpose: To correlate drusen morphology and outer retinal status with autofluorescence (AF) imaging in patients with intermediate age-related macular degeneration. Methods: Drusen type and morphology were analyzed using color fundus photography and spectral-domain optic coherence tomography, whereas fundus AF was used for drusen AF evaluation. Additional structural changes on spectral-domain optic coherence tomography, such as disruption of external limiting membrane, ellipsoid zone, and retinal pigment epithelium/Bruch membrane complex, as well as the presence of choroidal hypertransmission at correspondent locations were also evaluated and correlated with fundus AF findings. Spearman's correlation coefficient was used to analyze the correlation between spectral-domain optic coherence tomography morphological characteristics of drusen and AF appearance of the corresponding drusen. Strength of correlation was calculated (r), and a P value < 0.05 was considered statistically significant. Results: Two hundred and twenty-eight drusen from 53 eyes of 53 patients were analyzed, 130 soft drusen (57.02%) and 98 cuticular drusen (42.98%). Sixty percent of the drusen were isoautofluorescent (n = 136), 35% hyperautofluorescent (n = 80), and 5% hypoautofluorescent (n = 12). We found positive correlation between drusen AF and hyperreflective foci (r = 0.4). Outer retinal layers morphology (external limiting membrane and ellipsoid zone status and hypertransmission) also correlates with autofluorescent findings (r = 0.3). Conclusion: Multimodal imaging reveals a broad spectrum of ultrastructural changes, which may reflect different stages in the evolution of drusen. Our results suggest that drusen morphological characteristics and autofluorescent findings are correlated but other factors or cofactors may be involved. The described correlations will help us understand new progression biomarkers of nonexudative age-related macular degeneration.
C1 [Flores, Rita] CHULC Ctr Hosp Lisboa Cent, Dept Ophthalmol, Med Retina Serv, Alameda Santo Antonio Capuchos, P-1169050 Lisbon, Portugal.
   [Flores, Rita; Serra, Joana; Gouveia, Nelia; Pereira, Telmo; Tenreiro, Sandra; Seabra, Miguel C.] Univ Nova Lisboa, Fac Ciencias Med, CEDOC Chron Dis Res Ctr, Lisbon, Portugal.
   [Carneiro, Angela] Univ Porto, Dept Surg & Physiol, Fac Med, Porto, Portugal.
   [Mendes, Jorge M.; Coelho, Pedro S.] Ctr Hosp Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
   Univ Nova Lisboa, NOVA Informat Management Sch, Lisbon, Portugal.
C3 Universidade Nova de Lisboa; Universidade do Porto; Universidade Nova de
   Lisboa
RP Flores, R (通讯作者)，CHULC Ctr Hosp Lisboa Cent, Dept Ophthalmol, Med Retina Serv, Alameda Santo Antonio Capuchos, P-1169050 Lisbon, Portugal.
EM ritamariaflores@gmail.com
RI Seabra, Miguel C/M-3280-2013; Tenreiro, Sandra/A-9289-2013; Flores,
   Rita/AAU-9934-2020; S Coelho, Pedro/D-1888-2010
OI Seabra, Miguel C/0000-0002-6404-4892; Tenreiro,
   Sandra/0000-0001-7272-5842; Flores, Rita/0000-0002-7523-2418; S Coelho,
   Pedro/0000-0003-0828-9956
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gobel AP, 2016, GRAEF ARCH CLIN EXP, V254, P59, DOI 10.1007/s00417-015-3012-4
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holmen IC, 2019, OPHTHALMOL RETINA, V3, P724, DOI 10.1016/j.oret.2019.04.011
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P1937, DOI 10.1167/iovs.19-26566
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2017, JAMA OPHTHALMOL, V135, P403, DOI 10.1001/jamaophthalmol.2017.0104
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Zhang Q, 2019, INVEST OPHTH VIS SCI, V60, P3468, DOI 10.1167/iovs.19-26690
NR 32
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2021
VL 41
IS 3
BP 555
EP 562
DI 10.1097/IAE.0000000000002881
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL1OK
UT WOS:000656688600022
PM 32604342
DA 2022-11-30
ER

PT J
AU Kim, DY
   Fingler, J
   Zawadzki, RJ
   Park, SS
   Morse, LS
   Schwartz, DM
   Fraser, SE
   Werner, JS
AF Kim, Dae Yu
   Fingler, Jeff
   Zawadzki, Robert J.
   Park, Susanna S.
   Morse, Lawrence S.
   Schwartz, Daniel M.
   Fraser, Scott E.
   Werner, John S.
TI Optical imaging of the chorioretinal vasculature in the living human eye
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ocular circulation; ocular vasculature; optical angiography; ophthalmic
   imaging; Fourier-domain optical coherence tomography
ID COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; IN-VIVO; GEOGRAPHIC ATROPHY;
   HIGH-RESOLUTION; HIGH-SPEED; HUMAN RETINA; AUTOFLUORESCENCE; CIRCULATION
AB Detailed visualization of microvascular changes in the human retina is clinically limited by the capabilities of angiography imaging, a 2D fundus photograph that requires an intravenous injection of fluorescent dye. Whereas current angiography methods enable visualization of some retinal capillary detail, they do not adequately reveal the choriocapillaris or other microvascular features beneath the retina. We have developed a noninvasive microvascular imaging technique called phase-variance optical coherence tomography (pvOCT), which identifies vasculature three dimensionally through analysis of data acquired with OCT systems. The pvOCT imaging method is not only capable of generating capillary perfusion maps for the retina, but it can also use the 3D capabilities to segment the data in depth to isolate vasculature in different layers of the retina and choroid. This paper demonstrates some of the capabilities of pvOCT imaging of the anterior layers of choroidal vasculature of a healthy normal eye as well as of eyes with geographic atrophy (GA) secondary to age-related macular degeneration. The pvOCT data presented permit digital segmentation to produce 2D depth-resolved images of the retinal vasculature, the choriocapillaris, and the vessels in Sattler's and Haller's layers. Comparisons are presented between en face projections of pvOCT data within the superficial choroid and clinical angiography images for regions of GA. Abnormalities and vascular dropout observed within the choriocapillaris for pvOCT are compared with regional GA progression. The capability of pvOCT imaging of the microvasculature of the choriocapillaris and the anterior choroidal vasculature has the potential to become a unique tool to evaluate therapies and understand the underlying mechanisms of age-related macular degeneration progression.
C1 [Kim, Dae Yu; Fingler, Jeff; Fraser, Scott E.] CALTECH, Biol Imaging Ctr, Pasadena, CA 91125 USA.
   [Zawadzki, Robert J.; Park, Susanna S.; Morse, Lawrence S.; Werner, John S.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Schwartz, Daniel M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
C3 California Institute of Technology; University of California System;
   University of California Davis; University of California System;
   University of California San Francisco
RP Fraser, SE (通讯作者)，CALTECH, Biol Imaging Ctr, Pasadena, CA 91125 USA.
EM sefraser@caltech.edu; jswerner@ucdavis.edu
RI Zawadzki, Robert J./S-3236-2019; Zawadzki, Robert/E-7534-2011; Fraser,
   Scott/Y-3406-2019
OI Zawadzki, Robert J./0000-0002-9574-156X; Zawadzki,
   Robert/0000-0002-9574-156X; Fraser, Scott/0000-0002-5377-0223; Morse,
   Lawrence/0000-0002-1758-2348
FU National Eye Institute [EY014743]; Research to Prevent Blindness;
   Beckman Institute; That Man May See Foundation; Howard Hughes Medical
   Institute Med-into-Grad Initiative [56006769]; NATIONAL EYE INSTITUTE
   [R42EY021054, R01EY014743] Funding Source: NIH RePORTER
FX We thank R. H. Grubbs (Department of Chemistry, California Institute of
   Technology) for helpful discussions and support and S. Garcia (Vision
   Science and Advanced Retinal Imaging Laboratory, University of
   California, Davis Medical Center) for help with phase-variance optical
   coherence tomography data acquisition and acquiring fundus photographs.
   This research was funded in part by National Eye Institute Grant
   EY014743 (to J.S.W.), Research to Prevent Blindness (J.S.W., S.S.P., and
   L.S.M.), the Beckman Institute (S.E.F.), the That Man May See Foundation
   (D.M.S.), and Howard Hughes Medical Institute Med-into-Grad Initiative
   56006769 (to D.Y.K.).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brader HS, 2011, INVEST OPHTH VIS SCI, V52, P9218, DOI 10.1167/iovs.11-7493
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hendargo HC, 2011, BIOMED OPT EXPRESS, V2, P2175, DOI 10.1364/BOE.2.002175
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim DY, 2012, INVEST OPHTH VIS SCI, V53, P85, DOI 10.1167/iovs.11-8249
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Povazay B, 2009, INVEST OPHTH VIS SCI, V50, P1856, DOI 10.1167/iovs.08-2869
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Sunness JS, 1999, MOL VIS, V5
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
NR 25
TC 147
Z9 154
U1 1
U2 29
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 27
PY 2013
VL 110
IS 35
BP 14354
EP 14359
DI 10.1073/pnas.1307315110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 206ZC
UT WOS:000323564600059
PM 23918361
OA Green Published, Green Accepted, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Booth, BA
   Denham, LV
   Bouhanik, S
   Jacob, JT
   Hill, JM
AF Booth, Blake A.
   Denham, Lori Vidal
   Bouhanik, Saadallah
   Jacob, Jean T.
   Hill, James M.
TI Sustained-release ophthalmic drug delivery systems for treatment of
   macular disorders - Present and future applications
SO DRUGS & AGING
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   BIODEGRADABLE SCLERAL IMPLANT; RETINAL-PIGMENT EPITHELIUM; RANDOMIZED
   CLINICAL-TRIAL; ENDOTOXIN-INDUCED-UVEITIS; IN-VIVO; CONTRAST AGENTS;
   GENE-TRANSFER; LONG-TERM
AB Macular disease currently poses the greatest threat to vision in aging populations. Historically, most of this pathology could only be dealt with surgically, and then only after much damage to the macula had already occurred. Current pathophysiological insights into macular diseases have allowed the development of effective new pharmacotherapies. The field of drug delivery systems has advanced over the last several years with emphasis placed on controlled release of drug to specific areas of the eye. Its unique location and tendency toward chronic disease make the macula an important and attractive target for drug delivery systems, especially sustained-release systems. This review evaluates the current literature on the research and development of sustained-release posterior segment drug delivery systems that are primarily intended for macular disease with an emphasis on age-related macular degeneration. Current effective therapies include corticosteroids and anti-vascular endothelial growth factor compounds. Recent successes have been reported using anti-angiogenic drugs for therapy of age-related macular degeneration. This review also includes information on implantable devices (biodegradable and non-biodegradable), the use of injected particles (microspheres and liposomes) and future enhanced drug delivery systems, such as ultrasound drug delivery. The devices reviewed show significant drug release over a period of days or weeks. However, macular disorders are chronic diseases requiring years of treatment. Currently, there is no 'gold standard' for therapy and/or drug delivery. Future studies will focus on improving the efficiency and effectiveness of drug delivery to the posterior chamber. If successful, therapeutic modalities will significantly delay loss of vision and improve the quality of life for patients with chronic macular disorders.
C1 Louisiana State Univ, Hlth Sci Ctr, Ctr Eye, Dept Ophthalmol, New Orleans, LA 70112 USA.
   Tulane Univ, Dept Biomed Engn, New Orleans, LA 70118 USA.
   Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr, New Orleans, LA USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Tulane University; Louisiana State
   University System; Louisiana State University Health Sciences Center New
   Orleans; Louisiana State University System; Louisiana State University
   Health Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans
RP Hill, JM (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Ctr Eye, Dept Ophthalmol, 2020 Gravier St,Suite B, New Orleans, LA 70112 USA.
EM jhill@lsuhsc.edu
FU NEI NIH HHS [NEI-EY-006311, EY02377] Funding Source: Medline; NIA NIH
   HHS [NIA-AG-23055] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [P30EY002377, R01EY006311] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG023055] Funding Source: NIH RePORTER
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   *ALL INC, ALL COMPL ACQ OC PHA
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Bao SP, 1997, ULTRASOUND MED BIOL, V23, P953, DOI 10.1016/S0301-5629(97)00025-2
   Beeley NRF, 2006, J BIOMED MATER RES A, V76A, P690, DOI 10.1002/jbm.a.30567
   Beeley NRF, 2005, J BIOMED MATER RES A, V73A, P437, DOI 10.1002/jbm.a.30294
   Behar-Cohen FF, 1998, INVEST OPHTH VIS SCI, V39, P897
   BeharCohen FF, 1997, EXP EYE RES, V65, P533, DOI 10.1006/exer.1997.0364
   Bekeredjian R, 2006, ULTRASCHALL MED, V27, P134, DOI 10.1055/s-2005-858993
   Bekeredjian R, 2005, J AM COLL CARDIOL, V45, P329, DOI 10.1016/j.jacc.2004.08.067
   Bochot A, 2002, INVEST OPHTH VIS SCI, V43, P253
   Bochot A, 2000, PROG RETIN EYE RES, V19, P131, DOI 10.1016/S1350-9462(99)00014-2
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cheng LY, 2000, INVEST OPHTH VIS SCI, V41, P1523
   CHURCH CC, 1995, J ACOUST SOC AM, V97, P1510, DOI 10.1121/1.412091
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruysberg LPJ, 2002, J OCUL PHARMACOL TH, V18, P559, DOI 10.1089/108076802321021108
   Davis JL, 2004, CURR OPIN MOL THER, V6, P195
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dijkmans P A, 2004, Eur J Echocardiogr, V5, P245, DOI 10.1016/j.euje.2004.02.001
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   DORRELL MI, 2007, LP NATL ACAD SCI US, V104, P967
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Entezari M, 2005, EUR J OPHTHALMOL, V15, P746, DOI 10.1177/112067210501500614
   Feinstein SB, 2004, AM J PHYSIOL-HEART C, V287, pH450, DOI 10.1152/ajpheart.00134.2004
   Felt-Baeyens O, 2006, INT J PHARMACEUT, V322, P6, DOI 10.1016/j.ijpharm.2006.05.053
   Fialho SL, 2006, CURR EYE RES, V31, P525, DOI 10.1080/02713680600719036
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   GIORDANO GG, 1993, INVEST OPHTH VIS SCI, V34, P2743
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gramiak R, 1968, Invest Radiol, V3, P356
   Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1
   Haesslein A, 2006, J CONTROL RELEASE, V114, P251, DOI 10.1016/j.jconrel.2006.05.024
   HALLER JA, 2003, RETINA DEBATES
   HASHIZOE M, 1994, ARCH OPHTHALMOL-CHIC, V112, P1380, DOI 10.1001/archopht.1994.01090220130035
   Hashizoe M, 1997, CURR EYE RES, V16, P633, DOI 10.1076/ceyr.16.7.633.5063
   HASHIZOE M, 1995, CURR EYE RES, V14, P473, DOI 10.3109/02713689509003758
   Herrero-Vanrell R, 2000, PHARMACEUT RES, V17, P1323, DOI 10.1023/A:1026464124412
   Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9
   HINICAL AA, 2000, HDB PHARM CONTROLLED, P329
   Hoff L, 2000, J ACOUST SOC AM, V107, P2272, DOI 10.1121/1.428557
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P421, DOI 10.1016/j.ajo.2004.10.005
   Huber PE, 2000, GENE THER, V7, P1516, DOI 10.1038/sj.gt.3301242
   Jaffe GJ, 2000, RETINA-J RET VIT DIS, V20, P402, DOI 10.1097/00006982-200004000-00015
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 1998, OPHTHALMOLOGY, V105, P46, DOI 10.1016/S0161-6420(98)91176-9
   Jonas JB, 2006, OPHTHALMOLOGY, V113, P800, DOI 10.1016/j.ophtha.2006.01.002
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KHOOBEHI B, 1991, OPHTHALMIC SURG LAS, V22, P175
   Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   KIMURA H, 1994, INVEST OPHTH VIS SCI, V35, P2815
   KIMURA H, 1994, CURR EYE RES, V13, P353, DOI 10.3109/02713689409167299
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656
   Klein R, 1996, ANNU REV PUBL HEALTH, V17, P137
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klibanov AL, 2006, INVEST RADIOL, V41, P354, DOI 10.1097/01.rli.0000199292.88189.0f
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   KOST J, 1989, P NATL ACAD SCI USA, V86, P7663, DOI 10.1073/pnas.86.20.7663
   Kunou N, 2000, J CONTROL RELEASE, V68, P263, DOI 10.1016/S0168-3659(00)00267-4
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494
   Le Visage C, 2001, BIOMATERIALS, V22, P2229, DOI 10.1016/S0142-9612(00)00411-7
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, pS17, DOI 10.1097/00006982-200607001-00005
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Lu Ming, 2004, International Ophthalmology Clinics, V44, P41, DOI 10.1097/00004397-200404430-00007
   Mainardes RM, 2005, CURR DRUG TARGETS, V6, P363, DOI 10.2174/1389450053765914
   Mantipragada SB, 2003, BIOCHEMISTRY-US, V42, P9167, DOI 10.1021/bi034485q
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Miller DL, 1999, ULTRASOUND MED BIOL, V25, P1425, DOI 10.1016/S0301-5629(99)00105-2
   MITRA AK, 2002, OPHTHALMIC DRUG DELI
   Miyamoto H, 1997, CURR EYE RES, V16, P930, DOI 10.1076/ceyr.16.9.930.5042
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Morita Y, 1998, BIOL PHARM BULL, V21, P188
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   MORITERA T, 1994, CURR EYE RES, V13, P171, DOI 10.3109/02713689408995774
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, p[e1, 12]
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Mukherjee D, 2000, J AM COLL CARDIOL, V35, P1678, DOI 10.1016/S0735-1097(00)00575-1
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Norrby K, 2006, J CELL MOL MED, V10, P588, DOI 10.1111/j.1582-4934.2006.tb00423.x
   OGURA Y, 1995, SURV OPHTHALMOL, V39, pS17, DOI 10.1016/S0039-6257(05)80069-4
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Okabe K, 2003, INVEST OPHTH VIS SCI, V44, P2702, DOI 10.1167/iovs.02-0956
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Oshima Y, 1998, GENE THER, V5, P1347, DOI 10.1038/sj.gt.3300725
   Pelzek Christopher, 2002, Ophthalmol Clin North Am, V15, P555, DOI 10.1016/S0896-1549(02)00043-3
   PEYMAN GA, 1992, INT OPHTHALMOL, V16, P109, DOI 10.1007/BF00918942
   PEYMAN GA, 1988, INT OPHTHALMOL, V12, P175, DOI 10.1007/BF00130002
   Porter TR, 2000, IMAGING IN CARDIOVASCULAR DISEASE, P85
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Ryan S J, 1983, Trans New Orleans Acad Ophthalmol, V31, P43
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023
   Schutt EG, 2003, ANGEW CHEM INT EDIT, V42, P3218, DOI 10.1002/anie.200200550
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Shankar PM, 1999, J ACOUST SOC AM, V106, P2104, DOI 10.1121/1.428142
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Slakter Jason S, 2006, Ophthalmol Clin North Am, V19, P373
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Srikonda S., 2006, DESIGN CONTROLLED RE
   Strom C, 2005, INVEST OPHTH VIS SCI, V46, P3855, DOI 10.1167/iovs.05-0096
   Suggs LJ, 1996, PHYS PROPERTIES POLY, P615
   Sultana Yasmin, 2006, Current Drug Delivery, V3, P207, DOI 10.2174/156720106776359186
   Tan DTH, 2001, OPHTHALMOLOGY, V108, P2172, DOI 10.1016/S0161-6420(01)00839-9
   Tata DB, 1997, BIOCHEM BIOPH RES CO, V234, P64, DOI 10.1006/bbrc.1997.6578
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Toth CA, 2006, RETINA-J RET VIT DIS, V26, pS21, DOI 10.1097/00006982-200607001-00006
   Veloso AAS, 1997, INVEST OPHTH VIS SCI, V38, P665
   Voigt M, 2002, INVEST OPHTH VIS SCI, V43, P3299
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Yasukawa T, 2005, ADV DRUG DELIVER REV, V57, P2033, DOI 10.1016/j.addr.2005.09.005
   Yasukawa T, 2000, GRAEF ARCH CLIN EXP, V238, P186, DOI 10.1007/s004170050031
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Yokoyama A, 2001, INVEST OPHTH VIS SCI, V42, P3283
   Zderic V, 2004, J ULTRAS MED, V23, P1349, DOI 10.7863/jum.2004.23.10.1349
   Zhou TH, 1998, J CONTROL RELEASE, V55, P281, DOI 10.1016/S0168-3659(98)00061-3
NR 145
TC 28
Z9 30
U1 0
U2 15
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2007
VL 24
IS 7
BP 581
EP 602
DI 10.2165/00002512-200724070-00006
PG 22
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 202DF
UT WOS:000248881500006
PM 17658909
DA 2022-11-30
ER

PT J
AU Avisar, R
   Friling, R
   Snir, M
   Avisar, I
   Weinberger, D
AF Avisar, Rahamim
   Friling, Ronit
   Snir, Moshe
   Avisar, Inbal
   Weinberger, Dov
TI Estimation of prevalence and incidence rates and causes of blindness in
   Israel, 1998-2003
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE blindness; macular degeneration; glaucoma; visual field loss
ID VISUAL IMPAIRMENT; EYE; POPULATION; OLDER
AB Background: The prevalence and incidence of blindness in Israel appear to be comparable to other western countries. Comparisons are difficult because of different definitions of blindness, and the uniqueness of the Israeli Registry of the Blind.
   Objective: To characterize the population who were registered as Blind in Israel in the years 1998-2003 and estimate the prevalence and incidence of blindness by age and causes of blindness.
   Methods: A retrospective review of the annual report of the national Registry of the Blind in Israel between 1998 and 2003 identified 21,585 blind persons who received a certificate for blindness. Blind persons are identified by ophthalmologists throughout Israel and referred to the Registry of the Blind if they have a visual acuity of 3/60 or worse, or a visual field loss of < 20 degrees in their better eye. This report includes prevalence data on 21,585 persons enrolled in this review still alive and living in Israel in 2003. We estimated the prevalence rate of blindness nationwide and the incidence rate for each cause of blindness for every year.
   Results: The main leading causes of blindness in Israel in 1998 were (in percent of the total number of newly registered patients): age-related macular degeneration (20.1%), glaucoma (13.8%), myopic maculopathy.(12%), cataract (10.4%), diabetic retinopathy and maculopathy (10.1%), and optic atrophy (7.9%), and in 2003, 28%, 11.8%, 7.4%, 6.5%, 14.4% and 6.5% respectively.
   Conclusions: The results indicate that the incidence of age-related macular degeneration, diabetic retinopathy and maculopathy in Israel is increasing, while that of glaucoma, myopic maculopthy, optic atrophy and cataract is decreasing.
C1 Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Avisar, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol & External Eye Dis, Golda Campus,POB 121, IL-49372 Petah Tiqwa, Israel.
EM avisarr@hotmail.com
CR AVISAR R, 1981, HAREFUAH, V1000, P11
   Avisar Rahamim, 2003, Harefuah, V142, P94
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Khandekar R, 2002, BRIT J OPHTHALMOL, V86, P957, DOI 10.1136/bjo.86.9.957
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Lewallen S, 2001, BRIT J OPHTHALMOL, V85, P897, DOI 10.1136/bjo.85.8.897
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   *WHO, 2004, 282 WHO
   World Health Organization, 1980, INT CLASS IMP DIS HA, P79
NR 14
TC 34
Z9 34
U1 0
U2 3
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISRAEL MED ASSOC J
JI Isr. Med. Assoc. J.
PD DEC
PY 2006
VL 8
IS 12
BP 880
EP 881
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 122IF
UT WOS:000243218700019
PM 17214111
DA 2022-11-30
ER

PT J
AU Shrestha, A
   Suwal, R
   Shrestha, R
   Suwal, B
   Khadka, D
AF Shrestha, Arjun
   Suwal, Rinkal
   Shrestha, Rajan
   Suwal, Barsha
   Khadka, Deepak
TI Use of Intravitreal Bevacizumab Injection among Patients Undergoing
   Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive
   Cross-sectional Study
SO JOURNAL OF NEPAL MEDICAL ASSOCIATION
LA English
DT Article
DE bevacizumab; intravitreal injection; visual disorders
ID RANIBIZUMAB; AVASTIN
AB Introduction: Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital. Methods: This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal Health Research Council (Ref: 125/2020P). The sample size was calculated and the study enrolled all patients who received intravitreal Bevacizumab for retinal diseases using convenience sampling technique. Data were analyzed using Statistical Package for Social Science Version 21. Point estimate at 95% Confidence Interval was calculated, along with frequency and percentage for binary data. Results: Out of 959 total surgical retinal interventions done 296 (30.86%) at 95% Confidence Interval (27.93-33.78) patients received intravitreal Bevacizumab. Out of total intravitreal Bevacizumab injections, 143 (36.7%) injections were given to retinal vein occlusions patients, 127 (32.6%) injections were given to diabetic retinopathy patients and 66 (17%) injections was given to age-related macular degeneration patients. Males 176 (59.5%) outnumbered the females 120 (40.5%) in receiving intravitreal Bevacizumab. Mean baseline Logarithm of the Minimal Angle of Resolution visual acuity, 1.1, improved to, 0.75, after 3 months of intravitreal Bevacizumab. Conclusions: Intravitreal Bevacizumab was one of the commonest retinal interventions used. Retinal vein occlusion, diabetic retinopathy, and age-related macular degeneration were the commonest retinal diseases needing intravitreal Bevacizumab.
C1 [Shrestha, Arjun; Suwal, Rinkal; Suwal, Barsha; Khadka, Deepak] Hosp Children Eye ENT & Rehabil Serv, BP Eye Fdn, Dept Ophthalmol, Bhaktapur, Bagmati Provinc, Nepal.
   [Shrestha, Rajan] Hosp Children Eye ENT & Rehabil, BP Eye Fdn, Acad & Res Dept, Bhaktapur, Bagmati Provinc, Nepal.
RP Shrestha, A (通讯作者)，Hosp Children Eye ENT & Rehabil Serv, BP Eye Fdn, Dept Ophthalmol, Bhaktapur, Bagmati Provinc, Nepal.
EM arjundr@gmail.com
RI shrestha, rajan/GPW-6479-2022; Suwal, Rinkal/ACZ-4534-2022
OI shrestha, rajan/0000-0002-0703-4655; Suwal, Rinkal/0000-0002-2033-8610;
   Suwal, Barsha/0000-0002-1548-3469; Khadka, Deepak/0000-0001-8436-129X
CR Al-Hinai Ahmed S, 2015, Oman J Ophthalmol, V8, P166, DOI 10.4103/0974-620X.169896
   Arevalo JF, 2013, RETINA-J RET VIT DIS, V33, P403, DOI 10.1097/IAE.0b013e3182695b83
   Jain P, 2017, INDIAN J OPHTHALMOL, V65, P596, DOI 10.4103/ijo.IJO_992_16
   Kumluang S, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1086-1
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Shrestha MK, 2012, NEPAL J OPHTHALMOL, V4, P277, DOI http://dx.doi.org/10.3126/nepjoph.v4i2.6544
   Shrestha R, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01420-1
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Vyas S, 2016, NEPAL J OPHTHALMOL, V8, P54, DOI 10.3126/nepjoph.v8i1.16157
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Zarei M, 2020, CLIN OPHTHALMOL, V14, P1201, DOI 10.2147/OPTH.S256317
NR 11
TC 0
Z9 0
U1 0
U2 0
PU NEPAL MEDICAL ASSOC
PI KATHMANDU
PA NMA BUILDING, SIDDIHI SADAN, PO BOX 189, EXHIBITION RD, KATHMANDU,
   00000, NEPAL
SN 0028-2715
EI 1815-672X
J9 J NEPAL MED ASSOC
JI J. Nepal Med. Assoc.
PD SEP
PY 2021
VL 59
IS 241
BP 858
EP 861
DI 10.31729/jnma.5515
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA WQ4YW
UT WOS:000713824800006
PM 35199738
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Farber, MD
AF Farber, MD
TI National Registry for the Blind in Israel: Estimation of prevalence and
   incidence rates and causes of blindness
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE blindness epidemiology; blindness registry; blindness causes;
   age-related macular degeneration; glaucoma; diabetic retinopathy;
   cataract; optic nerve atrophy; Israel
ID VISUAL IMPAIRMENT; CHILDHOOD BLINDNESS; LOW-VISION; SCHOOL STUDENTS;
   PARTIAL SIGHT; GAZA-STRIP; WEST-BANK; EYE; POPULATION; EPIDEMIOLOGY
AB OBJECTIVE To describe the population registered as blind in Israel and estimate the prevalence and incidence of blindness, by age, sex and the causes of blindness.
   METHODS Israel has maintained a Registry for the Blind since 1987. Patients are identified by ophthalmologists and registered if they have a visual acuity of less than or equal to0.05 (20/400) or a visual field Of <20 degrees radius in their better eye. The Registry consists of all eligible citizens living in Israel at the time of registration. This report includes prevalence data on 18,891 persons enrolled in the Registry from 1987-1999 and still alive and living in Israel in 1999, and incidence data on 2,511 persons newly registered in 1999. Data were collected on visual acuity and visual field loss, cause of blindness, and patient demographics.
   RESULTS In 1999, the estimated prevalence rate of blindness nationwide was 0.31% and the estimated incidence rate was 0.037%. The major causes of blindness in the complete Registry were age related macular degeneration (AMD) and glaucoma (14%), followed by diabetic retinopathy (11%), cataract and myopic maculopathy (10%), and optic atrophy (8.4%). The leading causes of newly diagnosed blindness were age-related macular degeneration (AMD) (20%), glaucoma (14%), diabetic retinopathy (12%), Myopic maculopathy (11%), and optic atrophy and cataract (10%).
   CONCLUSIONS Israel has one of the few nationwide blindness registries in the world. The prevalence and incidence of blindness in Israel appear to be comparable to other western countries Comparisons are difficult because of different definitions of blindness, age distributions, and the uniqueness of the Israeli Registry.
C1 Hadassah Univ Hosp, Michaelson Inst Visual Rehabil, Jerusalem, Israel.
   Hadassah Univ Hosp, Dept Ophthalmol, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Farber, MD (通讯作者)，Hadassah Univ Hosp, Michaelson Inst Visual Rehabil, Str 24, Jerusalem, Israel.
EM mzober@netvision.net.il
CR Adeoye A, 1996, TROP MED INT HEALTH, V1, P672
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Balo PK, 2000, J FR OPHTALMOL, V23, P459
   BJORNSSON G, 1981, ACTA OPHTHALMOL, V59, P921
   BUCHER PJM, 1988, BRIT J OPHTHALMOL, V72, P721, DOI 10.1136/bjo.72.10.721
   CHAN CWC, 1991, AUST NZ J OPHTHALMOL, V19, P321, DOI 10.1111/j.1442-9071.1991.tb00680.x
   CORSIA Y, 2001, SERVICES BLIND V JAN
   DeCarlo D K, 1999, J Am Optom Assoc, V70, P647
   ELDER MJ, 1993, EYE, V7, P580, DOI 10.1038/eye.1993.126
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   FOSTER A, 1992, EYE, V6, P173, DOI 10.1038/eye.1992.34
   GILBERT CE, 1993, EYE, V7, P184, DOI 10.1038/eye.1993.39
   Graf M, 1999, KLIN MONATSBL AUGENH, V215, P50, DOI 10.1055/s-2008-1034669
   GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88
   Hornby SJ, 1999, BRIT J OPHTHALMOL, V83, P929, DOI 10.1136/bjo.83.8.929
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Khandekar R, 2002, BRIT J OPHTHALMOL, V86, P957, DOI 10.1136/bjo.86.9.957
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   MACDONALD AE, 1965, CAN MED ASSOC J, V92, P264
   Mansour AM, 1997, BRIT J OPHTHALMOL, V81, P905, DOI 10.1136/bjo.81.10.905
   MOLL AC, 1994, BRIT J OPHTHALMOL, V78, P275, DOI 10.1136/bjo.78.4.275
   Moorhead HB, 1973, STAT BLINDNESS MODEL
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   NEGREL AD, 1990, B WORLD HEALTH ORGAN, V68, P237
   NEGREL AD, 1995, MED TROP, V4, P409
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   NEWLAND HS, 1994, BRIT J OPHTHALMOL, V78, P344, DOI 10.1136/bjo.78.5.344
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   RAHI JS, 1995, EYE, V9, P545, DOI 10.1038/eye.1995.137
   RAPOZA PA, 1991, INT OPHTHALMOL, V15, P123, DOI 10.1007/BF01046432
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P395
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   SORSBY A, 1972, REPORTS PUBLIC HLTH
   Sorsby A, 1966, REPORTS PUBLIC HLTH
   SRIVASTAVA RN, 1978, J EPIDEMIOL COMMUN H, V32, P131, DOI 10.1136/jech.32.2.131
   THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P95, DOI 10.1136/bjo.73.2.95
   THOMSON IM, 1984, BRIT J OPHTHALMOL, V68, P598, DOI 10.1136/bjo.68.8.598
   Thylefors B, 1995, Ophthalmic Epidemiol, V2, P5, DOI 10.3109/09286589509071448
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Zerihun N, 1997, Ophthalmic Epidemiol, V4, P19
NR 44
TC 24
Z9 27
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD OCT
PY 2003
VL 10
IS 4
BP 267
EP 277
DI 10.1076/opep.10.4.267.15910
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 714WW
UT WOS:000184937300006
PM 14628969
DA 2022-11-30
ER

PT J
AU Kiss, C
   Michels, S
   Prager, F
   Weigert, G
   Geitzenauer, W
   Schmidt-Erfurth, U
AF Kiss, Christopher
   Michels, Stephan
   Prager, Franz
   Weigert, Guenther
   Geitzenauer, Wolfgang
   Schmidt-Erfurth, Ursula
TI Evaluation of anterior chamber inflammatory activity in eyes treated
   with intravitreal bevacizumab
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab (Avastin); choroidal
   neovascularization; intravitreal injection; laser flare meter
ID COHERENCE TOMOGRAPHY FINDINGS; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN; INJECTION; RANIBIZUMAB; EDEMA
AB Purpose: To evaluate the effect of intravitreal bevacizurnab on anterior chamber inflammatory activity.
   Methods: Sixty-one consecutive patients with neovascular age-related macular degeneration were examined before, 1 day, and 1 week after intravitreal administration of 1 mg of bevacizurnab (0.04 mL) for neovascular age-related macular degeneration. The intravitreal injection was performed under sterile conditions. Twenty-one fellow eyes served as controls. The anterior chamber inflammatory activity was evaluated using biomicroscopy and the laser flare meter (Kowa FM-500, Kowa Company, Ltd., Tokyo, Japan).
   Results: None of the 61 consecutive patients had a significant, clinically detectable inflammatory response within 1 week of follow-up. Anterior chamber inflammatory activity measured by the laser flare meter ranged from 1.9 counts/ms to 70.0 counts/ms (mean +/- SD, 13.2 +/- 16.9 counts/ms; 95% confidence interval [CI], 7.8-18.6) before treatment. One day and 1 week after injection, values were between 3.2 counts/ms and 30.0 counts/ms (mean +/- SD, 9.1 +/- 6.2 counts/ms; 95% CI, 7.2-11.1) and 2.0 counts/ms and 25.1 counts/ms (mean +/- SD, 7.3 +/- 4.6 counts/ms; 95% CI, 5.8-8.8), respectively. There was a significant reduction of anterior chamber flare at 1 week compared with baseline (P 0.031). The control eyes had constantly low flare measures.
   Conclusion: No inflammatory response was detected clinically and by the laser flare meter after intravitreal bevacizurnab administration. The slight reduction in anterior chamber flare could be due to the known antiinflammatory effect of anti-vascular endothelial growth factor therapy.
C1 Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Michels, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Grtl 18-20, A-1090 Vienna, Austria.
EM Stephan.michels@meduniwien.ac.at
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   ITTURALDE D, 2006, RETINA, V26, P279
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Mason JO, 2006, RETINA-J RET VIT DIS, V26, P356, DOI 10.1097/00006982-200603000-00018
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   MICHELS S, 2004, RETINAL PHYS    0816, P16
   Reichel E, 2005, OPHTHAL SURG LAS IM, V36, P270, DOI 10.3928/1542-8877-20050701-03
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2005, SPEKTRUM AUGENHEILKD, V19, P68, DOI 10.1007/BF03163961
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
NR 22
TC 49
Z9 52
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2006
VL 26
IS 8
BP 877
EP 881
DI 10.1097/01.iae.0000237080.10627.b7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AW
UT WOS:000246985400004
PM 17031286
DA 2022-11-30
ER

PT J
AU Macdonald, IM
   Sieving, PC
AF Macdonald, Ian M.
   Sieving, Pamela C.
TI American Journal of Ophthalmology Contributions to Ophthalmic Genetics
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID JACKSON-MEMORIAL-LECTURE; LEBER CONGENITAL AMAUROSIS; AGE-RELATED
   MACULOPATHY; COMPLEMENT-FACTOR-H; OPEN-ANGLE GLAUCOMA; MACULAR
   DEGENERATION; JAPANESE POPULATION; MOLECULAR-GENETICS; POLYMORPHISMS;
   RETINOBLASTOMA
AB PURPOSE: To review the contributions to ophthalmic genetics through the American Journal of Ophthalmology (AJO).
   DESIGN: Perspective.
   METHODS: A literature search to retrieve original articles, letters, editorials, and published lectures from 1966 to 2017, providing a 50-year review. Titles were excluded that gave no reference to genetics or that presented findings related to a nongenetic ocular condition.
   RESULTS: From a search of the Scopus database, 719 articles were ascertained. Of these, 115 were excluded because the title did not reference a genetic condition or have a focus on genetic factors; 4 were excluded because they described animal phenotypes (1966-1967); and 4 were excluded owing to having received no citations up to and including 2015. The highest number of citations was 283 times for a single article on familial aggregation in age-related macular degeneration. The Web of Science database yielded 771 articles; of these, 118 were excluded owing to not reporting human genetic studies; 55 received no citations. The highest number of citations was 307 for a single article, a 1991 paper on Leber hereditary optic neuropathy.
   CONCLUSIONS: The Journal's contributions to our understanding of the heritability of human ocular traits have been broad and deep, with international reach. The development of new techniques fostered new concepts and new approaches to rapidly expand the number of known single gene disorders with a defined molecular genetic cause. Reports on Mendelian and complex traits in the AJO abound, along with 6 Edward Jackson Memorial Lectures on retinal dystrophies, Leber congenital amaurosis, age-related macular degeneration, and glaucoma. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Macdonald, Ian M.] Univ Alberta, Dept Ophthalmol & Visual Sci, 7-030 Katz Bldg, Edmonton, AB T6G 2E1, Canada.
   [Sieving, Pamela C.] NEI, NIH, Bethesda, MD 20892 USA.
C3 University of Alberta; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Macdonald, IM (通讯作者)，Univ Alberta, Dept Ophthalmol & Visual Sci, 7-030 Katz Bldg, Edmonton, AB T6G 2E1, Canada.
EM macdonal@ualberta.ca
FU ALBERTA INNOVATES; FOUNDATION FIGHTING Blindness; Canadian Institutes
   for Health Research; Canada Foundation for Innovation; Alberta Innovates
   [201201139] Funding Source: researchfish
FX IAN M. MACDONALD RECEIVED GRANT SUPPORT FROM ALBERTA INNOVATES,
   FOUNDATION FIGHTING Blindness, Canadian Institutes for Health Research,
   Canada Foundation for Innovation.
CR Alward WLM, 2003, AM J OPHTHALMOL, V136, P904, DOI 10.1016/S0002-9394(03)00577-4
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   APPLE C, 1945, AM J OPHTHALMOL, V28, P1152
   ATTENBOROUGH VM, 1945, AM J OPHTHALMOL, V28, P1366
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0
   CRISWICK VG, 1969, AM J OPHTHALMOL, V68, P578, DOI 10.1016/0002-9394(69)91237-9
   CROSS HE, 1977, AM J OPHTHALMOL, V84, P548, DOI 10.1016/0002-9394(77)90450-0
   CROSS HE, 1973, AM J OPHTHALMOL, V75, P405, DOI 10.1016/0002-9394(73)91149-5
   DARR LP, 1945, AM J OPHTHALMOL, V28, P898
   Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hayashi H, 2008, AM J OPHTHALMOL, V145, P582, DOI 10.1016/j.ajo.2007.10.023
   Hewitt AW, 2006, AM J OPHTHALMOL, V142, P324, DOI 10.1016/j.ajo.2006.02.041
   HORWITZ D, 1945, AM J OPHTHALMOL, V28, P1368
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jacobson SG, 2017, AM J OPHTHALMOL, V177, P44, DOI 10.1016/j.ajo.2017.02.003
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   LICHTER PR, 1994, AM J OPHTHALMOL, V117, P706, DOI 10.1016/S0002-9394(14)70314-9
   Liesegang TJ, 2005, AM J OPHTHALMOL, V139, P530, DOI 10.1016/j.ajo.2004.11.049
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Mabuchi F, 2007, AM J OPHTHALMOL, V143, P125, DOI 10.1016/j.ajo.2006.09.028
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310
   NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4
   SANGER F, 1975, PROC R SOC SER B-BIO, V191, P317, DOI 10.1098/rspb.1975.0131
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 2007, AM J OPHTHALMOL, V144, P791, DOI 10.1016/j.ajo.2007.08.022
   TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6
   Trifan OC, 1998, AM J OPHTHALMOL, V126, P17, DOI 10.1016/S0002-9394(98)00073-7
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 40
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2018
VL 190
BP XVI
EP XXI
DI 10.1016/j.ajo.2018.03.004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GI1AY
UT WOS:000434102800002
PM 29530780
DA 2022-11-30
ER

PT J
AU Lee, B
   Chen, SY
   Moult, EM
   Yu, Y
   Alibhai, AY
   Mehta, N
   Baumal, CR
   Waheed, NK
   Fujimoto, JG
AF Lee, ByungKun
   Chen, Siyu
   Moult, Eric M.
   Yu, Yue
   Alibhai, A. Yasin
   Mehta, Nihaal
   Baumal, Caroline R.
   Waheed, Nadia K.
   Fujimoto, James G.
TI High-Speed, Ultrahigh-Resolution Spectral-Domain OCT with Extended
   Imaging Range Using Reference Arm Length Matching
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE Optical coherence tomography; ultrahigh-resolution OCT; spectral domain
   OCT; age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTORECEPTOR LAYER THICKNESS; MOTION
   CORRECTION; TRACKING; ANGIOGRAPHY
AB Purpose: To develop high-speed, extended-range, ultrahigh-resolution spectral-domain optical coherence tomography (UHR SD-OCT) and demonstrate scan protocols for clinical retinal imaging.
   Methods: A UHR SD-OCT operating at 840-nm with 150-nm bandwidths was developed. The axial imaging range was extended by dynamically matching reference arm length to the retinal contour during acquisition. Two scan protocols were demonstrated for imaging healthy participants and patients with dry age-related macular degeneration. A high-definition raster protocol with intra-B-scan reference arm length matching (ReALM) was used for high-quality cross-sectional imaging. A cube volume scan using horizontal and vertical rasters with inter-B-scan ReALM and software motion correction was used for en face and cross-sectional imaging. Linear OCT signal display enhanced visualization of outer retinal features.
   Results: UHR SD-OCT was demonstrated at 128- and 250-kHz A-scan rates with 2.7 mu m axial resolution and a 1.2-mm, 6-dB imaging range in the eye. Dynamic ReALM was used to maintain the retina within the 6-dB imaging range over wider fields of view. Outer retinal features, including the rod and cone interdigitation zones, retinal pigment epithelium, and Bruch's membrane were visualized and alterations observed in agerelated macular degeneration eyes.
   Conclusions: Technological advances and dynamic ReALM improve the imaging performance and clinical usability of UHR SD-OCT.
   Translational Relevance: These advances should simplify clinical imaging workflow, reduce imaging session times, and improve yield of high quality images. Improved visualization of photoreceptors, retinal pigment epithelium, and Bruch's membrane may facilitate diagnosis and monitoring of age-related macular degeneration and other retinal diseases.
C1 [Lee, ByungKun; Chen, Siyu; Moult, Eric M.; Yu, Yue; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Res Lab Elect, Cambridge, MA 02139 USA.
   [Alibhai, A. Yasin; Mehta, Nihaal; Baumal, Caroline R.; Waheed, Nadia K.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
C3 Massachusetts Institute of Technology (MIT); Tufts University
RP Fujimoto, JG (通讯作者)，MIT, Dept Elect Engn & Comp Sci, Res Lab Elect, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI CHEN, SI/GZL-4800-2022
FU National Institutes of Health [5-R01-EY011289-33]; Air Force Office of
   Scientific Research [FA9550-15-1-0473]; Beckman-Argyros Award for Vision
   Research; Retina Research Foundation
FX Supported by the National Institutes of Health (5-R01-EY011289-33), Air
   Force Office of Scientific Research (FA9550-15-1-0473), Beckman-Argyros
   Award for Vision Research, and Retina Research Foundation.
CR Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   American National Standards Institute, 2016, Z80362016 ANSI LAS I
   American National Standards Institute ANSI Z136.1-2014, 2014, Z13612014 ANSI LAS I
   An L, 2011, BIOMED OPT EXPRESS, V2, P2770, DOI 10.1364/BOE.2.002770
   Baumann B, 2007, OPT EXPRESS, V15, P13375, DOI 10.1364/OE.15.013375
   Birch DG, 2011, INVEST OPHTH VIS SCI, V52, P7141, DOI 10.1167/iovs.11-7509
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Braaf B, 2013, BIOMED OPT EXPRESS, V4, P51, DOI 10.1364/BOE.4.000051
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Chan A, 2006, RETINA-J RET VIT DIS, V26, P655, DOI 10.1097/00006982-200607000-00011
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Chong SP, 2017, BIOMED OPT EXPRESS, V8, P323, DOI 10.1364/BOE.8.000323
   Cua M, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.2.026007
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Gotzinger E, 2005, OPT EXPRESS, V13, P583, DOI 10.1364/OPEX.13.000583
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Hendargo HC, 2011, BIOMED OPT EXPRESS, V2, P2175, DOI 10.1364/BOE.2.002175
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kocaoglu OP, 2014, BIOMED OPT EXPRESS, V5, P4186, DOI 10.1364/BOE.5.004186
   Kocaoglu OP, 2011, BIOMED OPT EXPRESS, V2, P748, DOI 10.1364/BOE.2.000748
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Leitgeb RA, 2003, OPT LETT, V28, P2201, DOI 10.1364/OL.28.002201
   Lu CD, 2017, INVEST OPHTH VIS SCI, V58, P4632, DOI 10.1167/iovs.17-22171
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Potsaid B, 2008, OPT EXPRESS, V16, P15149, DOI 10.1364/OE.16.015149
   Povazay B, 2002, PROC SPIE, V4619, P90, DOI 10.1117/12.470466
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sheehy CK, 2012, BIOMED OPT EXPRESS, V3, P2611, DOI 10.1364/BOE.3.002611
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Vienola KV, 2012, BIOMED OPT EXPRESS, V3, P2950, DOI 10.1364/BOE.3.002950
   Wang R, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3593149
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2002, OPT LETT, V27, P1415, DOI 10.1364/OL.27.001415
   Yi J, 2015, BIOMED OPT EXPRESS, V6, P3701, DOI 10.1364/BOE.6.003701
   Yun SH, 2004, OPT EXPRESS, V12, P2977, DOI 10.1364/OPEX.12.002977
   Zawadzki RJ, 2008, OPT EXPRESS, V16, P8126, DOI 10.1364/OE.16.008126
   Zawadzki RJ, 2011, BIOMED OPT EXPRESS, V2, P1674, DOI 10.1364/BOE.2.001674
NR 44
TC 10
Z9 10
U1 3
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUN
PY 2020
VL 9
IS 7
AR 12
DI 10.1167/tvst.9.7.12
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG6VH
UT WOS:000617722000006
PM 32832219
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Caillaux, V
   Bastuji-Garin, S
   Zmuda, M
   Souied, EH
AF Leveziel, Nicolas
   Caillaux, Violaine
   Bastuji-Garin, Sylvie
   Zmuda, Mathieu
   Souied, Eric H.
TI Angiographic and Optical Coherence Tomography Characteristics of Recent
   Myopic Choroidal Neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PATHOLOGICAL MYOPIA; FLUORESCEIN ANGIOGRAPHY; MACULAR DEGENERATION;
   POSTERIOR STAPHYLOMA; EYES; POPULATION; LEAKAGE; DOMAIN
AB PURPOSE: To analyze the contribution of fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD OCT) to the diagnosis of recent choroidal neovascularization (CNV) associated with high myopia.
   DESIGN: Retrospective, observational case series.
   METHODS: Ninety eyes of 73 highly myopic patients (refractive error >=-6 diopters) with CNV in 1 or both eyes were included. Epidemiologic features, refractive error, fundus examination, fluorescein angiography, and SD OCT findings at onset of CNV were analyzed.
   RESULTS: Mean age at onset of CNV was 54.4 +/- 14 years. CNV was bilateral in 17 of 73 cases. Mean refractive error was -13.9 +/- 5.2 diopters. Myopic CNV was associated more frequently with patchy or geographic atrophy (P = .019). CNV was associated with exudative features on fluorescein angiography in 82% of cases (64/78), and on SD OCT in 48.6% of cases (36/74). There was no agreement about signs of active CNV between these 2 imaging methods (kappa = 25.7 +/- 10%; P = .0044). CNV area was significantly smaller in younger patients (< 55 years) than in older patients (0.57 mm(2) vs 1.21 mm(2), respectively; P = .023).
   CONCLUSIONS: Exudative features of myopic CNV are more obvious on FA than on SD OCT, suggesting that fluorescein angiography should be performed when new-onset myopic CNV is suspected. Myopic CNV occurring in older patients (55 years) is larger than those seen in younger patients and resembles CNV associated with age-related macular degeneration. This suggests an overlap between myopic CNV in older patients and age-related macular degeneration. (Am J Ophthalmol 2013;155:913-919. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Leveziel, Nicolas; Souied, Eric H.] Univ Paris Est Creteil, Grp Hosp Albert Chenevier Henri Mondor, AP HP, Fac Med Henri Mondor,Dept Ophthalmol, Creteil, France.
   [Leveziel, Nicolas; Caillaux, Violaine; Zmuda, Mathieu; Souied, Eric H.] Ctr Hosp Intercommunal, Dept Ophthalmol, Creteil, France.
   [Leveziel, Nicolas] Univ Poitiers Hosp, Dept Ophthalmol, Poitiers, France.
   [Bastuji-Garin, Sylvie] Univ Paris Est, Fac Med, Lab Invest Clin, Creteil, France.
   [Bastuji-Garin, Sylvie] Hop Henri Mondor, AP HP, Dept Clin Res & Publ Hlth, F-94010 Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil; CHU Poitiers; Universite de Poitiers; Universite de
   Franche-Comte; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP
RP Leveziel, N (通讯作者)，Ctr Hosp Univ Poitiers, 2 Rue Miletrie, F-86021 Poitiers, France.
EM nicolas.leveziel@chu-poitiers.fr
RI Bastuji-Garin, Sylvie/R-3479-2018
OI Bastuji-Garin, Sylvie/0000-0001-9855-5183
CR AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baba T, 2002, ACTA OPHTHALMOL SCAN, V80, P82, DOI 10.1034/j.1600-0420.2002.800116.x
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Fernandez-Robredo P, 2008, OPHTHALMOLOGY, V115
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hsiang HW, 2008, AM J OPHTHALMOL, V146, P102, DOI 10.1016/j.ajo.2008.03.010
   Ikuno Y, 2008, RETINA-J RET VIT DIS, V28, P1124, DOI 10.1097/IAE.0b013e318174417a
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Moriyama M, 2007, OPHTHALMOLOGY, V114, P1755, DOI 10.1016/j.ophtha.2006.11.034
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   NOBLE KG, 1982, OPHTHALMOLOGY, V89, P1099
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Shih YF, 2006, BRIT J OPHTHALMOL, V90, P546, DOI 10.1136/bjo.2005.081992
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
NR 20
TC 57
Z9 58
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2013
VL 155
IS 5
BP 913
EP 919
DI 10.1016/j.ajo.2012.11.021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 136SU
UT WOS:000318384500018
PM 23352343
DA 2022-11-30
ER

PT J
AU Hartmann, KI
   Gomez, ML
   Bartsch, DUG
   Schuster, AK
   Freeman, WR
AF Hartmann, Kathrin I.
   Gomez, Maria L.
   Bartsch, Dirk-Uwe G.
   Schuster, Alexander K.
   Freeman, William R.
TI EFFECT OF CHANGE IN DRUSEN EVOLUTION ON PHOTORECEPTOR INNER
   SEGMENT/OUTER SEGMENT JUNCTION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dry age-related macular degeneration; drusen regression; drusen
   progression; spectral domain optical coherence tomography; inner
   segment/outer segment junction
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; DEGENERATION; EYE
AB Purpose: To evaluate the integrity of photoreceptor inner segment/outer segment (IS/OS) junction after change of drusen size in age-related macular degeneration using spectral-domain optical coherence tomography.
   Methods: Drusen volume raster scans were performed with the Spectralis spectral-domain optical coherence tomography (Heidelberg Engineering) through 2,624 drusen in 14 eyes with clinically dry age-related macular degeneration, which had been longitudinally followed-up between 23 and 28 months without intervention (mean, 26.3 months). All eyes had Early Treatment Diabetic Retinopathy Study visual acuity. A total of 416 of 2,624 drusen were analyzed.
   Results: Of 416 drusen, 83 (20%) were found to have regressed spontaneously (Group A), 212 (51%) showed no change in size (Group B), and 121 (29%) progressed (Group C). Mean drusen size of all drusen was 63.7 +/- 25.7 mm. Cross-sectional analysis of drusen morphology showed a correlation between drusen size and disrupted IS/OS junction/photoreceptor integrity (r = -0.48, P < 0.001). Of the drusen that regressed over time, there was intact IS/OS junction integrity. Even drusen that caused a major disruption showed IS/OS restoration in 74% of the drusen (P < 0.001).
   Conclusion: Progression of drusen shows structural disruption of the IS/OS junction. After drusen regression, the IS/OS junction is either able to restore as drusen regress or was artifactitiously compressed and not initially visible because of the initial drusen compression of the IS/OS junctional line. Therefore, drusen evolution may play an important role in affecting the photoreceptor IS/OS junction integrity. RETINA 32:1492-1499, 2012
C1 [Hartmann, Kathrin I.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, La Jolla, CA 92037 USA.
   [Hartmann, Kathrin I.] Univ Munich, Dept Ophthalmol, Munich, Germany.
C3 University of California System; University of California San Diego;
   University of Munich
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
FU National Institutes of Health grant [NEI EY 07366, EY 016323]; RPB Inc.;
   Jacobs Retina Center; NATIONAL EYE INSTITUTE [R01EY007366, R01EY016323]
   Funding Source: NIH RePORTER
FX Supported in part by the National Institutes of Health grant NEI EY
   07366 (W.R.F.), EY 016323 (D.U.B.), RPB Inc., and an unrestricted grant
   from the Jacobs Retina Center.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Green W R, 1999, Mol Vis, V5, P27
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kozak I, 2009, RETINA, V30, P431
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Mojana F, 2011, RETINA-J RET VIT DIS, V31, P235, DOI 10.1097/IAE.0b013e3181ec80ad
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yehoshua Z, 2010, OPHTHALMIC SURG LASE, V41, P6
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 29
Z9 29
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1492
EP 1499
DI 10.1097/IAE.0b013e318242b949
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300009
PM 22481478
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, SJ
   Toma, HS
AF Kim, Stephen J.
   Toma, Hassanain S.
TI Inhibition of Choroidal Neovascularization by Intravitreal Ketorolac
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; TRIAMCINOLONE
   ACETONIDE; FACTOR-H; FACTOR EXPRESSION; COMPLEMENT; CYCLOOXYGENASE-2;
   RAT; PATHOGENESIS; VERTEPORFIN
AB Objective: To determine the inhibitory effect of intravitreal nonsteroidal anti-inflammatory drugs on choroidal neovascularization (CNV) in an animal model of age-related macular degeneration.
   Methods: Six laser burns of sufficient power to rupture the Bruch membrane were induced in the peripapillary area of each eye of 18 adult Brown Norway rats. Both eyes of each animal received the same 5-mu L intravitreal injection of 30 mg/mL of ketorolac tromethamine, 40 mg/mL of triamcinolone acetonide, or balanced salt solution. Fluorescein angiography was performed on days 14 and 21 after injection, animals were euthanized, and retinal pigment epithelium-choroid sclera (choroidal) flat mounts were prepared. Areas of abnormal vascular leakage on fluorescein angiography and vascular budding on choroidal mounts were measured and quantified using an image analysis program.
   Results: Intravitreal ketorolac significantly reduced CNV leakage on fluorescein angiography at 2 (P < .001) and 3 (P = .006) weeks compared with eyes injected with balanced salt solution, but intravitreal triamcinolone was a more potent inhibitor of CNV leakage than ketorolac (P < .001). Vascular budding on choroidal mounts was almost entirely suppressed with triamcinolone (P < .001) and significantly inhibited with ketorolac (P = .009).
   Conclusion: Intravitreal ketorolac significantly reduced laser-induced CNV leakage and vascular budding as determined by fluorescein angiography and choroidal flat mounts, respectively, although this effect was less than that of triamcinolone.
   Clinical Relevance: Intravitreal nonsteroidal anti-inflammatory drugs may be useful in the treatment of CNV owing to age-related macular degeneration or other causes and offer distinct clinical advantages over corticosteroids because of their lack of association with cataract formation or glaucoma.
C1 [Kim, Stephen J.; Toma, Hassanain S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Nashville, TN USA.
C3 Vanderbilt University
RP Kim, SJ (通讯作者)，Vanderbilt Eye Inst, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM skim30@gmail.com
FU Research to Prevent Blindness
FX This study was supported in part by an unrestricted institutional grant
   from Research to Prevent Blindness.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Baranano DE, 2009, BRIT J OPHTHALMOL, V93, P1387, DOI 10.1136/bjo.2009.157297
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bullard LE, 2003, INVEST OPHTH VIS SCI, V44, P1722, DOI 10.1167/iovs.01-1193
   CHANDLER DB, 1985, AM J OPHTHALMOL, V99, P686, DOI 10.1016/S0002-9394(14)76037-4
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Flach Allan Joseph, 2002, International Ophthalmology Clinics, V42, P1
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hu WZ, 2005, RETINA-J RET VIT DIS, V25, P1054, DOI 10.1097/00006982-200512000-00015
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Ju WK, 2002, J COMP NEUROL, V452, P392, DOI 10.1002/cne.10400
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P595, DOI 10.1097/IAE.0b013e31815e98a5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leung WK, 2003, INT J ONCOL, V23, P1317
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Monnier Yan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P31, DOI 10.2174/1568010053622975
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Rabiah PK, 1996, INVEST OPHTH VIS SCI, V37, P613
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   STRELOW SA, 1992, OPHTHALMIC SURG LAS, V23, P170
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Takano T, 2003, J PHARMACOL EXP THER, V305, P240, DOI 10.1124/jpet.102.043604
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 44
TC 31
Z9 34
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2010
VL 128
IS 5
BP 596
EP 600
DI 10.1001/archophthalmol.2010.69
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 593OE
UT WOS:000277466800010
PM 20457981
OA Bronze
DA 2022-11-30
ER

PT J
AU Nan, R
   Gor, J
   Lengyel, I
   Perkins, SJ
AF Nan, Ruodan
   Gor, Jayesh
   Lengyel, Imre
   Perkins, Stephen J.
TI Uncontrolled Zinc- and Copper-Induced Oligomerisation of the Human
   Complement Regulator Factor H and Its Possible Implications for Function
   and Disease
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE complement factor H; X-ray scattering; analytical ultracentrifugation;
   age-related macular degeneration; inflammation
ID HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION; FACTOR-I;
   BINDING-SITES; ANALYTICAL ULTRACENTRIFUGATION; SOLUTION SCATTERING;
   NEUTRON-SCATTERING; PROTEIN BETA-1H; C3B INACTIVATOR; CLINICAL-TRIAL
AB Polymorphisms in factor H (FH), a major regulator of complement activation, and the accumulation of high zinc concentrations in the outer retina are both associated with age-related macular degeneration. EH is inhibited by zinc, which causes FH to aggregate. To investigate thus, we quantitatively studied zinc-induced F:H: self-association by X-ray scattering and analytical ultracentrifugation to demonstrate uncontrolled FH oligomerisation in conditions corresponding to physiological levels of, FH and pathological levels of zinc in the outer retina. By scattering, FH at 2.8-7.0 mu M was unaffected until [Zn] increased to 20 mu M, whereupon the radius of gyration, R-G, values increased from 9 to 75 nm at [Zn]=200 mu M. The maximum dimension of FH increased from 32 to 50 urn, indicating that compact oligomers had formed. By ultracentrifugation, size-distribution analyses showed that monomeric FH at 5.57 S was the major species at [Zn] Lip to 60 mu M. At [Zn] above 60 mu M, a series of large oligomers were formed, ranging Lip to 100 S in size. Oligomerisation was reversed by ethylenediaminetetraacetic acid. Structurally distinct large oligomers were observed for Cu, while Ni, Cd and Fe showed low amounts of oligomers and Mg and Ca showed no change. Fluid-phase assays showed reduced FH activities that correlated with increased oligomer formation. The results were attributed to different degrees of stabilisation of weak self-dimerisation sites in FH by transition metals. The relevance of metal-induced FH: oligomer formation to complement regulation and age-related macular degeneration is discussed. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Nan, Ruodan; Gor, Jayesh; Perkins, Stephen J.] UCL, Div Biosci, Inst Struct & Mol Biol, London WC1E 6BT, England.
   [Lengyel, Imre] UCL, Inst Ophthalmol, Dept Ocular Biol & Therapeut, London EC1V 9EL, England.
C3 University of London; Birkbeck University London; University College
   London; University of London; University College London
RP Perkins, SJ (通讯作者)，UCL, Div Biosci, Inst Struct & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
RI Lengyel, Imre/B-5217-2009
OI Lengyel, Imre/0000-0001-7467-2174
FU [MRC-OX21];  [MRC-OX23]; BBSRC [BB/E013104/1] Funding Source: UKRI;
   Biotechnology and Biological Sciences Research Council [BB/E013104/1]
   Funding Source: researchfish
FX We thank the Biotechnology and Biological Sciences Research Council and
   the Mercer Fund of the Fight For Sight Charity for a Dorothy Hodgkin
   Postgraduate Award and equipment grant support as well as the Henry
   Smith Charity for equipment support. We also thank Dr. R. B. Sim and Dr.
   A. Dodds (MRC Immunochemistry Unit, Oxford) for the provision of
   MRC-OX21. and MRC-OX23 Sepharose and advice on C3 purifications as well
   as Ms. Keying Li for useful discussions. We are very grateful to Dr.
   Anuj Shukla and Dr. Emanuela Di Cola (European Synchrotron Radiation
   Facility, Grenoble, France) for excellent instrumental support as well
   as Prof. Alan C. Bird for useful discussions. I.L. thanks the Mercer
   Fund, the Special Trustees of Moorfields Eye Hospital and the Bill Brown
   Charitable Trust for support.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   *AREDS RES GROUP, 2002, J NUTR, V132, P687
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173
   DAY AJ, 1986, BIOCHEM SOC T, V14, P73, DOI 10.1042/bst0140073
   DODDS AW, 1993, METHOD ENZYMOL, V223, P46
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARRIES TC, 1990, COMPLEMENT INFLAMMAT, V7, P30, DOI 10.1159/000463124
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   FLINN JM, 2008, INVEST OPHTH VIS SCI, V49, pE1756
   Frederickson CJ, 2006, EXP NEUROL, V198, P285, DOI 10.1016/j.expneurol.2005.08.030
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Law SKA, 1995, COMPLEMENT
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Tsiftsoglou SA, 2004, J IMMUNOL, V173, P367, DOI 10.4049/jimmunol.173.1.367
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ullman CG, 1998, MOL IMMUNOL, V35, P503, DOI 10.1016/S0161-5890(98)00052-2
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
NR 56
TC 38
Z9 40
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD DEC 31
PY 2008
VL 384
IS 5
BP 1341
EP 1352
DI 10.1016/j.jmb.2008.10.030
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 388JR
UT WOS:000262016600026
PM 18976665
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Chen, LJ
   Yam, GHF
   Tham, CCY
   Pang, CP
AF Lai, Timothy Y. Y.
   Chen, Li Jia
   Yam, Gary H. F.
   Tham, Clement C. Y.
   Pang, Chi Pui
TI Development of novel drugs for ocular diseases: possibilities for
   individualized therapy
SO PERSONALIZED MEDICINE
LA English
DT Review
DE glaucoma; individualized therapy; macular disease
ID OPEN-ANGLE GLAUCOMA; COMPLEMENT FACTOR-H; DIABETIC MACULAR EDEMA;
   GINKGO-BILOBA EXTRACT; GENOME-WIDE SCAN; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; INTRAVITREAL BEVACIZUMAB AVASTIN; AGE-RELATED MACULOPATHY;
   INTRAOCULAR-PRESSURE RESPONSE; GENE POLYMORPHISM V16A
AB In clinical ophthalmology, new and old drug regimens are available for the treatment of major eye diseases, including potentially blinding conditions, such as glaucoma, and various macular diseases. In glaucoma, therapeutic treatment mainly deals with control of intraocular pressure at low levels but the clinical courses of patients can be very variable. Very often, specific drug combinations and dosages have to be formulated for individual glaucoma patients. In neovascular age-related macular degeneration, choroidal neovascularization can lead to progressive and irreversible visual impairment if not treated early. In recent years, clinical trials using photodynamic therapy with verteporfin and various anti-VEGF antibodies, such as ranibizumab and bevacizumab, have enhanced the treatment outcomes of neovascular age-related macular degeneration. In diabetic macular edema, intravitreal triamcinolone acetonide and anti-VEGF therapy are effective in some patients. Again, responses to treatment are not uniform in all macular patients. Traditional herbal medicine has long been known to play a role in the practice of personalized formulations in Asia. Potential preventive and therapeutic effects have been claimed in individual eye patients. Meanwhile, advanced technologies in molecular biology have led to identification of genes associated with many eye diseases and development of the concept of individual medicine, in which the genotype of a person can be used as a basis for disease prediction or prophylactic treatments. Moreover, pharmacogenomic studies have demonstrated the association of various genotypes or haplotypes with responses to drug therapies, providing hope for tailormade personalized treatments. The combination of genotypic information with clinical features for the prescription of treatment modes in eye diseases is under vigorous research.
C1 [Lai, Timothy Y. Y.; Chen, Li Jia; Yam, Gary H. F.; Tham, Clement C. Y.; Pang, Chi Pui] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Pang, Chi P/I-5388-2014; Tham, Chee Yung
   Clement/AAD-6528-2020; Lai, Timothy Y Y/AAC-2120-2020; Yam, Gary
   Hin-Fai/ABE-1710-2020
OI Chen, Li Jia/0000-0003-3500-5840; Tham, Chee Yung
   Clement/0000-0003-4407-6907; Lai, Timothy Y Y/0000-0002-7832-6428; 
CR Abhary S, 2010, ARCH OPHTHALMOL-CHIC, V128, P102, DOI 10.1001/archophthalmol.2009.355
   Abhary S, 2009, INVEST OPHTH VIS SCI, V50, P5552, DOI 10.1167/iovs.09-3694
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Al-Kateb H, 2007, DIABETES, V56, P2161, DOI 10.2337/db07-0376
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allingham RR, 2009, EXP EYE RES, V88, P837, DOI 10.1016/j.exer.2008.11.003
   Allingham RR, 2005, INVEST OPHTH VIS SCI, V46, P2002, DOI 10.1167/iovs.04-1477
   Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Awata T, 2005, BIOCHEM BIOPH RES CO, V333, P679, DOI 10.1016/j.bbrc.2005.05.167
   Awata T, 2004, DIABETES CARE, V27, P2184, DOI 10.2337/diacare.27.9.2184
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Baird PN, 2005, HUM GENET, V117, P249, DOI 10.1007/s00439-005-1296-x
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beranek M, 2002, AM J MED GENET, V109, P278, DOI 10.1002/ajmg.10372
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buraczynska M, 2009, HUM IMMUNOL, V70, P121, DOI 10.1016/j.humimm.2008.12.003
   Cellini M, 1998, ACTA OPHTHALMOL SCAN, V76, P41
   Chan CKM, 2006, BRIT J OPHTHALMOL, V90, P1137, DOI 10.1136/bjo.2006.093211
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Choi JH, 2007, PHARMACOGENET GENOM, V17, P403, DOI 10.1097/01.fpc.0000236337.41799.b3
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Crispim D, 2010, CLIN ENDOCRINOL, V72, P612, DOI 10.1111/j.1365-2265.2009.03684.x
   DAVIS L, 2009, 59 ANN M AM SOC HUM
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dilsiz N, 2006, GRAEF ARCH CLIN EXP, V244, P627, DOI 10.1007/s00417-005-0084-6
   Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fan BJ, 2006, CLIN BIOCHEM, V39, P249, DOI 10.1016/j.clinbiochem.2005.11.001
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fingert JH, 2002, SURV OPHTHALMOL, V47, P547, DOI 10.1016/S0039-6257(02)00353-3
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuchsjager-Mayrl G, 2005, MOL VIS, V11, P811
   GAUDRIC A, 1993, DIABETES METAB, V19, P422
   Gerzenstein SM, 2008, OPHTHALMIC GENET, V29, P166, DOI 10.1080/13816810802320217
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Goriely A, 2009, NAT GENET, V41, P1247, DOI 10.1038/ng.470
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Guo L, 2006, INVEST OPHTH VIS SCI, V47, P626, DOI 10.1167/iovs.05-0754
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2625, DOI 10.1167/iovs.03-0566
   Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2640, DOI 10.1167/iovs.03-0567
   Hare WA, 2009, INVEST OPHTH VIS SCI, V50, P2940, DOI 10.1167/iovs.08-2103
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hawrami K, 1996, HUM IMMUNOL, V46, P49, DOI 10.1016/0198-8859(95)00177-8
   HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0
   Hirooka K, 2004, CURR EYE RES, V28, P153, DOI 10.1076/ceyr.28.3.153.26246
   HIRSCHHORN JN, 2005, NATURE REV GENETICS, V6, P108
   Hudson BI, 2001, DIABETES, V50, P1505, DOI 10.2337/diabetes.50.6.1505
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060
   Ishii Y, 2003, INVEST OPHTH VIS SCI, V44, P1982, DOI 10.1167/iovs.02-0912
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jarvinen T, 2002, PHARMACOL THERAPEUT, V95, P203, DOI 10.1016/S0163-7258(02)00259-0
   Jia LY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1700, DOI 10.1001/archophthalmol.2008.512
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Kamiuchi K, 2002, DIABETIC MED, V19, P371, DOI 10.1046/j.1464-5491.2002.00694.x
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kao YL, 1998, J CLIN ENDOCR METAB, V83, P2589, DOI 10.1210/jc.83.7.2589
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kingsmore SF, 2008, NAT REV DRUG DISCOV, V7, P221, DOI 10.1038/nrd2519
   Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   KO BCB, 1995, DIABETES, V44, P727, DOI 10.2337/diabetes.44.7.727
   Kook D, 2008, RETINA-J RET VIT DIS, V28, P1053, DOI 10.1097/IAE.0b013e318176de48
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Lam DSC, 2007, BRIT J OPHTHALMOL, V91, P199, DOI 10.1136/bjo.2006.102848
   Lam DSC, 2009, RETINA-J RET VIT DIS, V29, P292, DOI 10.1097/IAE.0b013e31819a2d61
   Lam DSC, 2005, EYE, V19, P885, DOI 10.1038/sj.eye.6701686
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   LEE CM, 1991, OPHTHALMOLOGY, V98, P1594
   Lee SJ, 2006, METABOLISM, V55, P1681, DOI 10.1016/j.metabol.2006.08.011
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Li HT, 2008, MOL VIS, V14, P1698
   Maeda M, 2008, J DIABETES COMPLICAT, V22, P119, DOI 10.1016/j.jdiacomp.2006.12.002
   Malecki MT, 2008, DIABETES RES CLIN PR, V80, P139, DOI 10.1016/j.diabres.2007.11.001
   Matsubara Y, 2000, BLOOD, V95, P1560, DOI 10.1182/blood.V95.5.1560.005k43_1560_1564
   Matsumoto A, 2000, DIABETES RES CLIN PR, V50, P195, DOI 10.1016/S0168-8227(00)00194-7
   McCarty CA, 2008, ARCH OPHTHALMOL-CHIC, V126, P959, DOI 10.1001/archopht.126.7.959
   McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077
   MEYER BH, 1987, S AFR MED J, V71, P570
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068
   Mozaffarieh M, 2007, EXPERT OPIN EMERG DR, V12, P195, DOI 10.1517/14728214.12.2.195
   Nagi DK, 1997, DIABETES CARE, V20, P1304, DOI 10.2337/diacare.20.8.1304
   Nakanishi H, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000660
   Nakano M, 2009, P NATL ACAD SCI USA, V106, P12838, DOI 10.1073/pnas.0906397106
   Nemesure B, 2003, HUM GENET, V112, P600, DOI 10.1007/s00439-003-0910-z
   Nieminen T, 2005, EUR J CLIN PHARMACOL, V61, P811, DOI 10.1007/s00228-005-0052-4
   Nucci C, 2008, PROG BRAIN RES, V173, P451, DOI 10.1016/S0079-6123(08)01131-X
   Pang CP, 2006, MOL VIS, V12, P85
   Pang CP, 2002, INVEST OPHTH VIS SCI, V43, P3231
   Pardridge WM, 2005, MOL BIOTECHNOL, V30, P57, DOI 10.1385/MB:30:1:057
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Peterlin B, 2003, J HUM GENET, V48, P646, DOI 10.1007/s10038-003-0094-3
   Petrovic MG, 2005, DIABETES-METAB RES, V21, P470, DOI 10.1002/dmrr.546
   Petrovic MG, 2008, CLIN EXP OPHTHALMOL, V36, P168, DOI 10.1111/j.1442-9071.2007.01647.x
   Petrovic MG, 2008, DIS MARKERS, V24, P59, DOI 10.1155/2008/940703
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rao KN, 2009, P NATL ACAD SCI USA, V106, pE125, DOI 10.1073/pnas.0910416106
   Ren M, 1998, Zhongguo Zhong Xi Yi Jie He Za Zhi, V18, P652
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Rietveld I, 2006, DIABETES, V55, P2387, DOI 10.2337/db06-0021
   Ritch R, 2000, MED HYPOTHESES, V54, P221, DOI 10.1054/mehy.1999.0025
   Ritch Robert, 2005, Ophthalmol Clin North Am, V18, P597
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai M, 2007, OPHTHALMOLOGY, V114, P1039, DOI 10.1016/j.ophtha.2007.03.025
   Sarfarazi M, 1998, AM J HUM GENET, V62, P641, DOI 10.1086/301767
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schwartz SG, 2005, OPHTHALMOLOGY, V112, P2131, DOI 10.1016/j.ophtha.2005.08.014
   Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659
   SETO C, 1986, JPN J OPHTHALMOL, V30, P238
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Soheilian M, 2007, RETINA-J RET VIT DIS, V27, P1187, DOI 10.1097/IAE.0b013e31815ec261
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229
   Stoilova D, 1996, GENOMICS, V36, P142, DOI 10.1006/geno.1996.0434
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suriyapperuma SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P86, DOI 10.1001/archopht.125.1.86
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Taverna MJ, 2002, DIABETOLOGIA, V45, P436, DOI 10.1007/s00125-001-0769-2
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Trifan OC, 1998, AM J OPHTHALMOL, V126, P17, DOI 10.1016/S0002-9394(98)00073-7
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174
   Wang DY, 2006, INVEST OPHTH VIS SCI, V47, P5315, DOI 10.1167/iovs.06-0179
   Wang QL, 2004, HUM MOL GENET, V13, P1025, DOI 10.1093/hmg/ddh117
   Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974
   WHO, 134 WHO
   Wiggs JL, 1998, AM J HUM GENET, V63, P1549, DOI 10.1086/302098
   Wiggs JL, 2004, AM J HUM GENET, V74, P1314, DOI 10.1086/421533
   Wiggs JL, 2000, HUM MOL GENET, V9, P1109, DOI 10.1093/hmg/9.7.1109
   Wirtz MK, 1997, AM J HUM GENET, V60, P296
   Wirtz MK, 1999, ARCH OPHTHALMOL-CHIC, V117, P237
   Yang YF, 2009, J OCUL PHARMACOL TH, V25, P163, DOI 10.1089/jop.2008.0028
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 183
TC 3
Z9 3
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1741-0541
EI 1744-828X
J9 PERS MED
JI Pers. Med.
PD JUL
PY 2010
VL 7
IS 4
BP 371
EP 386
DI 10.2217/PME.10.25
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 626ZN
UT WOS:000280007400008
PM 29788646
DA 2022-11-30
ER

PT J
AU Lai, JC
   Lapolice, DJ
   Stinnett, SS
   Meyer, CH
   Arieu, LM
   Keller, MA
   Toth, CA
AF Lai, JC
   Lapolice, DJ
   Stinnett, SS
   Meyer, CH
   Arieu, LM
   Keller, MA
   Toth, CA
TI Visual outcomes following macular translocation with 360 degrees
   peripheral retinectomy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; SUBMACULAR SURGERY;
   DEGENERATION; RETINOTOMY
AB Objective: To evaluate visual outcomes following macular translocation with 360degrees peripheral retinectomy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
   Methods: In a prospective study, 15 consecutive patients with large subfoveal choroidal neovascularization underwent macular translocation with 360degrees peripheral retinectomy and silicone oil tamponade. Preoperative and postoperative photographs and fluorescein angiograms were obtained to evaluate lesion size and characteristics and translocation results. Standardized near and distance visual acuity and reading speed were measured preoperatively and 6 and 12 months postoperatively.
   Main Outcome Measures: Changes in and final levels of near and distance visual acuity and reading speed.
   Results: Median lesion size was 9 Macular Photocoagulation Study disc areas (range, 4-16 disc areas). In all patients, the fovea was successfully translocated off the sub-foveal lesion. The median near visual acuity logMAR score (logarithm of the minimum angle of resolution) improved significantly from 0.54 units to 0.40 units (Snellen equivalent, 20/70 to 20/50; P=.02) at the 6-month follow-up and stabilized at 0.54(12 months postoperatively; Snellen equivalent, 20/70). Seven (54%) of 13 patients and 7 (58%) of 12 patients achieved reading speeds of 70 words/min or greater at the 6-month and 12-month postoperative visits, respectively. Median preoperative distance visual acuity (20/100) was maintained at both the 6-month and 12-month examinations. No postoperative retinal detachments occurred in this series.
   Conclusion: Macular translocation with 360degrees peripheral retinectomy and silicone oil tamponade stabilizes and can sometimes improve near and distance visual acuity and reading speed in patients with vision loss from subfoveal neovascular age-related macular degeneration.
C1 Duke Univ, Med Ctr, Dept Ophthalmol, Vitreoretinal Serv, Durham, NC 27710 USA.
C3 Duke University
RP Toth, CA (通讯作者)，POB 3802, Durham, NC 27710 USA.
EM cynthia.toth@duke.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011; Meyer,
   Carsten/A-3981-2017
OI Toth, Cynthia/0000-0002-2324-0854; Meyer, Carsten/0000-0002-0530-5298;
   Stinnett, Sandra/0000-0001-7192-0195
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2001, OPHTHALMOLOGY, V108, P435, DOI 10.1016/S0161-6420(00)00666-7
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   *NAT TECHN INF SER, 1998, SUBM SURG TRIALS SST
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   SILVERSTONE B, 2000, LIGHTHOUSE HDB VISIO, V1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TOTH CA, 1999, AGE RELATED MACULAR, P353
   WOFF S, 1999, GRAEFES ARCH CLIN EX, V237, P51
NR 25
TC 56
Z9 57
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2002
VL 120
IS 10
BP 1317
EP 1324
DI 10.1001/archopht.120.10.1317
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603LG
UT WOS:000178560500007
PM 12365910
OA Bronze
DA 2022-11-30
ER

PT J
AU Montero, JA
   Ruiz-Moreno, JM
AF Montero, Javier A.
   Ruiz-Moreno, Jose M.
TI Treatment of Choroidal Neovascularization in High Myopia
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Bevacizumab; choroidal neovascularization; high myopia; pegaptanib;
   photodynamic therapy; ranibizumab; triamcinolone
ID COMBINED PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB AVASTIN;
   ENDOTHELIAL GROWTH-FACTOR; GENOME-WIDE SCAN; PATHOLOGICAL MYOPIA;
   MACULAR DEGENERATION; TRIAMCINOLONE ACETONIDE; SUBRETINAL
   NEOVASCULARIZATION; SUSCEPTIBILITY LOCUS; PEGAPTANIB SODIUM
AB High myopia affects approximately 2% of general population, and is a major cause of legal blindness in many developed countries. Choroidal neovascularization (CNV) is the most common vision-threatening complication of high myopia. Different therapeutic approaches have been attempted such as thermal laser photocoagulation, surgery and photodynamic therapy with verteporfin (PDT).
   The visual outcome of these therapies has been reported to be better than the natural history of the condition. However, the limited visual acuity improvement after PDT monotherapy and the appearance of subretinal fibrosis and chorioretinal atrophy prompted the association of other therapies. In the past few years a tremendous advance in the knowledge of the mechanisms underling CNV secondary to high myopia and age related macular degeneration has been achieved, leading to new therapeutic targets and novel drugs and combined therapies. These new therapeutic weapons have been designed to achieve a selective shut down of choroidal new vessels.
   Recent reviews have been published on the natural history and therapies for myopic CNV. Ohno-Matsui reported on the natural history of the condition as well as the outcome of laser photocoagulation, surgical extraction of CNV, foveal translocation and photodynamic therapy on myopic CNV in the short-term [1]. Soubrane et al. reviewed the new advances on surgery, laser photocoagulation and PDT, considering some of the potential effects of triamcinolone, pegaptanib and ranibizumab in CNV secondary to age related macular degeneration (AMD) [2]. Novack et al. reported on the pharmacological therapy of CNV in AMD [3]. The aim of this review is to summarize the recent advances in myopic CNV pathophysiology and the new therapeutic targets and drugs that are changing the clinical management of myopic CNV.
C1 [Montero, Javier A.] Pio del Rio Hortega Univ Hosp, Ophthalmol Unit, Valladolid 47012, Spain.
   [Montero, Javier A.; Ruiz-Moreno, Jose M.] Alicante Inst Ophthalmol, VISSUM, Retina Unit, Alicante, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Albacete Med Sch, E-13071 Ciudad Real, Spain.
C3 Universidad de Castilla-La Mancha
RP Montero, JA (通讯作者)，Pio del Rio Hortega Univ Hosp, Ophthalmol Unit, C Carraca S-N, Valladolid 47012, Spain.
EM javmonmor@hotmail.com
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
FU Spanish Ministry of Health, Instituto de Salud Carlos III, Red Tematica
   de Investigacion Cooperativa en Salud [RD07/0062]
FX This study has been supported in part by a grant of the Spanish Ministry
   of Health, Instituto de Salud Carlos III, Red Tematica de Investigacion
   Cooperativa en Salud "Patologia ocular del envejecimiento, calidad
   visual y calidad de vida" (RD07/0062).
CR AMBANI LM, 1975, CLIN GENET, V8, P358
   ANIJEET DR, 2006, EYE
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1035, DOI 10.1136/bjo.2007.130260
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BEIGHTON P, 1970, BRIT J OPHTHALMOL, V54, P263, DOI 10.1136/bjo.54.4.263
   Bennett MD, 2007, GRAEF ARCH CLIN EXP, V245, P903, DOI 10.1007/s00417-006-0472-6
   Bottoni Ferdinando, 2001, International Ophthalmology, V24, P249, DOI 10.1023/A:1025488429802
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Brancato R, 1996, Eur J Ophthalmol, V6, P39
   BRANCATO R, 1989, J FR OPHTALMOL, V12, P883
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Chan WM, 2007, BRIT J OPHTHALMOL, V91, P174, DOI 10.1136/bjo.2006.103606
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   CHAN WM, 2008, RETINA, P1308
   Ciner E, 2008, GENET EPIDEMIOL, V32, P454, DOI 10.1002/gepi.20318
   Ciner E, 2009, AM J OPHTHALMOL, V147, P512, DOI 10.1016/j.ajo.2008.09.004
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   Curtin BJ, 1985, MYOPIAS BASIC SCI CL
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Degenring RF, 2005, ACTA OPHTHALMOL SCAN, V83, P621, DOI 10.1111/j.1600-0420.2005.00506.x
   Díaz-de-Durana-Santa-Coloma E., 2006, Arch Soc Esp Oftalmol, V81, P685
   Ducourneau D, 1998, J FR OPHTALMOL, V21, P782
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Fan DSP, 2007, JPN J OPHTHALMOL, V51, P27, DOI 10.1007/s10384-006-0380-7
   Figurska Malgorzata, 2008, Klin Oczna, V110, P387
   FORSTER W, 1991, KLIN MONATSBL AUGENH, V199, P362, DOI 10.1055/s-2008-1046097
   Francois J, 1968, Int Ophthalmol Clin, V8, P839
   Frost MR, 2007, MOL VIS, V13, P1580
   GASS JDM, 1999, STEREOSCOPIC ATLAS M
   Gentle A, 2003, J BIOL CHEM, V278, P16587, DOI 10.1074/jbc.M300970200
   Georgalas I, 2007, CAN J OPHTHALMOL, V42, P341, DOI 10.3129/canjophthalmol.i07-042
   Georgijevic Ana, 2007, Srp Arh Celok Lek, V135 11-12, P629
   Gharbiya M, 2009, AM J OPHTHALMOL, V147, P84, DOI 10.1016/j.ajo.2008.07.022
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Halfter W, 2006, INVEST OPHTH VIS SCI, V47, P3586, DOI 10.1167/iovs.05-1480
   HALL J, 1974, Birth Defects Original Article Series, V10, P157
   Hall NF, 2009, INVEST OPHTH VIS SCI, V50, P2632, DOI 10.1167/iovs.08-2427
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   HAN DP, 2009, EYE
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Hayashi K, 2009, GRAEF ARCH CLIN EXP, V247, P609, DOI 10.1007/s00417-008-1021-2
   Heilmann K, 1970, Ber Zusammenkunft Dtsch Ophthalmol Ges, V70, P599
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Herrmann J, 1975, Birth Defects Orig Artic Ser, V11, P203
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Horle S, 2000, OPHTHALMOLOGICA, V214, P122, DOI 10.1159/000027480
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Jacobsen N, 2008, INVEST OPHTH VIS SCI, V49, P1322, DOI 10.1167/iovs.07-1144
   Jobling AI, 2004, J BIOL CHEM, V279, P18121, DOI 10.1074/jbc.M400381200
   Kojima A, 2006, ACTA OPHTHALMOL SCAN, V84, P749, DOI 10.1111/j.1600-0420.2006.00745.x
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P311, DOI 10.1007/s00417-008-0995-0
   Ladas ID, 2003, EUR J OPHTHALMOL, V13, P729, DOI 10.1177/112067210301300813
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Lam CY, 2008, INVEST OPHTH VIS SCI, V49, P3768, DOI 10.1167/iovs.07-1126
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Legeais JM, 1997, J FR OPHTALMOL, V20, P31
   LEVY JH, 1977, ANN OPHTHALMOL, V9, P1433
   Li YJ, 2009, INVEST OPHTH VIS SCI, V50, P3116, DOI 10.1167/iovs.08-2781
   Lopes MC, 2009, INVEST OPHTH VIS SCI, V50, P126, DOI 10.1167/iovs.08-2385
   Ruiz-Moreno JM, 2006, J REFRACT SURG, V22, P689
   Mandal S, 2007, EUR J OPHTHALMOL, V17, P620, DOI 10.1177/112067210701700422
   Marr JE, 2001, EYE, V15, P70, DOI 10.1038/eye.2001.17
   Marticorena J, 2006, AM J OPHTHALMOL, V142, P335, DOI 10.1016/j.ajo.2006.03.003
   Matsuda Satoshi, 2002, Nippon Ganka Gakkai Zasshi, V106, P708
   McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179
   McBrien NA, 2009, OPTOMETRY VISION SCI, V86, P23, DOI 10.1097/OPX.0b013e3181940669
   METGE P, 1994, MYOPIE FORTE, P14
   METLAPALLY R, 2009, INVEST OPHT IN PRESS
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller DG, 2001, CURR OPIN OPHTHALMOL, V12, P222, DOI 10.1097/00055735-200106000-00014
   Mones JM, 2009, EYE, V23, P1276, DOI 10.1038/eye.2009.88
   Montero JA, 2003, BRIT J OPHTHALMOL, V87, P173, DOI 10.1136/bjo.87.2.173
   Montero JA, 2007, BRIT J OPHTHALMOL, V91, P131, DOI 10.1136/bjo.2006.106526
   Morillo Sanchez M J, 2001, Arch Soc Esp Oftalmol, V76, P357
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Naiglin L, 2002, J MED GENET, V39, P118, DOI 10.1136/jmg.39.2.118
   Nallasamy S, 2007, MOL VIS, V13, P229
   Neroev V V, 2009, Vestn Oftalmol, V125, P55
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nishizaki R, 2009, EYE, V23, P222, DOI 10.1038/eye.2008.152
   Norton Thomas T., 1999, ILAR J, V40, P59
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Ohno-Matsui Kyoko, 2004, Curr Opin Ophthalmol, V15, P197, DOI 10.1097/01.icu.0000120709.35941.e9
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Paget S, 2008, EXP EYE RES, V86, P290, DOI 10.1016/j.exer.2007.11.001
   Paluru P, 2003, INVEST OPHTH VIS SCI, V44, P1830, DOI 10.1167/iovs.02-0697
   Paluru PC, 2005, INVEST OPHTH VIS SCI, V46, P2300, DOI 10.1167/iovs.04-1423
   PEMBERTON JW, 1966, ARCH OPHTHALMOL-CHIC, V76, P817
   PHILLIPS JR, 1995, OPHTHAL PHYSL OPT, V15, P357, DOI 10.1016/0275-5408(95)00062-I
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Potter MJ, 2006, GRAEF ARCH CLIN EXP, V244, P639, DOI 10.1007/s00417-005-0115-3
   Pruett R C, 1988, Acta Ophthalmol Suppl, V185, P117
   PRUETT RC, 1994, PRINCIPLES PRACTICE, P878
   RABB M F, 1981, International Ophthalmology Clinics, V21, P51, DOI 10.1097/00004397-198102130-00006
   RAFTERY J, 2007, BR J OPHTHALMOL
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rheaume MA, 2008, CAN J OPHTHALMOL, V43, P576, DOI 10.3129/i08-104
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Riise R, 1988, Acta Ophthalmol Suppl, V185, P109
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   ROSNER M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1508
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   RUBEN M, 1976, BRIT J OPHTHALMOL, V60, P517, DOI 10.1136/bjo.60.7.517
   Ruiz-Moreno JM, 2008, BRIT J OPHTHALMOL, V92, P792, DOI 10.1136/bjo.2007.132795
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Ruiz-Moreno JM, 2009, EYE, V23, P334, DOI 10.1038/sj.eye.6703052
   Ruiz-Moreno JM, 2003, BRIT J OPHTHALMOL, V87, P856, DOI 10.1136/bjo.87.7.856
   Ruiz-Moreno JM, 2002, EUR J OPHTHALMOL, V12, P117, DOI 10.1177/112067210201200207
   Ruiz-Moreno JM, 2001, BRIT J OPHTHALMOL, V85, P1041, DOI 10.1136/bjo.85.9.1041
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Schache M, 2009, MOL VIS, V15, P722
   SCHWARTZ DE, 1972, AM J OPHTHALMOL, V73, P955, DOI 10.1016/0002-9394(72)90466-7
   SCHWARTZ M, 1990, CLIN GENET, V38, P281
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Shimada N, 2008, AM J OPHTHALMOL, V145, P155, DOI 10.1016/j.ajo.2007.08.029
   Shimada N, 2006, AM J OPHTHALMOL, V142, P497, DOI 10.1016/j.ajo.2006.03.048
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   SILVA RM, 2008, RETINA
   Silva RM, 2008, RETINA-J RET VIT DIS, V28, P1117, DOI 10.1097/IAE.0b013e31817eda41
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   SOUBRANE G, 1994, CHOROIDAL NEOVASCULA
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   SPALLONE A, 1987, BRIT J OPHTHALMOL, V71, P504, DOI 10.1136/bjo.71.7.504
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Syniuta L A, 2001, Binocul Vis Strabismus Q, V16, P203
   Tabandeh H, 1999, OPHTHALMOLOGY, V106, P2063, DOI 10.1016/S0161-6420(99)90484-0
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   Tokoro T, 1988, Acta Ophthalmol Suppl, V185, P107
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tong L, 2009, OPHTHALMOLOGY, V116, P572, DOI 10.1016/j.ophtha.2008.10.020
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P344, DOI 10.1001/archopht.118.3.344
   Valkova M, 1971, Cesk Oftalmol, V27, P65
   VANALPHEN GWHM, 1986, VISION RES, V26, P723, DOI 10.1016/0042-6989(86)90086-6
   Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   WALLMAN J, 1987, SCIENCE, V237, P73, DOI 10.1126/science.3603011
   Weng Lei-Ming, 2006, Yichuan, V28, P486
   WERTELECKI W, 1992, J PEDIATR-US, V121, P558, DOI 10.1016/S0022-3476(05)81144-8
   Wu PC, 2009, EYE, V23, P2042, DOI 10.1038/eye.2008.404
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
   YINON U, 1984, CURR EYE RES, V3, P677, DOI 10.3109/02713688409003072
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   Yoshida T, 2002, OPHTHALMOLOGY, V109, P712, DOI 10.1016/S0161-6420(01)01007-7
   Yu Zhi-qiang, 2007, Zhonghua Yan Ke Za Zhi, V43, P233
   ZADNIK K, 1995, VISION RES, V35, P1283, DOI 10.1016/0042-6989(94)00234-D
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang QJ, 2004, MOL VIS, V10, P890
   Zhou JH, 2005, MOL VIS, V11, P414
   Ziemssen F, 2009, KLIN MONATSBL AUGENH, V226, P31, DOI 10.1055/s-2008-1027763
   1986, 3 INT C MYOP ROM
NR 173
TC 20
Z9 22
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD MAY
PY 2010
VL 11
IS 5
BP 630
EP 644
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 573TU
UT WOS:000275938600012
PM 20196722
DA 2022-11-30
ER

PT J
AU Amrite, AC
   Kompella, UB
AF Amrite, Aniruddha C.
   Kompella, Uday B.
TI Celecoxib inhibits proliferation of retinal pigment epithelial and
   choroid-retinal endothelial cells by a cyclooxygenase-2-independent
   mechanism
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID PROSTATE-CANCER CELLS; GROWTH-FACTOR; CYCLO-OXYGENASE-2 INHIBITOR;
   CHOLANGIOCARCINOMA CELLS; MACULAR DEGENERATION; AKT INACTIVATION; COX-2
   INHIBITORS; BREAST-CANCER; RAT MODEL; APOPTOSIS
AB Age-related macular degeneration (ARMD) is a leading cause of blindness. The major reason for severe vision loss in ARMD is choroidal neovascularization due to an elevation in the expression of angiogenic factors such as vascular endothelial growth factor (VEGF). Drugs with anti-VEGF and antiproliferative activities can be beneficial for the treatment of this disorder. We have previously demonstrated that celecoxib [a selective cyclooxygenase (Cox)-2 inhibitor] inhibits VEGF expression in retinal pigment epithelial cells. In this study, we investigated the antiproliferative effects of celecoxib in adult retinal pigment epithelial (ARPE-19) and choroidal endothelial (RF/6A) cells. The results indicate that celecoxib 1) causes a dose-dependent antiproliferative effect in ARPE-19 and RF/6A cells (IC50 of 23 and 13 mu M, respectively); 2) leads to a G(2)-M phase cell cycle arrest in these cell types; and 3) inhibits VEGF-induced proliferation of RF6A cells (IC50 of 20 mu M). In addition, 4) the concentrations of celecoxib required for antiproliferative effects are lower than those required for the cytotoxicity. These effects of celecoxib are by mechanisms independent of its Cox-2 inhibitory activity because rofecoxib (another Cox-2 inhibitor) had no effects on the proliferation or cell cycle distribution of the two cell types, and flurbiprofen (an inhibitor of Cox-1 and Cox-2) had weak antiproliferative effects on ARPE-19 cells, with IC50 of 90 mu M. In summary, celecoxib has potent antiproliferative effects in RF/6A and ARPE-19 cells; thus, it can be a potential new treatment in proliferative disorders of the choroid-retina such as choroidal neovascularization in age-related macular degeneration.
C1 [Amrite, Aniruddha C.; Kompella, Uday B.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
   [Kompella, Uday B.] Univ Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Kompella, UB (通讯作者)，985840 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM ukompell@unmc.edu
RI Kompella, U/C-9789-2011
FU NEI NIH HHS [R03 EY013842, R24 EY017045, R21 EY017360] Funding Source:
   Medline; NIDDK NIH HHS [R01 DK064172, R01 DK064172-03] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R21EY017360, R03EY013842, R24EY017045]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [R01DK064172] Funding Source: NIH RePORTER
CR Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Ayalasomayajula SP, 2004, PHARM RES-DORDR, V21, P1797, DOI 10.1023/B:PHAM.0000045231.51924.e8
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Barnes NLP, 2007, BRIT J CANCER, V96, P575, DOI 10.1038/sj.bjc.6603593
   BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1
   Basu GD, 2005, BREAST CANCER RES, V7, pR422, DOI 10.1186/bcr1019
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   CHERUVU NP, 2007, INVEST OPHTH VIS SCI, V49, P333
   Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003
   Desai KGH, 2003, J CHEM ENG DATA, V48, P942, DOI 10.1021/je020213z
   Dvory-Sobol H, 2006, EUR J CANCER, V42, P422, DOI 10.1016/j.ejca.2005.11.009
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gadgeel SM, 2007, J THORAC ONCOL, V2, P299, DOI 10.1097/01.JTO.0000263712.61697.69
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Heath EI, 2007, J NATL CANCER I, V99, P545, DOI 10.1093/jnci/djk112
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Johnson W D, 2001, Cardiovasc Radiat Med, V2, P221, DOI 10.1016/S1522-1865(02)00130-0
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396
   Lai GH, 2003, MOL CANCER THER, V2, P265
   Leahy KM, 2002, CANCER RES, V62, P625
   Li P, 2003, J PHARM SCI, V92, P951, DOI 10.1002/jps.10360
   Lin HP, 2004, MOL CANCER THER, V3, P1671
   Nam DH, 2004, ONCOL REP, V11, P263
   Niederberger E, 2004, BIOCHEM PHARMACOL, V68, P341, DOI 10.1016/j.bcp.2004.03.029
   Prasit P, 1999, BIOORG MED CHEM LETT, V9, P1773, DOI 10.1016/S0960-894X(99)00288-7
   Raghava S, 2007, EUR J PHARMACOL, V568, P68, DOI 10.1016/j.ejphar.2007.04.044
   Riazi-Esfahani M, 2006, CORNEA, V25, P801, DOI 10.1097/01.ico.0000220768.11778.60
   Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599
   Seddon JM, 2006, RETINA, P1017
   Seedher N, 2003, AAPS PharmSciTech, V4, pE33
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313
   Soo RA, 2006, ANN ONCOL, V17, P1625, DOI 10.1093/annonc/mdl283
   Spaide RF., 2006, AGE RELATED MACULAR, P23
   Wu T, 2004, MOL CANCER THER, V3, P299
   Yang HM, 2004, CIRCULATION, V110, P301, DOI 10.1161/01.CIR.0000135467.43430.16
   Zhang ZC, 2004, HEPATOLOGY, V39, P1028, DOI 10.1002/hep.20143
NR 40
TC 27
Z9 30
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD FEB
PY 2008
VL 324
IS 2
BP 749
EP 758
DI 10.1124/jpet.107.128918
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 255CB
UT WOS:000252633200037
PM 18032574
DA 2022-11-30
ER

PT J
AU Kim, H
   Csaky, KG
AF Kim, Hyuncheol
   Csaky, Karl G.
TI Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal
   neovascularization in rats
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Choroidal neovascularization; Nanoparticles; Integrin antagonist;
   Intravitreal injection
ID OCULAR DRUG-DELIVERY; MACULAR DEGENERATION; CYTOMEGALOVIRUS RETINITIS;
   POLY(DL-LACTIC ACID); GANCICLOVIR IMPLANT; POSTERIOR SEGMENT;
   ALPHA(V)BETA(3); CELLS; MICROSPHERES; ANGIOGENESIS
AB Choroidal neovascularization (CNV) is the major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present drug delivery may be limited by poor delivery to the choroid where CNV originates. The goal of this study was to develop a drug delivery system to deliver an integrin-antagonist peptide to the sub-retinal space. We developed polylactic acid/polylactic acid-polyethylene oxide nanoparticles (PLA/PLA-PEO) encapsulating the water-soluble integrin-antagonist pepticle, C16Y (C16Y-NP). The PLA/PLA-PEO nanoparticles were 302 +/- 85.1 nm in size and demonstrated a two-week sustained release, in vitro, of encapsulated C16Y. Injected nanoparticles did not demonstrate retinal toxicity as determined by histopathology. C16Y pepticle solution or C16Y-NP was injected 5 or 9 days post laser photocoagulation. A single intravitreal injection of C16Y pepticle and C16Y-NP solution at both 5 days and 9 days post laser photocoagulation statistically inhibited CNV (p<0.05). However, for the day 5 injections the area of choroidal neovascularization on day 12 was smaller for C16Y-NP than for C16Y pepticle solution (p<0.05) because of the short vitreous half-life of C16Y pepticle solution. These results demonstrate the importance of sustained release delivery for the treatment of choroidal neovascularization associated with age-related macular degeneration. The intravitreally administered PLA/PLA-PEO containing coumarin was found to penetrate the retina and localize to the RPE. These results suggest that nanoparticles of biodegradable polymers may be a potential useful delivery system for intravitreal injection of drugs in the treatment of AMD. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Kim, Hyuncheol] Sogang Univ, Seoul 121742, South Korea.
   [Csaky, Karl G.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Sogang University; Duke University
RP Kim, H (通讯作者)，Sogang Univ, 1 Shinsu Dong, Seoul 121742, South Korea.
EM hyuncheol@sogang.ac.kr
FU Sogang University internal research [200910005.01]
FX The work is supported in part by Sogang University internal research
   grant (200910005.01). The authors are grateful to Dr. Peter M. Bungay,
   National Institutes of Health, for his kind help and useful suggestions.
CR Bejjani R, 2005, MOL VIS, V11, P124
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Capello A, 2006, J NUCL MED, V47, P122
   Chen XY, 2006, MINI-REV MED CHEM, V6, P227, DOI 10.2174/138955706775475975
   Coombes AGA, 1998, J CONTROL RELEASE, V52, P311, DOI 10.1016/S0168-3659(98)00006-6
   de Kozak Y, 2004, EUR J IMMUNOL, V34, P3702, DOI 10.1002/eji.200425022
   Durairaj C, 2009, PHARM RES-DORDR, V26, P1236, DOI 10.1007/s11095-008-9728-7
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fialho SL, 2005, DRUG DELIV, V12, P109, DOI 10.1080/10717540590921432
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grayson ACR, 2004, J BIOMAT SCI-POLYM E, V15, P1281, DOI 10.1163/1568562041959991
   Gref R, 2003, BIOMATERIALS, V24, P4529, DOI 10.1016/S0142-9612(03)00348-X
   He Y, 2006, J OCUL PHARMACOL TH, V22, P121, DOI 10.1089/jop.2006.22.121
   Hironaka K, 2009, J CONTROL RELEASE, V136, P247, DOI 10.1016/j.jconrel.2009.02.020
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   Kerr JS, 2001, DRUG NEWS PERSPECT, V14, P143
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim H, 2009, PHARM RES-DORDR, V26, P329, DOI 10.1007/s11095-008-9745-6
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   Lee WK, 2005, J CONTROL RELEASE, V105, P77, DOI 10.1016/j.jconrel.2005.03.009
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Martinez-Sancho C, 2003, J MICROENCAPSUL, V20, P799, DOI 10.1080/02652040310001600532
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Morita Y, 1998, BIOL PHARM BULL, V21, P188
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018
   NISHIHARA H, 1991, ACTA SOC OPHTHALMOL, V95, P951
   Pannicke T, 2005, J NEUROIMMUNOL, V161, P145, DOI 10.1016/j.jneuroim.2005.01.003
   Panyam J, 2003, PHARM RES-DORDR, V20, P212, DOI 10.1023/A:1022219003551
   Ponce ML, 2003, EXP CELL RES, V285, P189, DOI 10.1016/S0014-4827(03)00056-9
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   Shane TS, 2003, AM J OPHTHALMOL, V136, P649, DOI 10.1016/S0002-9394(03)00333-7
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Solheim E, 2000, J BIOMED MATER RES, V49, P257, DOI 10.1002/(SICI)1097-4636(200002)49:2<257::AID-JBM15>3.0.CO;2-5
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4
   Speicher Matthew A, 2003, Expert Opin Emerg Drugs, V8, P239, DOI 10.1517/14728214.8.1.239
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Yasuda M, 2004, LIFE SCI, V75, P421, DOI 10.1016/j.lfs.2003.12.021
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
NR 50
TC 55
Z9 55
U1 2
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 3
PY 2010
VL 142
IS 2
BP 286
EP 293
DI 10.1016/j.jconrel.2009.10.031
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 573OG
UT WOS:000275922800019
PM 19895863
DA 2022-11-30
ER

PT J
AU Polat, OA
   Cetinkaya, Z
   Evereklioglu, C
   Karaca, C
   Erkilic, K
AF Polat, Osman A.
   Cetinkaya, Zekeriya
   Evereklioglu, Cem
   Karaca, Cagatay
   Erkilic, Kuddusi
TI Effect of Repeated Topical Povidone-Iodine and Antibiotic Applications
   on Meibomian Glands and Ocular Surface Parameters in Patients With
   Repeated Intravitreal Injections
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Article
DE Intravitreal injection; Povidone-iodine; Antibiotics; Meibomian gland
   loss; Ocular surface
ID ANTIGLAUCOMA MEDICATIONS; DYSFUNCTION
AB Objectives: To assess whether meibomian glands and ocular surface parameters are affected by repeated topical povidone-iodine and antibiotic applications in patients with repeated intravitreal injections. Methods: Forty-five patients with at least three previous intravitreal injections and 28 healthy controls were included in the study. In the injection group, 21 patients had age-related macular degeneration and 24 patients had diabetic macular edema. For each participant, infrared meibography for the upper and lower eyelids and noninvasive tear break-up time calculation were performed with a corneal topographer. Fluorescein tear break-up time and ocular surface disease index (OSDI) scores were also obtained. Noninvasive tear break-up time, fluorescein tear break-up time, and OSDI scores were recorded for each participant and compared between the injection and control groups. These parameters were also compared as a subgroup analysis between patients with age-related macular degeneration (AMD) and diabetic macular edema (DME). Results: Upper lid meibomian gland loss, lower lid meibomian gland loss ratios, and OSDI scores were significantly higher in the intravitreal injection group compared with the control group (P=0.004, P<0.001, P<0.001, respectively). Fluorescein tear break-up time and noninvasive tear break-up time were significantly lower in the intravitreal injection group compared with the control group (P<0.001, P<0.001). There was no significant difference between the AMD and DME groups for these parameters. Conclusion: This study showed for the first time that meibomian gland losses were significantly increased by repeated povidone-iodine and antibiotic applications in patients with repeated intravitreal injections. Ocular surface parameters were altered with higher ocular surface symptoms in those patients.
C1 [Polat, Osman A.; Evereklioglu, Cem; Karaca, Cagatay; Erkilic, Kuddusi] Erciyes Univ, Fac Med, Dept Ophthalmol, Kayseri, Turkey.
   [Cetinkaya, Zekeriya] Kahramanmaras Elbistan State Hosp, Dept Ophthalmol, Kahmaranmaras, Turkey.
C3 Erciyes University
RP Polat, OA (通讯作者)，Erciyes Univ, Fac Med, Dept Ophthalmol, Kayseri, Turkey.
EM osmanahmet@gmail.com
OI Polat, Osman Ahmet/0000-0002-3905-4941
CR Ali FS., 2020, OPHTHALMOL RETINA, V20, P30458
   Arita R, 2012, CORNEA, V31, P1229, DOI 10.1097/ICO.0b013e31823f8e7d
   Arita R, 2012, GRAEF ARCH CLIN EXP, V250, P1181, DOI 10.1007/s00417-012-1943-6
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156431
   Geerling G, 2017, OCUL SURF, V15, P179, DOI 10.1016/j.jtos.2017.01.006
   Grzybowski A, 2018, CURR OPIN OPHTHALMOL, V29, P19, DOI 10.1097/ICU.0000000000000437
   Sevim DG, 2020, EYE CONTACT LENS, V46, pS135, DOI 10.1097/ICL.0000000000000651
   Hunyor AP, 2018, ACTA OPHTHALMOL, V96, P435, DOI 10.1111/aos.13417
   Jiang XD, 2018, DRUG DES DEV THER, V12, P1269, DOI 10.2147/DDDT.S146556
   Knop E, 2011, INVEST OPHTH VIS SCI, V52, P1938, DOI 10.1167/iovs.10-6997c
   Laude A, 2017, CLIN OPHTHALMOL, V11, P1491, DOI 10.2147/OPTH.S136500
   Lee SY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218886
   Lin XL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3047867
   Mocan MC, 2016, J GLAUCOMA, V25, P770, DOI 10.1097/IJG.0000000000000495
   Mostafa EM, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2965872
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Pult H, 2013, CONTACT LENS ANTERIO, V36, P22, DOI 10.1016/j.clae.2012.10.074
   Ridder WH, 2017, OPTOMETRY VISION SCI, V94, P732, DOI 10.1097/OPX.0000000000001091
   Sabeti S, 2020, SURV OPHTHALMOL, V65, P205, DOI 10.1016/j.survophthal.2019.08.007
   Saedon H, 2017, CUTAN OCUL TOXICOL, V36, P343, DOI 10.1080/15569527.2017.1291665
   Schargus M, 2020, CLIN OPHTHALMOL, V14, P897, DOI 10.2147/OPTH.S207978
   Schmidl D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080589
   Srinivasan S, 2012, OPTOMETRY VISION SCI, V89, P788, DOI 10.1097/OPX.0b013e318253de93
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoo TK, 2019, INT OPHTHALMOL, V39, P2611, DOI 10.1007/s10792-019-01110-y
NR 25
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD DEC
PY 2021
VL 47
IS 12
BP 651
EP 654
DI 10.1097/ICL.0000000000000828
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5B1TG
UT WOS:000863357900006
PM 34570021
DA 2022-11-30
ER

PT J
AU Kahloun, R
   Khairallah, M
   Resnikoff, S
   Cicinelli, MV
   Flaxman, SR
   Das, A
   Jonas, JB
   Keeffe, JE
   Kempen, JH
   Leasher, J
   Limburg, H
   Naidoo, K
   Pesudovs, K
   Silvester, AJ
   Tahhan, N
   Taylor, HR
   Wong, TY
   Bourne, RRA
AF Kahloun, Rim
   Khairallah, Moncef
   Resnikoff, Serge
   Cicinelli, Maria Vittoria
   Flaxman, Seth R.
   Das, Aditi
   Jonas, Jost B.
   Keeffe, Jill E.
   Kempen, John H.
   Leasher, Janet
   Limburg, Hans
   Naidoo, Kovin
   Pesudovs, Konrad
   Silvester, Alexander J.
   Tahhan, Nina
   Taylor, Hugh R.
   Wong, Tien Yin
   Bourne, Rupert R. A.
CA Vision Loss Expert Grp Global
TI Prevalence and causes of vision loss in North Africa and Middle East in
   2015: magnitude, temporal trends and projections
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE North Africa and the Middle East; blindness; vision impairment;
   cataract; uncorrected refractive error; epidemiology
ID VISUAL IMPAIRMENT; DIABETIC-RETINOPATHY; AVOIDABLE BLINDNESS; GLOBAL
   PREVALENCE; CATARACT-SURGERY; RAPID ASSESSMENT; WORLDWIDE; DISTANCE
AB Background To assess the prevalence and causes of vision impairment in North Africa and the Middle East (NAME) from 1990 to 2015 and to forecast projections for 2020. Methods Based on a systematic review of medical literature, the prevalence of blindness (presenting visual acuity (PVA) <3/60 in the better eye), moderate and severe vision impairment (MSVI; PVA <6/18 but >= 3/60) and mild vision impairment (PVA <6/12 but >= 6/18) was estimated for 2015 and 2020. Results The age-standardised prevalence of blindness and MSVI for all ages and genders decreased from 1990 to 2015, from 1.72 (0.53-3.13) to 0.95% (0.32%-1.71%), and from 6.66 (3.09-10.69) to 4.62% (2.21%-7.33%), respectively, with slightly higher figures for women than men. Cataract was the most common cause of blindness in 1990 and 2015, followed by uncorrected refractive error. Uncorrected refractive error was the leading cause of MSVI in the NAME region in 1990 and 2015, followed by cataract. A reduction in the proportions of blindness and MSVI due to cataract, corneal opacity and trachoma is predicted by 2020. Conversely, an increase in the proportion of blindness attributable to uncorrected refractive error, glaucoma, age-related macular degeneration and diabetic retinopathy is expected. Conclusions In 2015 cataract and uncorrected refractive error were the major causes of vision loss in the NAME region. Proportions of vision impairment from cataract, corneal opacity and trachoma are expected to decrease by 2020, and those from uncorrected refractive error, glaucoma, diabetic retinopathy and age-related macular degeneration are predicted to increase by 2020.
C1 [Kahloun, Rim] Les Ophtalmologistes Associes Monastir, Monastir, Tunisia.
   [Khairallah, Moncef] Univ Monastir, Fattouma Bourguiba Univ Hosp, Dept Ophthalmol, Fac Med, Monastir, Tunisia.
   [Resnikoff, Serge; Naidoo, Kovin; Tahhan, Nina] Brien Holden Vision Inst, Sydney, NSW, Australia.
   [Resnikoff, Serge; Tahhan, Nina] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Cicinelli, Maria Vittoria] Ist Sci San Raffaele, Milan, Italy.
   [Flaxman, Seth R.] Imperial Coll London, Dept Math & Data Sci Inst, London, England.
   [Das, Aditi] Hlth Educ Yorkshire & Humber, London, England.
   [Jonas, Jost B.] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Keeffe, Jill E.] LV Prasad Eye Inst, Hyderabad, India.
   [Kempen, John H.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Kempen, John H.] MyungSung Christian Med Ctr & Med Sch, Discovery Eye Ctr, Addis Ababa, Ethiopia.
   [Leasher, Janet] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Naidoo, Kovin] Univ Kwazulu Natal, African Vis Res Inst, Durban, South Africa.
   [Pesudovs, Konrad] 5 Rose St, Glenelg, SA, Australia.
   [Silvester, Alexander J.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat Hlth, Parkville, Vic, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Singapore Eye Res Inst, Duke NUS Grad Med Sch, Singapore, Singapore.
   [Bourne, Rupert R. A.] Anglia Ruskin Univ, Sch Med, Vis & Eye Res Unit, Cambridge, England.
C3 Universite de Monastir; Hopital Fattouma Bourguiba; Brien Holden Vision
   Institute; University of New South Wales Sydney; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Imperial College
   London; Ruprecht Karls University Heidelberg; L. V. Prasad Eye
   Institute; Harvard University; Massachusetts Eye & Ear Infirmary; Nova
   Southeastern University; University of Kwazulu Natal; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; Anglia Ruskin
   University; University of Cambridge
RP Khairallah, M (通讯作者)，Univ Monastir, Fattouma Bourguiba Univ Hosp, Dept Ophthalmol, Fac Med, Monastir, Tunisia.
EM moncef.khairallah@yahoo.fr
RI Wong, Tien Yin/AAC-9724-2020; Resnikoff, Serge/N-2355-2019; Tejedor,
   Jaime/G-7728-2015; Naidoo, Kovin Shunmugam/AAF-5914-2020; cicinelli,
   maria vittoria/M-1611-2019; Kahloun, Rim/O-6421-2015; Leasher,
   Janet/B-8889-2016
OI Wong, Tien Yin/0000-0002-8448-1264; Resnikoff,
   Serge/0000-0002-5866-4446; cicinelli, maria
   vittoria/0000-0003-2938-0409; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Jonas, Jost/0000-0003-2972-5227; Tejedor
   Fraile, Jaime/0000-0001-5507-5622; Leasher, Janet/0000-0002-8779-5162;
   Pesudovs, Konrad/0000-0002-6322-9369; Kempen, John/0000-0002-2967-4792
FU Brien Holden Vision Institute
FX This study was funded by the Brien Holden Vision Institute. The results
   in this paper are prepared independent of the final estimates of the
   Global Burden of Diseases, Injuries, and Risk Factors Study.
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   Al Ghamdi AH, 2012, BRIT J OPHTHALMOL, V96, P1168, DOI 10.1136/bjophthalmol-2012-301874
   Al-Akily SA, 2017, SAUDI J OPHTHALMOL, V31, P25, DOI 10.1016/j.sjopt.2016.11.007
   [Anonymous], 2018, WSD13 REPORT UNIVERS
   [Anonymous], 2018, GLOBAL ACTION PLAN E
   [Anonymous], 2018, GUIDELINES SCH EYE H
   [Anonymous], 2018, GLOBAL ACTION PLAN I
   [Anonymous], 2018, GLOBAL VISION DATABA
   Bourne R, 2013, OPHTHAL EPIDEMIOL, V20, P33, DOI 10.3109/09286586.2012.741279
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gelman A, 2014, TEXTS STAT SCI, V3rd
   Kahloun R, 2014, EYE, V28, P986, DOI 10.1038/eye.2014.131
   Katibeh M, 2017, OPHTHAL EPIDEMIOL, V24, P381, DOI 10.1080/09286586.2017.1307993
   Kempen JH, 2011, OPHTHAL EPIDEMIOL, V18, P99, DOI 10.3109/09286586.2011.588908
   Khairallah M, 2015, INVEST OPHTH VIS SCI, V56, P6762, DOI 10.1167/iovs.15-17201
   Khairallah M, 2014, BRIT J OPHTHALMOL, V98, P605, DOI 10.1136/bjophthalmol-2013-304068
   Khandekar R, 2009, INDIAN J OPHTHALMOL, V57, P443, DOI 10.4103/0301-4738.57153
   Khanna R, 2011, CURR OPIN OPHTHALMOL, V22, P10, DOI 10.1097/ICU.0b013e3283414f50
   Mansouri K, 2013, GRAEF ARCH CLIN EXP, V251, P2609, DOI 10.1007/s00417-013-2464-7
   Mohammadi Seyed-Farzad, 2014, J Ophthalmic Vis Res, V9, P3
   Mohammadpour M, 2016, J CURR OPHTHALMOL, V28, P165, DOI 10.1016/j.joco.2016.08.011
   Rabiu MM, 2013, OPHTHAL EPIDEMIOL, V20, P26, DOI 10.3109/09286586.2012.746994
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   United Nations Department of Economic and Social Affairs, 2015, WORLD POP PROSP 2015
NR 27
TC 9
Z9 9
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2019
VL 103
IS 7
BP 863
EP 870
DI 10.1136/bjophthalmol-2018-312068
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF4HJ
UT WOS:000473042100001
PM 30209082
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Joseph, K
   Kulik, L
   Coughlin, B
   Kunchithapautham, K
   Bandyopadhyay, M
   Thiel, S
   Thielens, NM
   Holers, VM
   Rohrer, B
AF Joseph, Kusumam
   Kulik, Liudmila
   Coughlin, Beth
   Kunchithapautham, Kannan
   Bandyopadhyay, Mausumi
   Thiel, Steffen
   Thielens, Nicole M.
   Holers, V. Michael
   Rohrer, Baerbel
TI Oxidative Stress Sensitizes Retinal Pigmented Epithelial (RPE) Cells to
   Complement-mediated Injury in a Natural Antibody-, Lectin Pathway-, and
   Phospholipid Epitope-dependent Manner
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INDUCED CHOROIDAL NEOVASCULARIZATION; LIPID-PEROXIDATION PRODUCTS;
   MACULAR DEGENERATION AMD; MEMBRANE-ATTACK-COMPLEX; MANNOSE-BINDING
   LECTIN; FACTOR-H; ISCHEMIA/REPERFUSION INJURY; SERINE-PROTEASE;
   ALTERNATIVE PATHWAY; REPERFUSION INJURY
AB Uncontrolled activation of the alternative complement pathway (AP) is thought to be associated with age-related macular degeneration. Previously, we have shown that in retinal pigmented epithelial (RPE) monolayers, oxidative stress reduced complement inhibition on the cell surface, resulting in sublytic complement activation and loss of transepithelial resistance (TER), but the potential ligand and pathway involved are unknown. ARPE-19 cells were grown as monolayers on transwell plates, and sublytic complement activation was induced with H2O2 and normal human serum. TER deteriorated rapidly in H2O2-exposed monolayers upon adding normal human serum. Although the effect required AP activation, AP was not sufficient, because elimination of MASP, but not C1q, prevented TER reduction. Reconstitution experiments to unravel essential components of the lectin pathway (LP) showed that both ficolin and mannan-binding lectin can activate the LP through natural IgM antibodies (IgM-C2) that recognize phospholipid cell surface modifications on oxidatively stressed RPE cells. The same epitopes were found on human primary embryonic RPE monolayers. Likewise, mouse laser-induced choroidal neovascularization, an injury that involves LP activation, could be increased in antibody-deficient rag1(-/-) mice using the phospholipid-specific IgM-C2. In summary, using a combination of depletion and reconstitution strategies, we have shown that the LP is required to initiate the complement cascade following natural antibody recognition of neoepitopes, which is then further amplified by the AP. LP activation is triggered by IgM bound to phospholipids. Taken together, we have defined novel mechanisms of complement activation in oxidatively stressed RPE, linking molecular events involved in age-related macular degeneration, including the presence of natural antibodies and neoepitopes.
C1 [Joseph, Kusumam; Coughlin, Beth; Kunchithapautham, Kannan; Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Kulik, Liudmila; Holers, V. Michael] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO 80045 USA.
   [Thiel, Steffen] Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.
   [Thielens, Nicole M.] Univ Grenoble 1, CNRS, Inst Biol Struct, UMR 5075 CEA, F-38027 Grenoble 1, France.
   [Rohrer, Baerbel] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
C3 Medical University of South Carolina; University of Colorado System;
   University of Colorado Anschutz Medical Campus; Aarhus University;
   UDICE-French Research Universities; Communaute Universite Grenoble
   Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la
   Recherche Scientifique (CNRS); US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center
RP Rohrer, B (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA.
EM rohrer@musc.edu
RI Thielens, Nicole M/F-2512-2013
OI Thielens, Nicole M/0000-0002-7354-0302; Thiel,
   Steffen/0000-0002-4817-155X
FU National Institutes of Health Grant [R01EY019320, C06 RR015455];
   Department of Veterans Affairs Grant [I01 RX000444]; Foundation Fighting
   Blindness; Research to Prevent Blindness, Inc. (New York); NATIONAL
   CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY019320] Funding Source: NIH
   RePORTER; Veterans Affairs [I01RX000444] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01EY019320. This work was also supported by Department of
   Veterans Affairs Grant I01 RX000444, Foundation Fighting Blindness, and
   an unrestricted grant to the Medical University of South Carolina from
   Research to Prevent Blindness, Inc. (New York). Animal studies were
   conducted in a facility constructed with support from National
   Institutes of Health Grant C06 RR015455.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Banda NK, 2011, MOL IMMUNOL, V49, P281, DOI 10.1016/j.molimm.2011.08.021
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Faro J, 2008, CLIN EXP IMMUNOL, V151, P275, DOI 10.1111/j.1365-2249.2007.03538.x
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fleming SD, 2002, J IMMUNOL, V169, P2126, DOI 10.4049/jimmunol.169.4.2126
   Fraser DA, 2009, J IMMUNOL, V183, P6175, DOI 10.4049/jimmunol.0902232
   Frederiksen PD, 2005, SCAND J IMMUNOL, V62, P462, DOI 10.1111/j.1365-3083.2005.01685.x
   Gounopoulos P, 2007, Minerva Cardioangiol, V55, P821
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haas MS, 2010, CARDIOVASC RES, V87, P618, DOI 10.1093/cvr/cvq141
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jensenius JC, 2003, BIOCHEM SOC T, V31, P763, DOI 10.1042/BST0310763
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lacroix M, 2009, J IMMUNOL, V182, P456, DOI 10.4049/jimmunol.182.1.456
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   National Advisory Eye Council, 1999, VIS RES NAT PLAN 199
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Rajagopalan R, 2009, IMMUNOL LETT, V123, P114, DOI 10.1016/j.imlet.2009.02.013
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Rohrer B, 2012, OXID STRESS APPL BAS, P47, DOI 10.1007/978-1-61779-606-7_2
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rutar M, 2012, ADV EXP MED BIOL, V723, P31, DOI 10.1007/978-1-4614-0631-0_5
   Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Takahashi M, 2007, ADV EXP MED BIOL, V598, P93
   Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329
   Tateishi K, 2011, MICROBIOL IMMUNOL, V55, P817, DOI 10.1111/j.1348-0421.2011.00378.x
   Thiel S, 2009, J IMMUNOL, V182, P2939, DOI 10.4049/jimmunol.0802053
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Zacho RM, 2012, J BIOL CHEM, V287, P8071, DOI 10.1074/jbc.M111.301044
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang M, 2004, P NATL ACAD SCI USA, V101, P3886, DOI 10.1073/pnas.0400347101
   Zhang M, 2006, J IMMUNOL, V177, P4727, DOI 10.4049/jimmunol.177.7.4727
NR 69
TC 50
Z9 52
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2013
VL 288
IS 18
BP 12753
EP 12765
DI 10.1074/jbc.M112.421891
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 139AZ
UT WOS:000318555100032
PM 23493397
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Crawford, Y
   Ferrara, N
AF Crawford, Yongping
   Ferrara, Napoleone
TI Tumor and stromal pathways mediating refractoriness/resistance to
   anti-angiogenic therapies
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Review
ID ENDOTHELIAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE;
   MONOCLONAL-ANTIBODY; PDGF-C; PROLONGS SURVIVAL; SUPPRESSOR-CELLS;
   PROSTATE-CANCER; INHIBITS GROWTH; VEGF-A; METASTASIS
AB Identification and characterization of VEGF as an important regulator of angiogenesis, and FDA approval of the first anti-angiogenic drugs, has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease recurrence. Recent studies in several experimental models suggest that tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies.
C1 [Crawford, Yongping; Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3
   Cao YH, 2008, J MOL MED, V86, P785, DOI 10.1007/s00109-008-0337-z
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
   Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123
   Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227
   Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Gandhi L, 2009, CANCER PREV RES, V2, P330, DOI 10.1158/1940-6207.CAPR-08-0213
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Hainsworth JD, 2007, CLIN GENITOURIN CANC, V5, P427, DOI 10.3816/CGC.2007.n.030
   He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inoue K, 2000, CLIN CANCER RES, V6, P2635
   Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4
   Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001
   Lang SA, 2008, MOL CANCER THER, V7, P3509, DOI 10.1158/1535-7163.MCT-08-0373
   LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Loizos N, 2005, MOL CANCER THER, V4, P369
   Lokker NA, 2002, CANCER RES, V62, P3729
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x
   Mantovani A, 2008, LANCET, V371, P771, DOI 10.1016/S0140-6736(08)60241-X
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x
   Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270
   Matsurnori Y, 2006, ONCOL RES, V16, P15, DOI 10.3727/000000006783981260
   Melnyk O, 1999, J UROLOGY, V161, P960, DOI 10.1016/S0022-5347(01)61829-9
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2
   Ninomiya S, 2009, J SURG RES, V154, P196, DOI 10.1016/j.jss.2008.08.017
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Padera TP, 2008, MOL CANCER THER, V7, P2272, DOI 10.1158/1535-7163.MCT-08-0182
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019
   Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80071-8
   Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005
   Shaheen RM, 1999, CANCER RES, V59, P5412
   Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Shojaei F, 2008, TRENDS CELL BIOL, V18, P372, DOI 10.1016/j.tcb.2008.06.003
   Shojaei F, 2008, P NATL ACAD SCI USA, V105, P2640, DOI 10.1073/pnas.0712185105
   Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Shojaei F, 2009, P NATL ACAD SCI USA, V106, P6742, DOI 10.1073/pnas.0902280106
   Shojaei F, 2008, DRUG RESIST UPDATE, V11, P219, DOI 10.1016/j.drup.2008.09.001
   Siekmann AF, 2008, BIOESSAYS, V30, P303, DOI 10.1002/bies.20736
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   Sweeney P, 2002, CLIN CANCER RES, V8, P2714
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770
   Verheul HMW, 2007, CLIN CANCER RES, V13, P4201, DOI 10.1158/1078-0432.CCR-06-2553
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857
   WOLMARK N, 2009, J CLIN ONCOL S, V27
   Xian XJ, 2006, J CLIN INVEST, V116, P642, DOI 10.1172/JCI25705
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
   Yuan L, 2002, DEVELOPMENT, V129, P4797
   Zhong CL, 2009, CLIN CANCER RES, V15, P2675, DOI 10.1158/1078-0432.CCR-08-1954
NR 100
TC 110
Z9 114
U1 1
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
EI 1873-3735
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD DEC
PY 2009
VL 30
IS 12
BP 624
EP 630
DI 10.1016/j.tips.2009.09.004
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 538YU
UT WOS:000273221200004
PM 19836845
DA 2022-11-30
ER

PT J
AU Zhao, X
   Das, AV
   Bhattacharya, S
   Thoreson, WB
   Sierra, JR
   Mallya, KB
   Ahmad, I
AF Zhao, Xing
   Das, Ani V.
   Bhattacharya, Sumitra
   Thoreson, Wallace B.
   Sierra, Jorge Rodriguez
   Mallya, Kavita B.
   Ahmad, Iqbal
TI Derivation of neurons with functional properties from adult limbal
   epithelium: Implications in autologous cell therapy for photoreceptor
   degeneration
SO STEM CELLS
LA English
DT Article
DE stem cells; limbal epithelium; regeneration; retina; photoreceptor;
   neurons
ID EMBRYONIC STEM-CELLS; MAMMALIAN EYE; IN-VITRO; RETINAL PROGENITOR; BASAL
   CELLS; CYCLE EXIT; DIFFERENTIATION; EXPRESSION; TRANSPLANTATION;
   IDENTIFICATION
AB The limbal epithelium (LE), a circular and narrow epithelium that separates cornea from conjunctiva, harbors stem cells/progenitors in its basal layer that regenerate cornea. We have previously demonstrated that cells in the basal LE, when removed from their niche and cultured in reduced bond morphogenetic protein signaling, acquire properties of neural progenitors. Here, we demonstrate that LE-derived neural progenitors generate neurons with functional properties and can be directly differentiated along rod photoreceptor lineage in vitro and in vivo. These observations posit the LE as a potential source of neural progenitors for antologous cell therapy to treat photoreceptor degeneration in age-related macular degeneration and retinitis pigmentosa.
C1 [Zhao, Xing; Das, Ani V.; Bhattacharya, Sumitra; Thoreson, Wallace B.; Mallya, Kavita B.; Ahmad, Iqbal] Univ Nebraska Med Ctr, Durham Res Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
   [Sierra, Jorge Rodriguez] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Ahmad, I (通讯作者)，Univ Nebraska Med Ctr, Durham Res Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
EM iahmad@unmc.edu
RI Thoreson, Wallace B./F-6172-2010
OI Thoreson, Wallace B./0000-0001-7104-042X; Rodriguez-Sierra,
   Jorge/0000-0003-3106-7411
CR Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Ahmad I, 2004, SEMIN CELL DEV BIOL, V15, P53, DOI 10.1016/j.semcdb.2003.09.003
   Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   Ahmad S, 2007, STEM CELLS, V25, P1145, DOI 10.1634/stemcells.2006-0516
   Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103
   ALTSHULER D, 1992, DEVELOPMENT, V114, P947
   BARNSTABLE CJ, 1987, IMMUNOL REV, V100, P47, DOI 10.1111/j.1600-065X.1987.tb00527.x
   Bhattacharya S, 2003, INVEST OPHTH VIS SCI, V44, P2764, DOI 10.1167/iovs.02-0899
   CARD JP, 1978, J COMP NEUROL, V180, P43, DOI 10.1002/cne.901800104
   Chacko DM, 2003, VISION RES, V43, P937, DOI 10.1016/S0042-6989(02)00688-0
   Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3
   CLOUGH RW, 1983, AM J ANAT, V167, P205, DOI 10.1002/aja.1001670206
   COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6
   Das Ani M, 2005, Semin Ophthalmol, V20, P3, DOI 10.1080/08820530590921882
   Das AV, 2006, DEV BIOL, V299, P283, DOI 10.1016/j.ydbio.2006.07.029
   Das AV, 2005, VISION RES, V45, P1653, DOI 10.1016/j.visres.2004.12.017
   De Paiva CS, 2005, STEM CELLS, V23, P63, DOI 10.1634/stemcells.2004-0093
   Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088
   Gage PJ, 2005, INVEST OPHTH VIS SCI, V46, P4200, DOI 10.1167/iovs.05-0691
   Grueterich M, 2003, SURV OPHTHALMOL, V48, P631, DOI 10.1016/j.survophthal.2003.08.003
   HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X
   Kawai F, 2001, NEURON, V30, P451, DOI 10.1016/S0896-6273(01)00299-9
   Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152
   Kubo F, 2005, DEVELOPMENT, V132, P2759, DOI 10.1242/dev.01856
   Lavker RM, 2004, EXP EYE RES, V78, P433, DOI 10.1016/j.exer.2003.09.008
   Lehrer MS, 1998, J CELL SCI, V111, P2867
   Li W, 2007, CELL RES, V17, P26, DOI 10.1038/sj.cr.7310137
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Masai I, 2005, DEVELOPMENT, V132, P1539, DOI 10.1242/dev.01714
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Pan ZH, 2000, J NEUROPHYSIOL, V84, P2564, DOI 10.1152/jn.2000.84.5.2564
   Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0
   Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098
   Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769
   Pevny L, 2003, TRENDS NEUROSCI, V26, P351, DOI 10.1016/S0166-2236(03)00169-3
   Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684
   Salero E, 2007, P NATL ACAD SCI USA, V104, P2997, DOI 10.1073/pnas.0610879104
   SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49
   Schlotzer-Schrehardt U, 2005, EXP EYE RES, V81, P247, DOI 10.1016/j.exer.2005.02.016
   Schwab IR, 2000, NEW ENGL J MED, V343, P136, DOI 10.1056/NEJM200007133430211
   Seigel GM, 2003, MOL VIS, V9, P159
   Shkumatava A, 2005, EMBO REP, V6, P563, DOI 10.1038/sj.embor.7400416
   Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844
   Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202
   Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657
   WATANABE T, 1992, DEVELOPMENT, V114, P899
   Zenisek D, 2001, J NEUROSCI, V21, P4543, DOI 10.1523/JNEUROSCI.21-13-04543.2001
   Zhao X, 2005, DEV DYNAM, V232, P349, DOI 10.1002/dvdy.20290
   Zhao X, 2002, DEV BIOL, V250, P317, DOI 10.1006/dbio.2002.0793
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   ZIESKE JD, 1992, DEV BIOL, V151, P18, DOI 10.1016/0012-1606(92)90209-Y
NR 53
TC 28
Z9 29
U1 0
U2 4
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD APR
PY 2008
VL 26
IS 4
BP 939
EP 949
DI 10.1634/stemcells.2007-0727
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 288QD
UT WOS:000255000000011
PM 18203675
DA 2022-11-30
ER

PT J
AU Kiss, C
   Michels, S
   Prager, F
   Geitzenauer, W
   Schmidt-Erfurth, U
AF Kiss, Christopher
   Michels, Stephan
   Prager, Franz
   Geitzenauer, Wolfgang
   Schmidt-Erfurth, Ursula
TI Retinal pigment epithelium tears following intravitreal ranibizumab
   therapy
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE ranibizumab; choroidal neovascularization; retinal pigment epithelium;
   age-related macular degeneration
ID MACULAR DEGENERATION; INJECTION
AB Two patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) developed a retinal pigment epithelial (RPE) tear following intravitreal injection of ranibizumab. One patient developed the RPE tear within 2 weeks of the injection, the other within 6 weeks of a second injection. Both patients presented with vision loss of one line at diagnosis of the RPE tear. During long-term follow-up, visual acuity improved in one patient by one line and deteriorated in the second patient by three lines. RPE tears may occur after intravitreal injection of ranibizumab in patients with neovascular AMD, probably because of the rapid regression of the. brovascular membrane.
C1 Med Univ Vienna, Dept Ophthalmol & Optometry, Univ Klin Augenheilkunde & Optometrie, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Michels, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Univ Klin Augenheilkunde & Optometrie, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM stephan.michels@meduniwien.ac.at
CR Amiel H, 2006, ACTA OPHTHALMOL SCAN, V84, P147, DOI 10.1111/j.1600-0420.2005.00606.x
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2006, ACTA OPHTHALMOL SCAN, V84, P560, DOI 10.1111/j.1600-0420.2006.00703.x
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 8
TC 23
Z9 26
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2007
VL 85
IS 8
BP 902
EP 903
DI 10.1111/j.1600-0420.2007.00928.x
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 232MY
UT WOS:000251025000019
PM 17408387
DA 2022-11-30
ER

PT J
AU Li, ZX
   Keel, S
   Liu, C
   He, MG
AF Li, Zhixi
   Keel, Stuart
   Liu, Chi
   He, Mingguang
TI Can Artificial Intelligence Make Screening Faster, More Accurate, and
   More Accessible?
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; screening
ID OPTICAL COHERENCE TOMOGRAPHY; OPEN-ANGLE GLAUCOMA; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; AUTOMATED DETECTION; GLOBAL PREVALENCE;
   POPULATION; DIAGNOSIS; FEATURES; COST
AB Diabetic retinopathy, glaucoma, and age-related macular degeneration are leading causes of vision loss and blindness worldwide. They tend to be asymptomatic in the early phase of disease and therefore require active screening programs to identify the patients requiring referral and treatment. Deep learning-based artificial intelligence technology has recently become a major topic in the field of ophthalmology. This paper aimed to provide a general view of the major findings on the application of deep learning for the classification of eye diseases from common imaging modalities. In the future, it is expected that these technologies will be applied in real-world screening programs to improve their efficiency and affordability.
C1 [Li, Zhixi; Liu, Chi; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Keel, Stuart; He, Mingguang] Univ Melbourne, Dept Surg, Ctr Eye Res Australia, Ophthalmol, Melbourne, Vic, Australia.
C3 Sun Yat Sen University; Centre for Eye Research Australia; University of
   Melbourne
RP He, MG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM mingguang.he@unimelb.edu.au
RI He, Mingguang/AAY-5239-2020
OI He, Mingguang/0000-0002-6912-2810
FU Fundamental Research Funds of the State Key Laboratory in Ophthalmology;
   National Natural Science Foundation of China [81420108008]; Science and
   Technology Planning Project of Guangdong Province [2013B20400003]; Bupa
   Health Foundation Australia grant; University of Melbourne Research
   Accelerator Program; Centre for Eye Research Australia (CERA) Foundation
FX Supported in part by the Fundamental Research Funds of the State Key
   Laboratory in Ophthalmology, National Natural Science Foundation of
   China (81420108008), Science and Technology Planning Project of
   Guangdong Province (2013B20400003), and the Bupa Health Foundation
   Australia grant. M.H. receives support from the University of Melbourne
   Research Accelerator Program and the Centre for Eye Research Australia
   (CERA) Foundation. The CERA receives operational infrastructure support
   from the Victoria state government. The sponsor or funding organization
   had no role in the design or conduct of this research.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   Adhi M, 2016, OSLI RETINA, V47, P410, DOI 10.3928/23258160-20160419-03
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Armstrong KL, 2012, INDIAN J OPHTHALMOL, V60, P475, DOI 10.4103/0301-4738.100554
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Baskaran M, 2015, JAMA OPHTHALMOL, V133, P874, DOI 10.1001/jamaophthalmol.2015.1110
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bowd C, 2012, INVEST OPHTH VIS SCI, V53, P2382, DOI 10.1167/iovs.11-7951
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chakrabarty L, 2016, J GLAUCOMA, V25, P590, DOI 10.1097/IJG.0000000000000354
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   ElTanboly A, 2017, MED PHYS, V44, P914, DOI 10.1002/mp.12071
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Ganesan K, 2014, MED BIOL ENG COMPUT, V52, P663, DOI 10.1007/s11517-014-1167-5
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Keel S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22612-2
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P65, DOI 10.1016/j.cmpb.2016.03.018
   Oh E, 2015, INVEST OPHTH VIS SCI, V56, P3957, DOI 10.1167/iovs.15-16805
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Pizzarello L, 2004, ARCH OPHTHALMOL-CHIC, V122, P615, DOI 10.1001/archopht.122.4.615
   Quigley HA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1819, DOI 10.1001/archopht.119.12.1819
   Ramachandran N, 2018, CLIN EXP OPHTHALMOL, V46, P412, DOI 10.1111/ceo.13056
   Reus NJ, 2010, OPHTHALMOLOGY, V117, P717, DOI 10.1016/j.ophtha.2009.09.026
   Salam AA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3175-4
   Sandhu HS, 2018, INVEST OPHTH VIS SCI, V59, P3155, DOI 10.1167/iovs.17-23677
   Silva FR, 2013, ARQ BRAS OFTALMOL, V76, P170, DOI 10.1590/S0004-27492013000300008
   Singh A, 2016, COMPUT METH PROG BIO, V124, P108, DOI 10.1016/j.cmpb.2015.10.010
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   US Food and Drug Administration, FDA PERM MARK ART IN
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Vujosevic S, 2009, AM J OPHTHALMOL, V148, P111, DOI 10.1016/j.ajo.2009.02.031
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
NR 58
TC 16
Z9 18
U1 0
U2 10
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD NOV-DEC
PY 2018
VL 7
IS 6
SI SI
BP 436
EP 441
DI 10.22608/APO.2018438
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ4RW
UT WOS:000457162600010
PM 30556381
OA gold
DA 2022-11-30
ER

PT J
AU Battaglia-Parodi, M
   Sheth, S
   Papayannis, A
   Bandello, F
AF Battaglia-Parodi, Maurizio
   Sheth, Saumil
   Papayannis, Alessandro
   Bandello, Francesco
TI Treatment of serous pigment epithelium detachment with subthreshold
   micropulse diode laser photocoagulation: a case report
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Serous pigment epithelium detachment; Subthreshold micropulse laser
ID NATURAL-HISTORY
AB PURPOSE. To propose a possible treatment for symptomatic serous pigment epithelium detachment (SPED) in the setting of dry age-related macular degeneration.
   METHODS. A 60-year-old woman presented with a SPED, subfoveal in location, enlarging in size and with gradually worsening vision over 1 year of follow-up, without any evidence of choroidal neovascular membrane or neurosensory detachment until it was treated with subthreshold micropulse laser.
   RESULTS. The last follow-up showed complete resolution of the SPED with restoration of visual function.
   CONCLUSIONS. Subthreshold micropulse laser could serve as a useful therapeutic modality for the treatment of symptomatic SPED. (Eur J Ophthalmol 2009; 19: 887-9)
C1 [Battaglia-Parodi, Maurizio; Papayannis, Alessandro; Bandello, Francesco] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Sheth, Saumil] Aditya Jyot Eye Hosp, Dept Vitreoretina, Bombay, Maharashtra, India.
C3 University of Udine; Aditya Jyot Eye Hospital
RP Bandello, F (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria della Misericordia, I-33100 Udine, Italy.
EM francesco.bandello@uniud.it
RI bandello, francesco/AAH-2405-2019; Papayannis, Alessandro/AAU-3035-2020
OI bandello, francesco/0000-0003-3238-9682; Papayannis,
   Alessandro/0000-0002-4876-7433; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Lanzetta P, 2008, EUR J OPHTHALMOL, V18, P934, DOI 10.1177/112067210801800613
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633
NR 7
TC 2
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2009
VL 19
IS 5
BP 887
EP 889
DI 10.1177/112067210901900501
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 520LF
UT WOS:000271845100034
PM 19787617
DA 2022-11-30
ER

PT J
AU Wong, TY
   Loon, SC
   Saw, SM
AF Wong, TY
   Loon, SC
   Saw, SM
TI The epidemiology of age related eye diseases in Asia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID TANJONG-PAGAR SURVEY; ARAVIND COMPREHENSIVE EYE; POPULATION-BASED
   SURVEY; OPEN-ANGLE GLAUCOMA; ELDERLY CHINESE POPULATION; SOUTH INDIAN
   POPULATION; LOW-VISION SURVEY; REFRACTIVE ERRORS; RISK-FACTORS;
   UNITED-STATES
AB In the past decade, several large population based studies have provided new information on the prevalence of visual impairment and the major age related eye diseases in Asia. These include epidemiological studies from India, Taiwan, Mongolia, Singapore, and Japan. In particular, the epidemiology of refractive errors and glaucoma has been well characterised, providing insights not only into the public health implications of these conditions, but also into anatomical changes of the eye with ageing. In contrast, there are few well conducted population based studies on diabetic retinopathy and age related macular degeneration in Asia, two conditions that are likely to be important causes of blindness in the future.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore 117548, Singapore.
   Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; National
   University of Singapore; National University of Singapore
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
CR BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   Bourne RRA, 2004, OPHTHALMOLOGY, V111, P1150, DOI 10.1016/j.ophtha.2003.09.046
   Bourne RRA, 2003, BRIT J OPHTHALMOL, V87, P1069, DOI 10.1136/bjo.87.9.1069
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   CHEN MS, 1992, AM J OPHTHALMOL, V114, P723, DOI 10.1016/S0002-9394(14)74051-6
   Cheng CY, 2003, INVEST OPHTH VIS SCI, V44, P4630, DOI 10.1167/iovs.03-0169
   CHENG CY, 2000, CHIN MED J TAIPEI, V63, P641
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2002, BRIT J OPHTHALMOL, V86, P18, DOI 10.1136/bjo.86.1.18
   Dandona L, 1999, BRIT J OPHTHALMOL, V83, P937, DOI 10.1136/bjo.83.8.937
   Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dandona L, 2000, OPHTHALMOLOGY, V107, P1710, DOI 10.1016/S0161-6420(00)00274-8
   Dandona L, 2000, OPHTHALMOLOGY, V107, P1702, DOI 10.1016/S0161-6420(00)00275-X
   Dandona R, 1999, INVEST OPHTH VIS SCI, V40, P2810
   Dandona R, 2003, BRIT J OPHTHALMOL, V87, P133, DOI 10.1136/bjo.87.2.133
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Dunzhu S, 2003, BRIT J OPHTHALMOL, V87, P1443, DOI 10.1136/bjo.87.12.1443
   Foster PJ, 2003, INVEST OPHTH VIS SCI, V44, P3885, DOI 10.1167/iovs.03-0012
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Foster PJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P1235, DOI 10.1001/archopht.1996.01100140435011
   Foster PJ, 2001, BRIT J OPHTHALMOL, V85, P1277, DOI 10.1136/bjo.85.11.1277
   Foster PJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1105, DOI 10.1001/archopht.118.8.1105
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gazzard G, 2002, BRIT J OPHTHALMOL, V86, P1341, DOI 10.1136/bjo.86.12.1341
   HE M, 2005, EYE             0121
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hu C, 1989, Zhonghua Yan Ke Za Zhi, V25, P360
   HU TS, 1989, ARCH OPHTHALMOL-CHIC, V107, P666, DOI 10.1001/archopht.1989.01070010684027
   Husain R, 2005, OPHTHALMOLOGY, V112, P1255, DOI 10.1016/j.ophtha.2005.02.015
   Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029
   Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Krishnadas R, 2003, AM J OPHTHALMOL, V135, P830, DOI 10.1016/S0002-9394(02)02271-7
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P58, DOI 10.1167/iovs.04-0089
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Lim AS, 1979, AUST J OPHTHALMOL, V7, P23
   Lin LLK, 1999, OPTOMETRY VISION SCI, V76, P275, DOI 10.1097/00006324-199905000-00013
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Narendran V, 2002, BRIT J OPHTHALMOL, V86, P1014, DOI 10.1136/bjo.86.9.1014
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nirmalan PK, 2003, INVEST OPHTH VIS SCI, V44, P4639, DOI 10.1167/iovs.03-0011
   Ojaimi E, 2005, INVEST OPHTH VIS SCI, V46, P2748, DOI 10.1167/iovs.04-1324
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   OSMAN A, 1988, MED J MALAYSIA, V43, P235
   Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P600, DOI 10.1136/bjo.82.6.600
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Rahman MM, 2004, BRIT J OPHTHALMOL, V88, P1493, DOI 10.1136/bjo.2004.043612
   Raju P, 2004, INVEST OPHTH VIS SCI, V45, P4268, DOI 10.1167/iovs.04-0221
   Ramakrishnan R, 2003, OPHTHALMOLOGY, V110, P1484, DOI 10.1016/S0161-6420(03)00564-5
   Rema M, 2005, INVEST OPHTH VIS SCI, V46, P2328, DOI 10.1167/iovs.05-0019
   Sasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4210, DOI 10.1167/iovs.01-1221
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P1075, DOI 10.1136/bjo.87.9.1075
   Saw SM, 2002, INVEST OPHTH VIS SCI, V43, P3174
   Saw SM, 2002, INVEST OPHTH VIS SCI, V43, P332
   Saw SM, 2004, OPHTHALMOLOGY, V111, P2168, DOI 10.1016/j.ophtha.2004.05.032
   Seah SKL, 1997, ARCH OPHTHALMOL-CHIC, V115, P1436, DOI 10.1001/archopht.1997.01100160606014
   Seah SKL, 2002, OPHTHALMOLOGY, V109, P2058, DOI 10.1016/S0161-6420(02)01221-6
   Seet B, 2001, BRIT J OPHTHALMOL, V85, P521, DOI 10.1136/bjo.85.5.521
   SHIOSE Y, 1991, JPN J OPHTHALMOL, V35, P133
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   Venkata G, 2005, BRIT J OPHTHALMOL, V89, P257, DOI 10.1136/bjo.2004.056937
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   Wickremasinghe S, 2004, INVEST OPHTH VIS SCI, V45, P776, DOI 10.1167/iovs.03-0456
   Wong TY, 1999, ARCH OPHTHALMOL-CHIC, V117, P379, DOI 10.1001/archopht.117.3.379
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Wong TY, 2001, AM J OPHTHALMOL, V131, P176, DOI 10.1016/S0002-9394(00)00703-0
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P73
   Wong TY, 2001, ARCH OPHTHALMOL-CHIC, V119, P727, DOI 10.1001/archopht.119.5.727
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P990, DOI 10.1136/bjo.84.9.990
   Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P1479, DOI 10.1167/iovs.02-0526
   World Health Organization, 1997, WHOPBL9761
   Xu J, 2002, BRIT J OPHTHALMOL, V86, P723, DOI 10.1136/bjo.86.7.723
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   XU L, 2005, OPHTHALMOLOGY   0817
   YAMAMOTO T, 2005, OPHTHALMOLOGY   0817
   Zainal M, 1998, Med J Malaysia, V53, P46
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P506, DOI 10.1016/S0002-9394(98)00275-X
NR 93
TC 221
Z9 230
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2006
VL 90
IS 4
BP 506
EP 511
DI 10.1136/bjo.2005.083733
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 023CH
UT WOS:000236102400031
PM 16547337
OA Green Published
DA 2022-11-30
ER

PT J
AU Fraser-Bell, S
   Symes, R
   Vaze, A
AF Fraser-Bell, Samantha
   Symes, Richard
   Vaze, Anagha
TI Hypertensive eye disease: a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE hypertension; retina; retinopathy
ID RETINAL VEIN OCCLUSION; AGE-RELATED MACULOPATHY; RISK-FACTORS;
   DIABETIC-RETINOPATHY; ATHEROSCLEROSIS RISK; CARDIOVASCULAR-DISEASE;
   PROGRESSION; PREVALENCE; COMPLICATIONS; OPHTHALMOLOGY
AB Hypertension is a risk factor for a number of vision-threatening eye conditions including retinal vascular occlusion, retinal macroaneurysm and non arteritic anterior ischaemic optic neuropathy. In addition, hypertension may exacerbate the vision-threatening effects of diabetic retinopathy and has been implicated in the pathogenesis of age-related macular degeneration. The effects of sustained hypertension are directly visible in the eye as hypertensive retinopathy and choroidopathy, reflecting a pathological process occurring throughout the body. Close collaboration between ophthalmologists and general practitioners/physicians is needed to ensure that hypertensive patients are identified and treated. Timely intervention in these patients may reduce the risk of both vision-threatening and systemic complications.
C1 [Fraser-Bell, Samantha; Symes, Richard; Vaze, Anagha] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Fraser-Bell, Samantha] Univ Sydney, Sydney Adventist Hosp Clin Sch, Sydney, NSW, Australia.
   [Fraser-Bell, Samantha; Symes, Richard] Sydney Eye Hosp, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Fraser-Bell, S (通讯作者)，Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
EM samantha.fraserbell@sydney.edu.au
RI Fraser-Bell, Samantha/ABE-8574-2020
OI Fraser-Bell, Samantha/0000-0001-5646-9359
CR Aissopou EK, 2015, J HYPERTENS, V33, P2303, DOI 10.1097/HJH.0000000000000702
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arguedas JA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004349.pub2
   Bourke Karyn, 2004, J Clin Hypertens (Greenwich), V6, P471, DOI 10.1111/j.1524-6175.2004.3749.x
   Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2443, DOI 10.1016/j.ophtha.2014.07.019
   Christoffersen NLB, 1999, OPHTHALMOLOGY, V106, P2054, DOI 10.1016/S0161-6420(99)90483-9
   Chua B, 2005, AM J OPHTHALMOL, V139, P181, DOI 10.1016/j.ajo.2004.06.084
   Cremer A, 2016, J HUM HYPERTENS, V30, P463, DOI 10.1038/jhh.2015.112
   DICKERSIN K, 1995, JAMA-J AM MED ASSOC, V273, P625, DOI 10.1001/jama.1995.03520320035038
   Ehlers JP, 2011, SURV OPHTHALMOL, V56, P281, DOI 10.1016/j.survophthal.2010.11.006
   FICHTE C, 1978, American Journal of Ophthalmology, V85, P509
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Gottlieb JL, 1998, ARCH OPHTHALMOL-CHIC, V116, P577, DOI 10.1001/archopht.116.5.577
   Greiner K, 1999, AM J OPHTHALMOL, V128, P69, DOI 10.1016/S0002-9394(99)00074-4
   GUYER DR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1136
   HANKEY GJ, 1991, BMJ-BRIT MED J, V302, P499, DOI 10.1136/bmj.302.6775.499
   Hayreh SS, 2011, PROG RETIN EYE RES, V30, P359, DOI 10.1016/j.preteyeres.2011.05.001
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7
   Hayreh SS, 2001, AM J OPHTHALMOL, V131, P61, DOI 10.1016/S0002-9394(00)00709-1
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P60
   HAYREH SS, 1980, ARCH OPHTHALMOL-CHIC, V98, P1600, DOI 10.1001/archopht.1980.01020040452011
   HSUEH WA, 1992, HYPERTENSION, V20, P253, DOI 10.1161/01.HYP.20.2.253
   Jackson TL, 2013, EYE, V27, P644, DOI 10.1038/eye.2013.12
   Jacobson DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1403, DOI 10.1001/archopht.1997.01100160573008
   Jeganathan VSE, 2008, BRIT J OPHTHALMOL, V92, P1393, DOI 10.1136/bjo.2008.141689
   Kattah AG, 2013, ADV CHRONIC KIDNEY D, V20, P229, DOI 10.1053/j.ackd.2013.01.014
   Kawasaki R, 2010, STROKE, V41, P1826, DOI 10.1161/STROKEAHA.110.585042
   Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 2000, T AM OPHTHAL SOC, V98, P133
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Liew G, 2009, HEART, V95, P391, DOI 10.1136/hrt.2008.146670
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Muraoka Y, 2013, AM J OPHTHALMOL, V156, P706, DOI 10.1016/j.ajo.2013.05.021
   Ong YT, 2013, HYPERTENSION, V62, P706, DOI 10.1161/HYPERTENSIONAHA.113.01414
   PATZ A, 1978, NEW ENGL J MED, V298, P1451, DOI 10.1056/NEJM197806292982605
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834
   Recchia F M, 2000, Curr Opin Ophthalmol, V11, P462, DOI 10.1097/00055735-200012000-00013
   Rucker JC, 2004, CURR OPIN NEUROL, V17, P27, DOI 10.1097/00019052-200402000-00006
   SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005
   Sharma S, 1996, ARCH OPHTHALMOL-CHIC, V114, P1189, DOI 10.1001/archopht.1996.01100140389004
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Stein JD, 2012, CURR OPIN OPHTHALMOL, V23, P219, DOI 10.1097/ICU.0b013e3283524068
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   van den Born BJH, 2005, BMJ-BRIT MED J, V331, P73, DOI 10.1136/bmj.331.7508.73
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   WELLER RO, 1979, AGE AGEING, V8, P99, DOI 10.1093/ageing/8.2.99
   who, GLOB BRIEF HYP SIL K
   Wijman CAC, 2004, STROKE, V35, pE100, DOI 10.1161/01.STR.0000125009.05353.7c
   WILSON LA, 1979, LANCET, V1, P292
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2008, AM J EPIDEMIOL, V167, P51, DOI 10.1093/aje/kwm256
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2005, JAMA-J AM MED ASSOC, V293, P63, DOI 10.1001/jama.293.1.63
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2004, J AM SOC NEPHROL, V15, P2469, DOI 10.1097/01.ASN.0000136133.28194.E4
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 68
TC 62
Z9 63
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2017
VL 45
IS 1
BP 45
EP 53
DI 10.1111/ceo.12905
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL5PY
UT WOS:000394674400006
PM 27990740
DA 2022-11-30
ER

PT J
AU Doshi, RR
   Lowrance, MD
   Kim, BT
   Davis, JL
   Rosenfeld, PJ
AF Doshi, Rishi R.
   Lowrance, Matthew D.
   Kim, Brian T.
   Davis, Janet L.
   Rosenfeld, Philip J.
TI Epiretinal Macular Edema Associated With Thick Epiretinal Membranes
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY
AB High-resolution imaging with spectral-domain optical coherence tomography has identified an unusual group of epiretinal membranes (ERMs) in the presence of lamellar macular holes. These ERMs are unusually thick. The authors present the case of a patient with age-related macular degeneration who developed edema within a thickened ERM in both eyes after cataract surgery. The edema resolved with anti-vascular endothelial growth factor (VEGF) therapy. The authors propose that the VEGF-responsive fluid within these thick ERMs arose from fibrovascular tissue derived from the retina. Further studies with histopathology will be required to determine whether neovascular tissue is present in all cases of thickened ERMs with epiretinal edema.
C1 [Doshi, Rishi R.; Lowrance, Matthew D.; Kim, Brian T.; Davis, Janet L.; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Davis, Janet L/GPC-8037-2022
OI Davis, Janet L/0000-0001-6395-5881
FU Research to Prevent Blindness, NEI core center [P30 EY014801];
   Department of Defense [W81XWH-09-1-0675]; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX Supported by an unrestricted grant from Research to Prevent Blindness,
   NEI core center grant P30 EY014801 to the University of Miami, and
   Department of Defense grant W81XWH-09-1-0675.
CR Arevalo JF, 2007, J CATARACT REFR SURG, V33, P2098, DOI 10.1016/j.jcrs.2007.07.046
   FOOS RY, 1977, INVEST OPHTH VIS SCI, V16, P416
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   Parolini B, 2011, INVEST OPHTH VIS SCI, V52, P9074, DOI 10.1167/iovs.11-8227
   Snead DRJ, 2008, EYE, V22, P1310, DOI 10.1038/eye.2008.36
   Witkin AJ, 2006, OPHTHALMOLOGY, V113, P388, DOI 10.1016/j.ophtha.2005.10.047
   Yazici AT, 2011, RETINA-J RET VIT DIS, V31, P779, DOI 10.1097/IAE.0b013e3181ef8786
   Yonekawa Y, 2012, CURR OPIN OPHTHALMOL, V23, P26, DOI 10.1097/ICU.0b013e32834cd5f8
NR 8
TC 6
Z9 6
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2013
VL 44
IS 5
BP 508
EP 512
DI 10.3928/23258160-20130909-19
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 296NS
UT WOS:000330192400018
PM 24044720
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Omar, AF
AF Bakri, Sophie J.
   Omar, Ahmed F.
TI Delayed Scleral Buckle Infection Due to Alternaria Species
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Eye; Fungus; Scleral buckle; Infection; Alternaria; Retinal detachment
ID REMOVAL
AB Objective: To report a case of scleral buckle infection by Alternaria fungus.
   Case report: A 75-year-old male who underwent rhegmatogenous retinal detachment repair 11 years ago developed a scleral buckle infection during the course of serial injections of bevacizumab for the treatment of wet age-related macular degeneration. Removal of the scleral buckle was done and culture results revealed Alternaria species.
   Results: The infected scleral buckle was removed and the patient received oral voriconazole. The patient's best corrected visual acuity changed from 20/50 preoperatively to 20/150 six months after the procedure.
   Conclusion: Alternaria species may be encountered as a cause of scleral buckle infection.
C1 [Bakri, Sophie J.; Omar, Ahmed F.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM Bakri.sophie@mayo.edu
CR Bouhaimed M, 2008, MIDDLE EAST AFR J OP, V15, P28, DOI 10.4103/0974-9233.53371
   D'Amico DJ, 2008, NEW ENGL J MED, V359, P2346, DOI 10.1056/NEJMcp0804591
   Deokule S, 2003, EYE, V17, P697, DOI 10.1038/sj.eye.6700491
   MORRISON VA, 1993, MEDICINE, V72, P78, DOI 10.1097/00005792-199303000-00002
   Mukkamala K, 2010, RETINA-J RET VIT DIS, V30, P1250, DOI 10.1097/IAE.0b013e3181d2f15e
   Nguyen QD, 2001, RETINA-J RET VIT DIS, V21, P214
   SMIDDY WE, 1993, OPHTHALMIC SURG LAS, V24, P440
   VARTIVARIAN SE, 1993, CLIN INFECT DIS   S2, V17, P487
NR 8
TC 2
Z9 2
U1 1
U2 1
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0882-0538
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JAN
PY 2013
VL 28
IS 1
BP 9
EP 10
DI 10.3109/08820538.2012.702262
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 071KY
UT WOS:000313592700003
PM 23305432
DA 2022-11-30
ER

PT J
AU Heidary, G
   Vanderveen, D
   Smith, LE
AF Heidary, Gena
   Vanderveen, Deborah
   Smith, Lois E.
TI Retinopathy of Prematurity: Current Concepts in Molecular Pathogenesis
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE retinopathy; prematurity; VEGF; erythropoietin; IGF-1; polyunsaturated
   Omega-3 Fatty Acids; neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VASCULAR DEVELOPMENT; OXYGEN-INDUCED
   RETINOPATHY; IGF-I; NEOVASCULARIZATION; ERYTHROPOIETIN; MODEL; VEGF;
   ANGIOGENESIS; HYPOXIA
AB Retinopathy of prematurity is marked by the proliferative vascularization of the retina in preterm babies. An understanding of the molecular pathogenesis of ROP provides the basis for identifying novel therapeutic targets for treatment. Using the mouse model of oxygen-induced retinopathy, the roles of the hypoxia induced factors vascular endothelial growth factor and erythropoietin as well as the maternally derived factors insulin-like growth factor-1 and omega-3 polyunsaturated fatty acids have begun to be elucidated. Understanding the phase specific effects of these factors will serve to guide the development of non destructive treatments for ROP and for other ischemic retinopathies including diabetic retinopathy and neovascular age-related macular degeneration.
C1 [Heidary, Gena; Vanderveen, Deborah; Smith, Lois E.] Harvard Univ, Dept Ophthalmol, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School
RP Heidary, G (通讯作者)，Harvard Univ, Dept Ophthalmol, Sch Med, Childrens Hosp Boston, Fegan 4,300 Longwood Ave, Boston, MA 02115 USA.
EM Gena.Heidary@childrens.harvard.edu
OI Heidary, Gena/0000-0002-3557-0420; VanderVeen,
   Deborah/0000-0002-8649-0922
FU NEI NIH HHS [R01 EY017017] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY017017] Funding Source: NIH RePORTER
CR ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P397, DOI 10.1136/bjo.38.7.397
   Chan-Ling T, 2004, INVEST OPHTH VIS SCI, V45, P2020, DOI 10.1167/iovs.03-1169
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   CHEN J, 2008, INVEST OPHTHALMOL VI
   Chen J, 2008, J AAPOS, V12, P221, DOI 10.1016/j.jaapos.2008.02.001
   Chen J, 2008, J CLIN INVEST, V118, P526, DOI [10.1172/JC133813, 10.1172/JCI33813]
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Gilbert C, 2005, PEDIATRICS, V115, pE518, DOI 10.1542/peds.2004-1180
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Gilbert Clare, 2008, Community Eye Health, V21, P46
   Hellstrom A, 2002, J CLIN ENDOCR METAB, V87, P3413, DOI 10.1210/jc.87.7.3413
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Jaquet K, 2002, MICROVASC RES, V64, P326, DOI 10.1006/mvre.2002.2426
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Kherjee PKM, 2007, PROSTAG LEUKOTR ESS, V77, P233, DOI 10.1016/j.plefa.2007.10.022
   Langford K, 1998, HUM REPROD, V13, P1389, DOI 10.1093/humrep/13.5.1389
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016
   Lutty G, 2006, MOL VIS, V12, P532
   Madan A, 2003, FRONT BIOSCI-LANDMRK, V8, pD1030, DOI 10.2741/1056
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117
   PALMER EA, 1988, ARCH OPHTHALMOL-CHIC, V106, P471
   PATZ A, 1982, AM J OPHTHALMOL, V94, P715, DOI 10.1016/0002-9394(82)90297-5
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Ribatti D, 2003, EUR J CLIN INVEST, V33, P891, DOI 10.1046/j.1365-2362.2003.01245.x
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   ROTH AM, 1977, AM J OPHTHALMOL, V84, P636, DOI 10.1016/0002-9394(77)90377-4
   Shalev B, 2001, AM J OPHTHALMOL, V132, P76, DOI 10.1016/S0002-9394(01)00956-4
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Smith LEH, 2008, INVEST OPHTH VIS SCI, V49, P5177, DOI 10.1167/iovs.08-2584
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suk KK, 2008, J AAPOS, V12, P233, DOI 10.1016/j.jaapos.2007.08.009
   Tasman W, 2001, ARCH OPHTHALMOL-CHIC, V119, P1200, DOI 10.1001/archopht.119.8.1200
   Terry TL, 1942, AM J OPHTHALMOL, V25, P203, DOI DOI 10.1016/S0002-9394(42)92088-9
NR 42
TC 63
Z9 66
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2009
VL 24
IS 2
BP 77
EP 81
DI 10.1080/08820530902800314
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18RA
UT WOS:000208020700006
PM 19373690
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Li, X
   Wang, JQ
   Wang, LY
   Feng, GH
   Li, G
   Yu, MX
   Li, YF
   Liu, C
   Yuan, XW
   Zang, GX
   Li, ZH
   Zhao, L
   Ouyang, H
   Quan, QL
   Wang, GY
   Zhang, C
   Li, OL
   Xiang, JK
   Zhu, JK
   Li, W
   Zhou, Q
   Zhang, K
AF Li, Xin
   Wang, Jiaqiang
   Wang, Leyun
   Feng, Guihai
   Li, Gen
   Yu, Meixin
   Li, Yufei
   Liu, Chao
   Yuan, Xuewei
   Zang, Guangxi
   Li, Zhihuan
   Zhao, Ling
   Ouyang, Hong
   Quan, Qingli
   Wang, Guangyu
   Zhang, Charlotte
   Li, Oulan
   Xiang, Junkai
   Zhu, Jian-Kang
   Li, Wei
   Zhou, Qi
   Zhang, Kang
TI Impaired lipid metabolism by age-dependent DNA methylation alterations
   accelerates aging
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE aging; epigenetic alteration; lipid metabolism; ER stress; mitochondrial
   dysfunction
ID SYSTEMIC DHA; RESOLUTION; SENESCENCE; MEDIATORS; PROFILES; DAMAGE
AB Epigenetic alterations and metabolic dysfunction are two hallmarks of aging. However, the mechanism of how their interaction regulates aging, particularly in mammals, remains largely unknown. Here we show ELOVL fatty acid elongase 2 (Elovl2), a gene whose epigenetic alterations are most highly correlated with age prediction, contributes to aging by regulating lipid metabolism. Impaired Elovl2 function disturbs lipid synthesis with increased endoplasmic reticulum stress and mitochondria! dysfunction, leading to key accelerated aging phenotypes. Restoration of mitochondria! activity can rescue age-related macular degeneration (AMD) phenotypes induced by Elovl2 deficiency in human retinal pigmental epithelial (RPE) cells. We revealed an epigenetic-metabolism axis contributing to aging and potentially to antiaging therapy.
C1 [Li, Xin] Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
   [Wang, Jiaqiang; Wang, Leyun; Feng, Guihai; Li, Yufei; Liu, Chao; Yuan, Xuewei; Li, Wei; Zhou, Qi] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.
   [Li, Gen; Yu, Meixin; Quan, Qingli] Guangzhou Women & Children Med Ctr, Ctr Genet Dis Diag, Guangzhou 510005, Peoples R China.
   [Li, Gen; Yu, Meixin; Quan, Qingli; Xiang, Junkai; Zhang, Kang] Macau Univ Sci & Technol, Fac Med, Tapai 999078, Macau, Peoples R China.
   [Zang, Guangxi; Li, Zhihuan; Zhang, Charlotte; Li, Oulan] Guangzhou Regenerat Med & Hlth Guangdong Lab, Dept Bioinformat, Guangzhou 510005, Peoples R China.
   [Zhao, Ling; Ouyang, Hong] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510005, Peoples R China.
   [Wang, Guangyu] Tsinghua Univ, Dept Comp Sci & Technol, Beijing 100084, Peoples R China.
   [Zhu, Jian-Kang] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Ctr Plant Stress Biol, Shanghai 210602, Peoples R China.
   [Zhou, Qi] Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA.
C3 Massachusetts Institute of Technology (MIT); Whitehead Institute;
   Chinese Academy of Sciences; Institute of Zoology, CAS; Macau University
   of Science & Technology; Guangzhou Regenerative Medicine & Health
   Guangdong Laboratory (Bioisland Laboratory); Sun Yat Sen University;
   Tsinghua University; Chinese Academy of Sciences; Shanghai Institutes
   for Biological Sciences, CAS; Purdue University System; Purdue
   University; Purdue University West Lafayette Campus
RP Li, W; Zhou, Q (通讯作者)，Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing 100101, Peoples R China.; Zhang, K (通讯作者)，Macau Univ Sci & Technol, Fac Med, Tapai 999078, Macau, Peoples R China.; Zhu, JK (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Ctr Plant Stress Biol, Shanghai 210602, Peoples R China.; Zhou, Q (通讯作者)，Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47907 USA.
EM jkzhu@sibs.ac.cn; liwei@ioz.ac.cn; qzhou@ioz.ac.cn; kang.zhang@gmail.com
OI Ouyang, Hong/0000-0002-7622-7733
FU Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDA16030400]; National Natural Science Foundation of China [31621004,
   31471395, 31701286]; Guangzhou Regenerative Medicine and Health
   Guangdong Laboratory; Key Research Projects of the Frontier Science of
   the Chinese Academy of Sciences [QYZDY-SSW-SMC002]; Key Deployment
   Projects of the Chinese Academy of Sciences [ZDRW-ZS-2017-4]; National
   Basic Research Program of China [2014cB964801]; China Postdoctoral
   Science Foundation [2017M610990, 2017T100107]; China National
   Postdoctoral Program for Innovative Talents [BX201700243]; National Key
   Research and Development Program [2017YFA0103803]
FX We thank Qi Cheng and Junqiang Liang from Beijing Health OLight
   Technology Co. Ltd for their help with optical coherence tomography
   (OCT) and electroretinogram (ERG) services. We thank Chenghe Li,
   Wenqiang Gan, and Tiegang Li from the Institute of Materia Medica,
   Chinese Academy of Medical Sciences, and Peking Union Medical College
   for their help with the pathology section and MRI services. We thank
   Shiwen Li and Xili Zhu from the Institute of Zoology, Chinese Academy of
   Sciences, for their technical assistance. We thank Eppendorf, Leica, and
   Beckman for supplying the devices. This work was supported by grants
   from the Strategic Priority Research Program of the Chinese Academy of
   Sciences (XDA16030400 to Q.Z. and W.L.); National Natural Science
   Foundation of China (31621004 to Q.Z. and W.L., 31471395 to Q.Z., and
   31701286 to G.F.); Guangzhou Regenerative Medicine and Health Guangdong
   Laboratory (to G.Z. and Z.L.); the Key Research Projects of the Frontier
   Science of the Chinese Academy of Sciences (QYZDY-SSW-SMC002 to Q.Z.);
   the Key Deployment Projects of the Chinese Academy of Sciences
   (ZDRW-ZS-2017-4 to W.L.); the National Basic Research Program of China
   (2014cB964801 to W. L.); the China Postdoctoral Science Foundation
   (2017M610990 and 2017T100107 to J.W.); the China National Postdoctoral
   Program for Innovative Talents (BX201700243 to L.W.); and the National
   Key Research and Development Program (2017YFA0103803 to Q.Z.).
CR Alkhouri Naim, 2009, Expert Rev Gastroenterol Hepatol, V3, P445, DOI 10.1586/egh.09.32
   Bell CG, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1824-y
   Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048
   Booth LN, 2016, MOL CELL, V62, P728, DOI 10.1016/j.molcel.2016.05.013
   Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009
   Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681
   Choi JY, 2016, INT J OBESITY, V40, P1452, DOI 10.1038/ijo.2016.70
   Correia-Melo C, 2016, EMBO J, V35, P724, DOI 10.15252/embj.201592862
   Cruciani-Guglielmacci C, 2017, MOL METAB, V6, P340, DOI 10.1016/j.molmet.2017.01.009
   Ferre P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/j.1463-1326.2010.01275.x
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Guarente L, 2014, CELL METAB, V20, P706, DOI 10.1016/j.cmet.2014.10.015
   Han S, 2017, NATURE, V544, P185, DOI 10.1038/nature21686
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   Lee YS, 2014, CELL, V157, P1339, DOI 10.1016/j.cell.2014.05.012
   Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mitchell SJ, 2015, ANNU REV ANIM BIOSCI, V3, P283, DOI 10.1146/annurev-animal-022114-110829
   Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361
   Oishi Y, 2017, CELL METAB, V25, P412, DOI 10.1016/j.cmet.2016.11.009
   Pauter AM, 2017, J LIPID RES, V58, P111, DOI 10.1194/jlr.M070862
   Pauter AM, 2014, J LIPID RES, V55, P718, DOI 10.1194/jlr.M046151
   Salvado L, 2015, TRENDS ENDOCRIN MET, V26, P438, DOI 10.1016/j.tem.2015.05.007
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Slieker RC, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0191-3
   Sorrentino V, 2017, NATURE, V552, P187, DOI 10.1038/nature25143
   Stubbs TM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1203-5
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   White RR, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2061-8
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005
   Zadravec D, 2011, J LIPID RES, V52, P245, DOI 10.1194/jlr.M011346
   Zbiec-Piekarska R, 2015, FORENSIC SCI INT-GEN, V14, P161, DOI 10.1016/j.fsigen.2014.10.002
   Zhu TY, 2018, AGING-US, V10, P3541, DOI 10.18632/aging.101666
NR 40
TC 19
Z9 19
U1 1
U2 32
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 25
PY 2020
VL 117
IS 8
BP 4328
EP 4336
DI 10.1073/pnas.1919403117
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KQ2PV
UT WOS:000516771500059
PM 32029582
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Herbert, A
AF Herbert, Alan
TI Z-DNA and Z-RNA in human disease
SO COMMUNICATIONS BIOLOGY
LA English
DT Review
ID EDITING ENZYME ADAR1; Z-ALPHA DOMAIN; STRESS GRANULE FORMATION; B-Z
   JUNCTION; CRYSTAL-STRUCTURE; BINDING DOMAIN; ADENOSINE-DEAMINASE;
   STRUCTURAL BASIS; COMPLEX REVEALS; ALU REPEATS
AB Left-handed Z-DNA/Z-RNA is bound with high affinity by the Z alpha domain protein family that includes ADAR (a double-stranded RNA editing enzyme), ZBP1 and viral orthologs regulating innate immunity. Loss-of-function mutations in ADAR p150 allow persistent activation of the interferon system by Alu dsRNAs and are causal for Aicardi-Goutieres Syndrome. Heterodimers of ADAR and DICER1 regulate the switch from RNA-to protein-centric immunity. Loss of DICER1 function produces age-related macular degeneration, a different type of Alu-mediated disease. The overlap of Z-forming sites with those for the signal recognition particle likely limits invasion of primate genomes by Alu retrotransposons.
C1 [Herbert, Alan] InsideOutBio, Discovery, 42,8th St,Unit 3412, Charlestown, MA 02129 USA.
RP Herbert, A (通讯作者)，InsideOutBio, Discovery, 42,8th St,Unit 3412, Charlestown, MA 02129 USA.
EM alan.herbert@insideoutbio.com
RI Herbert, Alan/AAY-4286-2020
OI Herbert, Alan/0000-0002-0093-1572
CR Abbas YM, 2013, NATURE, V494, P60, DOI 10.1038/nature11783
   Ahl V, 2015, MOL CELL, V60, P715, DOI 10.1016/j.molcel.2015.10.003
   Ahmad S, 2018, CELL, V172, P797, DOI 10.1016/j.cell.2017.12.016
   Athanasiadis A, 2005, J MOL BIOL, V351, P496, DOI 10.1016/j.jmb.2005.06.028
   Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391
   Bae S, 2013, J PHYS CHEM B, V117, P13866, DOI 10.1021/jp409862j
   Bae S, 2011, J AM CHEM SOC, V133, P668, DOI 10.1021/ja107498y
   Bahn JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7355
   Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Bennett EA, 2008, GENOME RES, V18, P1875, DOI 10.1101/gr.081737.108
   Berger A, 2014, NUCLEIC ACIDS RES, V42, P11203, DOI 10.1093/nar/gku822
   Bothe JR, 2012, BIOCHEMISTRY-US, V51, P6871, DOI 10.1021/bi300785b
   Cao H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036823
   Cate JHD, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0176
   Champ PC, 2004, NUCLEIC ACIDS RES, V32, P6501, DOI 10.1093/nar/gkh988
   Chen LL, 2017, TRENDS CELL BIOL, V27, P480, DOI 10.1016/j.tcb.2017.01.002
   Chung WJ, 2015, P NATL ACAD SCI USA, V112, P2729, DOI 10.1073/pnas.1418718112
   Costa EA, 2018, SCIENCE, V359, P689, DOI 10.1126/science.aar3607
   D'Ascenzo L, 2018, NUCLEIC ACIDS RES, V46, P7989, DOI 10.1093/nar/gky578
   de Koning APJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002384
   de Rosa M, 2013, NUCLEIC ACIDS RES, V41, P9924, DOI 10.1093/nar/gkt743
   de Rosa M, 2010, P NATL ACAD SCI USA, V107, P9088, DOI 10.1073/pnas.1003182107
   DeFilippis VR, 2010, J VIROL, V84, P585, DOI 10.1128/JVI.01748-09
   Ditlevson JV, 2008, NUCLEIC ACIDS RES, V36, P3163, DOI 10.1093/nar/gkn136
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Feng S, 2011, NAT STRUCT MOL BIOL, V18, P169, DOI 10.1038/nsmb.1962
   Galipon J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020068
   George CX, 2016, J BIOL CHEM, V291, P6158, DOI 10.1074/jbc.M115.709014
   George CX, 2011, J INTERF CYTOK RES, V31, P99, DOI 10.1089/jir.2010.0097
   Grover D, 2004, BIOINFORMATICS, V20, P813, DOI 10.1093/bioinformatics/bth005
   Ha SC, 2005, NATURE, V437, P1183, DOI 10.1038/nature04088
   Ha SC, 2004, P NATL ACAD SCI USA, V101, P14367, DOI 10.1073/pnas.0405586101
   Ha SC, 2008, P NATL ACAD SCI USA, V105, P20671, DOI 10.1073/pnas.0810463106
   Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342
   Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200
   Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421
   Herbert A, 2001, P NATL ACAD SCI USA, V98, P12132, DOI 10.1073/pnas.211419898
   HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339
   HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x
   Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009
   Ivanova E, 2015, NUCLEIC ACIDS RES, V43, P2874, DOI 10.1093/nar/gkv048
   Kang HJ, 2014, J MOL BIOL, V426, P2594, DOI 10.1016/j.jmb.2014.05.001
   Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001
   Kawahara Y, 2006, FEBS LETT, V580, P2301, DOI 10.1016/j.febslet.2006.03.042
   Kelly SA, 2012, COMPR PHYSIOL, V2, P1417, DOI 10.1002/cphy.c110008
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504
   KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457
   Kolimi N, 2017, J BIOL CHEM, V292, P18732, DOI 10.1074/jbc.M117.796235
   Krol J, 2007, MOL CELL, V25, P575, DOI 10.1016/j.molcel.2007.01.031
   Kus K, 2015, J BIOL CHEM, V290, P30713, DOI 10.1074/jbc.M115.679407
   Lehnert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004456
   Leroy M, 2017, EMBO J, V36, P1167, DOI 10.15252/embj.201796540
   Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996
   Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9
   Lomakin IB, 2013, NATURE, V500, P307, DOI 10.1038/nature12355
   Lukic S, 2014, CELL DEATH DIFFER, V21, P381, DOI 10.1038/cdd.2013.150
   Ma Z, 2016, CELL HOST MICROBE, V19, P150, DOI 10.1016/j.chom.2016.01.010
   Maillard PV, 2013, SCIENCE, V342, P235, DOI 10.1126/science.1241930
   Mannion NM, 2014, CELL REP, V9, P1482, DOI 10.1016/j.celrep.2014.10.041
   Mao CD, 1997, NATURE, V386, P137, DOI 10.1038/386137b0
   Maruyama A, 2013, NUCLEIC ACIDS RES, V41, P5223, DOI 10.1093/nar/gkt243
   McCormick C, 2017, NAT REV IMMUNOL, V17, P647, DOI 10.1038/nri.2017.63
   McKenna SD, 2004, J INTERF CYTOK RES, V24, P119, DOI 10.1089/107999004322813363
   Ng SK, 2013, NUCLEIC ACIDS RES, V41, P9786, DOI 10.1093/nar/gkt750
   Nielsen MH, 2017, CELL SIGNAL, V35, P272, DOI 10.1016/j.cellsig.2017.01.026
   Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4
   Ota H, 2013, CELL, V153, P575, DOI 10.1016/j.cell.2013.03.024
   PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370
   PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206
   Pestal K, 2015, IMMUNITY, V43, P933, DOI 10.1016/j.immuni.2015.11.001
   Placido D, 2007, STRUCTURE, V15, P395, DOI 10.1016/j.str.2007.03.001
   POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3
   Price AL, 2004, GENOME RES, V14, P2245, DOI 10.1101/gr.2693004
   Ramaswami G, 2014, NUCLEIC ACIDS RES, V42, pD109, DOI 10.1093/nar/gkt996
   Rubin CM, 2002, NUCLEIC ACIDS RES, V30, P3253, DOI 10.1093/nar/gkf419
   Rutkowski AJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8126
   Sakurai M, 2017, NAT STRUCT MOL BIOL, V24, P534, DOI 10.1038/nsmb.3403
   Samarajiwa SA, 2014, J IMMUNOL, V192, P4425, DOI 10.4049/jimmunol.1302388
   Schade M, 1999, FEBS LETT, V458, P27, DOI 10.1016/S0014-5793(99)01119-9
   Schade M, 1999, P NATL ACAD SCI USA, V96, P12465, DOI 10.1073/pnas.96.22.12465
   Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761
   Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841
   Shin SI, 2016, DNA RES, V23, P477, DOI 10.1093/dnares/dsw031
   Solomon O, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01458-8
   Stellos K, 2016, NAT MED, V22, P1140, DOI 10.1038/nm.4172
   Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161
   Subramani VK, 2016, FEBS LETT, V590, P2275, DOI 10.1002/1873-3468.12238
   Szczesny B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19216-1
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Teplova M, 2010, STRUCTURE, V18, P1364, DOI 10.1016/j.str.2010.06.018
   Van Treeck B, 2018, P NATL ACAD SCI USA, V115, P2734, DOI 10.1073/pnas.1800038115
   Vasquez KM, 2013, MUTAT RES-FUND MOL M, V743, P118, DOI 10.1016/j.mrfmmm.2012.11.005
   Vitali P, 2010, NAT STRUCT MOL BIOL, V17, P1043, DOI 10.1038/nsmb.1864
   Voorhees RM, 2015, ELIFE, V4, DOI 10.7554/eLife.07975
   WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0
   Wu HX, 2016, ARTERIOSCL THROM VAS, V36, P1549, DOI 10.1161/ATVBAHA.115.307110
   Zheng YX, 2017, NUCLEIC ACIDS RES, V45, P3369, DOI 10.1093/nar/gkx050
NR 99
TC 52
Z9 53
U1 9
U2 36
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD JAN 7
PY 2019
VL 2
AR 7
DI 10.1038/s42003-018-0237-x
PG 10
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA HO7RX
UT WOS:000461147600001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Scholz, C
AF Scholz, Carmen
TI Perspectives on: Materials aspects for retinal prostheses
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Review
DE retinal prostheses; subretinal; epiretinal; microphotodiode; arrays;
   biocompatibility; hermeticity
ID SEMICONDUCTOR-BASED PHOTODIODES; AMORPHOUS ALUMINUM-OXIDE; LONG-TERM
   IMPLANTATION; ELECTRICAL-STIMULATION; MICROELECTRODE ARRAY; SUBRETINAL
   IMPLANTS; ELECTRODE ARRAY; GANGLION-CELLS; OPTIC-NERVE; IN-VITRO
AB Retinitis pigmentosa and age-related macular degeneration are both incurable eye diseases that lead to blindness due to photoreceptor degeneration. Electrically stimulating the remaining intact nerve cells may generate some useful vision for patients afflicted with these diseases. Various types of retinal prostheses, sub- and epi-retinal electrode arrays, as well as subretinal microphotodiode arrays are considered from a materials and biocompatibility point of view. Other, more innovative approaches to restoring vision, such as microfluidic pumps and activated nanosystems that deliver neurotransmitters in a controlled way and photodynamic therapy are being developed. This article discusses materials aspects of retinal prostheses that are currently in use or under development.
C1 Univ Alabama, Dept Chem, Huntsville, AL 35899 USA.
C3 University of Alabama System; University of Alabama Huntsville
RP Scholz, C (通讯作者)，Univ Alabama, Dept Chem, 301 Sparkman Dr, Huntsville, AL 35899 USA.
EM cscholz@chemsitry.uah.edu
CR BERGSTROM K, 1994, J BIOMAT SCI-POLYM E, V6, P123
   Besch D, 2003, DOC OPHTHALMOL, V106, P31, DOI 10.1023/A:1022427813898
   Bienkiewicz J, 2006, Med Device Technol, V17, P10
   Boehmer JP, 2003, AM J CARDIOL, V91, p53D, DOI 10.1016/S0002-9149(02)03380-5
   BUFFET J, 1975, MED PROG TECHNOL, V3, P133
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   Burton MJ, 1996, ARCH OTOLARYNGOL, V122, P1097
   Chow AY, 1998, OPHTHALMIC RES, V30, P195, DOI 10.1159/000055474
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   CHOW AY, 1993, INVEST OPHTH VIS SCI, V34, P835
   Chow AY, 2002, J REHABIL RES DEV, V39, P313
   Chow AY, 2001, IEEE T NEUR SYS REH, V9, P86, DOI 10.1109/7333.918281
   CHUDEN HG, 1985, AM J OTOL, V6, P461
   Clark G. M., 1990, COCHLEAR PROSTHESES
   Cogan SF, 2005, IEEE T BIO-MED ENG, V52, P1612, DOI 10.1109/TBME.2005.851503
   Cogan SF, 2003, J BIOMED MATER RES A, V67A, P856, DOI 10.1002/jbm.a.10152
   Cui XY, 2001, J BIOMED MATER RES, V56, P261, DOI 10.1002/1097-4636(200108)56:2<261::AID-JBM1094>3.0.CO;2-I
   Cui XY, 2003, BIOMATERIALS, V24, P777, DOI 10.1016/S0142-9612(02)00415-5
   Cui XY, 2001, SENSOR ACTUAT A-PHYS, V93, P8, DOI 10.1016/S0924-4247(01)00637-9
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Dejneka NS, 2001, BIOESSAYS, V23, P662, DOI 10.1002/bies.1092
   Dion I., 1993, Bio-Medical Materials and Engineering, V3, P51
   DION I, 1993, INT J ARTIF ORGANS, V16, P623, DOI 10.1177/039139889301600901
   DOBELLE WH, 1974, J PHYSIOL-LONDON, V243, P553, DOI 10.1113/jphysiol.1974.sp010766
   Eckhorn R, 2001, OPHTHALMOLOGE, V98, P369, DOI 10.1007/s003470170143
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   EMOTO K, 2001, HEART REPLACEMENT AR, P271
   Fang X, 2005, GRAEF ARCH CLIN EXP, V243, P49, DOI 10.1007/s00417-004-0957-0
   FANG X, 2005, GRAEFES ARCH CL 0804, P1
   Faulkner A, 2005, INVEST OPHTH VIS SCI, V46
   FISHMAN H, 2002, INVEST OPHTHALMOL, V43, P114
   Flinn ED, 2002, AEROSPACE AM, V40, P18
   Foerster O., 1929, J PSYCHOL NEUROL, V39, P435
   GENTLE CR, 1995, BIOMATERIALS, V16, P245, DOI 10.1016/0142-9612(95)92124-O
   GENTLE CR, 1987, USE CERAMICS PROSTHE, V16, P115
   Gosalia K, 2004, IEEE T BIO-MED ENG, V51, P1469, DOI 10.1109/TBME.2004.827548
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   Guven D, 2006, EXP EYE RES, V82, P81, DOI 10.1016/j.exer.2005.05.008
   Hamadouche M, 2002, J BONE JOINT SURG AM, V84A, P69, DOI 10.2106/00004623-200201000-00011
   Hammerle H, 2002, BIOMATERIALS, V23, P797, DOI 10.1016/S0142-9612(01)00185-5
   Hartl A, 2004, NAT MATER, V3, P736, DOI 10.1038/nmat1204
   Hayes JS, 2003, ARTIF ORGANS, V27, P1016, DOI 10.1046/j.1525-1594.2003.07309.x
   Henry BM, 1999, THIN SOLID FILMS, V355, P500, DOI 10.1016/S0040-6090(99)00461-7
   HIDA T, 1988, RETINA-J RET VIT DIS, V8, P148, DOI 10.1097/00006982-198808020-00013
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Humayun MS, 1998, EYE, V12, P605, DOI 10.1038/eye.1998.151
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   Iezzi R, 2001, INVEST OPHTH VIS SCI, V42, pS941
   IEZZI R, 2002, INVEST OPHTHALMOL E, V43
   Jakubiec B, 1998, J BIOMED MATER RES, V41, P519, DOI 10.1002/(SICI)1097-4636(19980915)41:4<519::AID-JBM2>3.0.CO;2-F
   Jensen RJ, 2005, J NEURAL ENG, V2, pS16, DOI 10.1088/1741-2560/2/1/003
   Jensen RJ, 2005, INVEST OPHTH VIS SCI, V46, P1486, DOI 10.1167/iovs.04-1018
   Jensen RJ, 2003, INVEST OPHTH VIS SCI, V44, P3533, DOI 10.1167/iovs.02-1041
   Jian W, 2004, LANGMUIR, V20, P11450, DOI 10.1021/la048740z
   Kammer S, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P823, DOI 10.1515/bmte.2002.47.s1b.823
   Kohler K, 2001, OPHTHALMOLOGE, V98, P364, DOI 10.1007/s003470170142
   Lakhanpal Rohit R, 2003, Curr Opin Ophthalmol, V14, P122, DOI 10.1097/00055735-200306000-00002
   LANGMAN AL, 2002, INVEST OPHTHALMOL E, V43
   Lee K, 2004, SENSOR ACTUAT B-CHEM, V102, P67, DOI 10.1016/j.snb.2003.10.018
   Lehnhardt E, 1992, Eur Arch Otorhinolaryngol Suppl, V1, P223
   Liu WT, 2000, IEEE J SOLID-ST CIRC, V35, P1487, DOI 10.1109/4.871327
   Liu WT, 2003, ARTIF ORGANS, V27, P986, DOI 10.1046/j.1525-1594.2003.07306.x
   Loewenstein JI, 2004, ARCH OPHTHALMOL-CHIC, V122, P587, DOI 10.1001/archopht.122.4.587
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Margalit E, 2000, RETINA-J RET VIT DIS, V20, P469, DOI 10.1097/00006982-200009000-00007
   Merabet LB, 2005, NAT REV NEUROSCI, V6, P71, DOI 10.1038/nrn1586
   Merrill E. W., 1983, AM SOC ARTIF INTERN, V6, P60
   Meyer JU, 2002, SENSOR ACTUAT A-PHYS, V97-8, P1, DOI 10.1016/S0924-4247(01)00807-X
   MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Montezuma SR, 2004, J REHABIL RES DEV, V41, P113, DOI 10.1682/JRRD.2004.02.0113
   MONTEZUMA SR, 2004, INVESTIGATIVE OPHTHA
   MOSS J, 1999, THESIS MIT
   Nakauchi K, 2005, GRAEF ARCH CLIN EXP, V243, P169, DOI 10.1007/s00417-004-1060-2
   NICHOLS MF, 1994, CRIT REV BIOMED ENG, V22, P39
   Noordegraaf J, 1997, Med Device Technol, V8, P14
   Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1
   Normann RA, 2001, VISION RES, V41, P1261, DOI 10.1016/S0042-6989(00)00273-X
   OHIRA A, 1991, GRAEF ARCH CLIN EXP, V229, P95, DOI 10.1007/BF00172270
   Otsuka H, 2004, LANGMUIR, V20, P11285, DOI 10.1021/la0483414
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   PATRICK JF, 1985, COCHLEAR IMPLANTS, P93
   Peachey NS, 1999, J REHABIL RES DEV, V36, P371
   Peterman MC, 2003, INVEST OPHTH VIS SCI, V44, P3144, DOI 10.1167/iovs.02-1097
   Peyman G, 1998, OPHTHALMIC SURG LAS, V29, P234
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Piehler J, 2000, BIOSENS BIOELECTRON, V15, P473, DOI 10.1016/S0956-5663(00)00104-4
   POTTS AM, 1970, INVEST OPHTH VISUAL, V9, P814
   Rattay F, 2004, IEEE T BIO-MED ENG, V51, P1659, DOI 10.1109/TBME.2004.828044
   Rivers TJ, 2002, ADV FUNCT MATER, V12, P33, DOI 10.1002/1616-3028(20020101)12:1<33::AID-ADFM33>3.0.CO;2-E
   Rizzo JF, 2004, RESTOR NEUROL NEUROS, V22, P429
   Rizzo JF, 1997, NEUROSCIENTIST, V3, P251, DOI 10.1177/107385849700300413
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Rizzo JF, 2001, OPHTHALMOLOGY, V108, P13, DOI 10.1016/S0161-6420(00)00430-9
   Rizzo JF, 1999, RETINAL DEGENERATIVE DISEASES AND EXPERIMENTAL THERAPY, P463, DOI 10.1007/978-0-585-33172-0_43
   ROBBLEE LS, 1980, BIOMATERIALS, V1, P135, DOI 10.1016/0142-9612(80)90035-6
   Rodger DC, 2005, IEEE ENG MED BIOL, V24, P52, DOI 10.1109/MEMB.2005.1511500
   ROJAHN M, 2003, THESIS U STUTTGART
   Sachs HG, 2004, GRAEF ARCH CLIN EXP, V242, P717, DOI 10.1007/s00417-004-0979-7
   SCHINDLER RA, 1992, LARYNGOSCOPE, V102, P1006
   Schmidt CE, 1997, P NATL ACAD SCI USA, V94, P8948, DOI 10.1073/pnas.94.17.8948
   Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507
   Schubert MB, 1999, SENSOR ACTUAT A-PHYS, V74, P193, DOI 10.1016/S0924-4247(98)00313-6
   Seo JM, 2004, MAT SCI ENG C-BIO S, V24, P185, DOI 10.1016/j.msec.2003.09.019
   Shirakura A, 2006, THIN SOLID FILMS, V494, P84, DOI 10.1016/j.tsf.2005.08.366
   SROOG CE, 1990, POLYIMIDES
   STIEGLITZ T, 1999, J INT FED MED BIO S2, V37, P1102
   Sweitzer R, 2006, J BIOACT COMPAT POL, V21, P5, DOI 10.1177/0883911506060202
   TASSICKER G E, 1956, Br J Physiol Opt, V13, P102
   TERR LI, 1989, AM J OTOL, V10, P339
   THEOGARAJAN L, 2006, POLYM PREPR, V47, P145
   THEOGARAJAN LS, 2004, ASS RES VIS OPTH
   THEOGARAJAN LS, 2007, POLYM PREPRINTS, V48, P1040
   Veraart C, 2003, ARTIF ORGANS, V27, P996, DOI 10.1046/j.1525-1594.2003.07305.x
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   VERAART C, 1993, IEEE T BIO-MED ENG, V40, P640, DOI 10.1109/10.237694
   Walter P, 1999, RETINA-J RET VIT DIS, V19, P546, DOI 10.1097/00006982-199911000-00012
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Weisenberg BA, 2002, J BIOMED MATER RES, V60, P283, DOI 10.1002/jbm.10076
   Wyatt J, 1996, IEEE SPECTRUM, V33, P47, DOI 10.1109/6.490056
   Xiao XC, 2006, J BIOMED MATER RES B, V77B, P273, DOI 10.1002/jbm.b.30448
   Yamada-Takamura Y, 2002, SURF COAT TECH, V153, P114, DOI 10.1016/S0257-8972(01)01697-8
   Yamamoto S, 2005, DIAM RELAT MATER, V14, P1112, DOI 10.1016/j.diamond.2004.10.025
   Yamauchi Y, 2005, J NEURAL ENG, V2, pS48, DOI 10.1088/1741-2560/2/1/007
   YUHTA T, 1994, J BIOMED MATER RES, V28, P217, DOI 10.1002/jbm.820280212
   Ziaie B, 1997, IEEE T BIO-MED ENG, V44, P909, DOI 10.1109/10.634643
   Ziv OR, 2005, J NEURAL ENG, V2, pS5, DOI 10.1088/1741-2560/2/1/002
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
   Zrenner E, 1997, OPHTHALMIC RES, V29, P269, DOI 10.1159/000268025
   Zrenner E, 2002, OPHTHALMOLOGICA, V216, P8, DOI 10.1159/000064650
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
NR 135
TC 19
Z9 20
U1 0
U2 20
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883-9115
EI 1530-8030
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD SEP
PY 2007
VL 22
IS 5
BP 539
EP 568
DI 10.1177/0883911507082160
PG 30
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA 223AU
UT WOS:000250342800006
DA 2022-11-30
ER

PT J
AU Pugazhendhi, A
   Hubbell, M
   Jairam, P
   Ambati, B
AF Pugazhendhi, Arunbalaji
   Hubbell, Margaret
   Jairam, Pooja
   Ambati, Balamurali
TI Neovascular Macular Degeneration: A Review of Etiology, Risk Factors,
   and Recent Advances in Research and Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; neovascular age-related macular
   degeneration; etiopathogenesis; risk factors; gene-therapy; anti-VEGF;
   future advancements
ID AGE-RELATED MACULOPATHY; RETINAL-PIGMENT EPITHELIUM; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; 15-YEAR CUMULATIVE INCIDENCE; OXIDATIVE STRESS;
   MEDITERRANEAN DIET; RACIAL-DIFFERENCES; CIGARETTE-SMOKING; CHOROIDAL
   NEOVASCULARIZATION; COMPLEMENT ACTIVATION
AB Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD's progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.
C1 [Pugazhendhi, Arunbalaji; Hubbell, Margaret; Ambati, Balamurali] Univ Oregon, Knights Campus Accelerating Sci Impact, Eugene, OR 97403 USA.
   [Jairam, Pooja] Columbia Univ, Columbia Irving Med Ctr, Vagelos Coll Phys & Surg, New York, NY 10032 USA.
C3 University of Oregon; Columbia University; NewYork-Presbyterian Hospital
RP Ambati, B (通讯作者)，Univ Oregon, Knights Campus Accelerating Sci Impact, Eugene, OR 97403 USA.
EM arunp@uoregon.edu; mhubbell@uoregon.edu; poojajairam@yahoo.com;
   bambati@uoregon.edu
OI Jairam, Meghan/0000-0002-2780-4223
CR ADAMIS AP, 1993, J CELL PHYSIOL, V193, P631, DOI DOI 10.1006/BBRC.1993.1671
   Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Akishima S, 2007, CIRC J, V71, P418, DOI 10.1253/circj.71.418
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alberg AJ, 2002, TOXICOLOGY, V180, P121, DOI 10.1016/S0300-483X(02)00386-4
   AMBATI BK, 2006, DRUGS, V443, P993, DOI DOI 10.1038/NATURE05249
   AMBATI J, 2012, P NATL ACAD SCI USA, V75, P26, DOI DOI 10.1016/J.NEURON.2012.06.018
   AMBATI J, 2003, INVEST OPHTH VIS SCI, V9, P1390, DOI DOI 10.1038/NM950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   [Anonymous], SAFETY TOLERABILITY, DOI DOI 10.1248/bpb.34.1841
   [Anonymous], AAVCAGSCD59 TREATMEN
   [Anonymous], SAFETY EFFICACY STUD
   [Anonymous], FOLLOW UP STUDY EVAL
   [Anonymous], RGX 314 GENE THERAPY
   [Anonymous], STUDY ADGVPEDF 11D N
   [Anonymous], ADVM 022 INTRAVITREA
   [Anonymous], EXPLORE PHASE 2 STUD
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BAMIAS G, 2012, NAT MED, V59, P451, DOI DOI 10.1016/J.CYTO.2012.06.014
   BAYLESS KJ, 2011, CIRCULATION, V48, P369, DOI DOI 10.1159/000324751
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BERG K, 2015, PLOS ONE, V122, P146, DOI DOI 10.1016/J.OPHTHA.2014.07.041
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   BLANKE CD, 2015, INT J MOL SCI, V20, P1353, DOI DOI 10.1634/THEONCOLOGIST.2015-0295
   BLICK SK, 2007, INVEST OPHTH VIS SCI, V67, P1199, DOI DOI 10.2165/00003495-200767080-00007
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buford TW, 2016, AGEING RES REV, V26, P96, DOI 10.1016/j.arr.2016.01.007
   CAI J, 2006, SCIENCE, V281, P3604, DOI DOI 10.1074/JBC.M507401200
   CAMPA C, 2016, J IMMUNOL RES, V17, P328, DOI DOI 10.2174/1573399811666150615151324
   CARMELIET P, 2001, PLOS ONE, V7, P575, DOI DOI 10.1038/87904
   Castro-Quezada I, 2014, NUTRIENTS, V6, P231, DOI 10.3390/nu6010231
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Clearkin L, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000257
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   COMPAN V, 2012, CELL REP, V37, P487, DOI DOI 10.1016/J.IMMUNI.2012.06.013
   CONSTABLE IJ, 2016, AM J OPHTHALMOL, V14, P168, DOI DOI 10.1016/J.EBIOM.2016.11.016
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   COULTAS L, 2005, EMBO J, V438, P937, DOI DOI 10.1038/NATURE04479
   Cp Juarez, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P30
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Danzig C, 2019, INVEST OPHTH VIS SCI, V60
   Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DAVIS S, 1996, P NATL ACAD SCI USA, V87, P1161, DOI DOI 10.1016/S0092-8674(00)81812-7
   DAWSON DW, 1999, BIOCHEM BIOPH RES CO, V285, P245, DOI DOI 10.1126/SCIENCE.285.5425.245
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DINARELLO CA, 2006, SCI REP-UK, V83, pS447, DOI DOI 10.1093/AJCN/83.2.447S
   Donati G, 1999, Semin Ophthalmol, V14, P2, DOI 10.3109/08820539909056057
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   DOYLE SL, 2012, ANNU REV IMMUNOL, V18, P791, DOI DOI 10.1038/NM.2717
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   DU Z, 2008, NATURE, V105, P2391, DOI DOI 10.1073/PNAS.0711506105
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   DUH EJ, 2002, AM J OPHTHALMOL, V43, P821
   DULAK J, 2000, MOL THER, V20, P659, DOI DOI 10.1161/01.ATV.20.3.659
   El Annan Jaafar, 2014, Int Ophthalmol Clin, V54, P141, DOI 10.1097/IIO.0000000000000027
   Espinosa-Heidmann, 2005, INVESTIG OPHTHALMOL, V46, P3507
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   ESPINOSAHEIDMAN.DG, 2003, NEURON, V44, P3586, DOI DOI 10.1167/IOVS.03-0038
   FAHEY E, 2019, BRIT J PHARMACOL, V10, P1426, DOI DOI 10.3389/FIMMU.2019.01426
   FELIERS D, 2005, P NATL ACAD SCI USA, V68, P1648, DOI DOI 10.1111/J.1523-1755.2005.00575.X
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   FERRARA N, 1989, OPHTHALMOLOGY, V161, P851, DOI DOI 10.1016/0006-291X(89)92678-8
   FERRARA N, 2004, DRUGS, V3, P391, DOI DOI 10.1038/NRD1381
   FIEDLER U, 2006, J CELL PHYSIOL, V12, P235, DOI DOI 10.1038/NM1351
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Figueroa AG, 2021, AM J MED, V134, P122, DOI 10.1016/j.amjmed.2020.05.038
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   FUKUMURA D, 2001, ONCOGENE, V98, P2604, DOI DOI 10.1073/PNAS.041359198
   Gabriel HE, 2006, CANCER EPIDEM BIOMAR, V15, P993, DOI 10.1158/1055-9965.EPI-05-0664
   Gao Z, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01400-5
   GARNOCKJONES KP, 2014, EMBO MOL MED, V74, P2211, DOI DOI 10.1007/S40265-014-0333-2
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   GERBER HP, 1999, BIOCHEM BIOPH RES CO, V5, P623, DOI DOI 10.1038/9467
   GERBER HP, 2003, NAT MED, V81, P20, DOI DOI 10.1007/S00109-002-0397-4
   Ghasemi Falavarjani Khalil, 2012, J Ophthalmic Vis Res, V7, P235
   Gunes FE, 2012, J AM COLL NUTR, V31, P167, DOI 10.1080/07315724.2012.10720024
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HARA K, 1991, Nippon Ganka Gakkai Zasshi, V95, P939
   HASLER J, 2006, CELL, V34, P5491, DOI DOI 10.1093/NAR/GKL706
   Head T, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00216
   HEIER JS, 2012, LANCET, V119, P2537, DOI DOI 10.1016/J.OPHTHA.2012.09.006
   HO AC, 2014, NEW ENGL J MED, V121, P2181, DOI DOI 10.1016/J.OPHTHA.2014.05.009
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Iriyama A, 2006, INVESTIG OPHTHALMOL, V47, P4146
   JETTEN N, 2014, CELL REP, V17, P109, DOI DOI 10.1007/S10456-013-9381-6
   JHA S, 2009, INT J MOL SCI, V183, P7623, DOI DOI 10.4049/JIMMUNOL.0902425
   JOHNSON KE, 2014, J MOL MED, V3, P647, DOI DOI 10.1089/WOUND.2013.0517
   Jorgenson E, 2016, EUR J HUM GENET, V24, P1049, DOI 10.1038/ejhg.2015.247
   JOUKOV V, 1996, ADV WOUND CARE, V15, P290, DOI DOI 10.1002/J.1460-2075.1996.TB00359.X
   JULIEN O, 2017, EUR J PHARMACOL, V24, P1380, DOI DOI 10.1038/CDD.2017.44
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   KANEKO H, 2011, P NATL ACAD SCI USA, V471, P325, DOI DOI 10.1038/NATURE09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim EJ, 2004, IMMUNOLOGY, V111, P27, DOI 10.1111/j.1365-2567.2004.01784.x
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Korpanty Grzegorz, 2011, J Thorac Dis, V3, P19, DOI 10.3978/j.issn.2072-1439.2010.11.11
   KOSMIDOU C, 2018, MOL CELL, V8, P461, DOI DOI 10.1038/S41598-017-17634-1
   KRISHNAN SM, 2014, FRONT PHYSIOL, V171, P5589, DOI DOI 10.1111/BPH.12876
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   KUWABARA M, 2006, ARTERIOSCL THROM VAS, V56, P95, DOI DOI 10.2170/PHYSIOLSCI.RP002305
   LAI CM, 2009, NATURE, V50, P4279, DOI DOI 10.1167/IOVS.08-3253
   LAMKANFI M, 2009, IMMUNITY, V5
   LAZZARA F, 2019, NAT REV DRUG DISCOV, V168, P341, DOI DOI 10.1016/J.BCP.2019.07.021
   Lee J, 2012, LIFE SCI, V91, P1058, DOI 10.1016/j.lfs.2012.06.032
   Lee J, 2011, ATHEROSCLEROSIS, V215, P281, DOI 10.1016/j.atherosclerosis.2011.01.003
   Leppanen VM, 2017, P NATL ACAD SCI USA, V114, P4376, DOI 10.1073/pnas.1616166114
   LEUNG DW, 1989, INT J BIOCHEM CELL B, V246, P1306, DOI DOI 10.1126/SCIENCE.2479986
   Li SF, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0469-4
   LI X, 2001, NATURE, V33, P421, DOI DOI 10.1016/S1357-2725(01)00027-9
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lien S., 2008, V181, P131
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   LIU RT, 2013, PLOS ONE, V54, P2225, DOI DOI 10.1167/IOVS.12-10849
   Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012
   Loskutova E, 2013, NUTRIENTS, V5, P1962, DOI 10.3390/nu5061962
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   MAISONPIERRE PC, 1997, CELL, V277, P55, DOI DOI 10.1126/SCIENCE.277.5322.55
   Mak RK, 2017, ACTA OPHTHALMOL, V95, P20, DOI 10.1111/aos.13178
   Manna P, 2015, METAB SYNDR RELAT D, V13, P423, DOI 10.1089/met.2015.0095
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   MARNEROS AG, 2013, IMMUNOL LETT, V4, P945, DOI DOI 10.1016/J.CELREP.2013.08.002
   Marseglia L, 2015, INT J MOL SCI, V16, P378, DOI 10.3390/ijms16010378
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MARTINON F, 2002, PLOS PATHOG, V10, P417, DOI DOI 10.1016/S1097-2765(02)00599-3
   MCLAUGHLIN AP, 2001, KIDNEY INT, V281, pC1448, DOI DOI 10.1152/AJPCELL.2001.281.5.C1448
   Melegh Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112676
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   MILLER JW, 1999, GRAEF ARCH CLIN EXP, V117, P1161, DOI DOI 10.1001/ARCHOPHT.117.9.1161
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITTER SK, 2014, J BIOL CHEM, V10, P1989, DOI DOI 10.4161/AUTO.36184
   MONAGHANBENSON E, 2010, FASEB J, V177, P2091, DOI DOI 10.2353/AJPATH.2010.090878
   Monk BJ, 2016, ANN ONCOL, V27, P33, DOI 10.1093/annonc/mdw093
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   MUROHARA T, 1998, AM J PHYSIOL-CELL PH, V97, P99, DOI DOI 10.1161/01.CIR.97.1.99
   Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423
   NAMBU H, 2005, SCIENCE, V204, P227, DOI DOI 10.1002/JCP.20292
   NEUFELD G, 1999, CURR OPIN CELL BIOL, V13, P9, DOI DOI 10.1096/FASEBJ.13.1.9
   NG DS, 2017, CSH PERSPECT MED, V7, P45081, DOI DOI 10.1038/SREP45081
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   OOMMEN S, 2011, SCIENCE, V286, P1083, DOI DOI 10.1074/JBC.M110.175158
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PARK DJ, 2015, ANN ONCOL, V18, P33, DOI DOI 10.1007/S10120-014-0397-4
   PLATANIA CBM, 2017, IMMUNITY, V138, P130, DOI DOI 10.1016/J.BCP.2017.05.001
   PLYUKHOVA AA, 2020, FRONT IMMUNOL, V9
   Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X
   Purves D, 2001, NEUROSCIENCE, V2nd
   RAKOCZY EP, 2019, INVEST OPHTH VIS SCI, V204, P113, DOI DOI 10.1016/J.AJO.2019.03.006
   Regenxbio Inc, LONG TERM FOLL UP ST
   REGULA JT, 2016, DIABETES RES CLIN PR, V8, P1265, DOI DOI 10.15252/EMMM.201505889
   Rimm E., 1993, Annals of the New York Academy of Sciences, V686, P323, DOI 10.1111/j.1749-6632.1993.tb39195.x
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Rohrer B, 2019, MOL VIS, V25, P79
   Romagnolo Donato F, 2017, Nutr Today, V52, P208, DOI 10.1097/NT.0000000000000228
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossino MG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061452
   ROUSSEAU S, 1997, AM J PATHOL, V15, P2169, DOI DOI 10.1038/SJ.ONC.1201380
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SCHAUWVLIEGHE AM, 2016, AM J OPHTHALMOL, V11
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Serra-Majem L, 2009, BRIT J NUTR, V101, pS21, DOI 10.1017/S0007114509990559
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   SHOKOLENKO I, 2009, ANN NY ACAD SCI, V37, P2539, DOI DOI 10.1093/NAR/GKP100
   SICA A, 2012, IMMUNOL REV, V122, P787, DOI DOI 10.1172/JCI59643
   Simha A, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007920.pub3
   Slabaugh M, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/1645269
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Stabeli, 2017, FRONT IMMUNOL, V8, P653, DOI 10.3389/fimmu.2017.00653
   STEFANINI FR, 2014, OPHTHALMOLOGY, V2014, DOI DOI 10.1155/2014/632307
   Stevens GA, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-22
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   TARALLO V, 2012, P NATL ACAD SCI USA, V149, P847, DOI DOI 10.1016/J.CELL.2012.03.036
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   THURSTON G, 2012, NAT MED, V2, DOI DOI 10.1101/CSHPERSPECT.A006650
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Tran KD, 2018, ASIA-PAC J OPHTHALMO, V7, P56, DOI 10.22608/APO.2017436
   Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev
   TSUTSUI H, 2004, NAT MED, V202, P115, DOI DOI 10.1111/J.0105-2896.2004.00205.X
   Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020
   VANASTEN F, 2018, NAT REV DRUG DISCOV, V13
   VANCUTSEM E, 2009, ONCOLOGIST, V27, P2231, DOI DOI 10.1200/JCO.2008.20.0238
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Verheul H M, 2000, Clin Breast Cancer, V1 Suppl 1, pS80, DOI 10.3816/CBC.2000.s.015
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   VORONOV E, 2014, J IMMUNOL, V5, P114, DOI DOI 10.3389/FPHYS.2014.00114
   Walshe TE, 2009, ARTERIOSCL THROM VAS, V29, P1185, DOI 10.1161/ATVBAHA.109.186742
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WATANABE D, 2005, SCI REP-UK, V139, P476, DOI DOI 10.1016/J.AJO.2004.10.004
   Wiktorowska-Owczarek A, 2010, POSTEP HIG MED DOSW, V64, P333
   WILLETT CG, 2004, ARTERIOSCL THROM VAS, V10, P145, DOI DOI 10.1038/NM988
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   WRIGHT CB, 2020, NATURE, V117, P2579, DOI DOI 10.1073/PNAS.1909761117
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xia T, 2018, J VITREORETINAL DIS, V2, P194, DOI [10.1177/2474126418782067, DOI 10.1177/2474126418782067]
   ZANDI S, 2015, J CLIN INVEST, V10, P1173, DOI DOI 10.1016/J.CELREP.2015.01.050
   ZHANG M, 2009, J CLIN MED, V26, P204, DOI DOI 10.1007/S11095-008-9718-9
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   ZHANG X, 2020, PHARM RES-DORDR, V162, DOI DOI 10.1016/J.DIABRES.2020.108083
   Zhao Yue, 2018, Drugs Context, V7, P212532, DOI 10.7573/dic.212532
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   ZHOU Q, 2014, CELL, V22, P378, DOI DOI 10.1038/MT.2013.243
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
   1990, ARCH OPHTHALMOL-CHIC, V108, P816, DOI DOI 10.1001/ARCHOPHT.1990.01070080058036
   1982, INVEST OPHTH VIS SCI, V100, P912, DOI DOI 10.1001/ARCHOPHT.1982.01030030920003
NR 261
TC 15
Z9 17
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 3
AR 1170
DI 10.3390/ijms22031170
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QD2MS
UT WOS:000615359800001
PM 33504013
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maram, J
   Srinivas, S
   Sadda, SR
AF Maram, Jyotsna
   Srinivas, Sowmya
   Sadda, Srinivas R.
TI Evaluating ocular blood flow
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Choroidal neovascularization; diabetic retinopathy; Doppler Fourier
   domain optical coherence tomography; glaucoma; optical coherence
   tomography; optical coherence tomography angiography
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPY; RETINAL
   VESSEL DIAMETERS; SOURCE OCT ANGIOGRAPHY; REAL-TIME MEASUREMENT; NERVE
   HEAD; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY;
   AMPLITUDE-DECORRELATION; MACULAR DEGENERATION
AB Studies have shown that vascular impairment plays an important role in the etiology and pathogenesis of various ocular diseases including glaucoma, age-related macular degeneration, diabetic retinopathy, and retinal venous occlusive disease. Thus, qualitative and quantitative assessment of ocular blood flow (BF) is a topic of interest for early disease detection, diagnosis, and management. Owing to the rapid improvement in technology, there are several invasive and noninvasive techniques available for evaluating ocular BF, with each of these techniques having their own limitations and advantages. This article reviews these important techniques, with a particular focus on Doppler Fourier domain optical coherence tomography (OCT) and OCT-angiography.
C1 [Maram, Jyotsna; Srinivas, Sowmya; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90095 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
CR Akil H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170476
   Al-Sheikh M, 2016, INVEST OPHTH VIS SCI, V57, P3907, DOI 10.1167/iovs.16-19570
   Ang M, 2015, OPHTHALMOLOGY, V122, P1740, DOI 10.1016/j.ophtha.2015.05.017
   Avila CP, 1998, AM J OPHTHALMOL, V126, P683, DOI 10.1016/S0002-9394(98)00114-7
   Bonini MA, 2015, RETINA-J RET VIT DIS, V35, P2339, DOI 10.1097/IAE.0000000000000850
   BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097
   BRIERS JD, 1982, INVEST OPHTH VIS SCI, V22, P255
   Caprioli J, 2010, AM J OPHTHALMOL, V149, P704, DOI 10.1016/j.ajo.2010.01.018
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dimitrova G, 2010, SURV OPHTHALMOL, V55, P193, DOI 10.1016/j.survophthal.2009.06.010
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Falavarjani KG, 2016, RETINA-J RET VIT DIS, V36, pS168, DOI 10.1097/IAE.0000000000001259
   Fang PP, 2016, OPHTHALMOLOGE, V113, P14, DOI 10.1007/s00347-015-0192-6
   FEKE GT, 1978, J OPT SOC AM, V68, P526, DOI 10.1364/JOSA.68.000526
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Fuchsjager-Mayrl G, 2002, INVEST OPHTH VIS SCI, V43, P1520
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Garcia JPS, 2002, OPHTHALMIC RES, V34, P295, DOI 10.1159/000065600
   Garhofer G, 2010, ACTA OPHTHALMOL, V88, P717, DOI 10.1111/j.1755-3768.2009.01587.x
   Garzozi HJ, 2001, ISRAEL MED ASSOC J, V3, P443
   GOEBEL W, 1995, INVEST OPHTH VIS SCI, V36, P864
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P1853
   Guan K, 2003, MICROVASC RES, V65, P145, DOI 10.1016/S0026-2862(03)00007-4
   Hafez AS, 2003, AM J OPHTHALMOL, V136, P1022, DOI 10.1016/S0002-9394(03)00632-9
   Hafez AS, 2003, OPHTHALMIC SUR LA IM, V34, P422
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Hardarson SH, 2013, ACTA OPHTHALMOL, V91, P1, DOI 10.1111/aos.12086
   Hardarson SH, 2010, AM J OPHTHALMOL, V150, P871, DOI 10.1016/j.ajo.2010.06.020
   Harris A, 2008, CAN J OPHTHALMOL, V43, P328, DOI 10.3129/i08-051
   Heitmar R, 2010, INVEST OPHTH VIS SCI, V51, P5833, DOI 10.1167/iovs.09-5136
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Hwang JC, 2012, INVEST OPHTH VIS SCI, V53, P3020, DOI 10.1167/iovs.11-8552
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603
   Konduru RK, 2012, OPHTHAL SURG LAS IM, V43, P25, DOI 10.3928/15428877-20111129-04
   Kuehlewein L, 2015, OSLI RETINA, V46, P249, DOI 10.3928/23258160-20150213-19
   Lee JC, 2013, INVEST OPHTH VIS SCI, V54, P6104, DOI 10.1167/iovs.13-12255
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   MAINSTER MA, 1982, OPHTHALMOLOGY, V89, P852, DOI 10.1016/s0161-6420(82)34714-4
   Maloca P, 2016, GRAEF ARCH CLIN EXP, V254, P1201, DOI 10.1007/s00417-015-3259-9
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   Matthiessen ET, 2004, EYE, V18, P400, DOI 10.1038/sj.eye.6700651
   Mohammad S., 1998, JPMI, V12, P8
   Mohindroo Chirayu, 2016, J Curr Glaucoma Pract, V10, P104
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   PATZ A, 1977, International Ophthalmology Clinics, V17, P1, DOI 10.1097/00004397-197701720-00003
   Pechauer AD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/121973
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Poddar R, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.12.126010
   Polska E, 2001, AM J PHYSIOL-HEART C, V280, pH1442, DOI 10.1152/ajpheart.2001.280.4.H1442
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Pournaras CJ, 2013, OPHTHALMOLOGICA, V229, P61, DOI 10.1159/000338186
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   RIVA CE, 1980, J OPT SOC AM, V70, P1234, DOI 10.1364/JOSA.70.001234
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Schmetterer L, 2007, SURV OPHTHALMOL, V52, pS134, DOI 10.1016/j.survophthal.2007.08.008
   Schmitt JM, 1999, IEEE J SEL TOP QUANT, V5, P1205, DOI 10.1109/2944.796348
   Schneider U, 1997, ACTA OPHTHALMOL SCAN, V75, P653
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Srienc Anja I, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00128
   Srinivas S, 2017, RETINA-J RET VIT DIS, V37, P2001, DOI 10.1097/IAE.0000000000001479
   Srinivas S, 2015, INVEST OPHTH VIS SCI, V56, P1569, DOI 10.1167/iovs.14-15038
   Staurenghi G, 2005, ARCH OPHTHALMOL-CHIC, V123, P244, DOI 10.1001/archopht.123.2.244
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Tamaki Y, 1997, JPN J OPHTHALMOL, V41, P49, DOI 10.1016/S0021-5155(96)00008-1
   TAMAKI Y, 1995, EXP EYE RES, V60, P373, DOI 10.1016/S0014-4835(05)80094-6
   Tayyari F, 2014, INVEST OPHTH VIS SCI, V55, P7716, DOI 10.1167/iovs.14-14430
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Wang JJ, 2006, OBESITY, V14, P206, DOI 10.1038/oby.2006.27
   WANG XJ, 1995, OPT LETT, V20, P1337, DOI 10.1364/OL.20.001337
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Wang YM, 2009, OPT EXPRESS, V17, P4061, DOI 10.1364/OE.17.004061
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   WILLIAMSON TH, 1994, BRIT J OPHTHALMOL, V78, P939, DOI 10.1136/bjo.78.12.939
   Wong TY, 2004, OPHTHALMOLOGY, V111, P1183, DOI 10.1016/j.ophtha.2003.09.039
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Yarmohammadi A, 2016, INVEST OPHTH VIS SCI, V57, pOCT451, DOI 10.1167/iovs.15-18944
NR 93
TC 16
Z9 16
U1 0
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2017
VL 65
IS 5
BP 337
EP 346
DI 10.4103/ijo.IJO_330_17
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6TX
UT WOS:000403376100003
PM 28573987
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pece, A
   Vitale, L
   Milani, P
   Pierro, L
AF Pece, Alfredo
   Vitale, Lucia
   Milani, Paolo
   Pierro, Luisa
TI Spontaneous Reattachment of the Margins of a Macular Retinal Pigment
   Epithelium Tear: Optical Coherence Tomography Documentation of a Case
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium tear,
   reattachment; Optical coherence tomography
ID PATHOGENESIS; THERAPY
AB Purpose: To document by optical coherence tomography (OCT) the reattachment of the margins of a retinal pigment epithelium (RPE) tear. Methods: Single case report, documented by OCT scans, autofluorescence and fluorescein angiography. Results: A 67-year-old male presented with a spontaneous RPE tear due to age-related macular degeneration in his right eye. Three months later we observed that the focal RPE tear had healed and there was a new intraretinal fluid, well documented by OCT imaging. Conclusions: OCT scans show the reattachment of the margins of an RPE tear healed by tissue remodelling, and illustrate how the disease can recur. Copyright (C) 2009 S. Karger AG, Basel
C1 [Pece, Alfredo; Vitale, Lucia] Univ Vita Salute, Osped Vizzolo Predabissi, Milan, Italy.
   [Milani, Paolo] Univ Vita Salute, Osped Fatebenefratelli Oftalm, Milan, Italy.
   [Pierro, Luisa] Univ Vita Salute, Osped San Raffaele, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele
RP Pece, A (通讯作者)，Via N Bixio 3, IT-20129 Milan, Italy.
EM Pece.retina@mclink.it
RI Pierro, Luisa/AAN-3900-2020
OI Milani, Paolo/0000-0002-0409-6201
FU Fondazione Retina 3000, Milano
FX This work was supported by the Fondazione Retina 3000, Milano.
CR CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
NR 13
TC 13
Z9 13
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 3
BP 159
EP 161
DI 10.1159/000236910
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513KU
UT WOS:000271322000005
PM 19752583
OA Bronze
DA 2022-11-30
ER

PT J
AU Palanki, MSS
   Cao, JG
   Chow, CP
   Dneprovskaia, E
   Mak, CC
   McPherson, A
   Pathak, VP
   Renick, J
   Soll, R
   Zeng, B
   Noronha, G
AF Palanki, Moorthy S. S.
   Cao, Jianguo
   Chow, Chun P.
   Dneprovskaia, Elena
   Mak, Chi Ching
   McPherson, Andrew
   Pathak, Ved P.
   Renick, Joel
   Soll, Richard
   Zeng, Binqi
   Noronha, Glenn
TI Development of novel benzotriazines for drug discovery
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE age-related macular degeneration; analgesic compounds; anti-inflammatory
   compounds; BCR-ABL; BCR-ABL-T3151; benzotriazine; bioreductive drugs;
   cancer drugs; kinase inhibitors; SRC; TG100801; tirapazamine; VEGFr2
ID ENDOTHELIAL GROWTH-FACTOR; KINASE DOMAIN MUTATIONS; BCR-ABL; TYROSINE
   KINASE; 1,2,4-BENZOTRIAZINE 1,4-DIOXIDES; DNA CLEAVAGE; SRC;
   3-AMINO-1,2,4-BENZOTRIAZINE; HYPOXIA; INHIBITION
AB Background: The synthesis of novel benzotriazine heterocycles was developed independently around the same time by Bischler, Bamberger and Arndt. Over the years, different groups have reported the synthesis of benzotriazine based compounds. Objective: This literature review gives an update on recent benzotriazine compounds and their applications. Conclusion: The benzotriazine core has been used in various drug discovery projects including anticancer, anti-inflammatory and antimalarial programs. Recently, the benzotriazine core was used to develop selective kinase inhibitors targeting SRC, VEGFr2, 8CR-ABL and BCR-ABL-T3151. Two benzotriazine based compounds, tirapazamine for the treatment of cancer and TG100801 for the treatment of age-related macular degeneration, have entered clinical trials.
C1 [Palanki, Moorthy S. S.; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Mak, Chi Ching; McPherson, Andrew; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi; Noronha, Glenn] TargeGen Inc, San Diego, CA 92121 USA.
RP Noronha, G (通讯作者)，TargeGen Inc, 9380 Judicial Dr, San Diego, CA 92121 USA.
EM Noronha@targegen.com
OI McPherson, Andrew/0000-0001-8579-8709
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anderson RF, 2003, CHEM RES TOXICOL, V16, P1477, DOI 10.1021/tx034116v
   Anderson RF, 2003, J AM CHEM SOC, V125, P748, DOI 10.1021/ja0209363
   Arndt F, 1913, BER DTSCH CHEM GES, V46, P3522, DOI 10.1002/cber.191304603133
   Bamberger, 1894, CHEM BER, V27, P1548, DOI DOI 10.1002/CBER.18940270276
   BAMBERGER E, 1892, CHEM BER, V25, P3201
   Birincioglu M, 2003, J AM CHEM SOC, V125, P11607, DOI 10.1021/ja0352146
   BISCHLER, 1889, BER, V22, P2801
   Boschelli DH, 2005, BIOORG MED CHEM LETT, V15, P4681, DOI 10.1016/j.bmcl.2005.07.061
   Boschelli DH, 2005, J MED CHEM, V48, P3891, DOI 10.1021/jm050175p
   Boschelli DH, 2004, J MED CHEM, V47, P6666, DOI 10.1021/jm049237m
   Boschelli DH, 2007, DRUG FUTURE, V32, P481, DOI 10.1358/dof.2007.032.06.1107656
   Brizel DM, 1999, RADIOTHER ONCOL, V53, P113, DOI 10.1016/S0167-8140(99)00102-4
   BROWN JM, 1993, BRIT J CANCER, V67, P1163, DOI 10.1038/bjc.1993.220
   Cao JG, 2007, BIOORG MED CHEM LETT, V17, P5812, DOI 10.1016/j.bmcl.2007.08.043
   Carraro F, 2006, J MED CHEM, V49, P1549, DOI 10.1021/jm050603r
   CERRI R, 1979, J HETEROCYCLIC CHEM, V16, P1005, DOI 10.1002/jhet.5570160534
   Daniels JS, 1996, J AM CHEM SOC, V118, P3380, DOI 10.1021/ja9510774
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DOUKAS J, J CELL PHYSL UNPUB
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Hay MP, 2003, J MED CHEM, V46, P169, DOI 10.1021/jm020367+
   HAY MP, 2007, J MED CHEM, DOI DOI 10.1021/J.M070670G
   HOCKEL M, 1991, CANCER RES, V51, P6098
   Inbaraj JJ, 2003, CHEM RES TOXICOL, V16, P164, DOI 10.1021/tx0256073
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Ito H, 2003, SURGERY, V134, P221, DOI 10.1067/msy.2003.224
   ITO S, 1982, B CHEM SOC JPN, V55, P859, DOI 10.1246/bcsj.55.859
   Jiang FQ, 2006, BIOORG MED CHEM LETT, V16, P4209, DOI 10.1016/j.bmcl.2006.05.095
   KANTARJIAN H, 2008, J NATL COMPR CANC NE, V2, pS43
   Katritzky AR, 1997, SYNTHETIC COMMUN, V27, P3963, DOI 10.1080/00397919708005918
   Kennedy AS, 1997, INT J RADIAT ONCOL, V37, P897, DOI 10.1016/S0360-3016(96)00539-1
   Khodja M, 2006, HETEROATOM CHEM, V17, P166, DOI 10.1002/hc.20200
   LIN AJ, 1972, J MED CHEM, V15, P1247, DOI 10.1021/jm00282a011
   Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799
   Manetti F, 2006, J MED CHEM, V49, P3278, DOI 10.1021/jm060236z
   Movsas B, 1999, UROLOGY, V53, P11, DOI 10.1016/S0090-4295(98)00500-7
   NAGAI K, 1991, J AM CHEM SOC, V113, P5099, DOI 10.1021/ja00013a077
   NORONHA G, 2007, FRONTIERS DRUG DESIG, V3, P121
   Noronha G, 2007, BIOORG MED CHEM LETT, V17, P602, DOI 10.1016/j.bmcl.2006.11.006
   Noronha G, 2006, BIOORG MED CHEM LETT, V16, P5546, DOI 10.1016/j.bmcl.2006.08.035
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   PEER J, 1995, LAB INVEST, V72, P638
   PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   REES CW, 1971, CHEM COMMUN, P695
   REGAN BA, 1980, J PHARM SCI, V69, P789, DOI 10.1002/jps.2600690711
   Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
   SCHWESINGER H, 1992, PHARMAZIE, V47, P60
   Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X
   Stratford IJ, 1998, ANTI-CANCER DRUG DES, V13, P519
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Suzuki H, 1997, SYNTHESIS-STUTTGART, P855
   TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
   Tokarski JS, 2006, CANCER RES, V66, P5790, DOI 10.1158/0008-5472.CAN-05-4187
   Trevino JG, 2006, MINI-REV MED CHEM, V6, P681, DOI 10.2174/138955706777435724
   VAUPEL P, 1991, CANCER RES, V51, P3316
   Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288
   WIDMAN, 1888, J PRAKT CHEM, V38, P192
   Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851
   Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182/blood-2005-03-1036
   WOLF FJ, 1954, J AM CHEM SOC, V76, P4611, DOI 10.1021/ja01647a032
   WOLF FJ, 1954, J AM CHEM SOC, V76, P3551, DOI 10.1021/ja01642a060
   ZEMAN EM, 1986, INT J RADIAT ONCOL, V12, P1239, DOI 10.1016/0360-3016(86)90267-1
NR 67
TC 7
Z9 7
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD JAN
PY 2009
VL 4
IS 1
BP 33
EP 49
DI 10.1517/17460440802580536
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 393TK
UT WOS:000262395700006
PM 23480335
DA 2022-11-30
ER

PT J
AU Kopel, AC
   Carvounis, PE
   Holz, ER
AF Kopel, Andrew C.
   Carvounis, Petros E.
   Holz, Eric R.
TI Bacillus cereus endophthalmitis following intravitreous bevacizumab
   injection
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB The first case. of Bacillus cereus endophthalmitis following an intravitreous injection of bevacizurnab is described. A 77-year-old man presented to a retina specialist with an active choroidal neovascularization related to age-related macular degeneration for which he received intravitreous bevacizumab (1.25 mg) and post-injection topical gatifloxacin. Eight hours later, the patient woke up with excruciating pain and a decline in vision associated with nausea and vomiting. A vitreous biopsy was performed that revealed B. cereus. Despite intravitreous injections of vancomycin and ceftazidime on day I and pars plana vitrectomy with repeat intravitreous injections on day 3, the eye did not recover light perception.
C1 [Kopel, Andrew C.; Carvounis, Petros E.; Holz, Eric R.] Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Holz, ER (通讯作者)，Baylor Coll Med, Dept Ophthalmol, 6560 Fannin,NC 205, Houston, TX 77030 USA.
OI Carvounis, Petros/0000-0002-3879-3486
CR Callegan MC, 2005, INVEST OPHTH VIS SCI, V46, P3233, DOI 10.1167/iovs.05-0410
   Das T, 2001, OPHTHALMOLOGY, V108, P1819, DOI 10.1016/S0161-6420(01)00762-X
   HEMADY R, 1990, BRIT J OPHTHALMOL, V74, P26, DOI 10.1136/bjo.74.1.26
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
NR 4
TC 12
Z9 12
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2008
VL 39
IS 2
BP 153
EP 154
DI 10.3928/15428877-20080301-10
PG 2
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 277RC
UT WOS:000254231400013
PM 18435343
DA 2022-11-30
ER

PT J
AU Wahl, HW
   Becker, S
   Burmedi, D
   Schilling, O
AF Wahl, HW
   Becker, S
   Burmedi, D
   Schilling, O
TI The role of primary and secondary control in adaptation to age-related
   vision loss: A study of older adults with macular degeneration
SO PSYCHOLOGY AND AGING
LA English
DT Article
ID IMPAIRMENT
AB This study examines the effect of primary and secondary control on 3 major outcomes experienced, by visually impaired older adults, that is, functional ability, adaptation to vision loss, and positive affect. The authors' theoretical model is based on the J. Heckhausen and R. Schulz (1995) control framework, as well as a conceptual integration of these outcomes, and they hypothesized that control beliefs can substantially contribute to explaining interindividual differences in these outcomes. A path model applied to data from a sample (N = 90) of visually impaired older adults, suffering from age-related macular degeneration, the major cause of vision loss in old age, generally supports this expectation.
C1 Heidelberg Univ, German Ctr Res Aging, D-69115 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Wahl, HW (通讯作者)，Heidelberg Univ, German Ctr Res Aging, Bergheimer Str 20, D-69115 Heidelberg, Germany.
EM wahl@dzfa.uni-heidelberg.de
CR AINLAY SC, 1988, J SOC ISSUES, V44, P79, DOI 10.1111/j.1540-4560.1988.tb02050.x
   Arbuckle J.L., 1999, AMOS 40 USERS GUIDE
   BALTES MM, 1992, PSYCHOL AGING, V7, P409, DOI 10.1037/0882-7974.7.3.409
   Baltes P. B., 1999, HDB THEORIES AGING, P153
   Bellmann C, 2001, ASSIST TECHN RES SER, V8, P49
   BRICKMAN P, 1982, AM PSYCHOL, V37, P368, DOI 10.1037//0003-066X.37.4.368
   Burmedi D, 2002, VIS IMPAIR RES, V4, P15, DOI [10.1076/vimr.4.1.15.15633, DOI 10.1076/VIMR.4.1.15.15633]
   Burmedi D., 2002, VISUAL IMPAIRMENT RE, V4, P47
   Goldstein E.B., 1989, SENSATION PERCEPTION
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   HECKHAUSEN J, 1999, OPTIMIZATION PRIMARY
   Horowitz A, 1998, J VISUAL IMPAIR BLIN, V92, P30, DOI 10.1177/0145482X9809200106
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   ORR AL, 1992, VISION AGING CROSSRO, P3
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Raykov T, 1995, STRUCT EQU MODELING, V2, P289, DOI 10.1080/10705519509540017
   Schulz R, 1999, J GERONTOL B-PSYCHOL, V54, pP139, DOI 10.1093/geronb/54B.3.P139
   Snellen H., 1862, PROBEBUCHSTABEN BEST
   VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1
   Wahl H. W., 2000, LIGHTHOUSE HDB VISIO, P1069
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2003, EUR PSYCHOL, V8, P168, DOI 10.1027//1016-9040.8.3.168
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
NR 23
TC 62
Z9 64
U1 1
U2 9
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0882-7974
EI 1939-1498
J9 PSYCHOL AGING
JI Psychol. Aging
PD MAR
PY 2004
VL 19
IS 1
BP 235
EP 239
DI 10.1037/0882-7974.19.1.235
PG 5
WC Gerontology; Psychology, Developmental
WE Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychology
GA 802IE
UT WOS:000220156400023
PM 15065949
DA 2022-11-30
ER

PT J
AU Iturriaga-Goyon, E
   Buentello-Volante, B
   Magana-Guerrero, FS
   Garfias, Y
AF Iturriaga-Goyon, Emilio
   Buentello-Volante, Beatriz
   Magana-Guerrero, Fatima Sofia
   Garfias, Yonathan
TI Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers
   in Eye Pathological Angiogenesis
SO CELLS
LA English
DT Review
DE molecular-targeted therapy aptamers; angiogenesis; nucleolin;
   pathological angiogenesis; SELEX; diabetic retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; EPITHELIUM-DERIVED
   FACTOR; CELL-SURFACE NUCLEOLIN; OXIDATIVE STRESS; ANTISENSE
   OLIGONUCLEOTIDES; MACULAR DEGENERATION; DNA APTAMER; TIP CELL;
   PROANGIOGENIC PROPERTIES
AB Aptamers are single-stranded DNA or RNA oligonucleotides that are currently used in clinical trials due to their selectivity and specificity to bind small molecules such as proteins, peptides, viral particles, vitamins, metal ions and even whole cells. Aptamers are highly specific to their targets, they are smaller than antibodies and fragment antibodies, they can be easily conjugated to multiple surfaces and ions and controllable post-production modifications can be performed. Aptamers have been therapeutically used for age-related macular degeneration, cancer, thrombosis and inflammatory diseases. The aim of this review is to highlight the therapeutic, diagnostic and prognostic possibilities associated with aptamers, focusing on eye pathological angiogenesis.
C1 [Iturriaga-Goyon, Emilio] Univ Nacl Autonoma Mexico, Fac Med, MD PhD PECEM Program, Mexico City 04510, DF, Mexico.
   [Iturriaga-Goyon, Emilio; Buentello-Volante, Beatriz; Magana-Guerrero, Fatima Sofia; Garfias, Yonathan] Inst Ophthalmol, Res Unit, Cell & Tissue Biol, Chimalpopoca 14, Mexico City 06800, DF, Mexico.
   [Iturriaga-Goyon, Emilio; Garfias, Yonathan] Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Av Univ 3000, Mexico City 04510, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma
   de Mexico
RP Garfias, Y (通讯作者)，Inst Ophthalmol, Res Unit, Cell & Tissue Biol, Chimalpopoca 14, Mexico City 06800, DF, Mexico.; Garfias, Y (通讯作者)，Univ Nacl Autonoma Mexico, Fac Med, Dept Biochem, Av Univ 3000, Mexico City 04510, DF, Mexico.
EM iturriemilio@gmail.com; bbuentello@institutodeoftalmologia.org;
   fatima.magana@institutodeoftalmologia.org; ygarfias@bq.unam.mx
OI Buentello Volante, Beatriz/0000-0003-4529-990X; Magana Guerrero, Fatima
   Sofia/0000-0002-1535-9898
FU CONACYT-Problemas Nacionales [2015-0311]; PAPIIT-DGAPA-UNAM [IN203821];
   CONACYT [769045]
FX This research and the APC were funded by CONACYT-Problemas Nacionales,
   grant number 2015-0311, and PAPIIT-DGAPA-UNAM, grant number IN203821.
   This manuscript is part of the PhD thesis of Emilio Iturriaga-Goyon, who
   is receiving a scholarship from CONACYT number 769045 and belongs to the
   PECEM Program.
CR Achari AE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061321
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Acquah C, 2021, CELL MOL BIOENG, V14, P209, DOI 10.1007/s12195-020-00664-7
   Adachi T, 2019, MOLECULES, V24, DOI 10.3390/molecules24234229
   Ahir BK, 2020, MOL NEUROBIOL, V57, P2461, DOI 10.1007/s12035-020-01892-8
   Akwii RG, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050471
   Al-Kharashi AS, 2018, SAUDI J OPHTHALMOL, V32, P318, DOI 10.1016/j.sjopt.2018.05.002
   Alarcon-Martinez L, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0761-z
   Alkhamis O, 2019, TRAC-TREND ANAL CHEM, V121, DOI 10.1016/j.trac.2019.115699
   Amato R, 2016, INVEST OPHTH VIS SCI, V57, P3066, DOI 10.1167/iovs.16-19285
   Annunziata CM, 2007, CLIN CANCER RES, V13, P6585, DOI 10.1158/1078-0432.CCR-07-0327
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Bae ON, 2013, ARTERIOSCL THROM VAS, V33, P1920, DOI 10.1161/ATVBAHA.113.301609
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Blanco R, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006569
   Bullard LE, 2003, INVEST OPHTH VIS SCI, V44, P1722, DOI 10.1167/iovs.01-1193
   Bunka DHJ, 2010, CURR OPIN PHARMACOL, V10, P557, DOI 10.1016/j.coph.2010.06.009
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Cai SD, 2018, ANALYST, V143, P5317, DOI 10.1039/c8an01467a
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Carvalho J, 2019, ORG BIOMOL CHEM, V17, P2992, DOI 10.1039/c9ob00318e
   Cayabyab R, 2016, NEONATOLOGY, V109, P369, DOI 10.1159/000444901
   Chen K, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1438
   Chen WQ, 2019, J CELL COMMUN SIGNAL, V13, P291, DOI 10.1007/s12079-019-00511-z
   Chen Z, 2016, SAUDI MED J, V37, P1312, DOI 10.15537/smj.2016.12.15972
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132
   Cirenajwis H, 2015, ONCOTARGET, V6, P12297, DOI 10.18632/oncotarget.3655
   Clapp C, 2008, AM J PHYSIOL-ENDOC M, V295, pE772, DOI 10.1152/ajpendo.90358.2008
   Comitato A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0613-y
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Cunha-Vaz J, 2017, DEV OPHTHALMOL, V58, P11, DOI 10.1159/000455265
   Dal Monte M, 2007, INVEST OPHTH VIS SCI, V48, P3480
   Darche M, 2020, FASEB J, V34, P5851, DOI 10.1096/fj.201901876R
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Domingueti CP, 2016, J DIABETES COMPLICAT, V30, P738, DOI 10.1016/j.jdiacomp.2015.12.018
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   El-Sanhouri A, 2008, INVEST OPHTHALMOL VI, V49, P2133
   Eng VA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232353
   Evers MM, 2015, ADV DRUG DELIVER REV, V87, P90, DOI 10.1016/j.addr.2015.03.008
   Fahling M, 2005, BBA-GENE STRUCT EXPR, V1731, P32, DOI 10.1016/j.bbaexp.2005.08.005
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fallah A, 2019, BIOMED PHARMACOTHER, V110, P775, DOI 10.1016/j.biopha.2018.12.022
   Fang XH, 2010, ACCOUNTS CHEM RES, V43, P48, DOI 10.1021/ar900101s
   Faryammanesh R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093173
   Felmeden DC, 2003, EUR HEART J, V24, P586, DOI 10.1016/S0195-668X(02)00635-8
   Fenwick EK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180252
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fujiki H, 2014, J CANCER RES CLIN, V140, P689, DOI 10.1007/s00432-014-1587-5
   Garcia C, 2008, J CLIN INVEST, V118, P2291, DOI [10.1172/JC134508, 10.1172/JCI34508]
   Gargett CE, 2001, REPRODUCTION, V121, P181, DOI 10.1530/rep.0.1210181
   Goveia J, 2014, CIRC RES, V115, P205, DOI 10.1161/CIRCRESAHA.114.304234
   Guerard S., 2014, J CLIN EXP DERMATOL, V4, P1, DOI [10.4172/2155-9554.S2-007, DOI 10.4172/2155-9554.S2-007]
   Guerin CL, 2015, THROMB HAEMOSTASIS, V113, P1084, DOI 10.1160/TH14-09-0748
   Gupta N, 2017, AM J CANCER RES, V7, P1252
   Haefliger JA, 2017, ARTERIOSCL THROM VAS, V37, P2136, DOI 10.1161/ATVBAHA.117.310072
   Han J, 2020, J CANCER, V11, P6902, DOI 10.7150/jca.49532
   Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641
   Harhaj NS, 2006, INVEST OPHTH VIS SCI, V47, P5106, DOI 10.1167/iovs.06-0322
   Haupt F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46308-3
   He F, 2020, CURR MED CHEM, V27, P2189, DOI 10.2174/0929867325666181008142831
   He XY, 2020, ADV MATER, V32, DOI 10.1002/adma.202000208
   Heldin CH, 2018, J INTERN MED, V283, P16, DOI 10.1111/joim.12690
   Hnik Peter, 2009, J Diabetes Sci Technol, V3, P924
   Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024
   Huang FF, 2019, ONCOL REP, V41, P590, DOI 10.3892/or.2018.6787
   Huang XP, 2018, ONCOTARGET, V9, P2220, DOI 10.18632/oncotarget.23346
   Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961
   Hwang DW, 2010, J NUCL MED, V51, P98, DOI 10.2967/jnumed.109.069880
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Kaur H, 2018, THERANOSTICS, V8, P4016, DOI 10.7150/thno.25958
   Ke X., 2017, FRONT LAB MED, V1, P69, DOI 10.1016/j.flm.2017.06.001
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kim M, 2018, MOLECULES, V23, DOI 10.3390/molecules23040830
   Kinoshita D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67217-w
   Kiss S, 2018, CLIN OPHTHALMOL, V12, P1625, DOI 10.2147/OPTH.S169143
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kong HY, 2013, BIOMOL THER, V21, P423, DOI 10.4062/biomolther.2013.085
   Koutsioumpa M, 2014, RECENT PAT ANTI-CANC, V9, DOI 10.2174/1574892808666131119095953
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Kwon W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604205
   Lai WY, 2014, BIOMATERIALS, V35, P2905, DOI 10.1016/j.biomaterials.2013.12.054
   Lakhin AV, 2013, ACTA NATURAE, V5, P34, DOI 10.32607/20758251-2013-5-4-34-43
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Le BT, 2019, MOL THER-NUCL ACIDS, V14, P142, DOI 10.1016/j.omtn.2018.11.007
   Le Rhun E, 2019, CANCER TREAT REV, V80, DOI 10.1016/j.ctrv.2019.101896
   Leblond A, 2017, AUTOIMMUN REV, V16, P594, DOI 10.1016/j.autrev.2017.04.005
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Lenke L, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00893
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li LY, 2014, BIOMATERIALS, V35, P3840, DOI 10.1016/j.biomaterials.2014.01.019
   Li T, 2021, MOLECULES, V26, DOI 10.3390/molecules26041067
   Li Y, 2018, FREE RADICAL BIO MED, V126, P1, DOI 10.1016/j.freeradbiomed.2018.07.009
   Li YL, 2016, CANCER BIOL MED, V13, P206, DOI 10.20892/j.issn.2095-3941.2015.0070
   Lin CN, 2021, MOL THER-NUCL ACIDS, V23, P757, DOI 10.1016/j.omtn.2020.12.025
   Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515
   MacLauchlan S, 2011, P NATL ACAD SCI USA, V108, pE1137, DOI 10.1073/pnas.1104357108
   Madonna R, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0342-4
   Martinez CE, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00290
   Meyer C, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/904750
   Mirau PA, 2018, LANGMUIR, V34, P2139, DOI 10.1021/acs.langmuir.7b02449
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Mongiat M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111822
   Moschos MM, 2013, J OCUL PHARMACOL TH, V29, P754, DOI 10.1089/jop.2012.0129
   Mukwaya A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32137
   Muppala S, 2015, ARTERIOSCL THROM VAS, V35, P1975, DOI 10.1161/ATVBAHA.115.305912
   Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367
   Murugeswari P, 2017, CYTOKINE, V95, P126, DOI 10.1016/j.cyto.2017.02.013
   Nejabati HR, 2017, GYNECOL ENDOCRINOL, V33, P668, DOI 10.1080/09513590.2017.1318375
   Newman AC, 2011, MOL BIOL CELL, V22, P3791, DOI 10.1091/mbc.E11-05-0393
   Nomura Y, 2010, NUCLEIC ACIDS RES, V38, P7822, DOI 10.1093/nar/gkq615
   Nunez-Amaro CD, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.27
   Odeh F, 2020, MOLECULES, V25, DOI 10.3390/molecules25010003
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Panina YA, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01656
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Park S, 2010, AM J PHYSIOL-CELL PH, V299, pC1468, DOI 10.1152/ajpcell.00246.2010
   Parma L, 2017, EUR J PHARMACOL, V816, P107, DOI 10.1016/j.ejphar.2017.04.028
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Placencio VR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133786
   Poimenidi E, 2016, VASC PHARMACOL, V80, P11, DOI 10.1016/j.vph.2016.02.008
   Pollina EA, 2008, CELL CYCLE, V7, P2056, DOI 10.4161/cc.7.13.6240
   Prodeus A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.11
   Puche N, 2012, ACTA OPHTHALMOL, V90, P357, DOI 10.1111/j.1755-3768.2010.01913.x
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Quiroz-Mercado J, 2016, GRAEF ARCH CLIN EXP, V254, P1753, DOI 10.1007/s00417-016-3409-8
   Reichhart N, 2014, EXP EYE RES, V126, P27, DOI 10.1016/j.exer.2014.05.005
   Reyes-Reyes EM, 2008, EXP CELL RES, V314, P2212, DOI 10.1016/j.yexcr.2008.03.016
   Reyes-Reyes EM, 2015, MOL ONCOL, V9, P1392, DOI 10.1016/j.molonc.2015.03.012
   Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148
   Rodriguez Paulo C, 2003, Cancer Chemother Biol Response Modif, V21, P351
   Roozbahani M, 2018, SCI J IRANIAN BLOOD, V15, P59
   Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6
   Ryman JT, 2017, CPT-PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sakai D, 2015, ADV DRUG DELIVER REV, V84, P159, DOI 10.1016/j.addr.2014.06.009
   Saleh M, 2011, ACTA ONCOL, V50, P477, DOI 10.3109/0284186X.2011.555781
   Samson FP, 2020, ACS OMEGA, V5, P21113, DOI 10.1021/acsomega.0c02763
   Santos GSP, 2018, EYE, V32, P483, DOI 10.1038/eye.2017.220
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Selvakumar LS, 2012, ANAL BIOCHEM, V427, P151, DOI 10.1016/j.ab.2012.05.020
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Shi HB, 2007, BLOOD, V110, P2899, DOI 10.1182/blood-2007-01-064428
   Shieh YA, 2010, ACS NANO, V4, P1433, DOI 10.1021/nn901374b
   Shirota H, 2015, VACCINES-BASEL, V3, P390, DOI 10.3390/vaccines3020390
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200
   Sletten T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090687
   Smith SJ, 2014, BRIT J OPHTHALMOL, V98, P292, DOI 10.1136/bjophthalmol-2013-303885
   Stapor PC, 2014, J VASC RES, V51, P163, DOI 10.1159/000362276
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Suraya R, 2021, RESPIR INVESTIG, V59, P291, DOI 10.1016/j.resinv.2020.12.007
   Tajrishi Marjan M, 2011, Commun Integr Biol, V4, P267, DOI 10.4161/cib.4.3.14884
   Talreja D, 2018, EXP EYE RES, V175, P20, DOI 10.1016/j.exer.2018.05.034
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tang YX, 2010, AM J PHYSIOL-CELL PH, V298, pC665, DOI 10.1152/ajpcell.00153.2009
   Tao XQ, 2020, BIOSENS BIOELECTRON, V168, DOI 10.1016/j.bios.2020.112537
   Tazhibi Mahdi, 2014, J Educ Health Promot, V3, P85, DOI 10.4103/2277-9531.139251
   Teichert M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16106
   Thijssen VLJL, 2018, J PATHOL, V246, P447, DOI 10.1002/path.5152
   Titchenell PM, 2012, BIOCHEM J, V446, P455, DOI 10.1042/BJ20111961
   Triebel J, 2015, AM J PHYSIOL-REG I, V309, pR1193, DOI 10.1152/ajpregu.00256.2015
   Tschulakow A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113701
   Turck N, 2006, J CELL PHYSIOL, V206, P545, DOI 10.1002/jcp.20501
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P2119, DOI 10.1200/JCO.2011.39.9824
   Venkatesh Vandana, 2018, Stem Cell Investig, V5, P5, DOI 10.21037/sci.2018.02.02
   Vivanco-Rojas O, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107977
   Walia A, 2015, BBA-GEN SUBJECTS, V1850, P2422, DOI 10.1016/j.bbagen.2015.09.007
   Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002
   Wang JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110531
   Wang XD, 2013, INVEST OPHTH VIS SCI, V54
   Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wu XQ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.925583
   Wu YR, 2010, P NATL ACAD SCI USA, V107, P5, DOI 10.1073/pnas.0909611107
   Xue KM, 2020, EXPERT OPIN INV DRUG, V29, P1163, DOI 10.1080/13543784.2020.1804853
   Yamamoto H, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00099
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang X, 2016, FASEB J, V30, P601, DOI 10.1096/fj.15-277962
   Yang XH, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0509-6
   Yazdian-Robati R, 2020, INT J BIOL MACROMOL, V155, P1420, DOI 10.1016/j.ijbiomac.2019.11.118
   Yeh S, 2015, OPHTHALMOLOGY, V122, P769, DOI 10.1016/j.ophtha.2014.10.013
   Yetkin-Arile B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46503-2
   Yoshida T, 2012, EXP EYE RES, V94, P41, DOI 10.1016/j.exer.2011.11.003
   Zeilbeck LF, 2016, EXP EYE RES, V145, P317, DOI 10.1016/j.exer.2015.12.001
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhang WY, 2019, BIOORG MED CHEM LETT, V29, P2393, DOI 10.1016/j.bmcl.2019.06.002
   Zhang Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24050941
   Zhang ZQ, 2013, BIOMATERIALS, V34, P9728, DOI 10.1016/j.biomaterials.2013.08.079
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 203
TC 1
Z9 1
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2021
VL 10
IS 6
AR 1455
DI 10.3390/cells10061455
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SX7FV
UT WOS:000665366900001
PM 34200613
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hogarty, DT
   Mackey, DA
   Hewitt, AW
AF Hogarty, Daniel T.
   Mackey, David A.
   Hewitt, Alex W.
TI Current state and future prospects of artificial intelligence in
   ophthalmology: a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; diabetic retinopathy; machine
   learning; ophthalmology
ID MACHINE LEARNING CLASSIFIERS; COLLAGEN CROSS-LINKING;
   DIABETIC-RETINOPATHY; KERATOCONUS DETECTION; MACULAR DEGENERATION;
   AUTOMATED IDENTIFICATION; CORNEAL TOPOGRAPHY; NEURAL-NETWORK; DEEP; AGE
AB Artificial intelligence (AI) has emerged as a major frontier in computer science research. Although AI has broad application across many medical fields, it will have particular utility in ophthalmology and will dramatically change the diagnostic and treatment pathways for many eye conditions such as corneal ectasias, glaucoma, age-related macular degeneration and diabetic retinopathy. However, given that AI has primarily been driven as a computer science, its concepts and terminology are unfamiliar to many medical professionals. Important key terms such as machine learning and deep learning are often misunderstood and incorrectly used interchangeably. This article presents an overview of AI and new developments relevant to ophthalmology.
C1 [Hogarty, Daniel T.; Mackey, David A.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Mackey, David A.; Hewitt, Alex W.] Univ Western Australia, Ctr Vis Sci, Lions Eye Inst, Perth, WA, Australia.
   [Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Lions Eye Institute; University of Western
   Australia; University of Tasmania; Menzies Institute for Medical
   Research
RP Hogarty, DT (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 731 Ferguson Rd, Mooroopna, Vic 3629, Australia.
EM daniel.hogarty93@gmail.com
RI Mackey, David A/H-5340-2014
OI Mackey, David A/0000-0001-7914-4709; Hewitt, Alex/0000-0002-5123-5999
CR Abbas Q, 2017, MED BIOL ENG COMPUT, V55, P1959, DOI 10.1007/s11517-017-1638-6
   Akyol K, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6814791
   Al-Jarrah Mohammad A., 2017, Journal of Medical Engineering & Technology, V41, P498, DOI 10.1080/03091902.2017.1358772
   Alfonso JF, 2012, J CATARACT REFR SURG, V38, P1576, DOI 10.1016/j.jcrs.2012.05.031
   Ambrosio R, 2017, J REFRACT SURG, V33, P434, DOI 10.3928/1081597X-20170426-02
   Arbelaez MC, 2012, OPHTHALMOLOGY, V119, P2231, DOI 10.1016/j.ophtha.2012.06.005
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Aslam TM, 2018, AM J OPHTHALMOL, V185, P94, DOI 10.1016/j.ajo.2017.10.015
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bordes A., 2014, EMNLP, P615, DOI DOI 10.3115/V1/D14-1067
   Brownlee J., 2016, MACH LEARN MASTERY, V3
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Caixinha M, 2016, IEEE T BIO-MED ENG, V63, P2326, DOI 10.1109/TBME.2016.2527787
   Campbell JP, 2016, JAMA OPHTHALMOL, V134, P651, DOI 10.1001/jamaophthalmol.2016.0611
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Checketts JX, 2017, JAMA DERMATOL, V153, P1229, DOI 10.1001/jamadermatol.2017.3109
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   De Neve W., 2017, P 2 INT WORKSH MULT, P89, DOI DOI 10.1145/3132635.3132650
   Dilsizian SE, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-013-0441-8
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Han SS, 2018, J INVEST DERMATOL, V138, P2275, DOI 10.1016/j.jid.2018.05.014
   Hidalgo IR, 2017, CORNEA, V36, P689, DOI 10.1097/ICO.0000000000001194
   Holland DR, 1997, OPHTHALMOLOGY, V104, P1409, DOI 10.1016/S0161-6420(97)30123-7
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Jiang JW, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0420-1
   Johnson KW, 2018, J AM COLL CARDIOL, V71, P2668, DOI 10.1016/j.jacc.2018.03.521
   Kawamorita T, 2009, J CATARACT REFR SURG, V35, P127, DOI 10.1016/j.jcrs.2008.10.019
   Keane M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009700.pub2
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kim SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177726
   Kovacs I, 2016, J CATARACT REFR SURG, V42, P275, DOI 10.1016/j.jcrs.2015.09.020
   KRACHMER JH, 1984, SURV OPHTHALMOL, V28, P293, DOI 10.1016/0039-6257(84)90094-8
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   MAEDA N, 1994, INVEST OPHTH VIS SCI, V35, P2749
   Ashraf MM, 2008, CORNEA, V27, P480, DOI 10.1097/ICO.0b013e31816485d3
   Mazzotta C, 2018, CORNEA, V37, P560, DOI 10.1097/ICO.0000000000001505
   Mikolov T., 2011, 2011 IEEE Workshop on Automatic Speech Recognition & Understanding (ASRU), P196, DOI 10.1109/ASRU.2011.6163930
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Navarrete-Dechent C, 2018, J INVEST DERMATOL, V138, P2277, DOI 10.1016/j.jid.2018.04.040
   Neill DB, 2013, IEEE INTELL SYST, V28, P92, DOI 10.1109/MIS.2013.51
   Oh E, 2015, INVEST OPHTH VIS SCI, V56, P3957, DOI 10.1167/iovs.15-16805
   Omodaka K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190012
   Patel VL, 2009, ARTIF INTELL MED, V46, P5, DOI 10.1016/j.artmed.2008.07.017
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Prahs P, 2018, OPHTHALMOLOGE, V115, P722, DOI 10.1007/s00347-018-0708-y
   Pramanik S, 2006, OPHTHALMOLOGY, V113, P1633, DOI 10.1016/j.ophtha.2006.02.058
   Rabinowitz YS, 1999, J CATARACT REFR SURG, V25, P1327, DOI 10.1016/S0886-3350(99)00195-9
   Raghavendra U, 2018, INFORM SCIENCES, V441, P41, DOI 10.1016/j.ins.2018.01.051
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   Raju M, 2017, STUD HEALTH TECHNOL, V245, P559, DOI 10.3233/978-1-61499-830-3-559
   Randleman JB, 2008, OPHTHALMOLOGY, V115, P37, DOI 10.1016/j.ophtha.2007.03.073
   Rozema JJ, 2016, CORNEA, V35, P860, DOI 10.1097/ICO.0000000000000802
   Safi H, 2018, SURV OPHTHALMOL, V63, P601, DOI 10.1016/j.survophthal.2018.04.003
   Samuel AL, 2000, IBM J RES DEV, V44, P207, DOI 10.1147/rd.441.0206
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Sharif MS, 2015, APPL SOFT COMPUT, V36, P269, DOI 10.1016/j.asoc.2015.07.019
   Smadja D, 2013, AM J OPHTHALMOL, V156, P237, DOI 10.1016/j.ajo.2013.03.034
   Souza MB, 2010, CLINICS, V65, P1223, DOI 10.1590/S1807-59322010001200002
   Thompson RF, 2018, RADIOTHER ONCOL, V129, P421, DOI 10.1016/j.radonc.2018.05.030
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Twa MD, 2004, CORNEA, V23, P447, DOI 10.1097/01.ico.0000122702.49054.12
   Vass C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003167.pub3
   Veli M, 2018, ACS NANO, V12, P2554, DOI 10.1021/acsnano.7b08375
   Wollensak G, 2003, AM J OPHTHALMOL, V135, P620, DOI 10.1016/S0002-9394(02)02220-1
   Xu KL, 2017, MOLECULES, V22, DOI 10.3390/molecules22122054
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P1143, DOI 10.1109/TBME.2013.2295605
   Zhang LL, 2017, IEEE INT C NETW SENS, P60, DOI 10.1109/ICNSC.2017.8000068
NR 75
TC 61
Z9 63
U1 6
U2 71
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2019
VL 47
IS 1
BP 128
EP 139
DI 10.1111/ceo.13381
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HL3KR
UT WOS:000458614400015
PM 30155978
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Xu, HP
   Kauppinen, A
AF Kaarniranta, Kai
   Xu, Heping
   Kauppinen, Anu
TI Mechanistical retinal drug targets and challenges
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Ageing; Autophagy; Phagocytosis; Inflammation; Oxidative stress
ID PIGMENT EPITHELIAL-CELLS; PHOTORECEPTOR OUTER SEGMENTS; NLRP3
   INFLAMMASOME ACTIVATION; MACULAR DEGENERATION; OXIDATIVE STRESS;
   MITOCHONDRIAL DYSFUNCTION; ALPHA-V-BETA-5 INTEGRIN; COMPLEMENT
   ACTIVATION; RPE DEGENERATION; ARPE-19 CELLS
AB The retina is constantly exposed to light that increases reactive oxygen species in retina. Oxidative stress, inflammation and neurodegeneration are the major contributors in the most common retinal diseases, such as age related macular degeneration (AMD), glaucoma and diabetic retinopathy (DR). Emerging developments and research for novel therapy targets and drug delivery to the posterior segment offer a promising future for the treatment of retinal diseases including rare hereditary diseases. In this review we discuss about promising mechanistical retinal drug targets. Vascular endothelial growth factor (VEGF) signaling and anti-VEGF treatments are excluded. Crown Copyright (C) 2018 Published by Elsevier B.V. All rights reserved.
C1 [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Univ Lodz, Dept Mol Genet, Lodz, Poland.
   [Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Xu, Heping] Cent S Univ, Aier Sch Ophthalmol, Changsha, Hunan, Peoples R China.
   [Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz; Queens University Belfast; Central
   South University; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.; Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Ctr Med Expt, Belfast, Antrim, North Ireland.
EM kai.kaarniranta@uef.fi; heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X
FU European Commission [EC H2020 MSCA - ITN - 722717]; Academy of Finland
   [296840, 297267, AK307341]; Finnish Eye Foundation; Paivikki and Sakari
   Sohlberg Foundation; Business of Finland; Kuopio University Hospital VTR
   [5503757]; University of Eastern Finland; European Commission: EC H2020
   [MSCA - ITN - 722717]; Fight for Sight [1361/62, 1425/1426, 1574/1575,
   5057/5058]; Diabetes UK [13/0004729, 16/0005537]; Emil Aaltonen
   Foundation; Finnish Cultural Foundation
FX Kai Kaarniranta: European Commission: EC H2020 MSCA - ITN - 722717;
   Academy of Finland (296840), the Finnish Eye Foundation, the Paivikki
   and Sakari Sohlberg Foundation, the Business of Finland, the Kuopio
   University Hospital VTR (5503757) and University of Eastern Finland.
   Heping Xu: European Commission: EC H2020, MSCA - ITN - 722717; Fight for
   Sight: 1361/62, 1425/1426, 1574/1575, and 5057/5058; Diabetes UK:
   13/0004729, 16/0005537.Anu Kauppinen: Academy of Finland (297267,
   AK307341), the Emil Aaltonen Foundation, the Paivikki and Sakari
   Sohlberg Foundation, the Finnish Cultural Foundation, and the Finnish
   Eye Foundation.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Balak DMW, 2017, CLIN IMMUNOL, V174, P63, DOI 10.1016/j.clim.2016.09.015
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265
   Cassel SL, 2009, SEMIN IMMUNOL, V21, P194, DOI 10.1016/j.smim.2009.05.002
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2010, EUR J IMMUNOL, V40, P2870, DOI 10.1002/eji.201040323
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320
   Jiang HR, 2001, INVEST OPHTH VIS SCI, V42, P177
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2017, ACTA OPHTHALMOL, V95, P335, DOI 10.1111/aos.13344
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kiser PD, 2017, J PHARMACOL EXP THER, V362, P131, DOI 10.1124/jpet.117.240721
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luo C, 2011, MOL VIS, V17, P1588
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Rodriguez-Muela N, 2012, AUTOPHAGY, V8, P286, DOI 10.4161/auto.8.2.18982
   Russo R, 2015, PROG BRAIN RES, V220, P87, DOI 10.1016/bs.pbr.2015.04.009
   Salminen A, 2017, AGEING RES REV, V37, P79, DOI 10.1016/j.arr.2017.05.004
   Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089
   Shealy D. J., 2008, V181, P101
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2003, J NEUROIMMUNOL, V142, P47, DOI 10.1016/S0165-5728(03)00258-3
   Yao JY, 2016, AUTOPHAGY, V12, P2439, DOI 10.1080/15548627.2016.1238553
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 79
TC 9
Z9 9
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB 15
PY 2018
VL 126
BP 177
EP 184
DI 10.1016/j.addr.2018.04.016
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GK5MY
UT WOS:000436220400012
PM 29698626
DA 2022-11-30
ER

PT J
AU Loskutova, E
   Nolan, J
   Howard, A
   Beatty, S
AF Loskutova, Ekaterina
   Nolan, John
   Howard, Alan
   Beatty, Stephen
TI Macular Pigment and Its Contribution to Vision
SO NUTRIENTS
LA English
DT Article
DE lutein; zeaxanthin; meso-zeaxanthin; visual performance; macular pigment
ID CONTRAST SENSITIVITY; BLUE-LIGHT; VISUAL PERFORMANCE; OPTICAL-DENSITY;
   IN-VITRO; CAROTENOIDS; LUTEIN; ZEAXANTHIN; DEGENERATION; IDENTIFICATION
AB Three dietary carotenoids, lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) accumulate at the central retina (macula), where they are collectively referred to as macular pigment (MP). MP's pre-receptoral absorption of blue light and consequential attenuation of the effects of chromatic aberration and light scatter are important for optimal visual function. Furthermore, antioxidant activity of MP's constituent carotenoids and the same blue light-filtering properties underlie the rationale for its putative protective role for age-related macular degeneration (AMD). Supplementation with L, Z and MZ augments MP and enhances visual performance in diseased and non-diseased eyes, and may reduce risk of AMD development and/or progression.
C1 [Loskutova, Ekaterina; Nolan, John; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Nolan, John; Beatty, Stephen] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [Howard, Alan] Univ Cambridge Downing Coll, Howard Fdn, Cambridge CB22 5LA, England.
C3 South East Technological University (SETU); University of Cambridge
RP Loskutova, E (通讯作者)，Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
EM kate@ivr.ie; jmnolan@wit.ie; alan.howard@howard-foundation.com;
   sbeatty@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Loskutova,
   Ekaterina/0000-0002-2438-9036
FU The Howard Foundation, Cambridge, UK [CB22 5LA]
FX Grant support was provided by The Howard Foundation, Cambridge, CB22
   5LA, UK.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Charalampidou S, 2011, EYE, V25, P1147, DOI 10.1038/eye.2011.123
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Hammond BR, 2012, VISION RES, V63, P58, DOI 10.1016/j.visres.2012.04.019
   Hammond BR, 2005, OPHTHAL PHYSL OPT, V25, P315, DOI 10.1111/j.1475-1313.2005.00271.x
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Kwok MCM, 2008, MOL CELL PROTEOMICS, V7, P1053, DOI 10.1074/mcp.M700571-MCP200
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Mainster MA, 2012, AM J OPHTHALMOL, V153, P587, DOI 10.1016/j.ajo.2012.01.008
   MARMOR MF, 1981, ANN OPHTHALMOL, V13, P1069
   Murray I.J., 2013, INVEST OPHT IN PRESS
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rubin LP, 2012, J PERINATOL, V32, P418, DOI 10.1038/jp.2011.87
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Sabour-Pickett S., 2011, MOL NUTR FOOD RES, P270
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Stahl W, 2001, BIOFACTORS, V15, P95, DOI 10.1002/biof.5520150209
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   van Herpen-Broekmans WMR, 2004, EUR J EPIDEMIOL, V19, P915, DOI 10.1007/s10654-004-5760-z
   Walls G L, 1933, Br J Ophthalmol, V17, P705, DOI 10.1136/bjo.17.12.705
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
NR 35
TC 35
Z9 36
U1 1
U2 31
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2013
VL 5
IS 6
BP 1962
EP 1969
DI 10.3390/nu5061962
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 169HS
UT WOS:000320771400007
PM 23760061
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Khachik, F
AF Khachik, Frederick
TI Synthesis of (3R,3 ' R)-Zeaxanthin and Its meso-Stereoisomer from (3R,3
   ' R,6 ' R)-Lutein via (3R)-3 ',4 '-Anhydrolutein
SO SYNTHESIS-STUTTGART
LA English
DT Article
DE optically active hydroxycarotenoids; partial synthesis; chiral
   resolution; regioselective hydroboration; highly conjugated polyenes
ID STRUCTURALLY RELATED-COMPOUNDS; ACTIVE NATURAL CAROTENOIDS; HUMAN
   PLASMA; TECHNICAL PROCEDURES; DIETARY CAROTENOIDS; OXIDATION-PRODUCTS;
   ALPHA-PINENE; ZEAXANTHIN; LUTEIN; IDENTIFICATION
AB A process has been developed for the partial synthesis of (3R,3'R)-zeaxanthin and (3R,3'S; meso)-zeaxanthin from commercially available (3R,3'R,6'R)-lutein. This involves the regioselective hydroboration of a dehydration product of lutein, namely (3R)-3',4'-didehydro-beta, beta-caroten-3-ol [(3R)-3',4'-anhydrolutein], to yield a mixture of (3R,3'R)-zeaxanthin and (3R,3'S; meso)-zeaxanthin followed by separation of these carotenoids by enzyme-mediated acylation. (3R,3'R,6'R)-Lutein, (3R,3'R)-zeaxanthin and its mesoisomer accumulate in human ocular tissues and have been implicated in the prevention of age-related macular degeneration (AMD).
C1 Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland College Park
RP Khachik, F (通讯作者)，Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
EM khachik@umd.edu
CR BELL HM, 1969, J ORG CHEM, V34, P3923, DOI 10.1021/jo01264a038
   Bernhard K., 1998, [No title captured], Patent No. [US 5780693, 5780693]
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BROWN HC, 1961, J ORG CHEM, V26, P631, DOI 10.1021/jo01061a630
   BROWN HC, 1959, J AM CHEM SOC, V81, P4108, DOI 10.1021/ja01524a073
   BROWN HC, 1995, J ORGANOMET CHEM, V500, P1, DOI 10.1016/0022-328X(95)00509-O
   CARREA G, 1992, TETRAHEDRON-ASYMMETR, V3, P775, DOI 10.1016/S0957-4166(00)80519-4
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2003, J NAT PROD, V66, P67, DOI 10.1021/np020376l
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1995, J CHROMATOGR B, V670, P219, DOI 10.1016/0378-4347(95)00169-7
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   Khachik F, 1995, US Patent, Patent No. [5,382,714, 5382714]
   Khachik F, 2007, J NAT PROD, V70, P220, DOI 10.1021/np060575v
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2006, PURE APPL CHEM, V78, P1551, DOI 10.1351/pac200678081551
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Khachik F, 2009, J ORG CHEM, V74, P3875, DOI 10.1021/jo900432r
   LOEBER DE, 1971, J CHEM SOC C, P404, DOI 10.1039/j39710000404
   MAYER H, 1980, HELV CHIM ACTA, V63, P1451, DOI 10.1002/hlca.19800630614
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   RODRIGUEZ GA, 1999, Patent No. 9903830
   RUTTIMANN A, 1980, HELV CHIM ACTA, V63, P1456, DOI 10.1002/hlca.19800630615
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SOUKUP M, 1990, HELV CHIM ACTA, V73, P868, DOI 10.1002/hlca.19900730412
   Torres-Cardona MD, 1996, Process for the isomerization of lutein, Patent No. 5523494
   VIRGILI S, 1997, Patent No. 9731894
   WIDMER E, 1990, HELV CHIM ACTA, V73, P861, DOI 10.1002/hlca.19900730411
   ZWEIFEL G, 1964, J AM CHEM SOC, V86, P393, DOI 10.1021/ja01057a021
NR 33
TC 2
Z9 2
U1 0
U2 8
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0039-7881
J9 SYNTHESIS-STUTTGART
JI Synthesis
PD FEB
PY 2012
VL 44
IS 3
BP 453
EP 459
DI 10.1055/s-0031-1289662
PG 7
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)
SC Chemistry
GA 891ZG
UT WOS:000300255100020
DA 2022-11-30
ER

PT J
AU Lauermann, JL
   Eter, N
   Alten, F
AF Lauermann, Jost L.
   Eter, Nicole
   Alten, Florian
TI Optical Coherence Tomography Angiography Offers New Insights into
   Choriocapillaris Perfusion
SO OPHTHALMOLOGICA
LA English
DT Review
DE Optical coherence tomography; Optical coherence tomography angiography;
   Spectral-domain optical coherence tomography; Swept-source optical
   coherence tomography; Choriocapillaris; Age-related macular
   degeneration; Central serous chorioretinopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT EPITHELIAL DETACHMENT; MACULAR
   DEGENERATION; OCT-ANGIOGRAPHY; SWEPT-SOURCE; GEOGRAPHIC ATROPHY;
   SPECTRAL-DOMAIN; MORPHOMETRIC-ANALYSIS; ULTRAHIGH-SPEED; CHOROIDAL
   NEOVASCULARIZATION
AB The choriocapillaris (CC) represents a fundamentally important vascular layer that is subject to physiologic changes with increasing age and that is also associated with a wide range of chorioretinal diseases. So far, information on blood flow in this specific layer has remained limited. With the advent of optical coherence tomography angiography (OCTA), new perspectives and possibilities of CC imaging have begun to evolve. This article shall review the opportunities and challenges of applying OCTA technology to the CC layer and summarize the current clinical efforts in OCTA CC imaging exemplarily in dry age-related macular degeneration and central serous chorioretinopathy. (c) 2018 S. Karger AG, Basel.
C1 [Lauermann, Jost L.; Eter, Nicole; Alten, Florian] Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, DE-48149 Munster, Germany.
C3 University of Munster
RP Lauermann, JL (通讯作者)，Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, DE-48149 Munster, Germany.
EM jost.lauermann@ukmuenster.de
CR Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alnawaiseh M, 2016, EXP EYE RES, V145, P417, DOI 10.1016/j.exer.2016.02.012
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chan SY, 2016, RETINA-J RET VIT DIS, V36, P2051, DOI 10.1097/IAE.0000000000001064
   Chatziralli I, 2017, INT OPHTHALMOL
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Feucht N, 2016, OSLI RETINA, V47, P322, DOI 10.3928/23258160-20160324-03
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P165
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lauermann JL, 2017, GRAEF ARCH CLIN EXP, V255, P1535, DOI 10.1007/s00417-017-3684-z
   Lauermann JL, 2017, OPHTHALMOLOGICA, V237, P238, DOI 10.1159/000464355
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Louzada RN, 2017, CAN J OPHTHALMOL, V52, P419, DOI 10.1016/j.jcjo.2016.12.012
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Montesano G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185256
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   Niu SJ, 2014, COMPUT BIOL MED, V54, P116, DOI 10.1016/j.compbiomed.2014.08.028
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Ploner S. B., 2016, RETINA S1, V36, P118, DOI DOI 10.1097/IAE.0000000000001328
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sacconi R, 2017, RETINA
   Saito M, 2017, GRAEFES ARCH CLIN EX
   Saito M, 2013, BRIT J OPHTHALMOL, V97, P775, DOI 10.1136/bjophthalmol-2012-302349
   Sambhav K, 2017, SURV OPHTHALMOL, V62, P838, DOI 10.1016/j.survophthal.2017.05.006
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Su GL, 2017, CLIN OPHTHALMOL, V11, P889, DOI 10.2147/OPTH.S135479
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Tittl M, 2005, INVEST OPHTH VIS SCI, V46, P4717, DOI 10.1167/iovs.05-0268
   Tittl M, 2003, ARCH OPHTHALMOL-CHIC, V121, P975, DOI 10.1001/archopht.121.7.975
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Veronese C, 2016, RETINA-J RET VIT DIS, V36, P645, DOI 10.1097/IAE.0000000000000914
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Wong KH, 2016, ACTA OPHTHALMOL, V94, P321, DOI 10.1111/aos.12779
   Xu YS, 2017, OPHTHALMOLOGICA, V237, P167, DOI 10.1159/000456676
   Yiu P, 2017, INVEST OPHTH VIS SCI, V58
   Zheng F, 2016, OSLI RETINA, V47, P517, DOI 10.3928/23258160-20160601-02
NR 68
TC 42
Z9 46
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 2-3
BP 74
EP 84
DI 10.1159/000485261
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ0QL
UT WOS:000427276000002
PM 29353272
OA Bronze
DA 2022-11-30
ER

PT S
AU MacAskill, MR
   Anderson, TJ
   Jones, RD
AF MacAskill, MR
   Anderson, TJ
   Jones, RD
BE Hyona, J
   Munoz, DP
   Heide, W
   Radach, R
TI Saccadic adaptation in neurological disorders
SO BRAIN'S EYE: NEUROBIOLOGICAL AND CLINICAL ASPECTS OF OCULOMOTOR RESEARCH
SE Progress in Brain Research
LA English
DT Review
CT 11th European Conference on Eye Movements
CY AUG 22-25, 2001
CL TURKU, FINLAND
ID INTERNALLY TRIGGERED SACCADES; SHORT-TERM ADAPTATION; ADAPTIVE-CONTROL;
   EYE-MOVEMENTS; GAIN ADAPTATION; PARKINSONS-DISEASE; OCULOMOTOR SYSTEM;
   BASAL GANGLIA; OCULAR DRIFT; LESIONS
AB The role of saccadic adaptive processes in recovery from the effects of various neurological disorders, such as myasthenia gravis, extraocular muscle palsies, and age-related macular degeneration, is reviewed. Studies of clinical populations (e.g. cerebellar disease, mild closed head injury, and opsoclonus) in which intrasaccadic displacement of visual targets has been used to stimulate adaptation are also reviewed. Our own data from such a study of 12 subjects with Parkinson's disease are presented, showing that visually guided adaptation is preserved in PD while memory-guided adaptation is impaired. This supports a model in which different brain regions subserve adaptation in different tasks.
C1 Christchurch Movement Disorders & Brain Res Grp, Christchurch, New Zealand.
   Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand.
   Christchurch Hosp, Dept Neurol, Christchurch, New Zealand.
   Christchurch Hosp, Dept Med Phys & Bioengn, Christchurch, New Zealand.
C3 University of Otago; Christchurch Hospital New Zealand; Christchurch
   Hospital New Zealand
RP MacAskill, MR (通讯作者)，Christchurch Sch Med, Dept Med, POB 4345, Christchurch, New Zealand.
EM michael.macaskill@chmeds.ac.nz
RI MacAskill, Michael/C-3467-2009
OI MacAskill, Michael/0000-0001-9073-0346; Jones,
   Richard/0000-0003-2287-3358
CR ABEL LA, 1978, ANN NEUROL, V4, P313, DOI 10.1002/ana.410040405
   ABRAMS RA, 1992, J EXP PSYCHOL HUMAN, V18, P922, DOI 10.1037/0096-1523.18.4.922
   Albano JE, 1996, VISION RES, V36, P2087, DOI 10.1016/0042-6989(96)89627-1
   ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119
   ASLIN RN, 1975, PERCEPT PSYCHOPHYS, V17, P293, DOI 10.3758/BF03203214
   BAHILL A T, 1975, Mathematical Biosciences, V24, P191, DOI 10.1016/0025-5564(75)90075-9
   BERTERA J H, 1988, Investigative Ophthalmology and Visual Science, V29, P135
   Brainard MS, 2000, NATURE, V404, P762, DOI 10.1038/35008083
   BRIDGEMAN B, 1975, VISION RES, V15, P719, DOI 10.1016/0042-6989(75)90290-4
   Carl J, 1985, INVESTIGATIVE OPHT S, V26, P258
   CHERASKIN E, 1992, J NATL MED ASSOC, V84, P873
   CRAWFORD TJ, 1989, BRAIN, V112, P1573, DOI 10.1093/brain/112.6.1573
   Desmurget M, 2000, EXP BRAIN RES, V132, P243, DOI 10.1007/s002210000342
   Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241
   Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0
   DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M
   DEUBEL H, 1994, BEHAV BRAIN SCI, V17, P259, DOI 10.1017/S0140525X00034397
   Deubel H, 1999, ATTENTION PERFORM, V17, P697
   DEUBEL H, 1995, STUD VIS INFORM PROC, V6, P177
   Deubel H, 1998, VISION RES, V38, P3147, DOI 10.1016/S0042-6989(98)00048-0
   Deubel H., 1987, EYE MOVEMENTS PHYSL, P181, DOI [10.1016/B978-0-444-70113-8.50030-8, DOI 10.1016/B978-0-444-70113-8.50030-8]
   Dodge R, 1900, PSYCHOL REV, V7, P454, DOI 10.1037/h0067215
   ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157
   FITZGIBBON EJ, 1985, ADV BIOSCI, V57, P329
   Frens MA, 1997, BRAIN RES BULL, V43, P473, DOI 10.1016/S0361-9230(97)80001-9
   FRENS MA, 1994, EXP BRAIN RES, V100, P293, DOI 10.1007/BF00227199
   Fuchs AF, 1996, J NEUROPHYSIOL, V76, P2522, DOI 10.1152/jn.1996.76.4.2522
   Gaymard B, 2001, EUR J NEUROSCI, V14, P554, DOI 10.1046/j.0953-816x.2001.01669.x
   GONSHOR A, 1976, J PHYSIOL-LONDON, V256, P381, DOI 10.1113/jphysiol.1976.sp011330
   HARRIS CM, 1995, VISION RES, V35, P691, DOI 10.1016/0042-6989(94)00163-G
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   HEITGER MH, 2001, NZ MED J, V114, P480
   Hodgson TL, 1999, NEUROPSYCHOLOGIA, V37, P927, DOI 10.1016/S0028-3932(98)00151-1
   KAPOULA Z, 1989, J NEUROPHYSIOL, V61, P879, DOI 10.1152/jn.1989.61.5.879
   KOMMERELL G, 1976, INVEST OPHTH VISUAL, V15, P657
   Kroller J, 1996, EXP BRAIN RES, V111, P477
   Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607
   Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506
   Lawrence AD, 2000, TRENDS COGN SCI, V4, P365, DOI 10.1016/S1364-6613(00)01535-7
   LUECK CJ, 1990, J NEUROL NEUROSUR PS, V53, P284, DOI 10.1136/jnnp.53.4.284
   MacAskill MR, 1999, CURRENT OCULOMOTOR RESEARCH, P93
   MacAskill MR, 2000, VISION RES, V40, P3405, DOI 10.1016/S0042-6989(00)00194-2
   MacAskill MR, 2002, BRAIN, V125, P1570, DOI 10.1093/brain/awf168
   McConkie GW, 1996, J EXP PSYCHOL HUMAN, V22, P563, DOI 10.1037/0096-1523.22.3.563
   McDowall J, 1996, NEW ZEAL J PSYCHOL, V25, P2
   MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071
   MEZEY LE, 2000, THESIS U COLL LONDON
   MILLER JM, 1981, J EXP PSYCHOL HUMAN, V7, P356, DOI 10.1037/0096-1523.7.2.356
   OPTICAN LM, 1980, J NEUROPHYSIOL, V44, P1058, DOI 10.1152/jn.1980.44.6.1058
   OPTICAN LM, 1985, J NEUROPHYSIOL, V54, P940, DOI 10.1152/jn.1985.54.4.940
   OPTICAN LM, 1986, EXP BRAIN RES, V64, P596, DOI 10.1007/BF00340497
   OPTICAN LM, 1985, J NEUROPHYSIOL, V54, P110, DOI 10.1152/jn.1985.54.1.110
   Phillips JO, 1997, J NEUROPHYSIOL, V78, P2817, DOI 10.1152/jn.1997.78.5.2817
   REULEN JPH, 1988, MED BIOL ENG COMPUT, V26, P20, DOI 10.1007/BF02441823
   ROBINSON DA, 1986, PROG BRAIN RES, V64, P411
   ROBINSON DA, 1975, INVEST OPHTH VISUAL, V14, P413
   Robinson FR, 1995, CURR OPIN NEUROBIOL, V5, P755, DOI 10.1016/0959-4388(95)80103-0
   Scudder CA, 1998, J NEUROPHYSIOL, V79, P704, DOI 10.1152/jn.1998.79.2.704
   Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005
   Straube A, 1997, J NEUROPHYSIOL, V77, P874, DOI 10.1152/jn.1997.77.2.874
   STRAUBE A, 1995, VISION RES, V35, P3451, DOI 10.1016/0042-6989(95)00076-Q
   Straube A, 2001, NEUROLOGY, V57, P2105, DOI 10.1212/WNL.57.11.2105
   STRAUBE A, 1995, NEURO-OPHTHALMOLOGY, V15, P67, DOI 10.3109/01658109509009645
   Takagi M, 1998, J NEUROPHYSIOL, V80, P1911, DOI 10.1152/jn.1998.80.4.1911
   Takagi M, 2001, VISION RES, V41, P3331, DOI 10.1016/S0042-6989(01)00016-5
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WAESPE W, 1992, BRAIN, V115, P1125, DOI 10.1093/brain/115.4.1125
   Wallman J, 1998, J NEUROPHYSIOL, V80, P2405, DOI 10.1152/jn.1998.80.5.2405
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER S G, 1988, Investigative Ophthalmology and Visual Science, V29, P135
   ZEE DS, 1976, ARCH NEUROL-CHICAGO, V33, P243, DOI 10.1001/archneur.1976.00500040027004
   Zee DS., 1999, NEUROLOGY EYE MOVEME
NR 72
TC 9
Z9 9
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0079-6123
BN 0-444-51097-4
J9 PROG BRAIN RES
JI Prog. Brain Res.
PY 2002
VL 140
BP 417
EP 431
PG 15
WC Neurosciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA BV82W
UT WOS:000180135500028
PM 12508606
DA 2022-11-30
ER

PT J
AU Novais, EA
   Badaro, E
   Regatieri, CVS
   Duker, J
   Bonomo, PPD
AF Novais, Eduardo Amorim
   Badaro, Emmerson
   Saito Regatieri, Caio Vinicius
   Duker, Jay
   de Oliveira Bonomo, Pedro Paulo
TI Regression of Drusen After Combined Treatment Using Photodynamic Therapy
   With Verteporfin and Ranibizumab
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PROPHYLACTIC LASER TREATMENT; CHOROIDAL BLOOD-FLOW; MACULAR
   DEGENERATION; PHOTOCOAGULATION; PATHOGENESIS; PREVALENCE; EXPRESSION;
   EYES
AB Drusen are the clinical hallmark of age-related macular degeneration. The regression of these deposits in patients treated with argon, krypton, or diode laser photocoagulation has been reported previously. However, previous protocols with conventional laser for drusen may result in retinal pigment epithelium (RPE) damage and unwanted scotomas. The authors report a case of complete regression of soft drusen in a 65-year-old man with central visual loss and metamorphopsia due to a drusenoid RPE detachment and soft drusen who underwent reduced-fluence photodynamic therapy (PDT) and three monthly intravitreal injections of ranibizumab. Reduced-fluence PDT combined with anti-VEGF therapy may reduce drusen without inducing RPE cell damage.
C1 [Novais, Eduardo Amorim; Badaro, Emmerson; Saito Regatieri, Caio Vinicius; de Oliveira Bonomo, Pedro Paulo] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023062 Sao Paulo, SP, Brazil.
   [Saito Regatieri, Caio Vinicius; Duker, Jay] Tufts Med Sch, Dept Ophthalmol, Boston, MA USA.
C3 Universidade Federal de Sao Paulo (UNIFESP); Tufts Medical Center; Tufts
   University
RP Regatieri, CVS (通讯作者)，Univ Fed Sao Paulo, Dept Oftalmol, Secretaria Adm, Rua Botucatu 821,1o Andar, BR-04023062 Sao Paulo, SP, Brazil.
EM caiore@gmail.com
RI Regatieri, Caio/G-8152-2014
OI Regatieri, Caio/0000-0003-1511-8696
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Figueira J, 2009, BRIT J OPHTHALMOL, V93, P1341, DOI 10.1136/bjo.2008.146712
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lavinsky D, 2011, INVEST OPHTH VIS SCI, V52, P4314, DOI 10.1167/iovs.10-6828
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tsuchihashi T, 2009, RETINA-J RET VIT DIS, V29, P1450, DOI 10.1097/IAE.0b013e3181ac2403
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
   Wetzig PC., 1994, T AM OPHTHALMOLOGICA, V92, P6
   Wilson AS, 2003, INVEST OPHTH VIS SCI, V44, P1426, DOI 10.1167/iovs.02-0622
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
NR 29
TC 4
Z9 4
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2015
VL 46
IS 2
BP 275
EP 278
DI 10.3928/23258160-20150213-16
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TZ
UT WOS:000353360100020
PM 25707058
DA 2022-11-30
ER

PT J
AU Zhong, HM
   Sun, XD
AF Zhong, Huimin
   Sun, Xiaodong
TI Contribution of Interleukin-17A to Retinal Degenerative Diseases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE retinal degenerative diseases; interleukin-17A; age-related macular
   degeneration; diabetic retinopathy; glaucoma
ID PIGMENT EPITHELIAL-CELLS; HERPESVIRUS SAIMIRI ENCODES;
   NECROSIS-FACTOR-ALPHA; ANTI-VEGF TREATMENT; MACULAR DEGENERATION;
   T-CELL; COMPLEMENT EXPRESSION; RETINITIS-PIGMENTOSA;
   DIABETIC-RETINOPATHY; SIGNAL-TRANSDUCTION
AB Retinal degenerative diseases are a leading cause of vision loss and blindness throughout the world, characterized by chronic and progressive loss of neurons and/or myelin. One of the common features of retinal degenerative diseases and central neurodegenerative diseases is chronic neuroinflammation. Interleukin-17A (IL-17A) is the cytokine most closely related to disease in its family. Accumulating evidence suggests that IL-17A plays a key role in human retinal degenerative diseases, including age-related macular degeneration, diabetic retinopathy and glaucoma. This review aims to provide an overview of the role of IL-17A participating in the pathogenesis of retinal degenerative diseases, which may open new avenues for potential therapeutic interventions.
C1 [Zhong, Huimin; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China.
   [Zhong, Huimin; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Zhong, Huimin; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Zhong, Huimin; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Zhong, Huimin; Sun, Xiaodong] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai, Peoples R China.
EM xdsun@sjtu.edu.cn
OI Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [82171076]
FX Funding This study received by support from the National Natural Science
   Foundation of China (No. 82171076).
CR Adams R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01894
   Afzal N, 2013, CLIN LAB, V59, P1311, DOI 10.7754/Clin.Lab.2013.121140
   Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
   Akhavanpoor M, 2017, CURR DRUG TARGETS, V18, P863, DOI 10.2174/1389450117666161229142155
   Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200
   Alivand MR, 2016, CURR EYE RES, V41, P1245, DOI 10.3109/02713683.2015.1095933
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Baltmr A, 2010, EXP EYE RES, V91, P554, DOI 10.1016/j.exer.2010.08.009
   Bastid J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00718
   Bie QL, 2016, SCI REP-UK, V6, DOI 10.1038/srep25447
   Blinder KJ, 2017, CLIN OPHTHALMOL, V11, P393, DOI 10.2147/OPTH.S128509
   Borkenstein A, 2013, MOL VIS, V19, P2306
   Borowczyk J, 2021, J ALLERGY CLIN IMMUN, V148, P40, DOI 10.1016/j.jaci.2020.12.628
   Brigas HC, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109574
   Byrne EM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070831
   Catterall T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69805-2
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen H, 2016, J INT MED RES, V44, P1403, DOI 10.1177/0300060516672369
   Chen JM, 2014, DEMENT GERIATR COGN, V38, P321, DOI 10.1159/000360606
   Chen JJ, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.566922
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen Y, 2018, MOL MED REP, V17, P4627, DOI 10.3892/mmr.2018.8460
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Chernykh VV, 2015, INDIAN J OPHTHALMOL, V63, P33, DOI 10.4103/0301-4738.151464
   Chidlow G, 2016, J GLAUCOMA, V25, P681, DOI 10.1097/IJG.0000000000000447
   Choueiri TK, 2011, CURR CLIN PHARMACOL, V6, P164, DOI 10.2174/157488411797189424
   Chung AS, 2013, NAT MED, V19, P1114, DOI 10.1038/nm.3291
   Cristiano C, 2019, BRIT J PHARMACOL, V176, P3544, DOI 10.1111/bph.14586
   Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davis BM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01747-8
   de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733
   Du SL, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0182-8
   Fernandez-Albarral JA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042066
   Fiala M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-76
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Fu XY, 2021, BIOCHEM BIOPH RES CO, V557, P77, DOI 10.1016/j.bbrc.2021.03.113
   Fukayama M, 2020, J DERMATOL, V47, P1287, DOI 10.1111/1346-8138.15508
   Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Gandhi J, 2021, J MYCOL MED, V31, DOI 10.1016/j.mycmed.2021.101136
   Glatt S, 2018, ANN RHEUM DIS, V77, P523, DOI 10.1136/annrheumdis-2017-212127
   Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627
   Gold R, 2008, AM J PATHOL, V172, P8, DOI 10.2353/ajpath.2008.070862
   Gramlich OW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0542-6
   Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Happel KI, 2003, J IMMUNOL, V170, P4432, DOI 10.4049/jimmunol.170.9.4432
   Hu WT, 2010, NEUROLOGY, V75, P2079, DOI 10.1212/WNL.0b013e318200d78d
   Huang CK, 2014, ONCOGENE, V33, P2968, DOI 10.1038/onc.2013.268
   Huang WB, 2014, INVEST OPHTH VIS SCI, V55, P1088, DOI 10.1167/iovs.13-13591
   Hwang SY, 2005, MOL CELLS, V19, P180
   Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012
   Jeon YJ, 2020, AM J RESP CELL MOL, V62, P95, DOI 10.1165/rcmb.2018-0377OC
   Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x
   Jumper JM, 2018, CLIN OPHTHALMOL, V12, P621, DOI 10.2147/OPTH.S163859
   Kamat SS, 2016, SEMIN OPHTHALMOL, V31, P147, DOI 10.3109/08820538.2015.1114858
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kawanokuchi J, 2008, J NEUROIMMUNOL, V194, P54, DOI 10.1016/j.jneuroim.2007.11.006
   Ke Y, 2009, J LEUKOCYTE BIOL, V86, P1377, DOI 10.1189/jlb.0409237
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Kostic M, 2014, SCAND J IMMUNOL, V79, P181, DOI 10.1111/sji.12147
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kubota R, 2020, DRUG DISCOV TODAY, V25, P292, DOI 10.1016/j.drudis.2019.11.013
   Kuchtey J, 2010, INVEST OPHTH VIS SCI, V51, P6441, DOI 10.1167/iovs.10-5216
   Lai YP, 2012, IMMUNITY, V37, P74, DOI 10.1016/j.immuni.2012.04.010
   Laprevotte E, 2017, ONCOTARGET, V8, P113360, DOI 10.18632/oncotarget.23008
   Lauffer F, 2020, J EUR ACAD DERMATOL, V34, P800, DOI 10.1111/jdv.16126
   Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773
   Li L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00347
   Li YJ, 2019, TOHOKU J EXP MED, V247, P87, DOI 10.1620/tjem.247.87
   Lindstrom SI, 2019, J DIABETES COMPLICAT, V33, P668, DOI 10.1016/j.jdiacomp.2019.05.016
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu HT, 2019, DIABETOLOGIA, V62, P2365, DOI 10.1007/s00125-019-04998-4
   Liu Z, 2019, BRAIN BEHAV IMMUN, V81, P630, DOI 10.1016/j.bbi.2019.07.026
   Luo C, 2018, AGING-US, V10, P1380, DOI 10.18632/aging.101474
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2011, MOL VIS, V17, P1588
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Ma J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38811-4
   Mac Nair CE, 2015, PROG MOL BIOL TRANSL, V134, P343, DOI 10.1016/bs.pmbts.2015.06.010
   Maitra A, 2007, P NATL ACAD SCI USA, V104, P7506, DOI 10.1073/pnas.0611589104
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021
   Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nies JF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00341
   Novatchkova M, 2003, TRENDS BIOCHEM SCI, V28, P226, DOI 10.1016/S0968-0004(03)00067-7
   Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pepple KL, 2018, OPHTHALMOLOGY, V125, P1977, DOI 10.1016/j.ophtha.2018.05.014
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Qian YC, 2007, NAT IMMUNOL, V8, P247, DOI 10.1038/ni1439
   Qiu AW, 2017, CELL PHYSIOL BIOCHEM, V41, P960, DOI 10.1159/000460514
   Qiu AW, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.117
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ramirez AI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61848-9
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Reed MD, 2020, NATURE, V577, P249, DOI 10.1038/s41586-019-1843-6
   Ren YB, 2019, CLIN EXP PHARMACOL P, V46, P875, DOI 10.1111/1440-1681.13141
   Robert M, 2017, AUTOIMMUN REV, V16, P984, DOI 10.1016/j.autrev.2017.07.009
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   ROUVIER E, 1993, J IMMUNOL, V150, P5445
   Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200
   Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233
   Shao L, 2016, ADIPOCYTE, V5, P270, DOI 10.1080/21623945.2016.1162358
   Shen F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000066
   Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Sigurdardottir S, 2019, CELL IMMUNOL, V341, DOI 10.1016/j.cellimm.2019.04.009
   Sohocki MM, 2001, HUM MUTAT, V17, P42, DOI 10.1002/1098-1004(2001)17:1<42::AID-HUMU5>3.0.CO;2-K
   Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117
   Stamp LK, 2008, ARTHRITIS RHEUM-US, V58, P1601, DOI 10.1002/art.23455
   Sun LC, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108718
   Sun Q, 2020, FREE RADICAL BIO MED, V147, P271, DOI 10.1016/j.freeradbiomed.2019.12.029
   Swaidani S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01293
   Swaidani S, 2009, J IMMUNOL, V182, P1631, DOI 10.4049/jimmunol.182.3.1631
   Tang C, 2018, NAT IMMUNOL, V19, P755, DOI 10.1038/s41590-018-0134-y
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Vandeghinste N, 2018, J INVEST DERMATOL, V138, P1555, DOI 10.1016/j.jid.2018.01.036
   Vazquez N, 2012, J INFECT DIS, V206, P1206, DOI 10.1093/infdis/jis492
   Wang F, 2020, KIDNEY INT, V97, P1219, DOI 10.1016/j.kint.2020.01.015
   Wang JD, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01062-y
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YN, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00593-6
   Wang YY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181411
   Wang ZJ, 2021, BIOENGINEERED, V12, P7061, DOI 10.1080/21655979.2021.1976502
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Xu HY, 2015, GRAEF ARCH CLIN EXP, V253, P1485, DOI 10.1007/s00417-014-2842-9
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019
   Xu M, 2017, IMMUNOL REV, V278, P185, DOI 10.1111/imr.12558
   Yadav KS, 2019, LIFE SCI, V221, P362, DOI 10.1016/j.lfs.2019.02.029
   Yang JL, 2016, BRAIN BEHAV IMMUN, V53, P84, DOI 10.1016/j.bbi.2015.11.005
   Yang YF, 2018, CANCER LETT, V422, P44, DOI 10.1016/j.canlet.2018.02.037
   Yao HY, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/6642600
   Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5
   Yao ZB, 2011, J IMMUNOL, V187, P4392
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zapadka TE, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094335
   Zapadka TE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103547
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang HJ, 2020, INT OPHTHALMOL, V40, P2763, DOI 10.1007/s10792-020-01463-9
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao YT, 2021, NEUROIMMUNOMODULAT, V28, P266, DOI 10.1159/000515662
   Zhong ZY, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100866
   Zhou J, 2017, CLIN IMMUNOL, V175, P91, DOI 10.1016/j.clim.2016.12.008
   Zhu YJ, 2016, IMMUNOLOGY, V147, P414, DOI 10.1111/imm.12571
NR 176
TC 1
Z9 1
U1 4
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 22
PY 2022
VL 13
AR 847937
DI 10.3389/fimmu.2022.847937
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 0I6NC
UT WOS:000779534300001
PM 35392087
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Poli, G
   Biasi, F
   Leonarduzzi, G
AF Poli, Giuseppe
   Biasi, Fiorella
   Leonarduzzi, Gabriella
TI Oxysterols in the pathogenesis of major chronic diseases
SO REDOX BIOLOGY
LA English
DT Review
DE Oxysterols; Oxidative stress; Inflammation; Human chronic diseases
ID CHOLESTEROL OXIDATION-PRODUCTS; AMYLOID-BETA; UP-REGULATION; IN-VITRO;
   EXPRESSION; CELLS; MATRIX-METALLOPROTEINASE-9; METABOLISM; PATHWAYS;
   RECEPTOR
AB Pathological accumulation of 27-carbon intermediates or end-products of cholesterol metabolism, named oxysterols, may contribute to the onset and especially to the development of major chronic diseases in which inflammation, but also oxidative damage and to a certain extent cell death, are hallmarks and primary mechanisms of progression. Indeed, certain oxysterols exercise strong pro-oxidant and pro-inflammatory effects at concentrations detectable in the lesions typical of atherosclerosis, neurodegenerative diseases, inflammatory bowel diseases, age-related macular degeneration, and other pathological conditions characterized by altered cholesterol uptake and/or metabolism. (C) 2013 The Authors. Published by Elsevier BY. Open access under CC WI -NC-ND license.
C1 [Poli, Giuseppe; Biasi, Fiorella; Leonarduzzi, Gabriella] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy.
C3 University of Turin
RP Poli, G (通讯作者)，Univ Turin, Dept Clin & Biol Sci, San Luigi Hosp, I-10043 Turin, Italy.
EM giuseppe.poli@unito.it
RI Leonarduzzi, Gabriella/AAA-6575-2019
OI LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X
FU Italian Ministry for the University, PRIN; CRT Foundation, Turin;
   University of Torino, Italy
FX The authors thank the Italian Ministry for the University, PRIN 2008 and
   2009, the CRT Foundation, Turin, and the University of Torino, Italy,
   for supporting research projects that formed the core of the present
   paper.
CR Biasi F, 2008, CARCINOGENESIS, V29, P890, DOI 10.1093/carcin/bgn106
   Biasi F, 2009, FREE RADICAL BIO MED, V47, P1731, DOI 10.1016/j.freeradbiomed.2009.09.020
   Bjorkhem I, 1999, CURR OPIN LIPIDOL, V10, P161, DOI 10.1097/00041433-199904000-00010
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200
   Caballero F, 2009, J HEPATOL, V50, P789, DOI 10.1016/j.jhep.2008.12.016
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312
   Canepa E, 2011, J ALZHEIMERS DIS, V25, P645, DOI 10.3233/JAD-2011-110053
   Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0
   Cheng D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017299
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Fiotti N, 2008, INT J CARDIOL, V127, P350, DOI 10.1016/j.ijcard.2007.05.011
   Gamba P, 2011, AGING CELL, V10, P403, DOI 10.1111/j.1474-9726.2011.00681.x
   Gargiulo S, 2011, FREE RADICAL BIO MED, V51, P844, DOI 10.1016/j.freeradbiomed.2011.05.030
   Hayden JM, 2002, J LIPID RES, V43, P26
   Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200
   Hu G, 2008, NEUROLOGY, V70, P1972, DOI 10.1212/01.wnl.0000312511.62699.a8
   Hughes TM, 2012, J ALZHEIMERS DIS, V30, P53, DOI 10.3233/JAD-2012-111460
   Iuliano L, 2011, CHEM PHYS LIPIDS, V164, P457, DOI 10.1016/j.chemphyslip.2011.06.006
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Leonarduzzi G, 2005, FREE RADICAL BIO MED, V39, P1152, DOI 10.1016/j.freeradbiomed.2005.06.024
   Leonarduzzi G., MOL ASPECTS MED, V25, P155
   Leonarduzzi G, 2010, MOL NUTR FOOD RES, V54, pS31, DOI 10.1002/mnfr.200900493
   Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799
   Mascia C, 2010, FREE RADICAL BIO MED, V49, P2049, DOI 10.1016/j.freeradbiomed.2010.09.033
   Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621
   Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200
   Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200
   Poli G, 2009, MOL ASPECTS MED, V30, P180, DOI 10.1016/j.mam.2009.02.003
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rosenblat M, 2002, ATHEROSCLEROSIS, V160, P69, DOI 10.1016/S0021-9150(01)00563-9
   Shafaati M, 2011, J LIPID RES, V52, P1004, DOI 10.1194/jlr.M014548
   Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239
   Smondyrev AM, 2001, CHEM PHYS LIPIDS, V112, P31, DOI 10.1016/S0009-3084(01)00160-8
   Solomon A, 2007, NEUROLOGY, V68, P751, DOI 10.1212/01.wnl.0000256368.57375.b7
   Sottero B, 2009, CURR MED CHEM, V16, P685, DOI 10.2174/092986709787458353
   Testa G, 2012, FREE RADICAL BIO MED, V53, P1708, DOI 10.1016/j.freeradbiomed.2012.08.581
   Torocsik D, 2009, MOL ASPECTS MED, V30, P134, DOI 10.1016/j.mam.2009.02.002
   Vance JE, 2012, DIS MODEL MECH, V5, P746, DOI 10.1242/dmm.010124
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Verdier Y, 2004, J PEPT SCI, V10, P229, DOI 10.1002/psc.573
   Zalba G, 2007, ARTERIOSCL THROM VAS, V27, P587, DOI 10.1161/01.ATV.0000256467.25384.c6
NR 46
TC 193
Z9 197
U1 0
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PY 2013
VL 1
IS 1
BP 125
EP 130
DI 10.1016/j.redox.2012.12.001
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA V38BC
UT WOS:000209317900020
PM 24024145
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gale, J
   Wells, AP
   Wilson, G
AF Gale, Jesse
   Wells, Anthony P.
   Wilson, Graham
TI Effects of Exercise on Ocular Physiology and Disease
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE exercise; eye diseases; physical activity; ocular; physiology; sport
ID DEPENDENT DIABETES-MELLITUS; RETINAL VEIN OCCLUSION; PIGMENTARY
   DISPERSION SYNDROME; CHOROIDAL BLOOD-FLOW; INTRAOCULAR-PRESSURE CHANGES;
   OPTIC-NERVE HEAD; PHYSICAL-ACTIVITY; RISK-FACTORS; ISOMETRIC-EXERCISE;
   GLAUCOMA PATIENTS
AB Regular exercise is a healthy lifestyle Choice with numerous benefits to general health. Ophthalmologists may face questions of the benefits or risks of exercise to eyes. Here the effects of acute exertion and regular physical activity oil ocular physiology and disease are reviewed. Intraocular pressure is transiently reduced by dynamic exercise. For the great majority of patients exercise is beneficial to the eves by reducing risk of central retinal occlusion and neovascular age-related macular degeneration, and by improving Control of systemic hypertension and diabetes. Ophthalmologists should be. advocates of regular exercise with appropriate eye protection. (Surv Ophthalmol 54:349-355, 2009. (c) 2009 Elsevier Inc. All rights reserved.)
C1 [Gale, Jesse; Wells, Anthony P.] Capital & Coast Districl Hlth Board, Dept Ophthalmol, Wellington, New Zealand.
   [Wells, Anthony P.] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Surg & Anaesthesia, Ophthalmol Unit, Wellington, New Zealand.
   [Wilson, Graham] Tairawhiti Dist Hlth Board, Dept Ophthalmol, Gisborne, New Zealand.
C3 University of Otago
RP Wilson, G (通讯作者)，Gisborne Hosp, Dept Ophthalmol, Private Bag 7001, Gisborne, New Zealand.
EM Graham.Wilson@tdh.org.nz
RI Gale, Jesse/AAB-7406-2019
OI Gale, Jesse/0000-0002-6616-445X
CR Amer Acad Pediat, 2004, OPHTHALMOLOGY, V111, P600, DOI 10.1016/j.ophtha.2003.12.027
   ASHKENAZI I, 1992, INVEST OPHTH VIS SCI, V33, P2874
   Avunduk AM, 1999, OPHTHALMOLOGICA, V213, P290, DOI 10.1159/000027441
   Barr A, 2000, BRIT J SPORT MED, V34, P456, DOI 10.1136/bjsm.34.6.456
   Baskaran M, 2006, OPHTHALMOLOGY, V113, P1327, DOI 10.1016/j.ophtha.2006.02.063
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   BIRO I, 1962, Klin Monbl Augenheilkd Augenarztl Fortbild, V140, P23
   Chen V, 1988, Metab Pediatr Syst Ophthalmol (1985), V11, P67
   Chipkin Stuart R., 2001, Cardiology Clinics, V19, P489, DOI 10.1016/S0733-8651(05)70231-9
   Christenson G N, 1988, J Am Optom Assoc, V59, P666
   CRUICKSHANKS KJ, 1992, DIABETES CARE, V15, P1267, DOI 10.2337/diacare.15.10.1267
   CRUICKSHANKS KJ, 1995, OPHTHALMOLOGY, V102, P1177, DOI 10.1016/S0161-6420(95)30893-7
   De Feo Pierpaolo, 2006, Acta Biomed, V77 Suppl 1, P14
   Dickerman RD, 1999, NEUROL RES, V21, P243, DOI 10.1080/01616412.1999.11740925
   DISDIER P, 1992, PRESSE MED, V21, P582
   ERA P, 1993, ACTA OPHTHALMOL, V71, P301
   Estacio RO, 1998, DIABETES CARE, V21, P291, DOI 10.2337/diacare.21.2.291
   Filipe JAC, 1997, OPHTHALMOLOGY, V104, P313
   FONG LP, 1994, MED J AUSTRALIA, V160, P743, DOI 10.5694/j.1326-5377.1994.tb125941.x
   Friedman DS, 2004, AM J OPHTHALMOL, V138, pS19, DOI 10.1016/j.ajo.2004.04.058
   Gallardo MJ, 2006, ADV THER, V23, P921, DOI 10.1007/BF02850214
   Gaudard A, 2002, CLIN HEMORHEOL MICRO, V27, P115
   GOLDBERG I, 1981, BRIT J OPHTHALMOL, V65, P56, DOI 10.1136/bjo.65.1.56
   Haargaard B, 2001, ACTA OPHTHALMOL SCAN, V79, P277, DOI 10.1034/j.1600-0420.2001.790313.x
   HARBIN G, 1989, MED SCI SPORT EXER, V21, P258
   HARRIS A, 1992, INVEST OPHTH VIS SCI, V33, P2229
   HARRIS A, 1994, INVEST OPHTH VIS SCI, V35, P3852
   HAYNES WL, 1990, AM J OPHTHALMOL, V109, P601, DOI 10.1016/S0002-9394(14)70696-8
   HAYNES WL, 1992, OPHTHALMOLOGY, V99, P1096
   Hoffman L G, 1984, J Am Optom Assoc, V55, P747
   IMES RK, 1989, J CLIN NEURO-OPHTHAL, V9, P178
   JAMPOL LM, 1981, NEW ENGL J MED, V305, P764
   Jehn A, 2002, ARCH OPHTHALMOL-CHIC, V120, P220
   JENSEN PK, 1995, AM J OPHTHALMOL, V120, P110, DOI 10.1016/S0002-9394(14)73767-5
   JONES NP, 1988, EYE, V2, P484, DOI 10.1038/eye.1988.97
   Kell RT, 2001, SPORTS MED, V31, P863, DOI 10.2165/00007256-200131120-00003
   Kiss B, 2001, MICROVASC RES, V61, P1, DOI 10.1006/mvre.2000.2269
   KIUCHI Y, 1994, JPN J OPHTHALMOL, V38, P191
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   KOSKELA PU, 1988, ACTA OPHTHALMOL, V66, P725
   KOSKELA PU, 1990, ACTA OPHTHALMOL, V68, P91
   KREJCI RC, 1981, AM J OPTOM PHYS OPT, V58, P144
   KRISKA AM, 1991, J CLIN EPIDEMIOL, V44, P1207, DOI 10.1016/0895-4356(91)90153-Z
   LANIGAN LP, 1989, EYE, V3, P39, DOI 10.1038/eye.1989.6
   LANIGAN LP, 1988, EYE, V2, P412, DOI 10.1038/eye.1988.75
   LAPORTE RE, 1986, PEDIATRICS, V78, P1027
   LEIGHTON DA, 1972, BRIT J OPHTHALMOL, V56, P126, DOI 10.1136/bjo.56.2.126
   LEIGHTON DA, 1970, BRIT J OPHTHALMOL, V54, P599, DOI 10.1136/bjo.54.9.599
   LEMPERT P, 1967, AM J OPHTHALMOL, V63, P1673, DOI 10.1016/0002-9394(67)93645-8
   Lovasik JV, 2003, INVEST OPHTH VIS SCI, V44, P2126, DOI 10.1167/iovs.02-0825
   MACEWEN CJ, 1987, BRIT J OPHTHALMOL, V71, P701, DOI 10.1136/bjo.71.9.701
   MARCUS DF, 1974, CLIN SCI MOL MED, V47, P249, DOI 10.1042/cs0470249
   MARCUS DF, 1970, INVEST OPHTH VISUAL, V9, P749
   Martin B, 1999, INVEST OPHTH VIS SCI, V40, P1011
   MCDANIEL DR, 1983, AM J OPTOM PHYS OPT, V60, P154
   Morgan AJ, 2007, BRIT J OPHTHALMOL, V91, P385, DOI 10.1136/bjo.2006.098574
   Movaffaghy A, 1998, EXP EYE RES, V67, P561, DOI 10.1006/exer.1998.0556
   MYERS KJ, 1974, INVEST OPHTH VISUAL, V13, P74
   Negi A, 2003, J ROY SOC MED, V96, P266, DOI 10.1258/jrsm.96.6.266
   ORCHARD TJ, 1990, DIABETES CARE, V13, P741, DOI 10.2337/diacare.13.7.741
   Pardhan S, 1995, EYE, V9, P50
   PASSO MS, 1987, AM J OPHTHALMOL, V103, P754, DOI 10.1016/S0002-9394(14)74388-0
   PASSO MS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1096, DOI 10.1001/archopht.1991.01080080056027
   Pournaras CJ, 2004, EUR J OPHTHALMOL, V14, P226, DOI 10.1177/112067210401400307
   Qureshi I A, 1996, Zhonghua Yi Xue Za Zhi (Taipei), V58, P317
   Qureshi I A, 1996, Korean J Ophthalmol, V10, P109
   QURESHI IA, 1995, JPN J PHYSIOL, V45, P561, DOI 10.2170/jjphysiol.45.561
   Qureshi IA, 1996, CLIN EXP PHARMACOL P, V23, P648, DOI 10.1111/j.1440-1681.1996.tb01751.x
   Qureshi IA, 1997, IND HEALTH, V35, P259, DOI 10.2486/indhealth.35.259
   Qureshi IA, 1995, ANN HUM BIOL, V22, P545, DOI 10.1080/03014469500004202
   Qureshi Imran Ahmad, 1997, JPMA (Journal of the Pakistan Medical Association), V47, P81
   Rasmidatta Somsak, 1998, Journal of the Medical Association of Thailand, V81, P169
   RAYMOND LA, 1980, AM J OPHTHALMOL, V90, P619, DOI 10.1016/S0002-9394(14)75128-1
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   ROJANAPONGPUN P, 1993, BRIT J OPHTHALMOL, V77, P25, DOI 10.1136/bjo.77.1.25
   Rouse M W, 1988, J Am Optom Assoc, V59, P946
   SARGENT RG, 1981, AM J OPTOM PHYS OPT, V58, P460
   SCHENKER HI, 1980, AM J OPHTHALMOL, V89, P598, DOI 10.1016/0002-9394(80)90073-2
   Schuman JS, 2000, OPHTHALMOLOGY, V107, P127, DOI 10.1016/S0161-6420(99)00015-9
   SELHORST JB, 1995, J NEURO-OPHTHALMOL, V15, P63
   Shah P, 2001, EYE, V15, P616, DOI 10.1038/eye.2001.196
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   SHAPIRO A, 1983, EUR J APPL PHYSIOL O, V52, P136, DOI 10.1007/BF00429041
   SMITH DL, 1989, OPHTHALMIC SURG LAS, V20, P561
   Sperduto RD, 1998, OPHTHALMOLOGY, V105, P765, DOI 10.1016/S0161-6420(98)95012-6
   STEWART RH, 1970, AM J OPHTHALMOL, V69, P245, DOI 10.1016/0002-9394(70)91285-7
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU
   Vieira GM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1251, DOI 10.1001/archopht.124.9.1251
   VINGER PF, 1994, CLIN OPHTHALMOL, V5, P1
   VUORI I, 2004, PHYS INACTIVITY DIS
   Wallberg-Henriksson H, 1998, SPORTS MED, V25, P25, DOI 10.2165/00007256-199825010-00003
   WATANABE Y, 1983, J SPORT MED PHYS FIT, V23, P373
   WOOD JM, 1994, OPTOMETRY VISION SCI, V71, P682, DOI 10.1097/00006324-199411000-00002
   WOODS RL, 1995, OPHTHAL PHYSL OPT, V15, P5, DOI 10.1046/j.1475-1313.1995.9592786.x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   YANNUZZI LA, 1993, AM J OPHTHALMOL, V116, P286
NR 100
TC 24
Z9 24
U1 1
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2009
VL 54
IS 3
BP 349
EP 355
DI 10.1016/j.survophthal.2009.02.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446VX
UT WOS:000266150700004
PM 19422963
DA 2022-11-30
ER

PT J
AU Mooney, I
   LaMotte, J
AF Mooney, Ingrid
   LaMotte, James
TI A review of the potential to restore vision with stem cells
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE neurogenesis; neurons; progenitor; retinal degeneration; stem cell
ID NEURAL PROGENITOR CELLS; OCULAR-SURFACE DISORDERS; ADULT MAMMALIAN EYE;
   LONG-TERM SURVIVAL; SUBRETINAL TRANSPLANTATION; NEURONAL
   DIFFERENTIATION; SUPERIOR COLLICULUS; RETINAL PROGENITOR; NEURITE
   OUTGROWTH; PRECURSOR CELLS
AB Vision research involving stem cells is a rapidly evolving field. Animal experiments have shown that in response to environmental cues, stem cells can repopulate damaged retinas, regrow neuronal axons, repair higher cortical pathways, and restore pupil reflexes, light responses and basic pattern recognition.
   Viable corneas have been grown from stem cells and transplanted into humans. Similarly, human trials to repair damaged retinas in retinitis pigmentosa and age-related macular degeneration patients have produced preliminary successes.
   This review attempts to place the collective contributions toward stem cell/vision research into a broader clinical model of how stem cells might ultimately be used to restore the entire visual pathway.
C1 So Calif Coll Optometry, Fullerton, CA 92831 USA.
RP LaMotte, J (通讯作者)，So Calif Coll Optometry, 2575 Yorba Linda Blvd, Fullerton, CA 92831 USA.
EM jlamotte@scco.edu
CR Aberg MAI, 2000, J NEUROSCI, V20, P2896
   Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069
   Ang LPK, 2007, AM J OPHTHALMOL, V143, P178, DOI 10.1016/j.ajo.2006.07.050
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   *BLIND WORLD MAG, 2006, STEM CELL PROM CUR V
   *BLIND WORLD MAG, 2006, RET PIGM RP PAT GETS
   BRUMMEDORF T, 1995, CELL ADHESION MOL IM
   CAJAL SR, 1928, DEGENERATION REGENER, V2, P583
   Canning DR, 1996, INT J DEV NEUROSCI, V14, P153, DOI 10.1016/0736-5748(96)00004-4
   CARTER DA, 1994, J NEUROSCI, V14, P590
   CARTER DA, 1989, J NEUROSCI, V9, P4042
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334
   Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510
   Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978
   Dogru M, 2005, AM J OPHTHALMOL, V140, P305, DOI 10.1016/j.ajo.2005.04.027
   EASTER SS, 1981, J NEUROSCI, V1, P793
   Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750
   Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999
   Fricker-Gates RA, 2002, J NEUROSCI, V22, P4045, DOI 10.1523/JNEUROSCI.22-10-04045.2002
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9
   HOLT CE, 1989, J NEUROSCI, V9, P3123
   KEIRSTEAD SA, 1989, SCIENCE, V246, P255, DOI 10.1126/science.2799387
   KENYON KR, 1989, OPHTHALMOLOGY, V96, P709
   Kim J, 2005, SCIENCE, V308, P1927, DOI 10.1126/science.1110175
   Kinoshita Shigeru, 2004, Ocul Surf, V2, P21
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Kordower JH, 1997, J COMP NEUROL, V387, P96, DOI 10.1002/(SICI)1096-9861(19971013)387:1<96::AID-CNE8>3.0.CO;2-I
   Lanza R, 2004, SCI AM, V290, P92, DOI 10.1038/scientificamerican0604-92
   Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536
   Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083
   Meyer JS, 2005, ANN NY ACAD SCI, V1049, P135, DOI 10.1196/annals.1334.013
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Otteson DC, 2003, VISION RES, V43, P927, DOI 10.1016/S0042-6989(02)00400-5
   Pedersen RA, 1999, SCI AM, V280, P68, DOI 10.1038/scientificamerican0499-68
   Pellegrini G, 1999, J CELL BIOL, V145, P769, DOI 10.1083/jcb.145.4.769
   Pressmar S, 2001, INVEST OPHTH VIS SCI, V42, P3311
   RICHARDSON PM, 1982, J NEUROCYTOL, V11, P949, DOI 10.1007/BF01148310
   Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1
   Shah S. G., 2006, Indian Journal of Ophthalmology, V54, P118
   SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5
   SNOW DM, 1991, DEVELOPMENT, V113, P1473
   Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663
   STIER H, 1995, DEVELOPMENT, V121, P1443
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   Thanos S, 1997, EXP BRAIN RES, V114, P483, DOI 10.1007/PL00005657
   THANOS S, 1992, EUR J NEUROSCI, V4, P691, DOI 10.1111/j.1460-9568.1992.tb00178.x
   THANOS S, 1991, J CELL SCI, P125
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201
   Wallace VA, 2007, CAN J OPHTHALMOL, V42, P442, DOI 10.3129/i07-047
   Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531
   Warfvinge K, 2005, ARCH OPHTHALMOL-CHIC, V123, P1385, DOI 10.1001/archopht.123.10.1385
   WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X
   Wojciechowski AB, 2002, EXP EYE RES, V75, P23, DOI 10.1006/exer.2001.1172
   Wojciechowski AB, 2002, STEM CELLS, V20, P163, DOI 10.1634/stemcells.20-2-163
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P324, DOI 10.1167/iovs.02-0132
   Zhao X, 2002, DEV BIOL, V250, P317, DOI 10.1006/dbio.2002.0793
NR 68
TC 5
Z9 6
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD JAN
PY 2008
VL 91
IS 1
BP 78
EP 84
DI 10.1111/j.1444-0938.2007.00184.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 235QP
UT WOS:000251249700008
PM 18045253
OA Bronze
DA 2022-11-30
ER

PT J
AU Xu, ND
   Xu, H
   Zhao, MW
   Xu, YS
   Huang, LZ
AF Xu, Ningda
   Xu, Hui
   Zhao, Mingwei
   Xu, Yongsheng
   Huang, Lvzhen
TI Associations of systemic, serum lipid and lipoprotein metabolic pathway
   gene variations with polypoidal choroidal vasculopathy in China
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; RISK; HEMORRHAGE; VARIANTS
AB Background
   To investigate the association of systemic, serum lipids and genetic variants in the high-density lipoprotein (HDL) metabolic pathway with polypoidal choroidal vasculopathy (PCV) in China.
   Methods
   The case-control study was included 150 controls and 66 cases with PCV. Serum levels of total cholesterol (TC), low-density lipoprotein (LDL), HDL, triglycerides (TG), apolipoprotein A1 (APOA1), apolipoprotein B (APOB) together with systemic risk factors including gender, hyperlipidemia, diabetes mellitus (DM), hypertension, coronary artery disease (CAD) and asthma were identified. All subjects were genotyped for four single nucleotide polymorphisms (SNPs) from three genes in the HDL metabolic pathway: rs10468017 of hepatic lipase (LIPC), rs12678919 of lipoprotein lipase (LPL), rs3764261 and rs173539 of cholesterol ester transfer protein (CETP) with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Students t-tests, chi-square tests, anova and logistic regression were used to evaluate associations.
   Results
   Hyperlipidemia was a risk factor (odds ratio (OR) = 1.19, P = 0.001) for PCV. HDL, LDL and APOB levels were associated with PCV (OR = 0.001, P = 0.004; OR = 0.099, P = 0.010; OR = 0.839, P = 0.018). Higher level of TC was potently associated with increased risk of PCV (OR = 109.8, P = 0.000). LIPC rs10468017 was a risk factor for PCV (OR = 11.68, P = 0.000). CETP rs3764261 conferred a decreased risk for PCV (OR = 0.08, P = 0.000). No associations of LPL rs12678919 or CETP rs173539 with PCV were found. Mean level of HDL increased with T allele of the CETP gene (p = 0.026): 1.24 mmol/L (+/- 0.31) for the GG genotype and 1.66 mmol/L (+/- 0.54) for the TT genotype. Additionally, T allele was associated with the following increase in APOA1: 136.78 mg/dl (+/- 20.53) for the CC genotype and 149.57 mg/dl (+/- 22.67) for the TT genotype of LIPC and 137.91 mg/dl (+/- 20.36) for the GG genotype and 162.67 mg/dl (+/- 22.50) for the TT genotype of CETP gene.
   Conclusion
   Our study suggested that the significant association was found between hyperlipidemia, the serum levels of TC, HDL, LDL and APOB and PCV. The result of present study also showed that the association of LIPC rs10468017 and CETP rs3764261 with PCV.
C1 [Xu, Ningda; Xu, Hui; Zhao, Mingwei; Xu, Yongsheng; Huang, Lvzhen] Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Hlth Sci Ctr,Coll Optometry, Dept Ophthalmol,Peoples Hosp,Eye Dis & Optometry, Beijing, Peoples R China.
C3 Peking University
RP Huang, LZ (通讯作者)，Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Hlth Sci Ctr,Coll Optometry, Dept Ophthalmol,Peoples Hosp,Eye Dis & Optometry, Beijing, Peoples R China.
EM drlvzhen123@163.com
FU National Natural Science Foundation of China [81470649, 81670870,
   81770943, 81470651]; Science and technology innovation project of
   Chinese academy of medical sciences [2018-I2M-HL-019]; Beijing Nova
   Program [Z161100004916058]; Huaxia Translational Medicine Fund for Young
   Scholars [2017-C-001]; Xiamen medical and health project [3502Z20189022]
FX This work was supported by the National Natural Science Foundation of
   China Grant (81470649, 81670870, 81770943, 81470651); Science and
   technology innovation project of Chinese academy of medical sciences
   (2018-I2M-HL-019), the Beijing Nova Program (Z161100004916058); Huaxia
   Translational Medicine Fund for Young Scholars (2017-C-001); Xiamen
   medical and health project (3502Z20189022). The funders had no role in
   the study design, data collection and analysis, decision to publish or
   preparation of the manuscript.
CR Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Chung YR, 2016, CAN J OPHTHALMOL, V51, P348, DOI 10.1016/j.jcjo.2016.02.012
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Gotoh N, 2004, OPHTHALMOLOGY, V138
   Grooth Greetje J. de, 2004, Journal of Lipid Research, V45, P1967
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144
   Ming-Zhen Y, 2018, J OPHTHALMOLOGY, V2018, P1
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Qingyu M, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0143924, DOI 10.1371/JOURNAL.PONE.0143924]
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Sun YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030040
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Xu H, 2019, INT J CLIN EXP PATHO, V12, P1782
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 34
TC 6
Z9 6
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2019
VL 14
IS 12
AR e0226763
DI 10.1371/journal.pone.0226763
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KN8GX
UT WOS:000515084600038
PM 31877157
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, L
   Gagey-Eilstein, N
   Broussy, S
   Reille-Seroussi, M
   Huguenot, F
   Vidal, M
   Liu, WQ
AF Wang, Lei
   Gagey-Eilstein, Nathalie
   Broussy, Sylvain
   Reille-Seroussi, Marie
   Huguenot, Florent
   Vidal, Michel
   Liu, Wang-Qing
TI Design and Synthesis of C-Terminal Modified Cyclic Peptides as VEGFR1
   Antagonists
SO MOLECULES
LA English
DT Article
DE VEGF; VEGFR; angiogenesis; cyclic peptides
ID BIOLOGICAL EVALUATION; GROWTH; ANGIOGENESIS; BINDING; MIMICKING;
   RECEPTORS; HEALTH
AB Previously designed cyclic peptide antagonist c[YYDEGLEE]-NH2 disrupts the interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). It represents a promising tool in the fight against cancer and age-related macular degeneration. We described in this paper the optimization of the lead peptide by C-terminal modification. A new strategy for the synthesis of cyclic peptides is developed, improving the cyclisation efficiency. At 100 mu M, several new peptides with an aromatic group flexibly linked at C-terminal end showed significantly increased receptor binding affinities in competition ELISA test. The most active peptide carrying a coumarin group may be a useful tool in anti-angiogenic biological studies.
C1 [Wang, Lei; Gagey-Eilstein, Nathalie; Broussy, Sylvain; Reille-Seroussi, Marie; Huguenot, Florent; Vidal, Michel; Liu, Wang-Qing] Univ Paris 05, Sorbonne Paris Cite, Fac Pharm Paris, CNRS,UMR 8638, F-75006 Paris, France.
   [Vidal, Michel] Hop Cochin, AP HP, UF Pharmacocinet & Pharmacochim, F-75014 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Universite Paris
   Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite
RP Vidal, M (通讯作者)，Univ Paris 05, Sorbonne Paris Cite, Fac Pharm Paris, CNRS,UMR 8638, 4 Ave Observ, F-75006 Paris, France.
EM lei.wang1@etu.parisdescartes.fr; nathalie.eilstein@parisdescartes.fr;
   sylvain.broussy@parisdescartes.fr; marie.reille@etu.parisdescartes.fr;
   florent.huguenot@parisdescartes.fr; michel.vidal@cch.aphp.fr;
   wangqing.liu@parisdescartes.fr
RI Broussy, Sylvain/AAX-1833-2020; Vidal, Michel/ABA-3396-2020; LIU,
   Wang-Qing/V-5422-2017
OI Broussy, Sylvain/0000-0003-3098-5317; LIU,
   Wang-Qing/0000-0003-0511-3058; Vidal, Michel/0000-0002-4858-1591;
   huguenot, florent/0000-0001-8400-0857; Reille-Seroussi,
   Marie/0000-0002-4136-1297
FU University Paris Descartes; Centre National de la Recherche Scientifique
   (Chaire de partenariat CNRS-UPD); ANR [ANR-2010-BLAN-1533-03, DOC2013
   0606849]; China Scholarship Council
FX This research was supported by the University Paris Descartes, the
   Centre National de la Recherche Scientifique (Chaire de partenariat
   CNRS-UPD to S. Broussy) and the ANR (ANR-2010-BLAN-1533-03). L. Wang
   acknowledges the China Scholarship Council for the donation of a
   scholarship. M. Reille-Seroussi acknowledges the ARC for the donation of
   a scholarship (grant DOC2013 0606849). We thank Pascale Leproux for the
   mass spectra analysis.
CR Aeluri M, 2014, CHEM REV, V114, P4640, DOI 10.1021/cr4004049
   Basile A, 2011, J MED CHEM, V54, P1391, DOI 10.1021/jm101435r
   Bello L, 2004, CLIN CANCER RES, V10, P4527, DOI 10.1158/1078-0432.CCR-04-0194
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   CHANG CD, 1980, INT J PEPT PROT RES, V15, P59
   Chen YY, 2014, ANGIOGENESIS, V17, P207, DOI 10.1007/s10456-013-9389-y
   Christinger H.W., 2003, J BIOL CHEM, V279, P10382
   D'Andrea LD, 2005, P NATL ACAD SCI USA, V102, P14215, DOI 10.1073/pnas.0505047102
   Diana D, 2011, J BIOL CHEM, V286, P41680, DOI 10.1074/jbc.M111.257402
   Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Finetti F, 2012, BIOCHEM PHARMACOL, V84, P303, DOI 10.1016/j.bcp.2012.04.011
   Gaucher J.F., 2014, J BIOL CHEM
   Gausepohl H, 1992, PEPTIDES CHEM BIOL, P523
   Gautier B, 2010, J MED CHEM, V53, P4428, DOI 10.1021/jm1002167
   Goncalves V., 2006, PHARMACHEM
   Goncalves V, 2008, J PEPT SCI, V14, P767, DOI 10.1002/psc.965
   Goncalves V, 2007, J MED CHEM, V50, P5135, DOI 10.1021/jm0706970
   Goncalves V, 2007, ANAL BIOCHEM, V366, P108, DOI 10.1016/j.ab.2007.03.027
   Garcia-Aranda MI, 2013, ORG BIOMOL CHEM, V11, P1896, DOI 10.1039/c3ob27312a
   Garcia-Aranda MI, 2011, BIOORGAN MED CHEM, V19, P7526, DOI 10.1016/j.bmc.2011.10.032
   Garcia-Aranda MI, 2011, BIOORGAN MED CHEM, V19, P1978, DOI 10.1016/j.bmc.2011.01.056
   Iyer S, 2010, J BIOL CHEM, V285, P23779, DOI 10.1074/jbc.M110.130658
   Jia HY, 2014, CHEMBIOCHEM, V15, P1161, DOI 10.1002/cbic.201300658
   Johnson T, 2000, J CHEM SOC PERK T 1, P2811, DOI 10.1039/b001694m
   Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107
   Lim NC, 2009, INORG CHEM, V48, P1173, DOI 10.1021/ic801322x
   Mullard A, 2012, NAT REV DRUG DISCOV, V11, P172, DOI 10.1038/nrd3680
   Nakamura K, 2001, ANAL BIOCHEM, V292, P280, DOI 10.1006/abio.2001.5098
   Reczek JJ, 2010, J ORG CHEM, V75, P2111, DOI 10.1021/jo100018f
   Shibuya M, 2014, BIOMOL THER, V22, P1, DOI 10.4062/biomolther.2013.113
   Spengler J, 2013, ACS COMB SCI, V15, P229, DOI 10.1021/co4000024
   Subiros-Funosas R, 2009, CHEM-EUR J, V15, P9394, DOI 10.1002/chem.200900614
   Vicari D, 2011, J BIOL CHEM, V286, P13612, DOI 10.1074/jbc.M110.216812
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Yamamoto T, 2007, J MED CHEM, V50, P2779, DOI 10.1021/jm061369n
   Ye YH, 2003, LETT PEPT SCI, V10, P571, DOI 10.1007/BF02442590
   Zilberberg L, 2003, J BIOL CHEM, V278, P35564, DOI 10.1074/jbc.M304435200
NR 41
TC 12
Z9 13
U1 1
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2014
VL 19
IS 10
BP 15391
EP 15407
DI 10.3390/molecules191015391
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AS7SX
UT WOS:000344456100003
PM 25264829
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Haddock, LJ
   Ramsey, DJ
   Young, LH
AF Haddock, Luis J.
   Ramsey, David J.
   Young, Lucy H.
TI Complications of Subspecialty Ophthalmic Care: Endophthalmitis after
   Intravitreal Injections of Anti-Vascular Endothelial Growth Factor
   Medications
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration (AMD); endophthalmitis; intravitreal
   injection; post-injection complications; vascular endothelial growth
   factor (VEGF)
ID CONTROLLED CLINICAL-TRIALS; MACULAR DEGENERATION; TOPICAL ANTIBIOTICS;
   POVIDONE-IODINE; FACTOR AGENTS; PROPHYLAXIS; VITRECTOMY; METAANALYSIS;
   PREVENTION; MANAGEMENT
AB The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.
C1 [Haddock, Luis J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
   Mass Gen Hosp, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Massachusetts General Hospital
RP Haddock, LJ (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM ljhaddock@med.miami.edu
RI Ramsey, David/AAW-2081-2021
OI Ramsey, David/0000-0002-5504-812X; Young, Lucy/0000-0001-8634-7512;
   Haddock, Luis/0000-0003-4179-6992
CR Ahmed Y, 2014, AM J OPHTHALMOL, V157, P503, DOI 10.1016/j.ajo.2013.12.001
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   Bhavsar AR, 2012, ARCH OPHTHALMOL-CHIC, V130, P809, DOI 10.1001/archophthalmol.2012.227
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chaudhary KM, 2013, RETINA-J RET VIT DIS, V33, P1407, DOI 10.1097/IAE.0b013e3182807659
   Chen RWS, 2013, JAMA OPHTHALMOL, V131, P840, DOI 10.1001/jamaophthalmol.2013.2524
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Englander M, 2013, BRIT J OPHTHALMOL, V97, P460, DOI 10.1136/bjophthalmol-2012-302435
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Fineman MS, 2013, RETINA-J RET VIT DIS, V33, P1968, DOI 10.1097/IAE.0b013e318287da92
   Friedman DA, 2013, RETINA-J RET VIT DIS, V33, P975, DOI 10.1097/IAE.0b013e3182877585
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Han DP, 1996, AM J OPHTHALMOL, V122, P830
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsu J, 2014, AM J OPHTHALMOL, V157, P514, DOI 10.1016/j.ajo.2013.10.003
   Jacobs DJ, 2011, CLIN OPHTHALMOL, V5, P739, DOI 10.2147/OPTH.S17975
   Lalwani GA, 2008, OPHTHALMOLOGY, V115, P473, DOI 10.1016/j.ophtha.2007.06.006
   Leng T, 2011, RETINA-J RET VIT DIS, V31, P344, DOI 10.1097/IAE.0b013e3181e09810
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Ramulu PY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1335, DOI 10.1001/archophthalmol.2010.224
   Schimel AM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1607, DOI 10.1001/archophthalmol.2011.370
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Wen JC, 2011, ARCH OPHTHALMOL-CHIC, V129, P1551, DOI 10.1001/archophthalmol.2011.227
   Wykoff CC, 2011, RETINA-J RET VIT DIS, V31, P633, DOI 10.1097/IAE.0b013e31821504f2
NR 33
TC 16
Z9 17
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD SEP-NOV
PY 2014
VL 29
IS 5-6
SI SI
BP 257
EP 262
DI 10.3109/08820538.2014.959616
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS0ZW
UT WOS:000344006400001
PM 25325851
DA 2022-11-30
ER

PT J
AU Sheu, SJ
AF Sheu, Shwu-Jiuan
TI INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL
   NEOVASCULARIZATION SECONDARY TO ENDOGENOUS ENDOPHTHALMITIS
SO KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE choroidal neovascularization; endophthalmitis; ranibizumab
AB Choroidal neovascularization is a major cause of visual loss in age-related macular degeneration. It is also a potential vision-threatening complication of pathologic myopia, uveitis, traumatic choroidal rupture and, rarely, endophthalmitis. Here, we report a 36-year-old woman with acute lymphocytic leukemia and fungal pneumonia after chemotherapy who developed endogenous endophthalmitis in both eyes. The infection was controlled by systemic antibiotic and antifungal agents. Unfortunately, choroidal neovascularization developed in the right macula I month later. One dose of intravitreal injection of ranibizumab (0.5 mg/0.05 mL) was given, and the macular exudates resolved rapidly. There was no recurrence or complications during the 10-month follow-up.
C1 [Sheu, Shwu-Jiuan] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Sheu, Shwu-Jiuan] Yuhing Jr Coll Hlth Care & Management, Kaohsiung, Taiwan.
C3 Kaohsiung Veterans General Hospital
RP Sheu, SJ (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Ophthalmol, 386 Ta Chung 1st Rd, Kaohsiung, Taiwan.
EM sjsheu@vghks.gov.tw
CR Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Tedeschi M, 2007, EUR J OPHTHALMOL, V17, P124, DOI 10.1177/112067210701700118
NR 4
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1607-551X
EI 2410-8650
J9 KAOHSIUNG J MED SCI
JI Kaohsiung J. Med. Sci.
PD NOV
PY 2009
VL 25
IS 11
BP 617
EP 620
DI 10.1016/S1607-551X(09)70566-2
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 520CX
UT WOS:000271818700007
PM 19858042
OA gold
DA 2022-11-30
ER

PT J
AU Asatryan, A
   Bazan, NG
AF Asatryan, Aram
   Bazan, Nicolas G.
TI Molecular mechanisms of signaling via the docosanoid neuroprotectin D1
   for cellular homeostasis and neuroprotection
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Review
DE cell death; lipid signaling; neurodegenerative disease; NF-kB
   transcription factor; retina
ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROLIFERATOR-ACTIVATED RECEPTORS;
   PIGMENT EPITHELIAL-CELLS; DOCOSAHEXAENOIC ACID; C-REL; TRANSCRIPTION
   FACTOR; OXIDATIVE STRESS; OXIDIZED OMEGA-3-FATTY-ACIDS; GENE-EXPRESSION
AB Docosahexaenoic acid, enriched in the brain and retina, generates docosanoids in response to disruptions of cellular homeostasis. Docosanoids include neuroprotectin D1 (NPD1), which is decreased in the CA1 hippocampal area of patients with early-stage Alzheimer's disease (AD). We summarize here how NPD1 elicits neuroprotection by up-regulating c-REL, a nuclear factor (NF)-B subtype that, in turn, enhances expression of BIRC3 (baculoviral inhibitor of apoptosis repeat-containing protein 3) in the retina and in experimental stroke, leading to neuroprotection. Elucidating the mechanisms of action of docosanoids will contribute to managing diseases, including stroke, AD, age-related macular degeneration, traumatic brain injury, Parkinson's disease, and other neurodegenerations.
C1 [Asatryan, Aram; Bazan, Nicolas G.] Louisiana State Univ Hlth New Orleans, Sch Med, Neurosci Ctr Excellence, 2020 Gravier St, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans
RP Bazan, NG (通讯作者)，Louisiana State Univ Hlth New Orleans, Sch Med, Neurosci Ctr Excellence, 2020 Gravier St, New Orleans, LA 70112 USA.
EM nbazan@lsuhsc.edu
RI Bazan, Nicolas/AAN-4121-2020
OI Bazan, Nicolas/0000-0002-9243-5444
FU National Institutes of Health from NIGMS [GM103340]; National Institutes
   of Health from NEI [EY005121]; National Institutes of Health from NINDS
   [NS046741]; Eye, Ear, Nose & Throat Foundation; Research to Prevent
   Blindness, Inc., New York; NATIONAL EYE INSTITUTE [R01EY005121] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
   [P30GM103340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKE [R01NS046741] Funding Source: NIH
   RePORTER
FX This work was supported in whole or in part by National Institutes of
   Health Grants GM103340 from NIGMS, EY005121 from NEI, and NS046741 from
   NINDS, the Eye, Ear, Nose & Throat Foundation, and in part by an
   unrestricted departmental grant from Research to Prevent Blindness,
   Inc., New York. This is the third article in the Thematic Minireview
   Series: "Inflammatory transcription confronts homeostatic disruptions."
   The authors declare that they have no conflicts of interest with the
   contents of this article. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Ahn HJ, 2008, LEARN MEMORY, V15, P539, DOI 10.1101/lm.866408
   Antony R, 2010, J BIOL CHEM, V285, P18301, DOI 10.1074/jbc.M109.095232
   Arnold CD, 2013, SCIENCE, V339, P1074, DOI 10.1126/science.1232542
   Astarita G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012538
   BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6
   BAZAN NG, 1982, BIOCHIM BIOPHYS ACTA, V712, P702, DOI 10.1016/0005-2760(82)90301-0
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X
   BAZAN NG, 1985, RETINAL DEGENERATION, P159
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0
   Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014
   BOK D, 1993, J CELL SCI, P189
   Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632
   Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097
   Burke SP, 2010, J BIOL CHEM, V285, P30061, DOI 10.1074/jbc.M110.125955
   Cabal-Hierro L, 2012, CELL SIGNAL, V24, P1297, DOI 10.1016/j.cellsig.2012.02.006
   Calandria JM, 2015, CELL DEATH DIFFER, V22, P1363, DOI 10.1038/cdd.2014.233
   Calandria JM, 2012, J BIOL CHEM, V287, P23726, DOI 10.1074/jbc.M111.287078
   Calandria JM, 2009, J BIOL CHEM, V284, P17877, DOI 10.1074/jbc.M109.003988
   Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64
   Conte D, 2006, MOL CELL BIOL, V26, P699, DOI 10.1128/MCB.26.2.699-708.2006
   Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Fatehi-Hassanabad Zahra, 2005, Nutr Metab (Lond), V2, P1, DOI 10.1186/1743-7075-2-1
   Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011
   Georgiadi A, 2012, ADV NUTR, V3, P127, DOI 10.3945/an.111.001602
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Gilmore Thomas D, 2011, Genes Cancer, V2, P695, DOI 10.1177/1947601911421925
   GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731
   Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17
   Guadagno JV, 2003, BRIT MED BULL, V65, P145, DOI 10.1093/bmb/65.1.145
   Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889
   HANNINK M, 1990, ONCOGENE, V5, P1843
   Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hong SH, 2014, J NEUROL SCI, V338, P135, DOI 10.1016/j.jns.2013.12.033
   Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200
   Jin HS, 2009, CANCER RES, V69, P1782, DOI 10.1158/0008-5472.CAN-08-2256
   Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857
   Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318
   Kolko M, 2007, INVEST OPHTH VIS SCI, V48, P1401, DOI 10.1167/iovs.06-0865
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001
   LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407
   Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003
   Levine M, 2014, CELL, V157, P13, DOI 10.1016/j.cell.2014.02.009
   Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6
   Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055
   Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200
   Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200
   Mattson MP, 2012, BASIC NEUROCHEMISTRY: PRINCIPLES OF MOLECULAR, CELLULAR, AND MEDICAL NEUROBIOLOGY, 8THEDITION, P663
   Mishra A, 2004, ARTERIOSCL THROM VAS, V24, P1621, DOI 10.1161/01.ATV.0000137191.02577.86
   Mokhtari D, 2009, AM J PHYSIOL-ENDOC M, V297, pE1067, DOI 10.1152/ajpendo.00212.2009
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Oksman M, 2006, NEUROBIOL DIS, V23, P563, DOI 10.1016/j.nbd.2006.04.013
   Rapoport SI, 2007, PROSTAG LEUKOTR ESS, V77, P251, DOI 10.1016/j.plefa.2007.10.023
   Reubold TF, 2012, CELL SIGNAL, V24, P1420, DOI 10.1016/j.cellsig.2012.03.007
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Sahlin C, 2007, EUR J NEUROSCI, V26, P882, DOI 10.1111/j.1460-9568.2007.05719.x
   Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666
   Sarnico I, 2009, INT REV NEUROBIOL, V85, P351, DOI 10.1016/S0074-7742(09)85024-1
   Sarnico I, 2009, J NEUROCHEM, V108, P475, DOI 10.1111/j.1471-4159.2008.05783.x
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Selye H, 1998, J NEUROPSYCH CLIN N, V10, P230
   Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]
   Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006
   Sethi S, 2002, BLOOD, V100, P1340, DOI 10.1182/blood-2002-01-0316
   Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070
   Stark DT, 2011, J NEUROSCI, V31, P13710, DOI 10.1523/JNEUROSCI.3544-11.2011
   Sullivan PG, 1999, J NEUROSCI, V19, P6248
   Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531
   Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006
   Turrens J., 2011, J PHYSL, V8, P695
   UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227
   Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200
   Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030
   Vince JE, 2009, J BIOL CHEM, V284, P35906, DOI 10.1074/jbc.M109.072256
   Viswanathan M, 1996, GENE, V170, P271, DOI 10.1016/0378-1119(95)00773-3
   Wang LW, 2010, NAT STRUCT MOL BIOL, V17, P1324, DOI 10.1038/nsmb.1920
   Xu M, 2016, ACTA PHARMACOL SIN, V37, P246, DOI 10.1038/aps.2015.125
   Zhang J., 2016, MATH PROBL ENG, V2016, P1, DOI DOI 10.1042/BSR20160076
   Zhao YH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015816, 10.1371/journal.pone.0016470]
NR 91
TC 50
Z9 51
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 28
PY 2017
VL 292
IS 30
BP 12390
EP 12397
DI 10.1074/jbc.R117.783076
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FC1ZM
UT WOS:000406636900005
PM 28615451
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Elbarbary, RA
   Takaku, H
   Tamura, M
   Nashimoto, M
AF Elbarbary, Reyad A.
   Takaku, Hiroaki
   Tamura, Masato
   Nashimoto, Masayuki
TI Inhibition of vascular endothelial growth factor expression by TRUE gene
   silencing
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE 5 '-Half-tRNA; sgRNA; tRNase Z(L); TRUE gene silencing; VEGF
ID 3' PROCESSING ENDORIBONUCLEASE; TRANSFER-RNA; TARGETING VEGF; OCULAR
   NEOVASCULARIZATION; TRNASE-ZL; CLEAVAGE; SIRNA; ANGIOGENESIS;
   SUPPRESSION; HEPTAMERS
AB Pathogenic angiogenesis in various diseases including cancer, autoimmune diseases, and age-related macular degeneration is thought to be regressed with anti-angiogenic drugs. TRUE gene silencing is a new technology to eliminate a specific mRNA using synthetic sgRNA and cellular tRNase Z(L). To discover anti-angiogenic sgRNAs, we applied TRUE silencing to the VEGF gene. We examined eight sgRNAs for efficacy in targeting exogenous human VEGF mRNA. Many of them worked efficiently in 293 and HeLa cells. Two of them downregulated the endogeneous VEGF gene expression in HeLa cells very efficiently, and the efficacy of these two sgRNAs surpassed that of siRNA extremely. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Elbarbary, Reyad A.; Takaku, Hiroaki; Nashimoto, Masayuki] Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Niigata 9568603, Japan.
   [Tamura, Masato] Hokkaido Univ, Dept Biochem & Mol Biol, Grad Sch Dent Med, Sapporo, Hokkaido 0608586, Japan.
C3 Niigata University; Hokkaido University
RP Nashimoto, M (通讯作者)，Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Higashijima 265-1, Niigata 9568603, Japan.
EM mnashimoto@nupals.ac.jp
RI tamura, masato/B-7304-2009
OI tamura, masato/0000-0003-3700-5203; Rzq, kareem/0000-0003-3784-9430
FU Ministry of Education, Culture, Sports and Technology of Japan
FX We thank Dr. T. Hashiguchi for providing us the plasmid pCI/hVEGF-A.
   This work was supported in part by a Grant-in-Aid for Scientific
   Research (B) from the Ministry of Education, Culture, Sports and
   Technology of Japan.
CR APPASANI K, 2005, RNA INTERFERENCE TEC
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Habu Y, 2005, NUCLEIC ACIDS RES, V33, P235, DOI 10.1093/nar/gki164
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Nakashima A, 2007, GENE THER, V14, P78, DOI 10.1038/sj.gt.3302841
   NASHIMOTO M, 1991, BIOCHEM BIOPH RES CO, V178, P1247, DOI 10.1016/0006-291X(91)91027-A
   NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642
   NASHIMOTO M, 1993, NUCLEIC ACIDS RES, V21, P4696, DOI 10.1093/nar/21.20.4696
   Nashimoto M, 1999, BIOCHEMISTRY-US, V38, P12089, DOI 10.1021/bi9911942
   NASHIMOTO M, 1992, NUCLEIC ACIDS RES, V20, P3737, DOI 10.1093/nar/20.14.3737
   Nashimoto M, 2000, FEBS LETT, V472, P179, DOI 10.1016/S0014-5793(00)01462-9
   Nashimoto M, 1998, NUCLEIC ACIDS RES, V26, P2565, DOI 10.1093/nar/26.11.2565
   NASHIMOTO M, 1996, RNA, V2, P2523
   Reich S, 2003, MOL VIS, V9, P210
   Scherer L., 2008, P201
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibata HS, 2005, J BIOL CHEM, V280, P22326, DOI 10.1074/jbc.M502048200
   Takaku H, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh092
   Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774
   Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337
   Tamura M, 2003, NUCLEIC ACIDS RES, V31, P4354, DOI 10.1093/nar/gkg641
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
NR 26
TC 20
Z9 21
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 20
PY 2009
VL 379
IS 4
BP 924
EP 927
DI 10.1016/j.bbrc.2008.12.173
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 407AT
UT WOS:000263336700024
PM 19135977
DA 2022-11-30
ER

PT J
AU Sarangarajan, R
   Apte, SP
AF Sarangarajan, R
   Apte, SP
TI Ocular melanogenesis: The role of antioxidants
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE melanin; melanogenesis; antioxidants; ocular degeneration; redox
ID NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION
   PATHWAY; CYCLIC-AMP; NEUTRAL SPHINGOMYELINASE; CERAMIDE PRODUCTION;
   TRANSCRIPTION FACTOR; SEPIA-OFFICINALIS; INDUCED APOPTOSIS
AB Given the propensity of a large number of melanogenic pathways that can be modulated by cellular redox status, a causal role of the deficiency of ocular pigments such as melanin in the pathogenesis of age-related macular degeneration and evidence that melanin production does occur in the adult eye, it seems not improbable that antioxidants ( or agents that modify cellular redox status) may have melanin stimulatory ( or inhibitory) effects that are superimposible on their effects as mere free radical scavengers. More empirical studies are needed to investigate this phenomenon so that antioxidant therapy may prove more beneficial to patients with ocular degenerative diseases. Copyright (C) 2004 S. Karger AG, Basel.
C1 Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Worcester, MA USA.
RP Apte, SP (通讯作者)，Baxter IV Syst, Murray Hill, NJ 07974 USA.
EM shireeshpapte@msn.com
CR AGUILAR JS, 1999, FREE RADIC BIOL MED, V26, P107
   Ancans J, 2000, FEBS LETT, V478, P57, DOI 10.1016/S0014-5793(00)01795-6
   Ao Y, 1998, EXP CELL RES, V244, P117, DOI 10.1006/excr.1998.4086
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Baudouin JE, 1996, J INVEST DERMATOL, V106, P428, DOI 10.1111/1523-1747.ep12343523
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747
   Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694
   BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030
   Brown DA, 2001, J PHOTOCH PHOTOBIO B, V63, P148, DOI 10.1016/S1011-1344(01)00212-3
   Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6
   CHEN Z, 1996, P AM ASSOC CANC RES, V37, pA1922
   COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0
   Cooksey CJ, 1996, QUANT STRUCT-ACT REL, V15, P498, DOI 10.1002/qsar.19960150606
   Dutkiewicz R, 2000, EXP EYE RES, V70, P563, DOI 10.1006/exer.1999.0819
   El-Husseini AE, 1998, J NEUROCHEM, V71, P676
   EVERETT SA, 2002, FREE RADIC BIOL MED, V32, P203
   Fernandez-Ayala DJM, 2000, ANTIOXID REDOX SIGN, V2, P263, DOI 10.1089/ars.2000.2.2-263
   Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1
   Fuller BB, 2001, EXP CELL RES, V262, P197, DOI 10.1006/excr.2000.5092
   Gesquiere L, 2000, FREE RADICAL BIO MED, V29, P181, DOI 10.1016/S0891-5849(00)00337-3
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5
   Gouaze V, 2001, MOL PHARMACOL, V60, P488
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x
   HEARING VJ, 1998, BIOCHEM BIOPH RES CO, V242, P579
   HEARING VJ, 1999, ANAL BIOCHEM, V270, P207
   Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198
   Hirobe T, 1998, EUR J CELL BIOL, V75, P184, DOI 10.1016/S0171-9335(98)80060-5
   Hu DN, 2001, EXP EYE RES, V73, P93, DOI 10.1006/exer.2001.1011
   Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200
   JARA JR, 1988, BIOCHIM BIOPHYS ACTA, V967, P296, DOI 10.1016/0304-4165(88)90023-2
   Joshi M, 1996, MELANOMA RES, V6, P121, DOI 10.1097/00008390-199604000-00006
   KIM Y, 1998, BIOCHEM BIOPH RES CO, V243, P801
   KIM YS, 2003, J DERMATOL SCI, V31, P193
   Land EJ, 2001, J PHOTOCH PHOTOBIO B, V64, P123, DOI 10.1016/S1011-1344(01)00220-2
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Lindquist NG, 1999, EXP EYE RES, V69, P431, DOI 10.1006/exer.1999.0718
   Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313
   Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867
   MARTIN A, 1993, PHYSL PHARM, P190
   Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348
   MEDRANO EE, 1999, EXP CELL RES, V253, P561
   Mehta G, 2001, TETRAHEDRON LETT, V42, P1987, DOI 10.1016/S0040-4039(01)00050-8
   MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9
   Moini H, 2002, ARCH BIOCHEM BIOPHYS, V397, P384, DOI 10.1006/abbi.2001.2680
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   Nofsinger JB, 2002, FREE RADICAL BIO MED, V32, P720, DOI 10.1016/S0891-5849(02)00763-3
   Nohl H, 1998, FREE RADICAL BIO MED, V25, P666, DOI 10.1016/S0891-5849(98)00105-1
   Nordlund James J., 1994, Annals of Dermatology, V6, P109
   Ohguchi K, 2003, BIOCHEM BIOPH RES CO, V307, P861, DOI 10.1016/S0006-291X(03)01284-1
   OKAZAKI T, 1989, J BIOL CHEM, V264, P19076
   Ozeki H, 1997, BBA-GEN SUBJECTS, V1336, P539, DOI 10.1016/S0304-4165(97)00068-8
   PACKER L, 1993, MOL ASPECTS MED, V14, P229, DOI 10.1016/0098-2997(93)90009-3
   PACKER L, 1999, FREE RADIC BIOL MED, V26, P174
   Palumbo A, 2000, J BIOL CHEM, V275, P16885, DOI 10.1074/jbc.M909509199
   Palumbo A, 1997, BIOCHEM BIOPH RES CO, V235, P429, DOI 10.1006/bbrc.1997.6734
   PARK CS, 1994, BIOCHEM BIOPH RES CO, V205, P85, DOI 10.1006/bbrc.1994.2633
   PARK KC, 2002, CELL SIGNAL, V14, P779
   Prota G, 2000, PIGM CELL RES, V13, P147, DOI 10.1034/j.1600-0749.2000.130305.x
   Prota G, 1998, EXP EYE RES, V67, P293, DOI 10.1006/exer.1998.0518
   Rao RJ, 2003, BIOORG MED CHEM LETT, V13, P2777, DOI 10.1016/S0960-894X(03)00494-3
   RAPP LM, 1980, VISION RES, V20, P1127, DOI 10.1016/0042-6989(80)90050-4
   RICHARD MJ, 2001, FREE RADIC BIOL MED, V31, P585
   RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0
   RomeroGraillet C, 1997, J CLIN INVEST, V99, P635, DOI 10.1172/JCI119206
   RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Sarangarajan R, 2001, PIGM CELL RES, V14, P437, DOI 10.1034/j.1600-0749.2001.140603.x
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Sarna T., 1998, PIGMENTARY SYSTEM PH, P333
   SASAKI H, 1995, INVEST OPHTH VIS SCI, V36, P1804
   Schallreuter KU, 1997, J INVEST DERMATOL, V109, P31, DOI 10.1111/1523-1747.ep12276418
   SCHALLREUTER KU, 1994, BBA-MOL BASIS DIS, V1226, P181, DOI 10.1016/0925-4439(94)90027-2
   Schallreuter KU, 2001, J PHOTOCH PHOTOBIO B, V64, P179, DOI 10.1016/S1011-1344(01)00235-4
   SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   SCHRAERMEYER U, 1993, PIGM CELL RES, V6, P193, DOI 10.1111/j.1600-0749.1993.tb00602.x
   Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354
   SLEPNEVA IA, 1995, BIOCHEM BIOPH RES CO, V214, P1246, DOI 10.1006/bbrc.1995.2420
   SmithThomas L, 1996, CURR EYE RES, V15, P1079, DOI 10.3109/02713689608995139
   SOLANO F, 1994, BIOCHEM BIOPH RES CO, V204, P1243, DOI 10.1006/bbrc.1994.2596
   STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928
   STAUBLE B, 1994, EUR J BIOCHEM, V226, P393, DOI 10.1111/j.1432-1033.1994.tb20064.x
   Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654
   THODY AJ, 1992, PIGM CELL RES, V5, P335, DOI 10.1111/j.1600-0749.1992.tb00558.x
   THOMPSON A, 1985, BIOCHIM BIOPHYS ACTA, V843, P49, DOI 10.1016/0304-4165(85)90048-0
   TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185
   UJIHARA H, 1993, JPN J PHARMACOL, V61, P375, DOI 10.1254/jjp.61.375
   URSINI F, 1995, METHOD ENZYMOL, V252, P38
   Vincensi MR, 1998, MELANOMA RES, V8, P53, DOI 10.1097/00008390-199802000-00009
   Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558
   Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069
   Wistrand PJ, 1997, SURV OPHTHALMOL, V41, pS129, DOI 10.1016/S0039-6257(97)80020-3
   WOLFF SP, 1987, EXP EYE RES, V45, P777, DOI 10.1016/S0014-4835(87)80095-7
   WOOD BA, 1988, J ANAT, V161, P1
   WOOD JM, 1995, BIOCHEM BIOPH RES CO, V206, P480, DOI 10.1006/bbrc.1995.1068
   Wu H, 2003, BIOCHEM BIOPH RES CO, V311, P948, DOI 10.1016/j.bbrc.2003.10.092
   Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803
   Yamamoto M, 1997, EXP EYE RES, V65, P645, DOI 10.1006/exer.1997.0370
   YONEMOTO K, 1983, BIOCHEM PHARMACOL, V32, P1379, DOI 10.1016/0006-2952(83)90450-1
   Yoshikawa M, 2002, BIOORGAN MED CHEM, V10, P1547, DOI 10.1016/S0968-0896(01)00422-9
   ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99
NR 109
TC 3
Z9 3
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2004
VL 36
IS 6
BP 303
EP 311
DI 10.1159/000081632
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883ON
UT WOS:000226022700001
PM 15627830
DA 2022-11-30
ER

PT J
AU Chen, E
   Ho, AC
   Garg, SJ
   Brown, GC
   Kaiser, RS
AF Chen, Eric
   Ho, Allen C.
   Garg, Sunir J.
   Brown, Gary C.
   Kaiser, Richard S.
TI Streptococcus mitis Endophthalmitis Presenting as Frosted Branch
   Angiitis After Intravitreal Pegaptanib Sodium Injection
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID BACTERIAL ENDOPHTHALMITIS; MACULAR DEGENERATION; EARLY SIGN; SAFETY
AB An 80-year-old woman presented with endophthalmitis and a frosted branch angiitis-like picture following intravitreal injection of pegaptanib sodium for age-related macular degeneration. After vitreous tap and injection of antibiotics, the patient underwent vitrectomy because her clinical condition worsened. Cultures grew Streptococcus mitis, and the patient's visual acuity stabilized at hand motions following unsuccessful repair of a retinal detachment complicated by proliferative vitreoretinopathy. Because S. mitis can cause an endophthalmitis that presents as frosted branch angiitis, it must be considered in the differential diagnosis of patients who present with frosted branch angiitis. [Ophthalmic Surg Lasers Imaging 2009;40:192-194.]
C1 [Chen, Eric; Ho, Allen C.; Garg, Sunir J.; Brown, Gary C.; Kaiser, Richard S.] Wills Eye Inst, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Chen, E (通讯作者)，Wills Eye Inst, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
OI Ho, Allen/0000-0003-3921-608X
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   GODLEY BF, 1993, AM J OPHTHALMOL, V116, P247, DOI 10.1016/S0002-9394(14)71301-7
   Harrison SA, 1997, AM J OPHTHALMOL, V123, P260, DOI 10.1016/S0002-9394(14)71048-7
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Kleiner RC, 1997, RETINA-J RET VIT DIS, V17, P370, DOI 10.1097/00006982-199709000-00002
   MAO LK, 1992, ARCH OPHTHALMOL-CHIC, V110, P798, DOI 10.1001/archopht.1992.01080180070030
   PACKER AJ, 1983, AM J OPHTHALMOL, V96, P66, DOI 10.1016/0002-9394(83)90456-7
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
NR 9
TC 13
Z9 13
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2009
VL 40
IS 2
BP 192
EP 194
DI 10.3928/15428877-20090301-06
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 418SU
UT WOS:000264170000018
PM 19320312
DA 2022-11-30
ER

PT J
AU Christie, JG
   Kompella, UB
AF Christie, Jennifer G.
   Kompella, Uday B.
TI Ophthalmic light sensitive nanocarrier systems
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID DIRECTED GENE DELIVERY; PHOTODYNAMIC THERAPY; DRUG-DELIVERY;
   VISIBLE-LIGHT; QUANTUM DOTS; PHOTOCHEMICAL TRANSFECTION; MACULAR
   DEGENERATION; POLYMERIC MICELLES; TARGETED DRUG; IN-VIVO
AB The eye is afflicted by chronic vision debilitating neovascular disorders, such as age-related macular degeneration, proliferative diabetic retinopathy, and corneal angiogenesis. Photodynamic therapy (PDT) is an innovative, evolving approach for treating neovascular diseases of the eye. PDT refers to the process of activating a light sensitive agent or carrier with non-thermal light to induce chemical reactions that ameliorate a pathological condition. Key components of PDT include a photosensitizer, a colloidal carrier or formulation and a light source. This article summarizes currently available clinical PDTs, desirable features of PDTs and photosensitizers, useful light sources for PDT and investigational nanosystems, and colloidal carriers for PDT.
C1 [Christie, Jennifer G.; Kompella, Uday B.] 985840 Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Kompella, Uday B.] 985840 Nebraska Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Kompella, UB (通讯作者)，985840 Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
EM ukompell@unmc.edu
RI Kompella, U/C-9789-2011
FU NEI NIH HHS [R21 EY017360, R21 EY017360-01A1, R24 EY017045, R24
   EY017045-02] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY017360, R24EY017045] Funding Source: NIH RePORTER
CR Amrite AC, 2006, INVEST OPHTH VIS SCI, V47, P1149, DOI 10.1167/iovs.05-0531
   ANDERSON VC, 1992, BIOCHIM BIOPHYS ACTA, V1109, P33, DOI 10.1016/0005-2736(92)90183-M
   Bakalova R, 2004, NAT BIOTECHNOL, V22, P1360, DOI 10.1038/nbt1104-1360
   Berg K, 1999, CANCER RES, V59, P1180
   Bloquel C, 2006, ADV DRUG DELIVER REV, V58, P1224, DOI 10.1016/j.addr.2006.07.023
   Bondurant B, 2001, BBA-BIOMEMBRANES, V1511, P113, DOI 10.1016/S0005-2736(00)00388-6
   Borras T, 2003, EXP EYE RES, V76, P643, DOI 10.1016/S0014-4835(03)00030-7
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Chaum E, 2002, SURV OPHTHALMOL, V47, P449, DOI 10.1016/S0039-6257(02)00336-3
   Clapp PJ, 1997, MACROMOLECULES, V30, P32, DOI 10.1021/ma960935t
   Derycke ASL, 2004, ADV DRUG DELIVER REV, V56, P17, DOI 10.1016/j.addr.2003.07.014
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   GROSSWEINER LI, 1982, PHOTOCHEM PHOTOBIOL, V36, P159, DOI 10.1111/j.1751-1097.1982.tb04358.x
   Hashida M, 2005, CHEM PHARM BULL, V53, P871, DOI 10.1248/cpb.53.871
   HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V
   Hogset A, 2000, HUM GENE THER, V11, P869, DOI 10.1089/10430340050015482
   Hogset Anders, 2002, Somatic Cell and Molecular Genetics, V27, P97, DOI 10.1023/A:1022979806314
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   LAMPARSKI H, 1992, BIOCHEMISTRY-US, V31, P685, DOI 10.1021/bi00118a008
   Liaw J, 2001, GENE THER, V8, P999, DOI 10.1038/sj.gt.3301485
   Martul EV, 2002, NEFROLOGIA, V22, P1
   MILLER H, 1993, ARCH OPHTHALMOL-CHIC, V111, P855, DOI 10.1001/archopht.1993.01090060145039
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Mohan RR, 2005, PROG RETIN EYE RES, V24, P537, DOI 10.1016/j.preteyeres.2005.04.001
   Mori Keisuke, 1997, Nippon Ganka Gakkai Zasshi, V101, P134
   Mueller A, 2000, MACROMOLECULES, V33, P4799, DOI 10.1021/ma000055l
   Nishiyama N, 2005, NAT MATER, V4, P934, DOI 10.1038/nmat1524
   Nishiyama N, 2003, BIOCONJUGATE CHEM, V14, P58, DOI 10.1021/bc025597h
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Normand N, 2005, MOL VIS, V11, P184
   PATHAK MA, 1984, BIOCHIM BIOPHYS ACTA, V798, P115, DOI 10.1016/0304-4165(84)90018-7
   Pervaiz S, 2006, CLIN EXP PHARMACOL P, V33, P551, DOI 10.1111/j.1440-1681.2006.04406.x
   Prasmickaite L, 2001, PHOTOCHEM PHOTOBIOL, V73, P388, DOI 10.1562/0031-8655(2001)073<0388:EODPFU>2.0.CO;2
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Raghava S, 2007, EUR J PHARMACOL, V568, P68, DOI 10.1016/j.ejphar.2007.04.044
   Renno RZ, 2001, ADV DRUG DELIVER REV, V52, P63, DOI 10.1016/S0169-409X(01)00195-8
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/jbc.M211891200
   Samia ACS, 2003, J AM CHEM SOC, V125, P15736, DOI 10.1021/ja0386905
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SCHUITMAKER JJ, 1990, INVEST OPHTH VIS SCI, V31, P1444
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   Sheppard JD, 2006, AM J OPHTHALMOL, V141, P524, DOI 10.1016/j.ajo.2005.11.003
   Torres PF, 2001, OCUL IMMUNOL INFLAMM, V9, P9, DOI 10.1076/ocii.9.1.9.3978
   VERMEERSCH G, 1991, PHOTOCHEM PHOTOBIOL, V54, P661, DOI 10.1111/j.1751-1097.1991.tb02072.x
   Weng JF, 2006, CURR MED CHEM, V13, P897, DOI 10.2174/092986706776361076
   YUI N, 1993, J CONTROL RELEASE, V26, P141, DOI 10.1016/0168-3659(93)90113-J
   Zeimer R, 2001, ADV DRUG DELIVER REV, V52, P49, DOI 10.1016/S0169-409X(01)00194-6
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
NR 48
TC 61
Z9 63
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD FEB
PY 2008
VL 13
IS 3-4
BP 124
EP 134
DI 10.1016/j.drudis.2007.12.005
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 269OD
UT WOS:000253657600005
PM 18275910
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Messner, A
   Werkmeister, RM
   Seidel, G
   Stegmann, H
   Schmetterer, L
   dos Santos, VA
AF Messner, Alina
   Werkmeister, Rene M.
   Seidel, Gerald
   Stegmann, Hannes
   Schmetterer, Leopold
   dos Santos, Valentin Aranha
TI Light-induced changes of the subretinal space of the temporal retina
   observed via optical coherence tomography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STIMULUS-INDUCED CHANGES; DARK-ADAPTATION; SCATTERING CHANGES; MACAQUE
   RETINA; OUTER RETINA; OPTOPHYSIOLOGY; PHYSIOLOGY; VISUALIZATION;
   HYDRATION; REVEALS
AB Photoreceptor function is impaired in many retinal diseases like age-related macular degeneration. Currently, assessment of the photoreceptor function for the early diagnosis and monitoring of these diseases is either subjective, as in visual field testing, requires contact with the eye, like in electroretinography, or relies on research prototypes with acquisition speeds unattained by conventional imaging systems. We developed an objective, noncontact method to monitor photoreceptor function using a standard optical coherence tomography system. This method can be used with various white light sources for stimulation. The technique was applied in five volunteers and detected a decrease of volume of the subretinal space associated with light adaptation processes of the retina.
C1 [Messner, Alina; Werkmeister, Rene M.; Stegmann, Hannes; Schmetterer, Leopold; dos Santos, Valentin Aranha] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
   [Seidel, Gerald] Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Schmetterer, Leopold] The Academia, Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Schmetterer, Leopold] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 636921, Singapore.
   [Stegmann, Hannes] Med Univ Vienna, Christian Doppler Lab Ocular & Dermal Effects Thi, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Graz; Medical
   University of Vienna; National University of Singapore; Singapore
   National Eye Center; Nanyang Technological University & National
   Institute of Education (NIE) Singapore; Nanyang Technological
   University; Medical University of Vienna
RP dos Santos, VA (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
EM valentin.aranhadossantos@meduniwien.ac.at
RI Werkmeister, Rene/ABD-6584-2020
OI Werkmeister, Rene/0000-0002-5147-5714; Messner,
   Alina/0000-0003-1876-7528; Schmetterer, Leopold/0000-0002-7189-1707
FU Vienna Science and Technology Fund (WWTF) [LS14-067]
FX The research has been funded by the Vienna Science and Technology Fund
   (WWTF) through project LS14-067. We thank Dr. Stefan Puchner for his
   help with the screening visits, Dr. Doreen Schmidl, Alexandra Rauch and
   Dr. Gerhard Garhofer for their help with organizational matters and Dr.
   Alexandre Tumlinson from Carl Zeiss Meditec Inc. for helping with the
   raw data access to the software.
CR Abramoff MD, 2006, INVEST OPHTH VIS SCI, V47, P715, DOI 10.1167/iovs.05-0008
   Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Almasian M, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.12.121314
   Arshavsky VY, 2012, J BIOL CHEM, V287, P1620, DOI 10.1074/jbc.R111.305243
   Bashkatov A. N., P SPIE
   Berkowitz BA, 2018, INVEST OPHTH VIS SCI, V59, P5957, DOI 10.1167/iovs.18-25682
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Deutsches Institut fur Normung e. V. Berlin, 2007, 1500422007 DIN ESO
   Devore JL, 2010, PROBABILITY STAT ENG
   dos Santos VA, 2016, BIOMED OPT EXPRESS, V7, P2650, DOI 10.1364/BOE.7.002650
   dos Santos VA, 2015, OPT EXPRESS, V23, P21043, DOI 10.1364/OE.23.021043
   Drexler W, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   GALLEMORE RP, 1994, VISUAL NEUROSCI, V11, P753, DOI 10.1017/S0952523800003059
   Goetz G, 2018, P NATL ACAD SCI USA, V115, pE2499, DOI 10.1073/pnas.1712763115
   Grieve K, 2008, INVEST OPHTH VIS SCI, V49, P713, DOI 10.1167/iovs.07-0837
   GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0
   Hanazono G, 2007, INVEST OPHTH VIS SCI, V48, P2903, DOI 10.1167/iovs.06-1294
   Hillmann D, 2016, P NATL ACAD SCI USA, V113, P13138, DOI 10.1073/pnas.1606428113
   HUANG B, 1992, J NEUROSCI, V12, P4243
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Kocaoglu OP, 2016, BIOMED OPT EXPRESS, V7, P4554, DOI 10.1364/BOE.7.004554
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Li H. H., 1976, Journal of Physical and Chemical Reference Data, V5, P329
   LI JD, 1994, VISUAL NEUROSCI, V11, P743, DOI 10.1017/S0952523800003047
   Li Y, 2016, INVEST OPHTH VIS SCI, V57, P105, DOI DOI 10.1167/I0VS.15-18539
   Lu CD, 2017, INVEST OPHTH VIS SCI, V58, P4632, DOI 10.1167/iovs.17-22171
   Miloudi C, 2015, INVEST OPHTH VIS SCI, V56, P7043, DOI 10.1167/iovs.15-17022
   Oppenheim A. V, 2010, DISCRETE TIME SIGNAL, VThird
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PANG SF, 1978, NEUROSCI LETT, V10, P221, DOI 10.1016/0304-3940(78)90229-X
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Schmoll T, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3463008
   Smedemark-Margulies N, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00018
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Srinivasan VJ, 2006, OPT LETT, V31, P2308, DOI 10.1364/OL.31.002308
   Srinivasan VJ, 2009, OPT EXPRESS, V17, P3861, DOI 10.1364/OE.17.003861
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki W, 2013, INVEST OPHTH VIS SCI, V54, P6345, DOI 10.1167/iovs.13-12381
   Tsunoda K, 2004, INVEST OPHTH VIS SCI, V45, P3820, DOI 10.1167/iovs.04-0394
   Tuchin V. V., 2006, OPTICAL CLEARING TIS
   UEHARA F, 1990, SCIENCE, V248, P1633, DOI 10.1126/science.2194288
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Yao XC, 2005, APPL OPTICS, V44, P2019, DOI 10.1364/AO.44.002019
   Yao XC, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.9.090901
   Zhang PF, 2017, P NATL ACAD SCI USA, V114, pE2937, DOI 10.1073/pnas.1620572114
NR 48
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 20
PY 2019
VL 9
AR 13632
DI 10.1038/s41598-019-50057-8
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IZ3RD
UT WOS:000487002100027
PM 31541190
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Basavarajappa, HD
   Lee, B
   Lee, H
   Sulaiman, RS
   An, H
   Magana, C
   Shadmand, M
   Vayl, A
   Rajashekhar, G
   Kim, EY
   Suh, YG
   Lee, K
   Seo, SY
   Corson, TW
AF Basavarajappa, Halesha D.
   Lee, Bit
   Lee, Hyungjun
   Sulaiman, Rania S.
   An, Hongchan
   Magana, Carlos
   Shadmand, Mehdi
   Vayl, Alexandra
   Rajashekhar, Gangaraju
   Kim, Eun-Yeong
   Suh, Young-Ger
   Lee, Kiho
   Seo, Seung-Yong
   Corson, Timothy W.
TI Synthesis and Biological Evaluation of Novel Homoisoflavonoids for
   Retinal Neovascularization
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CELL-PROLIFERATION;
   IN-VITRO; ANGIOGENESIS; INHIBITION; THERAPY; HYACINTHACEAE; RANIBIZUMAB;
   BEVACIZUMAB
AB Eye diseases characterized by excessive angiogenesis such as wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity are major causes of blindness. Cremastranone is an antiangiogenic, naturally occurring homoisoflavanone with efficacy in retinal and choroidal neovascularization models and antiproliferative selectivity for endothelial cells over other cell types. We undertook a cell-based structure activity relationship study to develop more potent cremastranone analogues, with improved antiproliferative selectivity for retinal endothelial cells. Phenylalanyl-incorporated homoisoflavonoids showed improved activity and remarkable selectivity for retinal microvascular endothelial cells. A lead compound inhibited angiogenesis in vitro without inducing apoptosis and had efficacy in the oxygen-induced retinopathy model in vivo.
C1 [Basavarajappa, Halesha D.; Sulaiman, Rania S.; Shadmand, Mehdi; Vayl, Alexandra; Rajashekhar, Gangaraju; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Sulaiman, Rania S.; Shadmand, Mehdi; Vayl, Alexandra; Rajashekhar, Gangaraju; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Magana, Carlos; Corson, Timothy W.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.
   [Lee, Bit; Lee, Hyungjun; Seo, Seung-Yong] Gachon Univ, Coll Pharm, Inchon 406840, South Korea.
   [Lee, Bit; Lee, Hyungjun; Seo, Seung-Yong] Gachon Univ, Gachon Inst Pharmaceut Sci, Inchon 406840, South Korea.
   [Sulaiman, Rania S.] Cairo Univ, Dept Biochem, Fac Pharm, Cairo 11562, Egypt.
   [An, Hongchan; Suh, Young-Ger] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   [Kim, Eun-Yeong; Lee, Kiho] Korea Univ, Coll Pharm, Sejong, South Korea.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Gachon University; Gachon University; Egyptian
   Knowledge Bank (EKB); Cairo University; Seoul National University (SNU);
   Korea University
RP Seo, SY (通讯作者)，Gachon Univ, Coll Pharm, Inchon 406840, South Korea.
EM syseo@gachon.ac.kr; tcorson@iupui.edu
RI An, Hongchan/J-3148-2014; Corson, Timothy W./B-6851-2009; Basavarajappa,
   Halesha Dhurvigere/V-2038-2019; Gangaraju, Rajashekhar/I-7852-2019
OI Corson, Timothy W./0000-0002-1402-7875; Basavarajappa, Halesha
   Dhurvigere/0000-0002-2840-5937; Gangaraju,
   Rajashekhar/0000-0002-6664-8286; An, Hongchan/0000-0001-6689-9571
FU International Retinal Research Foundation; Carl Marshall and Mildred
   Almen Reeves Foundation; Ralph W. and Grace M. Showalter Research Trust;
   IUPUI FORCES; Retina Research Foundation; Basic Science Research Program
   through National Research Foundation of Korea (NRF) by Ministry of
   Education [NRF-2013R1A1A2007151]; Pioneer Research Center Program
   through NRF by Ministry of Science, ICT & Future Planning
   [2014M3C1A3001556]; Korea Health Technology R&D Project through the
   Korea Health Industry Development Institute (KHIDI) by Ministry of
   Health Welfare [HI14C1135]; Cryptic Masons Medical Research Foundation;
   Ausich Graduate Scholarship from Kemin Health; National Institutes of
   Health, National Center for Advancing Translational Sciences, Clinical
   and Translational Sciences Award [KL2TR001106]; Research to Prevent
   Blindness, Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR001108, UL1TR002529, KL2TR001106] Funding Source: NIH RePORTER
FX This work was supported by grants from the International Retinal
   Research Foundation, Carl Marshall and Mildred Almen Reeves Foundation,
   Ralph W. and Grace M. Showalter Research Trust, IUPUI FORCES, and Retina
   Research Foundation to T.W.C., grants from the Basic Science Research
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education (NRF-2013R1A1A2007151), the Pioneer
   Research Center Program through the NRF funded by the Ministry of
   Science, ICT & Future Planning (2014M3C1A3001556), and the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health & Welfare (grant no.
   HI14C1135) to S.-Y.S., funds from the Cryptic Masons Medical Research
   Foundation to G.R., and the Ausich Graduate Scholarship from Kemin
   Health to H.D.B. This publication was also made possible in part by rant
   no. KL2TR001106 from the National Institutes of Health, National Center
   for Advancing Translational Sciences, Clinical and Translational
   Sciences Award, and by an unrestricted grant from Research to Prevent
   Blindness, Inc.
CR Basavarajappa HD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095694
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   du Toit K, 2005, BIOORGAN MED CHEM, V13, P2561, DOI 10.1016/j.bmc.2005.01.036
   du Toit K, 2010, NAT PROD RES, V24, P457, DOI 10.1080/14786410903335174
   Falkenstein IA, 2008, CURR EYE RES, V33, P599, DOI 10.1080/02713680802226582
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Fotsis T, 1997, CANCER RES, V57, P2916
   Hasebe Y, 2003, BIOL PHARM BULL, V26, P1379, DOI 10.1248/bpb.26.1379
   Hur S, 2010, J DERMATOL SCI, V59, P163, DOI 10.1016/j.jdermsci.2010.07.001
   Ivanova L, 2013, MOL BIOL REP, V40, P4571, DOI 10.1007/s11033-013-2547-x
   Jo DH, 2014, J MOL MED, V92, P1083, DOI 10.1007/s00109-014-1168-8
   Kim JH, 2008, MOL VIS, V14, P556
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Kim S, 2007, ARCH PHARM RES, V30, P18, DOI 10.1007/BF02977773
   Lee B, 2014, ORG BIOMOL CHEM, V12, P7673, DOI 10.1039/c4ob01604a
   Lee YS, 2014, ALLERGY, V69, P453, DOI 10.1111/all.12356
   Lin MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124558
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mulholland DA, 2013, NAT PROD REP, V30, P1165, DOI 10.1039/c3np70008a
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
NR 25
TC 47
Z9 49
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 25
PY 2015
VL 58
IS 12
BP 5015
EP 5027
DI 10.1021/acs.jmedchem.5b00449
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)
SC Pharmacology & Pharmacy
GA CL7FX
UT WOS:000357139000014
PM 26035340
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Busch, T
AF Busch, Theresa
TI APPROACHES TOWARD COMBINING PHOTODYNAMIC THERAPY WITH PHARMACEUTICALS
   THAT ALTER VASCULAR MICROENVIRONMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photodynamic therapy; vascular endothelial growth factor; verteporfin
AB Photodynamic therapy has been widely replaced by antiangiogenesis agents for the first-line therapy for exudative age-related macular degeneration (AMD). There is a strong basis for predicting that a combination of photodynamic therapy and antiangiogenesis agents may address the relative disadvantages of each. By improving the rates of response, photodynamic therapy has the potential to reduce the frequency with which intravitreal injections of antiangiogenesis agents are required. Antiangiogenesis agents may augment the activity of photodynamic therapy by inhibiting its counterproductive upregulation of vascular endothelial growth factor. Clinical studies of this combination are being advanced in both AMD and in the treatment of malignancies. RETINA 29:S36-S38, 2009
C1 Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Busch, T (通讯作者)，Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
EM buschtm@mail.med.upenn.edu
RI Busch, Theresa/J-5591-2019
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bhuvaneswari R, 2007, PHOTOCH PHOTOBIO SCI, V6, P1275, DOI 10.1039/b705763f
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   TARTAR O, 2006, AM J OPHTHALMOL, V142, P95
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P193, DOI 10.1001/archophthalmol.2007.40
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8
NR 8
TC 8
Z9 11
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
SU S
BP S36
EP S38
DI 10.1097/IAE.0b013e3181ad25e8
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700014
PM 19553798
DA 2022-11-30
ER

PT J
AU Rishi, P
   Rishi, E
   Sharma, M
   Maitray, A
   Bhende, M
   Gopal, L
   Sharma, T
   Ratra, D
   Sen, P
   Bhende, P
   Rao, C
   Susvar, P
AF Rishi, Pukhraj
   Rishi, Ekta
   Sharma, Minal
   Maitray, Aditya
   Bhende, Muna
   Gopal, Lingam
   Sharma, Tarun
   Ratra, Dhanashree
   Sen, Parveen
   Bhende, Pramod
   Rao, Chetan
   Susvar, Pradeep
TI Incidence, outcomes, and risk factors for hemorrhagic complications in
   eyes with polypoidal choroidal vasculopathy following photodynamic
   therapy in Indian subjects
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Complications; hemorrhage; photodynamic therapy; polypoidal choroidal
   vasculopathy; treatment
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; NEOVASCULAR
   MEMBRANES; COMBINATION THERAPY; VERTEPORFIN; MONOTHERAPY; BEVACIZUMAB;
   EXPRESSION; EFFICACY; VEGF
AB Purpose: To evaluate the incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy (PCV) following photodynamic therapy (PDT). Methods: Medical records of 94 eyes of 86 consecutive patients with PCV who underwent PDT between January 2007 and December 2014 were retrospectively reviewed. The diagnosis of PCV was based on clinical features and indocyanine green angiography. Eyes were treated with PDT monotherapy or a combination of PDT plus anti-vascular endothelial growth factor. PDT was performed at (standard [SFPDT] or reduced fluence RFPDT). Results: Ninety-four eyes had 119 PDT treatment sessions (mean: 1.3 sessions). Mean presenting vision was 0.46 +/- 0.44 logarithm of the minimum angle of resolution (logMAR). Following PDT, ten eyes (11%) of nine patients had hemorrhagic complications such as subretinal hemorrhage (SRH; n = 5), subretinal pigment epithelium (RPE) hemorrhage (n = 1), breakthrough vitreous hemorrhage (BVH; n = 3), and SRH with sub-RPE hemorrhage and BVH (n = 1). Median interval to hemorrhage following PDT was 2 months. Age (P = 0.842), duration of symptoms (P = 0.352), number of laser spots (P = 0.219), and laser spot size (LSS) (P = 0.096) were not significantly associated with increased risk of hemorrhagic complications. Female gender was associated with reduced risk of hemorrhage (P = 0.045). SFPDT was significantly associated with increased risk of hemorrhage (P = 0.026). The probability of developing hemorrhagic complications in SFPDT group was 0.24 compared to 0.07 in RFPDT group (P = 0.039). Multivariate logistic regression analysis showed SFPDT as the only significant risk factor for hemorrhage following PDT (odds ratio 5.3, 95% confidence interval 1.1-24.8, P = 0.03). Mean final vision was 0.61 +/- 0.53 logMAR at mean follow-up of 33 months (median = 22 months; range = 2-157 months). Conclusion: Age, LSS, number of laser spots, preexisting hemorrhages, or use of anticoagulants were not associated with increased risk of hemorrhagic complications. SFPDT was significantly associated with increased risk of hemorrhagic complications in such eyes.
C1 [Rishi, Pukhraj; Rishi, Ekta; Sharma, Minal; Maitray, Aditya; Bhende, Muna; Gopal, Lingam; Sharma, Tarun; Ratra, Dhanashree; Sen, Parveen; Bhende, Pramod; Rao, Chetan; Susvar, Pradeep] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
RP Rishi, P (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM docrishi@yahoo.co.in
RI Rishi, Pukhraj/AAZ-5296-2020; Maitray, Aditya/AAX-4540-2020; Ratra,
   Dhanashree/AAE-2517-2020; Sen, Parveen/W-4707-2019; Rao,
   Chetan/ABB-7630-2020
OI Maitray, Aditya/0000-0002-7569-687X; Ratra,
   Dhanashree/0000-0001-5687-6384; 
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rishi P, 2009, INDIAN J OPHTHALMOL, V57, P160, DOI 10.4103/0301-4738.45514
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 6
Z9 7
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD AUG
PY 2017
VL 65
IS 8
BP 712
EP 718
DI 10.4103/ijo.IJO_174_17
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE4VT
UT WOS:000408212100012
PM 28820157
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, LS
   Qu, LH
   Gui, Q
   Wang, SS
   Mao, JH
   Fu, XX
   Li, WD
   Wang, YY
   Yi, QY
AF Chen, Lishuang
   Qu, Linghui
   Gui, Qian
   Wang, Sangsang
   Mao, Jinghai
   Fu, Xiangxiang
   Li, Wendie
   Wang, Yanyan
   Yi, Quanyong
TI Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and
   After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal
   Vasculopathy and Vitreous Hemorrhage
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE aflibercept; conbercept; macular degeneration; ranibizumab; visual
   acuity
ID PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; COMPLICATIONS;
   INJECTION; OUTCOMES
AB Purpose: To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).</p>
   Methods: This was a retrospective study of patients who underwent PPV due to vitreous hemorrhage between October 2013 and June 2019 at Ningbo Eye Hospital. The patients who underwent PPV surgery due to PCV-secondary vitreous hemorrhage were included. The primary outcome was the changes in best-corrected visual acuity. The secondary outcome was the central macular thickness.</p>
   Results: Compared with the postoperative group (n = 20), the perioperative group (n = 18) showed a smaller number of postoperative anti-VEGF injections (5.1 +/- 0.8 vs. 8.0 +/- 1.5, P < 0.05) and lower frequencies of early hyphema (5.6% vs. 30.0%, P < 0.05), and recurrent vitreous hemorrhage (11.1% vs. 30.0%, P < 0.05). The logarithm of minimal angle resolution (LogMAR) was smaller in the perioperative group compared with the postoperative group at 1 week, 1 month, and 3 months after PPV (P < 0.05), but there were no differences thereafter. Compared with the postoperative group, the perioperative group had thinner fovea at 1 week, 1 month, and 3 months (P < 0.05), but the differences disappeared after 3 months.</p>
   Conclusion: In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery.</p>
C1 [Chen, Lishuang; Gui, Qian; Wang, Sangsang; Mao, Jinghai; Li, Wendie; Wang, Yanyan; Yi, Quanyong] Ningbo Eye Hosp, Dept Ophthalmol, 855 Bei Ming Chen Rd, Ningbo 315040, Zhejiang, Peoples R China.
   [Qu, Linghui] 74th Army Grp Hosp, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Fu, Xiangxiang] Yuyao Second Hosp, Dept Ophthalmol, Zhenjiang, Jiangsu, Peoples R China.
RP Yi, QY (通讯作者)，Ningbo Eye Hosp, Dept Ophthalmol, 855 Bei Ming Chen Rd, Ningbo 315040, Zhejiang, Peoples R China.
EM quanyong_yi@163.com
FU Natural Science Foundation of Ningbo City [2019A610351]; Projects of
   medical and health technology development program in Zhejiang province
   [2018KY735]; Natural Science Foundation of Guangdong Province
   [2018A030313935]
FX This study is supported by the Natural Science Foundation of Ningbo City
   (2019A610351) and by the Projects of medical and health technology
   development program in Zhejiang province (2018KY735); the Natural
   Science Foundation of Guangdong Province (2018A030313935).
CR Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho HJ, 2012, CAN J OPHTHALMOL, V47, P170, DOI 10.1016/j.jcjo.2012.01.005
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57297-8
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li X.X, 2012, CHIN J OCUL FUNDUS D, V28, P441
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin HC, 2014, EYE, V28, P797, DOI 10.1038/eye.2014.124
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Nayak S, 2015, SEMIN OPHTHALMOL, V30, P53, DOI 10.3109/08820538.2013.807849
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Xu W, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2923950
   Yang JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1245-4
   [于文贞 Yu Wenzhen], 2011, [中国实用眼科杂志, Chinese Journal of Practical Ophthalmology], V29, P262
   Zhang ZH, 2013, AM J OPHTHALMOL, V156, P106, DOI 10.1016/j.ajo.2013.02.008
   Zhou AY, 2014, WORLD J PEDIATR, V10, P262, DOI 10.1007/s12519-014-0502-0
NR 26
TC 1
Z9 1
U1 3
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC 1
PY 2021
VL 37
IS 10
BP 591
EP 596
DI 10.1089/jop.2021.0039
EA OCT 2021
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA XM2RB
UT WOS:000710971900001
PM 34678098
DA 2022-11-30
ER

PT J
AU Maity, A
AF Maity, Amit
TI MODULATING THE TUMOR MICROENVIRONMENT TO IMPROVE RADIOTHERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE radiation; thior microenvironment
ID RADIATION; INCREASES; RADIOSENSITIVITY; INHIBITORS; EXPRESSION; THERAPY;
   CANCER
AB Radiotherapy can ablate vascular tissue, but the antiangiogenic effect is counteracted by upregulation of endogenous proangiogenic signals, particularly vascular endothelial growth factor. This effect, which has long been a concern in oncology, is relevant to a discussion of radiation for the treatment of age-related macular degeneration (AMD). In oncology, a broad array of agents that target growth factors and receptors is being actively studied for the potential to enhance the activity of radiation in controlling malignancies. Progress with such combinations in oncology may be relevant to parallel strategies for treating and containing neovascularization in AMD and other retinal diseases. RETINA 29:S32-S33, 2009
C1 Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Maity, A (通讯作者)，Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
EM maity@xrt.upenn.edu
OI Maity, Amit/0000-0001-7151-2845
CR Gorski DH, 1999, CANCER RES, V59, P3374
   Gupta AK, 2007, NEOPLASIA, V9, P271, DOI 10.1593/neo.07124
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Pore N, 2006, NEOPLASIA, V8, P889, DOI 10.1593/neo.06535
   Pore N, 2006, CANCER RES, V66, P9252, DOI 10.1158/0008-5472.CAN-06-1239
   Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715
   Timke C, 2008, CLIN CANCER RES, V14, P2210, DOI 10.1158/1078-0432.CCR-07-1893
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
NR 9
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP S32
EP S33
DI 10.1097/IAE.0b013e3181ad248b
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HT
UT WOS:000267496700012
PM 19553796
DA 2022-11-30
ER

PT J
AU Russo, A
   Costagliola, C
   Delcassi, L
   Romano, MR
   Semeraro, F
AF Russo, Andrea
   Costagliola, Ciro
   Delcassi, Luisa
   Romano, Mario R.
   Semeraro, Francesco
TI A randomised controlled trial of ranibizumab with and without ketorolac
   eyedrops for exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Inflammation
ID BROMFENAC 0.09-PERCENT; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   RANIBIZUMAB; NEPAFENAC 0.1-PERCENT; 0.45-PERCENT; VERTEPORFIN;
   INHIBITION
AB Aims To evaluate whether ketorolac eyedrops and ranibizumab intravitreal injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularisation (CNV).
   Methods This was a pilot study of eyes with new-onset CNV. A total of 56 patients were enrolled consecutively and randomised in a 1:1 ratio to receive combination treatment with intravitreal ranibizumab and topical ketorolac (group 1) or ranibizumab alone (group 2). All patients received monthly 0.5-mg ranibizumab intravitreal injections for 3months, after which monthly injections were administered in accordance with the standard of care. Group 1 patients also self-administered one drop of ketorolac three times a day for 6months. All patients were followed up for 6months.
   Results At 6months, both groups showed a significant improvement in best-corrected visual acuity (both, p<0.001). Thetwo treatments did not show significant differences in terms of the number of ranibizumab injections required. However, the mean 6-month change in central macular thickness (CMT) in the combination group was -124 mu m (-29.7%; p<0.001), while in the ranibizumab-only group, the change was -86.9 mu m (-19.5%; p=0.001); thus, the combination treatment resulted in a greater reduction (p=0.003). The combination treatment had no adverse effects.
   Conclusions This pilot study is the first to prospectively investigate the efficacy and safety of a combination of 0.45% ketorolac eyedrops three times a day and intravitreal ranibizumab injections in patients with CNV, and suggests that topical ketorolac supplements the activity of intravitreal ranibizumab in reducing CMT in CNV.
C1 [Russo, Andrea; Delcassi, Luisa; Semeraro, Francesco] Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, I-25100 Brescia, Italy.
   [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Eye Clin, Campobasso, Italy.
   [Romano, Mario R.] Ist Clin Humanitas, Eye Clin, Milan, Italy.
C3 University of Brescia; University of Molise; IRCCS Humanitas Research
   Hospital
RP Russo, A (通讯作者)，Univ Brescia, Dept Neurol & Vis Sci, Eye Clin, Piazzale Spedale Civili 1, I-25100 Brescia, Italy.
EM dott.andrea.russo@me.com
RI Costagliola, Ciro/G-5707-2012; Semeraro, Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Asai T, 2006, CORNEA, V25, P224, DOI 10.1097/01.ico.0000177835.93130.d4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Bucci FA, 2011, ADV THER, V28, P1089, DOI 10.1007/s12325-011-0080-7
   Bucci FA, 2011, CURR MED RES OPIN, V27, P2235, DOI 10.1185/03007995.2011.626018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Colin J, 2007, DRUGS, V67, P1291, DOI 10.2165/00003495-200767090-00004
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Heier JS, 2009, RETINA-J RET VIT DIS, V29, P1310, DOI 10.1097/IAE.0b013e3181b094e6
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schoenberger SD, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/281981
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Wang MZ, 2012, RETINA-J RET VIT DIS, V32, P2158, DOI 10.1097/IAE.0b013e3182576d1d
   Yanni SE, 2010, EXP EYE RES, V91, P34, DOI 10.1016/j.exer.2010.03.019
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 25
TC 14
Z9 15
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2013
VL 97
IS 10
BP 1273
EP 1276
DI 10.1136/bjophthalmol-2013-303417
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 221EA
UT WOS:000324639200012
PM 23873901
DA 2022-11-30
ER

PT J
AU Lee, S
   Fallah, N
   Forooghian, F
   Ko, A
   Pakzad-Vaezi, K
   Merkur, AB
   Kirker, AW
   Albiani, DA
   Young, M
   Sarunic, MV
   Beg, MF
AF Lee, Sieun
   Fallah, Nader
   Forooghian, Farzin
   Ko, Ashley
   Pakzad-Vaezi, Kaivon
   Merkur, Andrew B.
   Kirker, Andrew W.
   Albiani, David A.
   Young, Mei
   Sarunic, Marinko V.
   Beg, Mirza Faisal
TI Comparative Analysis of Repeatability of Manual and Automated Choroidal
   Thickness Measurements in Nonneovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal thickness; segmentation;
   optical oherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   BLOOD-FLOW; SEGMENTATION; EYES; IMAGES; MODEL; OCT
AB PURPOSE. We compared the reproducibility and mutual agreement of the subfoveal choroidal thickness measurements by expert raters and an automated algorithm in enhanced depth imaging optical coherence tomography (EDI-OCT) images of eyes with nonneovascular agerelated macular degeneration (AMD).
   METHODS. We recruited 44 patients with nonneovascular AMD and EDI-OCT images were acquired. Subfoveal choroidal thickness was measured manually by two expert raters and automatically by a graph-cut-based algorithm. Drusen area was measured using the automated software (version 6) of Cirrus SD-OCT. The manual and automated choroidal thickness measurements were compared in reproducibility, mutual agreement, and correlation with drusen area.
   RESULTS. The mean subfoveal choroidal thickness was 246 +/- 63 mu m for the first rater, 214 +/- 68 for the second rater, and 209 +/- 53 for the automated algorithm. Intraclass correlation coefficients (ICC) and 95% confidence intervals (CI) were 0.96 (CI 0.94-0.98) between the raters, 0.85 (CI 0.77-0.90) between the first rater and the automated algorithm, and 0.84 (CI 0.75-0.89) between the second rater and the automated algorithm. Repeat scan measurement ICCs were 0.91 (CI 0.86-0.94) for the first rater, 0.96 (CI 0.94-0.97) for the second rater, and 0.87 (CI 0.80-0.92) for the automated algorithm. Manual and automated measurements were correlated with drusen area.
   CONCLUSIONS. The automated algorithm generally yielded smaller choroidal thickness than the raters with a moderate level of agreement. However, its repeat scan measurement repeatability was comparable to that of the manual measurements. The mean difference between the raters indicated possible biases in different raters and rating sessions. The correlation of the automated measurements with the drusen area was comparable to that of the manual measurements. Automated subfoveal choroidal thickness measurement has potential use in clinical practice and clinical trials, with possibility for reduced time and labor cost.
C1 [Lee, Sieun; Sarunic, Marinko V.; Beg, Mirza Faisal] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada.
   [Fallah, Nader] Rick Hansen Inst, Vancouver, BC, Canada.
   [Forooghian, Farzin; Ko, Ashley; Pakzad-Vaezi, Kaivon; Merkur, Andrew B.; Kirker, Andrew W.; Albiani, David A.; Young, Mei] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
C3 Simon Fraser University; University of British Columbia
RP Beg, MF (通讯作者)，Simon Fraser Univ, Sch Engn Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
EM leeau@sfu.ca; farzin.forooghian@gmail.com; msarunic@sfu.ca; mfbeg@sfu.ca
RI Fallah, Nader/D-4145-2012
OI Fallah, Nader/0000-0002-7746-4773; Sarunic, Marinko/0000-0002-5636-9056
FU Canadian National Institute for the Blind (CNIB); Canadian Institutes of
   Health Research (CIHR); Natural Sciences and Engineering Research
   Council of Canada (NSERC); Michael Smith Foundation for Health Research
   (MSFHR)
FX Supported by a New Researcher Grant from the Canadian National Institute
   for the Blind (CNIB), Canadian Institutes of Health Research (CIHR),
   Natural Sciences and Engineering Research Council of Canada (NSERC), and
   Michael Smith Foundation for Health Research (MSFHR).
CR Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Torzicky T, 2012, OPT EXPRESS, V20, P7564, DOI 10.1364/OE.20.007564
   Trattler WB, 2012, REV OPHTHALMOLOGY EX
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 23
TC 37
Z9 37
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2864
EP 2871
DI 10.1167/iovs.12-11521
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 156KV
UT WOS:000319821700055
PM 23538060
DA 2022-11-30
ER

PT J
AU Reche-Frutos, J
   Calvo-Gonzalez, C
   Donate-Lopez, J
   Garcia-Feijoo, J
AF Reche-Frutos, Juan
   Calvo-Gonzalez, Cristina
   Donate-Lopez, Juan
   Garcia-Feijoo, Julian
TI Early neovascular bridging of choroidal neovascularization after
   ranibizumab treatment
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; Ranibizumab; Optical coherence tomography;
   Neovascular bridging
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY
AB To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.
   Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.
   All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement.
   Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.
C1 [Reche-Frutos, Juan; Calvo-Gonzalez, Cristina; Donate-Lopez, Juan; Garcia-Feijoo, Julian] Hosp Clin Univ San Carlos, Madrid 28040, Spain.
RP Reche-Frutos, J (通讯作者)，Hosp Clin Univ San Carlos, Calle Prof Martin Lagos S-N, Madrid 28040, Spain.
EM rechejuan@yahoo.es
RI Donate-Lopez, Juan/AAB-5144-2019; GARCIA FEIJOO, JULIAN/G-9762-2017
OI Donate-Lopez, Juan/0000-0002-9944-6736; GARCIA FEIJOO,
   JULIAN/0000-0002-7772-5718
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lanzetta P, 2004, GRAEF ARCH CLIN EXP, V242, P840, DOI 10.1007/s00417-004-0904-0
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Olsen TW, 1996, OPHTHALMOLOGY, V103, P2061, DOI 10.1016/S0161-6420(96)30387-4
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
NR 8
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2009
VL 247
IS 10
BP 1427
EP 1430
DI 10.1007/s00417-009-1143-1
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 488AD
UT WOS:000269320000017
PM 19621235
DA 2022-11-30
ER

PT J
AU Murakami, Y
   Miller, JW
   Vavvas, DG
AF Murakami, Yusuke
   Miller, Joan W.
   Vavvas, Demetrios G.
TI RIP Kinase-Mediated Necrosis as an Alternative Mechanism of
   Photoreceptor Death
SO ONCOTARGET
LA English
DT Article
DE Photoreceptor; necroptosis; receptor interacting protein kinase
ID APOPTOSIS-INDUCING FACTOR; RECEPTOR-INTERACTING PROTEIN; ACTIVATING
   FACTOR-I; CELL-DEATH; RETINAL-DETACHMENT; MACULAR TRANSLOCATION;
   PROGRAMMED NECROSIS; EXPERIMENTAL-MODEL; CLINICAL-TRIAL; CYTOCHROME-C
AB Photoreceptor cell death is the terminal event in a variety of retinal disorders including age-related macular degeneration, retinitis pigmentosa, and retinal detachment. Apoptosis has been thought to be the major form of cell death in these diseases, however accumulating evidence suggests that another pathway, programmed necrosis is also important. Recent studies have shown that, when caspase pathways are blocked, receptor interacting protein (RIP) kinases promote necrosis and overcome apoptosis inhibition. Therefore, targeting of both caspase and RIP kinase pathways are required for effective photoreceptor protection. Here, we summarize the current knowledge of RIP kinase-mediated necrotic signaling and its contribution to photoreceptor death.
C1 [Murakami, Yusuke; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Vavvas, DG (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA.
EM demetrios_vavvas@meei.harvard.edu
OI Vavvas, Demetrios/0000-0002-8622-6478
FU Bacardi Fund; Research to Prevent Blindness Foundation; Lions Eye
   Research Fund; Onassis Foundation; Fight For Sight; Harvard
   Ophthalmology Department; NEI [EY014104]; NATIONAL EYE INSTITUTE
   [P30EY014104] Funding Source: NIH RePORTER
FX We would like to thank to Dr. Aristomenis Thanos for providing the
   scheme for Fig. 1, 2, 3 and 5. This work was supported by Bacardi Fund
   (DGV), Research to Prevent Blindness Foundation (DGV), Lions Eye
   Research Fund (DGV), Onassis Foundation (DGV), Fight For Sight Grant in
   Aid (DGV), Harvard Ophthalmology Department Support (DGV) and NEI grant
   EY014104 (MEEI Core Grant).
CR Arimura N, 2009, LAB INVEST, V89, P278, DOI 10.1038/labinvest.2008.165
   Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046
   Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Baskin-Bey ES, 2007, AM J TRANSPLANT, V7, P218, DOI 10.1111/j.1600-6143.2006.01595.x
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Danesh-Meyer HV, 2009, AM J OPHTHALMOL, V148, P186, DOI 10.1016/j.ajo.2009.03.029
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011
   Donovan M, 2002, CELL DEATH DIFFER, V9, P1220, DOI 10.1038/sj.cdd.4401105
   Doonan F, 2003, J NEUROSCI, V23, P5723
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   ERICKSON PA, 1983, INVEST OPHTH VIS SCI, V24, P927
   Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556
   Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004
   GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hisatomi T, 2003, AM J PATHOL, V162, P1869, DOI 10.1016/S0002-9440(10)64321-0
   Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3
   Hisatomi T, 2008, J CLIN INVEST, V118, P2025, DOI 10.1172/JCI34267
   Hisatomi T, 2009, EXP NEUROL, V218, P347, DOI 10.1016/j.expneurol.2009.03.007
   Hoglen NC, 2004, J PHARMACOL EXP THER, V309, P634, DOI 10.1124/jpet.103.062034
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jacobson SG, 2010, NEW ENGL J MED, V363, P1669, DOI 10.1056/NEJMcibr1007685
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Krysko O, 2004, APOPTOSIS, V9, P495, DOI 10.1023/B:APPT.0000031452.75162.75
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5
   Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008
   Morgan MJ, 2009, J IMMUNOL, V183, P3278, DOI 10.4049/jimmunol.0803428
   Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06
   Muppidi JR, 2006, CELL DEATH DIFFER, V13, P1641, DOI 10.1038/sj.cdd.4401855
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Nakazawa T, 2006, MOL VIS, V12, P867
   Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614
   Paquet-Durand F, 2007, J NEUROSCI, V27, P10311, DOI 10.1523/JNEUROSCI.1514-07.2007
   Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186
   Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200
   Ray SK, 2006, CURR MED CHEM, V13, P3425, DOI 10.2174/092986706779010342
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Roh M, 2011, INVEST OPHT IN PRESS
   Rohrer B, 2004, J BIOL CHEM, V279, P41903, DOI 10.1074/jbc.M405085200
   Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Sanges D, 2006, P NATL ACAD SCI USA, V103, P17366, DOI 10.1073/pnas.0606276103
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306
   Segura MF, 2007, J NEUROSCI, V27, P11228, DOI 10.1523/JNEUROSCI.3462-07.2007
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364
   Shiffman ML, 2010, ALIMENT PHARM THER, V31, P969, DOI 10.1111/j.1365-2036.2010.04264.x
   STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1
   Sumimoto H, 2008, FEBS J, V275, P3249, DOI 10.1111/j.1742-4658.2008.06488.x
   Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Upton JW, 2010, CELL HOST MICROBE, V7, P302, DOI 10.1016/j.chom.2010.03.006
   Valentino KL, 2003, INT J CLIN PHARM TH, V41, P441
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4
   Vanlangenakker N, 2010, CELL DEATH DIFFER
   Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200
   Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919
   Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477
   Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X
   Wang XD, 2001, GENE DEV, V15, P2922
   Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954
   Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007
   Wright KM, 2004, J CELL BIOL, V167, P303, DOI 10.1083/jcb.200406073
   Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001
   Yang YH, 2004, J BIOL CHEM, V279, P38820, DOI 10.1074/jbc.M401663200
   Yazdanpanah B, 2009, NATURE, V460, P1159, DOI 10.1038/nature08206
   Yoshizawa K, 2002, GRAEF ARCH CLIN EXP, V240, P214, DOI 10.1007/s00417-002-0427-5
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zacks DN, 2006, INVEST OPHTH VIS SCI, V47, P1691, DOI 10.1167/iovs.05-1209
   Zacks DN, 2003, INVEST OPHTH VIS SCI, V44, P1262, DOI 10.1167/iovs.02-0492
   Zacks DN, 2004, INVEST OPHTH VIS SCI, V45, P4563, DOI 10.1167/iovs.04-0598
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P964, DOI 10.1167/iovs.03-0439
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193
NR 113
TC 30
Z9 33
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2011
VL 2
IS 6
BP 497
EP 509
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 802KR
UT WOS:000293510200011
PM 21670490
DA 2022-11-30
ER

PT J
AU de la Zerda, A
   Paulus, YM
   Teed, R
   Bodapati, S
   Dollberg, Y
   Khuri-Yakub, BT
   Blumenkranz, MS
   Moshfeghi, DM
   Gambhir, SS
AF de la Zerda, Adam
   Paulus, Yannis M.
   Teed, Robert
   Bodapati, Sunil
   Dollberg, Yosh
   Khuri-Yakub, Butrus T.
   Blumenkranz, Mark S.
   Moshfeghi, Darius M.
   Gambhir, Sanjiv Sam
TI Photoacoustic ocular imaging
SO OPTICS LETTERS
LA English
DT Article
ID HIGH-RESOLUTION; MICROSCOPY
AB We developed a photoacoustic ocular imaging device and demonstrated its utility in imaging the deeper layers of the eye including the retina, choroid, and optic nerve. Using safe laser intensity, the photoacoustic system was able to visualize the blood distribution of an enucleated pig's eye and an eye of a living rabbit. Ultrasound images, which were simultaneously acquired, were overlaid on the photoacoustic images to visualize the eye's anatomy. Such a system may be used in the future for early detection and improved management of neovascular ocular diseases, including wet age-related macular degeneration and proliferative diabetic retinopathy. (C) 2010 Optical Society of America
C1 [de la Zerda, Adam; Teed, Robert; Bodapati, Sunil; Gambhir, Sanjiv Sam] Stanford Univ, Mol Imaging Program Stanford, Bio X Program, Palo Alto, CA 94305 USA.
   [de la Zerda, Adam; Teed, Robert; Bodapati, Sunil; Gambhir, Sanjiv Sam] Stanford Univ, Dept Radiol, Palo Alto, CA 94305 USA.
   [de la Zerda, Adam; Khuri-Yakub, Butrus T.] Stanford Univ, Dept Elect Engn, Palo Alto, CA 94305 USA.
   [Paulus, Yannis M.; Blumenkranz, Mark S.; Moshfeghi, Darius M.] Stanford Univ, Dept Ophthalmol, Palo Alto, CA 94305 USA.
   [Dollberg, Yosh] Act Ventures Grp, Baanana, Israel.
   [Gambhir, Sanjiv Sam] Stanford Univ, Dept Bioengn, Palo Alto, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University; Stanford
   University; Stanford University
RP Gambhir, SS (通讯作者)，Stanford Univ, Mol Imaging Program Stanford, Bio X Program, Palo Alto, CA 94305 USA.
EM sgambhir@stanford.edu
OI Khuri-Yakub, Butrus/0000-0003-3940-7898; Paulus,
   Yannis/0000-0002-0615-628X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
FU National Institutes of Heath (NIH) [NCI CCNE U54 CA119367, NCI ICMIC P50
   CA114747]; Bio-X Graduate Student Fellowship; U.S. Department of Defense
   (DoD) Breast Cancer Research Program-Predoctoral Traineeship Award;
   NATIONAL CANCER INSTITUTE [U54CA119367, P50CA114747] Funding Source: NIH
   RePORTER
FX We acknowledge funding support from the National Institutes of Heath
   (NIH) grants NCI CCNE U54 CA119367 (S. S. Gambhir) and NCI ICMIC P50
   CA114747 (S. S. Gambhir). A. de la Zerda acknowledges the Bio-X Graduate
   Student Fellowship and the U.S. Department of Defense (DoD) Breast
   Cancer Research Program-Predoctoral Traineeship Award for partially
   supporting this work. The authors also thank Srikant Vaithilingam,
   Te-Jen Ma, and Omer Oralkan for useful discussions.
CR American National Standards Institute American national standard for the safe use of lasers, 2000, Z13612000 ANSI INC
   De La Zerda A, 2008, NAT NANOTECHNOL, V3, P557, DOI 10.1038/nnano.2008.231
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kang SW, 2004, AM J OPHTHALMOL, V137, P313, DOI 10.1016/j.ajo.2003.09.016
   Laufer J, 2009, APPL OPTICS, V48, pD299, DOI 10.1364/AO.48.00D299
   Oh JT, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2210907
   Silverman RH, 2009, CLIN EXP OPHTHALMOL, V37, P54, DOI 10.1111/j.1442-9071.2008.01892.x
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Xie ZX, 2009, OPT LETT, V34, P1771, DOI 10.1364/OL.34.001771
   Xu MH, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2195024
   Zhang HF, 2006, NAT BIOTECHNOL, V24, P848, DOI 10.1038/nbt1220
NR 12
TC 102
Z9 104
U1 0
U2 25
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD FEB 1
PY 2010
VL 35
IS 3
BP 270
EP 272
DI 10.1364/OL.35.000270
PG 3
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 551GX
UT WOS:000274196100001
PM 20125691
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Whitehead, KA
   Langer, R
   Anderson, DG
AF Whitehead, Kathryn A.
   Langer, Robert
   Anderson, Daniel G.
TI Knocking down barriers: advances in siRNA delivery
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID SHORT INTERFERING RNA; IN-VIVO DELIVERY; MEDIATED DNA-TRANSFECTION; GENE
   DELIVERY; EFFICIENT DELIVERY; NONVIRAL DELIVERY; COMPLEX MICELLES;
   HIGHLY EFFICIENT; CATIONIC LIPIDS; PROTECTS MICE
AB In the 10 years that have passed since the Nobel prize-winning discovery of RNA interference (RNAi), billions of dollars have been invested in the therapeutic application of gene silencing in humans. Today, there are promising data from ongoing clinical trials for the treatment of age-related macular degeneration and respiratory syncytial virus. Despite these early successes, however, the widespread use of RNAi therapeutics for disease prevention and treatment requires the development of clinically suitable, safe and effective drug delivery vehicles. Here, we provide an update on the progress of RNAi therapeutics and highlight novel synthetic materials for the encapsulation and intracellular delivery of nucleic acids.
C1 [Langer, Robert; Anderson, Daniel G.] MIT, David H Koch Inst Integrated Canc Res, Cambridge, MA 02142 USA.
   [Whitehead, Kathryn A.; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02142 USA.
C3 Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT)
RP Anderson, DG (通讯作者)，MIT, David H Koch Inst Integrated Canc Res, Cambridge, MA 02142 USA.
EM dgander@mit.edu
RI Whitehead, Kathryn/G-7001-2012; Whitehead, Kathryn/ABF-3857-2020
OI Whitehead, Kathryn/0000-0002-0100-7824; Whitehead,
   Kathryn/0000-0002-0100-7824
CR Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494
   Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010
   Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   *ALN PHARM, 2008, ALN ACH 1 HUM PROOF
   Ameres SL, 2007, CELL, V130, P101, DOI 10.1016/j.cell.2007.04.037
   Arnold AS, 2007, J HYPERTENS, V25, P197, DOI 10.1097/01.hjh.0000254374.73241.ab
   Auguste DT, 2008, J CONTROL RELEASE, V130, P266, DOI 10.1016/j.jconrel.2008.06.004
   Barquinero J, 2004, GENE THER, V11, pS3, DOI 10.1038/sj.gt.3302363
   Bartlett DW, 2008, BIOTECHNOL BIOENG, V99, P975, DOI 10.1002/bit.21668
   Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Bogdanov AA, 2008, J CELL BIOCHEM, V104, P1113, DOI 10.1002/jcb.21689
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Braasch DA, 2004, BIOORG MED CHEM LETT, V14, P1139, DOI 10.1016/j.bmcl.2003.12.074
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   de Fougerolles A, 2008, CURR OPIN PHARMACOL, V8, P280, DOI 10.1016/j.coph.2008.04.005
   DeVincenzo J, 2008, ANTIVIR RES, V77, P225, DOI 10.1016/j.antiviral.2007.11.009
   Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975
   DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Frank-Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105
   Geisbert TW, 2006, J INFECT DIS, V193, P1650, DOI 10.1086/504267
   Grayson ACR, 2006, PHARM RES-DORDR, V23, P1868, DOI 10.1007/s11095-006-9009-2
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751
   Halder J, 2006, CLIN CANCER RES, V12, P4916, DOI 10.1158/1078-0432.CCR-06-0021
   Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104
   Hollins AJ, 2007, J DRUG TARGET, V15, P83, DOI 10.1080/10611860601151860
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Inoue T, 2007, J GENE MED, V9, P994, DOI 10.1002/jgm.1091
   *IS PHARM, 2008, GENZ IS BEG 2 PHAS 3
   Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706
   John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   Kichler A, 2004, J GENE MED, V6, pS3, DOI 10.1002/jgm.507
   Kim SH, 2008, J CONTROL RELEASE, V129, P107, DOI 10.1016/j.jconrel.2008.03.008
   Kircheis R, 2001, ADV DRUG DELIVER REV, V53, P341, DOI 10.1016/S0169-409X(01)00202-2
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kumar P, 2006, PLOS MED, V3, P505, DOI 10.1371/journal.pmed.0030096
   Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280
   Li WJ, 2007, PHARM RES-DORDR, V24, P438, DOI 10.1007/s11095-006-9180-5
   Li WJ, 2005, J GENE MED, V7, P67, DOI 10.1002/jgm.634
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Ma Z, 2005, BIOCHEM BIOPH RES CO, V330, P755, DOI 10.1016/j.bbrc.2005.03.041
   MacLachlan I., 2007, ANTISENSE DRUG TECHN, P237, DOI [10.1201/9780849387951.ch9, DOI 10.1201/9780849387951.CH9]
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   Martina MS, 2007, BIOMATERIALS, V28, P4143, DOI 10.1016/j.biomaterials.2007.05.025
   Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Merki E, 2008, CIRCULATION, V118, P743, DOI 10.1161/CIRCULATIONAHA.108.786822
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Niu XY, 2006, INT J GYNECOL CANCER, V16, P743, DOI 10.1111/j.1525-1438.2006.00384.x
   Oishi M, 2005, J AM CHEM SOC, V127, P1624, DOI 10.1021/ja044941d
   Okumura A, 2008, P NATL ACAD SCI USA, V105, P3974, DOI 10.1073/pnas.0710629105
   Oliveira S, 2007, INT J PHARM, V331, P211, DOI 10.1016/j.ijpharm.2006.11.050
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127
   Putnam D, 2006, NAT MATER, V5, P439, DOI 10.1038/nmat1645
   Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020
   Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101
   RAPPAPORT J, 1995, KIDNEY INT, V47, P1462, DOI 10.1038/ki.1995.205
   ROBBINS M, 2008, HUM GENE THER   0819, DOI DOI 10.1089/HGT.2008.131
   Rozema DB, 2007, P NATL ACAD SCI USA, V104, P12982, DOI 10.1073/pnas.0703778104
   Rust D M, 1998, Oncol Nurs Forum, V25, P35
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Sato Y, 2008, NAT BIOTECHNOL, V26, P431, DOI 10.1038/nbt1396
   Scherphof G., 1991, TARGETED DRUG DELIVE, P285
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682
   Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102
   Tan PH, 2005, GENE THER, V12, P59, DOI 10.1038/sj.gt.3302376
   Thomas M, 2005, P NATL ACAD SCI USA, V102, P5679, DOI 10.1073/pnas.0502067102
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   van de Water FM, 2006, DRUG METAB DISPOS, V34, P1393, DOI 10.1124/dmd.106.009555
   Vandenbroucke RE, 2008, J GENE MED, V10, P783, DOI 10.1002/jgm.1202
   VORNLOCHER HP, 2005, Patent No. 2005115481
   Wang YX, 2006, BIOMATERIALS, V27, P5292, DOI 10.1016/j.biomaterials.2006.05.049
   Werth S, 2006, J CONTROL RELEASE, V112, P257, DOI 10.1016/j.jconrel.2006.02.009
   Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Xia CF, 2007, PHARM RES, V24, P2309, DOI 10.1007/s11095-007-9460-8
   Yuan H, 2008, AM J PHYSIOL-RENAL, V295, pF605, DOI 10.1152/ajprenal.90268.2008
   Zamecnik J, 2004, NEUROPATH APPL NEURO, V30, P338, DOI 10.1046/j.1365-2990.2003.0541.x
   Zhang YJ, 2006, MOL THER, V14, P336, DOI 10.1016/j.ymthe.2006.04.001
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
   Zintchenko A, 2008, BIOCONJUGATE CHEM, V19, P1448, DOI 10.1021/bc800065f
NR 106
TC 2297
Z9 2441
U1 17
U2 1230
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD FEB
PY 2009
VL 8
IS 2
BP 129
EP 138
DI 10.1038/nrd2742
PG 10
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 404VQ
UT WOS:000263181500015
PM 19180106
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaszuba-Bartkowiak, K
   Nowak, MS
   Jurowski, P
   Gos, R
AF Kaszuba-Bartkowiak, Katarzyna
   Nowak, Michal S.
   Jurowski, Piotr
   Gos, Roman
TI The role of trimetazidine in the protection of the retina
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Review
DE trimetazidine; retinal ischaemic diseases; neurodegeneration;
   neuroprotection
ID ISCHEMIA; RATS
AB Tissue ischaemia is an important factor in the development of several eye diseases. The commonly accepted idea regarding management of ischaemic effects is that a normal blood flow should be increased. Trimetazidine, an anti-ischaemic agent, can have a positive effect on retina[ disorders with an ischaemic component. Trimetazidine seems to have an influence on selected visual parameters (improves visual acuity and contrast sensitivity) as an additional therapy in treatment of patients with primary open angle glaucoma and degenerative myopia A positive effect on other retinal disorders with an ischaemic component, e.g. diabetic retinopathy, age-related macular degeneration (AMD) or inflammatory diseases, requires further investigations.
C1 [Kaszuba-Bartkowiak, Katarzyna; Nowak, Michal S.; Jurowski, Piotr; Gos, Roman] Med Univ Lodz, Dept Ophthalmol & Visual Rehabil, Univ Hosp 2, PL-90549 Lodz, Poland.
C3 Medical University Lodz
RP Nowak, MS (通讯作者)，Med Univ Lodz, Dept Ophthalmol & Visual Rehabil, 113 Zeromskiego St, PL-90549 Lodz, Poland.
EM michaelnovak@interia.pl
RI Nowak, Michal Szymon/W-6290-2019
OI Nowak, Michal Szymon/0000-0001-6304-1545
CR Augustyniak E, 1990, Klin Oczna, V92, P86
   Barnett NL, 2004, EXP EYE RES, V79, P513, DOI 10.1016/j.exer.2004.06.022
   Czechowicz-Janicka K, 2001, PRZEW LEK, V7, P81
   Dreyer EB, 1999, JAMA-J AM MED ASSOC, V281, P306, DOI 10.1001/jama.281.4.306
   Mohand-Said S, 2002, OPHTHALMIC RES, V34, P300, DOI 10.1159/000065603
   Nowak MS, 2007, ARCH MED SCI, V3, P152
   Ozden S, 2001, OPHTHALMOLOGICA, V215, P309, DOI 10.1159/000050880
   Payet O, 2004, J OCUL PHARMACOL TH, V20, P85, DOI 10.1089/108076804772745491
   Romano C, 1998, INVEST OPHTH VIS SCI, V39, P416
   Synder A, 1992, Klin Oczna, V94, P53
NR 10
TC 2
Z9 3
U1 1
U2 2
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD SEP
PY 2007
VL 3
IS 3A
SI SI
BP S65
EP S66
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 279VD
UT WOS:000254382200012
DA 2022-11-30
ER

PT J
AU Dansingani, KK
   Balaratnasingam, C
   Naysan, J
   Freund, KB
AF Dansingani, Kunal K.
   Balaratnasingam, Chandrakumar
   Naysan, Jonathan
   Freund, K. Bailey
TI EN FACE IMAGING OF PACHYCHOROID SPECTRUM DISORDERS WITH SWEPT-SOURCE
   OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE pachychoroid; choroid; optical coherence tomography; en face;
   swept-source; angiography; central serous chorioretinopathy;
   pachychoroid pigment epitheliopathy; neovasculopathy;
   neovascularization; polypoidal
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   INDOCYANINE GREEN VIDEOANGIOGRAPHY; VASCULAR HYPERPERMEABILITY; PIGMENT
   EPITHELIOPATHY; NEOVASCULARIZATION; DEPTH; AUTOFLUORESCENCE;
   ANGIOGRAPHY; FEATURES
AB Purpose:To correlate clinical manifestations with choroidal morphology in pachychoroid disorders, including central serous chorioretinopathy, pachychoroid pigment epitheliopathy, pachychoroid neovasculopathy, and polypoidal choroidal vasculopathy, using en face swept-source optical coherence tomography (OCT).Methods:Patients with pachychoroid spectrum diagnoses were identified nonconsecutively through a review of charts and multimodal imaging. Each eye was categorized as uncomplicated pachychoroid, pachychoroid pigment epitheliopathy, central serous chorioretinopathy, pachychoroid neovasculopathy, or polypoidal choroidal vasculopathy. All patients included in this series then underwent bilateral swept-source OCT.Results:Sixty-six eyes of 33 patients were included. Numbers assigned to diagnostic categories were 8 uncomplicated pachychoroid, 13 pachychoroid pigment epitheliopathy, 27 central serous chorioretinopathy, 15 pachychoroid neovasculopathy, and 3 polypoidal choroidal vasculopathy. One eye was classified as normal. Swept-source OCT choroidal thickness maps confirmed increased thickness under the areas of pachychoroid pigment epitheliopathy, central serous chorioretinopathy, type 1 NV (pachychoroid neovasculopathy), or polyps (polypoidal choroidal vasculopathy). En face swept-source OCT showed dilated outer choroidal vessels in all eyes. In several eyes with a chronic disease, focal choriocapillaris atrophy with inward displacement of deep choroidal vessels was noted.Conclusion:Although clinical manifestations of pachychoroid spectrum disorders vary considerably, these entities share morphologic findings in the choroid, including increased thickness and dilated outer choroidal vessels. En face swept-source OCT localizes these changes to disease foci and shows additional findings that may unify our understanding of disease pathogenesis.
C1 [Dansingani, Kunal K.; Balaratnasingam, Chandrakumar; Naysan, Jonathan; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dansingani, Kunal K.; Balaratnasingam, Chandrakumar; Naysan, Jonathan; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [Naysan, Jonathan; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Naysan, Jonathan; Freund, K. Bailey] North Shore Long Isl Jewish Hlth Syst, Dept Ophthalmol, Manhasset, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; New York University;
   Northwell Health
RP Freund, KB (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kfnyf@aol.com
RI Dansingani, Kunal/D-1025-2015; Freund, K. Bailey/V-7488-2018
OI Dansingani, Kunal/0000-0002-7430-8601; Freund, K.
   Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat
   Hospital, New York; Macula Foundation, Inc, New York, NY
FX Supported by LuEsther T. Mertz Retinal Research Center, Manhattan Eye,
   Ear and Throat Hospital, New York, and The Macula Foundation, Inc, New
   York, NY.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Alasil T, 2014, AM J OPHTHALMOL
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Laviers H, 2014, GRAEF ARCH CLIN EXP, V252, P1871, DOI 10.1007/s00417-014-2840-y
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Orlock DA, 1997, INDOCYANINE GREEN AN, P62
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P5103, DOI 10.1167/iovs.08-2127
   Waldstein SM, 2015, EYE, V29, P409, DOI 10.1038/eye.2014.319
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 31
TC 237
Z9 248
U1 3
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2016
VL 36
IS 3
BP 499
EP 516
DI 10.1097/IAE.0000000000000742
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG1MW
UT WOS:000371833200009
PM 26335436
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Balsara, C
   Shahin, A
   Baviriseaty, N
   Czuma, R
   Sullivan, GA
AF Balsara, Charmi
   Shahin, Alexander
   Baviriseaty, Niharika
   Czuma, Richard
   Sullivan, Gregory A.
TI Charles Bonnet Syndrome Associated With Recurrent Hypertensive Crisis
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Article
DE Charles Bonnet syndrome; hypertensive crisis; visual hallucinations
ID COMPLEX VISUAL HALLUCINATIONS; REVERSIBLE ENCEPHALOPATHY SYNDROME;
   PATIENT; ANATOMY
AB Charles Bonnet syndrome (CBS) is a disorder of visual hallucinations in psychologically normal patients with ocular disease or damage to visual pathways. The etiology of CBS is not fully understood. It is associated with various triggers, with age-related macular degeneration the most common; other triggers are systemic diseases such as stroke, multiple sclerosis, and anemia as well as lighting issues, fatigue, and medical or surgical eye treatments. Visual disturbances such as decreased visual acuity, visual field deficits, or visual hallucinations are common in association with hypertensive encephalopathy. We describe a patient with episodic CBS triggered by recurrent hypertensive crises, which resolved with blood pressure management in the hospital setting.
C1 [Balsara, Charmi; Shahin, Alexander; Baviriseaty, Niharika; Czuma, Richard] Univ S Florida, Coll Med, Tampa, FL USA.
   [Sullivan, Gregory A.] Univ S Florida, James A Haley VA Hosp, Coll Med, Psychiat Consultat Liaison Serv, Tampa, FL USA.
   [Sullivan, Gregory A.] James A Haley VA Hosp, Mental Hlth & Behav Sci Serv 116A, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida; State
   University System of Florida; University of South Florida
RP Sullivan, GA (通讯作者)，James A Haley VA Hosp, Mental Hlth & Behav Sci Serv 116A, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.
EM cbalsara@usf.edu; avshahin@usf.edu; baviriseaty@usf.edu; rczuma@usf.edu;
   gregory.sullivan1@va.gov
CR Adachi N, 2000, PSYCHIAT CLIN NEUROS, V54, P157, DOI 10.1046/j.1440-1819.2000.00652.x
   Ashwin PT, 2007, J NEUROL SCI, V263, P184, DOI 10.1016/j.jns.2007.05.027
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P1043, DOI 10.3174/ajnr.A0929
   Behrendt RP, 2004, BEHAV BRAIN SCI, V27, P771, DOI 10.1017/S0140525X04000184
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   Choi EJ, 2005, ARCH NEUROL-CHICAGO, V62, P481, DOI 10.1001/archneur.62.3.481
   Cifuentes-Canorea P, 2018, NEUROLOGIA, V33, P473, DOI 10.1016/j.nrl.2016.04.009
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kaeser PF, 2009, EUR J OPHTHALMOL, V19, P494, DOI 10.1177/112067210901900331
   Kazui H, 2009, PSYCHOGERIATRICS, V9, P77, DOI 10.1111/j.1479-8301.2009.00288.x
   Komeima K, 2005, JPN J OPHTHALMOL, V49, P533, DOI 10.1007/s10384-005-0251-7
   Mascaro J, 2003, AGING CLIN EXP RES, V15, P518, DOI 10.1007/BF03327376
   McKinney AM, 2007, AM J ROENTGENOL, V189, P904, DOI 10.2214/AJR.07.2024
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   Santos-Bueso E, 2014, REV PSIQUIATR SALUD, V7, P152, DOI 10.1016/j.rpsm.2013.12.002
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   Stott VL, 2005, INTERN MED J, V35, P83, DOI 10.1111/j.1445-5994.2004.00750.x
   Tallaksen CME, 1998, EUR J NEUROL, V5, P615, DOI 10.1046/j.1468-1331.1998.560615.x
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   Vaughan CJ, 2000, LANCET, V356, P411, DOI 10.1016/S0140-6736(00)02539-3
NR 22
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD NOV
PY 2022
VL 28
IS 6
BP 509
EP 513
DI 10.1097/PRA.0000000000000662
PG 5
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Psychiatry
GA 6E9RQ
UT WOS:000883709900012
PM 36355592
DA 2022-11-30
ER

PT J
AU Stern, JH
   Tian, YZ
   Funderburgh, J
   Pellegrini, G
   Zhang, K
   Goldberg, JL
   Ali, RR
   Young, M
   Xie, YB
   Temple, S
AF Stern, Jeffrey H.
   Tian, Yangzi
   Funderburgh, James
   Pellegrini, Graziella
   Zhang, Kang
   Goldberg, Jeffrey L.
   Ali, Robin R.
   Young, Michael
   Xie, Yubing
   Temple, Sally
TI Regenerating Eye Tissues to Preserve and Restore Vision
SO CELL STEM CELL
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; RETINAL-PIGMENT EPITHELIUM; HUMAN IPS CELLS;
   HUMAN TRABECULAR MESHWORK; LENS REGENERATION; GANGLION-CELLS; MACULAR
   DEGENERATION; PROGENITOR CELLS; VISUAL FUNCTION; XENO-FREE
AB Ocular regenerative therapies are on track to revolutionize treatment of numerous blinding disorders, including corneal disease, cataract, glaucoma, retinitis pigmentosa, and age-related macular degeneration. A variety of transplantable products, delivered as cell suspensions or as preformed 3D structures combining cells and natural or artificial substrates, are in the pipeline. Here we review the status of clinical and preclinical studies for stem cell-based repair, covering key eye tissues from front to back, from cornea to retina, and including bioengineering approaches that advance cell product manufacturing. While recognizing the challenges, we look forward to a deep portfolio of sight-restoring, stem cell-based medicine.
C1 [Stern, Jeffrey H.; Temple, Sally] Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
   [Ali, Robin R.] UCL, Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
   [Ali, Robin R.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, City Rd, London EC1V 2PD, England.
   [Ali, Robin R.] UCL Inst Ophthalmol, City Rd, London EC1V 2PD, England.
   [Funderburgh, James] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   [Goldberg, Jeffrey L.] Stanford Univ, Byers Eye Inst, 2452 Watson Court, Palo Alto, CA 94303 USA.
   [Pellegrini, Graziella] Univ Modena & Reggio Emilia, Ctr Regenerat Med, Via G Gottardi 100, I-41125 Modena, Italy.
   [Tian, Yangzi; Xie, Yubing] SUNY Polytech Inst, Coll Nanoscale Sci & Engn, 257 Fuller Rd, Albany, NY 12203 USA.
   [Young, Michael] Harvard Med Sch, Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA 02114 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Zhang, Kang] Univ Calif San Diego, Inst Engn Med, La Jolla, CA 92093 USA.
   [Zhang, Kang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhang, Kang] Guangzhou Regenerat Med & Hlth Lab, Guangzhou 510060, Guangdong, Peoples R China.
   [Stern, Jeffrey H.; Ali, Robin R.; Temple, Sally] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Stanford University; Universita di Modena e Reggio Emilia;
   SUNY Polytechnic Institute; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego; Sun
   Yat Sen University; Guangzhou Regenerative Medicine & Health Guangdong
   Laboratory (Bioisland Laboratory); University of Michigan System;
   University of Michigan
RP Temple, S (通讯作者)，Neural Stem Cell Inst, Rensselaer, NY 12144 USA.; Temple, S (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
EM sallytemple@neuralsci.org
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; Ali, Robin/0000-0003-3126-6517
FU National Eye Institute (NEI), Bethesda, MD, USA [NEI 01EY022079]; Empire
   State Stem Cell Fund through New York State Department of Health
   [C028504]; Regenerative Research Foundation; Macular Vision Research
   Foundation [I01-BX002950]; UK Medical Research Council; European
   Research Council [ERC-2012-ADG_20120314]; RP Fighting Blindness; Carol
   and Dick Hertzberg Fund; Richard Annesser Fund; MRC [MR/J004553/1]
   Funding Source: UKRI; NATIONAL EYE INSTITUTE [P30EY003790, R01EY016415,
   P30EY026877, R01EY024642] Funding Source: NIH RePORTER; Veterans Affairs
   [I01BX002950] Funding Source: NIH RePORTER
FX We wish to acknowledge Dr. Sanford Greenberg and his wife Sue Greenberg
   for continuing to spur regenerative vision research with their campaign
   End Blindness 2020. We thank Rebecca Stern for the translation of
   Charles Bonnet's writing from French and for comments on the manuscript.
   Eustachio Attico and Virginia Sceberras, at the Centre for Regenerative
   Medicine, University of Modena and Reggio Emilia, via G. Gottardi 100,
   41125 Modena, Italy, assisted G. P. with manuscript editing. The authors
   are grateful for the following funding support: National Eye Institute
   (NEI), Bethesda, MD, USA, extramural grant NEI 01EY022079; the Empire
   State Stem Cell Fund through New York State Department of Health
   contract no. C028504; the Regenerative Research Foundation; and the
   Macular Vision Research Foundation (S.T. and J.H.S.); Research to
   Prevent Blindness, NEI P30-EY026877, Brightfocus, and VA Merit Award
   I01-BX002950 (J.L.G.); UK Medical Research Council, European Research
   Council (ERC-2012-ADG_20120314), and RP Fighting Blindness (R.R.A.); and
   Carol and Dick Hertzberg Fund and Richard Annesser Fund (K.Z.). Opinions
   expressed here are solely those of the authors and do not necessarily
   reflect those of the Empire State Stem Cell Board, the New York State
   Department of Health, or the State of New York.
CR Abu-Hassan DW, 2015, STEM CELLS, V33, P751, DOI 10.1002/stem.1885
   Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Aghaizu ND, 2017, PROG BRAIN RES, V231, P191, DOI 10.1016/bs.pbr.2017.01.001
   Al-Shamekh S, 2014, TRANSL RES, V163, P377, DOI 10.1016/j.trsl.2013.11.002
   Amano S, 2006, CORNEA, V25, pS73, DOI 10.1097/01.ico.0000247218.10672.7e
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Badea TC, 2009, NEURON, V61, P852, DOI 10.1016/j.neuron.2009.01.020
   Baranov P, 2013, TISSUE ENG PART C-ME, V19, P265, DOI [10.1089/ten.tec.2012.0217, 10.1089/ten.TEC.2012.0217]
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Barazzetti G, 2016, STEM CELL TRANSL MED, V5, P1058, DOI 10.5966/sctm.2015-0222
   Barbosa-Sabanero K, 2012, BIOCHEM J, V447, P321, DOI 10.1042/BJ20120813
   Barraquer J., 1965, CORNEA WORLD C
   Basu S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009644
   Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Bourne D, 2017, EYE, V31, P179, DOI 10.1038/eye.2016.272
   Brown NL, 2001, DEVELOPMENT, V128, P2497
   BRUNDIN P, 1986, EXP BRAIN RES, V65, P235
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Burnight ER, 2017, MOL THER, V25, P1999, DOI 10.1016/j.ymthe.2017.05.015
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chamling X, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18590
   Chang EE, 2012, OPHTHALMOLOGY, V119, P979, DOI 10.1016/j.ophtha.2011.11.003
   Chang KC, 2017, J NEUROSCI, V37, P4967, DOI 10.1523/JNEUROSCI.3430-13.2017
   Chen HY, 2016, MOL VIS, V22, P1077
   Chen SY, 2011, TISSUE ENG PART C-ME, V17, P537, DOI [10.1089/ten.tec.2010.0609, 10.1089/ten.TEC.2010.0609]
   Cheng J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0403-9
   Chhunchha B, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.60
   Cuenca N, 2013, INVEST OPHTH VIS SCI, V54, P6745, DOI 10.1167/iovs.13-12860
   Cvekl A, 2017, TRENDS GENET, V33, P677, DOI 10.1016/j.tig.2017.08.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daniszewski M, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.13
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   de Rham C, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/518135
   Decembrini S, 2014, STEM CELL REP, V2, P853, DOI 10.1016/j.stemcr.2014.04.010
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   DiStefano T, 2018, STEM CELL REP, V10, P300, DOI 10.1016/j.stemcr.2017.11.001
   Du YQ, 2007, INVEST OPHTH VIS SCI, V48, P5038, DOI 10.1167/iovs.07-0587
   Du YQ, 2016, INVEST OPHTH VIS SCI, V57
   Du YQ, 2013, INVEST OPHTH VIS SCI, V54, P1450, DOI 10.1167/iovs.12-11056
   Du YQ, 2012, INVEST OPHTH VIS SCI, V53, P1566, DOI 10.1167/iovs.11-9134
   Du YQ, 2009, STEM CELLS, V27, P1635, DOI 10.1002/stem.91
   Dziasko MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094283
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fan BJ, 2010, J CLIN INVEST, V120, P3064, DOI 10.1172/JCI43085
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200
   Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200
   Ganat YM, 2012, J CLIN INVEST, V122, P2928, DOI 10.1172/JCI58767
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Ghezzi CE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169504
   Gill KP, 2016, SCI REP-UK, V6, DOI 10.1038/srep30552
   Gonzalez G., 2018, REV DEV BIOL, V7
   Gonzalez P, 2006, EXP EYE RES, V82, P959, DOI 10.1016/j.exer.2005.10.006
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gornalusse GG, 2017, NAT BIOTECHNOL, V35, P765, DOI 10.1038/nbt.3860
   Graw J, 2010, CURR TOP DEV BIOL, V90, P343, DOI 10.1016/S0070-2153(10)90010-0
   Griffith M, 2016, J INTERN MED, V280, P276, DOI 10.1111/joim.12502
   Gwon A, 2006, SURV OPHTHALMOL, V51, P51, DOI 10.1016/j.survophthal.2005.11.005
   Hanson C, 2017, WORLD J STEM CELLS, V9, P127, DOI 10.4252/wjsc.v9.i8.127
   Hatou S, 2013, STEM CELLS DEV, V22, DOI 10.1089/scd.2012.0286
   Hayashi R, 2017, NAT PROTOC, V12, P683, DOI 10.1038/nprot.2017.007
   Hayashi R, 2016, NATURE, V531, P376, DOI 10.1038/nature17000
   Hertsenberg AJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171712
   Higa K, 2013, STEM CELL RES, V10, P147, DOI 10.1016/j.scr.2012.11.001
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Homma K, 2013, STEM CELLS, V31, P1149, DOI 10.1002/stem.1372
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Hoy SM, 2018, DRUGS, V78, P389, DOI 10.1007/s40265-018-0877-7
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu XJ, 2005, TISSUE ENG, V11, P1710, DOI 10.1089/ten.2005.11.1710
   Huang R, 2014, MOL VIS, V20, P1271
   Inagaki E, 2017, STEM CELL TRANSL MED, V6, P788, DOI 10.1002/sctm.16-0162
   Johnson M, 2006, EXP EYE RES, V82, P545, DOI 10.1016/j.exer.2005.10.011
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kelley MJ, 2009, EXP EYE RES, V88, P747, DOI 10.1016/j.exer.2008.10.024
   Kinoshita S, 2018, NEW ENGL J MED, V378, P995, DOI 10.1056/NEJMoa1712770
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Koizumi N, 2014, CORNEA, V33, pS25, DOI 10.1097/ICO.0000000000000240
   Kopczynski CC, 2014, J OCUL PHARMACOL TH, V30, P85, DOI 10.1089/jop.2013.0197
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kruczek K, 2017, STEM CELL REP, V8, P1659, DOI 10.1016/j.stemcr.2017.04.030
   Ksander BR, 2014, NATURE, V511, P353, DOI 10.1038/nature13426
   Kundu J, 2018, J BIOMED MATER RES B, V106, P891, DOI 10.1002/jbm.b.33901
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuroda T, 2013, BIOL PHARM BULL, V36, P189, DOI 10.1248/bpb.b12-00970
   Lakowski J, 2018, STEM CELLS, V36, P709, DOI 10.1002/stem.2775
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LaVail M M, 2001, Prog Brain Res, V131, P617
   Lawley E, 2015, J BIOMATER APPL, V29, P894, DOI 10.1177/0885328214547751
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lin HT, 2016, NATURE, V531, P323, DOI 10.1038/nature17181
   Liu YZ, 2018, NATURE, V556, pE3, DOI 10.1038/nature26150
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P1112, DOI 10.1016/j.stemcr.2017.03.024
   Massie I, 2015, METHODS MOL BIOL, V1235, P179, DOI 10.1007/978-1-4939-1785-3_15
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McCabe KL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145266
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Mikhailova A, 2016, EXP EYE RES, V146, P26, DOI 10.1016/j.exer.2015.11.021
   Molday RS, 2015, PROG MOL BIOL TRANSL, V134, P415, DOI 10.1016/bs.pmbts.2015.06.008
   Moore DL, 2011, MOL CELL NEUROSCI, V47, P233, DOI 10.1016/j.mcn.2011.05.005
   Moore DL, 2010, J NEURO-OPHTHALMOL, V30, P347, DOI 10.1097/WNO.0b013e3181e755af
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   NAS, 2017, NAV MAN PROC ENS QUA
   Ohlemacher SK, 2016, STEM CELLS, V34, P1553, DOI 10.1002/stem.2356
   Oliva MS, 2012, INDIAN J OPHTHALMOL, V60, P423, DOI 10.4103/0301-4738.100540
   Ontario H.Q.; Health Quality Ontario, 2008, ONTARIO HLTH TECHNOL, V8, P1
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0
   Prasov L, 2012, HUM MOL GENET, V21, P3681, DOI 10.1093/hmg/dds197
   Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Riera M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.10
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sangwan VS, 2017, CURR OPIN OPHTHALMOL, V28, P382, DOI 10.1097/ICU.0000000000000377
   Sangwan VS, 2011, BRIT J OPHTHALMOL, V95, P1525, DOI 10.1136/bjophthalmol-2011-300352
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Santos-Ferreira TF, 2017, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00105
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4015, DOI 10.1167/iovs.14-14668
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Shortt AJ, 2014, STEM CELL TRANSL MED, V3, P265, DOI 10.5966/sctm.2013-0025
   Shortt AJ, 2010, OCUL SURF, V8, P80, DOI 10.1016/S1542-0124(12)70072-1
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Sluch VM, 2017, STEM CELL TRANSL MED, V6, P1972, DOI 10.1002/sctm.17-0059
   Sluch VM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16595
   Smith JA, 2017, REJUV RES, V20, P1, DOI 10.1089/rej.2017.1932
   Solebo AL, 2018, NATURE, V556, pE1, DOI 10.1038/nature26148
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Song QL, 2016, EXP EYE RES, V151, P107, DOI 10.1016/j.exer.2016.08.004
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sridhar A, 2013, STEM CELL TRANSL MED, V2, P255, DOI 10.5966/sctm.2012-0101
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Stevens KR, 2018, CELL STEM CELL, V22, P294, DOI 10.1016/j.stem.2018.01.015
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sugino IK, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.8
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Syed-Picard FN, 2018, J TISSUE ENG REGEN M, V12, P59, DOI 10.1002/term.2363
   Tamm ER, 2009, EXP EYE RES, V88, P648, DOI 10.1016/j.exer.2009.02.007
   Teotia P, 2017, STEM CELLS, V35, P572, DOI 10.1002/stem.2513
   Tian Y, 2017, ACS BIOMATER SCI ENG, V3, P890, DOI 10.1021/acsbiomaterials.6b00757
   Torrejon KY, 2016, BIOTECHNOL BIOENG, V113, P1357, DOI 10.1002/bit.25899
   Trakhtenberg EF, 2018, EXP NEUROL, V300, P22, DOI 10.1016/j.expneurol.2017.10.025
   Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202
   Tsonis PA, 2004, EXP EYE RES, V78, P161, DOI 10.1016/j.exer.2003.10.022
   Umemoto T, 2013, CHINESE SCI BULL, V58, P4349, DOI 10.1007/s11434-013-5742-1
   Vavvas DG, 2018, NATURE, V556, pE2, DOI 10.1038/nature26149
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Waldron PV, 2018, STEM CELL REP, V10, P406, DOI 10.1016/j.stemcr.2017.12.008
   Wan J, 2016, CURR OPIN GENET DEV, V40, P41, DOI 10.1016/j.gde.2016.05.009
   Wang E, 2017, BIOMATERIALS, V143, P57, DOI 10.1016/j.biomaterials.2017.07.031
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Wilken MS, 2016, CURR OPIN GENET DEV, V40, P57, DOI 10.1016/j.gde.2016.05.028
   Wu J, 2014, EXP EYE RES, V120, P71, DOI 10.1016/j.exer.2014.01.005
   Wu W, 2016, ONCOTARGET, V7, P22819, DOI 10.18632/oncotarget.8185
   Xian BK, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0167-1
   Xie HT, 2012, INVEST OPHTH VIS SCI, V53, P279, DOI 10.1167/iovs.11-8441
   Yang CB, 2010, FASEB J, V24, P3274, DOI 10.1096/fj.10-157255
   Yokoo S, 2005, INVEST OPHTH VIS SCI, V46, P1626, DOI 10.1167/iovs.04-1263
   Yun HM, 2016, J OCUL PHARMACOL TH, V32, P253, DOI 10.1089/jop.2016.0005
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang LY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21021
   Zhao JGJ, 2016, INVEST OPHTH VIS SCI, V57, P6878, DOI 10.1167/iovs.16-20024
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu W, 2017, INVEST OPHTH VIS SCI, V58, P2054, DOI 10.1167/iovs.16-20672
   Zhu W, 2016, P NATL ACAD SCI USA, V113, pE3492, DOI 10.1073/pnas.1604153113
NR 189
TC 80
Z9 82
U1 6
U2 77
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUN 1
PY 2018
VL 22
IS 6
BP 834
EP 849
DI 10.1016/j.stem.2018.05.013
PG 16
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GI4BF
UT WOS:000434315200013
PM 29859174
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Tochitsky, I
   Kramer, RH
AF Tochitsky, Ivan
   Kramer, Richard H.
TI Optopharmacological tools for restoring visual function in degenerative
   retinal diseases
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Review
ID GANGLION-CELLS; ECTOPIC EXPRESSION; BIPOLAR CELLS; RESPONSES;
   RESTORATION; LIGHT; MICE; PROSTHESES; MORPHOLOGY; CHANNELS
AB Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are progressive retinal diseases that result from the death of rod and cone photoreceptors, ultimately leading to blindness. The only currently approved vision restoration treatment employs an implanted retinal 'chip' as a prosthetic device to electrically stimulate retinal neurons that survive after the photoreceptors are gone, thereby restoring light-driven neural signaling to the brain. Alternative strategies have been proposed, which would utilize optogenetic or optopharmacological tools to enable direct optical stimulation of surviving retinal neurons. Here, we review the latest studies evaluating the feasibility of these molecular tools as potential therapeutics for restoring visual function in human blinding disease.
C1 [Tochitsky, Ivan; Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley
RP Kramer, RH (通讯作者)，Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
EM rhkramer@berkeley.edu
OI Tochitsky, Ivan/0000-0003-0650-9193
FU NIH [PN2 EY018241, P30 EY003176]; Beckman Institute for Macular
   Research; Wynn-Gund grant from the Foundation Fighting Blindness;
   NATIONAL EYE INSTITUTE [R01EY018957, P30EY003176, PN2EY018241,
   R01EY024334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [T32GM066698] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS090527] Funding
   Source: NIH RePORTER
FX This work was supported by grants from the NIH (PN2 EY018241 and P30
   EY003176), a research grant from the Beckman Institute for Macular
   Research, and a Wynn-Gund grant from the Foundation Fighting Blindness.
CR Artigas JM, 2012, INVEST OPHTH VIS SCI, V53, P4076, DOI 10.1167/iovs.12-9471
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Beltran WA, 2010, GENE THER, V17, P1162, DOI 10.1038/gt.2010.56
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Busskamp V, 2011, CURR OPIN NEUROBIOL, V21, P942, DOI 10.1016/j.conb.2011.06.001
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Caporale N, 2011, MOL THER, V19, P1212, DOI 10.1038/mt.2011.103
   Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chuang AT, 2014, BRIT J OPHTHALMOL, V98, P852, DOI 10.1136/bjophthalmol-2013-303708
   Chuong AS, 2014, NAT NEUROSCI, V17, P1123, DOI 10.1038/nn.3752
   Cronin T, 2014, EMBO MOL MED, V6, P1175, DOI 10.15252/emmm.201404077
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   Fortin DL, 2008, NAT METHODS, V5, P331, DOI [10.1038/NMETH.1187, 10.1038/nmeth.1187]
   Gaub BM, 2014, P NATL ACAD SCI USA, V111, pE5574, DOI 10.1073/pnas.1414162111
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Ivanova E, 2010, INVEST OPHTH VIS SCI, V51, P5288, DOI 10.1167/iovs.10-5389
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Kramer RH, 2013, NAT NEUROSCI, V16, P816, DOI 10.1038/nn.3424
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Merabet LB, 2010, NAT REV NEUROSCI, V11, P44, DOI 10.1038/nrn2758
   Miyashita T, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00008
   Mourot A, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00005
   Mourot A, 2011, ACS CHEM NEUROSCI, V2, P536, DOI 10.1021/cn200037p
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   O'Brien EE, 2014, J COMP NEUROL, V522, P1155, DOI 10.1002/cne.23487
   Petersen-Jones S, 2005, J SMALL ANIM PRACT, V46, P371, DOI 10.1111/j.1748-5827.2005.tb00333.x
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Ross JW, 2012, INVEST OPHTH VIS SCI, V53, P501, DOI 10.1167/iovs.11-8784
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Weiland JD, 2011, OPHTHALMOLOGY, V118, P2227, DOI 10.1016/j.ophtha.2011.08.042
   Wilke RGH, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046016
   Winter JO, 2007, J BIOMAT SCI-POLYM E, V18, P1031, DOI 10.1163/156856207781494403
NR 41
TC 15
Z9 17
U1 2
U2 27
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
EI 1873-6882
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD OCT
PY 2015
VL 34
BP 74
EP 78
DI 10.1016/j.conb.2015.01.018
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CS5SU
UT WOS:000362139300012
PM 25706312
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Floyd, JL
   Grant, MB
AF Floyd, Jason L.
   Grant, Maria B.
TI The Gut-Eye Axis: Lessons Learned from Murine Models
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Age-related macular degeneration; Choroidal neovascularization; Diabetic
   retinopathy; Diet; Fecal microbiota transplant; Glaucoma; Gut
   microbiota; Intermittent fasting; Probiotic; Uveitis
ID OPEN-ANGLE GLAUCOMA; ANGIOTENSIN-II; INTESTINAL MICROBIOTA; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; METABOLIC SYNDROME;
   SJOGRENS-SYNDROME; RECEPTOR (TLR)2; RETINA AXIS; OBESITY
AB A healthy gut microbiota is essential in maintaining the human body in a homeostatic state by its functions in digestion and immune tolerance. Under states of aberrant microbial composition or function (dysbiosis), the gut microbiota induces systemic inflammation that can lead to the onset of many diseases. In this review, we describe some evidence, largely from rodent studies, that supports the possible role of a dysbiotic gut microbiota in the onset and exacerbation of ocular diseases, primarily diabetic retinopathy, age-related macular degeneration, choroidal neovascularization, and uveitis. Furthermore, we examine several potential therapeutic measures that show promise in restoring the gut microbiota to a eubiotic state, preventing the aforementioned disease pathologies.
C1 [Floyd, Jason L.; Grant, Maria B.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Grant, MB (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
EM mariagrant@uabmc.edu
OI Floyd, Jason L./0000-0002-7452-1680
FU National Institutes of Health [R01EY025383, R01EY012601, R01EY028858,
   R01EY028037, T32HL105349]; Research to Prevent Blindness
FX This manuscript was supported by the National Institutes of Health
   grants R01EY025383, R01EY012601, R01EY028858, R01EY028037 to M.B. Grant
   and T32HL105349 to J.L. Floyd. This manuscript was supported by
   unrestricted grant from Research to Prevent Blindness to UAB Department
   of Ophthalmology and Visual Sciences. No funding or sponsorship was
   received for the publication of this article.
CR Abdulaal MR, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/509456
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Allin KH, 2018, DIABETOLOGIA, V61, P810, DOI 10.1007/s00125-018-4550-1
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Atarashi K, 2011, CURR OPIN IMMUNOL, V23, P761, DOI 10.1016/j.coi.2011.11.002
   Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Barreau F, 2014, CURR OPIN MICROBIOL, V17, P91, DOI 10.1016/j.mib.2013.12.003
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Bibbo S, 2017, ANN MED, V49, P11, DOI 10.1080/07853890.2016.1222449
   Brunkwall L, 2017, DIABETOLOGIA, V60, P943, DOI 10.1007/s00125-017-4278-3
   Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]
   Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886
   Chaiwiang N, 2019, ACTA MICROBIOL IMM H, V66, P541, DOI 10.1556/030.66.2019.038
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chan JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41452-2
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Chen J, 2019, METHODS MOL BIOL, V1899, P211, DOI 10.1007/978-1-4939-8938-6_15
   Cheng CW, 2017, CELL, V168, P775, DOI 10.1016/j.cell.2017.01.040
   Clermont A, 2006, J HYPERTENS, V24, pS73, DOI 10.1097/01.hjh.0000220410.69116.f8
   Collins DW, 2016, MOL VIS, V22, P454
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   de Groot PF, 2017, GUT MICROBES, V8, P253, DOI 10.1080/19490976.2017.1293224
   den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012
   Dinan TG, 2017, PSYCHOSOM MED, V79, P920, DOI 10.1097/PSY.0000000000000519
   Dominguez JM, 2016, AM J PATHOL, V186, P1688, DOI 10.1016/j.ajpath.2016.01.023
   Duan YQ, 2019, CIRC RES, V125, P969, DOI 10.1161/CIRCRESAHA.119.315743
   Duan YQ, 2018, STEM CELLS, V36, P1430, DOI 10.1002/stem.2848
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
   Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8
   Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104
   Franzosa EA, 2014, P NATL ACAD SCI USA, V111, pE2329, DOI 10.1073/pnas.1319284111
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gavin PG, 2018, DIABETES CARE, V41, P2178, DOI 10.2337/dc18-0777
   Gerard P, 2016, CELL MOL LIFE SCI, V73, P147, DOI 10.1007/s00018-015-2061-5
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985
   Graspeuntner S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27757-8
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078
   Hayden MR, 2011, CARDIORENAL MED, V1, P193, DOI 10.1159/000329926
   Hergott CB, 2016, BLOOD, V127, P2460, DOI 10.1182/blood-2015-10-675173
   Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709
   Horai R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00232
   Horai R, 2017, EXPERT REV CLIN IMMU, V13, P291, DOI 10.1080/1744666X.2017.1288098
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   Jamshed H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061234
   Janowitz C, 2019, INVEST OPHTH VIS SCI, V60, P420, DOI 10.1167/iovs.18-24813
   Jarajapu YPR, 2013, DIABETES, V62, P1258, DOI 10.2337/db12-0808
   Jiang CM, 2017, J ALZHEIMERS DIS, V58, P1, DOI 10.3233/JAD-161141
   Karlsson FH, 2013, NATURE, V498, P99, DOI 10.1038/nature12198
   Kasselman LJ, 2018, ATHEROSCLEROSIS, V271, P203, DOI 10.1016/j.atherosclerosis.2018.02.036
   Kuklinski E, 2017, CLIN IMMUNOL, V182, P55, DOI 10.1016/j.clim.2017.04.017
   Larsen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009085
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017
   Lin L, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0187-3
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Ma J, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-257
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Mandl T, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1446-2
   Mangiola F, 2016, WORLD J GASTROENTERO, V22, P361, DOI 10.3748/wjg.v22.i1.361
   Mattson MP, 2017, AGEING RES REV, V39, P46, DOI 10.1016/j.arr.2016.10.005
   Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723
   Miller AG, 2010, DIABETES, V59, P3208, DOI 10.2337/db10-0552
   Moon J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229029
   Murphy AB, 2016, GUT-BRAIN AXIS: DIETARY, PROBIOTIC, AND PREBIOTIC INTERVENTIONS ON THE MICROBIOTA, P61, DOI 10.1016/B978-0-12-802304-4.00005-0
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Neves AL, 2013, J MOL ENDOCRINOL, V51, pR51, DOI 10.1530/JME-13-0079
   Nusbaum DJ, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fiy133
   Patterson RE, 2017, ANNU REV NUTR, V37, P371, DOI 10.1146/annurev-nutr-071816-064634
   Peterson CM, 2019, OBESITY, V27, P11, DOI 10.1002/oby.22384
   Prince LR, 2011, CURR OPIN PHARMACOL, V11, P397, DOI 10.1016/j.coph.2011.06.007
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Quigley EMM, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0802-6
   Radu M, 2013, JOVE-J VIS EXP, DOI 10.3791/50062
   Rausch P, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0743-1
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rojas M, 2010, INVEST OPHTH VIS SCI, V51, P1709, DOI 10.1167/iovs.09-3375
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268
   Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701
   Salki A, 2009, METABOLISM, V58, P708, DOI 10.1016/j.metabol.2009.01.013
   Schmidtner AK, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0556-9
   Silva KC, 2009, DIABETES, V58, P1382, DOI 10.2337/db09-0166
   Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229
   Sohail MU, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/9631435
   Sommer F, 2017, NAT REV MICROBIOL, V15, P630, DOI 10.1038/nrmicro.2017.58
   Sun LL, 2018, NAT MED, V24, P1919, DOI 10.1038/s41591-018-0222-4
   Sutton EF, 2018, CELL METAB, V27, P1212, DOI 10.1016/j.cmet.2018.04.010
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Vaughn BP, 2016, INFLAMM BOWEL DIS, V22, P2182, DOI 10.1097/MIB.0000000000000893
   Verma A, 2019, MOL THER-METH CLIN D, V14, P161, DOI 10.1016/j.omtm.2019.06.007
   Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155
   Wan RQ, 2003, J NUTR, V133, P1921, DOI 10.1093/jn/133.6.1921
   Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656
   Wiecek A, 2003, NEPHROL DIAL TRANSPL, V18, P16, DOI 10.1093/ndt/gfg1036
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Yang B, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0992-y
   Yassour M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0271-6
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang Y, 2013, FOOD SCI HUM WELL, V2, P167, DOI [10.1016/j.fshw.2013.09.002, DOI 10.1016/J.FSHW.2013.09.002]
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 104
TC 25
Z9 26
U1 0
U2 15
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2020
VL 9
IS 3
BP 499
EP 513
DI 10.1007/s40123-020-00278-2
EA JUL 2020
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MV3HE
UT WOS:000546168000002
PM 32617914
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xuan, WJ
   Moothedathu, AA
   Meng, T
   Gibson, DC
   Zheng, JH
   Xu, QG
AF Xuan, Wenjing
   Moothedathu, Aji Alex
   Meng, Tuo
   Gibson, David C.
   Zheng, Jinhua
   Xu, Qingguo
TI 3D engineering for optic neuropathy treatment
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID RETINAL GANGLION-CELL; PLURIPOTENT STEM-CELLS; IN-VITRO;
   TRANSPLANTATION; MODEL; DIFFERENTIATION; MATURATION; GENERATION; SHEETS
AB Ocular disorders, such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis pigmentosa (RP), and glaucoma, can cause irreversible visual loss, and affect the quality of life of millions of patients. However, only very few 3D systems can mimic human ocular pathophysiology, especially the retinal degenerative diseases, which involve the loss of retinal ganglion cells (RGCs), photoreceptors, or retinal pigment epithelial cells (RPEs). In this review, we discuss current progress in the 3D modeling of ocular tissues, and review the use of the aforementioned technologies for optic neuropathy treatment according to the categories of associated disease models and their applications in drug screening, mechanism studies, and cell and gene therapies.
C1 [Xuan, Wenjing; Moothedathu, Aji Alex; Meng, Tuo; Zheng, Jinhua; Xu, Qingguo] Virginia Commonwealth Univ, Dept Pharmaceut, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Gibson, David C.] Virginia Commonwealth Univ, Sch Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Zheng, Jinhua] Guizhou Med Univ, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
   [Xu, Qingguo] Virginia Commonwealth Univ, Ophthalmol, Ctr Pharmaceut Engn, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Xu, Qingguo] Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev ISB3D, Med Coll Virginia Campus, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Guizhou Medical University; Virginia Commonwealth University; Virginia
   Commonwealth University
RP Xu, QG (通讯作者)，Virginia Commonwealth Univ, Dept Pharmaceut, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Xu, QG (通讯作者)，Virginia Commonwealth Univ, Ophthalmol, Ctr Pharmaceut Engn, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Xu, QG (通讯作者)，Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev ISB3D, Med Coll Virginia Campus, Richmond, VA 23298 USA.
EM qxu@vcu.edu
RI Meng, Tuo/AGD-5727-2022; Xu, Qingguo/C-1962-2014
OI Meng, Tuo/0000-0003-4190-2521; M.R., Aji Alex/0000-0001-5453-4444; Xu,
   Qingguo/0000-0003-3191-0771
FU National Institutes of Health [R01EY027827]; US Food and Drug
   Administration [HHSF223201810114C]; George and Lavinia Blick Research
   Fund
FX This work was partially supported by the National Institutes of Health
   (R01EY027827), the US Food and Drug Administration (HHSF223201810114C),
   and the George and Lavinia Blick Research Fund.
CR Achberger K, 2019, ADV DRUG DELIVER REV, V140, P33, DOI 10.1016/j.addr.2018.05.005
   Alhadeff PA, 2017, J GLAUCOMA, V26, P498, DOI 10.1097/IJG.0000000000000640
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Aoki H, 2008, GRAEF ARCH CLIN EXP, V246, P255, DOI 10.1007/s00417-007-0710-6
   Aoki H, 2007, EXP EYE RES, V84, P868, DOI 10.1016/j.exer.2007.01.007
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   Bai J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00407
   Ben M'Barek K, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4568979
   Bharti K, US Patent App., Patent No. [16/347, 939, 16347939]
   BOEVER F, 1948, ARCH INT PHARMACOD T, V77, P1
   BOYCOTT BB, 1988, NEUROSCI RES, pS97, DOI 10.1016/0921-8696(88)90010-2
   Bull ND, 2011, INVEST OPHTH VIS SCI, V52, P3309, DOI 10.1167/iovs.10-6873
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Care RA, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107730
   Carelli V, 2017, HUM MOL GENET, V26, pR139, DOI 10.1093/hmg/ddx273
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chidlow G, 2011, ACTA NEUROPATHOL, V121, P737, DOI 10.1007/s00401-011-0807-1
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Choi SS, 2008, INVEST OPHTH VIS SCI, V49, P2103, DOI 10.1167/iovs.07-0980
   Chun BY, 2016, CURR OPIN OPHTHALMOL, V27, P475, DOI 10.1097/ICU.0000000000000314
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   DiStefano T, 2018, STEM CELL REP, V10, P300, DOI 10.1016/j.stemcr.2017.11.001
   Dutta D, 2017, TRENDS MOL MED, V23, P393, DOI 10.1016/j.molmed.2017.02.007
   Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102
   Giacomello M, 2020, NAT REV MOL CELL BIO, V21, P204, DOI 10.1038/s41580-020-0210-7
   Gill KP, 2016, SCI REP-UK, V6, DOI 10.1038/srep30552
   Goureau O., 2014, STEM CELL BIOL REGEN, P549
   Greco A, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.038
   Guo YL, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00361
   Heavner W, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008391
   Hombrebueno JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097970
   Huh D, 2012, LAB CHIP, V12, P2156, DOI 10.1039/c2lc40089h
   Huh D, 2011, TRENDS CELL BIOL, V21, P745, DOI 10.1016/j.tcb.2011.09.005
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kador KE, 2016, TISSUE ENG PT A, V22, P286, DOI [10.1089/ten.tea.2015.0373, 10.1089/ten.TEA.2015.0373]
   Kaji H., 2014, 18 INT C MIN SYST CH, P742
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kimura A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091584
   Lancaster MA, 2017, NAT BIOTECHNOL, V35, P659, DOI 10.1038/nbt.3906
   Lane A, 2020, STEM CELL REP, V15, P67, DOI 10.1016/j.stemcr.2020.05.007
   Ledford H., 2018, NATURE, DOI [10.1038/d41586-018-06195-6, DOI 10.1038/D41586-018-06195-6]
   Ledford H, 2020, NATURE, V579, P185, DOI 10.1038/d41586-020-00655-8
   Levin LA, 2002, PROG RETIN EYE RES, V21, P465, DOI 10.1016/S1350-9462(02)00012-5
   Li Q, 2006, J NEUROSCI RES, V84, P1656, DOI 10.1002/jnr.21087
   Liu HT, 2019, ADV MATER, V31, DOI 10.1002/adma.201902042
   Lorber B, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/1/015001
   Mahato B, 2020, NATURE, V581, P83, DOI 10.1038/s41586-020-2201-4
   Meir YJJ, 2020, ADV THER, V37, P1034, DOI 10.1007/s12325-020-01237-w
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Mishra S, 2015, BIOMED MICRODEVICES, V17, DOI 10.1007/s10544-015-0002-6
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Picaud S, 2019, P NATL ACAD SCI USA, V116, P26280, DOI 10.1073/pnas.1902292116
   Porciatti V, 2012, J NEURO-OPHTHALMOL, V32, P354, DOI 10.1097/WNO.0b013e3182745600
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Quinn PM, 2019, STEM CELL REP, V12, P906, DOI 10.1016/j.stemcr.2019.03.002
   Rabesandratana O, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00651
   Regent F, 2020, MOL VIS, V26, P97
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Sharma A, 2020, CELL STEM CELL, V26, P309, DOI 10.1016/j.stem.2020.02.011
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Sluch VM, 2017, STEM CELL TRANSL MED, V6, P1972, DOI 10.1002/sctm.17-0059
   Sluch VM, 2014, DEV OPHTHALMOL, V53, P111, DOI 10.1159/000358409
   Su PJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13591
   Szatko KP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17113-8
   Takebe T, 2013, NATURE, V499, P481, DOI 10.1038/nature12271
   Tanaka T, 2016, INVEST OPHTH VIS SCI, V57, P3348, DOI 10.1167/iovs.16-19166
   Teotia P, 2017, STEM CELLS, V35, P2239, DOI 10.1002/stem.2675
   Wong KY, 2012, J NEUROSCI, V32, P11478, DOI 10.1523/JNEUROSCI.1423-12.2012
   Wu FG, 2015, P NATL ACAD SCI USA, V112, pE1559, DOI 10.1073/pnas.1421535112
   Yu WH, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00053
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zhang J, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/734527
   Zhang Y, 2018, INVEST OPHTH VIS SCI, V59, P5266, DOI 10.1167/iovs.17-23632
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 81
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD JAN
PY 2020
VL 26
IS 1
BP 181
EP 188
DI 10.1016/j.drudis.2020.09.034
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RC2SV
UT WOS:000632655700008
PM 33038525
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thompsen, J
   Thompson, PD
AF Thompsen, Jeff
   Thompson, Paul D.
TI A systematic review of LDL apheresis in the treatment of cardiovascular
   disease
SO ATHEROSCLEROSIS
LA English
DT Review
DE apheresis; LDL apheresis; cholesterol; LDL cholesterol; atherosclerosis;
   coronary artery disease
ID LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; ANGIOGRAPHICALLY
   ASSESSED TRIAL; CELLULOSE ADSORPTION SYSTEM; FAMILIAL
   HYPERCHOLESTEROLEMIA; ARTERY-DISEASE; ATHEROSCLEROSIS REGRESSION;
   PLASMA-CONCENTRATIONS; SECONDARY PREVENTION; PRECIPITATION HELP
AB LDL apheresis is an effective method of lowering low-density lipoprotein (LDL) concentration in patients with familial hypercholesterolemia (FH) who are either refractory to treatment or intolerant of medical therapy. We searched the medical literature through July 2004 using PubMed and Medline and the search terms "LDL apheresis", "cardiovascular", and "disease" to identify apheresis techniques and to evaluate their effects on cardiovascular pathophysiology and clinical outcomes. We conclude that LDL apheresis reduces cardiovascular events in hypercholesterolemic patients and may be an effective treatment for other vascular diseases including cholesterol embolic disease, focal segmental glomerular sclerosis, sudden hearing loss, and age-related macular degeneration. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Hartford Hosp, Ishikari, Hokkaido 06102, Japan.
RP Thompson, PD (通讯作者)，Hartford Hosp, 80 Seymour St, Ishikari, Hokkaido 06102, Japan.
EM pthomps@harthosp.org
CR Aengevaeren WRM, 1996, J AM COLL CARDIOL, V28, P1696, DOI 10.1016/S0735-1097(96)00388-9
   Agishi T, 1996, Nihon Geka Gakkai Zasshi, V97, P563
   Bambauer R, 2000, Ther Apher, V4, P213, DOI 10.1046/j.1526-0968.2000.00180.x
   BUCHWALD H, 1988, BEITR INFUSIONSTHER, V23, P47
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   Empen K, 2002, J CLIN APHERESIS, V17, P38, DOI 10.1002/jca.10010
   Fell AJ, 2002, OPHTHALMOLOGE, V99, P780, DOI 10.1007/s00347-002-0614-0
   GORDON BR, 1992, AM J CARDIOL, V70, P1010, DOI 10.1016/0002-9149(92)90352-Y
   Gordon BR, 1998, AM J CARDIOL, V81, P407, DOI 10.1016/S0002-9149(97)00947-8
   Haas A., 1994, Ophthalmologe, V91, P283
   Hasegawa M, 2003, THER APHER DIAL, V7, P435, DOI 10.1046/j.1526-0968.2003.00081.x
   HENNERICI M, 1991, STROKE, V22, P989, DOI 10.1161/01.STR.22.8.989
   Hoffmann U, 2003, AM J CARDIOL, V91, P461, DOI 10.1016/S0002-9149(02)03248-4
   ILLINGWORTH DR, 1988, DRUGS, V36, P63, DOI 10.2165/00003495-198800363-00015
   Illingworth R, 2000, MED CLIN N AM, V84, P23, DOI 10.1016/S0025-7125(05)70205-4
   Jaeger BR, 2002, THER APHER, V6, P394, DOI 10.1046/j.1526-0968.2002.00427.x
   Kobayashi S, 2003, J CLIN APHERESIS, V18, P115, DOI 10.1002/jca.10055
   Koga N, 1999, J INTERN MED, V246, P35, DOI 10.1046/j.1365-2796.1999.00466.x
   Kroon AA, 1996, CIRCULATION, V93, P1826, DOI 10.1161/01.CIR.93.10.1826
   Kroon AA, 1996, ANN INTERN MED, V125, P945, DOI 10.7326/0003-4819-125-12-199612150-00001
   Kutsumi Y, 1998, ASAIO J, V44, pM666, DOI 10.1097/00002480-199809000-00073
   LANE DM, 1995, AM J CARDIOL, V75, P1124, DOI 10.1016/S0002-9149(99)80743-7
   LANE DM, 1995, ATHEROSCLEROSIS, V114, P203, DOI 10.1016/0021-9150(94)05484-Z
   Lechner H, 1998, NEUROEPIDEMIOLOGY, V17, P10, DOI 10.1159/000026148
   Leitinger N, 1996, ATHEROSCLEROSIS, V126, P305, DOI 10.1016/0021-9150(96)05919-9
   Mabuchi H, 1998, AM J CARDIOL, V82, P1489, DOI 10.1016/S0002-9149(98)00692-4
   Matsuzaki M, 2002, J AM COLL CARDIOL, V40, P220, DOI 10.1016/S0735-1097(02)01955-1
   Mellwig KP, 1998, ATHEROSCLEROSIS, V139, P173, DOI 10.1016/S0021-9150(98)00055-0
   Moriarty PM, 2001, ATHEROSCLEROSIS, V158, P495, DOI 10.1016/S0021-9150(01)00633-5
   Muso E, 1999, KIDNEY INT, V56, pS122, DOI 10.1046/j.1523-1755.1999.07130.x
   Nishimura S, 1999, ATHEROSCLEROSIS, V144, P409, DOI 10.1016/S0021-9150(98)00328-1
   Park JW, 1997, J HEART LUNG TRANSPL, V16, P290
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Richter WO, 1998, METABOLISM, V47, P863, DOI 10.1016/S0026-0495(98)90127-5
   Sato Y, 1996, ARTIF ORGANS, V20, P324, DOI 10.1111/j.1525-1594.1996.tb04452.x
   Schuff-Werner P., 2003, Zeitschrift fuer Kardiologie, V92, P28
   SCHUFFWERNER, 1997, JPN J APHERESIS, V16, P25
   SCHUFFWERNER P, 1994, EUR J CLIN INVEST, V24, P724, DOI 10.1111/j.1365-2362.1994.tb01068.x
   SEIDEL D, 1991, EUR J CLIN INVEST, V21, P375, DOI 10.1111/j.1365-2362.1991.tb01384.x
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Stadler RW, 1997, ATHEROSCLEROSIS, V128, P241, DOI 10.1016/S0021-9150(96)05998-9
   Suckfull M, 2002, LANCET, V360, P1811, DOI 10.1016/S0140-6736(02)11768-5
   Tamai O, 1997, CIRCULATION, V95, P76, DOI 10.1161/01.CIR.95.1.76
   Thiery J, 1998, CURR OPIN LIPIDOL, V9, P521, DOI 10.1097/00041433-199812000-00002
   THOMPSON GR, 1975, LANCET, V1, P1208
   THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003
   WALZL M, 1993, STROKE, V24, P1447, DOI 10.1161/01.STR.24.10.1447
   WALZL M, 1993, HAEMOSTASIS, V23, P192
   YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836
   Yokoyama K, 1998, CLIN NEPHROL, V50, P1
NR 50
TC 56
Z9 67
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD NOV
PY 2006
VL 189
IS 1
BP 31
EP 38
DI 10.1016/j.atherosclerosis.2006.02.030
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 097SD
UT WOS:000241467900004
PM 16546196
DA 2022-11-30
ER

PT J
AU Ulrich, JN
   Poudyal, G
   Marks, SJ
   Vrabec, TR
   Marks, B
   Thapa, ABS
   Shresta, MK
   Ruit, S
   Federman, JL
AF Ulrich, J. N.
   Poudyal, G.
   Marks, S. J.
   Vrabec, T. R.
   Marks, B.
   Thapa, A. B. S.
   Shresta, M. K.
   Ruit, S.
   Federman, J. L.
TI Ocular telemedicine between Nepal and the USA: prevalence of
   vitreoretinal disease in rural Nepal
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; DIABETIC-RETINOPATHY; EYE DISEASES; POPULATION;
   PREMATURITY; FEASIBILITY; DIAGNOSIS; BLINDNESS; INDIA
AB This study is aimed at reporting experiences with telemedicine between Nepal and the USA and at reporting the prevalence of age-related macular degeneration (AMD) and diabetic retinopathy (DR) in rural Nepal. AMD and DR are becoming more significant factors for non-reversible vision loss in rural Nepal due to increasing life expectancy and urbanisation. The prevalence of DM is low compared with the developed world, but the percentage of diabetics with DR is high, presumably due to limited access to healthcare. The higher prevalence of DM in Hetauda is explained as being due to a more urban lifestyle, dietary habits (more deep-fried food) and more advanced age.
C1 [Ulrich, J. N.] Geisinger Med Ctr, Dept Ophthalmol, Danville, PA 17822 USA.
   [Poudyal, G.; Thapa, A. B. S.; Shresta, M. K.; Ruit, S.] Tilganga Eye Ctr, Kathmandu, Nepal.
   [Vrabec, T. R.; Federman, J. L.] Henry & Corrine Bower Lab, Philadelphia, PA USA.
C3 Geisinger Medical Center
RP Ulrich, JN (通讯作者)，Geisinger Med Ctr, Dept Ophthalmol, 100 N Acad Ave, Danville, PA 17822 USA.
EM npilic@web.de
CR Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chiang MF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1531, DOI 10.1001/archopht.125.11.1531
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Dunzhu S, 2003, BRIT J OPHTHALMOL, V87, P1443, DOI 10.1136/bjo.87.12.1443
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Kennedy C, 2001, J TELEMED TELECARE, V7, pS20
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Linkous JD, 2004, TELEMED J E-HEALTH, V10, P469, DOI 10.1089/tmj.2004.10.469
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Qaddoumi I, 2008, PEDIATR BLOOD CANCER, V51, P241, DOI 10.1002/pbc.21489
   Scott KE, 2008, OPHTHALMOLOGY, V115, P1222, DOI 10.1016/j.ophtha.2007.09.006
   Shrestha M K, 2007, Nepal Med Coll J, V9, P225
   Skalet AH, 2008, J AAPOS, V12, P252, DOI 10.1016/j.jaapos.2007.11.009
   Taylor CR, 2007, DIABETES CARE, V30, P574, DOI 10.2337/dc06-1509
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 16
TC 11
Z9 11
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2009
VL 93
IS 5
BP 698
EP 699
DI 10.1136/bjo.2008.151357
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438BE
UT WOS:000265530100031
PM 19395632
DA 2022-11-30
ER

PT J
AU Nawrocka, ZA
   Nawrocka, Z
   Nawrocki, J
AF Nawrocka, Zofia Anna
   Nawrocka, Zofia
   Nawrocki, Jerzy
TI Vitrectomy for full thickness macular hole developed during the course
   of anti-VEGF treatment of type 1 neovascular AMD
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE AMD; CNV; inverted ILM flap technique; macular hole; neovascular age
   related macular degeneration
ID MEMBRANE FLAP TECHNIQUE; INJECTION
AB Purpose: To report a case of treatment of a full-thickness macular hole, which appeared after 10 months of anti-VEGF treatment in neovascular age related macular degeneration (nAMD). Methods: The patient was diagnosed as type 1 nAMD. The coexisting vitreomacular traction caused a full thickness macular hole after 10 months of treatment. Patients: A 68-year-old woman treated with anti VEGF. Results: Vitrectomy with the temporal inverted ILM flap technique succeeded in closing the hole. Further anti-VEGF treatment followed. Conclusion: FTMH is a rare complication or coexistence in nAMD. Vitrectomy and continuous anti-VEGF treatment might result in satisfactory anatomical and functional results.
C1 [Nawrocka, Zofia Anna; Nawrocka, Zofia; Nawrocki, Jerzy] Ophthalm Clin Jasne Blonia, Rojna 90, PL-91162 Lodz, Poland.
RP Nawrocka, ZA (通讯作者)，Ophthalm Clin Jasne Blonia, Rojna 90, PL-91162 Lodz, Poland.
EM zosia_n@yahoo.com
OI Nawrocka, Zofia Anna/0000-0001-8376-9218
CR Iacono P, 2018, RETINA-J RET VIT DIS, V38, P84, DOI 10.1097/IAE.0000000000001500
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1503, DOI 10.1097/IAE.0b013e31829232fd
   Michalewska Z, 2021, EUR J OPHTHALMOL, V31, P1320, DOI 10.1177/1120672120921376
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P1844, DOI 10.1097/IAE.0000000000000555
   Michalewska Z, 2014, RETINA-J RET VIT DIS, V34, P664, DOI 10.1097/IAE.0000000000000042
   Moisseiev E, 2010, CASE REP OPHTHALM, V1, P36, DOI 10.1159/000319827
   Okamoto T, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-114
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Yun C, 2016, INT J OPHTHALMOL-CHI, V9, P1364, DOI 10.18240/ijo.2016.09.24
NR 9
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2022
VL 32
IS 5
BP NP5
EP NP8
AR 11206721211002123
DI 10.1177/11206721211002123
EA MAR 2021
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3S5GW
UT WOS:000678265900001
PM 33740870
DA 2022-11-30
ER

PT J
AU Jiang, JJ
   Zhang, XR
   Tang, Y
   Li, SH
   Chen, J
AF Jiang, Jinjin
   Zhang, Xinru
   Tang, Yue
   Li, Shuhan
   Chen, Jing
TI Progress on ocular siRNA gene-silencing therapy and drug delivery
   systems
SO FUNDAMENTAL & CLINICAL PHARMACOLOGY
LA English
DT Review
DE age-related macular degeneration; glaucoma; RNA interference technology;
   siRNA drugs; non-viral vectors
ID ENDOTHELIAL GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; VEGF SIRNA;
   POSTERIOR SEGMENT; POLYETHYLENIMINE NANOPARTICLES; INTRAVITREAL
   INJECTION; MACULAR DEGENERATION; NONVIRAL VECTORS; RNA INTERFERENCE;
   CLINICAL-TRIAL
AB Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs.
C1 [Jiang, Jinjin; Zhang, Xinru; Tang, Yue] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China.
   [Jiang, Jinjin; Zhang, Xinru; Tang, Yue; Li, Shuhan; Chen, Jing] China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China.
C3 Guizhou Medical University; China Pharmaceutical University
RP Tang, Y (通讯作者)，Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, 1 DongQing Rd, Guiyang 550014, Peoples R China.; Tang, Y (通讯作者)，China Pharmaceut Univ, Dept Pharm, 639 Longmian Ave, Nanjing 211198, Peoples R China.
EM tangyue@cpu.edu.cn
RI zhang, xinru/GZK-8155-2022
FU Open Project of State Key Laboratory of Functions and Applications of
   Medicinal Plants of Guizhou Medicinal University [FAMP201805K]; Guizhou
   Science and Technology Platform Talents [[2017] 5101]
FX This work was funded by the Open Project of State Key Laboratory of
   Functions and Applications of Medicinal Plants of Guizhou Medicinal
   University (FAMP201805K) and Guizhou Science and Technology Platform
   Talents ([2017] 5101).
CR Ahmed Z, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.54
   Aleku M, 2008, CANCER RES, V68, P9788, DOI 10.1158/0008-5472.CAN-08-2428
   Solinis MA, 2015, EUR J PHARM BIOPHARM, V95, P331, DOI 10.1016/j.ejpb.2014.12.022
   Arranz-Romera A., 2018, J CONTROL RELEASE, V2019, P26
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Behar-Cohen F, 2012, THER DELIV, V3, P1135, DOI 10.4155/TDE.12.94
   Bloquel C, 2006, ADV DRUG DELIVER REV, V58, P1224, DOI 10.1016/j.addr.2006.07.023
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   BURNS E, 1992, AGE AGEING, V21, P168, DOI 10.1093/ageing/21.3.168
   Cai XJ, 2017, ACS APPL MATER INTER, V9, P9402, DOI 10.1021/acsami.6b16689
   Chang JN, 2010, HANDBOOK OF NON-INVASIVE DRUG DELIVERY SYSTEMS: NON-INVASIVE AND MINIMALLY-INVASIVE DRUG DELIVERY SYSTEMS FOR PHARMACEUTICAL AND PERSONAL CARE PRODUCTS, P165, DOI 10.1016/B978-0-8155-2025-2.10007-1
   Chaplot SP, 2014, J PHARM PHARMACOL, V66, P542, DOI 10.1111/jphp.12104
   Chen J, 2015, CHINESE J POLYM SCI, V33, P830, DOI 10.1007/s10118-015-1632-0
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Ciolino JB, 2009, SEMIN OPHTHALMOL, V24, P156, DOI 10.1080/08820530902802161
   Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760
   Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200
   Cunha-Vaz JG, 1997, DOC OPHTHALMOL, V93, P149, DOI 10.1007/BF02569055
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   Dejneka NS, 2008, MOL VIS, V14, P997
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Deng JJ, 2011, J MATER CHEM, V21, P5273, DOI 10.1039/c0jm03030a
   Dillinger AE, 2018, SMALL, V14, DOI 10.1002/smll.201803239
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   ELENA PP, 1990, J OCUL PHARMACOL, V6, P143, DOI 10.1089/jop.1990.6.143
   Eljarrat-Binstock E, 2010, PHARM RES-DORDR, V27, P530, DOI 10.1007/s11095-009-0042-9
   Farra R, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100547
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Foldvari M, 2016, J CONTROL RELEASE, V240, P165, DOI 10.1016/j.jconrel.2015.12.012
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Glaucoma C.J., 2013, INVESTIG OPHTHALMOL, V54
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gonzalez V, 2016, INVEST OPHTH VIS SCI, V57
   Gonzalez-Duarte A, 2020, J NEUROL, V267, P703, DOI 10.1007/s00415-019-09602-8
   Han H, 2016, MACROMOL BIOSCI, V16, P1583, DOI 10.1002/mabi.201600051
   Hanurry EY, 2020, MAT SCI ENG C-MATER, V106, DOI 10.1016/j.msec.2019.110245
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hsu KH, 2014, J DRUG DELIV SCI TEC, V24, P123, DOI 10.1016/S1773-2247(14)50021-4
   Huang XN, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107711
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kaji H, 2018, ADV DRUG DELIVER REV, V128, P148, DOI 10.1016/j.addr.2017.07.002
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim MG, 2017, BIOCHEM BIOPH RES CO, V489, P35, DOI 10.1016/j.bbrc.2017.05.103
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kowalczuk L, 2011, ULTRASOUND MED BIOL, V37, P1814, DOI 10.1016/j.ultrasmedbio.2011.07.010
   Kozielski KL, 2013, WIRES NANOMED NANOBI, V5, P449, DOI 10.1002/wnan.1233
   Kristen AV, 2019, NEURODEGENER DIS MAN, V9, P5, DOI 10.2217/nmt-2018-0033
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lee YW, 2018, J MICROBIOL BIOTECHN, V28, P367, DOI 10.4014/jmb.1711.11025
   Levin LA, 2007, CAN J OPHTHALMOL, V42, P403, DOI 10.3129/i07-046
   Li Z., 2011, PLOS ONE, DOI [10.1371/journal.pone.0026103, DOI 10.1371/JOURNAL.PONE.0026103]
   Lim YB, 2000, PHARMACEUT RES, V17, P811, DOI 10.1023/A:1007552007765
   Liu PF, 2012, BIOMATERIALS, V33, P4403, DOI 10.1016/j.biomaterials.2012.02.041
   Liu XX, 2012, NEW J CHEM, V36, P256, DOI 10.1039/c1nj20408d
   Loftsson T, 2017, INT J PHARMACEUT, V531, P413, DOI 10.1016/j.ijpharm.2017.04.010
   Madni A, 2017, INT J PHARMACEUT, V530, P326, DOI 10.1016/j.ijpharm.2017.07.065
   Mahnama A, 2014, CURR DRUG DELIV, V11, P123, DOI 10.2174/156720181101140212165729
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Martinez T, 2014, MOL THER, V22, P81, DOI 10.1038/mt.2013.216
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217
   Vicentini FTMD, 2013, PHARM RES-DORDR, V30, P915, DOI 10.1007/s11095-013-0971-1
   Mullin LB, 2013, IEEE T ULTRASON FERR, V60, P65, DOI 10.1109/TUFFC.2013.2538
   Murata N, 2008, J CONTROL RELEASE, V126, P246, DOI 10.1016/j.jconrel.2007.11.017
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nimesh S, 2009, EUR J PHARM BIOPHARM, V73, P43, DOI 10.1016/j.ejpb.2009.04.001
   Oliveira AV, 2017, MAT SCI ENG C-MATER, V77, P1275, DOI 10.1016/j.msec.2017.04.068
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Peng Q, 2009, BIOCONJUGATE CHEM, V20, P340, DOI 10.1021/bc800451j
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Peynshaert K, 2019, CURR EYE RES, V44, P465, DOI 10.1080/02713683.2019.1565890
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Pittella F, 2012, J CONTROL RELEASE, V161, P868, DOI 10.1016/j.jconrel.2012.05.005
   Puras G, 2013, EUR J PHARM SCI, V48, P323, DOI 10.1016/j.ejps.2012.11.009
   Qin YM, 2018, J PHARM PHARMACOL, V70, P1139, DOI 10.1111/jphp.12940
   Rittenhouse K.D., 2013, INVESTIG OPHTHALMOL, V55, P1232
   Villanueva JR, 2016, INT J PHARMACEUT, V511, P359, DOI 10.1016/j.ijpharm.2016.07.031
   Rupenthal ID, 2016, DRUG DELIV TRANSL RE, V6, P631, DOI 10.1007/s13346-016-0335-6
   Ruz V, 2014, INVEST OPHTH VIS SCI, V55
   Ryoo NK, 2017, NANOSCALE, V9, P15461, DOI 10.1039/c7nr03142d
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Schultheis B, 2014, J CLIN ONCOL, V32, P4141, DOI 10.1200/JCO.2013.55.0376
   Sepahvandi A, 2016, BIONANOSCIENCE, V6, P276, DOI 10.1007/s12668-016-0219-8
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002
   Singerman L., 2009, RETINA SUPPL, V29, P49
   Solano ECR, 2014, NUCLEIC ACID THER, V24, P258, DOI 10.1089/nat.2014.0489
   Souza JG, 2014, J PHARM PHARMACOL, V66, P507, DOI 10.1111/jphp.12132
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   St George JA, 2003, GENE THER, V10, P1135, DOI 10.1038/sj.gt.3302071
   Subrizi A, 2019, DRUG DISCOV TODAY, V24, P1446, DOI 10.1016/j.drudis.2019.02.001
   Suhr OB, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0326-6
   Tamboli V, 2011, THER DELIV, V2, P523, DOI [10.4155/TDE.11.20, 10.4155/tde.11.20]
   Titze-de-Almeida R, 2017, PHARM RES-DORDR, V34, P1339, DOI 10.1007/s11095-017-2134-2
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   TROPE GE, 1982, BRIT J OPHTHALMOL, V66, P788, DOI 10.1136/bjo.66.12.788
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Wang HJ, 2010, BIOMATERIALS, V31, P8741, DOI 10.1016/j.biomaterials.2010.07.082
   Watanabe K, 2009, MOL BIOSYST, V5, P1306, DOI 10.1039/b900880b
   WAX MB, 1987, INVEST OPHTH VIS SCI, V28, P420
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Weng YH, 2019, BIOTECHNOL ADV, V37, P801, DOI 10.1016/j.biotechadv.2019.04.012
   Xia JL, 2011, MACROMOL BIOSCI, V11, P211, DOI 10.1002/mabi.201000302
   Xing YF, 2013, SCI WORLD J, DOI [10.1155/2013/381219, 10.1155/2013/630654]
   Zhang XP, 2020, J CLIN PHARMACOL, V60, P37, DOI 10.1002/jcph.1480
NR 127
TC 22
Z9 26
U1 5
U2 46
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0767-3981
EI 1472-8206
J9 FUND CLIN PHARMACOL
JI Fundam. Clin. Pharmacol.
PD FEB
PY 2021
VL 35
IS 1
BP 4
EP 24
DI 10.1111/fcp.12561
EA MAY 2020
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QD2NY
UT WOS:000530917700001
PM 32298491
DA 2022-11-30
ER

PT J
AU Ikeuchi, T
   Kanan, Y
   Long, D
   de Vega, S
   Hozumi, K
   Nomizu, M
   Campochiaro, PA
   Yamada, Y
AF Ikeuchi, Tomoko
   Kanan, Yogita
   Long, Da
   de Vega, Susana
   Hozumi, Kentaro
   Nomizu, Motoyoshi
   Campochiaro, Peter A.
   Yamada, Yoshihiko
TI Fibulin-7 C-terminal fragment and its active synthetic peptide suppress
   choroidal and retinal neovascularization
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Fibulin-7; Angiogenesis; AMD; Retinopathy; ECM; Peptides
ID OXYGEN-INDUCED RETINOPATHY; MACULAR DEGENERATION; TUBE FORMATION; MODEL;
   RANIBIZUMAB; INHIBITION; INTERACTS; MATRIX; MOUSE; GENE
AB Wet age-related macular degeneration (AMD) and diabetic retinopathy are the leading causes of blindness through increased angiogenesis. Although VEGF-neutralizing proteins provide benefit, inconsistent responses indicate a need for new therapies. We previously identified the Fibulin-7 C-terminal fragment (Fbln7-C) as an angiogenesis inhibitor in vitro. Here we show that Fbln7-C inhibits neovascularization in vivo, in both a model of wet AMD involving choroidal neovascularization (CNV) and diabetic retinopathy involving oxygen-induced ischemic retinopathy. Furthermore, a short peptide sequence from Fbln7-C is responsible for the anti-angiogenic properties of Fbln7-C. Our work suggests Fbln7-C as a therapeutic candidate for wet AMD and ischemic retinopathy.
C1 [Ikeuchi, Tomoko; Yamada, Yoshihiko] Natl Inst Dent & Craniofacial Res, Mol Biol Sect, NIH, Bethesda, MD 20892 USA.
   [Kanan, Yogita; Long, Da; Campochiaro, Peter A.] Johns Hopkins Univ, Dept Ophthalmol, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Dept Neurosci, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [de Vega, Susana] Juntendo Univ, Dept Pathophysiol Locomot & Neoplast Dis, Grad Sch Med, Tokyo 1138421, Japan.
   [Hozumi, Kentaro; Nomizu, Motoyoshi] Tokyo Univ Pharm & Life Sci, Dept Pharm, Lab Clin Biochem, Hachioji, Tokyo 1920392, Japan.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Dental & Craniofacial Research (NIDCR); Johns Hopkins University; Johns
   Hopkins University; Juntendo University; Tokyo University of Pharmacy &
   Life Sciences
RP Ikeuchi, T; Yamada, Y (通讯作者)，NIDCR, NIH, Bldg 30,Rm 432,30 Convent Dr, Bethesda, MD 20814 USA.
EM tomoko.ikeuchi@nih.gov; yoshi.yamada@nih.gov
RI de Vega, Susana/AAH-4775-2020
FU Intramural Research Program of National Institute of Dental and
   Craniofacial Research; National Eye Institute [R01EB016121]; Japan
   Society for the Promotion of Science for Young Investigators [714175,
   26.04914]
FX This work was supported in part by the Intramural Research Program of
   National Institute of Dental and Craniofacial Research (Y.Y.), by the
   National Eye Institute R01EB016121 (P.A.C.) and by the Japan Society for
   the Promotion of Science for Young Investigators 714175 (T.I.) and
   26.04914 (S.V.).
CR Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   de Vega S, 2007, J BIOL CHEM, V282, P30878, DOI 10.1074/jbc.M705847200
   de Vega S, 2016, BIOPOLYMERS, V106, P184, DOI 10.1002/bip.22754
   de Vega S, 2014, ARCH BIOCHEM BIOPHYS, V545, P148, DOI 10.1016/j.abb.2014.01.013
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Hinderer S, 2016, ADV DRUG DELIVER REV, V97, P260, DOI 10.1016/j.addr.2015.11.019
   Hozumi K, 2009, BIOCHEMISTRY-US, V48, P5375, DOI 10.1021/bi900542u
   Ikeuchi T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36182-w
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Katagiri F, 2014, BIOCHEMISTRY-US, V53, P3699, DOI 10.1021/bi5003822
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95530
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
NR 25
TC 2
Z9 2
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2020
VL 129
AR 103986
DI 10.1016/j.mvr.2020.103986
PG 7
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA LG2BX
UT WOS:000527914000011
PM 32017943
DA 2022-11-30
ER

PT J
AU Azuma, S
   Makita, S
   Kasaragod, D
   Sugiyama, S
   Miura, M
   Yasuno, Y
AF Azuma, Shinnosuke
   Makita, Shuichi
   Kasaragod, Deepa
   Sugiyama, Satoshi
   Miura, Masahiro
   Yasuno, Yoshiaki
TI Clinical multi-functional OCT for retinal imaging
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; NERVE-FIBER LAYER; SUBRETINAL
   HYPERREFLECTIVE MATERIAL; POLARIZATION-SENSITIVE OCT; JONES-MATRIX;
   IN-VIVO; MACULAR DEGENERATION; POSTERIOR EYE; VARIANCE ALGORITHM;
   CHOROIDAL MELANIN
AB A compact clinical prototype multi-functional optical coherence tomography (OCT) device for the posterior human eye has been developed. This compact Jones-matrix OCT (JM-OCT) device integrates all components into a single package. Multiple image functions, i.e., scattering intensity, OCT angiography, and the degree of polarization uniformity, are obtained. The device has the capability for measuring local birefringence. Multi-functional imaging of several eyes with age-related macular degeneration is demonstrated. The compact JM-OCT device will be useful for the in vivo non-invasive investigation of abnormal tissues. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Azuma, Shinnosuke; Makita, Shuichi; Kasaragod, Deepa; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.
   [Sugiyama, Satoshi] Tomey Corp, Nagoya, Aichi 4510051, Japan.
   [Miura, Masahiro] Tokyo Med Univ, Ibaraki Med Ctr, 3-20-1 Chuo, Ami, Ibaraki 3000395, Japan.
   [Azuma, Shinnosuke; Makita, Shuichi; Kasaragod, Deepa; Miura, Masahiro; Yasuno, Yoshiaki] Computat Opt & Ophthalmol Grp, Tsukuba, Ibaraki 3058531, Japan.
C3 University of Tsukuba; Tokyo Medical University
RP Yasuno, Y (通讯作者)，Univ Tsukuba, Computat Opt Grp, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058573, Japan.; Yasuno, Y (通讯作者)，Computat Opt & Ophthalmol Grp, Tsukuba, Ibaraki 3058531, Japan.
EM yasuno@optlab2.bk.tsukuba.ac.jp
RI Makita, Shuichi/G-3806-2011; Yasuno, Yoshiaki/F-2586-2011
OI Makita, Shuichi/0000-0002-6614-3640; Yasuno,
   Yoshiaki/0000-0003-1645-7948
FU Japan Society for the Promotion of Science [15K13371]; Japan Science and
   Technology Agency [JPMJMI18G8]; Program for building Regional Innovation
   Ecosystems of Ministry of Education, Culture, Sports, Science and
   Technology
FX Japan Society for the Promotion of Science (15K13371); Japan Science and
   Technology Agency (JPMJMI18G8); Program for building Regional Innovation
   Ecosystems of Ministry of Education, Culture, Sports, Science and
   Technology.
CR American National Standards Institute, 2014, AM NAT STAND SAF US
   Azuma S, 2018, BIOMED OPT EXPRESS, V9, P2955, DOI 10.1364/BOE.9.002955
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2012, OPT EXPRESS, V20, DOI 10.1364/OE.20.010229
   Beer F, 2018, INVEST OPHTH VIS SCI, V59, P5579, DOI 10.1167/iovs.18-25311
   Braaf B, 2014, BIOMED OPT EXPRESS, V5, P2736, DOI 10.1364/BOE.5.002736
   Cense B, 2004, INVEST OPHTH VIS SCI, V45, P2606, DOI 10.1167/iovs.03-1160
   Cense B, 2002, OPT LETT, V27, P1610, DOI 10.1364/OL.27.001610
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   de Boer JF, 1999, OPT LETT, V24, P300, DOI 10.1364/OL.24.000300
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   Fan CM, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.110501
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Fukuda S, 2014, INVEST OPHTH VIS SCI, V55, P5200, DOI 10.1167/iovs.14-14474
   Gotzinger E, 2008, J BIOPHOTONICS, V1, P129, DOI 10.1002/jbio.200710009
   Hitzenberger CK, 2001, OPT EXPRESS, V9, P780, DOI 10.1364/OE.9.000780
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jiao SL, 2002, J BIOMED OPT, V7, P350, DOI 10.1117/1.1483878
   Ju MJ, 2013, OPT EXPRESS, V21, P19412, DOI 10.1364/OE.21.019412
   Kasaragod D, 2017, BIOMED OPT EXPRESS, V8, P653, DOI 10.1364/BOE.8.000653
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Li E, 2017, BIOMED OPT EXPRESS, V8, P1290, DOI 10.1364/BOE.8.001290
   Li QY, 2018, BIOMED OPT EXPRESS, V9, P5437, DOI 10.1364/BOE.9.005437
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lim Y, 2012, OPT LETT, V37, P1958, DOI 10.1364/OL.37.001958
   Lippok N, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800156
   Lippok N, 2015, OPT LETT, V40, P3954, DOI 10.1364/OL.40.003954
   Liu GJ, 2011, OPT EXPRESS, V19, P11429, DOI 10.1364/OE.19.011429
   Makita S, 2008, OPT EXPRESS, V16, P8406, DOI 10.1364/OE.16.008406
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Makita S, 2018, BIOMED OPT EXPRESS, V9, P4372, DOI 10.1364/BOE.9.004372
   Makita S, 2016, BIOMED OPT EXPRESS, V7, P1525, DOI 10.1364/BOE.7.001525
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Makita S, 2010, OPT EXPRESS, V18, P854, DOI 10.1364/OE.18.000854
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39688-z
   Miura M, 2017, INVEST OPHTH VIS SCI, V58, P4467, DOI 10.1167/iovs.17-22117
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Miura M, 2015, AM J OPHTHALMOL, V159, P528, DOI 10.1016/j.ajo.2014.12.002
   Moon S, 2010, OPT EXPRESS, V18, P24395, DOI 10.1364/OE.18.024395
   Nam AS, 2014, BIOMED OPT EXPRESS, V5, P3822, DOI 10.1364/BOE.5.003822
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Park BH, 2004, OPT LETT, V29, P2512, DOI 10.1364/OL.29.002512
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sugiyama S, 2015, BIOMED OPT EXPRESS, V6, P4951, DOI 10.1364/BOE.6.004951
   Takaya M., 2018, PCT Patent, Patent No. [WO2018225554(A1), 2018225554]
   Thevenaz P, 2007, MICROSC RES TECHNIQ, V70, P135, DOI 10.1002/jemt.20393
   Villiger M, 2018, OPTICA, V5, P1329, DOI 10.1364/OPTICA.5.001329
   Villiger M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28771
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Yamanari M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2841024
   Yamanari M, 2016, BIOMED OPT EXPRESS, V7, P3551, DOI 10.1364/BOE.7.003551
   Yamanari M, 2015, BIOMED OPT EXPRESS, V6, P369, DOI 10.1364/BOE.6.000369
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Yasuno Y, 2009, OPT EXPRESS, V17, P3980, DOI 10.1364/OE.17.003980
   Zotter S, 2013, INVEST OPHTH VIS SCI, V54, P72, DOI 10.1167/iovs.12-10089
NR 74
TC 4
Z9 4
U1 1
U2 3
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD NOV 1
PY 2019
VL 10
IS 11
BP 5724
EP 5743
DI 10.1364/BOE.10.005724
PG 20
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA JJ2MZ
UT WOS:000493997700020
PM 31799043
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Amoaku, WMK
AF Amoaku, W. M. K.
TI The Royal College of Ophthalmologists interim recommendations for the
   management of patients with age-related macular degeneration
SO EYE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   ENDOTHELIAL GROWTH-FACTOR; ARGON-LASER PHOTOCOAGULATION; PHOTODYNAMIC
   THERAPY; VERTEPORFIN; MACULOPATHY; RANIBIZUMAB; EYE; PREVALENCE
C1 Queens Med Ctr, Univ Hosp, Dept Ophthalmol & Visual Sci, Nottingham NG7 2UH, England.
C3 Nottingham University Hospital NHS Trust; University of Nottingham
RP Amoaku, WMK (通讯作者)，Queens Med Ctr, Univ Hosp, Dept Ophthalmol & Visual Sci, Clifton Blvd,Derby Rd, Nottingham NG7 2UH, England.
EM Wma@nottingham.ac.uk
OI Amoaku, Winfried/0000-0001-5028-7984
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHANG LK, 2006, INVEST OPHTHALMOL VI, V47
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   EVANS J, 1995, CAUSES BLINDNESS PAR
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MILLER JW, 2006, INVEST OPHTHALMOL VI, V47
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHMIDTERFURTH UM, 2006, INVEST OPHTHALMOL VI, V47
   STEFFENSMEIER AC, 2006, INVEST OPHTHALMOL VI, V47
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
NR 27
TC 11
Z9 12
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 864
EP 868
DI 10.1038/eye.2008.1
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800026
OA Bronze
DA 2022-11-30
ER

PT J
AU Awuah, SG
   You, Y
AF Awuah, Samuel G.
   You, Youngjae
TI Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic
   therapy
SO RSC ADVANCES
LA English
DT Review
ID SINGLET OXYGEN GENERATION; FLUORESCENT BODIPY DYES; GRAM-NEGATIVE
   BACTERIA; IMAGE-GUIDED SURGERY; IN-VITRO; NONPORPHYRIN PHOTOSENSITIZERS;
   DISTYRYL-BORADIAZAINDACENES; EFFICIENT PHOTOSENSITIZERS; ENDOSCOPIC
   DETECTION; PHOTO-INACTIVATION
AB Photodynamic therapy (PDT) has shown promise as an effective treatment modality for cancers and other localized diseases, such as age-related macular degeneration and actinic keratosis. PDT relies on light, photosensitizer and oxygen as elements in its mechanism of action. BODIPY photosensitizers that have been under extensive study over the past decade have been demonstrated as a new class of photosensitizers. In this review, we attempt to summarize the decade-long study of BODIPY-based photosensitizers. We provide an overview of the superior photophysical properties possessed by BODIPY-based agents and the various synthetic strategies employed that have led to improved and selective and/or targeted photosensitizers.
C1 [Awuah, Samuel G.; You, Youngjae] Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, Oklahoma City, OK 73117 USA.
   [Awuah, Samuel G.; You, Youngjae] Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma - Norman
RP Awuah, SG (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Pharmaceut Sci, Oklahoma City, OK 73117 USA.
EM youngjae-you@ouhsc.edu
RI You, Youngjae/T-2516-2019; You, Youngjae/F-7320-2010
OI You, Youngjae/0000-0003-0835-464X
FU Oklahoma Center for the Advancement of Science and Technology (OCAST)
FX We acknowledge the Oklahoma Center for the Advancement of Science and
   Technology (OCAST) for financial support and ChemAxon for free access to
   Instant JChem used in compiling the BODIPY database found in the ESI.
CR Adarsh N, 2011, ORG LETT, V13, P2146, DOI 10.1021/ol200572p
   Adarsh N, 2010, ORG LETT, V12, P5720, DOI 10.1021/ol102562k
   Akilov OE, 2006, CHEM BIOL, V13, P839, DOI 10.1016/j.chembiol.2006.06.008
   Allison RR, 2004, PHOTODIAGN PHOTODYN, V1, P27, DOI 10.1016/S1572-1000(04)00007-9
   Amin AN, 2012, CHEM COMMUN, V48, P206, DOI 10.1039/c1cc16071k
   Amir RJ, 2005, ANGEW CHEM INT EDIT, V44, P4378, DOI 10.1002/anie.200500842
   [Anonymous], HDB GUIDE FLUORERSCE
   [Anonymous], MODERN COLORANTS SYN
   Atilgan S, 2006, CHEM COMMUN, P4398, DOI 10.1039/b612347c
   AULER H., 1942, Z. Krebsforsck, V53, P65, DOI 10.1007/BF01792783
   Awuah S. G., 2011, ORG LETT
   Babilas P, 2010, PHOTODERMATOL PHOTO, V26, P118, DOI 10.1111/j.1600-0781.2010.00507.x
   Batat P, 2011, J PHYS CHEM A, V115, P14034, DOI 10.1021/jp2077775
   BERTOLONI G, 1990, FEMS MICROBIOL LETT, V71, P149
   Boens N, 2012, CHEM SOC REV, V41, P1130, DOI 10.1039/c1cs15132k
   BONNETT R, 1995, CHEM SOC REV, V24, P19, DOI 10.1039/cs9952400019
   Brancaleon L, 2002, LASER MED SCI, V17, P173, DOI 10.1007/s101030200027
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   Bullous AJ, 2011, PHOTOCH PHOTOBIO SCI, V10, P721, DOI 10.1039/c0pp00266f
   Busch TM, 2004, CLIN CANCER RES, V10, P4630, DOI 10.1158/1078-0432.CCR-04-0359
   Busch TM, 2002, CANCER RES, V62, P7273
   Buyukcakir O, 2009, ORG LETT, V11, P4644, DOI 10.1021/ol9019056
   Byrne AT, 2009, BRIT J CANCER, V101, P1565, DOI 10.1038/sj.bjc.6605247
   Cakmak Y, 2011, ANGEW CHEM INT EDIT, V50, P11937, DOI 10.1002/anie.201105736
   CAMERON IL, 1980, CANCER RES, V40, P1493
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   CHANDRA AK, 1978, J AM CHEM SOC, V100, P4964, DOI 10.1021/ja00484a007
   Chen B, 2006, CLIN CANCER RES, V12, P917, DOI 10.1158/1078-0432.CCR-05-1673
   Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10
   Chen J, 2000, J ORG CHEM, V65, P2900, DOI 10.1021/jo991927o
   Cihaner A, 2009, REACT FUNCT POLYM, V69, P62, DOI 10.1016/j.reactfunctpolym.2008.10.011
   Coskun A, 2005, ORG LETT, V7, P5187, DOI 10.1021/ol052020h
   Dai TH, 2010, LASER SURG MED, V42, P38, DOI 10.1002/lsm.20887
   De Silva AP, 2006, NAT MATER, V5, P787, DOI 10.1038/nmat1733
   DE SILVA AP, 1993, NATURE, V364, P42, DOI 10.1038/364042a0
   Deniz E, 2008, ORG LETT, V10, P3401, DOI 10.1021/ol801062h
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6
   Detty MR, 2004, J MED CHEM, V47, P3897, DOI 10.1021/jm040074b
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dosselli R, 2010, ACS MED CHEM LETT, V1, P35, DOI 10.1021/ml900021y
   Dost Z, 2006, TETRAHEDRON, V62, P8484, DOI 10.1016/j.tet.2006.06.082
   DOUGHERTY TJ, 1975, J NATL CANCER I, V55, P115, DOI 10.1093/jnci/55.1.115
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931
   Duman S, 2012, J ORG CHEM, V77, P4516, DOI 10.1021/jo300051v
   Eljamel MS, 2008, PHOTODIAGN PHOTODYN, V5, P260, DOI 10.1016/j.pdpdt.2008.11.003
   Erbas S, 2009, CHEM COMMUN, P4956, DOI 10.1039/b908485a
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   FOOTE CS, 1991, PHOTOCHEM PHOTOBIOL, V54, P659, DOI 10.1111/j.1751-1097.1991.tb02071.x
   Frimannsson DO, 2010, J MED CHEM, V53, P7337, DOI 10.1021/jm100585j
   Gallagher WM, 2005, BRIT J CANCER, V92, P1702, DOI 10.1038/sj.bjc.6602527
   Garrier J, 2011, PHOTODIAGN PHOTODYN, V8, P321, DOI 10.1016/j.pdpdt.2011.06.003
   Goeb S, 2007, ORG LETT, V9, P737, DOI 10.1021/ol0627404
   Gorman A, 2004, J AM CHEM SOC, V126, P10619, DOI 10.1021/ja047649e
   GOTTFRIED V, 1991, INT J RADIAT BIOL, V60, P349, DOI 10.1080/09553009114552121
   GOTTFRIED V, 1992, J PHOTOCH PHOTOBIO B, V12, P204, DOI 10.1016/1011-1344(92)85010-R
   Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940
   Hahn SM, 2006, CLIN CANCER RES, V12, P5464, DOI 10.1158/1078-0432.CCR-06-0953
   Hamblin MR, 2002, PHOTOCHEM PHOTOBIOL, V75, P51, DOI 10.1562/0031-8655(2002)075<0051:RCOWIB>2.0.CO;2
   Hamblin MR, 2001, CANCER RES, V61, P7155
   Han JY, 2009, ORG BIOMOL CHEM, V7, P34, DOI 10.1039/b818390b
   Hayashi Y, 2011, ORG LETT, V13, P2992, DOI 10.1021/ol200799u
   He H, 2011, J MED CHEM, V54, P3097, DOI 10.1021/jm101637g
   He H, 2011, CHEM COMMUN, V47, P4748, DOI 10.1039/c1cc10727e
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hoogendoorn S, 2011, ORG LETT, V13, P5656, DOI 10.1021/ol202379w
   Hoogendoorn S, 2011, CHEM COMMUN, V47, P9363, DOI 10.1039/c1cc12947c
   Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273
   Huang L, 2012, ORG LETT, V14, P2594, DOI 10.1021/ol3008843
   Jiao LJ, 2011, J ORG CHEM, V76, P9988, DOI 10.1021/jo201754m
   Jiao LJ, 2010, J ORG CHEM, V75, P6035, DOI 10.1021/jo101164a
   Jiao LJ, 2010, ORG BIOMOL CHEM, V8, P2517, DOI 10.1039/c001068e
   Josefsen LB, 2008, BRIT J PHARMACOL, V154, P1, DOI 10.1038/bjp.2008.98
   Juzenas P, 2002, PHOTOCH PHOTOBIO SCI, V1, P745, DOI 10.1039/b203459j
   Juzeniene A, 2007, PHOTOCH PHOTOBIO SCI, V6, P1234, DOI 10.1039/b705461k
   Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q
   KELLY JF, 1975, BRIT J CANCER, V31, P237, DOI 10.1038/bjc.1975.30
   KELLY JF, 1975, P ROY SOC MED, V68, P527, DOI 10.1177/003591577506800828
   Killoran J, 2002, CHEM COMMUN, P1862, DOI 10.1039/b204317c
   Kim S, 2009, J MATER CHEM, V19, P3181, DOI 10.1039/b813396d
   Kossodo S, 2001, Am J Cardiovasc Drugs, V1, P15, DOI 10.2165/00129784-200101010-00002
   KOZIAR JC, 1978, ACCOUNTS CHEM RES, V11, P334, DOI 10.1021/ar50129a003
   Kuimova MK, 2009, J AM CHEM SOC, V131, P332, DOI 10.1021/ja807484b
   Li X, 2012, ORG BIOMOL CHEM, V10, P2369, DOI 10.1039/c2ob07004a
   Li ZG, 2006, J ORG CHEM, V71, P1718, DOI 10.1021/jo052029x
   Lim SH, 2010, J MED CHEM, V53, P2865, DOI 10.1021/jm901823u
   LIPSON RL, 1961, J THORAC CARDIOV SUR, V42, P623, DOI 10.1016/S0022-5223(19)32560-7
   LIPSON RL, 1967, CANCER, V20, P2255, DOI 10.1002/1097-0142(196712)20:12<2255::AID-CNCR2820201229>3.0.CO;2-U
   LIPSON RL, 1964, DIS CHEST, V46, P676, DOI 10.1378/chest.46.6.676
   LIPSON RL, 1961, J NATL CANCER I, V26, P1
   LIPSON RL, 1960, ARCH DERMATOL, V82, P508, DOI 10.1001/archderm.1960.01580040026005
   Liu JY, 2009, CHEM COMMUN, P1517, DOI 10.1039/b821630d
   Loudet A, 2007, CHEM REV, V107, P4891, DOI 10.1021/cr078381n
   Lovell JF, 2010, CHEM REV, V110, P2839, DOI 10.1021/cr900236h
   LOWER SK, 1966, CHEM REV, V66, P199, DOI 10.1021/cr60240a004
   MacCormack MA, 2008, SEMIN CUTAN MED SURG, V27, P52, DOI 10.1016/j.sder.2007.12.001
   Maisch T, 2005, ANTIMICROB AGENTS CH, V49, P1542, DOI 10.1128/AAC.49.4.1542-1552.2005
   Maisch T, 2009, MINI-REV MED CHEM, V9, P974, DOI 10.2174/138955709788681582
   MALIK Z, 1992, J PHOTOCH PHOTOBIO B, V14, P262, DOI 10.1016/1011-1344(92)85104-3
   Mang TS, 2004, PHOTODIAGN PHOTODYN, V1, P43, DOI 10.1016/S1572-1000(04)00012-2
   MCCLURE DS, 1949, J CHEM PHYS, V17, P665, DOI 10.1063/1.1747359
   MCCLURE DS, 1949, J CHEM PHYS, V17, P905, DOI 10.1063/1.1747085
   McDonnell SO, 2005, J AM CHEM SOC, V127, P16360, DOI 10.1021/ja0553497
   MCGLYNN SP, 1962, J PHYS CHEM-US, V66, P2499, DOI 10.1021/j100818a042
   MCGLYNN SP, 1962, J CHEM PHYS, V37, P1818, DOI 10.1063/1.1733374
   McNaught AD, 1997, IUPAC COMPENDIUM CHE, V68, P2245
   Mei YJ, 2006, TETRAHEDRON LETT, V47, P2447, DOI 10.1016/j.tetlet.2006.01.091
   Mitsunaga M, 2012, BIOCONJUGATE CHEM, V23, P604, DOI 10.1021/bc200648m
   Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554
   Miura T, 2003, J AM CHEM SOC, V125, P8666, DOI 10.1021/ja035282s
   MOAN J, 1985, CANCER RES, V45, P1608
   MOAN J, 1990, J PHOTOCH PHOTOBIO B, V6, P343, DOI 10.1016/1011-1344(90)85104-5
   MOHR H, 1995, IMMUNOL INVEST, V24, P73, DOI 10.3109/08820139509062763
   Montalti M., 2006, HDB PHOTOCHEMISTRY
   MONTCOURRIER P, 1994, J CELL SCI, V107, P2381
   Niedre M, 2002, PHOTOCHEM PHOTOBIOL, V75, P382, DOI 10.1562/0031-8655(2002)075<0382:DNILDO>2.0.CO;2
   NITZAN Y, 1992, PHOTOCHEM PHOTOBIOL, V55, P89, DOI 10.1111/j.1751-1097.1992.tb04213.x
   Nyman ES, 2004, J PHOTOCH PHOTOBIO B, V73, P1, DOI 10.1016/j.jphotobiol.2003.10.002
   O'Connor AE, 2012, INT J CANCER, V130, P705, DOI 10.1002/ijc.26073
   O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x
   Ortiz MJ, 2012, TETRAHEDRON, V68, P1153, DOI 10.1016/j.tet.2011.11.070
   Ozlem S, 2009, J AM CHEM SOC, V131, P48, DOI 10.1021/ja808389t
   Pandey RK, 2006, LASER SURG MED, V38, P445, DOI 10.1002/lsm.20352
   Pang WD, 2012, CHEM COMMUN, V48, P5437, DOI 10.1039/c2cc30915g
   PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443
   Paul B, 2011, PHOTOCHEM PHOTOBIOL, V87, P1468, DOI 10.1111/j.1751-1097.2011.00988.x
   Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1
   Policard A, 1924, CR SOC BIOL, V91, P1423
   Qian G, 2010, CHEM-ASIAN J, V5, P1006, DOI 10.1002/asia.200900596
   Quartarolo AD, 2006, CHEM-EUR J, V12, P6797, DOI 10.1002/chem.200501636
   Rapozzi V, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12536
   Rogers MAT, 1943, NATURE, V151, P504, DOI 10.1038/151504a0
   Rogers MAT, 1943, J CHEM SOC, P590, DOI 10.1039/jr9430000590
   Rohand T, 2006, CHEM COMMUN, P266, DOI 10.1039/b512756d
   Rohand T, 2006, EUR J ORG CHEM, V2006, P4658, DOI 10.1002/ejoc.200600531
   Rousseau T, 2009, CHEM COMMUN, P1673, DOI 10.1039/b822770e
   Sahoo SK, 2002, BIOCONJUGATE CHEM, V13, P1031, DOI 10.1021/bc020010k
   Schmidt R, 2006, PHOTOCHEM PHOTOBIOL, V82, P1161, DOI 10.1562/2006-03-03-IR-833
   Senge MO, 2012, PHOTODIAGN PHOTODYN, V9, P170, DOI 10.1016/j.pdpdt.2011.10.001
   Shen Z, 2004, CHEM-EUR J, V10, P4853, DOI 10.1002/chem.200400173
   Sitkovsky M, 2005, NAT REV IMMUNOL, V5, P712, DOI 10.1038/nri1685
   Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040-4020(98)00015-5
   Szacilowski K, 2008, CHEM REV, V108, P3481, DOI 10.1021/cr068403q
   Thivierge C, 2007, ORG LETT, V9, P2135, DOI 10.1021/ol0706197
   Treibs A., 1986, LIEBIGS ANN CHEM, V718, P208
   Ulrich G, 2008, ANGEW CHEM INT EDIT, V47, P1184, DOI 10.1002/anie.200702070
   Ulrich G, 2007, SYNLETT, P1517, DOI 10.1055/s-2007-982557
   Umezawa K, 2008, J AM CHEM SOC, V130, P1550, DOI 10.1021/ja077756j
   Urano Y, 2009, NAT MED, V15, P104, DOI 10.1038/nm.1854
   von Tappeiner H., 1909, ERGEBN PHYSL, V8, P698
   Von Tappeiner H., 1903, MUNCH MED WOCHENSCHR, V1, P2042
   Wada M, 2001, TETRAHEDRON LETT, V42, P6711, DOI 10.1016/S0040-4039(01)01299-0
   Wainwright M, 1996, CHEM SOC REV, V25, P351, DOI 10.1039/cs9962500351
   Wainwright M, 2007, J PHOTOCH PHOTOBIO B, V86, P45, DOI 10.1016/j.jphotobiol.2006.07.005
   Wang DC, 2009, J ORG CHEM, V74, P7675, DOI 10.1021/jo901149y
   WEISHAUPT KR, 1976, CANCER RES, V36, P2326
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684
   WILKINSON F, 1993, J PHYS CHEM REF DATA, V22, P113, DOI 10.1063/1.555934
   WILKINSON F, 1995, J PHYS CHEM REF DATA, V24, P663, DOI 10.1063/1.555965
   Win MN, 2008, SCIENCE, V322, P456, DOI 10.1126/science.1160311
   Wolford L. T., 1990, HETEROATOM CHEM, V1, P389, DOI [10.1002/hc.520010507, DOI 10.1002/HC.520010507]
   Yogo T, 2005, J AM CHEM SOC, V127, P12162, DOI 10.1021/ja0528533
   Yogo T, 2008, P NATL ACAD SCI USA, V105, P28, DOI 10.1073/pnas.0611717105
   YUSTER P, 1949, J CHEM PHYS, V17, P1182, DOI 10.1063/1.1747140
   Zilidis G, 2008, PHOTODIAGN PHOTODYN, V5, P264, DOI 10.1016/j.pdpdt.2009.01.001
NR 165
TC 481
Z9 485
U1 28
U2 526
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2012
VL 2
IS 30
BP 11169
EP 11183
DI 10.1039/c2ra21404k
PG 15
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 051RR
UT WOS:000312145400001
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ferrara, N
   Gerber, HP
   LeCouter, J
AF Ferrara, N
   Gerber, HP
   LeCouter, J
TI The biology of VEGF and its receptors
SO NATURE MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; LINDAU
   TUMOR-SUPPRESSOR; GLAND-DERIVED VEGF; CELL GROWTH; SIGNAL-TRANSDUCTION;
   TYROSINE KINASE; MICROVASCULAR PERMEABILITY; INDUCED ANGIOGENESIS;
   MONOCLONAL-ANTIBODY
AB Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
C1 Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Adini A, 2002, CANCER RES, V62, P2749
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Broxmeyer HE, 1995, INT J HEMATOL, V62, P203
   Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978
   Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2003, AM J PATHOL, V162, P1881, DOI 10.1016/S0002-9440(10)64322-2
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Fong GH, 1999, DEVELOPMENT, V126, P3015
   Fraser HM, 2000, ENDOCRINOLOGY, V141, P995, DOI 10.1210/en.141.3.995
   Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Garner Alec, 1994, P1625
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Goede V, 1998, LAB INVEST, V78, P1385
   GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Haigh JJ, 2000, DEVELOPMENT, V127, P1445
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Kawasaki T, 1999, DEVELOPMENT, V126, P4895
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   LeCouter J, 2002, NAT MED, V8, P913, DOI 10.1038/nm0902-913
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Lee CG, 2000, CANCER RES, V60, P5565
   Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Maru Y, 1998, ONCOGENE, V16, P2585, DOI 10.1038/sj.onc.1201786
   Matsumoto T., 2001, SCI STKE, V112, P1
   Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   Mole DR, 2001, IUBMB LIFE, V52, P43
   Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244
   Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675
   PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x
   POOLE AR, 1991, CARTILAGE MOL ASPECT, P179
   Presta LG, 1997, CANCER RES, V57, P4593
   Prewett M, 1999, CANCER RES, V59, P5209
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Siemeister G, 1996, CANCER RES, V56, P2299
   Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tsuzuki Y, 2000, CANCER RES, V60, P6248
   van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wood JM, 2000, CANCER RES, V60, P2178
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   YANG JC, IN PRESS N ENGL J ME
   Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011
   YEN SSC, 1999, REPROD ENDOCRINOLOGY, P436
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zimmermann RC, 2001, J CLIN ENDOCR METAB, V86, P768, DOI 10.1210/jc.86.2.768
NR 136
TC 7163
Z9 7649
U1 35
U2 1217
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2003
VL 9
IS 6
BP 669
EP 676
DI 10.1038/nm0603-669
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 688PH
UT WOS:000183444100021
PM 12778165
DA 2022-11-30
ER

PT J
AU Chandra, S
   Rasheed, R
   Sen, P
   Menon, D
   Sivaprasad, S
AF Chandra, Shruti
   Rasheed, Rajna
   Sen, Piyali
   Menon, Deepthy
   Sivaprasad, Sobha
TI Inter-rater reliability for diagnosis of geographic atrophy using
   spectral domain OCT in age-related macular degeneration
SO EYE
LA English
DT Article
AB Purpose To evaluate the inter-rater reliability for identification of complete retinal pigment epithelium and outer retinal atrophy (cRORA) on SD-OCT images as defined by the Classification of Atrophy Meetings (CAM) group. Methods Fifty images of anonymized SD-OCT line scans of eyes with cRORA due to AMD were selected. Each .tiff image was saved in both black-on-white (BW) and white-on-black (WB) format. Five retina-trained clinicians graded both sets of images twice for the diagnosis of cRORA based on the CAM group definition. Fleiss kappa statistic was calculated for inter-rater reliability and Cohen's kappa statistic for intra-grader and inter-grader reliability between any two graders. Results The inter-grader reliability varied from as low as 0.28 to 0.92 for WB images and 0.34 to 0.86 for BW images. However, the inter-grader and intra-grader agreement was WB 0.92; BW 0.86 and 0.92 respectively, for graders accustomed to the CAM criteria. Fleiss kappa was 0.49 (p value < 0.0001) for WB images and 0.34 (p value < 0.0001 for BW images. Overall, the agreement was better using WB images for all parameters except RPE attenuation/loss. Conclusion There is significant variability in diagnosis of cRORA on SD-OCT by retina-trained ophthalmologists in the real world. The study highlights the need for training to recognise the different features of cRORA prior to its implementation in clinical practice.
C1 [Chandra, Shruti; Rasheed, Rajna; Sen, Piyali; Menon, Deepthy; Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, Moorfields Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Chandra, Shruti; Sen, Piyali; Sivaprasad, Sobha] UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Moorfields Biomed Res Ctr, Natl Inst Hlth Res, London, England.; Sivaprasad, S (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM sobha.sivaprasad@nhs.net
OI Chandra, Shruti/0000-0002-2634-9775; Sivaprasad,
   Sobha/0000-0001-8952-0659
FU Fight For Sight [1905]
FX The study is funded by Fight For Sight (Grant code 1905).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Biarnes M, 2014, INVEST OPHTH VIS SCI, V55, P8302, DOI 10.1167/iovs.13-13542
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Gendelman I, 2020, OPHTHALMOLOGY
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   StatsToDo, 2020, KAPPA COHEN FLEISS O
NR 13
TC 3
Z9 3
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 392
EP 397
DI 10.1038/s41433-021-01490-5
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000626461300001
PM 33686233
DA 2022-11-30
ER

PT J
AU McKay, GJ
   Silvestri, G
   Patterson, CC
   Hogg, RE
   Chakravarthy, U
   Hughes, AE
AF McKay, Gareth J.
   Silvestri, Giuliana
   Patterson, Christopher C.
   Hogg, Ruth E.
   Chakravarthy, Usha
   Hughes, Anne E.
TI Further Assessment of the Complement Component 2 and Factor B Region
   Associated with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK; VARIANT; GENE; SUSCEPTIBILITY; HAPLOTYPE;
   HTRA1; MACULOPATHY; INCREASES; DISEASE
AB PURPOSE. Polymorphic variation in genes involved in regulation of the complement system has been implicated as a major cause of genetic risk, in addition to the LOC387715/HTRA1 locus and other environmental influences. Previous studies have identified polymorphisms in the complement component 2 (CC2) and factor B (CFB) genes, as potential functional variants associated with AMD, in particular CFB R32Q and CC2 rs547154, both of which share strong linkage disequilibrium (LD).
   METHODS. Data derived from the HapMap Project were used to select 18 haplotype-tagging SNPs across the extended CC2/CFB region for genotyping, to measure the strength of LD in 318 patients with neovascular AMD and 243 age-matched control subjects to identify additional potential functional variants in addition to those originally reported.
   RESULTS. Strong LD was measured across this region as far as the superkiller viralicidic activity 2-like gene (SKIV2L). Nine SNPs were identified to be significantly associated with the genetic effect observed at this locus. Of these, a nonsynonymous coding variant SKIV2L R151Q (rs438999; OR, 0.48; 95% confidence interval [CI], 0.31-0.74; P < 0.001), was in strong LD with CFB R32Q, rs641153 (r(2) = 0.95) and may exert a functional effect. When assessed within a logistic regression model measuring the effects of genetic variation at the CFH and LOC387715/HTRA1 loci and smoking, the effect remained significant (OR, 0.38; 95% CI, 0.22-0.65; P < 0.001). Additional variation identified within this region may also confer a weaker but independent effect and implicate additional genes within the pathogenesis of AMD.
   CONCLUSIONS. Because of the high level of LD within the extended CC2/CFB region, variation within SKIV2L may exert a functional effect in AMD. (Invest Ophthalmol Vis Sci. 2009;50:533-539) DOI:10.1167/iovs.08-2275
C1 [McKay, Gareth J.; Silvestri, Giuliana; Hogg, Ruth E.; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci, Belfast, Antrim, North Ireland.
   [Patterson, Christopher C.; Hughes, Anne E.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP McKay, GJ (通讯作者)，Royal Victoria Hosp, Ctr Vis Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI Hughes, Anne/A-1307-2012; McKay, Gareth/AAZ-2601-2020; Hogg, Ruth
   E./ABC-9602-2020
OI McKay, Gareth/0000-0001-8197-6280; Hogg, Ruth E./0000-0001-9413-2669;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Guide Dogs for the Blind Association, UK [2005-01a]; Research and
   Development Office, Northern Ireland Health Personal Social Services
   [RRG 4.5]; ESRC [ES/G007438/1] Funding Source: UKRI; Economic and Social
   Research Council [ES/G007438/1] Funding Source: researchfish
FX Supported by Grant 2005-01a from the The Guide Dogs for the Blind
   Association, UK; and Grant RRG 4.5 from the Research and Development
   Office, Northern Ireland Health Personal Social Services.
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   DANGEL AW, 1995, NUCLEIC ACIDS RES, V23, P2120, DOI 10.1093/nar/23.12.2120
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gruen JR, 1997, BLOOD, V90, P4252
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEE SG, 1995, GENOMICS, V25, P660, DOI 10.1016/0888-7543(95)80008-A
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   REID DD, 1976, LANCET, V2, P979
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wickner RB, 1991, MOL CELLULAR BIOL YE, P263
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 29
TC 51
Z9 53
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2009
VL 50
IS 2
BP 533
EP 539
DI 10.1167/iovs.08-2275
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 397MD
UT WOS:000262665900006
PM 18806297
DA 2022-11-30
ER

PT J
AU Lukic, M
   Eleftheriadou, M
   Hamilton, RD
   Rajendram, R
   Bucan, K
   Patel, PJ
AF Lukic, Marko
   Eleftheriadou, Maria
   Hamilton, Robin D.
   Rajendram, Ranjan
   Bucan, Kajo
   Patel, Praveen J.
TI Four-year outcomes of aflibercept treatment for neovascular age-related
   macular degeneration: Results from real-life setting
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; retinal pathology; research;
   retina - medical therapies; molecular; genetics; pharmacology
ID CHOROIDAL NEOVASCULARIZATION; 7-YEAR OUTCOMES; RANIBIZUMAB; MARINA; AMD;
   HORIZON; ANCHOR; EYE
AB Background: To assess long-term structural and functional outcomes of intravitreal aflibercept (Eylea(R)) treatment for neovascular macular degeneration (nAMD) in a real-word setting. Design and methods: This was a retrospective, single-centre, non-randomized interventional cohort analysis. Data from treatment-naive patients with nAMD funded for treatment with intravitreal aflibercept in the period between 1 September 2013 and 28 February 2014 and who finished 4-year follow-up entered the analysis. Epidemiological data, visual acuity (VA) measured on ETDRS charts and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2, 3 and 4 were also recorded. Results: Ninety-four eyes of 89 patients finished 4-year follow-up. The mean number of aflibercept injections received over 4 years was 19.3. At baseline, the mean VA (SD) (Snellen) was 54.1 +/- 15.5 (20/100) ETDRS letters whilst the mean CSM (SD) was 296 +/- 81 mu m. At 4 years, the mean VA (SD) (Snellen) was 60.4 +/- 20.0 (20/63) ETDRS letters (p < 0.0001). Mean CSMT (SD) was 218 +/- 79 mu m (p < 0.0001). Thirty-three percent of eyes gained > 15 ETDRS letters at end of 4 years, and 66 (70%) eyes had no macular fluid at the end of the follow-up. Conclusion and relevance: The results suggest that good long-term morphological and functional treatment outcomes can be achieved using intravitreal aflibercept for nAMD in a real-life clinical setting.
C1 [Lukic, Marko; Eleftheriadou, Maria; Hamilton, Robin D.; Rajendram, Ranjan; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
   [Lukic, Marko; Eleftheriadou, Maria; Hamilton, Robin D.; Rajendram, Ranjan; Patel, Praveen J.] UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
   [Bucan, Kajo] Univ Hosp Centre Split, Ophthalmol Dept, Split, Croatia.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Lukic, M (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.; Lukic, M (通讯作者)，UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM m.lukic@nhs.net
OI Lukic, Marko/0000-0002-7636-8368
CR Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chatziralli I, 2018, EYE, V32, P1523, DOI 10.1038/s41433-018-0114-3
   Duval MV, 2017, J FR OPHTALMOL, V40, P270, DOI 10.1016/j.jfo.2016.11.012
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
NR 21
TC 3
Z9 3
U1 1
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2021
VL 31
IS 4
BP 1940
EP 1944
AR 1120672120938565
DI 10.1177/1120672120938565
EA JUN 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UB5GU
UT WOS:000543975000001
PM 32586117
DA 2022-11-30
ER

PT J
AU Schechet, S
   Hariprasad, SM
   Movahedan, A
   Skondra, D
AF Schechet, Sidney
   Hariprasad, Seenu M.
   Movahedan, Asadolah
   Skondra, Dimitra
TI Use of Optical Coherence Tomography Angiography in Masqueraders of Wet
   Age-Related Macular Degeneration and Choroidal Neovascularization
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
C1 [Schechet, Sidney; Hariprasad, Seenu M.; Movahedan, Asadolah; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave,MC2114, Chicago, IL 60637 USA.
C3 University of Chicago
RP Schechet, S (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave,MC2114, Chicago, IL 60637 USA.
EM schechets@gmail.com; retina@uchicago.edu; movahedan@gmail.com;
   dskondra@bsd.uchicago.edu
OI Schechet, Sidney/0000-0001-8996-3855
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   CARSKI TR, 1978, JAMA-J AM MED ASSOC, V240, P635
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chen Q, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5608250
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Musa F, 2006, ACTA OPHTHALMOL SCAN, V84, P740, DOI 10.1111/j.1600-0420.2006.00728.x
   Novais EA, 2016, OSLI RETINA, V47, P848, DOI 10.3928/23258160-20160901-09
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
NR 15
TC 3
Z9 3
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2018
VL 49
IS 2
BP 80
EP 85
DI 10.3928/23258160-20180129-01
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FX1XM
UT WOS:000425848800001
PM 29443356
DA 2022-11-30
ER

PT J
AU Lindner, E
   Woltsche, N
   Merle, D
   Steinwender, G
   Strohmaier, H
   Nairz, M
   Ivastinovic, D
AF Lindner, Ewald
   Woltsche, Nora
   Merle, David
   Steinwender, Gernot
   Strohmaier, Heimo
   Nairz, Manfred
   Ivastinovic, Domagoj
TI Prion Protein on Human Leukocytes Is Reduced in Iron Deficiency -
   Possible Implications for Age-related Macular Degeneration?
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Prion protein; iron; leukocytes; age-related macular degeneration;
   glaucoma
AB Purpose/Aim of the study: Studies in mouse models have suggested a role for the cellular prion protein in iron metabolism of the eye. Here we have investigated whether iron metabolism affects the expression of prion protein in humans.
   Materials and Methods: Patients presenting to the department of ophthalmology of the Medical University of Graz for reasons unrelated to prion diseases were enrolled. Parameters of iron metabolism, including ferritin and soluble transferrin receptor were measured by routine laboratory tests. Serum prion protein was determined by enzyme-linked immunosorbent assay. Surface prion protein on CD14(+) monocytes and CD4(+) T cells was analyzed by fluorescence activated cell sorting.
   Results: 95 patients were enrolled. Soluble transferrin receptor correlated significantly with prion protein levels on CD14(+)POM1(+) monocytes (P = .001, r = -0.7) and on CD4(+)POM1(+) T cells (P = .01, r = -0.62).
   Conclusion: Our findings suggest a connection between the physiological function of the prion protein and iron metabolism in humans.
C1 [Lindner, Ewald; Woltsche, Nora; Merle, David; Steinwender, Gernot; Ivastinovic, Domagoj] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
   [Strohmaier, Heimo] Ctr Med Res Graz, Core Facil Imaging, Graz, Austria.
   [Nairz, Manfred] Med Univ Innsbruck, Dept Gen Internal Med, Innsbruck, Austria.
C3 Medical University of Graz; Medical University of Innsbruck
RP Lindner, E (通讯作者)，Med Univ Graz, Dept Ophthalmol, Graz, Austria.
EM ewald.lindner@medunigraz.at
RI Lindner, Ewald/CAG-1831-2022; Lindner, Ewald/AEM-1071-2022
OI Lindner, Ewald/0000-0001-9651-8573; 
FU Adele-Rabensteiner-Foundation
FX This work was supported by the Adele-Rabensteiner-Foundation [012018].
CR Aguzzi A, 2008, ANNU REV NEUROSCI, V31, P439, DOI 10.1146/annurev.neuro.31.060407.125620
   Ashok A, 2018, EXP EYE RES, V175, P1, DOI 10.1016/j.exer.2018.05.031
   Asthana A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08821-1
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Cui QN, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107961
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Glier H, 2012, J IMMUNOL METHODS, V380, P65, DOI 10.1016/j.jim.2012.04.002
   Haldar S, 2015, J BIOL CHEM, V290, P5512, DOI 10.1074/jbc.M114.607507
   Haschka D, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98867
   Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999
   Krebs B, 2006, BIOCHEM BIOPH RES CO, V340, P13, DOI 10.1016/j.bbrc.2005.11.158
   Maret W, 2018, ADV EXP MED BIOL, V1055, P1, DOI 10.1007/978-3-319-90143-5_1
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Nairz M, 2020, MOL ASPECTS MED, V75, DOI 10.1016/j.mam.2020.100864
   Politopoulou G, 2000, HAEMATOLOGICA, V85, P580
   Scalabrino G, 2013, J CLIN NEUROSCI, V20, P134, DOI 10.1016/j.jocn.2012.08.004
   Singh A, 2013, J ALZHEIMERS DIS, V35, P541, DOI 10.3233/JAD-130218
   Singh A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006115
   Singh A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004468
   Suega Ketut, 2019, Open Access Maced J Med Sci, V7, P97, DOI 10.3889/oamjms.2019.012
   Tezel TH, 2009, INVEST OPHTH VIS SCI, V50, P1911, DOI 10.1167/iovs.07-1372
   Troost FJ, 2003, AM J CLIN NUTR, V78, P1018, DOI 10.1093/ajcn/78.5.1018
   Vallabh SM, 2019, P NATL ACAD SCI USA, V116, P7793, DOI 10.1073/pnas.1901947116
   Wang ZJ, 1998, INVEST OPHTH VIS SCI, V39, P631
   Wysokinski D, 2015, ACTA BIOCHIM POL, V62, P177, DOI 10.18388/abp.2014_843
   Yiannikourides Andronicos, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6030085
   Zhao M, 2018, CLIN IMMUNOL, V187, P113, DOI 10.1016/j.clim.2017.11.002
NR 27
TC 3
Z9 3
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG 3
PY 2021
VL 46
IS 8
BP 1178
EP 1183
DI 10.1080/02713683.2020.1863432
EA DEC 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TM0JB
UT WOS:000603915700001
PM 33317353
DA 2022-11-30
ER

PT J
AU Grossniklaus, HE
   Miskala, PH
   Green, WR
   Bressler, SB
   Hawkins, BS
   Toth, C
   Wilson, DJ
   Bressler, NM
AF Grossniklaus, HE
   Miskala, PH
   Green, WR
   Bressler, SB
   Hawkins, BS
   Toth, C
   Wilson, DJ
   Bressler, NM
CA Submacular Surg Trials Res Grp
TI Histopathologic and ultrastructural features of surgically excised
   subfoveal choroidal - Neovascular lesions submacular surgery trials
   report no. 7
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION; OCULAR HISTOPLASMOSIS; MEMBRANES
AB Objectives: To identify the histologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions from patients enrolled in the Submacular Surgery Trials and to compare them with clinical data.
   Methods: Surgically excised subfoveal choroidal neovascular lesions from patients enrolled in the Submacular Surgery Trials group N trial (lesion predominantly choroidal neovascularization [CNV] with evidence of classic CNV from age-related macular degeneration), group B trial (lesion predominantly hemorrhagic from age-related macular degeneration), and group H trial (idiopathic subfoveal CNV or subfoveal CNV from ocular histoplasmosis syndrome) between October 1, 1999, and September 1, 2001, were submitted to the pathology center. The lesion growth pattern (subretinal pigment epithelial [sub-RPE], subretinal, combined, or indeterminate) and the cellular and extracellular constituents were classified independently. Demographic, clinical, and fluorescein angiographic characteristics of patients, eyes, and lesions, respectively, were compared with the pathologic features.
   Results: Of 269 patients assigned to surgery during the 24 months that pathologic specimens were collected, surgical specimens from study eyes of 199 were submitted to the pathology center. Of the 199 routine histologic specimens processed, 144 (72%) were classified as CNV, 51 (26%) as fibrocellular tissue, and 4 (2%) as hemorrhage. The median specimen size was smaller in group H (932 X 208 pm) than in groups N (1980 X 325 pm) and B (1800 X 395 pm), The CNV growth pattern was determined in 91 (46%) of 199 specimens. Of 159 group N and group B lesions, 76 (48%) had an indeterminate growth pattern, 28 (18%) had a sub-RPE growth pattern, and 33 (21%) had sub-RPE and subretinal growth patterns. Of 40 group H lesions, 32 (80%) had an indeterminate growth pattern, 7 (18%) had a subretinal growth pattern, and 1 (2%) had a combined sub-RPE and subretinal pattern. Based on electron microscopy, the most common cellular lesion components were RPE, macrophages, erythrocytes, fibrocytes, and vascular endothelium; the most common extracellular components were 24-nm collagen and fibrin. Basal laminar and linear deposits were found in 80% (40/ 50) and 16% (8/49) of group N specimens, 66% (43/65) and 5% (3/65) of group B specimens, and 8% (2/26) and 0% (0/26) of group H specimens, respectively.
   Conclusions: Most surgically excised subfoveal specimens had evidence of CNV or tissue associated with CNV. The constituents in CNV were consistent with granulation tissue proliferation. The presence of basal deposits in surgically excised specimens suggested a clinical diagnosis of age-related macular degeneration, even when blood was the predominant component of the lesion. Correlation of growth patterns above or below the RPE with fluorescein angiographic patterns of classic or occult CNV was limited because most specimens had insufficient material to determine these patterns.
C1 Emory Univ, Ctr Eye, LF Montgomery Ophthalm Pathol Lab, Atlanta, GA 30322 USA.
C3 Emory University
RP Grossniklaus, HE (通讯作者)，Emory Univ, Ctr Eye, LF Montgomery Ophthalm Pathol Lab, BT428,1365 Clifton Rd NE, Atlanta, GA 30322 USA.
EM ophtheg@emory.edu
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; 
FU NATIONAL EYE INSTITUTE [U10EY011557, U10EY011547, U10EY011558,
   U10EY012662] Funding Source: NIH RePORTER; NEI NIH HHS [U10 EY 12662,
   U10 EY 11547, EY 11558, EY 11557] Funding Source: Medline
CR BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BYNOE LA, 1994, OPHTHALMOLOGY, V101, P1112
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   MEREDITH TA, 1977, SURV OPHTHALMOL, V22, P189, DOI 10.1016/0039-6257(77)90055-8
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   SAXE SJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P88, DOI 10.1001/archopht.1993.01090010092033
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
NR 25
TC 92
Z9 97
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2005
VL 123
IS 7
BP 914
EP 921
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 943KR
UT WOS:000230352900003
PM 16009831
DA 2022-11-30
ER

PT J
AU Saddala, MS
   Lennikov, A
   Mukwaya, A
   Fan, LJ
   Hu, ZM
   Huang, H
AF Saddala, Madhu Sudhana
   Lennikov, Anton
   Mukwaya, Anthony
   Fan, Lijuan
   Hu, Zhengmao
   Huang, Hu
TI Transcriptome-wide analysis of differentially expressed chemokine
   receptors, SNPs, and SSRs in the age-related macular degeneration
SO HUMAN GENOMICS
LA English
DT Article
DE AMD; RNA-Seq; Gene ontology; Human eye; Chemokine receptor
ID COMPLEMENT; ASSOCIATION; GENOME; CELLS; DATABASE; DRUSEN; SYSTEM; RISK
AB BackgroundAge-related macular degeneration (AMD) is the most common, progressive, and polygenic cause of irreversible visual impairment in the world. The molecular pathogenesis of the primary events of AMD is poorly understood. We have investigated a transcriptome-wide analysis of differential gene expression, single-nucleotide polymorphisms (SNPs), indels, and simple sequence repeats (SSRs) in datasets of the human peripheral retina and RPE-choroid-sclera control and AMD.Methods and resultsAdaptors and unbiased components were removed and checked to ensure the quality of the data sets. Molecular function, biological process, cellular component, and pathway analyses were performed on differentially expressed genes. Analysis of the gene expression datasets identified 5011 upregulated genes, 11,800 downregulated genes, 42,016 SNPs, 1141 indels, and 6668 SRRs between healthy controls and AMD donor material. Enrichment categories for gene ontology included chemokine activity, cytokine activity, cytokine receptor binding, immune system process, and signal transduction respectively. A functional pathways analysis identified that chemokine receptors bind chemokines, complement cascade genes, and create cytokine signaling in immune system pathway genes (p value <0.001). Finally, allele-specific expression was found to be significant for Chemokine (C-C motif) ligand (CCL) 2, 3, 4, 13, 19, 21; C-C chemokine receptor (CCR) 1, 5; chemokine (C-X-C motif) ligand (CXCL) 9, 10, 16; C-X-C chemokine receptor type (CXCR) 6; as well as atypical chemokine receptor (ACKR) 3,4 and pro-platelet basic protein (PPBP).ConclusionsOur results improve our overall understanding of the chemokine receptors' signaling pathway in AMD conditions, which may lead to potential new diagnostic and therapeutic targets.
C1 [Saddala, Madhu Sudhana; Lennikov, Anton; Fan, Lijuan; Huang, Hu] Univ Missouri, Mason Eye Inst, Columbia, MO 65212 USA.
   [Saddala, Madhu Sudhana; Lennikov, Anton; Fan, Lijuan; Huang, Hu] Johns Hopkins Univ, Wilmer Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [Mukwaya, Anthony] Linkoping Univ, Inst Clin & Expt Med, Fac Hlth Sci, Dept Ophthalmol, SF-58183 Linkoping, Sweden.
   [Hu, Zhengmao] Cent S Univ, Sch Life Sci, Ctr Med Genet, Changsha, Hunan, Peoples R China.
   [Hu, Zhengmao] Cent S Univ, Sch Life Sci, Hunan Key Lab Med Genet, Changsha, Hunan, Peoples R China.
   [Huang, Hu] Univ Missouri, Sch Med, Dept Ophthalmol, 1 Hosp Dr,MA102C, Columbia, MO 65212 USA.
C3 University of Missouri System; University of Missouri Columbia; Johns
   Hopkins University; Linkoping University; Central South University;
   Central South University; University of Missouri System; University of
   Missouri Columbia
RP Huang, H (通讯作者)，Univ Missouri, Mason Eye Inst, Columbia, MO 65212 USA.; Huang, H (通讯作者)，Johns Hopkins Univ, Wilmer Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM huangh1@missouri.edu
RI Saddala, Madhu Sudhana/C-6147-2018; Lennikov, Anton/N-4241-2015;
   Mukwaya, Anthony/K-2335-2019
OI Saddala, Madhu Sudhana/0000-0002-6373-7080; Lennikov,
   Anton/0000-0001-8625-1211; Mukwaya, Anthony/0000-0002-9645-8942
FU NIH [EY027824]; University of Missouri startup funds
FX Hu Huang group is supported by NIH grant (EY027824), and University of
   Missouri startup funds.
CR ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bachelerie F, 2014, NAT IMMUNOL, V15, P207, DOI 10.1038/ni.2812
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebert LA, 2005, MOL IMMUNOL, V42, P799, DOI 10.1016/j.molimm.2004.06.040
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hristov M, 2007, CIRC RES, V100, P590, DOI 10.1161/01.RES.0000259043.42571.68
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Lamkhioued B, 2000, AM J RESP CRIT CARE, V162, P723, DOI 10.1164/ajrccm.162.2.9901080
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Marques CP, 2008, J IMMUNOL, V181, P6417, DOI 10.4049/jimmunol.181.9.6417
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092
   Nawaz MI, 2013, EXP EYE RES, V109, P67, DOI 10.1016/j.exer.2013.01.008
   Pastinen T, 2006, HUM MOL GENET, V15, pR9, DOI 10.1093/hmg/ddl044
   Potok ME, 2013, CELL, V153, P759, DOI 10.1016/j.cell.2013.04.030
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Thiel T, 2003, THEOR APPL GENET, V106, P411, DOI 10.1007/s00122-002-1031-0
   Twine NA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016266
   Vinet J, 2013, BRIT J PHARMACOL, V168, P1375, DOI 10.1111/bph.12042
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weirick T, 2016, BRIEF BIOINFORM, V17, P678, DOI 10.1093/bib/bbv067
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008
NR 47
TC 14
Z9 14
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD MAR 20
PY 2019
VL 13
AR 15
DI 10.1186/s40246-019-0199-1
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HQ3PS
UT WOS:000462323600001
PM 30894217
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jabs, DA
   Van Natta, ML
   Pak, JW
   Danis, RP
   Hunt, PW
AF Jabs, Douglas A.
   Van Natta, Mark L.
   Pak, Jeong Won
   Danis, Ronald P.
   Hunt, Peter W.
TI Association of Retinal Vascular Caliber and Age-Related Macular
   Degeneration in Patients With the Acquired Immunodeficiency Syndrome
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE acquired immunodeficiency syndrome; age-related macular degeneration;
   retinal vascular caliber
ID OCULAR COMPLICATIONS; LIFE EXPECTANCY; VESSEL CALIBER; SEVERITY SCALE;
   HIV-INFECTION; RISK-FACTORS; EYE DISEASE; PREVALENCE; INFLAMMATION;
   ACTIVATION
AB PURPOSE. To evaluate the relationship between retinal vascular caliber and AMD in patients with AIDS.
   METHODS. Participants enrolled in the Longitudinal Study of the Ocular Complications of AIDS had retinal photographs taken at enrollment. Retinal vascular caliber (central retinal artery equivalent [CRAE] and central retinal vein equivalent [CRVE]) and intermediate-stage AMD were determined from these retinal photographs. Photographs were evaluated by graders at a centralized reading center, using the Age-Related Eye Disease Study grading system for AMD and semiautomated techniques for evaluating retinal vascular caliber.
   RESULTS. Of the 1171 participants evaluated, 110 (9.4%) had AMD and 1061 (90.6%) did not. Compared with participants without AMD, participants with AMD had larger mean CRAEs (151 +/- 16 mu m versus 147 +/- 16 mu m; P = 0.009) and mean CRVEs (228 +/- 24 mu m versus 223 +/- 25 mu m; P = 0.02). The unadjusted differences were: CRAE, 4.3 mu m (95% confidence interval [CI] 1.1-7.5; P = 0.009) and CRVE, 5.5 mu m (95% CI 0.7-10.3; P = 0.02). After adjustment for age, race/ethnicity, sex, human immunodeficiency syndrome (HIV) transmission category, smoking, enrollment and nadir CD4(+) T cells, and enrollment and maximum HIV load, the differences between patients with and without AMD were as follows: CRAE, 5.4 mu m (95% CI 2.3-8.5; P = 0.001) and CRVE, 6.0 mu m (95% CI 1.4-10.6; P = 0.01).
   CONCLUSIONS. In patients with AIDS, AMD is associated with greater retinal arteriolar and venular calibers, suggesting a role for shared pathogenic mechanisms, such as persistent systemic inflammation.
C1 [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
   [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Jabs, Douglas A.; Van Natta, Mark L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Pak, Jeong Won; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol, Sch Med & Publ Hlth, Madison, WI USA.
   [Hunt, Peter W.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of Wisconsin System; University of Wisconsin
   Madison; University of California System; University of California San
   Francisco
RP Jabs, DA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Ophthalmol, One Gustave L Levy Pl,Box 1183, New York, NY 10029 USA.
EM douglas.jabs@mssm.edu
RI Hunt, Peter W./P-2976-2017
OI Hunt, Peter W./0000-0002-4571-4870
FU National Eye Institute, the National Institutes of Health, Bethesda, MD,
   USA [R01 EY025093]; NATIONAL EYE INSTITUTE [R01EY025093] Funding Source:
   NIH RePORTER
FX Supported by Grant R01 EY025093 from the National Eye Institute, the
   National Institutes of Health, Bethesda, MD, USA to the Icahn School of
   Medicine at Mount Sinai, New York, NY, USA.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Altman DG., 1991, PRACTICAL STAT MED R, P241
   [Anonymous], 1992, MMWR Recomm Rep, V41, P1
   Braithwaite RS, 2008, ANN INTERN MED, V148, P178, DOI 10.7326/0003-4819-148-3-200802050-00004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Edison L, 2014, MMWR-MORBID MORTAL W, V63
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gangaputra S, 2012, AM J OPHTHALMOL, V153, P434, DOI 10.1016/j.ajo.2011.08.028
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Holtzer CD, 1998, AIDS, V12, P1931
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Ikram MK, 2013, OPHTHALMOLOGICA, V229, P125, DOI 10.1159/000342158
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008
   Jabs DA, 2007, OPHTHALMOLOGY, V114, P787, DOI 10.1016/j.ophtha.2006.07.065
   Jabs DA, 2017, AM J OPHTHALMOL, V179, P151, DOI 10.1016/j.ajo.2017.05.004
   Jabs DA, 2015, AM J OPHTHALMOL, V159, P1115, DOI 10.1016/j.ajo.2015.01.037
   Jabs DA, 2011, AM J OPHTHALMOL, V151, P198, DOI 10.1016/j.ajo.2010.10.018
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kaplan RC, 2007, CLIN INFECT DIS, V45, P1074, DOI 10.1086/521935
   Klein R, 2006, ARCH OPHTHALMOL-CHIC, V124, P87, DOI 10.1001/archopht.124.1.87
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Liew G, 2008, ARCH OPHTHALMOL-CHIC, V126, P1404, DOI 10.1001/archopht.126.10.1404
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pathai S, 2014, J GERONTOL A-BIOL, V69, P833, DOI 10.1093/gerona/glt168
   Shouse R. L., 2009, Morbidity and Mortality Weekly Report, V58, P661
   Sugar EA, 2012, AM J OPHTHALMOL, V153, P1016, DOI 10.1016/j.ajo.2011.11.014
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Wang WL, 2014, LANCET, V2, pe106
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
NR 41
TC 2
Z9 2
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2018
VL 59
IS 2
BP 904
EP 908
DI 10.1167/iovs.17-23334
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8LO
UT WOS:000426346300033
PM 29435590
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Sauer, L
   Komanski, CB
   Vitale, AS
   Hansen, ED
   Bernstein, PS
AF Sauer, Lydia
   Komanski, Christopher B.
   Vitale, Alexandra S.
   Hansen, Eric D.
   Bernstein, Paul S.
TI Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Eyes With Pigment
   Epithelial Detachments Due to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE FLIO; fluorescence lifetime imaging; age-related macular degeneration;
   lipofuscin; blood
ID TIME-RESOLVED AUTOFLUORESCENCE; FUNDUS AUTOFLUORESCENCE; DRUSEN;
   DISEASE; MACULOPATHY; PREVALENCE; HYPOTHESIS; ATROPHY
AB PURPOSE. To investigate fluorescence lifetime imaging ophthalmoscopy (FLIO) in neovascular AMD and pigment epithelial detachments (PEDs).
   METHODS. A total of 46 eyes with PEDs (>350 mu m) as well as age-matched healthy controls were included in this study. We found 28 eyes showed neovascular AMD (nvAMD), and 17 had nonneovascular (dry) AMD (dAMD). The Heidelberg Engineering FLIO excited fluorescence at 473 nm. Fluorescence decays were detected in two spectral channels (498-560 nm; 560-720 nm) to determine fluorescence lifetimes of endogenous fluorophores in their specific spectral emission ranges. Mean fluorescence lifetimes (tau(m)) were investigated. Multimodal imaging was reviewed by two ophthalmologists who circumscribed and classified PEDs as either serous (n = 4), hemorrhagic (n = 4), fibrovascular (n = 16), drusenoid (n = 17), or mixed (n = 5). Blood samples from a healthy subject and a patient with PED were investigated in a quartz cuvette.
   RESULTS. Eyes with nvAMD show similar FLIO patterns to dAMD: ring-shaped prolongations of sm 3 to 6 mm from the fovea. Different PED-forms show characteristic tau(m), while serous and hemorrhagic PEDs exhibit shortened tau(m), drusenoid PEDs show prolonged tau(m), and tau(m) in fibrovascular PEDs is variable. Areas corresponding to sub-/intraretinal fluid display shortened sm. Ex vivo studies of blood also show short tau(m).
   CONCLUSIONS. The previously described dAMD-related FLIO pattern is also present in nvAMD. Short sm in serous, fibrovascular, and hemorrhagic PEDs as well as sub/intraretinal fluid may disrupt this pattern. FLIO appears to differentiate between PEDs, hemorrhage, and fluid. Additionally, ex vivo studies of human blood help to better interpret FLIO images.
C1 [Sauer, Lydia; Komanski, Christopher B.; Vitale, Alexandra S.; Hansen, Eric D.; Bernstein, Paul S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU National Eye Institute of the National Institutes of Health
   [R01EY011600, P30EY014800]; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [P30EY014800, R01EY011600] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute of the National Institutes of
   Health under award numbers R01EY011600 and P30EY014800, and in part by
   an unrestricted departmental grant from Research to Prevent Blindness.
   The FLIO instrument was provided to the Moran Eye Center by Heidelberg
   Engineering for no cost. The authors alone are responsible for the
   content and writing of the paper.
CR Andersen KM, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.20
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Becker W., 2017, BH TCSPC HDB, V7th
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Dysli C, 2018, INVEST OPHTH VIS SCI, V59, P1769, DOI 10.1167/iovs.17-23336
   Dysli C, 2017, RETINA-J RET VIT DIS, V37, P2151, DOI 10.1097/IAE.0000000000001452
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P6714, DOI 10.1167/iovs.16-20392
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2015, INVEST OPHTH VIS SCI, V56, P3329, DOI 10.1167/iovs.14-16203
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gensure RH, 2018, INVEST OPHTH VIS SCI, V59
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Guo K, 2012, CHEM-EUR J, V18, P1303, DOI 10.1002/chem.201102935
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammer M, 2018, BIOMED OPT EXPRESS, V9, P3078, DOI 10.1364/BOE.9.003078
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Klemm M, 2013, CURR EYE RES, V38, P793, DOI 10.3109/02713683.2013.779723
   Lakowicz J.R., 2013, PRINCIPLES FLUORESCE
   LAKOWICZ JR, 1992, P NATL ACAD SCI USA, V89, P1271, DOI 10.1073/pnas.89.4.1271
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Peters S, 2011, PROC SPIE, V8086, DOI 10.1117/12.889807
   Sauer L, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.091415
   Sauer L, 2018, OPHTHALMOL RETINA, V2, P587, DOI 10.1016/j.oret.2017.10.008
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, P3094, DOI 10.1167/iovs.18-23886
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sauer L, 2017, ACTA OPHTHALMOL, V95, P481, DOI 10.1111/aos.13269
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmidt J, 2017, ACTA OPHTHALMOL, V95, P33, DOI 10.1111/aos.13174
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2005, BIOMED TECH, V50, P263, DOI 10.1515/BMT.2005.038
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2010, OPHTHALMOLOGE, V107, P1145, DOI 10.1007/s00347-010-2195-7
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Schweitzer D, 2009, OPHTHALMOLOGE, V106, P714, DOI 10.1007/s00347-009-1975-4
   Schweitzer D., 2014, NATURAL BIOMARKERS C, P317
   Schweitzer D, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.061106
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Schweitzer D, 2010, ESSENT OPHTHALMOL, P107, DOI 10.1007/978-3-540-85540-8_10
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
NR 52
TC 13
Z9 13
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2019
VL 60
IS 8
BP 3054
EP 3063
DI 10.1167/iovs.19-26835
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN6XZ
UT WOS:000478827000001
PM 31348823
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kitagawa, Y
   Shimada, H
   Kawamura, A
   Tanaka, K
   Mori, R
   Onoe, H
   Nakashizuka, H
AF Kitagawa, Yorihisa
   Shimada, Hiroyuki
   Kawamura, Akiyuki
   Tanaka, Koji
   Mori, Ryusaburo
   Onoe, Hajime
   Nakashizuka, Hiroyuki
TI A case of bilateral pachychoroid disease: polypoidal choroidal
   vasculopathy in one eye and peripheral exudative hemorrhagic
   chorioretinopathy in contralateral eye
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; Pachychoroid disease; Peripheral
   exudative hemorrhagic choroidal retinopathy; Polypoidal choroidal
   vasculopathy; Punctate hyperfluorescent spot
ID CENTRAL SEROUS CHORIORETINOPATHY
AB Background We report a case of bilateral pachychoroid disease manifesting polypoidal choroidal vasculopathy (PCV) with punctate hyperfluorescent spot (PHS) in one eye, and peripheral exudative hemorrhagic choroidal retinopathy (PEHCR) with central serous chorioretinopathy (CSC) and PHS in the contralateral eye. Case presentation : A 51-year-old healthy woman presented with complaint of blurred vision in her right eye. Corrected visual acuity was 20/20 in the right and 24/20 in the left eye. Fundus examination was normal in the left eye. In the right eye, fundus finding of an orange-red nodular lesion and optical coherence tomography (OCT) finding of polypoidal lesions led to a diagnosis of PCV. Four aflibercept intravitreal injections were performed in her right eye. After treatment, indocyanine green angiography (ICGA) confirmed residual polypoidal lesions with branching vascular networks and PHS with choroidal vascular hyperpermeability. OCT showed PHS associated with small sharp-peaked retinal pigment epithelium (RPE) elevation in peripheral fundus and small RPE elevation in posterior fundus. Based on the above findings, PCV with PHS was finally diagnosed in the right eye. Posttreatment corrected visual acuity in the right eye was 20/20. She presented again 32 months later, with complaint of vision loss in her left eye. Left corrected visual acuity was 20/20, and fundus examination showed mild vitreous hemorrhage. Vitrectomy was performed. In temporal midperipheral fundus, fluorescein angiography revealed CSC, and OCT showed pachychoroid. ICGA depicted abnormal choroidal networks and PHS in peripheral fundus. Furthermore, polypoidal lesions were confirmed by OCT. Based on the above findings, PEHCR and CSC with PHS was finally diagnosed in the left eye. Postoperative corrected visual acuity in the left eye was 20/20, and aflibercept intravitreal injection was performed for prevention of recurrence of vitreous hemorrhage. Conclusions This is the first case report of PCV with PHS in one eye, and PEHCR with CSC and PHS in the contralateral eye. This case suggests that PCV, PEHCR, and CSC may be linked pathologies of pachychoroid spectrum disease.
C1 [Kitagawa, Yorihisa; Shimada, Hiroyuki; Kawamura, Akiyuki; Tanaka, Koji; Mori, Ryusaburo; Onoe, Hajime; Nakashizuka, Hiroyuki] Nihon Univ, Sch Med, Dept Ophthalmol, 1-6 Surugadai, Tokyo 1018309, Japan.
C3 Nihon University
RP Shimada, H (通讯作者)，Nihon Univ, Sch Med, Dept Ophthalmol, 1-6 Surugadai, Tokyo 1018309, Japan.
EM sshimada@olive.ocn.ne.jp
CR Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Goel N, 2019, INDIAN J OPHTHALMOL, V67, P419, DOI 10.4103/ijo.IJO_714_18
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Lim HB, 2021, ACTA OPHTHALMOL, V99, pE117, DOI 10.1111/aos.14522
   Mantel I, 2012, AM J OPHTHALMOL, V153, P910, DOI 10.1016/j.ajo.2011.10.017
   Mantel I, 2009, AM J OPHTHALMOL, V148, P932, DOI 10.1016/j.ajo.2009.06.032
   Mashayekhi Arman, 2013, J Ophthalmic Vis Res, V8, P264
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Shroff D, 2021, RETINA-J RET VIT DIS, V41, P1518, DOI 10.1097/IAE.0000000000003063
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Vandefonteyne S, 2020, BRIT J OPHTHALMOL, V104, P874, DOI 10.1136/bjophthalmol-2018-313307
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 18
TC 1
Z9 1
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 4
PY 2021
VL 21
IS 1
AR 320
DI 10.1186/s12886-021-02067-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UM0RK
UT WOS:000693047700001
PM 34481477
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Vagge, A
   Testa, V
   Nicolo, M
   Traverso, CE
AF Desideri, L. Ferrio
   Vagge, A.
   Testa, V
   Nicolo, M.
   Traverso, C. E.
TI Risuteganib Broad-spectrum integrin inhibitor Treatment of diabetic
   macular edema Treatment of dry age-related macular degeneration
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Risuteganib; ALG-1001; Luminate; Integrin inhibitors; Diabetic macular
   edema; Age-related macular degeneration
ID THERAPY; LIFITEGRAST; ANTAGONIST
AB Although several anti-vascular endothelial growth factor (VEGF) agents have been largely employed for the treatment of various retinal diseases, other molecules with different therapeutic targets are being investigated. Among them, anti-integrin drugs have shown promising results for the treatment of ocular diseases. Risuteganib (ALG-1001, Luminate) is a novel anti-integrin drug formed by a synthetic arginyl-glycyl-aspartic (RGD) acid peptide which modulates the biological activities of several integrin isoforms. Results from phase II studies have outlined a promising clinical efficacy and tolerability profile for risuteganib in the treatment of diabetic macular edema and vitreous tractional macular syndrome. Moreover, ongoing trials are investigating its role for treating macular degeneration and retinal dystrophies. Further randomized, larger-scale trials will better characterize its potential clinical effectiveness for treating these vitreoretinal disorders.
C1 [Desideri, L. Ferrio; Vagge, A.; Testa, V; Nicolo, M.; Traverso, C. E.] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
   [Vagge, A.; Testa, V; Nicolo, M.; Traverso, C. E.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Nicolo, M.] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Desideri, LF (通讯作者)，IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
EM lorenzoferrodes@gmail.com
RI Desideri, Lorenzo Ferro/AAM-5368-2020
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   [Anonymous], PIP CLIN TRIALS
   Barra F, 2019, GYNECOL OBSTET INVES, V84, P107, DOI 10.1159/000493361
   Beltran M.A., 2018, INVEST OPHTHALMOL VI, V59
   Boyer D.S., 2012, INVEST OPHTHALMOL VI, V53
   Campa C, 2016, CURR DRUG TARGETS, V17, P328, DOI 10.2174/1573399811666150615151324
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Desideri LF, 2019, DRUG FUTURE, V44, P761, DOI 10.1358/dof.2019.44.10.3058864
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Donnenfeld ED, 2017, EXPERT OPIN PHARMACO, V18, P1517, DOI 10.1080/14656566.2017.1372748
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gonzalez-Salinas R, 2018, SEMIN OPHTHALMOL, V33, P634, DOI 10.1080/08820538.2017.1388411
   Hagemeyer CE, 2010, CURR PHARM DESIGN, V16, P4119
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kaiser P.K., 2013, INVEST OPHTHALMOL VI, V54
   Kenney C.M., 2018, INVEST OPHTHALMOL VI, V59
   Kuppermann B.D., 2016, INVEST OPHTHALMOL VI, V57
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mackel M.J., Patent No. [WO 2011060104, 2011060104]
   Mackel M.J., Patent No. [WO 2012154894, 2012154894]
   Maturi R., 2020, INVEST OPHTHALMOL VI, V61
   Milloud R, 2017, BIOL CELL, V109, P127, DOI 10.1111/boc.201600041
   Mould A Paul, 2019, Curr Protoc Cell Biol, V82, pe69, DOI 10.1002/cpcb.69
   Munoz-Ramon P V, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P75, DOI 10.1016/j.oftal.2019.09.011
   Pan L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2502-0
   Park SC, 2018, WORLD J GASTROENTERO, V24, P1868, DOI 10.3748/wjg.v24.i17.1868
   Pipeline, PIPELINE
   Pipeline, PIPELINE
   Quiroz-Mercado H, 2018, INVEST OPHTH VIS SCI, V59
   Schneider K., 2019, INVEST OPHTH VIS SCI, V60
   Schwab N, 2015, INT IMMUNOL, V27, P47, DOI 10.1093/intimm/dxu096
   Sepulveda-Vazquez H.E., 2012, INVEST OPHTHALMOL VI, V53
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Sun Y, 2013, J OCUL PHARMACOL TH, V29, P395, DOI 10.1089/jop.2012.0102
   Tirado V., 2019, INVEST OPHTHALMOL VI, V60
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Urias EA, 2017, VISION RES, V139, P221, DOI 10.1016/j.visres.2017.06.015
   Yang P., 1944, INVEST OPHTH VIS SCI, V60, P019
NR 39
TC 1
Z9 1
U1 0
U2 3
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2020
VL 45
IS 9
BP 633
EP 639
DI 10.1358/dof.2020.45.9.3161236
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NR2XV
UT WOS:000571427200002
DA 2022-11-30
ER

PT J
AU Wirth, MA
   Freiberg, F
   Pfau, M
   Wons, J
   Becker, MD
   Michels, S
AF Wirth, Magdalena A.
   Freiberg, Florentina
   Pfau, Maximilian
   Wons, Juliana
   Becker, Matthias D.
   Michels, Stephan
TI Optical coherence tomography angiography in age-related macular
   degeneration: persistence of vascular network in quiescent choroidal
   neovascularization
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
C1 [Wirth, Magdalena A.; Freiberg, Florentina; Pfau, Maximilian; Wons, Juliana; Becker, Matthias D.; Michels, Stephan] City Hosp Triemli, Zurich, Switzerland.
   [Becker, Matthias D.] Heidelberg Univ, Heidelberg, Germany.
   [Michels, Stephan] Univ Zurich, Zurich, Switzerland.
C3 Triemli Hospital; Ruprecht Karls University Heidelberg; University of
   Zurich
RP Wirth, MA (通讯作者)，Stadtspital Triemli Zurich, Dept Ophthalmol, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.
EM magdalena.wirth2@triemli.zuerich.ch
RI Pfau, Maximilian/N-1888-2019; Becker, Matthias/A-8733-2014
OI Pfau, Maximilian/0000-0001-9761-9640; 
FU Werner H. Spross Foundation (Zurich, Switzerland); Novartis Schweiz AG;
   Bayer Schweiz AG; Allergan; Novartis; Alimera; Bayer; Roche; Clanotech
FX This study was supported by the Werner H. Spross Foundation (Zurich,
   Switzerland). The 'Stiftung wissenschaftliche Forschung, Fonds
   Ophthalmologie, City Hospital Triemli' received research grants from
   Novartis Schweiz AG and Bayer Schweiz AG and payments for invited talks
   or advisory board participations for M.B and S.M. from Allergan,
   Novartis, Alimera, Bayer, Roche and Clanotech. None of the authors above
   has any conflict of interest related to this research.
CR Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Do DV, 2012, CASE REP OPHTHALM, V3, P384, DOI 10.1159/000338969
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Furuya M, 2005, VASC HEALTH RISK MAN, V1, P277, DOI 10.2147/vhrm.2005.1.4.277
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Wang Q, 2016, ACTA OPHTHALMOL, V94, P415, DOI 10.1111/aos.12841
NR 6
TC 9
Z9 11
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2017
VL 95
IS 4
BP 428
EP 430
DI 10.1111/aos.13226
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OJ
UT WOS:000403361300040
PM 27659278
OA Bronze
DA 2022-11-30
ER

PT J
AU Tsikata, E
   Lains, I
   Gil, J
   Marques, M
   Brown, K
   Mesquita, T
   Melo, P
   Cachulo, MD
   Kim, IK
   Vavvas, D
   Murta, JN
   Miller, JB
   Silva, R
   Miller, JW
   Chen, TC
   Husain, D
AF Tsikata, Edem
   Lains, Ines
   Gil, Joao
   Marques, Marco
   Brown, Kelsey
   Mesquita, Tania
   Melo, Pedro
   Cachulo, Maria da Luz
   Kim, Ivana K.
   Vavvas, Demetrios
   Murta, Joaquim N.
   Miller, John B.
   Silva, Rufino
   Miller, Joan W.
   Chen, Teresa C.
   Husain, Deeba
TI Automated Brightness and Contrast Adjustment of Color Fundus Photographs
   for the Grading of Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE image analysis; age-related macular degeneration; automated optimization
ID IMAGE-ANALYSIS; MACULOPATHY; FILM; EYE; PREVALENCE; DRUSEN;
   TRANSMISSION; DISEASE; SYSTEM; AMD
AB Purpose: The purpose of this study was to develop an algorithm to automatically standardize the brightness, contrast, and color balance of digital color fundus photographs used to grade AMD and to validate this algorithm by determining the effects of the standardization on image quality and disease grading.
   Methods: Seven-field color photographs of patients (> 50 years) with any stage of AMD and a control group were acquired at two study sites, with either the Topcon TRC-50DX or Zeiss FF-450 Plus cameras. Field 2 photographs were analyzed. Pixel brightness values in the red, green, and blue (RGB) color channels were adjusted in custom-built software to make the mean brightness and contrast of the images equal to optimal values determined by the Age-Related Eye Disease Study (AREDS) 2 group.
   Results: Color photographs of 370 eyes were analyzed. We found a wide range of brightness and contrast values in the images at baseline, even for those taken with the same camera. After processing, image brightness variability (brightest image-dimmest image in a color channel) was reduced 69-fold, 62-fold, and 96-fold for the RGB channels. Contrast variability was reduced 6-fold, 8-fold, and 13-fold, respectively, after adjustment. Of the 23% images considered nongradable before adjustment, only 5.7% remained nongradable.
   Conclusions: This automated software enables rapid and accurate standardization of color photographs for AMD grading.
   Translational Relevance: This work offers the potential to be the future of assessing and grading AMD from photos for clinical research and teleimaging.
C1 [Tsikata, Edem; Lains, Ines; Brown, Kelsey; Kim, Ivana K.; Vavvas, Demetrios; Miller, John B.; Miller, Joan W.; Chen, Teresa C.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA USA.
   [Tsikata, Edem; Chen, Teresa C.] Harvard Med Sch, Glaucoma Serv Massachusetts Eye & Ear, Boston, MA USA.
   [Lains, Ines; Gil, Joao; Marques, Marco; Cachulo, Maria da Luz; Murta, Joaquim N.; Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Lains, Ines; Gil, Joao; Cachulo, Maria da Luz; Murta, Joaquim N.; Silva, Rufino] Ctr Hosp & Univ Coimbra, Coimbra, Portugal.
   [Lains, Ines; Gil, Joao; Marques, Marco; Mesquita, Tania; Melo, Pedro; Cachulo, Maria da Luz; Silva, Rufino] Assoc Biomed Res & Innovat Light & Image, Coimbra, Portugal.
   [Lains, Ines; Kim, Ivana K.; Vavvas, Demetrios; Miller, John B.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Retina Serv Massachusetts Eye & Ear, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Universidade de
   Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de
   Coimbra (CHUC); Harvard University; Harvard Medical School
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, 243 Charles St,12th Floor, Boston, MA USA.
EM Deeba_Husain@meei.harvard.edu
RI Silva, Rufino M/J-2817-2012; Miller, John J/GZG-5663-2022; Murta,
   Joaquim/V-5494-2017
OI Silva, Rufino M/0000-0001-8676-0833; Murta, Joaquim/0000-0001-8926-5176;
   Vavvas, Demetrios/0000-0002-8622-6478; Husain,
   Deeba/0000-0002-8494-0950; Quadrado Gil, Joao/0000-0001-9032-1008; Kim,
   Ivana/0000-0003-0310-6129; Chen, Teresa/0000-0001-5327-2016
FU Miller Retina Research Fund; Miller Champalimaud Award; Portuguese
   Foundation for Science and Technology/Harvard Medical School Portugal
   Program [HMSP-ICJ/006/2013]; Fidelity Charitable Fund (Harvard
   University); Massachusetts Lions Eye Research Fund; American Glaucoma
   Society Mid-Career Award; National Institutes of Health [UL 1 RR025758];
   NATIONAL EYE INSTITUTE [R21EY023079, R01EY025362] Funding Source: NIH
   RePORTER
FX This project was financially supported by the Miller Retina Research
   Fund (MEE), the Miller Champalimaud Award (MEE), the Portuguese
   Foundation for Science and Technology/Harvard Medical School Portugal
   Program (HMSP-ICJ/006/2013), the Fidelity Charitable Fund (Harvard
   University), the Massachusetts Lions Eye Research Fund, an American
   Glaucoma Society Mid-Career Award, and a National Institutes of Health
   award (UL 1 RR025758).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bartling H, 2009, ACTA OPHTHALMOL, V87, P643, DOI 10.1111/j.1755-3768.2008.01321.x
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Fleming AD, 2006, INVEST OPHTH VIS SCI, V47, P1120, DOI 10.1167/iovs.05-1155
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   ITU, 1982, BT601 ITUR
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Neelam K, 2009, RETINA-J RET VIT DIS, V29, P192, DOI 10.1097/IAE.0b013e31818c178f
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Rasta SH, J MED SIGNALS SENS, V5, P40
   SAID FS, 1959, GERONTOLOGY, V3, P213, DOI 10.1159/000210900
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Somani R, 2005, CAN J OPHTHALMOL, V40, P293, DOI 10.1016/S0008-4182(05)80072-9
   Tanito M, 2010, J CATARACT REFR SURG, V36, P299, DOI 10.1016/j.jcrs.2009.08.036
   Teng T, 2002, MED BIOL ENG COMPUT, V40, P2, DOI 10.1007/BF02347689
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 29
TC 18
Z9 19
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2017
VL 6
IS 2
AR 3
DI 10.1167/tvst.6.2.3
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2GI
UT WOS:000410956600003
PM 28316876
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Qin, Y
   Dinabandhu, A
   Cao, X
   Sanchez, JC
   Jee, K
   Rodrigues, M
   Guo, CY
   Zhang, J
   Vancel, J
   Menon, D
   Khan, NS
   Ma, T
   Tzeng, SY
   Daoud, Y
   Green, JJ
   Semenza, GL
   Montaner, S
   Sodhi, A
AF Qin, Yu
   Dinabandhu, Aumreetam
   Cao, Xuan
   Sanchez, Jaron Castillo
   Jee, Kathleen
   Rodrigues, Murilo
   Guo, Chuanyu
   Zhang, Jing
   Vancel, Jordan
   Menon, Deepak
   Khan, Noore-Sabah
   Ma, Tao
   Tzeng, Stephany Y.
   Daoud, Yassine
   Green, Jordan J.
   Semenza, Gregg L.
   Montaner, Silvia
   Sodhi, Akrit
TI ANGPTL4 influences the therapeutic response of patients with neovascular
   age-related macular degeneration by promoting choroidal
   neovascularization
SO JCI INSIGHT
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOPOIETIN-LIKE 4; VASCULAR-PERMEABILITY;
   PIGMENT EPITHELIUM; FACTOR VEGF; HYPOXIA; EXPRESSION; ANGIOGENESIS;
   TARGET; MICE
C1 [Qin, Yu; Dinabandhu, Aumreetam; Cao, Xuan; Sanchez, Jaron Castillo; Jee, Kathleen; Rodrigues, Murilo; Guo, Chuanyu; Zhang, Jing; Vancel, Jordan; Khan, Noore-Sabah; Daoud, Yassine; Green, Jordan J.; Sodhi, Akrit] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD USA.
   [Qin, Yu] China Med Univ, Eye Hosp China Med Univ, Dept Ophthalmol,Affiliated Hosp 4, Key Lens Res Lab Liaoning Prov, Shenyang, Peoples R China.
   [Dinabandhu, Aumreetam; Menon, Deepak; Ma, Tao; Montaner, Silvia] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA.
   [Zhang, Jing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Clin Res Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Dept Biomed Engn, Inst Nano BioTechnol, Baltimore, MD USA.
   [Tzeng, Stephany Y.; Green, Jordan J.] Johns Hopkins Univ, Translat Tissue Engn Ctr, Sch Med, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Genet Med, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Radiat Oncol, Baltimore, MD USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Dept Biol Chem, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; China Medical
   University; University System of Maryland; University of Maryland
   Baltimore; Sun Yat Sen University; Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University;
   Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University
RP Sodhi, A (通讯作者)，Wilmer Eye Inst, Johns Hopkins Sch Med, 400 N Broadway St,Smith Bldg,4039, Baltimore, MD 21287 USA.; Montaner, S (通讯作者)，Univ Maryland, Dept Oncol & Diagnost Sci, 650 Baltimore St,7th North,Rm 7263, Baltimore, MD 21201 USA.
EM smontaner@umaryland.edu; asodhi1@jhmi.edu
RI Menon, Deepak/S-7899-2019; Rodrigues, Murilo/F-1684-2014
OI Menon, Deepak/0000-0002-6529-7859; Rodrigues,
   Murilo/0000-0001-9734-8617; Dinabandhu, Aumreetam/0000-0002-2879-5031;
   Guo, Chuanyu/0000-0001-8434-4916
FU National Eye Institute, NIH [R01EY029750, R01EY025705, R01EY031097,
   EY001765]; Research to Prevent Blindness Inc.; Alcon Research Institute;
   Irving Sisenwein Professorship in Ophthalmology; Sybil B. Harrington
   Stein Innovation Award for Macular Degeneration from Research to Prevent
   Blindness Inc.
FX This work was supported by National Eye Institute, NIH, grants
   R01EY029750 to AS, R01EY025705 to SM and AS, R01EY031097 to JJG, and
   EY001765 (the Wilmer Core Grant for Vision Research, Microscopy and
   Imaging Core Module). AS gratefully acknowledges the support he received
   as a Special Scholar Award recipient from Research to Prevent Blindness
   Inc., as recipient of the Alcon Young Investigator Award from the Alcon
   Research Institute, and from the Branna and Irving Sisenwein
   Professorship in Ophthalmology. GLS is a recipient of the Sybil B.
   Harrington Stein Innovation Award for Macular Degeneration from Research
   to Prevent Blindness Inc.
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Babapoor-Farrokhran S, 2015, P NATL ACAD SCI USA, V112, pE3030, DOI 10.1073/pnas.1423765112
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bosch-Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cao X, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144469
   De La Huerta I, 2020, JAMA OPHTHALMOL, V138, P972, DOI 10.1001/jamaophthalmol.2020.2723
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327
   Guo L, 2014, INFLAMM RES, V63, P13, DOI 10.1007/s00011-013-0678-0
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2021, JAMA OPHTHALMOL, V139, P542, DOI 10.1001/jamaophthalmol.2021.0221
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jee K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183320
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kersten S, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100150
   Khan M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081869
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kurihara T, 2014, ADV EXP MED BIOL, V801, P275, DOI 10.1007/978-1-4614-3209-8_35
   Landowski M, 2022, J OCUL PHARMACOL TH, V38, P3, DOI 10.1089/jop.2021.0067
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899
   Lutty G, 1999, MOL VIS, V5
   Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107
   Malik D, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37880
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oliner JD, 2012, INVEST OPHTH VIS SCI, V53, P2170, DOI 10.1167/iovs.11-7381
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Parker MW, 2012, BIOCHEMISTRY-US, V51, P9437, DOI 10.1021/bi3012143
   Paulus YM, 2017, HANDB EXP PHARMACOL, V242, P271, DOI 10.1007/164_2016_78
   Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639
   Rennel ES, 2011, MICROCIRCULATION, V18, P598, DOI 10.1111/j.1549-8719.2011.00120.x
   Rodrigues M, 2016, INVEST OPHTH VIS SCI, V57, P6739, DOI 10.1167/iovs.16-19513
   Rui Y, 2019, ACS APPL MATER INTER, V11, P10472, DOI 10.1021/acsami.8b20206
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Semenza GL, 2014, ANNU REV PHYSIOL, V76, P39, DOI 10.1146/annurev-physiol-021113-170322
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sodhi A, 2019, J CLIN INVEST, V129, P4593, DOI 10.1172/JCI120879
   Sodhi A, 2015, JAMA OPHTHALMOL, V133, P1375, DOI 10.1001/jamaophthalmol.2015.3723
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Wang ZY, 2009, MED HYPOTHESES, V72, P448, DOI 10.1016/j.mehy.2008.09.055
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912
   Zhang J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139202
NR 70
TC 0
Z9 0
U1 5
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JUL 8
PY 2022
VL 7
IS 13
DI 10.1172/jci.insight.157896
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 2Z6XM
UT WOS:000826718100001
PM 35653189
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kowalski, JP
   Peksinski, J
   Mikolajczak, G
AF Kowalski, Janusz P.
   Peksinski, Jakub
   Mikolajczak, Grzegorz
TI Controlling the Progression of Age-related Macular Degeneration Using
   the Image Quality Index and the Reference Image
SO ELEKTRONIKA IR ELEKTROTECHNIKA
LA English
DT Article
DE Digital image; data matching; quality measures
ID GRADING SYSTEM; MACULOPATHY
AB This paper presented a possible application of a digital image quality measure, called the Universal Quality Image Index Q, for the diagnostics of the eye fundus. The proposed method supports examination of the progression of macular degeneration allowing to reduce the number of errors during a subjective examination by an ophthalmologist. This occurs mostly when changes are small between successive examinations. This paper proposes an effective algorithm to eliminate the errors during the subjective assessment caused by inaccurate synchronization of examined images.
C1 [Kowalski, Janusz P.] Pomeranian Med Univ, Fac Med Biotechnol & Lab Med, PL-70204 Szczecin, Poland.
   [Peksinski, Jakub; Mikolajczak, Grzegorz] West Pomeranian Univ Technol, Fac Elect Engn, PL-71126 Szczecin, Poland.
C3 Pomeranian Medical University; West Pomeranian University of Technology
RP Kowalski, JP (通讯作者)，Pomeranian Med Univ, Fac Med Biotechnol & Lab Med, Rybacka St 1, PL-70204 Szczecin, Poland.
EM jpeksinski@zut.edu.pl
RI Pęksiński, Jakub/G-6846-2016; Mikołajczak, Grzegorz/J-6226-2016
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lech P, 2014, ELEKTRON ELEKTROTECH, V20, DOI 10.5755/j01.eee.20.4.6887
   Lech P, 2014, LECT NOTES COMPUT SC, V8671, P374, DOI 10.1007/978-3-319-11331-9_45
   Okarma K., 2008, INT C COMP VIS GRAPH
   Okarma K, 2012, OPT REV, V19, P349, DOI 10.1007/s10043-012-0055-1
   Peksinski J., 2013, PRZ ELEKTROTECHNICZN, V89, P282
   Peksinski J, 2012, LECT NOTES ARTIF INT, V7197, P294, DOI 10.1007/978-3-642-28490-8_31
   Peksinski J, 2011, 2011 34TH INTERNATIONAL CONFERENCE ON TELECOMMUNICATIONS AND SIGNAL PROCESSING (TSP), P527, DOI 10.1109/TSP.2011.6043674
   Rickman C., 2013, INVESTIGATIVE OPHTHA, V54
   Saine PJ, 2006, FUNDUS PHOTOGRAPHY W
   Wang Z, 2002, IEEE SIGNAL PROC LET, V9, P81, DOI 10.1109/97.995823
   Wang Z, 2009, IEEE SIGNAL PROC MAG, V26, P98, DOI 10.1109/MSP.2008.930649
NR 14
TC 4
Z9 4
U1 0
U2 1
PU KAUNAS UNIV TECHNOLOGY
PI KAUNAS
PA KAUNAS UNIV TECHNOL, DEPT ELECTRONICS ENGINEERING, STUDENTU STR 50,
   KAUNAS, LT-51368, LITHUANIA
SN 1392-1215
J9 ELEKTRON ELEKTROTECH
JI Elektron. Elektrotech.
PY 2015
VL 21
IS 6
BP 70
EP 74
DI 10.5755/j01.eee.21.6.13766
PG 5
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA CZ9BD
UT WOS:000367391900014
OA gold
DA 2022-11-30
ER

PT J
AU Zhou, Q
   Shaffer, J
   Ying, GS
AF Zhou, Qiang
   Shaffer, James
   Ying, Gui-shuang
TI Pseudodrusen in the Fellow Eye of Patients with Unilateral Neovascular
   Age-Related Macular Degeneration: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC-ATROPHY; CLINICAL CHARACTERISTICS; RISK-FACTOR; PREVALENCE;
   MACULOPATHY; PROGRESSION; LESIONS
AB Importance
   The fellow eye of patients with unilateral neovascular age-related degeneration (nAMD) is at increased risk of developing late AMD. Several cohort studies have evaluated the prevalence of pseudodrusen and the association between pseudodrusen and late AMD in the fellow eye of patients with unilateral nAMD. However, these studies have limited sample sizes and their results are inconsistent.
   Objective
   To evaluate the prevalence rate of pseudodrusen, and the association between pseudodrusen and incidence of late AMD (nAMD and geographic atrophy (GA)) in the fellow eye of patients with unilateral nAMD.
   Data Sources
   The PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched up to July 2015, as well as other systematic reviews.
   Study Selection
   All cohort studies for pseudodrusen with late AMD in the fellow eye of patients with unilateral nAMD.
   Data Extraction and Synthesis
   The numbers of patients with and without pseudodrusen at baseline and the numbers of incident nAMD and GA during follow up among patients with and without pseudodrusen were independently extracted by 2 authors. The results were pooled using random-effects meta-analysis. Heterogeneity was assessed using the I-2 test.
   Main Outcome Measures
   Prevalence rate of pseudodrusen, risk ratios (RRs) and their 95% confidence intervals (95% CIs) for associations between pseudodrusen and the incidence of nAMD and GA in the fellow eye.
   Results
   Five cohort studies (N = 677 patients) from 8 countries across 4 continents were included. The pooled prevalence rate of pseudodrusen in the fellow eye was 48.1% (95% CI: 36.7-59.5%, I-2 = 87%). Pseudodrusen were associated with an increased risk of nAMD (RR = 1.54, 95% CI: 1.10-2.16, I-2 = 42%), GA (RR = 4.70, 95% CI: 1.22-18.1, I-2 = 64%), and late AMD (RR = 2.03, 95% CI: 1.35-3.06, I-2 = 60%).
   Conclusions
   For patients with unilateral nAMD, pseudodrusen were present in about half of the fellow eyes. The presence of pseudodrusen was associated with a 1.5 times higher risk of developing nAMD, a 4.7 times higher risk of developing GA, and a 2 times higher risk of developing late AMD. Pseudodrusen should be considered in evaluating the risk of late AMD development; however, due to considerable heterogeneity across these studies, a larger study is needed to validate these findings.
C1 [Zhou, Qiang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Shaffer, James; Ying, Gui-shuang] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Capital Medical University; University of Pennsylvania
RP Zhou, Q (通讯作者)，Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
EM zhouqianghandan@sina.com
OI Zhou, Qiang/0000-0002-2351-3621
FU National Eye Institute, National Institutes of Health [R21EY023689, P30
   EY01583-26]; Foundation Fighting Blindness; Mackall Trust Funds;
   NATIONAL EYE INSTITUTE [P30EY001583, R21EY023689] Funding Source: NIH
   RePORTER
FX This work is supported by the National Eye Institute, National
   Institutes of Health grants R21EY023689, P30 EY01583-26, the Foundation
   Fighting Blindness, and the Mackall Trust Funds.
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   [Anonymous], 2008, OPHTHALMOLOGY, V115, P9, DOI [10.1016/j.ophtha.2008.03.008, DOI 10.1016/J.0PHTHA.2008.03.008]
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 50
TC 6
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2016
VL 11
IS 2
AR e0149030
DI 10.1371/journal.pone.0149030
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF3DG
UT WOS:000371223400030
PM 26895455
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sood, S
   Mandell, J
   Watane, A
   Friedman, S
   Parikh, R
AF Sood, Shefali
   Mandell, Jordan
   Watane, Arjun
   Friedman, Scott
   Parikh, Ravi
TI Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for
   Patients With Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; LEGAL BLINDNESS; OPHTHALMOLOGY
AB IMPORTANCE The study team investigated costs associated with the ranibizumab port delivery system (PDS) for neovascular age-related macular (nAMD), an alternative to conventional intravitreal anti-vascular endothelial growth factor (VEGF) injections.
   OBJECTIVE To investigate costs of intravitreal anti-VEGF injections vs ranibizumab PDS for patients with neovascular AMD (nAMD).
   DESIGN, SETTING, AND PARTICIPANTS This cost analysis used trial data and Medicare reimbursement rates and included patients with nAMD who were receiving ranibizumab, aflibercept, bevacizumab injections, or ranibizumab PDS.
   MAIN OUTCOMES AND MEASURES The number of intravitreal ranibizumab, aflibercept, and bevacizumab injections to break even with costs of ranibizumab PDS. Total direct medical costs over 1year and 5 years for the ranibizumab PDS arm with refills at fixed 6-month intervals compared with monthly or bimonthly injections were calculated using Medicare rates. Scenario and sensitivity analyses accounted for uncertainty and variation.
   RESULTS The mean (SD) number of ranibizumab, aflibercept, and bevacizumab injections to break even with the cost of ranibizumab PDS with 1 refill was 10.8 (1.3), 9.3 (1.1), and 34.5 (4.2), respectively. Ranibizumab PDS with fixed 6-month refills over 1 year cost $21016 ($2102). Comparatively, monthly intravitreal ranibizumab cost $1943 (95% CI, -$3047 to $6932; P = .34) more. aflibercept cost $5702 (95% CI, $253-$11151; P = .04) more, and bevacizumab cost $16 732 (95% CI, -$20170 to -$13 294. P < .001) less. For bimonthly injections. aflibercept cost $7658 (95% Cl. -$11649.52 to -$3665.61; P = .006) less. Over 5 years, monthly intravitreal ranibizumab projected to cost $25 581(95% CI, $2275-$48 887; P = .04) more, aflibercept cost $44 374 (95% CI, $18 623-$70125; P = .008) more, and bevacizumab cost $67 793 (95% CI, -$82 501to -$53 085; P < .001) less than PDS with fixed refills (mean [SD] cost, $89 218 [$8921]). For bimonthly injections, aflibercept cost $22 422 (95% CI, -$40 287 to -$45,56; P = .03) less. In scenario analyses, ranibizumab PDS with refills as needed offered cost savings compared with real-world intravitreal ranibizumab or aflibercept use at 5 years but not at 1year.
   CONCLUSIONS AND RELEVANCE In this cost analysis, ranibizumab PDS with 1 refill cost more than intravitreal ranibizumab or aflibercept injections if less than or equal to approximately 11 or 10 injections, respectively, are required within the first year. Long term, if less than 4.4 and 3.8 injections are needed per refill, intravitreal ranibizumab and aflibercept is lower cost. Ranibizumab PDS costs more than intravitreal bevacizumab injections throughout scenarios.
C1 [Sood, Shefali] NYU, Sch Med, New York, NY USA.
   [Mandell, Jordan] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Watane, Arjun] Yale Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT USA.
   [Friedman, Scott] Florida Retina Consultants, Lakeland, FL USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
   [Parikh, Ravi] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 New York University; University of Miami; Yale University; New York
   University
RP Parikh, R (通讯作者)，NYU, Sch Med, Manhattan Retina & Eye, 67 E 78th St,Unit 1C, New York, NY 10075 USA.
EM rap120@mail.harvard.edu
CR [Anonymous], 2022, GENENTECH OPHTHALMOL
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Centers for Medicare and Medicaid Services, 2022 ASP DRUG PRIC F
   Centers for Medicare Medicaid Services, PHYS FEE SCHED LOOK
   Chang JS, 2014, OPHTHALMOLOGY, V121, P946, DOI 10.1016/j.ophtha.2013.11.003
   de Carlo TE, 2017, CHOROIDAL DISORDERS, P73, DOI 10.1016/B978-0-12-805313-3.00006-5
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Glasser DB, 2020, OPHTHALMOLOGY, V127, P1688, DOI 10.1016/j.ophtha.2020.06.012
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kiss S, 2018, CLIN OPHTHALMOL, V12, P1625, DOI 10.2147/OPTH.S169143
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathenge Wanjiku, 2014, Community Eye Health, V27, P49
   McClard CK, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000669
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Parekh PK, 2018, OPHTHALMOL RETINA, V2, P659, DOI 10.1016/j.oret.2018.01.002
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Takahashi K, 2022, CLIN OPHTHALMOL, V16, P531, DOI 10.2147/OPTH.S345403
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 25
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2022
VL 140
IS 7
BP 716
EP 723
DI 10.1001/jamaophthalmol.2022.1819
EA JUN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3C7IR
UT WOS:000812370800004
PM 35708679
DA 2022-11-30
ER

PT J
AU Zhang, R
   Wang, LY
   Wang, YF
   Wu, CR
   Lei, CL
   Wang, MX
   Ma, L
AF Zhang, Rui
   Wang, Li-Yuan
   Wang, Ya-Feng
   Wu, Chang-Rui
   Lei, Chun-Ling
   Wang, Ming-Xu
   Ma, Le
TI Associations of the G1961E and D2177N variants in ABCA4 and the risk of
   age-related macular degeneration
SO GENE
LA English
DT Article
DE Age-related macular degeneration; ABCA4; Polymorphism
ID CASSETTE TRANSPORTER ABCA4; STARGARDT DISEASE GENE; FUNDUS
   AUTOFLUORESCENCE; ALLELIC VARIATION; SUSCEPTIBILITY; LIPOFUSCIN;
   JAPANESE; BISRETINOIDS; ACCUMULATION; MACULOPATHY
AB Objective: The aim of this study was to identify the relationship between G1961E and D2177N variants in the ABCA4 gene with AMD susceptibility.
   Design and methods: All eligible studies published up to October 2014 were obtained from MEDLINE, EMBASE, and ISI Web of Science. The pooled odds ratio (OR) with 95% confidence intervals (CIs) was calculated to evaluate the strength of this association.
   Results: Twenty-four studies enrolling 4580 AMD cases and 5180 controls were identified. Both G1961E (OR = 322,95% CI: 1.74-5.95) and D2177N (OR = 2.36, 95% CI: 1.41-3.93) variations showed significant associations with increased risk of AMD. In addition, a more significant relationship in the D2177N mutation with increased risk for AMD was found in Americans (OR = 4.31, 95% CI: 1.90-9.73), while no association was demonstrated in Europeans. For Asians, no carriers of the risk factor A allele in either variant were detected in any of AMD patients and control subjects.
   Conclusions: Significant evidence was found for a relationship between the G1961E and D2177N variants in ABCA4 with increased susceptibility to AMD, specifically for Americans. However, large-scale studies are still required to further validate these findings in different ethnicities. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Rui; Wang, Li-Yuan; Wang, Ya-Feng; Wang, Ming-Xu; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710061, Shaanxi, Peoples R China.
   [Wu, Chang-Rui] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian, Peoples R China.
   [Lei, Chun-Ling] Xi An Jiao Tong Univ, Hosp Xian 4, Xian, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Wang, MX (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM wangmx601@mail.xjtu.edu.cn; male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; China Postdoctoral Science Foundation [2014M560790]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059), the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008) and the
   China Postdoctoral Science Foundation (2014M560790).
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Contreras AV, 2014, MOL VIS, V20, P105
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hansen M., 2013, ACTA OPHTHALMOL, V91, P537
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kim SR, 2010, VISION RES, V50, P729, DOI 10.1016/j.visres.2009.09.015
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   McNeill RJ, 2000, INVEST OPHTH VIS SCI, V41, pS144
   Pawar AS, 2008, INVEST OPHTH VIS SCI, V49, P2743, DOI 10.1167/iovs.07-1499
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Ritter M, 2013, INVEST OPHTH VIS SCI, V54, P6416, DOI 10.1167/iovs.12-11550
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 2012, BBA-MOL CELL BIOL L, V1821, P99, DOI 10.1016/j.bbalip.2011.06.010
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Yi JH, 2012, MOL MED REP, V6, P1045, DOI 10.3892/mmr.2012.1063
NR 41
TC 6
Z9 7
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD AUG 1
PY 2015
VL 567
IS 1
BP 51
EP 57
DI 10.1016/j.gene.2015.04.068
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CL5DJ
UT WOS:000356979700007
PM 25921964
DA 2022-11-30
ER

PT J
AU Zayit-Soudry, S
   Duncan, JL
   Syed, R
   Menghini, M
   Roorda, AJ
AF Zayit-Soudry, Shiri
   Duncan, Jacque L.
   Syed, Reema
   Menghini, Moreno
   Roorda, Austin J.
TI Cone Structure Imaged With Adaptive Optics Scanning Laser Ophthalmoscopy
   in Eyes With Nonneovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; adaptive optics; cones; scanning laser
   ophthalmoscopy
ID GEOGRAPHIC ATROPHY; COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE;
   PROGRESSION; DRUSEN; PHOTORECEPTORS; MACULOPATHY; TOPOGRAPHY;
   LIPOFUSCIN; EVOLUTION
AB PURPOSE. To evaluate cone spacing using adaptive optics scanning laser ophthalmoscopy (AOSLO) in eyes with nonneovascular AMD, and to correlate progression of AOSLO-derived cone measures with standard measures of macular structure.
   METHODS. Adaptive optics scanning laser ophthalmoscopy images were obtained over 12 to 21 months from seven patients with AMD including four eyes with geographic atrophy (GA) and four eyes with drusen. Adaptive optics scanning laser ophthalmoscopy images were overlaid with color, infrared, and autofluorescence fundus photographs and spectral domain optical coherence tomography (SD-OCT) images to allow direct correlation of cone parameters with macular structure. Cone spacing was measured for each visit in selected regions including areas over drusen (n = 29), at GA margins (n = 14), and regions without drusen or GA (n = 13) and compared with normal, age-similar values.
   RESULTS. Adaptive optics scanning laser ophthalmoscopy imaging revealed continuous cone mosaics up to the GA edge and overlying drusen, although reduced cone reflectivity often resulted in hyporeflective AOSLO signals at these locations. Baseline cone spacing measures were normal in 13/13 unaffected regions, 26/28 drusen regions, and 12/14 GA margin regions. Although standard clinical measures showed progression of GA in all study eyes, cone spacing remained within normal ranges in most drusen regions and all GA margin regions.
   CONCLUSIONS. Adaptive optics scanning laser ophthalmoscopy provides adequate resolution for quantitative measurement of cone spacing at the margin of GA and over drusen in eyes with AMD. Although cone spacing was often normal at baseline and remained normal over time, these regions showed focal areas of decreased cone reflectivity. These findings may provide insight into the pathophysiology of AMD progression. (ClinicalTrials.gov number, NCT00254605.)
C1 [Zayit-Soudry, Shiri; Duncan, Jacque L.; Syed, Reema; Menghini, Moreno] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Roorda, Austin J.] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California Berkeley
RP Duncan, JL (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA.
EM duncanj@vision.ucsf.edu
OI Zayit Soudry, Shiri/0000-0002-8736-1823; Menghini,
   Moreno/0000-0002-1432-2524
FU Alan Laties Career Development Award, Foundation Fighting Blindness;
   National Institutes of Health [EY002162, EY014375]; Novartis Institutes
   for Biomedical Research; Foundation Fighting Blindness; Research to
   Prevent Blindness; Beckman Initiative for Macular Research; Bright-Focus
   Foundation; Bernard A. Newcomb Macular Degeneration Fund; That Man May
   See, Inc.; Hope for Vision; University of California at San Francisco
   Research Allocation Program Novel Clinical/Translational Methods Award;
   George and Rosalie Hearst Foundation; Novartis Institutes for Biomedical
   Research [EY014375]; NATIONAL EYE INSTITUTE [P30EY002162, R01EY014375]
   Funding Source: NIH RePORTER
FX Supported by grants from Alan Laties Career Development Award,
   Foundation Fighting Blindness (SZS); National Institutes of Health
   Grants EY002162, EY014375, Novartis Institutes for Biomedical Research,
   Foundation Fighting Blindness, Research to Prevent Blindness, Beckman
   Initiative for Macular Research (JLD), Bright-Focus Foundation (formerly
   The American Health Assistance Foundation), The Bernard A. Newcomb
   Macular Degeneration Fund, That Man May See, Inc., Hope for Vision (All
   JLD); University of California at San Francisco Research Allocation
   Program Novel Clinical/Translational Methods Award (RS); The George and
   Rosalie Hearst Foundation (MM); and the Novartis Institutes for
   Biomedical Research (EY014375; AR).
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Carroll J, 2008, ARCH OPHTHALMOL-CHIC, V126, P857, DOI 10.1001/archopht.126.6.857
   Chen YM, 2011, INVEST OPHTH VIS SCI, V52, P3281, DOI 10.1167/iovs.10-6538
   Choi SS, 2006, INVEST OPHTH VIS SCI, V47, P2080, DOI 10.1167/iovs.05-0997
   Chui TYP, 2008, J OPT SOC AM A, V25, P3021, DOI 10.1364/JOSAA.25.003021
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DEMONASTERIO FM, 1985, INVEST OPHTH VIS SCI, V26, P289
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Duncan JL, 2007, INVEST OPHTH VIS SCI, V48, P3283, DOI 10.1167/iovs.06-1422
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Godara P, 2012, ADV EXP MED BIOL, V723, P451, DOI 10.1007/978-1-4614-0631-0_57
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Li KY, 2007, J OPT SOC AM A, V24, P1358, DOI 10.1364/JOSAA.24.001358
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Lutty G, 1999, MOL VIS, V5
   Merino D, 2011, BIOMED OPT EXPRESS, V2, P2189, DOI 10.1364/BOE.2.002189
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   Roorda A, 2001, VISION RES, V41, P1291, DOI 10.1016/S0042-6989(01)00043-8
   Roorda A, 2007, INVEST OPHTH VIS SCI, V48, P2297, DOI 10.1167/iovs.06-1450
   Roorda A, 2002, J VISION, V2, P404, DOI 10.1167/2.5.4
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stevenson SB, 2005, PROC SPIE, V5688, P145, DOI 10.1117/12.591190
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Talcott KE, 2011, INVEST OPHTH VIS SCI, V52, P2219, DOI 10.1167/iovs.10-6479
   Tuten WS, 2012, OPTOMETRY VISION SCI, V89, P563, DOI 10.1097/OPX.0b013e3182512b98
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wolfing JI, 2006, OPHTHALMOLOGY, V113, P1014, DOI 10.1016/j.ophtha.2006.01.056
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhang YH, 2006, OPT LETT, V31, P1268, DOI 10.1364/OL.31.001268
NR 61
TC 55
Z9 55
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2013
VL 54
IS 12
BP 7498
EP 7509
DI 10.1167/iovs.13-12433
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265KH
UT WOS:000327949700042
PM 24135755
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, XC
   Cao, XG
   Zhao, MW
   Bao, YZ
AF Li, Xiaochun
   Cao, Xiaoguang
   Zhao, Mingwei
   Bao, Yongzhen
TI The Changes of Irisin and Inflammatory Cytokines in the Age-Related
   Macular Degeneration and Retinal Vein Occlusion
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE irisin; age-related macular degeneration (AMD); retinal vein occlusion
   (RVO); macular thickness; inflammatory factor
ID IMMUNOHISTOCHEMICAL LOCALIZATION; AQUEOUS-HUMOR; ASSOCIATION; CELLS;
   IDENTIFICATION; DISEASE; VEGF; FAT
AB PurposeAge-related macular degeneration (AMD) and retinal vein occlusion (RVO) are irreversible chorioretinal diseases, which might induce severe damage in visual function. The metabolic factor and inflammatory factors might play important roles in the pathogenesis of AMD and RVO. The levels of irisin and 14 cytokines were analyzed in aqueous humor of AMD and RVO eyes to evaluate the roles of irisin and inflammatory factors. MethodsWe collected aqueous humor samples from patients with AMD (n = 27), RVO (n = 30), and cataract (as control, n = 23) eyes. Samples were assayed using ELISA kit for irisin and a multiplex immunoassay kit for 14 cytokines. The macular thickness (MT) was measured with OCT in all included eyes. ResultsMT in the RVO group is significantly higher than that in the AMD or control group. Irisin levels in the aqueous samples of AMD and RVO eyes were both significantly lower than that in the control. Furthermore, a positive correlation was found between irisin and MT in the RVO. Compared with the controls, AMD eyes had significantly higher levels of BDNF, VEGF-A, VEGF-R1, VEGF-R2, IL-10, TNF-alpha, VCAM-1, IP-10, and MCP-1. Similarly, RVO eyes had significantly higher levels of BDNF, VEGF-A, VEGF-R1, VEGF-R2, IL-6, IL-8, IL-10, TNF-alpha, ICAM-1, VCAM-1, IP-10, and MCP-1. However, there was no significant difference between the levels of PDGF-BB or TNF-beta in these three groups. A negative correlation was found between VEGF-A and MT in AMD, as well as in control. Furthermore, a positive correlation was found between IL-6 and MT in the 80 included eyes, as well as in RVO. A positive correlation was found between ICAM-1 and MT in the 80 included eyes, as well as in RVO. ConclusionsThe metabolic factor, irisin levels in the aqueous humor are decreased in AMD and RVO eyes and show a positive correlation between irisin and MT in RVO eyes, prompting researchers to explore the relationship between irisin and macular edema. We also identified the higher expression of vascular growth factors (VEGF-A, VEGF-R1, and PDGF-BB), inflammatory cytokines (IL-6, IL-8, IL-10, and TNF-alpha), and chemokines (ICAM-1, VCAM-1, IP-10, and MCP-1) in AMD and RVO eyes.
C1 [Li, Xiaochun; Cao, Xiaoguang; Zhao, Mingwei; Bao, Yongzhen] Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   Eye Dis & Optometry Inst, Beijing, Peoples R China.
   [Li, Xiaochun; Cao, Xiaoguang; Zhao, Mingwei; Bao, Yongzhen] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Li, Xiaochun; Cao, Xiaoguang; Zhao, Mingwei; Bao, Yongzhen] Peking Univ Hlth Sci Ctr, Coll Optometry, Beijing, Peoples R China.
   [Li, Xiaochun] Peking Univ Int Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Bao, YZ (通讯作者)，Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Bao, YZ (通讯作者)，Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.; Bao, YZ (通讯作者)，Peking Univ Hlth Sci Ctr, Coll Optometry, Beijing, Peoples R China.
EM drbaoyz@sina.com
CR Ahmad Anas, 2020, J Immunoassay Immunochem, V41, P257, DOI 10.1080/15321819.2020.1726774
   Askari H, 2018, PHARMACOL RES, V129, P44, DOI 10.1016/j.phrs.2018.01.012
   Baiula M, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.617836
   Balasubramanian V, 2009, J PHYSIOL-LONDON, V587, P2753, DOI 10.1113/jphysiol.2009.170704
   Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Choi YK, 2013, DIABETES RES CLIN PR, V100, P96, DOI 10.1016/j.diabres.2013.01.007
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Crujeiras AB, 2014, METABOLISM, V63, P520, DOI 10.1016/j.metabol.2013.12.007
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Di Carlo E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153297
   Ding K, 2017, MABS-AUSTIN, V9, P269, DOI 10.1080/19420862.2016.1268305
   Dun SL, 2013, NEUROSCIENCE, V240, P155, DOI 10.1016/j.neuroscience.2013.02.050
   Ferrer-Martinez A, 2002, DEV DYNAM, V224, P154, DOI 10.1002/dvdy.10099
   Fontaine V, 2021, AGING-US, V13, P22040, DOI 10.18632/aging.203558
   Garcia-Horton A, 2016, THROMB RES, V148, P118, DOI 10.1016/j.thromres.2016.11.004
   Guler M, 2020, ARQ BRAS OFTALMOL, V83, P378, DOI 10.5935/0004-2749.20200046
   Gur FM, 2018, ANAT HISTOL EMBRYOL, V47, P174, DOI 10.1111/ahe.12345
   Hildebrandt J, 2022, GRAEF ARCH CLIN EXP, V260, P857, DOI 10.1007/s00417-021-05443-2
   Hu WC, 2016, ANN CLIN BIOCHEM, V53, P67, DOI 10.1177/0004563215582072
   Huang WC, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9421340
   Jabs DA, 2022, AIDS, V36, P177, DOI 10.1097/QAD.0000000000003104
   Jiang Y, 2017, ASIA-PAC J OPHTHALMO, V6, P546, DOI 10.22608/APO.2017459
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Khan AH, 2022, EYE, V36, P2192, DOI 10.1038/s41433-021-01824-3
   Lazzarini R, 2022, MOL CELL BIOCHEM, V477, P67, DOI 10.1007/s11010-021-04258-3
   Liu YY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95530
   Liukkonen MPK, 2022, ACTA OPHTHALMOL, V100, pE1153, DOI 10.1111/aos.15051
   Mao JB, 2022, ACTA OPHTHALMOL, V100, pE891, DOI 10.1111/aos.15008
   Marie M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223839
   Munoz IYM, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/7816806
   Papp C, 2017, INT J CHRONIC OBSTR, V12, P2023, DOI 10.2147/COPD.S135701
   Pedersen BK, 2009, J PHYSIOL-LONDON, V587, P5559, DOI 10.1113/jphysiol.2009.179515
   Peng J, 2017, MOL IMMUNOL, V91, P185, DOI 10.1016/j.molimm.2017.09.014
   Phillips C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00170
   Piya MK, 2014, AM J PHYSIOL-ENDOC M, V306, pE512, DOI 10.1152/ajpendo.00308.2013
   Ponto KA, 2019, J HYPERTENS, V37, P1372, DOI 10.1097/HJH.0000000000002057
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Shinojima A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10235496
   Sivaprasad S, 2015, EYE, V29, P1633, DOI 10.1038/eye.2015.164
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Tarakci BG, 2016, BIOTECH HISTOCHEM, V91, P423, DOI 10.1080/10520295.2016.1183820
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Vilkeviciute A, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/6622934
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.23
   Wang XJ, 2021, ADV CLIN EXP MED, V30, P893, DOI 10.17219/acem/125428
   Wautier JL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155315
   Wicinski M, 2021, LIFE-BASEL, V11, DOI 10.3390/life11050441
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wrann CD, 2013, CELL METAB, V18, P649, DOI 10.1016/j.cmet.2013.09.008
   Xia JP, 2019, BIOCHEM BIOPH RES CO, V508, P1264, DOI 10.1016/j.bbrc.2018.12.049
   Xin C, 2016, INT J OBESITY, V40, P443, DOI 10.1038/ijo.2015.199
   Yi QY, 2020, ACTA OPHTHALMOL, V98, pE309, DOI 10.1111/aos.14248
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   Yong HF, 2021, GRAEF ARCH CLIN EXP, V259, P3243, DOI 10.1007/s00417-021-05211-2
   Zeng YK, 2019, MOL VIS, V25, P756
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang Y, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022267
   Zsuga J, 2016, BEHAV NEUROSCI, V130, P6, DOI 10.1037/bne0000116
NR 59
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD MAR 17
PY 2022
VL 13
AR 861757
DI 10.3389/fendo.2022.861757
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 0H8QN
UT WOS:000778995000001
PM 35370941
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Potapenko, I
   la Cour, M
AF Potapenko, Ivan
   la Cour, Morten
TI Modelling and prognostication of growth in the number of patients
   treated for neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti&#8208; VEGF therapy; forecast model; neovascular AMD; population
   study; public healthcare; treatment incidences
ID PREVALENCE
AB Purpose The number of patients receiving anti-VEGF therapy has increased rapidly since its introduction in Denmark in 2007, placing an enormous pressure on the public healthcare system. In this study, we attempt to describe this growth and identify the factors driving it.
   Methods Data on treatment of the entire population of neovascular AMD patients in the Capital Region of Denmark between 2007 and 2019 was retrieved. The age and sex standardized incidences of first time treatment and changes in duration of treatment were analysed.
   Results The number of patients in active treatment increased from 576 in 2007 to 3684 in 2019. The growth was initially driven by accumulation of patients continuing anti-VEGF therapy for extended periods of time (259 patients/year). As larger numbers of patients began to be discharged, the increase slowed to 181 patients/year in late 2010s, with demographic change becoming the main growth driving factor. The incidence of first treatment increased slightly during the study period, mainly for individuals over 85 years. For patients under 85 years, treatment incidences closely followed neovascular AMD incidences from population studies. The likelihood of remaining in anti-VEGF treatment after the initial injection followed exponential decay curve (t(1/2) = 3.6 years). Based on this observation, a model was created to describe the number of patients in active treatment, which accurately described historical data (R-2 = 0.999), and forecast a linear growth of 138 patients/year until 2030.
   Conclusion Treatment incidences and modelling reported in this study might facilitate a more informed and accurate planning of future ophthalmology services.
C1 [Potapenko, Ivan; la Cour, Morten] Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Potapenko, Ivan; la Cour, Morten] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen
RP Potapenko, I (通讯作者)，Valdemar Hansens Vej 1-23, DK-2600 Glostrup, Denmark.
EM ivan.olegovich.potapenko@regionh.dk
OI Potapenko, Ivan/0000-0002-7201-655X
CR Baek SK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49749-y
   Bloch, 2013, THESIS U COPENHAGEN, DOI 10.1111/aos.12272
   Demir E, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3560-5
   Karagiannis DA, 2020, CLIN OPHTHALMOL, V14, P1417, DOI 10.2147/OPTH.S240417
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sedeh FB, 2017, DAN MED J, V64
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 12
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2021
VL 99
IS 8
BP E1348
EP E1353
DI 10.1111/aos.14802
EA FEB 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW9GS
UT WOS:000619121400001
PM 33599395
DA 2022-11-30
ER

PT J
AU Rusakevich, AM
   Zhou, B
   Wong, TP
   Wykoff, CC
AF Rusakevich, Alexander M.
   Zhou, Brenda
   Wong, Tien P.
   Wykoff, Charles C.
TI Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular
   Age-Related Macular Degeneration: Real-World Clinical Outcomes
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID TREAT-AND-EXTEND; RANIBIZUMAB; AFLIBERCEPT; THERAPY; TRIAL
AB BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular agerelated macular degeneration (nAMD).
   PATIENTS AND METHODS: Treatment-naive nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017.
   RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninety-one eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss.
   CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence.
C1 [Rusakevich, Alexander M.; Zhou, Brenda; Wong, Tien P.; Wykoff, Charles C.] Retina Consultants Houston, Houston, TX USA.
   [Wong, Tien P.; Wykoff, Charles C.] Houston Methodist Hosp, Weill Cornell Med Coll, Blanton Eye Inst, Houston, TX 77030 USA.
C3 Cornell University; The Methodist Hospital System; The Methodist
   Hospital - Houston
RP Wykoff, CC (通讯作者)，6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
OI Rusakevich, Alexander/0000-0002-0217-3330; Zhou,
   Brenda/0000-0002-9532-0570
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hwang RY, 2020, RETINA-J RET VIT DIS, V40, P679, DOI 10.1097/IAE.0000000000002446
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2019
VL 50
IS 9
BP E250
EP E256
DI 10.3928/23258160-20190905-17
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA JC5LI
UT WOS:000489323500005
PM 31589766
DA 2022-11-30
ER

PT J
AU Roberts, PK
   Nesper, PL
   Gill, MK
   Fawzi, AA
AF Roberts, Philipp K.
   Nesper, Peter L.
   Gill, Manjot K.
   Fawzi, Amani A.
TI SEMIAUTOMATED QUANTITATIVE APPROACH TO CHARACTERIZE TREATMENT RESPONSE
   IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Real-World Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; agerelated macular degeneration; optical
   coherence tomography; optical coherence tomography angiography;
   lacunarity; fractal dimension
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; ANGIOGRAPHY;
   RANIBIZUMAB
AB Purpose: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by optical coherence tomographic angiography.
   Methods: Patients undergoing individualized anti-vascular endothelial growth factor therapy of minimum 12 months duration were included in this cross-sectional observational study and imaged using optical coherence tomographic angiography. En face optical coherence tomographic angiography images were analyzed for quantitative features, such as junction density, vessel length, and lacunarity using validated software (Angiotool). Patients were divided into 2 groups depending on their individualized treatment interval: "good responders, treated less frequently than 6 weeks" versus "poor responders, treated every 6 weeks or more frequently." Nonparametric testing was used to assess differences between these groups.
   Results: Twenty-five eyes of 23 consecutive patients with a median 58-month history of choroidal neovascularization, treated by median of 34 anti-vascular endothelial growth factor injections, were included in the analysis. There was no significant difference between any of the microvascular choroidal neovascularization features between the 2 groups (P > 0.05).
   Conclusion: The semiautomated vessel segmentation software provides an objective and quantitative approach for choroidal neovascularization characterization. The consistently nonsignificant outcomes between the groups may provide evidence to support the "normalization hypothesis." This would suggest that regardless of treatment interval, individualized therapy in these eyes established vessel stability.
C1 [Roberts, Philipp K.; Nesper, Peter L.; Gill, Manjot K.; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 North Michigan Ave 440, Chicago, IL 60611 USA.
   [Roberts, Philipp K.] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Northwestern University; Feinberg School of Medicine; Medical University
   of Vienna
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, 645 North Michigan Ave 440, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558
FU NIH [DP3DK108248]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [DP3DK108248] Funding Source: NIH RePORTER
FX Research instrument support was provided by Optovue, Inc, Fremont, CA.
   This work was partly supported by NIH DP3DK108248 (AAF).
CR Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Gould DJ, 2011, MICROCIRCULATION, V18, P136, DOI 10.1111/j.1549-8719.2010.00075.x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guidolin D, 2004, LEUKEMIA, V18, P1745, DOI 10.1038/sj.leu.2403526
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 20
TC 27
Z9 28
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2017
VL 37
IS 8
BP 1492
EP 1498
DI 10.1097/IAE.0000000000001400
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB4JU
UT WOS:000406108700009
PM 27997513
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhao, H
   Roychoudhury, J
   Doggett, TA
   Apte, RS
   Ferguson, TA
AF Zhao, Hui
   Roychoudhury, Jayeeta
   Doggett, Teresa A.
   Apte, Rajendra S.
   Ferguson, Thomas A.
TI Age-Dependent Changes in FasL (CD95L) Modulate Macrophage Function in a
   Model of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macrophages; neovascularization; immune privilege; cytokine; cell
   migration; age-related macular degeneration
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; CORNEAL ALLOGRAFT SURVIVAL;
   IMMUNE PRIVILEGE; ENDOTHELIAL-CELLS; MOUSE MODEL; LIGAND; APOPTOSIS;
   ACTIVATION; DOXYCYCLINE; DEATH
AB PURPOSE. We examined the effect of aging on Fas ligand (FasL) function in a mouse model of choroidal neovascularization (CNV).
   METHODS. Young and aged mice were laser treated to induce CNV. Bone marrow chimeras were performed between young and aged mice. FasL protein expression was examined in the eye and soluble FasL (sFasL) was measured in the blood. Young and aged mice were treated with a matrix metalloprotease (MMP) inhibitor and systemic sFasL was neutralized by antibody treatment. Macrophages from young and aged mice were tested for sFasL-mediated cytokine production and migration.
   RESULTS. The elevated CNV response observed with aging was dependent on bone marrow-derived cells. FasL expression in the eye was increased with age, but decreased following laser treatment. Aged mice had higher levels of sFasL in the blood compared to young mice. Systemic treatment with an MMP inhibitor decreased bloodborne sFasL, and reduced CNV in young and aged mice. Systemic neutralization of sFasL reduced CNV only in aged mice. sFasL increased cytokine production in aged macrophages and proangiogenic M2 macrophages. Aged M2 macrophages had elevated Fas (CD95) expression and displayed increased migration in response to sFasL compared to M1 macrophages derived from young animals.
   CONCLUSIONS. Age modulates FasL function where increased MMP cleavage leads to a loss of function in the eye. The released form of FasL (sFasL) preferentially induces the migration of proangiogenic M2 macrophages into the laser lesions and increases proangiogenic cytokines promoting CNV. FasL may be a viable target for therapeutic intervention in aged-related neovascular disease.
C1 [Zhao, Hui; Roychoudhury, Jayeeta; Doggett, Teresa A.; Apte, Rajendra S.; Ferguson, Thomas A.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Ferguson, TA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid,Box 8096, St Louis, MO 63110 USA.
EM ferguson@vision.wustl.edu
FU National Institutes of Health [EY06765, EY015570, EY02687, EY019287];
   Department of Ophthalmology and Visual Science from Research to Prevent
   Blindness (New York, NY); The BrightFocus Foundation (Clarksburg, MD);
   NATIONAL EYE INSTITUTE [R01EY006765, R01EY019287, R01EY015570,
   F32EY006765, P30EY002687] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grants EY06765, EY015570,
   EY02687 (Department of Ophthalmology and Visual Science Core Grant),
   EY019287 (RSA), a Department of Ophthalmology and Visual Science grant
   from Research to Prevent Blindness (New York, NY), and The BrightFocus
   Foundation (Clarksburg, MD).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bajou K, 2008, CANCER CELL, V14, P324, DOI 10.1016/j.ccr.2008.08.012
   Barreiro R, 2003, INVEST OPHTH VIS SCI, V44, P1282, DOI 10.1167/iovs.02-0478
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Brown NJ, 2004, J IMMUNOL, V173, P7584, DOI 10.4049/jimmunol.173.12.7584
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Errami M, 2008, J PHARMACOL EXP THER, V324, P1196, DOI 10.1124/jpet.107.133975
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Fainaru O, 2008, FASEB J, V22, P3728, DOI 10.1096/fj.08-110494
   Ferguson TA, 2001, CELL DEATH DIFFER, V8, P771, DOI 10.1038/sj.cdd.4400891
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Ferguson TA, 2006, IMMUNOL REV, V213, P228, DOI 10.1111/j.1600-065X.2006.00430.x
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gregory MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017659
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hashimoto H, 1998, ARTHRITIS RHEUM, V41, P657, DOI 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.0.CO;2-N
   Hebda PA, 2003, WOUND REPAIR REGEN, V11, P373, DOI 10.1046/j.1524-475X.2003.11510.x
   Hsu HC, 2005, IMMUNOL REV, V205, P130, DOI 10.1111/j.0105-2896.2005.00270.x
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kovacs EJ, 2009, TRENDS IMMUNOL, V30, P319, DOI 10.1016/j.it.2009.03.012
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lecomte J, 2011, CELL MOL LIFE SCI, V68, P677, DOI 10.1007/s00018-010-0476-6
   Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   Muther PS, 2010, INVEST OPHTH VIS SCI, V51, P4831, DOI 10.1167/iovs.09-4923
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   Naumnik W., 2007, Experimental Oncology, V29, P132
   Niederkorn J Y, 1989, Reg Immunol, V2, P83
   Owonikoko TK, 2013, CANCER-AM CANCER SOC, V119, P1503, DOI 10.1002/cncr.27937
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Reilly LAO, 2009, NATURE, V461, P659, DOI 10.1038/nature08402
   Rossiter HB, 2008, J CELL BIOCHEM, V104, P525, DOI 10.1002/jcb.21643
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Rymkiewicz PD, 2012, IMMUNOL RES, V53, P235, DOI 10.1007/s12026-012-8289-3
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schulte M, 2007, CELL DEATH DIFFER, V14, P1040, DOI 10.1038/sj.cdd.4402101
   Seino K, 1998, J IMMUNOL, V161, P4484
   Semkova I, 2006, FASEB J, V20, P1689, DOI 10.1096/fj.05-5653fje
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Sierra-Filardi E, 2010, IMMUNOBIOLOGY, V215, P788, DOI 10.1016/j.imbio.2010.05.020
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stout RD, 2005, IMMUNOL REV, V205, P60, DOI 10.1111/j.0105-2896.2005.00260.x
   Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001
   Stuart PM, 2004, INVEST OPHTH VIS SCI, V45, P1169, DOI 10.1167/iovs.03-0932
   Stuart PM, 2003, INVEST OPHTH VIS SCI, V44, P93, DOI 10.1167/iovs.02-0299
   Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173
   Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vargo-Gogola T, 2002, ARCH BIOCHEM BIOPHYS, V408, P155, DOI 10.1016/S0003-9861(02)00525-8
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yap R, 2005, CLIN CANCER RES, V11, P6678, DOI 10.1158/1078-0432.CCR-05-0621
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zuccato E, 2007, J CELL SCI, V120, P191, DOI 10.1242/jcs.03315
NR 74
TC 22
Z9 24
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2013
VL 54
IS 8
BP 5321
EP 5331
DI 10.1167/iovs.13-12122
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228EA
UT WOS:000325167200022
PM 23821188
OA Green Published
DA 2022-11-30
ER

PT J
AU Cheng, Y
   Cheng, TJ
   Qu, Y
AF Cheng, Ying
   Cheng, Tongjie
   Qu, Yi
TI TIMP-3 suppression induces choroidal neovascularization by moderating
   the polarization of macrophages in age-related macular degeneration
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Choroidal neovascularization; Macrophages; Polarization; Tissue
   inhibitor of metalloproteinases-3
ID TISSUE INHIBITOR; ACTIVATION
AB Purpose: To investigate the role of tissue inhibitor of metalloproteinases-3 (TIMP-3) as a key moderator of macrophage polarization in choroidal neovascularization (CNV) lesions of model mice and in bone marrow-derived macrophage (BMDM).
   Method: We used siR-TIMP-3 to transfect BMDM and gave an intravitreal injection of siR-TIMP-3 to laser-induced CNV mice model, real time-PCR and western blot were applied for detecting the expressions of TIMP-3 and macrophages' biomarker. Besides, CNV lesions in different treatment groups of animal model were examined by the optical coherence tomography angiography (OCTA).
   Results: Our experimental data showed that lack of TIMP-3 stimulated M2 polarization proved by real time-PCR and western blot in BMDMs and CNV mice model. Moreover, intravitreal injection of siR-TIMP-3 accelerated CNV formation using OCTA, which indicated that TIMP-3 suppression is related to pro-angiogenesis of M2 macrophage.
   Conclusion: We showed that the absence of TIMP-3 leads to a more pro-angiogenic microenvironment, playing a key role in CNV formation by positively modulating M2 polarization. The role of TIMP-3 in the regulating inflammation and novel therapeutic target of nAMD needs to be further studied.
C1 [Cheng, Ying; Cheng, Tongjie; Qu, Yi] Shandong Univ, Qilu Hosp, Dept Geriatr, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University
RP Qu, Y (通讯作者)，Shandong Univ, Qilu Hosp, Dept Geriatr, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
EM yiqucn@sdu.edu.cn
FU National Natural Science foundation of China [31570789]
FX This study was partly supported by National Natural Science foundation
   of China (31570789). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alnawaiseh M, 2016, EXP EYE RES, V145, P417, DOI 10.1016/j.exer.2016.02.012
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Casagrande V, 2012, ARTERIOSCL THROM VAS, V32, P74, DOI 10.1161/ATVBAHA.111.238402
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gill SE, 2013, AM J RESP CELL MOL, V49, P768, DOI 10.1165/rcmb.2012-0377OC
   Gill SE, 2010, AM J PATHOL, V176, P64, DOI 10.2353/ajpath.2010.090158
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Ishibazawa A., 2015, AJOPHT, V160, P1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160
   Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y
   Smookler DS, 2006, J IMMUNOL, V176, P721, DOI 10.4049/jimmunol.176.2.721
   Tanino Y, 2010, J IMMUNOL, V184, P2677, DOI 10.4049/jimmunol.0903274
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
NR 23
TC 3
Z9 3
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD FEB
PY 2019
VL 106
BP 119
EP 126
DI 10.1016/j.molimm.2018.12.026
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA HJ9GP
UT WOS:000457507200014
PM 30594674
DA 2022-11-30
ER

PT J
AU Wu, W
   Weng, Y
   Guo, XN
   Feng, LF
   Xia, HL
   Jiang, ZQ
   Lou, JL
AF Wu, Wei
   Weng, Yan
   Guo, Xinnian
   Feng, Lingfang
   Xia, Hailing
   Jiang, Zhaoqiang
   Lou, Jianlin
TI The Association Between Serum Vitamin D Levels and Age-Related Macular
   Degeneration: A Systematic Meta-Analytic Review
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; serum vitamin D; systematic review; meta-analysis
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; 25-HYDROXYVITAMIN D;
   CIGARETTE-SMOKING; HYPOVITAMINOSIS-D; D DEFICIENCY; RISK; CONSUMPTION;
   MACULOPATHY; PREVALENCE
AB PURPOSE. We conducted a meta-analysis of individual studies reporting an association between serum vitamin D levels and AMD.
   METHODS. Relevant studies evaluating the association between serum vitamin D levels and AMD risk were identified by systematically searching four electronic literature databases (Ovid Medline, PubMed, EMBASE, and ISI Web of Science) censored by June 2015. Due to the heterogeneity of studies in categorizing serum vitamin D levels, all individual odds ratios (ORs) were recalculated and transferred for an increase of serum vitamin D levels by 10 ng/ml. Summary ORs and 95% confidence intervals (CIs) of AMD risk per 10-unit increase of serum vitamin D were obtained using standard meta-analysis. Publication bias was evaluated using funnel plots and Kendall's rank correlation tests.
   RESULTS. Ten individual studies were included and pooled in this meta-analysis. Meta-analysis of studies on AMD risk led to a pooled OR (95% CI) of 0.91 (0.69-1.22) for an increase of 25-hydroxy vitamin D by 10 ng/mL (P = 0.12). No indication for publication bias was found, but substantial heterogeneity was obtained (I-2 = 79.7%, P < 0.01). Estimates from subgroup analyses also did not show statistically significant associations of serum vitamin D levels with different stages (early AMD, late AMD, and advanced AMD) and subtypes of AMD (neovascular AMD and nonneovascular AMD; P > 0.05).
   CONCLUSIONS. There is no evidence to indicate an inverse association between serum vitamin D levels and any stages and subtypes of AMD risk, but opposite results from the United States and Korea resulted in this nonsignificance. Potential difference across various study designs might exist, based on few studies reporting in heterogeneous manners so far. More studies are needed to further confirm the causality of vitamin D and AMD, especially longitudinal studies.
C1 [Wu, Wei; Weng, Yan] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wu, Wei; Weng, Yan] Zhejiang Prov Key Lab Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
   [Guo, Xinnian; Feng, Lingfang; Xia, Hailing; Jiang, Zhaoqiang; Lou, Jianlin] Zhejiang Acad Med Sci, Inst Occupat Dis, 182 Tianmushan Rd, Hangzhou 310013, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang Academy of Medical Sciences
RP Lou, JL (通讯作者)，Zhejiang Acad Med Sci, Inst Occupat Dis, 182 Tianmushan Rd, Hangzhou 310013, Zhejiang, Peoples R China.
EM jianlinlou@163.com
FU Public Welfare Technology Project of Science Technology Department of
   Zhejiang Province, Hangzhou, Zhejiang, China [2015C33115]; Zhejiang
   Committee of Science and Technology, Hangzhou, Zhejiang, China
   [2015F10013]; Zhejiang Provincial Program for the Cultivation of
   High-level Innovative talents, Hangzhou, Zhejiang, China
FX Supported by grants from the Public Welfare Technology Project of
   Science Technology Department of Zhejiang Province ( 2015C33115;
   Hangzhou, Zhejiang, China), Zhejiang Committee of Science and Technology
   ( 2015F10013; Hangzhou, Zhejiang, China), Zhejiang Provincial Program
   for the Cultivation of High-level Innovative talents ( 2014; Hangzhou,
   Zhejiang, China).
CR Abraham A, 2011, EVIDENCE BASED OPHTH, V12, pe5
   Annweiler C, 2013, J ALZHEIMERS DIS, V33, P659, DOI 10.3233/JAD-2012-121432
   Annweiler C, 2012, OPHTHALMOLOGY, V119, P1090, DOI 10.1016/j.ophtha.2012.02.005
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Higgins JPT., 2022, COCHRANE HDB SYSTEMA
   Hollis BW, 2007, J STEROID BIOCHEM, V103, P473, DOI 10.1016/j.jsbmb.2006.11.004
   Huang Han-Yo, 2006, Evid Rep Technol Assess (Full Rep), P1
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hypponen E, 2007, AM J CLIN NUTR, V85, P860, DOI 10.1093/ajcn/85.3.860
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Liao Y, 2015, TUMOR BIOL, V36, P1567, DOI 10.1007/s13277-014-2728-9
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Lips P, 1999, OSTEOPOROSIS INT, V9, P394, DOI 10.1007/s001980050162
   Lipsey M. W., 2001, PRACTICAL META ANAL
   Mehta NR, 2005, FASEB J, V19, pA986
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168
   Scientific Advisory Committee on Nutrition (SACN), 2007, UPD VIT D
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Swanson MW, 2014, OPTOMETRY VISION SCI, V91, P865, DOI 10.1097/OPX.0000000000000315
   Uro M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130879
   Valipour G, 2014, J CLIN ENDOCR METAB, V99, P3863, DOI 10.1210/jc.2014-1887
   Yin L, 2011, PREV MED, V53, P10, DOI 10.1016/j.ypmed.2011.05.013
   Zeng JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126014
NR 43
TC 11
Z9 12
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 2168
EP 2177
DI 10.1167/iovs.15-18218
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700074
PM 27111565
OA gold
DA 2022-11-30
ER

PT J
AU McLaughlin, T
   Medina, A
   Perkins, J
   Yera, M
   Wang, JJ
   Zhang, SX
AF McLaughlin, Todd
   Medina, Andy
   Perkins, Jacob
   Yera, Maria
   Wang, Joshua J.
   Zhang, Sarah X.
TI Cellular stress signaling and the unfolded protein response in retinal
   degeneration: mechanisms and therapeutic implications
SO MOLECULAR NEURODEGENERATION
LA English
DT Review
DE Unfolded protein response; Metabolism; Endoplasmic reticulum stress;
   Retinal degeneration; Aging; Age related macular degeneration; Retinitis
   pigmentosa; Glaucoma; Diabetic retinopathy
ID ENDOPLASMIC-RETICULUM STRESS; TRABECULAR MESHWORK CELLS; ER STRESS;
   PIGMENT EPITHELIUM; DIABETIC-RETINOPATHY; MOLECULAR CHAPERONE; OXIDATIVE
   STRESS; RETINITIS-PIGMENTOSA; MOUSE MODEL; GLUCOSE-LEVELS
AB Background The retina, as part of the central nervous system (CNS) with limited capacity for self-reparation and regeneration in mammals, is under cumulative environmental stress due to high-energy demands and rapid protein turnover. These stressors disrupt the cellular protein and metabolic homeostasis, which, if not alleviated, can lead to dysfunction and cell death of retinal neurons. One primary cellular stress response is the highly conserved unfolded protein response (UPR). The UPR acts through three main signaling pathways in an attempt to restore the protein homeostasis in the endoplasmic reticulum (ER) by various means, including but not limited to, reducing protein translation, increasing protein-folding capacity, and promoting misfolded protein degradation. Moreover, recent work has identified a novel function of the UPR in regulation of cellular metabolism and mitochondrial function, disturbance of which contributes to neuronal degeneration and dysfunction. The role of the UPR in retinal neurons during aging and under disease conditions in age-related macular degeneration (AMD), retinitis pigmentosa (RP), glaucoma, and diabetic retinopathy (DR) has been explored over the past two decades. Each of the disease conditions and their corresponding animal models provide distinct challenges and unique opportunities to gain a better understanding of the role of the UPR in the maintenance of retinal health and function. Method We performed an extensive literature search on PubMed and Google Scholar using the following keywords: unfolded protein response, metabolism, ER stress, retinal degeneration, aging, age-related macular degeneration, retinitis pigmentosa, glaucoma, diabetic retinopathy. Results and conclusion We summarize recent advances in understanding cellular stress response, in particular the UPR, in retinal diseases, highlighting the potential roles of UPR pathways in regulation of cellular metabolism and mitochondrial function in retinal neurons. Further, we provide perspective on the promise and challenges for targeting the UPR pathways as a new therapeutic approach in age- and disease-related retinal degeneration.
C1 [McLaughlin, Todd; Medina, Andy; Perkins, Jacob; Yera, Maria; Wang, Joshua J.; Zhang, Sarah X.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Ophthalmol, 955 Main St, Buffalo, NY 14203 USA.
   [Yera, Maria; Wang, Joshua J.; Zhang, Sarah X.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Neurosci Program, Buffalo, NY 14203 USA.
   [Zhang, Sarah X.] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14203 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; State University of New York (SUNY) System; State
   University of New York (SUNY) Buffalo; State University of New York
   (SUNY) System; State University of New York (SUNY) Buffalo
RP Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Ophthalmol, 955 Main St, Buffalo, NY 14203 USA.; Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Neurosci Program, Buffalo, NY 14203 USA.; Zhang, SX (通讯作者)，Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14203 USA.
EM xzhang38@buffalo.edu
OI Zhang, Sarah/0000-0002-7848-3263
FU NIH/NEI [EY019949, EY025061, EY030970]; Brightfocus Foundation [NGR
   G2019302]; Research to Prevent Blindness
FX This work was supported, in part, by NIH/NEI Grants EY019949, EY025061,
   EY030970 (to SXZ), a research grant NGR G2019302 from the Brightfocus
   Foundation (to SXZ), and an Unrestricted Grant from Research to Prevent
   Blindness to the Department of Ophthalmology, the State University of
   New York at Buffalo.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Aboshiha J, 2016, BRIT J OPHTHALMOL, V100, P115, DOI 10.1136/bjophthalmol-2014-306505
   Adekeye A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083871
   Age-Related Eye Dis Study Res Grp, 2000, J NUTR, V130, p1516S, DOI 10.1093/jn/130.5.1516S
   Agrawal SA, 2017, HUM MOL GENET, V26, P2667, DOI 10.1093/hmg/ddx149
   Aguila M, 2020, HUM MOL GENET, V29, P1310, DOI 10.1093/hmg/ddaa049
   Allingham MJ, 2021, ADV EXP MED BIOL, V1256, P143, DOI 10.1007/978-3-030-66014-7_6
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Ansar M, 2015, HUM GENET, V134, P941, DOI 10.1007/s00439-015-1571-4
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Arno G, 2016, AM J HUM GENET, V99, P1305, DOI 10.1016/j.ajhg.2016.10.008
   Athanasiou D, 2017, HUM MOL GENET, V26, P4896, DOI 10.1093/hmg/ddx370
   Athanasiou D, 2018, PROG RETIN EYE RES, V62, P1, DOI 10.1016/j.preteyeres.2017.10.002
   Athanasiou D, 2017, HUM MOL GENET, V26, P305, DOI 10.1093/hmg/ddw387
   Athanasiou D, 2014, HUM MOL GENET, V23, P6594, DOI 10.1093/hmg/ddu385
   Athanasiou D, 2012, MOL BIOL CELL, V23, P3522, DOI 10.1091/mbc.E12-02-0168
   Batchelor-Regan H, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.652400
   Belforte N, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00466-z
   Bhatta M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0501-5
   Bhatta M, 2015, DIABETOLOGIA, V58, P2181, DOI 10.1007/s00125-015-3643-3
   Bhattarai KR, 2020, TRENDS CELL BIOL, V30, P672, DOI 10.1016/j.tcb.2020.05.004
   Bhootada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154779
   Bird A, 2021, BRIT J OPHTHALMOL, V105, P1469, DOI 10.1136/bjophthalmol-2020-317447
   Biswas S, 2019, ACTA OPHTHALMOL, V97, pE331, DOI 10.1111/aos.13983
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Boriushkin E, 2015, INVEST OPHTH VIS SCI, V56, P1374, DOI 10.1167/iovs.14-15196
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Chen C, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00658
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chen Y, 2012, DIABETOLOGIA, V55, P2533, DOI 10.1007/s00125-012-2594-1
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chernyshova K, 2019, INVEST OPHTH VIS SCI, V60, P3625, DOI 10.1167/iovs.19-27184
   Chiang WC, 2017, P NATL ACAD SCI USA, V114, P400, DOI 10.1073/pnas.1606387114
   Chiang WC, 2015, MOL NEUROBIOL, V52, P679, DOI 10.1007/s12035-014-8881-8
   Chiang WC, 2012, INVEST OPHTH VIS SCI, V53, P7159, DOI 10.1167/iovs.12-10222
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Comitato A, 2020, MOL NEUROBIOL, V57, P589, DOI 10.1007/s12035-019-01723-5
   Cunha DL, 2019, GENES-BASEL, V10, DOI 10.3390/genes10121050
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Das S, 2009, MOL BIOL CELL, V20, P2593, DOI 10.1091/mbc.E08-07-0790
   Deliyanti D, 2018, INVEST OPHTH VIS SCI, V59, P815, DOI 10.1167/iovs.17-22920
   Dentchev T, 2003, MOL VIS, V9, P184
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Eisenstein M, 2020, NAT METHODS, V17, P7, DOI 10.1038/s41592-019-0698-y
   Erdinest Nir, 2021, Vision (Basel), V5, DOI 10.3390/vision5040046
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Estebanez B, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01744
   Ferdous S, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.7.9
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Ghemrawi R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176127
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Grandjean JMD, 2020, J BIOL CHEM, V295, P15692, DOI 10.1074/jbc.REV120.010218
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787
   Hirsch I, 2014, APOPTOSIS, V19, P801, DOI 10.1007/s10495-013-0961-0
   Holoman NC, 2021, J NEUROSCI, V41, P3275, DOI 10.1523/JNEUROSCI.2010-20.2021
   Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200
   Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084
   Hu Y, 2012, NEURON, V73, P445, DOI 10.1016/j.neuron.2011.11.026
   Huang CX, 2015, INVEST OPHTH VIS SCI, V56, P6196, DOI 10.1167/iovs.15-16795
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Huang HL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.329
   Huang HB, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0076-1
   Hui QY, 2020, FREE RADICAL BIO MED, V146, P181, DOI 10.1016/j.freeradbiomed.2019.10.414
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Ido Y, 2010, ANTIOXID REDOX SIGN, V12, P39, DOI [10.1089/ars.2009.2502, 10.1089/ARS.2009.2502]
   Inokuchi Y, 2009, INVEST OPHTH VIS SCI, V50, P334, DOI 10.1167/iovs.08-2123
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ito Y, 2006, J PHARMACOL SCI, V102, P196, DOI 10.1254/jphs.FP0060711
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Joltikov KA, 2018, INVEST OPHTH VIS SCI, V59, P5481, DOI 10.1167/iovs.18-24955
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kasetti RB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19352-1
   Kasetti RB, 2016, INVEST OPHTH VIS SCI, V57, P6058, DOI 10.1167/iovs.16-19610
   Kelly K, 2018, NEURAL REGEN RES, V13, P1861, DOI 10.4103/1673-5374.239431
   Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580-020-0259-3
   Kim KY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.180
   Kohl S, 2015, NAT GENET, V47, P757, DOI 10.1038/ng.3319
   Kosmaoglou M, 2009, J CELL SCI, V122, P4465, DOI 10.1242/jcs.055228
   Kowluru RA, 2019, DIABETES, V68, P241, DOI 10.2337/dbi18-0016
   Kowluru RA, 2017, FREE RADICAL BIO MED, V103, P155, DOI 10.1016/j.freeradbiomed.2016.12.030
   Kroeger H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103196118
   Kroeger H, 2019, FEBS J, V286, P399, DOI 10.1111/febs.14522
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   Lamba D, 2008, CELL STEM CELL, V2, P538, DOI 10.1016/j.stem.2008.05.002
   Langrova H, 2008, INVEST OPHTH VIS SCI, V49, P5024, DOI 10.1167/iovs.07-1309
   Lee EJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95895-7
   LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331
   LEE TG, 1992, J BIOL CHEM, V267, P14238
   LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208
   Lee VK, 2018, DIABETOLOGIA, V61, P2422, DOI 10.1007/s00125-018-4696-x
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Lenox AR, 2015, NEUROSCI LETT, V609, P30, DOI 10.1016/j.neulet.2015.10.019
   Levine ES, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00242-z
   Li B, 2011, ACTA DIABETOL, V48, P103, DOI 10.1007/s00592-009-0170-z
   Li HR, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00437-4
   Li JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09653-5
   Li JM, 2011, J BIOL CHEM, V286, P4912, DOI 10.1074/jbc.M110.199729
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lin YC, 2020, DOC OPHTHALMOL, V140, P67, DOI 10.1007/s10633-019-09719-1
   Liu YH, 2016, J NEURO-ONCOL, V126, P455, DOI 10.1007/s11060-015-2003-y
   Liu YT, 2013, INVEST OPHTH VIS SCI, V54, P6382, DOI 10.1167/iovs.13-12128
   Long P, 2021, AGING-US, V13, P2750
   Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Ma JH, 2016, INVEST OPHTH VIS SCI, V57, P5244, DOI 10.1167/iovs.16-19232
   Ma JH, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/160140
   Marola OJ, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0220-4
   Martinez G, 2017, AGING CELL, V16, P615, DOI 10.1111/acel.12599
   Mastey RR, 2019, INVEST OPHTH VIS SCI, V60, P2631, DOI 10.1167/iovs.19-27047
   McLaughlin T, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060906
   McLaughlin T, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00267
   McLaughlin T, 2018, ADV EXP MED BIOL, V1074, P421, DOI 10.1007/978-3-319-75402-4_52
   McLaughlin T, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0250-z
   McLaughlin T, 2015, NEURAL REGEN RES, V10, P1211, DOI 10.4103/1673-5374.162696
   Medchalmi S, 2021, FEBS J, V288, P4576, DOI 10.1111/febs.15752
   Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97
   Mendes HF, 2008, HUM MOL GENET, V17, P3043, DOI 10.1093/hmg/ddn202
   Mendez AS, 2015, ELIFE, V4, DOI 10.7554/eLife.05434
   Meng LH, 2021, INT J OPHTHALMOL-CHI, V14, P766, DOI 10.18240/ijo.2021.05.19
   Michaelides M, 2004, BRIT J OPHTHALMOL, V88, P291, DOI 10.1136/bjo.2003.027102
   Michalakis S, 2017, J GENE MED, V19, DOI 10.1002/jgm.2944
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohammadnejad A, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.675587
   Naidoo N, 2014, AGING CELL, V13, P131, DOI 10.1111/acel.12158
   Naidoo N, 2011, AGING CELL, V10, P640, DOI 10.1111/j.1474-9726.2011.00699.x
   Nashine S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063205
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP66, DOI 10.1016/j.ophtha.2019.09.025
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Peters JC, 2015, INVEST OPHTH VIS SCI, V56, P3860, DOI 10.1167/iovs.14-16220
   Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8416763
   Plate L, 2016, ELIFE, V5, DOI 10.7554/eLife.15550
   Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Reis A, 2013, ACTA OPHTHALMOL, V91, DOI 10.1111/j.1755-3768.2013.1662.x
   Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219
   ROHEN JW, 1983, OPHTHALMOLOGY, V90, P758
   Roobol A, 2015, BIOCHEM J, V465, P213, DOI 10.1042/BJ20140852
   Rozpedek-Kaminska W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094494
   Rozpedek-Kaminska W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114171
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Samuel MA, 2011, J NEUROSCI, V31, P16033, DOI 10.1523/JNEUROSCI.3580-11.2011
   Schuster AK, 2020, DTSCH ARZTEBL INT, V117, P225, DOI 10.3238/arztebl.2020.0225
   Shim MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33830
   Shimazawa M, 2007, MOL VIS, V13, P578
   Shirwany NA, 2014, FRONT BIOSCI-LANDMRK, V19, P447, DOI 10.2741/4218
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Sohn J, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0830-4
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stamer WD, 2017, EXP EYE RES, V158, P112, DOI 10.1016/j.exer.2016.07.009
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291
   Sugita Y, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.586013
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Sun ZS, 2018, CELL DEATH DIFFER, V25, P1686, DOI 10.1038/s41418-018-0067-x
   Sundaram V, 2014, OPHTHALMOLOGY, V121, P234, DOI 10.1016/j.ophtha.2013.08.017
   Sundstrom JM, 2018, INVEST OPHTH VIS SCI, V59, P2264, DOI 10.1167/iovs.17-23678
   Swarup A, 2019, AM J PHYSIOL-CELL PH, V316, pC121, DOI 10.1152/ajpcell.00410.2018
   Takeda N, 2013, AM J PATHOL, V183, P774, DOI 10.1016/j.ajpath.2013.05.026
   Tang HZ, 2015, MOL MED REP, V12, P389, DOI 10.3892/mmr.2015.3417
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tsuruma K, 2012, MOL NUTR FOOD RES, V56, P713, DOI 10.1002/mnfr.201100607
   van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200
   VandenBosch LS, 2020, SEMIN CELL DEV BIOL, V97, P63, DOI 10.1016/j.semcdb.2019.04.001
   VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675
   Viegas FO, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.656000
   Wang K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24165-w
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang X, 2019, BIOCHEM BIOPH RES CO, V512, P914, DOI 10.1016/j.bbrc.2019.03.115
   Wang YW, 2019, INVEST OPHTH VIS SCI, V60, P265, DOI 10.1167/iovs.18-25477
   Wei QQ, 2019, DISCOV MED, V27, P189
   Wiggs JL, 2017, HUM MOL GENET, V26, pR21, DOI 10.1093/hmg/ddx184
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wu DM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145029
   Xu L, 2020, AMP ACTIVATED PROTEI, V2020
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Xu MC, 2015, INVEST OPHTH VIS SCI, V56, P3889, DOI 10.1167/iovs.15-16778
   Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799
   Yang J, 2019, DIABETOLOGIA, V62, P531, DOI 10.1007/s00125-018-4776-y
   Yang L, 2016, J NEUROSCI, V36, P5891, DOI 10.1523/JNEUROSCI.3709-15.2016
   Yao T, 2017, DIABETES, V66, P663, DOI 10.2337/db16-0533
   Ying Y, 2021, AGING-US, V13, P8628, DOI 10.18632/aging.202677
   Yumnamcha T, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121244
   Zarouchlioti C, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0534
   Zhang SX, 2015, PROG RETIN EYE RES, V45, P111, DOI 10.1016/j.preteyeres.2014.12.001
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhao YY, 2020, J CELL MOL MED, V24, P3469, DOI 10.1111/jcmm.15032
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhong YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038616
   Zhong YM, 2012, DIABETES, V61, P492, DOI 10.2337/db11-0315
   Zhong YM, 2012, ADV EXP MED BIOL, V723, P285, DOI 10.1007/978-1-4614-0631-0_37
   Zhu X, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238435
   Zode GS, 2014, J CLIN INVEST, V124, P1956, DOI 10.1172/JCI69774
   Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183
   Zukerman R, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010055
NR 220
TC 2
Z9 2
U1 5
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD MAR 28
PY 2022
VL 17
IS 1
AR 25
DI 10.1186/s13024-022-00528-w
PG 19
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 0A5IN
UT WOS:000773988300003
PM 35346303
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nakagawa, S
   Yamashiro, K
   Tsujikawa, A
   Otani, A
   Tamura, H
   Ooto, S
   Yoshimura, N
AF Nakagawa, Satoko
   Yamashiro, Kenji
   Tsujikawa, Akitaka
   Otani, Atsushi
   Tamura, Hiroshi
   Ooto, Sotaro
   Yoshimura, Nagahisa
TI THE TIME COURSE CHANGES OF CHOROIDAL NEOVASCULARIZATION IN ANGIOID
   STREAKS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angioid streaks; choroidal neovascularization; polypoidal choroidal
   vasculopathy
ID PSEUDOXANTHOMA ELASTICUM
AB Purpose: To assess the clinical course of choroidal neovascularization(CNV) in patients with angioid streaks using optical coherence tomography and fluorescein angiography/indocyanine green angiography.
   Methods: We examined a consecutive series of 88 eyes of 44 patients with angioid streaks using color fundus photography, optical coherence tomography, and fluorescein angiography/indocyanine green angiography.
   Results: At the initial visit, 33 eyes exhibited no CNV, 2 exhibited polypoidal choroidal vasculopathy, 8 exhibited Type 1 CNV, 32 exhibited active Type 2 CNV, and 13 exhibited a fibrotic scar. In addition to the 2 eyes that exhibited macular polypoidal choroidal vasculopathy at the initial visit, 3 exhibited peripapillary polypoidal lesions, and 2 exhibited polypoidal lesions at the edge of the preexisting Type 2 CNV/fibrosis. During the follow-up, Type 2 CNV developed in 4 eyes on the basis of Type 1 CNV. Visual acuity was worse in eyes with Type 2 CNV and fibrosis than in those with Type 1 CNV, while polypoidal choroidal vasculopathy did not affect the visual acuity.
   Conclusion: Eyes with angioid streaks can develop any form of CNV including polypoidal choroidal vasculopathy. Considering the worse visual acuity in eyes with Type 2 CNV and fibrosis, patients should be carefully observed so as to treat them promptly when Type 2 CNV occurred beneath the fovea. RETINA 33:825-833, 2013
C1 [Nakagawa, Satoko; Yamashiro, Kenji; Tsujikawa, Akitaka; Otani, Atsushi; Tamura, Hiroshi; Ooto, Sotaro; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
C3 Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
CR Aessopos A, 2002, BLOOD, V99, P30, DOI 10.1182/blood.V99.1.30
   Arvas S, 2002, EUR J OPHTHALMOL, V12, P473, DOI 10.1177/112067210201200605
   Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8
   Costa RA, 2003, OPHTHALMOLOGY, V110, P1192, DOI 10.1016/S0161-6420(03)00263-X
   DABBS TR, 1990, BRIT J OPHTHALMOL, V74, P579, DOI 10.1136/bjo.74.10.579
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Georgalas Ilias, 2009, Ther Clin Risk Manag, V5, P81
   Groenblad E., 1929, ACTA OPHTHALMOL, V7, P329
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Pece A, 1997, INDOCYANINE GREEN AN, P319
   Sayanagi K, 2009, OPHTHAL SURG LAS IM, V40, P195, DOI 10.3928/15428877-20090301-19
   Strandberg J., 1929, ZBL HAUT GESCHLECHTS, V31, P689
NR 15
TC 15
Z9 20
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 825
EP 833
DI 10.1097/IAE.0b013e31826b0bbe
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900021
PM 23114408
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Brown, HC
   Kindermann, S
   Sharma, S
AF Brown, Gary C.
   Brown, Melissa M.
   Brown, Heidi C.
   Kindermann, Sylvia
   Sharma, Sanjay
TI A value-based medicine comparison of interventions for subfoveal
   neovascular macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RANDOMIZED CLINICAL-TRIALS; CHOROIDAL
   NEOVASCULARIZATION; LASER PHOTOCOAGULATION; UTILITY VALUES; PHOTODYNAMIC
   THERAPY; DIABETIC-RETINOPATHY; VERTEPORFIN THERAPY; COST-EFFECTIVENESS;
   ADULT-POPULATION
AB Objective: To perform a value-based medicine analysis of clinical trials that evaluate the interventions of laser photocoagulation, intravitreal pegaptanib therapy, and photodynamic therapy (PDT) with verteporfin for the treatment of classic subfoveal choroidal neovascularization.
   Design: Reference case cost-utility analysis using value-based medicine principles, which use patient-based utility values and standardized, input variable criteria.
   Participants: Data from participants in the Macular Photocoagulation Study, Pegaptanib for Neovascular Age-Related Macular Degeneration Study, and the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study.
   Methods: Visual data were converted to a value-based format using time tradeoff utility analysis values from patients with macular degeneration. Costs were obtained from 2005 Medicare data. Outcomes (quality-adjusted life-years [QALYs]) and costs were discounted at a 3% annual rate.
   Main Outcome Measures: Interventional QALYs gained, percent improvement in quality of life, and dollars spent per QALY gained.
   Results: Laser photocoagulation confers a 4.4% (P = 0.03 versus pegaptanib therapy) improvement in quality of life for the reference case, whereas pegaptanib therapy confers a 5.9% improvement and PDT confers an 8.1% (P = 0.0002 versus pegaptanib therapy) improvement. The cost-utility associated with laser photocoagulation is $8179, that for pegaptanib therapy is $66 978, and that for PDT is $31 544. All sensitivity analyses remain within the conventional standards of cost-effectiveness.
   Conclusions: Photodynamic therapy confers greater patient value than intravitreal pegaptanib therapy and laser photocoagulation for the treatment of classic subfoveal choroidal neovascularization. Despite the fact that laser photocoagulation is the most cost-effective intervention, both PDT and pegaptanib therapy deliver greater value, and thus are both preferred over laser photocoagulation. Using an economic measure, photodynamic therapy is the preferred treatment among these 3 interventions.
C1 Ctr Value Based Med, Flourtown, PA 19031 USA.
   Wills Eye Hosp & Res Inst, Jefferson Med Coll, Retina Serv, Philadelphia, PA USA.
   Eye Res Inst, Philadelphia, PA USA.
   Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Queens Med Coll, Cost Effect Ocular Hlth Policy Unit, Kingston, ON, Canada.
C3 Jefferson University; University of Pennsylvania; University of
   Pennsylvania
RP Brown, GC (通讯作者)，Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
EM gbrown@valuebasedmedicine.com
CR Arias Elizabeth, 2004, Natl Vital Stat Rep, V52, P1
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
   Brown GC, 2000, J DIABETES COMPLICAT, V14, P18, DOI 10.1016/S1056-8727(00)00061-1
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, BRIT J OPHTHALMOL, V86, P8, DOI 10.1136/bjo.86.1.8
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   BROWN MM, 2005, EVIDENCE BASED VALUE, P125
   BROWN MM, 2005, T AM OPHTHAL SOC, V103, P173
   Center for Medicare and Medicaid Services, MED FEE SCH
   *CPT, 2005, CURR PROC TERM
   *CTR MED MED SERV, 2006, NAT PHYS FEE SCHED R
   *CTR MED MED SERV, MED COV AG DAT LMRP
   *GEN, LUC RAN
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
   Stein J D, 2002, J Clin Hypertens (Greenwich), V4, P181, DOI 10.1111/j.1524-6175.2002.00970.x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   2006, MACUGEN PEGAPTANIB S
   [No title captured]
NR 34
TC 54
Z9 54
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1170
EP 1178
DI 10.1016/j.ophtha.2006.09.019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600022
PM 17320964
DA 2022-11-30
ER

PT J
AU Wang, W
   He, M
   Zhang, XL
AF Wang, Wei
   He, Miao
   Zhang, Xiulan
TI Combined Intravitreal Anti-VEGF and Photodynamic Therapy versus
   Photodynamic Monotherapy for Polypoidal Choroidal Vasculopathy: A
   Systematic Review and Meta-Analysis of Comparative Studies
SO PLOS ONE
LA English
DT Article
ID COMBINATION THERAPY; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN; EFFICACY
AB Purpose: The aim of this study was to evaluate the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal vascular endothelial growth factor (VEGF) inhibitors compared to those of PDT alone in the treatment of polypoidal choroidal vasculopathy (PCV).
   Methods: A systematic search of Pubmed, Embase, and the Cochrane Library was performed to identify all comparative studies that compared the outcomes of the two approaches. Outcomes of interest included visual outcomes, anatomic variables, and adverse events.
   Results: Two randomised controlled trials and nine retrospective studies including a total of 543 cases were identified. At three and six months post-injection, no significant difference in visual acuity was found in the combined therapy group compared with the PDT monotherapy group, with pooled weighted mean differences (WMDs) of 0.074 (-0.021, 0.17) at three months and 0.082 (-0.013, 0.18) at six months. However, the mean changes in visual acuity at month 12 in the combined therapy group were significantly better than those in the PDT monotherapy group, with pooled WMDs of 0.11 (0.012, 0.21). Similar efficacy was found at 24 months (WMD: 0.21; 95% CI: 0.054, 0.36; P = 0.008). Patients in the combined therapy group also might benefit from reduced retinal haemorrhage (OR: 0.32; 95% CI: 0.14, 0.74; P = 0.008). Polyp regression, recurrence of PCV, central retinal thickness reduction, and pigment epithelial detachment resolution did not differ significantly between the two treatments.
   Conclusions: Combined treatment appeared to result in better visual acuity and lower retinal haemorrhage. However, combined treatment did not affect the resolution and recurrence of lesions. Given the inherent limitations of the included studies, future well-designed RCTs are awaited to confirm and update the findings of this analysis.
C1 [Wang, Wei; He, Miao; Zhang, Xiulan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Zhang, XL (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
EM zhangxl2@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81170849, 81371008]
FX This research was supported by the National Natural Science Foundation
   of China (81170849, 81371008). No additional external funding was
   received. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   de Crecchio G, 2011, CURR DRUG TARGETS, V12, P206, DOI 10.2174/138945011794182782
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee YA, 2012, AM J OPHTHALMOL, V154, P872, DOI 10.1016/j.ajo.2012.03.051
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1272, DOI 10.1097/IAE.0b013e318236e624
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Wells GA., NEWCASTLE OTTAWA SCA
NR 36
TC 43
Z9 43
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2014
VL 9
IS 10
AR e110667
DI 10.1371/journal.pone.0110667
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS0BL
UT WOS:000343943500044
PM 25343244
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Albert, DM
   Neekhra, A
   Wang, SJ
   Darjatmoko, SR
   Sorenson, CM
   Dubielzig, RR
   Sheibani, N
AF Albert, Daniel M.
   Neekhra, Aneesh
   Wang, Shoujian
   Darjatmoko, Soesiawati R.
   Sorenson, Christine M.
   Dubielzig, Richard R.
   Sheibani, Nader
TI Development of Choroidal Neovascularization in Rats With Advanced
   Intense Cyclic Light-Induced Retinal Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; PIGMENT-EPITHELIUM;
   PHOTORECEPTOR DEGENERATION; OXIDATIVE STRESS; MOUSE MODEL; SUBRETINAL
   NEOVASCULARIZATION; SURGICAL EXCISION; VISIBLE-LIGHT; AGE
AB Objectives: To study the progressive changes of intense cyclic light-induced retinal degeneration and to determine whether it results in choroidal neovascularization (CNV).
   Methods: Albino rats were exposed to 12 hours of 3000-lux cyclic light for 1, 3, or 6 months. Fundus examination, fundus photography, fluorescein and indocyanine green angiography, and optical coherence tomography were performed prior to euthanization. Light-exposed animals were euthanized after 1, 3, or 6 months for histopathological evaluation. Retinas were examined for the presence of 4-hydroxy-2-nonenal -and nitrotyrosine-modified proteins by immunofluorescence staining.
   Results: Long-term intense cyclic light exposure resulted in retinal degeneration with loss of the outer segments of photoreceptors and approximately two-thirds of the outer nuclear layer as well as development of subretinal pigment epithelium neovascularization after 1 month. Almost the entire outer nuclear layer was absent with the presence of CNV, which penetrated the Bruch membrane and extended into the outer retina after 3 months. Absence of the outer nuclear layer, multiple foci of CNV, retinal pigment epithelial fibrous metaplasia, and connective tissue bands containing blood vessels extending into the retina were observed after 6 months. All intense light-exposed animals showed an increased presence of 4-hydroxy-2-nonenal and nitrotyrosine staining. Optical coherence tomographic and angiographic studies confirmed retinal thinning and leakiness of the newly formed blood vessels.
   Conclusions: Our results suggest that albino rats develop progressive stages of retinal degeneration and CNV after long-term intense cyclic light exposure, allowing the detailed study of the pathogenesis and treatment of age-related macular degeneration.
   Clinical Relevance: The ability to study the progressive pathogenesis of age-related macular degeneration and CNV will provide detailed knowledge about the disease and aid in the development of target-specific therapy.
C1 [Albert, Daniel M.; Neekhra, Aneesh; Wang, Shoujian; Darjatmoko, Soesiawati R.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA.
   [Sorenson, Christine M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA.
   [Dubielzig, Richard R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Vet Med, Madison, WI 53792 USA.
   [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53792 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Sheibani, N (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 600 Highland Ave,K6-458 CSC, Madison, WI 53792 USA.
EM nsheibanikar@wisc.edu
RI Sheibani, Nader/AAG-2379-2020
OI Sheibani, Nader/0000-0003-2723-9217
FU National Institutes of Health [EY16995, EY18179, P30 EY16665]; Retina
   Research Foundation; NATIONAL EYE INSTITUTE [P30EY016665, R01EY018179,
   R01EY016695] Funding Source: NIH RePORTER
FX Funding/Support: This work was supported in part by grants EY16995 (Dr
   Sheibani), EY18179 (Dr Sheibani), and P30 EY16665 from the National
   Institutes of Health and an unrestricted departmental award from
   Research to Prevent Blindness. Dr Sheibani is a recipient of a research
   award from the Retina Research Foundation.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BURNS MS, 1990, CURR EYE RES, V9, P1061, DOI 10.3109/02713689008997580
   CALDWELL RB, 1989, CURR EYE RES, V8, P923
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Castellarin AA, 1998, BRIT J OPHTHALMOL, V82, P480, DOI 10.1136/bjo.82.5.480
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Green W R, 1999, Mol Vis, V5, P27
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   Kremers J.J.M., 1988, LASERS LIGHT OPHTHAL, V2, P41
   KUWABARA T, 1968, ARCH OPHTHALMOL-CHIC, V79, P69, DOI 10.1001/archopht.1968.03850040071019
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LANUM J, 1978, SURV OPHTHALMOL, V22, P221, DOI 10.1016/0039-6257(78)90070-X
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishikawa S, 1998, EXP EYE RES, V67, P509, DOI 10.1006/exer.1998.0538
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Obata H, 1996, CURR EYE RES, V15, P335, DOI 10.3109/02713689609007629
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   OSTEEN WK, 1972, AM J ANAT, V134, P5, DOI 10.1002/aja.1001340103
   OSTEEN WK, 1974, INVEST OPHTH VISUAL, V13, P334
   OSTEEN WK, 1972, Z ZELLFORSCH MIK ANA, V127, P306, DOI 10.1007/BF00306875
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099
   Pennesi ME, 2008, EXP EYE RES, V87, P561, DOI 10.1016/j.exer.2008.09.004
   Platt DH, 2005, FREE RADICAL BIO MED, V39, P1353, DOI 10.1016/j.freeradbiomed.2005.06.015
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   ULISS AE, 1986, OPHTHALMOLOGY, V93, P1599
   WEALE RA, 1989, PHOTOCHEM PHOTOBIOL, V50, P429, DOI 10.1111/j.1751-1097.1989.tb04181.x
   WEBER ML, 1989, CURR EYE RES, V8, P61, DOI 10.3109/02713688909013895
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Winkler BS, 1999, MOL VIS, V5
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349
   Zhao L, 2007, MOL VIS, V13, P873
NR 74
TC 24
Z9 27
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2010
VL 128
IS 2
BP 212
EP 222
DI 10.1001/archophthalmol.2009.395
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 553OC
UT WOS:000274375700008
PM 20142545
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Johnson, EJ
   Chung, HY
   Caldarella, SM
   Snodderly, DM
AF Johnson, Elizabeth J.
   Chung, Hae-Yun
   Caldarella, Susan M.
   Snodderly, D. Max
TI The influence of supplemental lutein and docosahexaenoic acid on serum,
   lipoproteins, and macular pigmentation
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FATTY-ACIDS; DIETARY-FAT; PLASMA; ZEAXANTHIN;
   CAROTENOIDS; METABOLISM; TRANSPORT; TISSUE; DEGENERATION
AB Background: Lutein and docosahexaenoic acid (DHA) may protect against age-related macular degeneration (AMD). Lutein is a component of macular pigment. DHA is in the retina.
   Objective: The objective of this 4-mo study was to determine the effects of lutein (12 mg/d) and DHA (800 mg/d) on their serum concentrations and macular pigment optical density (MPOD).
   Design: Forty-nine women (60-80 y) were randomly assigned to placebo, DHA, lutein, or lutein + DHA supplement. Serum was analyzed for lutein and DHA (0, 2, and 4 mo). MPOD was determined (0 and 4 mo) at 0.4, 1.5, 3, and 5 temporal retinal eccentricities. Serum was analyzed for lipoproteins (4 mo).
   Results: There was no interaction between lutein and DHA supple-mentations for serum lutein and MPOD. The lutein supplementation x DHA supplementation x month interaction was significant for serum DHA response (P < 0.05). In the lutein group, serum lutein increased from baseline at 2 and 4 mo (P < 0.001), and MPOD increased at 3.0 degrees (P < 0.01). In the DHA group, serum DHA increased at 2 and 4 mo (P < 0.0001), and MPOD increased at 0.4 degrees(P < 0.05). In the lutein + DHA group, serum lutein and DHA increased at 2 and 4 mo (P < 0.01), and MPOD increased at 0.4, 1.5, and 3 degrees (P = 0.06, 0.08, and 0.09, respectively). Differences from placebo in lipoprotein subfractions were greatest for the lutein + DHA group (4 mo).
   Conclusions: Lutein supplementation increased MPOD eccentrically. DHA resulted in central increases. These results may be due to changes in lipoproteins. Lutein and DHA may aid in prevention of age-related macular degeneration.
C1 [Johnson, Elizabeth J.] Tufts Univ, Res Ctr Aging, Jean Mayer US Dept Agr Human Nutr, Boston, MA 02111 USA.
   [Chung, Hae-Yun] Yonsei Univ, Seoul 120749, South Korea.
   [Caldarella, Susan M.; Snodderly, D. Max] Schepens Eye Res Inst, Boston, MA USA.
   [Snodderly, D. Max] Med Coll Georgia, Augusta, GA 30912 USA.
C3 Tufts University; Yonsei University; Harvard University; Schepens Eye
   Research Institute; University System of Georgia; Augusta University
RP Johnson, EJ (通讯作者)，Tufts Univ, Res Ctr Aging, Jean Mayer US Dept Agr Human Nutr, 711 Washington St, Boston, MA 02111 USA.
EM elizabeth.johnson@tufts.edu
OI Snodderly, Donald/0000-0002-3428-609X
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   BARKER F, 2005, INVEST OPHTH VIS SCI, V46, P1770
   BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0
   Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   BLOCK G, 1993, HHHQ DIETSYS ANAL SO
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chopra M, 2000, CLIN CHEM, V46, P1818
   ENDRES S, 1993, J LEUKOCYTE BIOL, V54, P599, DOI 10.1002/jlb.54.6.599
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Foulon T, 1999, SCAND J CLIN LAB INV, V59, P239, DOI 10.1080/00365519950185607
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HAMPTON GR, 1992, AGE RELATED MACULAR
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Li N, 1999, P SOC EXP BIOL MED, V220, P218, DOI 10.1046/j.1525-1373.1999.d01-37.x
   Li ZL, 2004, J NUTR, V134, P1724, DOI 10.1093/jn/134.7.1724
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MARANGONI F, 1993, BIOCHIM BIOPHYS ACTA, V1210, P55, DOI 10.1016/0005-2760(93)90049-F
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5
   Otvos James D, 2002, Clin Lab, V48, P171
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Patton G M, 1981, Methods Enzymol, V72, P8, DOI 10.1016/S0076-6879(81)72004-4
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SAS Institute Inc, 1999, SAS STAT US GUID
   SCHALCH W, 1992, CAROTENOIDS RETINA R
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Superko HR, 1998, AM J CARDIOL, V81, p52F, DOI 10.1016/S0002-9149(98)00263-X
   Thomas TR, 2004, METABOLISM, V53, P749, DOI 10.1016/j.metabol.2003.12.019
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
   AGE RELATED EYE DIS, V2
NR 53
TC 99
Z9 105
U1 3
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAY
PY 2008
VL 87
IS 5
BP 1521
EP 1529
DI 10.1093/ajcn/87.5.1521
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 301EZ
UT WOS:000255880500054
PM 18469279
OA Bronze
DA 2022-11-30
ER

PT J
AU Mukkamala, SK
   Costa, RA
   Fung, A
   Sarraf, D
   Gallego-Pinazo, R
   Freund, KB
AF Mukkamala, Sri Krishna
   Costa, Rogerio A.
   Fung, Adrian
   Sarraf, David
   Gallego-Pinazo, Roberto
   Freund, K. Bailey
TI Optical Coherence Tomographic Imaging of Sub-Retinal Pigment Epithelium
   Lipid
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; AGE-RELATED MACULOPATHY;
   DIABETIC-MACULAR-EDEMA; HYPERREFLECTIVE FOCI; APOLIPOPROTEIN-B; BASAL
   DEPOSITS; DEGENERATION; DRUSEN; CHOLESTEROL; DETACHMENT
AB Objective: To describe an optical coherence tomographic finding of layered hyperreflective bands beneath the retinal pigment epithelium (RPE), the so-called onion sign believed to represent lipid within a vascularized pigment epithelial detachment.
   Methods: This retrospective observational case series involved reviewing clinical histories of patients with the onion sign. Imaging studies analyzed included spectral-domain optical coherence tomography, color and red-free photographs, near infrared reflectance, fundus autofluorescence, and blue-light fundus autofluorescence.
   Results: A total of 22 eyes of 20 patients with sub-RPE hyperreflective bands were identified. There were 15 women and 5 men with a mean patient age of 76 years (range, 60-92 years). Snellen best-corrected visual acuities ranged from 20/25 to counting fingers, with a median of 20/80. Two patients had bilateral involvement, and 3 of 17 eyes had multifocal onion signs in the same eye. All eyes had neovascular age-related macular degeneration, with type 1 (sub-RPE) neovascularization. In all patients, the onion sign correlated with areas of yellow-gray exudates seen clinically that appeared bright on red-free and near infrared reflectance imaging. No specific fundus autofluorescence or blue-light fundus autofluorescence pattern was identified.
   Conclusions: The onion sign refers to layered hyperreflective bands in the sub-RPE space usually associated with chronic exudation from type 1 neovascularization in patients with age-related macular degeneration. With an associated bright near infrared reflectance, these bands may correspond to lipid, collagen, or fibrin. Because the onion sign colocalizes to areas of exudation that are known to consist of lipoprotein, we propose that this finding may represent layers of precipitated lipid in the sub-RPE space. To our knowledge, this is the first report of lipid detected in the sub-RPE space on clinical examination. Arch Ophthalmol. 2012;130(12):1547-1553. Published online August 13, 2012. doi:10.1001/archophthalmol.2012.2491
C1 [Mukkamala, Sri Krishna; Fung, Adrian; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Mukkamala, Sri Krishna; Fung, Adrian; Freund, K. Bailey] LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Mukkamala, Sri Krishna; Freund, K. Bailey] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Mukkamala, Sri Krishna; Freund, K. Bailey] Columbia Univ, Edward S Harkness Eye Inst, New York, NY USA.
   [Costa, Rogerio A.] Ctr Brasileiro Ciencias Visuais, Belo Horizonte, MG, Brazil.
   [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp, Dept Ophthalmol, Valencia, Spain.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   Columbia University; University of California System; University of
   California Los Angeles; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Greater Los Angeles Healthcare System
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Fl, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Costa, Rogerio A/E-6930-2013; Freund, K. Bailey/V-7488-2018
OI Costa, Rogerio A/0000-0002-0800-2233; Freund, K.
   Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center; Manhattan Eye, Ear, and
   Throat Institute; Macula Foundation Inc; Karl Kirchgessner Foundation
FX This study was supported by funding from the LuEsther T. Mertz Retinal
   Research Center; the Manhattan Eye, Ear, and Throat Institute; the
   Macula Foundation Inc; and the Karl Kirchgessner Foundation
   Ophthalmology Endowment Fund to Dr Sarraf.
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bressler Neil M, 2005, Retina, V25, P130, DOI 10.1097/00006982-200507001-00016
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Cusick M, 2003, OPHTHALMOLOGY, V110, P2126, DOI 10.1016/j.ophtha.2003.01.001
   Deak GG, 2010, OPHTHALMOLOGY, V117, P773, DOI 10.1016/j.ophtha.2009.09.027
   Fernandes BF, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-24
   Gragoudas ES, 1999, OPHTHALMOLOGY, V106, P1571, DOI 10.1016/S0161-6420(99)90455-4
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Holz FG, 2010, ESSENT OPHTHALMOL, P1, DOI 10.1007/978-3-540-85540-8
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lima LH, 2010, RETINA-J RET VIT DIS, V30, P542, DOI 10.1097/IAE.0b013e3181c713e4
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Nowilaty SR, 2010, MIDDLE EAST AFR J OP, V17, P224, DOI 10.4103/0974-9233.65501
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Otani T, 2001, AM J OPHTHALMOL, V131, P50, DOI 10.1016/S0002-9394(00)00661-9
   Othman IS, 2010, BRIT J OPHTHALMOL, V94, P606, DOI 10.1136/bjo.2009.168013
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 36
TC 16
Z9 16
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2012
VL 130
IS 12
BP 1547
EP 1553
DI 10.1001/archophthalmol.2012.2491
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 052KA
UT WOS:000312195300007
PM 22892986
OA Bronze
DA 2022-11-30
ER

PT J
AU Konstantopoulos, A
   Yadegarfar, G
   Madhusudhana, K
   Canning, CR
   Luff, AJ
   Anderson, DF
   Hossain, PN
AF Konstantopoulos, Aristides
   Yadegarfar, Ghasem
   Madhusudhana, Khrishnapa
   Canning, Chris R.
   Luff, Andrew J.
   Anderson, David F.
   Hossain, Parwez N.
TI Prognostic factors that determine visual outcome following cataract
   surgery complicated by vitreous loss
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Cataract; Phacoemulsification; Vitreous loss; Prognostic factors
ID POSTERIOR CAPSULE RUPTURE; RETAINED LENS FRAGMENTS; PARS-PLANA
   VITRECTOMY; RETINAL-DETACHMENT; PHACOEMULSIFICATION; EXTRACTION; EYES
AB PURPOSE. To identify prognostic factors that determine visual outcome following phacoemulsification cataract surgery complicated by vitreous loss.
   METHODS. A retrospective cohort study. All cases of vitreous loss during phacoemulsification surgery at a university hospital, between June 2000 and December 2005, were identified from the hospital computer database. By reviewing the medical notes, preoperative, intraoperative, and postoperative data were collected. Outcome of interest was presence of poor visual outcome (best-corrected visual acuity [BCVA]<6/12). Chi-square and Mann-Whitney U tests were used to compare groups of poor and good visual outcome.
   RESULTS. A total of 230 consecutive cases (eyes) were identified; medical notes were available for 228. Mean patient age was 78.4 years (SD 11); median follow-up 13.4 weeks (range 1-203). In multivariable logistic regression analysis poor visual outcome was independently associated with poor preoperative vision (BCVA<6/12) (OR 3.78, 95% CI 1.76-8.11), age-related macular degeneration (OR 3.04, 95% CI 1.16-8.00), cystoid macular edema (OR 3.85, 95% CI 1.29-11.51), and secondary pars plana vitrectomy (PPV) for nuclear fragment loss (OR 4.42, 95% CI 1.03-19.02). Primary PPV for nuclear fragment loss, age>70, ocular comorbidity, axial length, vitreous loss during irrigation/aspiration, or lens implantation, anterior chamber lens, and secondary lens implantation were not significant associations (p >= 0.05). In 33 (14.5%) eyes BCVA was reduced by at least one Snellen line compared to before surgery.
   CONCLUSIONS. Poor visual outcome was associated with poor preoperative vision, age-related macular degeneration, cystoid macular edema, and secondary PPV following nuclear fragment loss. Primary PPV for nuclear fragment loss was not a significant association. (Eur J Ophthalmol 2009; 19: 247-53)
C1 [Konstantopoulos, Aristides; Madhusudhana, Khrishnapa; Canning, Chris R.; Luff, Andrew J.; Anderson, David F.; Hossain, Parwez N.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
   [Yadegarfar, Ghasem] Univ Southampton, Southampton Gen Hosp, Sch Med, Publ Hlth Sci & Med Stat Div, Southampton SO9 5NH, Hants, England.
C3 University of Southampton; University of Southampton
RP Konstantopoulos, A (通讯作者)，Southampton Gen Hosp, Southampton Eye Unit, MP104,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM ariskons@yahoo.com
RI Yadegarfar, Ghasem G/G-3016-2017; Hossain, Parwez/AAB-6065-2022
OI Yadegarfar, Ghasem G/0000-0002-5331-3890; Hossain,
   Parwez/0000-0002-3131-2395
CR Al-Khaier A, 2001, J CATARACT REFR SURG, V27, P1199, DOI 10.1016/S0886-3350(01)00750-7
   Basti S, 2003, J CATARACT REFR SURG, V29, P532, DOI 10.1016/S0886-3350(02)01696-6
   Bhagwandien ACE, 2006, OPHTHALMOLOGY, V113, P643, DOI 10.1016/j.ophtha.2005.10.056
   Chan FA, 2003, J CATARACT REFR SURG, V29, P537, DOI 10.1016/S0886-3350(02)01622-X
   Ching HY, 2006, EYE, V20, P297, DOI 10.1038/sj.eye.6701864
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   Ionides A, 2001, BRIT J OPHTHALMOL, V85, P222, DOI 10.1136/bjo.85.2.222
   Kageyama T, 2001, BRIT J OPHTHALMOL, V85, P1038, DOI 10.1136/bjo.85.9.1038
   KIM JE, 1994, OPHTHALMOLOGY, V101, P1827
   Lai TYY, 2005, EYE, V19, P1157, DOI 10.1038/sj.eye.6701708
   Margherio RR, 1997, OPHTHALMOLOGY, V104, P1426, DOI 10.1016/S0161-6420(97)30120-1
   Onal S, 2004, OPHTHAL SURG LAS IM, V35, P219, DOI 10.3928/1542-8877-20040501-09
   Tan JHY, 2002, EYE, V16, P117, DOI 10.1038/sj/EYE/6700015
   Tuft SJ, 2006, OPHTHALMOLOGY, V113, P650, DOI 10.1016/j.ophtha.2006.01.001
   Westcott MC, 2000, BRIT J OPHTHALMOL, V84, P1380, DOI 10.1136/bjo.84.12.1380
   Zaidi FH, 2007, BRIT J OPHTHALMOL, V91, P731, DOI 10.1136/bjo.2006.104216
NR 17
TC 10
Z9 10
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2009
VL 19
IS 2
BP 247
EP 253
DI 10.1177/112067210901900212
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 439AO
UT WOS:000265598800012
PM 19253242
DA 2022-11-30
ER

PT J
AU Cherinet, FM
   Tekalign, SY
   Anbesse, DH
   Bizuneh, ZY
AF Cherinet, Fashe Markos
   Tekalign, Sophia Yoseph
   Anbesse, Dereje Hayilu
   Bizuneh, Zewdu Yenegeta
TI Prevalence and associated factors of low vision and blindness among
   patients attending St. Paul's Hospital Millennium Medical College, Addis
   Ababa, Ethiopia
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Low vision and blindness; St. Paul's hospital millennium medical
   college; Ethiopia
AB Background: Low vision and blindness are major public health problems. A vast burden of worlds visually impaired live in low-income settings especially in sub Saharan Africa. In such settings the blindness is associated with considerable disability and excess mortality, resulting in huge economic and social consequence. The main purpose of this study was to determine the prevalence and associated factors of low vision and blindness among patients at St. Paul's hospital millenium medical college.
   Methods: Institution based cross sectional design study was carried out from January to April, 2017 with sample size of 904. Systematic random sampling was used to recruit the study subjects. Retrospective medical chart review was done; data was entered into and analyzed by SPSS 23. Descriptive statistics such as frequency cross tabulation and chi-square test was carried out to translate data into information. P-value less than 0.05 was considered as statistically significant.
   Results: A total of 881 subjects with a response rate of 97.4% selected. The mean age of the study subjects was 44.53(SD: +/- 21.85) with a range of 1-100 years. The prevalence of low vision and blindness was 91 (10.3% (95% CI: 8.2, 12.3)), and 64 (7.3 95% CI: 5.7, 9.0)) respectively. Age (p-value < 0.001), cataract (p-value = 0.002), glaucoma (p-value = 0.002) and age related macular degeneration (p-value < 0.001) were significantly associated with low vision and blindness.
   Conclusion: Low vision and blindness found in this study was high. Age, cataract, glaucoma and age related macular degeneration were significantly associated with low vision and blindness. This amount of magnitude will be reduced if prevention, early diagnosis and management will be targeted towards avoidable causes of visual impairment.
C1 [Cherinet, Fashe Markos; Tekalign, Sophia Yoseph; Anbesse, Dereje Hayilu; Bizuneh, Zewdu Yenegeta] St Pauls Hosp, Dept Ophthalmol, Millennium Med Coll, Addis Ababa, Ethiopia.
RP Cherinet, FM (通讯作者)，St Pauls Hosp, Dept Ophthalmol, Millennium Med Coll, Addis Ababa, Ethiopia.
EM cheruyemark2015@gmail.com
RI Bizuneh, Zewdu/ABA-3747-2021
OI Bizuneh, Zewdu/0000-0002-4149-7207
FU SPHMMC
FX The study was funded by SPHMMC and funding was for data collection,
   processing and write up.
CR Al-Bdour MD, 2002, EUR J OPHTHALMOL, V12, P5, DOI 10.1177/112067210201200102
   Ansah DO, 2017, M J OPHT, V2, P17
   Berhane Y, 2007, ETHIOP J HLTH DEV, V21
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-7
   Eballe A Omgbwa, 2005, SANTE, V15, P241
   Eballe AO, 2011, CLIN OPHTHALMOL, V5, P1325, DOI 10.2147/OPTH.S23064
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Harrell J, 2001, Community Eye Health, V14, P68
   Herse Peter, 1997, Indian Journal of Ophthalmology, V45, P189
   Maake Modjadji M, 2015, Afr J Prim Health Care Fam Med, V7, P728, DOI 10.4102/phcfm.v7i1.728
   Malu K N, 2013, Niger Postgrad Med J, V20, P98
   Melese M, 2003, BRIT J OPHTHALMOL, V87, P677, DOI 10.1136/bjo.87.6.677
   MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Pathanapitoon K, 2007, RETINA-J RET VIT DIS, V27, P635, DOI 10.1097/01.iae.0000249575.38830.45
   Ramke J, 2007, BRIT J OPHTHALMOL, V91, P1117, DOI 10.1136/bjo.2006.106559
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P1075, DOI 10.1136/bjo.87.9.1075
   Schemann JF, 2006, OPHTHAL EPIDEMIOL, V13, P219, DOI 10.1080/09286580600681347
   Sijuwola Oo, 2012, J West Afr Coll Surg, V2, P38
   Thomson I, 1997, BRIT J OPHTHALMOL, V81, P578, DOI 10.1136/bjo.81.7.578
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Thylefors B, 1987, World Health Stat Q, V40, P129
   Wang WL, 2016, KAOHSIUNG J MED SCI, V32, P475, DOI 10.1016/j.kjms.2016.07.009
   *WHO, 1997, STRAT PREV BLIND NAT
   Woretaw H, 2015, INT J PHARM H CARE R, V03, P48
   World Health Organization, WHOPBL9761 WHO
   World Health Organization, 2005, PREV BLINDN VIS IMP
   World Health Organization, 2006, LIST OFF ICD 10 UPD
   World Health Organization VISION, 282 WHO VISION, P2020
   Zerihun N, 1997, Ophthalmic Epidemiol, V4, P19
NR 30
TC 16
Z9 16
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 3
PY 2018
VL 18
DI 10.1186/s12886-018-0899-7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GS2WM
UT WOS:000443424000003
PM 30176841
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bhisitkul, RB
   Mendes, TS
   Rofagha, S
   Enanoria, W
   Boyer, DS
   Sadda, SR
   Zhang, K
AF Bhisitkul, Robert B.
   Mendes, Thais S.
   Rofagha, Soraya
   Enanoria, Wayne
   Boyer, David S.
   Sadda, Srinivas R.
   Zhang, Kang
TI Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From
   the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF TRAP-EYE; GEOGRAPHIC ATROPHY; FOLLOW-UP; VISUAL-ACUITY;
   RANIBIZUMAB; DEGENERATION; EDEMA; VERTEPORFIN; MORPHOLOGY; INJECTION
AB PURPOSE: To assess the incidence and progression of macular atrophy and other key anatomic outcomes over 7 to 8 years in an early cohort of ranibizumab-treated exudative age-related macular degeneration patients.
   DESIGN: Follow-up analysis of long-term outcomes in a multicenter treatment cohort.
   METHODS: Fourteen study sites enrolled 65 previous subjects from the ranibizumab treatment arms of the ANCHOR, MARINA, and HORIZON trials. In a single update visit, clinical assessment and retinal imaging studies were performed, with comparison with each subject's prior results from the previous trials. Early Treatment Diabetic Retinopathy Study visual acuity was the primary outcome. Secondary outcomes, including area of macular atrophy and selected anatomic factors, were analyzed for associations with long-term vision outcomes.
   RESULTS: At a mean 7.3 years after ANCHOR or MARINA enrollment, mean visual acuity was 54 letters, study eyes having received a mean 1.6 injections per year since the HORIZON study. Macular atrophy was present in 98% of study eyes, the mean area increasing from 0.83 +/- 0.96 mm(2) at the ANCHOR or MARINA year 2 exit to 2.22 +/- 1.6 mm(2) at the SEVEN-UP visit, a growth rate of 0.28 mm(2)/year. Progression of macular atrophy was associated significantly with visual decline over this 5-year period (P < .001), and final macular atrophy lesion size was related significantly to final vision (P < .001). Other key anatomic outcomes (macular thickening, thinning, or fluid and submacular fibrosis) did not have significant effects on vision outcomes.
   CONCLUSIONS: Seven years after initiation of intensive ranibizumab therapy for exudative age-related macular degeneration, macular atrophy progression and severity were the primary anatomic determinants of visual outcomes. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Bhisitkul, Robert B.; Mendes, Thais S.; Rofagha, Soraya] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Enanoria, Wayne] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Boyer, David S.] Retina Vitreous Associates, Los Angeles, CA USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   Retina Vitreous Associates Medical Group; Doheny Eye Institute;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California San Diego
RP Bhisitkul, RB (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA.
EM BhisitkulR@vision.ucsf.edu
RI Zhang, Kang/Y-2740-2019; Mendes, Thais Sousa/R-7735-2019
OI Zhang, Kang/0000-0002-4549-1697; Mendes, Thais Sousa/0000-0001-5568-9958
FU Genentech (South San Francisco, CA); GlaxoSmithKline (Philadelphia, PA);
   Regeneron (Tarrytown, NY); Alcon (Fort Worth, TX); Allergan (Irvine,
   CA); Zeiss (Oberkochen, Germany); Optovue (Fremont, CA); Genentech,
   South San Francisco, California; National Eye Institute, National
   Institutes of Health, Bethesda, Maryland [EY002162]; That Man May See
   Foundation, San Francisco, California; Research to Prevent Blindness,
   Inc, New York, New York; Veterans Affairs [I01BX001898] Funding Source:
   NIH RePORTER
FX Dr Bhisitkul is a consultant for Genentech (South San Francisco, CA),
   Santen (Emeryville, CA), Allergan (Irvine, CA), Bausch & Lomb
   (Bridgewater, NY), Aerpio (Blue Ash, OH), Xoma (Berkeley, CA), and
   Iconic Therapeutics (South San Francisco, CA); his employer, the
   University of California, San Francisco, has received research grants
   from Genentech (South San Francisco, CA) and GlaxoSmithKline
   (Philadelphia, PA); and he holds stock options for Zordera (San
   Francisco, CA). Dr Rofagha has received a research grant from Regeneron
   (Tarrytown, NY). Dr Boyer is a consultant for Alcon (Fort Worth, TX),
   Allergan (Irvine, CA), Neurotech (Cumberland, RI), Novartis/QLT (Basel,
   Switzerland), Pfizer (New York, NY), and iCo Therapeutics (Vancouver,
   British Columbia) and has received research grants from Genentech (South
   San Francisco, CA), Regeneron (Tarrytown, NY), Alcon (Fort Worth, TX),
   and Allergan (Irvine, CA). Dr Sadda is a consultant for Genentech (South
   San Francisco, CA), Allergan (Irvine, CA), and Heidelberg Engineering
   (Carlsbad, CA); he has received research grants from Genentech (South
   San Francisco, CA), Zeiss (Oberkochen, Germany), and Optovue (Fremont,
   CA); and he holds patents with Topcon Medical Systems (Oakland, NJ).
   Kang Zhang is a consultant for Genentech (South San Francisco, CA) and
   Acucela (Seattle, WA), and he has received research grants from
   Genentech (South San Francisco, CA). The authors had control of all
   aspects of the study free from influence from Genentech. Supported by
   Genentech, South San Francisco, California, which participated in the
   enlistment of clinical investigators; Research to Prevent Blindness,
   Inc, New York, New York; Core Grant EY002162 from the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland; and That
   Man May See Foundation, San Francisco, California. Involve din Design
   and conduct of study (R.B.B., S.R., D.S.B., S.R.S., K.Z.); Collection
   and management of data (R.B.B., T.S.M., SR., D.S.B., S.R.S.); Analysis
   of data (R.B.B., T.S.M., S.R., W.E., S.R.S.); and Preparation and review
   of manuscript (R.B.B., T.S.M., S.R., W.E., D.S.B., S.R.S., K.Z.).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Dunavoelgyi R, 2012, RETINA-J RET VIT DIS, V32, P1471, DOI 10.1097/IAE.0b013e318236e805
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hao TF, 2013, FREE RADICAL BIO MED, V63, P421, DOI 10.1016/j.freeradbiomed.2013.05.036
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
NR 37
TC 134
Z9 139
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2015
VL 159
IS 5
BP 915
EP 924
DI 10.1016/j.ajo.2015.01.032
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5VW
UT WOS:000353365000012
PM 25640411
DA 2022-11-30
ER

PT J
AU Shao, L
   Xu, L
   Bin Wei, W
   Chen, CX
   Du, KF
   Ii, XP
   Yang, M
   Wang, YX
   You, QS
   Jonas, JB
AF Shao, Lei
   Xu, Lang
   Bin Wei, Wen
   Chen, Chang Xi
   Du, Kui Fang
   Ii, Xiao Peng
   Yang, Ming
   Wang, Ya Xing
   You, Qi Sheng
   Jonas, Jost B.
TI Visual Acuity and Subfoveal Choroidal Thickness: The Beijing Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; HIGHLY MYOPIC EYES; OLDER POPULATION;
   HEALTHY-SUBJECTS; CHINESE SUBJECTS; LOW-VISION; PREVALENCE; BLINDNESS;
   ASSOCIATION; MACULOPATHY
AB PURPOSE: To examine the association between best corrected visual acuity (BCVA) and subfoveal choroidal thickness.
   DESIGN: Population-based study.
   METHODS: The Beijing Eye Study 2011 included 3468 subjects with ages of 50 + years. The participants underwent an ophthalmologic examination including spectral-domain optical coherence tomography with enhanced depth imaging for measurement of choroidal thickness. BCVA was measured as logarithm of the minimal angle of resolution.
   RESULTS: Of the 3468 participants, choroidal measurements were available for 3233 (93.2%) subjects. In multivariate analysis, better BCVA was significantly associated with thicker subfoveal choroid (P < 0.001) in general and a subfoveal choroid thicker than 30 mu m (P < 0.001) in particular, after adjusting for younger age (P < 0.001), higher level of education (P < 0.001), taller body stature (P < 0.001), higher body mass index (P = 0.005), absence of glaucoma (P = 0.001), absence of diabetic retinopathy (P < 0.001), absence of late-stage age-related macular degeneration (P < 0.001), and axial length shorter than 26.0 mm (P < 0.001) (correlation coefficient r:0.56). If eyes with glaucoma, diabetic retinopathy, late-stage age-related macular degeneration or myopic retinopathy were excluded, better BCVA was still significantly associated with thicker subfoveal choroid (P < 0.001) and subfoveal choroid thicker than 30 mu m (P < 0.001) in multivariate analysis. In a reverse manner, thicker subfoveal choroid was associated with better BCVA (P < 0.001) after adjusting for younger age (P < 0.001), male gender (P < 0.001), longer axial length (P < 0.001), and higher corneal curvature radius (P < 0.001).
   CONCLUSIONS: Better visual acuity is strongly associated with thicker subfoveal choroid independent of additional factors, such as age, axial length, education level, and major ocular diseases. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Shao, Lei; Bin Wei, Wen; Du, Kui Fang] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Xu, Lang; Chen, Chang Xi; Wang, Ya Xing; You, Qi Sheng; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Ii, Xiao Peng; Yang, Ming] Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Ruprecht Karls University Heidelberg
RP Bin Wei, W (通讯作者)，Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM wenbing_wei@yahoo.com.cn
RI wang, YA XING/K-9671-2016; You, Qisheng/AAG-7153-2020
OI wang, YA XING/0000-0003-2749-7793; You, Qisheng/0000-0003-0743-7320;
   Jonas, Jost/0000-0003-2972-5227; , Ming/0000-0003-4932-3225
FU National Natural Science Foundation of China [81170890]; National Key
   Technology R&D Program of the Ministry of Science and Technology
   [2012BAH05F05, 2013BAH19F04]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST, and the following were reported.
   Supported by the National Natural Science Foundation of China (No.
   81170890) and the National Key Technology R&D Program of the Ministry of
   Science and Technology (No. 2012BAH05F05 and 2013BAH19F04). Dr Jonas is
   a consultant for Allergan Inc.; Merck Sharp & Dohme Co., Inc.; Alimera
   Co.; Boehringer Ingelheim Co., and Sanofi Co., and is a patent holder
   with CellMed AG, Alzenau, Germany. Design and conduct of study (L.S.,
   L.X., W.B.W., C.X.C., K.F.D., X.P.L., M.Y., Y.X.W., Q.S.Y., J.B.J.);
   Collection, management, analysis, and interpretation of data (L.S.,
   L.X., W.B.W., C.X.C., K.F.D., X.P.L., MY., Y.X.W., Q.S.Y., J.B.J.); and
   Preparation, review, or approval of manuscript (L.S., L.X., W.B.W.,
   C.X.C., K.F.D., X.P.L., MY., Y.X.W., Q.S.Y., J.B.J.).
CR Chen SJ, 2012, INVEST OPHTH VIS SCI, V53, P4868, DOI 10.1167/iovs.12-9919
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   Ho M, 2013, OPHTHALMOLOGY, V120, P1909, DOI 10.1016/j.ophtha.2013.02.005
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Jonas JB, 2013, INVEST OPHTH VIS SCI, V54, P1295, DOI 10.1167/iovs.12-11352
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lai TYY, 2008, EYE, V22, P209, DOI 10.1038/sj.eye.6702573
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Xu LA, 2010, ACTA OPHTHALMOL, V88, pe350, DOI 10.1111/j.1755-3768.2009.01770.x
   You QS, 2014, OPHTHALMOLOGY, V121, P220, DOI 10.1016/j.ophtha.2013.06.013
   Zhao L, 2014, ACTA OPHTHALMOL, V92, pE35, DOI 10.1111/aos.12240
NR 23
TC 70
Z9 73
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2014
VL 158
IS 4
BP 702
EP 709
DI 10.1016/j.ajo.2014.05.023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1PI
UT WOS:000342552900007
PM 24878308
DA 2022-11-30
ER

PT J
AU Xu, L
   Wang, YX
   Jonas, JB
AF Xu, Liang
   Wang, Ya Xing
   Jonas, Jost B.
TI Level of education associated with ophthalmic diseases. The Beijing Eye
   Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Socioeconomics; Education; Income; Glaucoma; Age-related macular
   degeneration; Arterial hypertension; Diabetes mellitus; Beijing eye
   study
ID AGE-RELATED MACULOPATHY; NUTRITION EXAMINATION SURVEY;
   SOCIOECONOMIC-STATUS; RISK-FACTORS; VISUAL IMPAIRMENT;
   CARDIOVASCULAR-DISEASE; MACULAR-DEGENERATION; OCULAR DIMENSIONS;
   URBAN-POPULATION; NATIONAL-HEALTH
AB To determine associations between educational level and ophthalmic diseases in Chinese.
   The population-based Beijing Eye Study, performed in 2006, enrolled 3,251 participants (age: 45+ years) out of 4,439 subjects invited to participate (response rate: 73.2%). The participants underwent an interview including questions concerning their educational level, and a detailed ophthalmic examination.
   Data on the level of education were available for 3,221 (99.1%) subjects, with 1,484 (46.1%) subjects living in the rural region. The mean age was 60.4 +/- 10.1 years (range: 45-89 years). In a multivariate analysis, a higher level of education was significantly associated with myopic refractive error, higher best-corrected visual acuity, lower degree of nuclear cataract, and lower prevalence of angle-closure glaucoma, and with the systemic parameters of lower age, male gender, urban region, taller body height, and lower body mass index. It was not significantly associated with intraocular pressure, amount of subcapsular cataract and cortical cataract, cataract surgery, and the prevalences of diabetes mellitus, retinal vein occlusions, chronic open-angle glaucoma, and age-related macular degeneration, and with the systemic parameters of fasting serum concentrations of glucose, high-density lipoproteins, low-density lipoproteins, cholesterol and triglycerides, systolic and diastolic blood pressure.
   In the Greater Beijing area, a higher level of education was associated with myopic refractive error, higher best-corrected visual acuity, and lower prevalence of nuclear cataract and angle-closure glaucoma, after adjusting for the systemic parameters of younger age, male gender, urban region, taller body height, lower body mass index less smoking and less alcohol consumption. Educational level was not significantly associated with intraocular pressure, cortical cataract, blood pressure, and frequencies of age-related macular degeneration, retinal vein occlusions and chronic open-angle glaucoma.
C1 [Xu, Liang; Wang, Ya Xing; Jonas, Jost B.] Capital Med Sci Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Med Sci Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou St, Beijing 100005, Peoples R China.
EM xlbio@yahoo.cn
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   *BEIJ MUN STAT BUR, 2002, BEIJ STAT YB 2001
   Berdeaux G, 2007, OPHTHAL EPIDEMIOL, V14, P80, DOI 10.1080/09286580600899691
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Eysteinsson T, 2005, ACTA OPHTHALMOL SCAN, V83, P734, DOI 10.1111/j.1600-0420.2005.00540.x
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kulmala J, 2008, OPHTHAL EPIDEMIOL, V15, P128, DOI 10.1080/09286580701840388
   Livingston PM, 1997, BRIT J OPHTHALMOL, V81, P574, DOI 10.1136/bjo.81.7.574
   LUOTO R, 1994, J EPIDEMIOL COMMUN H, V48, P348, DOI 10.1136/jech.48.4.348
   LYNCH J, 1995, CIRCULATION, V92, P1786, DOI 10.1161/01.CIR.92.7.1786
   Marengoni A, 2008, AM J PUBLIC HEALTH, V98, P1198, DOI 10.2105/AJPH.2007.121137
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Metcalf PA, 2008, NEW ZEAL MED J, V121, P45
   Mohan V, 2001, DIABETIC MED, V18, P280, DOI 10.1046/j.1464-5491.2001.00421.x
   PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460
   Sabanayagam C, 2007, J EPIDEMIOL, V17, P161, DOI 10.2188/jea.17.161
   Saw SM, 2002, INVEST OPHTH VIS SCI, V43, P1408
   van Hooijdonk C, 2008, J EPIDEMIOL COMMUN H, V62, P499, DOI 10.1136/jech.2007.060145
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816
   Winkleby MA, 1998, JAMA-J AM MED ASSOC, V280, P356, DOI 10.1001/jama.280.4.356
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1237
   Wu HM, 2007, CLIN EXP OPHTHALMOL, V35, P834, DOI 10.1111/j.1442-9071.2007.01638.x
   Xu F, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-170
   Xu L, 2008, EXP CLIN ENDOCR DIAB, V116, P69, DOI 10.1055/s-2007-985381
   Xu L, 2006, OPHTHALMOLOGY, V113, P747, DOI 10.1016/j.ophtha.2006.01.026
   Xu L, 2007, AM J OPHTHALMOL, V144, P541, DOI 10.1016/j.ajo.2007.05.038
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Yip JLY, 2007, BRIT J OPHTHALMOL, V91, P56, DOI 10.1136/bjo.2006.099549
   Yu ZJ, 2000, B WORLD HEALTH ORGAN, V78, P1296
NR 35
TC 22
Z9 23
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2010
VL 248
IS 1
BP 49
EP 57
DI 10.1007/s00417-009-1204-5
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 527IJ
UT WOS:000272360400007
PM 19821117
DA 2022-11-30
ER

PT J
AU Bayyoud, T
   Gelisken, F
   Rohrbach, JM
   Blumenstock, G
   Bartz-Schmidt, KU
   Thaler, S
AF Bayyoud, Tarek
   Gelisken, Faik
   Rohrbach, Jens Martin
   Blumenstock, Gunnar
   Bartz-Schmidt, Karl Ulrich
   Thaler, Sebastian
TI Outcomes after Descemet membrane endothelial keratoplasty over a period
   of 7 years at a tertiary referral center: endothelial cell density,
   central corneal thickness, and visual acuity
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Descemet membrane endothelial keratoplasty; Visual acuity; Endothelial
   cell density; Central corneal thickness
AB Purpose To better assess clinical trajectories of patients with or without ocular comorbidity after Descemet membrane endothelial keratoplasty. Background: To report on the outcomes of eyes with differing starting conditions following surgery. Design: Retrospective study at a University Eye Hospital. Participants: 361 eyes separated into group 1 (n=229; eyes with endothelial disease only) and group 2 (n=132; eyes with additional ocular comorbid conditions, such as herpetic eye disease 18/132 (13.6%), glaucoma 16/132 (12.1%), dry age-related macular degeneration 14/132 (10.6%), epiretinal membranes 10/132 (7.6%), and wet age-related macular degeneration 9/132 (6.8%)). Methods Consecutive eyes that underwent Descemet membrane endothelial keratoplasty over a follow-up period of up to 7 years at a tertiary referral center were reviewed. Main outcome measures were best-corrected visual acuity, postoperative complications, graft survival, central corneal thickness, and endothelial cell density. Results Postoperative best-corrected visual acuity at year 1 improved in both groups significantly (Wilcoxon signed rank test: group 1, p =.002; .63 to .23 logMAR; group 2, p <.001; 1.15 to .87 logMAR) with a group difference in favor of group 1 (p =.009, Mann-Whitney-Wilcoxon). A decrease of the endothelial cell density and central corneal thickness was noted at postoperative year 1 for both groups (paired t-tests (group 1, p <.001; group 2, p =.045) and paired t-tests (group 1, p <.001; group 2, p =.003). Complications were less common, and graft longevity was superior in group 1. Conclusion Eyes with different starting conditions might experience a visual improvement and benefit from surgery. Descemet membrane endothelial keratoplasty is a valid treatment for endothelial disorders in manifold of eyes. Further long-term studies are required.
C1 [Bayyoud, Tarek; Gelisken, Faik; Rohrbach, Jens Martin; Bartz-Schmidt, Karl Ulrich; Thaler, Sebastian] Univ Hosp Tubingen, Dept Ophthalmol, Tubingen, Baden Wurttembe, Germany.
   [Blumenstock, Gunnar] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Baden Wurttembe, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen
RP Bayyoud, T (通讯作者)，Univ Hosp Tubingen, Dept Ophthalmol, Tubingen, Baden Wurttembe, Germany.
EM tarek.bayyoud@med.uni-tuebingen.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Abdelmassih Y, 2019, CORNEA, V38, P553, DOI 10.1097/ICO.0000000000001891
   Baydoun L, 2017, CORNEA, V36, P379, DOI 10.1097/ICO.0000000000001111
   Birbal RS, 2019, AM J OPHTHALMOL, V199, P150, DOI 10.1016/j.ajo.2018.11.014
   Croghan C, 2018, EYE, V32, P655, DOI 10.1038/eye.2017.216
   Dapena I, 2009, CURR OPIN OPHTHALMOL, V20, P299, DOI 10.1097/ICU.0b013e32832b8d18
   Flockerzi E, 2018, AM J OPHTHALMOL, V188, P91, DOI 10.1016/j.ajo.2018.01.018
   Groeneveld-van Beek EA, 2013, ACTA OPHTHALMOL, V91, P145, DOI 10.1111/j.1755-3768.2012.02462.x
   Ham L, 2009, EYE, V23, P1990, DOI 10.1038/eye.2008.393
   Ham L, 2016, AM J OPHTHALMOL, V171, P113, DOI 10.1016/j.ajo.2016.08.038
   Melles GRJ, 2008, AM J OPHTHALMOL, V145, P222, DOI 10.1016/j.ajo.2007.09.021
   Melles GRJ, 2006, CORNEA, V25, P987, DOI 10.1097/01.ico.0000248385.16896.34
   Monnereau C, 2014, JAMA OPHTHALMOL, V132, P1192, DOI 10.1001/jamaophthalmol.2014.1710
   Ono T, 2017, JPN J OPHTHALMOL, V61, P131, DOI 10.1007/s10384-016-0489-2
   Pasari A, 2019, CORNEA, V38, P151, DOI 10.1097/ICO.0000000000001763
   Patel HY, 2011, CORNEA, V30, P760, DOI 10.1097/ICO.0b013e3182014668
   Rodriguez-Calvo-de-Mora M, 2015, OPHTHALMOLOGY, V122, P464, DOI 10.1016/j.ophtha.2014.09.004
   Schlogl A, 2016, AM J OPHTHALMOL, V169, P218, DOI 10.1016/j.ajo.2016.07.002
   Spaniol K, 2016, INT J OPHTHALMOL-CHI, V9, P390, DOI 10.18240/ijo.2016.03.11
   Tappin M, 2007, EYE, V21, P775, DOI 10.1038/sj.eye.6702326
   van Dijk K, 2014, AM J OPHTHALMOL, V158, P71, DOI 10.1016/j.ajo.2014.04.008
   van Dijk K, 2013, CONTACT LENS ANTERIO, V36, P13, DOI 10.1016/j.clae.2012.10.066
   Weller JM, 2015, CORNEA, V34, P1351, DOI 10.1097/ICO.0000000000000625
   Yoeruek E, 2015, CORNEA, V34, P1, DOI 10.1097/ICO.0000000000000288
   Yoeruek E, 2013, CORNEA, V32, P370, DOI 10.1097/ICO.0b013e318254fa06
NR 24
TC 4
Z9 4
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 259
IS 7
BP 1907
EP 1914
DI 10.1007/s00417-021-05152-w
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TI3LH
UT WOS:000629293900003
PM 33723638
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Liao, Y
   Zhang, HJ
   He, DX
   Wang, Y
   Cai, BX
   Chen, JM
   Ma, JX
   Liu, ZG
   Wu, YL
AF Liao, Yi
   Zhang, Houjian
   He, Danxue
   Wang, Yan
   Cai, Binxiang
   Chen, Jingmeng
   Ma, Jianxing
   Liu, Zuguo
   Wu, Yalin
TI Retinal Pigment Epithelium Cell Death Is Associated With NLRP3
   Inflammasome Activation by All-trans Retinal
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE all-trans retinal; atRAL; NLR family pyrin domain containing 3; NLRP3;
   retinal pigment epithelium; RPE; visual (retinoid) cycle
ID MACULAR DEGENERATION; IDENTIFICATION; INVOLVEMENT; RETINOPATHY;
   PYROPTOSIS; INHIBITOR; CLEAVAGE
AB PURPOSE. Visual (retinoid) cycle anomalies induce aberrant build-up of all-trans retinal (atRAL) in the retinal pigment epithelium (RPE), which is a cause of RPE atrophy in Stargardt disease type 1 and age-related macular degeneration. NLR family pyrin domain containing 3 (NLRP3) inflammasome activation is implicated in the etiology of age-related macular degeneration. Here, we elucidated the relationship between NLRP3 inflammasome activation and atRAL-induced death of RPE cells.
   METHODS. Cellular toxicities were assessed by MTS or MTT assays. Expression levels of mRNAs and proteins were determined by quantitative reverse transcription-polymerase chain reaction, Western blotting, or enzyme-linked immunosorbent assay. Fluorescence microscopy was used to examine intracellular signals. Ultrastructural features of organelles were examined by transmission electron microscope.
   RESULTS. Abnormal accumulation of atRAL was associated with a significant increase in the proportion of human ARPE-19 cells exhibiting features of apoptosis and Caspase-3/gasdermin E (GSDME)-mediated pyroptosis. These cells also exhibited elevated expression of NLRP3, ASC, cleaved Caspase-1/poly ADP-ribose polymerase (PARP)/Caspase-3/GSDME, interleukin-1 beta (IL-1 beta), and IL-18, as well as NLRP3 inflammasome-related genes (IL1B and IL18). After exposure of human ARPE-19 cells to excess atRAL, reactive oxygen species (ROS) (including mitochondrial ROS) and cathepsins released from lysosomes transmitted signals leading to NLRP3 inflammasome activation. Suppressing the production of ROS, NLRP3 inflammasome, Caspase-1, cathepsin B, or cathepsin D protected ARPE-19 cells against atRAL-associated cytotoxicity. Damage to mitochondria, lysosomes, and endoplasmic reticulum in atRAL-exposed ARPE-19 cells was partially alleviated by treatment with MCC950, a selective NLRP3 inflammasome inhibitor.
   CONCLUSIONS. Aberrant build-up of atRAL promotes the death of RPE cells via NLRP3 inflammasome activation.
C1 [Liao, Yi; Zhang, Houjian; He, Danxue; Cai, Binxiang; Liu, Zuguo; Wu, Yalin] Xiamen Univ, Sch Med, Fujian Prov Key Lab Ophthalmol & Visual Sci, Inst Eye, Xiangan South Rd, Xiamen 361102, Fujian, Peoples R China.
   [Wang, Yan] Southern Med Univ, Shenzhen Hosp, Dept Ophthalmol, Shenzhen, Peoples R China.
   [Chen, Jingmeng] Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China.
   [Ma, Jianxing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Harold Hamm Diabet Ctr, Oklahoma City, OK USA.
   [Wu, Yalin] Xiamen Univ, Shenzhen Res Inst, Shenzhen, Peoples R China.
C3 Xiamen University; Southern Medical University - China; Xiamen
   University; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Xiamen University
RP Wu, YL (通讯作者)，Xiamen Univ, Sch Med, Fujian Prov Key Lab Ophthalmol & Visual Sci, Inst Eye, Xiangan South Rd, Xiamen 361102, Fujian, Peoples R China.
EM yalinw@xmu.edu.cn
FU China National Natural Science Foundation [81870671, 81570857,
   81700864]; Natural Science Foundation of Fujian Province [2017J01148];
   Basic Research Program of Shenzhen Grant [JCYJ20180306173025004];
   Sanming Project of Medicine in Shenzhen Grant [SZSM201612022]
FX Supported in part by China National Natural Science Foundation Grants
   81870671 (YW), 81570857 (YW), and 81700864 (YL); Natural Science
   Foundation of Fujian Province Grant 2017J01148 (YW); the Basic Research
   Program of Shenzhen Grant JCYJ20180306173025004 (YW); and Sanming
   Project of Medicine in Shenzhen Grant SZSM201612022 (ZL, YW).
CR Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   Jiang H, 2017, J EXP MED, V214, P3219, DOI 10.1084/jem.20171419
   Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005
   Li J, 2016, TOXICOLOGY, V371, P41, DOI 10.1016/j.tox.2016.10.005
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Li J, 2013, J BIOL CHEM, V288, P35671, DOI 10.1074/jbc.M113.511386
   Liu X, 2016, INVEST OPHTH VIS SCI, V57, P1017, DOI 10.1167/iovs.15-18429
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Malik A, 2017, J CELL SCI, V130, P3955, DOI 10.1242/jcs.207365
   Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010
   Orlowski GM, 2015, J IMMUNOL, V195, P1685, DOI 10.4049/jimmunol.1500509
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
NR 32
TC 24
Z9 26
U1 5
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2019
VL 60
IS 8
BP 3034
EP 3045
DI 10.1167/iovs.18-26360
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IK5AG
UT WOS:000476597500009
PM 31311035
OA gold
DA 2022-11-30
ER

PT J
AU Graffe, A
   Beauchet, O
   Fantino, B
   Milea, D
   Annweiler, C
AF Graffe, Alix
   Beauchet, Olivier
   Fantino, Bruno
   Milea, Dan
   Annweiler, Cedric
TI Vitamin D and Macular Thickness in the Elderly: An Optical Coherence
   Tomography Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular thickness; vitamin D; neuroendocrinology; older adults;
   age-related macular degeneration; retina
ID D DEFICIENCY; DEGENERATION; ASSOCIATION; CALCITRIOL; IMPAIRMENT; HEALTH
AB PURPOSE. Vitamin D insufficiency is associated with age-related macular degeneration. Our objective was to determine whether low serum 25-hydroxyvitamin D (25OHD) concentration was associated with macular thickness among older adults with no signs of macular dysfunction.
   METHODS. Sixty-two French older community-dwellers with no patent macular dysfunction (mean +/- SD, 71.2 +/- 5.0 years; 45.2% female) included in the Gait and Alzheimer Interaction Tracking (GAIT) study (ClinicalTrials.gov number, NCT01315717) were separated into two groups according to serum 25OHD level (i.e., insufficient < 50 nmol/L or sufficient >= 50 nmol/L). The macular thickness was measured on 1000 mu m central macula with optical coherence tomography, and further binarized according to normal values of macular thickness (i.e., 267.74 mu m for males, and 255.60 mu m for females). Age, sex, number of comorbidities, cognitive disorders, body mass index, mean arterial pressure, visual acuity, intraocular pressure, serum calcium concentration and season of testing were considered as potential confounders.
   RESULTS. The mean serum 25OHD concentration was 61.2 +/- 26.3 nmol/L. Patients with vitamin D insufficiency had a reduced macular thickness compared to those without (232.9 +/- 40.4 mu m vs. 253.3 +/- 32.1 mu m, P = 0.042). After adjustment for potential confounders, vitamin D insufficiency was associated with a decreased macular thickness (beta = -59.4 mu m, P = 0.001). Consistently, the participants with vitamin D insufficiency had a 3.7-fold higher risk of having abnormally low macular thickness compared with those with sufficient 25OHD level (P = 0.042).
   CONCLUSIONS. Vitamin D insufficiency was associated with reduced macular thickness among older patients with no patent macular dysfunction. This implies that vitamin D insufficiency may be involved in macular thinning, and provides a scientific base for vitamin D replacement trials in age-related macular degeneration.
C1 [Graffe, Alix; Milea, Dan] Angers Univ Hosp, Dept Ophthalmol, F-49933 Angers 9, France.
   [Beauchet, Olivier; Fantino, Bruno; Annweiler, Cedric] Univ Angers, UNAM, Univ Memory Clin Angers, Angers Univ Hosp,Dept Neurosci,Div Geriatr Med,UP, Angers, France.
   [Milea, Dan] Glostrup Univ Hosp, Copenhagen, Denmark.
   [Milea, Dan] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Milea, Dan] Duke NUS Neurosci & Behav Dis, Singapore, Singapore.
   [Annweiler, Cedric] Univ Western Ontario, Schulich Sch Med & Dent, Dept Med Biophys, Robarts Res Inst, London, ON, Canada.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers;
   Universite d'Angers; Centre Hospitalier Universitaire d'Angers;
   University of Copenhagen; National University of Singapore; Singapore
   National Eye Center; Western University (University of Western Ontario)
RP Annweiler, C (通讯作者)，Angers Univ Hosp, Dept Neurosci, F-49933 Angers 9, France.
EM CeAnnweiler@chu-angers.fr
RI Beauchet, Olivier/AAP-8108-2020; Milea, Dan/AAT-8661-2021
OI Annweiler, Cedric/0000-0002-7199-8109
FU French Ministry of Health (Projet Hospitalier de Recherche Clinique
   National) [2009-A00533-54]
FX Supported by the French Ministry of Health (Projet Hospitalier de
   Recherche Clinique National No. 2009-A00533-54). The authors alone are
   responsible for the content and writing of the paper.
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Annweiler C, 2012, EUR J NEUROL, V19, P1023, DOI 10.1111/j.1468-1331.2012.03675.x
   Annweiler C, 2013, J AM GERIATR SOC, V61, P1026, DOI 10.1111/jgs.12249
   Annweiler C, 2012, OPHTHALMOLOGY, V119, P1090, DOI 10.1016/j.ophtha.2012.02.005
   Annweiler C, 2011, GERIATR PSYCHOL NEUR, V9, P259, DOI 10.1684/pnv.2011.0288
   [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   APA, 1994, DIAGNOSTIC STAT MANU
   Beauchet O, 2011, J AM GERIATR SOC, V59, P568, DOI 10.1111/j.1532-5415.2010.03299.x
   Chung I, 2007, J STEROID BIOCHEM, V103, P768, DOI 10.1016/j.jsbmb.2006.12.042
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Izzo Jr JL, 2008, HYPERTENSION PRIMER
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Rochon J, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-81
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704
   SAULENAS AM, 1988, ARCH OPHTHALMOL-CHIC, V106, P533, DOI 10.1001/archopht.1988.01060130579041
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Sole Gonzalez L, 2013, Arch Soc Esp Oftalmol, V88, P352, DOI 10.1016/j.oftal.2013.01.005
   Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543
   Vannier-Nitenberg C, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-55
   Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x
   Zittermann A, 2003, AM J CLIN NUTR, V78, P496, DOI 10.1093/ajcn/78.3.496a
NR 28
TC 19
Z9 19
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 5298
EP 5303
DI 10.1167/iovs.14-13918
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500083
PM 25028353
DA 2022-11-30
ER

PT J
AU Booij, JC
   van Soest, S
   Swagemakers, SMA
   Essing, AHW
   Verkerk, AJMH
   van der Spek, PJ
   Gorgels, TGMF
   Bergen, AAB
AF Booij, Judith C.
   van Soest, Simone
   Swagemakers, Sigrid M. A.
   Essing, Anke H. W.
   Verkerk, Annemieke J. M. H.
   van der Spek, Peter J.
   Gorgels, Theo G. M. F.
   Bergen, Arthur A. B.
TI Functional annotation of the human retinal pigment epithelium
   transcriptome
SO BMC GENOMICS
LA English
DT Article
ID GENE-EXPRESSION; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; MACULA;
   IDENTIFICATION; CELLS; DISRUPTION; PERIPHERY; GLUTAMATE; PROFILE
AB Background: To determine level, variability and functional annotation of gene expression of the human retinal pigment epithelium (RPE), the key tissue involved in retinal diseases like age-related macular degeneration and retinitis pigmentosa. Macular RPE cells from six selected healthy human donor eyes (aged 63-78 years) were laser dissected and used for 22k microarray studies (Agilent technologies). Data were analyzed with Rosetta Resolver, the web tool DAVID and Ingenuity software.
   Results: In total, we identified 19,746 array entries with significant expression in the RPE. Gene expression was analyzed according to expression levels, interindividual variability and functionality. A group of highly (n = 2,194) expressed RPE genes showed an overrepresentation of genes of the oxidative phosphorylation, ATP synthesis and ribosome pathways. In the group of moderately expressed genes (n = 8,776) genes of the phosphatidylinositol signaling system and aminosugars metabolism were overrepresented. As expected, the top 10 percent (n = 2,194) of genes with the highest interindividual differences in expression showed functional overrepresentation of the complement cascade, essential in inflammation in age-related macular degeneration, and other signaling pathways. Surprisingly, this same category also includes the genes involved in Bruch's membrane (BM) composition. Among the top 10 percent of genes with low interindividual differences, there was an overrepresentation of genes involved in local glycosaminoglycan turnover.
   Conclusion: Our study expands current knowledge of the RPE transcriptome by assigning new genes, and adding data about expression level and interindividual variation. Functional annotation suggests that the RPE has high levels of protein synthesis, strong energy demands, and is exposed to high levels of oxidative stress and a variable degree of inflammation. Our data sheds new light on the molecular composition of BM, adjacent to the RPE, and is useful for candidate retinal disease gene identification or gene dose-dependent therapeutic studies.
C1 [Booij, Judith C.; van Soest, Simone; Essing, Anke H. W.; Gorgels, Theo G. M. F.; Bergen, Arthur A. B.] Acad Arts & Sci KNAW, Inst Royal Netherlands, Netherlands Inst Neurosci NIN, Dept Mol Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands.
   [Swagemakers, Sigrid M. A.; Verkerk, Annemieke J. M. H.; van der Spek, Peter J.; Bergen, Arthur A. B.] Erasmus MC, Dept Bioinformat, NL-3015 GE Rotterdam, Netherlands.
   [Swagemakers, Sigrid M. A.] Erasmus MC, Dept Genet, NL-3015 GE Rotterdam, Netherlands.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam
RP Bergen, AAB (通讯作者)，Acad Arts & Sci KNAW, Inst Royal Netherlands, Netherlands Inst Neurosci NIN, Dept Mol Ophthalmogenet, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM j.booij@nin.knaw.nl; simonevansoest@hotmail.com;
   S.Swagemakers@inter.nl.net; a.essing@nin.knaw.nl;
   j.verkerk@erasmusmc.nl; p.vanderspek@erasmusmc.nl;
   t.gorgels@nin.knaw.nl; a.bergen@nin.knaw.nl
RI Bergen, Arthur/J-3637-2013
OI Verkerk, Annemieke JMH/0000-0002-7523-3656; Bergen,
   Arthur/0000-0002-6333-9576
FU Foundation Fighting Blindness [T-GE-0101-0172]; Netherlands Organization
   for Scientific Research (NWO) [948-00-013]; Royal Netherlands Academy of
   Arts and Sciences (KNAW); Algemene Nederlandse Vereniging ter Voorkoming
   van Blindheid (ANVVB); Amsterdams Universiteitsfonds
FX We thank Dr. L. Pels and co-workers of the Corneabank, Amsterdam, for
   providing donor eyes. This study was supported by grants from the
   Foundation Fighting Blindness (T-GE-0101-0172), The Netherlands
   Organization for Scientific Research (NWO; project 948-00-013), The
   Royal Netherlands Academy of Arts and Sciences (KNAW), de Algemene
   Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB) and het
   Edward en Marianne Blaauwfonds van het Amsterdams Universiteitsfonds.
CR [Anonymous], RETNET
   Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957
   Beuckmann CT, 1996, J NEUROSCI, V16, P6119
   BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431
   Buraczynska M, 2002, INVEST OPHTH VIS SCI, V43, P603
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dobbin K, 2003, BIOINFORMATICS, V19, P803, DOI 10.1093/bioinformatics/btg076
   EPISKOPOU V, 1993, P NATL ACAD SCI USA, V90, P2375, DOI 10.1073/pnas.90.6.2375
   Ershov AV, 2000, CURR EYE RES, V21, P968, DOI 10.1076/ceyr.21.6.968.6987
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70
   Hoshide R, 1996, GENOMICS, V38, P174, DOI 10.1006/geno.1996.0613
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Lee Norman H, 2007, Methods Mol Biol, V353, P265
   MIYAMOTO Y, 1994, INVEST OPHTH VIS SCI, V35, P3589
   PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882
   Rice DS, 2004, INVEST OPHTH VIS SCI, V45, P2767, DOI 10.1167/iovs.04-0020
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Schulz HL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-50
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Simon RM, 2003, BIOTECHNIQUES, P16
   Skern R, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-10
   STRAMM LE, 1989, INVEST OPHTH VIS SCI, V30, P2118
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200
   Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513
   TATE DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P963, DOI 10.1001/archopht.1993.01090070083023
   Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9
   Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0
   van Soest SS, 2007, MOL VIS, V13, P1608
   Wang Q, 2001, Ophthalmic Genet, V22, P133, DOI 10.1076/opge.22.3.133.2224
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 41
TC 36
Z9 42
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD APR 20
PY 2009
VL 10
AR 164
DI 10.1186/1471-2164-10-164
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 455YL
UT WOS:000266804800002
PM 19379482
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Avila, MP
   Farah, ME
   Santos, A
   Kapran, Z
   Duprat, JP
   Woodward, BW
   Nau, J
AF Avila, Marcos P.
   Farah, Michel Eid
   Santos, Arturo
   Kapran, Ziya
   Duprat, Joao Paulo
   Woodward, Benjamin W.
   Nau, Jeffrey
TI TWELVE-MONTH SAFETY AND VISUAL ACUITY RESULTS FROM A FEASIBILITY STUDY
   OF INTRAOCULAR, EPIRETINAL RADIATION THERAPY FOR THE TREATMENT OF
   SUBFOVEAL CNV SECONDARY TO AMD
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; retina; beta radiation; brachytherapy;
   medical device; intraocular; strontium; subfoveal choroidal
   neovascularization
ID CHOROIDAL NEOVASCULAR MEMBRANES; EXTERNAL-BEAM RADIOTHERAPY; HUMAN
   ENDOTHELIAL-CELLS; MACULAR DEGENERATION; PLAQUE RADIOTHERAPY;
   IRRADIATION; TRIAL; TELETHERAPY
AB Purpose: The purpose of this study was to evaluate the short-term safety and feasibility of intraocular, epiretinal delivery of beta radiation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration for 12 months. A 3-year follow-up period is planned to assess the long-term safety of the procedure.
   Methods: In this nonrandomized, multicenter feasibility study, 34 treatment-naive patients with predominantly classic, minimally classic, or occult lesions due to subfoveal choroidal neovascularization secondary to age-related macular degeneration received a single treatment with either 15 Gray (Gy) (8 patients) or 24 Gy (26 patients) beta radiation (strontium-90) using a novel intraocular delivery device. Adverse events and safety end-points were observed and recorded. Visual acuity was measured preoperatively and postoperatively using standard Early Treatment Diabetic Retinopathy Study vision charts.
   Results: Twelve months after treatment, no adverse events associated with exposure to radiation were observed. All patients in both 15 Gy (n = 4) and 24 Gy cohorts (n = 17) who met inclusion criteria and were treated according to protocol lost fewer than three lines of vision. Fifty percent (2/4) of the 15 Gy-treated patients and 76% (13/17) of the 24 Gy-treated patients improved or maintained their visual acuity at 12 months. In the 24 Gy group, 29% (5/17) gained three lines or more in visual acuity. The mean change in visual acuity observed at month 12 was +10.3 letters in the 24 Gy study cohort and -1.0 letters in the 15 Gy cohort.
   Conclusion: The short-term safety and efficacy of intraocular, epiretinal delivery of beta radiation for the treatment of subfoveal choroidal neovascularization was promising in this small study group and should be studied in a larger cohort of patients.
C1 [Avila, Marcos P.] Univ Fed Goias, Ctr Referencia Oftalmol, Goiania, Go, Brazil.
   [Farah, Michel Eid; Duprat, Joao Paulo] Univ Fed Sao Paulo, Dept Oftalmol, Sao Paulo, Brazil.
   [Santos, Arturo] Univ Guadalajara, SC Ctr Med Puerta Hierro, Ctr Retina Med Quirurg, Guadalajara 44430, Jalisco, Mexico.
   [Kapran, Ziya] Beyoglu Eye Res & Training Hosp, Eye Dept, Istanbul, Turkey.
   [Woodward, Benjamin W.; Nau, Jeffrey] NeoVista Inc, Fremont, CA USA.
C3 Universidade Federal de Goias; Universidade Federal de Sao Paulo
   (UNIFESP); Centro Medico Puerta de Hierro; Universidad de Guadalajara;
   Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research Hospital
RP Avila, MP (通讯作者)，Ctr Brasileiro Cirurgia Olhos, BR-74210010 Goiania, Go, Brazil.
EM retina@cbco.com.br
RI Farah, Michel Eid E/F-3285-2012; Santos, Arturo/O-3420-2019; Santos,
   Arturo/GQQ-1431-2022
OI Farah, Michel Eid E/0000-0001-5951-0193; Santos,
   Arturo/0000-0003-4640-7263
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Cheng LY, 2001, AM J OPHTHALMOL, V132, P881, DOI 10.1016/S0002-9394(01)01263-6
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   EISSNER G, 1995, BLOOD, V86, P4184, DOI 10.1182/blood.V86.11.4184.bloodjournal86114184
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2002, AGE-RELATED MACULAR DEGENERATION, P225
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   *GEN INC, 2007, LUC PRESCR INF
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Helbig H, 1997, GER J OPHTHALMOL, V5, P408
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOSOI Y, 1993, INT J RADIAT BIOL, V63, P631, DOI 10.1080/09553009314450821
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Mooteri SN, 1996, RADIAT RES, V145, P217, DOI 10.2307/3579177
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   ROSANDER K, 1995, ACTA ONCOL, V34, P111, DOI 10.3109/02841869509093648
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Thompson John T, 2003, Trans Am Ophthalmol Soc, V101, P485
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   VERHEIJ M, 1994, PROSTAGLANDINS, V48, P351, DOI 10.1016/0090-6980(94)90002-7
   Waters CM, 1996, RADIAT RES, V146, P321, DOI 10.2307/3579463
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   2006, PHASE 3B MULTICENTER
NR 48
TC 39
Z9 42
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 157
EP 169
DI 10.1097/IAE.0b013e3181985915
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407BR
UT WOS:000263339100004
PM 19202425
DA 2022-11-30
ER

PT J
AU Chandrasekaran, PR
   Madanagopalan, VG
AF Chandrasekaran, Priya R.
   Madanagopalan, V. G.
TI Role of Curcumin in Retinal Diseases-A review
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Curcumin; Diabetic Retinopathy; Age-Related Macular Degeneration;
   Retinitis Pigmentosa; Retinal Ischemia Reperfusion Injury
ID ENDOTHELIAL-CELLS; OXIDATIVE STRESS; PHOSPHOLIPID FORMULATION; MACULAR
   EDEMA; IN-VITRO; EXPRESSION; BIOAVAILABILITY; PROLIFERATION; SOLUBILITY;
   INHIBITOR
AB Purpose To review the role of curcumin in retinal diseases, COVID era, modification of the molecule to improve bioavailability and its future scope.
   Methods PubMed and MEDLINE searches were pertaining to curcumin, properties of curcumin, curcumin in retinal diseases, curcumin in diabetic retinopathy, curcumin in age-related macular degeneration, curcumin in retinal and choroidal diseases, curcumin in retinitis pigmentosa, curcumin in retinal ischemia reperfusion injury, curcumin in proliferative vitreoretinopathy and curcumin in current COVID era.
   Results In experimental models, curcumin showed its pleiotropic effects in retinal diseases like diabetic retinopathy by increasing anti-oxidant enzymes, upregulating HO-1, nrf2 and reducing or inhibiting inflammatory mediators, growth factors and by inhibiting proliferation and migration of retinal endothelial cells in a dose-dependent manner in HRPC, HREC and ARPE-19 cells. In age-related macular degeneration, curcumin acts by reducing ROS and inhibiting apoptosis inducing proteins and cellular inflammatory genes and upregulating HO-1, thioredoxin and NQO1. In retinitis pigmentosa, curcumin has been shown to delay structural defects of P23H gene in P23H-rhodopsin transgenic rats. In proliferative vitreoretinopathy, curcumin inhibited the action of EGF in a dose- and time-dependent manner. In retinal ischemia reperfusion injury, curcumin downregulates IL-17, IL-23, NFKB, STAT-3, MCP-1 and JNK. In retinoblastoma, curcumin inhibits proliferation, migration and apoptosis of RBY79 and SO-RB50. Curcumin has already proven its efficacy in inhibiting viral replication, coagulation and cytokine storm in COVID era.
   Conclusion Curcumin is an easily available spice used traditionally in Indian cooking. The benefits of curcumin are manifold, and large randomized controlled trials are required to study its effects not only in treating retinal diseases in humans but in their prevention too.
C1 [Chandrasekaran, Priya R.] Lotus Eye Hosp, Neuroophthalmol, Dept Med Retina, Uvea, Brindavan Rd, Salem 636016, Tamil Nadu, India.
   [Madanagopalan, V. G.] JB Eye Care & Retina Ctr, Vitreoretina Serv, Sarada Coll Rd, Salem 636007, Tamil Nadu, India.
RP Chandrasekaran, PR (通讯作者)，Lotus Eye Hosp, Neuroophthalmol, Dept Med Retina, Uvea, Brindavan Rd, Salem 636016, Tamil Nadu, India.
EM priya_rc@rediffmail.com
RI Chandrasekaran, R.C.Priya, Priya R/AAX-4865-2021
OI Chandrasekaran, R.C.Priya, Priya R/0000-0003-2393-1329
CR Allegra A, 2017, CANCER INVEST, V35, P1, DOI 10.1080/07357907.2016.1247166
   Allegri P, 2020, INVEST OPHTH VIS SCI, V61
   Arnal E, 2009, CURR EYE RES, V34, P928, DOI 10.3109/02713680903205238
   Baker M, 2017, NATURE, V541, P144, DOI 10.1038/541144a
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020
   Barry JL, 2020, INVEST OPHTH VIS SCI, V61
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhandarkar SS, 2007, ADV EXP MED BIOL, V595, P185
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bielskus I, 2020, INVEST OPHTH VIS SCI, V61
   Bisson J, 2016, J MED CHEM, V59, P1671, DOI 10.1021/acs.jmedchem.5b01009
   Bucolo C, 2019, J CELL PHYSIOL, V234, P17295, DOI 10.1002/jcp.28347
   Bucolo C, 2018, INVEST OPHTH VIS SCI, V59
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen Y, 2020, INT J NANOMED, V15, P3099, DOI 10.2147/IJN.S210320
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Cheng YH, 2019, EXP EYE RES, V179, P179, DOI 10.1016/j.exer.2018.11.017
   Chirapapaisan Niphon, 2012, J Med Assoc Thai, V95 Suppl 4, pS76
   Chiu J, 2008, CAN J PHYSIOL PHARM, V86, P365, DOI 10.1139/Y08-033
   Cole GM, 2007, ADV EXP MED BIOL, V595, P197
   Davis BM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29393-8
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Emoto Y, 2013, IN VIVO, V27, P583
   Farajipour H, 2019, J CELL BIOCHEM, V120, P6886, DOI 10.1002/jcb.28068
   Franzone F, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10222
   Gonzalez-Salazar A, 2011, CARDIOVASC TOXICOL, V11, P357, DOI 10.1007/s12012-011-9128-9
   Granata G, 2017, MOL PHARMACEUT, V14, P1610, DOI 10.1021/acs.molpharmaceut.6b01066
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Hanai H, 2009, CURR PHARM DESIGN, V15, P2087, DOI 10.2174/138161209788489177
   Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006
   Jena AB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81462-7
   Kakouri A, 2021, INVEST OPHTH VIS SCI, V62
   Khimmaktong Wipapan, 2014, Journal of the Medical Association of Thailand, V97, pS39
   Kim D, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070297
   Kim DC, 2012, BMB REP, V45, P221, DOI 10.5483/BMBRep.2012.45.4.221
   Knepper PA ., 2021, INVESTIG OPHTHALMOL, V62, P330
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Krishnaswamy K, 2008, ASIA PAC J CLIN NUTR, V17, P265
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Leiderman YI, 2009, SEMIN OPHTHALMOL, V24, P62, DOI 10.1080/08820530902800082
   Li MS, 2017, DRUG DEV IND PHARM, V43, P1846, DOI 10.1080/03639045.2017.1349787
   Li YP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5130-y
   Lin TC, 2019, CELL TRANSPLANT, V28, P1345, DOI 10.1177/0963689719860130
   Liu W, 2019, INVEST OPHTH VIS SCI, V60, P965, DOI 10.1167/iovs.18-26216
   Liu ZT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00479
   Lopez-Malo D, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010048
   Maharjan P, 2019, ARCH PHARM RES, V42, P909, DOI 10.1007/s12272-019-01154-9
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Martinez-Solis I, 2019, PLANTA MED, V85, P1292, DOI 10.1055/a-0947-5712
   Mazzolani F, 2018, EUR REV MED PHARMACO, V22, P3617, DOI 10.26355/eurrev_201806_15189
   Mazzolani F, 2012, CLIN OPHTHALMOL, V6, P801, DOI 10.2147/OPTH.S31859
   Miriyala S, 2007, ADV EXP MED BIOL, V595, P359
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048
   Nemmar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039554
   Noorafshan A, 2013, CURR PHARM DESIGN, V19, P2032
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Peddada KV, 2019, INT OPHTHALMOL, V39, P725, DOI 10.1007/s10792-018-0845-y
   Pittala V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1420892
   Platania CBM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00670
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Ren YX, 2018, CELL PHYSIOL BIOCHEM, V47, P2136, DOI 10.1159/000491525
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Sameermahmood Z, 2008, INVEST OPHTH VIS SCI, V49, P3305, DOI 10.1167/iovs.07-0456
   Scott PA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.5
   Seme MT, 2001, INVEST OPHTH VIS SCI, V42, P834
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Sreejayan, 1997, J PHARM PHARMACOL, V49, P105, DOI 10.1111/j.2042-7158.1997.tb06761.x
   Sun Y, 2014, INT J MOL MED, V34, P1013, DOI 10.3892/ijmm.2014.1861
   Suresh PS, 2020, INDIAN J CLIN BIOCHE, V35, P504, DOI 10.1007/s12291-020-00914-5
   Thimmulappa RK, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06350
   Vasireddy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021193
   Wang CY, 2012, DIABETES-METAB RES, V28, P329, DOI 10.1002/dmrr.2279
   Wang JQ, 2018, NANO RES, V11, P3453, DOI 10.1007/s12274-018-1994-z
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wang LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023194
   Wang SB, 2017, CLIN EXP HYPERTENS, V39, P711, DOI 10.1080/10641963.2017.1313854
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Yu XM, 2016, INT J MOL MED, V38, P861, DOI 10.3892/ijmm.2016.2676
   Zhang HJ, 2015, INT J CLIN EXP PATHO, V8, P9223
   Zhang J, 2017, CURR EYE RES, V42, P1597, DOI 10.1080/02713683.2016.1242753
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
NR 85
TC 3
Z9 3
U1 11
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2022
VL 260
IS 5
BP 1457
EP 1473
DI 10.1007/s00417-021-05542-0
EA JAN 2022
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0M9EN
UT WOS:000741243400003
PM 35015114
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Goktas, A
   Goktas, S
   Atas, M
   Demircan, S
   Yurtsever, Y
AF Goktas, Altan
   Goktas, Sertan
   Atas, Mustafa
   Demircan, Suleyman
   Yurtsever, Yusufcan
TI Short-term impact of intravitreal ranibizumab injection on axial ocular
   dimension and intraocular pressure
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Ranibizumab; intravitreal injection; intraocular pressure; biometry
ID MACULAR DEGENERATION; POSITION; LENGTH
AB Objective: To evaluate the short-term impact of intravitreal ranibizumab injection on axial ocular dimension (AOD) and intraocular pressure (IOP).
   Methods: A total of 31 patients who received 0.05 mL intravitreal ranibizumab injection (IRI) for age-related macular degeneration and 30 healthy volunteers were enrolled in the study. AODs i.e. anterior chamber depth and axial length were measured with IOL Master and IOP with noncontact tonometer before and 5 min, 30 min and 1 day after the injection.
   Results: Five minutes after the injection, mean IOP increased to 24.8 +/- 9.5 (13-46) mmHg from 14.5 +/- 2.3 (10-18) mmHg (p < 0.001). Thirty minutes after the injection, IOP decreased a mean level of 17.3 +/- 4.1 (11-26) mmHg. The change in axial length and anterior chamber depth measurements did not reach a statistical significance across the time points (p > 0.05, for all values). There was no correlation between biometric measurements and IOP before (r = 0.016, p = 0.948 for axial length and r = -0.48 p = 0.075 for anterior chamber depth) and 5 min after IRI (r = 0.049, p = 0.835 for axial length and r = -0.219 p = 0.367 for anterior chamber depth). Measurements of control group taken across same time points did not reveal statistically significant differences (p > 0.05, for all measurements).
   Conclusion: Although IOP increases transiently after the intravitreal injection of 0.05 mL ranibizumab, axial length and anterior chamber depth are not affected by this amount of injection, and the increase in IOP after the injection seems to be irrelevant to AL and anterior chamber depth. Therefore, it is postulated that ranibizumab can be used safely in patients with age-related macular degeneration who have shallow anterior chamber and/or short axial length simultaneously.
C1 [Goktas, Altan; Atas, Mustafa; Demircan, Suleyman; Yurtsever, Yusufcan] Training & Res Hosp, Dept Ophthalmol, Kayseri, Turkey.
   [Goktas, Sertan] Tekden Hosp, Eye Clin, Kayseri, Turkey.
C3 Kayseri Training & Research Hospital; Tekden Private Hospitals
RP Goktas, A (通讯作者)，Training & Res Hosp, Dept Ophthalmol, Kayseri, Turkey.
EM altandr@hotmail.com
RI Atas, Mustafa/K-2319-2013
OI Atas, Mustafa/0000-0003-0545-184X; Demircan,
   Suleyman/0000-0001-5250-6642
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUCHANAN RA, 1985, AM J OPTOM PHYS OPT, V62, P59
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Hill W.E., 2003, TECH OPHTHALMOL, V1, P62
   Hohn F, 2010, GRAEF ARCH CLIN EXP, V248, P1371, DOI 10.1007/s00417-010-1382-1
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Leydolt C, 2008, EYE, V22, P657, DOI 10.1038/sj.eye.6702709
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Read SA, 2011, OPHTHAL PHYSL OPT, V31, P398, DOI 10.1111/j.1475-1313.2011.00845.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
NR 13
TC 12
Z9 13
U1 0
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1556-9527
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD MAR
PY 2013
VL 32
IS 1
BP 23
EP 26
DI 10.3109/15569527.2012.696569
PG 4
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 031DF
UT WOS:000310618400006
PM 22737998
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Kuzniarz, M
   Craig, J
   Ball, M
   Luo, W
   Simpson, JM
AF Gillies, MC
   Kuzniarz, M
   Craig, J
   Ball, M
   Luo, W
   Simpson, JM
TI Intravitreal triamcinoloneo-induced elevated intraocular pressure is
   associated with the development of posterior subcapsular cataract
SO OPHTHALMOLOGY
LA English
DT Article
ID HUMAN TRABECULAR MESHWORK; GLUCOCORTICOID RECEPTOR; MACULAR
   DEGENERATION; BOVINE LENS; CORTICOSTEROIDS; GLAUCOMA; CELLS;
   DEXAMETHASONE; HYPERTENSION; ACETONIDE
AB Objective: To investigate the association between elevated intraocular pressure (IOP) and accelerated cataract formation in patients treated with intravitreal triamcinolone.
   Design: Analysis of longitudinal data from a randomized, double-masked, placebo-controlled trial of intravitreal triamcinolone for age-related macular degeneration (the Intravitreal Triamcinolone Study).
   Participants and Controls: Patients with phakic eyes who participated in a randomized clinical trial of intravitreal triamcinolone for age-related macular degeneration were studied. There were 57 phakic eyes in the treatment group and 54 phakic eyes in the control group. One eye per patient was studied. Intervention: Four milligrams of intravitreal triamcinolone or 1 ml subconjunctival saline.
   Main Outcome Measures: Intraocular pressure rise of at least 5 mmHg (IOP responders) and progression of posterior subcapsular cataract by 2 or more grades using photographic standards from the Age Related Eye Disease Study.
   Results: Progression of posterior subcapsular cataract (PSC) by 2 or more grades in the treatment group was significantly higher among 16 IOP responders (51% after 2 years) than among 37 nonresponders (3%; P<0.0001, log-rank test). There was no significant progression of PSC in the placebo group or the opposite eye of the treatment group. Progression of cortical cataracts also was significantly higher among responders than nonresponders (15% vs. 3%; P = 0.015, log-rank test). The progression of nuclear cataracts (13% vs. 3%) was not significantly different between IOP responders and nonresponders; (P = 0.3, log-rank test).
   Conclusions: Although steroid-related cataracts are unlikely to develop in eyes that do not experience elevated IOP after intravitreal triamcinolone, those eyes that do also have a very high risk of rapidly experiencing posterior subcapsular lens opacification. This strong association suggests that the mechanism responsible for the development of steroid-induced PSC cataract and raised IOP may be similar. (C) 2005 by the American Academy of Ophthalmology.
C1 Univ Sydney, Save Sight & Eye Hlth Inst, Dept Clin Ophthalmol, Sydney, NSW 2001, Australia.
   Sydney Eye Hosp, Sydney, NSW, Australia.
   Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA, Australia.
   Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; Flinders Medical Centre; University of Sydney
RP Gillies, MC (通讯作者)，Univ Sydney, Save Sight & Eye Hlth Inst, Dept Clin Ophthalmol, GPO Box 4337, Sydney, NSW 2001, Australia.
EM mark@eye.usyd.edu.au
RI gillies, mark c/B-3242-2012
OI Simpson, Judy M/0000-0001-5172-3004; Craig, Jamie/0000-0001-9955-9696
CR ADKUMAN L, 1996, AM J OPHTHALMOL, V122, P275
   Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ARMALY MANSOUR F., 1965, INVEST OPHTHALMOL, V4, P187
   BARTLETT JD, 1993, J OCUL PHARMACOL, V9, P35, DOI 10.1089/jop.1993.9.35
   BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500
   BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014
   Carnahan M C, 2000, Curr Opin Ophthalmol, V11, P478, DOI 10.1097/00055735-200012000-00016
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Clark AF, 1996, INVEST OPHTH VIS SCI, V37, P805
   CREIGHTON MO, 1983, EXP EYE RES, V37, P65, DOI 10.1016/0014-4835(83)90150-1
   Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dickerson JE, 1997, EXP EYE RES, V65, P507, DOI 10.1006/exer.1997.0359
   Fingert JH, 2001, INVEST OPHTH VIS SCI, V42, P145
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   HARDING JJ, 1989, ACTA OPHTHALMOL, V67, P510
   HERNANDEZ MR, 1983, INVEST OPHTH VIS SCI, V24, P1612
   HERSCHLER J, 1972, AM J OPHTHALMOL, V74, P501, DOI 10.1016/0002-9394(72)90916-6
   Hoyng C, 1998, GRAEF ARCH CLIN EXP, V236, P154, DOI 10.1007/s004170050057
   Jobling AI, 2001, EXP EYE RES, V72, P687, DOI 10.1006/exer.2001.1003
   JOHNSON DH, 1990, INVEST OPHTH VIS SCI, V31, P2568
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   KASS MA, 1989, GLAUCOMAS, P1161
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Mohan R, 1989, Indian J Ophthalmol, V37, P13
   Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743
   RAMSELL TG, 1980, BRIT J OPHTHALMOL, V64, P43, DOI 10.1136/bjo.64.1.43
   ROHEN JW, 1973, EXP EYE RES, V17, P19, DOI 10.1016/0014-4835(73)90164-4
   *SAS I, 2001, SAS COMP PROGR VERS
   SOUTHREN AL, 1978, SCIENCE, V200, P1177, DOI 10.1126/science.653363
   Stokes J, 2000, INVEST OPHTH VIS SCI, V41, P1629
   Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119
   URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9
   WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403
   WENK EJ, 1982, INVEST OPHTH VIS SCI, V22, P599
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
NR 37
TC 107
Z9 117
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2005
VL 112
IS 1
BP 139
EP 143
DI 10.1016/j.ophtha.2004.07.017
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886QG
UT WOS:000226242800024
PM 15629834
DA 2022-11-30
ER

PT J
AU Zhou, LX
   Shao, L
   Da Zhou, W
   Xu, L
   Li, R
   Bin Wei, W
AF Zhou, Ling Xiao
   Shao, Lei
   Da Zhou, Wen
   Xu, Liang
   Li, Rong
   Bin Wei, Wen
TI Beta zone parapapillary atrophy in elderly Chinese
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Beta zone; The Beijing eye study 2011; Colour optic disc photographs;
   Morphometrically analyze
ID CHORIORETINAL ATROPHY; GLAUCOMA EYES; HIGH MYOPIA; POPULATION
AB Purpose Assess the beta zone parapapillary atrophy in elderly Chinese. Patients and methods The Beijing Eye Study 2011 is a population-based cross-sectional study, which includes 3468 patients with the average age of 64.5 +/- 9.8 years. The beta zone of parapapillary atrophy was captured and analyzed morphometrically by using colour optic disc photographs. Results The beta zone was found in 1358 (39.9%) eyes, measuring 0.37 +/- 0.84 mm(2) in size, 203.5 +/- 81.8 degrees in circumferential angle, 0.36 +/- 0.27 mm in the maximum radial extent, the most often and longest in the temporal peripapillary region, followed by the temporal inferior region and the temporal superior region, the nasal region at least. Beta zone has statistically significant association with male gender (P = 0.001), myopic refractive error (P = 0.003), thinner retinal nerve fiber layer thickness (P<0.001), thinner subfoveal choroidal thickness (P<0.001), bigger size of optic disc size (P<0.001). The size of beta zone has statistically significant association with longer axial length (P = 0.004)?increasing age (P<0.001), urban (P = 0.025), cardiovascular disease history (P = 0.025), with age related macular degeneration (P = 0.038), myopic ametropia (P<0.001), thinner retinal nerve fiber layer thickness (P = 0.001), thinner subfoveal choroidal thickness (P<0.001), bigger size of optic disc size (P = 0.001). Conclusion The population prevalence of beta zone was 39.9% in elderly Chinese. The area of the beta zone has statistically significant association with age, urban, the thickness of retinal nerve fiber layer, age related macular degeneration, cardiovascular disease history, axial length, myopic refractive error, size of optic disc size, the thickness of subfoveal choroid.
C1 [Zhou, Ling Xiao; Li, Rong] Xian Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian, Shaanxi, Peoples R China.
   [Shao, Lei; Da Zhou, Wen; Bin Wei, Wen] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
   [Xu, Liang] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
C3 Xi'an Medical University; Capital Medical University; Capital Medical
   University
RP Bin Wei, W (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Hosp, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM weiwenbintr@163.com
FU Key Project of Science and Technology of Shaanxi Province [2022SF-339];
   National Natural Science Foundation of China [82000916]; priming
   scientific research foundation for the junior researcher in Beijing
   Tongren Hospital, Capital Medical University [2016-YJJ-ZLL-009]; Beijing
   Hospitals Authority Youth Programme [QML20180204]; Dongcheng District
   Outstanding Talent Nurturing Program [2020-dchrcpyzz-42]; priming
   scientific research foundation for the junior researcher in Beijing
   Tongren Hospital, Capital MedicalUniversity [2018-YJJ-ZZL-045]
FX This study was supported in part by grants from the Key Project of
   Science and Technology of Shaanxi Province (No.2022SF-339), National
   Natural Science Foundation of China (Nr. 82000916). The priming
   scientific research foundation for the junior researcher in Beijing
   Tongren Hospital, Capital Medical University (2016-YJJ-ZLL-009); Beijing
   Hospitals Authority Youth Programme, code:QML20180204;The priming
   scientific research foundation for the junior researcher in Beijing
   Tongren Hospital, Capital MedicalUniversity(No.2018-YJJ-ZZL-045).
   Dongcheng District Outstanding Talent Nurturing Program
   (2020-dchrcpyzz-42).
CR Akagi T, 2013, AM J OPHTHALMOL, V155, P927, DOI 10.1016/j.ajo.2012.12.014
   Anderson DR, 1987, RELATIONSHIP PERIPAP, P103
   Cho BJ, 2013, OPHTHALMOLOGY, V120, P528, DOI 10.1016/j.ophtha.2012.09.004
   Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255
   Elschnig A., 1901, DENKSCHR AKAD WISS, V70, P219
   Graham SL, 2013, J GLAUCOMA, V22, P98, DOI 10.1097/IJG.0b013e3182254bc0
   Guo Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P919
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P189, DOI 10.1136/bjo.87.2.189
   Jonas RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138701
   Kim M, 2013, OPHTHALMOLOGY, V120, P1790, DOI 10.1016/j.ophtha.2013.02.011
   Lu CK, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.10.106010
   Mataki N, 2018, ACTA OPHTHALMOL, V96, pE701, DOI 10.1111/aos.13702
   Ramrattan RS, 1999, OPHTHALMOLOGY, V106, P1588, DOI 10.1016/S0161-6420(99)90457-8
   Sullivan-Mee M, 2015, AM J OPHTHALMOL, V160, P637, DOI 10.1016/j.ajo.2015.06.024
   Teng CC, 2010, OPHTHALMOLOGY, V117, P909, DOI 10.1016/j.ophtha.2009.10.016
   Tezel G, 1997, ARCH OPHTHALMOL-CHIC, V115, P1503, DOI 10.1001/archopht.1997.01100160673001
   Wang Y, 2008, EYE, V22, P261, DOI 10.1038/sj.eye.6702601
   Wang YX, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100933
   Xu L, 2009, EYE, V23, P676, DOI 10.1038/sj.eye.6703104
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 25
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 11
PY 2022
VL 22
IS 1
AR 431
DI 10.1186/s12886-022-02651-0
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6C4KF
UT WOS:000881984700002
PM 36368942
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU O'Brien, KS
   Stevens, VM
   Byanju, R
   Kandel, RP
   Bhandari, G
   Bhandari, S
   Melo, JS
   Porco, TC
   Lietman, TM
   Keenan, JD
AF O'Brien, Kieran S.
   Stevens, Valerie M.
   Byanju, Raghunandan
   Kandel, Ram Prasad
   Bhandari, Gopal
   Bhandari, Sadhan
   Melo, Jason S.
   Porco, Travis C.
   Lietman, Thomas M.
   Keenan, Jeremy D.
CA Grp Information View
TI Cluster-randomised trial of community-based screening for eye disease in
   adults in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II)
   trial protocol
SO BMJ OPEN
LA English
DT Article
DE mass screening; glaucoma; diabetic retinopathy; age-related macular
   degeneration; randomised controlled trial
ID DIABETIC-RETINOPATHY; AVOIDABLE BLINDNESS; RAPID ASSESSMENT;
   VISUAL-ACUITY; OLDER-PEOPLE; RISK-FACTORS; PREVALENCE; POPULATION;
   VISION; CARE
AB Introduction The majority of blindness worldwide could be prevented or reversed with early diagnosis and treatment, yet identifying at-risk and prevalent cases of eye disease and linking them with care remain important obstacles to addressing this burden. Leading causes of blindness like glaucoma, diabetic retinopathy and age-related macular degeneration have detectable early asymptomatic phases and can cause irreversible vision loss. Mass screening for such diseases could reduce visual impairment at the population level.
   Methods and analysis This protocol describes a parallel-group cluster-randomised trial designed to determine whether community-based screening for glaucoma, diabetic retinopathy and age-related macular degeneration reduces population-level visual impairment in Nepal. A door-to-door population census is conducted in all study communities. All adults aged >= 60 years have visual acuity tested at the census visit, and those meeting referral criteria are referred to a local eye care facility for further diagnosis and management. Communities are subsequently randomised to a community-based screening programme or to no additional intervention. The intervention consists of a single round of screening including intraocular pressure and optical coherence tomography assessment of all adults >= 60 years old with enhanced linkage to care for participants meeting referral criteria. Four years after implementation of the intervention, masked outcome assessors conduct a repeat census to collect data on the primary outcome, visual acuity. Individuals with incident visual impairment receive a comprehensive ophthalmological examination to determine the cause of visual impairment. Outcomes are compared by treatment arm according to the originally assigned intervention.
   Ethics and dissemination The trial has received ethical approval from the University of California San Francisco Institutional Review Board, Nepal Netra Jyoti Sangh and the Nepal Health Research Council. Results of this trial will be disseminated through publication in peer-reviewed journals and presentation at local and international meetings.
C1 [O'Brien, Kieran S.; Stevens, Valerie M.; Melo, Jason S.; Porco, Travis C.; Lietman, Thomas M.; Keenan, Jeremy D.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
   [Byanju, Raghunandan; Bhandari, Gopal; Bhandari, Sadhan] Bharatpur Eye Hosp, Bharatpur, Nepal.
   [Kandel, Ram Prasad] Seva Fdn, Bharatpur, Nepal.
   [Porco, Travis C.; Lietman, Thomas M.; Keenan, Jeremy D.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Keenan, JD (通讯作者)，Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.; Keenan, JD (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
EM jeremy.keenan@ucsf.edu
OI Keenan, Jeremy/0000-0002-7118-1457; Melo, Jason/0000-0003-2116-4656
FU National Eye Institute of the National Institutes of Health
   [UG1EY028097]; Carl Zeiss Meditec [18G384]; Francis I Proctor
   Foundation; Carpenter Elementary School (Park Ridge, IL); Fortisure
   Foundation; Harper-Inglis Memorial for Eye Research; Peierls Foundation;
   Research to Prevent Blindness; Bofinger Glaucoma Research Fund; That Man
   May See
FX Research reported in this publication was supported by the National Eye
   Institute of the National Institutes of Health under award number
   UG1EY028097. Funding for OCT devices was provided by Tony and Kaz David,
   Francesca Applegarth, Carl Zeiss Meditec (grant number: 18G384), and the
   Francis I Proctor Foundation. Funding for cataract surgery subsidies was
   provided by Carpenter Elementary School (Park Ridge, IL). Additional
   support was provided by the Bofinger Glaucoma Research Fund, Fortisure
   Foundation, Harper-Inglis Memorial for Eye Research, the Peierls
   Foundation, Research to Prevent Blindness, and That Man May See. Grant
   or award numbers have been listed in this statement where applicable.
   The Data and Safety Monitoring Committee, appointed by the NIH, reviewed
   and approved submitting this manuscript for publication.
CR Bastawrous A, 2015, JAMA OPHTHALMOL, V133, P930, DOI 10.1001/jamaophthalmol.2015.1468
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Clarke EL, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001054.pub3
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hernandez RA, 2008, INT J TECHNOL ASSESS, V24, P203, DOI 10.1017/S0266462308080288
   Kumar RS, 2019, EYE, V33, P335, DOI 10.1038/s41433-018-0237-6
   McClintic SM, 2014, INVEST OPHTH VIS SCI, V55, P2935, DOI 10.1167/iovs.14-13980
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   Polack S, 2012, OPHTHALMOLOGY, V119, P1033, DOI 10.1016/j.ophtha.2011.11.002
   Pradhan S, 2018, BRIT J OPHTHALMOL, V102, P291, DOI 10.1136/bjophthalmol-2017-310716
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027, DOI 10.1136/bmj.327.7422.1027
   Tan NYQ, 2020, CURR OPIN OPHTHALMOL, V31, P91, DOI 10.1097/ICU.0000000000000649
   Tay T, 2006, CLIN EXP OPHTHALMOL, V34, P141, DOI 10.1111/j.1442-9071.2006.01139.x
   Thapa R, 2018, CLIN OPHTHALMOL, V12, P561, DOI 10.2147/OPTH.S157560
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Thapa SS, 2012, OPHTHALMOLOGY, V119, P759, DOI 10.1016/j.ophtha.2011.10.021
   Wilson JMG, 1968, PRINCIPLES PRACTICE, P164
   World Health Organization, 2003, DEAFN POB
NR 22
TC 0
Z9 0
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 10
AR e040219
DI 10.1136/bmjopen-2020-040219
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OI6BY
UT WOS:000583362600015
PM 33060092
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Picard, E
   Jonet, L
   Sergeant, C
   Vesvres, MH
   Behar-Cohen, F
   Courtois, Y
   Jeanny, JC
AF Picard, Emilie
   Jonet, Laurent
   Sergeant, Claire
   Vesvres, Marie-Helene
   Behar-Cohen, Francine
   Courtois, Yves
   Jeanny, Jean-Claude
TI Overexpressed or intraperitoneally injected human transferrin prevents
   photoreceptor degeneration in rd10 mice
SO MOLECULAR VISION
LA English
DT Article
ID HANDLING PROTEINS FERRITIN; RETINAL DEGENERATION; MACULAR DEGENERATION;
   IRON HOMEOSTASIS; CELL-DEATH; EXPRESSION; MOUSE; MODEL; DIFFERENTIATION;
   FERROPORTIN
AB Purpose: Retinal degeneration has been associated with iron accumulation in age-related macular degeneration (AMD), and in several rodent models that had one or several iron regulating protein impairments. We investigated the iron concentration and the protective role of human transferrin (hTf) in rd10 mice, a model of retinal degeneration.
   Methods: The proton-induced X-ray emission (PIXE) method was used to quantify iron in rd10 mice 2, 3, and 4 weeks after birth. We generated mice with the beta-phosphodiesterase mutation and hTf expression by crossbreeding rd10 mice with TghTf mice (rd10/hTf mice). The photoreceptor loss and apoptosis were evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling in 3-week-old rd10/hTf mice and compared with 3-week-old rd10 mice. The neuroprotective effect of hTf was analyzed in 5-day-old rd10 mice treated by intraperitoneal administration with hTf for up to 25 days. The retinal hTf concentrations and the thickness of the outer nuclear layer were quantified in all treated mice at 25 days postnatally.
   Results: PIXE analysis demonstrated an age-dependent iron accumulation in the photoreceptors of rd10 mice. The rd10/hTf mice had the rd10 mutation, expressed high levels of hTf, and showed a significant decrease in photoreceptor death. In addition, rd10 mice intraperitoneally treated with hTf resulted in the retinal presence of hTf and a dose-dependent reduction in photoreceptor degeneration.
   Conclusions: Our results suggest that iron accumulation in the retinas of rd10 mutant mice is associated with photoreceptor degeneration. For the first time, the enhanced survival of cones and rods in the retina of this model has been demonstrated through overexpression or systemic administration of hTf. This study highlights the therapeutic potential of Tf to inhibit iron-induced photoreceptor cell death observed in degenerative diseases such as retinitis pigmentosa and age-related macular degeneration.
C1 [Picard, Emilie; Jonet, Laurent; Behar-Cohen, Francine; Courtois, Yves; Jeanny, Jean-Claude] INSERM, Paris, France.
   [Picard, Emilie; Jonet, Laurent; Behar-Cohen, Francine; Courtois, Yves; Jeanny, Jean-Claude] Univ Paris 06, Ctr Rech Cordeliers, Paris, France.
   [Picard, Emilie; Jonet, Laurent; Behar-Cohen, Francine; Courtois, Yves; Jeanny, Jean-Claude] Univ Paris 05, Paris, France.
   [Sergeant, Claire; Vesvres, Marie-Helene] Univ Bordeaux, CNRS, UMR 5084, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Universite Paris Cite;
   Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite de Bordeaux
RP Picard, E (通讯作者)，CRC UMR S872 Team 17, 15 Rue Ecole Med, F-75006 Paris, France.
EM picardemilie@gmail.com
RI picard, Emilie/A-6919-2013
OI picard, Emilie/0000-0002-2689-0510
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barhoum R, 2008, NEUROSCIENCE, V155, P698, DOI 10.1016/j.neuroscience.2008.06.042
   Burdo JR, 2003, NEUROSCIENCE, V121, P883, DOI 10.1016/S0306-4522(03)00590-6
   Cassia R, 1997, J NEUROSCI RES, V50, P421, DOI 10.1002/(SICI)1097-4547(19971101)50:3<421::AID-JNR8>3.0.CO;2-K
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Davidson MG, 1998, EXP EYE RES, V66, P207, DOI 10.1006/exer.1997.0413
   De Vries B, 2004, TRANSPLANTATION, V77, P669, DOI 10.1097/01.TP.0000115002.28575.E7
   Deleon E, 2009, INVEST OPHTH VIS SCI, V50, P1360, DOI 10.1167/iovs.08-1856
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   ECKHERT CD, 1981, J HERED, V72, P130, DOI 10.1093/oxfordjournals.jhered.a109444
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gomme PT, 2005, DRUG DISCOV TODAY, V10, P267, DOI 10.1016/S1359-6446(04)03333-1
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   JEANNY JC, 2010, 19 BIENN M INT SOC E, P256
   Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Lecureuil C, 2004, HUM REPROD, V19, P1300, DOI 10.1093/humrep/deh297
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lesnikov V, 2001, EXP HEMATOL, V29, P477, DOI 10.1016/S0301-472X(00)00687-1
   Lesnikov VA, 2004, LAB INVEST, V84, P342, DOI 10.1038/labinvest.3700035
   Llabador Y., 1998, APPL NUCL MICROPROBE
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   MAXWELL JA, 1989, NUCL INSTRUM METH B, V43, P218, DOI 10.1016/0168-583X(89)90042-6
   MORETTO P, 1995, NUCL INSTRUM METH B, V104, P171, DOI 10.1016/0168-583X(95)00444-0
   MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515
   Picard E, 2008, MOL VIS, V14, P928
   Ponka P, 1999, KIDNEY INT, V55, pS2, DOI 10.1046/j.1523-1755.1999.055Suppl.69002.x
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Saleh MC, 2003, J NEUROSCI RES, V72, P587, DOI 10.1002/jnr.10619
   Sergeant C, 2004, METAL IONS BIOL MED, V8, P491
   Sergeant C, 1999, NUCL INSTRUM METH B, V158, P344, DOI 10.1016/S0168-583X(99)00354-7
   Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Zerpa GAD, 2000, J NEUROSCI RES, V61, P388, DOI 10.1002/1097-4547(20000815)61:4<388::AID-JNR5>3.0.CO;2-Q
NR 43
TC 30
Z9 31
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 8
PY 2010
VL 16
IS 280-84
BP 2612
EP 2625
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 697IH
UT WOS:000285506300001
PM 21179240
DA 2022-11-30
ER

PT J
AU Fang, IM
   Yang, CH
   Yang, CM
   Chen, MS
AF Fang, I-Mo
   Yang, Chang-Hao
   Yang, Chung-May
   Chen, Muh-Shy
TI Linoleic acid-induced expression of inducible nitric oxide synthase and
   cyclooxygenase II via p42/44 mitogen-activated protein kinase and
   nuclear factor-kappa B pathway in retinal pigment epithelial cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE linoleic acid; age-related macular degeneration; inducible nitric oxide
   synthase; cyclooxygenase II
ID SMOOTH-MUSCLE-CELLS; ENDOTHELIAL GROWTH-FACTOR; ROD OUTER SEGMENTS;
   CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; TRANSCRIPTION
   FACTOR; FATTY-ACIDS; DIETARY-FAT; TNF-ALPHA; RAT
AB High linoleic acid (LA) intake is known to correlate with age-related macular degeneration (AMD), but the molecular mechanisms remain unclear. This study was conducted to investigate the effects of LA on expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase II (COX-2) and their associated signaling pathways in human retinal pigment epithelial (RPE) cells. ARPE-19 cells were treated with different concentrations of LA. Expressions of iNOS and COX-2 were examined using semiquantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. Concentrations of nitric oxide (NO) and prostaglandin E-2 (PGE(2)) in the culture medium were determined by enzyme-link immunosorbent assay (ELISA). Activation of p42/44, p38, JNK mitogen-activated protein kinase (MAPK) and nuclear factors (NF)-kappa B were evaluated by Western blot analysis and electrophoretic mobility shift assay (EMSA). We found that LA induced expression of iNOS and COX-2 in RPE cells at the mRNA and protein levels in a time-and dose-dependent manner. Upregulation of iNOS and COX-2 resulted in increased production of NO and PGE(2). Moreover, LA caused degradation of I kappa B and increased NF-kappa B DNA binding activity. Effects of LA-induced iNOS and COX-2 expression were inhibited by a NF-kappa B inhibitor, pyrrolidine dithiocarbamate (PDTC). LA activated p42/44, but not p38 or JNK MAPK. Inhibition of p42/44 activity by PD98059 significantly reduced LA-induced activation of NF-kappa B. Linoleic acid-induced expression of iNOS and COX-2 as well as PGE(2) and NO release in RPE cells were sequentially mediated through activation of p42/p44, MAPK, then NF-kappa B. These results may provide new insights into both mechanisms of LA action on RPE cells and pathogenesis of age-related macular degeneration. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   Taipei City Hosp, Dept Ophthalmol, Zhongxiao Branch, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital; Taipei
   City Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chang-Hao/AAR-3759-2021; Yang, Chung-May/AAV-3737-2020
OI YANG, CHUNG-MAY/0000-0003-4082-420X; YANG, CHANG-HAO/0000-0002-4328-8716
CR AEKO K, 1996, CURR EYE RES, V15, P467
   AEKO K, 1998, PIGM CELL RES, V11, P320
   AEKO K, 1999, PIGM CELL RES, V12, P199
   AEKO K, 1996, OPHTHAL RES, V28, P8
   Alzoghaibi MA, 2004, AM J PHYSIOL-GASTR L, V286, pG528, DOI 10.1152/ajpgi.00189.2003
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008
   Chen CC, 1999, MOL PHARMACOL, V55, P481
   Chen CJ, 2006, NEUROCHEM INT, V49, P62, DOI 10.1016/j.neuint.2005.12.020
   Chen F, 1999, CLIN CHEM, V45, P7
   CHIOU GCY, 2001, J OCUL PHARMACOL TH, V17, P89
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   Dontsov AE, 1999, FREE RADICAL BIO MED, V26, P1436, DOI 10.1016/S0891-5849(99)00003-9
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322
   HENNING B, 2006, J NUTR BIOCH, V7, P766
   Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607
   Hsieh HL, 2006, J CELL PHYSIOL, V207, P757, DOI 10.1002/jcp.20621
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hu WZ, 2005, RETINA-J RET VIT DIS, V25, P1054, DOI 10.1097/00006982-200512000-00015
   Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4
   Katsuma S, 2005, J BIOL CHEM, V280, P19507, DOI 10.1074/jbc.M412385200
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kone BC, 2001, CARDIOVASC RES, V51, P429, DOI 10.1016/S0008-6363(01)00327-3
   Maingrette F, 2005, DIABETES, V54, P1506, DOI 10.2337/diabetes.54.5.1506
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x
   POINCELO.RP, 1970, BIOCHIM BIOPHYS ACTA, V202, P382, DOI 10.1016/0005-2760(70)90202-X
   RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Rhodus NL, 2005, CLIN IMMUNOL, V114, P278, DOI 10.1016/j.clim.2004.12.003
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Saraswathi V, 2004, J LIPID RES, V45, P794, DOI 10.1194/jlr.M300497-JLR200
   Sauer LA, 2001, BIOCHEM PHARMACOL, V61, P1455, DOI 10.1016/S0006-2952(01)00634-7
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Su HM, 1996, LIPIDS, V31, P1289, DOI 10.1007/BF02587915
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Toborek M, 1996, J LIPID RES, V37, P123
   Toborek M, 1997, J LIPID RES, V38, P2155
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   UEDA T, 1997, ANGIOGENESIS, V1, P174
   Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621
   XIE QW, 1994, J BIOL CHEM, V269, P4705
   Yang CM, 2002, CELL SIGNAL, V14, P899, DOI 10.1016/S0898-6568(02)00037-2
   Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355
NR 58
TC 23
Z9 23
U1 0
U2 6
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2007
VL 85
IS 5
BP 667
EP 677
DI 10.1016/j.exer.2007.07.021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238JU
UT WOS:000251444500011
PM 17825288
DA 2022-11-30
ER

PT J
AU Rouvas, A
   Gouliopoulos, N
   Douvali, M
   Koutsocheras, G
   Theodorou, M
   Bouratzis, N
   Bougatsou, P
   Theodossiadis, P
AF Rouvas, Alexandros
   Gouliopoulos, Nikolaos
   Douvali, Maria
   Koutsocheras, Georgios
   Theodorou, Maria
   Bouratzis, Nikolaos
   Bougatsou, Panagiota
   Theodossiadis, Panagiotis
TI One year outcomes of treat and extend and pro re nata (PRN) treatment
   regimens with aflibercept for polypoidal choroidal vasculopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE PCV; aflibercept; PDT; PRN; treat and extend
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INTRAVITREAL
   RANIBIZUMAB; SAFETY; NEOVASCULARIZATION; COMBINATION; RECURRENCE;
   EFFICACY
AB Purpose: To compare the 1-year outcomes of treat-and-extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy (PCV), by the means of visual acuity (VA), frequency of recurrence of polypoidal lesions and developed fibrosis, and the number of intravitreal injections, and thus to determine which one is preferable in the maintenance phase in PCV. Methods: In our prospective study, only naive and previously untreated PCV patients were included. Initially one session of photodynamic therapy (PDT) and three monthly intravitreal injections of 2.0 mg aflibercept (IAIs) were applied in 38 eyes. After this loading phase, they were re-examined and 30 PCV eyes with no exudative phenomena were included in the study. They were divided in two groups; in the first one (16 patients) the PRN treatment modality of IAIs was applied, while in the second one (14 patients) the treat-and-extend regimen was applied. Results: Over a 12-month period, VA significantly improved in treat-and-extend group (logMAR BCVA 0.41 +/- 0.15 vs 0.57 +/- 0.24 at baseline, p = 0.044), while in the PRN group VA remained stable (logMAR BCVA 0.70 +/- 0.36 vs 0.65 +/- 0.18 at baseline, p = 0.61). During the maintenance phase, the patients of treat-and-extend group did not encounter development/progression of fibrosis or any recurrent episodes, whereas the patients of PRN group had significantly more recurrent episodes (0 vs 1.37 +/- 0.5, p < 0.001) and the frequency of development/progression of fibrosis was significantly higher (0% vs 44%, p = 0.02). However, the treat-and-extend treatment regimen was accompanied by significantly more administered IAIs (6 +/- 0 vs 5.13 +/- 1.08, p = 0.006). Conclusion: We highlighted the superiority of treat-and-extend regime with IAIs, which seems to yield better functional outcomes by preventing recurrence and subfoveal fibrosis, although a greater number of injections is required.
C1 [Rouvas, Alexandros; Gouliopoulos, Nikolaos; Douvali, Maria; Koutsocheras, Georgios; Theodorou, Maria; Bouratzis, Nikolaos; Bougatsou, Panagiota; Theodossiadis, Panagiotis] Univ Athens, Med Sch, Attikon Gen Hosp Athens, Dept Ophthalmol, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon
RP Gouliopoulos, N (通讯作者)，Univ Athens, Attikon Gen Hosp Athens, Med Sch, Dept Ophthalmol 2, Lazaraki 51, Athens 16674, Greece.
EM ngouliopoulos@yahoo.gr
OI Gouliopoulos, Nikolaos/0000-0002-4154-1597
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas A, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0927-7
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
NR 48
TC 3
Z9 3
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 2868
EP 2875
AR 11206721211014717
DI 10.1177/11206721211014717
EA MAY 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA5GJ
UT WOS:000679360300001
PM 33951982
DA 2022-11-30
ER

PT J
AU Palanker, D
   Le Mer, Y
   Mohand-Said, S
   Sahel, JA
AF Palanker, D.
   Le Mer, Y.
   Mohand-Said, S.
   Sahel, J. A.
TI Simultaneous perception of prosthetic and natural vision in AMD patients
SO NATURE COMMUNICATIONS
LA English
DT Article
ID FREIBURG VISUAL-ACUITY; MACULAR DEGENERATION; PHOTOVOLTAIC RESTORATION;
   PREVALENCE
AB Atrophic age-related macular degeneration (AMD) results in visual impairment. Here the authors report interim analysis of open-label single group feasibility trial using a wireless photovoltaic subretinal implant in patients with atrophic AMD, and report that the patients exhibited prosthetic visual perception with acuity closely matching the pixel size during the 18-24 month follow-up period.
   Loss of photoreceptors in atrophic age-related macular degeneration (AMD) results in severe visual impairment. Since the low-resolution peripheral vision is retained in such conditions, restoration of central vision should not jeopardize the surrounding healthy retina and allow for simultaneous use of the natural and prosthetic sight. This interim report, prespecified in the study protocol, presents the first clinical results with a photovoltaic substitute of the photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic AMD. In this open-label single group feasibility trial (NCT03333954, recruitment completed), five patients with geographic atrophy have been implanted with a wireless 2 x 2 mm-wide 30 mu m-thick device, having 378 pixels of 100 mu m in size. All 5 patients achieved the primary outcome of the study by demonstrating the prosthetic visual perception in the former scotoma. The four patients with a subretinal placement of the chip demonstrated the secondary outcome: Landolt acuity of 1.17 +/- 0.13 pixels, corresponding to the Snellen range of 20/460-20/565. With electronic magnification of up to a factor of 8, patients demonstrated prosthetic acuity in the range of 20/63-20/98. Under room lighting conditions, patients could simultaneously use prosthetic central vision and their remaining peripheral vision in the implanted eye and in the fellow eye.
C1 [Palanker, D.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Palanker, D.] Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
   [Le Mer, Y.; Sahel, J. A.] Fdn Ophtalmol A de Rothschild, Dept Ophthalmol, Paris, France.
   [Mohand-Said, S.; Sahel, J. A.] Quinze Vingts Natl Eye Hosp, INSFRM DGOS 1423, Clin Invest Ctr, Paris, France.
   [Sahel, J. A.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   [Sahel, J. A.] Sorbonne Univ, Inst Vis, CNRS, INSERM, Paris, France.
C3 Stanford University; Stanford University; CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Centre National de la Recherche Scientifique (CNRS);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite
RP Palanker, D (通讯作者)，Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.; Palanker, D (通讯作者)，Stanford Univ, Hansen Expt Phys Lab, Stanford, CA 94305 USA.
EM palanker@stanford.edu
RI ; Sahel, Jose-Alain/F-3172-2017
OI Palanker, Daniel/0000-0002-0480-3025; Sahel,
   Jose-Alain/0000-0002-4831-1153
FU Pixium Vision SA; Sight Again project; Clinical Investigation Center at
   the Quinze-Vingts National Hospitalm - Inserm-DGOS, France; LabEx
   LIFESENSES [ANR-10-LABX-65]; IHU FOReSIGHT [ANR-18-IAHU-01]; National
   Institutes of Health [R01-EY027786]; NIH CORE grant [P30 EY08098];
   Research to Prevent Blindness, New York
FX The authors thank the patients who participated in the study; the Pixium
   Vision team who designed, fabricated, and tested the PRIMA system; the
   Scientific and Medical Advisory Board of Pixium Vision for its guidance
   on the clinical trial design; and all the scientific, research and
   development, medical, and clinical research staff who continue the
   patient care, rehabilitation, and evaluation. Studies were supported by:
   Pixium Vision SA; the Sight Again project (via Structural R&D Projects
   for Competitiveness and Investment for the Future funding managed by
   BpiFrance) and the Clinical Investigation Center at the Quinze-Vingts
   National Hospital, which is supported in part by the Inserm-DGOS, France
   and by LabEx LIFESENSES (ANR-10-LABX-65) and IHU FOReSIGHT
   (ANR-18-IAHU-01) grants. D.P. is supported in part by the National
   Institutes of Health (R01-EY027786). J.A.S. is supported in part by the
   NIH CORE grant P30 EY08098, and by unrestricted grant from Research to
   Prevent Blindness, New York.
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Bach M., FREIBURG VISION TEST
   Bach M, 2007, GRAEF ARCH CLIN EXP, V245, P965, DOI 10.1007/s00417-006-0474-4
   Castaldi E, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002569
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goetz GA, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056021
   Ho E, 2019, J NEURAL ENG, V16, DOI 10.1088/1741-2552/ab34b3
   Ho E, 2018, J NEUROPHYSIOL, V119, P389, DOI 10.1152/jn.00872.2016
   Huang TW, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/abe6b8
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   LIEBERMAN HR, 1982, BEHAV RES METH INSTR, V14, P21, DOI 10.3758/BF03202110
   Lorach H, 2016, BIOMED OPT EXPRESS, V7, P13, DOI 10.1364/BOE.7.000013
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Wang B.-Y, ELECT PHOTORECEPTORS, DOI [10.1101/2021.07.12.452093(2021, DOI 10.1101/2021.07.12.452093(2021]
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 21
TC 13
Z9 13
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 26
PY 2022
VL 13
IS 1
AR 513
DI 10.1038/s41467-022-28125-x
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YN7AJ
UT WOS:000747407100007
PM 35082313
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ma, WC
   Paik, DC
   Barile, GR
AF Ma, Wanchao
   Paik, David C.
   Barile, Gaetano R.
TI Bioactive Lysophospholipids Generated by Hepatic Lipase Degradation of
   Lipoproteins Lead to Complement Activation via the Classical Pathway
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; hepatic lipase; lipoproteins;
   lysophospholipids; complement activation; C-reactive protein; RPE
   cytotoxicity
ID C-REACTIVE PROTEIN; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   DENSITY-LIPOPROTEINS; APOLIPOPROTEIN-E; DRUSEN; GENE;
   LYSOPHOSPHATIDYLCHOLINE; MEMBRANE; VARIANT
AB PURPOSE. We determined bioactivity of lysophospholipids generated by degradation of the low-density (LDL), very low-density (VLDL), and high-density (HDL) lipoproteins with hepatic lipase (HL), cholesterol esterase (CE), and lipoprotein-associated phospholipase A2 (Lp-PLA2).
   METHODS. The LDL, VLDL, and HDL were treated with HL, CE, and Lp-PLA2 after immobilization on plates, and complement activation studies were performed with diluted human serum. Complement component 3 (C3) fixation, a marker for complement activation, was determined with a monoclonal anti-human C3d antibody. Enzymatic properties of HL and CE were assayed with triglyceride and phosphatidylcholine substrates for triglyceride hydrolase and phospholipase A activities. The ARPE-19 cells were used for viability studies.
   RESULTS. The HL degradation of human lipoproteins LDL, VLDL, or HDL results in the formation of modified lipoproteins that can activate the complement pathway. Complement activation is dose-and time-dependent upon HL and occurs via the classical pathway. Enzymatic studies suggest that the phospholipase A1 activity of HL generates complement-activating lysophospholipids. C-reactive protein (CRP), known to simultaneously interact with complement C1 and complement factor H (CFH), further enhances HL-induced complement activation. The lysophospholipids, 1-Palmitoyl-sn-glycero-3-phosphocholine and 1-Oleoyl-sn-glycero-3-phosphocholine, can be directly cytotoxic to ARPE-19 cells.
   CONCLUSIONS. The HL degradation of lipoproteins, known to accumulate in the outer retina and in drusen, can lead to the formation of bioactive lysophospholipids that can trigger complement activation and induce RPE cellular dysfunction. Given the known risk associations for age-related macular degeneration (AMD) with HL, CRP, and CFH, this study elucidates a possible damage pathway for age-related macular degeneration (AMD) in genetically predisposed individuals, that HL activity may lead to accumulation of lysophospholipids to initiate complement activation, with CFH dysregulation exacerbating the effects of this process.
C1 [Ma, Wanchao; Paik, David C.; Barile, Gaetano R.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University
RP Barile, GR (通讯作者)，Manhattan Eye Ear & Throat Hosp, 210 East 64 St, New York, NY 10065 USA.
EM gbarile@nshs.edu
FU Eye Surgery Fund; Glaubinger Foundation; Hearst Foundation; Research to
   Prevent Blindness; National Institutes of Health/National Education
   Institute (NIH/NEI, Bethesda, MD, USA) [P30 EY019007]; NATIONAL EYE
   INSTITUTE [P30EY019007] Funding Source: NIH RePORTER
FX Supported by the Eye Surgery Fund, Glaubinger Foundation, Hearst
   Foundation, Research to Prevent Blindness, and National Institutes of
   Health/National Education Institute (NIH/NEI, Bethesda, MD, USA) Core
   Grant P30 EY019007.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biro A, 2007, MOL IMMUNOL, V44, P1169, DOI 10.1016/j.molimm.2006.06.013
   Choi SJ, 2003, J BIOCHEM MOL BIOL, V36, P417
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   MARTIN GP, 1992, J PHARM PHARMACOL, V44, P646, DOI 10.1111/j.2042-7158.1992.tb05486.x
   Matsubara M, 2005, ATHEROSCLEROSIS, V178, P57, DOI 10.1016/j.atherosclerosis.2004.08.020
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Park S, 2010, J PHYSIOL PHARMACOL, V61, P375
   REYNOLDS LJ, 1992, ANAL BIOCHEM, V204, P190, DOI 10.1016/0003-2697(92)90160-9
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820
   VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 40
TC 4
Z9 5
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2014
VL 55
IS 10
BP 6187
EP 6193
DI 10.1167/iovs.14-14352
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DY
UT WOS:000343147100010
PM 25205869
OA Green Published
DA 2022-11-30
ER

PT J
AU Hollingsworth, TJ
   Wang, XD
   White, WA
   Simpson, RN
   Jablonski, MM
AF Hollingsworth, T. J.
   Wang, Xiangdi
   White, William A.
   Simpson, Raven N.
   Jablonski, Monica M.
TI Chronic Proinflammatory Signaling Accelerates the Rate of Degeneration
   in a Spontaneous Polygenic Model of Inherited Retinal Dystrophy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE inherited retinal dystrophy; inflammation; microglia; TNFa; JAK/STAT;
   NF-?B; NLRP3
ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; RETINITIS-PIGMENTOSA; MICROGLIAL
   PHAGOCYTOSIS; TRANSCRIPTION FACTOR; NLRP3 INFLAMMASOME; GENE-THERAPY;
   RHODOPSIN; ACTIVATION; PROTEIN
AB Collectively, retinal neurodegenerative diseases are comprised of numerous subtypes of disorders which result in loss of a varying cell types in the retina. These diseases can range from glaucoma, which results in retinal ganglion cell death, to age-related macular degeneration and retinitis pigmentosa, which result in cell death of the retinal pigment epithelium, photoreceptors, or both. Regardless of the disease, it's been recently found that increased release of proinflammatory cytokines and proliferation of active microglia result in a remarkably proinflammatory microenvironment that assists in the pathogenesis of the disease; however, many of the details of these inflammatory events have yet to be elucidated. In an ongoing study, we have used systems genetics to identify possible models of spontaneous polygenic age-related macular degeneration by mining the BXD family of mice using single nucleotide polymorphism analyses of known genes associated with the human retinal disease. One BXD strain (BXD32) was removed from the study as the rate of degeneration observed in these animals was markedly increased with a resultant loss of most all photoreceptors by 6 months of age. Using functional and anatomical exams including optokinetic nystamography, funduscopy, fluorescein angiography, and optical coherence tomography, along with immunohistochemical analyses, we show that the BXD32 mouse strain exhibits a severe neurodegenerative phenotype accompanied by adverse effects on the retinal vasculature. We also expose the concurrent establishment of a chronic proinflammatory microenvironment including the TNF alpha secretion and activation of the NF-kappa B and JAK/STAT pathways with an associated increase in activated macrophages and phagoptosis. We conclude that the induced neuronal death and proinflammatory pathways work synergistically in the disease pathogenesis to enhance the rate of degeneration in this spontaneous polygenic model of inherited retinal dystrophy.
C1 [Hollingsworth, T. J.; Wang, Xiangdi; White, William A.; Simpson, Raven N.; Jablonski, Monica M.] Univ Tennessee, Hamilton Eye Inst, Dept Ophthalmol, Hlth Sci Ctr, Memphis, TN USA.
   [Hollingsworth, T. J.; Jablonski, Monica M.] Univ Tennessee, Dept Anat & Neurobiol, Hlth Sci Ctr, Memphis, TN USA.
   [Jablonski, Monica M.] Univ Tennessee, Dept Pharmaceut Sci, Hlth Sci Ctr, Memphis, TN USA.
   [Jablonski, Monica M.] Univ Tennessee, Dept Genet Genom & Informat, Hlth Sci Ctr, Memphis, TN USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; University of Tennessee System; University of Tennessee
   Health Science Center; University of Tennessee System; University of
   Tennessee Health Science Center
RP Jablonski, MM (通讯作者)，Univ Tennessee, Hamilton Eye Inst, Dept Ophthalmol, Hlth Sci Ctr, Memphis, TN USA.; Jablonski, MM (通讯作者)，Univ Tennessee, Dept Anat & Neurobiol, Hlth Sci Ctr, Memphis, TN USA.; Jablonski, MM (通讯作者)，Univ Tennessee, Dept Pharmaceut Sci, Hlth Sci Ctr, Memphis, TN USA.; Jablonski, MM (通讯作者)，Univ Tennessee, Dept Genet Genom & Informat, Hlth Sci Ctr, Memphis, TN USA.
EM mjablonski@uthsc.edu
OI Hollingsworth, T.J./0000-0002-2119-521X
FU National Institutes of Health (NIH); National Eye Institute (NEI)
   [EY021200]; Research to Prevent Blindness (RPB) Catalyst Award for
   Innovative Research Approaches for Age-Related Macular Degeneration; RPB
   Challenge Award
FX This research was funded by the National Institutes of Health (NIH),
   National Eye Institute (NEI; EY021200 to MMJ), and Research to Prevent
   Blindness (RPB) Catalyst Award for Innovative Research Approaches for
   Age-Related Macular Degeneration (to MMJ) and RPB Challenge Award (to
   the Hamilton Eye Institute at UTHSC).
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Ashbrook DG, 2021, CELL SYST, V12, P235, DOI 10.1016/j.cels.2020.12.002
   Balic JJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17669-5
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bergsma D R, 1975, Birth Defects Orig Artic Ser, V11, P132
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Brown GC, 2012, TRENDS BIOCHEM SCI, V37, P325, DOI 10.1016/j.tibs.2012.05.002
   Burkard M, 2018, J CLIN INVEST, V128, P5663, DOI 10.1172/JCI96098
   Chintalapudi SR, 2019, FEBS J, V286, P4876, DOI 10.1111/febs.15006
   COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498
   Cremers F P M, 2004, Novartis Found Symp, V255, P68
   Darnowski JW, 2006, J BIOL CHEM, V281, P17707, DOI 10.1074/jbc.M600088200
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Geisert EE, 2020, MOL VIS, V26, P173
   Gorbatyuk MS, 2012, ADV EXP MED BIOL, V723, P191, DOI 10.1007/978-1-4614-0631-0_26
   HOHMANN HP, 1990, J BIOL CHEM, V265, P15183
   Hollingsworth TJ, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081163
   Hollingsworth TJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030630
   Hollingsworth TJ, 2013, J BIOL CHEM, V288, P29047, DOI 10.1074/jbc.M113.495184
   Hollingsworth TJ, 2012, INT REV CEL MOL BIO, V293, P1, DOI 10.1016/B978-0-12-394304-0.00006-3
   Hunt D.M., 2004, NOVARTIS FDN S, V255, P37177, DOI [10.1002/0470092645.ch4, DOI 10.1002/0470092645.CH4]
   Iannaccone A, 2017, EXP EYE RES, V155, P64, DOI 10.1016/j.exer.2016.12.006
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Jordan K.E., 2021, J OPHTHALMIC RES VIS, V1, DOI [10.54289/JORVC2100103, DOI 10.54289/JORVC2100103]
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525
   Kinuthia UM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564077
   Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055
   Matthews JR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-29
   MEICHLE A, 1990, J BIOL CHEM, V265, P8339
   Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623
   Nakashima K, 1998, SEMIN HEMATOL, V35, P210
   Narfstrom K, 2003, J HERED, V94, P31, DOI 10.1093/jhered/esg015
   ONeal TB, 2021, RETINITIS PIGMENTOSA
   Orlans HO, 2020, HUM GENE THER, V31, P730, DOI 10.1089/hum.2020.008
   Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rho J., 2021, ANIMAL MODELS MED BI, DOI [10.5772/intechopen.96601, DOI 10.5772/INTECHOPEN.96601]
   Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219
   Sandoval IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108135
   SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Toma C, 2010, J IMMUNOL, V184, P5287, DOI 10.4049/jimmunol.0903536
   Ucgun NI, 2020, MOL VIS, V26, P718
   Wakahara R, 2012, GENES CELLS, V17, P132, DOI 10.1111/j.1365-2443.2011.01575.x
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Yang JH, 2020, INT IMMUNOL, V32, P73, DOI 10.1093/intimm/dxz061
   Yi QY, 2020, ACTA OPHTHALMOL, V98, pE309, DOI 10.1111/aos.14248
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 59
TC 1
Z9 1
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 21
PY 2022
VL 13
AR 839424
DI 10.3389/fphar.2022.839424
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0V7BP
UT WOS:000788495900001
PM 35387333
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Singh, SR
   Parameswarappa, DC
   Govindahari, V
   Lupidi, M
   Chhablani, J
AF Singh, Sumit Randhir
   Parameswarappa, Deepika C.
   Govindahari, Vishal
   Lupidi, Marco
   Chhablani, Jay
TI Clinical and angiographic characterization of choroidal
   neovascularization in diabetic retinopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Diabetic retinopathy; diabetic choroidopathy; choroidal neovascular
   membrane
ID MACULAR DEGENERATION; CHINESE POPULATION; PREVALENCE; CHOROIDOPATHY;
   BURDEN; EDEMA
AB Background: To report the clinical and angiographic characteristics of choroidal neovascularization in patients with diabetic retinopathy. Methods: Patients of type 2 diabetes mellitus with presence of choroidal neovascularization in at least one eye were retrospectively analyzed. The study eyes were divided into three groups based on presence (active or scarred) or absence of choroidal neovascularization (fellow eyes). Imaging characteristics of active choroidal neovascularization were recorded using optical coherence tomography, fluorescein, and indocyanine angiography. Central macular thickness, subfoveal choroidal thickness, and large choroidal vessel layer thickness were compared at baseline and final visit. Results: Our study reports the prevalence rate of choroidal neovascularization in eyes with diabetic retinopathy (0.27%; 36 out of 13,382 eyes). A total of 64 eyes of 32 patients (age, mean +/- standard deviation: 68.5 +/- 9.3 years) with baseline visual acuity of 0.69 +/- 0.69 logarithm of minimum angle of resolution (Snellen equivalent 20/100) were included. Nonproliferative diabetic retinopathy (57 eyes) comprised the majority followed by proliferative diabetic retinopathy (7 eyes). Eyes with choroidal neovascularization (36, 56.25%) included both active (25) and scarred (11) choroidal neovascularization, with bilateral choroidal neovascularization in 4 patients. Type 1 choroidal neovascularization was the most common subtype of choroidal neovascularization on optical coherence tomography. Common etiologies for active choroidal neovascularization included age-related macular degeneration (3; 12%), myopia (1; 4%), and inflammatory choroidal neovascularization secondary to chorioretinitis (1; 4%). In the remaining 20 eyes, choroidal neovascularization formation was primarily due to diabetic choroidopathy. Conclusion: The prevalence of choroidal neovascularization in eyes with diabetic retinopathy is very low, with a lower prevalence of age-related macular degeneration. Diabetic choroidopathy plays a significant role in formation of choroidal neovascularization in eyes with diabetic retinopathy.
C1 [Singh, Sumit Randhir; Parameswarappa, Deepika C.; Govindahari, Vishal; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Banjara Hills, Hyderabad 500034, Telangana, India.
   [Singh, Sumit Randhir] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
   [Parameswarappa, Deepika C.] LV Prasad Eye Inst, Acad Eye Care Educ, Hyderabad, India.
   [Govindahari, Vishal] LV Prasad Eye Inst, Retina & Uveitis Serv, MTC Campus, Bhubaneswar, India.
   [Lupidi, Marco] Univ Perugia, Dept Biochem & Surg Sci, Sect Ophthalmol, Perugia, Italy.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; L. V. Prasad Eye
   Institute; L. V. Prasad Eye Institute; University of Perugia
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Banjara Hills, Hyderabad 500034, Telangana, India.
EM jay.chhablani@gmail.com
OI Govindahari, Vishal/0000-0002-1630-6798; Chhablani,
   Jay/0000-0003-1772-3558
CR Borrelli E, 2019, RETINA, DOI 10.1097/IAE.0000000000002538
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   FLETCHER J, 1990, BLOOD REV, V4, P103, DOI 10.1016/0268-960X(90)90033-O
   Fukushima I, 1997, AM J OPHTHALMOL, V124, P473, DOI 10.1016/S0002-9394(14)70863-3
   Hua R, 2017, ONCOTARGET, V8, P2034, DOI 10.18632/oncotarget.14020
   Hua R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083494
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Lutty GA, 1997, AM J PATHOL, V151, P707
   Lutty GA, 2017, VISION RES, V139, P161, DOI 10.1016/j.visres.2017.04.011
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Melancia D, 2016, GRAEF ARCH CLIN EXP, V254, P1453, DOI 10.1007/s00417-016-3360-8
   Minakaran N, 2013, INVEST OPHTH VIS SCI, V54
   Nagaoka T, 2004, BRIT J OPHTHALMOL, V88, P1060, DOI 10.1136/bjo.2003.035345
   Proctor B, 2007, INVEST OPHTHALMOL VI, V48, P2149
   Rasheed MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35640-9
   Sander B, 2001, INVEST OPHTH VIS SCI, V42, P433
   Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Wang JC, 2017, AM J OPHTHALMOL, V184, P75, DOI 10.1016/j.ajo.2017.09.030
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yoshikawa T, 2011, JPN J OPHTHALMOL, V55, P235, DOI 10.1007/s10384-011-0010-x
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
   Zylbermann R, 1997, EYE, V11, P872, DOI 10.1038/eye.1997.224
NR 32
TC 2
Z9 2
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2021
VL 31
IS 2
BP 584
EP 591
AR 1120672120902027
DI 10.1177/1120672120902027
EA JAN 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB1ZQ
UT WOS:000509842800001
PM 31984769
DA 2022-11-30
ER

PT J
AU Balaiya, S
   Murthy, RK
   Chalam, KV
AF Balaiya, Sankarathi
   Murthy, Ravi K.
   Chalam, Kakarla V.
TI Resveratrol inhibits proliferation of hypoxic choroidal vascular
   endothelial cells
SO MOLECULAR VISION
LA English
DT Article
ID S-PHASE ARREST; NF-KAPPA-B; INDUCED APOPTOSIS; INDUCIBLE FACTOR-1-ALPHA;
   LNCAP CELLS; HIF-ALPHA; RED WINE; ACTIVATION; EXPRESSION; GROWTH
AB Purpose: Resveratrol, a polyphenolic phytoalexin present in red wine, has a protective role against tumor-induced angiogenesis. Exudative age-related macular degeneration is characterized by hypoxia-induced choroidal vascular endothelial cell (CVEC) proliferation. In this study, we evaluated the effect of resveratrol on hypoxic CVECs and the underlying signaling pathways involved.
   Methods: CVECs (RF/6A) after induction of hypoxia with cobalt chloride (CoCl2, 200 mu M) were exposed to increasing doses of resveratrol (2, 4, 6, 8, 10, and 12 mu g/ml). Cell viability was measured with 4-[ 3-(4Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate (WST-1) colorimetric assay. The effect of resveratrol on hypoxia-induced vascular endothelial growth factor (VEGF) release was analyzed with enzyme-linked immunosorbent assay. The mechanistic pathway was further evaluated by analyzing phosphorylated stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) using immunoblot and cleaved caspase-3 with In-Cell enzyme-linked immunosorbent assay.
   Results: Resveratrol inhibited hypoxic CVEC proliferation. Hypoxia-induced VEGF release (30.9 +/- 2.6 pg/ml) was inhibited in a dose-dependent fashion by 2, 4, 6, 8, 10, and 12 mu g/ml resveratrol to 12.4 +/- 2.1, 11.0 +/- 1.9, 10.3 +/- 3.0, 7.5 +/- 1.9, 5.5 +/- 2.0, and 5.5 +/- 2.3 pg/ml, respectively. SAPK/JNK increased by 1.8-fold and 3.9-fold after treatment with 4 and 12 mu g/ml resveratrol, respectively. Significant increase in caspase-3 levels was observed with 12 mu g/ml resveratrol.
   Conclusions: Our study demonstrates that resveratrol suppresses hypoxic CVEC proliferation through activation of the SAPK/JNK pathway. Resveratrol, a nutritional supplement and inhibitor of CVECs, may be a useful adjunct to current anti-VEGF therapy in wet age-related macular degeneration.
C1 [Balaiya, Sankarathi; Murthy, Ravi K.; Chalam, Kakarla V.] Univ Florida, Coll Med, Dept Ophthalmol, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, 580,W,8th St,Tower 2, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019
OI Chalam, kakarla/0000-0001-9325-8665; Chalam, K V/0000-0002-0004-9416
CR Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Balaiya S, 2012, CUTAN OCUL TOXICOL, V31, P14, DOI 10.3109/15569527.2011.594697
   Balaiya S, 2012, MOL VIS, V18, P114
   Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje
   Cao ZX, 2004, CLIN CANCER RES, V10, P5253, DOI 10.1158/1078-0432.CCR-03-0588
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Garvin S, 2006, CANCER LETT, V231, P113, DOI 10.1016/j.canlet.2005.01.031
   Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jiang H, 2005, MOL CANCER THER, V4, P554, DOI 10.1158/1535-7163.MCT-04-0056
   Joe AK, 2002, CLIN CANCER RES, V8, P893
   Khan AA, 2010, AM J PATHOL, V177, P481, DOI 10.2353/ajpath.2010.090836
   Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019
   Kuo PL, 2002, LIFE SCI, V72, P23, DOI 10.1016/S0024-3205(02)02177-X
   Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8
   Mizutani K, 2001, CLIN EXP PHARMACOL P, V28, P55, DOI 10.1046/j.1440-1681.2001.03415.x
   Morris GZ, 2002, PROSTATE, V52, P319, DOI 10.1002/pros.10122
   Nagaoka T, 2007, INVEST OPHTH VIS SCI, V48, P4232, DOI 10.1167/iovs.07-0094
   Narayanan BA, 2003, INT J CANCER, V104, P204, DOI 10.1002/ijc.10932
   National Advisory Eye Council (US), 1993, NIH PUBL, V93-3186
   Niles RM, 2003, CANCER LETT, V190, P157, DOI 10.1016/S0304-3835(02)00676-6
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Roman V, 2002, BRIT J HAEMATOL, V117, P842, DOI 10.1046/j.1365-2141.2002.03520.x
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   Sareen D, 2007, MOL PHARMACOL, V72, P1466, DOI 10.1124/mol.107.039040
   She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0
   Su JL, 2005, CARCINOGENESIS, V26, P1, DOI 10.1093/carcin/bgh220
   Szende B, 2000, EXP MOL MED, V32, P88, DOI 10.1038/emm.2000.16
   Trapp V, 2010, ANGIOGENESIS, V13, P305, DOI 10.1007/s10456-010-9187-8
   Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Yang YT, 2009, MOL NUTR FOOD RES, V53, P407, DOI 10.1002/mnfr.200800123
   Zhang H, 2008, CHINESE GERMAN J CLI, V7, P230
   Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198
NR 41
TC 20
Z9 22
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 23
PY 2013
VL 19
BP 2385
EP 2392
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 272OG
UT WOS:000328469500003
PM 24319332
DA 2022-11-30
ER

PT J
AU Lau, LI
   Chiou, SH
   Liu, CJL
   Yen, MY
   Wei, YH
AF Lau, Ling-Ing
   Chiou, Shih-Hwa
   Liu, Catherine Jui-Ling
   Yen, May-Yung
   Wei, Yau-Huei
TI The Effect of Photo-oxidative Stress and Inflammatory Cytokine on
   Complement Factor H Expression in Retinal Pigment Epithelial Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID LIGHT-INDUCED DAMAGE; MACULAR DEGENERATION; BLUE-LIGHT; Y402H
   POLYMORPHISM; OXIDATIVE STRESS; INTERFERON-GAMMA; BRUCHS MEMBRANE; AGE;
   DRUSEN; MECHANISMS
AB PURPOSE. Genetic variation in complement factor H (CFH) has been implicated as a major risk factor for age-related macular degeneration (AMD). The reduction in CFH amount or its complement-modulating activity may lead to inadequate control of complement-driven inflammation at the outer retina. We explored the effect of photo-oxidative stress and inflammatory cytokine on the expression of CFH in retinal pigment epithelial (RPE) cells.
   METHODS. Cultured human RPE cells were exposed to blue light in the presence of interferon-gamma (IFN-gamma). CFH expression in cell lysate was examined by Western blot and the secretory CFH in culture medium was analyzed by ELISA. RPE cells were treated with vitamin C and exogenous superoxide dismutase mimetic (Tempol) before photo-oxidative treatments. The intracellular reactive oxygen species were examined by flow cytometry.
   RESULTS. IFN-gamma increased CFH expression in RPE and the expression was suppressed significantly under concomitant blue light illumination. The secretory CFH level also decreased significantly under blue light illumination, which was related to the decreased intracellular mRNA and protein expressions of CFH. The suppression was mediated through an oxidative mechanism, and was particularly related to superoxide anion generation. The suppression of CFH expression in RPE under blue light illumination was abrogated by vitamin C and Tempol.
   CONCLUSIONS. Photo-oxidative stress reduces the ability of IFN-gamma to increase CFH expression in RPE. Apart from reducing the oxidative damage, vitamin C reduces the suppression of CFH under photo-oxidative stress. These results suggest a new perspective of the interaction between oxidative stress and inflammation, and provide a potential novel treatment strategy for age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2011;52:6832-6841) DOI:10.1167/iovs.11-7815
C1 [Wei, Yau-Huei] Natl Yang Ming Univ, Dept Biochem & Mol Biol, Sch Med, Taipei 112, Taiwan.
   [Lau, Ling-Ing; Chiou, Shih-Hwa; Wei, Yau-Huei] Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan.
   [Lau, Ling-Ing; Chiou, Shih-Hwa; Liu, Catherine Jui-Ling; Yen, May-Yung] Natl Yang Ming Univ, Dept Ophthalmol, Sch Med, Taipei 112, Taiwan.
   [Lau, Ling-Ing; Chiou, Shih-Hwa; Liu, Catherine Jui-Ling; Yen, May-Yung] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Wei, Yau-Huei] Mackay Med Coll, Dept Med, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Taipei Veterans
   General Hospital; Mackay Medical College
RP Wei, YH (通讯作者)，Natl Yang Ming Univ, Dept Biochem & Mol Biol, Sch Med, 155 Li Nong St,Sec 2, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
RI Wei, Yau-Huei/ABA-6841-2021
OI Wei, Yau-Huei/0000-0002-6429-2546; Lau, Ling-Ing/0000-0001-6956-1496
FU Taipei Veterans General Hospital [VGH V99B2-001]; National Science
   Council, Taiwan [NSC 96-2314-B-075-050-MY2, NSC97-2320-B-010-013-MY3]
FX Supported by Grants VGH V99B2-001 from Taipei Veterans General Hospital,
   NSC 96-2314-B-075-050-MY2 and NSC97-2320-B-010-013-MY3 from National
   Science Council, Taiwan.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GABRIELIAN K, 1994, INVEST OPHTH VIS SCI, V35, P4253
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, P70
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollborn M, 2001, GRAEF ARCH CLIN EXP, V239, P294, DOI 10.1007/s004170100263
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024
   Nagineni CN, 1996, CYTOKINE, V8, P622, DOI 10.1006/cyto.1996.0083
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yang DL, 2009, INVEST OPHTH VIS SCI, V50, P4998, DOI 10.1167/iovs.09-3620
   Yoshida A, 2003, LAB INVEST, V83, P1117, DOI 10.1097/01.LAB.0000082393.02727.B5
NR 62
TC 21
Z9 22
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 6832
EP 6841
DI 10.1167/iovs.11-7815
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300061
PM 21743006
DA 2022-11-30
ER

PT J
AU Lim, HB
   Sung, JY
   Ahn, SI
   Jo, YJ
   Kim, JY
AF Lim, Hyung-Bin
   Sung, Jae-Yun
   Ahn, Seung-Il
   Jo, Young-Joon
   Kim, Jung-Yeul
TI Retinal Nerve Fiber Layer Thickness in Various Retinal Diseases
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; OPEN-ANGLE GLAUCOMA; MACULAR HOLE
   FORMATION; GANGLION-CELL COMPLEX; EPIRETINAL MEMBRANE; LONGITUDINAL
   CHANGES; EYE; DEGENERATION; VITRECTOMY; PREVALENCE
AB SIGNIFICANCE Peripapillary retinal nerve fiber layer (RNFL) thickness measurements may be influenced by the range and severity of lesions that are observed distinctively in each retinal disease.
   PURPOSE We investigated the effects of various macular (central serous chorioretinopathy, macular hole, epiretinal membrane, wet age-related macular degeneration) and retinal vascular (branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema) diseases on peripapillary RNFL thickness measurements using spectral-domain optical coherence tomography.
   METHODS Six hundred thirty-one eyes from 464 patients with various retinal diseases and 167 controls of similar age were included in this retrospective study. Using spectral-domain optical coherence tomography, we measured the thickness of the macula and the RNFL in both various retinal disease eyes and normal control eyes. Four sectorial and average RNFL thicknesses were compared between each disease and age-matched control eyes. The macular thicknesses were also compared.
   RESULTS In the macular disease group, superior (P = .033) and temporal (P = .024) quadrant RNFL thicknesses of central serous chorioretinopathy and temporal (P < .001) quadrant RNFL thicknesses of epiretinal membrane were greater than the age-matched control eyes. No RNFL measurements in macular hole or wet age-related macular degeneration differed significantly from the controls. In the retinal vascular disease group, all sectorial and average RNFL thicknesses of diabetic macular edema and central retinal vein occlusion were greater than those of the controls (all P < .05). In branch retinal vein occlusion, superior (P = .012) and temporal (P < .001) quadrant RNFL thicknesses were greater than those of the controls.
   CONCLUSIONS Peripapillary RNFL thickness measurements may be influenced by the range and severity of lesions that are observed distinctively in each retinal disease. It also appeared that macular disease had a local effect on RNFL thickness, whereas retinal vascular disease had a diffuse effect on RNFL thickness.
C1 [Lim, Hyung-Bin; Sung, Jae-Yun; Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.
   [Lim, Hyung-Bin] Armed Forces Capital Hosp, Dept Ophthalmol, Seongnam, South Korea.
   [Ahn, Seung-Il] Maleunnoon Eye Clin, Daejeon, South Korea.
   [Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Coll Med, Res Inst Med Sci, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University
RP Kim, JY (通讯作者)，Chungnam Natl Univ, Coll Med, Dept Ophthalmol, Daejeon, South Korea.; Kim, JY (通讯作者)，Chungnam Natl Univ, Coll Med, Res Inst Med Sci, Daejeon, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Asrani S, 2014, JAMA OPHTHALMOL, V132, P877, DOI 10.1001/jamaophthalmol.2014.954
   Barboni P, 2010, OPHTHALMOLOGY, V117, P623, DOI 10.1016/j.ophtha.2009.07.026
   Bonovas S, 2004, DIABETIC MED, V21, P609, DOI 10.1111/j.1464-5491.2004.01173.x
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Hwang DJ, 2014, INVEST OPHTH VIS SCI, V55, P4213, DOI 10.1167/iovs.13-13776
   Hwang YH, 2013, OPHTHALMOLOGY, V120, P1380, DOI 10.1016/j.ophtha.2012.12.048
   Kim CS, 2014, RETINA-J RET VIT DIS, V34, P525, DOI 10.1097/IAE.0b013e3182a2e746
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Lee SB, 2013, RETINA-J RET VIT DIS, V33, P188, DOI 10.1097/IAE.0b013e318261a710
   Lee SB, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14196
   Lee YH, 2012, INVEST OPHTH VIS SCI, V53, P5471, DOI 10.1167/iovs.12-9782
   Lee YH, 2016, BRIT J OPHTHALMOL, V100, P1035, DOI 10.1136/bjophthalmol-2015-307313
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Leung CK, 2009, OPHTHALMOLOGY, V116, P63
   Menke MN, 2005, INVEST OPHTH VIS SCI, V46, P3807, DOI 10.1167/iovs.05-0352
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Mwanza JC, 2011, OPHTHALMOLOGY, V118, P241, DOI 10.1016/j.ophtha.2010.06.036
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Oh J, 2014, OPTOMETRY VISION SCI, V91, P1328, DOI 10.1097/OPX.0000000000000401
   Reddy RK, 2013, CLIN OPHTHALMOL, V7, P1761, DOI 10.2147/OPTH.S49375
   Ross A, 2011, CURR OPIN OPHTHALMOL, V22, P166, DOI 10.1097/ICU.0b013e3283459826
   Rufer F, 2016, GRAEF ARCH CLIN EXP, V254, P2017, DOI 10.1007/s00417-016-3453-4
   Sevim MS, 2013, CURR EYE RES, V38, P180, DOI 10.3109/02713683.2012.738845
   Singh Ajay, 2009, Int Ophthalmol Clin, V49, P1, DOI 10.1097/IIO.0b013e31819fd164
   TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48
   Tornambe PE, 2003, RETINA-J RET VIT DIS, V23, P421, DOI 10.1097/00006982-200306000-00028
   Wang MY, 2013, J NEURO-OPHTHALMOL, V33, P172, DOI 10.1097/WNO.0b013e3182901969
   Yamashita T, 2013, INVEST OPHTH VIS SCI, V54, P5481, DOI 10.1167/iovs.12-11008
   Yuda K, 2010, GRAEF ARCH CLIN EXP, V248, P353, DOI 10.1007/s00417-009-1222-3
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 35
TC 7
Z9 7
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2018
VL 95
IS 3
BP 247
EP 255
DI 10.1097/OPX.0000000000001181
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY1EH
UT WOS:000426554100011
PM 29420438
DA 2022-11-30
ER

PT J
AU Wu, LC
   Sun, XH
   Zhou, XT
   Weng, CH
AF Wu, Liangcheng
   Sun, Xinghuai
   Zhou, Xingtao
   Weng, Chenghai
TI Causes and 3-year-incidence of blindness in Jing-An District, Shanghai,
   China 2001-2009
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID REPUBLIC-OF-IRELAND; VISUAL IMPAIRMENT; ADULT-POPULATION; PREVALENCE;
   EYE; REGISTRATION; GLAUCOMA; SYSTEM
AB Background: Registered data can provide valuable information regarding blindness. The purpose of this study was to evaluate the main causes and 3-year incidence of registered blindness in Jing-An district in Shanghai, China.
   Methods: Data from the blindness registry (age, gender and cause of visual disability) were collected and analyzed. The prevalence of blindness for 2003, 2007, 2009 and the 3 year incidence of blindness were calculated.
   Results: The reported blindness increased significantly from 113.7 per 100,000 in 2003 to 145.8 per 100,000 in 2006 to 165.9 per 100,000 in 2009 (P < 0.05, P < 0.05, respectively). Age significantly affects prevalence; the odd ratios (OR) were 2.57 in the 30 y - 49 y range (P < 0.001), 7.27 in the 50 y - 69 y range (P < 0.001) and 21.2 in the >= 70 y (P < 0.001). The 3-year incidence increased from 32.3 per 100,000 in 2001-2003 to 34.2 per 100,000 in 2004-2006 to 40.8 per 100,000 in 2007-2009. The causes of new blindness registered in 2001-2009 were myopic macular degeneration (19.4%), followed by glaucoma (17.7%), age-related macular degeneration (11.8%), optical nerve atrophy (9.4%), retinitis pigmentosa (8.6%), diabetic retinopathy (7.8%) and corneal opacity (5.8%).
   Conclusions: The 3-year incidence and prevalence of registered blindness increased in the past 9 years. The leading causes of new blindness were myopic macular degeneration, glaucoma and age-related macular degeneration. The pattern of causes has changed little in the past 9 years and is different from other locations in China. The pattern is similar to that of Taiwan, Hongkong, and Western countries.
C1 [Sun, Xinghuai; Zhou, Xingtao] Fundan Univ, Shanghai Med Coll, Eye & ENT Hosp, Shanghai, Peoples R China.
   [Wu, Liangcheng; Weng, Chenghai] Jing An Dist Cent Hosp, Shanghai, Peoples R China.
C3 Fudan University
RP Sun, XH (通讯作者)，Fundan Univ, Shanghai Med Coll, Eye & ENT Hosp, Shanghai, Peoples R China.
EM xhsun1962@yahoo.com.cn
RI zhou, xt/GWZ-9212-2022
FU Foundation of Health Science Research of the Health Bureau of Shanghai,
   China [2008-161]; Jing-An district health bureau, Shanghai, China
   [2010020103]; National Natural Science Foundation of China [81020108017]
FX This research was supported by Foundation of Health Science Research of
   the Health Bureau of Shanghai, China (No.: 2008-161), Shi-Bai-Qian Plans
   of Jing-An district health bureau, Shanghai, China (2010020103), and the
   Funds for International Cooperation and Exchange of the National Natural
   Science Foundation of China (Grant No. 81020108017).
CR [Anonymous], 2009, SHANGHAI STAT YB
   Avisar R, 2006, ISRAEL MED ASSOC J, V8, P880
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Chen Wen, 2009, Zhonghua Yan Ke Za Zhi, V45, P776
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang Xiao-bo, 2009, Zhonghua Yan Ke Za Zhi, V45, P786
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li Yin-yin, 2009, Zhonghua Yan Ke Za Zhi, V45, P781
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Liu Su, 2007, Zhonghua Yan Ke Za Zhi, V43, P722
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Song X J, 1992, Zhonghua Yan Ke Za Zhi, V28, P105
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   *WHO, 2004, DIS EYE ADN INT STAT, V1, P426
   World Health Organization, 1980, INT CLASS IMP DIS HA, P79
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yu X M, 1992, Zhonghua Yan Ke Za Zhi, V28, P363
   Zhang J X, 1990, Zhonghua Yan Ke Za Zhi, V26, P39
   Zhang S Y, 1992, Zhonghua Yan Ke Za Zhi, V28, P260
NR 24
TC 51
Z9 55
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 5
PY 2011
VL 11
AR 10
DI 10.1186/1471-2415-11-10
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 799KF
UT WOS:000293284900001
PM 21545726
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hatta, Y
   Ishikawa, K
   Nishihara, H
   Ozawa, S
   Ito, Y
   Terasaki, H
AF Hatta, Yoshiyuki
   Ishikawa, Kohei
   Nishihara, Hiroaki
   Ozawa, Shinsuke
   Ito, Yasuki
   Terasaki, Hiroko
TI EFFECT OF PHOTODYNAMIC THERAPY ALONE OR COMBINED WITH POSTERIOR SUBTENON
   TRIAMCINOLONE ACETONIDE OR INTRAVITREAL BEVACIZUMAB ON CHOROIDAL
   HYPOFLUORESCENCE BY INDOCYANINE GREEN ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; combination of photodynamic therapy;
   indocyanine green angiography; choriocapillaris hypoperfusion; choroidal
   hypofluorescence; triamcinolone acetonide; bevacizumab
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; NEOVASCULARIZATION
   SECONDARY; VERTEPORFIN; INJECTION; COMBINATION; AVASTIN; VEGF;
   EXPRESSION; OCCULT
AB Purpose: Choroidal hypofluorescence has been reported beneath the photodynamic therapy (PDT) site in clinical studies. We evaluated the choroidal hypofluorescence after combined PDT with posterior subtenon injection of triamcinolone acetonide or PDT with an intravitreal injection of bevacizumab for age-related macular degeneration.
   Methods: Two hundred and forty-two eyes with a subfoveal choroidal neovascularization caused by age-related macular degeneration were studied. Ninety-two eyes underwent PDT alone, 90 eyes underwent PDT with sub-Tenon injection of triamcinolone acetonide, and 60 eyes underwent PDT with intravitreal injection of bevacizumab. Verteporfin-induced choroidal hypoperfusion was determined by indocyanine green angiograms. The intensity of the diffuse fluorescence within the PDT site away from the choroidal neovascularization lesion and from the normal retina just peripheral to the optic disk was measured by densitometry (Topcon IMAGEnet computer system, Topcon, Tokyo, Japan) in the indocyanine green angiogram images obtained at 10 minutes 3 months after the PDT. The ratio of the average brightness of the retina within the PDT area to that of the retina peripheral to the optic disk (irradiated/nonirradiated retinal brightness ratio) was calculated for each angiogram.
   Results: The irradiated/nonirradiated retinal brightness ratio of the angiograms was 0.96 in the PDT-alone group, 0.85 in the sub-Tenon injection of triamcinolone acetonide-PDT group, and 0.89 in the intravitreal injection of bevacizumab-PDT group (Kruskal-Wallis H test, P < 0.05).
   Conclusion: The degree of choroidal hypofluorescence in the indocyanine green angiogram images 3 months after PDT in the sub-Tenon injection of triamcinolone acetonide and intravitreal injection of bevacizumab group was higher than that of PDT-alone group. Sub-Tenon injection of triamcinolone acetonide and intravitreal injection of bevacizumab can prolong the duration of the choroidal hypofluorescence after PDT. RETINA 30: 495-502, 2010
C1 [Ishikawa, Kohei] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Ishikawa, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM kohei@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Ito, Yasuki/M-4876-2014
OI Ito, Yasuki/0000-0001-9219-9261
FU Ministry of Education, Science, Sports and Culture, Japan [18791272,
   19500416, 16390497, 18390466]
FX Supported by Grants-in-Aid 18791272 (to K. I.), 19500416 (to Y.I.),
   16390497 (to H. T.), and 18390466 (to H. T.) from the Ministry of
   Education, Science, Sports and Culture, Japan.
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fingar VH, 1999, BRIT J CANCER, V79, P1702, DOI 10.1038/sj.bjc.6690271
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Michels S, 2000, KLIN MONATSBL AUGENH, V217, P94, DOI 10.1055/s-2000-10391
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 51
TC 12
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2010
VL 30
IS 3
BP 495
EP 502
DI 10.1097/IAE.0b013e3181bcedbe
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AD
UT WOS:000278548800018
PM 19996828
DA 2022-11-30
ER

PT J
AU Tschuor, P
   Pilly, B
   Venugopal, D
   Gale, RP
AF Tschuor, Patrizia
   Pilly, Bertrand
   Venugopal, Divya
   Gale, Richard Peter
TI Optimising assessment intervals improves visual outcomes in
   ranibizumab-treated age-related neovascular degeneration: using the
   stability phase as a benchmark
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Visual acuity; Injection
   number; Follow-up; Stability phase
ID MACULAR DEGENERATION; VERTEPORFIN; SECONDARY; ENGLAND; WALES
AB To observe visual acuity change in the stability phase when follow-up intervals are decreased in ranibizumab-treated neovascular age-related macular degeneration (nvAMD).
   Selection of patients was based on a review of a cohort of 189 eyes of 154 patients with nvAMD treated with intravitreal ranibizumab in routine clinical practice. Patients were transferred from a base hospital with a 8-week follow-up interval to a community eye clinic, enabling a new follow-up interval of 4 weeks. Staff, assessment, and treatment protocols were equivalent in the two centres. Patients were included when they were in the stability phase of treatment defined 1 month after having completed their three initiation treatments with ranibizumab. Each patient was required to have attended at least a further 12 visits; this means a follow-up time for a year or longer, consisting of six visits at the base hospital followed by six visits at the new eye clinic. The best-corrected visual acuity (BCVA), follow-up intervals and injection numbers were collected.
   Seventy-two eyes of 62 patients were included. The mean follow-up interval for the six visits in the base hospital was 56.81 days, and in the new eye centre 31.81 days. The BCVA loss in the base hospital was -1.13 letters, compared to a gain of +4.61 letters in the community eye clinic over the six visits. The number of ranibizumab injections was 3.67 in the base hospital, compared with 3.91 in the other centre over the respective periods.
   Visual acuity improves and severe visual loss decreases when follow-up intervals reduce from approximately 8 weeks to 4 weeks. Furthermore, using the stability phase to evaluate the outcome and effectiveness of our treatments for age-related macular degeneration appeared to be an efficient tool.
C1 [Tschuor, Patrizia; Pilly, Bertrand; Venugopal, Divya; Gale, Richard Peter] York Teaching Hosp, York YO31 8HE, N Yorkshire, England.
RP Tschuor, P (通讯作者)，York Teaching Hosp, Wigginton Rd, York YO31 8HE, N Yorkshire, England.
EM ptschuor@me.com; richard.gale@york.nhs.uk
CR Amoaku W, 2012, EYE, V26, P2
   [Anonymous], 2008, NICE TECHNOLOGY APPR
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Dagostar H, 2009, OPHTHALMOLOGY, V116, P1740
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   LALWANI GA, 2009, AM J OPHTHALMOL, V148, P43, DOI DOI 10.1016/J.AJO.2009.01.024
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
NR 19
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2013
VL 251
IS 10
BP 2327
EP 2330
DI 10.1007/s00417-013-2332-5
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 220PW
UT WOS:000324598500004
PM 23591940
DA 2022-11-30
ER

PT J
AU Jittpoonkuson, T
   Garcia, PMT
   Rosen, RB
AF Jittpoonkuson, T.
   Garcia, P. M. T.
   Rosen, R. B.
TI Correlation between fluorescein angiography and spectral-domain optical
   coherence tomography in the diagnosis of cystoid macular edema
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Aims To compare the ability to detect cystoid macular edema (CME) and its late complications between spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA).
   Methods Retrospective, observational, case series. 85 Eyes who had FA and SD-OCT performed on the same day at first visit and/or at follow-up visits were included. FA and SD-OCT images were evaluated for the evidences associated with CME and other structural changes of macula. FA and SD-OCT images were then superimposed to determine the relationships of diagnostic features between the two images. Main outcome measure was the correlation between FA and SD-OCT findings of macula in patients with CME.
   Results The common causes of CME in our study were retinal vein occlusion (RVO, 63%), diabetic retinopathy (DR, 21.18%) and posterior uveitis (3.53%). CME associated with RVO, age-related macular degeneration and DR were missed by FA in 18.52%, 33.33% and 33.33% of cases, respectively. Subretinal fluid was undetectable by FA in 54.55%, which mainly were in the RVO group. SD-OCT gave earlier CME diagnosis than FA in three (3.53%) eyes. Residual CME at follow-up visits were missed by FA in one (1.18%) eye. Late complications of long-standing CME (secondary macular hole (two eyes), secondary subretinal fluid (five eyes), retinal pigment epithelium detachment (one eye) and photoreceptor atrophy (one eye)) were detectable only by SD-OCT.
   Conclusions SD-OCT demonstrated greater sensitivity than FA in detecting CME, particularly those associated with RVO, DR and age-related macular degeneration. SD-OCT was also more sensitive than FA for detecting subretinal fluid and late complications of long-standing CME.
C1 [Jittpoonkuson, T.] Bangkok Metropolitan Adm Gen Hosp, Retina Serv, Dept Ophthalmol, Cent Hosp, Bangkok 10100, Thailand.
   [Garcia, P. M. T.; Rosen, R. B.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [Garcia, P. M. T.; Rosen, R. B.] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, New York, NY 10003 USA.
C3 New York Medical College; New York Eye & Ear Infirmary of Mount Sinai
RP Jittpoonkuson, T (通讯作者)，Bangkok Metropolitan Adm Gen Hosp, Retina Serv, Dept Ophthalmol, Cent Hosp, 514 Luang Rd, Bangkok 10100, Thailand.
EM dr.teerapat@yahoo.com
CR Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   GASS JDM, 1973, AM J OPHTHALMOL, V76, P500, DOI 10.1016/0002-9394(73)90738-1
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ikeda T, 1999, BRIT J OPHTHALMOL, V83, P12, DOI 10.1136/bjo.83.1.12
   Jaffe G, 2006, RETINAL IMAGING, V18, P206
   JAMPOL LM, 1994, RETINA, V2, P999
   Michishita Y, 2005, J HIGH ENERGY PHYS
   MILLAY RH, 1988, OPHTHALMOLOGY, V95, P930
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Ozdek SC, 2005, OPHTHALMOLOGICA, V219, P86, DOI 10.1159/000083266
   Podoleanu AG, 2008, PROG RETIN EYE RES, V27, P464, DOI 10.1016/j.preteyeres.2008.03.002
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Quinn C J, 1996, Optom Clin, V5, P111
   ROTH DB, 2008, NONPSEUDOPHAKIC CYST
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Scorolli L, 2007, ARCH OPHTHALMOL-CHIC, V125, P759, DOI 10.1001/archopht.125.6.759
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Tran HT, 2005, INVEST OPHTH VIS SCI, V46
   Tran THC, 2008, BRIT J OPHTHALMOL, V92, P922, DOI 10.1136/bjo.2007.136846
NR 20
TC 26
Z9 29
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2010
VL 94
IS 9
BP 1197
EP 1200
DI 10.1136/bjo.2009.170589
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 654YF
UT WOS:000282206500018
PM 19965832
DA 2022-11-30
ER

PT J
AU Kociok, N
   Joussen, AM
AF Kociok, Norbert
   Joussen, Antonia M.
TI Enhanced expression of the complement factor H mRNA in proliferating
   human RPE cells
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Differentially expressed mRNA reverse transcription-polymerase chain
   reaction; Complement factor H; Complement factor I; Retinal pigment
   epithelial cells
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; INTERFERON-GAMMA;
   ALTERNATIVE PATHWAY; REGULATORY PROTEINS; FACTOR-I; UP-REGULATION;
   VITREORETINOPATHY; SYSTEM; POLYMORPHISM
AB RPE cells are a major player in various diseases of the retina and choroid. Proliferating RPE cells are thought to be an initiating factor in proliferative vitreoretinopathy (PVR); the aging RPE cells are important in age-related macular degeneration (AMD). Early passages of cultured human retinal pigment epithelial cells were used as a model system to identify differentially expressed genes in proliferating retinal pigment epithelial (RPE) cells.
   A differential expression analysis (DEmRNA-PCR) was used to find differentially expressed mRNA in early passages of cultured human RPE cells. The detected mRNAs were identified by sequencing. Their differential expression was verified by semi-quantitative RT-PCR. The expression of the identified protein in vitro and its presence in surgically removed epiretinal membranes was demonstrated by western blotting and immunocytochemical analysis.
   DEmRNA-PCR detected a decreased expression of a band at approximately 530 bp in human RPE cells of passage 3 (P3) compared to P0. This band was identified as part of the human complement regulatory factor H, a cofactor to complement factor I. The mRNA expression of both regulatory proteins of the complement system was confirmed in freshly prepared human RPE cells and in cultured cells from P0 to P8. The protein expression was verified in cultured RPE cells. The expression of both proteins in surgically removed epiretinal membranes was demonstrated by immunohistochemistry.
   The identification of the differential expression of the regulatory factors H and I of the complement system in cultured RPE cells by a technique without any prerequisites demonstrates and confirms the importance of these factors in RPE cells. In addition to its known role in age-related macular degeneration, the presence of these complement factors in epiretinal membranes may also indicate a role of the complement system in proliferative retinopathy.
C1 [Kociok, Norbert; Joussen, Antonia M.] Univ Dusseldorf, Dept Ophthalmol, D-4000 Dusseldorf, Germany.
C3 Heinrich Heine University Dusseldorf
RP Kociok, N (通讯作者)，Charite Univ Med CVK, Dept Ophthalmol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM norbert.kociok@charite.de
RI Joussen, Antonia/AAA-6901-2022
FU DFG [Jo 324/ 6-2, Jo 324 / 7-1]
FX This study was supported by DFG Jo 324/6-2 (Emmy Noether Program) and
   DFG Jo 324 / 7-1.
CR Abe T, 1996, EXP EYE RES, V63, P201, DOI 10.1006/exer.1996.0109
   Bardenstein DS, 1997, CURR EYE RES, V16, P1270, DOI 10.1076/ceyr.16.12.1270.5028
   BAUDOUIN C, 1990, AM J OPHTHALMOL, V110, P593, DOI 10.1016/S0002-9394(14)77054-0
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Campochiaro PA, 1997, ARCH OPHTHALMOL-CHIC, V115, P237, DOI 10.1001/archopht.1997.01100150239014
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   DERODRIGUEZ CS, 2004, MOL IMMUNOL, V41, P355
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esser P, 1997, INVEST OPHTH VIS SCI, V38, P2852
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Gerritsma JSJ, 1997, CYTOKINE, V9, P276, DOI 10.1006/cyto.1996.0164
   GRISANTI S, 1991, INVEST OPHTH VIS SCI, V32, P2711
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kociok N, 1998, MOL BIOTECHNOL, V9, P25, DOI 10.1007/BF02752695
   Kociok N, 1999, J CELL BIOCHEM, V74, P194, DOI 10.1002/(SICI)1097-4644(19990801)74:2<194::AID-JCB5>3.3.CO;2-D
   LAPPIN DF, 1992, BIOCHEM J, V281, P437, DOI 10.1042/bj2810437
   LASS JH, 1990, INVEST OPHTH VIS SCI, V31, P1136
   Liszewski MK, 1996, ADV IMMUNOL, V61, P201
   Liversidge J, 1996, J IMMUNOL, V156, P3696
   Luo W, 1999, SCAND J IMMUNOL, V49, P487
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Meri S, 1998, VOX SANG, V74, P291, DOI 10.1111/j.1423-0410.1998.tb05434.x
   MINTA JO, 1998, BIOCHIM BIOPHYS ACTA, V286, P1442
   Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43
   PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019
   REID KBM, 1986, ESSAYS BIOCHEM, V22, P27
   RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Tsiftsoglou SA, 2006, BBA-PROTEINS PROTEOM, V1764, P1757, DOI 10.1016/j.bbapap.2006.09.007
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yu J, 2008, PROTEOMICS, V8, P3667, DOI 10.1002/pmic.200700824
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 36
TC 3
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2010
VL 248
IS 8
BP 1145
EP 1153
DI 10.1007/s00417-010-1371-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622RO
UT WOS:000279683300012
PM 20376478
DA 2022-11-30
ER

PT J
AU Borkar, DS
   Obeid, A
   Su, DC
   Storey, PP
   Gao, XX
   Regillo, CD
   Kaiser, RS
   Garg, SJ
   Hsu, J
AF Borkar, Durga S.
   Obeid, Anthony
   Su, Daniel C.
   Storey, Philip P.
   Gao, Xinxiao
   Regillo, Carl D.
   Kaiser, Richard S.
   Garg, Sunir J.
   Hsu, Jason
CA Wills Post Injection
TI Endophthalmitis Rates after Bilateral Same-Day Intravitreal
   Anti-Vascular Endothelial Growth Factor Injections
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF INJECTIONS; POSTINJECTION ENDOPHTHALMITIS; STREPTOCOCCUS
   ENDOPHTHALMITIS; INFECTIOUS ENDOPHTHALMITIS; FACTOR AGENTS;
   RISK-FACTORS; OUTCOMES; BEVACIZUMAB; METAANALYSIS; RETRACTION
AB PURPOSE: To evaluate practice patterns for bilateral same-day intravitreal anti-vascular endothelial growth factor (VEGF) injections and determine the rate of unilateral and bilateral postinjection endophthalmitis after bilateral same-day intravitreal anti-VEGF injections.
   DESIGN: Retrospective cohort study.
   METHODS: The records of a large academic private practice were electronically queried for all office visits, during which bilateral intravitreal anti-VEGF injections were performed between April 1, 2012 and August 21, 2017 for patients with a diagnosis of neovascular age related macular degeneration, diabetic macular edema, or retinal vein occlusion. Demographic information and indication for injection were recorded for each patient and office visit. Charts of patients with endophthalmitis were reviewed, and information was collected on presentation examination, culture data, and visual outcomes.
   RESULTS: During the study period, 101 932 bilateral same-day intravitreal anti-VEGF injections were performed over 50 966 office visits for 5890 patients. The mean (standard deviation) age of patients in this cohort was 74.2 (14.1) years and 60.6% of patients were female. The 2 most common indications for injection were neovascular age-related macular degeneration (54.3% of patients) and diabetic macular edema (35.4% of patients). Twentyeight cases of endophthalmitis (0.027% of total injections) occurred during the study period. There were no cases of bilateral endophthalmitis, and no patients had more than 1 occurrence of endophthalmitis.
   CONCLUSIONS: In this large cohort of patients undergoing bilateral same-day intravitreal anti-VEGF injections, there were no cases of bilateral endophthalmitis. Additionally, the overall rate of unilateral endophthalmitis was low and comparable to prior studies of unilateral injections. These results support the safety of bilateral same-day intravitreal anti-VEGF treatment. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Borkar, Durga S.; Obeid, Anthony; Su, Daniel C.; Storey, Philip P.; Gao, Xinxiao; Regillo, Carl D.; Kaiser, Richard S.; Garg, Sunir J.; Hsu, Jason; Wills Post Injection] Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
OI Ho, Allen/0000-0003-3921-608X
CR Abu-Yaghi NE, 2014, INT J OPHTHALMOL-CHI, V7, P1017, DOI 10.3980/j.issn.2222-3959.2014.06.20
   Bakri SJ, 2009, AM J OPHTHALMOL, V148, P66, DOI 10.1016/j.ajo.2009.02.013
   Casparis H, 2014, RETINA-J RET VIT DIS, V34, P12, DOI 10.1097/IAE.0b013e31829f74b0
   Chen E, 2011, RETINA-J RET VIT DIS, V31, P1525, DOI 10.1097/IAE.0b013e318221594a
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Davis RP, 2010, CLIN OPHTHALMOL, V4, P703
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Fineman MS, 2013, RETINA-J RET VIT DIS, V33, P1968, DOI 10.1097/IAE.0b013e318287da92
   Giocanti-Auregan A, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0317-y
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Gregori NZ, 2015, OSLI RETINA, V46, P643, DOI 10.3928/23258160-20150610-08
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Mahajan VB, 2011, RETINA-J RET VIT DIS, V31, P31, DOI 10.1097/IAE.0b013e3181ed8c80
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   McLaughlin MD, 2017, OPHTHALMOLOGY, V124, P667, DOI 10.1016/j.ophtha.2017.01.001
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Moshfeghi AA, 2011, SEMIN OPHTHALMOL, V26, P139, DOI 10.3109/08820538.2011.570847
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Nentwich MM, 2014, RETINA-J RET VIT DIS, V34, P943, DOI 10.1097/IAE.0000000000000011
   Okoye O, 2016, NIGER J CLIN PRACT, V19, P544, DOI 10.4103/1119-3077.183313
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Rahimy E, 2015, OPHTHALMOLOGY, V122, P1729, DOI 10.1016/j.ophtha.2015.02.001
   Rayess N, 2016, BRIT J OPHTHALMOL, V100, P1058, DOI 10.1136/bjophthalmol-2015-307707
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Tabatabaii Ali, 2013, Middle East Afr J Ophthalmol, V20, P87, DOI 10.4103/0974-9233.106402
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
NR 32
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2018
VL 194
BP 1
EP 6
DI 10.1016/j.ajo.2018.06.022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW8RI
UT WOS:000447246800004
PM 29981738
DA 2022-11-30
ER

PT J
AU Tawfik, A
   Mohamed, R
   Kira, D
   Alhusban, S
   Al-Shabrawey, M
AF Tawfik, Amany
   Mohamed, Riyaz
   Kira, Dina
   Alhusban, Suhib
   Al-Shabrawey, Mohamed
TI N-Methyl-D-aspartate receptor activation, novel mechanism of
   homocysteine-induced blood-retinal barrier dysfunction
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE N-Methyl-D-aspartate receptor; Homocysteine; Blood&#8211; retinal
   barrier; Cystathionine-&#946; &#8212; synthase and mouse
ID CYSTATHIONINE-BETA-SYNTHASE; BRAIN-BARRIER; PLASMA HOMOCYSTEINE; MACULAR
   DEGENERATION; GLUTAMATE RECEPTORS; HYPERHOMOCYSTEINEMIA; DISEASE;
   EXPRESSION; PATHOLOGY; MICE
AB Elevated levels of amino acid homocysteine (Hcy) recognized as hyperhomocysteinemia (HHcy) was reported in several human visual disorders, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Breakdown of blood-retinal barrier (BRB) is concomitant with vision loss in DR and AMD. We previously reported that HHcy alters BRB. Here, we tested the hypothesis that HHcy alters BRB via activation of N-methyl-D-aspartate receptor (NMDAR). Human retinal endothelial cells subjected to high level of Hcy and mouse model of HHcy were used. We injected Hcy intravitreal and used a mouse model of HHcy that lacks cystathionine-beta-synthase (CBS). RT-PCR, western blot, and immunofluorescence showed that retinal endothelial cells (RECs) express NMDAR at the gene and protein levels both in vitro and in vivo and this was increased by HHcy. We assessed BRB function and retinal morphology using fluorescein angiogram and optical coherence tomography (OCT) under HHcy with and without pharmacological inhibition of NMDAR by (MK801) or in mice lacking endothelial NMDAR (NMDAR(E-/-) mouse). Additionally, retinal albumin leakage and tight junction proteins ZO-1 and occludin were assessed by western blotting analysis. Inhibition or elimination of NMDAR was able to improve the altered retinal hyperpermeability and morphology under HHcy as indicated by significant decrease in retinal albumin leakage and restoration of tight junction proteins ZO-1 and occludin. Our findings underscore a potential role for endothelial NMDAR in mediating Hcy-induced breakdown of BRB and subsequently as a potential therapeutic target in retinal diseases associated with HHcy such as DR and AMD. Key messages center dot Elevated levels of homocysteine (Hcy) are defined as hyperhomocysteinemia (HHcy). center dot HHcy is implicated in diabetic retinopathy and age-related macular degeneration. center dot HHcy alters BRB via activation of N-methyl-D-aspartate receptor.
C1 [Tawfik, Amany; Kira, Dina; Alhusban, Suhib; Al-Shabrawey, Mohamed] Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, 1120 15th St,CB 1114, Augusta, GA 30912 USA.
   [Tawfik, Amany; Kira, Dina; Alhusban, Suhib; Al-Shabrawey, Mohamed] Augusta Univ, Med Coll Georgia MCG, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.
   [Tawfik, Amany; Al-Shabrawey, Mohamed] Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.
   [Tawfik, Amany; Al-Shabrawey, Mohamed] Augusta Univ, Dept Ophthalmol, Med Coll Georgia MCG, Augusta, GA 30912 USA.
   [Mohamed, Riyaz] Augusta Univ, Dept Physiol, Med Coll Georgia MCG, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University
RP Tawfik, A (通讯作者)，Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, 1120 15th St,CB 1114, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Med Coll Georgia MCG, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Ophthalmol, Med Coll Georgia MCG, Augusta, GA 30912 USA.
EM amtawfik@augusta.edu
FU American Heart Association (AHA) Scientist Development Grant
   [16SDG3070001]; NEI grant [1R01EY029751-02, 1R01EY030054-01A1,
   P30EY031631]
FX The authors received the fund provided by the American Heart Association
   (AHA) Scientist Development Grant award #16SDG3070001, and NEI grant
   awards 1R01EY029751-02, 1R01EY030054-01A1, and P30EY031631
CR Ajith TA, 2015, CLIN CHIM ACTA, V450, P316, DOI 10.1016/j.cca.2015.09.007
   Aydin E, 2008, EUR J OPHTHALMOL, V18, P226, DOI 10.1177/112067210801800210
   Beard RS, 2011, BLOOD, V118, P2007, DOI 10.1182/blood-2011-02-338269
   Booth GL, 2000, CAN MED ASSOC J, V163, P21
   Bossenmeyer-Pourie C, 2019, J PATHOL, V248, P291, DOI 10.1002/path.5254
   Campbell M, 2018, PROG RETIN EYE RES, V62, P120, DOI 10.1016/j.preteyeres.2017.09.003
   Cheng ZJ, 2009, CURR HYPERTENS REV, V5, P158, DOI 10.2174/157340209788166940
   CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6
   Christen WG, 2018, OPHTHALMOL RETINA, V2, P508, DOI 10.1016/j.oret.2017.10.001
   Christen WG, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2017.1362009
   Cunha-Vaz J, 2017, OPHTHALMOLOGICA, V237, P1, DOI 10.1159/000455809
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Deep SN, 2019, J BIOL CHEM, V294, P11154, DOI 10.1074/jbc.RA119.008820
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Domagala T B, 1998, J Cardiovasc Risk, V5, P239, DOI 10.1097/00043798-199808000-00006
   Dong N, 2018, INT OPHTHALMOL, V38, P737, DOI 10.1007/s10792-017-0528-0
   Dong YL, 2017, J NEUROIMMUNOL, V307, P7, DOI 10.1016/j.jneuroim.2017.03.005
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Elsherbiny NM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030393
   Ganapathy PS, 2011, INVEST OPHTH VIS SCI, V52, P5515, DOI 10.1167/iovs.10-6870
   Glynn-Servedio BE, 2017, CONSULT PHARM, V32, P511, DOI 10.4140/TCP.n.2017.511
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016
   Hallett PJ, 2004, PHARMACOL THERAPEUT, V102, P155, DOI 10.1016/j.pharmthera.2004.04.001
   Homme RP, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01268
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Jindal A, 2019, NEUROBIOL DIS, V127, P287, DOI 10.1016/j.nbd.2019.03.012
   Ju PJ, 2016, ACTA BIOCH BIOPH SIN, V48, P209, DOI 10.1093/abbs/gmv135
   Kamat PK, 2016, MOL NEUROBIOL, V53, P2451, DOI 10.1007/s12035-015-9212-4
   Karger AB, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013934
   Krizbai IA, 1998, J NEUROSCI RES, V54, P814
   Kuhlmann CRW, 2009, NEUROSCI LETT, V449, P168, DOI 10.1016/j.neulet.2008.10.096
   Lei XW, 2019, OPHTHALMIC RES, V62, P80, DOI 10.1159/000499020
   Lei XW, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0362-1
   LeMaistre JL, 2012, J CEREBR BLOOD F MET, V32, P537, DOI 10.1038/jcbfm.2011.161
   Li JC, 2006, AM J PHYSIOL-GASTR L, V291, pG219, DOI 10.1152/ajpgi.00097.2006
   Liu X, 2010, NEUROL SCI, V31, P699, DOI 10.1007/s10072-010-0241-5
   Malaguarnera G, 2015, CLIN OPHTHALMOL, V9, P1437, DOI 10.2147/OPTH.S77538
   Malaguarnera G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/191497
   McCully KS, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00324
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   MCCULLY KS, 1969, AM J PATHOL, V56, P111
   MCCULLY KS, 1970, AM J PATHOL, V61, P1
   Merello M, 1999, CLIN NEUROPHARMACOL, V22, P273
   Minniti G, 2014, EUR J OPHTHALMOL, V24, P735, DOI 10.5301/ejo.5000426
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Moore P, 2001, EXP EYE RES, V73, P45, DOI 10.1006/exer.2001.1009
   Moustafa AA, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00343
   Pang XM, 2014, ATHEROSCLEROSIS, V236, P73, DOI 10.1016/j.atherosclerosis.2014.06.021
   Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1
   Paul C, 2002, J PHARMACOL EXP THER, V302, P50, DOI 10.1124/jpet.302.1.50
   Poddar R, 2009, J NEUROCHEM, V110, P1095, DOI 10.1111/j.1471-4159.2009.06207.x
   Qureshi I, 2005, VASC MED, V10, P215, DOI 10.1191/1358863x05vm626oa
   Ramsey AJ, 2009, PROG BRAIN RES, V179, P51, DOI 10.1016/S0079-6123(09)17906-2
   Reijerkerk A, 2010, J NEUROCHEM, V113, P447, DOI 10.1111/j.1471-4159.2010.06598.x
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rodman MJ, 1989, YOUR GUIDE NEWEST DR, V52, P61
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
   Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003
   Sibarov DA, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00246
   Singh J, 2009, BRAIN RES BULL, V79, P157, DOI 10.1016/j.brainresbull.2009.02.005
   Tawfik A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010121
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Tawfik A, 2013, INVEST OPHTH VIS SCI, V54, P939, DOI 10.1167/iovs.12-10536
   Tomiyama M, 2005, MOL BRAIN RES, V136, P275, DOI 10.1016/j.molbrainres.2005.02.003
   Ukinc K, 2009, ENDOCRINE, V36, P255, DOI 10.1007/s12020-009-9218-7
   Vaccaro O, 2000, NUTR METAB CARDIOVAS, V10, P297
   WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585
   Yang Guoqing, 2002, Zhonghua Nei Ke Za Zhi, V41, P34
   Zhou HT, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1297
NR 72
TC 5
Z9 6
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD JAN
PY 2021
VL 99
IS 1
BP 119
EP 130
DI 10.1007/s00109-020-02000-y
EA NOV 2020
PG 12
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA PO2CY
UT WOS:000587076900001
PM 33159240
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Buyse, M
   Squifflet, P
   Coart, E
   Quinaux, E
   Punt, CJA
   Saad, ED
AF Buyse, Marc
   Squifflet, Pierre
   Coart, Elisabeth
   Quinaux, Emmanuel
   Punt, Cornelis J. A.
   Saad, Everardo D.
TI The impact of data errors on the outcome of randomized clinical trials
SO CLINICAL TRIALS
LA English
DT Article
DE Random errors; bias; age-related macular degeneration; colorectal
   neoplasms; source data verification
ID DATA QUALITY; CANCER; PROGRESSION; SURVIVAL; ONCOLOGY; COSTS
AB Background/aims: Considerable human and financial resources are typically spent to ensure that data collected for clinical trials are free from errors. We investigated the impact of random and systematic errors on the outcome of randomized clinical trials.
   Methods: We used individual patient data relating to response endpoints of interest in two published randomized clinical trials, one in ophthalmology and one in oncology. These randomized clinical trials enrolled 1186 patients with age-related macular degeneration and 736 patients with metastatic colorectal cancer. The ophthalmology trial tested the benefit of pegaptanib for the treatment of age-related macular degeneration and identified a statistically significant treatment benefit, whereas the oncology trial assessed the benefit of adding cetuximab to a regimen of capecitabine, oxaliplatin, and bevacizumab for the treatment of metastatic colorectal cancer and failed to identify a statistically significant treatment difference. We simulated trial results by adding errors that were independent of the treatment group (random errors) and errors that favored one of the treatment groups (systematic errors). We added such errors to the data for the response endpoint of interest for increasing proportions of randomly selected patients.
   Results: Random errors added to up to 50% of the cases produced only slightly inflated variance in the estimated treatment effect of both trials, with no qualitative change in the p-value. In contrast, systematic errors produced bias even for very small proportions of patients with added errors.
   Conclusion: A substantial amount of random errors is required before appreciable effects on the outcome of randomized clinical trials are noted. In contrast, even a small amount of systematic errors can severely bias the estimated treatment effects. Therefore, resources devoted to randomized clinical trials should be spent primarily on minimizing sources of systematic errors which can bias the analyses, rather than on random errors which result only in a small loss in power.
C1 [Buyse, Marc] IDDI, 757 N Point St, San Francisco, CA 94109 USA.
   [Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat IBioSta, Hasselt, Belgium.
   [Squifflet, Pierre; Coart, Elisabeth; Quinaux, Emmanuel; Saad, Everardo D.] IDDI, Louvain La Neuve, Belgium.
   [Punt, Cornelis J. A.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.
C3 International Drug Development Institute; Hasselt University;
   International Drug Development Institute; University of Amsterdam;
   Academic Medical Center Amsterdam
RP Buyse, M (通讯作者)，IDDI, 757 N Point St, San Francisco, CA 94109 USA.
EM marc.buyse@iddi.com
RI Buyse, Marc/J-4658-2013
CR Amit O, 2011, EUR J CANCER, V47, P1772, DOI 10.1016/j.ejca.2011.02.013
   Baigent C, 2008, CLIN TRIALS, V5, P49, DOI 10.1177/1740774507087554
   Bakobaki JM, 2012, CLIN TRIALS, V9, P257, DOI 10.1177/1740774511427325
   Bhattacharya S, 2009, J CLIN ONCOL, V27, P5958, DOI 10.1200/JCO.2009.22.4329
   BROSS I, 1954, BIOMETRICS, V10, P478, DOI 10.2307/3001619
   Califf RM, 1997, CONTROL CLIN TRIALS, V18, P651, DOI 10.1016/S0197-2456(96)00237-1
   COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408
   Dodd LE, 2013, CLIN TRIALS, V10, P754, DOI 10.1177/1740774513493973
   Eisenstein EL, 2008, CLIN TRIALS, V5, P75, DOI 10.1177/1740774507087551
   Erdmann J, 2005, J NATL CANCER I, V97, P1492, DOI 10.1093/jnci/dji363
   European Medicines Agency, EMAINSGCP394192011
   Ford R, 2009, EUR J CANCER, V45, P268, DOI 10.1016/j.ejca.2008.10.031
   George SL, 1997, CHANCE, V10, P3
   George Stephen L, 2015, Clin Investig (Lond), V5, P161, DOI 10.4155/cli.14.116
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kirkwood AA, 2013, CLIN TRIALS, V10, P783, DOI 10.1177/1740774513494504
   Korn EL, 2010, CLIN TRIALS, V7, P626, DOI 10.1177/1740774510382801
   Landray MJ, 2017, EUR HEART J, V38, P1632, DOI 10.1093/eurheartj/ehx086
   Lindblad AS, 2014, CLIN TRIALS, V11, P205, DOI 10.1177/1740774513508028
   Morrison BW, 2011, CLIN TRIALS, V8, P342, DOI 10.1177/1740774511402703
   Pronker E, 2011, BRIT J CLIN PHARMACO, V71, P467, DOI 10.1111/j.1365-2125.2010.03839.x
   Reith C, 2013, NEW ENGL J MED, V369, P1061, DOI 10.1056/NEJMsb1300760
   Saad ED, 2010, J CLIN ONCOL, V28, P1958, DOI 10.1200/JCO.2009.25.5414
   Shuchman M, 2007, NEW ENGL J MED, V357, P1365, DOI 10.1056/NEJMp078176
   Smith CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042433
   Sridhara R, 2010, JNCI-J NATL CANCER I, V102, P230, DOI 10.1093/jnci/djp515
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   US Department of Health and Human Services Food and Drug Administration, GUID IND OV CLIN INV
   Venet D, 2012, CLIN TRIALS, V9, P705, DOI 10.1177/1740774512447898
NR 30
TC 11
Z9 11
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD OCT
PY 2017
VL 14
IS 5
BP 499
EP 506
DI 10.1177/1740774517716158
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FJ2EB
UT WOS:000412535000012
PM 28641461
DA 2022-11-30
ER

PT J
AU Timberlake, GT
   Bothwell, RJ
   Moyer, K
AF Timberlake, George T.
   Bothwell, Rebecca J.
   Moyer, Kristen
TI Handwriting with a Preferred Retinal Locus for AMD with Scotomas
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE preferred retinal locus; PRL; macular scotoma; handwriting; scanning
   laser ophthalmoscope; hand-eye coordination; retinal map
ID VISUAL CONTROL; VISION; LOCATION; HAND
AB Purpose. Individuals with macular scotomas from age-related macular degeneration frequently have difficulty writing legibly. The purpose of this study was to investigate the causes of this difficulty by documenting the location of the retinal image of the pen used for writing in relation to the scotoma and fixational preferred retinal locus (fPRL).
   Methods. Subjects with macular scotomas from age-related macular degeneration and visually normal age-matched controls wrote words while observing their hand, pen, and text in a scanning laser ophthalmoscope. Scanning laser ophthalmoscope video images were analyzed to find the retinal positions of the subject's scotoma, fixation area, and pen tip.
   Results. Control subjects placed their fovea and scotoma subjects placed their fPRL on or very close to the pen tip for both cursive writing and printing. Scotoma subjects' written text sloped downward at a greater angle than controls'. Text angle was negatively correlated with fPRL eccentricity, visual acuity, and the amount the scotoma obscured the writing guides. When printing, control subjects placed their fovea precisely in the center of printing box guides, whereas scotoma subjects exhibited highly dispersed placement of the fPRL.
   Conclusions. The principal finding is that, because the retinal locations of the pen tip and the fPRL or fovea are coincident or very close, the fPRL and fovea are "monitoring" the pen tip and its location on the page. It is the PRL determined by asking subjects to fixate (i.e., the fPRL) that is used when handwriting, not a separate "handwriting" PRL. The poor handwriting performance of those with macular scotomas seems to be primarily caused by difficulty in placing letters in the appropriate location probably because of reduced visual acuity of the fPRL and scotoma obscuration of the area on which to write. (Optom Vis Sci 2013; 90: 455-465)
C1 [Timberlake, George T.; Bothwell, Rebecca J.; Moyer, Kristen] Kansas City Vet Adm Med Ctr, Kansas City, MO 64128 USA.
RP Timberlake, GT (通讯作者)，Kansas City VA Med Ctr, Res Dept, 4801 East Linwood Blvd, Kansas City, MO 64128 USA.
EM george.timberlake@va.gov
FU Department of Veterans Affairs Rehabilitation Research & Development
   Service [C6218R, C1000-R]
FX Supported by Department of Veterans Affairs Rehabilitation Research &
   Development Service grants C6218R and C1000-R.
CR Alamargot D, 2006, BEHAV RES METHODS, V38, P287, DOI 10.3758/BF03192780
   Dolman P, 1919, AM J OPHTHALMOL, V2, P287
   Hepp-Reymond MC, 2009, BRAIN RES BULL, V79, P365, DOI 10.1016/j.brainresbull.2009.05.013
   Marquardt C, 1999, EXP BRAIN RES, V128, P224, DOI 10.1007/s002210050841
   SMYTH MM, 1987, ACTA PSYCHOL, V65, P47, DOI 10.1016/0001-6918(87)90046-1
   SMYTH MM, 1989, ACTA PSYCHOL, V70, P253, DOI 10.1016/0001-6918(89)90025-5
   Timberlake GT, 2008, OPTOMETRY VISION SCI, V85, P270, DOI 10.1097/OPX.0b013e31816928b9
   Timberlake GT, 2012, INVEST OPHTH VIS SCI, V53, P1810, DOI 10.1167/iovs.11-9282
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   VANDOORN RRA, 1992, ACTA PSYCHOL, V81, P269, DOI 10.1016/0001-6918(92)90021-5
   VANDOORN RRA, 1993, ACTA PSYCHOL, V82, P275, DOI 10.1016/0001-6918(93)90016-K
   Watson GR, 2004, J VISION IMPAIRMENT, V98, P160
   Weisser-Pike O., 2005, INT C SERIES, V1282, P331
NR 13
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2013
VL 90
IS 5
BP 455
EP 465
DI 10.1097/OPX.0b013e31828e92eb
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131TW
UT WOS:000318020300010
PM 23528451
DA 2022-11-30
ER

PT J
AU Dong, LM
   Hawkins, BS
   Marsh, M
AF Dong, LM
   Hawkins, BS
   Marsh, M
TI Consistency between visual acuity scores obtained at different test
   distances - Theory vs observations in multiple studies
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; PHOTOCOAGULATION;
   CHARTS
AB Objective: To investigate the consistency of visual acuity (VA) scores measured at 2 different distances in patients with or at risk for choroidal neovascularization.
   Methods: Best-corrected VA scores measured at 2 distances for the same eyes at the same examinations were collected from 4 sets of randomized clinical trials among patients with or at risk of choroidal neovascularization. Within each trial, the pairs of VA scores were compared and their relationship was explored.
   Results: After adjustment for test distance, VA scores obtained at the closer distance were found to be systematically lower than those obtained at the farther distance in all data sets. In the Submacular Surgery Trials pilot study, the average discrepancy between 2- and 0.5-m VA scores was 7.5 letters. In an ancillary study of the Macular Photocoagulation Study, the discrepancy between 10-ft and 5-ft VA scores was 3.1 letters. In the Laser to Drusen Trial pilot study, the discrepancy between 3.2- and 1-m VA scores was 7.3 letters. In the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study, in which the VA scores at the closer test distance were censored, the estimated discrepancy between 2- and 1-m VA scores was 8.2 letters. Reduction in visual angle at closer test distance did not explain the discrepancy completely. Features of the macular lesion, poor accommodation of the elderly population with age-related macular degeneration, or the test charts did not account for the discrepancies.
   Conclusion: The VA scores at distances,less than 2 m were lower than expected in all 4 studies. The observed discrepancy was consistent with findings from a study among healthy young subjects, suggesting that the phenomenon is real and common.
C1 Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Hawkins, BS (通讯作者)，Wilmer Clin Trials & Biometry, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Freeman E, 1932, J OPT SOC AM, V22, P285, DOI 10.1364/JOSA.22.000285
   Giese WJ, 1946, J APPL PSYCHOL, V30, P91, DOI 10.1037/h0059718
   GREENE W, 1993, ECONOMETRIC ANAL, P694
   *MAC PHOT STUD GRO, 1997, MAC PHOT STUD MAN PR
   MAGUIRE MG, 1985, 2 NEI S EYE DIS EP J
   Monje M, 1970, Ber Zusammenkunft Dtsch Ophthalmol Ges, V70, P291
   MUSYLEV FI, 1937, ACTA OPHTHALMOL, V15, P216
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   SLOAN LL, 1951, AMA ARCH OPHTHALMOL, V45, P704, DOI 10.1001/archopht.1951.01700010719013
   *SUBM SURG TRIALS, 1998, SUBM SURG TRIALS MAN
   TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382
NR 15
TC 15
Z9 15
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2002
VL 120
IS 11
BP 1523
EP 1533
DI 10.1001/archopht.120.11.1523
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 614RE
UT WOS:000179203400013
PM 12427067
OA Bronze
DA 2022-11-30
ER

PT J
AU Arias, L
   Caminal, JM
   Badia, MB
   Rubio, MJ
   Catala, J
   Pujol, O
AF Arias, Luis
   Caminal, Jose M.
   Badia, Maria B.
   Rubio, Marcos J.
   Catala, Jaume
   Pujol, Octavio
TI INTRAVITREAL INFLIXIMAB IN PATIENTS WITH MACULAR DEGENERATION WHO ARE
   NONRESPONDERS TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal infliximab; antitumor necrosis factor agent; neovascular
   age-related macular degeneration; resistance to antivascular endothelial
   growth factor therapy
ID ANTITUMOR NECROSIS FACTOR; BEVACIZUMAB; RABBIT; MODEL
AB Purpose: The purpose of this study was to determine the efficacy and safety of intravitreal infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration in patients who are nonresponders to antivascular endothelial growth factor therapy.
   Methods: Prospective, noncomparative, interventional case series. The primary inclusion criteria for patients consisted of previous treatment with five or more intravitreal injections of bevacizumab and/or ranibizumab, visual loss, angiographic leakage, and intraretinal and/or subretinal fluid on spectral domain optical coherence tomography. At Day 0, a single intravitreal injection of infliximab (2 mg/0.05 mL) was administered. Best-corrected visual acuity testing measured with Early Treatment Diabetic Retinopathy Study charts and spectral domain optical coherence tomography scans were performed on Days 0, 3, 7, 30, 60, and 90. Fluorescein angiography was performed at days 0 and 90. The development of systemic antibodies against infliximab (human antichimeric antibodies) was not sought. Main outcome measures were changes in best-corrected visual acuity, foveal thickness, and lesion size.
   Results: We included four patients. At Day 90, the best-corrected visual acuity change was -18, +3, +4, and -4 letters, respectively. Intraretinal and/or subretinal fluid on spectral domain optical coherence tomography scans was not significantly reduced in any case. Lesion size was not reduced in any case. Two patients developed intraocular inflammation with high intraocular pressure 3 and 5 weeks after the infliximab injection, respectively. One case was controlled with topical medication, and one case required posterior vitrectomy.
   Conclusion: Intravitreal infliximab showed no significant visual or anatomical benefit for the treatment of choroidal neovascularization secondary to age-related macular degeneration in patients who were nonresponders to antivascular endothelial growth factor therapy. In addition, half of the cases developed intraocular inflammation. RETINA 30:1601-1608, 2010
C1 [Arias, Luis; Caminal, Jose M.; Rubio, Marcos J.; Catala, Jaume; Pujol, Octavio] Hosp Univ Bellvitge, Dept Ophthalmol, Barcelona 08907, Spain.
   [Arias, Luis] Ctr Med Teknon, Inst Macula & Retina, Barcelona, Spain.
   [Badia, Maria B.] Hosp Univ Bellvitge, Dept Pharm, Barcelona 08907, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Institut d'Investigacio
   Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital;
   University of Barcelona
RP Arias, L (通讯作者)，Hosp Univ Bellvitge, Dept Ophthalmol, C Feixa Llarga Sn, Barcelona 08907, Spain.
EM luisarias@telefonica.net
RI Rubio Caso, Marcos Javier/L-6866-2013
OI Rubio Caso, Marcos Javier/0000-0002-7072-9855; ARIAS,
   LUIS/0000-0001-7041-5576; Caminal, JM/0000-0001-9563-0344
CR Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Canete JD, 2004, ARTHRITIS RHEUM, V50, P1636, DOI 10.1002/art.20181
   Diaz-Llopis M, 2008, J OCUL PHARMACOL TH, V24, P351, DOI 10.1089/jop.2007.0104
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gómez-Ulla F., 2009, Arch Soc Esp Oftalmol, V84, P377
   Keystone EC, 2005, J RHEUMATOL, V32, P8
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, pS230
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Pulido JS, 2010, RETINA-J RET VIT DIS, V30, P1, DOI 10.1097/IAE.0b013e3181cde727
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2009, AM J OPHTHALMOL, V147, P761, DOI 10.1016/j.ajo.2009.01.011
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   Tsilimbaris Miltiadis K, 2007, Semin Ophthalmol, V22, P75, DOI 10.1080/08820530701418243
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 21
TC 45
Z9 47
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1601
EP 1608
DI 10.1097/IAE.0b013e3181e9f942
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600007
PM 21060271
DA 2022-11-30
ER

PT J
AU Modarres, M
   Naseripour, M
   Falavarjani, KG
   Nikeghbali, A
   Hashemi, M
   Parvaresh, MM
AF Modarres, Mehdi
   Naseripour, Masood
   Falavarjani, Khalil Ghasemi
   Nikeghbali, Aminollah
   Hashemi, Masih
   Parvaresh, Mohammad Mehdi
TI INTRAVITREAL INJECTION OF 2.5 MG VERSUS 1.25 MG BEVACIZUMAB (AVASTIN)
   FOR TREATMENT OF CNV ASSOCIATED WITH AMD
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization
ID RETINA STUDY-GROUP; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   BEVACKUMAB AVASTIN; FOLLOW-UP; RANIBIZUMAB; ANTIBODY; MACULOPATHY;
   SECONDARY; SAFETY
AB Purpose: To compare the safety and efficacy of intravitreal injections of 1.25 and 2.5 mg bevacizumab for treatment of choroidal neovascularization associated with age-related macular degeneration.
   Methods: In this prospective, randomized, comparative clinical trial, 86 patients with active choroidal neovascularization associated with age-related macular degeneration were studied. Baseline best-corrected visual acuity in the study eye was from 20/40 to 20/2000. Patients were randomly assigned to receive intravitreal injections of 2.5 (39 patients) or 1.25 mg (47 patients) of intravitreal bevacizumab. Best-corrected visual acuity measurement and clinical ocular examination were performed at 1 week, 1 month and then monthly for 5 months. Fluorescein angiography and optical coherence tomography were performed at 1 month and 3 months after each injection.
   Results: The mean change in best-corrected visual acuity was -0.06 +/- 0.3 logMAR in 1.25 mg and -0.07 +/- 0.34 in 2.5 mg groups in 3 months (P = 0.9) and -0.06 +/- 0.27 logMAR in 1.25 mg and -0.09 +/- 0.28 in 2.5 mg groups in 5 months (P = 0.6). There was no significant difference in visual acuity between the two groups at any time point during the study. The mean change in foveal thickness was -49 +/- 36 mu in 1.25 mg and -65 +/- 31 mu in 2.5 mg group (P = 0.6). In 2.5 mg group, three cases of vitreous reaction and one case of massive subretinal hemorrhage were observed.
   Conclusion: Intravitreal injection of 2.5 mg bevacizumab has the same efficacy as 1.25 mg, but may be associated with a higher rate of adverse events.
C1 [Modarres, Mehdi; Naseripour, Masood; Falavarjani, Khalil Ghasemi; Nikeghbali, Aminollah; Hashemi, Masih; Parvaresh, Mohammad Mehdi] Iran Univ Med Sci, Eye Res Ctr, Dept Ophthalmol, Tehran, Iran.
C3 Iran University of Medical Sciences
RP Falavarjani, KG (通讯作者)，Rassoul Akram Hosp, Eye Res Ctr, Sattarkhan Niayesh St, Tehran 14455364, Iran.
EM drghasemi@yahoo.com
RI Naseripour, Masood/A-6998-2018; Falavarjani, Khalil Ghasemi/I-4029-2019;
   Naseripour, Masood/P-8976-2018; Modarres, Mehdi/D-2598-2011
OI Naseripour, Masood/0000-0003-1217-3470; Ghasemi Falavarjani,
   Khalil/0000-0001-5221-1844
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chieh JJ, 2007, ANN OPHTHALMOL, V39, P51, DOI 10.1007/BF02697326
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 31
TC 39
Z9 39
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2009
VL 29
IS 3
BP 319
EP 324
DI 10.1097/IAE.0b013e318198148e
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RK
UT WOS:000264306700006
PM 19287288
DA 2022-11-30
ER

PT J
AU Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
   Liu, CC
AF Metelitsina, Tatyana I.
   Grunwald, Juan E.
   DuPont, Joan C.
   Ying, Gui-shuang
   Liu, Chengcheng
TI Effect of viagra on retinal vein diameter in AMD patients
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE sildenafil citrate (viagra); retinal vein diameter; age-related macular
   degeneration (AMD)
ID CHOROIDAL BLOOD-FLOW; MACULAR DEGENERATION; HEALTHY-SUBJECTS;
   SMOOTH-MUSCLE; NITRIC-OXIDE; SILDENAFIL; VASODILATATION; RELAXATION
AB The aim of the present study was to investigate the effect of sildenafil citrate (viagra) on retinal venous diameter in patients with age-related macular degeneration (AMD). We investigated 14 male patients in a double-masked, randomized, placebo-controlled, crossover study. In each subject, one eye with typical non-exudative AMD fundus features was studied. Each of the subjects received 100 mg dose of sildenafil or matching placebo on two separate study visits. Monochromatic fundus photographs were obtained in the study eye before dosing and then 30, 90, 180 and 300 min later. Measurements of the diameter of the major retinal veins from digitized negatives were carried out using "Vessel map" static vessel analysis program (IMEDOS GmbH, Weimar, Germany). Statistical analysis of the data comparing the effect of sildenafil and placebo on venous diameters was performed using analysis of variance (ANOVA) for repeated measures. An analysis of variance (ANOVA) comparing the effects of sildenafil citrate and placebo on retinal vein diameters showed a significant interaction between time and treatment (P = 0.03). In comparison to placebo, sildenafil citrate produced a statistically significant vasodilatation of major retinal veins of 4.7% at 90 min (P = 0.004), 5.5% at 180 min (P < 0.0001) and 5.8% at 300 min (P < 0.0001). At 30 min there was a 2.2% difference, which was not statistically significant (P = 0.14). Our results suggest that in patients with age-related macular degeneration, sildenafil citrate (viagra) produces a statistically significant vasodilatation of major retinal veins that is similar to what has been reported in normal subjects. Whether this vasodilatation is associated with changes in retinal blood flow needs to be further investigated. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Grunwald, JE (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM tanya.metelisina@uphs.upenn.edu; juangrun@mail.med.upenn.edu;
   dupontj@mail.med.upenn.edu; gsying@mail.med.upenn.edu;
   liuch@mail.med.upenn.edu
CR Boolell M, 1996, Int J Impot Res, V8, P47
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495
   GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2002, AM J OPHTHALMOL, V133, P809, DOI 10.1016/S0002-9394(02)01391-0
   IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171
   IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Metelitsina TI, 2005, EXP EYE RES, V81, P159, DOI 10.1016/j.exer.2005.01.017
   Pache M, 2002, BRIT J OPHTHALMOL, V86, P156, DOI 10.1136/bjo.86.2.156
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Polak K, 2003, INVEST OPHTH VIS SCI, V44, P4872, DOI 10.1167/iovs.03-0177
   SATO E, 2005, EYE             0603
NR 16
TC 18
Z9 19
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2006
VL 83
IS 1
BP 128
EP 132
DI 10.1016/j.exer.2005.11.012
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 054WD
UT WOS:000238408400014
PM 16530757
DA 2022-11-30
ER

PT J
AU Hua, J
   Spee, C
   Kase, S
   Rennel, ES
   Magnussen, AL
   Qiu, Y
   Varey, A
   Dhayade, S
   Churchill, AJ
   Harper, SJ
   Bates, DO
   Hinton, DR
AF Hua, Jing
   Spee, Christine
   Kase, Satoru
   Rennel, Emma S.
   Magnussen, Anette L.
   Qiu, Yan
   Varey, Alex
   Dhayade, Sandeep
   Churchill, Amanda J.
   Harper, Steven J.
   Bates, David O.
   Hinton, David R.
TI Recombinant Human VEGF(165)b Inhibits Experimental Choroidal
   Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SPLICE VARIANT;
   DIABETIC-RETINOPATHY; ANGIOGENIC ISOFORMS; VEGF; EXPRESSION;
   PERMEABILITY; THERAPY; RANIBIZUMAB
AB PURPOSE. Vascular endothelial growth factor (VEGF-A) is the principal stimulator of angiogenesis in wet age-related macular degeneration (AMD). However, VEGF-A is generated by alternate splicing into two families, the proangiogenic VEGF-A(xxx) family and the antiangiogenic VEGF-A(xxx)b family. It is the proangiogenic family that is responsible for the blood vessel growth seen in AMD.
   METHODS. To determine the role of antiangiogenic isoforms of VEGF-A as inhibitors of choroidal neovascularization, the authors used a model of laser-induced choroidal neovascularization in the mouse eye and investigated VEGF-A(165)b effects on endothelial cells and VEGFRs in vitro.
   RESULTS. VEGF-A(165)b inhibited VEGF-A(165)-mediated endothelial cell migration with a dose effect similar to that of ranibizumab and bevacizumab and 200-fold more potent than that of pegaptanib. VEGF-A(165)b bound both VEGFR1 and VEGFR2 with affinity similar to that of VEGF-A(165). After laser injury, mice were injected either intraocularly or subcutaneously with recombinant human VEGF-A(165)b. Intraocular injection of rhVEGF-A(165)b gave a pronounced dose-dependent inhibition of fluorescein leakage, with an IC50 of 16 pg/eye, neovascularization (IC50, 0.8 pg/eye), and lesion as assessed by histologic staining (IC50, 8 pg/eye). Subcutaneous administration of 100 mu g twice a week also inhibited fluorescein leakage and neovascularization and reduced lesion size.
   CONCLUSIONS. These results show that VEGF-A(165)b is a potent antiangiogenic agent in a mouse model of age-related macular degeneration and suggest that increasing the ratio of antiangiogenic-to-proangiogenic isoforms may be therapeutically effective in this condition. (Invest Ophthalmol Vis Sci. 2010; 51:4282-4288) DOI:10.1167/iovs.09-4360
C1 [Hua, Jing; Rennel, Emma S.; Magnussen, Anette L.; Qiu, Yan; Varey, Alex; Dhayade, Sandeep; Harper, Steven J.; Bates, David O.] Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs,Bristol Heart Inst, Bristol BS2 8EJ, Avon, England.
   [Spee, Christine; Kase, Satoru; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Churchill, Amanda J.] Univ Bristol, Unit Ophthalmol, Bristol Eye Hosp, Bristol BS2 8EJ, Avon, England.
C3 University of Bristol; University of Southern California; Bristol Eye
   Hospital; University of Bristol
RP Bates, DO (通讯作者)，Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs,Bristol Heart Inst, Southwell St, Bristol BS2 8EJ, Avon, England.
EM dave.bates@bris.ac.uk
RI Varey, Alex/A-8349-2013
OI Varey, Alex/0000-0001-8705-3321; Dhayade, Sandeep/0000-0002-1681-8216;
   Bates, David/0000-0003-4850-2360; Varey, Alexander/0000-0002-7665-8015
FU Wellcome Trust [79736, 69029]; Fight for Sight; British Heart Foundation
   [BS/06/005]; Cancer Research UK [C18064/A5730]; National Eye Research
   Centre; Richard Bright VEGF Research Trust; North Bristol NHS Trust
   Adrian Wright Bequest into Disability in the Elderly; PhiloGene Inc.;
   National Institutes of Health [EY03040]; Arnold and Mabel Beckman
   Foundation; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH
   RePORTER
FX Supported by Wellcome Trust Grants 79736 (JH) and 69029 (YQ), Fight for
   Sight (ER), British Heart Foundation Grant BS/06/005 (DOB), Cancer
   Research UK Grant C18064/A5730 (AHV), the National Eye Research Centre,
   the Richard Bright VEGF Research Trust and the North Bristol NHS Trust
   Adrian Wright Bequest into Disability in the Elderly (AM), PhiloGene
   Inc. (SD), National Institutes of Health Core Grant EY03040, and the
   Arnold and Mabel Beckman Foundation.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054
   Bates DO, 2002, CANCER RES, V62, P4123
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bevan HS, 2008, NEPHRON PHYSIOL, V110, P57, DOI 10.1159/000177614
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cebe-Suarez S, 2008, FASEB J, V22, P3078, DOI 10.1096/fj.08-107219
   Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490
   Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141
   Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619
   EPSTEIN RJ, 1990, CORNEA, V9, P318
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN, 2009, PHAS 3 C 08 STUD AV
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lathi KG, 2001, ANESTH ANALG, V92, P19
   Magnussen AL, 2010, INVEST OPHTH VIS SCI, V51, P4273, DOI 10.1167/iovs.09-4296
   Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   POTGENS AJG, 1994, J BIOL CHEM, V269, P32879
   Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839
   Qiu Y, 2008, FASEB J, V22, P1104, DOI 10.1096/fj.07-9718com
   Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309
   Rennel ES, 2008, EUR J CANCER, V44, P1883, DOI 10.1016/j.ejca.2008.05.027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schumacher VA, 2007, J AM SOC NEPHROL, V18, P719, DOI 10.1681/ASN.2006020124
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Woolard J, 2009, MICROCIRCULATION, V16, P572, DOI 10.1080/10739680902997333
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
NR 47
TC 56
Z9 65
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4282
EP 4288
DI 10.1167/iovs.09-4360
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100062
PM 20237252
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Gunnlaugsdottir, E
   Arnarsson, A
   Jonasson, F
AF Gunnlaugsdottir, Elin
   Arnarsson, Arsaell
   Jonasson, Fridbert
TI Five-year incidence of visual impairment and blindness in older
   Icelanders: the Reykjavik Eye Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; blindness; cataract; geographic
   atrophy; incidence; visual impairment
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; AGE-RELATED MACULOPATHY; COPENHAGEN
   CITY EYE; LOW-VISION; MACULAR DEGENERATION; LENS OPACIFICATION;
   ADULT-POPULATION; SEE PROJECT; PREVALENCE
AB Purpose:
   This study examined age, sex and cause-specific 5-year incidence of visual impairment and blindness in a middle-aged and elderly Icelandic population.
   Methods:
   The study cohort consisted of a population-based, random sample of citizens aged >= 50 years. Of 1379 eligible subjects, 1045 underwent a baseline examination in 1996; 846 of the 958 survivors (88.2%) underwent a 5-year follow-up examination in 2001. All participants underwent an extensive ophthalmological examination including best corrected visual acuity (BCVA) using a Snellen chart. We used World Health Organization (WHO) criteria, which define visual impairment as BCVA in the better eye of < 6/18 and >= 3/60 and blindness as BCVA in the better eye of < 3/60. We also used US criteria, which consider BCVA of < 6/12 and > 6/60 in the better eye to represent visual impairment and BCVA of < 6/60 in the better eye to represent blindness. The causes of incident visual loss in either eye were determined. Deterioration or improvement in vision were defined as a loss or gain of >= 2 Snellen lines.
   Results:
   According to WHO criteria, 5-year incidence of bilateral visual impairment and blindness were 1.07% (95% confidence interval [CI] 0.37-1.76) and 0.35% (95% CI 0.00-0.76), respectively. Using US criteria, equivalent incidence of bilateral visual impairment and blindness were 3.49% (95% CI 2.24-4.74) and 0.95% (95% CI 0.29-1.60), respectively. Age-related macular degeneration and cataract were the major causes of incident visual impairment and blindness.
   Conclusions:
   Incidences of visual impairment and blindness increased significantly with age. Age-related macular degeneration, present in 75% of affected persons, was the most common cause of 5-year incident legal blindness in this middle-aged and elderly Icelandic population.
C1 [Gunnlaugsdottir, Elin; Arnarsson, Arsaell; Jonasson, Fridbert] Univ Iceland, Fac Med, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
   [Arnarsson, Arsaell] Univ Akureyri, Dept Social Sci, Akureyri, Iceland.
C3 University of Iceland; University of Akureyri
RP Jonasson, F (通讯作者)，Univ Eye Dept, IS-101 Reykjavik, Iceland.
EM fridbert@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021
CR Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Foran S, 2003, OPHTHALMOLOGY, V110, P41, DOI 10.1016/S0161-6420(02)01295-2
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Gudmundsdottir E, 2005, OPHTHALMOLOGY, V112, P672, DOI 10.1016/j.ophtha.2004.11.039
   Gudmundsdottir E, 2000, ACTA OPHTHALMOL SCAN, V78, P642, DOI 10.1034/j.1600-0420.2000.078006642.x
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P99
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, EYE, V17, P747, DOI 10.1038/sj.eye.6700374
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Leske MC, 2004, OPHTHALMOLOGY, V111, P118, DOI 10.1016/j.ophtha.2003.04.002
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   *ORG EC COOP DEV, 2007, HLTH GLANC OECD IND
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 38
TC 28
Z9 28
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2010
VL 88
IS 3
BP 358
EP 366
DI 10.1111/j.1755-3768.2008.01445.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589CO
UT WOS:000277122600025
PM 19222399
OA Bronze
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Campanella, J
   Beauchamp, GR
AF Brown, GC
   Brown, MM
   Campanella, J
   Beauchamp, GR
TI The cost-utility of photodynamic therapy in eyes with neovascular
   macular degeneration - A value-based reappraisal with 5-year data
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL-ACUITY; DIABETIC-RETINOPATHY; RECOMMENDATIONS;
   HEALTH
AB PURPOSE: To assess the value conferred by photodynamic therapy (PDT) and the cost,utility of PDT for the treatment of classic, subfoveal choroidal neovascularization associated with age-related macular degeneration (ARMD).
   DESIGN: Average cost-utility analysis utilizing clinical trial data, patient-based time tradeoff utility preferences, and a third party insurer cost perspective.
   METHODS: Five-year visual acuity data from the TAP (Treatment of Age-related Macular Degeneration With Photodynamic Therapy) Investigation were modeled into a 12-year, value,based, reference case, Costa utility model utilizing year 2004 Medicare costs and an outcome of $/QALY (dollars/quality-adjusted life, year). Discounting of outcomes and costs using net present value analysis with a 3% annual rate was performed as recommended by the Panel for Cost, Effectiveness in Health and Medicine.
   RESULTS: PDT with verteporfin (Visudyne) dye for classic subfoveal choroidal neovascularization confers an 8.1% quality of life (value) improvement over the 12-year life expectancy of the reference case, while during the last 8 years the value improvement is 9.5%. The average cost,utility of the intervention is $31,103/ QALY (quality-adjusted life year). Extensive one-way sensitivity analysis values range from $20,736/QALY if treatment efficacy is increased by 50% to $62,207 if treatment efficacy is decreased by 50%, indicating robustness of the model.
   CONCLUSIONS: PDT using verteporfin dye to treat classic subfoveal choroidal neovascularization is a very cost-effective treatment by conventional standards. The marked improvement in cost effectiveness compared with a previous report results from the facts that the treatment benefit increasingly accrues during 5 years of follow-up while the number of yearly treatments diminishes markedly during that time. (Am J Ophthalmol 2005;140:679-687. (c) 2005 by Elsevier Inc. All rights reserved).
C1 Ctr Value Based Med, Flourtown, PA 19031 USA.
   Wills Eye Hosp & Res Inst, Jefferson Med Coll, Retina Serv, Philadelphia, PA USA.
   Univ Penn, Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   Eye Res Inst, Philadelphia, PA USA.
   Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   Univ Texas, SW Med Ctr, Dallas, TX 75230 USA.
C3 Jefferson University; University of Pennsylvania; University of
   Pennsylvania; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas
RP Brown, GC (通讯作者)，Ctr Value Based Med, Box 335, Flourtown, PA 19031 USA.
EM gbrown@valuebasedmedicine.com
CR Arias Elizabeth, 2004, Natl Vital Stat Rep, V52, P1
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   BROWN GC, IN PRESS CURR OPIN O
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   BROWN MM, 2005, VALUE BASED MED EVID
   *CTR MED MED SERV, 2004, Q DRUG FREE UPD
   DAMODARAN A, 1997, CORPORATE FINANCE TH, P37
   DRUMMOND MF, 2000, METHODS EC EVALUATIO, P139
   ELLWEIN EB, STAT DAT UPD HU 1981
   *FDA, 2005, REC MARK WITHDR SAF
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heudebert GR, 2000, J GEN INTERN MED, V15, P175, DOI 10.1046/j.1525-1497.2000.02639.x
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Kallmes DF, 1997, AM J NEURORADIOL, V18, P1453
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307
   *MAC PHOT STUD GRO, 1993, ARCH OPHTHALMOL-CHIC, V107, P1374
   Realini T, 2002, OPHTHALMOLOGY, V109, P1955, DOI 10.1016/S0161-6420(02)01437-9
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253
NR 43
TC 55
Z9 57
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2005
VL 140
IS 4
BP 679
EP 687
DI 10.1016/j.ajo.2005.04.061
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 975YD
UT WOS:000232699100015
PM 16226519
DA 2022-11-30
ER

PT J
AU Chieh, JJ
   Stinnett, SS
   Toth, CA
AF Chieh, Janet J.
   Stinnett, Sandra S.
   Toth, Cynthia A.
TI CENTRAL AND PERICENTRAL RETINAL SENSITIVITY AFTER MACULAR TRANSLOCATION
   SURGERY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration
ID SCANNING LASER OPHTHALMOSCOPE; PIGMENT EPITHELIAL TEAR; FUNDUS
   PERIMETRY; VISUAL FUNCTION; CHOROIDAL NEOVASCULARIZATION; 360-DEGREE
   RETINOTOMY; DEGENERATION; FOVEA
AB Purpose: To evaluate the separate contribution of the retina versus retinal pigment epithelium (RPE)-choriocapillaris to visual function after treatment of neovascular age-related macular degeneration by measuring retinal sensitivity across three areas after macular translocation surgery.
   Methods: Using the Nidek microperimeter-1, we tested retinal sensitivity across three areas in 35 patients after macular translocation surgery. Microperimetry scores ranged from -2 (no response to brightest stimulus) to 20 (response with 20 dB neutral density filtering). Median retinal sensitivity score (MRSS) for the central 10-degrees (Area 1, fovea translocated over healthier RPE) was compared with acuity, reading speed and MRSS of adjacent areas: Area 2, retina over site of choroidal neovascularization removal and Area 3, retina over undisturbed RPE.
   Results: In 27 of 35 eyes in this study (77%), the MRSS for Area 1, was greater than Area 2. Area 1 was a median of 3.0 decibels (dB) greater in sensitivity (range, 16 greater-2 lower) than Area 2 (P <= 0.001), and 5.0 dB lower (range, 2 greater-12 lower) than Area 3 (P : 0.001). The median of the MRSS (25th/75th percentile) for Areas 1, 2 and 3 were 2.0 (0.0/6.0), -2.0 (-2.0/-2.0) and 9 (4.0/12.0), respectively. The MRSS for Area 1 correlated with reading speed more than with acuity.
   Conclusions: Sensitivity of the translocated macula was significantly greater than in Area 2, retina over abnormal RPE-choriocapillaris, suggesting that disturbed RPE-choriocapillaris significantly limits retinal function. Area 1 sensitivity was lower than in retina unaffected by age-related macular degeneration over undisturbed RPE, suggesting that persisting retinal dysfunction can limit vision recovery.
C1 [Chieh, Janet J.; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Stinnett, Sandra S.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA.
   [Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Biomed Engn, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Room 107,Erwin Rd,POB 3802, Durham, NC 27710 USA.
EM toth004@mc.duke.edu
FU Euan and Angelica Baird; Lions Club of Danville, Virginia
FX Supported partially by Euan and Angelica Baird: and The Lions Club of
   Danville, Virginia.
CR Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Fine EM, 1999, VISION RES, V39, P747, DOI 10.1016/S0042-6989(98)00142-4
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Iijima H, 1999, RETINA-J RET VIT DIS, V19, P198, DOI 10.1097/00006982-199905000-00004
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   Yoshitani S, 2003, OPHTHALMIC SUR LA IM, V34, P217, DOI 10.3928/1542-8877-20030501-12
NR 15
TC 9
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1522
EP 1529
DI 10.1097/IAE.0b013e318186c634
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373LH
UT WOS:000260972600020
PM 18827740
DA 2022-11-30
ER

PT J
AU Sripathi, SR
   Hu, MW
   Turaga, RC
   Mertz, J
   Liu, MM
   Wan, J
   Maruotti, J
   Wahlin, KJ
   Berlinicke, CA
   Qian, J
   Zack, DJ
AF Sripathi, Srinivasa R.
   Hu, Ming-Wen
   Turaga, Ravi Chakra
   Mertz, Joseph
   Liu, Melissa M.
   Wan, Jun
   Maruotti, Julien
   Wahlin, Karl J.
   Berlinicke, Cynthia A.
   Qian, Jiang
   Zack, Donald J.
TI Proteome Landscape of Epithelial-to-Mesenchymal Transition (EMT) of
   Retinal Pigment Epithelium Shares Commonalities With
   Malignancy-Associated EMT
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CANCER; EXPRESSION; CELLS; PATHWAY; RPE;
   SNAIL; TMT; OVEREXPRESSION; PROLIFERATION
AB Stress and injury to the retinal pigment epithelium (RPE) often lead to dedifferentiation and epithelial-to-mesenchymal transition (EMT). These processes have been implicated in several retinal diseases, including proliferative vitreoretinopathy, diabetic retinopathy, and age-related macular degeneration. Despite the importance of RPE-EMT and the large body of data characterizing malignancy-related EMT, comprehensive proteomic studies to define the protein changes and pathways underlying RPE-EMT have not been reported. This study sought to investigate the temporal protein expression changes that occur in a human-induced pluripotent stem cell-based RPE-EMT model. We utilized multiplexed isobaric tandem mass tag labeling followed by high-resolution tandem MS for precise and in-depth quantification of the RPE-EMT proteome. We have identified and quantified 7937 protein groups in our tandem mass tag-based MS analysis. We observed a total of 532 proteins that are differentially regulated during RPE-EMT. Furthermore, we integrated our proteomic data with prior transcriptomic (RNA-Seq) data to provide additional insights into RPE-EMT mechanisms. To validate these results, we have performed a label-free single-shot data-independent acquisition MS study. Our integrated analysis indicates both the commonality and uniqueness of RPE-EMT compared with malignancy-associated EMT. Our comparative analysis also revealed that multiple age-related macular degeneration-associated risk factors are differentially regulated during RPE-EMT. Together, our integrated dataset provides a comprehensive RPE-EMT atlas and resource for understanding the molecular signaling events and associated biological pathways that underlie RPE-EMT onset. This resource has already facilitated the identification of chemical modulators that could inhibit RPE-EMT, and it will hopefully aid in ongoing efforts to develop EMT inhibition as an approach for the treatment of retinal disease.
C1 [Sripathi, Srinivasa R.; Hu, Ming-Wen; Mertz, Joseph; Liu, Melissa M.; Berlinicke, Cynthia A.; Qian, Jiang; Zack, Donald J.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Stem Cell Ocular Regenerat Med Ctr,Wilmer Eye Ins, Baltimore, MD 21205 USA.
   [Turaga, Ravi Chakra] Caris Life Sci, Res & Dev, Tempe, AZ USA.
   [Wan, Jun] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Maruotti, Julien] Phenocell, Res & Dev, Grasse, France.
   [Wahlin, Karl J.] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Dept Mol Biol & Genet,Dept Genet Med, Baltimore, MD 21205 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Inst NanoBioTechnol, Whiting Sch Engn Baltimore, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Indiana University System; Indiana University
   Bloomington; University of California System; University of California
   San Diego; Johns Hopkins University; Johns Hopkins University
RP Sripathi, SR; Zack, DJ (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Stem Cell Ocular Regenerat Med Ctr,Wilmer Eye Ins, Baltimore, MD 21205 USA.; Zack, DJ (通讯作者)，Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Dept Mol Biol & Genet,Dept Genet Med, Baltimore, MD 21205 USA.; Zack, DJ (通讯作者)，Johns Hopkins Univ, Inst NanoBioTechnol, Whiting Sch Engn Baltimore, Baltimore, MD 21205 USA.
EM ssripat1@jhmi.edu; dzack@jhmi.edu
RI TURAGA, RAVI C/B-5559-2009; Wan, Jun/H-7132-2013
OI TURAGA, RAVI C/0000-0001-9075-7645; Liu, Melissa/0000-0002-4385-9507;
   Wahlin, Karl/0000-0002-0494-8304; Wan, Jun/0000-0001-9286-6562; Mertz,
   Joseph/0000-0003-3158-809X
FU Maryland Stem Cell Research Fund; Knights Templar Eye Foundation; Edward
   N. & Della L. Thome Memorial Foundation; Research to Prevent Blindness;
   Foundation Fighting Blindness; Bright-Focus Foundation; National
   Institutes of Health [P30EY001765]; Guerrieri Family Foundation
FX We thank Raja Sekhar Nirujogi (MRC PPU, University of Dundee) for
   fruitful discussion and critical reading of the article. We thank Robert
   O'Meally, Robert Cole (Johns Hopkins Mass Spectrometry and Proteomics
   Facility), Brendan Lilley, Madhu Sudhana Saddala, Xitiz Chamling, Pingwu
   Zhang, Bibhudatta Mishra, Claire Bell, Rebakah Mikeasky, Wan Jin Jahng
   (American University of Nigeria), James T. Handa, Noriko Esumi, Debasish
   Sinha, and Hui Zhang (Johns Hopkins University School of Medicine) for
   their insightful suggestions and discussion. We also thankfully
   acknowledge generous funding from Maryland Stem Cell Research Fund,
   Knights Templar Eye Foundation, Edward N. & Della L. Thome Memorial
   Foundation, Research to Prevent Blindness, Foundation Fighting
   Blindness, Bright-Focus Foundation, National Institutes of Health
   (P30EY001765), and the Guerrieri Family Foundation. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003
   Bekker-Jensen DB, 2017, CELL SYST, V4, P587, DOI 10.1016/j.cels.2017.05.009
   Beranova-Giorgianni S, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6020022
   Bhise NS, 2013, INT J NANOMED, V8, P4641, DOI 10.2147/IJN.S53830
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Boles NC, 2020, STEM CELL REP, V14, P631, DOI 10.1016/j.stemcr.2020.03.009
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Brenes A, 2019, BIOINFORMATICS, V35, P1441, DOI 10.1093/bioinformatics/bty823
   Cai YQ, 2018, J CANCER, V9, P521, DOI 10.7150/jca.22355
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X
   D'Angelo E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01122
   Damle NP, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz133
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374
   Dou CW, 2019, ONCOGENE, V38, P1239, DOI 10.1038/s41388-018-0505-8
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Eid S, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-016-1433-7
   Erdjument-Bromage H, 2018, METHODS MOL BIOL, V1741, P135, DOI 10.1007/978-1-4939-7659-1_11
   Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gervasi M, 2012, J CELL BIOL, V196, P589, DOI 10.1083/jcb.201109045
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Gruenbacher G, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00394
   He H, 2017, SCI REP-UK, V7, DOI 10.1038/srep43736
   He SK, 2010, INVEST OPHTH VIS SCI, V51, P543, DOI 10.1167/iovs.09-3475
   Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2
   Huang FK, 2017, J PROTEOME RES, V16, P1121, DOI 10.1021/acs.jproteome.6b00374
   Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238
   Huang J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3875-3
   Hyakusoku H, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0284-4
   Iwadate Y, 2016, ONCOL LETT, V11, P1615, DOI 10.3892/ol.2016.4113
   Jiang LH, 2020, CELL, V183, P269, DOI 10.1016/j.cell.2020.08.036
   Jiang SY, 2019, CANCER RES, V79, P3063, DOI 10.1158/0008-5472.CAN-18-3295
   Jin HY, 2019, THERANOSTICS, V9, P265, DOI 10.7150/thno.27246
   Kagiali ZCU, 2019, MOL CELL PROTEOMICS, V18, P1756, DOI 10.1074/mcp.RA119.001446
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Khan MI, 2016, AM J PHYSIOL-RENAL, V311, pF424, DOI 10.1152/ajprenal.00138.2016
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Liu WG, 2017, ONCOTARGET, V8, P74962, DOI 10.18632/oncotarget.20472
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586
   Masuda T, 2010, J BIOL CHEM, V285, P26933, DOI 10.1074/jbc.M110.130294
   Matsumoto E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212369
   McAlister GC, 2012, ANAL CHEM, V84, P7469, DOI 10.1021/ac301572t
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nirujogi RS, 2021, BIOCHEM J, V478, P299, DOI 10.1042/BCJ20200930
   Nirujogi RS, 2015, PROTEOMICS, V15, P487, DOI 10.1002/pmic.201400371
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Palma CD, 2016, MOL CELL PROTEOMICS, V15, P906, DOI 10.1074/mcp.M115.052910
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Priglinger CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146887
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Ramesh V, 2020, TRENDS CANCER, V6, P942, DOI 10.1016/j.trecan.2020.06.005
   Ribatti D, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100773
   Saika Shizuya, 2009, Front Biosci (Schol Ed), V1, P376, DOI 10.2741/e32
   Seol HS, 2014, CANCER LETT, V353, P232, DOI 10.1016/j.canlet.2014.07.019
   Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Shukla S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/7852742
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sripathi SR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.1
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Sun YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1350-6
   Swarup A, 2019, AM J PHYSIOL-CELL PH, V316, pC121, DOI 10.1152/ajpcell.00410.2018
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Tyanova S, 2018, METHODS MOL BIOL, V1711, P133, DOI 10.1007/978-1-4939-7493-1_7
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vallejo A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14294
   Wang CH, 2017, CELL PHYSIOL BIOCHEM, V42, P729, DOI 10.1159/000477890
   Wang KX, 2018, ONCOGENE, V37, P5340, DOI 10.1038/s41388-018-0311-3
   Wehde BL, 2018, CELL REP, V25, P2192, DOI 10.1016/j.celrep.2018.10.063
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   Wisniewski JR, 2014, MOL CELL PROTEOMICS, V13, P3497, DOI 10.1074/mcp.M113.037309
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9
   Yang S, 2015, DISCOV MED, V20, P207
   Zecha J, 2019, MOL CELL PROTEOMICS, V18, P1468, DOI 10.1074/mcp.TIR119.001385
   Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013
   Zhou B, 2016, CANCER LETT, V382, P11, DOI 10.1016/j.canlet.2016.08.017
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhu LF, 2012, LAB INVEST, V92, P744, DOI 10.1038/labinvest.2012.8
   Zhu QC, 2013, ASIAN PAC J CANCER P, V14, P2689, DOI 10.7314/APJCP.2013.14.5.2689
NR 100
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PY 2021
VL 20
AR 100131
DI 10.1016/j.mcpro.2021.100131
PG 19
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA UX3BO
UT WOS:000700718900001
PM 34455105
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arias, L
   Roman, I
   Masuet-Aumatell, C
   Rubio, MJ
   Caminal, JM
   Catala, J
   Pujol, O
AF Arias, Luis
   Roman, Isabel
   Masuet-Aumatell, Cristina
   Rubio, Marcos J.
   Caminal, Josep M.
   Catala, Jaume
   Pujol, Octavio
TI ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN
   MACULAR DEGENERATION Relationship with the Number of Injections
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; flexible
   regimen; intravitreal ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY
AB Purpose: To evaluate the efficacy and safety of a flexible regimen with intravitreal injections of ranibizumab in patients with naive choroidal neovascularization secondary to age-related macular degeneration and to determine whether the final outcome is related to the number of injections.
   Methods: Prospective, noncomparative, consecutive case series study. We included 90 eyes of 88 patients that were initially treated with 3 consecutive monthly intravitreal injections of ranibizumab, and thereafter, follow-up visits were progressively spread out to a maximum of 8 weeks apart in the absence of visual acuity loss and signs of lesion activity. The primary end points were changes in visual acuity (Early Treatment Diabetic Retinopathy Study letters), foveal thickness measured by spectral-domain optical coherence tomography, and lesion size (LS) measured by fluorescein angiography.
   Results: The median visual acuity improved from 53 letters at baseline to 60 letters at Month 1 (P < 0.0001), 63 letters at Month 3 (P < 0.0001), and 60 letters at Month 12 (P < 0.0001). A significant reduction was also observed in foveal thickness and LS (P < 0.0001). The mean number of injections was 4.4, and the mean number of visits was 8.0. Treatment consisted of 3 injections for 40% of patients, and 60% of patients received more than 3 injections. No significant association was observed between the visual acuity improvement and the number of injections. No relevant side effects were observed.
   Conclusion: A flexible regimen with ranibizumab therapy is efficacious and safe in patients with neovascular age-related macular degeneration, reducing both the burden of injections and follow-up visits. The visual acuity improvement was independent of the number of injections. RETINA 31: 1261-1267, 2011
C1 [Arias, Luis; Rubio, Marcos J.; Caminal, Josep M.; Catala, Jaume; Pujol, Octavio] Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona 08907, Spain.
   [Roman, Isabel; Masuet-Aumatell, Cristina] Bellvitge Univ Hosp, Dept Prevent Med, Barcelona 08907, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Institut d'Investigacio
   Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital;
   University of Barcelona
RP Arias, L (通讯作者)，Bellvitge Univ Hosp, Dept Ophthalmol, C Feixa Llarga Sn, Barcelona 08907, Spain.
EM luisarias@telefonica.net
RI Masuet-Aumatell, Cristina/E-5028-2017; Rubio Caso, Marcos
   Javier/L-6866-2013
OI Masuet-Aumatell, Cristina/0000-0001-7000-7345; Rubio Caso, Marcos
   Javier/0000-0002-7072-9855; Caminal, JM/0000-0001-9563-0344; ARIAS,
   LUIS/0000-0001-7041-5576
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gómez-Ulla F., 2009, Arch Soc Esp Oftalmol, V84, P377
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
NR 17
TC 20
Z9 20
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2011
VL 31
IS 7
BP 1261
EP 1267
DI 10.1097/IAE.0b013e318207d152
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 794CA
UT WOS:000292871700005
PM 21499194
DA 2022-11-30
ER

PT J
AU Xu, L
   You, QS
   Jonas, JB
AF Xu, Liang
   You, Qi Sheng
   Jonas, Jost B.
TI Refractive error, ocular and general parameters and ophthalmic diseases.
   The Beijing Eye Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Refractive error; Hyperopia; Myopia; Intraocular pressure; Age-related
   macular degeneration; Open-angle glaucoma; Angle-closure glaucoma;
   Trachoma; Pterygium; Diabetic retinopathy; Beijing Eye Study
ID AGE-RELATED MACULOPATHY; RISK-FACTORS; INTRAOCULAR-PRESSURE; ADULT
   CHINESE; ATHEROSCLEROSIS RISK; RURAL-POPULATION; ANTERIOR-CHAMBER; VEIN
   OCCLUSION; NORTHERN CHINA; PREVALENCE
AB To assess relationships between refractive error and ocular and general parameters.
   The Beijing Eye Study is a population-based study which included 4,439 Chinese subjects examined in 2001, with a follow-up examination in 2006, in which 3,251 (73.2%) subjects participated.
   In multivariate regression analysis, increasing (hyperopic) refractive error was significantly associated with the systemic parameters of higher age (P < 0.001), rural region (P < 0.001), lower education level (P = 0.004), higher frequency of ever smoking (P = 0.02), and higher body mass index (P = 0.02). Adjusted for the systemic parameters, increasing (hyperopic) refractive error was significantly associated with higher best-corrected visual acuity (P < 0.001), lower anterior chamber depth (P < 0.001) and narrower chamber angle (P < 0.001), lower intraocular pressure (P = 0.001), lower amount of nuclear cataract (P = 0.007), smaller beta zone of parapapillary atrophy (P < 0.001), a lower prevalence of open-angle glaucoma (P = 0.01), and a higher prevalence of age-related macular degeneration (P = 0.04). Refractive error was not significantly (P > 0.05) associated with the prevalence of trachoma, non-glaucomatous optic nerve damage, and retinal vein occlusions, nor with mortality.
   In the adult Chinese population, hyperopic subjects compared with myopic subjects were older, lived predominately in the rural regions, had a lower level of education, smoked more, and were more obese. In addition, the hyperopic subjects had a lower intraocular pressure, a higher best-corrected visual acuity, a shallower anterior chamber depth and narrower anterior chamber angle, lower amount of nuclear cataract, smaller beta zone of parapapillary atrophy, a lower prevalence of open-angle glaucoma, and a higher prevalence of age-related macular degeneration.
C1 [Xu, Liang; You, Qi Sheng; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou St, Beijing 100005, Peoples R China.
EM xlbio@yahoo.cn
RI You, Qisheng/AAG-7153-2020; You, Qisheng/A-3619-2014
OI You, Qisheng/0000-0003-0743-7320; You, Qisheng/0000-0003-0743-7320
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Ophthalmology, V98, P786
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cheng CY, 2003, INVEST OPHTH VIS SCI, V44, P4630, DOI 10.1167/iovs.03-0169
   CHEW S J, 1988, SMJ Singapore Medical Journal, V29, P201
   CHOW Y C, 1990, SMJ Singapore Medical Journal, V31, P472
   Dandona R, 1999, INVEST OPHTH VIS SCI, V40, P2810
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EONG KGA, 1998, SINGAP MED J, V34, P480
   Hosaka A, 1988, Acta Ophthalmol Suppl, V185, P37
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   HYAMS SW, 1977, BRIT J OPHTHALMOL, V61, P428, DOI 10.1136/bjo.61.6.428
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334
   Kawase K, 2008, BRIT J OPHTHALMOL, V92, P1175, DOI 10.1136/bjo.2007.128819
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   Lin L L, 1988, Acta Ophthalmol Suppl, V185, P29
   Lin LLK, 1999, OPTOMETRY VISION SCI, V76, P275, DOI 10.1097/00006324-199905000-00013
   Lin LLK, 2001, J FORMOS MED ASSOC, V100, P684
   LING S L, 1987, SMJ Singapore Medical Journal, V28, P288
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Memarzadeh F, 2008, AM J OPHTHALMOL, V146, P69, DOI 10.1016/j.ajo.2008.03.015
   Mitchell P, 1999, OPHTHALMOLOGY, V106, P2010, DOI 10.1016/S0161-6420(99)90416-5
   NANGIA V, 2009, OPHTHALMOLO IN PRESS
   Saw S M, 2001, Ophthalmic Epidemiol, V8, P227, DOI 10.1076/opep.8.4.227.1609
   Saw SM, 1996, EPIDEMIOL REV, V18, P175, DOI 10.1093/oxfordjournals.epirev.a017924
   Saw SM, 2002, INVEST OPHTH VIS SCI, V43, P3174
   SAWADA A, 2008, OPHTHALMOLOGY, V115
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Van Newkirk M R, 1997, Trans Am Ophthalmol Soc, V95, P715
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wang S, 2006, OPHTHALMOLOGY, V113, P1752, DOI 10.1016/j.ophtha.2006.05.019
   WANG YX, 2009, ACTA OPHTHA IN PRESS
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Wong TY, 2003, OPHTHALMOLOGY, V110, P211, DOI 10.1016/S0161-6420(02)01260-5
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Wu HM, 2001, OPTOMETRY VISION SCI, V78, P234, DOI 10.1097/00006324-200104000-00012
   Wu SY, 1999, INVEST OPHTH VIS SCI, V40, P2179
   Xu L, 2005, AM J OPHTHALMOL, V140, P913, DOI 10.1016/j.ajo.2005.04.050
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 49
TC 11
Z9 14
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2010
VL 248
IS 5
BP 721
EP 729
DI 10.1007/s00417-009-1233-0
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 575ML
UT WOS:000276071100014
PM 19937051
DA 2022-11-30
ER

PT J
AU Barbazetto, I
   Burdan, A
   Bressler, NM
   Bressler, SB
   Haynes, L
   Kapetanios, AD
   Lukas, J
   Olsen, K
   Potter, M
   Reaves, A
   Rosenfeld, P
   Schachat, AP
   Strong, HA
   Wenkstern, A
   Burdan, M
   Reaves, D
AF Barbazetto, I
   Burdan, A
   Bressler, NM
   Bressler, SB
   Haynes, L
   Kapetanios, AD
   Lukas, J
   Olsen, K
   Potter, M
   Reaves, A
   Rosenfeld, P
   Schachat, AP
   Strong, HA
   Wenkstern, A
   Burdan, M
   Reaves, D
TI Photodynamic therapy of subfoveal choroidal neovascularization with
   verteporfin - Fluorescein angiographic guidelines for evaluation and
   treatment - TAP and VIP report no. 2
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; MACULAR DEGENERATION; PHOTOCOAGULATION;
   LESIONS; OCCULT
AB Objective: To describe fluorescein angiographic guidelines for the use of verteporfin therapy in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or other conditions based on 2-year vision outcomes from the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation and Verteporfin in Photodynamic Therapy (VIP) Trial.
   Methods: Three multicenter, double-masked, placebo-controlled randomized clinical trials at 28 ophthalmology clinical centers in Europe and North America involving prospectively identified patients with best-corrected visual acuity (Snellen equivalent) of approximately 20/20 to 20/200, subfoveal CNV secondary to AMD or pathologic myopia with evidence of CNV, and a lesion greatest linear dimension of 5400 mum or less. Fluorescein angiography was to be performed on all patients at enrollment and at regular 3-month follow-up visits through 2 years. The initial treatment laser spot size and all subsequent treatment decisions were based on the investigator's interpretation of these fluorescein angiograms. Photographic materials forwarded to the Wilmer Photograph Reading Center were reviewed by masked graders.
   Main Outcome Measures: Baseline angiographic features, including lesion composition and size, morphologic response to treatment during follow-up (eg, absence of leakage), and reliability (K values) of grading selected characteristics based on a 10% regrading of baseline visits.
   Results: Terms and examples of different lesions and lesion components are provided to assist recognition of fluorescein angiographic characteristics of choroidal neovascular lesions that were important in determining when and where to apply verteporfin therapy. The K statistics for agreement of identification of lesion characteristics by the Wilmer Photograph Reading Center for these trials ranged from 0.70 to 0.85.
   Conclusions: Ophthalmologists should consider interpreting fluorescein angiographic images of subfoveal lesions with terms provided to follow recommendations regarding which patients are most likely to benefit from verteporfin therapy based on results from the TAP Investigation and VIP Trial.
C1 Novartis Ophthalm Inc, Med Informat, Duluth, GA 30097 USA.
   Med Univ Lubeck, Klin Augenheilkunde, D-23538 Lubeck, Germany.
   Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
   QLT Inc, Vancouver, BC, Canada.
   Hop Cantonal Geneva, CH-1211 Geneva, Switzerland.
   Allgemeines Krankenhaus Wien, Klin Augenheilkunde & Optometrie, Vienna, Austria.
   Retina Vitreus Consultants, Pittsburgh, PA USA.
   Univ British Columbia, Vancouver Gen Hosp, Eye Care Ctr, Vancouver, BC V5Z 1M9, Canada.
   Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33152 USA.
C3 Novartis; University of Lubeck; Johns Hopkins University; University of
   Geneva; University of British Columbia; Bascom Palmer Eye Institute;
   University of Miami
RP Bressler, SB (通讯作者)，Novartis Ophthalm Inc, Med Informat, 11695 Johns Creek Pkwy, Duluth, GA 30097 USA.
RI Wenkstern, Andrea/AAV-5035-2021
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Ladd BS, 2001, AM J OPHTHALMOL, V132, P659, DOI 10.1016/S0002-9394(01)01198-9
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *TREATM AG REL MAC, IN PRESS AM J OPHTHA
   2002, RETINA, V22, P6
NR 13
TC 174
Z9 188
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2003
VL 121
IS 9
BP 1253
EP 1268
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 721QT
UT WOS:000185327600005
PM 12963608
DA 2022-11-30
ER

PT J
AU You, QS
   Choy, BKN
   Chan, JCH
   Ng, ALK
   Shih, KRC
   Cheung, JJC
   Wong, JKW
   Shum, JWH
   Ni, MHY
   Lai, JS
   Leung, GM
   Wong, TY
   Wong, IYH
AF You, Qi Sheng
   Choy, Bonnie K. N.
   Chan, Jonathan C. H.
   Ng, Alex L. K.
   Shih, Kendrick C.
   Cheung, Janice J. C.
   Wong, Jasper K. W.
   Shum, Jennifer W. H.
   Ni, Michael Y.
   Lai, Jimmy Sm
   Leung, Gabriel M.
   Wong, Tien Yin
   Wong, Ian Y. H.
TI Prevalence and Causes of Visual Impairment and Blindness among Adult
   Chinese in Hong Kong - The Hong Kong Eye Study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Hong Kong; prevalence; eye diseases; visual impairment; cataract
ID VISION IMPAIRMENT; POPULATION; URBAN; CLASSIFICATION; GLAUCOMA;
   DISTANCE; ACUITY
AB Purpose: To investigate the prevalence, associations, and causes of visual impairment and blindness in the adult population of Hong Kong. Methods: This cross-sectional population-based study included 2018 (870, 43% male) randomly selected adults with a mean age 52 +/- 16 years (range 18-90 years) in Hong Kong. Each participant underwent comprehensive ophthalmic examinations. Presenting visual acuity (PVA) and best-corrected visual acuity (BCVA) of each eye was recorded. Prevalence of visual impairment and blindness was calculated using both World Health Organization (WHO) and United States (US) definitions, based on BCVA and PVA. Results: Visual acuity measurements were available for 1952 (96.8%) participants. The prevalence of visual impairment, based on BCVA value, using WHO and US definition, was 1.0 +/- 0.1% and 2.7 +/- 0.4%, respectively. The prevalence of visual impairment, based on PVA value, was 5.1 +/- 0.5% and 14.0 +/- 0.8%, using WHO and US definition, respectively. Multivariate analysis demonstrated the presence of visual impairment (PVA, WHO definition) increased significantly with older age (odds ratio 1.039, P < .001) and thinner central cornea thickness (odds ratio 0.994, P = .014), but not significantly associated with other socioeconomic, systemic or ocular parameters after adjusting for age and central corneal thickness. Under-correction of refractive error was the most common reason for presenting visual impairment. Causes of impaired BCVA were cataract (37%), age-related macular degeneration (26%), diabetic macular edema (11%), glaucoma (11%), epiretinal membrane (5%), and unknown (11%). Conclusion: The prevalence of visual impairment in Hong Kong increased significantly with older age and thinner central corneal thickness. The major causes for impairment were under-correction of refractive error, cataract, and age-related macular degeneration.
C1 [You, Qi Sheng; Choy, Bonnie K. N.; Chan, Jonathan C. H.; Ng, Alex L. K.; Shih, Kendrick C.; Cheung, Janice J. C.; Wong, Jasper K. W.; Shum, Jennifer W. H.; Lai, Jimmy Sm; Wong, Ian Y. H.] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.
   [You, Qi Sheng] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, WA USA.
   [Ni, Michael Y.; Leung, Gabriel M.] Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Wong, Tien Yin] Singapore Natl Eye Ctr, Dept Ophthalmol, Singapore, Singapore.
   [Wong, Ian Y. H.] Hong Kong Sanat & Hosp, Dept Ophthalmol, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; Singapore National Eye
   Center
RP Wong, IYH (通讯作者)，Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.
EM ianyhwong@gmail.com
RI You, Qisheng/AAG-7153-2020; Chan, Jonathan/ABE-6588-2020; Wong, Tien
   Yin/AAC-9724-2020; Shih, Kendrick Co/E-9883-2010
OI You, Qisheng/0000-0003-0743-7320; Chan, Jonathan/0000-0002-0177-8178;
   Wong, Tien Yin/0000-0002-8448-1264; Shih, Kendrick
   Co/0000-0001-6255-2941; Leung, Gabriel/0000-0002-2503-6283
FU Jessie & George Ho Charitable Foundation - Hong Kong Jockey Club
   Charities Trust
FX The present study is part of the `Chloe Ho Safeguarding Vision
   Initiative' and was funded by the Jessie & George Ho Charitable
   Foundation. It was also funded by the Hong Kong Jockey Club Charities
   Trust, which funded the establishment of the FAMILY cohort from 2007 to
   2014. The funding organization had no role in the design or conduct of
   this research.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foreman J, 2018, JAMA OPHTHALMOL, V136, P240, DOI 10.1001/jamaophthalmol.2017.6457
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Kahloun R, 2019, BRIT J OPHTHALMOL, V103, P863, DOI 10.1136/bjophthalmol-2018-312068
   Keeffe JE, 2019, BRIT J OPHTHALMOL, V103, P878, DOI 10.1136/bjophthalmol-2018-311946
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Lee JWY, 2014, CLIN OPHTHALMOL, V8, P1987, DOI 10.2147/OPTH.S70903
   Leung GM, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyu257
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Saw SM, 2004, OPHTHALMOLOGY, V111, P2168, DOI 10.1016/j.ophtha.2004.05.032
   SHUM JWH, 2016, MEDICINE, V95
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Varma R, 2016, JAMA OPHTHALMOL, V134, P785, DOI 10.1001/jamaophthalmol.2016.1261
   Wang XZ, 2014, OPHTHALMOLOGY, V121, P1837, DOI 10.1016/j.ophtha.2014.03.017
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   You QS, 2011, OPHTHALMOLOGY, V118, P1069, DOI 10.1016/j.ophtha.2010.09.032
   Zhao JL, 2019, AM J OPHTHALMOL, V197, P80, DOI 10.1016/j.ajo.2018.09.011
NR 30
TC 9
Z9 9
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD SEP 2
PY 2020
VL 27
IS 5
BP 354
EP 363
DI 10.1080/09286586.2020.1755444
EA APR 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA2ZD
UT WOS:000527577800001
PM 32310706
DA 2022-11-30
ER

PT J
AU McMonnies, CW
AF McMonnies, Charles W.
TI Hyperbaric oxygen therapy and the possibility of ocular complications or
   contraindications
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE eye disease; hyperbaric oxygen therapy; oxidative stress
ID OXIDATIVE STRESS; ULTRAVIOLET-RADIATION; ANTIOXIDANT STATUS; NUCLEAR
   CATARACT; EXPOSURE; EPITHELIUM; EFFICACY; DISEASES; TENSION; BRAIN
AB Hyperbaric oxygen therapy increases oxygen pressure and the concentration of reactive oxygen species in blood and tissues. Increased oxygen pressure may be beneficial in some diseases, such as in the treatment of diabetic leg ulcers and diabetic retinopathy; however, due to their cytotoxic properties, an excess of reactive oxygen species in tissues and/or deficiencies in antioxidant activity, may contribute to complications of hyperbaric oxygen therapy, such as cataract. This review examines the possibility that increased tissue concentrations of reactive oxygen species may also exacerbate other ocular diseases. For example, reactive oxygen species and deficiencies in antioxidant activities contribute to the pathogenetic processes in keratoconus. Such impact may be exacerbated by exposure to additional reactive oxygen species during hyperbaric oxygen therapy. The senescent eye may be particularly prone to oxidative damage as exemplified by conditions such as macular degeneration and cataract. Because of its high consumption of oxygen, the retina is particularly susceptible to oxidative stress, which plays a major role in retinopathy. For example, under normal conditions age-related macular degeneration involves oxidative stress and death of the retinal pigment epithelial cells. Hyperbaric oxygen therapy may exacerbate these processes. In addition to cataract, age-related macular degeneration and keratoconus, there may be other ocular diseases for which exposure to hyperbaric oxygen therapy-related oxidative stress may be significantly adverse. In all such cases, careful pre-examination and evaluation of the potential risk and benefit from this form of therapy appears to be warranted. Unless it could interfere with the benefits of hyperbaric oxygen therapy, antioxidant dietary supplementation may be indicated in conjunction with any hyperbaric oxygen therapy, when there are co-existing diseases for which oxidative stress could have significantly adverse side effects. Delivery of hyperbaric oxygen therapy may need to be modified or it may even be contraindicated in these cases.
C1 Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2052, Australia.
C3 University of New South Wales Sydney
RP McMonnies, CW (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2052, Australia.
EM c.mcmonnies@unsw.edu.au
CR Arnal E, 2011, INVEST OPHTH VIS SCI, V52, P8592, DOI 10.1167/iovs.11-7732
   Bakker DJ, 2000, DIABETES-METAB RES, V16, pS55, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR132>3.0.CO;2-T
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benedetti S, 2004, CLIN BIOCHEM, V37, P312, DOI 10.1016/j.clinbiochem.2003.12.001
   BERGMANSON JPG, 1995, OPHTHAL PHYSL OPT, V15, P83, DOI 10.1046/j.1475-1313.1995.9598237h.x
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chang YH, 2006, CLIN EXP OPHTHALMOL, V34, P584, DOI 10.1111/j.1442-9071.2006.01280.x
   Cheung IMY, 2013, CLIN EXP OPTOM, V96, P188, DOI 10.1111/cxo.12025
   Chwa M, 2008, INVEST OPHTH VIS SCI, V49, P4361, DOI 10.1167/iovs.08-1969
   Cristina Kenney M, 2003, Cont Lens Anterior Eye, V26, P139
   DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214
   Dennog C, 1999, MUTAT RES-FUND MOL M, V428, P83, DOI 10.1016/S1383-5742(99)00034-4
   Eken A, 2005, CLIN BIOCHEM, V38, P1133, DOI 10.1016/j.clinbiochem.2005.09.001
   Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1
   Evanger K, 2004, ACTA OPHTHALMOL SCAN, V82, P449, DOI 10.1111/j.1395-3907.2004.00290.x
   Fatt I., 1978, PHYSL EYE, P131
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Kalani M, 2002, J DIABETES COMPLICAT, V16, P153, DOI 10.1016/S1056-8727(01)00182-9
   Kindwall EP, 2011, ENCY OCCUPATIONAL HL
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kranke P, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004123.PUB2
   KWAN M, 1972, INVEST OPHTH VISUAL, V11, P108
   McMonnies CW, 2013, CLIN EXP OPTOM, V96, P197, DOI 10.1111/j.1444-0938.2012.00726.x
   Oguz H, 2008, SURV OPHTHALMOL, V53, P112, DOI 10.1016/j.survophthal.2007.12.002
   Oter S, 2005, CLIN BIOCHEM, V38, P706, DOI 10.1016/j.clinbiochem.2005.04.005
   PALMQUIST BM, 1984, BRIT J OPHTHALMOL, V68, P113, DOI 10.1136/bjo.68.2.113
   Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119
   Schindl A, 2002, MICROVASC RES, V64, P240, DOI 10.1006/mvre.2002.2429
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506
   Uysal B, 2010, PANCREAS, V39, P9, DOI 10.1097/MPA.0b013e3181bb5ae3
   vansLeeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101
   Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
NR 36
TC 33
Z9 35
U1 1
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAR
PY 2015
VL 98
IS 2
BP 122
EP 125
DI 10.1111/cxo.12203
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC6TI
UT WOS:000350501000004
PM 25308346
OA Bronze
DA 2022-11-30
ER

PT J
AU Nangia, V
   Jonas, JB
   George, R
   Lingam, V
   Ellwein, L
   Cicinelli, MV
   Das, A
   Flaxman, SR
   Keeffe, JE
   Kempen, JH
   Leasher, J
   Limburg, H
   Naidoo, K
   Pesudovs, K
   Resnikoff, S
   Silvester, AJ
   Tahhan, N
   Taylor, HR
   Wong, TY
   Bourne, RRA
AF Nangia, Vinay
   Jonas, Jost B.
   George, Ronnie
   Lingam, Vijaya
   Ellwein, Leon
   Cicinelli, Maria Vittoria
   Das, Aditi
   Flaxman, Seth R.
   Keeffe, Jill E.
   Kempen, John H.
   Leasher, Janet
   Limburg, Hans
   Naidoo, Kovin
   Pesudovs, Konrad
   Resnikoff, Serge
   Silvester, Alexander J.
   Tahhan, Nina
   Taylor, Hugh R.
   Wong, Tien Y.
   Bourne, Rupert R. A.
CA Vision Loss Expert Grp Global
TI Prevalence and causes of blindness and vision impairment: magnitude,
   temporal trends and projections in South and Central Asia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE global burden of disease study; vision loss expert group; vision loss;
   blindness; vision impairment; refractive error; cataract; glaucoma;
   macular degeneration; epidemiology
ID GLOBAL PREVALENCE; VISUAL IMPAIRMENT; RANIBIZUMAB; POPULATION; WORLDWIDE
AB Background To assess prevalence and causes of vision loss in Central and South Asia. Methods A systematic review of medical literature assessed the prevalence of blindness (presenting visual acuity<3/60 in the better eye), moderate and severe vision impairment (MSVI; presenting visual acuity <6/18 but >= 3/60) and mild vision impairment (MVI; presenting visual acuity <6/12 and >= 6/18) in Central and South Asia for 1990, 2010, 2015 and 2020. Results In Central and South Asia combined, age-standardised prevalences of blindness, MSVI and MVI in 2015 were for men and women aged 50+years, 3.72% (80% uncertainty interval (UI): 1.39-6.75) and 4.00% (80% UI: 1.41-7.39), 16.33% (80% UI: 8.55-25.47) and 17.65% (80% UI: 9.00-27.62), 11.70% (80% UI: 4.70-20.32) and 12.25% (80% UI:4.86-21.30), respectively, with a significant decrease in the study period for both gender. In South Asia in 2015, 11.76 million individuals (32.65% of the global blindness figure) were blind and 61.19 million individuals (28.3% of the global total) had MSVI. From 1990 to 2015, cataract (accounting for 36.58% of all cases with blindness in 2015) was the most common cause of blindness, followed by undercorrected refractive error (36.43%), glaucoma (5.81%), age-related macular degeneration (2.44%), corneal diseases (2.43%), diabetic retinopathy (0.16%) and trachoma (0.04%). For MSVI in South Asia 2015, most common causes were undercorrected refractive error (accounting for 66.39% of all cases with MSVI), followed by cataract (23.62%), age-related macular degeneration (1.31%) and glaucoma (1.09%). Conclusions One-third of the global blind resided in South Asia in 2015, although the age-standardised prevalence of blindness and MSVI decreased significantly between 1990 and 2015.
C1 [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [George, Ronnie; Lingam, Vijaya] Med Res Fdn, Dept Glaucoma, Chennai, Tamil Nadu, India.
   [Ellwein, Leon] NEI, NIH, Bethesda, MD 20892 USA.
   [Cicinelli, Maria Vittoria] Ist Sci San Raffaele, Milan, Italy.
   [Das, Aditi] Hlth Educ Yorkshire & Humber, Humber, England.
   [Flaxman, Seth R.] Imperial Coll, Data Sci Inst, Dept Math, London, England.
   [Keeffe, Jill E.] Eye Inst, Hyderabad, Telangana, India.
   [Kempen, John H.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Epidemiol, Boston, MA 02114 USA.
   [Kempen, John H.] MyungSung Christian Med Ctr & Med Sch, Discovery Eye Ctr, Addis Ababa, Ethiopia.
   [Leasher, Janet] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Naidoo, Kovin] Univ Kwazulu Natal, African Vis Res Inst, Durban, South Africa.
   [Naidoo, Kovin; Resnikoff, Serge; Tahhan, Nina] Brien Holden Vis Inst, Sydney, NSW, Australia.
   [Pesudovs, Konrad] 5 Rose St, Glenelg, SA, Australia.
   [Resnikoff, Serge; Tahhan, Nina] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Silvester, Alexander J.] Royal Liverpool Univ Hosp, Pauls Eye Unit, Liverpool, Merseyside, England.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Duke NUS Grad Med Sch, Singapore, Singapore.
   [Bourne, Rupert R. A.] Anglia Ruskin Univ, Sch Med, Vis & Eye Res Unit, Cambridge, England.
C3 Suraj Eye Institute; Ruprecht Karls University Heidelberg; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Imperial College London; Harvard University; Massachusetts Eye & Ear
   Infirmary; Nova Southeastern University; University of Kwazulu Natal;
   Brien Holden Vision Institute; University of New South Wales Sydney;
   Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Melbourne; National University of Singapore; Singapore National Eye
   Center; Anglia Ruskin University; University of Cambridge
RP Bourne, RRA (通讯作者)，Anglia Ruskin Univ, Sch Med, Vis & Eye Res Unit, Cambridge, England.
EM rb@rupertbourne.co.uk
RI cicinelli, maria vittoria/M-1611-2019; Tejedor, Jaime/G-7728-2015; Wong,
   Tien Yin/AAC-9724-2020; Braithwaite, Tasanee/AAZ-1118-2020; Naidoo,
   Kovin Shunmugam/AAF-5914-2020
OI cicinelli, maria vittoria/0000-0003-2938-0409; Wong, Tien
   Yin/0000-0002-8448-1264; Braithwaite, Tasanee/0000-0002-3025-4066;
   Jonas, Jost/0000-0003-2972-5227; Kempen, John/0000-0002-2967-4792;
   Gazzard, Gus/0000-0003-1982-5005; Pesudovs, Konrad/0000-0002-6322-9369;
   george, ronnie/0000-0001-7368-0252; Topouzis, Fotis/0000-0002-8966-537X;
   Dreer, Laura/0000-0002-4728-5467; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Gichuhi, Stephen/0000-0002-7062-4869;
   Tejedor Fraile, Jaime/0000-0001-5507-5622
FU Brien Holden Vision Institute
FX This study was funded by the Brien Holden Vision Institute. The results
   in this paper are prepared independently of the final estimates of the
   Global Burden of Diseases, Injuries and Risk Factors study. The funders
   had no role in study design, data collection and analysis, decision to
   publish or preparation of the manuscript.
CR Bourne R, 2007, BRIT J OPHTHALMOL, V91, P420, DOI 10.1136/bjo.2006.106724
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gelman A, 2014, TEXTS STAT SCI, V3rd
   Jonas JB, 2014, BRIT J OPHTHALMOL, V98, P592, DOI 10.1136/bjophthalmol-2013-303998
   Jonas JB, 2013, DIABETES CARE, V36, pE69, DOI 10.2337/dc12-2377
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI [10.1016/S0140-6736(16)31460-X, 10.1016/S0140-6736(16)31470-2]
   Khanna RC, 2012, INDIAN J OPHTHALMOL, V60, P492, DOI 10.4103/0301-4738.100560
   Khanna RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035701
   Raman R, 2009, OPHTHALMOLOGY, V116, P311, DOI 10.1016/j.ophtha.2008.09.010
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   UN, 2015, ESAPWP241 UN
   Vijaya L, 2006, BRIT J OPHTHALMOL, V90, P407, DOI 10.1136/bjo.2005.081406
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
NR 19
TC 25
Z9 26
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2019
VL 103
IS 7
BP 871
EP 877
DI 10.1136/bjophthalmol-2018-312292
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF4HJ
UT WOS:000473042100002
PM 30409914
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Finger, RP
   Fenwick, E
   Owsley, C
   Holz, FG
   Lamoureux, EL
AF Finger, Robert P.
   Fenwick, Eva
   Owsley, Cynthia
   Holz, Frank G.
   Lamoureux, Ecosse L.
TI Visual Functioning and Quality of Life under Low Luminance: Evaluation
   of the German Low Luminance Questionnaire
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; CONTRAST SENSITIVITY; MACULAR DEGENERATION;
   DARK-ADAPTATION; VISION LOSS; IMPACT; RASCH; IMPAIRMENT
AB PURPOSE. To validate the German-translated Low Luminance Questionnaire (LLQ), a vision-related quality of life scale assessing mainly mesopic and scotopic functioning, and to determine the relationship between the severity of vision impairment, ocular conditions, and low luminance-related visual functioning.
   METHODS. In all, 274 participants, 184 patients with visual acuity < 6/12 or a long-standing symptomatic eye condition and 90 controls, were recruited from an outpatient clinic at a German eye hospital. Participants underwent a clinical examination and completed the German LLQ and VF-14 scales. The validity and psychometric properties of the scales were assessed using Rasch analysis exploring key indices, such as instrument unidimensionality, discriminant ability, and targeting of item difficulty to patient ability. Multivariate analyses of low luminance functioning were adjusted for conventional visual functioning (VF-14 scores).
   RESULTS. The 30-item German LLQ initially displayed poor fit to the Rasch model. Following Rasch-guided iterative adjustments to the scale, a 23-item LLQ emerged as a valid and uni-dimensional scale. Visual functioning under low luminance consistently declined with worsening vision loss. Compared with patients with no vision impairment, those with mild or moderate/severe vision impairment recorded significantly poorer low luminance functioning scores (mean change, -6.33 and -16.62; P = 0.032 and P < 0.001, respectively). Age-related macular degeneration and cataract were independently associated with low luminance visual functioning, as was worse self-reported health.
   CONCLUSIONS. Low luminance functioning is considerably compromised in visually impaired patients even at the mild spectrum of visual acuity loss. Additionally, the impact of age-related macular degeneration and cataract on patients' low luminance functioning is substantially independent of vision impairment. (Invest Ophthalmol Vis Sci. 2011; 52: 8241-8249) DOI:10.1167/iovs.11-7858
C1 [Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Finger, Robert P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Lamoureux, Ecosse L.] Singapore Eye Res Inst, Singapore, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Bonn; University of Alabama
   System; University of Alabama Birmingham; National University of
   Singapore; Singapore National Eye Center
RP Finger, RP (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Ctr Eye Res Australia, Level 1,32 Gisborne St, Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
RI Lamoureux, Ecosse/Z-5482-2019; Owsley, Cynthia/B-7986-2014
OI Finger, Robert P/0000-0003-4253-7597
FU German Research Foundation [FI-1540/5-5]
FX Supported in part by Operational Infrastructure Support from the
   Victorian Government (Consultation, Education, and Research Associates);
   and Research Fellowship Grant FI-1540/5-5 of the German Research
   Foundation (RPF).
CR Ahmadian L, 2008, OPHTHAL EPIDEMIOL, V15, P345, DOI 10.1080/09286580802227402
   ALEXANDER KR, 1992, INVEST OPHTH VIS SCI, V33, P1846
   Brabyn J, 2001, OPTOMETRY VISION SCI, V78, P264, DOI 10.1097/00006324-200105000-00008
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   BRODY BL, OPHTHALMOLOGY, V108, P1891
   Chen PP, 1997, J GLAUCOMA, V6, P192
   Cheng KKF, 2011, NURS RES, V60, P256, DOI 10.1097/NNR.0b013e318221f731
   Cochrane GM, 2011, INVEST OPHTH VIS SCI, V52, P1632, DOI 10.1167/iovs.10-6079
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Finger RP, 2011, GRAEF ARCH CLIN EXP, V249, P1245, DOI 10.1007/s00417-011-1646-4
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Gothwal VK, 2011, CLIN EXP OPTOM, V94, P52, DOI 10.1111/j.1444-0938.2010.00554.x
   Hohberger B, 2007, GRAEF ARCH CLIN EXP, V245, P1805, DOI 10.1007/s00417-007-0662-x
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Lamoureux E, 2010, GRAEF ARCH CLIN EXP, V248, P527, DOI 10.1007/s00417-009-1260-x
   Linacre J., 2002, USERS GUIDE WINSTEPS
   Linacre J., 2012, USERS GUIDE WINSTEPS
   Linacre JM, 2008, WINSTEPS RASCH MEASU
   Linacre JM., 1994, RASCH MEASUREMENT T, V7, P328
   LUDLOW LH, 1995, EDUC PSYCHOL MEAS, V55, P967, DOI 10.1177/0013164495055006005
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Nomura H, 2003, JPN J OPHTHALMOL, V47, P299, DOI 10.1016/S0021-5155(03)00011-X
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Norquist JM, 2004, MED CARE, V42, P25, DOI 10.1097/01.mlr.0000103530.13056.88
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pesudovs K, 2004, OPTOMETRY VISION SCI, V81, P769, DOI 10.1097/00006324-200410000-00009
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Pieh C, 2009, OPHTHALMOLOGE, V106, P420, DOI 10.1007/s00347-008-1778-z
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sloan Jeff A, 2005, COPD, V2, P57
   SLOANE ME, 1988, J OPT SOC AM A, V5, P2181, DOI 10.1364/JOSAA.5.002181
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P865
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 45
TC 23
Z9 25
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2011
VL 52
IS 11
BP 8241
EP 8249
DI 10.1167/iovs.11-7858
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 834MY
UT WOS:000295966600059
PM 21908584
DA 2022-11-30
ER

PT J
AU Kashiwagi, K
   Shibuya, T
   Tsukahara, S
AF Kashiwagi, K
   Shibuya, T
   Tsukahara, S
TI De novo age-related retinal disease and intraocular-pressure changes
   during a 10-year period in a Japanese adult population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; aging; epiretinal membrane; glaucoma;
   intraocular pressure
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; MACULAR DEGENERATION; EPIRETINAL
   MEMBRANES; PREVALENCE; GLAUCOMA; MACULOPATHY; AUSTRALIA; STUDY/
AB Purpose: To determine the proportion of age-related ophthalmologic diseases discovered in a healthy Japanese adult population, as well as to evaluate the age-related changes in intraocular pressure (IOP) in this population during a 10-year period.
   Methods: Ophthalmologic surveys were conducted in 1988 and 1998 at Tamaho-cho in Yamanashi Prefecture. The target population of the first survey was 1389 subjects over 40 years of age, and of these, 1250 subjects (473 men and 777 women) participated in the survey. Their mean age was 57.8 +/- 11.9 years. Of these 1250 subjects, 245 subjects participated in the second ophthalmologic survey in 1998. The cases of glaucoma or age-related ophthalmologic diseases developing over the intervening 10-year period were determined among the subjects who had been diagnosed with no ophthalmologic abnormalities in the 1988 survey. We also compared the IOP values of the 219 subjects who were diagnosed with no ophthalmologic abnormalities in either the 1988 or the 1998 survey.
   Results: The number of cases in the 1998 survey with newly discovered ocular diseases were as follows: two cases (0.82%) of normal-tension glaucoma, two cases (0.82%) of epiretinal membrane, one case (0.41%) of age-related macular degeneration, one case (0.41%) of angle-closure glaucoma, and one case (0.41%) of branch retinal vein occlusion. The mean IOP of the 219 subjects diagnosed with no ophthalmic abnormalities in either survey was 13.88 +/- 3.04 mmHg in 1988, which declined significantly to 13.16 +/- 2.75 mmHg in 1998 (P < 0.0001).
   Conclusions: The 10-year follow-up of the 245 subjects participating in both surveys showed one or two de novo cases of age-related macular degeneration, epiretinal membrane, branch retinal vein occlusion, normal-tension glaucoma, or angle-closure glaucoma. IOP was found to decline significantly with age. (C) Japanese Ophthalmological Society 2005.
C1 Univ Yamanashi, Fac Med, Dept Ophthalmol, Tamaho, Yamanashi 4093898, Japan.
C3 University of Yamanashi
RP Kashiwagi, K (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, 1110 Shimokato, Tamaho, Yamanashi 4093898, Japan.
EM kenjik@yamanashi.ac.jp
CR Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Fraser-Bell S, 2003, OPHTHALMOLOGY, V110, P34, DOI 10.1016/S0161-6420(02)01443-4
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GIUFFRE G, 1995, ACTA OPHTHALMOL SCAN, V73, P222
   Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1994, Trans Am Ophthalmol Soc, V92, P403
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nomura H, 1999, OPHTHALMOLOGY, V106, P2016, DOI 10.1016/S0161-6420(99)90417-7
   Nomura H, 2002, CURR EYE RES, V24, P81, DOI 10.1076/ceyr.24.2.81.8161
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   ROTH A M, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P1047
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SHIOSE Y, 1990, SURV OPHTHALMOL, V34, P413, DOI 10.1016/0039-6257(90)90122-C
   SHIOSE Y, 1991, JPN J OPHTHALMOL, V35, P133
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong TY, 2003, OPHTHALMOLOGY, V110, P211, DOI 10.1016/S0161-6420(02)01260-5
NR 20
TC 11
Z9 11
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN-FEB
PY 2005
VL 49
IS 1
BP 36
EP 40
DI 10.1007/s10384-004-0143-2
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 894JA
UT WOS:000226786100007
PM 15692772
DA 2022-11-30
ER

PT J
AU Ogura, Y
   Iida, T
   Lee, WK
   Cheung, CMG
   Mitchell, P
   Leal, S
   Schmelter, T
   Ishibashi, T
AF Ogura, Yuichiro
   Iida, Tomohiro
   Lee, Won Ki
   Cheung, Chui Ming Gemmy
   Mitchell, Paul
   Leal, Sergio
   Schmelter, Thomas
   Ishibashi, Tatsuro
TI Efficacy and safety of intravitreal aflibercept for polypoidal choroidal
   vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET
   study
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Antivascular endothelial growth factor; Anti-VEGF;
   Photodynamic therapy; Polypoidal choroidal vasculopathy
AB Purpose To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) versus IVT-AFL plus rescue photodynamic therapy (IVT-AFL + rPDT) in the subgroup of Japanese patients with polypoidal choroidal vasculopathy (PCV) enrolled in the PLANET study. Study design A 96-week, double-masked, sham-controlled phase-3b/4 randomized clinical trial conducted at multiple centers from May 2014 to August 2016. Patients and methods Patients with PCV (BCVA 73-24 ETDRS letters [20/40-20/320 Snellen]) received 3 initial monthly doses of IVT-AFL 2 mg. At week 12, the patients were randomly assigned 1:1 to IVT-AFL + sham PDT or IVT-AFL + rPDT. Patients not requiring rescue received IVT-AFL every 8 weeks; those requiring rescue received IVT-AFL monthly plus sham/active PDT. Following week 52, the treatment intervals could be extended > 8 weeks. Results The baseline demographics for the 159 Japanese patients were balanced. At week 96, the mean BCVA change was + 9.7 (IVT-AFL) versus + 9.5 letters (IVT-AFL + rPDT) (least-squares mean difference of - 0.3; 95% CI, - 3.7 to 3.1); the mean central subfield thickness reduction was - 148.0 mu m versus - 145.9 mu m. Overall, 17.1% of the patients required rescue PDT. At week 96, 25.0% (IVT-AFL) and 37.9% (IVT-AFL + rPDT) of the patients had complete polyp regression; 84.1% (IVT-AFL) and 88.4% (IVT-AFL + rPDT) of the patients had no evidence of active polyps. The mean number of injections (weeks 52-96) were 4.6 (IVT-AFL) and 4.5 (IVT-AFL + rPDT). Overall, 36.0% (IVT-AFL) and 33.8% (IVT-AFL + rPDT) of the patients experienced ocular treatment-emergent adverse events. Conclusion IVT-AFL monotherapy was efficacious for the treatment of Japanese patients with PCV, and the addition of rescue PDT did not show additional benefits.
C1 [Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Lee, Won Ki] Nune Eye Hosp, Seoul, South Korea.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Leal, Sergio] Bayer Consumer Care AG, Basel, Switzerland.
   [Schmelter, Thomas] Bayer Pharmaceut, Berlin, Germany.
   [Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Fukuoka, Japan.
C3 Nagoya City University; Tokyo Women's Medical University; Singapore
   National Eye Center; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; University of
   Sydney; Westmead Institute for Medical Research; Bayer AG; Bayer AG;
   Bayer Healthcare Pharmaceuticals; Kyushu University
RP Ogura, Y (通讯作者)，Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan.
EM ogura.yuichiro@me.com
RI Schmelter, Thomas/AAS-3728-2021
OI Schmelter, Thomas/0000-0003-1358-3172
FU Bayer Consumer Care AG, Basel, Switzerland
FX Funding was provided by Bayer Consumer Care AG, Basel, Switzerland for
   the overall study and for medical writing and editorial assistance for
   this article.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wong TY, 2019, RETINA-J RET VIT DIS, V39, P537, DOI 10.1097/IAE.0000000000001986
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 30
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAY
PY 2021
VL 65
IS 3
BP 344
EP 353
DI 10.1007/s10384-020-00805-5
EA JAN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RV2FS
UT WOS:000609099200001
PM 33474611
DA 2022-11-30
ER

PT J
AU Lai, KB
   Li, Y
   Zhou, LJ
   Zhong, XJ
   Huang, CX
   Xu, FB
   Lu, L
   Ge, J
   Jin, CJ
AF Lai, Kunbei
   Li, Ying
   Zhou, Lijun
   Zhong, Xiaojin
   Huang, Chuangxin
   Xu, Fabao
   Lu, Lin
   Ge, Jian
   Jin, Chenjin
TI Comparison of the effects of photodynamic therapy, intravitreal
   ranibizumab and combination for polypoidal choroidal vasculopathy under
   1+PRN regimen
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Ranibizumab;
   Combination therapy; Cost-benefit
ID MACULAR DEGENERATION; PROGNOSTIC-FACTORS; VERTEPORFIN; MONOTHERAPY;
   EFFICACY; SAFETY
AB Background: The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of "1+ pro re nata(PRN)" treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for PCV.
   Methods: Fifty-seven eyes of 57 patients completed the 12 months' follow-up in this prospective study. The patients in the PDT arm(n = 23), ranibizumab arm(n = 18), or combination arm(n = 16) underwent a session of PDT, IVR or combination of both at baseline followed by additional IVR as needed. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT) and the regression rate of polyps were evaluated. Cost-benefit analysis was also performed.
   Results: At Month 12, the mean logMAR VA improved from 0.90 +/- 0.52 to 0.75 +/- 0.57 in the PDT group (P < 0.05), from 0.96 +/- 0.58 to 0.77 +/- 0.41 in the IVR group (P < 0.05), and from 0.94 +/- 0.55 to 0.72 +/- 0.44 in the combination group (P < 0.05), respectively. The CFT decreased from 478.04 +/- 156.70 mu m, 527.5 +/- 195.90 mu m, and 522.63 +/- 288. 40 mu m at the baseline to 366.43 +/- 148.28 mu m, 373.17 +/- 134.88 mu m and 328.44 +/- 103.25 in the PDT group (P < 0.05), IVR group (P < 0.01), and the combination group (P < 0.05), respectively. However, no statistical difference was found between groups (P > 0.05). PDT treatment (60.87%) was superior to the IVR therapy (22.22%) in achieving complete regression of polyps (P < 0.05). Cost-benefit analysis showed that IVR treatment cost the least money for improving per 0.1logMAR units and the combination therapy demanded the least money for reducing per 100 mu m of CFT.
   Conclusions: PDT, IVR and the combination therapy have similar efficacy in the VA improvement as well as the reduction of CFT under the "1 + PRN" treatment regimen.
C1 [Lai, Kunbei; Li, Ying; Zhou, Lijun; Zhong, Xiaojin; Huang, Chuangxin; Xu, Fabao; Lu, Lin; Ge, Jian; Jin, Chenjin] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Ge, J; Jin, CJ (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM gejian@mail.sysu.edu.cn; jinchj@mail.sysu.edu.cn
FU Science and Technology Planning Project of Guangdong Province
   [2012B061700081]; Fundamental Research Funds of the State Key Laboratory
   of Ophthalmology [2016QN06]; Medical Scientific Research Foundation of
   Guangdong Province [A201633]; Natural Science Foundation of Guangdong
   Province [2016A030310212]; National Natural Science Foundation of China
   [81600741]
FX This study was supported by grants from the Science and Technology
   Planning Project of Guangdong Province(recipient: Chenjin Jin; award
   number: 2012B061700081), the Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology (recipient: Kunbei Lai; award number:
   2016QN06), the Medical Scientific Research Foundation of Guangdong
   Province (recipient: Kunbei Lai; award number: A201633), the Natural
   Science Foundation of Guangdong Province (recipient: Kunbei Lai; award
   number: 2016A030310212) and National Natural Science Foundation of China
   (recipient: Kunbei Lai; award number: 81600741). The funding
   organizations had no role in the study design, conduct of this research,
   data analysis, decision to publish, or preparation of the manuscript.
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Kang HM, 2014, OPHTHALMOLOGICA, V231, P86, DOI 10.1159/000354546
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 27
TC 5
Z9 5
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 20
PY 2018
VL 18
AR 144
DI 10.1186/s12886-018-0801-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK2FW
UT WOS:000435943200001
PM 29925341
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cannon, E
AF Cannon, Eric
TI Managed Care Opportunities and Approaches to Supporting Appropriate
   Selection of Treatment for Sight Preservation
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID MACULAR DEGENERATION; COST-EFFECTIVENESS; BEVACIZUMAB; RANIBIZUMAB;
   INTERVENTIONS; STABILITY; BURDEN; IMPACT
AB When evaluating the impact of vision-destroying diseases, pharmacologic therapies represent a significant cost to patients, insurance providers, and society. Currently, up to 11 million people in the United States have some form of age-related macular degeneration (AMD), which is one of the leading causes of vision loss in older Americans. Ophthalmologists have administered more than 6 million intravitreal injections of aflibercept, bevacizumab, pegaptanib, and ranibizumab last year. Comprehensive assessment requires managed care administrators and clinicians to understand the direct and indirect costs of vision loss as well as the comparative safety and efficacy profiles for each agent. In AMD, it is critical to understand the established and emerging treatment patterns.
C1 [Cannon, Eric] SelectHlth, Pharm Benefits, Murray, UT 84123 USA.
RP Cannon, E (通讯作者)，SelectHlth, Pharm Benefits, Murray, UT 84123 USA.
EM eric.cannon@selecthealth.org
FU Regeneron Pharmaceuticals, Inc.
FX This activity is supported by an independent medical educational grant
   from Regeneron Pharmaceuticals, Inc.
CR American Academy of Ophthalmology, AG REL MAC DEG PREF
   [Anonymous], 2016, AG REL MAC DEG FACTS
   [Anonymous], FACTS AG REL MAC DEG
   Avery Robert L, 2019, Retin Cases Brief Rep, V13, P130, DOI 10.1097/ICB.0000000000000570
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Basta N, SP CHANNEL CONTINUES
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brown MM, 2014, CURR OPIN OPHTHALMOL, V25, P171, DOI 10.1097/ICU.0000000000000040
   Cohen D, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k4035
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Dang A., 2017, USE QALY HEALTHCARE
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Fuller D., 2013, TACKLE WHITE BAGGING
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Gower EW, 2017, AM J OPHTHALMOL, V184, P157, DOI 10.1016/j.ajo.2017.10.010
   Khalili H, 2015, EYE, V29, P820, DOI 10.1038/eye.2015.28
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Kuehn BM, 2013, JAMA-J AM MED ASSOC, V309, P864, DOI 10.1001/jama.2013.1719
   Li Emily, 2016, R I Med J (2013), V99, P15
   Mackey TK, 2015, NAT REV CLIN ONCOL, V12, P302, DOI 10.1038/nrclinonc.2015.35
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Neumann PJ, 2010, NEW ENGL J MED, V363, P1495, DOI 10.1056/NEJMp1007168
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Ricci Federico, 2016, Digit J Ophthalmol, V22, P41, DOI 10.5693/djo.01.2016.03.001
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Shah AR, 2016, DEV OPHTHALMOL, V55, P376, DOI 10.1159/000438965
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2013, OPHTHALMOLOGY, V120, P1835, DOI 10.1016/j.ophtha.2013.02.002
   Sun XD, 2011, NEW ENGL J MED, V365, P378, DOI 10.1056/NEJMc1106415
   Trivizki O, 2018, OPHTHALMOLOGICA, V240, P163, DOI 10.1159/000492681
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Williams G., 2014, REV OPHTHALMOL
   World Health Organization, GLOB DAT VIS IMP 201
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 43
TC 1
Z9 1
U1 0
U2 1
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JUL
PY 2019
VL 25
IS 7
SU S
BP S182
EP S187
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA JQ3JO
UT WOS:000498845600002
PM 31419089
DA 2022-11-30
ER

PT J
AU Sene, A
   Apte, RS
AF Sene, Abdoulaye
   Apte, Rajendra S.
TI Eyeballing cholesterol efflux and macrophage function in disease
   pathogenesis
SO TRENDS IN ENDOCRINOLOGY AND METABOLISM
LA English
DT Review
DE macrophage; AMD; atherosclerosis; cholesterol efflux; lipids
ID HIGH-DENSITY-LIPOPROTEIN; MACULAR DEGENERATION; HEPATIC LIPASE;
   ACCELERATES ATHEROSCLEROSIS; LIPID CONCENTRATIONS; GENETIC-VARIANTS; HDL
   CHOLESTEROL; BRUCHS MEMBRANE; RECEPTOR LXR; ACCUMULATION
AB Disorders of lipid metabolism are strongly associated with cardiovascular disease. Recently, there has been significant focus on how tissues process lipid deposits. Impaired cholesterol efflux has been shown to be crucial in mediating lipid deposition in atherosclerosis. The inability of macrophages to effectively efflux cholesterol from tissues initiates inflammation, plaque neovascularization, and subsequent rupture. Recent studies suggest that inability to effectively efflux cholesterol from tissues may have global implications far beyond atherosclerosis, extending to the pathophysiology of unrelated diseases. We examine the unifying mechanisms by which impaired cholesterol efflux facilitates tissue-specific inflammation and disease progression in age-related macular degeneration (AMD), a blinding eye disease, and in atherosclerosis, a disease associated with significant cardiovascular morbidity.
C1 [Sene, Abdoulaye; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 South Euclid Ave, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
RI Sene, Abdoulaye/D-3342-2015
OI Sene, Abdoulaye/0000-0001-9194-7264
FU National Institutes of Health [K08EY016139, R01EY019287, P30EY02687]; US
   Civilian Research and Development Foundation; Carl Marshall Reeves and
   Mildred Almen Reeves Foundation Award; Research to Prevent Blindness
   Career Development Award; International Retina Research Foundation;
   American Health Assistance Foundation; Lacy Foundation Research Award;
   Thome Foundation; NATIONAL EYE INSTITUTE [R01EY019287, P30EY002687,
   K08EY016139] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (grants
   K08EY016139, R01EY019287, and Vision Core grant P30EY02687), the US
   Civilian Research and Development Foundation, the Carl Marshall Reeves
   and Mildred Almen Reeves Foundation Award, a Research to Prevent
   Blindness Career Development Award, the International Retina Research
   Foundation, the American Health Assistance Foundation, a Lacy Foundation
   Research Award, and the Thome Foundation. We thank Nicole Zapata for
   help with illustrations and Dr Clay Semenkovich for his insightful
   comments.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Adorni MP, 2007, J LIPID RES, V48, P2453, DOI 10.1194/jlr.M700274-JLR200
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045
   Baldan A, 2006, ARTERIOSCL THROM VAS, V26, P2301, DOI 10.1161/01.ATV.0000240051.22944.dc
   Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278
   Barter P, 2011, ATHEROSCLEROSIS SUPP, V12, P267, DOI 10.1016/S1567-5688(11)70885-6
   Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Costet P, 2000, J BIOL CHEM, V275, P28240
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dahlof Bjorn, 2010, Am J Cardiol, V105, p3A, DOI 10.1016/j.amjcard.2009.10.007
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerin I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/jbc.M110.152090
   GORDON DJ, 1989, NEW ENGL J MED, V321, P1311
   Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Horie T, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003376
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Khallou-Laschet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008852
   KRAMSCH DM, 1971, J CLIN INVEST, V50, P1666, DOI 10.1172/JCI106656
   Kratzer A, 2009, J LIPID RES, V50, P312, DOI 10.1194/jlr.M800376-JLR200
   Leitinger N, 2013, ARTERIOSCL THROM VAS, V33, P1120, DOI 10.1161/ATVBAHA.112.300173
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497
   Marquart TJ, 2013, ARTERIOSCL THROM VAS, V33, P455, DOI 10.1161/ATVBAHA.112.300639
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   Mayerl C, 2006, VIRCHOWS ARCH, V449, P96, DOI 10.1007/s00428-006-0176-7
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Out R, 2008, ARTERIOSCL THROM VAS, V28, P258, DOI 10.1161/ATVBAHA.107.156935
   Out R, 2006, ARTERIOSCL THROM VAS, V26, P2295, DOI 10.1161/01.ATV.0000237629.29842.4c
   Qiao JH, 1997, AM J PATHOL, V150, P1687
   Quinet EM, 2009, J LIPID RES, V50, P2358, DOI 10.1194/jlr.M900037-JLR200
   Rader DJ, 2012, NAT MED, V18, P1344, DOI 10.1038/nm.2937
   Ranalletta M, 2006, ARTERIOSCL THROM VAS, V26, P2308, DOI 10.1161/01.ATV.0000242275.92915.43
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Robbins CS, 2013, NAT MED, V19, P1166, DOI 10.1038/nm.3258
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   Rotllan N, 2013, ARTERIOSCL THROM VAS, V33, P1973, DOI 10.1161/ATVBAHA.113.301732
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Santamarina-Fojo S, 2004, ARTERIOSCL THROM VAS, V24, P1750, DOI 10.1161/01.ATV.0000140818.00570.2d
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Soyal SM, 2011, ATHEROSCLEROSIS, V216, P374, DOI 10.1016/j.atherosclerosis.2011.01.052
   Stoger JL, 2012, ATHEROSCLEROSIS, V225, P461, DOI 10.1016/j.atherosclerosis.2012.09.013
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700
   Wang X, 2007, J CLIN INVEST, V117, P2216, DOI 10.1172/JCI32057
   Westerterp M, 2013, CIRC RES, V112, P1456, DOI 10.1161/CIRCRESAHA.113.301086
   Whitcup S.M., 2013, J INFLAMM, V2013
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Yvan-Charvet L, 2007, J CLIN INVEST, V117, P3900, DOI 10.1172/JCI33372
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 80
TC 33
Z9 34
U1 0
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1043-2760
EI 1879-3061
J9 TRENDS ENDOCRIN MET
JI Trends Endocrinol. Metab.
PD MAR
PY 2014
VL 25
IS 3
BP 107
EP 114
DI 10.1016/j.tem.2013.10.007
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AD8JI
UT WOS:000333511900001
PM 24252662
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Do, DV
   Haller, JA
   Heier, JS
   Kaiser, PK
AF Quan Dong Nguyen
   Do, Diana V.
   Haller, Julia A.
   Heier, Jeffrey S.
   Kaiser, Peter K.
TI Putting Theories and Results into Practice Managing Cases
SO OPHTHALMOLOGY
LA English
DT Article
AB The following are highlights from a case discussion, which was moderated by the Course Director, Quan Dong Nguyen, MD, MSc. The faculty reviewed 3 case studies and discussed their different approaches to managing the treatment of each patient. They also fielded questions from audience members about their management suggestions and the potential US Food and Drug Administration approval of aflibercept, which was not approved at the time of this discussion. In addition, the 2-year CATT (Comparison of Age-Related Macular Degeneration Treatments Trials) results and 1-year IVAN (Inhibit Vascular Endothelial Growth Factor in Age-Related Choroidal Neovascularization) results were not released at the time this discussion took place. (c) 2013 by the American Academy of Ophthalmology.
C1 [Quan Dong Nguyen; Do, Diana V.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Haller, Julia A.] Thomas Jefferson Univ, Wills Eye Inst, Philadelphia, PA 19107 USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Vitreoretinal Serv, Boston, MA USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Lerner Coll Med, Cleveland, OH 44106 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Jefferson University;
   Ophthalmic Consultants of Boston; Case Western Reserve University;
   Cleveland Clinic Foundation
RP Nguyen, QD (通讯作者)，Johns Hopkins Univ Hosp, Maumenee Bldg 745,600 North Wolfe St, Baltimore, MD 21287 USA.
EM qnguyen4@jhmi.edu
OI Kaiser, Peter/0000-0001-5126-045X
FU Abbott Laboratories; Genentech, Inc.; Heidelberg Engineering; Lux
   Biosciences; Novartis Pharmaceuticals Corporation; Pfizer, Inc.;
   Regeneron Pharmaceuticals, Inc.; Alimera Sciences; Alcon Laboratories;
   Allergan, Inc.; Genzyme Corporation; GlaxoSmithKline; NeoVista, Inc.;
   Notal Vision; Ophthotech Corporation; Paloma Pharmaceuticals; Regeneron
   Pharmaceuticals, Inc, Tarrytown, NY
FX Quan Dong Nguyen (Dr. Do's spouse) - Financial support - Abbott
   Laboratories, Genentech, Inc., Heidelberg Engineering, Lux Biosciences,
   Novartis Pharmaceuticals Corporation, Pfizer, Inc., and Regeneron
   Pharmaceuticals, Inc.; Consultant-Bausch & Lomb and Santen
   Pharmaceutical, Inc.; Diana V. Do (Dr. Nguyen's spouse) - Financial
   support - Genentech, Inc., Heidelberg Engineering, and Regeneron
   Pharmaceuticals, Inc.; Jeffrey S. Heier - Consultant - Acucela, Alcon
   Laboratories, Allergan, Inc., ForSight Labs, Fovea Pharmaceuticals,
   Genentech, Inc., Genzyme Corporation, GlaxoSmithKline, NeoVista, Inc.,
   Notal Vision, Oraya Therapeutics, Paloma Pharmaceuticals, Pfizer, Inc.,
   Regeneron Pharmaceuticals, Inc., and Sequenom, Inc.; Financial support -
   Alimera Sciences, Alcon Laboratories, Allergan, Inc., Genentech, Inc.,
   Genzyme Corporation, GlaxoSmithKline, NeoVista, Inc., Notal Vision,
   Novartis Pharmaceuticals Corporation, Ophthotech Corporation, Paloma
   Pharmaceuticals, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.;
   Supported by an educational grant from Regeneron Pharmaceuticals, Inc,
   Tarrytown, NY.
CR Gever J., 2011, MEDPAGE TODAY
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
NR 2
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
SU S
BP S16
EP S22
DI 10.1016/j.ophtha.2013.01.060
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140UW
UT WOS:000318682500005
PM 23642782
DA 2022-11-30
ER

PT J
AU Huang, GC
   Chen, LJ
   Liu, HC
   Chen, YJ
AF Huang, Gwo-Che
   Chen, Lee-Jen
   Liu, Hung-Chang
   Chen, Yu-Jen
TI Development of vitreous haemorrhage during treatment with bevacizumab
   for metastatic rectal cancer
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article
ID COHERENCE TOMOGRAPHY FINDINGS; COLORECTAL-CANCER; INTRAVITREAL
   INJECTION; PHASE-II; FLUOROURACIL; LEUCOVORIN; PACLITAXEL; AVASTIN(R);
   TRIAL
AB Bevacizumab is a recombinant humanized monoclonal antibody with activity against vascular endothelial growth factor used in the treatment of various cancers. This case report describes a 65-year-old male with rectal cancer who developed a vitreous haemorrhage during treatment with bevacizumab. After vitrectomy the vitreous haemorrhage subsided and visual acuity was restored. The patient had evidence of age-related macular degeneration (AMD), which may have induced the development of vitreous haemorrhage. This implies that AMD might serve as a risk factor for vitreous haemorrhage in cancer patients treated with systemic bevacizumab. Ophthalmological examination to identify AMD lesions may be necessary prior to administration of bevacizumab. Vitrectomy could serve as a management tool for bevacizumab-associated vitreous haemorrhage.
C1 [Huang, Gwo-Che; Chen, Yu-Jen] Mackay Mem Hosp, Dept Radiat Oncol, Taipei 10449, Taiwan.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei 10449, Taiwan.
   [Liu, Hung-Chang] Mackay Mem Hosp, Dept Thorac Surg, Taipei 10449, Taiwan.
C3 Mackay Memorial Hospital; Mackay Memorial Hospital; Mackay Memorial
   Hospital
RP Chen, YJ (通讯作者)，Mackay Mem Hosp, Dept Radiat Oncol, 92 Chung Shan N Rd, Taipei 10449, Taiwan.
EM chenmdphd@yahoo.com
CR [Anonymous], 1997, AJCC CANC STAGING MA
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz H, 2006, SEMIN ONCOL, V33, pS26, DOI 10.1053/j.seminoncol.2006.08.001
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   LINDGREN G, 1995, AM J OPHTHALMOL, V119, P458, DOI 10.1016/S0002-9394(14)71232-2
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ryan S. J., 2006, RETINA
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Spraul CW, 1997, SURV OPHTHALMOL, V42, P3, DOI 10.1016/S0039-6257(97)84041-6
NR 14
TC 4
Z9 4
U1 0
U2 0
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1173-2563
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PY 2008
VL 28
IS 8
BP 523
EP 526
DI 10.2165/00044011-200828080-00007
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 333RW
UT WOS:000258171000007
PM 18598098
DA 2022-11-30
ER

PT J
AU Szabolcs, P
   Krammer-Lukas, S
AF Szabolcs, Peter
   Krammer-Lukas, Stephanie
TI Functional nutrition for the elderly
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Article
DE Vitamins; minerals; functional ingredients; healthy ageing; age-related
   conditions
ID OMEGA-3-FATTY-ACIDS
AB In the health industry, it has long been understood that elderly people have additional nutritional requirements to their younger counterparts. However, scientists continue to research the effects of ageing on our bodies and minds and the market for targeted functional foods, beverages and dietary supplements is still relatively underdeveloped. This article outlines the key health concerns affecting elderly people and the macro- and micronutrients, such as lutein, calcium and vitamin D, needed to support healthy ageing. The paper goes on to discuss how these vitamins, minerals and functional ingredients work in synergy with the body to help maintain good health and prevent age-related conditions such as age-related macular degeneration (AMD) and osteoporosis.
C1 [Szabolcs, Peter; Krammer-Lukas, Stephanie] DSM Nutr Prod Ltd, R&D Human Nutr & Hlth, CH-4002 Basel, Switzerland.
C3 DSM NV
RP Szabolcs, P (通讯作者)，DSM Nutr Prod Ltd, R&D Human Nutr & Hlth, POB 2676, CH-4002 Basel, Switzerland.
CR Babatsikou F., 2010, HEAL SCI J, V4, P24
   Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff-Ferrari HA, 2004, AM J CLIN NUTR, V80, P752
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Friedman D.S., ARCH OPTHSMOL, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hannah E.L, 2001, JAMA-J AM MED ASSOC, V285, P2736
   Holub BJ, 2002, CAN MED ASSOC J, V166, P608
   Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, 2010, DIET REF INT CALC VI
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Marini H, 2008, J CLIN ENDOCR METAB, V93, P4787, DOI 10.1210/jc.2008-1087
   Seddon J.M., 2004, JAMA-J AM MED ASSOC, V9, P1413
   Xu Q., 2008, THESIS, P3
NR 14
TC 0
Z9 0
U1 0
U2 16
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD JAN-FEB
PY 2012
VL 23
IS 1
SU S
BP 30
EP 32
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 953CR
UT WOS:000304845000006
DA 2022-11-30
ER

PT J
AU Al-Hussaini, H
   Schneiders, M
   Lundh, P
   Jeffery, G
AF Al-Hussaini, Heba
   Schneiders, Matthew
   Lundh, Peter
   Jeffery, Glen
TI Drusen are associated with local and distant disruptions to human
   retinal pigment epithelium cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE RPE; drusen; AMD; binucleation
ID MACULAR DEGENERATION; POSTMORTEM EYES; PREVALENCE; DISEASE
AB Drusen are extra-cellular deposits that form between the retinal pigment epithelium (RPE) and Bruch's membrane (BM). Numerous and/or confluent drusen are a significant risk factor for age-related macular degeneration (AMD). Here, using whole mounted human RPE preparation we show that RPE cell morphology changes in association with drusen. These changes included an increase in cell size and distortion in the regularity of their distribution. Further, although binucleation is relatively rare in human RPE, there was a marked increase in the number of binucleated RPE cell associated with individual druse. Surprisingly many of these changes were found at distances up to 400 mu m from drusen. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Jeffery, Glen] UCL, Div Visual Sci, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London
RP Jeffery, G (通讯作者)，UCL, Div Visual Sci, Inst Ophthalmol, Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
FU Kuwait University
FX This research was supported by the Rosetree Trust and Fight for Sight
   UK. Heba Al-Hosaini was supported by a fellowship from Kuwait
   University.
CR BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   LEWIS H, 1986, AM J OPHTHALMOL, V102, P801, DOI 10.1016/0002-9394(86)90417-4
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
NR 12
TC 34
Z9 36
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2009
VL 88
IS 3
BP 610
EP 612
DI 10.1016/j.exer.2008.09.021
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 427MR
UT WOS:000264783900034
PM 18992244
DA 2022-11-30
ER

PT J
AU Rothmayer, M
   Dultz, W
   Frins, E
   Zhan, Q
   Tierney, D
   Schmitzer, H
AF Rothmayer, Mark
   Dultz, Wolfgang
   Frins, Erna
   Zhan, Qiwen
   Tierney, Dennis
   Schmitzer, Heidrun
TI Nonlinearity in the rotational dynamics of Haidinger's brushes
SO APPLIED OPTICS
LA English
DT Article
ID MACULAR PIGMENT; BIREFRINGENCE; MODEL; DICHROISM; LUTEIN
AB Haidinger's brushes are an entoptic effect of the human visual system that enables us to detect polarized light. However, individual perceptions of Haidinger's brushes can vary significantly. We find that the birefringence of the cornea influences the rotational motion and the contrast of Haidinger's brushes and may offer an explanation for individual differences. We have devised an experimental setup to simulate various phase shifts of the cornea and found a switching effect in the rotational dynamics of Haidinger's brushes. In addition, age related macular degeneration reduces the polarization effect of the macula and thus also leads to changes in the brush pattern. (C) 2007 Optical Society of America.
C1 Xavier Univ, Cincinnati, OH 45207 USA.
   Goethe Univ Frankfurt, D-60054 Frankfurt, Germany.
   Inst Fis, Montevideo 113000, Uruguay.
   Univ Dayton, Dayton, OH 45469 USA.
C3 Xavier University; Goethe University Frankfurt; University of Dayton
RP Schmitzer, H (通讯作者)，Xavier Univ, Cincinnati, OH 45207 USA.
EM schmitzer@xavier.edu
OI Frins, Erna/0000-0002-3733-9118
CR ANN E, 2006, COMMUNICATION
   ARJMANDI S, 2004, INT C SCI WAIK
   BOEHM G., 1940, ACTA OPHTHALMOL [COPENHAGEN], V18, P109
   BONE RA, 1980, VISION RES, V20, P213, DOI 10.1016/0042-6989(80)90105-4
   BONE RA, 1983, APPL OPTICS, V22, P775, DOI 10.1364/AO.22.000775
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   BRINK HBK, 1988, J OPT SOC AM A, V5, P49, DOI 10.1364/JOSAA.5.000049
   BRONSTEIN IN, 1981, TASCHENBUCH MATH
   *FRANK WOOL CO, POL AZ POL FLIPS RES
   GRIFFIN JR, 1976, BINOCULAR ANOMALIES
   HELMHOLTZ H, 1924, TREATISE PHYS OPTICS, V2, P301
   HEMENGER RP, 1982, J OPT SOC AM, V72, P734, DOI 10.1364/JOSA.72.000734
   HOCHHEIMER BF, 1982, APPL OPTICS, V21, P3811, DOI 10.1364/AO.21.003811
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P82
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   MISSON GP, 1993, OPHTHAL PHYSL OPT, V13, P392, DOI 10.1111/j.1475-1313.1993.tb00497.x
   Misson GP, 2003, OPHTHAL PHYSL OPT, V23, P441, DOI 10.1046/j.1475-1313.2003.00138.x
   MYROWITZ E, 1979, AM J OPTOM PHYS OPT, V56, P305
   NAYLOR EJ, 1954, J PHYSIOL-LONDON, V124, P543, DOI 10.1113/jphysiol.1954.sp005127
   Ramachandran G.N., 1961, ENCY PHYS, VXXV/1, P1
   SHUTE CCD, 1974, NATURE, V250, P163, DOI 10.1038/250163a0
   SMITH RW, 1975, J PHYSL, V246, P37
   STANWORTH A, 1955, T OPHTHAL SOC UK, V75, P67
   STANWORTH A, 1950, J OPHTHAMOL, V34, P282
   SUMMERS DM, 1970, J OPT SOC AM, V60, P271, DOI 10.1364/JOSA.60.000271
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WALD G., 1949, DOCUMENTA OPHTHALMOL, V3, P94, DOI 10.1007/BF00162600
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
NR 29
TC 12
Z9 14
U1 1
U2 9
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1559-128X
EI 2155-3165
J9 APPL OPTICS
JI Appl. Optics
PD OCT 10
PY 2007
VL 46
IS 29
BP 7244
EP 7251
DI 10.1364/AO.46.007244
PG 8
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 228ZE
UT WOS:000250770300023
PM 17932536
DA 2022-11-30
ER

PT J
AU Yang, X
   Yu, XW
   Zhang, DD
   Fan, ZG
AF Yang, Xue
   Yu, Xiao-Wei
   Zhang, Dan-Dan
   Fan, Zhi-Gang
TI Blood-retinal barrier as a converging pivot in understanding the
   initiation and development of retinal diseases
SO CHINESE MEDICAL JOURNAL
LA English
DT Review
DE Blood-retinal barrier; Retinal inflammatory diseases; Age-related
   macular degeneration; Diabetic retinopathy; Primary open-angle glaucoma;
   Neuroinflammation
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY;
   MITOCHONDRIAL DYSFUNCTION; MACULAR-DEGENERATION; OXIDATIVE STRESS; GUT
   MICROBIOTA; INFLAMMATION; ACTIVATION; BREAKDOWN
AB Clinical ophthalmologists consider each retinal disease as a completely unique entity. However, various retinal diseases, such as uveitis, age-related macular degeneration, diabetic retinopathy, and primary open-angle glaucoma, share a number of common pathogenetic pathways. Whether a retinal disease initiates from direct injury to the blood-retinal barrier (BRB) or a defect/injury to retinal neurons or glia that impairs the BRB secondarily, the BRB is a pivotal point in determining the prognosis as self-limiting and recovering, or developing and progressing to a clinical phenotype. The present review summarizes our current knowledge on the physiology and cellular and molecular pathology of the BRB, which underlies its pivotal role in the initiation and development of common retinal diseases.
C1 [Yang, Xue; Yu, Xiao-Wei; Zhang, Dan-Dan; Fan, Zhi-Gang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Fan, ZG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM fanzhg3@mail.sysu.edu.cn
FU Major Project of National Natural Science Foundation of China
   (NSFC)Guangdong Province Joint Fund [3030902113080]; Science and
   Technology Planning Project of Guangdong Province [303090100502050-18];
   Guangzhou Science and Technology Plan Project [201803040020,
   201903010065]
FX This study was supported by grants from the Major Project of National
   Natural Science Foundation of China (NSFC)Guangdong Province Joint Fund
   (No. 3030902113080), the Science and Technology Planning Project of
   Guangdong Province (No. 303090100502050-18), and the Guangzhou Science
   and Technology Plan Project (Nos. 201803040020 and 201903010065).
CR Ahlers C, 2009, ACTA OPHTHALMOL, V87, P511, DOI 10.1111/j.1755-3768.2008.01468.x
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Bamforth SD, 1996, ACTA NEUROPATHOL, V91, P624, DOI 10.1007/s004010050476
   Barber AJ, 2015, SCI CHINA LIFE SCI, V58, P541, DOI 10.1007/s11427-015-4856-x
   Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144589
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen YG, 2018, CHINESE MED J-PEKING, V131, P1618, DOI 10.4103/0366-6999.235112
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Coburn PS, 2015, INVEST OPHTH VIS SCI, V56, P7303, DOI 10.1167/iovs.15-17488
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Diedrichs-Mohring M, 2018, PROG RETIN EYE RES, V65, P107, DOI 10.1016/j.preteyeres.2018.02.003
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Fardini Y, 2011, MOL MICROBIOL, V82, P1468, DOI 10.1111/j.1365-2958.2011.07905.x
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Forrester JV, 2018, AM J OPHTHALMOL, V189, P77, DOI 10.1016/j.ajo.2018.02.019
   Frey T, 2011, ANTIOXID REDOX SIGN, V15, P1271, DOI 10.1089/ars.2011.3906
   Furtado JM, 2012, IMMUNOL CELL BIOL, V90, P912, DOI 10.1038/icb.2012.21
   Gu XW, 2014, AM J PATHOL, V184, P541, DOI 10.1016/j.ajpath.2013.10.022
   Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454
   Hayreh SS, 2015, RETINA-J RET VIT DIS, V35, P29, DOI 10.1097/IAE.0000000000000256
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Imai A, 2017, AM J PATHOL, V187, P999, DOI 10.1016/j.ajpath.2017.01.014
   Jong AY, 2001, INFECT IMMUN, V69, P4536, DOI 10.1128/IAI.69.7.4536-4544.2001
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klein R, 2010, OPHTHALMOLOGY, V117, P63, DOI 10.1016/j.ophtha.2009.06.051
   Kowluru RA, 2018, EXPERT OPIN THER TAR, V22, P233, DOI 10.1080/14728222.2018.1439921
   Kowluru RA, 2015, BBA-MOL BASIS DIS, V1852, P2474, DOI 10.1016/j.bbadis.2015.08.001
   Kusuhara S, 2018, DIABETES METAB J, V42, P364, DOI 10.4093/dmj.2018.0182
   Lally DR, 2016, SURV OPHTHALMOL, V61, P759, DOI 10.1016/j.survophthal.2016.03.010
   Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9
   Liu SA, 2018, CHINESE MED J-PEKING, V131, P2852, DOI 10.4103/0366-6999.246069
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Maenz M, 2014, PROG RETIN EYE RES, V39, P77, DOI 10.1016/j.preteyeres.2013.12.005
   Mahajan N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8458472
   Mander KA, 2018, J COMP PATHOL, V158, P51, DOI 10.1016/j.jcpa.2017.11.003
   Mangan BG, 2007, VET OPHTHALMOL, V10, P117, DOI 10.1111/j.1463-5224.2007.00585.x
   Mecha M, 2016, PHARMACOL THERAPEUT, V166, P40, DOI 10.1016/j.pharmthera.2016.06.011
   Mietelska-Porowska A, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4626540
   Miloudi K, 2016, J CLIN INVEST, V126, P3006, DOI 10.1172/JCI84767
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Morrison DJ, 2016, GUT MICROBES, V7, P189, DOI 10.1080/19490976.2015.1134082
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Najeeb BH, 2017, INVEST OPHTH VIS SCI, V58, P3986, DOI 10.1167/iovs.17-21510
   Noda K, 2014, FASEB J, V28, P2038, DOI 10.1096/fj.12-215715
   Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116
   Opdenakker G, 2019, CELL MOL LIFE SCI, V76, P3157, DOI 10.1007/s00018-019-03177-3
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   ROBINSON JVA, 1975, BRIT J EXP PATHOL, V56, P14
   Romaniuk VM, 2013, EMERG MED CLIN N AM, V31, P399, DOI 10.1016/j.emc.2013.02.003
   Sampson TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/j.chom.2015.04.011
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   Senatorov VV, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8283
   Shechter R, 2013, NAT REV IMMUNOL, V13, P206, DOI 10.1038/nri3391
   Singh PK, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92340
   Song HB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175159
   Spadoni I, 2017, NAT REV IMMUNOL, V17, P761, DOI 10.1038/nri.2017.100
   Spielman LJ, 2018, NEUROCHEM INT, V120, P149, DOI 10.1016/j.neuint.2018.08.005
   Suematsu M, 2002, MICROCIRCULATION, V9, P259, DOI 10.1038/sj.mn.7800141
   Tan SY, 2014, LAB INVEST, V94, P777, DOI 10.1038/labinvest.2014.72
   Thaiss CA, 2016, NATURE, V535, P65, DOI 10.1038/nature18847
   Tien T, 2017, INVEST OPHTH VIS SCI, V58, P2915, DOI 10.1167/iovs.16-21355
   Tonade D, 2017, DIABETOLOGIA, V60, P2111, DOI 10.1007/s00125-017-4381-5
   Trost A, 2015, EXP EYE RES, V136, P59, DOI 10.1016/j.exer.2015.05.010
   Uhl PB, 2014, J PROTEOMICS, V109, P50, DOI 10.1016/j.jprot.2014.06.020
   Wang HX, 2016, CHINESE MED J-PEKING, V129, P2373, DOI 10.4103/0366-6999.190667
   Weinreb RN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.67
   Willermain F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041056
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang HY, 2015, BRAIN RES, V1623, P74, DOI 10.1016/j.brainres.2015.03.012
NR 78
TC 12
Z9 11
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0366-6999
EI 2542-5641
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD NOV 5
PY 2020
VL 133
IS 21
BP 2586
EP 2594
DI 10.1097/CM9.0000000000001015
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OL7FC
UT WOS:000585499900008
PM 32852382
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Behar-Cohen, F
   Dernigoghossian, M
   Andrieu-Soler, C
   Levy, R
   Cohen, R
   Zhao, M
AF Behar-Cohen, Francine
   Dernigoghossian, Marilyn
   Andrieu-Soler, Charlotte
   Levy, Rinath
   Cohen, Raphael
   Zhao, Min
TI Potential antiedematous effects of intravitreous anti-VEGF, unrelated to
   VEGF neutralization
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID MACULAR DEGENERATION; BARRIER BREAKDOWN; RANIBIZUMAB; PHARMACOKINETICS;
   BEVACIZUMAB; EXPRESSION; PRIMATE; DRUGS; EDEMA
AB The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR). It has revolutionized the visual prognosis of patients with macular edema. The antiedematous effect is dependent on an intravitreous dose of drug, which varies between patients and requires frequent and repeated injections to maintain its effects. At the time when optimizing the duration of anti-VEGF effects is a major challenge, understanding how anti-VEGF reduces macular edema is crucial. We discuss herein how antiVEGF exerts antiedematous effects and raise the hypothesis that mechanisms, unrelated to VEGF neutralization, might have been underestimated.
C1 [Behar-Cohen, Francine; Dernigoghossian, Marilyn; Andrieu-Soler, Charlotte; Levy, Rinath; Cohen, Raphael; Zhao, Min] Ctr Rech Cordeliers, INSERM, UMR S 1138, Team 17, Paris, France.
   [Behar-Cohen, Francine; Dernigoghossian, Marilyn; Levy, Rinath; Cohen, Raphael; Zhao, Min] Univ Paris 06, Sorbonne Univ, Ctr Rech Cordeliers, UMR S 1138, Paris, France.
   [Behar-Cohen, Francine; Dernigoghossian, Marilyn; Levy, Rinath; Cohen, Raphael; Zhao, Min] Paris Descartes Univ, Sorbonne Paris Cite, Ctr Rech Cordeliers, UMR S 1138, Paris, France.
   [Andrieu-Soler, Charlotte] Univ Montpellier, CNRS, IGMM, Montpellier, France.
   [Behar-Cohen, Francine] Ophtalmopole Hop Cohin, AP HP, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; Centre National de la Recherche
   Scientifique (CNRS); Universite de Montpellier; Assistance Publique
   Hopitaux Paris (APHP); UDICE-French Research Universities; Universite
   Paris Cite
RP Behar-Cohen, F (通讯作者)，Ctr Rech Cordeliers, INSERM, UMR S 1138, Team 17, Paris, France.; Behar-Cohen, F (通讯作者)，Univ Paris 06, Sorbonne Univ, Ctr Rech Cordeliers, UMR S 1138, Paris, France.; Behar-Cohen, F (通讯作者)，Paris Descartes Univ, Sorbonne Paris Cite, Ctr Rech Cordeliers, UMR S 1138, Paris, France.; Behar-Cohen, F (通讯作者)，Ophtalmopole Hop Cohin, AP HP, Paris, France.
EM Francine.behar@gmail.com
RI Zhao, Min/AAX-7664-2020
OI Zhao, Min/0000-0002-5418-7275; Andrieu-Soler,
   Charlotte/0000-0002-3287-6117; behar cohen, francine/0000-0001-8571-9513
CR Behar-Cohen F., 2019, Patent No. [WO2019043179, 2019043179]
   Campochiaro PA, 2016, AM J OPHTHALMOL, V168, P13, DOI 10.1016/j.ajo.2016.04.017
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   Comitato R, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040093
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Hillier R. J., 2016, RETINA, V37, P761
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Li XM, 2014, INVEST OPHTH VIS SCI, V55, P6224, DOI 10.1167/iovs.14-14613
   Lv J, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/9216791
   MARMOR MF, 1985, JPN J OPHTHALMOL, V29, P131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sangroongruangsri S, 2018, EXPERT REV CLIN PHAR, V11, P903, DOI 10.1080/17512433.2018.1507735
   Shimura M, 2008, ACTA OPHTHALMOL, V86, P377, DOI 10.1111/j.1600-0420.2007.01074.x
   Sitohy B, 2017, AM J PATHOL, V187, P2337, DOI 10.1016/j.ajpath.2017.06.010
   Solomon S. D, 2014, COCHRANE DB SYST REV, V2014
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Tauseef M, 2016, FASEB J, V30, P102, DOI 10.1096/fj.15-275891
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Visanji NP, 2018, NEUROSCI LETT, V665, P18, DOI 10.1016/j.neulet.2017.11.001
   Wahl V, 2013, NEUROSCIENCE, V246, P59, DOI 10.1016/j.neuroscience.2013.04.045
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Zhang CH, 2016, DISCOV MED, V21, P227
NR 30
TC 4
Z9 4
U1 1
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2019
VL 24
IS 8
SI SI
BP 1436
EP 1439
DI 10.1016/j.drudis.2019.05.034
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IX7GP
UT WOS:000485852100004
PM 31173913
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Liu, C
   Liu, XF
   Qi, J
   Pant, OP
   Lu, CW
   Hao, JL
AF Liu, Cong
   Liu, Xiufen
   Qi, Jing
   Pant, Om Prakash
   Lu, Cheng-wei
   Hao, Jilong
TI DJ-1 in Ocular Diseases: A Review
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Review
DE DJ-1; ocular disease; oxidative stress
ID PI3K/AKT SIGNALING PATHWAY; PRIMARY-OPEN-ANGLE; ENDOTHELIAL
   CORNEAL-DYSTROPHY; INCREASED OXIDATIVE STRESS; GLUTATHIONE LEVELS
   OCCURS; NORMAL-TENSION GLAUCOMA; REGULATING KINASE 1; INDUCED APOPTOSIS;
   UVEAL MELANOMA; PARKINSONS-DISEASE
AB Protein deglycase DJ-1 (Parkinson disease protein 7) is a 20 kDa protein encoded by PARK7 gene. It is also known as a redox-sensitive chaperone and sensor that protect cells against oxidative stress-induced cell death in many human diseases. Though increasing evidence implicates that DJ-1 may also participate in ocular diseases, the overview of DJ-1 in ocular diseases remains elusive. In this review, we discuss the role as well as the underlying molecular mechanisms of DJ-1 in ocular diseases, including Fuchs endothelial corneal dystrophy (FECD), age-related macular degeneration (AMD), cataracts, and ocular neurodegenerative diseases, highlighting that DJ-1 may serve as a very striking therapeutic target for ocular diseases.
C1 [Liu, Cong; Liu, Xiufen; Qi, Jing; Pant, Om Prakash; Lu, Cheng-wei; Hao, Jilong] Jilin Univ, Hosp 1, Dept Ophthalmol, Jilin, Jilin, Peoples R China.
C3 Jilin University
RP Lu, CW; Hao, JL (通讯作者)，Jilin Univ, Hosp 1, Dept Ophthalmol, Jilin, Jilin, Peoples R China.
EM lcwchina800@sina.com; 289736582@qq.com
OI Pant, Om Prakash/0000-0002-2966-4383
CR Andersen MR, 2017, CLIN OPHTHALMOL, V11, P1519, DOI 10.2147/OPTH.S142206
   Babizhayev MA, 2016, AM J THER, V23, pE98, DOI 10.1097/MJT.0b013e3181ea31ff
   Bande MF, 2012, INVEST OPHTH VIS SCI, V53, P62, DOI 10.1167/iovs.11-7948
   Blackinton J, 2009, J BIOL CHEM, V284, P6476, DOI 10.1074/jbc.M806599200
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Bonilha VL, 2015, EXP EYE RES, V139, P22, DOI 10.1016/j.exer.2015.07.014
   Chan JYH, 2015, PHARMACOL THERAPEUT, V156, P69, DOI 10.1016/j.pharmthera.2015.09.005
   Chaudhary P, 2011, J NEUROIMMUNOL, V233, P90, DOI 10.1016/j.jneuroim.2010.12.002
   Chen LL, 2015, J CANCER RES CLIN, V141, P315, DOI 10.1007/s00432-014-1804-2
   Dong ZY, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00191
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Gherghel D, 2013, INVEST OPHTH VIS SCI, V54, P3333, DOI 10.1167/iovs.12-11256
   Gilgun-Sherki Y, 2004, J NEUROL, V251, P261, DOI 10.1007/s00415-004-0348-9
   Goyal A, 2014, CURR EYE RES, V39, P823, DOI 10.3109/02713683.2011.556299
   Guo X, 2017, ADV BIOL REGUL
   Guo XL, 2011, INVEST OPHTH VIS SCI, V52, P2696, DOI 10.1167/iovs.10-6015
   Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536
   Harada C, 2010, CELL DEATH DIFFER, V17, P1751, DOI 10.1038/cdd.2010.62
   Hattori K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-9
   Hod Y, 2004, J CELL BIOCHEM, V92, P1221, DOI 10.1002/jcb.20159
   Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8
   Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200
   Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6
   Im JY, 2012, HUM MOL GENET, V21, P3013, DOI 10.1093/hmg/dds131
   Jung KA, 2010, MOLECULES, V15, P7266, DOI 10.3390/molecules15107266
   Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102
   Kaliki S, 2015, INDIAN J OPHTHALMOL, V63, P93, DOI 10.4103/0301-4738.154367
   Kawarazaki Y, 2014, EXPERT OPIN THER TAR, V18, P651, DOI 10.1517/14728222.2014.896903
   Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010
   Kim YC, 2009, INT J ONCOL, V35, P1331, DOI 10.3892/ijo_00000451
   Kimura A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2817252
   Larabee CM, 2016, MOL VIS, V22, P1503
   Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200
   Lev N, 2009, J NEURAL TRANSM, V116, P151, DOI 10.1007/s00702-008-0134-4
   Liao GX, 2016, NEUROSCIENCE, V331, P40, DOI 10.1016/j.neuroscience.2016.06.019
   Linge A, 2012, INVEST OPHTH VIS SCI, V53, P4634, DOI 10.1167/iovs.11-9019
   Liu CL, 2014, INVEST OPHTH VIS SCI, V55, P5551, DOI 10.1167/iovs.14-14580
   Liu SF, 2010, HEPATO-GASTROENTEROL, V57, P1247
   MacKeigan JP, 2003, CANCER RES, V63, P6928
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218
   Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132
   Nakazawa T, 2003, CURR EYE RES, V26, P55, DOI 10.1076/ceyr.26.1.55.14254
   Osborne NN, 2013, CURR OPIN PHARMACOL, V13, P16, DOI 10.1016/j.coph.2012.09.002
   Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011
   Ramasamy P, 2014, EXP EYE RES, V118, P1, DOI 10.1016/j.exer.2013.09.005
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Seki M, 2008, PROG BRAIN RES, V173, P495, DOI 10.1016/S0079-6123(08)01134-5
   Shen Z, 2011, EUR J HISTOCHEM, V55, P50, DOI 10.4081/ejh.2011.e9
   Sun J, 2015, MOL VIS, V21, P955
   Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074
   Taira T, 2001, GENE, V263, P285, DOI 10.1016/S0378-1119(00)00590-4
   Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200
   Vedana G, 2016, CLIN OPHTHALMOL, V10, P321, DOI 10.2147/OPTH.S83467
   Waak J, 2009, J BIOL CHEM, V284, P14245, DOI 10.1074/jbc.M806902200
   Wang BL, 2017, AGING CELL, V16, P244, DOI 10.1111/acel.12548
   Wang XL, 2012, J NEUROCHEM, V121, P830, DOI 10.1111/j.1471-4159.2012.07734.x
   Wei Y, 2007, PLOS COMPUT BIOL, V3, P120, DOI 10.1371/journal.pcbi.0030010
   Yang XG, 2017, J MOL NEUROSCI, V61, P581, DOI 10.1007/s12031-017-0899-8
   Yuen HF, 2008, CANCER EPIDEM BIOMAR, V17, P3593, DOI 10.1158/1055-9965.EPI-08-0214
   Zhong N, 2006, J BIOL CHEM, V281, P20940, DOI 10.1074/jbc.M601935200
   Zhou WB, 2006, J MOL BIOL, V356, P1036, DOI 10.1016/j.jmb.2005.12.030
   Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200
   Ziaei A, 2013, INVEST OPHTH VIS SCI, V54, P6724, DOI 10.1167/iovs.13-12699
NR 67
TC 6
Z9 6
U1 0
U2 5
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2018
VL 15
IS 5
BP 430
EP 435
DI 10.7150/ijms.23428
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FZ0TS
UT WOS:000427286600003
PM 29559831
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Goncalves, V
   Gautier, B
   Garbay, C
   Vidal, M
   Inguimbert, N
AF Goncalves, Victor
   Gautier, Benoit
   Garbay, Christiane
   Vidal, Michel
   Inguimbert, Nicolas
TI Structure-based design of a bicyclic peptide antagonist of the vascular
   endothelial growth factor receptors
SO JOURNAL OF PEPTIDE SCIENCE
LA English
DT Article
DE angiogenesis; antagonist; Flt-1; peptide cyclization; vascular
   endothelial growth factor; VEGF receptor
ID CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; VEGF; ANGIOGENESIS; BINDING;
   SITE
AB Dysregulated angiogenesis is implicated in several pathologies, including cancer and age-related macular degeneration. A potential antiangiogenic strategy consists in developing VEGF receptor ligands capable of preventing VEGF binding and the subsequent activation of these receptors. Herein, we describe the structure-based design of a VEGF-mimicking peptide, VG3F. This 25-mer peptide was doubly cyclized, on-resin, by formation of both a disulfide bridge and an intramolecular amide bond to constrain it to adopt a bioactive conformation. Tested on in vitro assays, VG3F was able to prevent VEGF binding to VEGF receptor 1 and inhibit both VEGF-induced signal transduction and cell migration. Copyright (C) 2007 European Peptide Society and John Wiley & Sons, Ltd.
C1 [Goncalves, Victor; Gautier, Benoit; Garbay, Christiane; Vidal, Michel; Inguimbert, Nicolas] Univ Paris 05, UFR Biomed, Lab Pharmacochim Mol & Cellulaire, FR-75006 Paris, France.
   [Goncalves, Victor; Gautier, Benoit; Garbay, Christiane; Vidal, Michel; Inguimbert, Nicolas] INSERM, U648, F-75006 Paris, France.
C3 UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm)
RP Vidal, M (通讯作者)，Lab Pharmacochim Mol & Cellulaire, UFR Biomed, 45 Rue Saints Peres, FR-75270 Paris 06, France.
EM michel.vidal@univ-paris5.fr; nicolas.inguimbert@univ-paris5.fr
RI Inguimbert, Nicolas/N-3703-2015; Vidal, Michel/ABA-3396-2020; Goncalves,
   Victor/B-7560-2009; Goncalves, Victor/O-1099-2019
OI Inguimbert, Nicolas/0000-0002-0309-9048; Goncalves,
   Victor/0000-0001-9854-4409; Goncalves, Victor/0000-0001-9854-4409;
   Gautier, Benoit/0000-0002-8249-2525; Vidal, Michel/0000-0002-4858-1591
CR Alcaro MC, 2004, J PEPT SCI, V10, P218, DOI 10.1002/psc.512
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   CHANG CD, 1978, INT J PEPT PROT RES, V11, P246
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   D'Andrea LD, 2006, CHEM BIOL DRUG DES, V67, P115, DOI 10.1111/j.1747-0285.2006.00356.x
   El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   GONCALVES V, 2006, PHARMACHEM, P15
   Goncalves V, 2007, ANAL BIOCHEM, V366, P108, DOI 10.1016/j.ab.2007.03.027
   Joseph CG, 2004, J MED CHEM, V47, P6702, DOI 10.1021/jm0492756
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   MAZUR S, 1979, J AM CHEM SOC, V101, P677, DOI 10.1021/ja00497a032
   Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Zilberberg L, 2003, J BIOL CHEM, V278, P35564, DOI 10.1074/jbc.M304435200
NR 19
TC 15
Z9 15
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1075-2617
J9 J PEPT SCI
JI J. Pept. Sci.
PD JUN
PY 2008
VL 14
IS 6
BP 767
EP 772
DI 10.1002/psc.965
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 317RD
UT WOS:000257036400013
PM 18044812
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
   Peyman, GA
AF Moshfeghi, AA
   Peyman, GA
TI Micro- and nanoparticulates
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE age-related macular degeneration; microparticulates; nanoparticulates;
   drug delivery; pharmacotherapy; choroidal neovascularization
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; ENDOTHELIAL GROWTH-FACTOR;
   DRUG-DELIVERY; GANCICLOVIR IMPLANT; CYTOMEGALOVIRUS RETINITIS; IN-VIVO;
   VEGF; MICROSPHERES; NEOVASCULARIZATION; THERAPY
AB Objectives: Pharmacotherapeutics has begun to play an increasingly important role in the management of patients with neovascular age-related macular degeneration (AMD). Because micro- and nano-particulates are currently being evaluated as a potential drug-delivery option for AMD patients, the purpose of this analysis was to describe how micro- and nanoparticulates have been used experimentally and what their potential clinical applications may be.
   Findings: Micro- and nano-particulates have been used primarily on a pre-clinical basis as new drug-delivery devices in experimental models of neovascular AMD.
   Conclusions: It is likely that micro- and nano-particulates will become an important component of targeted clinical pharmacotherapeutics in patients with neovascular AMD. (c) 2005 Published by Elsevier B.V.
C1 Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   Tulane Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.
C3 Bascom Palmer Eye Institute; Tulane University
RP Moshfeghi, AA (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM amoshfeghi@med.miami.edu; gpeyman@tulane.edu
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Duker JS, 1995, OPHTHALMIC SURG LAS, V26, P442
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   GIORDANO GG, 1993, INVEST OPHTH VIS SCI, V34, P2743
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kranz H, 2000, J PHARM SCI-US, V89, P1558
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LIEBERMAN RM, 1994, NEW ENGL J MED, V330, P868, DOI 10.1056/NEJM199403243301219
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   MCCUEN BW, 1981, AM J OPHTHALMOL, V91, P785, DOI 10.1016/0002-9394(81)90013-1
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Murray TG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1286, DOI 10.1001/archopht.1997.01100160456013
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   PEYMAN GA, 1992, INT OPHTHALMOL, V16, P109, DOI 10.1007/BF00918942
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   RAHIMY MH, 1994, J DRUG TARGET, V2, P289, DOI 10.3109/10611869409015909
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Scott IU, 2003, AM J OPHTHALMOL, V136, P737, DOI 10.1016/S0002-9394(03)00266-6
   Sone H, 1999, LIFE SCI, V65, P2573, DOI 10.1016/S0024-3205(99)00526-3
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
NR 39
TC 66
Z9 69
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 13
PY 2005
VL 57
IS 14
BP 2047
EP 2052
DI 10.1016/j.addr.2005.09.006
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 996QD
UT WOS:000234188300005
PM 16298454
DA 2022-11-30
ER

PT J
AU Masuda, T
   Shimazawa, M
   Hara, H
AF Masuda, Tomomi
   Shimazawa, Masamitsu
   Hara, Hideaki
TI The kallikrein system in retinal damage/protection
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Kallikrein; Glaucoma; Diabetic retinopathy; Age-related macular
   degeneration; Ocular ischemic syndrome; Vascular endothelial growth
   factor
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; VASCULAR
   DYSFUNCTION; PLASMA; ANGIOGENESIS; PRESSURE; PROTECTS; GLAUCOMA; VEGF
AB Kallikrein is a serine protease involved in the kallikrein-kinnin system. Kallikrein is derived from the blood plasma or tissue, and is correlated with aggravation and improvement in eye diseases, such as, glaucoma, diabetic retinopathy, age-related macular degeneration, and ocular ischemic syndrome. The plasma kallikrein stimulates retinal vascular permeability and intraocular hemorrhage. On the other hand, we had reported that the tissue kallikrein normalizes retinal vasopermeability and inhibited retinal neovascularization and retinal ischemic injuiy. The protective mechanisms of the tissue-derived kallikrein include the cleavage of vascular endothelial growth factor (VEGF), which suggests that the tissue kallikrein could be potentially-effective against any disease involving the VEGF production. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Masuda, Tomomi; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu, Japan.
EM masuda@gmail.com; shimazawa@gifu-pu.ac.jp; hidehara@gifu-pu.ac.jp
OI Hara, Hideaki/0000-0003-2046-9001
CR Arden G B, 2006, J Br Menopause Soc, V12, P64, DOI 10.1258/136218006777525703
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Clermont A, 2011, DIABETES, V60, P1590, DOI 10.2337/db10-1260
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fleischman D, 2013, SAUDI J OPHTHALMOL, V27, P97, DOI 10.1016/j.sjopt.2013.03.002
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fukuhara J, 2013, INVEST OPHTH VIS SCI, V54, P274, DOI 10.1167/iovs.12-10512
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kato N, 2009, EUR J PHARMACOL, V606, P187, DOI 10.1016/j.ejphar.2009.01.027
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu J, 2013, INVEST OPHTH VIS SCI, V54, P1086, DOI 10.1167/iovs.12-10537
   Llobet A, 1999, INVEST OPHTH VIS SCI, V40, P113
   Malaguarnera G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/191497
   Masuda T, 2014, EUR J PHARMACOL, V738, P74, DOI 10.1016/j.ejphar.2014.05.033
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nakamura S, 2011, ARTERIOSCL THROM VAS, V31, P1041, DOI 10.1161/ATVBAHA.111.223594
   Papageorgiou PC, 2014, J HYPERTENS, V32, P1523, DOI 10.1097/HJH.0000000000000192
   Pathak M, 2013, THROMB HAEMOSTASIS, V110, P423, DOI 10.1160/TH12-11-0840
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Sharif NA, 1996, EXP EYE RES, V63, P631, DOI 10.1006/exer.1996.0157
   Sharif NA, 2014, DRUG DEVELOP RES, V75, P211, DOI 10.1002/ddr.21174
   SIVALINGAM A, 1991, INT OPHTHALMOL, V15, P15, DOI 10.1007/BF00150974
   Webb JG, 2011, J OCUL PHARMACOL TH, V27, P539, DOI 10.1089/jop.2011.0187
   Webb JG, 2003, EXP EYE RES, V76, P283, DOI 10.1016/S0014-4835(02)00313-5
   Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226
   Xia CF, 2006, HUM GENE THER, V17, P206, DOI 10.1089/hum.2006.17.206
NR 30
TC 9
Z9 10
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD FEB 15
PY 2015
VL 749
BP 161
EP 163
DI 10.1016/j.ejphar.2014.10.007
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CB6UI
UT WOS:000349761800019
PM 25448306
DA 2022-11-30
ER

PT J
AU Picaud, S
   Sahel, JA
AF Picaud, Serge
   Sahel, Jose-Alain
TI Retinal prostheses: Clinical results and future challenges
SO COMPTES RENDUS BIOLOGIES
LA English
DT Article
DE Neuroprostheses; Vision; Retina; Blindness; Rehabilitation
ID ELECTRICAL-STIMULATION; ARTIFICIAL VISION; VISUAL-PERCEPTION; BLIND;
   IMPLANTATION; FEASIBILITY; SIMULATION; RESOLUTION; DYNAMICS; DIAMOND
AB Retinal prostheses aim at restoring visual perception in blind patients affected by retinal diseases leading to the loss of photoreceptors, such as age-related macular degeneration or retinitis pigmentosa. Recent clinical trials have demonstrated the feasibility of this approach for restoring useful vision. Despite a limited number of electrodes (60), and therefore of pixels, some patients were able to read words and to recognize high-contrast objects. Face recognition and independent locomotion in unknown urban environments imply technological breakthroughs to increase the number and density of electrodes. This review presents recent clinical results and discusses future solutions to answer the major technological challenges. (c) 2014 Published by Elsevier Masson SAS on behalf of Academie des sciences.
C1 [Picaud, Serge; Sahel, Jose-Alain] INSERM, Inst Vis, U968, F-75012 Paris, France.
   [Picaud, Serge; Sahel, Jose-Alain] Sorbonne Univ, Univ Paris 06, Inst Vis, UMR S968, F-75012 Paris, France.
   [Picaud, Serge; Sahel, Jose-Alain] CNRS, Inst Vis, UMR 7210, F-75012 Paris, France.
   [Picaud, Serge; Sahel, Jose-Alain] Fdn Ophtalmol Adolphe de Rothschild, F-75019 Paris, France.
   [Sahel, Jose-Alain] Ctr Hosp Natl Ophtalmol Quinze Vingts, F-75012 Paris, France.
   [Sahel, Jose-Alain] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Sahel, Jose-Alain] Acad Sci, Inst France, F-75006 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; UDICE-French
   Research Universities; Sorbonne Universite; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; CHNO des Quinze-Vingts; UDICE-French Research
   Universities; Sorbonne Universite; University of London; University
   College London
RP Picaud, S (通讯作者)，INSERM, Inst Vis, U968, 17 Rue Moreau, F-75012 Paris, France.
EM serge.picaud@inserm.fr
RI Sahel, Jose-Alain/F-3172-2017; Picaud, Serge/H-4012-2014
OI Sahel, Jose-Alain/0000-0002-4831-1153; Picaud, Serge/0000-0002-0548-5145
FU INSERM; University Pierreet-Marie-Curie (Paris-6), CNRS,
   Ophthalmological Foundation Rothschild (Paris); National Agency for
   Research (ANR RETINA, ANR MEDINAS), "Fondation de la recherche medicale;
   French national program "Investing for the Future" (LABEX LIFESENSES)
   [ANR-10-LABX-65]; ITMO Technology For Health, Federation of the Blind of
   France; City of Paris; Regional Council of Ile-de-France; European
   Community [280433]
FX This project is supported by INSERM, University Pierreet-Marie-Curie
   (Paris-6), CNRS, Ophthalmological Foundation Rothschild (Paris), the
   National Agency for Research (ANR RETINA, ANR MEDINAS), "Fondation de la
   recherche medicale", the French national program "Investing for the
   Future" (LABEX LIFESENSES [ANR-10-LABX-65]), ITMO Technology For Health,
   Federation of the Blind of France, the City of Paris, the Regional
   Council of Ile-de-France, the European Community (NEUROCARE project:
   FP7/2007-2013 grant agreement No. 280433) (DREAMS project: number
   FP6-NMP-2006-33345).
CR Amedi A, 2010, RESTOR NEUROL NEUROS, V28, P143, DOI [10.3233/RNN-2010-0497, 10.3233/RNN-2010-0503]
   Bendali A., 2013, ADV HLTH MAT
   Bergonzo P, 2011, IRBM, V32, P91, DOI 10.1016/j.irbm.2011.01.032
   Besch D, 2008, BRIT J OPHTHALMOL, V92, P1361, DOI 10.1136/bjo.2007.131961
   Brelen ME, 2005, J NEURAL ENG, V2, pS22, DOI 10.1088/1741-2560/2/1/004
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Cogan SF, 2008, ANNU REV BIOMED ENG, V10, P275, DOI 10.1146/annurev.bioeng.10.061807.160518
   Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278
   da Cruz L., 2013, BR J OPHTHALMOL
   Djilas M, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046020
   DOBELLE WH, 1974, SCIENCE, V183, P440, DOI 10.1126/science.183.4123.440
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Froger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042017
   Gollisch T, 2010, NEURON, V65, P150, DOI 10.1016/j.neuron.2009.12.009
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   Hadjinicolaou AE, 2012, BIOMATERIALS, V33, P5812, DOI 10.1016/j.biomaterials.2012.04.063
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Joucla S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004828
   Kiran R, 2012, SENSORS-BASEL, V12, P7669, DOI 10.3390/s120607669
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Kolomiets B, 2010, NEUROBIOL DIS, V38, P47, DOI 10.1016/j.nbd.2009.12.025
   Lauritzen TZ, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00168
   Lichtsteiner P, 2008, IEEE J SOLID-ST CIRC, V43, P566, DOI 10.1109/JSSC.2007.914337
   Lorach H, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/6/066004
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Morimoto T, 2011, INVEST OPHTH VIS SCI, V52, P6785, DOI 10.1167/iovs.10-6971
   Palanker D, 2004, INVEST OPHTH VIS SCI, V45, P3266, DOI 10.1167/iovs.03-1327
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Roska B, 2001, NATURE, V410, P583, DOI 10.1038/35069068
   Salzmann J, 2006, BRIT J OPHTHALMOL, V90, P1183, DOI 10.1136/bjo.2005.089110
   Sommerhalder J, 2004, VISION RES, V44, P1693, DOI 10.1016/j.visres.2004.01.017
   Sommerhalder J, 2003, VISION RES, V43, P269, DOI 10.1016/S0042-6989(02)00481-9
   Striem-Amit E, 2012, NEURON, V76, P640, DOI 10.1016/j.neuron.2012.08.026
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   VICTOR JD, 1988, J PHYSIOL-LONDON, V405, P289, DOI 10.1113/jphysiol.1988.sp017334
   VICTOR JD, 1987, J PHYSIOL-LONDON, V386, P219, DOI 10.1113/jphysiol.1987.sp016531
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Wang LL, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/4/046014
   Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Wilke R, 2011, INVEST OPHTH VIS SCI, V52, P5995, DOI 10.1167/iovs.10-6946
   Wilms M, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-50
   Zeitz O, 2009, KLIN MONATSBL AUGENH, V226, P149, DOI 10.1055/s-0028-1109078
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 58
TC 34
Z9 34
U1 1
U2 41
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 1631-0691
EI 1768-3238
J9 CR BIOL
JI C. R. Biol.
PD MAR
PY 2014
VL 337
IS 3
BP 214
EP 222
DI 10.1016/j.crvi.2014.01.001
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AF8TC
UT WOS:000334987500009
PM 24702848
DA 2022-11-30
ER

PT J
AU Shah, CP
   Hsu, J
   Garg, SJ
   Fischer, DH
   Kaiser, R
AF Shah, Chirag P.
   Hsu, Jason
   Garg, Sunir J.
   Fischer, David H.
   Kaiser, Richard
TI Retinal pigment epithelial tear after intravitreal bevacizumab injection
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION
AB PURPOSE: To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal bevacizurnabinjection for exudative age-related macular degeneration (AMD).
   DESIGN: Observational case series.
   METHODS: Two patients presented with occult choroidal neovascularization secondary to AMD. Both patients received intravitreal bevacizumab injections.
   RESULTS: The first patient developed a RPE tear shortly after a third intravitreal bevacizumab injection. The second patient developed a RPE tear 10 days after a second intravitreal bevacizurnab injection.
   CONCLUSIONS: Although RPE tears may occur spontaneously as part of the natural history of exudative AMD, patients may develop visually devastating RIPE tears after repeat intravitreal bevacizumab injection. Further studies are needed to determine the incidence of RPE tears after intravitreal bevacizumab injections.
C1 Thomas Jefferson Univ, Retina Serv, Wills Eye Hosp, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Garg, SJ (通讯作者)，Thomas Jefferson Univ, Retina Serv, Wills Eye Hosp, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM sunirgarg@yahoo.com
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 7
TC 60
Z9 64
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1070
EP 1072
DI 10.1016/j.ajo.2006.07.037
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100030
PM 17157598
DA 2022-11-30
ER

PT J
AU Di Cello, L
   Desideri, LF
   Vagge, A
   Nicolo, M
   Traverso, CE
AF Di Cello, L.
   Ferro Desideri, L.
   Vagge, A.
   Nicolo, M.
   Traverso, C. E.
TI KSI-301
SO DRUGS OF THE FUTURE
LA English
DT Article
DE VEGF; KSI-301; Antibody-biopolymer conjugate; Wet age-related macular
   degeneration; Diabetic macular edema; Retinal vein occlusion
ID THERAPY
AB Anti-vascular endothelial growth factor (VEGF) agents currently represent the first-line treatment option for exudative macular diseases. The treatment burden with VEGF drugs shows that many patients are chronically undertreated and do not achieve optimal vision outcomes as a result of high-frequency injections, the high financial costs, and the risk of adverse ocular and systemic adverse events. Although various treatment regimens have been investigated in order to reduce treatment frequency and improve compliance, there is the need to find new long-lasting therapies. KSI-301 is a novel, 950 kDa-sized, antibody biopolymer anti-VEGF drug, which has shown promising results for treating wet age-related macular degeneration, diabetic macular edema and retina vein occlusions.
C1 [Di Cello, L.; Ferro Desideri, L.; Vagge, A.; Nicolo, M.; Traverso, C. E.] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
   [Vagge, A.; Nicolo, M.; Traverso, C. E.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Nicolo, M.] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Desideri, LF (通讯作者)，IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
EM lorenzoferrodes@gmail.com
CR [Anonymous], 2021, EX DEG 2021 ANN M FE
   Bandello F, 2017, DEV OPHTHALMOL, V58, P102, DOI 10.1159/000455277
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campa C, 2016, CURR DRUG TARGETS, V17, P328, DOI 10.2174/1573399811666150615151324
   Desideri LF, 2020, DRUG FUTURE, V45, P633, DOI 10.1358/dof.2020.45.9.3161236
   Desideri LF, 2020, DRUG TODAY, V56, P311, DOI 10.1358/dot.2020.56.5.3137164
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Desideri LF, 2021, EXPERT OPIN BIOL TH, V21, P553, DOI 10.1080/14712598.2021.1915278
   Guttman Krader C., 2020, MODERN RETINA 1101
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Ip M, 2018, ASIA-PAC J OPHTHALMO, V7, P40, DOI 10.22608/APO.2017442
   Liang H, 2018, INVEST OPHTH VIS SCI, V59
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nicolo M, 2020, OPHTHALMOLOGICA, V243, P453, DOI 10.1159/000507711
   Patel S.S., 2020, INVESTIG OPHTHALMOL, V61, P4286
   Patel S.S., INVEST OPHTHALMOL VI, V60
   Sinclair J, 2019, INVEST OPHTH VIS SCI, V60
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
NR 21
TC 0
Z9 0
U1 0
U2 0
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD NOV
PY 2021
VL 46
IS 11
BP 865
EP 869
DI 10.1358/dof.2021.46.11.3295949
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XC0OD
UT WOS:000721718900001
DA 2022-11-30
ER

PT J
AU Heitmar, R
   Brown, J
   Kyrou, I
AF Heitmar, Rebekka
   Brown, James
   Kyrou, Ioannis
TI Saffron (Crocus sativus L.) in Ocular Diseases: A Narrative Review of
   the Existing Evidence from Clinical Studies
SO NUTRIENTS
LA English
DT Review
DE saffron; Crocus Sativus L; crocin; crocetin; supplements; anti-oxidant;
   anti-inflammatory; AMD; diabetes; glaucoma
ID MACULAR DEGENERATION; SAFETY EVALUATION; DOUBLE-BLIND; SUPPLEMENTATION;
   SENSITIVITY; CROCETIN; DEPRESSION; AFFRON(R); TOXICITY; EFFICACY
AB Saffron (Crocus sativus L.) and its main constituents, i.e., crocin and crocetin, are natural carotenoid compounds, which have been reported to possess a wide spectrum of properties and induce pleiotropic anti-inflammatory, anti-oxidative, and neuroprotective effects. An increasing number of experimental, animal, and human studies have investigated the effects and mechanistic pathways of these compounds in order to assess their potential therapeutic use in ocular diseases (e.g., in age related macular degeneration, glaucoma, and diabetic maculopathy). This narrative review presents the key findings of published clinical studies that examined the effects of saffron and/or its constituents in the context of ocular disease, as well as an overview of the proposed underlying mechanisms mediating these effects.
C1 [Heitmar, Rebekka; Brown, James] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
   [Kyrou, Ioannis] Aston Univ, Aston Med Sch, Aston Med Res Inst, Birmingham B4 7ET, W Midlands, England.
   [Kyrou, Ioannis] Univ Hosp Coventry & Warwickshire NHS Trust, WISDEM, Coventry CV2 2DX, W Midlands, England.
   [Kyrou, Ioannis] Univ Warwick, Warwick Med Sch, Div Biomed Sci, Translat & Expt Med, Coventry CV4 7AL, W Midlands, England.
C3 Aston University; Aston University; University of Warwick; University of
   Warwick
RP Heitmar, R (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM R.Heitmar1@aston.ac.uk; j.e.p.brown@aston.ac.uk; I.Kyrou@aston.ac.uk
RI Brown, James E/A-7503-2012; Heitmar, Rebekka/J-6164-2019
OI Heitmar, Rebekka/0000-0002-7657-1788
CR Abou-Hany HO, 2018, CHEM-BIOL INTERACT, V284, P90, DOI 10.1016/j.cbi.2018.02.001
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Alavizadeh SH, 2014, FOOD CHEM TOXICOL, V64, P65, DOI 10.1016/j.fct.2013.11.016
   Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Bonyadi MHJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-399
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Broadhead GK, 2016, CRIT REV FOOD SCI, V56, P2767, DOI 10.1080/10408398.2013.879467
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen XH, 2016, PSYCHOSOMATICS, V57, P465, DOI 10.1016/j.psym.2016.04.003
   Chew Emily Y, 2013, Invest Ophthalmol Vis Sci, V54, pORSF42, DOI 10.1167/iovs13-12914
   Christodoulou E, 2015, J PHARM PHARMACOL, V67, P1634, DOI 10.1111/jphp.12456
   Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3
   Di Marco F, 2013, AM J NEURODEGENER DI, V2, P208
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Ernst PE, 2002, BJOG-INT J OBSTET GY, V109, P227
   European Food Safety Authority (EFSA), 2019, FOOD SUPPL
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ghaffari S, 2019, BIOMED PHARMACOTHER, V109, P21, DOI 10.1016/j.biopha.2018.10.031
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Hausenblas HA, 2015, J INTEGR MED-JIM, V13, P231, DOI 10.1016/S2095-4964(15)60176-5
   Hosseini A, 2018, IRAN J BASIC MED SCI, V21, P1091, DOI 10.22038/IJBMS.2018.31243.7529
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Bagur MJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23010030
   Kell G, 2017, COMPLEMENT THER MED, V33, P58, DOI 10.1016/j.ctim.2017.06.001
   Kyrou I., 2018, ENDOTEXT
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Li YL, 2018, FRONT PLANT SCI, V9, DOI [10.3389/fpls.2018.00190, 10.3389/fphar.2018.01341]
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lopresti AL, 2018, J AFFECT DISORDERS, V232, P349, DOI 10.1016/j.jad.2018.02.070
   Lv BC, 2016, NEUROCHEM RES, V41, P1949, DOI 10.1007/s11064-016-1905-1
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Modaghegh MH, 2008, PHYTOMEDICINE, V15, P1032, DOI 10.1016/j.phymed.2008.06.003
   Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Moshiri M, 2015, DRUG RES, V65, P287, DOI 10.1055/s-0034-1375681
   Musch DC, 2019, AM J OPHTHALMOL, V197, P128, DOI 10.1016/j.ajo.2018.09.015
   Office of Dietary Supplements (ODS), 2011, DIET SUPPL BACKGR IN
   Pashirzad M, 2019, J CELL PHYSIOL, V234, P14601, DOI 10.1002/jcp.28177
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Poma Anna, 2012, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V11, P37
   Potnuri AG, 2018, BIOMED PHARMACOTHER, V101, P174, DOI 10.1016/j.biopha.2018.02.068
   Pourmasoumi M, 2019, PHARMACOL RES, V139, P348, DOI 10.1016/j.phrs.2018.11.038
   Rahiman N, 2018, MICROVASC RES, V118, P82, DOI 10.1016/j.mvr.2018.03.003
   Razavi BM, 2017, J SCI FOOD AGR, V97, P1679, DOI 10.1002/jsfa.8134
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Rios JL, 1996, PHYTOTHER RES, V10, P189, DOI 10.1002/(SICI)1099-1573(199605)10:3&lt;189::AID-PTR754&gt;3.0.CO;2-C
   Sacca SC, 2016, J CELL PHYSIOL, V231, P1876, DOI 10.1002/jcp.25305
   Schmidt M, 2007, WIEN MED WOCHENSCHR, V157, P315, DOI 10.1007/s10354-007-0428-4
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Sung YY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111625
   Toth B, 2019, PLANTA MED, V85, P24, DOI 10.1055/a-0660-9565
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Umigai N, 2011, PHYTOMEDICINE, V18, P575, DOI 10.1016/j.phymed.2010.10.019
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   WHO (World Health Organization), 2007, MON SEL MED PLANTS, V3
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi L, 2007, J NUTR BIOCHEM, V18, P64, DOI 10.1016/j.jnutbio.2006.03.010
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yaribeygi H, 2019, J CELL PHYSIOL, V234, P8610, DOI 10.1002/jcp.27843
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 72
TC 30
Z9 31
U1 0
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAR 18
PY 2019
VL 11
IS 3
AR 649
DI 10.3390/nu11030649
PG 14
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA HT1YT
UT WOS:000464361100010
PM 30889784
OA Green Accepted, Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ferrara, N
AF Ferrara, Napoleone
TI Pathways mediating VEGF-independent tumor angiogenesis
SO CYTOKINE & GROWTH FACTOR REVIEWS
LA English
DT Review
DE Angiogenesis; VEGF; Bv8; Myeloid cells; Fibroblasts
ID ENDOTHELIAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; ANTI-VEGF;
   BLOOD-VESSELS; IN-VIVO; STROMAL FIBROBLASTS; PROLONGS SURVIVAL;
   SUPPRESSOR-CELLS; PROGENITOR CELLS; INNATE IMMUNITY
AB FDA approval of several inhibitors of the VEGF pathway has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease progression. So far the lack of predictive biomarkers has precluded identification of patients most likely to respond to such treatments. Recent suggest that both tumor and non-tumor (stromal) cell types are involved in the reduced responsiveness to the treatments. The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies. (C) 2009 Elsevier Ltd. All rights reserved.
C1 Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
CR ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008-5472.CAN-08-2590
   Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bendelac A, 1997, CURR OPIN IMMUNOL, V9, P1, DOI 10.1016/S0952-7915(97)80151-3
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3
   Broxterman HJ, 2003, DRUG RESIST UPDATE, V6, P111, DOI 10.1016/S1368-7646(03)00026-8
   Cao YH, 2008, J MOL MED, V86, P785, DOI 10.1007/s00109-008-0337-z
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029
   CHEN HX, 2009, NAT REV CLIN ONCOL
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crawford Y, 2009, TRENDS PHARMACOL SCI, V30, P624, DOI 10.1016/j.tips.2009.09.004
   Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   De Palma M, 2007, TRENDS IMMUNOL, V28, P519, DOI 10.1016/j.it.2007.09.004
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123
   Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4
   Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289
   Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227
   Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104
   Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Escudier BJ, 2009, J CLIN ONCOL, V27
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Gandhi L, 2009, CANCER PREV RES, V2, P330, DOI 10.1158/1940-6207.CAPR-08-0213
   Gerber HP, 2007, P NATL ACAD SCI USA, V104, P3478, DOI 10.1073/pnas.0611492104
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2
   GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261
   Gothert JR, 2004, BLOOD, V104, P1769, DOI 10.1182/blood-2003-11-3952
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hida K, 2005, CANCER RES, V65, P2507, DOI 10.1158/0008-5472.CAN-05-0002
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174
   Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kerber M, 2008, CANCER RES, V68, P7342, DOI 10.1158/0008-5472.CAN-07-6241
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Lang L, 2008, GASTROENTEROLOGY, V134, P379, DOI 10.1053/j.gastro.2007.12.038
   LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x
   Mantovani A, 2008, LANCET, V371, P771, DOI 10.1016/S0140-6736(08)60241-X
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Mollay C, 1999, EUR J PHARMACOL, V374, P189, DOI 10.1016/S0014-2999(99)00229-0
   Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood-2006-04-016030
   Naumov GN, 2008, APMIS, V116, P569, DOI 10.1111/j.1600-0463.2008.01213.x
   Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307
   Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103
   Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019
   Presta LG, 1997, CANCER RES, V57, P4593
   Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Rini BI, 2006, EXPERT OPIN PHARMACO, V7, P453, DOI 10.1517/14656566.7.4.453
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005
   SHAKED Y, 2009, CANC RES
   Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shibuya M, 2008, BMB REP, V41, P278, DOI 10.5483/BMBRep.2008.41.4.278
   Shojaei F, 2008, TRENDS CELL BIOL, V18, P372, DOI 10.1016/j.tcb.2008.06.003
   Shojaei F, 2008, P NATL ACAD SCI USA, V105, P2640, DOI 10.1073/pnas.0712185105
   Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Shojaei F, 2009, P NATL ACAD SCI USA, V106, P6742, DOI 10.1073/pnas.0902280106
   Shojaei F, 2008, DRUG RESIST UPDATE, V11, P219, DOI 10.1016/j.drup.2008.09.001
   Siekmann AF, 2008, BIOESSAYS, V30, P303, DOI 10.1002/bies.20736
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   Smith JK, 2004, ONCOL RES, V14, P175, DOI 10.3727/000000003772462298
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857
   WOLMARK N, 2009, J CLIN ONCOL S, V27
   Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
   Yuan L, 2002, DEVELOPMENT, V129, P4797
   Zhong CL, 2009, CLIN CANCER RES, V15, P2675, DOI 10.1158/1078-0432.CCR-08-1954
NR 135
TC 221
Z9 243
U1 1
U2 38
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6101
EI 1879-0305
J9 CYTOKINE GROWTH F R
JI Cytokine Growth Factor Rev.
PD FEB
PY 2010
VL 21
IS 1
SI SI
BP 21
EP 26
DI 10.1016/j.cytogfr.2009.11.003
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 582JH
UT WOS:000276592700004
PM 20005148
DA 2022-11-30
ER

PT J
AU Mehta, SC
   Kelley, RF
   Tesar, DB
AF Mehta, Shrenik C.
   Kelley, Robert F.
   Tesar, Devin B.
TI Protein conjugates and fusion proteins as ocular therapeutics
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID RANIBIZUMAB; PHARMACOKINETICS; BEVACIZUMAB; PEGAPTANIB; INJECTION;
   DISEASES; APTAMER; DARPINS; BINDING; DRUGS
AB Long-acting delivery (LAD) of ocular therapeutics has potential to improve the standard of care for ocular diseases, such as age-related macular degeneration (AMD), by increasing patient compliance and reducing overall treatment burden on patients and healthcare providers. Although relatively few ocular LAD technologies are currently on the market, a variety of emergent and novel protein engineering-based technologies are being investigated in both the laboratory and clinical settings. Here, we review some of the key indications and treatments that would benefit from the development of LAD for the treatment of ocular diseases and examine the current state of LAD technologies that leverage protein-engineering approaches as well as nascent technologies with potential for future impact.
C1 [Mehta, Shrenik C.; Kelley, Robert F.; Tesar, Devin B.] Genentech Inc, Drug Delivery Dept, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Tesar, DB (通讯作者)，Genentech Inc, Drug Delivery Dept, San Francisco, CA 94080 USA.
EM tesar.devin@gene.com
CR Ahmadpour S, 2018, CURR DRUG DELIV, V15, P331, DOI 10.2174/1567201814666171120122352
   Altiok EI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155990
   Altiok EI, 2016, BIOMATERIALS, V93, P95, DOI 10.1016/j.biomaterials.2016.03.017
   Apellis Pharmaceuticals, 2017, AP PHARM ANN APL 2 M
   Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Boersma YL, 2018, METHODS MOL BIOL, V1798, P307, DOI 10.1007/978-1-4939-7893-9_23
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   Castagnetti M, 2006, PEDIATR SURG INT, V22, P274, DOI 10.1007/s00383-005-1630-3
   CLAUSEN R, 1991, GRAEF ARCH CLIN EXP, V229, P186, DOI 10.1007/BF00170555
   de Oliveira AL, 2016, REV PORT INVESTIG CO, V2, P3
   Degat MC, 2009, J BIOMED MATER RES A, V88A, P174, DOI 10.1002/jbm.a.31884
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, P13
   Francois C., Patent No. [US1012517162, 10125171]
   Fuchs H, 2017, J OCUL PHARMACOL TH, V33, P115, DOI 10.1089/jop.2016.0083
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   GREGORIADIS G, 1993, FEBS LETT, V315, P271, DOI 10.1016/0014-5793(93)81177-2
   Haeckel A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157193
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hutton-Smith LA, 2017, MOL PHARMACEUT, V14, P2690, DOI 10.1021/acs.molpharmaceut.7b00164
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Laing S, 2018, INVEST OPTHAMOL VIS, V59, P4071
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Logeart-Avramoglou D, 2002, BIOCHEM PHARMACOL, V63, P129, DOI 10.1016/S0006-2952(01)00834-6
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   MAURICE DM, 1959, AM J OPHTHALMOL, V47, P361, DOI 10.1016/S0002-9394(14)78042-0
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Novartis, 2018, NEW AN NOV PHAS 3 BR
   Oh HS, 2005, CURR EYE RES, V30, P291, DOI 10.1080/02713680590923267
   Paleos CM, 2017, BIOCONJUGATE CHEM, V28, P1611, DOI 10.1021/acs.bioconjchem.7b00186
   Sebag J, 1989, VITREOUS STRUCTURE F
   Shatz W, 2019, EXPERT OPIN DRUG DEL, V16, P43, DOI 10.1080/17425247.2019.1553953
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Shitama T, 2008, PROTEOM CLIN APPL, V2, P1265, DOI 10.1002/prca.200800017
   Smirnov IV, 2015, METHODS MOL BIOL, V1321, P389, DOI 10.1007/978-1-4939-2760-9_26
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023
   Tesar D, 2017, MABS-AUSTIN, V9, P1297, DOI 10.1080/19420862.2017.1372078
   Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yuen KCJ, 2013, J CLIN ENDOCR METAB, V98, P2595, DOI 10.1210/jc.2013-1437
NR 44
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2019
VL 24
IS 8
SI SI
BP 1440
EP 1445
DI 10.1016/j.drudis.2019.05.025
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IX7GP
UT WOS:000485852100005
PM 31202674
DA 2022-11-30
ER

PT J
AU Fletcher, EC
   Chong, NV
AF Fletcher, E. C.
   Chong, N. V.
TI Looking beyond Lucentis on the management of macular degeneration
SO EYE
LA English
DT Review
DE age-related macular degeneration; oxidative stress; protein kinase
   inhibitors; angiogenesis; siRNA; VEGF trap
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; RISK-FACTORS; OXIDATIVE
   STRESS; BRUCHS MEMBRANE; PROTECTIVE ROLE; IRIS COLOR; ZEAXANTHIN;
   PIGMENT; LUTEIN
AB Purpose Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. In the past decade, AMD research has improved our understanding of the pathogenesis of the condition. There is no doubt that anti-VEGF therapies will play a major role in the reduction of blindness, but it needs close monitoring and frequent treatments. In this review we summarise the key pathophysiology of the condition and some of the new treatment strategies under development.
   Methods Literature review. Results Oxidative stress, inflammation, hypoxia, and angiogenesis are key pathophysiological processes in AMD, this diversity has provided a variety of possible areas amenable to modification to enhance the treatment options for AMD.
C1 [Fletcher, E. C.; Chong, N. V.] Oxford Eye Hosp, Oxford OX3 9DU, England.
RP Chong, NV (通讯作者)，Oxford Eye Hosp, Headley Rd, Oxford OX3 9DU, England.
EM victor@eretina.org
RI Chong, Ngaihang V/A-5141-2009; Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X
CR Bernhard D, 2007, CURR MED CHEM, V14, P1703
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chang LT, 2007, J CARDIOVASC PHARM, V49, P20, DOI 10.1097/FJC.0b013e31802ba4ec
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   O'Connell E, 2006, ANN ACAD MED SINGAP, V35, P821
   Paciaroni M, 2007, CEREBROVASC DIS, V24, P170, DOI 10.1159/000104474
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   SNEDDON JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774
   Suzuki M, 2007, MOL VIS, V13, P772
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Winkler BS, 1999, MOL VIS, V5
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 47
TC 8
Z9 9
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 742
EP 750
DI 10.1038/sj.eye.6703008
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800002
PM 18188178
OA Bronze
DA 2022-11-30
ER

PT J
AU Fang, LY
   Cunefare, D
   Wang, C
   Guymer, RH
   Li, ST
   Farsiu, S
AF Fang, Leyuan
   Cunefare, David
   Wang, Chong
   Guymer, Robyn H.
   Li, Shutao
   Farsiu, Sina
TI Automatic segmentation of nine retinal layer boundaries in OCT images of
   non-exudative AMD patients using deep learning and graph search
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID DIABETIC MACULAR EDEMA; GEOGRAPHIC ATROPHY; CLASSIFICATION;
   DEGENERATION; FLUID
AB We present a novel framework combining convolutional neural networks (CNN) and graph search methods (termed as CNN-GS) for the automatic segmentation of nine layer boundaries on retinal optical coherence tomography (OCT) images. CNN-GS first utilizes a CNN to extract features of specific retinal layer boundaries and train a corresponding classifier to delineate a pilot estimate of the eight layers. Next, a graph search method uses the probability maps created from the CNN to find the final boundaries. We validated our proposed method on 60 volumes (2915 B-scans) from 20 human eyes with non-exudative age-related macular degeneration (AMD), which attested to effectiveness of our proposed technique. (C) 2017 Optical Society of America
C1 [Fang, Leyuan; Cunefare, David; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Fang, Leyuan; Wang, Chong; Li, Shutao] Hunan Univ, Coll Elect & Informat Engn, Changsha 410082, Hunan, Peoples R China.
   [Guymer, Robyn H.] Australia Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg, Ctr Eye Res, Melbourne, Vic 3002, Australia.
   [Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University; Hunan University; Royal Victorian Eye & Ear Hospital;
   Duke University
RP Fang, LY (通讯作者)，Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.; Fang, LY (通讯作者)，Hunan Univ, Coll Elect & Informat Engn, Changsha 410082, Hunan, Peoples R China.
EM leyuan.fang@duke.edu
OI Wang, Chong/0000-0003-0022-0217; Guymer, Robyn/0000-0002-9441-4356;
   Farsiu, Sina/0000-0003-4872-2902
FU Duke/Duke-NUS pilot collaborative grant; National Natural Science
   Foundation of China (NSFC) [61325007, 61501180]
FX Duke/Duke-NUS pilot collaborative grant and National Natural Science
   Foundation of China (NSFC) (61325007, 61501180).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Antony B, 2011, BIOMED OPT EXPRESS, V2, P2403, DOI 10.1364/BOE.2.002403
   Bavinger JC, 2016, INVEST OPHTH VIS SCI, V57, P208, DOI 10.1167/iovs.15-17281
   Bhat S, 2013, IEEE T MED IMAGING, V32, P578, DOI 10.1109/TMI.2012.2231692
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2012, BIOMED OPT EXPRESS, V3, P1127, DOI 10.1364/BOE.3.001127
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Cunefare D, 2016, BIOMED OPT EXPRESS, V7, P2036, DOI 10.1364/BOE.7.002036
   DeBuc C., 2011, IMAGE SEG, V1, P15, DOI DOI 10.5772/628
   Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Dou Q, 2016, IEEE T MED IMAGING, V35, P1182, DOI 10.1109/TMI.2016.2528129
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2015, IEEE T MED IMAGING, V34, P1306, DOI 10.1109/TMI.2014.2387336
   Farsiu S., 2008, P PHOT W OPHTH TECHN, P1
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ghorbel I, 2011, PATTERN RECOGN, V44, P1590, DOI 10.1016/j.patcog.2011.01.012
   Hinton GE, 2006, SCIENCE, V313, P504, DOI 10.1126/science.1127647
   Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Karri SPK, 2016, BIOMED OPT EXPRESS, V7, P2888, DOI 10.1364/BOE.7.002888
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keller B, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076015
   Knoll Brianna, 2016, Alzheimers Dement (Amst), V4, P85
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   LaRocca F, 2011, BIOMED OPT EXPRESS, V2, P1524, DOI 10.1364/BOE.2.001524
   LeCun Y., 1989, ADV NEURAL INFORM PR, V2, P396, DOI DOI 10.1111/DSU.12130
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li C, 2016, PROC CVPR IEEE, P2479, DOI 10.1109/CVPR.2016.272
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Malamos P, 2011, RETINA-J RET VIT DIS, V31, P453, DOI 10.1097/IAE.0b013e3181eef031
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   McDonough K, 2015, 2015 IEEE CONFERENCE ON COMPUTATIONAL INTELLIGENCE IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY (CIBCB), P194
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Niepert M, 2016, PR MACH LEARN RES, V48
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Oliveira J, 2017, BIOMED OPT EXPRESS, V8, P281, DOI 10.1364/BOE.8.000281
   Ouyang WL, 2015, PROC CVPR IEEE, P2403, DOI 10.1109/CVPR.2015.7298854
   Pereira S, 2016, IEEE T MED IMAGING, V35, P1240, DOI 10.1109/TMI.2016.2538465
   Polans J, 2017, OPT LETT, V42, P17, DOI 10.1364/OL.42.000017
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Roth HR, 2016, IEEE T MED IMAGING, V35, P1170, DOI 10.1109/TMI.2015.2482920
   Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003
   Sheet D, 2015, I S BIOMED IMAGING, P777, DOI 10.1109/ISBI.2015.7163987
   Simonett J.M., 2016, SCI REP-UK, V6, P1
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Sui XD, 2017, NEUROCOMPUTING, V237, P332, DOI 10.1016/j.neucom.2017.01.023
   Tian J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133908
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   VEDALDI A, 2015, P 23 ACM INT C MULT, P689, DOI DOI 10.1145/2733373.2807412
   Wang J, 2016, BIOMED OPT EXPRESS, V7, P1577, DOI 10.1364/BOE.7.001577
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Zheng S, 2015, IEEE I CONF COMP VIS, P1529, DOI 10.1109/ICCV.2015.179
NR 63
TC 305
Z9 313
U1 12
U2 132
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAY 1
PY 2017
VL 8
IS 5
BP 2732
EP 2744
DI 10.1364/BOE.8.002732
PG 13
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA ET7TD
UT WOS:000400500400024
PM 28663902
OA Green Published, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Kaewkhaw, R
   Swaroop, M
   Homma, K
   Nakamura, J
   Brooks, M
   Kaya, KD
   Chaitankar, V
   Michael, S
   Tawa, G
   Zou, JZ
   Rao, M
   Zheng, W
   Cogliati, T
   Swaroop, A
AF Kaewkhaw, Rossukon
   Swaroop, Manju
   Homma, Kohei
   Nakamura, Jutaro
   Brooks, Matthew
   Kaya, Koray Dogan
   Chaitankar, Vijender
   Michael, Sam
   Tawa, Gregory
   Zou, Jizhong
   Rao, Mahendra
   Zheng, Wei
   Cogliati, Tiziana
   Swaroop, Anand
TI Treatment Paradigms for Retinal and Macular Diseases Using 3-D Retina
   Cultures Derived From Human Reporter Pluripotent Stem Cell Lines
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE human retina development; disease modeling; photoreceptor; high
   throughput screening; chemical screens; drug discovery; transcriptome;
   next generation sequencing; three-dimensional organoid culture;
   fluorescent reporter
ID HUMAN IPS CELLS; GENE-THERAPY; PHOTORECEPTOR PRECURSORS; NEURAL RETINA;
   REGENERATIVE MEDICINE; FATE DETERMINATION; VERTEBRATE RETINA; HUMAN
   ESCS; DEGENERATION; EXPRESSION
AB We discuss the use of pluripotent stem cell lines carrying fluorescent reporters driven by retinal promoters to derive three-dimensional (3-D) retina in culture and how this system can be exploited for elucidating human retinal biology, creating disease models in a dish, and designing targeted drug screens for retinal and macular degeneration. Furthermore, we realize that stem cell investigations are labor-intensive and require extensive resources. To expedite scientific discovery by sharing of resources and to avoid duplication of efforts, we propose the formation of a Retinal Stem Cell Consortium. In the field of vision, such collaborative approaches have been enormously successful in elucidating genetic susceptibility associated with age-related macular degeneration.
C1 [Kaewkhaw, Rossukon; Homma, Kohei; Nakamura, Jutaro; Brooks, Matthew; Kaya, Koray Dogan; Chaitankar, Vijender; Cogliati, Tiziana; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Kaewkhaw, Rossukon] Mahidol Univ, Ramathibodi Hosp, Fac Med, Res Ctr, Bangkok 10400, Thailand.
   [Swaroop, Manju; Michael, Sam; Tawa, Gregory; Zheng, Wei] NIH, Natl Therapeut Rare & Neglected Dis, Natl Ctr Adv Translat Sci, Rockville, MD USA.
   [Zou, Jizhong] NHLBI, iPSC Core, Ctr Mol Med, Bldg 10, Bethesda, MD 20892 USA.
   [Rao, Mahendra] New York Stem Cell Fdn, Res Inst, New York, NY USA.
   [Homma, Kohei] Nippon Med Sch, Dept Physiol, 1-1-5 Sendagi, Tokyo 113, Japan.
   [Nakamura, Jutaro] Yokohama City Univ, Dept Ophthalmol, Sch Med, Yokohama, Kanagawa 232, Japan.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Mahidol University; National Institutes of Health (NIH) - USA;
   NIH National Center for Advancing Translational Sciences (NCATS);
   National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); The New York Stem Cell Foundation; Nippon
   Medical School; Yokohama City University
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov
RI Zheng, Wei/GOE-5990-2022; Zheng, Wei/J-8889-2014; Homma,
   Kohei/AAF-6716-2021
OI Zheng, Wei/0000-0003-1034-0757; Homma, Kohei/0000-0002-6253-8047;
   Swaroop, Anand/0000-0002-1975-1141; Nakamrua,
   Jutaro/0000-0002-5565-5050; Swaroop, Manju/0000-0002-0576-1664; Zou,
   Jizhong/0000-0003-1021-0549
FU Intramural Research Program of the National Eye Institute, National
   Institutes of Health [ZO1 EY000450, EY000474]; Japan Society for the
   Promotion of Science (JSPS); JSPS Postdoctoral Fellowships for Research
   Abroad (Kaitoku-NIH); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [ZICTR000242, ZIATR000018] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [ZIAEY000546, ZIAEY000474, Z01EY000450] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [ZICHL006145] Funding Source: NIH RePORTER
FX Supported by Intramural Research Program (ZO1 EY000450 and EY000474) of
   the National Eye Institute, National Institutes of Health. KH and JN
   were supported by grant-in-aid for Young Scientists (B) from the Japan
   Society for the Promotion of Science (JSPS) and JSPS Postdoctoral
   Fellowships for Research Abroad (Kaitoku-NIH).
CR Ader M, 2014, CURR OPIN CELL BIOL, V31, P23, DOI 10.1016/j.ceb.2014.06.013
   Agathocleous M, 2009, ANNU REV CELL DEV BI, V25, P45, DOI 10.1146/annurev.cellbio.042308.113259
   Akimoto M, 2006, P NATL ACAD SCI USA, V103, P3890, DOI 10.1073/pnas.0508214103
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bassett EA, 2012, TRENDS NEUROSCI, V35, P565, DOI 10.1016/j.tins.2012.05.004
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Bermingham-McDonogh O, 2011, NEURON, V71, P389, DOI 10.1016/j.neuron.2011.07.015
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Braam SR, 2010, ANN NY ACAD SCI, V1188, P52, DOI 10.1111/j.1749-6632.2009.05083.x
   Brooks MJ, 2011, MOL VIS, V17, P3034
   Chen Y, 2016, ANNU REV PHARMACOL, V56, P273, DOI 10.1146/annurev-pharmtox-010715-103033
   Danno H, 2008, P NATL ACAD SCI USA, V105, P5408, DOI 10.1073/pnas.0710954105
   Desbordes SC, 2008, CELL STEM CELL, V2, P602, DOI 10.1016/j.stem.2008.05.010
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Furukawa A, 2002, J NEUROSCI, V22, P1640, DOI 10.1523/JNEUROSCI.22-05-01640.2002
   Gamm DM, 2013, NAT BIOTECHNOL, V31, P712, DOI 10.1038/nbt.2648
   Grieshammer U, 2014, STEM CELL TRANSL MED, V3, P1253, DOI 10.5966/sctm.2014-0191
   Grskovic M, 2011, NAT REV DRUG DISCOV, V10, P915, DOI 10.1038/nrd3577
   Hambright D, 2012, MOL VIS, V18, P920
   He Lei, 2009, Human Genomics, V3, P195
   Hockemeyer D, 2011, NAT BIOTECHNOL, V29, P731, DOI 10.1038/nbt.1927
   Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562
   Homma K, 2013, STEM CELLS, V31, P1149, DOI 10.1002/stem.1372
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Kaewkhaw R, 2015, STEM CELLS, V33, P3504, DOI 10.1002/stem.2122
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Lee G, 2012, NAT BIOTECHNOL, V30, P1244, DOI 10.1038/nbt.2435
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Mellough CB, 2015, STEM CELLS, V33, P2416, DOI 10.1002/stem.2023
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Muranishi Y, 2011, J NEUROSCI, V31, P16792, DOI 10.1523/JNEUROSCI.3109-11.2011
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nasonkin I, 2009, STEM CELLS, V27, P2414, DOI 10.1002/stem.177
   Ng L, 2011, J NEUROSCI, V31, P11118, DOI 10.1523/JNEUROSCI.1709-11.2011
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Postel K, 2013, MOL VIS, V19, P2058
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Roger JE, 2014, J CLIN INVEST, V124, P631, DOI 10.1172/JCI72722
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Stenkamp DL, 2011, PROG RETIN EYE RES, V30, P395, DOI 10.1016/j.preteyeres.2011.06.004
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Tabar V, 2014, NAT REV GENET, V15, P82, DOI 10.1038/nrg3563
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Trifunovic D, 2012, CURR MOL MED, V12, P598, DOI 10.2174/156652412800620048
   Tsai YC, 2015, STEM CELLS, V33, P2537, DOI 10.1002/stem.2032
   Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310
   Welsbie DS, 2013, P NATL ACAD SCI USA, V110, P4045, DOI 10.1073/pnas.1211284110
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wu SM, 2011, NAT CELL BIOL, V13, P497, DOI 10.1038/ncb0511-497
   Wu ZJ, 2015, HUM MOL GENET, V24, P3956, DOI 10.1093/hmg/ddv134
   Yanai A, 2015, TISSUE ENG PT A, V21, P1763, DOI [10.1089/ten.TEA.2014.0669, 10.1089/ten.tea.2014.0669]
   Yang HJ, 2015, PROG RETIN EYE RES, V46, P1, DOI 10.1016/j.preteyeres.2015.01.005
   YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou PY, 2015, J CELL SCI, V128, P2169, DOI 10.1242/jcs.169086
   Zou JZ, 2011, BLOOD, V118, P4599, DOI 10.1182/blood-2011-02-335554
   Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023
NR 68
TC 23
Z9 23
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 5
SI SI
DI 10.1167/iovs.15-17639
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8NC
UT WOS:000378039300011
PM 27116668
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Adhi, M
   Read, SP
   Liu, JJ
   Fujimoto, JG
   Duker, JS
AF Adhi, Mehreen
   Read, Sarah P.
   Liu, Jonathan J.
   Fujimoto, James G.
   Duker, Jay S.
TI High-Speed Ultrahigh-Resolution OCT of Bruch's Membrane in
   Membranoproliferative Glomerulonephritis Type 2
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID DRUSEN
AB Membranoproliferative glomerulonephritis (MPGN) type 2 is characterized by electron-dense deposits in the glomerular basement membrane and drusen-like deposits in Bruch's membrane. Over time, atrophic changes in the retina and retinal pigment epithelium occur, which can progress to choroidal neovascularization (CNV). This report describes a patient with MPGN type 2 who developed progressive loss of vision secondary to CNV. High-speed ultrahigh-resolution optical coherence tomography (UHR-OCT) showed an irregular Bruch's membrane that measured 10 mu m beneath the foveal center. High-speed UHR-OCT can potentially be used to analyze Bruch's membrane in secondary ocular manifestations of diseases such as MPGN type 2 and primary retinal diseases such as age-related macular degeneration.
C1 [Adhi, Mehreen; Read, Sarah P.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Liu, Jonathan J.; Fujimoto, James G.] MIT, Elect Res Lab, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
C3 Tufts Medical Center; Massachusetts Institute of Technology (MIT)
RP Duker, JS (通讯作者)，New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
EM jduker@tuftsmedicalcenter.org
RI Adhi, Mehreen/AAS-9733-2021
FU Research to Prevent Blindness unrestricted grant; NIH [R01-EY11289-27,
   R01-EY13178-12, R01-EY013516-09, R01-EY018184-05]; Air Force Office of
   Scientific Research [FA9550-10-1-0551, FA9550-10-1-0063,
   FA9550-12-1-0499]; Massachusetts Lions Club; Carl Zeiss Meditec and
   Optovue; NATIONAL EYE INSTITUTE [R01EY018184, R01EY013178, R01EY013516,
   R01EY011289] Funding Source: NIH RePORTER
FX Supported in part by a Research to Prevent Blindness unrestricted grant
   to the New England Eye Center, NIH contracts R01-EY11289-27,
   R01-EY13178-12, R01-EY013516-09, and R01-EY018184-05, Air Force Office
   of Scientific Research FA9550-10-1-0551, FA9550-10-1-0063, and
   FA9550-12-1-0499, and the Massachusetts Lions Club.; Dr. Fujimoto
   receives royalties from intellectual property owned by MIT and licensed
   to Carl Zeiss Meditec and Optovue and has stock options in Optovue. Dr.
   Duker receives research support from Carl Zeiss Meditec and Optovue. The
   remaining authors have no financial or proprietary interest in the
   materials presented herein.
CR D'souza YB, 2009, KIDNEY INT, V75, P824, DOI 10.1038/ki.2008.658
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   McAvoy CE, 2005, EYE, V19, P985, DOI 10.1038/sj.eye.6701697
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ritter M, 2010, BRIT J OPHTHALMOL, V94, P1112, DOI 10.1136/bjo.2009.159475
   Yoshida M, 2002, BRIT J OPHTHALMOL, V86, P737, DOI 10.1136/bjo.86.7.737
   1985, AM J KIDNEY DIS, V6, P161
NR 9
TC 5
Z9 5
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2014
VL 45
IS 6
BP 614
EP 617
DI 10.3928/23258160-20141118-20
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0PQ
UT WOS:000347299300024
PM 25423645
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Seddon, JM
AF Seddon, Johanna M.
TI Genetic and Environmental Underpinnings to Age-Related Ocular Diseases
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE environment; genetics; age-related eye diseases; ORSF symposium
ID C-REACTIVE PROTEIN; MACULAR DEGENERATION; HIGH-RISK; ASSOCIATION;
   PROGRESSION; DIETARY; CFH; MACULOPATHY; PREVALENCE; GENOTYPES
AB Age-related macular degeneration (AMD), cataract, glaucoma and diabetic retinopathy are common causes of visual loss. Both environmental and genetic factors contribute to the development of these diseases. The modifiable factors related to some of these age-related and visually threatening diseases are smoking, obesity, and dietary factors, and a cardiovascular risk profile. Many common and a few rare genetic factors are associated with AMD. The role of genetic variants for the other diseases are less clear. Interactions between environmental, therapeutic, and genetic factors are being explored. Knowledge of genetic risk and environmental factors, especially for AMD, has grown markedly over the past 2.5 decades and has led to some sight-saving approaches in preventive management.
C1 [Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health [R01-EY11309]; Massachusetts Lions Eye
   Research Fund, Inc.; Research to Prevent Blindness; Foundation Fighting
   Blindness; Macular Degeneration Research Fund of the Ophthalmic
   Epidemiology and Genetics Service, New England Eye Center, Tufts Medical
   Center, Tufts University School of Medicine; NATIONAL EYE INSTITUTE
   [R01EY011309] Funding Source: NIH RePORTER
FX Supported in part by R01-EY11309 from the National Institutes of Health,
   Massachusetts Lions Eye Research Fund, Inc., a Research to Prevent
   Blindness Challenge Grant to the New England Eye Center, Department of
   Ophthalmology, Tufts University School of Medicine, the Foundation
   Fighting Blindness, and the Macular Degeneration Research Fund of the
   Ophthalmic Epidemiology and Genetics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine.
CR Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2013, RETINA, P1134
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2011, INVEST OPHTH VIS SCI, V52, P7593, DOI 10.1167/iovs.11-7510
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Ye J, 2012, INVEST OPHTH VIS SCI, V53, P3885, DOI 10.1167/iovs.12-9820
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 33
TC 28
Z9 29
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2013
VL 54
IS 14
SI SI
DI 10.1167/iovs.13-13234
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 278IX
UT WOS:000328884600006
PM 24335064
OA Green Published
DA 2022-11-30
ER

PT J
AU Salomon, RG
   Hong, L
   Hollyfield, JG
AF Salomon, Robert G.
   Hong, Li
   Hollyfield, Joe G.
TI Discovery of Carboxyethylpyrroles (CEPs): Critical Insights into AMD,
   Autism, Cancer, and Wound Healing from Basic Research on the Chemistry
   of Oxidized Phospholipids
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; HIGH-FUNCTIONING AUTISM; INCREASED OXIDATIVE
   STRESS; SCAVENGER RECEPTOR CD36; FACTOR-H POLYMORPHISM; TOLL-LIKE
   RECEPTORS; MACULAR DEGENERATION; ATHEROSCLEROTIC LESIONS; BRUCHS
   MEMBRANE; WHITE-MATTER
AB Basic research, exploring the hypothesis that 2-(omega-carboxyethyl)pyrrole (CEP) modifications of proteins are generated nonenzymatically in vivo is delivering a bonanza of molecular mechanistic insights into age-related macular degeneration, autism, cancer, and wound healing. CEPs are produced through covalent modification of protein lysyl e-amino groups by gamma-hydroxyalkenal phospholipids that are formed by oxidative cleavage of docosahexaenate-containing phospholipids. Chemical synthesis of CEP-modified proteins and the production of highly specific antibodies that recognize them preceded and facilitated their detection in vivo and enabled exploration of their biological occurrence and activities. This investigational approach, from the chemistry of biomolecules to disease phenotype, is proving to be remarkably productive.
C1 [Salomon, Robert G.; Hong, Li] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Hollyfield, Joe G.] Cleveland Clin Lerner Coll Med, Dept Ophthalmol, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Case Western Reserve University;
   Cleveland Clinic Foundation
RP Salomon, RG (通讯作者)，Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
EM rgs@case.edu
RI Salomon, Robert G/C-3463-2008
OI Salomon, Robert/0000-0001-9456-3557
FU National Institutes of Health [GM021249, EY016813, R0I-EY014240]; State
   of Ohio [05-29]; Foundation Fighting Blindness, Research to Prevent
   Blindness; Macular Vision Research Foundation; Wolf Family Foundation;
   Llura and Gordon Gund Foundation; NATIONAL EYE INSTITUTE [R01EY016813,
   R01EY014240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER
FX We are grateful to the National Institutes of Health for Grants GM021249
   and EY016813 in support of research in the laboratory of R.G.S.
   presented in this review. Research in the laboratory of J.G.H. is
   supported by National Institutes of Health Grant R0I-EY014240; BRTT from
   the State of Ohio (05-29); Foundation Fighting Blindness, Research to
   Prevent Blindness, Macular Vision Research Foundation, Wolf Family
   Foundation, and Llura and Gordon Gund Foundation.
CR ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006
   Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Castelli F, 2002, BRAIN, V125, P1839, DOI 10.1093/brain/awf189
   Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007
   Choi J, 2011, BIOORGAN MED CHEM, V19, P580, DOI 10.1016/j.bmc.2010.10.058
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/circ.105.10.1158
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eitel J, 2008, J IMMUNOL, V181, P2664, DOI 10.4049/jimmunol.181.4.2664
   Equils O, 2004, J IMMUNOL, V172, P7642, DOI 10.4049/jimmunol.172.12.7642
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans T. A., 2008, AM J BIOCH BIOTECHNO, V4, P61, DOI DOI 10.3844/AJBBSP.2008.61.72
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLSE B, 1978, REV NEUROL, V134, P699
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Grote K, 2010, BLOOD, V115, P2543, DOI 10.1182/blood-2009-05-224402
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hoff HF, 2003, ARTERIOSCL THROM VAS, V23, P275, DOI 10.1161/01.ATV.0000051407.42536.73
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320
   James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366
   James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Just MA, 2004, BRAIN, V127, P1811, DOI 10.1093/brain/awh199
   Just MA, 2007, CEREB CORTEX, V17, P951, DOI 10.1093/cercor/bhl006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Keller F, 2003, MOL NEUROBIOL, V28, P1, DOI 10.1385/MN:28:1:1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koshino H, 2005, NEUROIMAGE, V24, P810, DOI 10.1016/j.neuroimage.2004.09.028
   Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Meagher EA, 2000, FREE RADICAL BIO MED, V28, P1745, DOI 10.1016/S0891-5849(00)00232-X
   Mottron L, 2003, J CHILD PSYCHOL PSYC, V44, P904, DOI 10.1111/1469-7610.00174
   Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Osada Y, 2009, J BIOCHEM, V145, P387, DOI 10.1093/jb/mvn176
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1791, DOI 10.1021/tx200207z
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   Schjetne KW, 2003, J IMMUNOL, V171, P32, DOI 10.4049/jimmunol.171.1.32
   SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717
   Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605
   Somanath PR, 2009, J CELL PHYSIOL, V218, P394, DOI 10.1002/jcp.21612
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104
   WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200
   Yao H, 2009, J NEUROCHEM, V108, P835, DOI 10.1111/j.1471-4159.2008.05838.x
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yorbik O, 2002, PROSTAG LEUKOTR ESS, V67, P341, DOI 10.1054/plef.2002.0439
   Zoroglu SS, 2004, EUR ARCH PSY CLIN N, V254, P143, DOI 10.1007/s00406-004-0456-7
NR 75
TC 38
Z9 38
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD NOV
PY 2011
VL 24
IS 11
BP 1803
EP 1816
DI 10.1021/tx200206v
PG 14
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA 848VF
UT WOS:000297082500002
PM 21875030
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ideta, R
   Yanagi, Y
   Tamaki, Y
   Tasaka, F
   Harada, A
   Kataoka, K
AF Ideta, R
   Yanagi, Y
   Tamaki, Y
   Tasaka, F
   Harada, A
   Kataoka, K
TI Effective accumulation of polyion complex micelle to experimental
   choroidal neovascularization in rats
SO FEBS LETTERS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; drug
   delivery system; nanotechnotogy; polyion complex micelle
ID BLOCK-COPOLYMER MICELLES; MACULAR DEGENERATION; DRUG-DELIVERY; POLYMER;
   CORE; GENE
AB Exudative age-related macular degeneration, characterized by choroidal neovascularization (CNV), is a major cause of visual loss. In this study, we examined the distribution of the polyion complex (PIC) micelle encapsulating FITC-P(Lys) in blood and in experimental CNV in rats to investigate whether PIC micelle can be used for treatment of CNV. We demonstrate that PIC micelle has long-circulating characteristics, accumulating to the CNV lesions and is retained in the lesion for as long as 168 h after intravenous administration. These results raise the possibility that PIC micelles can be used for achieving effective drug targeting to CNV. (C) 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   Santen Pharmaceut Co Ltd, Div Res & Dev, Nara 6300101, Japan.
   Osaka Prefecture Univ, Grad Sch Engn, Dept Appl Mat Sci, Sakai, Osaka 5998531, Japan.
   Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan.
C3 University of Tokyo; Santen Pharmaceutical Co Ltd; Osaka Metropolitan
   University; University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Kataoka, Kazunori/K-7108-2012; Yanagi,
   Yasuo/AAF-2670-2020
OI Kataoka, Kazunori/0000-0002-8591-413X; Yanagi,
   Yasuo/0000-0002-0362-7285; Harada, Atsushi/0000-0002-9485-2110
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Harada A, 2001, EUR J PHARM SCI, V13, P35, DOI 10.1016/S0928-0987(00)00205-0
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   Harada A, 2001, J CONTROL RELEASE, V72, P85, DOI 10.1016/S0168-3659(01)00264-4
   Harada-Shiba M, 2002, GENE THER, V9, P407, DOI 10.1038/sj.gt.3301665
   Hunt DWC, 2003, IDRUGS, V6, P464
   Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mizumura Y, 2001, JPN J CANCER RES, V92, P328, DOI 10.1111/j.1349-7006.2001.tb01099.x
   Nakanishi T, 2001, J CONTROL RELEASE, V74, P295, DOI 10.1016/S0168-3659(01)00341-8
   Nishiyama N, 2001, PHARMACEUT RES, V18, P1035, DOI 10.1023/A:1010908916184
   Nishiyama N, 2003, ADV EXP MED BIOL, V519, P155
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Yanagi Y, 2003, INVEST OPHTH VIS SCI, V44, P751, DOI 10.1167/iovs.02-0222
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Yasukawa T, 1999, INVEST OPHTH VIS SCI, V40, P2690
NR 22
TC 33
Z9 35
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD JAN 16
PY 2004
VL 557
IS 1-3
BP 21
EP 25
DI 10.1016/S0014-5793(03)01315-2
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 769JZ
UT WOS:000188648100004
PM 14741335
OA Bronze
DA 2022-11-30
ER

PT J
AU Morya, AK
   Janti, SS
   Sisodiya, P
   Tejaswini, A
   Prasad, R
   Mali, KR
   Gurnani, B
AF Morya, Arvind Kumar
   Janti, Siddharam S.
   Sisodiya, Priya
   Tejaswini, Antervedi
   Prasad, Rajendra
   Mali, Kalpana R.
   Gurnani, Bharat
TI Everything real about unreal artificial intelligence in diabetic
   retinopathy and in ocular pathologies
SO WORLD JOURNAL OF DIABETES
LA English
DT Review
DE Artificial intelligence; Diabetic retinopathy; Deep learning; Machine
   learning; Ophthalmology
ID MACULAR DEGENERATION; AUTOMATED DETECTION; NEURAL-NETWORK; TOMOGRAPHY;
   SMARTPHONE; ALGORITHM; KERATOCONUS; VALIDATION; DIAGNOSIS; PROGRESSION
AB Artificial Intelligence is a multidisciplinary field with the aim of building platforms that can make machines act, perceive, reason intelligently and whose goal is to automate activities that presently require human intelligence. From the cornea to the retina, artificial intelligence (AI) is expected to help ophthalmologists diagnose and treat ocular diseases. In ophthalmology, computerized analytics are being viewed as efficient and more objective ways to interpret the series of images and come to a conclusion. AI can be used to diagnose and grade diabetic retinopathy, glaucoma, age-related macular degeneration, cataracts, IOL power calculation, retinopathy of prematurity and keratoconus. This review article intends to discuss various aspects of artificial intelligence in ophthalmology.
C1 [Morya, Arvind Kumar; Janti, Siddharam S.; Tejaswini, Antervedi] All India Inst Med Sci Bibinagar, Dept Ophthalmol, Hyderabad 508126, Telangana, India.
   [Sisodiya, Priya] Sadguru Netra Chikitsalaya, Dept Ophthalmol, Chitrakoot 485001, Madhya Pradesh, India.
   [Prasad, Rajendra] RP Eye Inst, Dept Ophthalmol, New Delhi 110001, India.
   [Mali, Kalpana R.] All India Inst Med Sci, Dept Pharmacol, , Telangana, Hyderabad 508126, Telangana, India.
   [Gurnani, Bharat] Aravind Eye Hosp & Post Grad Inst Ophthalmol, Dept Ophthalmol, Pondicherry 605007, Pondicherry, India.
   [Morya, Arvind Kumar] All India Inst Med Sci Bibinagar, Dept Ophthalmol, Warangal Rd, Hyderabad 508126, Telangana, India.
RP Morya, AK (通讯作者)，All India Inst Med Sci Bibinagar, Dept Ophthalmol, Warangal Rd, Hyderabad 508126, Telangana, India.
EM bulbul.morya@gmail.com
CR Akkara J., 2018, KERALA J OPHTHALMOL, V30, P54
   Akram MU, 2014, COMPUT METH PROG BIO, V114, P141, DOI 10.1016/j.cmpb.2014.01.010
   Akyol K, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6814791
   Ambrosio R, 2017, J REFRACT SURG, V33, P434, DOI 10.3928/1081597X-20170426-02
   Aslam TM, 2018, AM J OPHTHALMOL, V185, P94, DOI 10.1016/j.ajo.2017.10.015
   Blencowe H, 2013, PEDIATR RES, V74, P4, DOI 10.1038/pr.2013.203
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Chan C, 2015, CORNEA, V34, P996, DOI 10.1097/ICO.0000000000000529
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   De Neve W., 2017, P 2 INT WORKSH MULT, P89, DOI DOI 10.1145/3132635.3132650
   Deng L, 2013, FOUND TRENDS SIGNAL, V7, pI, DOI 10.1561/2000000039
   Eleiwa T, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00209-z
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Goldbaum MH, 2005, INVEST OPHTH VIS SCI, V46, P3676, DOI 10.1167/iovs.04-1167
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gu H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75027-3
   Hassan T, 2016, APPL OPTICS, V55, P454, DOI 10.1364/AO.55.000454
   Hwang ES, 2018, OPHTHALMOLOGY, V125, P1862, DOI 10.1016/j.ophtha.2018.06.020
   Imani E, 2015, COMPUT MED IMAG GRAP, V43, P78, DOI 10.1016/j.compmedimag.2015.03.004
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kessel K, 2020, OCUL ONCOL PATHOL, V6, P58, DOI 10.1159/000500896
   Kovacs I, 2016, J CATARACT REFR SURG, V42, P275, DOI 10.1016/j.jcrs.2015.09.020
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li AN, 2016, IEEE ENG MED BIO, P1328, DOI 10.1109/EMBC.2016.7590952
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lin A, 2003, AM J OPHTHALMOL, V135, P49, DOI 10.1016/S0002-9394(02)01836-6
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Lopes BT, 2018, AM J OPHTHALMOL, V195, P223, DOI 10.1016/j.ajo.2018.08.005
   Matsuba S, 2019, INT OPHTHALMOL, V39, P1269, DOI 10.1007/s10792-018-0940-0
   Morya AK, 2021, CLIN OPHTHALMOL, V15, P1023, DOI 10.2147/OPTH.S289425
   Namperumalsamy P, 2003, DIABETES CARE, V26, P1831, DOI 10.2337/diacare.26.6.1831
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Oh E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-106
   Padhy SK, 2019, INDIAN J OPHTHALMOL, V67, P1004, DOI 10.4103/ijo.IJO_1989_18
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Raghavendra U, 2018, INFORM SCIENCES, V441, P41, DOI 10.1016/j.ins.2018.01.051
   Raja C, 2015, COMPUT BIOL MED, V63, P196, DOI 10.1016/j.compbiomed.2015.05.018
   Rajalakshmi R, 2018, EYE, V32, P1138, DOI 10.1038/s41433-018-0064-9
   Ryan ME, 2015, OPHTHALMOLOGY, V122, P2038, DOI 10.1016/j.ophtha.2015.06.011
   Saad A, 2010, INVEST OPHTH VIS SCI, V51, P5546, DOI 10.1167/iovs.10-5369
   SAMUEL AL, 1959, IBM J RES DEV, V3, P211, DOI 10.1147/rd.33.0210
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Shah P, 2020, INDIAN J OPHTHALMOL, V68, P398, DOI 10.4103/ijo.IJO_966_19
   Sharif MS, 2015, APPL SOFT COMPUT, V36, P269, DOI 10.1016/j.asoc.2015.07.019
   Singh A, 2016, COMPUT METH PROG BIO, V124, P108, DOI 10.1016/j.cmpb.2015.10.010
   Sosale B, 2020, INDIAN J OPHTHALMOL, V68, P391, DOI 10.4103/ijo.IJO_1203_19
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srivastava R, 2014, J MED IMAGING, V1, DOI 10.1117/1.JMI.1.1.014502
   Tan LZ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.23
   Tavakkoli A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78696-2
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Valverde C, 2016, INDIAN J OPHTHALMOL, V64, P26, DOI 10.4103/0301-4738.178140
   Vinciguerra R, 2017, J REFRACT SURG, V33, P399, DOI 10.3928/1081597X-20170213-01
   Wang JY, 2018, EBIOMEDICINE, V35, P361, DOI 10.1016/j.ebiom.2018.08.033
   Wang MY, 2019, INVEST OPHTH VIS SCI, V60, P365, DOI 10.1167/iovs.18-25568
   Wang S, 2017, IEEE T BIO-MED ENG, V64, P990, DOI [10.1109/TBME.2016.2585344, 10.1109/TBME.2016.2632522]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yazid H, 2012, J MED SYST, V36, P1997, DOI 10.1007/s10916-011-9659-4
   Yedidya T, 2007, LECT NOTES COMPUT SC, V4791, P792
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P1143, DOI 10.1109/TBME.2013.2295605
NR 65
TC 0
Z9 0
U1 1
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
EI 1948-9358
J9 WORLD J DIABETES
JI World J. Diabetes
PD OCT 15
PY 2022
VL 13
IS 10
BP 822
EP 834
DI 10.4239/wjd.v13.i10.822
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 5V4MJ
UT WOS:000877204400003
PM 36311999
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Copland, DA
   Theodoropoulou, S
   Liu, J
   Dick, AD
AF Copland, David A.
   Theodoropoulou, Sofia
   Liu, Jian
   Dick, Andrew D.
TI A Perspective of AMD Through the Eyes of Immunology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE inflammation; dry AMD; immunotherapy; microglia
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; PIGMENT EPITHELIAL-CELLS;
   EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; CENTRAL-NERVOUS-SYSTEM; MEMBRANE
   ATTACK COMPLEX; MACULAR-DEGENERATION; NLRP3 INFLAMMASOME; T-CELLS;
   SUBRETINAL INFLAMMATION
AB Despite strong genetic associations, compelling human histological data and numerous hypotheses generated with supportive animal data, the mechanisms of inflammation or inflammatory control of cell health during progression of age-related macular degeneration arguably remain elusive. This perspective delivers a view that maintaining tissue health requires active immune cellular and tissue pathways, but when responses are perturbed or exaggerated, chronic inflammation is destructive. There are potential pathways and processes to enable understanding and determine how potential causative factors including altered cellular metabolism, senescence, oxidative stress disrupt tissue homeostasis are engaged. Establishing differences in the immune phenotype between normal aging and AMD, and how the inter-relatedness of these triggers contribute to pathobiology is integral for future therapeutic success.
C1 [Copland, David A.; Theodoropoulou, Sofia; Liu, Jian; Dick, Andrew D.] Univ Bristol, Translat Hlth Sci Ophthalmol, Bristol, Avon, England.
   [Copland, David A.; Dick, Andrew D.] Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr Ophthalmol, London, England.
   [Copland, David A.; Dick, Andrew D.] UCL, Inst Ophthalmol, London, England.
   [Theodoropoulou, Sofia; Dick, Andrew D.] Bristol Eye Hosp, Bristol, Avon, England.
C3 University of Bristol; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Bristol Eye Hospital
RP Dick, AD (通讯作者)，Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Lower Maudlin St, Bristol BS8 2UR, Avon, England.
EM a.dick@bristol.ac.uk
RI Copland, David/AAG-2368-2019; Copland, David/AAE-5334-2020
OI Copland, David/0000-0002-2257-4270; Theodoropoulou,
   Sofia/0000-0003-3038-5354; Dick, Andrew/0000-0002-0742-3159
FU The Dunhill Medical Trust [R138/1109] Funding Source: Medline
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Akbar AN, 2017, CLIN EXP IMMUNOL, V187, P4, DOI 10.1111/cei.12876
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Boldison J, 2014, J IMMUNOL, V192, P4541, DOI 10.4049/jimmunol.1301390
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campbell M, 2014, EXPERT REV CLIN IMMU, V10, P1273, DOI 10.1586/1744666X.2014.950231
   Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen M, 2012, AM J PATHOL, V180, P235, DOI 10.1016/j.ajpath.2011.09.020
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen XT, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0235-6
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chu CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063002
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2007, AM J PATHOL, V171, P580, DOI 10.2353/ajpath.2007.070272
   Copland DA, 2008, INVEST OPHTH VIS SCI, V49, P5458, DOI 10.1167/iovs.08-2348
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erny D, 2017, IMMUNOLOGY, V150, P7, DOI 10.1111/imm.12645
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784
   Geng S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13436
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Ginhoux F, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020537
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880
   Hess C, 2016, IMMUNITY, V45, P240, DOI 10.1016/j.immuni.2016.08.003
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horie S, 2013, SCI REP, DOI [10.1038/srep03072.98, DOI 10.1038/SREP03072.98]
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Jain A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00553
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Kerr EC, 2008, J AUTOIMMUN, V31, P354, DOI 10.1016/j.jaut.2008.08.006
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Kielczewski JL, 2016, J IMMUNOL, V196, P1013, DOI 10.4049/jimmunol.1501570
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   LIU J, 2016, SCI REP UK, V6
   Liu J., 2013, PLOS ONE, V8
   London A, 2013, J IMMUNOL, V190, P3570, DOI 10.4049/jimmunol.1202076
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Mankan AK, 2012, CLIN EXP IMMUNOL, V167, P369, DOI 10.1111/j.1365-2249.2011.04534.x
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Matcovitch-Natan O, 2016, SCIENCE, V353, DOI 10.1126/science.aad8670
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miyata M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7062
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Murphy AJ, 2016, CELL METAB, V23, P155, DOI 10.1016/j.cmet.2015.09.024
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Ng TF, 2009, INVEST OPHTH VIS SCI, V50, P5472, DOI 10.1167/iovs.08-2877
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Okin D, 2012, CURR BIOL, V22, pR733, DOI 10.1016/j.cub.2012.07.029
   OWENS R, 2017, FRONT CELL NEUROSCI, V11
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084
   Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38
   Perry VH, 2013, SEMIN IMMUNOPATHOL, V35, P601, DOI 10.1007/s00281-013-0382-8
   Prendergast RA, 1998, INVEST OPHTH VIS SCI, V39, P754
   Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923
   Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615
   Reyes NJ, 2017, NAT REV IMMUNOL, V17, P322, DOI 10.1038/nri.2017.13
   Saban DR, 2018, CELL IMMUNOL, V330, P79, DOI 10.1016/j.cellimm.2018.04.008
   Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shemer A, 2015, SEMIN IMMUNOPATHOL, V37, P613, DOI 10.1007/s00281-015-0519-z
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vilahur G, 2009, J THROMB HAEMOST, V7, P485, DOI 10.1111/j.1538-7836.2008.03244.x
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wen HT, 2012, NAT IMMUNOL, V13, P352, DOI 10.1038/ni.2228
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477
   Yerbury JJ, 2016, J NEUROCHEM, V137, P489, DOI 10.1111/jnc.13575
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
   Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R
   Zhou R, 2012, J IMMUNOL, V188, P1742, DOI 10.4049/jimmunol.1102415
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 155
TC 28
Z9 30
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD83
EP AMD92
DI 10.1167/iovs.18-23893
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GN7JZ
UT WOS:000439314600004
PM 30025105
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Aggio, FB
   Farah, ME
   de Melo, GB
   d'Azevedo, PA
   Pignatri, ACC
   Hofling-Lima, AL
AF Aggio, F. B.
   Farah, M. E.
   de Melo, G. B.
   d'Azevedo, P. A.
   Pignatri, A. C. C.
   Hofling-Lima, A. L.
TI Acute endophthalmitis following intravitreal bevacizumab (Avastin)
   injection
SO EYE
LA English
DT Article
DE intravitreal bevacizumab; endophthalmitis; ocular inflammation; VEGF
ID MACULAR DEGENERATION
AB Purpose: To report two cases of acute endophthalmitis following intravitreal bevacizumab injection.
   Methods: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of bevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. Vitreous samples were obtained, followed by the injection of vancomycin 1 mg/0.1 ml and ceftazidime 2.25 mg/0.1 ml. Pulsed-field gel electrophoresis (PFGE) was used to determine whether the isolated microorganisms were the same.
   Results: Coagulase-negative staphylococci were identified and isolated from the vitreous specimen of both patients. PFGE revealed different patterns of banding, excluding that interpatient contamination occured.
   Conclusions: Infectious endophthalmitis is a potential complication of intravitreal bevacizumab injection.
C1 Univ Fed Sao Paulo, Vis Inst, BR-01239010 Sao Paulo, SP, Brazil.
   Univ Fed Sao Paulo, Special Lab Clin Microbiol, Div Infect Dis, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP de Melo, GB (通讯作者)，Univ Fed Sao Paulo, Vis Inst, R Sabara 16 Ap 113, BR-01239010 Sao Paulo, SP, Brazil.
EM gustavobmelo@yahoo.com.br
RI Farah, Michel Eid E/F-3285-2012; Hofling-Lima, Ana Luisa/C-8865-2012;
   Melo, Gustavo/AAD-3844-2019; Hofling-Lima, Ana Luisa/O-7438-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; Melo,
   Gustavo/0000-0001-5765-2008; Hofling-Lima, Ana
   Luisa/0000-0003-0338-3951; Pignatari, Antonio/0000-0002-2146-8476
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beadle J, 2003, ADV APPL MICROBIOL, V53, P243, DOI 10.1016/S0065-2164(03)53007-6
   FUNG AE, 2006, BR J OPHTHALMOL
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426
   Trindade P. A., 2003, Braz J Infect Dis, V7, P32, DOI 10.1590/S1413-86702003000100005
NR 8
TC 32
Z9 39
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2007
VL 21
IS 3
BP 408
EP 409
DI 10.1038/sj.eye.6702683
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141US
UT WOS:000244604900018
PM 17277758
OA Bronze
DA 2022-11-30
ER

PT J
AU Dalkara, D
   Goureau, O
   Marazova, K
   Sahel, JA
AF Dalkara, Deniz
   Goureau, Olivier
   Marazova, Katia
   Sahel, Jose-Alain
TI Let There Be Light: Gene and Cell Therapy for Blindness
SO HUMAN GENE THERAPY
LA English
DT Review
ID LEBER CONGENITAL AMAUROSIS; RETINAL PIGMENTED EPITHELIUM; OPTIMIZED
   ALLOTOPIC EXPRESSION; RESTORES VISUAL RESPONSES; PLURIPOTENT STEM-CELLS;
   CONE VIABILITY FACTOR; PHASE-I TRIAL; RETINITIS-PIGMENTOSA; MOUSE MODEL;
   PHOTORECEPTOR PRECURSORS
AB Retinal degenerative diseases are a leading cause of irreversible blindness. Retinal cell death is the main cause of vision loss in genetic disorders such as retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis, as well as in complex age-related diseases such as age-related macular degeneration. For these blinding conditions, gene and cell therapy approaches offer therapeutic intervention at various disease stages. The present review outlines advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies. A significant body of preclinical evidence and initial clinical results pave the way for further development of these cutting edge treatments for patients with retinal degenerative disorders.
C1 [Dalkara, Deniz; Goureau, Olivier; Marazova, Katia; Sahel, Jose-Alain] Univ Paris 06, Sorbonne Univ, INSERM, CNRS,Inst Vis, Paris, France.
   [Sahel, Jose-Alain] Ctr Hosp Natl Ophtalmol Quinze Vingts, DHU Sight Restore, INSERM DHOS CIC 1423, Paris, France.
   [Sahel, Jose-Alain] Fdn Ophtalmol Adolphe de Rothschild, Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite
RP Dalkara, D (通讯作者)，Inst Vis, 17 Rue Moreau, F-75012 Paris, France.
EM deniz.dalkara@gmail.com
RI Dalkara, Deniz/D-5057-2017; Sahel, Jose-Alain/F-3172-2017; GOUREAU,
   Olivier/ABH-9547-2020; GOUREAU, Olivier/F-2752-2017
OI Dalkara, Deniz/0000-0003-4112-9321; Sahel,
   Jose-Alain/0000-0002-4831-1153; GOUREAU, Olivier/0000-0001-7730-9143;
   GOUREAU, Olivier/0000-0001-7730-9143
FU Institut National de la Sante et de la Recherche Medicale (INSERM);
   Pierre et Marie Curie Universite (UPMC); Centre National de la Recherche
   Scientifique (CNRS); Foundation Fighting Blindness (FFB)
   [CD-CL-0808-0466-CHNO]; French State program Investissements d'Avenir
   [LABEX LIFESENSES: ANR-10-LABX-65]
FX This work was supported by the Institut National de la Sante et de la
   Recherche Medicale (INSERM), Pierre et Marie Curie Universite (UPMC),
   the Centre National de la Recherche Scientifique (CNRS), Foundation
   Fighting Blindness (FFB) (CD-CL-0808-0466-CHNO), and the French State
   program Investissements d'Avenir managed by the Agence Nationale de la
   Recherche (LABEX LIFESENSES: ANR-10-LABX-65).
CR Adijanto J, 2015, EUR J PHARM BIOPHARM, V95, P353, DOI 10.1016/j.ejpb.2014.12.028
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Andrieu-Soler C, 2006, MOL VIS, V12, P1334
   Ashtari M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8791
   Ashtari M, 2011, J CLIN INVEST, V121, P2160, DOI 10.1172/JCI57377
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bemelmans AP, 2005, J GENE MED, V7, P1367, DOI 10.1002/jgm.788
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Binley K, 2013, INVEST OPHTH VIS SCI, V54, P4061, DOI 10.1167/iovs.13-11871
   Bonnet C, 2008, BBA-MOL CELL RES, V1783, P1707, DOI 10.1016/j.bbamcr.2008.04.018
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Boyd RE, 2016, GENE THER, V23, P223, DOI 10.1038/gt.2015.96
   Boye SL, 2013, HUM GENE THER, V24, P189, DOI 10.1089/hum.2012.193
   Boye SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011306
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Caras IW, 2014, STEM CELL TRANSL MED, V3, P1393, DOI 10.5966/sctm.2014-0221
   Cashman SM, 2007, MOL THER, V15, P1640, DOI 10.1038/sj.mt.6300203
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Cehajic-Kapetanovic J, 2015, CURR BIOL, V25, P2111, DOI 10.1016/j.cub.2015.07.029
   Chadderton N, 2013, EUR J HUM GENET, V21, P62, DOI 10.1038/ejhg.2012.112
   Chen FK, 2014, J CLIN MED, V3, P1511, DOI 10.3390/jcm3041511
   Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P526, DOI 10.1167/iovs.14-15895
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Colella P, 2010, CURR GENE THER, V10, P371, DOI 10.2174/156652310793180670
   Cronin T, 2014, EMBO MOL MED, V6, P1175, DOI 10.15252/emmm.201404077
   Cwerman-Thibault H, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.3
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2011, MOL THER, V19, P1602, DOI 10.1038/mt.2011.62
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Decembrini S, 2014, STEM CELL REP, V2, P853, DOI 10.1016/j.stemcr.2014.04.010
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Duisit G, 2002, MOL THER, V6, P446, DOI 10.1006/mthe.2002.0690
   Eberle D, 2011, INVEST OPHTH VIS SCI, V52, P6462, DOI 10.1167/iovs.11-7399
   Ellouze S, 2008, AM J HUM GENET, V83, P373, DOI 10.1016/j.ajhg.2008.08.013
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Feuer WJ, OPHTHALMOLO IN PRESS, DOI [10.1016/j.ophtha.2015.10.025., DOI 10.1016/J.OPHTHA.2015.10.025]
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Greenberg KP, 2007, INVEST OPHTH VIS SCI, V48, P1844, DOI 10.1167/iovs.05-1570
   Han ZC, 2015, FASEB J, V29, P2535, DOI 10.1096/fj.15-270363
   Han ZC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052189
   Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833
   Haurigot V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041511
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Jacobson SG, 2013, CLIN GENET, V84, P175, DOI 10.1111/cge.12165
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jacobson SG, 2011, INVEST OPHTH VIS SCI, V52, P70, DOI 10.1167/iovs.10-6127
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Koch SF, 2015, J CLIN INVEST, V125, P3704, DOI 10.1172/JCI82462
   Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807
   Komaromy AM, 2013, MOL THER, V21, P1131, DOI 10.1038/mt.2013.50
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Li YM, 2009, INVEST OPHTH VIS SCI, V50, P1336, DOI 10.1167/iovs.08-2589
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Lipinski DM, 2015, MOL THER, V23, P1308, DOI 10.1038/mt.2015.68
   Mace E, 2015, MOL THER, V23, P7, DOI 10.1038/mt.2014.154
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2006, EXP EYE RES, V83, P1118, DOI 10.1016/j.exer.2006.05.019
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Manfredi A, 2013, HUM GENE THER, V24, P982, DOI 10.1089/hum.2013.154
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   O'Reilly M, 2014, HUM GENE THER, V25, P488, DOI 10.1089/hum.2014.045
   Ou JX, 2015, J CLIN INVEST, V125, P2891, DOI 10.1172/JCI81380
   Pauwels K, 2009, CURR GENE THER, V9, P459, DOI 10.2174/156652309790031120
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Petrs-Silva H, 2009, MOL THER, V17, P463, DOI 10.1038/mt.2008.269
   Puppo A, 2014, GENE THER, V21, P855, DOI 10.1038/gt.2014.57
   Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Scalabrino ML, 2015, HUM MOL GENET, V24, P6229, DOI 10.1093/hmg/ddv341
   Scholl HPN, 2014, LANCET, V383, P1105, DOI 10.1016/S0140-6736(14)60033-7
   Schwartz SD, 2015, LANCET, V386, P30, DOI 10.1016/S0140-6736(15)61203-X
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   StemCells, 2014, INT RES SHOW IMPR VI
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sun H, 2000, METHOD ENZYMOL, V315, P879
   Sweigard JH, 2010, INVEST OPHTH VIS SCI, V51, P2219, DOI 10.1167/iovs.09-4367
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tan MH, 2009, HUM MOL GENET, V18, P2099, DOI 10.1093/hmg/ddp133
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Testa F, 2011, INVEST OPHTH VIS SCI, V52, P5618, DOI 10.1167/iovs.10-6543
   Thompson DA, 2015, INVEST OPHTH VIS SCI, V56, P918, DOI 10.1167/iovs.14-16049
   Trapani I, 2015, HUM MOL GENET, V24, P6811, DOI 10.1093/hmg/ddv386
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Uretsky S, 2015, 12 INT S OC PHARM TH
   van Wyk M, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002143
   Vandenberghe LH, 2012, GENE THER, V19, P162, DOI 10.1038/gt.2011.151
   Von Seggern DJ, 2003, MOL THER, V7, P27, DOI 10.1016/S1525-0016(02)00030-8
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 133
TC 83
Z9 89
U1 1
U2 50
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB 1
PY 2016
VL 27
IS 2
BP 134
EP 147
DI 10.1089/hum.2015.147
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA DF3KE
UT WOS:000371241900008
PM 26751519
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Hangai, M
   He, SK
   Hoffmann, S
   Lim, JI
   Ryan, SJ
   Hinton, DR
AF Hangai, M
   He, SK
   Hoffmann, S
   Lim, JI
   Ryan, SJ
   Hinton, DR
TI Sequential induction of angiogenic growth factors by TNF-alpha in
   choroidal endothelial cells
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE angiogenesis; choriocapillaris; cytokine; growth factors; gene
   expression
ID RECEPTOR TYROSINE KINASES; SUBRETINAL NEOVASCULAR MEMBRANES;
   RETINAL-PIGMENT EPITHELIUM; TIE2 RECEPTOR; CONSTITUTIVE EXPRESSION;
   ANGIOPOIETIN-1 AND-2; MACULAR DEGENERATION; UP-REGULATION; IN-VITRO;
   VEGF
AB Inflammatory mediators have been proposed to play a critical role in the pathogenesis of choroidal neovascularization, a blinding complication of age-related macular degeneration. We evaluated the expression of TNF-alpha in human choroidal neovascular membranes and found that it colocalized with cells expressing VEGF, angiopoictin (Ang)-l and Ang2. In cultured choroidal endothelial cells we found that TNF-alpha increased Ang2 mRNA (increased transcription) and protein levels prior to those of Ang] and VEGF. The results raise the possibility that during neovascularization, TNF-alpha may modulate endothelial plasticity and survival by sequential inactivation of Tie2 followed by activation of Tie2 and VEGF receptors. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ So Calif, Dept Ophthalmol, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90089 USA.
   Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dept Pathol, Los Angeles, CA USA.
   Univ So Calif, Keck Sch Med, Beckman Macular Res Ctr, Doheny Eye Inst, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of Southern California; Doheny Eye
   Institute; University of Southern California; Doheny Eye Institute;
   University of Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Dept Ophthalmol, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90089 USA.
EM dhinton@hsc.usc.edu
FU NATIONAL EYE INSTITUTE [R01EY001545, P30EY003040] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY03040, EY01545] Funding Source: Medline
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   DAMATO RJ, 1995, OPHTHALMOLOGY, V102, P1261, DOI 10.1016/S0161-6420(95)30876-7
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090
   FERRARA N, 1995, ANN NY ACAD SCI, V752, P246, DOI 10.1111/j.1749-6632.1995.tb17435.x
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277
   Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   Hashimoto T, 2004, ENDOTHELIUM-J ENDOTH, V11, P207, DOI 10.1080/10623320490512417
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Kampfer H, 2001, LAB INVEST, V81, P361, DOI 10.1038/labinvest.3780244
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296
   Kimura H, 1999, INVEST OPHTH VIS SCI, V40, P524
   Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2
   Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852
   MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Otani A, 2001, DIABETES, V50, P867, DOI 10.2337/diabetes.50.4.867
   Papapetropoulos A, 1999, LAB INVEST, V79, P213
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1377, DOI 10.1001/archopht.1986.01050210131040
   POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296
   ROBAYE B, 1991, AM J PATHOL, V138, P447
   RYAN SJ, 2001, RETINA, V1, P1003
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SATO N, 1987, J NATL CANCER I, V79, P1383
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   SAXE SJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P88, DOI 10.1001/archopht.1993.01090010092033
   Scott BB, 2002, J RHEUMATOL, V29, P230
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0
   Willam C, 2000, CIRC RES, V87, P370
   Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514
NR 70
TC 46
Z9 57
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD FEB
PY 2006
VL 171
IS 1-2
BP 45
EP 56
DI 10.1016/j.jneuroim.2005.09.018
PG 12
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 009LW
UT WOS:000235114500006
PM 16288810
DA 2022-11-30
ER

PT J
AU Oz, I
   Kaplan, I
   Kleinman, S
   Arbel, S
   Shuster, A
AF Oz, I
   Kaplan, I
   Kleinman, S.
   Arbel, S.
   Shuster, A.
TI Medication-related osteonecrosis of the jaws associated with
   intravitreal administration of ranibizumab
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE MRONJ; Anti-angiogenic agent; Ranibizumab
AB Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication that, in the majority of cases, is related to antiresorptive agents. Numerous articles have described cases of MRONJ in bisphosphonate-naive patients treated with anti-angiogenic agents administered via various routes. A single case of MRONJ after intravitreal injection of bevacizumab has been reported. We report a case of MRONJ after intravitreal injection of a different anti-angiogenic agent - ranibizumab - for the treatment of neovascular age-related macular degeneration, in a bisphosphonate-naive patient. Although it may be a rare complication, patients treated with multiple doses of anti-angiogenic agents should be monitored for the possible early diagnosis of MRONJ.
C1 [Oz, I; Kaplan, I; Kleinman, S.; Arbel, S.; Shuster, A.] Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg & Maxillofacial, 6 Weizmann, IL-64239 Tel Aviv, Israel.
   [Kaplan, I] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel.
   [Kaplan, I] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Shuster, A.] Tel Aviv Univ, Goldschleger Sch Dent Med, Dept Oral & Maxillofacial Surg, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel
   Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv University
RP Shuster, A (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Otolaryngol Head & Neck Surg & Maxillofacial, 6 Weizmann, IL-64239 Tel Aviv, Israel.
EM amirshu@tlvmc.gov.il
OI Oz, Itay/0000-0003-1274-9767
CR Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   FDA Report, 2012, CLIN REV, V141, P99
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549-010-0866-3
   Hopp RN, 2012, J ORAL MAXIL SURG, V70, P632, DOI 10.1016/j.joms.2011.02.104
   McCarthy G, 2019, ADV THER, V36, P632, DOI 10.1007/s12325-019-0894-2
   Owosho AA, 2018, OR SURG OR MED OR PA, V125, P440, DOI 10.1016/j.oooo.2018.02.003
   Pimolbutr K, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8071579
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
NR 9
TC 1
Z9 1
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901-5027
EI 1399-0020
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD DEC
PY 2020
VL 49
IS 12
BP 1589
EP 1591
DI 10.1016/j.ijom.2020.05.017
PG 3
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA OY9AV
UT WOS:000594532500011
PM 32616306
DA 2022-11-30
ER

PT J
AU Huang, DD
   Xu, CJ
   Guo, RR
   Ji, J
   Liu, W
AF Huang, Dandan
   Xu, Chenjia
   Guo, Ruru
   Ji, Jian
   Liu, Wei
TI Anterior lens capsule: biomechanical properties and biomedical
   engineering perspectives
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE anterior lens capsule; biomedical engineering; cell cultivation
ID RETINAL-PIGMENT EPITHELIUM; MECHANICAL-PROPERTIES; FLAP TRANSPLANTATION;
   MITOMYCIN-C; AGE; CELLS; SUBSTRATE; MEMBRANE; TRABECULECTOMY; MANAGEMENT
AB Anterior lens capsule, as the thickest basement membrane in the body, has its unique physiology characteristics. In ophthalmology, many attempts have been made to culture different kinds of cells including iris pigment epithelial cells, retinal pigment epithelial cells, corneal epithelium and endothelium cells, trabecular meshwork cells etc and anterior lens capsule has been confirmed to be served as an excellent scaffold for the growth and expansion of different ocular cells. Furthermore, anterior lens capsule also has unique potential in gestation evaluation and the treatment of various ocular diseases, including corneal ulcer, glaucoma, age-related macular degeneration and macular hole, etc. Here, we provide an overview of the biomechanical properties and biomedical engineering perspectives of anterior lens capsule.
C1 [Huang, Dandan] Hubei Univ Med, Taihe Hosp, Dept Ophthalmol, Shiyan, Peoples R China.
   [Xu, Chenjia; Guo, Ruru; Ji, Jian; Liu, Wei] Tianjin Med Univ, Tianjin Key Lab Retinal Funct & Dis, Tianjin Int Joint Res & Dev Ctr Ophthalmol & Visi, Eye Hosp,Eye Inst, Tianjin, Peoples R China.
   [Xu, Chenjia; Guo, Ruru; Ji, Jian; Liu, Wei] Tianjin Med Univ, Sch Optometry, Eye Hosp, Tianjin, Peoples R China.
   [Liu, Wei] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, Groningen, Netherlands.
C3 Hubei University of Medicine; Tianjin Medical University; Tianjin
   Medical University; University of Groningen
RP Liu, W (通讯作者)，Tianjin Med Univ, Eye Hosp, 251 Fukang Rd, Tianjin 300384, Peoples R China.
EM weiliu05@tmu.edu.cn
RI Liu, Wei/GLN-6132-2022
OI Liu, Wei/0000-0001-9037-8792
FU Science & Technology Development Fund of Tianjin Education Commission
   for Higher Education [2016YD09]; Tianjin Clinical Key Discipline Project
   [TJLCZD XKQ023]
FX This work was supported by a grant from The Science & Technology
   Development Fund of Tianjin Education Commission for Higher Education
   (grant number: 2016YD09) and Tianjin Clinical Key Discipline Project
   (grant number: TJLCZD XKQ023). The funders had no role in the design of
   the study; in the collection, analyses, or interpretation of data; in
   the writing of the manuscript, or in the decision to publish the
   results.
CR Albert R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047187
   Anwar M, 1997, J CATARACT REFR SURG, V23, P1103, DOI 10.1016/S0886-3350(97)80088-0
   ASSIA EI, 1991, INVEST OPHTH VIS SCI, V32, P2835
   Avetisov KS, 2020, J MECH BEHAV BIOMED, V103, DOI 10.1016/j.jmbbm.2019.103600
   Barraquer RI, 2006, INVEST OPHTH VIS SCI, V47, P2053, DOI 10.1167/iovs.05-1002
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chen HJ, 2018, OPHTHALMIC RES, V59, P155, DOI 10.1159/000486576
   Chen SN, 2016, RETINA-J RET VIT DIS, V36, P163, DOI 10.1097/IAE.0000000000000674
   Collignon-Brach J, 1993, Bull Soc Belge Ophtalmol, V247, P79
   Danysh BP, 2009, EXP EYE RES, V88, P151, DOI 10.1016/j.exer.2008.08.002
   Das GK, 2018, SEMIN OPHTHALMOL, V33, P143, DOI 10.1080/08820538.2016.1182558
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Dong J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0489-0
   Emarah AM, 2011, J GLAUCOMA, V20, P514, DOI 10.1097/IJG.0b013e3181efe1d5
   Feng YQ, 2014, CURR EYE RES, V39, P541, DOI 10.3109/02713683.2013.853803
   FISHER RF, 1969, J PHYSIOL-LONDON, V201, P1, DOI 10.1113/jphysiol.1969.sp008739
   Galal A, 2007, CORNEA, V26, P473, DOI 10.1097/ICO.0b013e318033bd0f
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   HITTNER H M, 1981, Journal of Pediatric Ophthalmology and Strabismus, V18, P52
   HITTNER HM, 1977, J PEDIATR-US, V91, P455, DOI 10.1016/S0022-3476(77)81324-3
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Kopsachilis N, 2013, CELL TISSUE BANK, V14, P407, DOI 10.1007/s10561-012-9332-2
   Kopsachilis N, 2012, CLIN EXP OPHTHALMOL, V40, P187, DOI 10.1111/j.1442-9071.2011.02678.x
   Kozak I, 2004, CORNEA, V23, P797, DOI 10.1097/01.ico.0000134195.71981.e2
   Kozak I, 2003, CORNEA, V22, P359, DOI 10.1097/00003226-200305000-00015
   Kozak I, 2004, Cesk Slov Oftalmol, V60, P261
   Krag S, 2003, PROG RETIN EYE RES, V22, P749, DOI 10.1016/S1350-9462(03)00063-6
   Krag S, 1999, ACTA OPHTHALMOL SCAN, V77, P364, DOI 10.1034/j.1600-0420.1999.770326.x
   Krag S, 1997, INVEST OPHTH VIS SCI, V38, P357
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Lu D, 2009, EYE, V23, P195, DOI 10.1038/eye.2008.96
   Morizane Y, 2014, AM J OPHTHALMOL, V157, P861, DOI 10.1016/j.ajo.2013.12.028
   Nagpal Jitender, 2004, Indian Pediatr, V41, P817
   Navaratnam J, 2015, J FUNCT BIOMATER, V6, P917, DOI 10.3390/jfb6030917
   Nguyen KN, 2018, ACTA BIOMATER, V65, P21, DOI 10.1016/j.actbio.2017.10.037
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Patel M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00043
   Pedrigi RM, 2007, VISION RES, V47, P1781, DOI 10.1016/j.visres.2007.03.014
   Peng J, 2018, RETINA-J RET VIT DIS, V38, P2177, DOI 10.1097/IAE.0000000000001830
   Rekas M, 2010, CURR MED RES OPIN, V26, P2025, DOI 10.1185/03007995.2010.500857
   Ronci M, 2011, J PROTEOME RES, V10, P3522, DOI 10.1021/pr200148k
   SASIVIMOLKUL W, 1986, Journal of the Medical Association of Thailand, V69, P38
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   SMITH S, 1994, AM J OPHTHALMOL, V118, P332, DOI 10.1016/S0002-9394(14)72957-5
   Spinozzi D, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720923577
   Spinozzi D, 2019, CURR EYE RES, V44, P243, DOI 10.1080/02713683.2018.1536215
   Stamate Alina-Cristina, 2019, Rom J Ophthalmol, V63, P166
   Sueiras VM, 2019, MOL VIS, V25, P593
   Sueiras VM, 2015, MOL VIS, V21, P316
   Talu S, 2018, MOL VIS, V24, P902
   Tan XW, 2013, J MATER SCI-MATER M, V24, P967, DOI 10.1007/s10856-012-4848-3
   Telinius N, 2020, CURR EYE RES, V45, P945, DOI 10.1080/02713683.2019.1706747
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Van den Bogerd B, 2018, J TISSUE ENG REGEN M, V12, pE2020, DOI 10.1002/term.2633
   Wang W, 2010, DISCOV MED, V9, P13
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Yepez Juan B, 2018, Retin Cases Brief Rep, V12, P286, DOI 10.1097/ICB.0000000000000513
   Yoeruek E, 2009, CORNEA, V28, P416, DOI 10.1097/ICO.0b013e31818c2c36
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Ziebarth NM, 2005, INVEST OPHTH VIS SCI, V46, P1690, DOI 10.1167/iovs.05-0039
   Ziebarth NM, 2011, EXP EYE RES, V92, P490, DOI 10.1016/j.exer.2011.03.008
NR 64
TC 4
Z9 4
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2021
VL 99
IS 3
BP E302
EP E309
DI 10.1111/aos.14600
EA SEP 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RW8PX
UT WOS:000567777100001
PM 32914585
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Sistiabudi, R
   Ivanisevic, A
AF Sistiabudi, Rizaldi
   Ivanisevic, Albena
TI Collagen-binding peptide interaction with retinal tissue surfaces
SO LANGMUIR
LA English
DT Article
ID ANTERIOR LENS CAPSULE; HUMAN BRUCHS MEMBRANE; PIGMENT-EPITHELIUM;
   MACULAR DEGENERATION; TRANSPLANTATION; TRANSLOCATION; SUPPORT; LAYERS;
   REATTACHMENT
AB One of the current challenges in treating age-related macular degeneration (AMD) is the surface modification of the retinal Bruch membrane. In this study, the collagen fibers of the inner collagenous zone of the Bruch membrane were identified as type I and type III. Subsequently, the adsorption of a collagen-binding peptide onto the inner collagenous zone surface was investigated. The collagen-binding peptide was able to bind specifically to the collagen fibers while maintaining the biological activity of the N-terminus biotin tag. These results indicate that the collagen-binding peptide may be used as an anchor to immobilize bioactive molecules on the inner collagenous zone surface of the Bruch membrane.
C1 [Sistiabudi, Rizaldi; Ivanisevic, Albena] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
   [Ivanisevic, Albena] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University West
   Lafayette Campus; Purdue University System; Purdue University; Purdue
   University West Lafayette Campus
RP Ivanisevic, A (通讯作者)，Purdue Univ, Weldon Sch Biomed Engn, 206 S Martin Jischke Dr, W Lafayette, IN 47907 USA.
EM albena@purdue.edu
RI Sistiabudi, Rizaldi/AAR-6668-2020
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2000, INVEST OPHTH VIS SCI, V41, pS858
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   KORAH R, 2004, CANCER RES, V64, P5414
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Ricard-Blum S, 2005, TOP CURR CHEM, V247, P35, DOI 10.1007/b103819
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Sistiabudi R, 2007, J PHYS CHEM C, V111, P11676, DOI 10.1021/jp072757j
   Tezel TH, 1997, INVEST OPHTH VIS SCI, V38, P4393
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Tye CE, 2005, J BIOL CHEM, V280, P13487, DOI 10.1074/jbc.M408923200
   Wang AY, 2005, J AM CHEM SOC, V127, P4130, DOI 10.1021/ja0431915
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 21
TC 20
Z9 20
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 4
PY 2008
VL 24
IS 5
BP 1591
EP 1594
DI 10.1021/la703561d
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science
GA 266TP
UT WOS:000253460200003
PM 18254650
DA 2022-11-30
ER

PT J
AU Burke, JM
   Hjelmeland, LM
AF Burke, JM
   Hjelmeland, LM
TI Mosaicism of the retinal pigment epithelium: seeing the small picture
SO MOLECULAR INTERVENTIONS
LA English
DT Review
ID EXPERIMENTAL CHIMERAS; MORPHOMETRIC ANALYSIS; LYSOSOMAL-ENZYMES;
   CELL-ADHESION; HUMAN RPE; AGE; MECHANISMS; EXPRESSION; MELANIN; GROWTH
AB The retinal pigment epithelium (RPE) is a monolayer of cells that appear phenotypically regular, but which exhibit striking cell-cell variability in content of melanin and lipofuscin granules, and in expression of many proteins. This naturally occurring cell heterogeneity likely arises by normal mechanisms regulating gene expression during development and postnatal aging. The consequence is a tissue in which individual cells may differ in their ability to support adjacent photoreceptors, and which may respond differentially to oxidative stress and other environmental influences that contribute to cell dysfunction during aging. The inherent variability of RPE cells is probably one factor contributing to the characteristically patchy pattern of retinal diseases like age-related macular degeneration.
C1 Med Coll Wisconsin, Inst Eye, Dept Ophthalmol & Cell Biol, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Inst Eye, Dept Neurobiol & Anat, Milwaukee, WI 53226 USA.
   Univ Calif Davis, Dept Ophthalmol, Davis, CA 95616 USA.
C3 Medical College of Wisconsin; Medical College of Wisconsin; University
   of California System; University of California Davis
RP Burke, JM (通讯作者)，Med Coll Wisconsin, Inst Eye, Dept Ophthalmol & Cell Biol, 925 N 87th St, Milwaukee, WI 53226 USA.
EM jburke@mcw.edu
RI Datta, Sayantan/D-1369-2010
FU NATIONAL EYE INSTITUTE [R01EY013722, R01EY015284, P30EY001931] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY006473, EY013722, P30 EY01931,
   EY015284] Funding Source: Medline
CR Aguirre GD, 2002, EXP EYE RES, V75, P431, DOI 10.1006/exer.2002.2037
   Ando A, 2000, EXP EYE RES, V70, P89, DOI 10.1006/exer.1999.0750
   Bandyopadhyay D, 2003, EXP GERONTOL, V38, P1299, DOI 10.1016/j.exger.2003.09.009
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beck JA, 2004, HUM MOL GENET, V13, P1219, DOI 10.1093/hmg/ddh134
   Besch D, 2003, VISION RES, V43, P3095, DOI 10.1016/j.visres.2003.09.020
   BODENSTEIN L, 1987, DEV BIOL, V121, P205, DOI 10.1016/0012-1606(87)90153-9
   BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   BURKE JM, 1991, INVEST OPHTH VIS SCI, V32, P2042
   Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963
   Burke JM, 2000, INVEST OPHTH VIS SCI, V41, P1945
   Burke JM, 1996, EXP EYE RES, V62, P63, DOI 10.1006/exer.1996.0008
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1789
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   BURKE JM, 1993, CURR EYE RES, V12, P1073, DOI 10.3109/02713689309033505
   Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478
   CABRAL L, 1990, INVEST OPHTH VIS SCI, V31, P670
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Collinson JM, 2004, INT J DEV BIOL, V48, P793, DOI 10.1387/ijdb.041885jc
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Frohlich E, 2001, GRAEF ARCH CLIN EXP, V239, P25, DOI 10.1007/s004170000218
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   IANNACCONE PM, 1987, CELL DIFFER DEV, V21, P79, DOI 10.1016/0045-6039(87)90415-5
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   LAVAIL MM, 1987, EXP EYE RES, V44, P877, DOI 10.1016/S0014-4835(87)80050-7
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176
   McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374
   McLaren MJ, 1996, INVEST OPHTH VIS SCI, V37, P1213
   Miyamura N, 2004, INVEST OPHTH VIS SCI, V45, P1562, DOI 10.1167/iovs.02-0761
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   MURRAY TG, 1991, ARCH OPHTHALMOL-CHIC, V109, P1012, DOI 10.1001/archopht.1991.01080070124049
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   NEWSOME DA, 1994, PROG RETIN EYE RES, V13, P101, DOI 10.1016/1350-9462(94)90006-X
   OWARIBE K, 1988, CELL TISSUE RES, V254, P301
   Pollack JS, 1998, ARCH OPHTHALMOL-CHIC, V116, P1633, DOI 10.1001/archopht.116.12.1633
   Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9
   Rapaport DH, 1995, J COMP NEUROL, V363, P359, DOI 10.1002/cne.903630303
   Rapaport DH, 1996, PERSPECT DEV NEUROBI, V3, P147
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   SANYAL S, 1988, EXP EYE RES, V46, P731, DOI 10.1016/S0014-4835(88)80059-9
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SCHMIDT GH, 1986, J EMBRYOL EXP MORPH, V91, P197
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C
   STREISINGER G, 1989, DEV BIOL, V131, P60, DOI 10.1016/S0012-1606(89)80038-7
   Treichel JL, 2004, RETINA-J RET VIT DIS, V24, P309, DOI 10.1097/00006982-200404000-00023
   Tycko B, 2003, ANN NY ACAD SCI, V983, P43, DOI 10.1111/j.1749-6632.2003.tb05961.x
   Vajaranant TS, 2002, OPHTHALMOLOGY, V109, P560, DOI 10.1016/S0161-6420(01)00984-8
   VONRUCKMANN A, 1998, RETINAL PIGMENT EPIT, P224
   WATZKE RC, 1993, CURR EYE RES, V12, P133, DOI 10.3109/02713689308999481
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WEST JD, 1976, J EMBRYOL EXP MORPH, V35, P445
   Youssoufian H, 2002, NAT REV GENET, V3, P748, DOI 10.1038/nrg906
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 64
TC 72
Z9 79
U1 1
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 1534-0384
J9 MOL INTERV
JI Mol. Interv.
PD AUG
PY 2005
VL 5
IS 4
BP 241
EP 249
DI 10.1124/mi.5.4.7
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 961EZ
UT WOS:000231646000008
PM 16123538
DA 2022-11-30
ER

PT J
AU Adachi, T
   Nakamura, Y
AF Adachi, Tatsuo
   Nakamura, Yoshikazu
TI Aptamers: A Review of Their Chemical Properties and Modifications for
   Therapeutic Application
SO MOLECULES
LA English
DT Review
DE aptamer; RNA therapeutics; chemical modifications; conformational
   plasticity
ID IN-VITRO SELECTION; T7 RNA-POLYMERASE; CRYSTAL-STRUCTURE; DNA APTAMERS;
   TUMOR-GROWTH; WEB SERVER; HT-SELEX; PROTEIN; BINDING; TRANSCRIPTION
AB Aptamers are short, single-stranded oligonucleotides that bind to specific target molecules. The shape-forming feature of single-stranded oligonucleotides provides high affinity and excellent specificity toward targets. Hence, aptamers can be used as analogs of antibodies. In December 2004, the US Food and Drug Administration approved the first aptamer-based therapeutic, pegaptanib (Macugen), targeting vascular endothelial growth factor, for the treatment of age-related macular degeneration. Since then, however, no aptamer medication for public health has appeared. During these relatively silent years, many trials and improvements of aptamer therapeutics have been performed, opening multiple novel directions for the therapeutic application of aptamers. This review summarizes the basic characteristics of aptamers and the chemical modifications available for aptamer therapeutics.
C1 [Adachi, Tatsuo; Nakamura, Yoshikazu] RIBOMIC Inc, Minato Ku, Tokyo 1080071, Japan.
   [Nakamura, Yoshikazu] Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.
C3 University of Tokyo
RP Adachi, T (通讯作者)，RIBOMIC Inc, Minato Ku, Tokyo 1080071, Japan.
EM t.adachi@ribomic.com; nak@ims.u-tokyo.ac.jp
CR Adler A, 2008, COMB CHEM HIGH T SCR, V11, P16, DOI 10.2174/138620708783398331
   Alam KK, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.4
   ASHLEY GW, 1992, J AM CHEM SOC, V114, P9731, DOI 10.1021/ja00051a001
   AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20
   Barberan-Soler S, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1488-z
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Carlson-Stevermer J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01875-9
   Cassiday LA, 2003, P NATL ACAD SCI USA, V100, P3930, DOI 10.1073/pnas.0736013100
   Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112
   Chen TJ, 2016, NAT CHEM, V8, P557, DOI [10.1038/NCHEM.2493, 10.1038/nchem.2493]
   Cowperthwaite MC, 2008, J MOL EVOL, V67, P95, DOI 10.1007/s00239-008-9130-4
   CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019
   Davies DR, 2012, P NATL ACAD SCI USA, V109, P19971, DOI 10.1073/pnas.1213933109
   DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001
   Denichenko P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09523-0
   Dollins CM, 2008, CHEM BIOL, V15, P675, DOI 10.1016/j.chembiol.2008.05.016
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Gaus HJ, 2019, NUCLEIC ACIDS RES, V47, P1110, DOI 10.1093/nar/gky1260
   Gelinas AD, 2016, CURR OPIN STRUC BIOL, V36, P122, DOI 10.1016/j.sbi.2016.01.009
   Gevertz J, 2005, RNA, V11, P853, DOI 10.1261/rna.7271405
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   GRIFFITHS AD, 1987, NUCLEIC ACIDS RES, V15, P4145, DOI 10.1093/nar/15.10.4145
   Guillerez J, 2005, P NATL ACAD SCI USA, V102, P5958, DOI 10.1073/pnas.0407141102
   Gupta S, 2017, NUCLEIC ACID THER, V27, P345, DOI 10.1089/nat.2017.0683
   Hamada M, 2018, BIOCHIMIE, V145, P8, DOI 10.1016/j.biochi.2017.10.005
   Hervas-Stubbs S, 2016, ONCOTARGET, V7, P4522, DOI 10.18632/oncotarget.6608
   Hirasawa S, 2019, BIOCONJUGATE CHEM, V30, P2323, DOI 10.1021/acs.bioconjchem.9b00235
   Hirota M, 2016, NUCLEIC ACID THER, V26, P10, DOI 10.1089/nat.2015.0567
   Horn WT, 2004, RNA, V10, P1776, DOI 10.1261/rna.7710304
   Hoshika S, 2019, SCIENCE, V363, P884, DOI 10.1126/science.aat0971
   Huang DB, 2003, P NATL ACAD SCI USA, V100, P9268, DOI 10.1073/pnas.1632011100
   Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l
   Ito K, 2000, NATURE, V403, P680, DOI 10.1038/35001115
   Jarosch F, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl463
   Jhaveri S, 1998, BIOORG MED CHEM LETT, V8, P2285, DOI 10.1016/S0960-894X(98)00414-4
   Jiang P, 2014, BIOINFORMATICS, V30, P2665, DOI 10.1093/bioinformatics/btu348
   Kasahara Y, 2010, BIOORG MED CHEM LETT, V20, P1626, DOI 10.1016/j.bmcl.2010.01.028
   Kato Y, 2005, NUCLEIC ACIDS RES, V33, P2942, DOI 10.1093/nar/gki578
   Keefe AD, 2008, CURR OPIN PHARMACOL, V8, P147, DOI 10.1016/j.coph.2007.12.005
   Khan T, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.55
   Kimoto M, 2013, NAT BIOTECHNOL, V31, P453, DOI 10.1038/nbt.2556
   King DJ, 1998, BIOCHEMISTRY-US, V37, P16489, DOI 10.1021/bi981780f
   Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112
   Klussmann S., 2006, APTAMER HDB FUNCTION
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   KOSTYUK DA, 1995, FEBS LETT, V369, P165, DOI 10.1016/0014-5793(95)00732-O
   Jonathan WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093441
   Kotula JW, 2012, NUCLEIC ACID THER, V22, P187, DOI 10.1089/nat.2012.0347
   Kuhlmann M, 2017, MOL THER-NUCL ACIDS, V9, P284, DOI 10.1016/j.omtn.2017.10.004
   Kupakuwana GV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019395
   Kuwahara Masayasu, 2013, Artif DNA PNA XNA, V4, P39, DOI 10.4161/adna.25786
   Lai WY, 2014, BIOMATERIALS, V35, P2905, DOI 10.1016/j.biomaterials.2013.12.054
   Lato SM, 2002, NUCLEIC ACIDS RES, V30, P1401, DOI 10.1093/nar/30.6.1401
   Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x
   Lee CH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.30
   Li JL, 2014, NUCL MED BIOL, V41, P179, DOI 10.1016/j.nucmedbio.2013.10.008
   Liang HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140733
   Limsirichai P, 2016, MOL THER, V24, P499, DOI 10.1038/mt.2015.213
   Long SB, 2008, RNA, V14, P2504, DOI 10.1261/rna.1239308
   Maasch C, 2010, J BIOL CHEM, V285, P40012, DOI 10.1074/jbc.M110.178533
   Macdonald J, 2017, ACS CHEM NEUROSCI, V8, P777, DOI 10.1021/acschemneuro.6b00369
   Mahlknecht G, 2013, P NATL ACAD SCI USA, V110, P8170, DOI 10.1073/pnas.1302594110
   Mai JH, 2018, MOL PHARMACEUT, V15, P1814, DOI 10.1021/acs.molpharmaceut.7b01169
   Soldevilla MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185169
   Matsunaga K, 2015, SCI REP-UK, V5, DOI 10.1038/srep18478
   Meyer AJ, 2015, NUCLEIC ACIDS RES, V43, P7480, DOI 10.1093/nar/gkv734
   Mi J, 2006, NUCLEIC ACIDS RES, V34, P3577, DOI 10.1093/nar/gkl482
   Miyakawa S, 2008, RNA, V14, P1154, DOI 10.1261/rna.1005808
   Moreno A, 2019, CELL CHEM BIOL, V26, P634, DOI 10.1016/j.chembiol.2019.02.001
   Muller J, 2008, J THROMB HAEMOST, V6, P2105, DOI 10.1111/j.1538-7836.2008.03162.x
   Munafo DB, 2010, RNA, V16, P2537, DOI 10.1261/rna.2242610
   Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4
   Nakamura Y, 2012, GENES CELLS, V17, P344, DOI 10.1111/j.1365-2443.2012.01596.x
   Nakamura Y, 2011, WIRES RNA, V2, P647, DOI 10.1002/wrna.81
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nolte A, 1996, NAT BIOTECHNOL, V14, P1116, DOI 10.1038/nbt0996-1116
   Nomura Y, 2010, NUCLEIC ACIDS RES, V38, P7822, DOI 10.1093/nar/gkq615
   Ouellet E, 2014, BIOTECHNOL BIOENG, V111, P2265, DOI 10.1002/bit.25294
   Pan WH, 2009, MOLECULES, V14, P1353, DOI 10.3390/molecules14041353
   Parekh P, 2013, BIOMATERIALS, V34, P8909, DOI 10.1016/j.biomaterials.2013.07.099
   Pech A, 2017, NUCLEIC ACIDS RES, V45, P3997, DOI 10.1093/nar/gkx079
   Dao P, 2016, CELL SYST, V3, P62, DOI 10.1016/j.cels.2016.07.003
   Pinheiro VB, 2012, SCIENCE, V336, P341, DOI 10.1126/science.1217622
   Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   Rockey WM, 2011, BIOORGAN MED CHEM, V19, P4080, DOI 10.1016/j.bmc.2011.05.010
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Sato K, 2009, NUCLEIC ACIDS RES, V37, pW277, DOI 10.1093/nar/gkp367
   Schmidt EGW, 2017, J BIOL CHEM, V292, P13312, DOI 10.1074/jbc.M117.794248
   Schoetzau T, 2003, BIOCONJUGATE CHEM, V14, P919, DOI 10.1021/bc0256547
   Sefah K, 2014, P NATL ACAD SCI USA, V111, P1449, DOI 10.1073/pnas.1311778111
   SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747
   Skogen M, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-65
   Sleep D, 2013, BBA-GEN SUBJECTS, V1830, P5526, DOI 10.1016/j.bbagen.2013.04.023
   SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Thiel WH, 2015, METHODS MOL BIOL, V1218, P187, DOI 10.1007/978-1-4939-1538-5_11
   Thiel WH, 2011, NUCLEIC ACID THER, V21, P253, DOI 10.1089/nat.2011.0288
   Tsukakoshi K, 2012, ANAL CHEM, V84, P5542, DOI 10.1021/ac300330g
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ueki R, 2019, CHEM COMMUN, V55, P2672, DOI 10.1039/c8cc08080a
   Ueki R, 2016, ANGEW CHEM INT EDIT, V55, P579, DOI 10.1002/anie.201508572
   Vater A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng130
   Wang HL, 2018, MOL THER-NUCL ACIDS, V10, P187, DOI 10.1016/j.omtn.2017.12.003
   Wang ZM, 2016, NAT CHEM, V8, P698, DOI [10.1038/NCHEM.2517, 10.1038/nchem.2517]
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Wurster SE, 2008, RNA, V14, P1037, DOI 10.1261/rna.878908
   Xu WC, 2011, CHEM COMMUN, V47, P4998, DOI 10.1039/c1cc10161g
   Yamashige R, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1068
   Yang XZ, 2012, ACS NANO, V6, P771, DOI 10.1021/nn204240b
   Zamay TN, 2014, NUCLEIC ACID THER, V24, P160, DOI 10.1089/nat.2013.0471
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 113
TC 85
Z9 85
U1 9
U2 46
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2019
VL 24
IS 23
AR 4229
DI 10.3390/molecules24234229
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KC6OK
UT WOS:000507294400028
PM 31766318
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Saharinen, P
   Eklund, L
   Alitalo, K
AF Saharinen, Pipsa
   Eklund, Lauri
   Alitalo, Kari
TI Therapeutic targeting of the angiopoietin-TIE pathway
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; MULTIPLE-ORGAN
   DYSFUNCTION; INHIBITS TUMOR-GROWTH; ISCHEMIA-REPERFUSION INJURY;
   OVARIAN-CANCER TRINOVA-1; LEVELS PREDICT MORTALITY; DIABETIC MACULAR
   EDEMA; NECROSIS-FACTOR-ALPHA; ACUTE KIDNEY INJURY
AB The endothelial angiopoietin (ANG)-TIE growth factor receptor pathway regulates vascular permeability and pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. Drugs that target the ANG-TIE pathway are in clinical development for oncological and ophthalmological applications. The aim is to complement current vascular endothelial growth factor (VEGF)-based anti-angiogenic therapies in cancer, wet age-related macular degeneration and macular oedema. The unique function of the ANG-TIE pathway in vascular stabilization also renders this pathway an attractive target in sepsis, organ transplantation, atherosclerosis and vascular complications of diabetes. This Review covers key aspects of the function of the ANG-TIE pathway in vascular disease and describes the recent development of novel therapeutics that target this pathway.
C1 [Saharinen, Pipsa; Alitalo, Kari] Univ Helsinki, Biomedicum Helsinki, Wihuri Res Inst, Haartmaninkatu 8,POB 63, FI-00014 Helsinki, Finland.
   [Saharinen, Pipsa; Alitalo, Kari] Univ Helsinki, Biomedicum Helsinki, Translat Canc Biol Program, Haartmaninkatu 8,POB 63, FI-00014 Helsinki, Finland.
   [Eklund, Lauri] Univ Oulu, Oulu Ctr Cell Matrix Res, Fac Biochem & Mol Med, Bioctr Oulu, Aapistie 5A, SF-90220 Oulu, Finland.
C3 University of Helsinki; Wihuri Research Institute; University of
   Helsinki; University of Oulu
RP Alitalo, K (通讯作者)，Univ Helsinki, Biomedicum Helsinki, Wihuri Res Inst, Haartmaninkatu 8,POB 63, FI-00014 Helsinki, Finland.; Alitalo, K (通讯作者)，Univ Helsinki, Biomedicum Helsinki, Translat Canc Biol Program, Haartmaninkatu 8,POB 63, FI-00014 Helsinki, Finland.
EM kari.alitalo@helsinki.fi
RI Saharinen, Pipsa I/C-9601-2016; Alitalo, Kari K/J-5013-2014
OI Saharinen, Pipsa I/0000-0003-2652-0584; Alitalo, Kari
   K/0000-0002-7331-0902
FU Academy of Finland [271845, 292816, 284605]; Jenny and Antti Wihuri
   Foundation; Sigrid Juselius Foundation; Cancer Society of Finland;
   University of Helsinki; European Research Council [ERC-2010-AdG-268804];
   People Programme (Marie Curie Actions) of the European Union's Seventh
   Framework FP7 under Research Executive Agency [317250 VESSEL]; European
   Union FP7 HEALTH [305707]; Leducq Foundation [11CVD03]; Helsinki
   University Hospital's Government Special State Subsidy for Health
   Sciences; Novo Nordisk Foundation; Jane and Aatos Erkko Foundation;
   Cancer Foundation Finland sr [170145, 150065, 150130, 170102] Funding
   Source: researchfish
FX The authors would like to thank P. Bono for critically reviewing the
   manuscript and V.-M. Leppanen for help with figure 6. Work in the
   authors' laboratories was funded by the Academy of Finland (grant
   numbers 271845 (to K.A. and P.S.), 292816 (to K.A.) and 284605 (to
   L.E.)); the Jenny and Antti Wihuri Foundation (K.A. and PS); the Sigrid
   Juselius Foundation (K.A. and P.S.); the Cancer Society of Finland (K.A.
   and P.S.); the University of Helsinki; the European Research Council
   (ERC-2010-AdG-268804); the People Programme (Marie Curie Actions) of the
   European Union's Seventh Framework FP7/2007-2013 under Research
   Executive Agency grant agreement number 317250 VESSEL; the European
   Union FP7 HEALTH (grant number 305707); the Leducq Foundation (grant
   11CVD03); the Helsinki University Hospital's Government Special State
   Subsidy for Health Sciences; the Novo Nordisk Foundation; and the Jane
   and Aatos Erkko Foundation.
CR Abdulmalek K, 2001, AM J PHYSIOL-LUNG C, V281, pL582, DOI 10.1152/ajplung.2001.281.3.L582
   Abou-Khalil R, 2009, CELL STEM CELL, V5, P298, DOI 10.1016/j.stem.2009.06.001
   Alfieri A, 2012, CRIT CARE, V16, DOI 10.1186/cc11666
   Anisimov A, 2013, CIRCULATION, V127, P424, DOI 10.1161/CIRCULATIONAHA.112.127472
   Aspelund A, 2014, J CLIN INVEST, V124, P3975, DOI 10.1172/JCI75395
   Atkins MB, 2015, J CLIN ONCOL, V33, P3431, DOI 10.1200/JCO.2014.60.6012
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005
   Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7
   Bartlett CS, 2016, ANNU REV PHYSIOL, V78, P437, DOI 10.1146/annurev-physiol-021115-105412
   Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212
   Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921
   Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459
   Bhaskar A, 2013, LEUKEMIA RES, V37, P410, DOI 10.1016/j.leukres.2012.12.014
   Bitto A, 2008, CLIN SCI, V114, P707, DOI 10.1042/CS20070250
   Bocharov EV, 2017, BIOCHEMISTRY-US, V56, P1697, DOI 10.1021/acs.biochem.6b01085
   Boscolo E, 2015, J CLIN INVEST, V125, P3491, DOI 10.1172/JCI76004
   Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525
   Brouwers J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064850
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown JL, 2010, MOL CANCER THER, V9, P145, DOI 10.1158/1535-7163.MCT-09-0554
   Buddingh KT, 2014, J AM COLL SURGEONS, V218, P26, DOI 10.1016/j.jamcollsurg.2013.09.021
   Byun SJ, 2007, AM J PATHOL, V171, P1682, DOI 10.2353/ajpath.2007.070142
   Cahoon JM, 2015, DIABETES, V64, P4247, DOI 10.2337/db14-1030
   Calfee CS, 2012, CRIT CARE MED, V40, P1731, DOI 10.1097/CCM.0b013e3182451c87
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P545, DOI 10.1016/j.ophtha.2014.09.023
   Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082
   Castel P, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1164
   Castillo SD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9982
   Chan B, 2008, BIOCHEM BIOPH RES CO, V371, P475, DOI 10.1016/j.bbrc.2008.04.091
   Chan B, 2009, FEBS LETT, V583, P1023, DOI 10.1016/j.febslet.2009.02.027
   Chang FC, 2014, J AM SOC NEPHROL, V25, P1198, DOI 10.1681/ASN.2013050542
   Chen L, 2016, CANCER RES, V76, P6828, DOI 10.1158/0008-5472.CAN-16-1114
   Chen-Konak L, 2003, FASEB J, V17, P2121, DOI 10.1096/fj.02-1151fje
   Cho CH, 2006, P NATL ACAD SCI USA, V103, P4946, DOI 10.1073/pnas.0506352103
   Cho CH, 2005, CIRC RES, V97, P86, DOI 10.1161/01.RES.0000174093.64855.a6
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5553, DOI 10.1073/pnas.0307575101
   Choi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140502
   Choi HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7943
   Coelho AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090009
   Conroy AL, 2012, CRIT CARE MED, V40, P952, DOI 10.1097/CCM.0b013e3182373157
   Costa PZ, 2013, LIFE SCI, V92, P1037, DOI 10.1016/j.lfs.2013.04.001
   Coxon A, 2010, MOL CANCER THER, V9, P2641, DOI 10.1158/1535-7163.MCT-10-0213
   D'Amico G, 2014, J CLIN INVEST, V124, P824, DOI 10.1172/JCI68897
   Dalton AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163732
   Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704
   Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103
   Daly C, 2013, CANCER RES, V73, P108, DOI 10.1158/0008-5472.CAN-12-2064
   David S, 2012, CRIT CARE MED, V40, P3034, DOI 10.1097/CCM.0b013e31825fdc31
   David S, 2012, NEPHROL DIAL TRANSPL, V27, P1867, DOI 10.1093/ndt/gfr551
   David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189
   David S, 2011, CYTOKINE, V55, P251, DOI 10.1016/j.cyto.2011.04.005
   Davis S, 2003, NAT STRUCT BIOL, V10, P38, DOI 10.1038/nsb880
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Demolli S, 2015, J MOL CELL CARDIOL, V88, P111, DOI 10.1016/j.yjmcc.2015.10.009
   Dessapt-Baradez C, 2014, J AM SOC NEPHROL, V25, P33, DOI 10.1681/ASN.2012121218
   DUMONT DJ, 1992, ONCOGENE, V7, P1471
   Eklund L, 2013, EXP CELL RES, V319, P1271, DOI 10.1016/j.yexcr.2013.03.011
   Falcon BL, 2009, AM J PATHOL, V175, P2159, DOI 10.2353/ajpath.2009.090391
   Fang YY, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1075-6
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Feng Y, 2008, CELL PHYSIOL BIOCHEM, V21, P129, DOI 10.1159/000113755
   Feng YX, 2007, THROMB HAEMOSTASIS, V97, P99, DOI 10.1160/TH06-05-0277
   Feng YX, 2009, THROMB HAEMOSTASIS, V102, P120, DOI 10.1160/TH08-09-0567
   Feng YX, 2009, CELL PHYSIOL BIOCHEM, V23, P277, DOI 10.1159/000218174
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Fischer M, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-59
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Frye M., 2015, J EXP MED
   Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603
   Ganter MT, 2008, ANN SURG, V247, P320, DOI 10.1097/SLA.0b013e318162d616
   Garcia-Manero G, 2015, CLIN CANCER RES, V21, P985, DOI 10.1158/1078-0432.CCR-14-1765
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gayed BA, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0019-4
   Gerlicz Z, 2014, DERMATOLOGY, V228, P233, DOI 10.1159/000357806
   Ghosh CC, 2016, P NATL ACAD SCI USA, V113, P2472, DOI 10.1073/pnas.1519467113
   Ghosh CC, 2015, CRIT CARE MED, V43, pE230, DOI 10.1097/CCM.0000000000000993
   Giuliano JS, 2007, SHOCK, V28, P650, DOI 10.1097/shk.0b013e318123867b
   Giuliano JS, 2014, PEDIATR CRIT CARE ME, V15, pE1, DOI 10.1097/PCC.0b013e3182a553bb
   Goede V, 2010, BRIT J CANCER, V103, P1407, DOI 10.1038/sj.bjc.6605925
   Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164
   Golledge J, 2014, STROKE, V45, P1064, DOI 10.1161/STROKEAHA.113.004339
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Hadem J, 2012, CRIT CARE MED, V40, P1499, DOI 10.1097/CCM.0b013e318241e34e
   Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962
   Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104
   Han S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9260
   Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012
   Hashiyama M, 1996, BLOOD, V87, P93
   Hashizume H, 2010, CANCER RES, V70, P2213, DOI 10.1158/0008-5472.CAN-09-1977
   Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683
   Helfrich I, 2009, CLIN CANCER RES, V15, P1384, DOI 10.1158/1078-0432.CCR-08-1615
   Herbst RS, 2009, J CLIN ONCOL, V27, P3557, DOI 10.1200/JCO.2008.19.6683
   Hernandez-Bartolome A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066143
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Holopainen T, 2012, J NATL CANCER I, V104, P461, DOI 10.1093/jnci/djs009
   Hong DS, 2014, ONCOTARGET, V5, P11154, DOI 10.18632/oncotarget.2568
   Hou HA, 2008, LEUKEMIA RES, V32, P904, DOI 10.1016/j.leukres.2007.08.010
   Huang JZ, 2009, INT J ONCOL, V34, P79, DOI 10.3892/ijo_00000131
   Hughes DP, 2003, CIRC RES, V92, P630, DOI 10.1161/01.RES.0000063422.38690.DC
   Im JH, 2013, INT J CANCER, V132, P315, DOI 10.1002/ijc.27677
   Ito K, 2016, SCIENCE, V354, P1156, DOI 10.1126/science.aaf5530
   Jain V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-383
   Jary M, 2015, CANCER EPIDEM BIOMAR, V24, P603, DOI 10.1158/1055-9965.EPI-14-1059
   Jeansson M, 2011, J CLIN INVEST, V121, P2278, DOI 10.1172/JCI46322
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Jin HR, 2011, DIABETES, V60, P969, DOI 10.2337/db10-0354
   Jongjitwimol J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094182
   Jung YJ, 2012, BIOCHEM BIOPH RES CO, V420, P498, DOI 10.1016/j.bbrc.2012.03.019
   Jung YJ, 2009, AM J PHYSIOL-RENAL, V297, pF952, DOI 10.1152/ajprenal.00064.2009
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kanakaraj P, 2012, MABS-AUSTIN, V4, P600, DOI 10.4161/mabs.21227
   Kang HC, 2015, J PEDIATR-US, V167, P957, DOI 10.1016/j.jpeds.2015.07.049
   Karlan BY, 2012, J CLIN ONCOL, V30, P362, DOI 10.1200/JCO.2010.34.3178
   Kather JN, 2014, INVEST OPHTH VIS SCI, V55, P4295, DOI 10.1167/iovs.13-13619
   Keskin D, 2015, CELL REP, V10, P1066, DOI 10.1016/j.celrep.2015.01.035
   Kienast Y, 2013, CLIN CANCER RES, V19, P6730, DOI 10.1158/1078-0432.CCR-13-0081
   Kim DH, 2009, KIDNEY INT, V76, P1180, DOI 10.1038/ki.2009.387
   Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24
   Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3
   Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200
   Kim KE, 2007, ARTERIOSCL THROM VAS, V27, P564, DOI 10.1161/01.ATV.0000256458.82320.be
   Kim M, 2016, J CLIN INVEST, V126, P3511, DOI 10.1172/JCI84871
   Kim SR, 2008, EXP MOL MED, V40, P320, DOI 10.3858/emm.2008.40.3.320
   Kloepper J, 2016, P NATL ACAD SCI USA, V113, P4476, DOI 10.1073/pnas.1525360113
   Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2
   Koh GY, 2013, TRENDS MOL MED, V19, P31, DOI 10.1016/j.molmed.2012.10.010
   Koh YJ, 2010, CANCER CELL, V18, P171, DOI 10.1016/j.ccr.2010.07.001
   Koksal BT, 2014, ALLERGY ASTHMA PROC, V35, P482, DOI 10.2500/aap.2014.35.3793
   Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002
   Korhonen EA, 2016, J CLIN INVEST, V126, P3495, DOI 10.1172/JCI84923
   Kosacka J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032881
   Kranidioti H, 2009, IMMUNOL LETT, V125, P65, DOI 10.1016/j.imlet.2009.06.006
   Kumpers P, 2010, INTENS CARE MED, V36, P462, DOI 10.1007/s00134-009-1726-7
   Kurniati NF, 2013, INTENS CARE MED, V39, P1262, DOI 10.1007/s00134-013-2899-7
   Kwon MH, 2013, J SEX MED, V10, P2912, DOI 10.1111/jsm.12278
   Le CTK, 2015, AM J PATHOL, V185, P2949, DOI 10.1016/j.ajpath.2015.07.010
   Lee HJ, 2004, FASEB J, V18, P1200, DOI 10.1096/fj.03-1466com
   Lee HS, 2014, J BIOL CHEM, V289, P31330, DOI 10.1074/jbc.M114.572594
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lee J, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006666
   Lee SW, 2011, MOL MED, V17, P1095, DOI 10.2119/molmed.2011.00106
   Lee S, 2007, NEPHROL DIAL TRANSPL, V22, P396, DOI 10.1093/ndt/gfl598
   Leow CC, 2012, INT J ONCOL, V40, P1321, DOI 10.3892/ijo.2012.1366
   Leppanen VM, 2017, P NATL ACAD SCI USA, V114, P4376, DOI 10.1073/pnas.1616166114
   Li L, 2015, J DIABETES COMPLICAT, V29, P568, DOI 10.1016/j.jdiacomp.2015.02.006
   Li P, 2015, INT J CLIN EXP PATHO, V8, P660
   Lim HS, 2004, DIABETES CARE, V27, P2918, DOI 10.2337/diacare.27.12.2918
   Limaye N, 2015, AM J HUM GENET, V97, P914, DOI 10.1016/j.ajhg.2015.11.011
   Limaye N, 2009, NAT GENET, V41, P118, DOI 10.1038/ng.272
   Lin SM, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000878
   Liu KL, 2014, CRIT CARE, V18, DOI 10.1186/cc13876
   Lopez-Mejias R, 2013, CLIN EXP RHEUMATOL, V31, P761
   Lorbeer R, 2013, EUR J HEART FAIL, V15, P1327, DOI 10.1093/eurjhf/hft117
   Loukovaara S, 2014, GRAEF ARCH CLIN EXP, V252, P881, DOI 10.1007/s00417-013-2508-z
   Lukasz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066861
   Luks VL, 2015, J PEDIATR-US, V166, P1048, DOI 10.1016/j.jpeds.2014.12.069
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Fiusa MML, 2013, CRIT CARE, V17, DOI 10.1186/cc12848
   Lymperopoulou K, 2015, CYTOKINE, V73, P163, DOI 10.1016/j.cyto.2015.01.022
   Maffei R, 2010, BLOOD, V116, P584, DOI 10.1182/blood-2009-11-252494
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Makhoul I., 2014, AM J CLIN ONCOL-CANC, V39, P248
   Makowska JS, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0112-6
   Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852
   Mankhambo LA, 2010, CRIT CARE, V14, DOI 10.1186/cc9025
   Mazzieri R, 2011, CANCER CELL, V19, P512, DOI 10.1016/j.ccr.2011.02.005
   Minami T, 2013, CELL REP, V4, P709, DOI 10.1016/j.celrep.2013.07.021
   Miyahara K, 2013, BRIT J CANCER, V109, P2072, DOI 10.1038/bjc.2013.554
   Mofarrahi M, 2008, AM J PHYSIOL-LUNG C, V294, pL955, DOI 10.1152/ajplung.00449.2007
   Molnar MZ, 2014, TRANSPL INT, V27, P541, DOI 10.1111/tri.12293
   Monk BJ, 2016, GYNECOL ONCOL, V143, P27, DOI 10.1016/j.ygyno.2016.07.112
   Monk BJ, 2014, LANCET ONCOL, V15, P799, DOI 10.1016/S1470-2045(14)70244-X
   Monk BJ, 2013, GYNECOL ONCOL, V130, P636, DOI 10.1016/j.ygyno.2013.05.023
   Moore JO, 2017, P NATL ACAD SCI USA, V114, P4382, DOI 10.1073/pnas.1617800114
   Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6
   Morisada T, 2005, BLOOD, V105, P4649, DOI 10.1182/blood-2004-08-3382
   Motzer RJ, 2014, CANCER CHEMOTH PHARM, V74, P739, DOI 10.1007/s00280-014-2539-0
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Murali R, 2015, ONCOTARGET, V6, P36041, DOI 10.18632/oncotarget.5936
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Natynki M, 2015, HUM MOL GENET, V24, P6374, DOI 10.1093/hmg/ddv349
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nikolakopoulou S, 2014, COPD, V11, P46, DOI 10.3109/15412555.2013.829436
   Nishimura M, 1999, FEBS LETT, V448, P254, DOI 10.1016/S0014-5793(99)00381-6
   Nottebaum AF, 2008, J EXP MED, V205, P2929, DOI 10.1084/jem.20080406
   Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F
   Ogura S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90905
   Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732
   Oh N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15291
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030
   Ong T, 2010, CRIT CARE MED, V38, P1845, DOI 10.1097/CCM.0b013e3181eaa5bf
   Orfanos SE, 2007, CRIT CARE MED, V35, P199, DOI 10.1097/01.CCM.0000251640.77679.D7
   Osborn AJ, 2015, HUM MOL GENET, V24, P926, DOI 10.1093/hmg/ddu505
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Papadopoulos KP, 2016, CLIN CANCER RES, V22, P1348, DOI 10.1158/1078-0432.CCR-15-1221
   Pappa CA, 2014, J CANCER RES CLIN, V140, P1801, DOI 10.1007/s00432-014-1731-2
   Parikh SM, 2013, VIRULENCE, V4, P517, DOI 10.4161/viru.24906
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Park BH, 2010, BONE, V46, P1442, DOI 10.1016/j.bone.2010.02.004
   Park DY, 2014, J CLIN INVEST, V124, P3960, DOI 10.1172/JCI75392
   Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698
   Patel JI, 2005, BRIT J OPHTHALMOL, V89, P480, DOI 10.1136/bjo.2004.049940
   Pauta M, 2015, LIVER INT, V35, P1383, DOI 10.1111/liv.12505
   Pemovska T, 2015, NATURE, V519, P102, DOI 10.1038/nature14119
   Peterson TE, 2016, P NATL ACAD SCI USA, V113, P4470, DOI 10.1073/pnas.1525349113
   Pfister F, 2008, DIABETES, V57, pA234, DOI 10.2337/db08-0325
   Pfister F, 2010, ACTA DIABETOL, V47, P59, DOI 10.1007/s00592-009-0099-2
   Pietila R, 2012, J CELL SCI, V125, P2212, DOI 10.1242/jcs.098020
   Poss J, 2015, EUR J HEART FAIL, V17, P1152, DOI 10.1002/ejhf.342
   Poss J, 2015, CLIN RES CARDIOL, V104, P380, DOI 10.1007/s00392-014-0787-y
   Porat RM, 2004, CIRC RES, V94, P394, DOI 10.1161/01.RES.0000111803.92923.D6
   Prapansilp P, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-50
   Prenner SB, 2015, ATHEROSCLEROSIS, V238, P370, DOI 10.1016/j.atherosclerosis.2014.12.023
   Qiu Y, 2016, ACTA DIABETOL, V53, P81, DOI 10.1007/s00592-015-0752-x
   Rangasamy S, 2011, INVEST OPHTH VIS SCI, V52, P3784, DOI 10.1167/iovs.10-6386
   Rasmussen AL, 2014, SCIENCE, V346, P987, DOI 10.1126/science.1259595
   Rautiola J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153745
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059
   Rohan TE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju136
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryu JK, 2015, SCI REP-UK, V5, DOI 10.1038/srep09222
   Saharinen P, 2005, J CELL BIOL, V169, P239, DOI 10.1083/jcb.200411105
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015
   Sako K, 2009, J BIOL CHEM, V284, P5592, DOI 10.1074/jbc.M806928200
   Salmon AHJ, 2009, CARDIOVASC RES, V83, P24, DOI 10.1093/cvr/cvp093
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sato T, 2011, AM J OPHTHALMOL, V151, P353, DOI 10.1016/j.ajo.2010.08.037
   Savant S, 2015, CELL REP, V12, P1761, DOI 10.1016/j.celrep.2015.08.024
   Schmittnaegel M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9670
   Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505
   Scholz A, 2007, AM J GASTROENTEROL, V102, P2471, DOI 10.1111/j.1572-0241.2007.01377.x
   Sfiligoi C, 2003, INT J CANCER, V103, P466, DOI 10.1002/ijc.10851
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5
   Shin HY, 2010, J NEUROSCI RES, V88, P1052, DOI 10.1002/jnr.22274
   Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558
   Singh H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029319
   Singh H, 2010, MICROVASC RES, V79, P121, DOI 10.1016/j.mvr.2010.01.005
   Smith BD, 2015, MOL CANCER THER, V14, P2023, DOI 10.1158/1535-7163.MCT-14-1105
   Soblet J, 2013, MOL SYNDROMOL, V4, P179, DOI 10.1159/000348327
   Soblet J, 2017, J INVEST DERMATOL, V137, P207, DOI 10.1016/j.jid.2016.07.034
   Souma T, 2016, J CLIN INVEST, V126, P2575, DOI 10.1172/JCI85830
   Srivastava K, 2014, CANCER CELL, V26, P880, DOI 10.1016/j.ccell.2014.11.005
   Stiehl T, 2014, CRIT CARE MED, V42, pE654, DOI 10.1097/CCM.0000000000000524
   Sung HK, 2009, AM J PHYSIOL-ENDOC M, V297, pE402, DOI 10.1152/ajpendo.00122.2009
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Syrjala SO, 2015, AM J TRANSPLANT, V15, P2075, DOI 10.1111/ajt.13296
   Syrjala SO, 2014, AM J TRANSPLANT, V14, P1096, DOI 10.1111/ajt.12672
   Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052
   Tabruyn SP, 2010, AM J PATHOL, V177, P3233, DOI 10.2353/ajpath.2010.100059
   Tadros A, 2003, BLOOD, V102, P4407, DOI 10.1182/blood-2003-05-1602
   Tammela T, 2005, BLOOD, V105, P4642, DOI 10.1182/blood-2004-08-3327
   Theelen TL, 2015, ATHEROSCLEROSIS, V241, P297, DOI 10.1016/j.atherosclerosis.2015.05.018
   Thomas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054923
   Thomson BR, 2014, J CLIN INVEST, V124, P4320, DOI 10.1172/JCI77162
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Thurston G, 2005, DEVELOPMENT, V132, P3317, DOI 10.1242/dev.01888
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Thurston G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006650
   Tressel SL, 2007, ARTERIOSCL THROM VAS, V27, P2150, DOI 10.1161/ATVBAHA.107.150920
   Tsai YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135181
   Tuuminen R, 2015, ACTA OPHTHALMOL, V93, pE515, DOI 10.1111/aos.12401
   Ubezio B, 2016, ELIFE, V5, DOI 10.7554/eLife.12167
   Ueda N, 2014, BIOL BLOOD MARROW TR, V20, P1335, DOI 10.1016/j.bbmt.2014.04.030
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904
   van de Weg CAM, 2014, J CLIN VIROL, V60, P328, DOI 10.1016/j.jcv.2014.05.001
   Veikkola T, 2003, FASEB J, V17, P2006, DOI 10.1096/fj.03-0179com
   Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0
   Wada T, 2012, CRIT CARE, V16, DOI 10.1186/cc11648
   Wada T, 2012, CRIT CARE, V16, DOI 10.1186/cc11309
   Wang XE, 2014, TRANSL ONCOL, V7, P188, DOI 10.1016/j.tranon.2014.02.003
   Wang Y, 2015, J NEUROL SCI, V356, P72, DOI 10.1016/j.jns.2015.05.038
   Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212
   Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824
   Westra J, 2011, RHEUMATOLOGY, V50, P665, DOI 10.1093/rheumatology/keq378
   Whitcomb DC, 2010, AM J GASTROENTEROL, V105, P2287, DOI 10.1038/ajg.2010.183
   Wilhelm K, 2016, NATURE, V529, P216, DOI 10.1038/nature16498
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8
   Woo KV, 2011, J CLIN INVEST, V121, P1624, DOI 10.1172/JCI42040
   Wouters V, 2010, EUR J HUM GENET, V18, P414, DOI 10.1038/ejhg.2009.193
   Xie ZH, 2012, BLOOD, V119, P4321, DOI 10.1182/blood-2011-08-375816
   Yamakawa M, 2004, AM J PHYSIOL-RENAL, V287, pF649, DOI 10.1152/ajprenal.00028.2004
   Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7
   Ye CS, 2011, J VASC SURG, V54, P1760, DOI 10.1016/j.jvs.2011.06.098
   Youn SW, 2011, BLOOD, V117, P4376, DOI 10.1182/blood-2010-07-295964
   Yu XH, 2013, P NATL ACAD SCI USA, V110, P7205, DOI 10.1073/pnas.1216890110
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
   Yuen D, 2014, INVEST OPHTH VIS SCI, V55, P3320, DOI 10.1167/iovs.13-13779
   Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6
   Zhou HJ, 2016, NAT MED, V22, P1033, DOI 10.1038/nm.4169
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
   Zinter MS, 2016, AM J PHYSIOL-LUNG C, V310, pL224, DOI 10.1152/ajplung.00336.2015
NR 313
TC 224
Z9 237
U1 6
U2 93
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD SEP
PY 2017
VL 16
IS 9
BP 635
EP +
DI 10.1038/nrd.2016.278
PG 27
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA FF3DO
UT WOS:000408775900017
PM 28529319
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Khan, A
   Petropoulos, IN
   Ponirakis, G
   Malik, RA
AF Khan, A.
   Petropoulos, I. N.
   Ponirakis, G.
   Malik, R. A.
TI Visual complications in diabetes mellitus: beyond retinopathy
SO DIABETIC MEDICINE
LA English
DT Review
ID OPEN-ANGLE GLAUCOMA; ISCHEMIC OPTIC NEUROPATHY; BLUE MOUNTAINS EYE;
   RISK-FACTORS; CONTRAST SENSITIVITY; GLYCEMIC CONTROL; REFRACTIVE
   PROPERTIES; ACUTE HYPERGLYCEMIA; CATARACT-SURGERY; TYPE-2
AB Diabetic retinopathy is the most common cause of vision loss in people with diabetes mellitus; however, other causes of visual impairment/loss include other retinal and non-retinal visual problems, including glaucoma, age-related macular degeneration, non-arteritic anterior ischaemic optic neuropathy and cataracts. Additionally, when a person with diabetes complains of visual disturbance despite a visual acuity of 6/6, abnormalities in refraction, contrast sensitivity, straylight and amplitude of accommodation should be considered. We review and highlight these visual problems for physicians who manage people with diabetes to ensure timely referral and treatment to limit visual disability, which can have a significant impact on daily living, especially for those participating in sports and driving.
C1 [Khan, A.; Petropoulos, I. N.; Ponirakis, G.; Malik, R. A.] Weill Cornell Med Qatar, Doha, Qatar.
C3 Weill Cornell Medical College Qatar
RP Malik, RA (通讯作者)，Weill Cornell Med Qatar, Doha, Qatar.
EM ram2045@qatar-med.cornell.edu
RI Ponirakis, Georgios/T-7207-2019; Malik, Rayaz/H-9231-2019
OI Ponirakis, Georgios/0000-0002-6936-1248; Malik,
   Rayaz/0000-0002-7188-8903; Khan, Adnan/0000-0003-4647-6672
CR Adnan, 2015, CLIN EXP OPTOM, V98, P481, DOI 10.1111/cxo.12270
   Adnan, 2015, BIOMED OPT EXPRESS, V6, P1282, DOI 10.1364/BOE.6.001282
   Adnan, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15376
   Al Kahtani ES, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0272-7
   Bang CN, 2015, AM J CARDIOL, V116, P1840, DOI 10.1016/j.amjcard.2015.09.026
   Boland MV, 2007, J GLAUCOMA, V16, P406, DOI 10.1097/IJG.0b013e31806540a1
   Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076653
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Chopra V, 2008, OPHTHALMOLOGY, V115, P227, DOI 10.1016/j.ophtha.2007.04.049
   Chu CJ, 2016, OPHTHALMOLOGY, V123, P316, DOI 10.1016/j.ophtha.2015.10.001
   de Voogd S, 2006, OPHTHALMOLOGY, V113, P1827, DOI 10.1016/j.ophtha.2006.03.063
   Falck A, 1998, ACTA OPHTHALMOL SCAN, V76, P238, DOI 10.1034/j.1600-0420.1998.760223.x
   Furushima M, 1999, JPN J OPHTHALMOL, V43, P398, DOI 10.1016/S0021-5155(99)00098-2
   Giambene B, 2009, GRAEF ARCH CLIN EXP, V247, P693, DOI 10.1007/s00417-008-0981-6
   Golay M, 2013, BMJ CASE REPORTS, V2013
   Hellgren KJ, 2014, DIABETES, V63, P3104, DOI 10.2337/db13-1628
   Huntjens B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052947
   International Diabetes Federation, 2015, IDF DIABETES ATLAS
   Jacobsen N, 2008, ACTA OPHTHALMOL, V86, P510, DOI 10.1111/j.1600-0420.2007.01104.x
   Jiang DQ, 2015, DIABETES RES CLIN PR, V108, pE1, DOI 10.1016/j.diabres.2015.02.004
   Jin YY, 2012, IRAN J PEDIATR, V22, P125
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P295, DOI 10.1016/S0002-9394(14)71170-5
   Krol CG, 2014, DIABETES CARE, V37, pE45, DOI 10.2337/dc13-2244
   Lee MS, 2011, OPHTHALMOLOGY, V118, P959, DOI 10.1016/j.ophtha.2011.01.054
   Leske MC, 2008, OPHTHALMOLOGY, V115, P85, DOI 10.1016/j.ophtha.2007.03.017
   Li HY, 2010, INT J OPHTHALMOL, V10, P618
   Li L, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-94
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SF, 2009, OPHTHALMOLOGICA, V223, P68, DOI 10.1159/000173714
   Man REK, 2013, CLIN EXP OPHTHALMOL, V41, P293, DOI 10.1111/j.1442-9071.2012.02872.x
   Man REK, 2013, INVEST OPHTH VIS SCI, V54, P7691, DOI 10.1167/iovs.13-12412
   MANTYJARVI M, 1988, ACTA OPHTHALMOL, V66, P267
   Michael R, 2009, ACTA OPHTHALMOL, V87, P666, DOI 10.1111/j.1755-3768.2008.01326.x
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Nakamura M, 2005, OPHTHALMOLOGICA, V219, P1, DOI 10.1159/000081775
   Negahban Kambiz, 2002, Curr Opin Ophthalmol, V13, P419, DOI 10.1097/00055735-200212000-00013
   Newman-Casey PA, 2011, OPHTHALMOLOGY, V118, P1318, DOI 10.1016/j.ophtha.2010.11.022
   NIELSEN NV, 1983, ACTA OPHTHALMOL, V61, P662
   North RV, 1997, DIABETES CARE, V20, P1724, DOI 10.2337/diacare.20.11.1724
   Okamoto F, 2000, BRIT J OPHTHALMOL, V84, P1097, DOI 10.1136/bjo.84.10.1097
   Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252
   Poh S, 2016, DIABETES RES CLIN PR, V113, P86, DOI 10.1016/j.diabres.2016.01.016
   Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345
   Schwartz AV, 2008, DIABETES CARE, V31, P391, DOI 10.2337/dc07-1152
   Shazly TA, 2009, SEMIN OPHTHALMOL, V24, P113, DOI 10.1080/08820530902800801
   Skeel RL, 2006, J CLIN EXP NEUROPSYC, V28, P696, DOI 10.1080/13803390590954173
   Steffes P G, 1999, Diabetes Technol Ther, V1, P129, DOI 10.1089/152091599317332
   Tan GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1354, DOI 10.1001/archophthalmol.2009.268
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48
   Van den Berg TJTP., 2010, ENCY EYE, V3, P173
   VANDENBERG TJTP, 1991, DOC OPHTHALMOL, V78, P177, DOI 10.1007/BF00165678
   Verrotti A, 1998, ANN MED, V30, P369, DOI 10.3109/07853899809029936
   Wiemer NGM, 2008, OPHTHALMOLOGY, V115, P2017, DOI 10.1016/j.ophtha.2008.06.032
   Wiemer NGM, 2008, GRAEF ARCH CLIN EXP, V246, P993, DOI 10.1007/s00417-008-0810-y
   Wiemer NGM, 2009, ACTA OPHTHALMOL, V87, P176, DOI 10.1111/j.1755-3768.2008.01212.x
   Wolff BE, 2015, DOC OPHTHALMOL, V130, P131, DOI 10.1007/s10633-014-9476-4
NR 60
TC 38
Z9 40
U1 0
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD APR
PY 2017
VL 34
IS 4
BP 478
EP 484
DI 10.1111/dme.13296
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA EP6LL
UT WOS:000397490900004
PM 27917530
DA 2022-11-30
ER

PT J
AU van Grinsven, MJJP
   Theelen, T
   Witkamp, L
   van der Heijden, J
   van de Ven, JPH
   Hoyng, CB
   van Ginneken, B
   Sanchez, CI
AF van Grinsven, Mark J. J. P.
   Theelen, Thomas
   Witkamp, Leonard
   van der Heijden, Job
   van de Ven, Johannes P. H.
   Hoyng, Carel B.
   van Ginneken, Bram
   Sanchez, Clara I.
TI Automatic differentiation of color fundus images containing drusen or
   exudates using a contextual spatial pyramid approach
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID DIABETIC MACULAR EDEMA; RETINAL IMAGES; GLOBAL PREVALENCE; BRIGHT
   LESIONS; RETINOPATHY; DEGENERATION
AB We developed an automatic system to identify and differentiate color fundus images containing no lesions, drusen or exudates. Drusen and exudates are lesions with a bright appearance, associated with age-related macular degeneration and diabetic retinopathy, respectively. The system consists of three lesion detectors operating at pixel-level, combining their outputs using spatial pooling and classification with a random forest classifier. System performance was compared with ratings of two independent human observers using human-expert annotations as reference. Kappa agreements of 0.89, 0.97 and 0.92 and accuracies of 0.93, 0.98 and 0.95 were obtained for the system and observers, respectively. (C) 2016 Optical Society of America
C1 [van Grinsven, Mark J. J. P.; van Ginneken, Bram; Sanchez, Clara I.] Radboud Univ Nijmegen, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [Theelen, Thomas; van de Ven, Johannes P. H.; Hoyng, Carel B.; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Witkamp, Leonard; van der Heijden, Job] KSYOS TeleMed Ctr, Amstelveen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP van Grinsven, MJJP (通讯作者)，Radboud Univ Nijmegen, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
EM Mark.vanGrinsven@radboudumc.nl
RI Theelen, Thomas/A-3192-2012; van Ginneken, Bram/A-3728-2012; Gutierrez,
   Clara Isabel Sanchez/N-3580-2014
OI Theelen, Thomas/0000-0001-9067-1171; van Ginneken,
   Bram/0000-0003-2028-8972; 
FU ZonMw grant: "A cost-effective solution for the prevention of blindness
   using computer-aided diagnosis and fundus photography" [11.631.0003]
FX Supported by a ZonMw grant: "A cost-effective solution for the
   prevention of blindness using computer-aided diagnosis and fundus
   photography," with project number 11.631.0003.
CR Abramoff M. D., 2006, AUTOMATIC DETECTION
   Agurto C., 2012, Proceedings of the 2012 IEEE Southwest Symposium on Image Analysis & Interpretation (SSIAI 2012), P13, DOI 10.1109/SSIAI.2012.6202441
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Akram UM, 2012, J MED SYST, V36, P3151, DOI 10.1007/s10916-011-9802-2
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, p[iii, ix, 124]
   Kauppi T, 2007, C MED IM UN AN
   Kauppi T., 2006, DIARETDB0 EVALUATION
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lazebnik S., 2006, 2006 IEEE COMP SOC C, P2169
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Nagi DK, 2009, DIABETIC MED, V26, P1301, DOI 10.1111/j.1464-5491.2009.02838.x
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2009, MED IMAGE ANAL, V13, P859, DOI 10.1016/j.media.2009.08.003
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Pires R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096814
   Rocha A, 2012, IEEE T BIO-MED ENG, V59, P2244, DOI 10.1109/TBME.2012.2201717
   Samuelson FW, 2006, I S BIOMED IMAGING, P1312
   Sanchez CI, 2012, MED IMAGE ANAL, V16, P50, DOI 10.1016/j.media.2011.05.004
   Sanchez CI, 2009, MED IMAGE ANAL, V13, P650, DOI 10.1016/j.media.2009.05.005
   Sidibe D, 2015, COMPUT BIOL MED, V62, P175, DOI 10.1016/j.compbiomed.2015.04.026
   Sivaprasad S, 2012, SURV OPHTHALMOL, V57, P347, DOI 10.1016/j.survophthal.2012.01.004
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sundaresan V., 2015, OPHTH MED IM AN WORK
   van Grinsven MJJP, 2013, I S BIOMED IMAGING, P1444
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu L, 2013, WORLD J DIABETES, V4, P290, DOI 10.4239/wjd.v4.i6.290
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 36
TC 6
Z9 6
U1 0
U2 12
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAR 1
PY 2016
VL 7
IS 3
BP 709
EP 725
DI 10.1364/BOE.7.000709
PG 17
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA DG4JR
UT WOS:000372039000001
PM 27231583
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, N
   Zhao, L
   Wei, YK
   Ea, VL
   Nian, H
   Wei, R
AF Li, Na
   Zhao, Lu
   Wei, Yankai
   Ea, Vicki L.
   Nian, Hong
   Wei, Ruihua
TI Recent advances of exosomes in immune-mediated eye diseases
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE Exosomes; Sjogren's syndrome; Corneal allograft rejection; Autoimmune
   uveitis; Age-related macular degeneration; Biomarkers; Drug delivery
ID CELL-DERIVED EXOSOMES; MESENCHYMAL STEM-CELL; EXTRACELLULAR VESICLES;
   TRANSFERRIN RECEPTOR; SJOGRENS-SYNDROME; DENDRITIC CELLS; AQUEOUS-HUMOR;
   IN-VITRO; RESPONSES; MECHANISMS
AB Exosomes, nanosized extracellular vesicles of 30-150 nm, are shed by almost all cell types. Bearing proteins, lipids, RNAs, and DNAs, exosomes have emerged as vital biological mediators in cell-to-cell communication, affecting a plethora of physiological and pathological processes. Particularly, mounting evidence indicates that immunologically active exosomes can regulate both innate and adaptive immune responses. Herein, we review recent advances in the research of exosomes in several immune-mediated eye diseases, including Sjogren's syndrome (SS) dry eye, corneal allograft rejection, autoimmune uveitis, and age-related macular degeneration (AMD). Additionally, we discuss the potential of exosomes as novel biomarkers and drug delivery vesicles for the diagnosis and treatment of eye diseases.
C1 [Li, Na; Zhao, Lu; Wei, Yankai; Ea, Vicki L.; Nian, Hong; Wei, Ruihua] Tianjin Med Univ, Eye Hosp, Eye Inst, Tianjin Key Lab Retinal Funct & Dis, 251 Fukang Rd, Tianjin 300384, Peoples R China.
   [Li, Na; Zhao, Lu; Wei, Yankai; Ea, Vicki L.; Nian, Hong; Wei, Ruihua] Tianjin Med Univ, Eye Hosp, Sch Optometry, 251 Fukang Rd, Tianjin 300384, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Nian, H; Wei, R (通讯作者)，Tianjin Med Univ, Eye Hosp, Eye Inst, Tianjin Key Lab Retinal Funct & Dis, 251 Fukang Rd, Tianjin 300384, Peoples R China.
EM nianhong@126.com; rwei@tmu.edu.cn
OI Ea, Vicki/0000-0002-5450-6264
FU National Natural Science Foundation of China [81770901, 81570834];
   Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry [48]; Tianjin Clinical Key Discipline
   Project [TJLCZDXKT003]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81770901, 81570834), the Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry (No. 48), and the Tianjin Clinical Key Discipline Project
   (TJLCZDXKT003).
CR Aiello S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08617-3
   Anel A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020154
   Bai LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04559-y
   Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020
   Barros FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00730
   Basu J, 2016, EXPERT OPIN BIOL TH, V16, P489, DOI 10.1517/14712598.2016.1131976
   Batrakova EV, 2015, J CONTROL RELEASE, V219, P396, DOI 10.1016/j.jconrel.2015.07.030
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153
   Bose T, 2016, AUTOIMMUN REV, V15, P1181, DOI 10.1016/j.autrev.2016.09.001
   Boyiadzis M, 2017, LEUKEMIA, V31, P1259, DOI 10.1038/leu.2017.91
   Buschow SI, 2009, TRAFFIC, V10, P1528, DOI 10.1111/j.1600-0854.2009.00963.x
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Chan BD, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800149
   Chong WP, 2015, J EXP MED, V212, P1739, DOI 10.1084/jem.20141678
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   de Andrade FA, 2016, AUTOIMMUN REV, V15, P258, DOI 10.1016/j.autrev.2015.12.001
   Di Zazzo A, 2017, SURV OPHTHALMOL, V62, P816, DOI 10.1016/j.survophthal.2016.12.010
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Domenis R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31707-9
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Gain P, 2016, JAMA OPHTHALMOL, V134, P167, DOI 10.1001/jamaophthalmol.2015.4776
   Gallo A, 2016, EBIOMEDICINE, V10, P216, DOI 10.1016/j.ebiom.2016.06.041
   Generali E, 2017, CLIN REV ALLERG IMMU, V53, P357, DOI 10.1007/s12016-017-8639-y
   Gonzalez E, 2015, EXPERT REV MOL DIAGN, V15, P907, DOI 10.1586/14737159.2015.1043272
   Gonzalez-Nolasco B, 2018, CURR OPIN ORGAN TRAN, V23, P22, DOI 10.1097/MOT.0000000000000489
   Goules AV, 2017, CLIN IMMUNOL, V182, P30, DOI 10.1016/j.clim.2017.03.007
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009
   Grigor'eva A. E., 2016, Biomeditsinskaya Khimiya, V62, P99, DOI 10.18097/PBMC20166201099
   Gurunathan S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040307
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Han KY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40548
   Han L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0980-8
   Haque S, 2016, NANOMED-NANOTECHNOL, V12, P1703, DOI 10.1016/j.nano.2016.03.002
   Harting MT, 2018, STEM CELLS, V36, P79, DOI 10.1002/stem.2730
   Huang C, 2018, DIABETES, V67, P1639, DOI 10.2337/db17-1587
   Jangamreddy JR, 2018, ACTA BIOMATER, V69, P120, DOI 10.1016/j.actbio.2018.01.011
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Kahroba H, 2019, CELL MOL LIFE SCI, V76, P1747, DOI 10.1007/s00018-019-03035-2
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kapsogeorgou EK, 2005, ARTHRITIS RHEUM-US, V52, P1517, DOI 10.1002/art.21005
   Keino H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/1679197
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knickelbein JE, 2016, INVEST OPHTH VIS SCI, V57, P4101, DOI 10.1167/iovs.15-18353
   Krishna U, 2017, POSTGRAD MED J, V93, P766, DOI 10.1136/postgradmedj-2017-134891
   Leszczynska A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33169-5
   Li JB, 2019, BIOCHEM BIOPH RES CO, V510, P565, DOI 10.1016/j.bbrc.2019.02.005
   Li SL, 2018, NUCLEIC ACIDS RES, V46, pD106, DOI 10.1093/nar/gkx891
   Li X, 2016, INVEST OPHTH VIS SCI, V57, P5161, DOI 10.1167/iovs.15-17824
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   Liu C, 2019, NAT BIOMED ENG, V3, P183, DOI 10.1038/s41551-018-0343-6
   Lopez-Miguel A, 2016, AM J OPHTHALMOL, V161, P133, DOI 10.1016/j.ajo.2015.09.039
   Manoussakis MN, 2010, J AUTOIMMUN, V35, P219, DOI 10.1016/j.jaut.2010.06.011
   Marino J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00582
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9
   Mavragani CP, 2017, ANNU REV MED, V68, P331, DOI 10.1146/annurev-med-043015-123313
   Mavragani CP, 2014, ANNU REV PATHOL-MECH, V9, P273, DOI 10.1146/annurev-pathol-012513-104728
   McKelvey Kelly J, 2015, J Circ Biomark, V4, P7, DOI 10.5772/61186
   Meng WR, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0982-6
   Morishita M, 2016, BIOMATERIALS, V111, P55, DOI 10.1016/j.biomaterials.2016.09.031
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Munagala R, 2016, CANCER LETT, V371, P48, DOI 10.1016/j.canlet.2015.10.020
   Muntasell A, 2007, EMBO J, V26, P4263, DOI 10.1038/sj.emboj.7601842
   Murphy DE, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0223-5
   Nolte-'t Hoen ENM, 2009, BLOOD, V113, P1977, DOI 10.1182/blood-2008-08-174094
   Nussenblatt RB, 2013, INT REV IMMUNOL, V32, P97, DOI 10.3109/08830185.2012.740536
   Okoye IS, 2014, IMMUNITY, V41, P89, DOI [10.1016/j.immuni.2014.05.019, 10.1016/j.immuni.2014.08.008]
   Pakravan K, 2017, CELL ONCOL, V40, P457, DOI 10.1007/s13402-017-0335-7
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5
   Pandey RK, 2018, INT J BIOL MACROMOL, V107, P1278, DOI 10.1016/j.ijbiomac.2017.09.110
   Papotto PH, 2014, AUTOIMMUN REV, V13, P909, DOI 10.1016/j.autrev.2014.05.003
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev-biochem-013118-111902
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pepple KL, 2018, OPHTHALMOLOGY, V125, P1977, DOI 10.1016/j.ophtha.2018.05.014
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Ratay ML, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700733
   Ren K, 2019, ODONTOLOGY, V107, P271, DOI 10.1007/s10266-018-0395-9
   Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622
   Samaeekia R, 2018, INVEST OPHTH VIS SCI, V59, P5194, DOI 10.1167/iovs.18-24803
   Sandhya P, 2017, CURR RHEUMATOL REV, V13, P5, DOI 10.2174/1573397112666160714164149
   Satitpitakul V, 2018, AM J PATHOL, V188, P2016, DOI 10.1016/j.ajpath.2018.05.010
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Seo Y, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5126156
   Sevgi DD, 2017, GRAEF ARCH CLIN EXP, V255, P1801, DOI 10.1007/s00417-017-3689-7
   Shenoda BB, 2016, CLIN MED INSIGHTS-PA, V9, P1, DOI 10.4137/CPath.S39925
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591
   Shigemoto-Kuroda T, 2017, STEM CELL REP, V8, P1214, DOI 10.1016/j.stemcr.2017.04.008
   Skotland T, 2017, PROG LIPID RES, V66, P30, DOI 10.1016/j.plipres.2017.03.001
   Tariq M, 2018, CORNEAL GRAFT REJECT
   Tassew NG, 2017, CELL REP, V20, P99, DOI 10.1016/j.celrep.2017.06.009
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Vincent-Schneider H, 2002, INT IMMUNOL, V14, P713, DOI 10.1093/intimm/dxf048
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang H, 2019, MOL IMMUNOL, V111, P64, DOI 10.1016/j.molimm.2019.04.004
   Wassmer SJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep45329
   Wen D, 2016, J CONTROL RELEASE, V238, P166, DOI 10.1016/j.jconrel.2016.07.044
   Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136
   Williams C, 2014, CELL RES, V24, P766, DOI 10.1038/cr.2014.44
   Williams R, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701328
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu H, 2019, CLIN IMMUNOL
   Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8
   Yamaguchi T, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23651
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zhang QY, 2018, J CELL PHYSIOL, V233, P6832, DOI 10.1002/jcp.26436
   Zhang W, 2019, INVEST OPHTH VIS SCI, V60, P294, DOI 10.1167/iovs.18-25617
   Zhao JL, 2019, CARDIOL RES PRACT, V2019, DOI 10.1155/2019/1376515
   Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164
NR 119
TC 41
Z9 44
U1 4
U2 28
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 30
PY 2019
VL 10
IS 1
AR 278
DI 10.1186/s13287-019-1372-0
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA IU4RG
UT WOS:000483573900001
PM 31470892
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rhone, M
   Basu, A
AF Rhone, Michael
   Basu, Arpita
TI Phytochemicals and age-related eye diseases
SO NUTRITION REVIEWS
LA English
DT Review
DE age-related eye diseases; anthocyanins; lutein; oxidative stress;
   zeaxanthin
ID GINKGO-BILOBA EXTRACT; PIGMENT EPITHELIAL-CELLS; INDUCED OXIDATIVE
   STRESS; OPEN-ANGLE GLAUCOMA; OCULAR BLOOD-FLOW; MACULAR DEGENERATION;
   ANTIOXIDANT SUPPLEMENTATION; EXPERIMENTAL CATARACT; CIGARETTE-SMOKING;
   VITAMIN-C
AB Cataracts, glaucoma, and age-related macular degeneration (AMD) are common causes of blindness in the elderly population of the United States. Additional risk factors include obesity, smoking, and inadequate antioxidant status. Phytochemicals, as antioxidants and anti-inflammatory agents, may help prevent or delay the progression of these eye diseases. Observational and clinical trials support the safety of higher intakes of the phytochemicals lutein and zeaxanthin and their association with reducing risks of cataracts in healthy postmenopausal women and improving clinical features of AMD in patients. Additional phytochemicals of emerging interest, like green tea catechins, anthocyanins, resveratrol, and Ginkgo biloba, shown to ameliorate ocular oxidative stress, deserve more attention in future clinical trials. (C) 2008 International Life Sciences Institute.
C1 [Rhone, Michael; Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA.
C3 Oklahoma State University System; Oklahoma State University - Stillwater
RP Basu, A (通讯作者)，Oklahoma State Univ, Dept Nutr Sci, 301 Human Environm Sci, Stillwater, OK 74078 USA.
EM arpita.basu@okstate.edu
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beit-Yannai E, 2007, EYE, V21, P658, DOI 10.1038/sj.eye.6702353
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bonovas S, 2004, PUBLIC HEALTH, V118, P256, DOI 10.1016/j.puhe.2003.09.009
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Chung HS, 1999, J OCUL PHARMACOL TH, V15, P233, DOI 10.1089/jop.1999.15.233
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Durukan AH, 2006, J CATARACT REFR SURG, V32, P1041, DOI 10.1016/j.jcrs.2006.02.041
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fernandez MM, 2008, CURR OPIN OPHTHALMOL, V19, P66, DOI 10.1097/ICU.0b013e3282f2d7b6
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gupta SK, 2002, OPHTHALMIC RES, V34, P258, DOI 10.1159/000063881
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Head K A, 2001, Altern Med Rev, V6, P141
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Karlsen A, 2007, J NUTR, V137, P1951
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Ko ML, 2005, FREE RADICAL BIO MED, V39, P365, DOI 10.1016/j.freeradbiomed.2005.03.025
   Kuzniarz M, 2001, AM J OPHTHALMOL, V132, P19, DOI 10.1016/S0002-9394(01)00922-9
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Mares JA, 2004, NUTR REV, V62, P28, DOI 10.1301/nr.2004.jan.28-32
   Matsumoto H, 2006, EXP EYE RES, V83, P348, DOI 10.1016/j.exer.2005.12.019
   Mazza G, 2002, J AGR FOOD CHEM, V50, P7731, DOI 10.1021/jf020690l
   Meyer CH, 2005, DEV OPHTHALMOL, V38, P103, DOI 10.1159/000082771
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Miura D, 2004, CLIN EXP METASTAS, V21, P445, DOI 10.1007/s10585-004-2698-1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mozaffarieh M, 2007, SURV OPHTHALMOL, V52, pS174, DOI 10.1016/j.survophthal.2007.08.013
   Nelson JL, 2003, J NUTR, V133, P3117, DOI 10.1093/jn/133.10.3117
   Nishida S, 2004, CLIN CHIM ACTA, V339, P129, DOI 10.1016/j.cccn.2003.10.004
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   Ohira Akihiro, 2008, Nippon Ganka Gakkai Zasshi, V112, P22
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004
   RICHER S, 2004, REV OPTOM S, V141, P12
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Santosa S, 2005, CAN MED ASSOC J, V173, P861, DOI 10.1503/cmaj.1031425
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Shih PH, 2007, J AGR FOOD CHEM, V55, P9427, DOI 10.1021/jf071933i
   SHOVLIN JP, 2007, REV OPTOM, V144, P1
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STOKKERMANS T, 2005, REV OPTOM S, P8
   Sun WM, 2008, ADV EXP MED BIOL, V614, P179, DOI 10.1007/978-0-387-74911-2_21
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   Thiagarajan G, 2002, EXP EYE RES, V75, P421, DOI 10.1006/exer.2002.2035
   Wattanapenpaiboon N, 2003, ASIA PAC J CLIN NUTR, V12, P363
   West AL, 2006, AM J OPHTHALMOL, V141, P157, DOI 10.1016/j.ajo.2005.07.033
   Wimpissinger B, 2007, ACTA OPHTHALMOL SCAN, V85, P445, DOI 10.1111/j.1600-0420.2007.00887.x
   Zafra-Stone S, 2007, MOL NUTR FOOD RES, V51, P675, DOI 10.1002/mnfr.200700002
   Zhang B, 2007, BRAIN RES, V1159, P40, DOI 10.1016/j.brainres.2007.05.029
NR 65
TC 81
Z9 82
U1 1
U2 25
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD AUG
PY 2008
VL 66
IS 8
BP 465
EP 472
DI 10.1111/j.1753-4887.2008.00078.x
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 332JF
UT WOS:000258078600005
PM 18667008
DA 2022-11-30
ER

PT J
AU Zeng, R
   Garg, I
   Miller, JB
AF Zeng, Rebecca
   Garg, Itika
   Miller, John B.
TI Complete Resolution of Central Soft Drusen without Geographic Atrophy or
   Choroidal Neovascularization
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; drusen resolution; multivitamin
   supplementation; antioxidant supplementation; geographic atrophy;
   choroidal neovascularization
ID ALPHA-LIPOIC ACID; MACULAR DEGENERATION; EYE DISEASE
AB The treatment and prevention of dry age-related macular degeneration (AMD) traditionally involve lifestyle modifications and antioxidant supplementation, including the AREDS2 formula. We present a case of a woman with dry AMD in her right eye with several large, confluent central drusen on her exam and optical coherence tomography B-scan. Over the course of a year, the drusen almost completely disappeared, but the retinal layers were preserved without the development of geographic atrophy or choroidal neovascularization. While the exact cause of this phenomenon is unclear, it was thought to be associated with this patient's strict daily use of numerous dietary supplements. This case highlights the potential in exploring alternative medicine supplements in the treatment of AMD.
C1 [Zeng, Rebecca; Garg, Itika; Miller, John B.] Harvard Retinal Imaging Lab, Boston, MA 02114 USA.
   [Zeng, Rebecca; Garg, Itika; Miller, John B.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Miller, JB (通讯作者)，Harvard Retinal Imaging Lab, Boston, MA 02114 USA.; Miller, JB (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
EM rebecca_zeng@meei.harvard.edu; itika_garg@meei.harvard.edu;
   john_miller@meei.harvard.edu
RI Garg, Itika/AIE-7779-2022; Miller, John J/GZG-5663-2022
OI Garg, Itika/0000-0002-9537-8561; 
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Allegrini D, 2021, J MED FOOD, DOI 10.1089/jmf.2020.0199
   Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Dithmar S, 2013, EYE, V27, P779, DOI 10.1038/eye.2013.35
   Giannaccare G, 2020, MAR DRUGS, V18, DOI 10.3390/md18050239
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kim BJ, 2020, OPHTHALMOL RETINA, V4, P889, DOI 10.1016/j.oret.2020.03.019
   Kim MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71401-3
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Querques G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81810-7
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Shin EY, 2019, MAT SCI ENG C-MATER, V103, DOI 10.1016/j.msec.2019.109787
   Simes DC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010138
   Sun YD, 2012, ANN NUTR METAB, V60, P293, DOI 10.1159/000338444
   Tao Y, 2016, TOHOKU J EXP MED, V240, P209, DOI 10.1620/tjem.240.209
   Terluk MR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5174957
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 23
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1637
DI 10.3390/jcm11061637
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0C1UH
UT WOS:000775106300001
PM 35329963
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Henry, MP
   Hawkins, JR
   Boyle, J
   Bridger, JM
AF Henry, Marianne P.
   Hawkins, J. Ross
   Boyle, Jennifer
   Bridger, Joanna M.
TI The Genomic Health of Human Pluripotent Stem Cells: Genomic Instability
   and the Consequences on Nuclear Organization
SO FRONTIERS IN GENETICS
LA English
DT Review
DE aneuploidy; genome; stem cell; chromosome; nucleus (positioning)
ID DNA-DAMAGE RESPONSE; RAPID PRENATAL-DIAGNOSIS; HISTONE H4 ACETYLATION;
   A-TYPE LAMINS; GENE-EXPRESSION; CHROMATIN-STRUCTURE; TOPOISOMERASE-II;
   STRAND BREAKS; IN-VITRO; EXTRACELLULAR-SUPEROXIDE
AB Human pluripotent stem cells (hPSCs) are increasingly used for cell-based regenerative therapies worldwide, with embryonic and induced pluripotent stem cells as potential treatments for debilitating and chronic conditions, such as age-related macular degeneration, Parkinson's disease, spinal cord injuries, and type 1 diabetes. However, with the level of genomic anomalies stem cells generate in culture, their safety may be in question. Specifically, hPSCs frequently acquire chromosomal abnormalities, often with gains or losses of whole chromosomes. This review discusses how important it is to efficiently and sensitively detect hPSC aneuploidies, to understand how these aneuploidies arise, consider the consequences for the cell, and indeed the individual to whom aneuploid cells may be administered.
C1 [Henry, Marianne P.; Hawkins, J. Ross; Boyle, Jennifer] Natl Inst Biol Stand & Controls, Adv Therapies Div, Potters Bar, Herts, England.
   [Henry, Marianne P.; Bridger, Joanna M.] Brunel Univ London, Lab Nucl & Genom Hlth, Div Biosci, Dept Life Sci,Coll Hlth & Life Sci, London, England.
C3 National Institute for Biological Standards & Control; Brunel University
RP Boyle, J (通讯作者)，Natl Inst Biol Stand & Controls, Adv Therapies Div, Potters Bar, Herts, England.; Bridger, JM (通讯作者)，Brunel Univ London, Lab Nucl & Genom Hlth, Div Biosci, Dept Life Sci,Coll Hlth & Life Sci, London, England.
EM jennifer.boyle@nibsc.org; joanna.bridger@brunel.ac.uk
RI Hawkins, Ross/M-7702-2014
OI Bridger, Joanna/0000-0003-3999-042X
FU National Institute for Biological Standards and Controls
FX Internal PhD for MH funded by an award from National Institute for
   Biological Standards and Controls.
CR Adida C, 1998, AM J PATHOL, V152, P43
   AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0
   Alcobia I, 2000, BLOOD, V95, P1608, DOI 10.1182/blood.V95.5.1608.005k32_1608_1615
   Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029
   Amendola M, 2014, CURR OPIN CELL BIOL, V28, P61, DOI 10.1016/j.ceb.2014.03.003
   Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X
   Apostolou E, 2013, CELL STEM CELL, V12, P699, DOI 10.1016/j.stem.2013.04.013
   Armstrong L, 2005, STEM CELLS, V23, P516, DOI 10.1634/stemcells.2004-0269
   Artus J, 2006, CELL CYCLE, V5, P499, DOI 10.4161/cc.5.5.2500
   Askree SH, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-116
   Avery S, 2013, STEM CELL REP, V1, P379, DOI 10.1016/j.stemcr.2013.10.005
   Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865
   Baarlink C, 2013, SCIENCE, V340, P864, DOI 10.1126/science.1235038
   Badylak SF, 2011, ANNU REV BIOMED ENG, V13, P27, DOI 10.1146/annurev-bioeng-071910-124743
   Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285
   Baker M., 2009, NAT REP STEM CELLS, DOI [10.1038/stemcells.2009.32, DOI 10.1038/STEMCELLS.2009.32]
   Balasubramanian B, 1998, P NATL ACAD SCI USA, V95, P9738, DOI 10.1073/pnas.95.17.9738
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker RA, 2016, J PARKINSON DIS, V6, P57, DOI 10.3233/JPD-160798
   Bartova E, 2001, CHROMOSOMA, V110, P360, DOI 10.1007/s004120100141
   Bartova E, 2008, DEV DYNAM, V237, P3690, DOI 10.1002/dvdy.21773
   Baumann C, 2007, CELL, V128, P101, DOI 10.1016/j.cell.2006.11.041
   Becker KA, 2006, J CELL PHYSIOL, V209, P883, DOI 10.1002/jcp.20776
   Beil M, 2002, CYTOMETRY, V47, P217, DOI 10.1002/cyto.10077
   Ben-David U, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5825
   Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bickmore WA, 2013, CELL, V152, P1270, DOI 10.1016/j.cell.2013.02.001
   Bilic J, 2012, STEM CELLS, V30, P33, DOI 10.1002/stem.700
   Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099
   Blum B, 2008, ADV CANCER RES, V100, P133, DOI 10.1016/S0065-230X(08)00005-5
   BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   Bonnet-Garnier A, 2018, CHROMOSOMA, V127, P387, DOI 10.1007/s00412-018-0671-z
   Boyle S, 2001, HUM MOL GENET, V10, P211, DOI 10.1093/hmg/10.3.211
   Briand N, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00073
   Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2
   Bridger JM, 1998, TRENDS GENET, V14, P403, DOI 10.1016/S0168-9525(98)01572-8
   Bridger JM, 2007, FEBS J, V274, P1354, DOI 10.1111/j.1742-4658.2007.05694.x
   Bridger JM, 2014, ADV EXP MED BIOL, V773, P263, DOI 10.1007/978-1-4899-8032-8_12
   Bridger JM, 2011, ADVANCES IN NUCLEAR ARCHITECTURE, P149, DOI 10.1007/978-90-481-9899-3_5
   Brimble SN, 2004, STEM CELLS DEV, V13, P585, DOI 10.1089/scd.2004.13.585
   Brown A, 2018, CELL MOL LIFE SCI, V75, P3771, DOI 10.1007/s00018-018-2891-z
   Bunch JT, 2005, MOL CELL BIOL, V25, P5567, DOI 10.1128/mcb.25.13.5567-5578.2005
   Butler JT, 2009, J CELL BIOCHEM, V107, P609, DOI 10.1002/jcb.22183
   Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399
   Caine A, 2005, LANCET, V366, P123, DOI 10.1016/S0140-6736(05)66790-6
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08
   Castellanos E, 2008, CURR BIOL, V18, P1209, DOI 10.1016/j.cub.2008.07.029
   Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632
   Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777
   Chen KG, 2014, CELL STEM CELL, V14, P13, DOI 10.1016/j.stem.2013.12.005
   Chung MK, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-22
   Cimini D, 2002, J CELL SCI, V115, P507
   Cimini D, 1999, MUTAGENESIS, V14, P563, DOI 10.1093/mutage/14.6.563
   Cirigliano V, 2004, MOL HUM REPROD, V10, P839, DOI 10.1093/molehr/gah108
   Clements CS, 2016, METHODS MOL BIOL, V1411, P387, DOI 10.1007/978-1-4939-3530-7_24
   Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012
   Coffinier C, 2010, P NATL ACAD SCI USA, V107, P5076, DOI 10.1073/pnas.0908790107
   Constantinescu D, 2006, STEM CELLS, V24, P474, DOI 10.1634/stemcells.2006-erratum.2
   Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075
   Criscione SW, 2016, TRENDS GENET, V32, P751, DOI 10.1016/j.tig.2016.09.005
   Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119
   Czapiewski R, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00082
   D'Hulst C, 2013, STEM CELL REP, V1, P350, DOI 10.1016/j.stemcr.2013.08.003
   Damelin M, 2005, CANCER CELL, V8, P479, DOI 10.1016/j.ccr.2005.11.004
   de Wit E, 2013, NATURE, V501, P227, DOI 10.1038/nature12420
   Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980
   Deshpande DM, 2006, ANN NEUROL, V60, P32, DOI 10.1002/ana.20901
   Desmarais JA, 2012, STEM CELLS, V30, P1385, DOI 10.1002/stem.1117
   Di Stefano B, 2018, NAT METHODS, V15, P732, DOI 10.1038/s41592-018-0104-1
   Ding X, 2007, DEV CELL, V12, P863, DOI 10.1016/j.devcel.2007.03.018
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Dolezalova D, 2012, STEM CELLS, V30, P1362, DOI 10.1002/stem.1108
   Donaghue C, 2005, PRENATAL DIAG, V25, P65, DOI 10.1002/pd.1086
   Downie SE, 1997, MOL HUM REPROD, V3, P585, DOI 10.1093/molehr/3.7.585
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   Durrbaum M, 2016, FEBS J, V283, P791, DOI 10.1111/febs.13591
   Eckersley-Maslin MA, 2013, NUCLEUS-PHILA, V4, P53, DOI 10.4161/nucl.23384
   El Khattabi LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155009
   Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345
   Espada J, 2008, J CELL BIOL, V181, P27, DOI 10.1083/jcb.200801096
   Farooq T, 2019, ADV EXP MED BIOL, V1084, P95, DOI 10.1007/5584_2018_195
   Fedorova E, 2008, BBA-MOL CELL RES, V1783, P2174, DOI 10.1016/j.bbamcr.2008.07.018
   Felgentreff K, 2014, P NATL ACAD SCI USA, V111, P8889, DOI 10.1073/pnas.1323649111
   FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491
   FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315
   Filion TM, 2009, J CELL PHYSIOL, V220, P586, DOI 10.1002/jcp.21735
   Finch KA, 2008, J CELL SCI, V121, P655, DOI 10.1242/jcs.025205
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Flores I, 2008, GENE DEV, V22, P654, DOI 10.1101/gad.451008
   Foster HA, 2005, J CELL SCI, V118, P1811, DOI 10.1242/jcs.02301
   Foster HA, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-30
   Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083
   Fritz B, 2001, EUR J HUM GENET, V9, P539, DOI 10.1038/sj.ejhg.5200669
   Galiova G, 2004, BLOOD CELL MOL DIS, V33, P4, DOI 10.1016/j.bcmd.2004.03.006
   Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897
   Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105
   Gilchrist Susan, 2004, Chromosome Res, V12, P505
   Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798
   Glinsky G, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00667
   Godini R, 2019, J CELL PHYSIOL, V234, P6489, DOI 10.1002/jcp.27386
   Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017
   GORBSKY GJ, 1994, CANCER RES, V54, P1042
   Gotzmann J, 2006, HISTOCHEM CELL BIOL, V125, P33, DOI 10.1007/s00418-005-0050-8
   Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017
   Greco E, 2015, NEW ENGL J MED, V373, P2089, DOI 10.1056/NEJMc1500421
   GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0
   Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216
   Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015
   Guo F, 2014, CELL STEM CELL, V15, P447, DOI 10.1016/j.stem.2014.08.003
   HAAF T, 1988, CANCER GENET CYTOGEN, V30, P73, DOI 10.1016/0165-4608(88)90094-5
   Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3
   Hadjimichael C, 2017, STEM CELL REP, V8, P1366, DOI 10.1016/j.stemcr.2017.03.006
   Halaschek-Wiener J, 2007, J GERONTOL A-BIOL, V62, P3, DOI 10.1093/gerona/62.1.3
   Harikumar A, 2015, EMBO REP, V16, P1609, DOI 10.15252/embr.201541011
   Harrison NJ, 2007, INT J ANDROL, V30, P275, DOI 10.1111/j.1365-2605.2007.00762.x
   He SW, 2017, J BIOL CHEM, V292, P18542, DOI 10.1074/jbc.M117.810457
   Herault A, 2017, NATURE, V544, P53, DOI 10.1038/nature21693
   Herberts CA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-29
   Hernandez L, 2010, DEV CELL, V19, P413, DOI 10.1016/j.devcel.2010.08.013
   Herszfeld D, 2006, NAT BIOTECHNOL, V24, P351, DOI 10.1038/nbt1197
   HICKMAN AW, 1994, CANCER RES, V54, P5797
   Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6
   HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689
   HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159
   Horakova AH, 2010, CELL STRUCT FUNCT, V35, P31, DOI 10.1247/csf.09021
   Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148
   Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774
   Huang JJ, 2011, CELL RES, V21, P779, DOI 10.1038/cr.2011.16
   HULSPAS R, 1994, CHROMOSOMA, V103, P286, DOI 10.1007/BF00352253
   Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950
   Huycke MM, 2002, CARCINOGENESIS, V23, P529, DOI 10.1093/carcin/23.3.529
   Huycke MM, 2001, MOL MICROBIOL, V42, P729, DOI 10.1046/j.1365-2958.2001.02638.x
   Itoh N, 1998, J CELL SCI, V111, P3275
   JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kapinas K, 2015, J CELL PHYSIOL, V230, P63, DOI 10.1002/jcp.24681
   Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
   Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333
   Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117
   Kim Y, 2013, CELL RES, V23, P1420, DOI 10.1038/cr.2013.118
   Kim Y, 2011, SCIENCE, V334, P1706, DOI 10.1126/science.1211222
   Kinoshita T, 2011, BIOCHEM BIOPH RES CO, V407, P321, DOI 10.1016/j.bbrc.2011.03.013
   Kuga T, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.6
   Kulashreshtha M, 2016, NUCLEIC ACIDS RES, V44, P8272, DOI 10.1093/nar/gkw573
   Kuroda M, 2004, J CELL SCI, V117, P5897, DOI 10.1242/jcs.01508
   Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6
   Lamm N, 2016, CELL STEM CELL, V18, P253, DOI 10.1016/j.stem.2015.11.003
   Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872
   Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250
   LEHNER CF, 1987, J CELL BIOL, V105, P577, DOI 10.1083/jcb.105.1.577
   Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242
   Li T, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.565
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   LIN F, 1995, GENOMICS, V27, P230, DOI 10.1006/geno.1995.1036
   Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211
   Lin YC, 2012, NAT IMMUNOL, V13, P1196, DOI 10.1038/ni.2432
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   Lisaingo K, 2014, MOL BIOL CELL, V25, P1958, DOI 10.1091/mbc.E13-10-0564
   Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200
   Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730
   Lu JJ, 2016, STEM CELLS DEV, V25, P740, DOI 10.1089/scd.2015.0393
   Lu XY, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000327
   Luu PL, 2018, EPIGENOMICS-UK, V10, P149, DOI 10.2217/epi-2017-0098
   Ma L, 2009, NAT CELL BIOL, V11, P246, DOI 10.1038/ncb1832
   Mahy NL, 2002, J CELL BIOL, V159, P753, DOI 10.1083/jcb.200207115
   Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631
   Mallon BS, 2014, STEM CELL RES, V12, P376, DOI 10.1016/j.scr.2013.11.010
   Malone CJ, 2003, CELL, V115, P825, DOI 10.1016/S0092-8674(03)00985-1
   Manning M, 2010, GENET MED, V12, P742, DOI 10.1097/GIM.0b013e3181f8baad
   Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   Mariotti LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079541
   Mattout A, 2011, J MOL CELL BIOL, V3, P341, DOI 10.1093/jmcb/mjr028
   Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017
   Mehta IS, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r5
   Menten B, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039453
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Mertzanidou A, 2013, HUM REPROD, V28, P256, DOI 10.1093/humrep/des362
   Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017
   Meshorer E, 2008, J CELL BIOL, V181, P9, DOI 10.1083/jcb.200802155
   Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006
   Minissi S, 1999, MUTAGENESIS, V14, P43, DOI 10.1093/mutage/14.1.43
   Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19
   Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403
   Momcilovic O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013410
   Mull AN, 2014, STEM CELL RES, V12, P539, DOI 10.1016/j.scr.2014.01.002
   Munne S, 1998, PRENATAL DIAG, V18, P1459, DOI 10.1002/(SICI)1097-0223(199812)18:13<1459::AID-PD514>3.0.CO;2-V
   MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5
   Na J, 2014, PROTEIN CELL, V5, P569, DOI 10.1007/s13238-014-0073-9
   Nagaria PK, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3826249
   NAGASAWA H, 1992, CANCER RES, V52, P6394
   Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x
   Nera B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10132
   Noatynska A, 2012, J CELL BIOL, V199, P1025, DOI 10.1083/jcb.201209015
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Norppa H, 2003, MUTAGENESIS, V18, P221, DOI 10.1093/mutage/18.3.221
   Novik V, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-18
   Ogilvie CM, 2005, J HISTOCHEM CYTOCHEM, V53, P285, DOI 10.1369/jhc.4B6409.2005
   Okae H, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004868
   Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890
   ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x
   Orsztynowicz M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182398
   Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Papp B, 2011, CELL RES, V21, P486, DOI 10.1038/cr.2011.28
   Parada LA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-r44
   Parada LA, 2002, TRENDS CELL BIOL, V12, P425, DOI 10.1016/S0962-8924(02)02351-6
   Pardo B, 2005, EMBO J, V24, P3117, DOI 10.1038/sj.emboj.7600778
   Pekovic V, 2008, J ANAT, V213, P5, DOI 10.1111/j.1469-7580.2008.00928.x
   Peric-Hupkes D, 2010, COLD SH Q B, V75, P517, DOI 10.1101/sqb.2010.75.014
   Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016
   Perovanovic J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4991
   Peterson SE, 2014, J BIOL CHEM, V289, P4578, DOI 10.1074/jbc.R113.516419
   Phillips-Cremins JE, 2014, CURR OPIN CELL BIOL, V28, P96, DOI 10.1016/j.ceb.2014.04.006
   POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164
   Prokocimer M, 2009, J CELL MOL MED, V13, P1059, DOI [10.1111/j.1582-4934.2009.00676.x, 10.1111/j.1582-4934.2008.00676.x]
   Pucci F, 2013, CELL STEM CELL, V12, P479, DOI 10.1016/j.stem.2013.01.018
   Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007
   Ranade D, 2017, CHROMOSOMA, V126, P223, DOI 10.1007/s00412-016-0580-y
   Razafsky D, 2009, J CELL BIOL, V186, P461, DOI 10.1083/jcb.200906068
   Reuter VE, 2005, MODERN PATHOL, V18, pS51, DOI 10.1038/modpathol.3800309
   ROBER RA, 1989, DEVELOPMENT, V105, P365
   Robson MI, 2016, MOL CELL, V62, P834, DOI 10.1016/j.molcel.2016.04.035
   Rohrabaugh S, 2008, STEM CELLS DEV, V17, P1017, DOI 10.1089/scd.2007.0260
   Ronn RE, 2017, STEM CELLS, V35, P197, DOI 10.1002/stem.2503
   Sachdev NM, 2017, FERTIL STERIL, V107, P6, DOI 10.1016/j.fertnstert.2016.10.006
   Sachdeva K, 2017, GENET TEST MOL BIOMA, V21, P674, DOI 10.1089/gtmb.2017.0108
   Salsman J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.151
   Sartore RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020667
   Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2
   Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708
   Schneider RP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2946
   Sellner LN, 2004, HUM MUTAT, V23, P413, DOI 10.1002/humu.20035
   Sexton T, 2012, CELL, V148, P458, DOI 10.1016/j.cell.2012.01.010
   Sfeir A, 2009, CELL, V138, P90, DOI 10.1016/j.cell.2009.06.021
   Shaffer LG, 2007, AM J MED GENET C, V145C, P87, DOI 10.1002/ajmg.c.30114
   Simon DN, 2011, NAT REV MOL CELL BIO, V12, P695, DOI 10.1038/nrm3207
   Simon DN, 2010, NUCLEUS-PHILA, V1, P264, DOI 10.4161/nucl.1.3.11799
   Singer ZS, 2014, MOL CELL, V55, P319, DOI 10.1016/j.molcel.2014.06.029
   Skalnikova M, 2000, CHROMOSOME RES, V8, P487
   Smith ER, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860-017-0125-0
   Solomon S, 2015, STEM CELL REV REP, V11, P1, DOI 10.1007/s12015-014-9574-4
   Solovei I, 2013, CELL, V152, P584, DOI 10.1016/j.cell.2013.01.009
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Spann TP, 2002, J CELL BIOL, V156, P603, DOI 10.1083/jcb.200112047
   Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100
   Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420
   STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9
   Stopper H, 2003, MUTAGENESIS, V18, P243, DOI 10.1093/mutage/18.3.243
   Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459
   Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9
   Suvorova II, 2016, CELL CYCLE, V15, P52, DOI 10.1080/15384101.2015.1120927
   Swift J, 2014, J CELL SCI, V127, P3005, DOI 10.1242/jcs.149203
   Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanabe H, 2002, P NATL ACAD SCI USA, V99, P4424, DOI 10.1073/pnas.072618599
   Tanaka T, 2000, J CELL SCI, V113, P697
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Taylor TH, 2014, HUM REPROD UPDATE, V20, P571, DOI 10.1093/humupd/dmu016
   Theunissen TW, 2017, DEVELOPMENT, V144, P4496, DOI 10.1242/dev.157404
   Tokunaga K, 2014, SCI REP-UK, V4, DOI 10.1038/srep06996
   Tsai MY, 2006, SCIENCE, V311, P1887, DOI 10.1126/science.1122771
   Turner M, 2013, CELL STEM CELL, V13, P382, DOI 10.1016/j.stem.2013.08.003
   Tusell L, 2010, BIOCHEM SOC T, V38, P1698, DOI 10.1042/BST0381698
   Uchiyama Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep22985
   UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6
   Utani KI, 2007, MOL CANCER RES, V5, P695, DOI 10.1158/1541-7786.MCR-07-0031
   Vallabhaneni H, 2018, STEM CELLS, V36, P1501, DOI 10.1002/stem.2861
   van Echten-Arends J, 2011, HUM REPROD UPDATE, V17, P620, DOI 10.1093/humupd/dmr014
   van Steensel B, 2017, CELL, V169, P780, DOI 10.1016/j.cell.2017.04.022
   van Veghel-Plandsoen MM, 2011, EUR J HUM GENET, V19, P1009, DOI 10.1038/ejhg.2011.60
   Volpi EV, 2000, J CELL SCI, V113, P1565
   Wang XM, 2008, CANCER RES, V68, P9909, DOI 10.1158/0008-5472.CAN-08-1551
   Wei Z, 2013, CELL STEM CELL, V13, P36, DOI 10.1016/j.stem.2013.05.010
   Weierich C, 2003, CHROMOSOME RES, V11, P485, DOI 10.1023/A:1025016828544
   WEIMER R, 1992, HUM GENET, V88, P673, DOI 10.1007/BF02265296
   Weissbein U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12144
   Weissbein U, 2014, J CELL BIOL, V204, P153, DOI 10.1083/jcb.201310135
   Wiblin AE, 2005, J CELL SCI, V118, P3861, DOI 10.1242/jcs.02500
   WiCell, 2017, COMB POW KAR ACGH
   Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7
   Woodbine L, 2011, NUCLEIC ACIDS RES, V39, P6986, DOI 10.1093/nar/gkr331
   Worman HJ, 2007, EXP CELL RES, V313, P2121, DOI 10.1016/j.yexcr.2007.03.028
   Wydner KL, 1996, GENOMICS, V32, P474, DOI 10.1006/geno.1996.0146
   Xiang BX, 2008, AM J MED GENET A, V146A, P1942, DOI 10.1002/ajmg.a.32411
   Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033
   Yan JB, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-68
   Yang CB, 2008, STEM CELLS, V26, P850, DOI 10.1634/stemcells.2007-0677
   Yang S, 2008, GENE CHROMOSOME CANC, V47, P665, DOI 10.1002/gcc.20574
   Yao GD, 2016, SCI REP-UK, V6, DOI 10.1038/srep23995
   Yermilov V, 1996, FEBS LETT, V399, P67, DOI 10.1016/S0014-5793(96)01288-4
   Yoshihara M, 2017, CELL REP, V21, P308, DOI 10.1016/j.celrep.2017.09.060
   Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102
   Zhang ML, 2016, EMBO J, V35, P2285, DOI 10.15252/embj.201593103
   Zhang MJ, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0313-0
   Zhang RS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S5-S8
   Zhao R, 2014, P NATL ACAD SCI USA, V111, P15768, DOI 10.1073/pnas.1417518111
   Zheng XB, 2015, MOL BIOL CELL, V26, P2685, DOI 10.1091/mbc.E15-04-0210
   Zhou G, 2016, CELL REP, V15, P919, DOI 10.1016/j.celrep.2016.03.084
   Zuo BF, 2012, BIOL OPEN, V1, P1118, DOI 10.1242/bio.20121586
NR 306
TC 16
Z9 16
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JAN 21
PY 2019
VL 9
AR 623
DI 10.3389/fgene.2018.00623
PG 20
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HI1VL
UT WOS:000456233000001
PM 30719030
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI SIREV-OFTARED Joint Congress, Madrid, Spain, June 29-30, 2018 Abstracts
SO OPHTHALMIC RESEARCH
LA English
DT Article
AB This 10th Annual Congress on CONTROVERSIES IN OPHTHALMOLOGY meeting which focuses on Ophthalmic Research, contains approximately 57 abstracts and 21 poster presentation written in English. Topics include retina of a retinitis pigmentosa,animal differential diagnosis in pharmacy office with and without optometry section, lipid metabolism, polymorphisms with age-related macular degeneration ,thioredoxin retinal degeneration, macular layer segmentation,optical coherence tomography in glaucoma, langerhans cell histiocytosis, ocular surface temperature, aqueous-deficient dry eye, brain volume, visoperceptive damage in premature children, retinopathy of prematurity incidence, cellular interactions, retinal degeneration in retinitis pigmentosa mitochondrial function, oral supplementation of r-lipoic acid, bilateral retinal detachment after laser photocoagulation, different lipid layer patterns, pars planitis in childhood, epiretinal membrane and glaucoma progression in smokers.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2018
VL 60
IS 2
BP 116
EP 137
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP4MF
UT WOS:000440839600010
DA 2022-11-30
ER

PT J
AU Dong, LF
   Yao, J
   Wang, XQ
   Shan, K
   Yang, H
   Yan, B
   Jiang, Q
AF Dong, Ling-Feng
   Yao, Jin
   Wang, Xiao-Qun
   Shan, Kun
   Yang, Hong
   Yan, Biao
   Jiang, Qin
TI Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell
   function: Implication for treating ocular neovascular disorder
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Lenalidomide; Ocular angiogenesis; Anti-proliferative; Anti-inflammatory
ID DIABETIC-RETINOPATHY; ANGIOGENESIS; THERAPY; THALIDOMIDE; MITOMYCIN;
   SURGERY; MYELOMA
AB Ocular angiogenesis is an important pathologic character of several ocular diseases, such as retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration (AMD). Inhibition of ocular angiogenesis has great therapeutic value for treating these dieses. Here we show that lenalidomide, an anti-tumor drug, has great anti-angiogenic potential in ocular diseases. Lenalidomide inhibits retinal endothelial cell viability in normal and pathological condition, and inhibits VEGF-induced endothelial cell migration and tube formation in vitro. Moreover, lenalidomide inhibits ocular angiogenesis in vivo through the reduction of angiogenesis- and inflammation-related protein expression. Collectively, lenalidomide is a promising drug for treating ocular angiogenesis through its anti-proliferative and anti-inflammatory property. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Dong, Ling-Feng; Yao, Jin; Wang, Xiao-Qun; Shan, Kun; Yang, Hong; Yan, Biao; Jiang, Qin] Nanjing Med Univ, Hosp Eye, Nanjing, Jiangsu, Peoples R China.
   [Dong, Ling-Feng; Yao, Jin; Wang, Xiao-Qun; Shan, Kun; Yang, Hong; Yan, Biao; Jiang, Qin] Nanjing Med Univ, Sch Clin Med 4, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Jiang, Q (通讯作者)，Nanjing Med Univ, Hosp Eye, Nanjing, Jiangsu, Peoples R China.
EM yanbiao1982@hotmail.com; jiangqin710@126.com
FU National Natural Science Foundation of China [81371055]; National
   clinical key construction project [(2012) 649]; Medical Science and
   Technology Development Project Fund of Nanjing [ZKX 12047, YKK13227]
FX This work was generously supported by grants from the National Natural
   Science Foundation of China (Grant No. 81371055 to Q.J.), grants from
   the National clinical key construction project [Grant No. (2012) 649 to
   Q.J.], and grants from the Medical Science and Technology Development
   Project Fund of Nanjing (Grant No. ZKX 12047 to Q.J. and Gran No.
   YKK13227 to B.Y).
CR Akarsu C, 2003, CLIN EXP OPHTHALMOL, V31, P199, DOI 10.1046/j.1442-9071.2003.00645.x
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chanan-Khan AA, 2008, J CLIN ONCOL, V26, P1544, DOI 10.1200/JCO.2007.14.5367
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   KITAZAWA Y, 1991, ARCH OPHTHALMOL-CHIC, V109, P1693, DOI 10.1001/archopht.1991.01080120077030
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062
   Raghava S, 2007, EUR J PHARMACOL, V568, P68, DOI 10.1016/j.ejphar.2007.04.044
   Rajappa M, 2010, ADV CLIN CHEM, V50, P103, DOI 10.1016/S0065-2423(10)50006-4
   Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470-2045(09)70284-0
   Sherris David, 2007, Angiogenesis, V10, P71, DOI 10.1007/s10456-007-9068-y
   Tilleul P, 1997, OPHTHALMIC RES, V29, P218, DOI 10.1159/000268016
   Vallet S, 2008, LEUKEMIA LYMPHOMA, V49, P1238, DOI 10.1080/10428190802005191
   Xu HZ, 2011, INVEST OPHTH VIS SCI, V52, P2160, DOI 10.1167/iovs.10-6518
   Yan B, 2014, INVEST OPHTH VIS SCI, V55, P941, DOI 10.1167/iovs.13-13221
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 23
TC 7
Z9 7
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 2
PY 2015
VL 465
IS 4
BP 678
EP 684
DI 10.1016/j.bbrc.2015.08.014
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CS0WI
UT WOS:000361782500005
PM 26255966
DA 2022-11-30
ER

PT J
AU Wagner, E
   Frank, MM
AF Wagner, Eric
   Frank, Michael M.
TI Therapeutic potential of complement modulation
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Review
ID HEMOLYTIC-UREMIC SYNDROME; MANNOSE-BINDING LECTIN; ELEVATION
   MYOCARDIAL-INFARCTION; ENTIRE C1QR(2)S(2) COMPLEX; TRAUMATIC
   BRAIN-INJURY; TH2 EFFECTOR FUNCTIONS; ALTERNATIVE PATHWAY; FACTOR-H; C1
   INHIBITOR; FACTOR-B
AB The complement system is an essential component of innate immunity that has been more recently recognized as an unexpected player in various pathological states. These include age-related macular degeneration, atypical haemolytic uraemic syndrome, allergy, foetal loss, and axonal and myelin degradation after trauma. Its importance has also been recognized in physiological processes including haematopoietic stem cell homing to the bone marrow, liver regeneration and modulation of adaptive immune responses. Although the complement system has long been known to be involved in autoimmune and inflammatory diseases, few agents that target the complement system are currently approved for clinical use. However, renewed interest in modulating this system in various pathological conditions has emerged, and several agents are now in development.
C1 [Frank, Michael M.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
   [Wagner, Eric] Univ Laval, Ctr Rech Rhumatol & Immunol, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Wagner, Eric] Univ Laval, Dept Microbiol Infectiol & Immunol, Quebec City, PQ, Canada.
   [Frank, Michael M.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.
C3 Duke University; Laval University; Laval University; Duke University
RP Frank, MM (通讯作者)，Duke Univ, Med Ctr, Dept Pediat, Box 2611, Durham, NC 27710 USA.
EM frank007@mc.duke.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
CR Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047
   Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104
   Asghar SS, 2000, FRONT BIOSCI-LANDMRK, V5, pE63, DOI 10.2741/asghar
   Atkinson C, 2008, J IMMUNOL, V180, P1231, DOI 10.4049/jimmunol.180.2.1231
   Atkinson JP, 2006, J CLIN INVEST, V116, P1215, DOI 10.1172/JCI28622
   Baig K, 2007, ANN THORAC SURG, V83, P1477, DOI 10.1016/j.athoracsur.2006.10.049
   Baldwin WM, 2004, AM J TRANSPLANT, V4, P311, DOI 10.1111/j.1600-6143.2004.00348.x
   BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520
   Basta M, 2008, MOL IMMUNOL, V45, P4073, DOI 10.1016/j.molimm.2008.07.012
   Beinrohr L, 2008, TRENDS MOL MED, V14, P511, DOI 10.1016/j.molmed.2008.09.009
   Bergmann-Leitner ES, 2007, VACCINE, V25, P7732, DOI 10.1016/j.vaccine.2007.08.030
   Bergmann-Leitner ES, 2006, CLIN IMMUNOL, V121, P177, DOI 10.1016/j.clim.2006.07.001
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Bureeva S, 2005, DRUG DISCOV TODAY, V10, P1535, DOI 10.1016/S1359-6446(05)03592-0
   Caliezi C, 2002, CRIT CARE MED, V30, P1722, DOI 10.1097/00003246-200208000-00008
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   Casanova JL, 2004, J EXP MED, V199, P1295, DOI 10.1084/jem.20040537
   Chen CH, 1998, IMMUNOLOGY, V95, P648
   Chen CH, 1998, CLIN IMMUNOL IMMUNOP, V87, P68, DOI 10.1006/clin.1997.4515
   Cicardi M, 2005, SPRINGER SEMIN IMMUN, V27, P286, DOI 10.1007/s00281-005-0001-4
   Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362
   Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001
   Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x
   Dragon-Durey MA, 2005, SPRINGER SEMIN IMMUN, V27, P359, DOI 10.1007/s00281-005-0003-2
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926
   Drouin SM, 2001, J IMMUNOL, V167, P4141, DOI 10.4049/jimmunol.167.8.4141
   DUHRSEN U, 2009, BLOOD, V113, P3885
   Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324
   Epstein TG, 2008, DRUGS, V68, P2561, DOI 10.2165/0003495-200868180-00003
   Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x
   Fattouch K, 2007, EUR J CARDIO-THORAC, V32, P326, DOI 10.1016/j.ejcts.2007.04.038
   Frank M. M., 1998, HUMAN COMPLEMENT SYS, P1
   Frank MM, 2000, IMMUNOL RES, V22, P137, DOI 10.1385/IR:22:2-3:137
   Fritzinger DC, 2009, DEV COMP IMMUNOL, V33, P105, DOI 10.1016/j.dci.2008.07.006
   Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4
   Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959
   Hamilton SR, 2006, SCIENCE, V313, P1441, DOI 10.1126/science.1130256
   Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Hepburn NJ, 2008, MOL IMMUNOL, V45, P395, DOI 10.1016/j.molimm.2007.06.144
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164
   Hollmer M, 2007, NAT BIOTECHNOL, V25, P4, DOI 10.1038/nbt0107-4
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   Inal JM, 2005, J IMMUNOL, V174, P356, DOI 10.4049/jimmunol.174.1.356
   Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200
   Jarva H, 2003, MOL IMMUNOL, V40, P95, DOI 10.1016/S0161-5890(03)00108-1
   Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609
   Jokiranta TS, 2007, MOL IMMUNOL, V44, P3889, DOI 10.1016/j.molimm.2007.06.003
   Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X
   Jongerius I, 2007, J EXP MED, V204, P2461, DOI 10.1084/jem.20070818
   Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Koehl J, 2006, CURR OPIN MOL THER, V8, P529
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Lazar HL, 2004, CIRCULATION, V110, pII274, DOI 10.1161/01.CIR.0000138315.99788.eb
   Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13
   Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033
   LI JS, 2006, EXPERT REV CARDIOVAS, V4, P659
   Lin T, 2007, TRANSPL INT, V20, P481, DOI 10.1111/j.1432-2277.2006.00448.x
   Liszewski MK, 2008, J IMMUNOL, V181, P4199, DOI 10.4049/jimmunol.181.6.4199
   Locke JE, 2009, AM J TRANSPLANT, V9, P231, DOI 10.1111/j.1600-6143.2008.02451.x
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   MAROM Z, 1985, J EXP MED, V161, P657, DOI 10.1084/jem.161.4.657
   Mathieu MC, 2005, IMMUNOL LETT, V100, P139, DOI 10.1016/j.imlet.2005.03.003
   Mitchell DA, 2007, MOL IMMUNOL, V44, P2997, DOI 10.1016/j.molimm.2006.12.027
   Mocco J, 2006, J NEUROSURG, V105, P595, DOI 10.3171/jns.2006.105.4.595
   Mollnes TE, 2006, MOL IMMUNOL, V43, P107, DOI 10.1016/j.molimm.2005.06.014
   Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332
   Nielsen EW, 2007, MOL IMMUNOL, V44, P1819, DOI 10.1016/j.molimm.2006.10.003
   Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527
   OSOFSKY SG, 1977, J PEDIATR-US, V90, P180, DOI 10.1016/S0022-3476(77)80626-4
   Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5
   Patel H, 2006, J AM SOC NEPHROL, V17, P1102, DOI 10.1681/ASN.2005101116
   Petersen KA, 2006, J CLIN IMMUNOL, V26, P465, DOI 10.1007/s10875-006-9037-z
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Ratajczak J, 2004, BLOOD, V103, P2071, DOI 10.1182/blood-2003-06-2099
   Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x
   RICKLIN D, 2008, NAT BIOTECHNOL, V25, P1265
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348
   Speth C., 2008, FUNDAMENTAL IMMUNOLO, P1047
   Sprong T, 2003, BLOOD, V102, P3702, DOI 10.1182/blood-2003-03-0703
   STEGALL M, 2009, AM SOC TRANSPL WINT
   Struber M, 1999, INTENS CARE MED, V25, P1315, DOI 10.1007/s001340051065
   SULLIVAN K, 2004, IMMUNOLOGIC DISORDER, P652
   Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103
   Testa L, 2008, J THORAC CARDIOV SUR, V136, P884, DOI 10.1016/j.jtcvs.2007.12.062
   Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005
   Thielmann M, 2006, EUR J CARDIO-THORAC, V30, P285, DOI 10.1016/j.ejcts.2006.04.022
   Thorgersen EB, 2009, INFECT IMMUN, V77, P725, DOI 10.1128/IAI.01305-08
   Thurman JM, 2006, J AM SOC NEPHROL, V17, P707, DOI 10.1681/ASN.2005070698
   TRAPP RG, 1987, J RHEUMATOL, V14, P135
   Trouw LA, 2001, MOL IMMUNOL, V38, P199, DOI 10.1016/S0161-5890(01)00043-8
   Valdimarsson H, 2003, BIOCHEM SOC T, V31, P768, DOI 10.1042/bst0310768
   Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222
   VONZABERN I, 1993, ACTIVATORS INHIBITOR, P127
   WAGNER E, 2001, MED IMMUNOLOGY, P341
   WAGNER E, 2001, CLIN DIAGNOSIS MANAG, P892
   WAGNER E, 1998, HUMAN COMPLEMENT SYS, P527
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269
   WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562
   Whipple EC, 2007, MOL IMMUNOL, V44, P377, DOI 10.1016/j.molimm.2006.02.032
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Wills-Karp Marsha, 2007, Proc Am Thorac Soc, V4, P247, DOI 10.1513/pats.200704-046AW
   Yazdanbakhsh K, 2005, TRANSFUSION, V45, p122S, DOI 10.1111/j.1537-2995.2005.00526.x
   Younger JG, 2001, J APPL PHYSIOL, V90, P2289, DOI 10.1152/jappl.2001.90.6.2289
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 122
TC 154
Z9 188
U1 0
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
EI 1474-1784
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD JAN
PY 2010
VL 9
IS 1
BP 43
EP 56
DI 10.1038/nrd3011
PG 14
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 566GD
UT WOS:000275357200023
PM 19960015
OA Bronze
DA 2022-11-30
ER

PT J
AU Sadaka, A
   Durand, ML
   Gilmore, MS
AF Sadaka, Ama
   Durand, Marlene L.
   Gilmore, Michael S.
TI Bacterial endophthalmitis in the age of outpatient intravitreal
   therapies and cataract surgeries: Host-microbe interactions in
   intraocular infection
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Endophthalmitis; Staphylococcus aureus; Coagulase-negative
   staphylococci; Streptococcus pneumoniae; Enterococcus faecalis; Bacillus
ID RESISTANT STAPHYLOCOCCUS-AUREUS; COAGULASE-NEGATIVE STAPHYLOCOCCI;
   CASSETTE CHROMOSOME MEC; TUMOR-NECROSIS-FACTOR; BIOSYNTHESIS-ACTIVATING
   PHEROMONE; MELANOCYTE-STIMULATING HORMONE; ACUTE-ONSET ENDOPHTHALMITIS;
   FIBRINOGEN-BINDING PROTEIN; AQUEOUS-HUMOR PENETRATION; QUORUM-SENSING
   SYSTEM
AB Bacterial endophthalmitis is a sight threatening infection of the interior structures of the eye. Incidence in the US has increased in recent years, which appears to be related to procedures being performed on an aging population. The advent of outpatient intravitreal therapy for management of age-related macular degeneration raises yet additional risks. Compounding the problem is the continuing progression of antibiotic resistance. Visual prognosis for endophthalmitis depends on the virulence of the causative organism, the severity of intraocular inflammation, and the timeliness of effective therapy. We review the current understanding of the pathogenesis of bacterial endophthalmitis, highlighting opportunities for the development of improved therapeutics and preventive strategies. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Sadaka, Ama; Gilmore, Michael S.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Sadaka, Ama; Gilmore, Michael S.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   [Durand, Marlene L.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
   [Gilmore, Michael S.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Massachusetts
   General Hospital; Harvard University; Harvard Medical School
RP Gilmore, MS (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM michael_gilmore@meei.harvard.edu
FU NATIONAL EYE INSTITUTE [R01EY008289] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI083214]
   Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008289-22] Funding
   Source: Medline; NIAID NIH HHS [P01 AI083214-05, P01 AI083214] Funding
   Source: Medline
CR Albrecht E, 2011, BRIT J OPHTHALMOL, V95, P1385, DOI 10.1136/bjo.2010.187963
   Allegretti M, 2005, CURR MED CHEM, V12, P217, DOI 10.2174/0929867053363379
   Allensworth JJ, 2011, J LEUKOCYTE BIOL, V90, P1159, DOI 10.1189/jlb.0511249
   American Academy of Ophthalmology Cataract and Anterior segment Panel, 2011, PREF PRACT PATT GUID
   Anand A R, 2000, Indian J Ophthalmol, V48, P123
   Asbell PA, 2008, AM J OPHTHALMOL, V145, P951, DOI 10.1016/j.ajo.2008.01.025
   Asbell PA, 2008, J CATARACT REFR SURG, V34, P814, DOI 10.1016/j.jcrs.2008.01.016
   Baillif S, 2008, J CATARACT REFR SURG, V34, P153, DOI 10.1016/j.jcrs.2007.07.058
   Bainbridge JWB, 1998, BRIT J OPHTHALMOL, V82, P1312, DOI 10.1136/bjo.82.11.1312
   Barbier F, 2010, J INFECT DIS, V202, P270, DOI 10.1086/653483
   Barrett A.J., 1998, HDB PROTEOLYTIC ENZY
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Bausz M, 2006, J CATARACT REFR SURG, V32, P1691, DOI 10.1016/j.jcrs.2006.05.019
   Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607
   Beenken KE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010790
   Bekeredjian-Ding I, 2007, J IMMUNOL, V178, P2803, DOI 10.4049/jimmunol.178.5.2803
   Bera A, 2007, J BACTERIOL, V189, P280, DOI 10.1128/JB.01221-06
   Beveridge TJ, 1997, FEMS MICROBIOL REV, V20, P291, DOI 10.1016/S0168-6445(97)00012-0
   BEYER TL, 1984, INVEST OPHTH VIS SCI, V25, P108
   Bischoff M, 2004, J BACTERIOL, V186, P4085, DOI 10.1128/JB.186.13.4085-4099.2004
   Blum-Hareuveni T, 2006, GRAEF ARCH CLIN EXP, V244, P253, DOI 10.1007/s00417-005-1163-4
   Boles BR, 2011, TRENDS MICROBIOL, V19, P449, DOI 10.1016/j.tim.2011.06.004
   BOOTH MC, 1995, INVEST OPHTH VIS SCI, V36, P1828
   Booth MC, 1997, INFECT IMMUN, V65, P1550, DOI 10.1128/IAI.65.4.1550-1556.1997
   Brandl K, 2008, NATURE, V455, P804, DOI 10.1038/nature07250
   Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249
   Bucher RS, 2005, ARCH OPHTHALMOL-CHIC, V123, P649, DOI 10.1001/archopht.123.5.649
   Bunschoten A, 2011, AMINO ACIDS, V40, P731, DOI 10.1007/s00726-010-0711-3
   Caiazza NC, 2003, J BACTERIOL, V185, P3214, DOI 10.1128/JB.185.10.3214-3217.2003
   Callegan MC, 1999, INFECT IMMUN, V67, P3348, DOI 10.1128/IAI.67.7.3348-3356.1999
   Callegan MC, 2005, INVEST OPHTH VIS SCI, V46, P3233, DOI 10.1167/iovs.05-0410
   Callegan MC, 1999, INFECT IMMUN, V67, P3357, DOI 10.1128/IAI.67.7.3357-3366.1999
   Callegan MC, 2003, INFECT IMMUN, V71, P3116, DOI 10.1128/IAI.71.6.3116-3124.2003
   Callegan MC, 2002, INFECT IMMUN, V70, P5381, DOI 10.1128/IAI.70.10.5381-5389.2002
   Callegan MC, 2002, CLIN MICROBIOL REV, V15, P111, DOI 10.1128/CMR.15.1.111-124.2002
   Callegan MC, 2002, DNA CELL BIOL, V21, P367, DOI 10.1089/10445490260099647
   Callegan MC, 2006, INVEST OPHTH VIS SCI, V47, P4461, DOI 10.1167/iovs.06-0301
   Camargo RLBC, 2008, J BACTERIOL, V190, P2253, DOI 10.1128/JB.00043-08
   Cardillo JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P81, DOI 10.1001/archophthalmol.2009.352
   Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119
   Cavuoto K, 2008, OPHTHALMOLOGY, V115, P51, DOI 10.1016/j.ophtha.2007.03.076
   CEDERGREN L, 1993, PROTEIN ENG, V6, P441, DOI 10.1093/protein/6.4.441
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P565
   Chambers HF, 1997, CLIN MICROBIOL REV, V10, P781, DOI 10.1128/CMR.10.4.781
   Chang DF, 2007, J CATARACT REFR SURG, V33, P1801, DOI 10.1016/j.jcrs.2007.07.009
   Chang JH, 2006, BRIT J OPHTHALMOL, V90, P103, DOI 10.1136/bjo.2005.072686
   Chen E, 2011, RETINA-J RET VIT DIS, V31, P1525, DOI 10.1097/IAE.0b013e318221594a
   Cheng AG, 2011, TRENDS MICROBIOL, V19, P225, DOI 10.1016/j.tim.2011.01.007
   Chhabra S, 2006, AM J OPHTHALMOL, V142, P852, DOI 10.1016/j.ajo.2006.05.024
   Chien YT, 1999, J BIOL CHEM, V274, P37169, DOI 10.1074/jbc.274.52.37169
   Coburn PS, 2004, SCIENCE, V306, P2270, DOI 10.1126/science.1103996
   Corbin BD, 2008, SCIENCE, V319, P962, DOI 10.1126/science.1152449
   Cramton SE, 2001, INFECT IMMUN, V69, P4079, DOI 10.1128/IAI.69.6.4079-4085.2001
   Crane IJ, 2008, SEMIN IMMUNOPATHOL, V30, P165, DOI 10.1007/s00281-008-0106-7
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Das T, 1999, BRIT J OPHTHALMOL, V83, P1050, DOI 10.1136/bjo.83.9.1050
   DAVID DB, 1994, BRIT J OPHTHALMOL, V78, P577, DOI 10.1136/bjo.78.7.577
   De Kaspar HM, 2008, RETINA-J RET VIT DIS, V28, P326, DOI 10.1097/IAE.0b013e3181237cf8
   de Kaspar HM, 2005, ARCH OPHTHALMOL-CHIC, V123, P161, DOI 10.1001/archopht.123.2.161
   De Lencastre H, 1999, MICROB DRUG RESIST, V5, P163, DOI 10.1089/mdr.1999.5.163
   DEBEER D, 1994, APPL ENVIRON MICROB, V60, P4339, DOI 10.1128/AEM.60.12.4339-4344.1994
   Deramo VA, 2008, AM J OPHTHALMOL, V145, P413, DOI 10.1016/j.ajo.2007.10.020
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   DICKEY JB, 1991, AM J OPHTHALMOL, V112, P278, DOI 10.1016/S0002-9394(14)76728-5
   Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7
   Dunman PM, 2001, J BACTERIOL, V183, P7341, DOI 10.1128/JB.183.24.7341-7353.2001
   Engelbert M, 2005, INVEST OPHTH VIS SCI, V46, P2479, DOI 10.1167/iovs.04-1139
   Engelbert M, 2004, INFECT IMMUN, V72, P3628, DOI 10.1128/IAI.72.6.3628-3633.2004
   Ermis SS, 2007, CURR EYE RES, V32, P337, DOI 10.1080/02713680701215595
   Ermis SS, 2005, TOHOKU J EXP MED, V205, P223, DOI 10.1620/tjem.205.223
   Ferguson AW, 2003, BRIT J OPHTHALMOL, V87, P163, DOI 10.1136/bjo.87.2.163
   Finks J, 2009, EMERG INFECT DIS, V15, P943, DOI 10.3201/eid1506.081312
   Friswell M, 2010, GUT LIVER, V4, P295, DOI 10.5009/gnl.2010.4.3.295
   Fukuda M, 2002, CORNEA, V21, pS86, DOI 10.1097/01.ico.0000263125.99262.42
   Gan IM, 2005, GRAEF ARCH CLIN EXP, V243, P1186, DOI 10.1007/s00417-005-1182-1
   Gan IM, 2005, GRAEF ARCH CLIN EXP, V243, P1200, DOI 10.1007/s00417-005-0133-1
   Gans J. de, 2002, New England Journal of Medicine, V347, P1549, DOI 10.1056/NEJMoa021334
   Garza-Gonzalez E, 2010, J MED MICROBIOL, V59, P323, DOI 10.1099/jmm.0.015800-0
   Garzozi HJ, 2000, BRIT J OPHTHALMOL, V84, P554, DOI 10.1136/bjo.84.5.554
   Gertz S, 2000, J BACTERIOL, V182, P6983, DOI 10.1128/JB.182.24.6983-6991.2000
   Ghelardi E, 2007, APPL ENVIRON MICROB, V73, P4089, DOI 10.1128/AEM.02345-06
   Giacometti A, 2000, J CLIN MICROBIOL, V38, P918, DOI 10.1128/JCM.38.2.918-922.2000
   Giese MJ, 1999, CURR EYE RES, V18, P177, DOI 10.1076/ceyr.18.3.177.5370
   Gilmore MS, 2005, P NATL ACAD SCI USA, V102, P8401, DOI 10.1073/pnas.0503828102
   GILMORE MS, 1989, J BACTERIOL, V171, P744, DOI 10.1128/jb.171.2.744-753.1989
   Goerke C, 2004, INT J MED MICROBIOL, V294, P195, DOI 10.1016/j.ijmm.2004.06.013
   Gotz F, 2002, MOL MICROBIOL, V43, P1367, DOI 10.1046/j.1365-2958.2002.02827.x
   Grandgirard D, 2008, J INFECT DIS, V197, P1519, DOI 10.1086/587942
   Guiral S, 2005, P NATL ACAD SCI USA, V102, P8710, DOI 10.1073/pnas.0500879102
   Gungor SG, 2011, BRIT J OPHTHALMOL, V95, P1272, DOI 10.1136/bjo.2010.179762
   Guo BN, 2007, INFECT IMMUN, V75, P2991, DOI 10.1128/IAI.01741-06
   Haas W, 2002, NATURE, V415, P84, DOI 10.1038/415084a
   Haas W, 2011, AM J OPHTHALMOL, V152, P567, DOI 10.1016/j.ajo.2011.03.010
   Han DP, 1996, AM J OPHTHALMOL, V122, P830
   Hancock LE, 2004, J BACTERIOL, V186, P5629, DOI 10.1128/JB.186.17.5629-5639.2004
   Hartford O, 2001, MICROBIOL-SGM, V147, P2545, DOI 10.1099/00221287-147-9-2545
   Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162
   HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x
   HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140
   Haynes RJ, 2000, INVEST OPHTH VIS SCI, V41, P3026
   Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x
   Hendriksen WT, 2008, J BACTERIOL, V190, P590, DOI 10.1128/JB.00917-07
   Hirst RA, 2008, J INFECT DIS, V197, P744, DOI 10.1086/527322
   Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101
   HOWES EL, 1994, INVEST OPHTH VIS SCI, V35, P4031
   Huhtinen M, 2001, INVEST OPHTH VIS SCI, V42, P1816
   HUI FM, 1995, GENE, V153, P25, DOI 10.1016/0378-1119(94)00841-F
   Huntzinger E, 2005, EMBO J, V24, P824, DOI 10.1038/sj.emboj.7600572
   Huseby M, 2007, J BACTERIOL, V189, P8719, DOI 10.1128/JB.00741-07
   Jarraud S, 2000, J BACTERIOL, V182, P6517, DOI 10.1128/JB.182.22.6517-6522.2000
   Jefferson KK, 2004, J BACTERIOL, V186, P2449, DOI 10.1128/JB.186.8.2449-2456.2004
   JETT BD, 1995, INVEST OPHTH VIS SCI, V36, P9
   JEVONS MP, 1963, LANCET, V1, P904
   Ji GY, 1997, SCIENCE, V276, P2027, DOI 10.1126/science.276.5321.2027
   Jonas JB, 2000, OPHTHALMOLOGY, V107, P823, DOI 10.1016/S0161-6420(00)00079-8
   Juarez-Verdayes Marco Adan, 2006, Rev Latinoam Microbiol, V48, P238
   KANCLERSKI K, 1987, J CLIN MICROBIOL, V25, P222, DOI 10.1128/JCM.25.2.222-225.1987
   Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000
   KATTAN HM, 1991, OPHTHALMOLOGY, V98, P227
   Kazakova SV, 2005, NEW ENGL J MED, V352, P468, DOI 10.1056/NEJMoa042859
   Kim SJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1180, DOI 10.1001/archophthalmol.2011.213
   Kinnebrew MA, 2010, J INFECT DIS, V201, P534, DOI 10.1086/650203
   Klein KS, 2009, OPHTHALMOLOGY, V116, P1225, DOI 10.1016/j.ophtha.2009.02.031
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   Kobayakawa S, 2005, CURR EYE RES, V30, P741, DOI 10.1080/02713680591005959
   Kodjikian L, 2010, INVEST OPHTH VIS SCI
   Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589
   Kong KF, 2006, INT J MED MICROBIOL, V296, P133, DOI 10.1016/j.ijmm.2006.01.042
   KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157
   Kullik I, 1998, J BACTERIOL, V180, P4814, DOI 10.1128/JB.180.18.4814-4820.1998
   Lalwani GA, 2008, OPHTHALMOLOGY, V115, P473, DOI 10.1016/j.ophtha.2007.06.006
   Lamont M, 2006, EYE, V20, P981, DOI 10.1038/sj.eye.6702096
   Leng T, 2011, RETINA-J RET VIT DIS, V31, P344, DOI 10.1097/IAE.0b013e3181e09810
   Lerner LE, 1997, INVEST OPHTH VIS SCI, V38, P1222
   Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]
   Liu F, 2008, CURR EYE RES, V33, P761, DOI 10.1080/02713680802344690
   Mac Ivan, 2003, Curr Opin Ophthalmol, V14, P91, DOI 10.1097/00055735-200304000-00007
   Majerczyk CD, 2008, J BACTERIOL, V190, P2257, DOI 10.1128/JB.01545-07
   Majerczyk CD, 2010, J BACTERIOL, V192, P2861, DOI 10.1128/JB.00220-10
   Major JC, 2010, AM J OPHTHALMOL, V149, P278, DOI 10.1016/j.ajo.2009.08.023
   Manna A, 2001, INFECT IMMUN, V69, P885, DOI 10.1128/IAI.69.2.885-896.2001
   MAO LK, 1992, ARCH OPHTHALMOL-CHIC, V110, P798, DOI 10.1001/archopht.1992.01080180070030
   Marshall MJ, 2000, J NAT TOXINS, V9, P125
   MCMENAMIN PG, 1994, INVEST OPHTH VIS SCI, V35, P3234
   Meredith T A, 1996, Trans Am Ophthalmol Soc, V94, P241
   Meredith TA, 1996, T AM OPHTHAL SOC, V94, P252
   Miller D, 2006, ARCH OPHTHALMOL-CHIC, V124, P479, DOI 10.1001/archopht.124.4.479
   Miller DM, 2007, OPHTHAL SURG LAS IM, V38, P446, DOI 10.3928/15428877-20071101-01
   Miller JJ, 2005, AM J OPHTHALMOL, V139, P983, DOI 10.1016/j.ajo.2005.01.025
   Miragaia M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007722
   Montan PG, 2002, J CATARACT REFR SURG, V28, P977, DOI 10.1016/S0886-3350(01)01269-X
   MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995
   MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x
   MORFELDT E, 1988, MOL GEN GENET, V211, P435, DOI 10.1007/BF00425697
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Moyer AL, 2008, INFECT IMMUN, V76, P1358, DOI 10.1128/IAI.01330-07
   Moyer AL, 2009, INVEST OPHTH VIS SCI, V50, P3783, DOI 10.1167/iovs.08-3051
   Murata M, 2005, OPHTHALMOLOGICA, V219, P287, DOI 10.1159/000086113
   Murjaneh S, 2010, BRIT J OPHTHALMOL, V94, P1410, DOI 10.1136/bjo.2009.176883
   Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007
   Nakayama J, 2001, MOL MICROBIOL, V41, P145, DOI 10.1046/j.1365-2958.2001.02486.x
   Nakayama J, 2006, J BACTERIOL, V188, P8321, DOI 10.1128/JB.00865-06
   Nayak N, 2008, Nepal Med Coll J, V10, P48
   Ng EWM, 2002, RETINA-J RET VIT DIS, V22, P622, DOI 10.1097/00006982-200210000-00014
   Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998
   Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x
   Ong-Tone L, 2007, J CATARACT REFR SURG, V33, P59, DOI 10.1016/j.jcrs.2006.09.015
   Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759
   ORMEROD LD, 1993, OPHTHALMOLOGY, V100, P724
   Otto M, 1999, FEBS LETT, V450, P257, DOI 10.1016/S0014-5793(99)00514-1
   Otto M, 2009, NAT REV MICROBIOL, V7, P555, DOI 10.1038/nrmicro2182
   Palmqvist N, 2004, MICROBES INFECT, V6, P188, DOI 10.1016/j.micinf.2003.11.005
   Parmar P, 2006, AM J OPHTHALMOL, V141, P1160, DOI 10.1016/j.ajo.2006.01.046
   Pastagia M, 2011, ANTIMICROB AGENTS CH, V55, P738, DOI 10.1128/AAC.00890-10
   PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987
   PATON JC, 1983, INFECT IMMUN, V41, P1212, DOI 10.1128/IAI.41.3.1212-1216.1983
   Paton JC, 1997, MICROB DRUG RESIST, V3, P1, DOI 10.1089/mdr.1997.3.1
   Pelz A, 2005, J BIOL CHEM, V280, P32493, DOI 10.1074/jbc.M505070200
   Peng YJ, 2010, J BIOMED MATER RES A, V94A, P426, DOI 10.1002/jbm.a.32697
   Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x
   Petropoulos IK, 2006, GRAEF ARCH CLIN EXP, V244, P1322, DOI 10.1007/s00417-006-0261-2
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Pierre DJ, 2010, BRIT J OPHTHALMOL, V94, P390, DOI 10.1136/bjo.2009.163774
   Pijl BJ, 2010, AM J OPHTHALMOL, V149, P482, DOI 10.1016/j.ajo.2009.09.021
   Pohl K, 2009, J BACTERIOL, V191, P2953, DOI 10.1128/JB.01492-08
   Postma B, 2004, J IMMUNOL, V172, P6994, DOI 10.4049/jimmunol.172.11.6994
   Qin X, 2000, INFECT IMMUN, V68, P2579, DOI 10.1128/IAI.68.5.2579-2586.2000
   Raad I, 1998, CLIN INFECT DIS, V26, P1182, DOI 10.1086/520285
   Ramadan RT, 2008, INVEST OPHTH VIS SCI, V49, P4482, DOI 10.1167/iovs.08-2085
   Ramadan RT, 2006, CURR EYE RES, V31, P955, DOI 10.1080/02713680600976925
   Rechtin TM, 1999, MOL MICROBIOL, V33, P307, DOI 10.1046/j.1365-2958.1999.01474.x
   Romero P, 2006, J CATARACT REFR SURG, V32, P438, DOI 10.1016/j.jcrs.2005.12.135
   Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Schmidt KA, 2001, INFECT IMMUN, V69, P4749, DOI 10.1128/IAI.69.8.4749-4758.2001
   Seles S, 2007, KLIN MONATSBL AUGENH, V224, P606, DOI 10.1055/s-2007-963338
   Shah GK, 2000, OPHTHALMOLOGY, V107, P486, DOI 10.1016/S0161-6420(99)00139-6
   Shamsuddin N, 2011, J IMMUNOL, V186, P7089, DOI 10.4049/jimmunol.1100565
   Shankar N, 2004, INT J MED MICROBIOL, V293, P609, DOI 10.1078/1438-4221-00301
   Sharifi E, 2009, OPHTHALMOLOGY, V116, P1887, DOI 10.1016/j.ophtha.2009.03.014
   Shirodkar AR, 2010, CLIN OPHTHALMOL, V4, P211
   SINGH KP, 1992, IMMUNOPHARM IMMUNOT, V14, P79, DOI 10.3109/08923979209009214
   Sinha P, 1999, IMMUNOL LETT, V67, P157, DOI 10.1016/S0165-2478(98)00187-4
   Slamti L, 2002, EMBO J, V21, P4550, DOI 10.1093/emboj/cdf450
   SMITH MA, 1991, ANTIMICROB AGENTS CH, V35, P1298, DOI 10.1128/AAC.35.7.1298
   Smith Stephen R., 2007, International Ophthalmology Clinics, V47, P173, DOI 10.1097/IIO.0b013e31803778f7
   Sonenshein AL, 2007, NAT REV MICROBIOL, V5, P917, DOI 10.1038/nrmicro1772
   Sonenshein AL, 2005, CURR OPIN MICROBIOL, V8, P203, DOI 10.1016/j.mib.2005.01.001
   Song ZM, 2005, J EXP MED, V201, P755, DOI 10.1084/jem.20040429
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Strober W, 2010, NAT MED, V16, P1195, DOI 10.1038/nm1110-1195
   Suzuki T, 2008, J CATARACT REFR SURG, V34, P1776, DOI 10.1016/j.jcrs.2008.06.033
   Suzuki T, 2011, INVEST OPHTH VIS SCI, V52, P3187, DOI 10.1167/iovs.10-6558
   Taban M, 2005, ARCH OPHTHALMOL-CHIC, V123, P613, DOI 10.1001/archopht.123.5.613
   Tang CW, 2007, CAN J OPHTHALMOL, V42, P477, DOI 10.3129/i07-057
   Taylor AW, 2009, EYE, V23, P1885, DOI 10.1038/eye.2008.382
   TAYLOR AW, 1992, CURR EYE RES, V11, P1199, DOI 10.3109/02713689208999545
   Taylor AW, 2005, J NEUROIMMUNOL, V162, P43, DOI 10.1016/j.jneuroim.2005.01.008
   Tegmark K, 2000, MOL MICROBIOL, V37, P398, DOI 10.1046/j.1365-2958.2000.02003.x
   Tenover FC, 2006, J CLIN MICROBIOL, V44, P108, DOI 10.1128/JCM.44.1.108-118.2006
   Thomas VC, 2008, J BACTERIOL, V190, P5690, DOI 10.1128/JB.00314-08
   THOMPSON JT, 1993, OPHTHALMOLOGY, V100, P1468
   THOMPSON WS, 1995, OPHTHALMOLOGY, V102, P1696
   Thurlow LR, 2010, INFECT IMMUN, V78, P4936, DOI 10.1128/IAI.01118-09
   TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167, DOI 10.1128/IAI.61.10.4167-4172.1993
   Tweten RK, 2005, INFECT IMMUN, V73, P6199, DOI 10.1128/IAI.73.10.6199-6209.2005
   Uchiyama S, 2009, J EXP MED, V206, P1845, DOI 10.1084/jem.20090386
   van de Beek D, 2009, MED MALADIES INFECT, V39, P531, DOI 10.1016/j.medmal.2009.02.033
   Vandersteegen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024418
   Villari P, 2000, J CLIN MICROBIOL, V38, P1740, DOI 10.1128/JCM.38.5.1740-1746.2000
   Vuong C, 2004, CELL MICROBIOL, V6, P753, DOI 10.1111/j.1462-5822.2004.00401.x
   Vuong C, 2000, J INFECT DIS, V182, P1688, DOI 10.1086/317606
   WAKEFIELD D, 1990, ARCH OPHTHALMOL-CHIC, V108, P219, DOI 10.1001/archopht.1990.01070040071033
   WALEV I, 1993, INFECT IMMUN, V61, P4972, DOI 10.1128/IAI.61.12.4972-4979.1993
   Wang R, 2007, NAT MED, V13, P1510, DOI 10.1038/nm1656
   Wejde G, 2005, ACTA OPHTHALMOL SCAN, V83, P7, DOI 10.1111/j.1600-0420.2005.00377.x
   West ES, 2005, OPHTHALMOLOGY, V112, P1388, DOI 10.1016/j.ophtha.2005.02.028
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   Wiskur BJ, 2008, INVEST OPHTH VIS SCI, V49, P1480, DOI 10.1167/iovs.07-1303
   Witzenrath M, 2009, CRIT CARE MED, V37, P642, DOI 10.1097/CCM.0b013e31819586a6
   Wright JS, 2005, P NATL ACAD SCI USA, V102, P1691, DOI 10.1073/pnas.0407661102
   Wu PC, 2006, J OCUL PHARMACOL TH, V22, P54, DOI 10.1089/jop.2006.22.54
   Wykoff CC, 2010, AM J OPHTHALMOL, V150, P392, DOI 10.1016/j.ajo.2010.04.010
   Xu KD, 2000, MICROBIOL-UK, V146, P547, DOI 10.1099/00221287-146-3-547
   Yanagihori H, 2006, J INVEST DERMATOL, V126, P1534, DOI 10.1038/sj.jid.5700203
   Yarwood JM, 2004, J BACTERIOL, V186, P1838, DOI 10.1128/JB.186.6.1838-1850.2004
   Yildirim O, 2002, OPHTHALMIC RES, V34, P349, DOI 10.1159/000067047
   Yoshida J, 2010, J CATARACT REFR SURG, V36, P1499, DOI 10.1016/j.jcrs.2010.04.030
   Yu-Wai-Man P, 2008, J CATARACT REFR SURG, V34, P447, DOI 10.1016/j.jcrs.2007.10.041
   Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2
   Zhang KY, 2009, ANTIMICROB AGENTS CH, V53, P531, DOI 10.1128/AAC.01118-08
NR 253
TC 50
Z9 55
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2012
VL 31
IS 4
BP 316
EP 331
DI 10.1016/j.preteyeres.2012.03.004
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 960IF
UT WOS:000305380500003
PM 22521570
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Woronkowicz, M
   Skopinski, P
AF Woronkowicz, Malgorzata
   Skopinski, Piotr
TI Embryonic stem cells and retinal regeneration
SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Review
DE embryonic stem cells; retina; RPE; photoreceptors; ganglion cells;
   regenerative medicine
ID IN-VITRO; PIGMENT EPITHELIUM; VISUAL FUNCTION; ES CELLS;
   DIFFERENTIATION; MOUSE; RPE; GENERATION; PRECURSORS; SURVIVAL
AB The potential of embryonic stem cells (ESCs) to differentiate into various cell types make them prime candidates to play an important role in the future of regenerative medicine. A wide range of retinal degenerative diseases which are the leading cause of irreversible blindness worldwide may be potentially treated by stem cell therapies. Common retinal neurodegenerative pathologies mainly affect one of three ocular cell types: ganglion cells (e.g. glaucoma), photoreceptors (e.g. retinitis pigmentosa) and retinal pigment epithelium (RPE) cells (e.g. age-related macular degeneration). This article summarizes the latest advances made in embryonic stem cell-based medicine for retinal diseases and presents some obstacles which need to be overcome before ESCs can be used safely and effectively.
C1 [Skopinski, Piotr] Med Univ Warsaw, Ctr Biostruct Res, Dept Histol & Embryol, PL-02004 Warsaw, Poland.
   [Woronkowicz, Malgorzata] Med Univ Warsaw, Dept Ophthalmol, Fac Med 2, PL-02004 Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw
RP Skopinski, P (通讯作者)，Med Univ Warsaw, Ctr Biostruct Res, Dept Histol & Embryol, Chalubinskiego 5, PL-02004 Warsaw, Poland.
EM pskopin@wp.pl
OI Skopinski, Piotr/0000-0001-5794-9346
CR Aoki H, 2006, EXP EYE RES, V82, P265, DOI 10.1016/j.exer.2005.06.021
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bi YY, 2009, NEUROSCI RES, V65, P215, DOI 10.1016/j.neures.2009.07.008
   Blum B, 2009, NAT BIOTECHNOL, V27, P281, DOI 10.1038/nbt.1527
   Canham MA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000379
   Carr AJ, 2009, MOL VIS, V15, P283
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007-0576
   Cohen AR, 2010, NAT METHODS, V7, P213, DOI [10.1038/NMETH.1424, 10.1038/nmeth.1424]
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hara A, 2010, NEUROSCI LETT, V477, P138, DOI 10.1016/j.neulet.2010.04.050
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jagatha B, 2009, BIOCHEM BIOPH RES CO, V380, P230, DOI 10.1016/j.bbrc.2009.01.038
   Kayama M, 2010, OPHTHALMIC RES, V43, P79, DOI 10.1159/000247592
   Klassen H, 2004, PROG RETIN EYE RES, V23, P149, DOI 10.1016/j.preteyeres.2004.01.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Limb GA, 2008, BRIT MED BULL, V85, P47, DOI 10.1093/bmb/ldn008
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Pressmar S, 2001, INVEST OPHTH VIS SCI, V42, P3311
   Rodin S, 2010, NAT BIOTECHNOL, V28, P611, DOI 10.1038/nbt.1620
   Sugie Y, 2005, BIOCHEM BIOPH RES CO, V332, P241, DOI 10.1016/j.bbrc.2005.04.125
   Tabata Y, 2004, MOL CELL BIOL, V24, P4513, DOI 10.1128/MCB.24.10.4513-4521.2004
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Yang HD, 2002, J COMP NEUROL, V443, P275, DOI 10.1002/cne.10116
   Yu D, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E10
   Yue FM, 2010, BIOCHEM BIOPH RES CO, V394, P877, DOI 10.1016/j.bbrc.2010.03.008
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zhao Xing, 2006, V330, P401
NR 42
TC 1
Z9 1
U1 0
U2 4
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1426-3912
EI 1644-4124
J9 CENT EUR J IMMUNOL
JI Central Eur. J. Immunol.
PY 2010
VL 35
IS 4
BP 267
EP 272
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 729ZD
UT WOS:000287992300018
DA 2022-11-30
ER

PT J
AU Bordet, T
   Behar-Cohen, F
AF Bordet, Thierry
   Behar-Cohen, Francine
TI Ocular gene therapies in clinical practice: viral vectors and nonviral
   alternatives
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID LEBER CONGENITAL AMAUROSIS; IN-VIVO; ADENOASSOCIATED VIRUS; MACULAR
   DEGENERATION; RETINAL DEGENERATION; DNA NANOPARTICLES; RPE65 MUTATIONS;
   INTRAVITREOUS INJECTION; SUBRETINAL INJECTION; LIPID NANOPARTICLES
AB Ocular gene therapy has entered into clinical practice. Although viral vectors are currently the best option to replace and/or correct genes, the optimal method to deliver these treatments to the retinal pigment epithelial (RPE) cells and/or photoreceptor cells remains to be improved to increase transduction efficacy and reduce iatrogenic risks. Beyond viral-mediated gene replacement therapies, nonviral gene delivery approaches offer the promise of sustained fine-tuned expression of secreted therapeutic proteins that can be adapted to the evolving stage of the disease course and can address more common nongenetic retinal diseases, such as age-related macular degeneration (AMD). Here, we review current gene therapy strategies for ocular diseases, with a focus on clinical stage products.
C1 [Bordet, Thierry] Eyevensys SAS, Paris, France.
   [Behar-Cohen, Francine] INSERM, UMR S 1138, Ctr Rech Cordeliers, Team 17, Paris, France.
   [Behar-Cohen, Francine] Ophtalmopole Hop Cochin, Hop Paris, AP HP, Paris, France.
   [Behar-Cohen, Francine] Univ Paris 06, Sorbonne Univ, UMR S 1138, Ctr Rech Cordeliers, Paris, France.
   [Behar-Cohen, Francine] Paris Descartes Univ, Sorbonne Paris Cite, UMR S 1138, Ctr Rech Cordeliers, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French
   Research Universities; Universite Paris Cite; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite
RP Behar-Cohen, F (通讯作者)，INSERM, UMR S 1138, Ctr Rech Cordeliers, Team 17, Paris, France.; Behar-Cohen, F (通讯作者)，Ophtalmopole Hop Cochin, Hop Paris, AP HP, Paris, France.; Behar-Cohen, F (通讯作者)，Univ Paris 06, Sorbonne Univ, UMR S 1138, Ctr Rech Cordeliers, Paris, France.; Behar-Cohen, F (通讯作者)，Paris Descartes Univ, Sorbonne Paris Cite, UMR S 1138, Ctr Rech Cordeliers, Paris, France.
EM Francine.behar@gmail.com
RI BORDET, THIERRY/AIA-7041-2022
OI BORDET, THIERRY/0000-0002-3648-2270; behar cohen,
   francine/0000-0001-8571-9513
CR Adijanto J, 2015, EUR J PHARM BIOPHARM, V95, P353, DOI 10.1016/j.ejpb.2014.12.028
   Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andrieu-Soler C, 2007, MOL VIS, V13, P692
   [Anonymous], 2018, NAT BIOTECHNOL, V36, P6, DOI 10.1038/nbt0118-6a
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Batabyal S, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.6.060504
   Battaglia L, 2016, EXPERT OPIN DRUG DEL, V13, P1743, DOI 10.1080/17425247.2016.1201059
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Binley K, 2013, INVEST OPHTH VIS SCI, V54, P4061, DOI 10.1167/iovs.13-11871
   Bloquel C, 2006, FASEB J, V20, P389, DOI 10.1096/fj.05-4737fje
   Calip GS, 2018, INT J CANCER, V143, P1062, DOI 10.1002/ijc.31407
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cervia LD, 2018, MOL PHARMACEUT, V15, P3617, DOI 10.1021/acs.molpharmaceut.8b00207
   Cervia LD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171699
   Chalberg TW, 2006, INVEST OPHTH VIS SCI, V47, P4083, DOI 10.1167/iovs.06-0092
   Chen X, 2008, MOL THER, V16, P333, DOI 10.1038/sj.mt.6300365
   Cideciyan AV, 2019, NAT MED, V25, P225, DOI 10.1038/s41591-018-0295-0
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Clement N, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.2
   Czugala M, 2016, NANOMEDICINE-UK, V11, P1787, DOI 10.2217/nnm-2016-0144
   DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637
   Dezawa M, 2002, MICRON, V33, P1, DOI 10.1016/S0968-4328(01)00002-6
   Dick AD, 2017, EYE, V31, P87, DOI 10.1038/eye.2016.177
   Dismuke DJ, 2013, CURR GENE THER, V13, P434
   El Sanharawi M, 2013, GENE THER, V20, P1093, DOI 10.1038/gt.2013.36
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   EMA, 2015, EMA
   Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916
   Garweg JG, 2016, OPHTHALMOLOGE, V113, P1036, DOI 10.1007/s00347-016-0306-9
   Grieger JC, 2005, J VIROL, V79, P9933, DOI 10.1128/JVI.79.15.9933-9944.2005
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Gruter O, 2005, GENE THER, V12, P942, DOI 10.1038/sj.gt.3302485
   Han ZC, 2012, NANOMEDICINE-UK, V7, P521, DOI [10.2217/nnm.11.158, 10.2217/NNM.11.158]
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Johnson CJ, 2008, MOL VIS, V14, P2211
   Kaemmerer WF, 2018, BIOENG TRANSL MED, V3, P166, DOI 10.1002/btm2.10090
   Kay C, 2017, RETINA SPECIALIST
   Kelley RA, 2018, INT J NANOMED, V13, P1361, DOI 10.2147/IJN.S157000
   Koirala A, 2014, ADV EXP MED BIOL, V801, P703, DOI 10.1007/978-1-4614-3209-8_88
   Koirala A, 2013, HUM MOL GENET, V22, P1632, DOI 10.1093/hmg/ddt013
   Kowalczuk L, 2009, INVEST OPHTH VIS SCI, V50, P1761, DOI 10.1167/iovs.08-3027
   Lambricht L, 2016, EXPERT OPIN DRUG DEL, V13, P295, DOI 10.1517/17425247.2016.1121990
   LI TS, 1994, INVEST OPHTH VIS SCI, V35, P2543
   Lopes VS, 2013, GENE THER, V20, P824, DOI 10.1038/gt.2013.3
   Maddalena A, 2018, MOL THER, V26, P524, DOI 10.1016/j.ymthe.2017.11.019
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Masse F, 2019, MED RES REV, V39, P302, DOI 10.1002/med.21509
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nickerson JM, 2014, METHODS MOL BIOL, V1121, P165, DOI 10.1007/978-1-4614-9632-8_15
   Oliveira AV, 2017, MAT SCI ENG C-MATER, V77, P1275, DOI 10.1016/j.msec.2017.04.068
   Picard E, 2015, FREE RADICAL BIO MED, V89, P1105, DOI 10.1016/j.freeradbiomed.2015.08.018
   Nguyen QD, 2016, LANCET, V388, P1183, DOI 10.1016/S0140-6736(16)31339-3
   Ramachandran PS, 2017, HUM GENE THER, V28, P154, DOI 10.1089/hum.2016.111
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosazza C, 2016, CURR GENE THER, V16, P98, DOI 10.2174/1566523216666160331130040
   Rosazza C, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2015.59
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sersa G, 2015, CANCER IMMUNOL IMMUN, V64, P1315, DOI 10.1007/s00262-015-1724-2
   Sharma A, 2011, NANOMED-NANOTECHNOL, V7, P505, DOI 10.1016/j.nano.2011.01.006
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Smith D.C, 2017, DRUG DEV DELIV
   Souied EH, 2008, EXP EYE RES, V87, P168, DOI 10.1016/j.exer.2008.04.009
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Touchard E, 2012, GENE THER, V19, P886, DOI 10.1038/gt.2011.154
   Touchard E, 2009, GENE THER, V16, P862, DOI 10.1038/gt.2009.43
   Touchard E, 2018, J CONTROL RELEASE, V285, P244, DOI 10.1016/j.jconrel.2018.07.013
   Touchard E, 2012, MOL THER, V20, P1559, DOI 10.1038/mt.2011.304
   Touchard E, 2010, J GENE MED, V12, P904, DOI 10.1002/jgm.1517
   Trapani I, 2018, TRENDS MOL MED, V24, P669, DOI 10.1016/j.molmed.2018.06.006
   Trapani I, 2014, PROG RETIN EYE RES, V43, P108, DOI 10.1016/j.preteyeres.2014.08.001
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Tsourounis M, 2015, THER INNOV REGUL SCI, V49, P239, DOI 10.1177/2168479014553033
   Wan CF, 2015, MOL MED REP, V12, P4803, DOI 10.3892/mmr.2015.4054
   Wang YH, 2015, J FUNCT BIOMATER, V6, P379, DOI 10.3390/jfb6020379
   Zulliger R, 2015, J CONTROL RELEASE, V219, P471, DOI 10.1016/j.jconrel.2015.10.007
NR 88
TC 42
Z9 44
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2019
VL 24
IS 8
SI SI
BP 1685
EP 1693
DI 10.1016/j.drudis.2019.05.038
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IX7GP
UT WOS:000485852100029
PM 31173914
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Huang, YM
   Enzmann, V
   Ildstad, ST
AF Huang, Yiming
   Enzmann, Volker
   Ildstad, Suzanne T.
TI Stem Cell-Based Therapeutic Applications in Retinal Degenerative
   Diseases
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Retinal degeneration; Stem cells; Regeneration
ID MARROW STROMAL CELLS; PIGMENT EPITHELIAL-CELLS; REGULATORY T-CELLS;
   PROGENITOR CELLS; MACULAR DEGENERATION; FACILITATING CELLS; IN-VITRO;
   SUBRETINAL NEOVASCULARIZATION; DIRECTED DIFFERENTIATION; NEURAL
   PROGENITORS
AB Retinal degenerative diseases that target photoreceptors or the adjacent retinal pigment epithelium (RPE) affect millions of people worldwide. Retinal degeneration (RD) is found in many different forms of retinal diseases including retinitis pigmentosa (RP), age-related macular degeneration (AMD), diabetic retinopathy, cataracts, and glaucoma. Effective treatment for retinal degeneration has been widely investigated. Gene-replacement therapy has been shown to improve visual function in inherited retinal disease. However, this treatment was less effective with advanced disease. Stem cell-based therapy is being pursued as a potential alternative approach in the treatment of retinal degenerative diseases. In this review, we will focus on stem cell-based therapies in the pipeline and summarize progress in treatment of retinal degenerative disease.
C1 [Huang, Yiming; Ildstad, Suzanne T.] Univ Louisville, Inst Cellular Therapeut, Louisville, KY 40202 USA.
   [Enzmann, Volker] Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Louisville; University of Bern; University Hospital of
   Bern
RP Ildstad, ST (通讯作者)，Univ Louisville, Inst Cellular Therapeut, 570 S Preston St,Suite 404, Louisville, KY 40202 USA.
EM suzanne.ildstad@louisville.edu
OI Enzmann, Volker/0000-0003-4384-4855
FU NIH [R01 DK069766]; Commonwealth of Kentucky Research Challenge Trust;
   W. M. Keck Foundation; Jewish Hospital Foundation; Swiss National
   Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [R01DK069766] Funding Source: NIH RePORTER
FX The authors thank Haval Shirwan, Larry Bozulic, and Deborah Ramsey for
   review of the manuscript and helpful comments; Carolyn DeLautre for
   manuscript preparation. This work was supported in part by the
   following: NIH R01 DK069766. This publication was also made possible by
   the Commonwealth of Kentucky Research Challenge Trust Fund; the W. M.
   Keck Foundation; The Jewish Hospital Foundation; and the Swiss National
   Science Foundation.
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abmad I, 2001, INVEST OPHTH VIS SCI, V42, P2743
   Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P
   Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439
   ARAMANT RB, 1994, CELL TRANSPLANT, V3, P461, DOI 10.1177/096368979400300603
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534
   BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brownstein Z, 2004, PEDIATR RES, V55, P995, DOI 10.1203/01.PDR.0000125258.58267.56
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034
   Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035
   Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Colson YL, 2004, BLOOD, V104, P3829, DOI 10.1182/blood-2004-01-0393
   Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330
   Dawn B, 2006, CIRC RES, V98, P1098, DOI 10.1161/01.RES.0000218454.76784.66
   DCRUZ PM, 2009, HUM MOL GENET, V9, P645
   Dharmaraj S R, 2000, Ophthalmic Genet, V21, P135
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Dong X, 2003, NEUROREPORT, V14, P143, DOI 10.1097/00001756-200301200-00026
   ELDIRINI AA, 1991, RETINA-J RET VIT DIS, V11, P244, DOI 10.1097/00006982-199111020-00010
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Enzmann V, 2003, INVEST OPHTH VIS SCI, V44, P5417, DOI 10.1167/iovs.03-0468
   FRANK RN, 1989, CURR EYE RES, V8, P239, DOI 10.3109/02713688908997565
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Friedlander Martin, 2007, Angiogenesis, V10, P89, DOI 10.1007/s10456-007-9070-4
   Fugier-Vivier IJ, 2005, J EXP MED, V201, P373, DOI 10.1084/jem.20041399
   Gaillard F, 2007, VISION RES, V47, P2815, DOI 10.1016/j.visres.2007.06.018
   Gandy KL, 1999, IMMUNITY, V11, P579, DOI 10.1016/S1074-7613(00)80133-8
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Grimes HL, 2004, EXP HEMATOL, V32, P946, DOI 10.1016/j.exphem.2004.07.011
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
   Huang YM, 2008, DIABETES, V57, pA542
   Huang YM, 2010, TRANSPLANTATION, V89, P677, DOI 10.1097/TP.0b013e3181c9dc7d
   Huang YM, 2004, BLOOD, V104, P873, DOI 10.1182/blood-2003-11-3910
   Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   JOBST K, 1967, NEOPLASMA, V14, P435
   Karnieli O, 2007, STEM CELLS, V25, P2837, DOI 10.1634/stemcells.2007-0164
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kucia M, 2007, LEUKEMIA, V21, P297, DOI 10.1038/sj.leu.2404470
   Kucia M, 2006, LEUKEMIA, V20, P857, DOI 10.1038/sj.leu.2404171
   Kucia MJ, 2008, STEM CELLS, V26, P2083, DOI 10.1634/stemcells.2007-0922
   Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3
   Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   Liu SY, 1998, ARCH BIOCHEM BIOPHYS, V357, P37, DOI 10.1006/abbi.1998.0817
   LIU Y, 2009, EXPT HEMATOLOGY, V37
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Marano RJ, 2006, BIOTECH HISTOCHEM, V81, P59, DOI 10.1080/10520290600799131
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Martinat C, 2006, P NATL ACAD SCI USA, V103, P2874, DOI 10.1073/pnas.0511153103
   Merhi-Soussi F, 2006, STEM CELLS, V24, P2060, DOI 10.1634/stemcells.2005-0311
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nagar S, 2009, NEUROSCIENCE, V160, P517, DOI 10.1016/j.neuroscience.2009.02.056
   Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Neipp M, 1998, BLOOD, V92, P3177, DOI 10.1182/blood.V92.9.3177.421k51_3177_3188
   NOELL WK, 1953, AM J OPHTHALMOL, V36, P103, DOI 10.1016/0002-9394(53)90159-7
   OHKUMA H, 1982, JPN J OPHTHALMOL, V26, P150
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Paczkowska E, 2009, STROKE, V40, P1237, DOI 10.1161/STROKEAHA.108.535062
   PARYSEK LM, 1985, NEUROSCIENCE, V15, P869, DOI 10.1016/0306-4522(85)90084-3
   Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906
   Puzio-Kuter AM, 2009, NAT BIOTECHNOL, V27, P914, DOI 10.1038/nbt1009-914
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Reh TA, 1998, J NEUROBIOL, V36, P206, DOI 10.1002/(SICI)1097-4695(199808)36:2<206::AID-NEU8>3.0.CO;2-5
   Reh TA, 2006, NATURE, V444, P156, DOI 10.1038/444156a
   Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezzoug F, 2008, J IMMUNOL, V180, P49, DOI 10.4049/jimmunol.180.1.49
   Samadikuchaksaraei A, 2006, TISSUE ENG, V12, P867, DOI 10.1089/ten.2006.12.867
   Sanganalmath SK, 2009, J MOL CELL CARDIOL, V47, P528, DOI 10.1016/j.yjmcc.2009.07.009
   SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110
   Schuchert MJ, 2000, NAT MED, V6, P904, DOI 10.1038/78667
   Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7
   Shimazaki T, 2003, HORM RES, V60, P1, DOI 10.1159/000074492
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Shirahashi H, 2004, CELL TRANSPLANT, V13, P197, DOI 10.3727/000000004783984016
   Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157
   Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taylor KN, 2007, J IMMUNOL, V179, P2153, DOI 10.4049/jimmunol.179.4.2153
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Virchow R., 1855, ARCH PATHOLOGISCHE A, V8, P23
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Westerfeld Corey, 2008, Semin Ophthalmol, V23, P59, DOI 10.1080/08820530701745249
   Wojakowski W, 2009, J AM COLL CARDIOL, V53, P1, DOI 10.1016/j.jacc.2008.09.029
   Xu WR, 2004, EXP BIOL MED, V229, P623, DOI 10.1177/153537020422900706
   Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zhao Xing, 2006, V330, P401
   Zuba-Surma EK, 2008, J MOL CELL CARDIOL, V44, P865, DOI 10.1016/j.yjmcc.2008.02.279
NR 146
TC 63
Z9 74
U1 0
U2 34
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD JUN
PY 2011
VL 7
IS 2
BP 434
EP 445
DI 10.1007/s12015-010-9192-8
PG 12
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 747CJ
UT WOS:000289297600019
PM 20859770
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Kitzmann, AS
AF Bakri, Sophie J.
   Kitzmann, Anna S.
TI Retinal pigment epithelial tear after intravitreal ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB AVASTIN
AB PURPOSE: To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal injection of 0.05 mg ranibizumab.
   DESIGN: Observational case report.
   METHODS: Two patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD) were treated with an intravitreal injection of ranibizumab.
   RESULTS: Both patients were found to have a RPE tear on follow-up visits at one month, confirmed by optical coherence tomography (OCT) and by fluorescein or indocyanine green angiography.
   CONCLUSIONS: RPE tears may occur after intravitreal injection of ranibizumab. Further study is needed to determine whether CNV membranes associated with pigment epithelial detachments (PED) are more likely to develop RPE tears after treatment with anti-vascular endothelial growth factor (anti-VEGF) agents.
C1 Mayo Clin, Coll Med, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Coll Med, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 7
TC 53
Z9 60
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2007
VL 143
IS 3
BP 505
EP 507
DI 10.1016/j.ajo.2006.11.047
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141CZ
UT WOS:000244555700019
PM 17317396
DA 2022-11-30
ER

PT J
AU Ji, YG
   Shi, HF
AF Ji, Yonggang
   Shi, Haifang
TI Constrained Bayesian doubly elastic net Lasso for linear quantile mixed
   models
SO JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION
LA English
DT Article
DE Linear quantile mixed regression; Cholesky decomposition; Bayesian
   elastic net; partially collapsed Gibbs sampling
ID RANDOM EFFECTS SELECTION; LONGITUDINAL DATA; REGRESSION-MODEL
AB In this article, we propose a novel constrained Bayesian elastic net approach for linear quantile mixed model shrinkage. A partially collapsed Gibbs sampling algorithm is developed for efficient posterior computation based on a modified Cholesky decomposition for the covariance matrix of random effects and an asymmetric Laplace distribution for the error distribution. We demonstrate the proposed method based on simulated data and an experimental dataset from a longitudinal study of age-related macular degeneration trial. Both simulation studies and real data analysis indicate that the proposed constrained Bayesian elastic net approach is competitive with the existing methods under a variety of scenarios, such as presence of a large number of covariates and collinearity.
C1 [Ji, Yonggang; Shi, Haifang] Civil Aviat Univ China, Sch Sci, Tianjin, Peoples R China.
C3 Civil Aviation University of China
RP Ji, YG (通讯作者)，Civil Aviat Univ China, Sch Sci, Tianjin, Peoples R China.
EM ygji@cauc.edu.cn
OI Shi, Haifang/0000-0001-9486-9572; Ji, YongGang/0000-0002-5912-8231
FU Scientific Research Start-up Foundation of the Civil Aviation University
   of China [2012QD09X]; Fundamental Research Funds for the Central
   Universities [3122014K013]
FX The first author was supported by the Scientific Research Start-up
   Foundation of the Civil Aviation University of China [grant number
   2012QD09X]. The second author was supported by the Fundamental Research
   Funds for the Central Universities [grant number 3122014K013].
CR Aghamohammadi A, 2017, STAT PAP, V58, P1035, DOI 10.1007/s00362-015-0737-4
   Alhamzawi R, 2014, J STAT COMPUT SIM, V84, P868, DOI 10.1080/00949655.2012.731689
   Alshaybawee T, 2017, J APPL STAT, V44, P853, DOI 10.1080/02664763.2016.1189515
   ANDREWS DF, 1974, J ROY STAT SOC B MET, V36, P99
   Bondell HD, 2010, BIOMETRICS, V66, P1069, DOI 10.1111/j.1541-0420.2010.01391.x
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Chen Z, 2003, BIOMETRICS, V59, P762, DOI 10.1111/j.0006-341X.2003.00089.x
   Chernozhukov V, 2013, ECONOMETRICA, V81, P535, DOI 10.3982/ECTA8405
   Diggle P., 2002, J AM STAT ASSOC, V90, DOI DOI 10.2307/2983303
   Du YT, 2013, CAN J STAT, V41, P596, DOI 10.1002/cjs.11192
   Galarza CE, 2017, STAT INTERFACE, V10, P471, DOI 10.4310/SII.2017.v10.n3.a10
   Galecki A, 2013, SPRINGER TEXTS STAT, P245, DOI 10.1007/978-1-4614-3900-4_13
   Geraci M, 2007, BIOSTATISTICS, V8, P140, DOI 10.1093/biostatistics/kxj039
   Geraci M, 2014, STAT COMPUT, V24, P461, DOI 10.1007/s11222-013-9381-9
   Harding M, 2014, J ECONOMETRICS, V178, P101, DOI 10.1016/j.jeconom.2013.08.010
   Kinney SK, 2007, BIOMETRICS, V63, P690, DOI 10.1111/j.1541-0420.2007.00771.x
   Koenker R, 2004, J MULTIVARIATE ANAL, V91, P74, DOI 10.1016/j.jmva.2004.05.006
   Kozumi H, 2011, J STAT COMPUT SIM, V81, P1565, DOI 10.1080/00949655.2010.496117
   Li Q, 2010, BAYESIAN ANAL, V5, P151, DOI 10.1214/10-BA506
   Lipsitz SR, 1997, J R STAT SOC C-APPL, V46, P463, DOI 10.1111/1467-9876.00084
   Lu Y., 2015, J MACH LEARN RES, V44, P277
   Peng H, 2012, J MULTIVARIATE ANAL, V109, P109, DOI 10.1016/j.jmva.2012.02.005
   Powell J, 2016, 21034 NBER
   Seber G.A.F., 1977, LINEAR REGRESSION AN
   Sriram K, 2016, J R STAT SOC A STAT, V179, P177, DOI 10.1111/rssa.12111
   Xu PR, 2015, STAT BIOSCI, V7, P108, DOI 10.1007/s12561-013-9105-x
   Yu KM, 2005, COMMUN STAT-THEOR M, V34, P1867, DOI 10.1080/03610920500199018
   Yu KM, 2001, STAT PROBABIL LETT, V54, P437, DOI 10.1016/S0167-7152(01)00124-9
   Yuan XH, 2017, SCI CHINA MATH, V60, P147, DOI 10.1007/s11425-015-0175-y
   Zou H, 2008, ANN STAT, V36, P1108, DOI 10.1214/07-AOS507
NR 30
TC 0
Z9 0
U1 5
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0094-9655
EI 1563-5163
J9 J STAT COMPUT SIM
JI J. Stat. Comput. Simul.
PD FEB 11
PY 2022
VL 92
IS 3
BP 579
EP 609
DI 10.1080/00949655.2021.1968398
EA AUG 2021
PG 31
WC Computer Science, Interdisciplinary Applications; Statistics &
   Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematics
GA YJ2BT
UT WOS:000690328300001
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Green, C
   Goodfellow, J
   Kubie, J
AF Green, Catherine
   Goodfellow, Jonathan
   Kubie, Jessica
TI Eye care in the elderly
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
DE eye diseases; aged
ID BLUE MOUNTAINS EYE; NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; ELECTRONIC
   MULTICENTER AUDIT; COMMUNITY SUPPORT SERVICES; VISUAL IMPAIRMENT;
   AUSTRALIAN POPULATION; VISION LOSS; CATARACT; HEALTH
AB Background
   Eye disease and visual impairment are common in the elderly and are associated with social and functional decline, the need to access community support services, depression, falls, nursing home placement and increased mortality.
   Objective
   To provide guidance for general practitioners in the detection and recommended management of the most important eye conditions in the elderly in Australia: refractive error, cataract, diabetic retinopathy, age-related macular degeneration and glaucoma.
   Discussion
   Timely detection and treatment of eye disease can greatly reduce its morbidity. Elderly patients should be encouraged to undergo eye testing every 2 years. Health professionals, including general practitioners, optometrists and ophthalmologists should work collaboratively to ensure patients have access to appropriate disease detection and treatment.
C1 [Green, Catherine] Royal Victorian Eye & Ear Hosp, Glaucoma Unit, Melbourne, Vic, Australia.
   [Green, Catherine] Univ Melbourne, Ctr Eye Res, Melbourne, Vic 3010, Australia.
   [Goodfellow, Jonathan] Torbay Hosp, Torquay, Devon, England.
   [Kubie, Jessica] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.
C3 Royal Victorian Eye & Ear Hospital; University of Melbourne; University
   of Exeter
RP Green, C (通讯作者)，Royal Victorian Eye & Ear Hosp, Glaucoma Unit, Melbourne, Vic, Australia.
EM seagreen@bigpond.com
FU HCA International Foundation
FX Jonathan Goodfellow acknowledges financial assistance from HCA
   International Foundation in supporting his fellowship training.
CR Age-Related Eye Disease Study Research Group, 8 AG REL EYE DIS STU
   Benzimra JD, 2009, EYE, V23, P10, DOI 10.1038/sj.eye.6703069
   CAMPBELL A J, 1981, Age and Ageing, V10, P264, DOI 10.1093/ageing/10.4.264
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   El-Hindy N, 2009, EYE, V23, P50, DOI 10.1038/sj.eye.6703031
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JACK CIA, 1995, GERONTOLOGY, V41, P280
   Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   National Health and Medical Research Council, GUID MAN DIAB RET
   Owsley C, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.118547
   Owsley C, 2007, ARCH OPHTHALMOL-CHIC, V125, P1471, DOI 10.1001/archopht.125.11.1471
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Stratton IM, 2006, DIABETOLOGIA, V49, P1761, DOI 10.1007/s00125-006-0297-1
   Tapp RJ, 2003, DIABETES CARE, V26, P1731, DOI 10.2337/diacare.26.6.1731
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang JJ, 1999, AUST NZ J PUBL HEAL, V23, P147, DOI 10.1111/j.1467-842X.1999.tb01225.x
NR 26
TC 9
Z9 11
U1 0
U2 9
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD JUL
PY 2014
VL 43
IS 7
BP 447
EP 450
PG 4
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AS0DH
UT WOS:000343948100012
PM 25006605
DA 2022-11-30
ER

PT J
AU Acton, JH
   Greenstein, VC
AF Acton, Jennifer H.
   Greenstein, Vivienne C.
TI Fundus-driven perimetry (microperimetry) compared to conventional static
   automated perimetry: similarities, differences, and clinical
   applications
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
ID SCANNING LASER OPHTHALMOSCOPE; ROD-CONE INTERACTION; RETINAL
   SENSITIVITY; MACULAR DEGENERATION; FUNCTIONAL-CHANGES; VISUAL-FIELD;
   NIDEK MP1; AUTOFLUORESCENCE; DISEASE; THICKNESS
AB Fundus-driven perimetry, commonly known as microperimetry, is a technique for measuring visual field sensitivity, whilst simultaneously viewing the fundus. In this article, we review the technique, focusing on the MP-1 microperimeter (Nidek Instruments, Inc, Padua, Italy); we compare it with conventional static automated perimetry, emphasizing the importance of understanding the effects of the different stimulus conditions and data analyses on the interpretation of microperimetry data. The clinical applications of the technique, in the evaluation of functional and structural changes that accompany retinal diseases, are illustrated by its use in patients with age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. In addition, the advantages and limitations of the technique are summarized.
C1 [Acton, Jennifer H.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
   [Greenstein, Vivienne C.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Greenstein, Vivienne C.] NYU, Dept Ophthalmol, New York, NY 10016 USA.
C3 Cardiff University; Columbia University; New York University
RP Acton, JH (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Maindy Rd, Cardiff CF24 4LU, S Glam, Wales.
EM jenniferhacton@gmail.com
RI Acton, Jennifer/AAU-3307-2021
OI Acton, Jennifer/0000-0002-0347-7651
FU National Institutes of Health [R01 EY02115, R01 EY09076]; NATIONAL EYE
   INSTITUTE [R01EY002115, R01EY009076] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants R01
   EY02115 and R01 EY09076.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Acton JH, 2012, OPTOMETRY VISION SCI, V89, P1050, DOI 10.1097/OPX.0b013e31825da18c
   Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   Bengtsson B, 1997, ACTA OPHTHALMOL SCAN, V75, P368
   Burke TR, 2011, INVEST OPHTH VIS SCI, V52, P8006, DOI 10.1167/iovs.11-7693
   Cappello E, 2009, RETINA-J RET VIT DIS, V29, P1111, DOI 10.1097/IAE.0b013e3181a3b832
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Crossland M.D., 2012, INVEST OPHTH VIS SCI, V53, P4822
   Finger RP, 2009, INVEST OPHTH VIS SCI, V50, P1366, DOI 10.1167/iovs.08-2032
   FRUMKES TE, 1973, VISION RES, V13, P1269, DOI 10.1016/0042-6989(73)90202-2
   GREENSTEIN VC, 1992, CLIN VISION SCI, V7, P1
   Greenstein VC, 2012, RETINA-J RET VIT DIS, V32, P349, DOI 10.1097/IAE.0b013e31821dfc17
   HOOD DC, 1990, VISION RES, V30, P51, DOI 10.1016/0042-6989(90)90127-7
   Hood DC, 2009, INVEST OPHTH VIS SCI, V50, P2328, DOI 10.1167/iovs.08-2936
   INATOMI A, 1979, DOC OPHTHALMOL P SER, V19, P359
   Johnson CA, 2011, OPTOMETRY VISION SCI, V88, pE8, DOI 10.1097/OPX.0b013e3182004c3b
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kani K, 1979, DOC OPHTHALMOL P SER, V19, P341
   Kani K., 1977, DOCUMENTA OPHTHALMOL, P231
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P84, DOI 10.1136/bjo.2007.124016
   Kriechbaum K, 2009, OPHTHALMOLOGY, V116, P2415, DOI 10.1016/j.ophtha.2009.05.001
   LATCH M, 1977, J PHYSIOL-LONDON, V269, P517, DOI 10.1113/jphysiol.1977.sp011912
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Popovic P, 2005, GRAEF ARCH CLIN EXP, V243, P1018, DOI 10.1007/s00417-005-1186-x
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Seiple W, 2011, OPTOMETRY VISION SCI, V89, P1182
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Varano M, 2010, RETINA-J RET VIT DIS, V30, P413, DOI 10.1097/IAE.0b013e3181bd2d23
   Wakabayashi T, 2010, ACTA OPHTHALMOL, V88, pE177, DOI 10.1111/j.1755-3768.2010.01926.x
   Woods RL, VIS 2008 MARCH 9 INT
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
NR 47
TC 36
Z9 37
U1 0
U2 10
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 358
EP 363
DI 10.1016/j.jcjo.2013.03.021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300018
PM 24093180
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, D
   Shah, V
   Rauck, BM
   Friberg, TR
   Wang, YD
AF Park, Daewon
   Shah, Veeral
   Rauck, Britta M.
   Friberg, Thomas R.
   Wang, Yadong
TI An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for
   Age-Related Wet Macular Degeneration
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE age-related wet macular degeneration; compatibility; hydrogels; retinal
   cells; sustained release
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; FACTOR THERAPY;
   PHARMACOKINETICS; BEVACKUMAB; COPOLYMER; SECONDARY; INJECTION
AB Reverse thermal gels have numerous biomedical implications, as they undergo physical gelation upon temperature increases and can incorporate biomolecules to promote tissue repair. Such a material is developed for the sustained release of bevacizumab (Avastin), a drug used to treat age-related macular degeneration. The polymer, poly(ethylene glycol)-poly(serinol hexamethylene urethane) (ESHU), forms a physical gel when heated to 37 degrees C and shows good cytocompatibility with ocular cells. ESHU is capable of sustaining bevacizumab release over 17weeks in vitro, and the release kinetics can be altered by changing the drug dose and the ESHU concentration. These results suggest that ESHU is biologically safe, and suitable for ocular drug delivery.
C1 [Park, Daewon] Univ Colorado Denver, Dept Bioengn, Aurora, CO 80045 USA.
   [Shah, Veeral; Friberg, Thomas R.] Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15219 USA.
   [Rauck, Britta M.; Wang, Yadong] Univ Pittsburgh, Dept Bioengn, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Wang, YD (通讯作者)，Univ Pittsburgh, Dept Bioengn, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.
EM yaw20@pitt.edu
RI Wang, Yadong/AAC-3381-2020; Park, Daewon/W-8128-2019
OI Wang, Yadong/0000-0003-2067-382X; 
FU ocular tissue engineering and regenerative ophthalmology (OTERO)
   Postdoctoral Fellowship; Louis J. Fox Center for Vision Restoration;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [T32EB003392] Funding Source: NIH RePORTER
FX This work was supported by ocular tissue engineering and regenerative
   ophthalmology (OTERO) Postdoctoral Fellowship provided by the Louis J.
   Fox Center for Vision Restoration.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anderson OA, 2010, DRUG DISCOV TODAY, V15, P272, DOI 10.1016/j.drudis.2010.02.004
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Couch SM, 2011, SEMIN OPHTHALMOL, V26, P114, DOI 10.3109/08820538.2011.577130
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Ehlers JP, 2011, RETINA-J RET VIT DIS, V31, P1856, DOI 10.1097/IAE.0b013e31820d59a5
   El-Mollayess GM, 2011, SEMIN OPHTHALMOL, V26, P69, DOI 10.3109/08820538.2010.545100
   Hacker MC, 2009, J BIOMED MATER RES A, V88A, P976, DOI 10.1002/jbm.a.31942
   He CL, 2008, J CONTROL RELEASE, V127, P189, DOI 10.1016/j.jconrel.2008.01.005
   Hung KH, 2010, J OCUL PHARMACOL TH, V26, P85, DOI 10.1089/jop.2009.0090
   Julian K, 2011, ACTA OPHTHALMOL, V89, P179, DOI 10.1111/j.1755-3768.2010.02046.x
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Minh KN, 2010, MACROMOL BIOSCI, V10, P563, DOI 10.1002/mabi.200900402
   Miyake T., 2009, INVEST OPHTH VIS SCI, V51, P1606
   Ogura M, 2007, LANGMUIR, V23, P9429, DOI 10.1021/la701384q
   Oh HJ, 2008, MACROMOLECULES, V41, P8204, DOI 10.1021/ma8014504
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Park D, 2011, BIOMATERIALS, V32, P777, DOI 10.1016/j.biomaterials.2010.09.044
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Salam A, 2011, ACTA OPHTHALMOL, V89, P405, DOI 10.1111/j.1755-3768.2010.02079.x
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Swindle-Reilly KE, 2009, INVEST OPHTH VIS SCI, V50, P4840, DOI 10.1167/iovs.08-2891
   Tang Y, 2009, INT J PHARMACEUT, V365, P34, DOI 10.1016/j.ijpharm.2008.08.018
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 29
TC 22
Z9 25
U1 0
U2 25
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-5187
EI 1616-5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD APR
PY 2013
VL 13
IS 4
BP 464
EP 469
DI 10.1002/mabi.201200384
PG 6
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA 132BS
UT WOS:000318043400008
PM 23316011
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Blagosklonny, MV
AF Blagosklonny, Mikhail V.
TI Validation of anti-aging drugs by treating age-related diseases
SO AGING-US
LA English
DT Review
DE Anti-aging drugs; diseases; cancer; atherosclerosis; resveratrol;
   rapamycin; metformin
ID SMALL-MOLECULE ACTIVATORS; AKT/PROTEIN KINASE-B; EXTENDS LIFE-SPAN; P70
   S6 KINASE; CARDIAC-HYPERTROPHY; CALORIE RESTRICTION; MAMMALIAN TARGET;
   ALZHEIMERS-DISEASE; REDUCED INCIDENCE; KAPOSIS-SARCOMA
AB Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend-life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular-degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could bevalidated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.
C1 [Blagosklonny, Mikhail V.] Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA.
C3 Ordway Research Institute
RP Blagosklonny, MV (通讯作者)，Roswell Pk Canc Inst, Elm St, Buffalo, NY 14203 USA.
EM Blagosklonny@oncotarget.com
CR An WL, 2003, AM J PATHOL, V163, P591, DOI 10.1016/S0002-9440(10)63687-5
   Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625
   Anisimov VN, 2005, B EXP BIOL MED+, V139, P721, DOI 10.1007/s10517-005-0389-9
   ANISIMOV VN, 2006, CURR DRUG TARGETS, P7
   Bartke A, 2006, TRENDS ENDOCRIN MET, V17, P33, DOI 10.1016/j.tem.2006.01.002
   Basso MD, 2003, TRANSPLANT P, V35, P3136, DOI 10.1016/j.transproceed.2003.10.050
   Bauer JH, 2004, P NATL ACAD SCI USA, V101, P12980, DOI 10.1073/pnas.0403493101
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458
   Blagosklonny MV, 2008, REJUV RES, V11, P801, DOI 10.1089/rej.2008.0722
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Bonegio RGB, 2005, J AM SOC NEPHROL, V16, P2063, DOI 10.1681/ASN.2004030180
   Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535
   BRITO PM, 2008, ATHEROSCLER IN PRESS
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Campistol JM, 2006, J AM SOC NEPHROL, V17, P581, DOI 10.1681/ASN.2005090993
   Cao ZX, 2004, CLIN CANCER RES, V10, P5253, DOI 10.1158/1078-0432.CCR-03-0588
   CARLSON RP, 1993, J PHARMACOL EXP THER, V266, P1125
   Chan AYM, 2008, J BIOL CHEM, V283, P24194, DOI 10.1074/jbc.M802869200
   Cheang KI, 2006, GYNECOL ENDOCRINOL, V22, P595, DOI 10.1080/09513590601005847
   Cullen NP, 2006, BRIT J HOSP MED, V67, P72, DOI 10.12968/hmed.2006.67.2.20465
   Curtis R, 2005, NAT REV DRUG DISCOV, V4, P569, DOI 10.1038/nrd1777
   DEMIDENKO ZN, 2009, CELL CYCLE IN PRESS, V8
   DILMAN VM, 1980, GERONTOLOGY, V26, P241, DOI 10.1159/000212423
   Elloso MM, 2003, AM J TRANSPLANT, V3, P562, DOI 10.1034/j.1600-6143.2003.00094.x
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Everitt AV, 2007, ANN NY ACAD SCI, V1114, P428, DOI 10.1196/annals.1396.005
   Farrell Rachel, 2005, Expert Opin Emerg Drugs, V10, P797, DOI 10.1517/14728214.10.4.797
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   Foroncewicz B, 2005, TRANSPL INT, V18, P366, DOI 10.1111/j.1432-2277.2004.00070.x
   Frojdo S, 2007, BIOCHEM J, V406, P511, DOI 10.1042/BJ20070236
   Gabele E, 2005, J BIOL CHEM, V280, P13374, DOI 10.1074/jbc.M409444200
   Gao XM, 2006, J HYPERTENS, V24, P1663, DOI 10.1097/01.hjh.0000239304.01496.83
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024
   Ha TZ, 2005, FREE RADICAL BIO MED, V39, P1570, DOI 10.1016/j.freeradbiomed.2005.08.002
   Hadley EC, 2005, CELL, V120, P557, DOI 10.1016/j.cell.2005.01.030
   Haider UGB, 2002, MOL PHARMACOL, V62, P772, DOI 10.1124/mol.62.4.772
   Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740
   Hayflick L, 2000, NATURE, V408, P267, DOI 10.1038/35041709
   Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361
   Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255
   Johnson JA, 2002, DIABETES CARE, V25, P2244, DOI 10.2337/diacare.25.12.2244
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y
   Khurana V, 2006, CURR BIOL, V16, P230, DOI 10.1016/j.cub.2005.12.042
   Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665
   Law BK, 2005, CRIT REV ONCOL HEMAT, V56, P47, DOI 10.1016/j.critrevonc.2004.09.009
   Lawrence DM, 2004, J VASC SURG, V40, P334, DOI 10.1016/j.jvs.2004.05.020
   Legendre C, 2003, TRANSPLANT P, V35, p151S, DOI 10.1016/S0041-1345(03)00241-0
   Li X, 2005, FEBS J, V272, P4211, DOI 10.1111/j.1742-4658.2005.04833.x
   Ma KL, 2007, AM J PHYSIOL-HEART C, V292, pH2721, DOI 10.1152/ajpheart.01174.2006
   Mabuchi S, 2007, CANCER RES, V67, P2408, DOI 10.1158/0008-5472.CAN-06-4490
   Marsland AM, 2002, EUR J DERMATOL, V12, P618
   Mathew T, 2004, CLIN TRANSPLANT, V18, P446, DOI 10.1111/j.1399-0012.2004.00188.x
   McMullen JR, 2004, CIRCULATION, V109, P3050, DOI 10.1161/01.CIR.0000130641.08705.45
   Medvedik O, 2007, PLOS BIOL, V5, P2330, DOI 10.1371/journal.pbio.0050261
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mohsin N, 2005, Exp Clin Transplant, V3, P366
   Morrisett JD, 2002, J LIPID RES, V43, P1170, DOI 10.1194/jlr.M100392-JLR200
   Morrisett JD, 2003, TRANSPL P, V35, p143S, DOI 10.1016/S0041-1345(03)00233-1
   Mueller MA, 2008, ATHEROSCLEROSIS, V198, P39, DOI 10.1016/j.atherosclerosis.2007.09.019
   Nungaray N, 2005, TRANSPL P, V37, P3727, DOI 10.1016/j.transproceed.2005.09.125
   Ong CT, 2007, EXP DERMATOL, V16, P394, DOI 10.1111/j.1600-0625.2007.00550.x
   Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015
   Pakala R, 2005, J CARDIOVASC PHARM, V46, P481, DOI 10.1097/01.fjc.0000177985.14305.15
   Palomba S, 2007, J CLIN ENDOCR METAB, V92, P3498, DOI 10.1210/jc.2007-1009
   Pannu J, 2004, CURR OPIN RHEUMATOL, V16, P739, DOI 10.1097/01.bor.0000137894.63091.1a
   PASCUAL J, 2006, NEPHROL DIAL TRANSPL, V3, P38
   Perls T, 2002, CURR OPIN GENET DEV, V12, P362, DOI 10.1016/S0959-437X(02)00310-6
   Poulalhon N, 2006, J BIOL CHEM, V281, P33045, DOI 10.1074/jbc.M606366200
   Rizell M, 2005, ACTA ONCOL, V44, P496, DOI 10.1080/02841860510044610
   Rodriguez AE, 2006, J AM COLL CARDIOL, V47, P1522, DOI 10.1016/j.jacc.2005.12.052
   Rovira J, 2008, TRANSPL INT, V21, P992, DOI 10.1111/j.1432-2277.2008.00710.x
   SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040
   Sakaguchi M, 2006, BIOCHEM BIOPH RES CO, V340, P296, DOI 10.1016/j.bbrc.2005.12.012
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   Shegogue D, 2004, J BIOL CHEM, V279, P23166, DOI 10.1074/jbc.M401238200
   Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002
   Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88
   Sinclair DA, 2006, SCI AM, V294, P48, DOI 10.1038/scientificamerican0306-48
   Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987
   Tu VC, 2002, J PHARMACOL EXP THER, V300, P1101, DOI 10.1124/jpet.300.3.1101
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a
   Waksman Ron, 2003, Cardiovasc Radiat Med, V4, P34, DOI 10.1016/S1522-1865(03)00121-5
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Westphal CH, 2007, TRENDS BIOCHEM SCI, V32, P555, DOI 10.1016/j.tibs.2007.09.008
   Wilson Peter W F, 2002, Am J Geriatr Cardiol, V11, P119
   Wu MJ, 2006, KIDNEY INT, V69, P2029, DOI 10.1038/sj.ki.5000161
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yakupoglu YK, 2006, TRANSPL P, V38, P358, DOI 10.1016/j.transproceed.2006.01.019
   Zamboni M, 2005, INT J OBESITY, V29, P1011, DOI 10.1038/sj.ijo.0803005
   Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188
   Zmonarski SC, 2005, TRANSPL P, V37, P964, DOI 10.1016/j.transproceed.2004.12.172
NR 107
TC 121
Z9 133
U1 2
U2 27
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAR
PY 2009
VL 1
IS 3
BP 281
EP 288
DI 10.18632/aging.100034
PG 8
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 579UM
UT WOS:000276401000003
PM 20157517
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Thumann, G
   Hueber, A
   Dinslage, S
   Schaefer, F
   Yasukawa, T
   Kirchhof, B
   Yafai, Y
   Eichler, W
   Bringmann, A
   Wiedemann, P
AF Thumann, G
   Hueber, A
   Dinslage, S
   Schaefer, F
   Yasukawa, T
   Kirchhof, B
   Yafai, Y
   Eichler, W
   Bringmann, A
   Wiedemann, P
TI Characteristics of iris and retinal pigment epithelial cells cultured on
   collagen type I membranes
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; cell transplantation; iris pigment
   epithelium; retinal pigment epithelium; subretinal surgery
ID ANTERIOR LENS CAPSULE; MACULAR DEGENERATION; EXPERIMENTAL
   TRANSPLANTATION; FOLLOW-UP; SUPPORT; TRANSLOCATION; RPE; CYTOSKELETON;
   GROWTH
AB Purpose: Transplantation of pigment epithelial cells is a promising treatment modality to repair retinal damage in age-related macular degeneration. For this purpose, it is necessary to establish cell culture techniques that allow acquisition of proper functional and morphological characteristics by the cells to be transplanted. Methods: Primary retinal pigment epithelial (RPE) and iris pigment epithelial (IPE) cells grown to confluence on collagen membranes were examined for morphology, adhesion, proliferation, apoptosis, as well as viability after ex vivo transplantation. Results: Pigment epithelial cells adhere, proliferate, form monolayers, acquire differentiated properties, and remain viable during transplantation to the subretinal space. Conclusions: Pigment epithelial cells cultured on collagen membranes acquire differentiated characteristics and are amenable to be transplanted as cell monolayers.
C1 RWTH Aachen Univ, IZK BIOMAT, Dept Ophthalmol, D-52074 Aachen, Germany.
   Univ Cologne, Dept Ophthalmol, Cologne, Germany.
   Univ Leipzig, Dept Ophthalmol, D-7010 Leipzig, Germany.
C3 RWTH Aachen University; University of Cologne; Leipzig University
RP Thumann, G (通讯作者)，RWTH Aachen Univ, IZK BIOMAT, Dept Ophthalmol, Paulwelsstr 30, D-52074 Aachen, Germany.
EM G.Thumann@uni-koeln.de
RI Hueber, Arno/C-1592-2010
OI Hueber, Arno/0000-0003-2157-126X
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2000, CURR EYE RES, V20, P268
   Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Abuzakouk M, 1996, J IMMUNOL METHODS, V194, P211, DOI 10.1016/0022-1759(96)00038-5
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Crafoord S, 2001, ACTA OPHTHALMOL SCAN, V79, P509, DOI 10.1034/j.1600-0420.2001.790517.x
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   FUCHS U, 1991, INVEST OPHTH VIS SCI, V32, P3178
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Lauer G, 2001, PLAST RECONSTR SURG, V107, P25, DOI 10.1097/00006534-200101000-00005
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   McLellan GJ, 1997, RES VET SCI, V63, P245, DOI 10.1016/S0034-5288(97)90028-X
   MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   NIMNI ME, 1988, CALCIFIED TISSUE INT, V42, P313, DOI 10.1007/BF02556366
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   THUMANN G, IN PRESS OPHTHALMOLO
   TURKSEN K, 1987, CELL TISSUE RES, V248, P95, DOI 10.1007/BF01239968
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   von Recum H, 1998, J CONTROL RELEASE, V55, P121, DOI 10.1016/S0168-3659(98)00042-X
   Zhang QQ, 1999, ARTIF CELL BLOOD SUB, V27, P245, DOI 10.3109/10731199909117697
NR 34
TC 26
Z9 29
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAR
PY 2006
VL 31
IS 3
BP 241
EP 249
DI 10.1080/02713680600556966
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 021AA
UT WOS:000235953500004
PM 16531281
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Ghiglione, D
   Polizzi, A
   Calabria, G
AF Nicolo, M
   Ghiglione, D
   Polizzi, A
   Calabria, G
TI Choroidal hemangioma treated with photodynamic therapy using
   verteporfin: Report of a case
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE choroidal hemangioma; photodynamic therapy; verteporfin
ID SEROUS RETINAL-DETACHMENT; TRANSPUPILLARY THERMOTHERAPY; PATHOLOGICAL
   MYOPIA; BEAM IRRADIATION; NEOVASCULARIZATION
AB PURPOSE. To report the results of treatment of circumscribed choroidal hemangioma with a single application of photodynamic therapy (PDT) with verteporfin according to the Treatment of Age-related Macular Degeneration with Photodynamic Therapy study.
   METHODS. A 44-year-old man with unilateral decreased vision and macular subretinal fluid secondary to a circumscribed choroidal hemangioma diagnosed by fluorescein and indocyanine green angiography and ultrasonography underwent PDT with verteporfin therapy.
   RESULTS. One year after PDT, subretinal fluid was absent and visual acuity improved.
   CONCLUSIONS. The results obtained in this case are in keeping with previously reported results; however, future randomized studies are necessary to evaluate and standardize different infusion times in order to obtain maximum efficacy of treatment.
C1 Univ Genoa, Eye Clin, Dept Neurol, Sez Clin Oculist, I-16132 Genoa, Italy.
   Univ Genoa, Eye Clin, Dept Ophthalmol, I-16132 Genoa, Italy.
   Univ Genoa, Eye Clin, Dept Genet, I-16132 Genoa, Italy.
C3 University of Genoa; University of Genoa; University of Genoa
RP Nicolo, M (通讯作者)，Univ Genoa, Eye Clin, Dept Neurol, Sez Clin Oculist, Pax 9 Osp San Martino,Lgo R Benzi 10, I-16132 Genoa, Italy.
OI Nicolo, Massimo/0000-0002-7824-3091
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FINGER PT, 1991, AM J OPHTHALMOL, V111, P240, DOI 10.1016/S0002-9394(14)72267-6
   Fuchs AV, 2002, GRAEF ARCH CLIN EXP, V240, P7, DOI 10.1007/s004170100350
   Garcia-Arumi J, 2000, OPHTHALMOLOGY, V107, P351, DOI 10.1016/S0161-6420(99)00046-9
   GASS JDM, 1977, STEREOSCOPIC ATLAS M, V130, P393
   Hannouche D, 1997, OPHTHALMOLOGY, V104, P1780, DOI 10.1016/S0161-6420(97)30026-8
   Kamal A, 2000, EYE, V14, P701, DOI 10.1038/eye.2000.187
   MACLEAN AL, 1960, AM J OPHTHALMOL, V50, P3, DOI 10.1016/0002-9394(60)90833-3
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   MEYER-SCHWICKERATH G, 1956, Doc Ophthalmol, V10, P91
   NORTON EWD, 1967, ARCH OPHTHALMOL-CHIC, V78, P121
   Othmane IS, 1999, ARCH OPHTHALMOL-CHIC, V117, P136
   Piccolino FC, 1999, RETINA-J RET VIT DIS, V19, P30, DOI 10.1097/00006982-199901000-00005
   Rapizzi E, 1999, AM J OPHTHALMOL, V127, P481, DOI 10.1016/S0002-9394(98)00362-6
   Ritland JS, 2001, ACTA OPHTHALMOL SCAN, V79, P184, DOI 10.1034/j.1600-0420.2001.079002184.x
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1155
   SCHEPENS CL, 1958, ARCH OPHTHALMOL-CHIC, V60, P72, DOI 10.1001/archopht.1958.00940080086012
   Schilling H, 1997, BRIT J OPHTHALMOL, V81, P267, DOI 10.1136/bjo.81.4.267
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   SMITH JL, 1963, ARCH OPHTHALMOL-CHIC, V9, P51
   Zografos L, 1998, AM J OPHTHALMOL, V126, P261, DOI 10.1016/S0002-9394(98)00150-0
   Zografos L, 1996, AM J OPHTHALMOL, V121, P190, DOI 10.1016/S0002-9394(14)70584-7
NR 27
TC 7
Z9 7
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD AUG-SEP
PY 2003
VL 13
IS 7
BP 656
EP 661
DI 10.1177/112067210301300711
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 727TD
UT WOS:000185674800011
PM 14552602
DA 2022-11-30
ER

PT J
AU Gellermann, W
   Ermakov, IV
   McClane, RW
   Bernstein, PS
AF Gellermann, W
   Ermakov, IV
   McClane, RW
   Bernstein, PS
TI Raman imaging of human macular pigments
SO OPTICS LETTERS
LA English
DT Article
ID DENSITY; REFLECTOMETRY; DEGENERATION; FOVEAL
AB We have imaged the spatial distribution of macular carotenoid pigments (MPs) in the human retina, employing Raman spectroscopy. Using excised human eyecups as initial test samples and resonant excitation of the pigment molecules with narrow-bandwidth blue light from a mercury arc lamp, we record Raman images originating from the carbon-carbon double-bond stretch vibrations of the molecules. Preliminary Raman images reveal significant differences in the MPs of different samples in regard to absolute levels as well as spatial variation. This technique holds promise as a method of rapid screening of MPs in large populations at risk for vision loss from age-related macular degeneration, a leading cause of blindness. (C) 2002 Optical Society of America.
C1 Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   Univ Utah, Dixon Laser Inst, Salt Lake City, UT 84112 USA.
   Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Gellermann, W (通讯作者)，Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
EM werner@physics.utah.edu
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   EMAKOV IV, 2001, OPT LETT, V26, P202
   GELLERMANN W, IN PRESS J OPT SOC A
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KOYAMA Y, 1988, J RAMAN SPECTROSC, V19, P37, DOI 10.1002/jrs.1250190107
   Schalch W., 1999, NUTR ENV INFLUENCES
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   VANNORREN D, 1989, VISION RES, V29, P1825, DOI 10.1016/0042-6989(89)90163-6
   VANNORREN D, 1986, VISION RES, V26, P313, DOI 10.1016/0042-6989(86)90028-3
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
NR 16
TC 28
Z9 29
U1 2
U2 10
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD MAY 15
PY 2002
VL 27
IS 10
BP 833
EP 835
DI 10.1364/OL.27.000833
PG 3
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 555GJ
UT WOS:000175786100013
PM 18007943
DA 2022-11-30
ER

PT J
AU Husain, A
   Khadka, A
   Ehrlicher, A
   Saint-Geniez, M
   Krishnan, R
AF Husain, Amjad
   Khadka, Arogya
   Ehrlicher, Allen
   Saint-Geniez, Magali
   Krishnan, Ramaswamy
TI Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR
   pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Angiogenesis; AMD; Rigidity; Endothelial cell; RPE; Contraction;
   Proliferation
ID VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL-CELL; TRACTION; STIFFNESS;
   GROWTH; ANGIOGENESIS; FORCES; AGE
AB While it is now well-established that substrate stiffness regulates vascular endothelial growth factor-A (VEGF-A) mediated signaling and functions, causal mechanisms remain poorly understood. Here, we report an underlying role for the PI3K/Akt/mTOR signaling pathway. This pathway is activated on stiffer substrates, is amplified by VEGF-A stimulation, and correlates with enhanced endothelial cell (EC) proliferation, contraction, pro-angiogenic secretion, and capillary-like tube formation. In the settings of advanced age-related macular degeneration, characterized by EC and retinal pigment epithelial (RPE)mediated angiogenesis, these data implicate substrate stiffness as a novel causative mechanism and Akt/ mTOR inhibition as a novel therapeutic pathway. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Husain, Amjad; Krishnan, Ramaswamy] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
   [Husain, Amjad] IISER, Innovat & Incubat Ctr Entrepreneurship, Bhopal 462066, MP, India.
   [Husain, Amjad] IISER, Ctr Sci & Soc, Bhopal 462066, MP, India.
   [Khadka, Arogya; Saint-Geniez, Magali] Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Ehrlicher, Allen] McGill Univ, Dept Bioengn, Montreal, PQ H3A0C3, Canada.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School; Indian Institute of Science Education & Research (IISER)
   - Bhopal; Indian Institute of Science Education & Research (IISER) -
   Bhopal; McGill University
RP Krishnan, R (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
EM rkrishn2@bidmc.harvard.edu
RI ; SAINT-GENIEZ, MAGALI/Q-1875-2018
OI Ehrlicher, Allen/0000-0003-3030-979X; SAINT-GENIEZ,
   MAGALI/0000-0001-9897-138X; Krishnan, Ramaswamy/0000-0003-4994-0709;
   Husain, Amjad/0000-0002-1557-2963
CR Boldock L, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12361
   Bordeleau F, 2017, P NATL ACAD SCI USA, V114, P492, DOI 10.1073/pnas.1613855114
   Butler JP, 2002, AM J PHYSIOL-CELL PH, V282, pC595, DOI 10.1152/ajpcell.00270.2001
   Byfield FJ, 2009, J BIOMECH, V42, P1114, DOI 10.1016/j.jbiomech.2009.02.012
   Canver AC, 2016, J BIOMECH, V49, P1369, DOI 10.1016/j.jbiomech.2015.12.037
   Choi YK, 2010, J BIOL CHEM, V285, P32116, DOI 10.1074/jbc.M110.131284
   Connor Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9671
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Hanjaya-Putra D, 2010, J CELL MOL MED, V14, P2436, DOI 10.1111/j.1582-4934.2009.00981.x
   Hardin CC, 2018, BIOCHEM BIOPH RES CO, V495, P749, DOI 10.1016/j.bbrc.2017.11.066
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Khoo CP, 2011, TISSUE ENG PART C-ME, V17, P895, DOI [10.1089/ten.tec.2011.0150, 10.1089/ten.TEC.2011.0150]
   Kilarski WW, 2009, NAT MED, V15, P657, DOI 10.1038/nm.1985
   Kniazeva E, 2009, AM J PHYSIOL-CELL PH, V297, pC179, DOI 10.1152/ajpcell.00018.2009
   Krishnan R, 2012, AM J PHYSIOL-CELL PH, V303, pC368, DOI 10.1152/ajpcell.00074.2012
   Krishnan R, 2011, AM J PHYSIOL-CELL PH, V300, pC146, DOI 10.1152/ajpcell.00195.2010
   LaValley DJ, 2017, CONVERG SCI PHYS ONC, V3, DOI 10.1088/2057-1739/aa9263
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765
   Ng MR, 2012, J CELL BIOL, V199, P545, DOI 10.1083/jcb.201207148
   Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936
   Rokhzan R, 2019, LAB INVEST, V99, P138, DOI 10.1038/s41374-018-0136-2
   Sack KD, 2016, J CELL PHYSIOL, V231, P2026, DOI 10.1002/jcp.25312
   Sasore T, 2014, ADV EXP MED BIOL, V801, P805, DOI 10.1007/978-1-4614-3209-8_101
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Trepat X, 2009, NAT PHYS, V5, P426, DOI 10.1038/NPHYS1269
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Umesh V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101771
   Underwood CJ, 2014, AM J PHYSIOL-HEART C, V307, pH152, DOI 10.1152/ajpheart.00995.2013
   van Beijnum JR, 2008, NAT PROTOC, V3, P1085, DOI 10.1038/nprot.2008.71
   VERNON RB, 1992, J TECHNIC METHOD PAT, V66, P536
   Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776
   Xue Q, 2009, ARTERIOSCL THROM VAS, V29, P1172, DOI 10.1161/ATVBAHA.109.185918
   Yang MT, 2011, INTEGR BIOL-UK, V3, P663, DOI 10.1039/c0ib00156b
   Yeh YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046889
   Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041
   Yoshie H, 2018, BIOPHYS J, V114, P2194, DOI 10.1016/j.bpj.2018.02.045
NR 39
TC 4
Z9 4
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2022
VL 586
BP 27
EP 33
DI 10.1016/j.bbrc.2021.11.030
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA ZS1ZK
UT WOS:000768269900003
PM 34823219
OA Bronze
DA 2022-11-30
ER

PT J
AU Wright, AF
   Chakarova, CF
   El-Aziz, MMA
   Bhattacharya, SS
AF Wright, Alan F.
   Chakarova, Christina F.
   El-Aziz, Mai M. Abd
   Bhattacharya, Shomi S.
TI Photoreceptor degeneration: genetic and mechanistic dissection of a
   complex trait
SO NATURE REVIEWS GENETICS
LA English
DT Review
ID HUMAN RETINITIS-PIGMENTOSA; FACTOR-H POLYMORPHISM; LEBER CONGENITAL
   AMAUROSIS; EMBRYONIC STEM-CELLS; MACULAR DEGENERATION; RETINAL
   DYSTROPHY; VISUAL FUNCTION; MOUSE MODEL; FUNDUS AUTOFLUORESCENCE; CONE
   PHOTORECEPTORS
AB The retina provides exquisitely sensitive vision that relies on the integrity of a uniquely vulnerable cell, the photoreceptor (PR). The genetic and mechanistic causes of retinal degeneration due to PR cell death-which occurs in conditions such as retinitis pigmentosa and age-related macular degeneration-are being successfully dissected. Over one hundred loci, some containing common variants but most containing rare variants, are implicated in the genetic architecture of this complex trait. This genetic heterogeneity results in equally diverse disease mechanisms that affect almost every aspect of PR function but converge on a common cell death pathway. Although genetic and mechanistic diversity creates challenges for therapy, some approaches-particularly gene-replacement therapy-are showing considerable promise.
C1 [Wright, Alan F.] MRC, Inst Genet & Mol Med, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Chakarova, Christina F.; El-Aziz, Mai M. Abd; Bhattacharya, Shomi S.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of Edinburgh; University of London; University College London
RP Wright, AF (通讯作者)，MRC, Inst Genet & Mol Med, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.
EM alan.wright@hgu.mrc.ac.uk; smbcssb@ucl.ac.uk
RI Chakarova, Christina/C-9479-2013; Bhattacharya, Shom/N-2926-2016
OI Bhattacharya, Shom/0000-0002-1601-6344
FU Macula Vision Research Foundation, Fight for Sight; British Retinitis
   Pigmentosa Society; UK Medical Research Council; Medical Research
   Council [MC_U127584475, G0700704B] Funding Source: researchfish; MRC
   [MC_U127584475] Funding Source: UKRI
FX We acknowledge the support of the Macula Vision Research Foundation,
   Fight for Sight, the British Retinitis Pigmentosa Society and the UK
   Medical Research Council (A. F. W.).
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Beales PL, 2003, AM J HUM GENET, V72, P1187, DOI 10.1086/375178
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P3985, DOI 10.1167/iovs.08-3364
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848
   Briscoe AD, 2004, GENE, V332, P107, DOI 10.1016/j.gene.2004.02.037
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Bui BV, 2003, INVEST OPHTH VIS SCI, V44, P2708, DOI 10.1167/iovs.02-1054
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Campbell M, 2009, P NATL ACAD SCI USA, V106, P17817, DOI 10.1073/pnas.0908561106
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   Chen B, 2009, SCIENCE, V323, P256, DOI 10.1126/science.1166226
   Chung DC, 2009, CURR OPIN OPHTHALMOL, V20, P377, DOI 10.1097/ICU.0b013e32832f802a
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Cideciyan AV, 2005, P NATL ACAD SCI USA, V102, P5233, DOI 10.1073/pnas.0408892102
   Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098
   Clarke G, 2005, J THEOR BIOL, V233, P515, DOI 10.1016/j.jtbi.2004.10.028
   Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4
   Cook MC, 2006, CURR OPIN IMMUNOL, V18, P627, DOI 10.1016/j.coi.2006.07.011
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dreyer B, 2000, EUR J HUM GENET, V8, P500, DOI 10.1038/sj.ejhg.5200491
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Fleckenstein M, 2009, EYE, V23, P567, DOI 10.1038/eye.2008.59
   Fliegauf M, 2007, NAT REV MOL CELL BIO, V8, P880, DOI 10.1038/nrm2278
   Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gardiner J, 2009, NEUROSCIENTIST, V15, P47, DOI 10.1177/1073858408325269
   GELLER AM, 1993, VISION RES, V33, P1509, DOI 10.1016/0042-6989(93)90144-L
   Gerdes JM, 2009, CELL, V137, P32, DOI 10.1016/j.cell.2009.03.023
   Gherman A, 2006, NAT GENET, V38, P961, DOI 10.1038/ng0906-961
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   Gorbatyuk M, 2007, EXP EYE RES, V84, P44, DOI 10.1016/j.exer.2006.08.014
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   Grunwald JE, 1996, AM J OPHTHALMOL, V122, P502, DOI 10.1016/S0002-9394(14)72109-9
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025
   Hendrickson A, 2005, MACULAR DEGENERATION, P1, DOI 10.1007/3-540-26977-0_1
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102
   Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011
   JAY M, 1982, BRIT J OPHTHALMOL, V66, P405, DOI 10.1136/bjo.66.7.405
   Jellinger KA, 2009, J NEURAL TRANSM, V116, P1111, DOI 10.1007/s00702-009-0240-y
   Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   Khanna H, 2009, NAT GENET, V41, P739, DOI 10.1038/ng.366
   Kimura M., 1983, NEUTRAL THEORY MOL E
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kosmaoglou M, 2008, PROG RETIN EYE RES, V27, P434, DOI 10.1016/j.preteyeres.2008.03.001
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   LI ZY, 1995, J NEUROSCI, V15, P5429
   LI ZY, 1995, RETINAL DEGENERATION, V2, P1
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039
   MacDonald IM, 2007, CAN J OPHTHALMOL, V42, P399, DOI 10.3129/i07-039
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Malhotra JD, 2008, P NATL ACAD SCI USA, V105, P18525, DOI 10.1073/pnas.0809677105
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   McMahon A, 2010, BRIT J OPHTHALMOL, V94, P1127, DOI 10.1136/bjo.2008.149286
   Mordes D, 2007, NEUROBIOL DIS, V26, P291, DOI 10.1016/j.nbd.2006.08.026
   Mortimer SE, 2008, J BIOL CHEM, V283, P36354, DOI 10.1074/jbc.M806143200
   Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053
   Nakamura T, 2007, CELL MOL LIFE SCI, V64, P1609, DOI 10.1007/s00018-007-6525-0
   Nelms KA, 2001, IMMUNITY, V15, P409, DOI 10.1016/S1074-7613(01)00199-6
   NOELL W, 1953, 211210004 USAF, V122, P104
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Pacione LR, 2003, ANNU REV NEUROSCI, V26, P657, DOI 10.1146/annurev.neuro.26.041002.131416
   Padnick-Silver L, 2006, INVEST OPHTH VIS SCI, V47, P3683, DOI 10.1167/iovs.05-1284
   Paskowitz DM, 2006, BRIT J OPHTHALMOL, V90, P1060, DOI 10.1136/bjo.2006.097436
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   QUINTILIANI M, 1986, INT J RADIAT BIOL, V50, P573, DOI 10.1080/09553008614550981
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89
   Renner AB, 2009, AM J OPHTHALMOL, V147, P518, DOI 10.1016/j.ajo.2008.09.007
   Ripps H, 2002, EXP EYE RES, V74, P327, DOI 10.1006/exer.2002.1155
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robson AG, 2008, DOC OPHTHALMOL, V116, P79, DOI 10.1007/s10633-007-9087-4
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Ryan S. J., 2005, RETINA
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Shu X, 2008, HUM MUTAT, V29, P605, DOI 10.1002/humu.20733
   Smith AJ, 2009, TRENDS GENET, V25, P156, DOI 10.1016/j.tig.2009.02.003
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szlyk JP, 2001, OPHTHALMOLOGY, V108, P65, DOI 10.1016/S0161-6420(00)00413-9
   Thompson EA, 1997, AM J HUM GENET, V60, P197
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772
   Tschernutter M, 2006, BRIT J OPHTHALMOL, V90, P718, DOI 10.1136/bjo.2005.084897
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   van Wijk E, 2004, AM J HUM GENET, V74, P738, DOI 10.1086/383096
   van Wijk E, 2009, HUM MOL GENET, V18, P51, DOI 10.1093/hmg/ddn312
   Vervoort R, 2000, NAT GENET, V25, P462, DOI 10.1038/78182
   Vithana EN, 2003, INVEST OPHTH VIS SCI, V44, P4204, DOI 10.1167/iovs.03-0253
   West JD, 2006, CHEM RES TOXICOL, V19, P173, DOI 10.1021/tx050321u
   WHIKEHART DR, 2003, BIOCH EYE
   Wolfrum U, 2000, CELL MOTIL CYTOSKEL, V46, P95, DOI 10.1002/1097-0169(200006)46:2<95::AID-CM2>3.0.CO;2-Q
   Woodson JD, 2008, NAT REV GENET, V9, P383, DOI 10.1038/nrg2348
   Wright A, 2003, TRENDS GENET, V19, P97, DOI 10.1016/S0168-9525(02)00033-1
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
   Wright AF, 2009, TRENDS GENET, V25, P253, DOI 10.1016/j.tig.2009.04.006
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 151
TC 431
Z9 440
U1 2
U2 73
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1471-0056
EI 1471-0064
J9 NAT REV GENET
JI Nat. Rev. Genet.
PD APR
PY 2010
VL 11
IS 4
BP 273
EP 284
DI 10.1038/nrg2717
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 570YN
UT WOS:000275714800007
PM 20212494
DA 2022-11-30
ER

PT J
AU Hosseini, H
   Rabina, G
   Pettenkofer, M
   Au, A
   Chehaibou, I
   Heilweil, G
   Weiner, AJ
   Ip, M
   Loewenstein, A
   Schwartz, SD
AF Hosseini, Hamid
   Rabina, Gilad
   Pettenkofer, Moritz
   Au, Adrian
   Chehaibou, Ismael
   Heilweil, Gad
   Weiner, Adam J.
   Ip, Michael
   Loewenstein, Anat
   Schwartz, Steven D.
TI Clinical characteristics and visual outcomes of non-resolving subretinal
   fluid in neovascular AMD despite continuous monthly anti-VEGF
   injections: a long-term follow-up
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Subretinal fluid; Anti-VEGF; Macular
   neovascularization; Non-resolving
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB;
   ACUITY; TRIAL
AB Purpose To describe the clinical characteristics and visual outcomes of neovascular age-related macular degeneration (NV-AMD) patients with irregular pigment epithelium detachment (PED) and non-resolving subretinal fluid (SRF) despite continuous monthly injections of anti-vascular endothelial growth factor (VEGF). Methods This is a retrospective case series, including NV-AMD patients treated in a tertiary academic practice. Inclusion criteria were NV-AMD diagnosis, with irregular PED, and non-resolving SRF treated with continuous monthly anti-VEGF intravitreal injections. Data collection included best corrected visual acuity (BCVA), central macular thickness (CMT), sub-foveal choroidal thickness (SFCT), and type and location of PED as seen on optical coherence tomography (OCT). Results A total of 738 patients with NV-AMD underwent anti-VEGF injections during the follow-up period and 20 eyes of 19 patients (14 females and 5 males) met the inclusion criteria. Average age was 81.7 +/- 6.6 years, mean follow-up time was 32.1 +/- 23.5 months, and mean number of injections was 31.3 +/- 24.2. Mean VA was 0.26 +/- 0.21 logMAR (Snellen 20/36) at baseline versus 0.20 +/- 0.23 logMAR (Snellen 20/32) at the end of the follow-up (P = 0.28). All eyes presented with sub-foveal, type 1 macular neovascularization (MNV). Average sub-foveal choroidal thickness changed from 189.70 +/- 68.46 mu m at baseline to 169.00 +/- 63.06 mu m (P < 0.001) at last follow-up. Conclusion Patients with type 1 NV-AMD, irregular PED, and non-resolving SRF and under continuous treatment of monthly anti-VEGF injections may maintain good visual acuity after long period of time.
C1 [Hosseini, Hamid; Rabina, Gilad; Pettenkofer, Moritz; Au, Adrian; Chehaibou, Ismael; Heilweil, Gad; Weiner, Adam J.; Schwartz, Steven D.] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retina Div,Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Rabina, Gilad; Loewenstein, Anat] Tel Aviv Univ, Dept Ophthalmol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
   [Chehaibou, Ismael] Univ Paris, Dept Ophthalmol, Hop Lariboisiere, AP HP, F-75010 Paris, France.
   [Ip, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv Sourasky Medical Center; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP;
   UDICE-French Research Universities; Universite Paris Cite; Doheny Eye
   Institute; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA
RP Rabina, G (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retina Div,Dept Ophthalmol, Los Angeles, CA 90095 USA.; Rabina, G (通讯作者)，Tel Aviv Univ, Dept Ophthalmol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
EM giladrabina@hotmail.com
OI Rabina, Gilad/0000-0002-9206-8373
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P8, DOI 10.1016/j.oret.2018.09.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Domalpally A, 2019, OPHTHALMOL RETINA, V3, P326, DOI 10.1016/j.oret.2019.01.004
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Mimouni M, 2018, JPN J OPHTHALMOL, V62, P652, DOI 10.1007/s10384-018-0619-0
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Shin Joong Won, 2012, Korean J Ophthalmol, V26, P255, DOI 10.3341/kjo.2012.26.4.255
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 33
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2021
VL 259
IS 5
BP 1153
EP 1160
DI 10.1007/s00417-020-05024-9
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY3DR
UT WOS:000593446800005
PM 33245430
DA 2022-11-30
ER

PT J
AU Ngo, L
   Han, JH
AF Ngo, L.
   Han, J. -H.
TI Multi-level deep neural network for efficient segmentation of blood
   vessels in fundus images
SO ELECTRONICS LETTERS
LA English
DT Article
AB The exact blood vessel trees segmented from fundus images provide important information required for screening and following-up of diabetic retinopathy and age-related macular degeneration. The trained deep neural network presents an automated prediction of the blood vessels in retinal fundus camera images in the publicly DRIVE database with accuracy up to 0.9533 and area under the receiver operating characteristic curve up to 0.9752, which is better than manual recognition by expert human eyes. A resizing technique is introduced and applied to the multi-level network combining dropout and spatialdropout layers to obtain more generalised training. The proposed model has the potential for the classification of other types of images.
C1 [Ngo, L.; Han, J. -H.] Korea Univ, Dept Brain & Cognit Engn, 145 Anam Rd, Seoul 02841, South Korea.
C3 Korea University
RP Han, JH (通讯作者)，Korea Univ, Dept Brain & Cognit Engn, 145 Anam Rd, Seoul 02841, South Korea.
EM hanjaeho@korea.ac.kr
RI Ngo, Lua/AAG-5537-2019
FU MSIP (Ministry of Science, ICT and Future Planning), Korea, under the
   ITRC (Information Technology Research Center) [IITP-2017-2016-0-00464];
   National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [NRF-2017R1A2B2003808]; Korea University
FX This research was supported in part by the MSIP (Ministry of Science,
   ICT and Future Planning), Korea, under the ITRC (Information Technology
   Research Center) support program (IITP-2017-2016-0-00464) supervised by
   the IITP (Institute for Information & Communications Technology
   Promotion). This work was supported in part by the National Research
   Foundation of Korea (NRF) grant funded by the Korea government (MSIP)
   (NRF-2017R1A2B2003808). This research was also supported in part by
   Korea University Future Research Grant.
CR Azzopardi G, 2015, MED IMAGE ANAL, V19, P46, DOI 10.1016/j.media.2014.08.002
   Dash J, 2015, 2015 INTERNATIONAL CONFERENCE ON COMPUTATIONAL INTELLIGENCE AND NETWORKS (CINE), P166, DOI 10.1109/CINE.2015.39
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Glorot X., 2011, AISTATS, P315, DOI DOI 10.1177/1753193410395357
   LeCun Y, 1989, NEURAL COMPUT, V1, P541, DOI 10.1162/neco.1989.1.4.541
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Melinscak M., 2015, INT C COMP VIS THEOR
   Roychowdhury S, 2015, IEEE J BIOMED HEALTH, V19, P1118, DOI 10.1109/JBHI.2014.2335617
   Silver D, 2016, NATURE, V529, P484, DOI 10.1038/nature16961
   Tompson J., 2014, NIPS, P1799
   Tompson J, 2015, PROC CVPR IEEE, P648, DOI 10.1109/CVPR.2015.7298664
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Youssef D, 2012, COMPUT METH PROG BIO, V108, P1052, DOI 10.1016/j.cmpb.2012.06.006
NR 14
TC 30
Z9 35
U1 0
U2 11
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 0013-5194
EI 1350-911X
J9 ELECTRON LETT
JI Electron. Lett.
PD AUG 3
PY 2017
VL 53
IS 16
BP 1096
EP 1097
DI 10.1049/el.2017.2066
PG 2
WC Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA FD8FZ
UT WOS:000407761900009
DA 2022-11-30
ER

PT J
AU Wu, ZG
   Zhou, P
   Li, XX
   Wang, H
   Luo, DL
   Qiao, HY
   Ke, X
   Huang, J
AF Wu, Zhigang
   Zhou, Peng
   Li, Xiaoxin
   Wang, Hui
   Luo, Delun
   Qiao, Huaiyao
   Ke, Xiao
   Huang, Jian
TI Structural Characterization of a Recombinant Fusion Protein by
   Instrumental Analysis and Molecular Modeling
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ELECTROSPRAY MASS-SPECTROMETRY;
   LIQUID-CHROMATOGRAPHY; MONOCLONAL-ANTIBODY; SAMPLE PREPARATION;
   DEAMIDATION SITES; MEMBRANE-PROTEIN; IDENTIFICATION; RECEPTOR;
   NEOVASCULARIZATION
AB Conbercept is a genetically engineered homodimeric protein for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins. Its huge, highly variable architecture makes characterization and development of a functional assay difficult. In this study, the primary structure, number of disulfide linkages and glycosylation state of conbercept were characterized by high-performance liquid chromatography, mass spectrometry, and capillary electrophoresis. Molecular modeling was then applied to obtain the spatial structural model of the conbercept-VEGF-A complex, and to study its inter-atomic interactions and dynamic behavior. This work was incorporated into a platform useful for studying the structure of conbercept and its ligand binding functions.
C1 [Wu, Zhigang; Luo, Delun; Qiao, Huaiyao; Ke, Xiao] Chengdu Kanghong Biotechnol Inc, Chengdu, Peoples R China.
   [Zhou, Peng; Huang, Jian] Univ Elect Sci & Technol China, Ctr Bioinformat, Chengdu 610054, Peoples R China.
   [Li, Xiaoxin] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China.
   [Wang, Hui] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogens & Biosecur, Beijing, Peoples R China.
C3 University of Electronic Science & Technology of China; Peking
   University; Beijing Institute of Microbiology & Epidemiology
RP Wu, ZG (通讯作者)，Chengdu Kanghong Biotechnol Inc, Chengdu, Peoples R China.
EM wuzhigang@cnkh.com; hj@uestc.edu.cn
RI wu, zhi/GXH-3041-2022; Huang, Jian/G-8437-2011
OI Huang, Jian/0000-0003-3282-8892; Zhou, Peng/0000-0001-5681-9937
FU 973 projects [2011CB510200]; National Natural Science Foundation of
   China [61071177]; Program for New Century Excellent Talents in
   University [NCET-12-0088]
FX The authors acknowledge the following funding supports: the 973 projects
   2011CB510200, the National Natural Science Foundation of China No.
   61071177 and the Program for New Century Excellent Talents in University
   (NCET-12-0088). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Ahn J, 2010, J CHROMATOGR B, V878, P403, DOI 10.1016/j.jchromb.2009.12.013
   Argueso P, 2003, INVEST OPHTH VIS SCI, V44, P86, DOI 10.1167/iovs.02-0181
   Bongers J, 2011, J CHROMATOGR A, V1218, P8140, DOI 10.1016/j.chroma.2011.08.089
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chelius D, 2005, ANAL CHEM, V77, P6004, DOI 10.1021/ac050672d
   CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gaza-Bulseco G, 2008, ANAL CHEM, V80, P9491, DOI 10.1021/ac801617u
   Gorman JJ, 2002, MASS SPECTROM REV, V21, P183, DOI 10.1002/mas.10025
   Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351
   Gupta K, 2010, ANAL CHEM, V82, P8313, DOI 10.1021/ac101867e
   HJERTEN S, 1987, J CHROMATOGR, V387, P127, DOI 10.1016/S0021-9673(01)94519-4
   Krokhin OV, 2006, ANAL CHEM, V78, P6645, DOI 10.1021/ac061017o
   KRUEGER DE, 1980, SURV OPHTHALMOL, V24, P614, DOI 10.1016/0039-6257(80)90122-8
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li CY, 2006, BIOCHEMISTRY-US, V45, P12117, DOI 10.1021/bi060627f
   Li XJ, 2008, J AM SOC MASS SPECTR, V19, P855, DOI 10.1016/j.jasms.2008.02.011
   MaAuley A, 2008, PROTEIN SCI, V17, P95, DOI 10.1110/ps.073134408
   Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311
   Mack S, 2009, ELECTROPHORESIS, V30, P4049, DOI 10.1002/elps.200800690
   Makino Y, 2000, J BIOCHEM-TOKYO, V128, P175, DOI 10.1093/oxfordjournals.jbchem.a022738
   Manabe T, 1997, ELECTROPHORESIS, V18, P92, DOI 10.1002/elps.1150180118
   Manabe T, 1997, ELECTROPHORESIS, V18, P1159, DOI 10.1002/elps.1150180723
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miller JW, 1997, AM J PATHOL, V151, P13
   Mundt AA, 2001, ANAL BIOCHEM, V299, P147, DOI 10.1006/abio.2001.5416
   Raju TS, 1996, BIOTECHNOL APPL BIOC, V24, P191
   Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799
   Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Spassov VZ, 2008, PROTEIN ENG DES SEL, V21, P91, DOI 10.1093/protein/gzm083
   Spiess C, 1997, J BIOL CHEM, V272, P22125, DOI 10.1074/jbc.272.35.22125
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takemoto L, 2001, CURR EYE RES, V22, P148, DOI 10.1076/ceyr.22.2.148.5524
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Timm V, 2010, J CHROMATOGR B, V878, P777, DOI 10.1016/j.jchromb.2010.01.036
   Wei Z, 2005, DEV BIOLOGICALS, V122, P29
   Wu Jiang, 2008, V446, P1, DOI 10.1007/978-1-60327-084-7_1
   Xie HW, 2009, ANAL CHEM, V81, P5699, DOI 10.1021/ac900468j
   Yang YZ, 2009, J CHROMATOGR A, V1216, P3767, DOI 10.1016/j.chroma.2009.02.059
   Yeung YA, 2010, CANCER RES, V70, P3269, DOI 10.1158/0008-5472.CAN-09-4580
   Zeng R, 1999, ACTA BIOCH BIOPH SIN, V31, P695
   Zhang W, 2002, ANAL BIOCHEM, V311, P1, DOI 10.1016/S0003-2697(02)00394-9
   Zhou P, 2009, J COMPUT CHEM, V30, P940, DOI 10.1002/jcc.21109
NR 51
TC 40
Z9 45
U1 0
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 4
PY 2013
VL 8
IS 3
AR e57642
DI 10.1371/journal.pone.0057642
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 099PY
UT WOS:000315634900032
PM 23469213
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Zhang, RZ
   Gascon, R
   Miller, RG
   Gelinas, DF
   Mass, J
   Lancero, M
   Narvaez, A
   McGrath, MS
AF Zhang, Rongzhen
   Gascon, Ron
   Miller, Robert G.
   Gelinas, Deborah F.
   Mass, Jason
   Lancero, Mariselle
   Narvaez, Amy
   McGrath, Michael S.
TI MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in
   sporadic amyotrophic lateral sclerosis (sALS)
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE CCR2; MCP-1; inflammation; monocyte/macrophage activation; sporadic ALS
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER;
   CHEMOATTRACTANT PROTEIN-1; MULTIPLE-SCLEROSIS; FUNCTIONAL EXPRESSION;
   DENDRITIC CELLS; MACROPHAGE RECRUITMENT; CHEMOTACTIC PROTEIN-1; CYTOKINE
   EXPRESSION; MOLECULAR-CLONING
AB Recent studies suggest that monocyte activation may play a role in ALS pathogenesis. Therefore, monocyte CCR2, the receptor for monocyte cbemoattractant protein-1 (MCP-1), and plasma levels of MCP-1 were measured in 42 sALS patients, 38 healthy and 34 age-related macular degeneration (ARMD) controls. MCP-1 was elevated in both sALS and ARMD patients, but CCR2 levels were significantly decreased on sALS but not on ARMD monocytes. Loss of monocyte CCR2 expression was inversely correlated with degree of monocyte/macrophage activation in sALS and this decrease was unlikely due to receptor down-regulation given the ARMD results. Defective monocyte/macrophages may play an active role in sALS. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94110 USA.
   Calif Pacific Med Ctr, San Francisco, CA 94115 USA.
C3 San Francisco General Hospital Medical Center; University of California
   System; University of California San Francisco; California Pacific
   Medical Center
RP McGrath, MS (通讯作者)，Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 3,Room 207, San Francisco, CA 94110 USA.
EM mmcgrath@php.ucsf.edu
FU PHS HHS [U01-066529] Funding Source: Medline
CR Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282
   Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285
   Baron P, 2005, MUSCLE NERVE, V32, P541, DOI 10.1002/mus.20376
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752
   Fenoglio C, 2004, NEUROBIOL AGING, V25, P1169, DOI 10.1016/j.neurobiolaging.2003.11.008
   Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899
   Floris S, 2004, J NEUROIMMUNOL, V148, P172, DOI 10.1016/j.jneuroim.2003.11.005
   Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69
   Frankenberger M, 1996, BLOOD, V87, P373
   Gelanis Deborah F., 2001, Curr Treat Options Neurol, V3, P133, DOI 10.1007/s11940-001-0048-z
   Graves MC, 2004, AMYOTROPH LATERAL SC, V5, P213, DOI 10.1080/14660820410020286
   Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723
   Harkness KA, 2003, J NEUROIMMUNOL, V142, P1, DOI 10.1016/S0165-5728(03)00251-0
   Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805
   Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214
   Horckmans M, 2006, FEBS LETT, V580, P747, DOI 10.1016/j.febslet.2005.12.091
   Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713
   ISHIHARA K, 1997, CATTECH, V1, P51
   Kennedy KJ, 1998, J NEUROIMMUNOL, V92, P98, DOI 10.1016/S0165-5728(98)00187-8
   Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655
   McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8
   McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191
   McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2
   Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5
   Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97
   MOORE DH, 2005, AMYOTROPH LATERAL S1, V6, P15
   Owens T, 2005, BRAIN RES REV, V48, P178, DOI 10.1016/j.brainresrev.2004.12.007
   Pashenkov M, 2002, J NEUROIMMUNOL, V122, P106, DOI 10.1016/S0165-5728(01)00451-9
   Peterson KE, 2004, J VIROL, V78, P6449, DOI 10.1128/JVI.78.12.6449-6458.2004
   Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X
   Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758
   Stamatovic SM, 2003, J CELL SCI, V116, P4615, DOI 10.1242/jcs.00755
   Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055
   Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050
   Van Coillie E, 1999, CYTOKINE GROWTH F R, V10, P61, DOI 10.1016/S1359-6101(99)00005-2
   Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699
   Wilms H, 2003, J NEUROIMMUNOL, V144, P139, DOI 10.1016/j.jneuroim.2003.08.042
   Zhang RZ, 2005, J NEUROIMMUNOL, V159, P215, DOI 10.1016/j.jneuroim.2004.10.009
   ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902
NR 48
TC 49
Z9 51
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD OCT
PY 2006
VL 179
IS 1-2
BP 87
EP 93
DI 10.1016/j.jneuroim.2006.06.008
PG 7
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 102ON
UT WOS:000241821800010
PM 16857270
DA 2022-11-30
ER

PT J
AU Roizenblatt, R
   Farah, ME
   Castro, J
   Cardillo, JA
   Costa, RA
   Roizenblatt, J
AF Roizenblatt, R
   Farah, ME
   Castro, J
   Cardillo, JA
   Costa, RA
   Roizenblatt, J
TI Diode laser modifications for treatment of choroidal neovascularisation
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE choroidal neovascularisation; diode laser parameters; laser treatment;
   macular degeneration
ID TRANSPUPILLARY THERMOTHERAPY; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INDOCYANINE GREEN
AB The aim of this paper is to describe various diode laser modifications and their use in treating choroidal neovascularisation in age-related macular degeneration. Diode lasers are used to treat selected choroidal neovascular membranes. Alterations in microprocessor connectivity, and parameters such as maximum spot size, light delivery time and coupled Joule meter, were made so that ophthalmic surgeons could specify treatment possibilities. A trimodal (photocoagulation, transpupillary thermotherapy and photodynamic therapy) application laser device coupled to a single light source has been developed. The new diode laser modifications were technically successful. Microprocessor connectivity was obtained, larger spot sizes were achieved, light delivery time could be extended and energy parameters were available at the display.
C1 UNIFESP, EPM, Retina & Vitreous Dept, BR-04023062 Sao Paulo, Brazil.
   Univ Fed Sao Carlos, Ophthalm Opt Lab, BR-13560 Sao Carlos, Brazil.
   Univ Sao Paulo, Sch Med, Retina & Vitreous Dept, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Carlos; Universidade de Sao Paulo
RP Roizenblatt, R (通讯作者)，UNIFESP, EPM, Retina & Vitreous Dept, Rua Botucatu 822, BR-04023062 Sao Paulo, Brazil.
RI Costa, Rogerio A/E-6930-2013; Neto, Jarbas C Castro/G-2915-2014; Farah,
   Michel Eid E/F-3285-2012
OI Costa, Rogerio A/0000-0002-0800-2233; Farah, Michel Eid
   E/0000-0001-5951-0193; Cardillo, Jose Augusto/0000-0002-5791-3201
CR Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   MARMOR MF, 1998, RETINAL PIGMENT EPIT, P587
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
NR 5
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER-VERLAG LONDON LTD
PI GODALMING
PA SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND
SN 0268-8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PY 2003
VL 18
IS 1
BP 43
EP 44
DI 10.1007/s10103-002-0249-z
PG 2
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Surgery
GA 666VZ
UT WOS:000182198300008
PM 12627272
DA 2022-11-30
ER

PT J
AU McFarland, TJ
   Zhang, Y
   Appukuttan, B
   Stout, JT
AF McFarland, TJ
   Zhang, Y
   Appukuttan, B
   Stout, JT
TI Gene therapy for proliferative ocular diseases
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE adeno-associated virus; adenovirus; age-related macular degeneration;
   angiogenesis; endo : kringle-5; eye disease; lentivirus; pigment
   epithelial-derived factor
ID RECOMBINANT ADENOASSOCIATED VIRUS; IN-VIVO; MACULAR DEGENERATION;
   PLASMID DNA; ADENOVIRAL VECTORS; LENTIVIRAL VECTOR; VIRAL VECTORS;
   CHOROIDAL NEOVASCULARIZATION; RNA INTERFERENCE; IMMUNE-RESPONSE
AB Proliferative ocular diseases encompass a wide variety of pathological processes with adverse cellular differentiation, proliferation and migration as common features. Pathologies may involve neovascular responses associated with diabetic retinopathy, retinopathy of prematurity or age-related macular degeneration. These diseases are quite prevalent and account for substantial visual impairment and blindness worldwide. Although treatment strategies are largely surgical, advances in our understanding of the proteins crucial to cell transdifferentiation, proliferation and migration, along with better gene transfer techniques, have greatly increased the potential for biological treatment options. In this report, the most common proliferative ocular vascular diseases and existing therapeutic modalities will be reviewed and an overview of possible gene therapy options will be discussed, along with potential candidate genes.
C1 OHSU, Casey Eye Inst, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP McFarland, TJ (通讯作者)，OHSU, Casey Eye Inst, 3375 SW Terwilliger BLVD, Portland, OR 97239 USA.
CR Afzal A, 2003, CIRC RES, V93, P500, DOI 10.1161/01.RES.0000091260.78959.BC
   Aggarwal Rajiv, 2002, Indian Journal of Pediatrics, V69, P83, DOI 10.1007/BF02723783
   Akimoto M, 1998, EXP EYE RES, V67, P395, DOI 10.1006/exer.1998.0531
   Anand V, 2002, MOL THER, V5, P125, DOI 10.1006/mthe.2002.0525
   Anderson WF, 2002, HUM GENE THER, V13, P1, DOI 10.1089/10430340152712610
   BARTON K, 1995, CELL IMMUNOL, V164, P133, DOI 10.1006/cimm.1995.1152
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Bergeron LJ, 2003, CURR MED CHEM, V10, P2589, DOI 10.2174/0929867033456486
   Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459
   Breyer Benjamin, 2001, Current Gene Therapy, V1, P149, DOI 10.2174/1566523013348689
   Buning H, 2003, GENE THER, V10, P1142, DOI 10.1038/sj.gt.3301976
   CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567
   CHAUDHURI A, 2002, CATIONIC LIPOSOMES P
   Cheng JC, 2003, MOL GENET METAB, V80, P121, DOI 10.1016/j.ymgme.2003.08.011
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Crombleholme TM, 2000, WOUND REPAIR REGEN, V8, P460, DOI 10.1046/j.1524-475x.2000.00460.x
   Daheshia M, 1997, J IMMUNOL, V159, P1945
   Danis R P, 2001, Expert Opin Pharmacother, V2, P395, DOI 10.1517/14656566.2.3.395
   DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733
   DRACK AV, 1995, PEDIAT OPHTHALMOLOGY, P563
   Erles K, 1999, J MED VIROL, V59, P406, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;406::AID-JMV22&gt;3.0.CO;2-N
   Federico M, 1999, CURR OPIN BIOTECH, V10, P448, DOI 10.1016/S0958-1669(99)00008-7
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Grant CA, 1997, CURR EYE RES, V16, P949, DOI 10.1076/ceyr.16.9.949.5046
   Grimm D, 2002, METHODS, V28, P146, DOI 10.1016/S1046-2023(02)00219-0
   HAMILTON AM, 1996, MANAGEMENT DIABETIC, P296
   Handa A, 2000, J GEN VIROL, V81, P2077, DOI 10.1099/0022-1317-81-8-2077
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Hawkins BS, 1999, MOL VIS, V5
   Hoerle S, 2002, GRAEF ARCH CLIN EXP, V240, P197, DOI 10.1007/s00417-002-0432-8
   Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Jones S. E., 1994, Gene Therapy, V1, pS61
   Kashani-Sabet M, 2002, J INVEST DERM SYMP P, V7, P76, DOI 10.1046/j.1523-1747.2002.19642.x
   Kearns WG, 1996, GENE THER, V3, P748
   KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875
   Kootstra NA, 2003, ANNU REV PHARMACOL, V43, P413, DOI 10.1146/annurev.pharmtox.43.100901.140257
   Kovesdi I, 1997, CURR OPIN BIOTECH, V8, P583, DOI 10.1016/S0958-1669(97)80033-X
   Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1
   Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7
   Li SL, 2001, DRUGS TODAY, V37, P629, DOI 10.1358/dot.2001.37.9.844222
   Liu L, 2003, GENE THER, V10, P180, DOI 10.1038/sj.gt.3301861
   Long MB, 2003, J CLIN INVEST, V112, P312, DOI 10.1172/JCI200319386
   Lotery AJ, 2002, HUM GENE THER, V13, P689, DOI 10.1089/104303402317322258
   LYSENKO VS, 2003, VESTN ROS AKAD MED+, V5, P44
   Mandava N, 2002, INVEST OPHTH VIS SCI, V43, P3338
   Mazda O., 2002, Current Gene Therapy, V2, P379, DOI 10.2174/1566523023347814
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Murthy RC, 2003, INVEST OPHTH VIS SCI, V44, P1837, DOI 10.1167/iovs.02-0853
   Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923
   O'Connell S. R., 1999, VITREORETINAL DIS ES, P213
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pleyer U, 2001, EXP EYE RES, V73, P1, DOI 10.1006/exer.2001.1005
   Puerta-Fernandez E, 2003, FEMS MICROBIOL REV, V27, P75, DOI 10.1016/S0168-6445(03)00020-2
   Reich S, 2003, MOL VIS, V9, P210
   Reynolds JD, 2001, PEDIATR DRUGS, V3, P263, DOI 10.2165/00128072-200103040-00003
   Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Smith LEH, 2002, ACTA PAEDIATR, V91, P26, DOI 10.1080/08035250260095771
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   St George JA, 2003, GENE THER, V10, P1135, DOI 10.1038/sj.gt.3302071
   Stechschulte SU, 2001, INVEST OPHTH VIS SCI, V42, P1975
   Steinkuller PG, 1999, J AAPOS, V3, P26, DOI 10.1016/S1091-8531(99)70091-1
   Stout AU, 2003, PEDIATR CLIN N AM, V50, P77, DOI 10.1016/S0031-3955(02)00111-6
   Tseng JF, 2002, SURGERY, V132, P857, DOI 10.1067/msy.2002.127680
   Urtti A, 2000, J DRUG TARGET, V7, P413, DOI 10.3109/10611860009102216
   Wang Feng, 2002, Zhonghua Yan Ke Za Zhi, V38, P520
   Wasan EK, 1996, J PHARM SCI-US, V85, P427, DOI 10.1021/js9504752
   Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yu WZ, 2003, OPHTHALMIC RES, V35, P239, DOI 10.1159/000072143
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998
NR 76
TC 23
Z9 27
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUL
PY 2004
VL 4
IS 7
BP 1053
EP 1058
DI 10.1517/14712598.4.7.1053
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 839OO
UT WOS:000222794600005
PM 15268673
DA 2022-11-30
ER

PT J
AU Chan, WM
   Lam, DSC
   Lai, TYY
   Liu, DTL
   Li, KKW
   Yao, Y
   Wong, TH
AF Chan, WM
   Lam, DSC
   Lai, TYY
   Liu, DTL
   Li, KKW
   Yao, Y
   Wong, TH
TI Photodynamic therapy with verteporfin for symptomatic polypoidal
   choroidal vasculopathy - One-year results of a prospective case series
SO OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   PIGMENT EPITHELIAL DETACHMENTS; MACULAR DEGENERATION;
   CLINICOPATHOLOGICAL CORRELATION; NEOVASCULARIZATION SECONDARY;
   PHOTOCOAGULATION; TRANSLOCATION; HEMORRHAGE; LESIONS
AB Objective: To determine the efficacy of photodynamic therapy (PDT) with verteporfin as a treatment for symptomatic polypoidal choroidal vasculopathy (PCV).
   Design: Prospective consecutive, 2-centered, noncomparative interventional case series.
   Participants: Twenty-one Asian patients with 22 eyes presenting with serosanguinous maculopathy due to PCV and an initial best-corrected visual acuity (BCVA) of 20/40 or worse were recruited prospectively. All patients had angiographic leakage seen on fluorescein angiograms (FAs) and features of PCV seen with indocyanine green (ICG) angiography.
   Methods: Intravenous infusion of verteporfin at a dose of 6 mg/m(2) of body surface area over 10 minutes was administered. Five minutes after the completion of infusion, a 689-nm laser was applied for 83 seconds, with a light dose of 50 J/cm(2). The laser spot size was chosen to cover the polyps and the surrounding abnormally dilated choroidal vessels shown on ICG angiography plus an extra 1000-mum margin. Photodynamic therapy retreatment was performed if leakage from the polyps was found on both repeat FAs and ICG angiography at regular 3-month follow-up intervals.
   Main Outcome Measures: The proportion of eyes with stable or improved vision at a 1-year follow-up. Secondary outcome measures included change in mean BCVA and the changes in clinical and angiographic features in FAs and ICG angiography. The total number of PDT sessions and any complications were also recorded.
   Results: Stable or improved vision was achieved in 21 (95%) of the 22 eyes at the 1-year follow-up. Ten (45%) eyes had a moderate gain in vision (improved by greater than or equal to3 lines), whereas 1 (5%) eye suffered a moderate visual loss (decrease by greater than or equal to3 lines). The mean BCVA improved from a logarithm of the minimum angle of resolution(logMAR) of 0.73 to 0.60, an equivalent of 1.3 lines of improvement. The change in logMAR BCVA at 12 months was statistically significant (Wilcoxon signed-ranks test, P = 0.009). Complete absence of leakage in FAs and total regression of the polyps in ICG angiography were observed in 20 (91%) and 21 (95%) eyes, respectively. Severe loss of vision due to massive subretinal hemorrhage occurred in 1 eye; otherwise, there were no other serious treatment-related adverse events.
   Conclusions: The 1-year results of PDT in treating PCV of the macular type with serosanguinous presentations are encouraging. Further studies with longer follow-up and randomized controlled trials are warranted to assess the long-term safety and efficacy of PDT relative to observation or other treatment modalities. (C) 2004 by the American Academy of Ophthalmology.
C1 Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Chinese People's Liberation Army General Hospital
RP Chan, WM (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 3-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020; Li,
   Kenneth/M-4140-2017
OI Lai, Timothy Y Y/0000-0002-7832-6428; Li, Kenneth/0000-0001-9440-8063
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   *SPSS INC, 2002, SPSS VERS 10 1 0
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 35
TC 240
Z9 263
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2004
VL 111
IS 8
BP 1576
EP 1584
DI 10.1016/j.ophtha.2003.12.056
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 841RP
UT WOS:000222949400025
PM 15288991
DA 2022-11-30
ER

PT J
AU Wang, WY
   Yang, CH
   Chen, TC
   Hsieh, YT
   Ho, TC
   Yang, CM
   Liu, FY
   Lai, TT
AF Wang, Wen-Yi
   Yang, Chang-Hao
   Chen, Ta-Ching
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Yang, Chung-May
   Liu, Fang-Yu
   Lai, Tso-Ting
TI Quantitative analysis of branching neovascular networks in polypoidal
   choroidal vasculopathy by optical coherence tomography angiography after
   photodynamic therapy and anti-vascular endothelial growth factor
   combination therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Branching neovascular network; Optical coherence tomography angiography;
   Photodynamic therapy; Polypoidal choroidal vasculopathy
ID MACULAR DEGENERATION; FLUORESCEIN ANGIOGRAPHY; VERTEPORFIN; RANIBIZUMAB;
   CONSENSUS; EFFICACY; SAFETY
AB Purpose To study serial changes in branching neovascular networks (BNN) by using optical coherence tomography angiography (OCTA) in patients with polypoidal choroidal vasculopathy (PCV) who underwent combined photodynamic therapy (PDT) and anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods In this retrospective study of 30 PCV patients who underwent combined therapy, OCTA images obtained at baseline and 1, 3, and 6 months after treatment were collected. The vessel area, vessel percentage area, average vessel length, and presence of polypoidal lesions on OCTA images as well as best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT) were recorded at each time point. Results The BNN- and polypoidal lesion-detection rates on baseline OCTA images were 100% and 71%, respectively. The vessel area decreased during the first 3 months, and increased 6 months post-treatment, showing significant differences from baseline (p = 0.031). The vessel percentage area also reduced 1 and 3 months post-treatment (p = 0.025) and increased 6 months post-treatment. Continuous polypoidal lesion regression was observed from 1 to 3 and 6 months post-treatment (p = 0.031, p = 0.004, p = 0.002, respectively, in comparison with baseline). Patients with a decreasing vessel area over 6 months showed greater choroidal thickness than those with increasing vessel area (p = 0.004). Conclusions The BNN showed initial regression but were enlarged at 6 months after therapy. Patients showing continuous BNN regression showed a thicker choroid at baseline. This difference should be considered during treatment for PCV, and OCTA could be used for follow-up evaluations of PCV patients.
C1 [Wang, Wen-Yi; Yang, Chang-Hao; Chen, Ta-Ching; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Liu, Fang-Yu; Lai, Tso-Ting] Natl Taiwan Univ Hosp, Dept Ophthalmol, Chung Shan S Rd 7, Taipei 100, Taiwan.
   [Yang, Chang-Hao; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May] Natl Taiwan Univ, Coll Med, Taipei, Taiwan.
   [Chen, Ta-Ching; Lai, Tso-Ting] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Liu, Fang-Yu] Natl Def Med Ctr, Triserv Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University; National Defense
   Medical Center; Tri-Service General Hospital
RP Lai, TT (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, Chung Shan S Rd 7, Taipei 100, Taiwan.; Lai, TT (通讯作者)，Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
EM b91401005@ntu.edu.tw
OI Lai, Tso-Ting/0000-0002-8247-7018; YANG, CHUNG-MAY/0000-0003-4082-420X;
   YANG, CHANG-HAO/0000-0002-4328-8716
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Asano-Shimizu K, 2020, INT OPHTHALMOL, V40, P1335, DOI 10.1007/s10792-020-01299-3
   Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Hagag Ahmed M, 2017, Taiwan J Ophthalmol, V7, P115, DOI 10.4103/tjo.tjo_31_17
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hsia Y, 2019, PHOTODIAGN PHOTODYN, V27, P227, DOI 10.1016/j.pdpdt.2019.06.004
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Iesato Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0952-6
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Palkar AH, 2019, TAIWAN J OPHTHALMOL, V9, P72, DOI 10.4103/tjo.tjo_35_18
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sayanagi Kaori, 2019, Am J Ophthalmol Case Rep, V15, P100485, DOI 10.1016/j.ajoc.2019.100485
   Shen YS, 2021, EUR J OPHTHALMOL, V31, P1267, DOI 10.1177/1120672120913012
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Su ZA, 2012, J OCUL PHARMACOL TH, V28, P410, DOI 10.1089/jop.2011.0221
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   von der Emde L, 2020, OPHTHALMOLOGICA, V243, P120, DOI 10.1159/000503609
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 38
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2022
VL 260
IS 7
BP 2249
EP 2260
DI 10.1007/s00417-022-05583-z
EA FEB 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2H0GI
UT WOS:000752813000001
PM 35133487
DA 2022-11-30
ER

PT J
AU Richardson, QR
   Zhang, YN
   Deiner, MS
   Wang, ST
   Bhisitkul, JM
   Arnold, BF
   Bhisitkul, RB
AF Richardson, Quintin R.
   Zhang, Youning
   Deiner, Michael S.
   Wang, Suling T.
   Bhisitkul, Jonah M.
   Arnold, Benjamin F.
   Bhisitkul, Robert B.
TI Macular Atrophy Incidence, Progression, and Visual Acuity Effects in
   5-Year Treatment of Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GEOGRAPHIC ATROPHY; 7-YEAR OUTCOMES; RANIBIZUMAB; GROWTH; ANCHOR;
   MARINA; HORIZON; EXTEND; EYES
AB BACKGROUND AND OBJECTIVE: Macular atrophy (MA) contributes to declining vision during pro-longed anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macu-lar degeneration (nAMD) so greater understanding of its incidence, evolution, and impact on visual acuity is merited.MATERIALS AND METHODS: This is a retrospective review of nAMD patients receiving anti-VEGF ther-apy for >= 5 years. Near-infrared reflectance images and vision data were extracted every 6 months. MA lesion areas were measured using ImageJ.RESULTS: Vision showed a mean decline of-1.2 let-ters/year. Eyes with MA showed a greater decrease of-1.6 letters/year compared to eyes without MA (-0.7 letters/year). Cumulative incidence of MA was 38% at 5 years. MA was significantly associ-ated with declining vision, showing a-0.7 letter de-crease for every 1 mm2 increase in lesion size.CONCLUSION: Over a 5-year course of nAMD treat-ment, MA affected most eyes, and MA progression was significantly associated with vision decline.
C1 [Richardson, Quintin R.; Zhang, Youning; Deiner, Michael S.; Wang, Suling T.; Bhisitkul, Jonah M.; Arnold, Benjamin F.; Bhisitkul, Robert B.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Deiner, Michael S.; Arnold, Benjamin F.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA USA.
   [Bhisitkul, Robert B.] Univ Calif San Francisco, Dept Ophthalmol, Wayne & Gladys Valley Ctr Vis, 490 Illinois St,54H, San Francisco, CA 94158 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Bhisitkul, RB (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, Wayne & Gladys Valley Ctr Vis, 490 Illinois St,54H, San Francisco, CA 94158 USA.
EM Robert.Bhisitkul@ucsf.edu
FU All May See Foundation; Research to Prevent Blindness; Research to
   Prevent Blindness Medical Student Eye Research Fellowship; Core Grant
   for Vision Research from the National Institutes of Health-National Eye
   Institute [EY002162]; Genentech; Roche
FX This study was supported in part by the All May See Foundation,
   unrestricted grants from Research to Prevent Blindness, the Research to
   Prevent Blindness Medical Student Eye Research Fellowship, and a Core
   Grant for Vision Research from the National Institutes of
   Health-National Eye Institute (EY002162). RBB receives research grants
   from Genentech and Roche. The remaining authors have no relevant
   financial relationships to disclose. No proprietary interests exist for
   the materials described in the article.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Daien V, 2020, BRIT J OPHTHALMOL, V104, P1064, DOI 10.1136/bjophthalmol-2019-315055
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruppert D., 2003, SEMIPARAMETRIC REGRE
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Therneau T., 2015, PACKAGE SURVIVAL ANA, DOI DOI 10.1198/TECH.2004.S740
   Wood SN., 2017, GEN ADDITIVE MODELS, DOI 10.1201/9781315370279
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2022
VL 53
IS 10
BP 546
EP +
DI 10.3928/23258160-20220914-01
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 5S7XP
UT WOS:000875398000003
PM 36239676
DA 2022-11-30
ER

PT J
AU Almony, A
   Keyloun, KR
   Shah-Manek, B
   Multani, JK
   McGuiness, CB
   Chen, CC
   Campbell, JH
AF Almony, Arghavan
   Keyloun, Katelyn R.
   Shah-Manek, Bijal
   Multani, Jasjit K.
   McGuiness, Catherine B.
   Chen, Chi-Chang
   Campbell, Joanna H.
TI Clinical and economic burden of neovascular age-related macular
   degeneration by disease status: a US claims-based analysis
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID VEGF TREATMENT PATTERNS; VISUAL IMPAIRMENT; MEDICARE COSTS; RANIBIZUMAB;
   AFLIBERCEPT; PREVALENCE; THERAPY; OUTCOMES; EYE; COMORBIDITY
AB BACKGROUND: New treatment alternatives have revolutionized the management of nAMD. However, there is limited evidence on the clinical and economic burden of nAMD in commercially insured US patients.
   OBJECTIVES: To examine the clinical and economic burden in patients with nAMD by disease status in the commercially insured US patient population and to identify drivers of nAMD-related costs.
   METHODS: Patients with at least 1 International Classification of Diseases, 10th Revision Clinical Modification (ICD-10-CM) diagnosis for nAMD were identified from the IQVIA PharMetrics Plus database between April 2016 and August 2017 (index period). Patients had continuous enrollment for at least 6 months before and at least 12 months after the index date. Eye-level disease status was reported, along with intravitreal anti-VEGF treatment patterns. Health care resource utilization (HRU) (all-cause and nAMD-related) and direct health care costs were estimated over the 12 month follow-up period. Outcomes associated with falls and fractures were also assessed. Multivariate analysis identified drivers of annual nAMD-related outpatient costs among patients with anti-VEGF therapy. Incident patients (defined as those without an nAMD diagnosis 6 months prior to the index date) with at least 18 months of continuous enrollment after the index date were identified for a subset analysis to evaluate documented changes in disease status.
   RESULTS: A total of 6,076 patients with nAMD were identified for the prevalent cohort; 60.1%, 17.2%, and 5.9% had active CNV, inactive CNV, and inactive scar disease stage at index, respectively. The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD=$11,612]) compared with the inactive CNV ($2,406 [513.$5,510]) and inactive scar ($1,198 [SD=$3,035]) groups (P<0.0001). About 10% of prevalent patients had a falVfracture claim over 12 months of follow-up. A total of 3,623 prevalent patients (59.6%) were eligible for the anti-VEGF treatment patterns analysis (mean [SD] duration of therapy=7.7 [4.5] months; mean [SD] number of injections=6.0 [3.7]). Qualified incident cases comprised 17.8% (n=1,081) of the prevalent cohort. Approximately 20% of incident eyes with active CNV at baseline transitioned to inactive CNV. A total of 427 incident patients (39.5%) qualified for anti-VEGF treatment patterns analysis (mean [SD] duration of therapy=6.2 [4.7] months, mean [SD] number of injections =5.2 [3.5]). Significant drivers of total nAMD-related costs were the initial anti-VEGF agent and anti-VEGF injection frequency (P<0.0001) in both prevalent and incident cohorts.
   CONCLUSIONS: The clinical and economic burden of nAMD treatment is substantial to the US healthcare system, where economic burden is higher among those with active CNV. Appropriate treatment may increase the duration of inactive disease periods and preserve visual acuity white lowering costs.
C1 [Almony, Arghavan] Carolina Eye Associates, Southern Pines, NC USA.
   [Keyloun, Katelyn R.; Campbell, Joanna H.] Allergan, Global Hlth Econ & Outcomes Res, Irvine, CA 94063 USA.
   [Shah-Manek, Bijal] Noesis Hlthcare Technol Inc, Global Hlth Econ & Outcomes Res, Redwood City, CA USA.
   [Multani, Jasjit K.] IQVIA Inc, Hlth Econ & Outcomes Res, Real World Evidence, Falls Church, VA USA.
   [McGuiness, Catherine B.; Chen, Chi-Chang] IQVIA Inc, Hlth Econ & Outcomes Res, Real World Evidence, Plymouth, PA USA.
C3 AbbVie; Allergan
RP Keyloun, KR (通讯作者)，Allergan, Global Hlth Econ & Outcomes Res, Irvine, CA 94063 USA.
EM katelyn.keyloun@abbvie.com
FU Allergan, an AbbVie Company
FX This study was funded by Allergan, an AbbVie Company. Allergan employees
   were involved in the study design, interpreta-tion of data, writing of
   the manuscript, and the decision to submit for publication. Keyloun and
   Campbell are employees of Allergan. Multani, McGuiness, and Chen are
   employees of IQVIA, which received funding from Allergan for conducting
   the analysis. Almony and Shah-Manek have nothing to disclose.
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13
   HCPLive, 2018, ASRS PREF TRENDS SU
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   IQVIA, US CLAIMS IQVIA PHAR
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Kiss S, 2020, J MANAG CARE SPEC PH, V26, P253, DOI 10.18553/jmcp.2020.19245
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   National Eye Institute, AGE RELATED MACULAR
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Silva-Garcia R, 2014, CLIN OPHTHALMOL, V8, P2529, DOI 10.2147/OPTH.S68028
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Vision problems in the U.S, 2008, PREV AD VIS IMP AG R
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
NR 42
TC 0
Z9 0
U1 0
U2 1
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD SEP
PY 2021
VL 27
IS 9
BP 1260
EP 1272
PG 13
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA UN4HF
UT WOS:000693976400010
PM 34464210
OA Bronze
DA 2022-11-30
ER

PT J
AU Vyas, CH
   Cheung, CMG
   Tan, C
   Chee, C
   Wong, K
   Jordan-Yu, JMN
   Wong, TY
   Tan, A
   Fenner, B
   Sim, S
   Teo, KYC
AF Vyas, Chinmayi Himanshuroy
   Cheung, Chui Ming Gemmy
   Tan, Colin
   Chee, Caroline
   Wong, Kelly
   Jordan-Yu, Janice Marie N.
   Wong, Tien Yin
   Tan, Anna
   Fenner, Beau
   Sim, Shaun
   Teo, Kelvin Yi Chong
TI Multicentre, randomised clinical trial comparing intravitreal
   aflibercept monotherapy versus aflibercept combined with reduced-fluence
   photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal
   vasculopathy
SO BMJ OPEN
LA English
DT Article
DE clinical trials; medical ophthalmology; medical retina
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; RANIBIZUMAB;
   THICKNESS; VERTEPORFIN; RESISTANCE; EFFICACY; EYES
AB PurposeTo compare the efficacy and safety of intravitreal aflibercept (IVA) monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) (IVA+RF-PDT) for the treatment of polypoidal choroidal vasculopathy (PCV).Methods and analysisMulticentred, double-masked, randomised controlled trial to compare the two treatment modalities. The primary outcome of the study is to compare the 52-week visual outcome of IVA versus IVA+RF PDT. One hundred and sixty treatment-naive patients with macular PCV confirmed on indocyanine green angiography will be recruited from three centres in Singapore. Eligible patients will be randomised (1:1 ratio) into one of the following groups: IVA monotherapy group-aflibercept monotherapy with sham photodynamic therapy (n=80); combination group-aflibercept with RF-PDT (n=80). Following baseline visit, all patients will be monitored at 4 weekly intervals during which disease activity will be assessed based on best-corrected visual acuity (BCVA), ophthalmic examination findings, optical coherence tomography (OCT) and angiography where indicated. Eyes that meet protocol-specified retreatment criteria will receive IVA and sham/RF-PDT according to their randomisation group. Primary endpoint will be assessed as change in BCVA at week 52 from baseline. Secondary endpoints will include anatomical changes based on OCT and dye angiography as well as safety assessment. Additionally, we will be collecting optical coherence tomography angiography data prospectively for exploratory analysis.Ethics and disseminationThis study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the ICH E6 guidelines of Good Clinical Practice and the applicable regulatory requirements. Approval from the SingHealth Centralised Institutional Review Board has been sought prior to commencement of the study.Trial registration numberNCT03941587.
C1 [Vyas, Chinmayi Himanshuroy; Cheung, Chui Ming Gemmy; Wong, Kelly; Jordan-Yu, Janice Marie N.; Wong, Tien Yin; Tan, Anna; Teo, Kelvin Yi Chong] Singapore Eye Res Inst, Singapore, Singapore.
   [Vyas, Chinmayi Himanshuroy; Cheung, Chui Ming Gemmy; Wong, Tien Yin; Tan, Anna; Fenner, Beau; Sim, Shaun; Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, Med Retina, Singapore, Singapore.
   [Tan, Colin] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Chee, Caroline] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; Tan Tock Seng Hospital; National
   University of Singapore
RP Teo, KYC (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.; Teo, KYC (通讯作者)，Singapore Natl Eye Ctr, Med Retina, Singapore, Singapore.
EM kelvin.teo.y.c@singhealth.com.sg
RI Tan, Colin S/K-8972-2012; Wong, Tien Yin/AAC-9724-2020
OI Tan, Colin S/0000-0003-3088-5690; Wong, Tien Yin/0000-0002-8448-1264;
   Fenner, Beau/0000-0002-5356-7604; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Teo, Kelvin/0000-0002-7458-7081
FU National Medical Research Council Singapore open fund large
   collaborative grant [NMRC/LCG/004/2018]; Singapore Eye Research
   Institute/Singapore National Eye Centre (reference: SERI)
   [R1735/58/2020]
FX Financial support is provided by the National Medical Research Council
   Singapore open fund large collaborative grant (NMRC/LCG/004/2018). Trial
   sponsor: Singapore Eye Research Institute/Singapore National Eye Centre
   (reference: SERI Ref. No. R1735/58/2020). Address: 11 Third Hospital
   Avenue, Singapore 168751, Singapore.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2021, RETINA-J RET VIT DIS, V41, P387, DOI 10.1097/IAE.0000000000002902
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Marques JP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015785
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mendonca LSM, 2021, OPHTHALMOLOGY, V128, P1109, DOI 10.1016/j.ophtha.2020.12.022
   Ngo WK, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01419-8
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Teo KYC, 2019, ASIA-PAC J OPHTHALMO, V8, P165, DOI 10.22608/APO.201909
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 46
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2021
VL 11
IS 7
AR e050252
DI 10.1136/bmjopen-2021-050252
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TM0QA
UT WOS:000675259000011
PM 34266844
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Paun, CC
   Ersoy, L
   Schick, T
   Groenewoud, JMM
   Lechanteur, YT
   Fauser, S
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
AF Paun, Constantin C.
   Ersoy, Lebriz
   Schick, Tina
   Groenewoud, Joannes M. M.
   Lechanteur, Yara T.
   Fauser, Sascha
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Genetic Variants and Systemic Complement Activation Levels Are
   Associated With Serum Lipoprotein Levels in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE SNP; lipoprotein; AMD; complement system; lipids
ID TRANSFER PROTEIN-DEFICIENCY; PIGMENT EPITHELIAL-CELLS; GENOME-WIDE
   ASSOCIATION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; APOLIPOPROTEIN-E;
   LIPID-LEVELS; CHOLESTEROL; PLASMA; APOE
AB PURPOSE. Genetic variants in genes encoding components of lipid metabolism have been associated with AMD. The aims of this study were to evaluate the relation of these genetic variants with serum lipid levels in AMD) in a large case-control cohort (n = 3070) and to test for correlations between lipids and complement activation.
   METHODS. Single nucleotide polymorphisms (SNPs) in eight lipid metabolism genes, previously described to be associated with AMD, were genotyped and tested for their association in our case-control cohort. Serum apolipoprotein B (ApoB), apolipoprotein AI (Apo-AI), cholesterol, triglycerides (TG), high-density lipoprotein-cholesterol (HIM!), and complement activation levels (C3d/C3) were measured and tested for association with AMD. Non-HDL cholesterol and LDL were inferred based on the measurements of the other lipids and lipoproteins. General linear models and chi(2) tests were used to evaluate the relation of SNPs and lipids/lipoproteins to the disease as well as their interrelations.
   RESULTS. Significant genotypic associations with AMD were observed for SNPs in CETP, APOE, and FADS1. The serum levels of Apo-AI and HDLC were significantly higher in patients compared with controls. Triglycerides (TG) levels were lower in AMD compared with controls. A cumulative effect was observed for APOE and CETP genotypes on HDLC and Apo-AI levels. Complement activation levels correlated positively with HDLC and Apo-AI, and negatively with TG. Both the lipids/lipoproteins and the complement activation levels associate independently to AMI).
   CONCLUSIONS. This study bridges the gap between genetic associations and physiological lipid levels in MID. Additionally, the observed correlations between complement activation and lipid levels link two major systems that previously were always assessed independently.
C1 [Paun, Constantin C.; Lechanteur, Yara T.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands.
   [Paun, Constantin C.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, NL-6525 EX Nijmegen, Netherlands.
   [Ersoy, Lebriz; Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth & Evidence, NL-6525 EX Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Cologne; Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Internal Zip 409,Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Lehtimäki, Terho/AAD-1094-2022; Hollander, Anneke den/N-4911-2014; de
   Jong, Eiko/P-3407-2015; Groenewoud, Hans JMM/R-3588-2017; Lechanteur,
   Yara/ABB-6875-2020
OI Lehtimäki, Terho/0000-0002-2555-4427; de Jong, Eiko/0000-0001-6520-0407;
   Groenewoud, Hans JMM/0000-0002-4974-150X; Lechanteur,
   Yara/0000-0003-0951-4625
FU Foundation Fighting Blindness Center Grant (Columbia, MD, USA)
   [C-GE-0811-0548-RAD04]; Netherlands Organization for Scientific Research
   (Vidi Innovational Research Award, Den Haag, Zuid-Holland, The
   Netherlands) [016.096.309]
FX Supported by the Foundation Fighting Blindness Center Grant to the
   Radboud University Medical Center (Grant C-GE-0811-0548-RAD04; Columbia,
   MD, USA) and the Netherlands Organization for Scientific Research (Vidi
   Innovational Research Award 016.096.309 to AIdH; Den Haag, Zuid-Holland,
   The Netherlands).
CR Aledo R, 2015, REV ESP CARDIOL, V68, P305, DOI 10.1016/j.rec.2014.04.015
   Bel-Serrat S, 2014, BRIT J NUTR, V112, P2049, DOI 10.1017/S0007114514003183
   Birner-Gruenberger R, 2014, PROG LIPID RES, V56, P36, DOI 10.1016/j.plipres.2014.07.003
   BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chrysohoou Christina, 2003, Eur J Cardiovasc Prev Rehabil, V10, P355, DOI 10.1097/01.hjr.0000065928.57001.4d
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   de Grooth GJ, 2004, J LIPID RES, V45, P1967, DOI 10.1194/jlr.R400007-JLR200
   Deelen J, 2011, AGING CELL, V10, P686, DOI 10.1111/j.1474-9726.2011.00705.x
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gautier T, 2000, J BIOL CHEM, V275, P37504, DOI 10.1074/jbc.M007210200
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Holliday EG, 2013, PLOS ONE, V8
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537
   INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   KINOSHITA M, 1993, J LIPID RES, V34, P261
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kontush A, 2014, CARDIOVASC RES, V103, P341, DOI 10.1093/cvr/cvu147
   Langsted A, 2008, CIRCULATION, V118, P2047, DOI 10.1161/CIRCULATIONAHA.108.804146
   Lusis AJ, 2008, NAT GENET, V40, P129, DOI 10.1038/ng0208-129
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Norata GD, 2012, ATHEROSCLEROSIS, V220, P11, DOI 10.1016/j.atherosclerosis.2011.06.045
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Papp AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031930
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shamai L, 2011, OBES SURG, V21, P42, DOI 10.1007/s11695-010-0170-7
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sorli JV, 2006, CLIN CHIM ACTA, V366, P196, DOI 10.1016/j.cca.2005.10.001
   Sun L, 2014, EXP GERONTOL, V55, P129, DOI 10.1016/j.exger.2014.04.003
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Toeller M, 1999, EXP CLIN ENDOCR DIAB, V107, P512, DOI 10.1055/s-0029-1232560
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
NR 65
TC 34
Z9 36
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2015
VL 56
IS 13
BP 7766
EP 7773
DI 10.1167/iovs.15-17035
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB1BU
UT WOS:000368243800017
PM 26641553
OA Green Published
DA 2022-11-30
ER

PT J
AU Cha, DM
   Woo, SJ
   Kim, HJ
   Lee, C
   Park, KH
AF Cha, Dong Min
   Woo, Se Joon
   Kim, Hye-Jung
   Lee, Cheolju
   Park, Kyu Hyung
TI Comparative Analysis of Aqueous Humor Cytokine Levels Between Patients
   With Exudative Age-Related Macular Degeneration and Normal Controls
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE aqueous humor; exudative age-related macular degeneration; insulin-like
   growth factor binding protein-2; vascular endothelial growth factor;
   insulin-like growth factor; Raybio
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-BINDING PROTEIN-2; MONOCYTE
   CHEMOATTRACTANT PROTEIN-1; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   EPITHELIUM-DERIVED FACTOR; FACTOR-I; PIGMENT-EPITHELIUM;
   DIABETIC-RETINOPATHY; IGF-II; CELLS
AB PURPOSE. To investigate the cytokine markers associated with exudative AMD present in aqueous humor. This goal was achieved by comparing the concentrations of more than 500 molecules in aqueous humor, between exudative AMD patients and controls.
   METHODS. Aqueous humor samples were acquired from 20 patients with exudative AMD and 20 control subjects. Raybio human antibody array technology was used to simultaneously screen for any difference in the expression of any of 507 molecules. To validate the antibody array result, concentrations of insulin-like growth factor binding protein 2 (IGFBP-2), insulin-like growth factor-1 (IGF-1), and VEGF were measured by ELISA.
   RESULTS. Twenty molecules studied exhibited intergroup differences. Twelve molecules including IGFBP-2, IGFBP-6, IGFBP-7, and glucocorticoid-induced tumor necrosis factor receptor family related gene (GITR) ligand, were detected in high densities in exudative AMD patients. Eight other molecules were present at higher concentrations in control patients. ELISA confirmed that IGFBP-2 levels were higher in patients with exudative AMD (7.47 +/- 6.19 ng/mL) in comparison with control subjects (3.07 +/- 3.34 ng/mL, P = 0.008). IGF-1 and VEGF levels were also increased in the former group (2.20 +/- 0.26 vs. 1.99 +/- 0.35 ng/mL, P = 0.040; 122.25 +/- 63.24 vs. 86.98 +/- 44.41 pg/mL, P = 0.048, respectively).
   CONCLUSIONS. The pattern of cytokine expression in the aqueous humor of exudative AMD patients varies from that of normal control subjects. The increased levels of IGFBP-2 and IGF-1 in exudative AMD eyes indicate that the altered expression of IGF-related molecules may be involved in disease pathogenesis and suggests potential biomarkers for exudative AMD.
C1 [Cha, Dong Min; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Coll Med, Songnam, South Korea.
   [Cha, Dong Min] Jeju Natl Univ, Coll Med, Dept Ophthalmol, Jeju Natl Univ Hosp, Cheju, South Korea.
   [Kim, Hye-Jung; Lee, Cheolju] Korea Inst Sci & Technol, Theragnosis Res Ctr, Seoul, South Korea.
   [Kim, Hye-Jung] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA.
   [Lee, Cheolju] Univ Sci & Technol, Dept Biol Chem, Taejon, South Korea.
C3 Seoul National University (SNU); Jeju National University; Korea
   Institute of Science & Technology (KIST); Vanderbilt University
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 166 Gumiro, Songnam 463707, Gyeoggi Do, South Korea.
EM jiani4@snu.ac.kr
FU Seoul National University Bundang Hospital [02-2005-028]; National
   Research Foundation of Korea (NRF); Ministry of Education, Science, and
   Technology [2009-0072603, 2012R1A1A2008943]; Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea [A111161]
FX Supported by a research grant of Seoul National University Bundang
   Hospital (02-2005-028); National Research Foundation of Korea (NRF)
   grants funded by the Ministry of Education, Science, and Technology
   (2009-0072603, 2012R1A1A2008943); and grants from the Korea Health
   Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
   (Grant No. A111161).
CR ARNOLD DR, 1993, EXP EYE RES, V56, P555, DOI 10.1006/exer.1993.1069
   Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121
   Badinga L, 1999, J MOL ENDOCRINOL, V23, P277, DOI 10.1677/jme.0.0230277
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10
   FELDMAN EL, 1994, J CELL PHYSIOL, V158, P198, DOI 10.1002/jcp.1041580124
   Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229
   Guidry C, 2011, INVEST OPHTH VIS SCI, V52, P303, DOI 10.1167/iovs.10-5920
   Hoeflich A, 2001, ENDOCRINOLOGY, V142, P1889, DOI 10.1210/en.142.5.1889
   Hoflich A, 1998, FEBS LETT, V434, P329, DOI 10.1016/S0014-5793(98)01011-4
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kim BJ, 2004, INVEST OPHTH VIS SCI, V45, P3170, DOI 10.1167/iovs.03-0919
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Miao H, 2012, MOL VIS, V18, P574
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Mukherjee S, 2007, INVEST OPHTH VIS SCI, V48, P1892, DOI 10.1167/iovs.06-1095
   Nocentini G, 2012, BRIT J PHARMACOL, V165, P2089, DOI 10.1111/j.1476-5381.2011.01753.x
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Shaw LC, 2004, REV ENDOCR METAB DIS, V5, P199, DOI 10.1023/B:REMD.0000032408.18015.b1
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   SLOOTWEG MC, 1995, ENDOCRINOLOGY, V136, P4210, DOI 10.1210/en.136.10.4210
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   Sprenger CC, 1999, CANCER RES, V59, P2370
   Sun T, 2011, CURR EYE RES, V36, P341, DOI 10.3109/02713683.2010.545498
   Sung HJ, 2012, MOL VIS, V18, P234
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wilkinson-Berka JL, 2006, CURR MED CHEM, V13, P3307, DOI 10.2174/092986706778773086
NR 42
TC 28
Z9 31
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 10
BP 7038
EP 7044
DI 10.1167/iovs.13-12730
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 246VI
UT WOS:000326567700067
PM 24106111
DA 2022-11-30
ER

PT J
AU Thiele, S
   Rauscher, FG
   Wiedemann, P
   Dawczynski, J
AF Thiele, Simone
   Rauscher, Franziska Georgia
   Wiedemann, Peter
   Dawczynski, Jens
TI Influence of macular oedema on the measurement of macular pigment
   optical density
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular pigment optical density; Age-related macular degeneration;
   Diabetic retinopathy; Macular oedema; Fundus reflectometry;
   One-wavelength reflection method; Optical coherence tomography (OCT)
ID HUMAN CRYSTALLINE LENS; EYE DISEASE; AGE; AUTOFLUORESCENCE; CAROTENOIDS;
   LUTEIN; DEGENERATION; ZEAXANTHIN; REFLECTION; ANCILLARY
AB The purpose of this study was to determine macular pigment optical density (MPOD) in patients with macular degeneration as well as in patients with non-proliferative diabetic retinopathy.
   Fifty-one phakic patients with either age-related macular degeneration (60 eyes of 30 patients; average age, 70.9 years) or non-proliferative diabetic retinopathy (42 eyes of 21 patients; average age, 61.7 years) were included in this cross-sectional study. Within the groups, patients were divided into those suffering from macular oedema and those with no oedema. An intra-subject comparison between eyes was carried out in both groups. Data were investigated on the basis of the coefficient of determination (R (2)). Macular pigment optical density was measured by fundus reflectometry using the one-wavelength reflection method (Visucam 500; Carl Zeiss Meditec AG, Jena, Germany), in conformity with the method described by Schweitzer et al. (2010). We evaluated the maximum optical density in the measurement area (max OD) and the average optical density across the reference area in the measurement area (mean OD). Specifically, the influence of macular oedema on macular pigment optical density was examined. The subsequent measurement of retinal thickness was carried out by spectral-domain optical coherence tomography (Spectralis SD-OCT, Heidelberg Engineering GmbH, Heidelberg, Germany).
   The current study included two groups. The first group consisted of patients with non-proliferative diabetic retinopathy, as follows: no macular oedema on either side (max OD: R (2) = 43.2 %, p = 0.16; mean OD: R (2) = 68.7 %, p = 0.04); one-sided macular oedema (max OD: R-2 = 16 %, p = 0.60; mean OD: R-2 = 100 %, p = 0.04); or macular oedema in both eyes (max OD: R-2 = 79.7 %, p < 0.01; mean OD: R-2 = 81.4 %, p < 0.01). The second group comprised patients with age-related macular degeneration (AMD), as follows: non-exudative changes on both sides (max OD: R-2 = 64.0 %, p = 0.20; mean OD: R (2) = 16 %, p = 0.60); one-sided exudative macular changes (max OD: R (2) = 50.6 %, p < 0.01; mean OD: R (2) = 20.8 %, p = 0.04); or exudative macular degeneration on both sides (max OD: 3 R (2) = 6.0 %, p = 0.29; mean OD: R (2)= 81.0 %, p = 0.04). The data available presented a correlation of MPOD values of both eyes of an individual within the groups investigated. In this respect, the data of the partner eyes within the group of patients with diabetic retinopathy were more highly correlated with each other than the values of both eyes of patients suffering from age-related macular degeneration.
   The present study showed that macular oedema did not seem to have an influence on a valid measurement of MPOD by one-wavelength fundus reflectometry. Thus, meaningful data could also be obtained on patients with exudative retinal changes.
C1 [Thiele, Simone; Rauscher, Franziska Georgia; Wiedemann, Peter; Dawczynski, Jens] Univ Hosp Leipzig, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.
C3 Leipzig University
RP Dawczynski, J (通讯作者)，Univ Hosp Leipzig, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM jens.dawczynski@medizin.uni-leipzig.de
RI Rauscher, Franziska/AAV-8222-2021
OI Rauscher, Franziska/0000-0003-0183-0340
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Artigas JM, 2012, INVEST OPHTH VIS SCI, V53, P4076, DOI 10.1167/iovs.12-9471
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Buhl A., 2014, SPSS 22 EINFUHRUNG M
   Buzzi F., 1782, OPUSCOLI SCELTI SCI, V5, P87
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Collins J, 1997, AUGENHEILKUNDE
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   Dawczynski J, 2012, KLIN MONATSBL AUGENH, V229, P69, DOI 10.1055/s-0031-1273339
   Dawczynski J, 2011, KLIN MONATSBL AUGENH, V228, P57, DOI 10.1055/s-0029-1245353
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dietze H, 2008, OPTOMETRISCHE UNTERS
   FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036
   Hammer M, 2003, OPHTHALMOLOGE, V100, P611, DOI 10.1007/s00347-002-0782-y
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Komar B, 2014, GRAEF ARCH CLIN EXP, V252, P1717, DOI 10.1007/s00417-014-2627-1
   Koo E, 2014, AM J CLIN NUTR
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krohne TU, 2003, KLIN MONATSBL AUGENH, V220, P521, DOI 10.1055/s-2003-41872
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Massin P, 2002, EUR J OPHTHALMOL, V12, P102, DOI 10.1177/112067210201200205
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Moreno A, 2013, NUTR HOSP, V28, P53, DOI 10.3305/nh.2013.28.sup2.6714
   Murray IJ, 2013, GRAEF ARCH CLIN EXP, V251, P2355, DOI 10.1007/s00417-013-2430-4
   Pipis A, 2013, OSLI RETINA, V44, P260, DOI 10.3928/23258160-20130503-09
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakanishi Y, 2012, OPHTHALMOLOGICA, V228, P174, DOI 10.1159/000336721
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stringham JM, 2005, NUTR REV, V63, P59, DOI 10.1111/j.1753-4887.2005.tb00122.x
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Tsika C, 2011, ACTA OPHTHALMOL, V89, pE573, DOI 10.1111/j.1755-3768.2011.02170.x
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Wolf S, 2006, GRAEF ARCH CLIN EXP, V244, P1562, DOI 10.1007/s00417-006-0336-0
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Zagers NPA, 2005, VISION RES, V45, P1745, DOI 10.1016/j.visres.2004.12.011
NR 53
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2016
VL 254
IS 3
BP 455
EP 465
DI 10.1007/s00417-015-3079-y
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF3SK
UT WOS:000371267600006
PM 26100452
DA 2022-11-30
ER

PT J
AU Zhou, Y
AF Zhou, Ying
TI Two Co(II)-coordination polymers: reducing the inflammasome activation
   and exerting treatment activity on age-related macular degeneration
SO INORGANIC AND NANO-METAL CHEMISTRY
LA English
DT Article
DE Coordination complexes; macular degeneration; solvothermal condition
AB Two new cobalt(II) coordination polymers based on H(4)bpta (H(4)bpta = 3,3 ',5,5 '-biphenyltetracarboxylic acid) and N-donor ligands, namely [Co-2(1,3-bimb)(2)(bpta)] (n) center dot 2nH(2)O (1) and [Co-2(1,4-bib)(2)(bpta)] (n) center dot 2n(H2O center dot DMF) (2), (1,4-bib = 1,4-bis(imidazol-1-yl)benzene, 1,3-bimb = 1,3-bis((1H-imidazol-1-yl)methyl)benzene), have been obtained under solvothermal conditions. Series of biological experiments were performed for the biological activity evaluation. Firstly, the western blotting assay was performed to evaluate the inflammasome activation in the endothelial cells of retina after compound treatment. Besides, the enzyme linked immunosorbent assay (ELISA) detection kit was used to measure the down-stream production of the inflammasome activation.
C1 [Zhou, Ying] Shandong Management Univ, Coll Ind & Commerce, Jinan, Shandong, Peoples R China.
C3 Shandong Management University
RP Zhou, Y (通讯作者)，Shandong Management Univ, Coll Ind & Commerce, Jinan, Shandong, Peoples R China.
EM zhouying200506@163.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Chen DM, 2019, J SOLID STATE CHEM, V278, DOI 10.1016/j.jssc.2019.120906
   Chen DM, 2019, CRYSTENGCOMM, V21, P4696, DOI 10.1039/c9ce00760a
   Duan CX, 2020, IND ENG CHEM RES, V59, P18857, DOI 10.1021/acs.iecr.0c02437
   Ghorai P, 2019, CRYST GROWTH DES, V19, P6431, DOI 10.1021/acs.cgd.9b00891
   Han Z, 2015, J MATER CHEM A, V3, P23716, DOI 10.1039/c5ta05605e
   Jiang N, 2020, INT J ELECTROCHEM SC, V15, P5520, DOI 10.20964/2020.06.50
   Li AL, 2020, CRYSTENGCOMM, V22, P2656, DOI 10.1039/d0ce00077a
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Seco JM, 2016, INORG CHEM, V55, P11230, DOI 10.1021/acs.inorgchem.6b01845
   Shi YS, 2020, CRYSTENGCOMM, V22, P4875, DOI 10.1039/d0ce00594k
   Shi YS, 2020, J MOL STRUCT, V1201, DOI 10.1016/j.molstruc.2019.127218
   Tian SY, 2020, SUPRAMOL CHEM, V32, P365, DOI 10.1080/10610278.2020.1739285
   Wei XJ, 2020, J SOLID STATE CHEM, V284, DOI 10.1016/j.jssc.2020.121218
   Xiao QQ, 2019, POLYHEDRON, V158, P342, DOI 10.1016/j.poly.2018.11.016
   Xiao QQ, 2019, INORG CHEM, V58, P15696, DOI 10.1021/acs.inorgchem.9b02534
   Xu Y, 2018, J MOL STRUCT, V1155, P72, DOI 10.1016/j.molstruc.2017.11.005
   Yang YJ, 2020, CRYSTENGCOMM, V22, P1166, DOI 10.1039/c9ce01546a
   Zhang X, 2013, CRYST GROWTH DES, V13, P3177, DOI 10.1021/cg400579w
   Zhao JW, 2021, SCI TOTAL ENVIRON, V752, DOI 10.1016/j.scitotenv.2020.141932
   Zhu H, 2020, J SOLID STATE CHEM, V282, DOI 10.1016/j.jssc.2019.121132
NR 22
TC 0
Z9 0
U1 2
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2470-1556
EI 2470-1564
J9 INORG NANO-MET CHEM
JI Inorg. Nano-Met. Chem.
PD JAN 2
PY 2022
VL 52
IS 1
BP 144
EP 150
DI 10.1080/24701556.2020.1862230
EA DEC 2020
PG 7
WC Chemistry, Inorganic & Nuclear; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics
GA XX8FY
UT WOS:000604991700001
DA 2022-11-30
ER

PT J
AU Chaikitmongkol, V
   Nanegrungsunk, O
   Patikulsila, D
   Ruamviboonsuk, P
   Bressler, NM
AF Chaikitmongkol, Voraporn
   Nanegrungsunk, Onnisa
   Patikulsila, Direk
   Ruamviboonsuk, Paisan
   Bressler, Neil M.
TI Repeatability and Agreement of Visual Acuity Using the ETDRS Number
   Chart, Landolt C Chart, or ETDRS Alphabet Chart in Eyes With or Without
   Sight-Threatening Diseases
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY
AB IMPORTANCE The Early Treatment Diabetic Retinopathy Study (ETDRS) alphabet chart is not feasible for measuring best-corrected visual acuity (BCVA) for individuals who are unfamiliar with the Roman alphabet. The ETDRS Landolt C chart is an alternative, but it may not reflect true BCVA among those with confusion between left and right. The ETDRS number chart might overcome these limitations, but little is known regarding its reliability.
   OBJECTIVE To evaluate repeatability and agreement of BCVA using the ETDRS number chart or Landolt C chart compared with ETDRS alphabet charts in healthy and diseased eyes.
   DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study was conducted in Thailand from July 1, 2015, to June 30, 2016, among 154 adult Thai individuals. Those who could read Roman alphabets were classified into the following 4 groups, using 1 eye per participant: group A, which comprised 60 healthy eyes (BCVA, 20/20-20/25); group B, which comprised 40 eyes with age-related cataract, diabetic macular edema, or age-related macular degeneration (BCVA, 20/20-20/40); group C, which comprised 40 eyes with age-related cataract, diabetic macular edema, or age-related macular degeneration (BCVA, 20/50-20/100); and group D, which comprised 14 eyes with age-related cataract, diabetic macular edema, or age-related macular degeneration (BCVA, 20/125-20/200).
   INTERVENTIONS Two standardized 4-m BCVA measurements with 3 different Precision Vision ETDRS charts (PV number, Landolt C, and alphabet), in random sequence, performed 30 minutes apart.
   MAIN OUTCOMES AND MEASURES Repeatability, agreement, and testing duration of BCVA.
   RESULTS Of 154 Thai participants (82 women and 72 men; mean [SD] age, 52.9 [18.2] years), the ETDRS number chart had strong repeatability coefficients (group A, 0.61 [95% CI, 0.42-0.75]; group B, 0.87 [95% CI, 0.78-0.93]; group C, 0.81 [95% CI, 0.67-0.90]; and group D, 0.81 [95% CI, 0.49-0.94]). Concordance correlation coefficients between the number and alphabet chartswere also strong (group A, 0.89 [95% CI, 0.82-0.93]; group B, 0.97 [95% CI, 0.94-0.98]; group C, 0.92 [95% CI, 0.86-0.96]; and group D, 0.96 [95% CI, 0.87-0.99]), while the concordance correlation coefficients between the Landolt C and alphabet chartswere lower (group A, 0.72 [95% CI, 0.52-0.83]; group B, 0.83 [95% CI, 0.68-0.91]; group C, 0.79 [95% CI, 0.61-0.89]; and group D, 0.89 [95% CI, 0.66-0.97]). The mean letter score difference between the number and alphabet chartswas 1 (95% limits of agreement, -4 to + 6) compared with -7 (95% limits of agreement, -18 to + 5; P < .001) between the Landolt C and alphabet charts.
   CONCLUSIONS AND RELEVANCE The repeatability coefficients and concordance correlation coefficients suggest that ETDRS number charts are viable for measuring BCVA in clinical practice and trials for individuals who are unfamiliar with the Roman alphabet.
C1 [Chaikitmongkol, Voraporn; Patikulsila, Direk] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai, Thailand.
   [Nanegrungsunk, Onnisa] Chiang Mai Univ, Dept Ophthalmol, Fac Med, Chiang Mai, Thailand.
   [Ruamviboonsuk, Paisan] Rajvithi Hosp, Dept Ophthalmol, Retina Div, Bangkok, Thailand.
   [Bressler, Neil M.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Retina Div, Baltimore, MD 21218 USA.
C3 Chiang Mai University; Chiang Mai University; Rajavithi Hospital; Johns
   Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, Retina Div, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Chaikitmongkol, Voraporn/0000-0003-0426-7602
FU Research Committee, Faculty of Medicine, Chiang Mai University
FX Funding of this study was provided by the Research Committee, Faculty of
   Medicine, Chiang Mai University and unrestricted funds to Johns Hopkins
   University for retina research.
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Koenig S, 2014, GRAEF ARCH CLIN EXP, V252, P1093, DOI 10.1007/s00417-014-2670-y
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   Ruamviboonsuk P, 2003, AM J OPHTHALMOL, V136, P662, DOI 10.1016/S0002-9394(03)00394-5
   Treacy MP, 2015, OPHTHALMOLOGY, V122, P1062, DOI 10.1016/j.ophtha.2014.11.024
   1980, ADV OPHTHALMOL, V41, P103
NR 10
TC 12
Z9 12
U1 2
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2018
VL 136
IS 3
BP 286
EP 290
DI 10.1001/jamaophthalmol.2017.6290
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY6TC
UT WOS:000426994200014
PM 29346499
OA Green Published
DA 2022-11-30
ER

PT J
AU Jang, LN
   Gianniou, C
   Ambresin, A
   Mantel, I
AF Jang, Liuna
   Gianniou, Christina
   Ambresin, Aude
   Mantel, Irmela
TI Refractory subretinal fluid in patients with neovascular age-related
   macular degeneration treated with intravitreal ranibizumab: visual
   acuity outcome
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Refractory subretinal
   fluid; Ranibizumab; Anti-VEGF; Intravitreal injections
ID SUBGROUP ANALYSIS; EFFICACY; SAFETY
AB To investigate the functional outcome of eyes with neovascular AMD (nAMD) and subretinal fluid (SRF) refractory to treatment with ranibizumab.
   Retrospective chart review of consecutive treatment-refractory SRF in nAMD despite monthly ranibizumab injections during 12 months or more. Data were evaluated for baseline characteristics, location of the refractory SRF, mean visual acuity (VA) change, number of injections, and timepoint of first complete disappearance of SRF.
   Forty-five eyes in 44 patients (mean age of 76 years) were included. The mean follow-up was 32.4 months (range 12-73 months). The mean number of injections was 11.6 in the first year and 27.5 over follow-up. The refractory SRF was located subfoveally in 66.7 %. In 12 eyes (26.7 %), complete absorption of SRF was found after a mean of 22.6 months (range, 13-41 months). Mean VA increased by 10.4, 8.2, and 8.6 letters by month 12, 24, and 36, respectively.
   Neovascular AMD with SRF refractory to monthly retreatment with ranibizumab may still allow good and maintained visual improvement, even if the fluid is located subfoveally. SRF may progressively absorb under continuous monthly treatment. The necessity to treat refractory SRF with monthly injections could be questioned and would need future investigations.
C1 [Jang, Liuna; Gianniou, Christina; Ambresin, Aude; Mantel, Irmela] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Jang, Liuna; Gianniou, Christina; Ambresin, Aude; Mantel, Irmela] Jules Gonin Eye Hosp, Lausanne, Switzerland.
   [Jang, Liuna; Gianniou, Christina; Ambresin, Aude; Mantel, Irmela] Fdn Asile Aveugles, Lausanne, Switzerland.
   [Mantel, Irmela] Univ Eye Hosp Jules Gonin, CH-1000 Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Ave France Case Postale 133, CH-1000 Lausanne, Switzerland.
EM i.mantel.widmer@gmx.ch
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Roisman L, 2014, RETINA-J RET VIT DIS, V34, P713, DOI 10.1097/IAE.0b013e3182a323fe
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 15
TC 20
Z9 20
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 253
IS 8
BP 1211
EP 1216
DI 10.1007/s00417-014-2789-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9AA
UT WOS:000358736700002
PM 25267418
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lennikov, A
   Saddala, MS
   Mukwaya, A
   Tang, SB
   Huang, H
AF Lennikov, Anton
   Saddala, Madhu Sudhana
   Mukwaya, Anthony
   Tang, Shibo
   Huang, Hu
TI Autoimmune-Mediated Retinopathy in CXCR5-Deficient Mice as the Result of
   Age-Related Macular Degeneration Associated Proteins Accumulation
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE age macular degeneration; AMD; CXCR5; CXCL13; autoantibody; CRYAA;
   CRYAB; amyloid beta
ID RETINAL-PIGMENT EPITHELIUM; ALPHA-B-CRYSTALLIN; COMPLEMENT-SYSTEM;
   CELL-DEATH; EXPRESSION; PATHOGENESIS; MACULOPATHY; DYSFUNCTION;
   ACTIVATION; KNOCKOUT
AB Previous research has shown that CXCR5(-/-) mice develop retinal degeneration (RD) with age, a characteristic related to age macular degeneration (AMD). RD in these mice is not well-understood, and in this study, we sought to characterize further the RD phenotype and to gain mechanistic insights into the function of CXCR5 in the retina. CXCR5(-/-) and WT control mice were used. Fundus images demonstrated a significant (p < 0.001) increase of hypo-pigmented spots in the retina of aged CXCR5(-/-) mice compared with WT control mice. PAS staining indicated localization of deposits in the sub-retinal pigment epithelia (RPE) layer. AMD-associated proteins Cryab, amyloid beta, and C3d were detected within the RPE/sub-RPE tissues by immunofluorescence (IF). In addition, western blot analysis of COX-2, Arg1, and VEGF-a revealed an increase in the signaling of these molecules within the RPE/choroid complex. Transmission electron microscopy (TEM) indicated a drusen-like structure of sub-RPE deposits with an accumulation of vacuolated cellular debris. Loss of photoreceptors was detected by peanut lectin staining and was corroborated by a reduction in MAP2 signaling. Loss of blood-retinal barrier integrity was demonstrated by a reduction of ZO-1 expression. Inflammatory cells were detected in the sub-RPE space, with an increase in IBA-1 positive microglia cells on the surface of the RPE. Mass spectrometry analysis of CXCR5(-/-) mouse RPE/choroid proteins extracts, separated by SDS-page and incubated with autologous serum, identified autoantibodies against AMD-associated proteins: Cryaa, Cryab, and Anxa2. In vitro evaluations in BV-2 cell culture indicated a significant increase in production of Arg-1 (p < 0.001) and COX-2 (p < 0.01) in the presence of anti-CXCR5 antibody when compared with Igg-treated control BV-2 cells stimulated with IL-4 and TNF alpha/IFN gamma, respectively. Anti-CXCR5 antibody treatment without stimulating agents did not affect Arg-1 and COX-2 expression; this suggests that CXCR5 may have a regulatory role in microglia cells activation. These results indicate that with age, CXCR5(-/-) mice develop RD characterized by microglia dysfunction, increased production of CXCL13 in the RPE progressive photoreceptor, neuronal loss, and sub-RPE deposition of cellular debris, resulting in the production of immunogenic proteins and autoimmune-mediated RD.
C1 [Lennikov, Anton; Saddala, Madhu Sudhana; Huang, Hu] Univ Missouri, Dept Ophthalmol, Columbia, MO 65211 USA.
   [Lennikov, Anton; Saddala, Madhu Sudhana; Huang, Hu] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
   [Mukwaya, Anthony] Linkoping Univ, Dept Ophthalmol, Fac Hlth Sci, Inst Clin & Expt Med, Linkoping, Sweden.
   [Tang, Shibo] Cent S Univ, Aier Sch Ophthalmol, Aier Eye Inst, Changsha, Hunan, Peoples R China.
C3 University of Missouri System; University of Missouri Columbia; Johns
   Hopkins University; Linkoping University; Central South University
RP Huang, H (通讯作者)，Univ Missouri, Dept Ophthalmol, Columbia, MO 65211 USA.; Huang, H (通讯作者)，Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.
EM huangh1@health.missouri.edu
RI TANG, Shi/GXH-5719-2022; Saddala, Madhu Sudhana/C-6147-2018; Mukwaya,
   Anthony/K-2335-2019
OI Saddala, Madhu Sudhana/0000-0002-6373-7080; Mukwaya,
   Anthony/0000-0002-9645-8942
FU BrightFocus Foundation [M2014124]; Missouri University start-up fund (Hu
   Huang research group); NSFC fund [81870677]
FX This work was supported by BrightFocus Foundation (M2014124), Missouri
   University start-up fund (Hu Huang research group), and NSFC fund
   (81870677).
CR Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Aloisi F, 2008, J NEUROIMMUNOL, V198, P106, DOI 10.1016/j.jneuroim.2008.04.025
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Dentchev T, 2003, MOL VIS, V9, P184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   HAN ZP, 2017, PLOS ONE, V12
   Hornik TC, 2016, J CELL SCI, V129, P65, DOI 10.1242/jcs.174631
   Huber AK, 2015, ADV NEUROIMMUNE BIOL, V6, P1, DOI 10.3233/NIB-150101
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Jung WK, 2010, BRIT J PHARMACOL, V159, P1274, DOI 10.1111/j.1476-5381.2009.00615.x
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kielczewski JL, 2016, J IMMUNOL, V196, P1013, DOI 10.4049/jimmunol.1501570
   Kizil C, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-27
   Larti F, 2015, EUR J HUM GENET, V23, P416, DOI 10.1038/ejhg.2014.152
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Latta CH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0243-6
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Magliozzi R, 2004, J NEUROIMMUNOL, V148, P11, DOI 10.1016/j.jneuroim.2003.10.056
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374
   Mitkin NA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09330
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patil R, 2018, J OCUL PHARMACOL TH, V34, P177, DOI 10.1089/jop.2017.0024
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Stuart MJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-31
   Tanabe S, 2018, NAT NEUROSCI, V21, P506, DOI 10.1038/s41593-018-0106-4
   Torres M, 2003, BIOFACTORS, V17, P287, DOI 10.1002/biof.5520170128
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   van Noort JM, 2010, J NEUROPATH EXP NEUR, V69, P694, DOI 10.1097/NEN.0b013e3181e4939c
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Waehre A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018668
   Xiao H, 2014, TUMOR BIOL, V35, P5273, DOI 10.1007/s13277-014-1686-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang Q, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0652-1
   Zhao SH, 2010, CHINESE MED J-PEKING, V123, P713, DOI 10.3760/cma.j.issn.0366-6999.2010.06.014
   Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604
NR 52
TC 11
Z9 11
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 14
PY 2019
VL 10
AR 1903
DI 10.3389/fimmu.2019.01903
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA IQ4JZ
UT WOS:000480718300001
PM 31474986
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dong, ZZ
   Li, J
   Leng, YX
   Sun, XR
   Hu, HL
   He, Y
   Tan, ZQ
   Ge, J
AF Dong, Zhizhang
   Li, Juan
   Leng, Yunxia
   Sun, Xuerong
   Hu, Huiling
   He, Yuan
   Tan, Zhiqun
   Ge, Jian
TI Cyclic intensive light exposure induces retinal lesions similar to
   age-related macular degeneration in APPswe/PS1 bigenic mice
SO BMC NEUROSCIENCE
LA English
DT Article
ID INDUCED PHOTORECEPTOR DEGENERATION; AMYLOID-BETA; ALZHEIMERS-DISEASE;
   MOUSE MODEL; CHOROIDAL NEOVASCULARIZATION; MECHANISMS; PROTEIN; DRUSEN;
   ACTIVATION; DAMAGE
AB Background: Intensive light exposure and beta-amyloid (A beta) aggregates have been known as a risk factor for macular degeneration and an important component in the pathologic drusen structure involved in this disorder, respectively. However, it is unknown whether A beta deposition mediates or exacerbates light exposure-induced pathogenesis of macular degeneration. Several studies including the one from us already showed accumulation of A beta deposits in the retina in Alzheimer's transgenic mice. Using histopathological analysis combined with electroretinographic functional assessment, we investigated the effects of cyclic intensive light exposure (CILE) on the architecture of retina and related function in the APPswe/PS1bigenic mouse.
   Results: Histopathological analysis has found significant loss of outer nuclear layer/photoreceptor outer segment and outer plexiform layer along with abnormal hypo- and hyper-pigmentation in the retinal pigment epithelium (RPE), remarkable choroidal neovascularization (CNV), and exaggerated neuroinflammatory responses in the outer retina of APPswe/PS1 bigenic mice following cyclic intensive light exposure (CILE), whereas controls remained little change contrasted with age-matched non-transgenic littermates. CILE-induced degenerative changes in RPE are further confirmed by transmission electron microcopy and manifest as formation of basal laminar deposits, irregular thickening of Bruch's membrane (BrM), deposition of outer collagenous layer (OCL) in the subretinal space, and vacuolation in the RPE. Immunofluorescence microscopy reveals drusenoid A beta deposits in RPE as well as neovessels attached which are associated with disruption of RPE integrity and provoked neuroinflammatory response as indicated by markedly increased retinal infiltration of microglia. Moreover, both immunohistochemistry and Western blots detect an induction of vascular endothelial growth factor (VEGF) in RPE, which corroborates increased CNV in the outer retina in the bigenic mice challenged by CILE.
   Conclusions: Our findings demonstrate that degenerative changes in the outer retina in the APPswe/PS1 bigenic mouse induced by CILE are consistent with these in AMD. These results suggest that an Alzheimer's transgenic animal model with accumulation of A beta deposits might be an alternative animal model for AMD, if combined with other confounding factors such as intensive light exposure for AMD.
C1 [Tan, Zhiqun] Univ Calif Irvine, Sch Med, Dept Neurol, Irvine, CA 92697 USA.
   [Dong, Zhizhang; Li, Juan; Leng, Yunxia; Sun, Xuerong; Hu, Huiling; He, Yuan; Ge, Jian] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Tan, Zhiqun] Univ Calif Irvine, Sch Med, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; Sun
   Yat Sen University; University of California System; University of
   California Irvine
RP Tan, ZQ (通讯作者)，Univ Calif Irvine, Sch Med, Dept Neurol, Irvine, CA 92697 USA.
EM tanz@uci.edu; gejian@mail.sysu.edu.cn
FU National Basic Research Program of China (973) [2007CB512207]; National
   Natural Science Foundation of China [30973266]; University of California
   Irvine Alzheimer's Disease Research Center
FX The study was supported by National Basic Research Program of China
   (973) 2007CB512207 and National Natural Science Foundation of China
   (30973266) to JG and University of California Irvine Alzheimer's Disease
   Research Center Grant to ZT.
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789
   Boscolo E, 2007, INT J MOL MED, V19, P581
   BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cai ZY, 2011, NEUROMOL MED, V13, P223, DOI 10.1007/s12017-011-8155-9
   Castellani RJ, 2011, J PATHOL, V224, P147, DOI 10.1002/path.2885
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Duncan JL, 2010, ARCH OPHTHALMOL-CHIC, V128, P244, DOI 10.1001/archophthalmol.2009.399
   El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004
   Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753
   Hageman GS., 2008, AGE RELATED MACULAR
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Hollborn M, 2008, INVEST OPHTH VIS SCI, V49, P1262, DOI 10.1167/iovs.07-0879
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043
   Li J, 2011, BIOCHEM BIOPH RES CO, V410, P40, DOI 10.1016/j.bbrc.2011.05.101
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marco-Gomariz MA, 2006, J COMP NEUROL, V498, P163, DOI 10.1002/cne.21028
   MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001
   Santos AM, 2010, J COMP NEUROL, V518, P477, DOI 10.1002/cne.22227
   Thakker DR, 2009, P NATL ACAD SCI USA, V106, P4501, DOI 10.1073/pnas.0813404106
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wakisaka Y, 2010, J CEREBR BLOOD F MET, V30, P56, DOI 10.1038/jcbfm.2009.183
   Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang B, 2005, AM J PATHOL, V167, P1361, DOI 10.1016/S0002-9440(10)61223-0
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
NR 54
TC 6
Z9 7
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2202
J9 BMC NEUROSCI
JI BMC Neurosci.
PD MAR 24
PY 2012
VL 13
AR 34
DI 10.1186/1471-2202-13-34
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 932ZW
UT WOS:000303330000001
PM 22443196
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Eris, E
   Vural, E
AF Eris, Erdem
   Vural, Esra
TI Early retinal and choroidal effect of photodynamic treatment in patients
   with polypoidal choroidal vasculopathy with or without anti-vascular
   endothelial growth factor: An optical coherence tomography angiography
   study
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Photodynamic therapy; Vascular
   endothelial growth factor; OCT angiography
ID THERAPY; RANIBIZUMAB; NEOVASCULARIZATION; COMBINATION
AB Purpose: To evaluate the early retinal and choroidal effects of the anti-vascular endothelial growth factor (antiVEGF) therapy combined with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).
   Methods: Patients diagnosed as having PCV were included in the study. In group 1, intravitreal ranibizumab and PDT was applied to six eyes. In group 2, PDT treatment only was applied to four eyes. Optical coherence tomography (OCT) angiography images and best-corrected visual acuity (BCVA) were taken from all patients before treatment and 3 days after surgery.
   Results: The mean age of the patients was 66.00 +/- 6.28 years. In group 1, the initial BCVA was 0.70 +/- 0.35 logMAR and the final BCVA was 1.1 +/- 0.78 logMAR. In group 2, the initial BCVA was 0.47 +/- 0.17 logMAR and the final BCVA was 0.50 +/- 0.21 logMAR. In group 1, flow rate significantly decreased in the superficial area (p = 0.028), the flow rate also decreased in other layers but they were not statistically significant (p < 0.05). In group 2, the flow rate decreased but these changes were not statistically significant (p > 0.05). Vascular constriction and choroidal ischemia were seen in two patients in group 1.
   Conclusion: In the short term, retinal and choroidal blood flow decreased after PDT treatment. However, statistically significant changes were seen only in the superficial area in group 1.
C1 [Eris, Erdem] Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Bereketzade Cami Sok 2, Istanbul, Turkey.
   [Vural, Esra] Mardin Govt Hosp, Mardin, Turkey.
C3 University of Health Sciences Turkey; Mardin State Hospital
RP Eris, E (通讯作者)，Univ Hlth Sci, Beyoglu Eye Training & Res Hosp, Bereketzade Cami Sok 2, Istanbul, Turkey.
EM erdem-eris@hotmail.com
CR Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Demircan A, 2018, PHOTODIAGN PHOTODYN, V21, P375, DOI 10.1016/j.pdpdt.2018.01.015
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Peiretti E., 2018, RETINA
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sakurai M, 2014, CLIN OPHTHALMOL, V8, P235, DOI 10.2147/OPTH.S54578
   Suzuki N, 2016, AM J OPHTHALMOL, V161, P126, DOI 10.1016/j.ajo.2015.09.038
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhao M, 2017, INT J OPHTHALMOL-CHI, V10, P413, DOI 10.18240/ijo.2017.03.14
NR 20
TC 2
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2019
VL 25
BP 1
EP 6
DI 10.1016/j.pdpdt.2018.10.007
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HU1VJ
UT WOS:000465059600001
PM 30352287
DA 2022-11-30
ER

PT J
AU Mann, SS
   Rutishauser-Arnold, Y
   Peto, T
   Jenkins, SA
   Leung, I
   Xing, W
   Bird, AC
   Bunce, C
   Webster, AR
AF Mann, Samantha S.
   Rutishauser-Arnold, Yvonne
   Peto, Tunde
   Jenkins, Sharon A.
   Leung, Irene
   Xing, Wen
   Bird, Alan C.
   Bunce, Catey
   Webster, Andrew R.
TI The symmetry of phenotype between eyes of patients with early and late
   bilateral age-related macular degeneration (AMD)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Geographic atrophy; Phenotype; Symmetry
ID BRUCH MEMBRANE CHANGE; CHOROIDAL NEOVASCULARIZATION; FAMILIAL
   AGGREGATION; POSTMORTEM EYES; 2ND EYE; MACULOPATHY; DRUSEN; RISK;
   LESIONS; POLYMORPHISM
AB Macular degeneration is known to be a bilateral disease. This study set out to determine the symmetry of phenotype between eyes of patients with bilateral early AMD (or drusen) or late-stage AMD. This may be important information when considering the likelihood of anti-VEGF treatment.
   This prospective, observational, cross-sectional study graded the color fundus photographs of both eyes of 1,114 Caucasian patients with either early or late-stage AMD. Patients were recruited from a tertiary referral UK population. The main outcomes were phenotype, comparison of number, type and overall area of drusen in early AMD and symmetry of late AMD.
   The overall agreement of phenotype in the entire cohort of patients was 53%, kappa statistic (kappa)=0.31, (95% CI = 0.27-0.36). Within this group, a total of 271 patients were identified with bilateral soft and hard drusen (early AMD). Symmetry of phenotype within this group was high in terms of total of area of drusen (agreement = 79%, weighted kappa = 0.75) and number of drusen. In those with bilateral geographic atrophy (GA), symmetry between area of GA was moderate (agreement 72%, weighted kappa = 0.54), and in those with bilateral neovascular disease (choroidal neovascularization or pigment epithelial detachment), symmetry was poor (agreement 45%, weighted kappa = 0.16). Out of the entire cohort, 62% (n = 688) had neovascular disease in at least one eye and 37.5% of these had bilateral disease.
   The observed symmetry of phenotype between eyes with drusen appears to reduce in GA and neovascular forms of AMD. Overall, 53% of the cohort had symmetrical disease in terms of phenotype, 23% had neovascular disease in both eyes, 9.3% had GA in both eyes, and 39% of patients had neovascular disease in one eye and non-neovascular disease in the other. This may have implications for the potential need for anti-VEGF treatment of AMD in second eye involvement.
C1 [Jenkins, Sharon A.; Webster, Andrew R.] Inst Ophthalmol, London EC1V 9EL, England.
   [Mann, Samantha S.; Rutishauser-Arnold, Yvonne; Peto, Tunde; Jenkins, Sharon A.; Leung, Irene; Xing, Wen; Bird, Alan C.; Bunce, Catey; Webster, Andrew R.] Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Mann, SS (通讯作者)，St Thomas Hosp, Westminster Bridge Rd, London SE1 7EH, England.
EM samantha.mann45@googlemail.com
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Bunce, Catey/0000-0002-0935-3713
FU Medical Research Council; Foundation for Fighting Blindness; Friends of
   Moorfield's
FX Supported by Grants from: The Medical Research Council (SD and SJ), The
   Foundation for Fighting Blindness (SD) and the Friends of Moorfield's
   (TP).
CR BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   LEWIS H, 1986, AM J OPHTHALMOL, V102, P801, DOI 10.1016/0002-9394(86)90417-4
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   ROY M, 1990, Eye (London), V4, P813
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 28
TC 21
Z9 21
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2011
VL 249
IS 2
BP 209
EP 214
DI 10.1007/s00417-010-1483-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 723ML
UT WOS:000287510600008
PM 20737163
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Flood, VM
   Joachim, N
   Burlutsky, G
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Flood, Victoria M.
   Joachim, Nichole
   Burlutsky, George
   Mitchell, Paul
TI Combined influence of poor health behaviours on the prevalence and
   15-year incidence of age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIETARY MODIFICATION; 10-YEAR INCIDENCE; LIFE-STYLE; RISK; CAROTENOIDS;
   MACULOPATHY; PIGMENT; QUESTIONNAIRE; ASSOCIATIONS; PROGRESSION
AB We aimed to establish the collective influence of four lifestyle practices (physical activity, diet, smoking and alcohol consumption) on the prevalence and incidence of AMD. At baseline, 2428 participants aged 49+ with complete lifestyle and AMD data were examined, and of these, 1903 participants were re-examined 15 years later. AMD was assessed from retinal photographs. A health behaviour score was calculated, allocating 1 point for each poor behaviour: current smoking; fruits and vegetables consumed < 4 serves daily; < 3 episodes of physical activity per week; and > 2 alcoholic drinks per day. Cross-sectional analysis showed that participants who engaged in all 4 poor health behaviours (n = 29) versus those who did not engage in unhealthy behaviours (reference group; n = 677) had greater odds of any and late AMD: multivariable-adjusted OR, 5.14 (95% CI, 1.04-25.45) and OR 29.53 (95% CI 2.72-321.16), respectively. A marginally non-significant association was observed between increasing number of poor health behaviours and 15-year incidence of early AMD (multivariable-adjusted P-trend = 0.08). Our data suggests that motivating patients with AMD to eat better, exercise more, limit alcohol intake and avoid smoking seems advisable to decelerate the development or worsening of existing AMD.
C1 [Gopinath, Bamini; Liew, Gerald; Joachim, Nichole; Burlutsky, George; Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
   [Flood, Victoria M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.
   [Flood, Victoria M.] Western Sydney Local Hlth Dist, Westmead Hosp, Westmead, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney
RP Gopinath, B (通讯作者)，Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
EM bamini.gopinath@sydney.edu.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022; Gopinath,
   Bamini/K-4286-2019
OI Flood, Victoria M/0000-0001-5310-7221; Gopinath,
   Bamini/0000-0003-3573-359X
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Blackmores and Macular Disease Foundation Australia Dr
   Paul Beaumont Fellowship
FX The Blue Mountains Eye and Hearing Studies were supported by the
   Australian National Health and Medical Research Council (Grant Nos
   974159, 991407, 211069, 262120). Bamini Gopinath is supported by a
   Blackmores and Macular Disease Foundation Australia Dr Paul Beaumont
   Fellowship.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Institute of Health National Heart Foundation & Risk Factor Prevalence Study Management Committee, 1980, RISK FACT PREV STUD
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Gopinath B, 2010, ARCH INTERN MED, V170, P1605, DOI 10.1001/archinternmed.2010.303
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kvaavik E, 2010, ARCH INTERN MED, V170, P711, DOI 10.1001/archinternmed.2010.76
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McLennan W. A. S., 1995, CONFIDENTIALISED UNI
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   National Health and Medical Research Council, 2009, AUSTR GUID RED HLTH
   National Health & Medical Research Council, 2003, DIET GUID AUSTR AD
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Vincent HK, 2007, DIABETES OBES METAB, V9, P813, DOI 10.1111/j.1463-1326.2007.00692.x
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 38
TC 8
Z9 8
U1 0
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 28
PY 2017
VL 7
AR 4359
DI 10.1038/s41598-017-04697-3
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EY8SX
UT WOS:000404268900047
PM 28659620
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Akuffo, KO
   Beatty, S
   Stack, J
   Peto, T
   Leung, I
   Corcoran, L
   Power, R
   Nolan, JM
AF Akuffo, Kwadwo Owusu
   Beatty, Stephen
   Stack, Jim
   Peto, Tunde
   Leung, Irene
   Corcoran, Laura
   Power, Rebecca
   Nolan, John M.
TI Concordance of Macular Pigment Measurement Using Customized
   Heterochromatic Flicker Photometry and Fundus Autofluorescence in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular pigment; customized heterochromatic flicker photometry; fundus
   autofluorescence; age-related macular degeneration; concordance;
   agreement
ID DUAL-WAVELENGTH AUTOFLUORESCENCE; OPTICAL-DENSITY; VISUAL FUNCTION;
   CAROTENOID FORMULATIONS; OCULAR FUNDUS; IN-VIVO; LUTEIN; ZEAXANTHIN;
   SUPPLEMENTATION; IDENTIFICATION
AB PURPOSE. We compared macular pigment (MP) measurements using customized heterochromatic flicker photometry (Macular Metrics Densitometer) and dual-wavelength fundus autofluorescence (Heidelberg Spectralis HRA + OCT MultiColor) in subjects with early agerelated macular degeneration (AMD).
   METHODS. Macular pigment was measured in 117 subjects with early AMD (age, 44-88 years) using the Densitometer and Spectralis, as part of the Central Retinal Enrichment Supplementation Trial (CREST; ISRCTN13894787). Baseline and 6-month study visits data were used for the analyses. Agreement was investigated at four different retinal eccentricities, graphically and using indices of agreement, including Pearson correlation coefficient (precision), accuracy coefficient, and concordance correlation coefficient (ccc).
   RESULTS. Agreement was poor between the Densitometer and Spectralis at all eccentricities, at baseline (e.g., at 0.25 degrees eccentricity, accuracy = 0.63, precision = 0.35, ccc = 0.22) and at 6 months (e.g., at 0.25 degrees eccentricity, accuracy = 0.52, precision = 0.43, ccc = 0.22). Agreement between the two devices was significantly greater for males at 0.5 degrees and 1.0 degrees of eccentricity. At all eccentricities, agreement was unaffected by cataract grade.
   CONCLUSIONS. In subjects with early AMD, MP measurements obtained using the Densitometer and Spectralis are not statistically comparable and should not be used interchangeably in either the clinical or research setting. Despite this lack of agreement, statistically significant increases in MP, following 6 months of supplementation with macular carotenoids, were detected with each device, confirming that these devices are capable of measuring change in MP within subjects over time. (http://www.controlled-trials.com number, ISRCTN13894787.)
C1 [Akuffo, Kwadwo Owusu; Beatty, Stephen; Stack, Jim; Corcoran, Laura; Power, Rebecca; Nolan, John M.] Waterford Inst Technol, Sch Hlth Sci, Macular Pigment Res Grp, Carriganore, Waterford, Ireland.
   [Peto, Tunde; Leung, Irene] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde; Leung, Irene] UCL Inst Ophthalmol, London, England.
C3 South East Technological University (SETU); University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Akuffo, KO (通讯作者)，Waterford Inst Technol, Vis Res Ctr, Macular Pigment Res Grp, West Campus, Carriganore, Waterford, Ireland.
EM kakuffo@wit.ie
RI Akuffo, Kwadwo Owusu/J-2036-2019; Peto, Tunde/G-8812-2018; Nolan,
   John/N-4921-2014
OI Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Peto,
   Tunde/0000-0001-6265-0381; Nolan, John/0000-0002-5503-7084; Power,
   Rebecca/0000-0002-8493-6417
FU European Research Council [281096]; Howard Foundation (Cambridge, UK);
   NIHR BMRC at Moorfields Eye Hospital NHS Foundation Trust and UCL IoO
   (London, UK)
FX Supported by the European Research Council Grant 281096, the European
   Research Council (KOA, LC, RP, JMN), the Howard Foundation (Cambridge,
   UK; JMN), and the NIHR BMRC at Moorfields Eye Hospital NHS Foundation
   Trust and UCL IoO (London, UK; TP, IL).
CR Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Firdous AP, 2015, PHARM BIOL, V53, P961, DOI 10.3109/13880209.2014.950673
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Igras E, 2013, BRIT J OPHTHALMOL, V97, P994, DOI 10.1136/bjophthalmol-2013-303153
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson EJ, 2012, AM J CLIN NUTR, V96, p1161S, DOI 10.3945/ajcn.112.034611
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Lin L, 2012, STATISTICAL TOOLS FOR MEASURING AGREEMENT, P1, DOI 10.1007/978-1-4614-0562-7
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loughman J., 2010, J OPTOM, V3, P74
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Nolan JM, 2014, J ALZHEIMERS DIS, V42, P1191, DOI 10.3233/JAD-140507
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   R Core Team, 2008, R A LANGUAGE AND ENV
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Scanlon G, 2015, RETINA-J RET VIT DIS, V35, P1808, DOI 10.1097/IAE.0000000000000551
   Sharifzadeh M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.096010
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 40
TC 13
Z9 13
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2015
VL 56
IS 13
BP 8207
EP 8214
DI 10.1167/iovs.15-17822
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB1BU
UT WOS:000368243800073
PM 26720473
OA Green Published
DA 2022-11-30
ER

PT J
AU Karaca, EE
   Yildiz, BK
   Cubuk, MO
   Ozdek, S
AF Karaca, Emine Esra
   Yildiz, Burcin Kepez
   Cubuk, Mehmet Ozgur
   Ozdek, Sengul
TI EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
   Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; epiretinal membrane; vitreomacular interface
ID POSTERIOR VITREOMACULAR ADHESION; VITREOUS DETACHMENT; PIGMENT
   EPITHELIUM; RISK-FACTOR; TRACTION; PATHOGENESIS; RANIBIZUMAB;
   VERTEPORFIN; EDEMA
AB Purpose:To iatients with neovascular age-related macular degenernvestigate the role of epiretinal membrane (ERM) on outcomes of anti-vascular endothelial growth factor therapy in pation (nAMD).Methods:This study is a retrospective observational case series and was conducted at the Gazi University School of Medicine, Ankara, Turkey. The reports of the patients with a diagnosis of new-onset nAMD, who were aged at least 50 years and treated with intravitreal anti-vascular endothelial growth factors (ranibizumab or bevacuzimab) between October 2010 and September 2013 in our retina clinic, were reviewed for the vitreomacular interface changes.Results:The study included 90 eyes of 90 patients with nAMD. The mean age of the patients was 70 7.5 years, with 35 (38.9%) being male and 55 (61.1%) being female. According to the examinations with optical coherence tomography and B-mode ultrasonography, 43 patients had concurrent vitreomacular adhesion (30 focal, 13 broad; Group 1). Twenty-nine patients had complete posterior vitreous detachment (Group 2) and 18 patients (Group 3) had ERM. The number of injections was highest for the patients with ERM (Group 3), and this difference was statistically significant (P < 0.001). The mean interval between injections and the mean longest interval were shorter in Group 3 (P < 0.05).Conclusion:The presence of ERM in association with nAMD seems to increase the number of anti-vascular endothelial growth factor injections and decrease the injection intervals for the treatment of nAMD. Although the anatomical and functional results are similar in eyes with or without ERM, the increased need for anti-vascular endothelial growth factors may mean that these membranes may decrease the penetration of the drugs through these membranes, which may act as a physical barrier. Additionally, increased inflammation in patients with ERM probably requires more frequent injections.
C1 [Karaca, Emine Esra] Sorgun State Hosp, Dept Ophthalmol, TR-66700 Yozgat, Turkey.
   [Yildiz, Burcin Kepez] Yozgat State Hosp, Dept Ophthalmol, Yozgat, Turkey.
   [Karaca, Emine Esra; Yildiz, Burcin Kepez; Cubuk, Mehmet Ozgur; Ozdek, Sengul] Gazi Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
C3 Diyarbakir Training & Research Hospital; Yozgat Sorgun State Hospital;
   Yozgat Sorgun State Hospital; Gazi University
RP Karaca, EE (通讯作者)，Sorgun State Hosp, Dept Ophthalmol, TR-66700 Yozgat, Turkey.
EM emineesra@yahoo.com
RI Karaca, Emine Esra/ABH-8913-2022; Özdek, Şengül/CAF-5314-2022; Cubuk,
   Mehmet Ozgur/GVU-1411-2022
OI Karaca, Emine Esra/0000-0001-7124-4174; Özdek,
   Şengül/0000-0002-7494-4106; 
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Capeans C, 1998, GRAEF ARCH CLIN EXP, V236, P481, DOI 10.1007/s004170050109
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Glittenberg C, 2009, OPHTHAL SURG LAS IM, V40, P127, DOI 10.3928/15428877-20090301-08
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P32, DOI 10.1016/j.ajo.2009.07.036
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   ROLDAN M, 1989, ANN OPHTHALMOL, V21, P141
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   SEBAG J, 1984, SURV OPHTHALMOL, V28, P493, DOI 10.1016/0039-6257(84)90231-5
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 31
TC 14
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2015
VL 35
IS 8
BP 1540
EP 1546
DI 10.1097/IAE.0000000000000531
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4HX
UT WOS:000359843700006
PM 25768251
DA 2022-11-30
ER

PT J
AU Grossniklaus, HE
   Brooks, HL
   Sippy, BD
   Liu, PB
AF Grossniklaus, HE
   Brooks, HL
   Sippy, BD
   Liu, PB
TI Retinal translocation and photodynamic therapy for age-related macular
   degeneration with classic choroidal neovascularization: A
   clinicopathologic case report
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID PIGMENT EPITHELIUM; MEMBRANES
C1 Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   Tallahassee Mem Reg Med Ctr, Tallahassee, FL USA.
C3 Emory University
RP Grossniklaus, HE (通讯作者)，Emory Univ, Ctr Eye, LF Montgomery Ophthalm Pathol Lab, BT 428,1365 Clifton Rd NE, Atlanta, GA 30322 USA.
EM ophtheg@emory.edu
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   BERECZKI A, 2001, BR J OPHTHALMOL, P550
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Green WR, 1996, OPHTHALMIC PATHOLOGY, P667
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   GROSSNIKLAUS HE, 1988, ARCH OPHTHALMOL-CHIC, V106, P78, DOI 10.1001/archopht.1988.01060130084034
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LIN SC, 1994, CURR EYE RES, V13, P513, DOI 10.3109/02713689408999883
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Regillo C D, 2000, Curr Opin Ophthalmol, V11, P166, DOI 10.1097/00055735-200006000-00002
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Roig-Melo EA, 2000, EUR J OPHTHALMOL, V10, P297, DOI 10.1177/112067210001000405
   ROYSTER AJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P1608, DOI 10.1001/archopht.1988.01060140776054
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Vander J F, 2000, Curr Opin Ophthalmol, V11, P159, DOI 10.1097/00055735-200006000-00001
NR 26
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2002
VL 22
IS 6
BP 818
EP 824
DI 10.1097/00006982-200212000-00027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 627UQ
UT WOS:000179954900027
PM 12476118
DA 2022-11-30
ER

PT J
AU Chen, XD
   Luo, YF
AF Chen, Xiaodong
   Luo, Yunfeng
TI Association of GSTM1, GSTT1, and GSTP1 Ile105Val polymorphisms with risk
   of age-related macular degeneration: a meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Glutathione S-transferases; polymorphisms; age-related macular
   degeneration; meta-analysis
ID S-TRANSFERASE POLYMORPHISMS; GENETIC POLYMORPHISMS; OXIDATIVE STRESS; PI
   ISOFORM; GLUTATHIONE; CANCER; EXPRESSION; PROTECTS; DISEASE; FAMILY
AB Background This study determined to evaluate the association between glutathione S-transferase (GST) polymorphisms, namely, GSTM1 (rs1183423000, presence/absence), GSTT1 (rs1601993659, presence/absence), and GSTP1 Ile105Val (rs1695, A>G) polymorphisms, and AMD risk. Methods We searched PubMed, Embase, and Web of Science databases from January 2000 to June 2021. The odds ratio (OR) and 95% confidence interval (95% CI) were used as effect sizes. Heterogeneity was assessed using the heterogeneity metric I-2. Results Five relevant studies involving 875 patients with AMD and 966 healthy controls were included in this meta-analysis, four studies concerning GSTM1 null polymorphism, four studies regarding GSTT1 null polymorphism, and four studies on GSTP1 Ile105Val polymorphism. The GSTM1 null polymorphism, GSTT1 null polymorphism and GSTP1 Ile105Val polymorphism were not significantly associated with AMD risk (OR 1.13, 95% CI 0.73-1.75, p = 0.59; OR 1.05, 95% CI 0.81-1.36, p = 0.69; OR 1.20, 95% CI 0.97-1.47, p = 0.09, respectively). There was no association between the combined GSTM1 null genotype and GSTT1 null genotype and AMD risk (OR 1.16, 95% CI 0.42-3.17, p = 0.77). Subgroup analyses revealed that the GSTM1 null genotype was associated with an increased risk of AMD in the Turkish population (OR 1.67, 95% CI 1.13-2.47, p = 0.01) and the GSTM1 null genotype was associated with a decreased incidence of non-exudative AMD (OR 0.72, 95% CI 0.52-0.99, p = 0.01). There was no obvious risk of publication bias found. Conclusions This meta-analysis indicated that there were no significant associations between GSTM1, GSTT1, and GSTP1 Ile105Val polymorphisms and AMD risk.
C1 [Chen, Xiaodong] Nanchang Univ, Dept Ophthalmol & Optometry, Nanchang, Jiangxi, Peoples R China.
   [Luo, Yunfeng] Nanchang Univ, Jiangxi Clin Res Ctr Ophthalm Dis, Jiangxi Res Inst Ophthalmol & Visual Sci, Jiangxi Prov Key Lab Ophthalmol,Affiliated Eye Ho, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Luo, YF (通讯作者)，Nanchang Univ, Jiangxi Res Inst Ophthalmol & Visual Sci, Affiliated Eye Hosp, 463 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM lyf008cn@qq.com
RI Luo, Yunfeng/C-4824-2015
OI Luo, Yunfeng/0000-0002-2503-3517
FU National Natural Science Foundation of China [81760239]; Natural Science
   Foundation of Jiangxi Province [20202BABL206063]; Health Commission of
   Jiangxi Province [202210716]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81760239), Natural Science Foundation of Jiangxi Province
   (No.20202BABL206063) and Health Commission of Jiangxi Province
   (No.202210716)
CR Ahmed CM, 2016, MOL VIS, V22, P294
   Ahuja P, 2005, NEUROSCIENCE, V131, P935, DOI 10.1016/j.neuroscience.2004.11.012
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   BROWN K, 2022, EYE LOND
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garner IC., 2020, THESIS U S FLORIDA
   Gu H, 2012, RETINA-J RET VIT DIS, V32, P1967, DOI 10.1097/IAE.0b013e31824dae04
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hunter AA, 2016, CURR EYE RES, V41, P410, DOI 10.3109/02713683.2015.1016179
   Joshi P., 2009, INVEST OPHTH VIS SCI, V50
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katoh T, 2008, PHARMACOGENOMICS, V9, P93, DOI 10.2217/14622416.9.1.93
   Lechanteur Y., 2016, THESIS RADBOUD U NIJ
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Lu Y, 2013, GENE, V527, P311, DOI 10.1016/j.gene.2013.06.031
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Mann J, 2001, BRIT MED J, V323, P1000, DOI 10.1136/bmj.323.7319.1000
   McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223
   Othman H, 2012, MOL BIOL REP, V39, P3299, DOI 10.1007/s11033-011-1098-2
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Parl FF, 2005, CANCER LETT, V221, P123, DOI 10.1016/j.canlet.2004.06.016
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sameer AS, 2012, DNA CELL BIOL, V31, P74, DOI 10.1089/dna.2011.1297
   Schneider J, 2004, CANCER LETT, V208, P65, DOI 10.1016/j.canlet.2004.01.002
   Schnekenburger M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00170
   Sreekumar PG, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050661
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sun L, 2010, INVEST OPHTH VIS SCI, V51, P6381, DOI 10.1167/iovs.10-5815
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Toma C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050653
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   Whalen R, 1998, SEMIN LIVER DIS, V18, P345, DOI 10.1055/s-2007-1007169
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan Q, 2021, ADV EXP MED BIOL, V1256, P191, DOI 10.1007/978-3-030-66014-7_7
   Yu YB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054037
NR 44
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP 3
PY 2022
VL 43
IS 5
BP 615
EP 621
DI 10.1080/13816810.2022.2090009
EA JUN 2022
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 4V9QE
UT WOS:000814539000001
PM 35730167
DA 2022-11-30
ER

PT J
AU Tosi, GM
   Caldi, E
   Neri, G
   Nuti, E
   Marigliani, D
   Baiocchi, S
   Traversi, C
   Cevenini, G
   Tarantello, A
   Fusco, F
   Nardi, F
   Orlandini, M
   Galvagni, F
AF Tosi, Gian Marco
   Caldi, Elena
   Neri, Giovanni
   Nuti, Elisabetta
   Marigliani, Davide
   Baiocchi, Stefano
   Traversi, Claudio
   Cevenini, Gabriele
   Tarantello, Antonio
   Fusco, Fiorella
   Nardi, Federica
   Orlandini, Maurizio
   Galvagni, Federico
TI HTRA1 and TGF-beta 1 Concentrations in the Aqueous Humor of Patients
   With Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE HTRA1; TGF-beta; VEGFA; age-related macular degeneration; choroidal
   neovascularization
ID SMALL-VESSEL DISEASE; HIGH-TEMPERATURE REQUIREMENT; GROWTH-FACTOR-BETA;
   CHOROIDAL NEOVASCULARIZATION; CHROMOSOME 10Q26; SERINE-PROTEASE;
   SUSCEPTIBILITY; GENE; VARIANTS; RETINA
AB PURPOSE. The purpose of this study was to evaluate the expression of high-temperature requirement A serine peptidase 1 (HTRA1), TGF-beta 1, bone morphogenetic protein 4 (BMP4), growth differentiation factor 6 (GDF6), and VEGFA proteins in the aqueous humor of patients with naive choroidal neovascularization (nCNV) secondary to AMD.
   METHODS. We measured by ELISA the concentrations of HTRA1, TGF-beta 1, BMP4, GDF6, and VEGFA in the aqueous humor of 23 patients affected by nCNV who received three consecutive monthly intravitreal injections of 0.5 mg ranibizumab. Samples were collected at baseline (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). Twenty-three age-matched cataract patients served as controls.
   RESULTS. Bone morphogenetic protein 4 and GDF6 were not detectable in any samples. Baseline HTRA1 was higher than controls (P < 0.0001) and higher than both the month 1 (P < 0.0001) and the month 2 (P < 0.0001) values. Baseline VEGFA was higher than controls (P < 0.0001), not different from month 1 value (P = 0.0821), but higher than month 2 value (P < 0.0001). Baseline TGF-beta 1 was higher than controls (P = 0.0015) and not different from month 1 (P = 0.129) and month 2 values (P = 0.5529). No correlation was found in naive patients between concentrations of HTRA1 and TGF-beta 1, HTRA 1 and VEGFA, or TGF-beta 1 and VEGFA.
   CONCLUSIONS. In nCNV patients, HTRA1 and TGF-beta 1 were significantly higher compared to controls. After treatment, TGF-beta 1 was persistently elevated, while HTRA1 returned to control levels, suggesting the involvement of TGF-beta 1 and HTRA1 in neovascular AMD and a VEGFA-independent role for TGF-beta 1.
C1 [Tosi, Gian Marco; Neri, Giovanni; Nuti, Elisabetta; Marigliani, Davide; Baiocchi, Stefano; Traversi, Claudio; Tarantello, Antonio; Fusco, Fiorella] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, Siena, Italy.
   [Caldi, Elena; Nardi, Federica; Orlandini, Maurizio; Galvagni, Federico] Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.
   [Cevenini, Gabriele] Univ Siena, Dept Med Biotechnol, Siena, Italy.
C3 University of Siena; University of Siena; University of Siena
RP Orlandini, M; Galvagni, F (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, Via A Moro 2, I-53100 Siena, Italy.
EM maurizio.orlandini@unisi.it; federico.galvagni@unisi.it
RI Orlandini, Maurizio/AAF-8247-2020; Fusco, Fiorella/ABH-7370-2020;
   Galvagni, Federico/F-9186-2013; CEVENINI, Gabriele/S-1973-2018
OI Orlandini, Maurizio/0000-0002-6112-4889; Fusco,
   Fiorella/0000-0002-0574-2471; Nardi, Federica/0000-0002-4155-1429;
   baiocchi, stefano/0000-0002-3846-1895; CEVENINI,
   Gabriele/0000-0002-7212-573X
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Bai YJ, 2014, MOL VIS, V20, P1258
   Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Melissa S, 2012, EXP EYE RES, V94, P4, DOI 10.1016/j.exer.2010.07.006
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 35
TC 31
Z9 32
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2017
VL 58
IS 1
BP 162
EP 167
DI 10.1167/iovs.16-20922
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ1EW
UT WOS:000392954300020
PM 28114575
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wang, HB
   Han, XK
   Kunz, E
   Hartnett, ME
AF Wang, Haibo
   Han, Xiaokun
   Kunz, Eric
   Hartnett, M. Elizabeth
TI Thy-1 Regulates VEGF-Mediated Choroidal Endothelial Cell Activation and
   Migration: Implications in Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Thy-1; chorodial endothelial cells; VEGF; choroidal neovacularization;
   cell migration
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; BRUCHS MEMBRANE; GROWTH-FACTOR;
   IN-VIVO; RPE; DRUSEN; TRANSMIGRATION; CHOLESTEROL; MODULATOR; SURVIVAL
AB PURPOSE. This study addresses the hypothesis that age-related stresses upregulate Thy-1 in choroidal endothelial cells (CECs) and contribute to CEC activation and migration, processes important in choroidal neovascularization (CNV).
   METHODS. Measurements were made of Thy-1 protein (Western blot) in CECs and Thy-1 mRNA (real time quantitative PCR) in CECs treated with VEGF, CCL11, or PBS or in RPE/choroids from young or old donors or lasered or nonlasered mice. Immunolabeled Thy-1 in ocular sections was compared from young versus old human donor eyes or those with or without neovascular AMD or from lasered versus nonlasered mice. Choroidal endothelial cells transfected with Thy-1 or control siRNA or pretreated with Thy-1 blocking peptide or control were stimulated with VEGF or 7-ketocholesterol (7-KC). Choroidal endothelial cell migration, proliferation, cytoskeletal stress fibers, Rac1 activation, and phosphorylated VEGF receptor 2 (VEGFR2), integrin b3, and Src were measured. Statistics were performed using ANOVA.
   RESULTS. Thy-1 was expressed in retinal ganglion cells and in vascular endothelial-cadherinlabeled choroid and localized to human or mouse laser-induced CNV lesions. Thy-1 protein and mRNA were significantly increased in CECs treated with VEGF or CCL11 and in RPE/ choroids from aged versus young donor eyes or from lasered mice versus nonlasered controls. Knockdown or inhibition of Thy-1 in CECs significantly reduced VEGF-induced CEC migration and proliferation, stress fiber formation and VEGFR2, Src, integrin b3 and Rac1 activation, and 7-KC-induced Rac1 and Src activation.
   CONCLUSIONS. Thy-1 in CECs regulates VEGF-induced CEC activation and migration and links extracellular 7-KC to intracellular signaling. Future studies elucidating Thy-1 mechanisms in neovascular AMD are warranted.
C1 [Wang, Haibo; Han, Xiaokun; Kunz, Eric; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Han, Xiaokun] China Med Univ, Affiliated Hosp 4, Dept Ophthalmol, Shenyang, Peoples R China.
C3 Utah System of Higher Education; University of Utah; China Medical
   University
RP Hartnett, ME (通讯作者)，65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM ME.Hartnett@hsc.utah.edu
FU National Institutes of Health (Bethesda, MD, USA) [EY014800,
   R01EY015130, R01EY017011]; Research to Prevent Blindness, Inc. (New
   York, NY, USA); NATIONAL EYE INSTITUTE [P30EY014800, R01EY017011,
   R01EY015130] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (Bethesda, MD, USA)
   Grants EY014800, R01EY015130 (MEH), and R01EY017011 (MEH) and an
   unrestricted grant from Research to Prevent Blindness, Inc. (New York,
   NY, USA) to the Department of Ophthalmology & Visual Sciences,
   University of Utah.
CR Awasthi A, 2010, J EXP MED, V207, P1923, DOI 10.1084/jem.20100040
   Bradley JS, 2009, BIOFACTORS, V35, P258, DOI 10.1002/biof.41
   Bukovsky A, 2009, AGING-US, V1, P157, DOI 10.18632/aging.100024
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Leung CKS, 2009, EXP EYE RES, V88, P831, DOI 10.1016/j.exer.2008.09.006
   Leyton Lisette, 2014, Adv Neurobiol, V8, P3
   Lorenc VE, 2015, INVEST OPHTH VIS SCI, V56, P6948, DOI 10.1167/iovs.15-17496
   Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015
   Avalos AM, 2009, J CELL SCI, V122, P3462, DOI 10.1242/jcs.034827
   Miyagawa-Yamaguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093054
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Ravelli C, 2013, ANGIOGENESIS, V16, P235, DOI 10.1007/s10456-012-9309-6
   Rege TA, 2006, BBA-MOL CELL RES, V1763, P991, DOI 10.1016/j.bbamcr.2006.08.008
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 37
TC 9
Z9 9
U1 2
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2016
VL 57
IS 13
BP 5525
EP 5534
DI 10.1167/iovs.16-19691
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI4ND
UT WOS:000392469600060
PM 27768790
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Bhutto, I
   Lutty, G
AF Bhutto, Imran
   Lutty, Gerard
TI Understanding age-related macular degeneration (AMD): Relationships
   between the photoreceptor/retinal pigment epithelium/Bruch's
   membrane/choriocapillaris complex
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Age-related macular degeneration; Bruch's membrane; Choriocapillaris;
   Retinal pigment epithelium; Photoreceptors
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; CHOROIDAL BLOOD-FLOW;
   BRUCHS MEMBRANE IMPLICATIONS; VASCULAR-PERMEABILITY FACTOR; FACIAL-NERVE
   STIMULATION; NITRIC-OXIDE SYNTHASE; FACTOR-H POLYMORPHISM;
   EPITHELIAL-CELLS; MORPHOMETRIC-ANALYSIS
AB There is a mutualistic symbiotic relationship between the components of the photoreceptor/retinal pigment epithelium (RPE)/Bruch's membrane (BrMb)/choriocapillaris (CC) complex that is lost in AMD. Which component in the photoreceptor/RPE/BrMb/CC complex is affected first appears to depend on the type of AMD. In atrophic AMD (similar to 85-90% of cases), it appears that large confluent drusen formation and hyperpigmentation (presumably dysfunction in RPE) are the initial insult and the resorption of these drusen and loss of RPE (hypopigmentation) can be predictive for progression of geographic atrophy (GA). The death and dysfunction of photoreceptors and CC appear to be secondary events to loss in RPE.
   In neovascular AMD (similar to 10-15% of cases), the loss of choroidal vasculature may be the initial insult to the complex. Loss of CC with an intact RPE monolayer in wet AMD has been observed. This may be due to reduction in blood supply because of large vessel stenosis. Furthermore, the environment of the CC, basement membrane and intercapillary septa, is a proinflammatory milieu with accumulation of complement components as well as proinflammatory molecules like CRP during AMD. In this toxic milieu, CC die or become dysfunction making adjacent RPE hypoxic. These hypoxic cells then produce angiogenic substances like VEGF that stimulate growth of new vessels from CC, resulting in choroidal neovascularization (CNV). The loss of CC might also be a stimulus for drusen formation since the disposal system for retinal debris and exocytosed material from RPE would be limited. Ultimately, the photoreceptors die of lack of nutrients, leakage of serum components from the neovascularization, and scar formation.
   Therefore, the mutualistic symbiotic relationship within the photoreceptor/RPE/BrMb/CC complex is lost in both forms of AMD. Loss of this functionally integrated relationship results in death and dysfunction of all of the components in the complex. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Bhutto, Imran; Lutty, Gerard] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, G (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 N Broadway, Baltimore, MD 21287 USA.
EM Glutty1@jhmi.edu
FU NIH [EY016151, EY09357, EY01765]; Altsheler-Durell Foundation; American
   Health Assistance Foundation; NATIONAL EYE INSTITUTE [P30EY001765,
   R01EY016151, R01EY009357] Funding Source: NIH RePORTER
FX Studies from the Lutty lab were funded by NIH grants EY016151 (GL),
   EY09357 (GL), EY01765 (Wilmer); the Altsheler-Durell Foundation;
   American Health Assistance Foundation; and an unrestricted gift from RPB
   (Wilmer). Gerard Lutty is an RPB Senior Investigator. The authors
   acknowledge the D. Scott McLeod for creation of the figures.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto IA, 2004, ENCY MICROVASCULATUR
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BILL A, 1991, EXP EYE RES, V53, P3, DOI 10.1016/0014-4835(91)90138-5
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T
   BOST LM, 1994, EXP EYE RES, V58, P545, DOI 10.1006/exer.1994.1048
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Braun RD, 1997, AM J PHYSIOL-HEART C, V272, pH1444, DOI 10.1152/ajpheart.1997.272.3.H1444
   Bron AJ, 1997, ANATOMY EYE ORBIT
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   CAMPOCHIARO PA, 1989, EXP EYE RES, V49, P217, DOI 10.1016/0014-4835(89)90092-4
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carron JA, 2000, INT J BIOCHEM CELL B, V32, P1137, DOI 10.1016/S1357-2725(00)00065-0
   CARUELLE D, 1989, J CELL BIOCHEM, V39, P117, DOI 10.1002/jcb.240390204
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA., 2009, J LIPID RES
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dehghan A, 2007, DIABETES CARE, V30, P2695, DOI 10.2337/dc07-0348
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Economou MA, 2008, ACTA OPHTHALMOL, V86, P930, DOI [10.1111/j.1755-3768.2008.01188.x, 10.1111/j.1755-3768.2008.01182.x, 10.1111/j.1755-3768.2008.01185.x, 10.1111/j.1755-3768.2008.01184.x]
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FLUGEL C, 1994, INVEST OPHTH VIS SCI, V35, P592
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1972, ARCH OPHTHALMOL-CHIC, V87, P70, DOI 10.1001/archopht.1972.01000020072015
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   FRIEDMAN E, 1964, INVEST OPHTH VISUAL, V3, P539
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   FURNESS JB, 1992, CELL TISSUE RES, V270, P125, DOI 10.1007/BF00381887
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gu XL, 2003, AM J PHYSIOL-CELL PH, V285, pC546, DOI 10.1152/ajpcell.00424.2002
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Gurguz O, 2001, EUR J OPHTHALMOL, V11, P62
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P6706, DOI 10.1073/pnas.88.15.6706
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   HOGAN M J, 1961, Trans Pac Coast Otoophthalmol Soc Annu Meet, V42, P61
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   ISHIGOOKA H, 1993, INVEST OPHTH VIS SCI, V34, P2813
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent D, 2003, MOL VIS, V9, P747
   KHALIQ A, 1995, EXP EYE RES, V60, P415, DOI 10.1016/S0014-4835(05)80098-3
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Kim YG, 2011, ACTA OPHTHALMOL, V89, pE52, DOI 10.1111/j.1755-3768.2010.01958.x
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUMMER W, 1992, NEUROREPORT, V3, P653, DOI 10.1097/00001756-199207000-00028
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lauber H, 1936, HDB MIKROSKOPISCHEN
   LINSENMEIER RA, 1989, INVEST OPHTH VIS SCI, V30, P612
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lutty G, 1999, MOL VIS, V5
   Lutty GA., 2009, EXP EYE RES
   Maeda H, 1998, GRAEF ARCH CLIN EXP, V236, P207, DOI 10.1007/s004170050066
   Mainous AG, 2003, FAM MED, V35, P112
   MANN RM, 1993, INVEST OPHTH VIS SCI, V34, P1394
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   MARTIN DS, 1992, BRAIN RES, V577, P261, DOI 10.1016/0006-8993(92)90282-E
   MATSUMOTO M, 1994, INVEST OPHTH VIS SCI, V35, P4245
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   McLaughlin T, 2002, CIRCULATION, V106, P2908, DOI 10.1161/01.CIR.0000041046.32962.86
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   McLeod DS, 1996, INVEST OPHTH VIS SCI, V37, P300
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MILLER AS, 1983, AUST J OPHTHALMOL, V11, P185, DOI 10.1111/j.1442-9071.1983.tb01077.x
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   MORRIS JL, 1993, J AUTONOM NERV SYST, V42, P11, DOI 10.1016/0165-1838(93)90337-T
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   NILSSON SFE, 1985, EXP EYE RES, V40, P841, DOI 10.1016/0014-4835(85)90129-0
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PARISH WE, 1976, CLIN ALLERGY, V6, P543, DOI 10.1111/j.1365-2222.1976.tb01939.x
   Park CW, 2002, AM J KIDNEY DIS, V40, P1230, DOI 10.1053/ajkd.2002.36891
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Rallidis LS, 2002, CLIN CARDIOL, V25, P505, DOI 10.1002/clc.4960251106
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   ROWE IF, 1984, CLIN EXP IMMUNOL, V58, P237
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209
   SCANU AM, 1991, ADV EXP MED BIOL, V285, P295
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sengupta N, 2010, INVEST OPHTH VIS SCI, V51, P2697, DOI 10.1167/iovs.09-4137
   Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STAURENGHI G, 1992, OPHTHALMOLOGICA, V205, P178, DOI 10.1159/000310337
   Stenvinkel P, 2000, NEPHROL DIAL TRANSPL, V15, P1624, DOI 10.1093/ndt/15.10.1624
   STERNFELD MD, 1989, CURR EYE RES, V8, P1029, DOI 10.3109/02713688908997395
   STJERNSCHANTZ J, 1980, ACTA PHYSIOL SCAND, V109, P45, DOI 10.1111/j.1748-1716.1980.tb06562.x
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1999, MOL VIS, V5
   TALMAGE EK, 1993, J AUTONOM NERV SYST, V43, P83, DOI 10.1016/0165-1838(93)90324-N
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Uno K, 2010, EXP EYE RES, V90, P493, DOI 10.1016/j.exer.2009.12.012
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weikel K.A., 2011, INVEST OPHTHALMOL VI
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 217
TC 603
Z9 621
U1 10
U2 145
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 295
EP 317
DI 10.1016/j.mam.2012.04.005
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900002
PM 22542780
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Studnicka, J
   Rencova, E
   Rozsival, P
   Dusova, J
   Dubska, Z
   Chrapek, O
   Kolar, P
   Kandrnal, V
   Pitrova, S
   Rehak, J
AF Studnicka, Jan
   Rencova, Eva
   Rozsival, Pavel
   Dusova, Jaroslava
   Dubska, Zora
   Chrapek, Oldrich
   Kolar, Petr
   Kandrnal, Vit
   Pitrova, Sarka
   Rehak, Jiri
TI Effects of treatment change in patients with neovascular age-related
   macular degeneration; Results from the Czech National Registry
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE age-related macular degeneration; choroidal neovascular membrane; visual
   acuity; ranibizumab; pegaptanib; photodynamic therapy with verteporfin
ID DOSING REGIMEN; RANIBIZUMAB; PEGAPTANIB
AB Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment.
   Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period.
   Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7% subjects treated with ranibizumab, 20.5% with pegaptanib and 22% with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +/- 3 letters and 43 +/- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +/- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +/- 2.1 months.
   Conclusion. BCVA loss was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium.
C1 [Kolar, Petr] Univ Hosp Brno, Dept Ophthalmol, Brno, Czech Republic.
   [Studnicka, Jan; Rencova, Eva; Rozsival, Pavel; Dusova, Jaroslava] Charles Univ Prague, Dept Ophthalmol, Fac Med Hradec Kralove, Prague, Czech Republic.
   [Studnicka, Jan; Rencova, Eva; Rozsival, Pavel; Dusova, Jaroslava] Univ Hosp, Hradec Kralove, Czech Republic.
   [Dubska, Zora] Charles Univ Prague, Dept Ophthalmol, Fac Med 1, Prague, Czech Republic.
   [Dubska, Zora] Gen Univ Hosp, Prague, Czech Republic.
   [Chrapek, Oldrich; Rehak, Jiri] Univ Hosp Olomouc, Dept Ophthalmol, Olomouc, Czech Republic.
   [Kandrnal, Vit] Masaryk Univ Brno, Inst Biostat & Anal, Fac Med, Brno, Czech Republic.
   [Kandrnal, Vit] Masaryk Univ Brno, Fac Sci, Brno, Czech Republic.
   [Pitrova, Sarka] Private Eye Clin, Prague, Czech Republic.
C3 University Hospital Brno; Charles University Prague; Charles University
   Prague; General University Hospital Prague; University Hospital Olomouc;
   Institute of Biostatistics & Analyses; Masaryk University Brno; Masaryk
   University Brno
RP Kolar, P (通讯作者)，Univ Hosp Brno, Dept Ophthalmol, Brno, Czech Republic.
EM pe-kolar@seznam.cz
RI Studnička, Jan/AAC-4127-2022; Studnicka, Jan/K-2875-2017; Chrapek,
   Oldrich/ABD-9894-2020
OI Studnicka, Jan/0000-0002-9911-4379; Chrapek,
   Oldrich/0000-0002-1403-4936; Kolar, Petr/0000-0003-3709-4648
FU Novartis Pharma AG
FX Grant from Novartis Pharma AG was received for the national registry
   AMADEUS.
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 10
TC 1
Z9 1
U1 0
U2 3
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PY 2012
VL 156
IS 4
BP 359
EP 364
DI 10.5507/bp.2012.100
PG 6
WC Engineering, Biomedical; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Research & Experimental Medicine
GA 063GB
UT WOS:000312983100013
PM 23202275
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Muftuoglu, IK
   Arcinue, CA
   Tsai, FF
   Alam, M
   Gaber, R
   Camacho, N
   You, QS
   Freeman, WR
AF Muftuoglu, Ilkay Kilic
   Arcinue, Cheryl A.
   Tsai, Frank F.
   Alam, Mostafa
   Gaber, Raouf
   Camacho, Natalia
   You, Qisheng
   Freeman, William R.
TI Long-Term Results of Pro Re data Regimen of Aflibercept Treatment in
   Persistent Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   AFLIBERCEPT; RANIBIZUMAB; EYES; OUTCOMES; VEGF; BEVACIZUMAB; RECURRENT;
   FLUID
AB PURPOSE: To determine the 24-month results of patients who had pro re nata (PRN) aflibercept treatment owing to recurrent or resistant neovascular macular degeneration.
   DESIGN: Retrospective, interventional, consecutive case series.
   METHODS: Eighty-one eyes of 78 patients with resistant or multiple recurrences of intraretinal or subretinal fluid while receiving monthly bevacizumab or ranibizumab injections and were switched to strict, as-needed aflibercept treatment with every-8-weeks spectral-domain optical coherence tomography (SDOCT)-guided monitoring were included. If there was a persistence of fluid despite this treatment, more frequent aflibercept injections were considered. Anatomic outcomes including maximum retinal thickness, central macular thickness, maximum pigment epithelial detachment height, maximum fluid height, and visual acuity (VA) were assessed at given follow-ups.
   RESULTS: All anatomic endpoints significantly improved following 3 consecutive aflibercept injections, which were maintained through 24 months (P <.05 for all endpoints at all visits). Thirty-seven eyes (45.6%) required more frequent injections with monthly SDOCT-guided monitoring at a median of 37 weeks (interquartile range, 30-62 weeks) to adequately treat the retinal fluid. Seventy-one of 81 eyes (87.7%) became completely dry on at least 1 follow-up visit; however, there was no significant improvement in VA during the study period.
   CONCLUSION: Aflibercept injection with an as-needed regimen was effective in many eyes previously treated with monthly bevacizumab or ranibizumab injections that had persistent or recurrent fluid. Despite significant improvement in anatomic outcomes, vision remained stable throughout the 2-year follow-up, likely because this cohort of patients had advanced choroidal neovascular membrane upon enrollment (recurrent or resistant). (C) 2016 Elsevier Inc. All rights reserved.
C1 [Muftuoglu, Ilkay Kilic; Arcinue, Cheryl A.; Tsai, Frank F.; Alam, Mostafa; Gaber, Raouf; Camacho, Natalia; You, Qisheng; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, 94093 Campus Point Dr, La Jolla, CA 92037 USA.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, 94093 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Gaber, Raouf/GSN-8206-2022; You, Qisheng/AAG-7153-2020
OI You, Qisheng/0000-0003-0743-7320
FU UCSD VISION RESEARCH CENTER CORE GRANT [R01EY07366]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [P30EY022589] Funding Source: NIH
   RePORTER
FX THIS WORK WAS SUPPORTED IN PART BY UCSD VISION RESEARCH CENTER CORE
   GRANT R01EY07366 (TO W.R.F.), and an unrestricted grant from Research to
   Prevent Blindness to the Department of Ophthalmology, University of
   California San Diego. The funding organizations had no role in the
   design or conduct of this research.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nagiel Aaron, 2015, Retin Cases Brief Rep, V9, P269, DOI 10.1097/ICB.0000000000000184
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 22
TC 22
Z9 22
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2016
VL 167
BP 1
EP 9
DI 10.1016/j.ajo.2016.03.038
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP9OQ
UT WOS:000378826100001
PM 27049000
DA 2022-11-30
ER

PT J
AU Adrean, SD
   Chaili, S
   Pirouz, A
   Grant, S
AF Adrean, Sean D.
   Chaili, Siyang
   Pirouz, Ash
   Grant, Scott
TI Results of patients with neovascular age-related macular degeneration
   managed by a treat-extend-stop protocol without recurrence
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF; Choroidal neovascularization; Fibrovascular scar; Geographic
   atrophy; Macular degeneration; Treat-and-extend; Treat-extend-stop
ID LONG-TERM OUTCOMES; ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB;
   GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; EFFICACY; THERAPY;
   REGIMEN; ANCHOR; MARINA
AB Purpose To assess vision, injection quantity, initial lesion size, and final anatomic status in patients with nAMD completing the treat-extend-stop (TES) protocol.
   Methods Patients with nAMD received >= 3 monthly anti-VEGF injections followed by 1-2 week injection interval extensions, with intra/subretinal fluid resolution on SD-OCT, to 12 weeks. With quiescent disease, and 2 quarterly injections, patients were monitored alone beginning at 4 weeks extending by 1-2 week intervals until quarterly monitoring.
   Results Eighty-eight of 143 eyes with nAMD completed the TES protocol without disease recurrence. Sixteen (18.2%) developed sub-foveal geographic atrophy (GA), 25 (28.4%) developed fibrovascular scarring (FV) and 47 (53.4%) developed regressed choroidal neovascularization (rCNV) with 16.9 +/- 13.3 average injections between the 3 groups which was not statistically significant. Average treatment time was 30.3 +/- 26.1 months and subsequent follow-up was 23.2 +/- 19.8 months. Average lesion size for FV was 18.77 +/- 10.8mm(2) vs. GA at 12.00 +/- 9.99mm(2) vs. regressed CNV at 7.12 +/- 6.5mm(2) (p < 0.05). Pre, post, and final vision for GA was 39.6 letters (20/160) vs. 32.7 letters (20/200 + 2, p =0.4725) vs. 25.0 letters (20/320, p = 0.0865); FV was 22.4 letters (20/400 + 2) vs. 11.6 letters (20/640, p = 0.0351) vs. 11.0 letters (20/640 +1, p=0.0226), and rCNV was 56.4 letters (20/80 +1) vs. 69.5 letters (20/40, p < 0.001) vs. 67.3 letters (20/40-2, p = 0.0016). In the rCNV group, 17/46 eyes gained >= 3 lines and 30/46 eyes achieved >= 20/40 vision. Non-central GA expanded 0.226 +/- 0.126 mm vs 0.225 +/- 0.098 mm during and after treatment completion over 24 months (p = 0.99).
   Conclusions Central GA or FV portends worse visual outcomes vs. rCNV after cessation of therapy. Anti-VEGF therapy may not affect the rate of GA expansion. Final anatomic character and location are key determinants of final vision.
C1 [Adrean, Sean D.; Chaili, Siyang; Pirouz, Ash; Grant, Scott] Retina Consultants Orange Cty, 301 W Bastanchury Ave 285, Fullerton, CA 92835 USA.
   [Chaili, Siyang] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37212 USA.
C3 Vanderbilt University
RP Adrean, SD (通讯作者)，Retina Consultants Orange Cty, 301 W Bastanchury Ave 285, Fullerton, CA 92835 USA.
EM seadrean@yahoo.com
OI Adrean, Sean/0000-0001-6004-0643
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miyamoto N, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S133332
   Munk MR, 2018, OPHTHALMOL RETINA, V2, P288, DOI 10.1016/j.oret.2017.07.010
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Richard AJ, 2021, CURR OPIN OPHTHALMOL, V32, P247, DOI 10.1097/ICU.0000000000000763
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 33
TC 1
Z9 1
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2021
VL 259
IS 12
BP 3665
EP 3673
DI 10.1007/s00417-021-05283-0
EA JUL 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW6CP
UT WOS:000672256400002
PM 34251484
DA 2022-11-30
ER

PT J
AU Gattoussi, S
   Cougnard-Gregoire, A
   Delyfer, MN
   Rougier, MB
   Schweitzer, C
   Delcourt, C
   Korobelnik, JF
AF Gattoussi, Sarra
   Cougnard-Gregoire, Audrey
   Delyfer, Marie-Noelle
   Rougier, Marie-Benedicte
   Schweitzer, Cedric
   Delcourt, Cecile
   Korobelnik, Jean-Francois
TI Vitreomacular Adhesion and Its Association With Age-Related Macular
   Degeneration in a Population-Based Setting: The Alienor Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE vitreomacular adhesion; age-related macular degeneration; risk factors;
   epidemiology
ID MACULOPATHY; RISK; PREVALENCE; CLASSIFICATION; EYE; ABNORMALITIES;
   PATHOGENESIS; INFLAMMATION
AB PURPOSE. The purpose of this study was to describe vitreomacular adhesion (VMA), diagnosed with spectral-domain optical coherence tomography (SD-OCT), its risk factors, and its association with AMD in a population-based study of French elderly subjects.
   METHODS. Six hundred twenty-two of 624 (99.7%) participants of the Alienor study (Bordeaux, France), >= 75 years of age, had gradable SD-OCT scans of the macula in at least one eye. VMA was defined as visible perifoveal vitreous separation with remaining vitreomacular attachment and unperturbed foveal morphologic features. Late AMD was classified from retinal color photographs, SD-OCT, and ophthalmologic history. Early AMD was classified from retinal photographs and defined by the presence of large drusen and/or reticular drusen and/or pigmentary abnormalities.
   RESULTS. The prevalence of VMA was 15.8%, decreased with age (18.1% in subjects 75 to 84 years of age versus 8.9% after 85 years of age), and was higher in men than women (20.6% vs. 12.8%). VMA also tended to be less frequent in eyes with a history of cataract surgery (odds ratio [OR] = 0.66, P = 0.05), after adjustment for age and sex. No associations of VMA with other risk factors (cardiovascular risk factors, dietary intake of omega-3 fatty acids, lifetime ultraviolet radiation exposure, major AMD genetic polymorphisms) were found. After multivariate adjustment, VMA was not significantly associated with early or late AMD (OR = 1.14, P = 0.70 and OR = 0.78, P = 0.51 for early and late AMD, respectively).
   CONCLUSIONS. VMA was visible on SD-OCT in 16% in this sample of elderly French subjects but was not associated with AMD. Prospective studies of the associations of VMA with AMD are needed.
C1 [Gattoussi, Sarra; Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Schweitzer, Cedric; Delcourt, Cecile; Korobelnik, Jean-Francois] Univ Bordeaux, ISPED, Bordeaux, France.
   [Gattoussi, Sarra; Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Schweitzer, Cedric; Delcourt, Cecile; Korobelnik, Jean-Francois] INSERM, Bordeaux Populat Hlth Res Ctr, U1219, Bordeaux, France.
   [Gattoussi, Sarra; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte; Schweitzer, Cedric; Delcourt, Cecile; Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Delcourt, C (通讯作者)，Univ Bordeaux, INSERM, U1219, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@isped.fr
RI Delyfer, Marie-Noelle/T-3304-2019; COUGNARD-GREGOIRE,
   Audrey/T-4443-2019; SCHWEITZER, CEDRIC/AAY-2787-2020; KOROBELNIK,
   Jean-Francois/A-5448-2016; Delcourt, Cecile/I-2627-2013
OI COUGNARD-GREGOIRE, Audrey/0000-0002-1494-5764; Delcourt,
   Cecile/0000-0002-2099-0481; Gattoussi, Sarra/0000-0002-8905-7112;
   Schweitzer, Cedric/0000-0002-2162-9479
FU Laboratoires Thea (Clermont-Ferrand, France); Universite de Bordeaux
   (Bordeaux, France); Fondation Voir et Entendre (Paris, France); Caisse
   Nationale de Solidarite pour l'Autonomie
FX Supported by Laboratoires Thea (Clermont-Ferrand, France), Universite de
   Bordeaux (Bordeaux, France), Fondation Voir et Entendre (Paris, France),
   and Caisse Nationale de Solidarite pour l'Autonomie. Laboratoires Thea
   participated in the design of the study, but none of the sponsors
   participated in the collection, management, statistical analysis, and
   interpretation of the data, nor in the preparation, review, or approval
   of the present manuscript.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   MCDONNELL PJ, 1985, OPHTHALMOLOGY, V92, P1208
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Meuer SM, 2015, OPHTHALMOLOGY, V122, P787, DOI 10.1016/j.ophtha.2014.10.014
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 8
Z9 10
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2017
VL 58
IS 4
BP 2180
EP 2186
DI 10.1167/iovs.16-20741
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9SY
UT WOS:000400649600029
PM 28399268
OA gold
DA 2022-11-30
ER

PT J
AU Nguyen, V
   Puzo, M
   Sanchez-Monroy, J
   Gabrielle, PH
   Garcher, CC
   Baudin, F
   Wolff, B
   Castelnovo, L
   Michel, G
   O'Toole, L
   Barthelmes, D
   Gillies, MC
AF Nguyen, Vuong
   Puzo, Martin
   Sanchez-Monroy, Jorge
   Gabrielle, Pierre-Henry
   Garcher, Catherine C.
   Baudin, Florian
   Wolff, Benjamin
   Castelnovo, Laurent
   Michel, Guillaume
   O'Toole, Louise
   Barthelmes, Daniel
   Gillies, Mark C.
TI ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL
   GROWTH FACTOR
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intraretinal fluid; neovascular age-related macular degeneration;
   subretinal fluid
ID GEOGRAPHIC ATROPHY; VISUAL-ACUITY; FLUID; RISK
AB Purpose: Assess the relationship between subretinal fluid (SRFL), intraretinal fluid, and visual outcomes of neovascular age-related degeneration in routine clinical practice. Methods: Treatment-naive eyes enrolled in the Fight Retinal Blindness! registry after January 2017 were identified. Lesion activity was graded at each visit as inactive, active not SRFL only (A-NSRFL only), or active SRFL only (A-SRFL only). Eyes were grouped based on initial activity as follows: 1) initially A-NSRFL only or 2) initially A-SRFL only, and their predominant activity status over 12 months was as follows: 1) mostly inactive, 2) mostly A-NSRFL only, or 3) mostly A-SRFL only. Results: Seven hundred and three eyes were eligible for analysis. Initially A-NSRFL only had a similar adjusted mean 12-month visual acuity change to initially A-SRFL eyes (5.7 vs. 6.9 letters; P = 0.165), but their final visual acuity was worse (62.5 vs. 67.5 letters at 12 months; P = 0.003). The adjusted mean 12-month visual acuity change between the predominant activity groups was significantly different (P = 0.005), with mostly inactive (7.6 letters) and mostly A-SRFL only (7.5 letters) eyes gaining more than mostly A-NSRFL only eyes (3.6 letters). Conclusion: Eyes with SRFL only had similar outcomes at 1 year to eyes that were mostly inactive. Intraretinal fluid was associated with worse visual outcomes, highlighting the importance of distinguishing between intraretinal fluid and SRFL when managing neovascular age-related degeneration.
C1 [Nguyen, Vuong; Gabrielle, Pierre-Henry; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Puzo, Martin; Sanchez-Monroy, Jorge] Miguel Servet Univ Hosp, Dept Ophthalmol, Zaragoza, Spain.
   [Gabrielle, Pierre-Henry; Garcher, Catherine C.; Baudin, Florian] Dijon Univ Hosp, Dept Ophthalmol, Dijon, France.
   [Wolff, Benjamin; Castelnovo, Laurent; Michel, Guillaume] Maison Rouge Ophthalmol Ctr, Strasbourg, France.
   [O'Toole, Louise] Mater Private Hosp, Eye Ctr, Dublin, Ireland.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol Zurich, Zurich, Switzerland.
C3 University of Sydney; Miguel Servet University Hospital; CHU Dijon
   Bourgogne; Mater Private Hospital; University of Zurich; University
   Zurich Hospital
RP Nguyen, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM phuc.nguyen@sydney.edu.au
RI BAUDIN, Florian/AHA-7176-2022; GABRIELLE, Pierre-Henry/Y-4971-2018
OI GABRIELLE, Pierre-Henry/0000-0002-9688-4845; SANCHEZ-MONROY,
   JORGE/0000-0001-5743-1520; PUZO, MARTIN/0000-0002-5048-4846
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); Macula Disease
   Foundation, Australia; NHMRC practitioner fellowship; Walter and Gertrud
   Siegenthaler Foundation, Zurich, Switzerland; Swiss National Foundation;
   Novartis; Bayer
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012), and a
   grant from the Macula Disease Foundation, Australia. M. C. Gillies is a
   Sydney Medical Foundation Fellow and is supported by an NHMRC
   practitioner fellowship. D. Barthelmes was supported by the Walter and
   Gertrud Siegenthaler Foundation, Zurich, Switzerland and the Swiss
   National Foundation. Funding was also provided by Novartis and Bayer.
   Novartis made nonbinding comments on the design of the study.
CR Bhandari S, 2020, OPHTHALMOLOGY, V127, P608, DOI 10.1016/j.ophtha.2019.11.018
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brooks ME, 2017, R J, V9, P378, DOI 10.32614/RJ-2017-066
   Daien V, 2020, BRIT J OPHTHALMOL, V104, P1064, DOI 10.1136/bjophthalmol-2019-315055
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jackson C., 2019, MULTISTATE MODELLING
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194
   R Development Core Team, 2022, R LANG ENV STAT COMP
   Razavi H, 2015, CLIN EXP OPHTHALMOL, V43, P707, DOI 10.1111/ceo.12658
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Therneau Terry M., PACKAGE SURVIVAL ANA
   Therneau TM., COXME MIXED EFFECTS
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x
NR 30
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2021
VL 41
IS 7
BP 1446
EP 1454
DI 10.1097/IAE.0000000000003061
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5LP
UT WOS:000711809200013
PM 33332811
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Yaghy, A
   Lee, AY
   Keane, PA
   Keenan, TDL
   Mendonca, LSM
   Lee, CS
   Cairns, AM
   Carroll, J
   Chen, H
   Clark, J
   Cukras, CA
   de Sisternes, L
   Domalpally, A
   Durbin, MK
   Goetz, KE
   Grassmann, F
   Haines, JL
   Honda, N
   Hu, ZJ
   Mody, C
   Orozco, LD
   Owsley, C
   Poor, S
   Reisman, C
   Ribeiro, R
   Sadda, SR
   Sivaprasad, S
   Staurenghi, G
   Ting, DS
   Tumminia, S
   Zalunardo, L
   Waheed, NK
AF Yaghy, Antonio
   Lee, Aaron Y.
   Keane, Pearse A.
   Keenan, Tiarnan D. L.
   Mendonca, Luisa S. M.
   Lee, Cecilia S.
   Cairns, Anne Marie
   Carroll, Joseph
   Chen, Hao
   Clark, Julie
   Cukras, Catherine A.
   de Sisternes, Luis
   Domalpally, Amitha
   Durbin, Mary K.
   Goetz, Kerry E.
   Grassmann, Felix
   Haines, Jonathan L.
   Honda, Naoto
   Hu, Zhihong Jewel
   Mody, Christopher
   Orozco, Luz D.
   Owsley, Cynthia
   Poor, Stephen
   Reisman, Charles
   Ribeiro, Ramiro
   Sadda, Srinivas R.
   Sivaprasad, Sobha
   Staurenghi, Giovanni
   Ting, Daniel SW.
   Tumminia, Santa J.
   Zalunardo, Luca
   Waheed, Nadia K.
TI Artificial intelligence-based strategies to identify patient populations
   and advance analysis in age-related macular degeneration clinical trials
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; AUTOMATED DETECTION;
   DRUG DEVELOPMENT; FLUID VOLUMES; RETINAL FLUID; PREDICTORS; IMAGES;
   QUANTIFICATION; IDENTIFICATION
C1 [Yaghy, Antonio; Waheed, Nadia K.] Tufts Univ, New England Eye Ctr, Med Ctr, Boston, MA USA.
   [Lee, Aaron Y.; Lee, Cecilia S.] Univ Washington, Dept Ophthalmol, Seattle, WA USA.
   [Lee, Aaron Y.; Lee, Cecilia S.] Karalis Johnson Retina Ctr, Seattle, WA USA.
   [Keane, Pearse A.] Moorfields Eye Hosp, London, England.
   [Keenan, Tiarnan D. L.; Cukras, Catherine A.] NEI, NIH, Div Epidemiol & Clin Applicat, Bethesda, MD USA.
   [Mendonca, Luisa S. M.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Cairns, Anne Marie] Optos Plc, Dunfermline, Scotland.
   [Carroll, Joseph] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, 925 N 87th St, Milwaukee, WI 53226 USA.
   [Chen, Hao] Genentech Inc, South San Francisco, CA USA.
   [Clark, Julie] Iver Bio, Parsippany, NJ USA.
   [de Sisternes, Luis; Durbin, Mary K.] Carl Zeiss Meditec Inc, Dublin, CA USA.
   [Domalpally, Amitha] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Goetz, Kerry E.; Tumminia, Santa J.] NEI, NIH, Off Director, Bethesda, MD USA.
   [Grassmann, Felix] Hlth & Med Univ, Potsdam, Germany.
   [Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Sch Med, Cleveland, OH USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Sch Med, Cleveland, OH USA.
   [Honda, Naoto] Nidek Co Ltd, Gamagori, Aichi, Japan.
   [Hu, Zhihong Jewel] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA.
   [Mody, Christopher; Reisman, Charles] Heidelberg Engn, Heidelberg, Germany.
   [Orozco, Luz D.] Genentech Inc, Dept Bioinformat, South San Francisco, CA 94080 USA.
   [Owsley, Cynthia] Univ Alabama Birmingham, Heersink Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Poor, Stephen] Novartis Inst Biomed Res, Dept Ophthalmol, Cambridge, MA USA.
   [Ribeiro, Ramiro] Apellis Pharmaceut, Waltham, MA USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, Doheny Eye Inst, David Geffen Sch Med, Los Angeles, CA USA.
   [Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Ting, Daniel SW.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Duke NUS Med Sch, Singapore, Singapore.
   [Zalunardo, Luca] Icare USA Inc, Raleigh, NC USA.
   [Waheed, Nadia K.] New England Eye Ctr, 260 Tremont St Biewend,Bldg,9th11th floors, Boston, MA 02116 USA.
C3 Tufts University; University of Washington; University of Washington
   Seattle; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Universidade Federal de Sao Paulo
   (UNIFESP); Medical College of Wisconsin; Roche Holding; Genentech; Carl
   Zeiss AG; University of Wisconsin System; University of Wisconsin
   Madison; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Case Western Reserve University; Case Western Reserve
   University; Nidek Co., Ltd; Doheny Eye Institute; University of
   California System; University of California Los Angeles; Roche Holding;
   Genentech; University of Alabama System; University of Alabama
   Birmingham; Novartis; Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Milan; Luigi Sacco Hospital;
   National University of Singapore; Singapore National Eye Center
RP Waheed, NK (通讯作者)，New England Eye Ctr, 260 Tremont St Biewend,Bldg,9th11th floors, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
RI Yaghy, Antonio/AAN-8961-2020
OI Yaghy, Antonio/0000-0002-5054-495X; Sivaprasad,
   Sobha/0000-0001-8952-0659; Keane, Pearse/0000-0002-9239-745X
FU Massachusetts Lions Eye Research Fund
FX Support was provided in part by the Massachusetts Lions Eye Research
   Fund.
CR aao, REG DAT AN OV AM AC
   Abbas A., 2022, GRAEF ARCH CLIN EXP, V1, P1, DOI [10.1007/S00417-021-05544-Y/FIGURES/7, DOI 10.1007/S00417-021-05544-Y/FIGURES/7]
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Adams CP, 2006, HEALTH AFFAIR, V25, P420, DOI 10.1377/hlthaff.25.2.420
   Adhi M, 2016, OSLI RETINA, V47, P410, DOI 10.3928/23258160-20160419-03
   Arslan J, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.57
   Artificial Intelligence, ARTIF INTELL
   Babenko B., 2019, PREDICTING PROGR AGE
   Banerjee I., 2019, DEEP LEARNING APPROA
   Bearman J., 1974, BIOMETCIC NOTE
   Bhardwaj C, 2021, J DIGIT IMAGING, V34, P440, DOI 10.1007/s10278-021-00418-5
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Botkin JR, 2014, J COMMUN GENET, V5, P205, DOI 10.1007/s12687-013-0175-8
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Bui PTA, 2022, EYE, V36, P2013, DOI 10.1038/s41433-021-01747-z
   Buolamwini J, 2018, P MACH LEARN RES, V81, P77
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Carlisle B, 2015, CLIN TRIALS, V12, P77, DOI 10.1177/1740774514558307
   Castelvecchi D, 2016, NATURE, V537, P20, DOI 10.1038/538020a
   Cder Cber, ADJUSTING COVARIATES
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   clinicaltrials, SEARCH AG REL MAC DE
   clinicaltrials, SEARCH ACT NOT RECR
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Csaky KG, 2019, SURV OPHTHALMOL, V64, P353, DOI 10.1016/j.survophthal.2019.01.014
   Cunefare D, 2019, BIOMED OPT EXPRESS, V10, P3815, DOI 10.1364/BOE.10.003815
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dickman SL, 2017, LANCET, V389, P1431, DOI 10.1016/S0140-6736(17)30398-7
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dwork C., 2011, FAIRNESS AWARENESS
   fda, FD C ACT CHAPTER DRU
   fda, CLIN RES STEP 3 CLIN
   Feng DH, 2020, IEEE ENG MED BIO, P5428, DOI 10.1109/EMBC44109.2020.9176743
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guo Y, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.54
   healthdatagateway, MOORFIELDS AMD DATAS
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Jensen CD, 2012, OBESITY, V20, P2250, DOI 10.1038/oby.2012.96
   Jiang J, 2020, ANN INTERN MED, V172, P159, DOI 10.7326/M19-1759
   Karyotaki E, 2015, PSYCHOL MED, V45, P2717, DOI 10.1017/S0033291715000665
   Keefe JR, 2021, PSYCHOTHER RES, V31, P432, DOI 10.1080/10503307.2020.1784487
   Keenan T.D.L., OPHTHALMOL SCI, V1, DOI [10.1016/J.XOPS.2021.100034/ATTACHMENT/475D143D-F9D7-4BD6-B72E-2B9D0357F14A, DOI 10.1016/J.XOPS.2021.100034/ATTACHMENT/475D143D-F9D7-4BD6-B72E-2B9D0357F14A]
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keenan Tiarnan D L, 2021, Ophthalmol Sci, V1, P100057, DOI 10.1016/j.xops.2021.100057
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Khan SM, 2021, LANCET DIGIT HEALTH, V3, pE51, DOI 10.1016/S2589-7500(20)30240-5
   Kihara Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8029
   Knight W, 2017, TECHNOL REV, V120, P54
   Kopcke F, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-37
   Krouse HJ, 2020, OTOLARYNG HEAD NECK, V163, P65, DOI 10.1177/0194599820926463
   LASAGNA L, 1979, CLIN PHARMACOL THER, V25, P751
   Lee CS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.9
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Liu HR, 2019, JAMA OPHTHALMOL, V137, P1353, DOI 10.1001/jamaophthalmol.2019.3501
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Loo J, 2018, BIOMED OPT EXPRESS, V9, P2681, DOI 10.1364/BOE.9.002681
   McDermott MBA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb1655
   McHugh RK, 2013, AM J ADDICTION, V22, P18, DOI 10.1111/j.1521-0391.2013.00317.x
   Mehta N, 2020, JAMA OPHTHALMOL, V138, P1017, DOI 10.1001/jamaophthalmol.2020.2769
   Morgan S, 2011, HEALTH POLICY, V100, P4, DOI 10.1016/j.healthpol.2010.12.002
   Nazir T, 2021, SENSORS-BASEL, V21, DOI 10.3390/s21165283
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   oxfordbrc.nihr, WORLDS 1 GEN THER OP
   Pekala M, 2019, COMPUT BIOL MED, V114, DOI 10.1016/j.compbiomed.2019.103445
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Ryu H.J., 2018, WORKSH FAIRN ACC TRA
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Shimasaki Noriko, 2020, NAT REV DRUG DISCOV, V19, P200, DOI [10.1038/s41573-019-0052-1, DOI 10.1038/S41573-019-0052-1, 10.1038/s41573-019-0024-5, DOI 10.1038/S41573-019-0024-5]
   Soares RR, 2021, AM J OPHTHALMOL, V229, P160, DOI 10.1016/j.ajo.2021.04.001
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Sumaroka A, 2019, INVEST OPHTH VIS SCI, V60, P2551, DOI 10.1167/iovs.19-27156
   Suvarna Viraj, 2010, Perspect Clin Res, V1, P57
   Tak N, 2021, CUREUS, V13, DOI 10.7759/cureus.17579
   Thoma A, 2010, CAN J SURG, V53, P205
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang YL, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3445
   Watson Judith M, 2006, BMC Med Res Methodol, V6, P34, DOI 10.1186/1471-2288-6-34
   Westhoff CL, 2012, CONTRACEPTION, V85, P465, DOI 10.1016/j.contraception.2011.09.019
   Williams N., 2021, OPTIMIZING PRECISION
   wired, OUR MACHINES NOW HAV
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zhang BH, 2018, PROCEEDINGS OF THE 2018 AAAI/ACM CONFERENCE ON AI, ETHICS, AND SOCIETY (AIES'18), P335, DOI 10.1145/3278721.3278779
   Zheng C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.29
NR 103
TC 0
Z9 0
U1 5
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2022
VL 220
AR 109092
DI 10.1016/j.exer.2022.109092
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1U5FH
UT WOS:000805438000004
PM 35525297
DA 2022-11-30
ER

PT J
AU Salimiaghdam, N
   Singh, L
   Singh, MK
   Chwa, M
   Atilano, SR
   Mohtashami, Z
   Nesburn, AB
   Kuppermann, BD
   Lu, SY
   Kenney, MC
AF Salimiaghdam, Nasim
   Singh, Lata
   Singh, Mithalesh K.
   Chwa, Marilyn
   Atilano, Shari R.
   Mohtashami, Zahra
   Nesburn, Anthony B.
   Kuppermann, Baruch D.
   Lu, Stephanie Y.
   Kenney, M. Cristina
TI Impacts of Bacteriostatic and Bactericidal Antibiotics on the
   Mitochondria of the Age-Related Macular Degeneration Cybrid Cell Lines
SO BIOMOLECULES
LA English
DT Article
DE AMD cybrids; mtDNA haplogroups; antibiotics; bacteriostatic;
   bactericidal
ID TETRACYCLINE ANTIBIOTICS; ORAL FLUOROQUINOLONES; DNA; RISK;
   PHOTOTOXICITY; EPIDEMIOLOGY; MECHANISM; APOPTOSIS; ARPE-19; BIOLOGY
AB We assessed the potential negative effects of bacteriostatic and bactericidal antibiotics on the AMD cybrid cell lines (K, U and J haplogroups). AMD cybrid cells were created and cultured in 96-well plates and treated with tetracycline (TETRA) and ciprofloxacin (CPFX) for 24 h. Reactive oxygen species (ROS) levels, mitochondrial membrane potential (Delta psi M), cellular metabolism and ratio of apoptotic cells were measured using H2DCFDA, JC1, MTT and flow cytometry assays, respectively. Expression of genes of antioxidant enzymes, and pro-inflammatory and pro-apoptotic pathways were evaluated by quantitative real-time PCR (qRT-PCR). Higher ROS levels were found in U haplogroup cybrids when treated with CPFX 60 mu g/mL concentrations, lower Delta psi M of all haplogroups by CPFX 120 mu g/mL, diminished cellular metabolism in all cybrids with CPFX 120 mu g/mL, and higher ratio of dead cells in K and J cybrids. CPFX 120 mu g/mL induced overexpression of IL-33, CASP-3 and CASP-9 in all cybrids, upregulation of TGF-beta 1 and SOD2 in U and J cybrids, respectively, along with decreased expression of IL-6 in J cybrids. TETRA 120 mu g/mL induced decreased ROS levels in U and J cybrids, increased cellular metabolism of treated U cybrids, higher ratio of dead cells in K and J cybrids and declined Delta psi M via all TETRA concentrations in all haplogroups. TETRA 120 mu g/mL caused upregulation of IL-6 and CASP-3 genes in all cybrids, higher CASP-7 gene expression in K and U cybrids and downregulation of the SOD3 gene in K and U cybrids. Clinically relevant dosages of ciprofloxacin and tetracycline have potential adverse impacts on AMD cybrids possessing K, J and U mtDNA haplogroups in vitro.
C1 [Salimiaghdam, Nasim; Singh, Lata; Singh, Mithalesh K.; Chwa, Marilyn; Atilano, Shari R.; Mohtashami, Zahra; Nesburn, Anthony B.; Kuppermann, Baruch D.; Lu, Stephanie Y.; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine; Cedars
   Sinai Medical Center; University of California System; University of
   California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.; Kenney, MC (通讯作者)，Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM salimiag@hs.uci.edu; drlata.singh@aiims.edu; mithales@hs.uci.edu;
   mchwa@hs.uci.edu; satilano@hs.uci.edu; zmohtash@hs.uci.edu;
   anesburn@hs.uci.edu; bdkupper@hs.uci.edu; sylu@hs.uci.edu;
   mkenney@hs.uci.edu
OI mohtashami, zahra/0000-0002-3718-7302; Singh, Mithalesh
   Kumar/0000-0002-1812-9860
FU Discovery Eye Foundation; Polly and Michael Smith, Edith and Roy Carver;
   Iris and B. Gerald Cantor Foundation; Max Factor Family Foundation; NEI
   [R01 EY027363]; Research to Prevent Blindness; Institute for Clinical
   and Translational Science (ICTS) at University of California Irvine [ULI
   TR001414/TR/NCATS]
FX This research was funded by Discovery Eye Foundation, Polly and Michael
   Smith, Edith and Roy Carver, Iris and B. Gerald Cantor Foundation, Max
   Factor Family Foundation, and NEI R01 EY027363 (MCK). Supported in part
   by an Unrestricted Departmental Grant from Research to Prevent
   Blindness. We acknowledge the support of the Institute for Clinical and
   Translational Science (ICTS) at University of California Irvine (ULI
   TR001414/TR/NCATS). NS was a Beckman Foundation Fellow in Retinal
   Degeneration Research.
CR Ahler E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064561
   Andersson SGE, 2003, PHILOS T R SOC B, V358, P165, DOI 10.1098/rstb.2002.1193
   Asiabi P, 2020, J ASSIST REPROD GEN, V37, P2545, DOI 10.1007/s10815-020-01901-8
   Boguszewska K, 2020, MOLECULES, V25, DOI 10.3390/molecules25122857
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001
   Ding LH, 2017, J TOXICOL SCI, V42, P267, DOI 10.2131/jts.42.267
   DOUGHERTY JM, 1991, INVEST OPHTH VIS SCI, V32, P2970
   Duewelhenke N, 2007, ANTIMICROB AGENTS CH, V51, P54, DOI 10.1128/AAC.00729-05
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Etminan M, 2012, JAMA-J AM MED ASSOC, V307, P1414, DOI 10.1001/jama.2012.383
   Falagas ME, 2007, INT J ANTIMICROB AG, V29, P374, DOI 10.1016/j.ijantimicag.2006.11.011
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fife D, 2014, DRUG SAFETY, V37, P171, DOI 10.1007/s40264-014-0138-y
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476
   Hamblin MR, 2019, FUTURE MED CHEM, V11, P2427, DOI 10.4155/fmc-2018-0513
   Hangas A, 2018, NUCLEIC ACIDS RES, V46, P9625, DOI 10.1093/nar/gky793
   Hsiao CJJ, 2010, CHEM-BIOL INTERACT, V188, P204, DOI 10.1016/j.cbi.2010.07.017
   Hutchings MI, 2019, CURR OPIN MICROBIOL, V51, P72, DOI 10.1016/j.mib.2019.10.008
   Jones CN, 2009, MITOCHONDRION, V9, P429, DOI 10.1016/j.mito.2009.08.001
   Kalghatgi S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006055
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Katz L, 2016, J IND MICROBIOL BIOT, V43, P155, DOI 10.1007/s10295-015-1723-5
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kohanski MA, 2007, CELL, V130, P797, DOI 10.1016/j.cell.2007.06.049
   Lewis T, 2014, J ATHL TRAINING, V49, P422, DOI 10.4085/1062-6050-49.2.09
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Musial-Kopiejka M, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19042303
   Nacht J, 2016, J EMERG MED, V5, P805, DOI [10.1016/j.jemermed.2016.03.014, DOI 10.1016/J.JEMERMED.2016.03.014]
   Pan XS, 1997, ANTIMICROB AGENTS CH, V41, P471, DOI 10.1128/AAC.41.2.471
   Prescott JF, 2014, VET MICROBIOL, V171, P273, DOI 10.1016/j.vetmic.2014.02.035
   Roberts MC, 2020, BACTERIAL RESISTANCE TO ANTIBIOTICS - FROM MOLECULES TO MAN, P101
   Salimiaghdam N, 2022, EXP EYE RES, V214, DOI 10.1016/j.exer.2021.108857
   Salimiaghdam N, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2020-000458
   Salimiaghdam N, 2019, OPEN OPHTHALMOL J, V13, P90, DOI 10.2174/1874364101913010090
   Samarakoon N, 2007, CLIN EXP OPHTHALMOL, V35, P102, DOI 10.1111/j.1442-9071.2007.01427.x
   Sanchez AR, 2004, INT J DERMATOL, V43, P709, DOI 10.1111/j.1365-4632.2004.02108.x
   Sandler C, 2005, INFLAMM RES, V54, P304, DOI 10.1007/s00011-005-1358-5
   Sandler C, 2005, INT IMMUNOPHARMACOL, V5, P1611, DOI 10.1016/j.intimp.2005.04.013
   Sapadin AN, 2006, J AM ACAD DERMATOL, V54, P258, DOI 10.1016/j.jaad.2005.10.004
   Smith A, 2001, DRUGS, V61, P747, DOI 10.2165/00003495-200161060-00004
   Sodhi Mohit, 2020, Pharmacotherapy, V40, P487, DOI 10.1002/phar.2395
   Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X
   WAGAI N, 1992, ARCH TOXICOL, V66, P392, DOI 10.1007/BF02035128
   WALLACE I, 1989, INVEST OPHTH VIS SCI, V30, P1594
   Zakeri B, 2008, BIOCHEM CELL BIOL, V86, P124, DOI 10.1139/O08-002
NR 50
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAY
PY 2022
VL 12
IS 5
AR 675
DI 10.3390/biom12050675
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 1R3RV
UT WOS:000803291100001
PM 35625603
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Solomon, SD
   Lindsley, KB
   Krzystolik, MG
   Vedula, SS
   Hawkins, BS
AF Solomon, Sharon D.
   Lindsley, Kristina B.
   Krzystolik, Magdalena G.
   Vedula, Satyanarayana S.
   Hawkins, Barbara S.
TI Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular
   Age-Related Macular Degeneration Findings from a Cochrane Systematic
   Review
SO OPHTHALMOLOGY
LA English
DT Article
AB Topic: To summarize the relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, Inc.), using findings from a Cochrane Eyes and Vision Group systematic review.
   Methods: For this systematic review, we included only randomized controlled trials in which the 2 anti-VEGF agents had been compared directly. The primary outcome was 1-year gain in best-corrected visual acuity (BCVA) of >= 15 letters. We followed Cochrane methods for trial selection, data extraction, and data analyses. Relative effects of bevacizumab versus ranibizumab are presented as estimated risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs).
   Results: We identified 6 eligible randomized controlled trials with 2809 participants. The proportion of eyes that gained >= 15 letters of BCVA by 1 year was similar for the 2 agents when the same regimens were compared (RR, 0.90; 95% CI, 0.73-1.11). The mean change in BCVA from baseline also was similar (MD, -0.5 letter; 95% CI, -1.6 to +0.6). Other BCVA and quality of life outcomes were similar for the 2 agents. One-year treatment cost with ranibizumab was 5.1 and 25.5 times the cost for bevacizumab in the 2 largest trials. Ocular adverse events were uncommon (<1%), and rates were similar for the 2 agents.
   Conclusions: We found no important difference in effectiveness or safety between bevacizumab and ranibizumab for NVAMD treatment, but there was a large cost difference. (C) 2016 by the American Academy of Ophthalmology.
C1 [Solomon, Sharon D.; Hawkins, Barbara S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Lindsley, Kristina B.; Hawkins, Barbara S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Krzystolik, Magdalena G.] Massachusetts Eye & Ear Infirm, Retina Serv, Providence, RI USA.
   [Vedula, Satyanarayana S.] Johns Hopkins Univ, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Harvard
   University; Massachusetts Eye & Ear Infirmary; Johns Hopkins University
RP Hawkins, BS (通讯作者)，Wilmer Eye Inst, Johns Hopkins Sch Med, 9430 Diamondback Dr, Columbia, MD 21045 USA.
EM bhawkins@jhmi.edu
FU Cochrane Eyes and Vision Group US Project [U01 EY-020522]; National Eye
   Institute, National Institutes of Health, US Department of Health and
   Human Services, Bethesda, Maryland; Research to Prevent Blindness, New
   York, New York; NATIONAL EYE INSTITUTE [U01EY020522] Funding Source: NIH
   RePORTER
FX The author(s) have no proprietary or commercial interest in any
   materials discussed in this article. K.B.L., S.S.V., and B.S.H.: Salary
   support from the Cochrane Eyes and Vision Group US Project, cooperative
   agreement U01 EY-020522 with the National Eye Institute, the National
   Institutes of Health, US Department of Health and Human Services,
   Bethesda, Maryland.; S.D.S. and B.S.H.: Support from an unrestricted
   grant to the Wilmer Eye Institute from Research to Prevent Blindness,
   New York, New York.
CR [Anonymous], 2012, REV MANAGER REVMAN C
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, P1508
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krystolik MG, 2008, COCHRANE DB SYST REV
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   U.S. Department of Health and Human Services, 5U10EY02353002 US DE
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
NR 23
TC 43
Z9 46
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2016
VL 123
IS 1
BP 70
EP +
DI 10.1016/j.ophtha.2015.09.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4GE
UT WOS:000367060700027
PM 26477843
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Christen, WG
   Glynn, RJ
   Manson, JE
   MacFadyen, J
   Bubes, V
   Schvartz, M
   Buring, JE
   Sesso, HD
   Gaziano, JM
AF Christen, William G.
   Glynn, Robert J.
   Manson, Joann E.
   MacFadyen, Jean
   Bubes, Vadim
   Schvartz, Miriam
   Buring, Julie E.
   Sesso, Howard D.
   Gaziano, J. Michael
TI Effects of Multivitamin Supplement on Cataract and Age-Related Macular
   Degeneration in a Randomized Trial of Male Physicians
SO OPHTHALMOLOGY
LA English
DT Article
ID VITAMIN-E SUPPLEMENTATION; BETA-CAROTENE; EYE DISEASE; VISUAL FUNCTION;
   CARDIOVASCULAR-DISEASE; ALPHA-TOCOPHEROL; CLINICAL-TRIAL; LUTEIN; RISK;
   ANTIOXIDANT
AB Purpose: To test whether long-term multivitamin supplementation affects the incidence of cataract or agerelated macular degeneration (AMD) in a large cohort of men.
   Design: Randomized, double-blind, placebo-controlled trial.
   Participants: A total of 14 641 US male physicians aged <= 50 years.
   Intervention: Daily multivitamin or placebo.
   Main Outcome Measures: Incident cataract and visually significant AMD responsible for a reduction in bestcorrected visual acuity to 20/30 or worse based on self-reports confirmed by medical record review.
   Results: During an average of 11.2 years of treatment and follow-up, a total of 1817 cases of cataract and 281 cases of visually significant AMD were confirmed. There were 872 cataracts in the multivitamin group and 945 cataracts in the placebo group (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.83-0.99; P 0.04). For visually significant AMD, there were 152 cases in the multivitamin group and 129 cases in the placebo group (HR, 1.19; 95% CI, 0.94-1.50; P = 0.15).
   Conclusions: These randomized trial data from a large cohort of middle-aged and older US male physicians indicate that long-term daily multivitamin use modestly and significantly decreased the risk of cataract but had no significant effect on visually significant AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Christen, William G.; Glynn, Robert J.; Manson, Joann E.; MacFadyen, Jean; Bubes, Vadim; Schvartz, Miriam; Buring, Julie E.; Sesso, Howard D.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
   [Christen, William G.; Glynn, Robert J.; Manson, Joann E.; MacFadyen, Jean; Bubes, Vadim; Schvartz, Miriam; Buring, Julie E.; Sesso, Howard D.; Gaziano, J. Michael] Harvard Univ, Sch Med, Boston, MA USA.
   [Buring, Julie E.; Sesso, Howard D.; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
   [Glynn, Robert J.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
   [Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, Boston, MA 02115 USA.
   [Gaziano, J. Michael] VA Boston Healthcare Syst, Boston, MA USA.
   [Buring, Julie E.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
   [Manson, Joann E.; Buring, Julie E.; Sesso, Howard D.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Brigham & Women's Hospital;
   Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Harvard University; VA Boston Healthcare
   System; Harvard University; Harvard Medical School; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health
RP Christen, WG (通讯作者)，900 Commonwealth Ave East, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
FU National Institutes of Health; DSM Nutritional Products Inc.;
   Bristol-Meyers Squibb; AstraZeneca; Novartis; nonprofit Aurora
   Foundation; Tomato Products Wellness Council; Cambridge Theranostics,
   Ltd.; Veterans Administration; BASF Corporation; Pfizer Inc.;
   Nutritional Products Inc.; National Eye Institute [CA 097193]; National
   Institutes of Health (Bethesda, MD) [CA 34944, CA 40360, HL 26490, HL
   34595]; BASF Corporation (Florham Park, NJ); NATIONAL CANCER INSTITUTE
   [R01CA040360, R01CA097193] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [P30DK040561] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): W. G. C. received
   research funding support from the National Institutes of Health and DSM
   Nutritional Products Inc. (formerly Roche Vitamins). R. J. G. received
   investigator-initiated research funding from the National Institutes of
   Health, Bristol-Meyers Squibb, AstraZeneca, and Novartis, and signed a
   consulting agreement with Merck to give an invited talk. J. E. M.
   received investigator-initiated research funding from the National
   Institutes of Health and assistance with study pills and packaging from
   BASF and Cognis Corporations for the WAFACS and from Pronova BioPharma
   and Pharmavite for the VITamin D and OmegA-3 TriaL, and funding from the
   nonprofit Aurora Foundation. J. E. B. received investigator-initiated
   research funding from the National Institutes of Health and assistance
   with study pills and packaging from Natural Source Vitamin E Association
   and Bayer Healthcare for the Women's Health Study. H. D. S. received
   investigator-initiated research funding from the National Institutes of
   Health, the Tomato Products Wellness Council, and Cambridge
   Theranostics, Ltd. J. M. G. received investigator-initiated research
   funding from the National Institutes of Health, the Veterans
   Administration, and the BASF Corporation; assistance with study agents
   and packaging from BASF Corporation and Pfizer Inc. (formerly Wyeth,
   American Home Products, and Lederle); and assistance with study
   packaging provided by D. S. M. Nutritional Products Inc. (formerly Roche
   Vitamins). No other authors reported financial disclosures. Supported by
   Grants CA 097193 (which included funding from the National Eye Institute
   and the National Institute on Aging), CA 34944, CA 40360, HL 26490, and
   HL 34595 from the National Institutes of Health (Bethesda, MD), and an
   investigator-initiated grant from BASF Corporation (Florham Park, NJ).
   Study agents and packaging were provided by BASF Corporation and Pfizer
   Inc. (formerly Wyeth, American Home Products, and Lederle) (New York,
   NY), and study packaging was provided by DSM Nutritional Products, Inc.
   (formerly Roche Vitamins) (Parsippany, NJ). The National Institutes of
   Health, BASF, Pfizer Inc., and DSM Nutritional Products Inc., had no
   role in the study design; conduct of the study; collection, management,
   analysis, and interpretation of the data; or preparation, review, or
   approval of the manuscript.
CR Agte V, 2010, OPHTHALMIC RES, V44, P166, DOI 10.1159/000316477
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Christen WG, 2004, OPHTHAL EPIDEMIOL, V11, P401, DOI 10.1080/09286580490515152
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 2003, ARCH OPHTHALMOL-CHIC, V121, P372, DOI 10.1001/archopht.121.3.372
   Christen WG, 2008, OPHTHALMOLOGY, V115, P822, DOI 10.1016/j.ophtha.2007.06.040
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, ARCH OPHTHALMOL-CHIC, V128, P1397, DOI 10.1001/archophthalmol.2010.266
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, 2008, Ophthalmology, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N G, 1999, Curr Opin Ophthalmol, V10, P464, DOI 10.1097/00055735-199912000-00016
   Cui YH, 2013, AM J CLIN NUTR, V98, P778, DOI 10.3945/ajcn.112.053835
   EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862
   GERSTER H, 1989, Z ERNAHRUNGSWISS, V28, P56, DOI 10.1007/BF02025566
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Gritz DC, 2006, BRIT J OPHTHALMOL, V90, P847, DOI 10.1136/bjo.2005.088104
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   MARESPERLMAN JA, 1995, INVEST OPHTH VIS SCI, V36, P276
   McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009
   Milton RC, 2006, OPHTHALMOLOGY, V113, P1264, DOI 10.1016/j.ophtha.2006.02.054
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   National Eye Institute, 2013, NAT PLAN EY VIS RES
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   TAYLOR A, 1992, ANN NY ACAD SCI, V669, P111
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, J EPIDEMIOL COMMUN H, V52, P468, DOI 10.1136/jech.52.7.468
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
NR 57
TC 42
Z9 43
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2014
VL 121
IS 2
BP 525
EP 534
DI 10.1016/j.ophtha.2013.09.038
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 302CO
UT WOS:000330579200018
PM 24268861
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sulzbacher, F
   Roberts, P
   Munk, MR
   Kaider, A
   Kroh, ME
   Sacu, S
   Schmidt-Erfurth, U
AF Sulzbacher, Florian
   Roberts, Philipp
   Munk, Marion R.
   Kaider, Alexandra
   Kroh, Maria Elisabeth
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
CA Vienna Eye Study Ctr
TI Relationship of Retinal Morphology and Retinal Sensitivity in the
   Treatment of Neovascular Age-Related Macular Degeneration Using
   Aflibercept
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE neovascular AMD; microperimetry; spectral-domain OCT
ID OPTICAL COHERENCE TOMOGRAPHY; TEST-RETEST VARIABILITY; INTRAVITREAL
   AFLIBERCEPT; SPECTRAL-DOMAIN; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB;
   MICROPERIMETRY; FEATURES; OUTCOMES
AB PURPOSE. To relate the functional response to distinct morphological features of the retina during aflibercept treatment for neovascular AMD (nAMD).
   METHODS. A total of 726 retinal locations in 22 consecutive eyes presenting with treatmentnaive nAMD underwent a standardized examination with spectral-domain optical coherence tomography (SD-OCT) and topographic microperimetry (MP) at baseline, after 3 and 12 months of continuous intravitreal aflibercept therapy. The retinal sensitivity at each stimulus location was registered to the corresponding location on SD-OCT morphology. Subsequently, the microperimetric responses were evaluated with respect to the following underlying SD-OCT features: neovascular complex (NVC), subretinal fluid (SRF), intraretinal fluid (IRF), intraretinal cystoid space (IRC), serous pigment epithelium detachment (sPED), and fibrovascular pigment epithelium detachment (fPED).
   RESULTS. Baseline sensitivity was reduced to mean values of 1.8 dB in NVC, 2.2 dB in IRC, 2.8 dB in IRF, 2.6 dB in sPED, 3.6 dB in SRF, and 4.6 dB in fPED. Improvements in retinal sensitivity were most pronounced during the initial 3-month interval, when significant recovery was documented for SRF and sPED with +4.0/5.5 dB (P < 0.0001) and to a lesser extent for IRF, IRC, fPED, with +1.1, 1.7, 2.3 dB, respectively. From month 3 to 12, the additional benefit ranged from 0.3 to 1.0 dB (P > 0.05 for each category).
   CONCLUSIONS. Significant functional benefits following intravitreal aflibercept treatment could be detected over all defined morphological pathologies. The level of improvement varied dependent on the associated feature with the best prognosis for visual improvement in SRF and sPED and least with intraretinal fluid and particularly intraretinal cysts.
C1 [Sulzbacher, Florian; Roberts, Philipp; Munk, Marion R.; Kroh, Maria Elisabeth; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Kaider, Alexandra] Med Univ Vienna, Sect Clin Biometr, Ctr Med Stat Informat & Intelligent Syst, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Ritter, Markus/0000-0003-1406-8340; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Mitsch, Christoph/0000-0002-5361-5418
CR Acton JH, 2012, OPTOMETRY VISION SCI, V89, P1050, DOI 10.1097/OPX.0b013e31825da18c
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Issa PC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012864
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Seiple W, 2012, OPTOMETRY VISION SCI, V89, P1182, DOI 10.1097/OPX.0b013e3182640c83
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 33
TC 23
Z9 23
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2015
VL 56
IS 2
BP 1158
EP 1167
DI 10.1167/iovs.14-14298
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BC
UT WOS:000352137300058
PM 25503456
DA 2022-11-30
ER

PT J
AU Zapata, MA
   Bures, A
   Gallego-Pinazo, R
   Gutierrez-Sanchez, E
   Olenik, A
   Pastor, S
   Ruiz-Medrano, J
   Salinas, C
   Otero-Romero, S
   Abraldes, M
AF Zapata, Miguel A.
   Bures, Anniken
   Gallego-Pinazo, Roberto
   Gutierrez-Sanchez, Estanislao
   Olenik, Andrea
   Pastor, Salvador
   Ruiz-Medrano, Jorge
   Salinas, Cecilia
   Otero-Romero, Susana
   Abraldes, Maximino
CA Optretina Reading Grp
TI Prevalence of age-related macular degeneration among optometric
   telemedicine users in Spain: a retrospective nationwide population-based
   study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Epidemiology; Macula; Prevalence;
   Retinal disorders; Retina; Risk factors; Telemedicine
AB Purpose To evaluate the prevalence of AMD among optometric telemedicine users in Spain and to identify risk factors.
   Methods Retrospective analysis of a nationwide database conducted on subjects attending to optometry centers, between January 2013 and December 2019. Fundus photographs were performed by optometrists, using non-mydriatic cameras, and evaluated by a group of 12 retina specialists.
   Results Among the 119,877 subjects included, the overall prevalence of AMD was 7.6%. The prevalence of early, intermediate, and advanced AMD was 2.9%, 2.7%, and 2.0%, respectively. Of the 9129 AMD subjects, 1161 (12.7%) had geographic atrophy, and 1089 (11.9%) had neovascular AMD, either scar (4.5%) or exudative (7.4%). There was a significant association between AMD and age (per year older, adjusted odds ratio, OR 1.116; 95% CI 1.114 to 1.119, p<0.0001). Women had higher prevalence (adjusted OR 1.17; 95% CI 1.12 to 1.23, p<0.0001). Every diopter (spherical equivalent) of progress toward hyperopia was associated with a significant increase in early AMD prevalence (adjusted OR 1.02, 95 CI 1.01 to 1.04, p=0.0074). Presence of diabetes was associated with a lower AMD prevalence (p<0.0001).
   Conclusions The prevalence of AMD (any eye and any severity) was 7.6%, with a prevalence of advanced AMD of 2.0%. Older age and women were significantly associated with a higher prevalence of AMD, whereas myopia and presence of diabetes were associated with significantly lower odds of any AMD.
C1 [Zapata, Miguel A.] Optretina, Barcelona, Spain.
   [Zapata, Miguel A.] Hosp Valle De Hebron, Passeig Roser 126, Barcelona 08195, Spain.
   [Bures, Anniken; Gallego-Pinazo, Roberto; Gutierrez-Sanchez, Estanislao; Olenik, Andrea; Pastor, Salvador; Ruiz-Medrano, Jorge; Salinas, Cecilia; Abraldes, Maximino] Optretina Image Reading Team, Barcelona, Spain.
   [Bures, Anniken; Salinas, Cecilia] Inst Microcirugia Ocular, IMO, Barcelona, Spain.
   [Gallego-Pinazo, Roberto] Oftalvist, Valencia, Spain.
   [Gutierrez-Sanchez, Estanislao] Hosp Univ Virgen Macarena, Seville, Spain.
   [Pastor, Salvador] Hosp Clin Univ, Valladolid, Spain.
   [Ruiz-Medrano, Jorge] Hosp Puerta de Hierro, Madrid, Spain.
   [Otero-Romero, Susana] Hosp Valle De Hebron, Serv Med Prevent & Epidemiol, Barcelona, Spain.
   [Abraldes, Maximino] Complexo Hosp Univ Santiago de Compostela, La Coruna, Spain.
C3 Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen
   Macarena; Universidad de la Laguna; Hospital Puerta de
   Hierro-Majadahonda; Hospital Universitari Vall d'Hebron; Complexo
   Hospitalario Universitario de Santiago de Compostela
RP Zapata, MA (通讯作者)，Optretina, Barcelona, Spain.; Zapata, MA (通讯作者)，Hosp Valle De Hebron, Passeig Roser 126, Barcelona 08195, Spain.
EM zapatavictori@hotmail.com
RI Sanchez, Estanislao Gutierrez/P-7776-2018; Ruiz-Medrano,
   Jorge/N-6256-2016
OI Sanchez, Estanislao Gutierrez/0000-0003-4851-680X; Ruiz-Medrano,
   Jorge/0000-0002-1105-9265; Zapata, Miguel Angel/0000-0002-0096-4569
FU Allergan S.A.
FX Support for this assistance was funded by Allergan S.A.
CR [Anonymous], 2020, I NACL ESTADISTICA I
   [Anonymous], 2018, DIABETIC EYE SCREENI
   Arslan S, 2019, J AM COLL NUTR, V38, P424, DOI 10.1080/07315724.2018.1538830
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Damian Javier, 2006, Aten Primaria, V38, P51, DOI 10.1157/13090016
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   LagoBouza JR, PREVALENCIA DEGRADAC
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Olmedo-Requena R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030488
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Ram?rez-Sebasti?n, 1991, REV ESP GERIATR GERO, V26, P21
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 35
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 259
IS 7
BP 1993
EP 2003
DI 10.1007/s00417-021-05093-4
EA FEB 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TI3LH
UT WOS:000617400100004
PM 33576860
DA 2022-11-30
ER

PT J
AU Weng, HY
   Huang, TL
   Chang, PY
   Ho, WT
   Hsu, YR
   Chen, FT
   Chen, YJ
   Wang, JK
AF Weng, Hsin-Yu
   Huang, Tzu-Lun
   Chang, Pei-Yao
   Ho, Wei-Ting
   Hsu, Yung-Ray
   Chen, Fang-Ting
   Chen, Yun-Ju
   Wang, Jia-Kang
TI Comparison of Two-Year Outcome of Photodynamic Therapy in Combination
   with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal
   Vasculopathy
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE intravitreal injection; aflibercept; ranibizumab; photodynamic therapy;
   polypoidal choroidal vasculopathy
AB Purpose: To compare the two-year visual and anatomical outcomes of combination therapy of photodynamic therapy (PDT) with intravitreal aflibercept (IVA) or intravitreal ranibizumab (IVR) for patients with polypoidal choroidal vasculopathy (PCV), and to investigate the clinical factors with final visual outcome and retreatment. Methods: A retrospective medical chart review was performed for 55 eyes from 55 patients with PCV treated by a combination therapy of prompt PDT with either IVA (n = 30) or IVR (n = 25). Baseline data and treatment outcomes during the 24-month follow-up were compared between the two groups. Primary outcomes were the changes in best-corrected visual acuity (BCVA) and the rate of complete polyp regression. Secondary outcomes were the changes in central retinal thickness (CRT) and the rate of dry macula. Retreatment was administered in cases with persistent or recurrent submacular or intramacular fluid. Results: The BCVA significantly improved in the IVA/PDT group at every 6-month visit compared to the baseline. In the IVR/PDT group, there was a significant improvement of BCVA only at 6-months and 12-months, but not at 18-months and 24-months compared to the baseline. There were no significant differences in the BCVA change or CRT change between the two groups at every 6-month visit. A complete polyp regression rate at 3-months was 53.3% in IVA/PDT, and 52.0% in IVR/PDT. Significantly higher dry macula rate in Month 6 and 18 in the IVA/PDT group than in IVR/PDT group. Retreatment was performed in 26.7% patients in IVA/PDT, and in 60.0% patients in the IVR/PDT group. There were significantly lower retreatment rates in the IVA/PDT group than those in the IVR/PDT group. Better final BCVA was associated with better baseline BCVA and a younger age. Retreatment was associated with complete polyp regression at 3-months. Conclusions: Significant visual improvement was demonstrated in the IVA/PDT group at every 6-month visit, but only at a 6-month and a 12-month follow-up in the IVR/PDT group. Although changes of the BCVA/CRT and complete polyp regression rate were comparable between two groups, the IVA/PDT group required less retreatment and attained more dry macula results. Better baseline BCVA and younger age were associated with a better visual outcome.
C1 [Weng, Hsin-Yu; Huang, Tzu-Lun; Chang, Pei-Yao; Ho, Wei-Ting; Hsu, Yung-Ray; Chen, Fang-Ting; Chen, Yun-Ju; Wang, Jia-Kang] Far Eastern Mem Hosp, Dept Ophthalmol, New Taipei 220, Taiwan.
   [Huang, Tzu-Lun; Wang, Jia-Kang] Yuan Ze Univ, Dept Elect Engn, Taoyuan 320, Taiwan.
   [Chang, Pei-Yao; Ho, Wei-Ting; Wang, Jia-Kang] Natl Taiwan Univ, Dept Med, Taipei 10617, Taiwan.
   [Ho, Wei-Ting; Wang, Jia-Kang] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan.
   [Wang, Jia-Kang] Oriental Inst Technol, Dept Healthcare Adm, New Taipei 22061, Taiwan.
   [Wang, Jia-Kang] Oriental Inst Technol, Dept Nursing, New Taipei 22061, Taiwan.
C3 Far Eastern Memorial Hospital; Yuan Ze University; National Taiwan
   University; National Yang Ming Chiao Tung University; Asia Eastern
   University of Science & Technology; Asia Eastern University of Science &
   Technology
RP Wang, JK (通讯作者)，Far Eastern Mem Hosp, Dept Ophthalmol, New Taipei 220, Taiwan.; Wang, JK (通讯作者)，Yuan Ze Univ, Dept Elect Engn, Taoyuan 320, Taiwan.; Wang, JK (通讯作者)，Natl Taiwan Univ, Dept Med, Taipei 10617, Taiwan.; Wang, JK (通讯作者)，Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan.; Wang, JK (通讯作者)，Oriental Inst Technol, Dept Healthcare Adm, New Taipei 22061, Taiwan.; Wang, JK (通讯作者)，Oriental Inst Technol, Dept Nursing, New Taipei 22061, Taiwan.
EM shinyuweng@hotmail.com; huang.tzulum@gmail.com; peiyao@seed.net.tw;
   rbaggioh@gmail.com; scherzoray@gmail.com; fiona700816@gmail.com;
   yjchen2006@ntu.edu.tw; jiakangw2158@gmail.com
OI Wang, Jia-Kang/0000-0003-3157-3613
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Ito A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235213
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Saito M, 2013, GRAEF ARCH CLIN EXP, V251, P2099, DOI 10.1007/s00417-013-2323-6
   Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427
   Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 22
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD FEB
PY 2021
VL 11
IS 3
AR 1194
DI 10.3390/app11031194
PG 9
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA QD1BB
UT WOS:000615261900001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nassisi, M
   Fan, WY
   Shi, Y
   Lei, JQ
   Borrelli, E
   Ip, M
   Sadda, SR
AF Nassisi, Marco
   Fan, Wenying
   Shi, Yue
   Lei, Jianqin
   Borrelli, Enrico
   Ip, Michael
   Sadda, Srinivas R.
TI Quantity of Intraretinal Hyperreflective Foci in Patients With
   Intermediate Age-Related Macular Degeneration Correlates With 1-Year
   Progression
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   intraretinal hyperreflective foci; age-related macular degeneration
   progression
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT
   EPITHELIAL DETACHMENT; GEOGRAPHIC ATROPHY; NATURAL-HISTORY; EYES;
   MIGRATION; PREDICTOR; DISEASE
AB PURPOSE. The purpose of this study was to evaluate the correlation between quantity of intraretinal hyperreflective foci (HRF) in the eye with intermediate AMD and progression to late AMD.
   METHODS. Volume optical coherence tomography (OCT) scans from 114 eyes of 114 patients were retrospectively reviewed. HRF were assessed both qualitatively and quantitatively. Five sequential en face slabs from midretina were thresholded to isolate the HRF. These five slabs were recombined, and HRF area was measured in the whole 6 x 6-mm image (HRFTOT) and within the central 3-mm (HRF3mm) and 5-mm (HRF5mm) regions. These measurements were correlated with the development of late AMD (defined as choroidal neovascularization [CNV] and/or complete RPE and photoreceptor atrophy [cRORA]) after 1 year of follow-up.
   RESULTS. HRF area in all three regions showed significant correlations with progression to late AMD: R = 0.610 for HRF3mm, R = 0.622 for HRF5mm, and R = 0.614 for HRFTOT (all P < 0.001). Correlations remained significant with progression to cRORA alone, though not for progression to CNV alone. While qualitative assessment of HRF (i.e., presence of HRF: yes or no) also showed a significant correlation with progression to late AMD (R = 0.454, P < 0.001) and atrophy alone (R = 0.445, P < 0.001), they were weaker than by HRF quantification.
   CONCLUSIONS. The area of HRF from en face OCT in eyes with intermediate AMD correlates with the 1-year risk of progression to late AMD, and in particular with the development of atrophy.
C1 [Nassisi, Marco; Fan, Wenying; Shi, Yue; Lei, Jianqin; Borrelli, Enrico; Ip, Michael; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
   [Nassisi, Marco; Fan, Wenying; Shi, Yue; Lei, Jianqin; Borrelli, Enrico; Ip, Michael; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Fan, Wenying] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian, Shaanxi, Peoples R China.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Capital Medical
   University; Xi'an Jiaotong University; G d'Annunzio University of
   Chieti-Pescara
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Nassisi, Marco/P-9939-2019; Borrelli, Enrico/AAR-3693-2020; fan,
   wenying/GSI-5125-2022
OI Nassisi, Marco/0000-0002-9354-9005; Borrelli,
   Enrico/0000-0003-2815-5031; 
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kon Y, 2008, RETINA-J RET VIT DIS, V28, P864, DOI 10.1097/IAE.0b013e3181669795
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P1372, DOI 10.1097/IAE.0000000000000929
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Matet A, 2018, RETINA-J RET VIT DIS, V38, P1403, DOI 10.1097/IAE.0000000000001729
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Srinivas S, 2018, RETINA-J RET VIT DIS, V38, P231, DOI 10.1097/IAE.0000000000001545
   Vujosevic S., 2013, J DIABETES RES, V2013, DOI DOI 10.1155/2013/491835
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 32
TC 49
Z9 50
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2018
VL 59
IS 8
BP 3431
EP 3439
DI 10.1167/iovs.18-24143
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM7KT
UT WOS:000438365900011
PM 30025092
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Reiter, GS
   Told, R
   Baumann, L
   Sacu, S
   Schmidt-Erfurth, U
   Pollreisz, A
AF Reiter, Gregor S.
   Told, Reinhard
   Baumann, Lukas
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
   Pollreisz, Andreas
TI INVESTIGATING A GROWTH PREDICTION MODEL IN ADVANCED AGE-RELATED MACULAR
   DEGENERATION WITH SOLITARY GEOGRAPHIC ATROPHY USING QUANTITATIVE
   AUTOFLUORESCENCE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; geographic atrophy; junctional zone; lipofuscin; OCT; qAF; retinal
   pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; FUNDUS
   AUTOFLUORESCENCE; END-POINTS; PROGRESSION; EYES; CLASSIFICATION;
   DENSITY; DRUSEN; IMPACT
AB Purpose: To investigate geographic atrophy (GA) progression using quantitative autofluorescence (qAF) in eyes with solitary GA. Methods: Forty-three eyes of 26 patients (age 79.7 +/- 7.2 years; 28 women; 16 pseudophakic) underwent spectral-domain optical coherence tomography and qAF imaging at baseline and after 12 months. The junctional zone (A(JZ)) and a nonaffected 300-mu m-wide control area (A(C)) were delineated on spectral-domain optical coherence tomography scans and transferred to the qAF image. Linear mixed models were calculated to investigate the association between GA progression and qAF, age, and baseline GA area. Mixed model analyses of variance were used to investigate differences in qAF between areas. Results: Quantitative autofluorescence of the three inferior sections of both the A(JZ)(P= 0.028;P= 0.014 andP= 0.032) and the A(C)(P= 0.043;P= 0.02 andP= 0.028) were significantly associated with GA progression after 12 months. However, qAF measurements were not associated with GA progression in the overall model (P> 0.05). Mean qAF was significantly lower in the A(JZ)and growth area (A(G12)) than in the A(C)(bothP <= 0.001). Conclusion: The authors report a statistically significant association between GA growth area and qAF measurements at specific retinal locations and a significant difference in qAF between the GA border and unaffected areas outside the lesion. Quantitative autofluorescence measurements may be limitedly useful for predicting GA progression.
C1 [Reiter, Gregor S.; Told, Reinhard; Sacu, Stefan; Schmidt-Erfurth, Ursula; Pollreisz, Andreas] Med Univ Vienna, Vienna Clin Trial Ctr VTC, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Baumann, Lukas] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM schmidt-erfurth@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Baumann, Lukas/0000-0001-7931-7470; Reiter, Gregor/0000-0001-7661-4015;
   Told, Reinhard/0000-0003-2046-7081
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   Armenti ST, 2016, JOVE-J VIS EXP, DOI 10.3791/53577
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P1471, DOI 10.1167/iovs.13-13834
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gliem M, 2017, INVEST OPHTH VIS SCI, V58, P6159, DOI 10.1167/iovs.17-22007
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Orellana-Rios J, 2018, OSLI RETINA, V49, pS34, DOI 10.3928/23258160-20180814-06
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Qu J, 2017, RETINA, V0, P1
   Qu JF, 2018, RETINA-J RET VIT DIS, V38, P1456, DOI 10.1097/IAE.0000000000001824
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P1937, DOI 10.1167/iovs.19-26566
   Reiter GS, 2019, ACTA OPHTHALMOL, V97, pE526, DOI 10.1111/aos.13987
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2017, AM J OPHTHALMOL, V54, P739
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
NR 43
TC 6
Z9 6
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1657
EP 1664
DI 10.1097/IAE.0000000000002653
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800004
PM 31584560
DA 2022-11-30
ER

PT J
AU Vu, HTV
   Robman, L
   McCarty, CA
   Taylor, HR
   Hodge, A
   McCarty, CA
   Taylor, H
AF Vu, HTV
   Robman, L
   McCarty, CA
   Taylor, HR
   Hodge, A
   McCarty, CA
   Taylor, H
TI Does dietary lutein and zeaxanthin increase the risk of age related
   macular degeneration? The Melbourne Visual Impairment Project
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CAROTENOIDS; MACULOPATHY; EYE
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Canc Council Victoria, Carlton, Vic, Australia.
   Marshfield Clin Res Fdn, Marshfield, WI USA.
C3 Centre for Eye Research Australia; University of Melbourne; Cancer
   Council Victoria
RP Taylor, HR (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM h.taylor@unimelb.edu.au
OI Hodge, Allison/0000-0001-5464-2197; McCarty,
   Catherine/0000-0003-1089-0142; Taylor, Hugh/0000-0002-9437-784X
CR Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Hodge A, 2000, AUST NZ J PUBL HEAL, V24, P576, DOI 10.1111/j.1467-842X.2000.tb00520.x
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Manzi F, 2002, PUBLIC HEALTH NUTR, V5, P347, DOI 10.1079/PHN2002258
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   WILLETT W, 1990, MONOGRAPHS EPIDEMIOL
NR 10
TC 16
Z9 19
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2006
VL 90
IS 3
BP 389
EP 390
DI 10.1136/bjo.2005.078055
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013QS
UT WOS:000235424800036
PM 16488968
OA Green Published
DA 2022-11-30
ER

PT J
AU Madeira, MH
   Boia, R
   Santos, PF
   Ambrosio, AF
   Santiago, AR
AF Madeira, Maria H.
   Boia, Raquel
   Santos, Paulo F.
   Ambrosio, Antonio F.
   Santiago, Ana R.
TI Contribution of Microglia-Mediated Neuroinflammation to Retinal
   Degenerative Diseases
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; OPTIC-NERVE HEAD;
   ENDOTHELIAL GROWTH-FACTOR; LATERAL GENICULATE-NUCLEUS; NEURAL
   CELL-DEATH; GANGLION-CELLS; EXPERIMENTAL GLAUCOMA; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY
AB Retinal degenerative diseases are major causes of vision loss and blindness worldwide and are characterized by chronic and progressive neuronal loss. One common feature of retinal degenerative diseases and brain neurodegenerative diseases is chronic neuroinflammation. There is growing evidence that retinal microglia, as in the brain, become activated in the course of retinal degenerative diseases, having a pivotal role in the initiation and propagation of the neurodegenerative process. A better understanding of the events elicited and mediated by retinal microglia will contribute to the clarification of disease etiology and might open new avenues for potential therapeutic interventions. This review aims at giving an overview of the roles of microglia-mediated neuroinflammation in major retinal degenerative diseases like glaucoma, age-related macular degeneration, and diabetic retinopathy.
C1 [Madeira, Maria H.; Boia, Raquel; Santos, Paulo F.; Ambrosio, Antonio F.; Santiago, Ana R.] Univ Coimbra, Fac Med, Ctr Ophthalmol & Vis Sci, IBILI, P-3004548 Coimbra, Portugal.
   [Santos, Paulo F.; Ambrosio, Antonio F.; Santiago, Ana R.] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal.
   [Santos, Paulo F.] Univ Coimbra, Dept Life Sci, Coimbra, Portugal.
   [Ambrosio, Antonio F.; Santiago, Ana R.] AIBILI, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Universidade de Coimbra
RP Santiago, AR (通讯作者)，Univ Coimbra, Fac Med, Ctr Ophthalmol & Vis Sci, IBILI, P-3004548 Coimbra, Portugal.
EM asantiago@fmed.uc.pt
RI Madeira, Maria H./AAD-4755-2019; dos Santos, Paulo Fernando
   Martins/AAC-6818-2020; Boia, Raquel/AFQ-4282-2022; Ambrósio, António
   F/I-3722-2012; Santiago, Ana Raquel/I-6566-2013; Boia,
   Raquel/GWB-9999-2022
OI Madeira, Maria H./0000-0001-6282-3553; dos Santos, Paulo Fernando
   Martins/0000-0002-2225-455X; Boia, Raquel/0000-0002-0479-3066; Ambrósio,
   António F/0000-0002-0477-1641; Santiago, Ana Raquel/0000-0002-7541-7041;
   
FU Foundation for Science and Technology and COMPETE-FEDER
   [SFRH/BD/75839/2011, PTDC/BIM-MEC/0913/2012, PTDC/NEU-OSD/1113/2012,
   PEst-C/SAU/UI3282/2011-2013, PEst-C/SAU/LA0001/2013-2014]; AIBILI,
   Portugal
FX This work was supported by Foundation for Science and Technology and
   COMPETE-FEDER (SFRH/BD/75839/2011, PTDC/BIM-MEC/0913/2012,
   PTDC/NEU-OSD/1113/2012, PEst-C/SAU/UI3282/2011-2013, and
   PEst-C/SAU/LA0001/2013-2014) and AIBILI, Portugal.
CR Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Al-Gayyar MM, 2013, EUR CYTOKINE NETW, V24, P27, DOI 10.1684/ecn.2013.0334
   Albini TA, 2005, BRIT J OPHTHALMOL, V89, P901, DOI 10.1136/bjo.2004.060293
   Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   ASHWELL KWS, 1989, VISUAL NEUROSCI, V2, P437, DOI 10.1017/S0952523800012335
   Aveleira C, 2010, CYTOKINE, V49, P279, DOI 10.1016/j.cyto.2009.11.014
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Bailey JNC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017186
   Balaiya S, 2011, CLIN OPHTHALMOL, V5, P553, DOI 10.2147/OPTH.S19453
   Baltmr A, 2010, EXP EYE RES, V91, P554, DOI 10.1016/j.exer.2010.08.009
   Bamforth SD, 1997, AM J PATHOL, V150, P329
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   Barthelmes D., 2014, BRIT J OPHTHALMOLOGY
   Behl Y, 2008, AM J PATHOL, V172, P1411, DOI 10.2353/ajpath.2008.071070
   Behl Y, 2009, DIABETES, V58, P917, DOI 10.2337/db08-0537
   Bessero AC, 2010, CURR OPIN NEUROL, V23, P10, DOI 10.1097/WCO.0b013e3283344461
   Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029
   Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560
   Bilimoria P. M., 2014, BRAIN RES
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Brubaker RF, 1996, AM J OPHTHALMOL, V121, P473, DOI 10.1016/S0002-9394(14)75421-2
   Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carmo A, 2000, MEDIAT INFLAMM, V9, P243, DOI 10.1080/09629350020025764
   Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan WY, 2007, BRAIN RES REV, V53, P344, DOI 10.1016/j.brainresrev.2006.11.002
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen KH, 1999, INVEST OPHTH VIS SCI, V40, P2627
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cheung W, 2008, OPTOMETRY VISION SCI, V85, P406, DOI 10.1097/OPX.0b013e31817841e5
   Chidlow G, 2012, NEUROBIOL DIS, V48, P568, DOI 10.1016/j.nbd.2012.07.026
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Cho KJ, 2011, BRAIN RES, V1403, P67, DOI 10.1016/j.brainres.2011.06.005
   Chua J, 2012, MOL VIS, V18, P431
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cordeiro MF, 2011, AM J OPHTHALMOL, V152, P715, DOI 10.1016/j.ajo.2011.06.015
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Costa GN, 2012, MOL CELL NEUROSCI, V50, P113, DOI 10.1016/j.mcn.2012.04.003
   Crehan H, 2012, INT J ALZHEIMERS DIS, V2012, DOI DOI 10.1155/2012/983640
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cukras CA, 2012, INVEST OPHTH VIS SCI, V53, P3865, DOI 10.1167/iovs.11-9413
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   Cvenkel B, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/939602
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053
   de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   ELASRAR AM, 1992, AM J OPHTHALMOL, V114, P731, DOI 10.1016/S0002-9394(14)74052-8
   Ellis-Behnke Rutledge G, 2013, J Glaucoma, V22 Suppl 5, pS32, DOI 10.1097/IJG.0b013e3182934aca
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Eyo UB, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/456857
   Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007
   Ferrer-Martin RM, 2014, EXP EYE RES, V121, P42, DOI 10.1016/j.exer.2014.02.015
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47
   FRANKEL DH, 1992, J AM ACAD DERMATOL, V26, P720, DOI 10.1016/0190-9622(92)70100-T
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu WX, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032127, 10.1371/journal.pone.0040003, 10.1371/journal.pone.0036949, 10.1186/1746-1596-7-49]
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Fuse N, 2010, TOHOKU J EXP MED, V221, P1, DOI 10.1620/tjem.221.1
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Gaucher D, 2007, VISION RES, V47, P612, DOI 10.1016/j.visres.2006.11.017
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Grus FH, 2008, J GLAUCOMA, V17, P79, DOI 10.1097/IJG.0b013e318156a592
   Gupta N, 2006, BRIT J OPHTHALMOL, V90, P674, DOI 10.1136/bjo.2005.086769
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172
   HAMMES HP, 1995, MOL MED, V1, P527, DOI 10.1007/BF03401589
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang T, 2012, BIOCHEM BIOPH RES CO, V421, P214, DOI 10.1016/j.bbrc.2012.03.139
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   Ibrahim AS, 2010, MOL VIS, V16, P2033
   Imamura K, 2009, NEUROREPORT, V20, P139, DOI 10.1097/WNR.0b013e32831d7f82
   Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516
   Ito Y, 2009, EXP EYE RES, V89, P246, DOI 10.1016/j.exer.2009.03.013
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Joachim SC, 2005, GRAEF ARCH CLIN EXP, V243, P817, DOI 10.1007/s00417-004-1094-5
   Joachim SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040616
   Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317
   Johnson EC, 2009, EXP EYE RES, V88, P808, DOI 10.1016/j.exer.2009.02.004
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7
   Joussen AM, 2009, MOL VIS, V15, P1418
   Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kizawa J, 2006, JPN J OPHTHALMOL, V50, P367, DOI 10.1007/s10384-006-0326-0
   Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589
   Kolb H., 1995, WEBVISION ORG RETINA
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Labin AM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5319
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Laspas P, 2011, INVEST OPHTH VIS SCI, V52, P8835, DOI 10.1167/iovs.10-6889
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Levkovitch-Verbin H, 2014, GRAEF ARCH CLIN EXP, V252, P761, DOI 10.1007/s00417-014-2588-4
   Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014
   Luna JD, 1997, J NEUROSCI RES, V49, P268, DOI 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Markiewicz L, 2013, ACTA OPHTHALMOL, V91, pE516, DOI 10.1111/aos.12149
   Matsubara H, 2006, JPN J OPHTHALMOL, V50, P211, DOI 10.1007/s10384-005-0315-8
   Mihaly K, 1998, CELL MOL LIFE SCI, V54, P1154, DOI 10.1007/s000180050243
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006
   Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962
   NATHAN C, 1994, J BIOL CHEM, V269, P13725
   Nelson R., 1995, WEBVISION ORG RETINA
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Neufeld AH, 2002, EXP EYE RES, V75, P521, DOI 10.1006/exer.2002.2042
   Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944
   Neufeld AH, 1997, ARCH OPHTHALMOL-CHIC, V115, P497, DOI 10.1001/archopht.1997.01100150499009
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Pascale A, 2012, PHARMACOL RES, V66, P19, DOI 10.1016/j.phrs.2012.03.002
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Polazzi E, 2010, PROG NEUROBIOL, V92, P293, DOI 10.1016/j.pneurobio.2010.06.009
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   Qu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067094
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   QUIGLEY HA, 1983, ARCH OPHTHALMOL-CHIC, V101, P1301
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Reichelt J, 2008, CURR EYE RES, V33, P253, DOI 10.1080/02713680701871157
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Reis A, 2014, DIABETES, V63, P3926, DOI 10.2337/db13-1673
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5
   Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Santiago AR, 2007, NEUROBIOL DIS, V25, P464, DOI 10.1016/j.nbd.2006.10.023
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Sappington R. M., 2008, INVEST OPHTHALMOL, V49, P3005
   Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P3860, DOI 10.1167/iovs.05-1408
   Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407
   Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schuetz E, 2004, BRAIN RES BULL, V62, P391, DOI 10.1016/j.brainresbull.2003.10.008
   Scott IU, 2014, JAMA OPHTHALMOL, V132, P535, DOI 10.1001/jamaophthalmol.2014.93
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shareef S, 1999, INVEST OPHTH VIS SCI, V40, P2884
   Shimazawa M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030526
   Sierra A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106048
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   SIMONSEN SE, 1980, ACTA OPHTHALMOL, V58, P865
   Sims Stephanie M, 2012, Am J Neurodegener Dis, V1, P168
   Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279
   Sugama Shuei, 2009, Inflammation & Allergy Drug Targets, V8, P277
   Takeda N, 2001, DIABETOLOGIA, V44, P1043, DOI 10.1007/s001250100588
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Taylor S, 2011, EXP EYE RES, V92, P338, DOI 10.1016/j.exer.2011.01.012
   Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Tezel G., 2008, INVEST OPHTHALMOL, V50, P1001
   THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   van Dijk HW, 2012, INVEST OPHTH VIS SCI, V53, P2715, DOI 10.1167/iovs.11-8997
   Vidal L, 2006, BRAIN RES BULL, V70, P406, DOI 10.1016/j.brainresbull.2006.07.009
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/491835
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Weber AJ, 2000, INVEST OPHTH VIS SCI, V41, P1370
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Yao HL, 2014, NEURAL REGEN RES, V9, P1047, DOI 10.4103/1673-5374.133169
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang C, 2005, EXP EYE RES, V81, P700, DOI 10.1016/j.exer.2005.04.008
   Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9
NR 224
TC 138
Z9 142
U1 0
U2 25
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
VL 2015
AR 673090
DI 10.1155/2015/673090
PG 15
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA CF3KB
UT WOS:000352446300001
PM 25873768
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Dong, ZY
   Santeford, A
   Ban, N
   Lee, TJ
   Smith, C
   Ornitz, DM
   Apte, RS
AF Dong, Zhenyu
   Santeford, Andrea
   Ban, Norimitsu
   Lee, Tae Jun
   Smith, Craig
   Ornitz, David M.
   Apte, Rajendra S.
TI FGF2-induced STAT3 activation regulates pathologic neovascularization
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Choroidal neovascularization; Endothelial cell; Fibroblast growth
   factor; STAT3; Choroid sprouting; Macular degeneration; Retina
ID FIBROBLAST-GROWTH-FACTOR; CHOLESTEROL EFFLUX; VEGF; BEVACIZUMAB;
   AFLIBERCEPT; INJURY; MICE; THERAPY; DISEASE; FGF2
AB Cell-autonomous endothelial cell (EC) fibroblast growth factor receptor (FGFR) signaling through FGFR1/2 is essential for injury-induced wound vascularization and pathologic neovascularization as in blinding eye diseases such as age-related macular degeneration. Which FGF ligand(s) is critical in regulating angiogenesis is unknown. Utilizing ex vivo models of choroidal endothelial sprouting and in vivo models of choroidal neovascularization (CNV), we demonstrate here that only FGF2 is the essential ligand. Though FGF-FGFR signaling can activate multiple intracellular signaling pathways, we show that FGF2 regulates pathogenic angiogenesis via STAT3 activation. The identification of FGF2 as a critical mediator in aberrant neovascularization provides a new opportunity for developing multi-target therapies in blinding eye diseases especially given the limitations of anti-VEGF monotherapy.
C1 [Dong, Zhenyu; Santeford, Andrea; Ban, Norimitsu; Lee, Tae Jun; Apte, Rajendra S.] Dept Ophthalmol & Visual Sci, 660 S Euclid Ave, St Louis, MO 63110 USA.
   [Smith, Craig; Ornitz, David M.; Apte, Rajendra S.] Dept Dev Biol, 660 S Euclid Ave, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.
   [Ban, Norimitsu] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Washington University (WUSTL); Columbia University
RP Apte, RS (通讯作者)，660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.; Ornitz, DM (通讯作者)，660 S Euclid Ave,Box 8103, St Louis, MO 63110 USA.
EM dornitz@wustl.edu; apte@wustl.edu
OI Lee, Tae Jun/0000-0003-2699-2573
FU NIH [R21 EY026707-01, R01 EY019287-06, P30 EY02687]; Starr Foundation;
   Carl Marshall Reeves and Mildred Almen Reeves Foundation; Bill and Emily
   Kuzma Family Gift for Retinal Research; Physician Scientist Award from
   Research to Prevent Blindness; Jeffrey Fort Innovation Fund; Glenn
   Foundation for Medical Research; Thome Foundation; VitreoRetinal Surgery
   Foundation; Research to Prevent Blindness; Nelson Trust Award from
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY002687,
   R21EY026707, R01EY019287] Funding Source: NIH RePORTER
FX This work was supported by NIH Grants R21 EY026707-01 (R.S.A. and
   D.M.O.), R01 EY019287-06 (R.S.A.), P30 EY02687 (Vision Core Grant); the
   Starr Foundation (R.S.A.); the Carl Marshall Reeves and Mildred Almen
   Reeves Foundation (R.S.A.); the Bill and Emily Kuzma Family Gift for
   Retinal Research (R.S.A.); a Physician Scientist Award and a Nelson
   Trust Award from Research to Prevent Blindness (R.S.A.); the Jeffrey
   Fort Innovation Fund (R.S.A.); the Glenn Foundation for Medical Research
   and the Thome Foundation (R.S.A.). Additional funding comes from an
   unrestricted grant to the Department of Ophthalmology and Visual
   Sciences of Washington University School of Medicine from Research to
   Prevent Blindness. Z.D. was supported by the VitreoRetinal Surgery
   Foundation.
CR Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Apte RS, 2016, JAMA OPHTHALMOL, V134, P285, DOI 10.1001/jamaophthalmol.2015.5469
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Ban N, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91455
   Chen PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep33407
   Colvin JS, 2001, DEVELOPMENT, V128, P2095
   Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gerber HP, 2005, CANCER RES, V65, P671
   GOSPODAROWICZ D, 1978, J CELL BIOL, V77, P774, DOI 10.1083/jcb.77.3.774
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   House SL, 2016, AM J PHYSIOL-HEART C, V310, pH559, DOI 10.1152/ajpheart.00758.2015
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Spooner K, 2019, ACTA OPHTHALMOL, V97, P15, DOI 10.1111/aos.13802
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Trokovic R, 2003, EMBO J, V22, P1811, DOI 10.1093/emboj/cdg169
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Xu XL, 1998, DEVELOPMENT, V125, P753
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201
NR 35
TC 14
Z9 14
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2019
VL 187
AR 107775
DI 10.1016/j.exer.2019.107775
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB9FO
UT WOS:000488887100013
PM 31449793
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cruess, A
   Maberley, D
   Wong, D
   Chen, J
AF Cruess, Alan
   Maberley, David
   Wong, David
   Chen, John
TI The treatment of wet AMD in Canada: access to therapy (policy review)
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE macular degeneration; blindness; health care economics; health care
   quality; access; evaluation
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; RESOURCE UTILIZATION; RANIBIZUMAB; BURDEN; VERTEPORFIN;
   PROGRESSION; ILLNESS; UTILITY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in North America, affecting 2 million Canadians older than age 50 years. AMD is subdivided into 2 types: an atrophic form, so-called "dry" AMD, and an exudative or "wet" form, characterized by the presence of choroidal neovascularization (CNV). Since 2000, after decades with no effective therapy aside from thermal obliterative laser treatment of CNV, 3 new treatments have been approved, each offering significant therapeutic advances at increasingly higher prices, and in an increasingly cost-containment-oriented payer environment. Many of Canada's public drug plans have been relatively slow to fund evidence-based, approved treatments. This paper reviews the disease, as well as the current private and public coverage for wet AMD treatments.
C1 [Cruess, Alan] Dalhousie Univ, Dept Ophthalmol, Halifax, NS, Canada.
   [Maberley, David] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   [Wong, David] St Michaels Hosp Ctr, Toronto, ON, Canada.
   [Chen, John] Montreal Retinal & Laser Inst, Montreal, PQ, Canada.
C3 Dalhousie University; University of British Columbia; University of
   Toronto; Saint Michaels Hospital Toronto
RP Cruess, A (通讯作者)，Dalhousie Univ Capitol Hlth, Dept Ophthalmol, Halifax, NS B3H 2Y9, Canada.
EM alan.cruess@dal.ca
OI Wong, David/0000-0003-1376-845X
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   *AMD ALL INT, AMD INF TREATM RES
   *AMD CAN, WET AMD OV
   Anis AH, 2004, CAN MED ASSOC J, V171, P565, DOI 10.1503/cmaj.1020352
   *BORG INC, 2008, IMAM DAT
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   *CAN AG DRUGS TECH, 2008, TECHN REP MAN NEOV A
   *CAN AG DRUGS TECH, 2008, CEDAC FIN REC REC RE
   *CAN AG DRUGS TECH, 2007, CDR DRUG PLANS RESP
   *CAN AG DRUGS TECH, 2008, CDR PROC PROC COMM D
   *CAN AG DRUGS TECH, 2006, CEDAC FIN REC REAS R
   *CANT COMM, CLEAR VIS SOL CAN VI
   Collier R, 2009, CAN MED ASSOC J, V180, P279, DOI 10.1503/cmaj.082040
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   *HLTH CAN, ACC THER PROD REG PR
   KESEN MR, 2008, AMD RES CURRENT NEED
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   *NAT EYE I, NAT I HLTH 2009
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   *ONT MIN HLTH LONG, DRUGS AR APPR REV PR
   *PAT MED PRIC REV, REP NEW PAT DRUGS
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   *SASK HLTH, 2008, FORM COMM B
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tierney M, 2008, CAN MED ASSOC J, V178, P432, DOI 10.1503/cmaj.070713
   *TUFTS CTR STUD DR, 2009, OUTL 2009, P2
   WYATT G, 2008, 2007 WYATT HLTH INT
   1999, ARCH OPTHALMOL, V117, P1329
   2008, IMS PROVINCIAL REIMB, V11, P67
   HLTH TECHNOLOGIES SE
NR 38
TC 5
Z9 5
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2009
VL 44
IS 5
BP 548
EP 556
DI 10.3129/i09-140
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 510JZ
UT WOS:000271085900012
PM 19789590
DA 2022-11-30
ER

PT J
AU Im, E
   Kazlauskas, A
AF Im, Eunok
   Kazlauskas, Andrius
TI PtdIns-4,5-P-2 as a potential therapeutic target for pathologic
   angiogenesis
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE angiogenesis; phosphatidylinositol 3-kinase; phospholipase C;
   PtdIns-4,5-P-2
ID MACULAR DEGENERATION; BIPOLAR-DISORDER; CANDIDATE GENE;
   PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOINOSITIDE BINDING;
   PSYCHIATRIC-DISORDERS; FERM DOMAIN; CELL-LINES; ACTIVATION; MEMBRANE
AB A variety of diseases arise, at least in part, when the events controlling the formation and stability of blood vessels are deregulated. For instance, the growth and survival of solid tumors are tightly linked to their ability to undergo vascularization. Similarly, pathologic angiogenesis of the retina or choroid underscores blinding diseases that afflict a substantial percentage of the world's population. Therefore, it is of great interest to develop antiangiogenic drugs that will relieve the burden of vascular diseases such as cancer, age-related macular degeneration and proliferative diabetic retinopathy. In this article, the authors highlight their recent discovery that PtdIns-4,5-P-2 can regulate vessel stability. This finding identifies PtdIns-4,5-P-2 as a novel target for angiogenesis therapies.
C1 Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute
RP Kazlauskas, A (通讯作者)，Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM andrius.kazlauskas@schepens.harvard.edu
FU NEI NIH HHS [EY016385, R01 EY018344] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY018344, R03EY016385] Funding Source: NIH RePORTER
CR Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140
   Albo D, 2004, CURR PHARM DESIGN, V10, P27, DOI 10.2174/1381612043453522
   Atack JR, 1997, MED RES REV, V17, P215, DOI 10.1002/(SICI)1098-1128(199703)17:2<215::AID-MED3>3.0.CO;2-2
   ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Balla T, 2005, J CELL SCI, V118, P2093, DOI 10.1242/jcs.02387
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bunce MW, 2006, BBA-MOL CELL BIOL L, V1761, P560, DOI 10.1016/j.bbalip.2006.03.002
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chaudhary A, 1998, CHEM BIOL, V5, P273, DOI 10.1016/S1074-5521(98)90620-2
   Chellaiah MA, 2006, EUR J CELL BIOL, V85, P311, DOI 10.1016/j.ejcb.2006.01.008
   Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200
   Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7
   Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49
   DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185
   Dings RPM, 2003, CANCER RES, V63, P382
   Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456
   Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h
   Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032
   Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Geddes JR, 2004, AM J PSYCHIAT, V161, P217, DOI 10.1176/appi.ajp.161.2.217
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Halstead JR, 2005, TRENDS PHARMACOL SCI, V26, P654, DOI 10.1016/j.tips.2005.10.004
   Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692
   Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4
   Hirata A, 2004, CANCER SCI, V95, P614, DOI 10.1111/j.1349-7006.2004.tb02496.x
   Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548
   Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   IRVINE R, 2000, SCI STKE, pRE1
   Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292
   Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Manetti F, 2000, CURR PHARM DESIGN, V6, P1897, DOI 10.2174/1381612003398528
   Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200
   Mellado Begona, 2006, Clin Transl Oncol, V8, P706, DOI 10.1007/s12094-006-0116-7
   Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799
   Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487
   Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415
   Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522
   Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2
   Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002
   Paulhe F, 2001, J BIOL CHEM, V276, P41832, DOI 10.1074/jbc.M105459200
   Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4
   Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281
   Roberts HF, 2005, FEBS LETT, V579, P2868, DOI 10.1016/j.febslet.2005.04.027
   Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584
   Saito T, 2003, AM J MED GENET B, V116B, P77, DOI 10.1002/ajmg.b.10042
   Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763
   Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200
   Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5
   Soares JC, 2001, NEUROSCI LETT, V299, P150, DOI 10.1016/S0304-3940(00)01775-4
   Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6
   Stopkova P, 2003, AM J MED GENET B, V123B, P50, DOI 10.1002/ajmg.b.20012
   Stopkova P, 2004, PSYCHIAT RES, V127, P157, DOI 10.1016/j.psychres.2004.03.003
   Stopkova P, 2004, BIOL PSYCHIAT, V55, P981, DOI 10.1016/j.biopsych.2004.01.014
   Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8
   Ungewickell A, 2005, P NATL ACAD SCI USA, V102, P18854, DOI 10.1073/pnas.0509740102
   Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535
   Webster KA, 2003, CIRCULATION, V108, P2954, DOI 10.1161/01.CIR.0000097188.26010.E8
   Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1
   Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574
NR 73
TC 4
Z9 4
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD APR
PY 2007
VL 11
IS 4
BP 443
EP 451
DI 10.1517/14728222.11.4.443
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 149EB
UT WOS:000245128700004
PM 17373875
DA 2022-11-30
ER

PT J
AU Masuda, T
   Shimazawa, M
   Hara, H
AF Masuda, Tomomi
   Shimazawa, Masamitsu
   Hara, Hideaki
TI Retinal Diseases Associated with Oxidative Stress and the Effects of a
   Free Radical Scavenger (Edaravone)
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID ENDOPLASMIC-RETICULUM STRESS; PROLIFERATIVE DIABETIC-RETINOPATHY;
   NITRIC-OXIDE; MACULAR DEGENERATION; CELL-DEATH; IN-VITRO; MITOCHONDRIAL
   DYSFUNCTION; PIGMENT-EPITHELIUM; DOWN-REGULATION; AQUEOUS-HUMOR
AB Oxidative stress plays a pivotal role in developing and accelerating retinal diseases including age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO). An excess amount of reactive oxygen species (ROS) can lead to functional and morphological impairments in retinal pigment epithelium (RPE), endothelial cells, and retinal ganglion cells (RGCs). Here we demonstrate that edaravone, a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogenesis through inhibiting JNK and p38 MAPK pathways in AMD, glaucoma, DR, and RVO animal models. These data suggest that the therapeutic strategy for targeting oxidative stress may be important for the treatment of these ocular diseases, and edaravone may be useful for treating retinal diseases associated with oxidative stress.
C1 [Masuda, Tomomi; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu, Japan.
C3 Gifu Pharmaceutical University
RP Shimazawa, M (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu, Japan.
EM shimazawa@gifu-pu.ac.jp
OI Hara, Hideaki/0000-0003-2046-9001
CR Adachi T, 2011, FREE RADICAL RES, V45, P1083, DOI 10.3109/10715762.2011.595408
   Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70
   Aksar AT, 2015, INT J OPHTHALMOL-CHI, V8, P239, DOI 10.3980/j.issn.2222-3959.2015.02.05
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Amemiya S, 2005, EUR J PHARMACOL, V516, P125, DOI 10.1016/j.ejphar.2005.04.036
   Angayarkanni N, 2008, EYE, V22, P969, DOI 10.1038/sj.eye.6703062
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 1976, AM J OPHTHALMOL, V81, P383
   Aung T, 2004, BRIT J OPHTHALMOL, V88, P88, DOI 10.1136/bjo.88.1.88
   Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Becatti M, 2016, J THROMB HAEMOST, V14, P2287, DOI 10.1111/jth.13482
   Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Brubaker RF, 1996, AM J OPHTHALMOL, V121, P473, DOI 10.1016/S0002-9394(14)75421-2
   Cash TP, 2007, FREE RADICAL BIO MED, V43, P1219, DOI 10.1016/j.freeradbiomed.2007.07.001
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Chaudhary P, 1998, BRAIN RES, V792, P154, DOI 10.1016/S0006-8993(98)00212-1
   Chen WG, 2010, BIOCHEMISTRY-US, V49, P3129, DOI 10.1021/bi9016632
   Cheng KC, 2009, EYE, V23, P2024, DOI 10.1038/eye.2009.230
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   Danesh-Meyer H. V., 2009, AM J OPHTHALMOL, V148
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c
   Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JCI200317863
   Fernandez-Durango R, 2008, INVEST OPHTH VIS SCI, V49, P2506, DOI 10.1167/iovs.07-1363
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Fridovich I, 1978, Ciba Found Symp, P77
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Fuma S, 2015, MOL VIS, V21, P883
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   GEORGE P, 1947, NATURE, V160, P41, DOI 10.1038/160041a0
   Ghanem AA, 2010, CURR EYE RES, V35, P295, DOI 10.3109/02713680903548970
   Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980
   Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Golden TR, 2002, AGING CELL, V1, P117, DOI 10.1046/j.1474-9728.2002.00015.x
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Goyal A, 2014, CURR EYE RES, V39, P823, DOI 10.3109/02713683.2011.556299
   Granger DN, 2004, HYPERTENSION, V43, P924, DOI 10.1161/01.HYP.0000123070.31763.55
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guo L, 2006, INVEST OPHTH VIS SCI, V47, P626, DOI 10.1167/iovs.05-0754
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Higa A, 2012, CELL SIGNAL, V24, P1548, DOI 10.1016/j.cellsig.2012.03.011
   Hironaka K, 2011, EUR J PHARM BIOPHARM, V79, P119, DOI 10.1016/j.ejpb.2011.01.019
   Honkanen RA, 2003, ARCH OPHTHALMOL-CHIC, V121, P183
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Imamura T, 2014, EXP EYE RES, V129, P24, DOI 10.1016/j.exer.2014.10.019
   Inagaki T, 2016, FREE RADICAL RES, V50, P645, DOI 10.3109/10715762.2016.1162300
   Inokuchi Y, 2009, J PHARMACOL EXP THER, V329, P687, DOI 10.1124/jpet.108.148676
   Iso T, 2016, MOL CELL BIOL, V36, P3100, DOI 10.1128/MCB.00389-16
   Izuta H, 2010, MOL VIS, V16, P130
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kiang AS, 2014, ADV EXP MED BIOL, V801, P783, DOI 10.1007/978-1-4614-3209-8_98
   Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010
   Ko ML, 2001, NEUROSCI LETT, V305, P139, DOI 10.1016/S0304-3940(01)01830-4
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Koss MJ, 2012, ACTA OPHTHALMOL, V90, pe98, DOI 10.1111/j.1755-3768.2011.02292.x
   Kotwal R.S., 2009, J SPEC OPER MED, V9, P59
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028
   Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558
   Laursen JB, 2001, CIRCULATION, V103, P1282
   Levin LA, 1999, SURV OPHTHALMOL, V43, pS98, DOI 10.1016/S0039-6257(99)00027-2
   Li J, 2013, INT J MOL SCI, V14, P24438, DOI 10.3390/ijms141224438
   Liu R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/902842
   Lloyd RV, 1997, FREE RADICAL BIO MED, V22, P885, DOI 10.1016/S0891-5849(96)00432-7
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Maeno T, 2009, BRIT J OPHTHALMOL, V93, P1479, DOI 10.1136/bjo.2008.154930
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003
   Maraldi T, 2010, INT J ONCOL, V36, P1581, DOI 10.3892/ijo_00000645
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Masuda T, 2016, EXP EYE RES, V146, P196, DOI 10.1016/j.exer.2016.03.020
   McKibbin M, 1999, EYE, V13, P31, DOI 10.1038/eye.1999.6
   Meyer CH, 2007, OPHTHALMOLOGE, V104, P952, DOI 10.1007/s00347-007-1634-6
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P6015, DOI 10.1167/iovs.09-3643
   Mortuza R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054514
   Moserova I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032972
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   MUROTA SI, 1990, ANN NY ACAD SCI, V598, P182, DOI 10.1111/j.1749-6632.1990.tb42289.x
   Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097/IAE.0b013e31816576d5
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   Nakajima Y, 2008, BRAIN RES, V1226, P226, DOI 10.1016/j.brainres.2008.06.026
   Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408
   Nakazawa Toru, 2009, Nippon Ganka Gakkai Zasshi, V113, P1060
   Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944
   Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5
   Niwa M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010110
   Nonaka Y, 2008, NEUROSCI LETT, V441, P224, DOI 10.1016/j.neulet.2008.06.033
   Ogishima H, 2011, INVEST OPHTH VIS SCI, V52, P9710, DOI 10.1167/iovs.11-8160
   Ohira S, 2015, INVEST OPHTH VIS SCI, V56, P3541, DOI 10.1167/iovs.14-15918
   Ojino K, 2014, BIOL PHARM BULL, V37, P424, DOI 10.1248/bpb.b13-00778
   Ozawa Y, 2011, EXP DIABETES RES, DOI 10.1155/2011/108328
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Peters O, 1998, J CEREBR BLOOD F MET, V18, P196, DOI 10.1097/00004647-199802000-00011
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   PUTTING BJ, 1992, INVEST OPHTH VIS SCI, V33, P3385
   Qin T, 2016, AM J EMERG MED, V34, P1944, DOI 10.1016/j.ajem.2016.06.084
   QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Recchioni R, 2002, METABOLISM, V51, P1384, DOI 10.1053/meta.2002.35579
   Reeg S, 2015, ANTIOXID REDOX SIGN, V23, P239, DOI 10.1089/ars.2014.6062
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797
   Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Sarkar S, 2010, MOL BIOL CELL, V21, P2138, DOI 10.1091/mbc.E10-01-0062
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Shah R. S., 2015, JOVE-J VIS EXP, V2015
   Sharma R, 2004, ANTIOXID REDOX SIGN, V6, P289, DOI 10.1089/152308604322899350
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031
   Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238
   Simoncini S, 2005, INT IMMUNOL, V17, P489, DOI 10.1093/intimm/dxh229
   Song Y, 2008, ACTA PHARMACOL SIN, V29, P823, DOI 10.1111/j.1745-7254.2008.00822.x
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
   Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577
   Sun Z, 2007, MOL CELL BIOL, V27, P6334, DOI 10.1128/MCB.00630-07
   TENHUNEN R, 1969, J BIOL CHEM, V244, P6388
   Tsubota Kazuo, 2007, Nippon Ganka Gakkai Zasshi, V111, P193
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P6729, DOI 10.1167/iovs.11-9378
   Tsuruma K, 2012, J PHARMACOL SCI, V118, P351, DOI 10.1254/jphs.11110FP
   Tsuruma K, 2011, MOL VIS, V17, P3556
   Uchibayashi R, 2011, J NEUROSCI RES, V89, P1783, DOI 10.1002/jnr.22691
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Varma R, 2007, OPHTHALMOLOGY, V114, P1332, DOI 10.1016/j.ophtha.2006.10.023
   Wang AL, 2008, MOL VIS, V14, P644
   Wang HB, 2016, MOL VIS, V22, P116
   WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597
   Watanabe T, 2008, CARDIOVASC THER, V26, P101, DOI 10.1111/j.1527-3466.2008.00041.x
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Yamada H, 2006, BRAIN RES, V1071, P75, DOI 10.1016/j.brainres.2005.11.072
   Yamamoto T, 1997, BRAIN RES, V762, P240, DOI 10.1016/S0006-8993(97)00490-3
   Yamamoto Y, 1996, REDOX REP, V2, P333, DOI 10.1080/13510002.1996.11747069
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65
   Yoshida H, 2005, ATHEROSCLEROSIS, V179, P97, DOI 10.1016/j.atherosclerosis.2004.10.037
   Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x
   Yuan DQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099219
   Yuan Y, 2014, BMC NEUROSCI, V15, DOI 10.1186/s12868-014-0125-3
   Yucel YH, 2006, ARCH OPHTHALMOL-CHIC, V124, P217, DOI 10.1001/archopht.124.2.217
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zhang DX, 2007, AM J PHYSIOL-HEART C, V292, pH2023, DOI 10.1152/ajpheart.01283.2006
   Zhang X, 2014, NITRIC OXIDE-BIOL CH, V40, P10, DOI 10.1016/j.niox.2014.05.001
NR 180
TC 110
Z9 112
U1 2
U2 25
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 9208489
DI 10.1155/2017/9208489
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EK7SY
UT WOS:000394126700001
PM 28194256
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fort, PE
   Lampi, KJ
AF Fort, Patrice E.
   Lampi, Kirsten J.
TI New focus on alpha-crystallins in retinal neurodegenerative diseases
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE crystallins; retinal diseases; neurodegeneration; apoptosis
ID HEAT-SHOCK-PROTEIN; INDUCED CELL-DEATH; B-CRYSTALLIN; A-CRYSTALLIN; RAT
   RETINA; LENS CRYSTALLINS; INDUCED APOPTOSIS; GENE-EXPRESSION;
   2-DIMENSIONAL ELECTROPHORESIS; INTRAOCULAR-PRESSURE
AB The crystallin proteins were initially identified as structural proteins of the ocular lens and have been recently demonstrated to be expressed in normal retina. They are dramatically upregulated by a large range of retinal diseases including diabetic retinopathy, age-related macular degeneration, uveitis, trauma and ischemia. The crystallin family of proteins is composed of alpha-, beta- and gamma-crystallin. Alpha-crystallins, which are small heat shock proteins, have received substantial attention recently. This review summarizes the current knowledge of alpha-crystallins in retinal diseases, their roles in retinal neuron cell survival and retinal inflammation, and the regulation of their expression and activity. Their potential role in the development of new treatments for neurodegenerative diseases is also discussed. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Fort, Patrice E.] Penn State Univ, Dept Ophthalmol, Hershey, PA 17033 USA.
   [Lampi, Kirsten J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Oregon Health &
   Science University
RP Fort, PE (通讯作者)，Penn State Univ, Dept Ophthalmol, 500 Univ Dr,H166, Hershey, PA 17033 USA.
EM pef11@psu.edu
OI Fort, Patrice/0000-0003-3956-1908
FU NEI NIH HHS [R01 EY012239] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY012239] Funding Source: NIH RePORTER
CR Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200
   BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259
   Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884
   Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924
   Chen L, 2008, INVEST OPHTH VIS SCI, V49, P4476, DOI 10.1167/iovs.08-1971
   CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391
   Cvekl A, 2007, PROG RETIN EYE RES, V26, P555, DOI 10.1016/j.preteyeres.2007.07.002
   Fischer D, 2008, MOL CELL NEUROSCI, V37, P471, DOI 10.1016/j.mcn.2007.11.002
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Gehlbach P, 2006, NEUROSCIENCE, V137, P447, DOI 10.1016/j.neuroscience.2005.08.084
   GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x
   Holcakova J, 2008, INT J BIOL MARKER, V23, P48, DOI 10.1177/172460080802300108
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934
   Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200
   Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237
   JAKOB U, 1993, J BIOL CHEM, V268, P1517
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200
   Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kataoka K, 2007, J BIOCHEM, V141, P775, DOI 10.1093/jb/mvm105
   Kim YH, 2007, NEUROBIOL DIS, V28, P293, DOI 10.1016/j.nbd.2007.07.017
   Kumar PA, 2005, ARCH BIOCHEM BIOPHYS, V444, P77, DOI 10.1016/j.abb.2005.09.021
   Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481
   LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Liedtke T, 2007, MOL CELL PROTEOMICS, V6, P895, DOI 10.1074/mcp.M600245-MCP200
   Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015
   LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671
   Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510
   Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x
   Miyara N, 2008, JPN J OPHTHALMOL, V52, P84, DOI 10.1007/s10384-007-0507-5
   Munemasa Y, 2009, INVEST OPHTH VIS SCI, V50, P3869, DOI 10.1167/iovs.08-3138
   Nagaraj RH, 2005, ANN NY ACAD SCI, V1043, P158, DOI 10.1196/annals.1333.020
   Naskar R, 2006, MOL VIS, V12, P1199
   Organisciak D, 2006, PHOTOCHEM PHOTOBIOL, V82, P1088, DOI 10.1562/2005-06-30-RA-599
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   PERRY RE, 1987, EXP EYE RES, V44, P269, DOI 10.1016/S0014-4835(87)80011-8
   PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277
   Piri N, 2007, BRAIN RES, V1141, P1, DOI 10.1016/j.brainres.2006.11.095
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Santhoshkumar P, 2009, BIOCHEMISTRY-US, V48, P5066, DOI 10.1021/bi900085v
   Saraswathy S., 2009, INVEST OPHTHALMOL VI
   Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155
   Shih M, 1998, Mol Vis, V4, P4
   Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004
   Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865
   SWAMY MS, 1987, INVEST OPHTH VIS SCI, V28, P1693
   SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vanita, 2001, J MED GENET, V38, P392, DOI 10.1136/jmg.38.6.392
   Vazquez-Chona F, 2004, INVEST OPHTH VIS SCI, V45, P2737, DOI 10.1167/iovs.03-1047
   Wang YD, 2007, CURR EYE RES, V32, P891, DOI 10.1080/02713680701593702
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940
   WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403
   Wu N, 2009, OPHTHALMIC RES, V42, P21, DOI 10.1159/000219681
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Ying X, 2008, J MOL NEUROSCI, V35, P253, DOI 10.1007/s12031-007-9010-1
   Yu AL, 2007, EXP EYE RES, V84, P694, DOI 10.1016/j.exer.2006.12.008
   Zabel C, 2006, J PROTEOME RES, V5, P1948, DOI 10.1021/pr0601077
   Zhan XQ, 2008, MOL CELL PROTEOMICS, V7, P864, DOI 10.1074/mcp.M700417-MCP200
NR 73
TC 50
Z9 51
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2011
VL 92
IS 2
BP 98
EP 103
DI 10.1016/j.exer.2010.11.008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 720DT
UT WOS:000287261100002
PM 21115004
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Andriessen, EMMA
   Binet, F
   Fournier, F
   Hata, M
   Dejda, A
   Mawambo, G
   Crespo-Garcia, S
   Pilon, F
   Buscarlet, M
   Beauchemin, K
   Bougie, V
   Cumberlidge, G
   Wilson, AM
   Bourgault, S
   Rezende, FA
   Beaulieu, N
   Delisle, JS
   Sapieha, P
AF Andriessen, Elisabeth M. M. A.
   Binet, Francois
   Fournier, Frederik
   Hata, Masayuki
   Dejda, Agnieszka
   Mawambo, Gaelle
   Crespo-Garcia, Sergio
   Pilon, Frederique
   Buscarlet, Manuel
   Beauchemin, Karine
   Bougie, Veronique
   Cumberlidge, Garth
   Wilson, Ariel M.
   Bourgault, Steve
   Rezende, Flavio A.
   Beaulieu, Normand
   Delisle, Jean-Sebastien
   Sapieha, Przemyslaw
TI Myeloid-resident neuropilin-1 promotes choroidal neovascularization
   while mitigating inflammation
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; angiogenesis; inflammation;
   mononuclear phagocytes; neuropilin-1
AB Age-related macular degeneration (AMD) in its various forms is a leading cause of blindness in industrialized countries. Here, we provide evidence that ligands for neuropilin-1 (NRP1), such as Semaphorin 3A and VEGF-A, are elevated in the vitreous of patients with AMD at times of active choroidal neovascularization (CNV). We further demonstrate that NRP1-expressing myeloid cells promote and maintain CNV. Expression of NRP1 on cells of myeloid lineage is critical for mitigating production of inflammatory factors such as IL6 and IL1 beta. Therapeutically trapping ligands of NRP1 with an NRP1-derived trap reduces CNV. Collectively, our findings identify a role for NRP1-expressing myeloid cells in promoting pathological angiogenesis during CNV and introduce a therapeutic approach to counter neovascular AMD.
C1 [Andriessen, Elisabeth M. M. A.; Sapieha, Przemyslaw] Univ Montreal, Dept Biomed Sci, Montreal, PQ, Canada.
   [Binet, Francois; Beauchemin, Karine; Bougie, Veronique; Cumberlidge, Garth; Beaulieu, Normand; Sapieha, Przemyslaw] SemaThera Inc, Montreal, PQ, Canada.
   [Binet, Francois; Dejda, Agnieszka; Crespo-Garcia, Sergio; Pilon, Frederique; Wilson, Ariel M.; Rezende, Flavio A.; Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Fournier, Frederik; Hata, Masayuki; Mawambo, Gaelle; Crespo-Garcia, Sergio; Buscarlet, Manuel; Sapieha, Przemyslaw] Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ, Canada.
   [Delisle, Jean-Sebastien] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Dept Med, Montreal, PQ, Canada.
   [Bourgault, Steve] Univ Quebec Montreal, Dept Chem, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Universite de Montreal; University of Quebec; University of Quebec
   Montreal
RP Sapieha, P (通讯作者)，Univ Montreal, Dept Biomed Sci, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，SemaThera Inc, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.; Sapieha, P (通讯作者)，Univ Montreal, Dept Biochem & Mol Med, Montreal, PQ, Canada.
EM mike.sapieha@umontreal.ca
RI Crespo-Garcia, Sergio/H-7643-2019
OI Crespo-Garcia, Sergio/0000-0002-8640-9135; Delisle,
   Jean-Sebastien/0000-0003-1460-7287
FU Foundation Fighting Blindness Canada; SemaThera Inc.; Canadian
   Institutes of Health Research [148460]; Diabetes Canada
   [DI-3-18-5444-PS]; Heart and Stroke Foundation of Canada
   [G-16-00014658]; Natural Sciences and Engineering Research Council of
   Canada [418637]; Fonds de Recherche en Ophtalmologie de l'Universite de
   Montreal (FROUM); Reseau en Recherche en Sante de la Vision; CIHR; Fonds
   de Recherche Sante du Quebec (FRQS) scholarship
FX We dedicate this study to memory of our colleague and friend Normand
   Beaulieu who made invaluable contributions to the understanding of
   Neuropilin biology and the translational merit of targeting its ligands.
   P.S. holds the Wolfe Professorship in Translational Research and a
   Canada Research Chair in Retinal Cell Biology. This work was supported
   by operating grants to P.S from The Foundation Fighting Blindness Canada
   and SemaThera Inc. Additional funding was provided by the Canadian
   Institutes of Health Research (Foundation grant #148460), the Diabetes
   Canada (DI-3-18-5444-PS), Heart and Stroke Foundation of Canada
   (G-16-00014658), and Natural Sciences and Engineering Research Council
   of Canada (418637), the Fonds de Recherche en Ophtalmologie de
   l'Universite de Montreal (FROUM), and the Reseau en Recherche en Sante
   de la Vision. M.H. holds the Banting Fellowship from the CIHR. S.C-G.
   holds a Fonds de Recherche Sante du Quebec (FRQS) scholarship.
CR Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6
   Ball SG, 2010, BIOCHEM J, V427, P29, DOI 10.1042/BJ20091512
   BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Carrer A, 2012, CANCER RES, V72, P6371, DOI 10.1158/0008-5472.CAN-12-0762
   Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007
   Cerani A, 2013, CELL METAB, V18, P505, DOI 10.1016/j.cmet.2013.09.003
   Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0
   Chen XJ, 2019, MOL CARCINOGEN, V58, P388, DOI 10.1002/mc.22936
   Crespo-Garcia Sergio, 2017, Invest Ophthalmol Vis Sci, V58, P4997, DOI 10.1167/iovs.16-21283
   Dai XY, 2017, FASEB J, V31, P2881, DOI 10.1096/fj.201601238R
   Dejda A, 2016, INVEST OPHTH VIS SCI, V57, P1530, DOI 10.1167/iovs.15-18598
   Dejda A, 2014, J CLIN INVEST, V124, P4807, DOI 10.1172/JCI76492
   Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538
   Fantin A, 2013, BLOOD, V121, P2352, DOI 10.1182/blood-2012-05-424713
   Fernandez-Robredo P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169865
   Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funasaka T, 2014, GLYCOBIOLOGY, V24, P886, DOI 10.1093/glycob/cwu086
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Geretti E, 2008, ANGIOGENESIS, V11, P31, DOI 10.1007/s10456-008-9097-1
   Glinka Y, 2011, CARCINOGENESIS, V32, P613, DOI 10.1093/carcin/bgq281
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Joyal JS, 2011, BLOOD, V117, P6024, DOI 10.1182/blood-2010-10-311589
   Jubb AM, 2012, J PATHOL, V226, P50, DOI 10.1002/path.2989
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lepelletier Y, 2007, P NATL ACAD SCI USA, V104, P5545, DOI 10.1073/pnas.0700705104
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200
   Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Miyauchi JT, 2018, CANCER RES, V78, P685, DOI 10.1158/0008-5472.CAN-17-1435
   Muhl L, 2017, J CELL SCI, V130, P1365, DOI 10.1242/jcs.200493
   Nakamura F, 2002, ADV EXP MED BIOL, V515, P55
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Oussa NAE, 2016, J IMMUNOL, V197, P3927, DOI 10.4049/jimmunol.1601116
   Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626
   Raimondi C, 2016, PROG RETIN EYE RES, V52, P64, DOI 10.1016/j.preteyeres.2016.02.003
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Renand A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085589
   Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544
   Rizzolio S., 2017, NEUROPILINS ROLE FUN, P23, DOI DOI 10.1007/978-3-319-48824-0_3
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Roy S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01228
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sodhi A, 2019, J CLIN INVEST, V129, P4593, DOI 10.1172/JCI120879
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8
   Takamatsu H, 2012, TRENDS IMMUNOL, V33, P127, DOI 10.1016/j.it.2012.01.008
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wilson AM, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan4626
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
NR 71
TC 1
Z9 1
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAY 7
PY 2021
VL 13
IS 5
AR e11754
DI 10.15252/emmm.201911754
EA APR 2021
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA RY1VF
UT WOS:000641171700001
PM 33876574
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, J
   Ferrucci, S
AF Lee, Jimin
   Ferrucci, Steven
TI Peripapillary subretinal neovascular membranes: A review
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Review
DE Peripapillary subretinal neovascularization; Juxtapapillary subretinal
   neovascularization; Age-related macular degeneration; Choroidal
   neovascular membrane
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL BEVACIZUMAB; LASER
   PHOTOCOAGULATION; OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY;
   SURGICAL-TREATMENT; NATURAL-HISTORY; VERTEPORFIN; SURGERY; REMOVAL
AB Peripapillary subretinal neovascular membranes (PSRNVM) are most commonly associated with age-related macular degeneration and idiopathic causes in older patients. In younger patients, the condition has been linked to a wide variety of other conditions. As with the more commonly occurring macular form of choroidal neovascular membranes, PSRNVM can also lead to severe vision loss. Therefore, clinicians must take care to avoid overlooking this event to provide appropriate management and treatment. Current knowledge of PSRNVM suggests the importance of regular examinations of the affected eye in both treated and untreated cases to watch for progression and recurrence, which are unpredictable, and also of the fellow eye because there is a high risk of bilateral involvement. Optometry 2011;82:681-688
C1 [Lee, Jimin; Ferrucci, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
   [Lee, Jimin; Ferrucci, Steven] Sepulveda Vet Affairs Ambulatory Care Ctr Nursing, Sepulveda, CA USA.
   [Ferrucci, Steven] So Calif Coll Optometry, Fullerton, CA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System
RP Ferrucci, S (通讯作者)，Sepulveda Vet Affairs Ambulatory Care Ctr, Dept Optometry, 16111 Plummer St 112E, Sepulveda, CA 91343 USA.
EM steven.ferrucci@va.gov
CR Aisenbrey S, 2007, BRIT J OPHTHALMOL, V91, P1027, DOI 10.1136/bjo.2006.108118
   Almony A, 2008, OPHTHALMOLOGY, V115, P540, DOI 10.1016/j.ophtha.2007.08.045
   ANNESLEY WH, 1986, GRAEF ARCH CLIN EXP, V224, P101, DOI 10.1007/BF02141478
   Bains HS, 2003, RETINA-J RET VIT DIS, V23, P469, DOI 10.1097/00006982-200308000-00004
   Bernstein PS, 2008, RETINA-J RET VIT DIS, V28, P81, DOI 10.1097/IAE.0b013e31815e9351
   Blinder KJ, 2005, OPHTHAL SURG LAS IM, V36, P358, DOI 10.3928/1542-8877-20050901-03
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   CIALDINI AP, 1989, OPHTHALMIC SURG LAS, V20, P93
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gass JDM, 1973, T AM ACAD OPHTHALMOL, V77, P310
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Kertes PJ, 2004, RETINA-J RET VIT DIS, V24, P219, DOI 10.1097/00006982-200404000-00005
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Kokame GT, 2005, RETINA-J RET VIT DIS, V25, P564, DOI 10.1097/00006982-200507000-00004
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Postelmans L, 2008, BRIT J OPHTHALMOL, V92, P721, DOI 10.1136/bjo.2007.135095
   REESE A, 1962, AM J OPHTHALMOL, V43, P897
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SILVESTRI G, 1993, EYE, V7, P398, DOI 10.1038/eye.1993.78
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spandau UHM, 2007, ACTA OPHTHALMOL SCAN, V85, P340, DOI 10.1111/j.1600-0420.2006.00832.x
   Squirrell DM, 2009, CLIN EXP OPHTHALMOL, V37, P368, DOI 10.1111/j.1442-9071.2009.02044.x
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 32
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD NOV
PY 2011
VL 82
IS 11
BP 681
EP 688
DI 10.1016/j.optm.2011.04.104
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 843QL
UT WOS:000296687200006
PM 21873121
DA 2022-11-30
ER

PT J
AU Mimura, T
   Amano, S
   Sugiura, T
   Funatsu, H
   Yamagami, S
   Oshika, T
   Araie, M
   Eguchi, S
AF Mimura, T
   Amano, S
   Sugiura, T
   Funatsu, H
   Yamagami, S
   Oshika, T
   Araie, M
   Eguchi, S
TI 10-year follow-up study of secondary transscleral ciliary sulcus fixated
   posterior chamber intraocular lenses
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IMPLANTATION
AB PURPOSE: To study the outcome of transscleral ciliary sulcus fixated posterior chamber intraocular lenses (transscleral fixation of PC IOLs) at 10 years after surgery.
   DESIGN: Longitudinal observational study.
   METHOD: A total of 16 patients (16 eyes) who had undergone transscleral fixation of PC IOL were studied. We evaluate the clinical outcome in each patient at 10 years after the operation.
   SETTING: The Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
   RESULTS: Visual loss and other complications occurred within 2 years of the operation but not later. Postoperative complications were cystoid macular edema in three eyes (18.8%) and age,related macular degeneration in one eye (6.3%).
   CONCLUSION: It is important to carefully observe and adequately treat patients for 2 years postoperatively.
C1 Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   Eguchi Eye Clin, Hakodate, Hokkaido, Japan.
   Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Ibaraki, Japan.
   Tokyo Womens Med Univ, Dept Ophthalmol, Ctr Diabet, Tokyo, Japan.
   Sugiura Eye Clin, Shizuoka, Japan.
C3 University of Tokyo; University of Tsukuba; Tokyo Women's Medical
   University
RP Mimura, T (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
CR Dick HB, 2001, CURR OPIN OPHTHALMOL, V12, P47, DOI 10.1097/00055735-200102000-00009
   HAHN TW, 1992, J CATARACT REFR SURG, V18, P174, DOI 10.1016/S0886-3350(13)80927-3
   MITTELVIEFHAUS H, 1993, OPHTHALMIC SURG LAS, V24, P542
   Shigeeda T, 2002, J CATARACT REFR SURG, V28, P1689, DOI 10.1016/S0886-3350(01)01178-6
   STARK WJ, 1988, OPHTHALMIC SURG LAS, V19, P240
   Sugiura Takeshi, 1995, Nippon Ganka Gakkai Zasshi, V99, P811
NR 6
TC 25
Z9 27
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2003
VL 136
IS 5
BP 931
EP 933
DI 10.1016/S0002-9394(03)00893-6
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735ZW
UT WOS:000186146000027
PM 14597054
DA 2022-11-30
ER

PT J
AU Palejwala, NV
   Lauer, AK
AF Palejwala, N. V.
   Lauer, A. K.
TI AFLIBERCEPT: AN UPDATE ON RECENT MILESTONES ACHIEVED
SO DRUGS OF TODAY
LA English
DT Article
DE Aflibercept; VEgF Trap-Eye; Diabetic macular edema; Neovascular wet
   age-related macular degeneration; Macular edema; Branch retinal vein
   occlusion
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; OCCLUSION 12-MONTH OUTCOMES; III RANDOMIZED-TRIAL;
   INTRAVITREAL AFLIBERCEPT; MACULAR EDEMA; VEGF-TRAP; SUSTAINED BENEFITS;
   PHASE-I
AB In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.
C1 [Palejwala, N. V.; Lauer, A. K.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Retina Vitreous Div, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Lauer, AK (通讯作者)，Oregon Hlth & Sci Univ, Vitreoretinal Div, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM lauera@ohsu.edu
FU National Institute of Health Core Grant [NIH P30EY010572]; Prevent
   Blindness, New York, New York
FX Unrestricted Grant, Research to Prevent Blindness, New York, New York;
   National Institute of Health Core Grant (NIH P30EY010572).
CR Adler A., 2007, P AM ASS CANC RES, V48
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   [Anonymous], 2008, DRUGS R&D, V9, P261
   Barrios CH, 2010, BREAST CANCER RES TR, V121, P121, DOI 10.1007/s10549-010-0788-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Campochiaro PA, 2014, OPHTHALMOLOGY
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Eudge J. S., 2007, P NATL ACAD SCI USA, V104, P18363
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   Korobelnik J., 2014, ACTA OPHTHALMOL, V92, DOI [10.1111/j.1755-3768.2014.3472, DOI 10.1111/J.1755-3768.2014.3472]
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lockhart AC, 2010, J CLIN ONCOL, V28, P207, DOI 10.1200/JCO.2009.22.9237
   Lutty GA, 2011, INVEST OPHTH VIS SCI, V52, P4039, DOI 10.1167/iovs.10-6798
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2012, CURR DIABETES REV, V8, P237, DOI 10.2174/157339912800840488
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Cidon EU, 2010, CLIN MED INSIGHTS-ON, V4, P55, DOI 10.4137/CMO.S5214
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
NR 50
TC 5
Z9 5
U1 0
U2 7
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD DEC
PY 2014
VL 50
IS 12
BP 779
EP 790
DI 10.1358/dot.2014.50.12.2245587
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AX9OE
UT WOS:000347231000001
PM 25588083
DA 2022-11-30
ER

PT J
AU Perera, CO
   Yen, GM
AF Perera, Conrad O.
   Yen, Gan Mei
TI Functional properties of carotenoids in human health
SO INTERNATIONAL JOURNAL OF FOOD PROPERTIES
LA English
DT Review
DE carotenoids; human health; toxicity; bioavailability; nutrition;
   absorption and transport
ID LIQUID-CHROMATOGRAPHIC ANALYSIS; CELL-CYCLE PROGRESSION; OXIDATIVE
   DNA-DAMAGE; BETA-CAROTENE; VITAMIN-A; DIETARY CAROTENOIDS;
   INTESTINAL-ABSORPTION; ALPHA-TOCOPHEROL; PROSTATE-CANCER; HUMAN PLASMA
AB Carotenoids are compounds of great dietery importance. Recent interest in carotenoids has been stimulated by epidemiological studies that strongly suggest that consumption of carotenoid-rich foods reduces the incidence of several diseases such as cancers, cardiovascular diseases, age-related macular degeneration, cataracts, diseases related to low immune function, and other degenerative diseases. Health benefits of carotenoids are derived from; the fruits and vegetables in the diet, particularly from cooked products containing oil, or from supplements of their extracts, such as tomato sauce, dried tomatoes, or those suspended in oil. This article provides a brief overview of the chemistry of carotenoids-their absorption, transport bioavailability, metabolism, and their action as antioxidants, and in the prevention of a number of common diseases.
C1 Natl Univ Singapore, Dept Chem, Food Sci & Technol Programme, Singapore 117548, Singapore.
C3 National University of Singapore
RP Perera, CO (通讯作者)，POB 462, Palmerston North 5301, New Zealand.
EM conradperera@gmail.com
OI Perera, Conrad/0000-0001-9525-6962
CR Afanas'ev IB, 2005, MED HYPOTHESES, V64, P127, DOI 10.1016/j.mehy.2004.05.009
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Amir H, 1999, NUTR CANCER, V33, P105, DOI 10.1080/01635589909514756
   Amsellem-Ouazana D, 2004, PROG UROL, V14, P573
   Astorg P, 1997, TRENDS FOOD SCI TECH, V8, P406, DOI 10.1016/S0924-2244(97)01092-3
   BARUA AB, 1993, J CHROMATOGR-BIOMED, V617, P257, DOI 10.1016/0378-4347(93)80496-Q
   Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996
   BENDICH A, 1994, PURE APPL CHEM, V66, P1017, DOI 10.1351/pac199466051017
   Black HS, 1998, NUTR CANCER, V31, P212, DOI 10.1080/01635589809514705
   Boileau TWM, 2002, EXP BIOL MED, V227, P914, DOI 10.1177/153537020222701012
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bonzongo JCJ, 2003, CHEMOSPHERE, V52, P1263, DOI 10.1016/S0045-6535(03)00533-2
   Borel P, 2005, ANN BIOL CLIN-PARIS, V63, P165
   Borel P, 1996, J LIPID RES, V37, P250
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   BOWEN PE, 1995, AM J CLIN NUTR, V62, P1403
   Breithaupt DE, 2003, BRIT J NUTR, V90, P795, DOI 10.1079/BJN2003962
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Britton, 1993, CAROTENOIDS PHOTOSYN, P1
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Camara B, 2004, ARCH BIOCHEM BIOPHYS, V430, P16, DOI 10.1016/j.abb.2004.06.028
   CANFIELD LM, 1990, METHOD ENZYMOL, V189, P418
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Castenmiller JJM, 1997, PURE APPL CHEM, V69, P2145, DOI 10.1351/pac199769102145
   Chen LW, 2001, JNCI-J NATL CANCER I, V93, P1872, DOI 10.1093/jnci/93.24.1872
   CHEW BP, 1995, J NUTR, V125, pS1804, DOI 10.1093/jn/125.suppl_6.1804S
   Chew BP, 2004, J NUTR, V134, p257S, DOI 10.1093/jn/134.1.257S
   CLAVELCHAPELTON F, 1977, CANC DETECT PREV, V21, P426
   Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823
   Collins AR, 2001, MUTAT RES-FUND MOL M, V475, P21, DOI 10.1016/S0027-5107(01)00071-9
   Cooper DA, 1999, NUTR REV, V57, P201, DOI 10.1111/j.1753-4887.1999.tb06944.x
   Coral-Hinostroza GN, 2004, COMP BIOCHEM PHYS C, V139, P99, DOI 10.1016/j.cca.2004.09.011
   Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003
   Cser MA, 2004, ANN NUTR METAB, V48, P156, DOI 10.1159/000078379
   Cui JK, 2001, J BIOMED SCI, V8, P336, DOI 10.1007/BF02258375
   Czeczuga-Semeniuk E, 2003, NEOPLASMA, V50, P280
   DAUDU PA, 1994, AM J CLIN NUTR, V60, P969, DOI 10.1093/ajcn/60.6.969
   DAVIES BH, 1970, PHYTOCHEMISTRY, V9, P797, DOI 10.1016/S0031-9422(00)85183-3
   De Flora S, 1999, MUTAGENESIS, V14, P153, DOI 10.1093/mutage/14.2.153
   dePee S, 1996, EUR J CLIN NUTR, V50, pS38
   DIETZ JM, 1988, PLANT FOOD HUM NUTR, V38, P333, DOI 10.1007/BF01091731
   Dorgan JF, 1998, CANCER CAUSE CONTROL, V9, P89, DOI 10.1023/A:1008857521992
   During A, 2004, ARCH BIOCHEM BIOPHYS, V430, P77, DOI 10.1016/j.abb.2004.03.024
   During A, 1998, J NUTR, V128, P1614, DOI 10.1093/jn/128.10.1614
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   ELGORAB M, 1973, BIOCHIM BIOPHYS ACTA, V306, P58, DOI 10.1016/0005-2760(73)90208-7
   ELGORAB MI, 1975, BIOCHIM BIOPHYS ACTA, V401, P265, DOI 10.1016/0005-2736(75)90310-7
   EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   *FAO WHO, 1967, FAO NUTR REP SER, V41, P1
   FARIN D, 1983, PHYTOCHEMISTRY, V22, P403, DOI 10.1016/0031-9422(83)83012-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FREI B, 1997, FALL WINTER NEWSLETT
   Fuhrman B, 1997, NUTR METAB CARDIOVAS, V7, P433
   Furr HC, 1997, J NUTR BIOCHEM, V8, P364, DOI 10.1016/S0955-2863(97)00060-0
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   GERSTER H, 1993, INT J VITAM NUTR RES, V63, P93
   Giovannucci E, 2002, JNCI-J NATL CANCER I, V94, P391, DOI 10.1093/jnci/94.5.391
   GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767
   Goodwin TW, 1976, CHEM BIOCH PLANT PIG, P225
   GUGGER ET, 1992, J NUTR, V122, P115, DOI 10.1093/jn/122.1.115
   Hail N, 2001, CANCER RES, V61, P6698
   HALLIWELL B, 1999, FREE RADICAL BIO MED, P530
   Hata TR, 2000, J INVEST DERMATOL, V115, P441, DOI 10.1046/j.1523-1747.2000.00060.x
   Heinrich U, 2003, J NUTR, V133, P98, DOI 10.1093/jn/133.1.98
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hernell O., 1992, SEMINARS GASTROINTES, V3, P189
   HIGDON J, 2003, VITAMIN A
   Hof KHV, 1999, BRIT J NUTR, V82, P203, DOI 10.1017/S0007114599001385
   HOLLANDER D, 1978, AM J PHYSIOL, V235, pE686, DOI 10.1152/ajpendo.1978.235.6.E686
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Hornero-Mendez D, 2000, J AGR FOOD CHEM, V48, P1617, DOI 10.1021/jf9912046
   JOHNSON EJ, 1992, AM J CLIN NUTR, V56, P128, DOI 10.1093/ajcn/56.1.128
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAPLAN LA, 1990, METHOD ENZYMOL, V189, P155
   Kathe SD, 2004, J BIOL CHEM, V279, P18511, DOI 10.1074/jbc.M313598200
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KHACHIK F, 1995, J CHROMATOGR B, V670, P219, DOI 10.1016/0378-4347(95)00169-7
   Kim MK, 2001, NUTR RES, V21, P797, DOI 10.1016/S0271-5317(01)00300-1
   Klipstein-Grobusch K, 2000, ATHEROSCLEROSIS, V148, P49, DOI 10.1016/S0021-9150(99)00221-X
   Kohlmeier L, 1997, AM J EPIDEMIOL, V146, P618, DOI 10.1093/oxfordjournals.aje.a009327
   Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   KRINSKY NI, 1958, ARCH BIOCHEM BIOPHYS, V73, P233, DOI 10.1016/0003-9861(58)90259-5
   Krinsky NI, 2001, NUTRITION, V17, P815, DOI 10.1016/S0899-9007(01)00651-7
   Lacker T, 1999, J CHROMATOGR A, V854, P37, DOI 10.1016/S0021-9673(99)00584-1
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   LEE MA, 1995, J HEPATOL, V23, P550, DOI 10.1016/0168-8278(95)80061-1
   Levy J., 2004, HERBALGRAM, V62, P49
   Levy LW, 1997, ANALYST, V122, P977, DOI 10.1039/a701304c
   Li E, 2003, CURR OPIN LIPIDOL, V14, P241, DOI 10.1097/00041433-200306000-00003
   Livny O, 2002, J NUTR, V132, P3754, DOI 10.1093/jn/132.12.3754
   Lyan B, 2001, J CHROMATOGR B, V751, P297, DOI 10.1016/S0378-4347(00)00488-6
   Maharshak N, 2003, INT J DERMATOL, V42, P178, DOI 10.1046/j.1365-4362.2003.01657.x
   Marchetti P, 1999, CANCER RES, V59, P6257
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   McEligot AJ, 1999, CANCER EPIDEM BIOMAR, V8, P227
   Mecocci P, 2002, ARCH NEUROL-CHICAGO, V59, P794, DOI 10.1001/archneur.59.5.794
   MEYDANI SN, 1995, AM J CLIN NUTR, V62, P1462
   Miller EC, 2002, UROL CLIN N AM, V29, P83, DOI 10.1016/S0094-0143(02)00020-4
   Moise AR, 2005, TRENDS PLANT SCI, V10, P178, DOI 10.1016/j.tplants.2005.02.006
   Moore T, 1930, BIOCHEM J, V24, P692, DOI 10.1042/bj0240692
   Nahum A, 2001, ONCOGENE, V20, P3428, DOI 10.1038/sj.onc.1204452
   Nara E, 2001, NUTR CANCER, V39, P273, DOI 10.1207/S15327914nc392_18
   OLSON JA, 1994, PURE APPL CHEM, V66, P1011, DOI 10.1351/pac199466051011
   Olson JA., 1999, MODERN NUTR HLTH DIS, P525
   Omenn GS, 2004, CHEST, V125, p123S, DOI 10.1378/chest.125.5_suppl.123S
   Oshima S, 1997, J NUTR, V127, P1475, DOI 10.1093/jn/127.8.1475
   Ouedraogo GD, 2003, PHOTOCHEM PHOTOBIOL, V77, P192, DOI 10.1562/0031-8655(2003)077<0192:SROSET>2.0.CO;2
   Palace VP, 1999, FREE RADICAL BIO MED, V26, P746, DOI 10.1016/S0891-5849(98)00266-4
   Palozza P, 2003, NUTR CANCER, V47, P76, DOI 10.1207/s15327914nc4701_10
   Palozza Paola, 2004, Current Pharmacogenomics, V2, P35, DOI 10.2174/1570160043476169
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Parker RS, 1999, P NUTR SOC, V58, P155, DOI 10.1079/PNS19990021
   Perez-Galvez A, 2003, BRIT J NUTR, V89, P787, DOI 10.1079/BJN2003842
   PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L
   POOR CL, 1992, J NUTR, V122, P262, DOI 10.1093/jn/122.2.262
   POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132
   Pryor WA, 2000, NUTR REV, V58, P39
   Puduvalli VK, 2005, CANCER RES, V65, P1547, DOI 10.1158/0008-5472.CAN-04-0786
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   REBOUL E, 2003, CLIN NUTR, V22, pS103
   RIBAYAMERCADO JD, 1995, J NUTR, V125, P1854, DOI 10.1093/jn/125.7.1854
   Rich GT, 1998, LIPIDS, V33, P985, DOI 10.1007/s11745-998-0296-5
   Riedl J, 1999, J NUTR, V129, P2170, DOI 10.1093/jn/129.12.2170
   Rock CL, 1998, J NUTR, V128, P913, DOI 10.1093/jn/128.5.913
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   Ruhl R, 2004, EUR J NUTR, V43, P336, DOI 10.1007/s00394-004-0475-1
   Ruhl R, 2004, INT J VITAM NUTR RES, V74, P279, DOI 10.1024/0300-9831.74.4.279
   Russell RM, 2004, J NUTR, V134, p262S, DOI 10.1093/jn/134.1.262S
   Sauberlich H E, 1974, Vitam Horm, V32, P251
   SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   Sesso HD, 2005, CANCER EPIDEM BIOMAR, V14, P1074, DOI 10.1158/1055-9965.EPI-04-0683
   Sesso HD, 2004, AM J CLIN NUTR, V79, P47
   Sharoni Y, 2004, ARCH BIOCHEM BIOPHYS, V430, P89, DOI 10.1016/j.abb.2004.03.009
   Sharoni Y, 2002, PURE APPL CHEM, V74, P1469, DOI 10.1351/pac200274081469
   SHI HL, 1991, BRAIN RES BULL, V26, P235, DOI 10.1016/0361-9230(91)90233-A
   SINGH VN, 1991, AM J CLIN NUTR, V53, pS386, DOI 10.1093/ajcn/53.1.386S
   SIVAKUMAR B, 1997, 16 INT C NUTR MONTR, P127
   Slattery ML, 2000, AM J CLIN NUTR, V71, P575
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N
   Stahl W, 2001, J NUTR, V131, P1449, DOI 10.1093/jn/131.5.1449
   Stahl W, 1996, ARCH BIOCHEM BIOPHYS, V336, P1, DOI 10.1006/abbi.1996.0525
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Steghens JP, 1997, J CHROMATOGR B, V694, P71, DOI 10.1016/S0378-4347(97)00140-0
   Takashi M, 2001, CANCER LETT, V172, P103, DOI 10.1016/S0304-3835(01)00635-8
   Terry P, 2002, NUTR CANCER, V42, P167, DOI 10.1207/S15327914NC422_3
   Toba T, 1997, LIFE SCI, V61, P839, DOI 10.1016/S0024-3205(97)00566-3
   Tso Patrick, 1994, P1867
   TYCZKOWSKI JK, 1988, POULTRY SCI, V67, P787, DOI 10.3382/ps.0670787
   Tyssandier V, 2003, AM J PHYSIOL-GASTR L, V284, pG913, DOI 10.1152/ajpgi.00410.2002
   van der Horst-Graat JM, 2004, BRIT J NUTR, V92, P113, DOI 10.1079/BJN20041155
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
   Walfisch Y, 2003, BRIT J NUTR, V90, P759, DOI 10.1079/BJN2003955
   Watzl B, 2003, ANN NUTR METAB, V47, P255, DOI 10.1159/000072397
   Weedon B.C., 1995, CAROTENOIDS, V1, P27
   WESTERGAARD H, 1976, J CLIN INVEST, V58, P97, DOI 10.1172/JCI108465
   WHITE WS, 1994, J AM COLL NUTR, V13, P665
   Willstaedt H, 1936, H-S Z PHYSIOL CHEM, V240, P10, DOI 10.1515/bchm2.1936.240.1-2.10
   Wright ME, 2003, CANCER CAUSE CONTROL, V14, P85, DOI 10.1023/A:1022565601937
   Wyss A, 2004, J NUTR, V134, p246S, DOI 10.1093/jn/134.1.246S
   Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521
   YAO LL, 1995, FASEB J, V9, pA458
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   You CS, 1996, AM J CLIN NUTR, V64, P177, DOI 10.1093/ajcn/64.2.177
   Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7
   ZHANG LX, 1991, CARCINOGENESIS, V12, P2109, DOI 10.1093/carcin/12.11.2109
   ZHANG LX, 1992, CANCER RES, V52, P5707
NR 181
TC 119
Z9 123
U1 7
U2 100
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1094-2912
EI 1532-2386
J9 INT J FOOD PROP
JI Int. J. Food Prop.
PY 2007
VL 10
IS 2
BP 201
EP 230
DI 10.1080/10942910601045271
PG 30
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 166HP
UT WOS:000246370100002
OA Bronze
DA 2022-11-30
ER

PT J
AU Meri, S
   Haapasalo, K
AF Meri, Seppo
   Haapasalo, Karita
TI Function and Dysfunction of Complement Factor H During Formation of
   Lipid-Rich Deposits
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE apoE; C-reactive protein; adiponectin; HDL; amyloid-beta; protein
ID C-REACTIVE PROTEIN; LOW-DENSITY-LIPOPROTEIN; POLYANION BINDING-SITE;
   APOLIPOPROTEIN-E; ALTERNATIVE PATHWAY; MACULAR DEGENERATION;
   ALZHEIMERS-DISEASE; Y402H POLYMORPHISM; APOPTOTIC CELLS; INNATE IMMUNITY
AB Complement-mediated inflammation or dysregulation in lipid metabolism are associated with the pathogenesis of several diseases. These include age-related macular degeneration (AMD), C3 glomerulonephritis (C3GN), dense deposit disease (DDD), atherosclerosis, and Alzheimer's disease (AD). In all these diseases, formation of characteristic lipid-rich deposits is evident. Here, we will discuss molecular mechanisms whereby dysfunction of complement, and especially of its key regulator factor H, could be involved in lipid accumulation and related inflammation. The genetic associations to factor H polymorphisms, the role of factor H in the resolution of inflammation in lipid-rich deposits, modification of macrophage functions, and complement-mediated clearance of apoptotic and damaged cells indicate that the function of factor H is crucial in limiting inflammation in these diseases.
C1 [Meri, Seppo; Haapasalo, Karita] Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, Finland.
   [Meri, Seppo] Univ Helsinki, Dept Bacteriol & Immunol, Translat Immunol Res Program, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki
RP Haapasalo, K (通讯作者)，Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, Finland.
EM karita.haapasalo@helsinki.fi
OI Haapasalo, Karita/0000-0002-9619-625X
FU Jane and Aatos Erkko Foundation [15032019]; Finnish Foundation for
   Cardiovascular Research [08042019]; Academy of Finland [331108];
   Helsinki University Hospital Funds (VTR)
FX The study was supported by the Jane and Aatos Erkko Foundation
   (15032019), Finnish Foundation for Cardiovascular Research (08042019),
   Academy of Finland (331108), and Helsinki University Hospital Funds
   (VTR).
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Amdahl H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172675
   Asami T, 1999, PEDIATR NEPHROL, V13, P233, DOI 10.1007/s004670050599
   AVERY VM, 1993, J IMMUNOL, V151, P5545
   Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6
   Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305
   Braesch-Andersen S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079908
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348
   CHOY LN, 1992, J BIOL CHEM, V267, P12736
   Csincsi AI, 2015, J IMMUNOL, V194, P4963, DOI 10.4049/jimmunol.1403121
   Cutillo G, 2020, CELL MOL IMMUNOL, V17, P313, DOI 10.1038/s41423-020-0388-9
   DAHA MR, 1977, J IMMUNOL, V119, P812
   Deban L, 2011, CELL TISSUE RES, V343, P237, DOI 10.1007/s00441-010-1018-0
   Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EIKELENBOOM P, 1989, VIRCHOWS ARCH B, V56, P259
   FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9
   Fonseca MI, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-4
   Frieden C, 2012, P NATL ACAD SCI USA, V109, P8913, DOI 10.1073/pnas.1207022109
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabrielsson BG, 2003, OBES RES, V11, P699, DOI 10.1038/oby.2003.100
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Golovanova NK, 1998, CLIN CHIM ACTA, V272, P197, DOI 10.1016/S0009-8981(98)00013-8
   Haapasalo K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01750
   Haapasalo K, 2015, J BIOL CHEM, V290, P28977, DOI 10.1074/jbc.M115.669226
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100
   Hatters DM, 2006, J MOL BIOL, V361, P932, DOI 10.1016/j.jmb.2006.06.080
   Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2
   HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963
   Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Hyvarinen S, 2014, J BIOL CHEM, V289, P4295, DOI 10.1074/jbc.M113.527416
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jeon H, 2010, J NEUROIMMUNOL, V229, P63, DOI 10.1016/j.jneuroim.2010.07.001
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Karvonen J, 2003, CIRCULATION, V108, P2107, DOI 10.1161/01.CIR.0000092891.55157.A7
   Kaye S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00545
   Kiskis J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13489
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Koutsouraki E, 2014, J ALZHEIMERS DIS, V42, pS163, DOI 10.3233/JAD-132633
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Laine P, 2002, AM J CARDIOL, V90, P404, DOI 10.1016/S0002-9149(02)02498-0
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malik TH, 2010, CIRCULATION, V122, P1948, DOI 10.1161/CIRCULATIONAHA.110.981365
   Marais AD, 2019, PATHOLOGY, V51, P165, DOI 10.1016/j.pathol.2018.11.002
   Moreno-Navarrete JM, 2010, DIABETES, V59, P200, DOI 10.2337/db09-0700
   MATHIESON PW, 1993, J EXP MED, V177, P1827, DOI 10.1084/jem.177.6.1827
   McGeer EG, 2001, NEUROBIOL AGING, V22, P843, DOI 10.1016/S0197-4580(01)00288-3
   Meesmann HM, 2010, J CELL SCI, V123, P3347, DOI 10.1242/jcs.066696
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   Meri S, 2016, FEBS LETT, V590, P2418, DOI 10.1002/1873-3468.12284
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Montecucco F, 2008, CLIN INTERV AGING, V3, P341
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nissila E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02701
   Norata GD, 2009, CIRCULATION, V120, P699, DOI 10.1161/CIRCULATIONAHA.108.806547
   OBRIEN KD, 1994, AM J PATHOL, V144, P538
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Pickering MC, 2013, KIDNEY INT, V84, P1079, DOI 10.1038/ki.2013.377
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Reiner AP, 2013, HUM MOL GENET, V22, P3381, DOI 10.1093/hmg/ddt189
   ROSS GD, 1978, J EXP MED, V147, P730, DOI 10.1084/jem.147.3.730
   Salminen A, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.117.001731
   SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sethi S, 2013, MAYO CLIN PROC, V88, P1284, DOI 10.1016/j.mayocp.2013.08.002
   Sethi S, 2009, KIDNEY INT, V75, P952, DOI 10.1038/ki.2008.657
   Shao YP, 1997, J NEUROPATH EXP NEUR, V56, P376, DOI 10.1097/00005072-199704000-00006
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shen Y, 2003, PROG NEUROBIOL, V70, P463, DOI 10.1016/j.pneurobio.2003.08.001
   Smith RJH, 2019, NAT REV NEPHROL, V15, P129, DOI 10.1038/s41581-018-0107-2
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027
   Taskinen S, 2005, BIOCHEM BIOPH RES CO, V329, P1208, DOI 10.1016/j.bbrc.2005.02.091
   Terwel D, 2011, J NEUROSCI, V31, P7049, DOI 10.1523/JNEUROSCI.6546-10.2011
   Todd RF, 1996, J CLIN INVEST, V98, P1, DOI 10.1172/JCI118752
   Tulamo R, 2006, NEUROSURGERY, V59, P1069, DOI 10.1227/01.NEU.0000245598.84698.26
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vlaicu SI, 2016, IMMUNOL RES, V64, P1, DOI 10.1007/s12026-015-8669-6
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong EKS, 2014, J AM SOC NEPHROL, V25, P2425, DOI 10.1681/ASN.2013070732
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yin CJ, 2019, NAT MED, V25, P496, DOI 10.1038/s41591-018-0336-8
   Zanjani H, 2005, ALZ DIS ASSOC DIS, V19, P55, DOI 10.1097/01.wad.0000165506.60370.94
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zhang D, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-3
NR 107
TC 7
Z9 7
U1 4
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 8
PY 2020
VL 11
AR 611830
DI 10.3389/fimmu.2020.611830
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA PH7VT
UT WOS:000600616000001
PM 33363547
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Itoh, Y
   Vasanji, A
   Ehlers, JP
AF Itoh, Yuji
   Vasanji, Amit
   Ehlers, Justis P.
TI Volumetric ellipsoid zone mapping for enhanced visualisation of outer
   retinal integrity with optical coherence tomography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID HYDROXYCHLOROQUINE RETINOPATHY; HIGH-SPEED; OCRIPLASMIN; PROGRESSION;
   THERAPY
AB Objective assessment of retinal layer integrity with optical coherence tomography (OCT) is currently limited. The ellipsoid zone (EZ) has been identified as an important feature on OCT that has critical prognostic value in macular disorders. In this report, we describe a novel assessment tool for EZ integrity that provides visual and quantitative assessment across an OCT data set. Using this algorithm, we describe the findings in multiple clinical examples, including normal controls, age-related macular degeneration, drug effects (eg, ocriplasmin, hydroxychloroquine) and effects of surgical manipulation (eg, following membrane peeling using intraoperative OCT). EZ mapping provides both en face visualisation of EZ integrity and EZ-retinal pigment epithelium height. Additionally, volumetric, area and linear measurements are feasible using this assessment tool.
C1 [Itoh, Yuji; Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Ophthalm Imaging Ctr, Cleveland, OH 44106 USA.
   [Vasanji, Amit] ImageIQ, Cleveland, OH USA.
C3 Cleveland Clinic Foundation
RP Ehlers, JP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,i30, Cleveland, OH 44195 USA.
EM ehlersj1@yahoo.com
FU NIH/NEI [K23-EY022947-01A1]; Ohio Department of Development
   [TECH-13-059]; Research to Prevent Blindness; Machemer Foundation
   Fellowship; NATIONAL EYE INSTITUTE [K23EY022947] Funding Source: NIH
   RePORTER
FX NIH/NEI K23-EY022947-01A1 (JPE); Ohio Department of Development
   TECH-13-059 (JPE); Research to Prevent Blindness (Cole Eye Institutional
   Grant); Machemer Foundation Fellowship (YI).
CR Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Ehlers JP, 2015, INVEST OPHTH VIS SCI, V56, P1141, DOI 10.1167/iovs.14-15765
   Itoh Y, 2014, OPHTHALMOLOGY, V121, P2506, DOI 10.1016/j.ophtha.2014.07.044
   Marmor MF, 2014, JAMA OPHTHALMOL, V132, P1105, DOI 10.1001/jamaophthalmol.2014.1099
   Mititelu M, 2013, JAMA OPHTHALMOL, V131, P1187, DOI 10.1001/jamaophthalmol.2013.4244
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Rodriguez-Padilla JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P775, DOI 10.1001/archopht.125.6.775
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P356, DOI 10.1136/bjophthalmol-2013-304219
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
NR 11
TC 37
Z9 37
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2016
VL 100
IS 3
BP 295
EP 299
DI 10.1136/bjophthalmol-2015-307105
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE9SN
UT WOS:000370979300002
PM 26201354
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Struharova, K
   Cernak, M
AF Struharova, K.
   Cernak, M.
TI Fundus autofluorescence in age-related macular disease imaged with a
   laser scanning ophthalmoscope
SO BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
LA English
DT Article
DE fundus autofluorescence; lipofuscin; retinal pigment epithelium (RPE);
   age-related macular degeneration (ARMD); geographic atrophy; confocal
   laser scan ophthalmoscopy (cSLO)
ID GEOGRAPHIC ATROPHY; DEGENERATION; LIPOFUSCIN; DRUSEN; EYES
AB Age-related macular degeneration (ARMD) as the most common cause of legal blindness in industrialized countries remains an incompletely understood, complex retinal disease. Prophylactic and therapeutic options are still limited. Sensitive diagnostic tools and prognostic markers to evaluate disease stage and progression in the individual patient are needed. The retinal pigment epithelium (RPE) plays a key role in the disease process both in early and late variants of AMD. An excessive accumulation of lipofuscin granules in the lysosomal compartment of RPE cells represents a common downstream pathogenetic pathway in various retinal diseases including AMD. Fundus autofluorescence (FAF) imaging allows the visualization of the topographic distribution of lipofuscin over large retinal areas (Fig. 3, Ref. 13). Full Text in PDF www.elis.sk.
C1 [Struharova, K.; Cernak, M.] Univ Hosp Cyril & Metod, Ophthalm Dept, SK-85107 Bratislava, Slovakia.
RP Struharova, K (通讯作者)，Univ Hosp Cyril & Metod, Ophthalm Dept, Antolska 11, SK-85107 Bratislava, Slovakia.
EM katystruhar@gmail.com
CR Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   KITIGAWA K, 1989, OPTHALMOLOGICA, V199, P116
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   von Ruckmann A, 1997, ARCH OPHTHALMOL-CHIC, V36, P718
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 12
TC 2
Z9 2
U1 0
U2 6
PU COMENIUS UNIV
PI BRATISLAVA I
PA SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA
SN 0006-9248
J9 BRATISL MED J
JI Bratisl. Med. J.
PY 2012
VL 113
IS 2
BP 114
EP 116
DI 10.4149/BLL_2012_026
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 904NO
UT WOS:000301205300013
PM 22394043
OA Bronze
DA 2022-11-30
ER

PT J
AU Di Staso, F
   Ciancaglini, M
   Abdolrahimzadeh, S
   D'Apolito, F
   Scuderi, G
AF Di Staso, Federico
   Ciancaglini, Marco
   Abdolrahimzadeh, Solmaz
   D'Apolito, Fabian
   Scuderi, Gianluca
TI Optical Coherence Tomography of Choroid in Common Neurological Diseases
SO IN VIVO
LA English
DT Review
DE Optical coherence tomography; choroid; Alzheimer; Parkinson; multiple
   sclerosis; phakomatoses; Sturge-Weber syndrome; review
ID STURGE-WEBER-SYNDROME; AXIAL LENGTH; BLOOD-FLOW; THICKNESS; VOLUME; SEX;
   AGE; ABNORMALITIES; FEATURES; ADULTS
AB The choroid is involved directly and indirectly in many pathological conditions such as age-related macular degeneration, myopia-related chorioretinal atrophy and central serous chorioretinopathy. Optical coherence tomography (OCT) has gradually become a fundamental part of modern resources in the hands of ophthalmologists. The enhanced depth imaging technique and swept-source OCT make a great contribution to conventional in vivo choroid assessment. This review focuses on the most common neurological conditions in which choroid assessment by OCT may provide help in early diagnosis and be used as an interdisciplinary follow-up tool. In order to avoid evaluation biases and misdiagnosis, the main and most common physiological and para-physiological conditions in which the choroid may show alterations are also reviewed.
C1 [Di Staso, Federico; Abdolrahimzadeh, Solmaz; D'Apolito, Fabian; Scuderi, Gianluca] Sapienza Univ Rome, St Andrea Hosp, NESMOS Dept, Ophthalmol Unit, Rome, Italy.
   [Ciancaglini, Marco] Univ Aquila, San Salvatore Hosp, Eye Clin, Laquila, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of
   L'Aquila
RP Ciancaglini, M (通讯作者)，Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy.
EM marco.ciancaglini@cc.univaq.it
RI Di+Staso, Federico/AER-7388-2022; Di+Staso, Federico/AAF-8381-2022
OI Di+Staso, Federico/0000-0002-6103-2941; Di+Staso,
   Federico/0000-0002-6103-2941; Ciancaglini, Marco/0000-0001-5888-7976
CR Abdolrahimzadeh S, 2016, CURR EYE RES, V41, P1614, DOI 10.3109/02713683.2015.1135962
   Abdolrahimzadeh S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3043026
   Abdolrahimzadeh S, 2015, BRIT J OPHTHALMOL, V99, P789, DOI 10.1136/bjophthalmol-2014-306062
   Akarsu C, 2004, GRAEF ARCH CLIN EXP, V242, P990, DOI 10.1007/s00417-004-0948-1
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001
   Arora KS, 2013, JAMA OPHTHALMOL, V131, P1216, DOI 10.1001/jamaophthalmol.2013.4044
   Ayata A, 2008, CLIN EXP OPHTHALMOL, V36, P390, DOI 10.1111/j.1442-9071.2008.001742.x
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Bayhan HA, 2015, CLIN EXP OPHTHALMOL, V43, P145, DOI 10.1111/ceo.12386
   Bulut M, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7291257
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Capriotti Teri, 2016, Home Healthc Now, V34, P300, DOI 10.1097/NHH.0000000000000398
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chang L, 2013, AM J OPHTHALMOL, V155, P991, DOI 10.1016/j.ajo.2013.01.016
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8
   Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7
   Cunha Joao Paulo, 2017, Alzheimers Dement (Amst), V8, P11, DOI 10.1016/j.dadm.2017.03.004
   Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9
   Curatolo P, 2015, LANCET NEUROL, V14, P733, DOI 10.1016/S1474-4422(15)00069-1
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Eraslan M, 2016, ACTA OPTHALMOLOGICA, V94, P68, DOI DOI 10.1111/A0S.12809
   Esen E, 2016, OPHTHALMOLOGICA, V235, P65, DOI 10.1159/000441152
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   Grieshaber MC, 2007, SURV OPHTHALMOL, V52, pS144, DOI 10.1016/j.survophthal.2007.08.010
   Gupta P, 2015, AM J OPHTHALMOL, V159, P293, DOI 10.1016/j.ajo.2014.10.034
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P563, DOI 10.1016/S1350-9462(01)00004-0
   Higueros E, 2017, ACTAS DERMO-SIFILOGR, V108, P407, DOI 10.1016/j.ad.2016.09.022
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jett K, 2010, GENET MED, V12, P1, DOI 10.1097/GIM.0b013e3181bf15e3
   Kalaria RN, 2012, J NEUROL SCI, V322, P141, DOI 10.1016/j.jns.2012.07.032
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep09497
   Makino S, 2014, CLIN OPHTHALMOL, V8, P165, DOI 10.2147/OPTH.S56327
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P494, DOI 10.1080/08820538.2017.1307423
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Murphy OC, 2020, MULT SCLER J, V26, P815, DOI 10.1177/1352458519845116
   NYBOER JH, 1976, ARCH OPHTHALMOL-CHIC, V94, P1277
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Osmanbasoglu OA, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/687165
   Pache M, 2003, EUR NEUROL, V49, P164, DOI 10.1159/000069085
   Patton N, 2005, J ANAT, V206, P319, DOI 10.1111/j.1469-7580.2005.00395.x
   Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985
   Pichi F, 2016, RETINA-J RET VIT DIS, V36, P1199, DOI 10.1097/IAE.0000000000000829
   Podoleanu AG, 2008, PROG RETIN EYE RES, V27, P464, DOI 10.1016/j.preteyeres.2008.03.002
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Rao RC, 2014, OSLI RETINA, V45, P466, DOI 10.3928/23258160-20140818-01
   Recupero SM, 1998, EYE, V12, P212, DOI 10.1038/eye.1998.50
   Rhodes LA, 2014, INVEST OPHTH VIS SCI, V56, P1872, DOI DOI 10.1167/I0VS.14-16179
   Robertson DM, 1991, ANN N Y ACAD SCI, V615, P17
   Ruiz-Medrano J, 2014, INVEST OPHTH VIS SCI, V55, P3532, DOI 10.1167/iovs.14-13868
   Samueli S, 2015, WIEN KLIN WOCHENSCHR, V127, P619, DOI 10.1007/s00508-015-0758-y
   Sanchez-Cano A, 2014, AM J OPHTHALMOL, V158, P574, DOI 10.1016/j.ajo.2014.05.035
   Satue M, 2018, CURR EYE RES, V43, P109, DOI 10.1080/02713683.2017.1370116
   Shields Carol L, 2005, Curr Opin Ophthalmol, V16, P141, DOI 10.1097/01.icu.0000158258.01681.40
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CSH, 2012, INVEST OPHTH VIS SCI, V53, P1639, DOI 10.1167/iovs.12-9566
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Toyokawa N, 2012, OPHTHAL SURG LAS IM, V43, P109, DOI 10.3928/15428877-20120102-06
   Tuncer I, 2015, INT OPHTHALMOL, V35, P403, DOI 10.1007/s10792-014-9962-4
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Vale TC, 2015, J NEUROL NEUROSUR PS, V86, P547, DOI 10.1136/jnnp-2014-307867
   Viola F, 2012, OPHTHALMOLOGY, V119, P369, DOI 10.1016/j.ophtha.2011.07.046
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wong WT, 2008, CURR OPIN OPHTHALMOL, V19, P213, DOI 10.1097/ICU.0b013e3282fb7c04
   Zeng Jing, 2012, Zhonghua Yan Ke Za Zhi, V48, P1093
NR 71
TC 8
Z9 8
U1 1
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD SEP-OCT
PY 2019
VL 33
IS 5
BP 1403
EP 1409
DI 10.21873/invivo.11617
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IV0ZV
UT WOS:000484008000002
PM 31471385
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Duncan, R
AF Duncan, Ruth
TI Polymer therapeutics as nanomedicines: new perspectives
SO CURRENT OPINION IN BIOTECHNOLOGY
LA English
DT Review
ID INHIBITOR; DELIVERY; HUMANS; TRIAL; SIRNA; RNAI
AB A growing number of polymer therapeutics have entered routine clinical use as nano-sized medicines. Early products were developed as anticancer agents, but treatments for a range of diseases and different routes of administration have followed - recently the PEGylated-anti-TNF Fab Cimzia (R) for rheumatoid arthritis and the PEG-aptamer Macugen (R) for age related macular degeneration. New polymer therapeutic concepts continue to emerge with a growing number of conjugates entering clinical development, for example PEGylated-aptamers and a polymer-based siRNA delivery system. 'Hot' topics of the past 2 years include; emerging issues relating to polymer safety, the increasing use of biodegradable polymers, design of technologies for combination therapy, potential biomarkers for patient individualisation of treatment and Regulatory challenges for 'follow-on/generic' polymer therapeutics.
C1 Ctr Invest Principe Felipe, Polymer Therapeut Lab, E-46012 Valencia, Spain.
C3 Prince Felipe Research Center
RP Duncan, R (通讯作者)，Ctr Invest Principe Felipe, Polymer Therapeut Lab, Av Autopista Saler 16, E-46012 Valencia, Spain.
EM profruthduncan@btinternet.com
CR Aghemo A, 2010, NAT REV GASTRO HEPAT, V7, P485, DOI 10.1038/nrgastro.2010.101
   Apostolovic B, 2010, BIOMACROMOLECULES, V11, P1187, DOI 10.1021/bm901313c
   AWADA A, 2010, 33 ANN CTRC AACR SAN
   BARZ M, 2011, POLYM CHEM, DOI DOI 10.1039/COPY00406E
   Besheer A, 2009, J PHARM SCI-US, V98, P4420, DOI 10.1002/jps.21675
   Blencowe CA, 2011, POLYM CHEM-UK, V2, P773, DOI 10.1039/c0py00324g
   BOULTON ME, 2009, INVEST OPHTHALMOL VI, V50
   Calderon M, 2010, ADV MATER, V22, P190, DOI 10.1002/adma.200902144
   Chipman SD, 2006, INT J NANOMED, V1, P375, DOI 10.2147/nano.2006.1.4.375
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Davis ME, 2009, ADV DRUG DELIVER REV, V61, P1189, DOI 10.1016/j.addr.2009.05.005
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   DEACON S, 2008, P 35 ANN M EXP CONTR
   Deacon SPE, 2011, BIOMACROMOLECULES, V12, P19, DOI 10.1021/bm100843e
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Dhal PK, 2009, ADV DRUG DELIVER REV, V61, P1121, DOI 10.1016/j.addr.2009.05.004
   DIPETRILLO T, 2011, AM J CLIN ONCOL-CANC, DOI DOI 10.1097/COC.0B013E318201A126
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   DUNCAN R, NANOMEDICINES MICROS
   Duncan R, 2008, BIOMACROMOLECULES, V9, P1146, DOI 10.1021/bm701073n
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Edinger D, 2011, WIRES NANOMED NANOBI, V3, P33, DOI 10.1002/wnan.97
   Fang J, 2010, EXP BIOL MED, V235, P487, DOI 10.1258/ebm.2009.009304
   Feldman EJ, 2011, J CLIN ONCOL, V29, P979, DOI 10.1200/JCO.2010.30.5961
   Ferenci P, 2011, EXPERT OPIN DRUG SAF, V10, P529, DOI 10.1517/14740338.2011.555079
   Ferguson EL, 2009, BIOMACROMOLECULES, V10, P1358, DOI 10.1021/bm8013022
   Floyd WC, 2011, J AM CHEM SOC, V133, P2390, DOI 10.1021/ja110582e
   Gaspar R, 2009, ADV DRUG DELIVER REV, V61, P1220, DOI 10.1016/j.addr.2009.06.003
   Greco F, 2009, ADV DRUG DELIVER REV, V61, P1203, DOI 10.1016/j.addr.2009.05.006
   Hardwicke J, 2010, BRIT J OPHTHALMOL, V94, P1566, DOI 10.1136/bjo.2009.177295
   Hardwicke J, 2010, MOL PHARMACEUT, V7, P699, DOI 10.1021/mp9002656
   Harmatz P, 2007, BRIT J HAEMATOL, V138, P374, DOI 10.1111/j.1365-2141.2007.06651.x
   Herth MM, 2010, BIOORG MED CHEM LETT, V20, P5454, DOI 10.1016/j.bmcl.2010.07.092
   Herth MM, 2009, BIOMACROMOLECULES, V10, P1697, DOI 10.1021/bm8014736
   Jakacki RI, 2011, NEUROLOGY, V76, P265, DOI 10.1212/WNL.0b013e318207b031
   Jaspers K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016159
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Lammers T, 2010, NANO TODAY, V5, P197, DOI 10.1016/j.nantod.2010.05.001
   Lammers T, 2009, BIOMATERIALS, V30, P3466, DOI 10.1016/j.biomaterials.2009.02.040
   Longmire M, 2008, CURR TOP MED CHEM, V8, P1180, DOI 10.2174/156802608785849021
   Matsumura Y, 2009, CANCER SCI, V100, P572, DOI 10.1111/j.1349-7006.2009.01103.x
   Melancon MP, 2011, MOL IMAGING, V10, P28, DOI 10.2310/7290.2011.00007
   Menjoge AR, 2011, J CONTROL RELEASE, V150, P326, DOI 10.1016/j.jconrel.2010.11.023
   Nowotnik DP, 2009, ADV DRUG DELIVER REV, V61, P1214, DOI 10.1016/j.addr.2009.06.004
   Rihova B, 2010, MOL PHARMACEUT, V7, P1027, DOI 10.1021/mp100121g
   Santamaria B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006634
   SAUSVILLE EA, 2010, J CLIN ONCOL S15, V28
   Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   Seymour LW, 2009, INT J ONCOL, V34, P1629, DOI 10.3892/ijo_00000293
   Stern L, 2009, BIOCONJUGATE CHEM, V20, P500, DOI 10.1021/bc800448u
   Thompson CB, 2010, MOL CANCER THER, V9, P3052, DOI 10.1158/1535-7163.MCT-10-0470
   Tiemann K, 2009, EMBO MOL MED, V1, P142, DOI 10.1002/emmm.200900023
   Van S, 2010, INT J NANOMED, V5, P825, DOI 10.2147/IJN.S13482
   VERGOTE IB, 2010, J CLIN ONCOL S7, V28
   Veronese FM, 2009, MILESTONES DRUG THER, P1, DOI 10.1007/978-3-7643-8679-5
   Vicent MJ, 2010, J CONTROL RELEASE, V142, P277, DOI 10.1016/j.jconrel.2009.10.026
   Vicent MJ, 2005, ANGEW CHEM INT EDIT, V44, P4061, DOI 10.1002/anie.200462960
   Webster R, 2009, MILESTONES DRUG THER, P127, DOI 10.1007/978-3-7643-8679-5_8
   Weinstain R, 2010, CHEM COMMUN, V46, P553, DOI 10.1039/b919329d
   Zhang Rongsheng, 2010, J Diabetes Sci Technol, V4, P532
NR 61
TC 183
Z9 193
U1 4
U2 156
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0958-1669
EI 1879-0429
J9 CURR OPIN BIOTECH
JI Curr. Opin. Biotechnol.
PD AUG
PY 2011
VL 22
IS 4
BP 492
EP 501
DI 10.1016/j.copbio.2011.05.507
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 815LD
UT WOS:000294526200004
PM 21676609
DA 2022-11-30
ER

PT J
AU Ji, YG
   Shi, HF
AF Ji, Yonggang
   Shi, Haifang
TI Bayesian variable selection in linear quantile mixed models for
   longitudinal data with application to macular degeneration
SO PLOS ONE
LA English
DT Article
ID REGRESSION-MODEL
AB This paper presents a Bayesian analysis of linear mixed models for quantile regression based on a Cholesky decomposition for the covariance matrix of random effects. We develop a Bayesian shrinkage approach to quantile mixed regression models using a Bayesian adaptive lasso and an extended Bayesian adaptive group lasso. We also consider variable selection procedures for both fixed and random effects in a linear quantile mixed model via the Bayesian adaptive lasso and extended Bayesian adaptive group lasso with spike and slab priors. To improve mixing of the Markov chains, a simple and efficient partially collapsed Gibbs sampling algorithm is developed for posterior inference. Simulation experiments and an application to the Age-Related Macular Degeneration Trial data to demonstrate the proposed methods.
C1 [Ji, Yonggang; Shi, Haifang] Civil Aviat Univ China, Sch Sci, Tianjin, Peoples R China.
C3 Civil Aviation University of China
RP Shi, HF (通讯作者)，Civil Aviat Univ China, Sch Sci, Tianjin, Peoples R China.
EM hfshi@cauc.edu.cn
OI Ji, YongGang/0000-0002-5912-8231; Shi, Haifang/0000-0001-9486-9572
FU Fundamental Research Funds for the Central Universities [3122014K013]
FX The second author was supported by the Fundamental Research Funds for
   the Central Universities (Grant No.3122014K013).
CR Aghamohammadi A, 2017, STAT PAP, V58, P1035, DOI 10.1007/s00362-015-0737-4
   Alhamzawi R, 2014, J STAT COMPUT SIM, V84, P868, DOI 10.1080/00949655.2012.731689
   Alhamzawi R, 2012, STAT MODEL, V12, P279, DOI 10.1177/1471082X1101200304
   Alshaybawee T, 2017, J APPL STAT, V44, P853, DOI 10.1080/02664763.2016.1189515
   Armagan A, 2013, STAT SINICA, V23, P119, DOI 10.5705/ss.2011.048
   Barbieri MM, 2004, ANN STAT, V32, P870, DOI 10.1214/009053604000000238
   Bondell HD, 2010, BIOMETRICS, V66, P1069, DOI 10.1111/j.1541-0420.2010.01391.x
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Canay IA, 2011, ECONOMET J, V14, P368, DOI 10.1111/j.1368-423X.2011.00349.x
   Carvalho CM, 2010, BIOMETRIKA, V97, P465, DOI 10.1093/biomet/asq017
   Chen Z, 2003, BIOMETRICS, V59, P762, DOI 10.1111/j.0006-341X.2003.00089.x
   Chernozhukov V, 2013, ECONOMETRICA, V81, P535, DOI 10.3982/ECTA8405
   Galarza CE, 2017, STAT INTERFACE, V10, P471, DOI 10.4310/SII.2017.v10.n3.a10
   Galecki A, 2013, SPRINGER TEXTS STAT, P1, DOI 10.1007/978-1-4614-3900-4
   Geraci M, 2007, BIOSTATISTICS, V8, P140, DOI 10.1093/biostatistics/kxj039
   Geraci M, 2014, STAT COMPUT, V24, P461, DOI 10.1007/s11222-013-9381-9
   Graham BS, 2018, J ECONOMETRICS, V206, P305, DOI 10.1016/j.jeconom.2018.06.004
   Griffin JE, 2010, BAYESIAN ANAL, V5, P171, DOI 10.1214/10-BA507
   Harding M, 2014, J ECONOMETRICS, V178, P101, DOI 10.1016/j.jeconom.2013.08.010
   Harding M, 2009, ECON LETT, V104, P133, DOI 10.1016/j.econlet.2009.04.025
   Ibrahim JG, 2011, BIOMETRICS, V67, P495, DOI 10.1111/j.1541-0420.2010.01463.x
   Ji YG, 2012, COMPUT STAT DATA AN, V56, P827, DOI 10.1016/j.csda.2011.10.003
   Kinney SK, 2007, BIOMETRICS, V63, P690, DOI 10.1111/j.1541-0420.2007.00771.x
   Kobayashi G, 2017, BAYESIAN ANAL, V12, P161, DOI 10.1214/16-BA996
   Koenker R, 2004, J MULTIVARIATE ANAL, V91, P74, DOI 10.1016/j.jmva.2004.05.006
   Kozumi H, 2011, J STAT COMPUT SIM, V81, P1565, DOI 10.1080/00949655.2010.496117
   Li Q, 2010, BAYESIAN ANAL, V5, P533, DOI 10.1214/10-BA521
   Li Q, 2010, BAYESIAN ANAL, V5, P151, DOI 10.1214/10-BA506
   LIU JS, 1994, BIOMETRIKA, V81, P27, DOI 10.1093/biomet/81.1.27
   Lu Y., 2015, J MACH LEARN RES, V44, P277
   Peng H, 2012, J MULTIVARIATE ANAL, V109, P109, DOI 10.1016/j.jmva.2012.02.005
   Seber G.A.F., 1977, LINEAR REGRESSION AN
   Sriram K, 2016, J R STAT SOC A STAT, V179, P177, DOI 10.1111/rssa.12111
   van der Pas S, 2017, ELECTRON J STAT, V11, P3196, DOI 10.1214/17-EJS1316
   van Dyk DA, 2008, J AM STAT ASSOC, V103, P790, DOI 10.1198/016214508000000409
   Yan Y, 2017, WORKING PAPER
   Yu KM, 2005, COMMUN STAT-THEOR M, V34, P1867, DOI 10.1080/03610920500199018
   Yu KM, 2001, STAT PROBABIL LETT, V54, P437, DOI 10.1016/S0167-7152(01)00124-9
NR 38
TC 0
Z9 0
U1 3
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 26
PY 2020
VL 15
IS 10
AR e0241197
DI 10.1371/journal.pone.0241197
PG 34
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA OP8VY
UT WOS:000588370000048
PM 33104698
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, K
   Han, ZC
AF Wang, Kai
   Han, Zongchao
TI Injectable hydrogels for ophthalmic applications
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Injectable hydrogels; Ophthalmology; Drug delivery system; Regenerative
   medicine
ID PLURIPOTENT STEM-CELLS; OCULAR DRUG-DELIVERY; HYALURONIC-ACID; CHITOSAN
   HYDROGELS; VISUAL IMPAIRMENT; GLAUCOMA THERAPY; EXTENDED-RELEASE;
   INTRAOCULAR-LENS; PEG HYDROGEL; IN-VITRO
AB The demand for effective eye therapies is driving the development of injectable hydrogels as new medical devices for controlled delivery and filling purposes. This article introduces the properties of injectable hydrogels and summarizes their versatile application in the treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, and intraocular cancers. A number of injectable hydrogels are approved by FDA as surgery sealants, tissue adhesives, and are now being investigated as a vitreous humor substitute. Research on hydrogels for drug, factor, nanoparticle, and stem cell delivery is still under pre-clinical investigation or in clinical trials. Although substantial progress has been achieved using injectable hydrogels, some challenging issues must still be overcome before they can be effectively used in medical practice.
C1 [Wang, Kai; Han, Zongchao] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Carolina Inst Nano Med, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Han, ZC (通讯作者)，Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
EM zongchao@med.unc.edu
RI Wang, Kai/AAE-4566-2021; Wang, Kai/GQI-1260-2022
OI Wang, Kai/0000-0002-4419-9598; Wang, Kai/0000-0002-4419-9598; Han,
   Zongchao/0000-0002-2019-395X
FU U.S. National Eye Institute [R21EY024059, R01EY026564]; Carolina Center
   of Nanotechnology Excellence; UNC Junior Faculty Development Award; NC
   TraCS Translational Research Grant [550KR151611]; NATIONAL EYE INSTITUTE
   [R21EY024059, R01EY026564] Funding Source: NIH RePORTER
FX This work was supported in part by the U.S. National Eye Institute
   (R21EY024059 & R01EY026564, Z.H.), the Carolina Center of Nanotechnology
   Excellence (Z.H.), the UNC Junior Faculty Development Award (Z.H.), and
   the NC TraCS Translational Research Grant (550KR151611, Z.H.). The
   authors thank Cassandra Janowski Barnhart, M.P.H. (Department of
   Ophthalmology, University of North Carolina at Chapel Hill) for her
   critical reading of the manuscript. The authors declare no conflicts of
   interest.
CR Aliyar HA, 2005, BIOMACROMOLECULES, V6, P204, DOI 10.1021/bm049574c
   Annabi N, 2014, ADV MATER, V26, P85, DOI 10.1002/adma.201303233
   Annaka M, 2011, BIOMACROMOLECULES, V12, P4011, DOI 10.1021/bm201012f
   Anumolu SS, 2010, BIOMATERIALS, V31, P964, DOI 10.1016/j.biomaterials.2009.10.010
   Balasubramaniam J, 2003, DRUG DELIV, V10, P185, DOI 10.1080/713840402
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Basuki JS, 2017, ANGEW CHEM INT EDIT, V56, P966, DOI 10.1002/anie.201610618
   Bennett J, 2016, LANCET, V388, P661, DOI 10.1016/S0140-6736(16)30371-3
   Bhattarai N, 2005, J CONTROL RELEASE, V103, P609, DOI 10.1016/j.jconrel.2004.12.019
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Burdick JA, 2006, BIOMATERIALS, V27, P452, DOI 10.1016/j.biomaterials.2005.06.034
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Canola K, 2007, INVEST OPHTH VIS SCI, V48, P446, DOI 10.1167/iovs.06-0190
   Cao YX, 2007, J CONTROL RELEASE, V120, P186, DOI 10.1016/j.jconrel.2007.05.009
   Caprioli J, 2010, AM J OPHTHALMOL, V149, P704, DOI 10.1016/j.ajo.2010.01.018
   Chang J, 2014, POLYMER, V55, P4627, DOI 10.1016/j.polymer.2014.07.031
   Chien Y, 2012, BIOMATERIALS, V33, P8003, DOI 10.1016/j.biomaterials.2012.07.029
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Groot JH, 2001, BIOMACROMOLECULES, V2, P628, DOI 10.1021/bm005622r
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Eljarrat-Binstock E, 2008, J CONTROL RELEASE, V126, P156, DOI 10.1016/j.jconrel.2007.11.016
   Fathi M, 2015, BIOIMPACTS, V5, P159, DOI 10.15171/bi.2015.31
   Feng SF, 2013, SCI REP-UK, V3, DOI 10.1038/srep01838
   Fernandez MM, 2008, CURR OPIN OPHTHALMOL, V19, P66, DOI 10.1097/ICU.0b013e3282f2d7b6
   Fitzpatrick SD, 2012, ACTA BIOMATER, V8, P2517, DOI 10.1016/j.actbio.2012.03.018
   Fitzpatrick SD, 2010, BIOMACROMOLECULES, V11, P2261, DOI 10.1021/bm100299j
   Francis BA, 2011, OPHTHALMOLOGY, V118, P1466, DOI 10.1016/j.ophtha.2011.03.028
   Garagorri N, 2008, ACTA BIOMATER, V4, P1139, DOI 10.1016/j.actbio.2008.05.007
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Han ZC, 2015, FASEB J, V29, P2535, DOI 10.1096/fj.15-270363
   Hao XJ, 2012, BIOMATERIALS, V33, P5659, DOI 10.1016/j.biomaterials.2012.04.052
   Hayashi K, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0044
   Hertz J, 2013, ACTA BIOMATER, V9, P7622, DOI 10.1016/j.actbio.2013.04.048
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hoffman AS, 2012, ADV DRUG DELIVER REV, V64, P18, DOI 10.1016/j.addr.2012.09.010
   Hsiao MH, 2014, ACTA BIOMATER, V10, P3188, DOI 10.1016/j.actbio.2014.03.016
   Hsiue GH, 2002, BIOMATERIALS, V23, P457, DOI 10.1016/S0142-9612(01)00127-2
   Hutten M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104564
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jancevski M, 2010, CURR OPIN OPHTHALMOL, V21, P10, DOI 10.1097/ICU.0b013e328332f575
   Jung HJ, 2013, J CONTROL RELEASE, V165, P82, DOI 10.1016/j.jconrel.2012.10.010
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Khan S, 2016, CURR OPIN ORGAN TRAN, V21, P484, DOI 10.1097/MOT.0000000000000348
   Kholdebarin R, 2008, CAN J OPHTHALMOL, V43, P454, DOI [10.3129/i08-076, 10.1139/i08-076]
   Kirchhof S, 2015, EUR J PHARM BIOPHARM, V95, P227, DOI 10.1016/j.ejpb.2015.05.016
   Klassen H, 2008, NAT BIOTECHNOL, V26, P187, DOI 10.1038/nbt0208-187
   Kleinberg TT, 2011, SURV OPHTHALMOL, V56, P300, DOI 10.1016/j.survophthal.2010.09.001
   Kwon JW, 2005, J CATARACT REFR SURG, V31, P607, DOI 10.1016/j.jcrs.2004.05.051
   Lai JY, 2012, BIOMATERIALS, V33, P2372, DOI 10.1016/j.biomaterials.2011.11.085
   Lai JY, 2010, J MATER SCI-MATER M, V21, P1899, DOI 10.1007/s10856-010-4035-3
   Lajavardi L, 2009, J CONTROL RELEASE, V139, P22, DOI 10.1016/j.jconrel.2009.05.033
   Li YL, 2012, CHEM SOC REV, V41, P2193, DOI 10.1039/c1cs15203c
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Liu YJ, 2010, AAPS PHARMSCITECH, V11, P610, DOI 10.1208/s12249-010-9413-0
   Maia J, 2009, ACTA BIOMATER, V5, P1948, DOI 10.1016/j.actbio.2009.02.008
   Marigo V., 2014, PHOTORECEPTOR TRANSP, P309
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mawad D, 2012, CURR PHARM DESIGN, V18, P2558, DOI 10.2174/138161212800492895
   Mazumder MAJ, 2012, J BIOMED MATER RES A, V100A, P1877, DOI 10.1002/jbm.a.34021
   Mead B, 2015, STEM CELL RES, V14, P243, DOI 10.1016/j.scr.2015.02.003
   Nguyen MK, 2014, PROG POLYM SCI, V39, P1235, DOI 10.1016/j.progpolymsci.2013.12.001
   Misra GR, 2011, AAPS ADV PHARM SCI, V2, P291, DOI 10.1007/978-1-4419-9920-7_12
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Mitra RN, 2016, WIRES NANOMED NANOBI, V8, P160, DOI 10.1002/wnan.1356
   Muzzarelli RAA, 2009, CARBOHYD POLYM, V77, P1, DOI 10.1016/j.carbpol.2009.01.016
   Norouzi M, 2016, DRUG DISCOV TODAY, V21, P1835, DOI 10.1016/j.drudis.2016.07.006
   Overstreet DJ, 2012, J POLYM SCI POL PHYS, V50, P881, DOI 10.1002/polb.23081
   Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peak CW, 2013, COLLOID POLYM SCI, V291, P2031, DOI 10.1007/s00396-013-3021-y
   Peng HT, 2010, EXPERT REV MED DEVIC, V7, P639, DOI [10.1586/erd.10.40, 10.1586/ERD.10.40]
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Gomes JAP, 2010, INVEST OPHTH VIS SCI, V51, P1408, DOI 10.1167/iovs.09-4029
   Pratoomsoot C, 2008, BIOMATERIALS, V29, P272, DOI 10.1016/j.biomaterials.2007.09.031
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Sagoo MS, 2015, FUTURE ONCOL, V11, P2641, DOI 10.2217/fon.15.212
   Sakiyama-Elbert SE, 2014, ACTA BIOMATER, V10, P1581, DOI 10.1016/j.actbio.2013.08.045
   Schramm C, 2012, INVEST OPHTH VIS SCI, V53, P613, DOI 10.1167/iovs.11-7322
   Seif-Naraghi SB, 2012, ACTA BIOMATER, V8, P3695, DOI 10.1016/j.actbio.2012.06.030
   Shibata H, 2010, P NATL ACAD SCI USA, V107, P17894, DOI 10.1073/pnas.1006911107
   Spierer O, 2015, J CATARACT REFR SURG, V41, P492, DOI 10.1016/j.jcrs.2015.02.002
   Strappe PM, 2005, EUR J PHARM BIOPHARM, V61, P126, DOI 10.1016/j.ejpb.2005.06.006
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sultana Y, 2006, DRUG DELIV, V13, P215, DOI 10.1080/10717540500309164
   Tan HP, 2009, BIOMATERIALS, V30, P2499, DOI 10.1016/j.biomaterials.2008.12.080
   Tao Y, 2013, ACTA BIOMATER, V9, P5022, DOI 10.1016/j.actbio.2012.09.026
   Trese M, 2012, MATERIALS, V5, P108, DOI 10.3390/ma5010108
   Turaka K, 2012, PEDIATR BLOOD CANCER, V59, P121, DOI 10.1002/pbc.23278
   Ulijn RV, 2007, MATER TODAY, V10, P40, DOI 10.1016/S1369-7021(07)70049-4
   Van Vlierberghe S, 2011, BIOMACROMOLECULES, V12, P1387, DOI 10.1021/bm200083n
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang K, 2016, ACTA BIOMATER, V36, P143, DOI 10.1016/j.actbio.2016.03.016
   Wang K, 2015, MATER TECHNOL, V30, pB198, DOI 10.1179/17535557B15Y.000000008
   Wang K, 2015, J BIOMED MATER RES A, V103, P2839, DOI 10.1002/jbm.a.35430
   Wang YF, 2012, BIOMATERIALS, V33, P2681, DOI 10.1016/j.biomaterials.2011.12.031
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wollensak G, 2003, AM J OPHTHALMOL, V135, P620, DOI 10.1016/S0002-9394(02)02220-1
   Xinming Li, 2008, Cont Lens Anterior Eye, V31, P57, DOI 10.1016/j.clae.2007.09.002
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yang JA, 2014, PROG POLYM SCI, V39, P1973, DOI 10.1016/j.progpolymsci.2014.07.006
   Yang LQ, 2010, ACTA PHARMACOL SIN, V31, P1625, DOI 10.1038/aps.2010.125
   Yin HB, 2010, J BIOMED MATER RES B, V92B, P129, DOI 10.1002/jbm.b.31498
   Yoo MK, 2005, DRUG DEV IND PHARM, V31, P455, DOI 10.1080/03639040500214688
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zarembinski TI, 2014, ACTA BIOMATER, V10, P94, DOI 10.1016/j.actbio.2013.09.029
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zheng M, 2016, FASEB J, V30, P1076, DOI 10.1096/fj.15-280511
NR 117
TC 57
Z9 58
U1 8
U2 167
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 28
PY 2017
VL 268
BP 212
EP 224
DI 10.1016/j.jconrel.2017.10.031
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA FP0WT
UT WOS:000417329800020
PM 29061512
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Stahl, A
   Paschek, L
   Martin, G
   Gross, NJ
   Feltgen, N
   Hansen, LL
   Agostini, HT
AF Stahl, A.
   Paschek, L.
   Martin, G.
   Gross, N. J.
   Feltgen, N.
   Hansen, L. L.
   Agostini, H. T.
TI Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE)
   and inhibits RPE-induced sprouting angiogenesis in vitro
SO FEBS LETTERS
LA English
DT Article
DE angiogenesis; spheroid; RPE; endothelial; CNV; rapamycin
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULAR MEMBRANES;
   SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN;
   SECRETION; RESISTANT; SIROLIMUS; PATHWAYS
AB Anti-VEGF treatment has become accepted first-line treatment for choroidal neovascularisation (CNV) in age-related macular degeneration. However, VEGF-inhibition does not always lead to sustained CNV-reduction. In this study, the effect of rapamycin was superior to VEGF-inhibition in a co-culture assay of endothelial cells (ECs) and retinal pigment epithelium (RPE). Rapamycin reduced EC sprouting in groups that did not respond to anti-VEGF treatment. Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation. Rapamycin might therefore be a therapeutic option for CNV patients that do not respond sufficiently to the established anti-VEGF treatments. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
C1 [Stahl, A.; Paschek, L.; Martin, G.; Gross, N. J.; Feltgen, N.; Hansen, L. L.; Agostini, H. T.] Univ Eye Hosp Freiburg, Cell Biol Lab, D-79106 Freiburg, Germany.
C3 University of Freiburg
RP Agostini, HT (通讯作者)，Univ Eye Hosp Freiburg, Cell Biol Lab, Killianstr 5, D-79106 Freiburg, Germany.
EM hansjuergen.agostini@uniklinik-freiburg.de
RI Hansen, Lutz L/A-1390-2011
FU the Forschungskommission Freiburg
FX The authors wish to thank Beatrix Flugel and Annegret Mattes for
   excellent technical support. Confocal imaging was supported by the
   Deutsche Forschungsgemeinschaft (HA1582/21) to Georg Kochs and Otto
   Haller, Department of Virology, University of Freiburg. This work was
   funded by the Forschungskommission Freiburg ( A. S.).
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   AVERY RL, 2006, OPHTHALMOLOGY, V113
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Blumenkranz MS, 2008, ARVO
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DAMICO DJ, 2006, OPHTHALMOLOGY, V113
   Dejneka NS, 2004, MOL VIS, V10, P964
   Dichtl W, 2006, ATHEROSCLEROSIS, V186, P321, DOI 10.1016/j.atherosclerosis.2005.08.016
   Dugel DU, 2008, ARVO
   Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kochiadakis GE, 2008, EUR HEART J, V29, P733, DOI 10.1093/eurheartj/ehn060
   Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341
   Korff T, 1999, J CELL SCI, V112, P3249
   Kwon YS, 2006, EXP MOL MED, V38, P173, DOI 10.1038/emm.2006.21
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   MORENOPARAMO D, 2008, ARVO
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROMOGARCIA E, 2008, ARVO
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosenthal R, 2003, ADV EXP MED BIOL, V533, P107
   Rosenthal R, 2007, MOL VIS, V13, P443
   Salmon JH, 2008, ARVO
   Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813
   Schlunck G, 2002, EXP EYE RES, V74, P571, DOI 10.1006/exer.2001.1148
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Shi WY, 2006, INVEST OPHTH VIS SCI, V47, P3339, DOI 10.1167/iovs.05-1425
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stahl A, 2005, FEBS LETT, V579, P5338, DOI 10.1016/j.febslet.2005.09.005
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 42
TC 61
Z9 62
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD SEP 3
PY 2008
VL 582
IS 20
BP 3097
EP 3102
DI 10.1016/j.febslet.2008.08.005
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 347EL
UT WOS:000259123300021
PM 18703055
OA Bronze
DA 2022-11-30
ER

PT J
AU Elmasry, K
   Ibrahim, AS
   Abdulmoneim, S
   Al-Shabrawey, M
AF Elmasry, Khaled
   Ibrahim, Ahmed S.
   Abdulmoneim, Samer
   Al-Shabrawey, Mohamed
TI Bioactive lipids and pathological retinal angiogenesis
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; DIABETIC MACULAR
   EDEMA; POLYUNSATURATED FATTY-ACIDS; OXYGEN-INDUCED RETINOPATHY;
   HIGH-DOSE SUPPLEMENTATION; MULLER GLIAL-CELLS; ADULT HUMAN RETINA;
   CHOROIDAL NEOVASCULARIZATION; MICROVASCULAR DYSFUNCTION
AB Angiogenesis, disruption of the retinal barrier, leukocyte-adhesion and oedema are cardinal signs of proliferative retinopathies that are associated with vision loss. Therefore, identifying factors that regulate these vascular dysfunctions is critical to target pathological angiogenesis. Given the conflicting role of bioactive lipids reported in the current literature, the goal of this review is to provide the reader a clear road map of what has been accomplished so far in the field with specific focus on the role of polyunsaturated fatty acids (PUFAs)-derived metabolites in proliferative retinopathies. This necessarily entails a description of the different retina cells, blood retina barriers and the role of (PUFAs)-derived metabolites in diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration as the most common types of proliferative retinopathies.
C1 [Elmasry, Khaled; Ibrahim, Ahmed S.; Abdulmoneim, Samer; Al-Shabrawey, Mohamed] Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA.
   [Elmasry, Khaled; Abdulmoneim, Samer; Al-Shabrawey, Mohamed] Augusta Univ, Cellular Biol & Anat, MCG, Augusta, GA 30912 USA.
   [Elmasry, Khaled; Al-Shabrawey, Mohamed] Mansoura Univ, Dept Anat, Fac Med, Mansoura, Egypt.
   [Ibrahim, Ahmed S.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura, Egypt.
   [Ibrahim, Ahmed S.; Al-Shabrawey, Mohamed] Augusta Univ, MCG, Dept Ophthalmol, Augusta, GA 30912 USA.
   [Ibrahim, Ahmed S.; Al-Shabrawey, Mohamed] Augusta Univ, MCG, Culver Vis Discovery Inst, Augusta, GA 30912 USA.
   [Elmasry, Khaled] Harvard Med Sch, Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA USA.
   [Elmasry, Khaled] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Egyptian Knowledge Bank (EKB); Mansoura
   University; Egyptian Knowledge Bank (EKB); Mansoura University;
   University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Schepens Eye Research Institute;
   Harvard University; Harvard Medical School
RP Al-Shabrawey, M (通讯作者)，Augusta Univ, Anat Coll Georgia, 1120 15th St,CB2602, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Dent Coll Georgia, 1120 15th St,CB2602, Augusta, GA 30912 USA.; Al-Shabrawey, M (通讯作者)，Augusta Univ, Med Coll Georgia, 1120 15th St,CB2602, Augusta, GA 30912 USA.
EM malshabrawey@augusta.edu
RI ibrahim, ahmed/D-5241-2017
OI ibrahim, ahmed/0000-0001-8480-6252; Al-Shabrawey,
   Mohamed/0000-0001-5362-7972
FU National Eye Institute [R01EY023315]; American Heart Association
   [18CDA34080403]; NATIONAL EYE INSTITUTE [R01EY023315] Funding Source:
   NIH RePORTER
FX This work has been supported by the National Eye Institute grant
   R01EY023315 (MA) and the American Heart Association grant 18CDA34080403
   (ASI).
CR Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS1, DOI 10.1111/bph.13882
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13877, 10.1111/bph.13882]
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Anderson Christina G, 2004, J Perinatol, V24, P164, DOI 10.1038/sj.jp.7211067
   ANDERSON DH, 1976, J ULTRA MOL STRUCT R, V55, P119, DOI 10.1016/S0022-5320(76)80087-1
   Arroba AI, 2017, ACTA DIABETOL, V54, P527, DOI 10.1007/s00592-017-0984-z
   ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P397, DOI 10.1136/bjo.38.7.397
   Attachoo Anchalee, 2014, Journal of the Medical Association of Thailand, V97, pS26
   Augustin AJ, 1997, BRIT J OPHTHALMOL, V81, P58, DOI 10.1136/bjo.81.1.58
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x
   BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3
   Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241
   Bleich D, 1998, INT J MOL MED, V1, P265
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler SB, 2013, JAMA OPHTHALMOL, V131, P1033, DOI 10.1001/jamaophthalmol.2013.4154
   Brzezinski JA, 2015, DEVELOPMENT, V142, P3263, DOI 10.1242/dev.127043
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Callanan DG, 2013, OPHTHALMOLOGY, V120, P1843, DOI 10.1016/j.ophtha.2013.02.018
   Campbell Matthew, 2012, Adv Exp Med Biol, V763, P70
   Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Capozzi ME, 2014, INVEST OPHTH VIS SCI, V55, P4253, DOI 10.1167/iovs.14-14216
   Capra V, 2013, MED RES REV, V33, P364, DOI 10.1002/med.21251
   Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735
   Caughey GE, 2001, J IMMUNOL, V167, P2831, DOI 10.4049/jimmunol.167.5.2831
   Caughey GE, 2001, J BIOL CHEM, V276, P37839
   Chattopadhyay R, 2015, J LIPID RES, V56, P562, DOI 10.1194/jlr.M055566
   Chattopadhyay R, 2014, J BIOL CHEM, V289, P3148, DOI 10.1074/jbc.M113.528190
   Chen M, 2005, DIABETOLOGIA, V48, P486, DOI 10.1007/s00125-005-1673-y
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   CHEN XS, 1994, J BIOL CHEM, V269, P13979
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chow LC, 2003, PEDIATRICS, V111, P339, DOI 10.1542/peds.111.2.339
   Claar D, 2015, EXPERT REV RESP MED, V9, P55, DOI 10.1586/17476348.2015.992783
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Dai M, 2012, J CELL PHYSIOL, V227, P596, DOI 10.1002/jcp.22762
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Diabetes C, 2015, DIABETES, V64, P631, DOI DOI 10.2337/DB14-0930
   Dobrian AD, 2011, PROG LIPID RES, V50, P115, DOI 10.1016/j.plipres.2010.10.005
   Dreyfuss JL, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/892043
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   El Kebir D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00060
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Elmasry K, 2018, DIABETOLOGIA, V61, P1220, DOI 10.1007/s00125-018-4560-z
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Ereso AQ, 2009, J SURG RES, V156, P183, DOI 10.1016/j.jss.2009.01.009
   Escartin C, 2007, J NEUROSCI, V27, P7094, DOI 10.1523/JNEUROSCI.0174-07.2007
   Evans JR, 2014, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD011234
   Faulkner J, 2015, J DIABETES METAB, V6, DOI 10.4172/2155-6156.1000555
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Filippi L, 2013, J PEDIATR-US, V163, P1570, DOI 10.1016/j.jpeds.2013.07.049
   Freire MO, 2013, PERIODONTOL 2000, V63, P149, DOI 10.1111/prd.12034
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gillies MC, 2011, OPHTHALMOLOGY, V118, P866, DOI 10.1016/j.ophtha.2010.09.029
   GORDON WC, 1990, J NEUROSCI, V10, P2190
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Goswami Shyamal K, 2013, Subcell Biochem, V61, P527, DOI 10.1007/978-94-007-4525-4_23
   Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1087
   Harada C, 2003, NEUROSCIENCE, V122, P229, DOI 10.1016/S0306-4522(03)00599-2
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hauck SM, 2006, MOL CELL BIOL, V26, P2746, DOI 10.1128/MCB.26.7.2746-2757.2006
   Heckmann M, 2008, OPHTHALMOLOGE, V105, P1101, DOI 10.1007/s00347-008-1789-9
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hosoya Ken-ichi, 2012, Adv Exp Med Biol, V763, P85
   Hu J, 2014, J EXP MED, V211, P281, DOI 10.1084/jem.20131494
   Huang H, 2016, PROSTAG OTH LIPID M, V122, P45, DOI 10.1016/j.prostaglandins.2015.12.007
   Ibrahim AS, 2017, BBA-MOL CELL BIOL L, V1862, P636, DOI 10.1016/j.bbalip.2017.03.010
   Ibrahim AS, 2015, J LIPID RES, V56, P599, DOI 10.1194/jlr.M056069
   Ibrahim AS, 2015, BBA-MOL CELL BIOL L, V1851, P290, DOI 10.1016/j.bbalip.2014.12.017
   Ibrahim AS, 2011, DIABETES, V60, P1122, DOI 10.2337/db10-1160
   Issan Y, 2013, PROSTAG OTH LIPID M, V100, P15, DOI 10.1016/j.prostaglandins.2012.12.002
   Iwase T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174427
   JIANG B, 1994, J CELL SCI, V107, P2499
   Jin YP, 2009, INVEST OPHTH VIS SCI, V50, P4743, DOI 10.1167/iovs.08-2462
   Kang SW, 2006, ARCH OPHTHALMOL-CHIC, V124, P653, DOI 10.1001/archopht.124.5.653
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Kenyon V, 2011, J MED CHEM, V54, P5485, DOI 10.1021/jm2005089
   Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318
   Kim GH, 2013, ANTIOXID REDOX SIGN, V18, P1920, DOI 10.1089/ars.2012.4926
   Kinzig A, 1999, GENOMICS, V58, P158, DOI 10.1006/geno.1999.5816
   Kolb H., 1995, WEBVISION ORG RETINA
   Konkel A, 2011, BBA-PROTEINS PROTEOM, V1814, P210, DOI 10.1016/j.bbapap.2010.09.009
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2
   KUHN H, 1990, EUR J BIOCHEM, V191, P221, DOI 10.1111/j.1432-1033.1990.tb19113.x
   KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273
   Kuhn H, 2015, BBA-MOL CELL BIOL L, V1851, P308, DOI 10.1016/j.bbalip.2014.10.002
   Kundumani-Sridharan V, 2013, J BIOL CHEM, V288, P15830, DOI 10.1074/jbc.M113.453290
   Lam DSC, 2007, OPHTHALMOLOGY, V114, P2162, DOI 10.1016/j.ophtha.2007.02.006
   Lan YL, 2017, CURR PHARM DESIGN, V23, P4948, DOI 10.2174/1381612823666170714144844
   Laybutt DR, 2002, J BIOL CHEM, V277, P10912, DOI 10.1074/jbc.M111751200
   Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Lee Soo Jeong, 2011, Korean J Ophthalmol, V25, P299, DOI 10.3341/kjo.2011.25.5.299
   Li Z, 2016, CURR MOL MED, V16, P553, DOI 10.2174/1566524016666160607090538
   Ma YH, 2011, J NEUROSCI RES, V89, P969, DOI 10.1002/jnr.22628
   Malamas A, 2017, INT J OPHTHALMOL-CHI, V10, P300, DOI 10.18240/ijo.2017.02.19
   Meruvu S, 2005, J BIOL CHEM, V280, P36633, DOI 10.1074/jbc.M508260200
   Meyer-Kirchrath J, 2004, BIOCHEM PHARMACOL, V67, P757, DOI 10.1016/j.bcp.2003.07.022
   Michaelis UR, 2008, INVEST OPHTH VIS SCI, V49, P1242, DOI 10.1167/iovs.07-1087
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Miranda GE, 2011, INVEST OPHTH VIS SCI, V52, P6580, DOI 10.1167/iovs.10-7065
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Morgan AH, 2015, REDOX BIOL, V4, P40, DOI 10.1016/j.redox.2014.11.005
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nunemaker CS, 2008, AM J PHYSIOL-ENDOC M, V295, pE1065, DOI 10.1152/ajpendo.90371.2008
   Ohira T, 2010, J BIOL CHEM, V285, P3451, DOI 10.1074/jbc.M109.044131
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   PATZ A, 1953, AM J OPHTHALMOL, V36, P1511, DOI 10.1016/0002-9394(53)91779-6
   Pearson PA, 2011, OPHTHALMOLOGY, V118, P1580, DOI 10.1016/j.ophtha.2011.02.048
   Politi LE, 2001, INVEST OPHTH VIS SCI, V42, P3008
   Radmark O, 2015, BBA-MOL CELL BIOL L, V1851, P331, DOI 10.1016/j.bbalip.2014.08.012
   Rai G, 2010, J MED CHEM, V53, P7392, DOI 10.1021/jm1008852
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   RICCI B, 1990, DOC OPHTHALMOL, V74, P171, DOI 10.1007/BF02482606
   Rickert KW, 1999, BIOCHEMISTRY-US, V38, P12218, DOI 10.1021/bi990834y
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Ryan AD, 2010, CURR OPIN PHARMACOL, V10, P166, DOI 10.1016/j.coph.2010.02.005
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   Sala A, 2010, PHARMACOL REP, V62, P503, DOI 10.1016/S1734-1140(10)70306-6
   Sales KJ, 2008, MOL CELL ENDOCRINOL, V285, P51, DOI 10.1016/j.mce.2008.01.016
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389
   SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X
   Sears DD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007250
   Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004
   Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shen JH, 2016, DISCOV MED, V22, P129
   Shin Eui Seok, 2014, J Ophthalmic Vis Res, V9, P362, DOI 10.4103/2008-322X.143378
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Spite Matthew, 2014, Cell Metab, V19, P21, DOI 10.1016/j.cmet.2013.10.006
   Stahl A, 2018, OPHTHALMOLOGE, V115, P456, DOI 10.1007/s00347-018-0720-2
   Su YX, 2018, PHOTODIAGN PHOTODYN, V22, P263, DOI 10.1016/j.pdpdt.2018.05.002
   Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055
   Suzuki M, 2007, MOL VIS, V13, P772
   Suzuki M, 2012, EUR J OPHTHALMOL, V22, P495, DOI 10.5301/ejo.5000032
   TERRY TL, 1946, J PEDIATR, V29, P770, DOI 10.1016/S0022-3476(46)80009-X
   Tikhonenko M, 2010, DIABETES, V59, P219, DOI 10.2337/db09-0728
   Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106
   Tin Win, 2002, Semin Neonatol, V7, P361, DOI 10.1053/siny.2002.0130
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Unterlauft JD, 2012, NEUROCHEM RES, V37, P1524, DOI 10.1007/s11064-012-0747-8
   van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500
   Vaziri Kamyar, 2015, Rev Diabet Stud, V12, P196, DOI 10.1900/RDS.2015.12.196
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   VENTRESCA MR, 1990, CAN J OPHTHALMOL, V25, P186
   Villegas-Becerril E., 2006, Arch Soc Esp Oftalmol, V81, P641
   Wallace JL, 2019, BRIT J PHARMACOL, V176, P1000, DOI 10.1111/bph.14178
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
   WOLFE SA, 1991, PLAST RECONSTR SURG, V88, P174, DOI 10.1097/00006534-199107000-00049
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xu HP, 2017, VISION RES, V139, P39, DOI 10.1016/j.visres.2017.04.013
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Yao HL, 2014, NEURAL REGEN RES, V9, P1047, DOI 10.4103/1673-5374.133169
   Yu ZY, 2006, ARCH BIOCHEM BIOPHYS, V455, P188, DOI 10.1016/j.abb.2006.09.002
   Zhang HJ, 2013, J ENDOCRINOL INVEST, V36, P385, DOI 10.3275/8654
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhang SC, 2000, INVEST OPHTH VIS SCI, V41, P887
   Zheng XR, 2012, BEHAV BRAIN RES, V230, P108, DOI 10.1016/j.bbr.2012.01.026
   Zhou XH, 2009, MOL VIS, V15, P438
NR 190
TC 21
Z9 21
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JAN
PY 2019
VL 176
IS 1
SI SI
BP 93
EP 109
DI 10.1111/bph.14507
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HD4SW
UT WOS:000452519400009
PM 30276789
OA Green Published
DA 2022-11-30
ER

PT J
AU Mcvey, D
   Hamilton, MM
   Hsu, C
   King, CR
   Brough, DE
   Wei, LL
AF McVey, Duncan
   Hamilton, Melissa M.
   Hsu, Chi
   King, C. Richter
   Brough, Douglas E.
   Wei, Lisa L.
TI Repeat administration of proteins to the eye with a single intraocular
   injection of an adenovirus vector
SO MOLECULAR THERAPY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; HUMORAL
   IMMUNE-RESPONSES; HEPATIC GENE-EXPRESSION; RETINOIC ACID; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; THERAPY; INHIBITION; ENHANCER
AB Delivery of therapeutic proteins, such as antiangiogenic proteins, to the eye is a demonstrated method for the control of age-related macular degeneration (AMD). However, one of the key limitations is the requirement for frequent and repeated intraocular injections. In this article, we demonstrate that repeated protein production in the eye can be stimulated from the cytomegalovirus (CMV) promoter without repeat intraocular injections using a small molecule, all- trans retinoic acid (ATRA). ATRA by systemic delivery can stimulate protein production multiple times in the eye. Administration of ATRA resulted in stimulation of gene expression to relevant levels that block abnormal blood vessel growth in an experimental animal model for AMD. These data support the principles of this technological discovery to therapeutic applications for chronic ocular diseases.
C1 [Hamilton, Melissa M.; Wei, Lisa L.] GenVec Inc, Preclin Sci, Gaithersburg, MD 20878 USA.
   [McVey, Duncan; Hsu, Chi; Brough, Douglas E.] GenVec Inc, Vector Sci, Gaithersburg, MD 20878 USA.
   [King, C. Richter] GenVec Inc, Res, Gaithersburg, MD 20878 USA.
RP Wei, LL (通讯作者)，GenVec Inc, Preclin Sci, 65 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.
EM lwei@genvec.com
CR Angulo A, 1996, MOL ENDOCRINOL, V10, P781, DOI 10.1210/me.10.7.781
   [Anonymous], 2001, HUM GENE THER, V12, P315
   Bhawan J, 2005, CUTIS, V75, P25
   BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8
   Brisaert M, 2000, INT J PHARM, V199, P49, DOI 10.1016/S0378-5173(00)00366-5
   Brough DE, 1996, J VIROL, V70, P6497, DOI 10.1128/JVI.70.9.6497-6501.1996
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao H, 2004, BLOOD, V103, P701, DOI 10.1182/blood-2003-02-0478
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen P, 2000, GENE THER, V7, P587, DOI 10.1038/sj.gt.3301137
   DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401
   DAMATO RJ, 1995, OPHTHALMOLOGY, V102, P1261, DOI 10.1016/S0161-6420(95)30876-7
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414
   Gaetano C, 2000, GENE THER, V7, P1624, DOI 10.1038/sj.gt.3301296
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Guo ZS, 1996, GENE THER, V3, P802
   Hamilton MM, 2006, INVEST OPHTH VIS SCI, V47, P299, DOI 10.1167/iovs.05-0731
   Hickman MA, 1995, ADV DRUG DELIVER REV, V17, P265, DOI 10.1016/0169-409X(95)00060-K
   Hoffman LM, 1997, INVEST OPHTH VIS SCI, V38, P2224
   Isenmann S, 2001, BRAIN RES, V892, P229, DOI 10.1016/S0006-8993(00)02957-7
   Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Kunchala SR, 2000, INDIAN J BIOCHEM BIO, V37, P71
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1610
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Mori M, 2001, INVEST OPHTH VIS SCI, V42, P1312
   Murphy PT, 1996, BONE MARROW TRANSPL, V18, P641
   Nyberg Kara, 2004, Mol Ther, V10, P976, DOI 10.1016/j.ymthe.2004.10.011
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   RASMUSSEN HS, 2003, PRECLINICA, V1, P77
   Reichel MB, 2001, BRIT J OPHTHALMOL, V85, P341, DOI 10.1136/bjo.85.3.341
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rotondaro L, 1996, GENE, V168, P195, DOI 10.1016/0378-1119(95)00767-9
   Selek H, 2000, EUR J OPHTHALMOL, V10, P121, DOI 10.1177/112067210001000205
   SOONG HK, 1988, OPHTHALMOLOGY, V95, P1442
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   THORNE EG, 1992, BRIT J DERMATOL, V127, P31, DOI 10.1111/j.1365-2133.1992.tb16985.x
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Woolson R., 2002, STAT METHODS ANAL BI
   YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995
   YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4
NR 49
TC 5
Z9 7
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD AUG
PY 2008
VL 16
IS 8
BP 1444
EP 1449
DI 10.1038/mt.2008.124
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 334VQ
UT WOS:000258249800018
PM 18545220
OA hybrid
DA 2022-11-30
ER

PT J
AU Garfinkel, RA
   Berinstein, DM
   Frantz, R
AF Garfinkel, RA
   Berinstein, DM
   Frantz, R
TI Treatment of choroidal neovascularization through the implantable
   miniature telescope
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SAFETY
AB PURPOSE: To report a case of thermal laser photocoagulation of a choroidal neovasacular membrane through the implantable miniature telescope UNIT).
   DESIGN: Interventional case report.
   METHODS: Focal thermal laser photocoagulation was performed. Complete ablation of the neovascular lesion, visual acuity, and integrity of the IMT were assessed.
   RESULTS: An 81-year-old woman with a history of IMT implantation for advanced geographic atrophy related to age,related macular degeneration developed an extrafoveal choroidal neovascular lesion. The patient underwent focal laser photocoagulation through the telescope without complication. Three months after treatment, no evidence of recurrence was noted, and visual acuity remained at 20/200. The IMT was not altered by the treatment.
   CONCLUSIONS: Focal thermal laser photocoagulation through an IMT can successfully treat choroidal neovascularization without damaging the device.
C1 Retina Grp Washington, Chevy Chase, MD 20815 USA.
RP Berinstein, DM (通讯作者)，Retina Grp Washington, 5454 Wisconsin Ave,Suite 1540, Chevy Chase, MD 20815 USA.
EM danberi@yahoo.com
CR Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Rosner M, 2003, J CATARACT REFR SURG, V29, P1005, DOI 10.1016/S0886-3350(02)01647-4
NR 2
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2006
VL 141
IS 4
BP 766
EP 767
DI 10.1016/j.ajo.2005.11.005
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030GG
UT WOS:000236621800034
PM 16564826
DA 2022-11-30
ER

PT J
AU Sarkar, A
   Sodha, SJ
   Junnuthula, V
   Kolimi, P
   Dyawanapelly, S
AF Sarkar, Aira
   Sodha, Srushti Jayesh
   Junnuthula, Vijayabhaskarreddy
   Kolimi, Praveen
   Dyawanapelly, Sathish
TI Novel and investigational therapies for wet and dry age-related macular
SO DRUG DISCOVERY TODAY
LA English
DT Review
DE Dry AMD; Wet AMD; Anti-VEGF agents; Port delivery system; Biosimilars;
   Bispecific antibodies; Gene therapy
ID IN-VITRO; INTRAOCULAR-PRESSURE; GEOGRAPHIC ATROPHY; DEGENERATION;
   RANIBIZUMAB; INHIBITOR; DISEASE; SYSTEM; IBI302; VEGF
AB Age-related macular degeneration (AMD) is a macular degenerative eye disease, the major cause of irreversible loss of central vision. In this review, we highlight current progress and future perspectives of novel and investigational therapeutic strategies in the drug pipeline, including anti-vascular endothelial growth factor (VEGF) agents, bispecific antibodies, biosimilars, small molecules, gene therapy, and long-acting drug delivery strategies for both dry and wet AMD. We anticipate that biologics with dual functionalities and combined therapies with long-acting capabilities will lead the wet AMD pipeline. Sustained-release platforms also show potential. However, significant breakthroughs are yet to be made for dry AMD. The personalized approach might be well suited in the scenario of diverse genetic variations in both conditions.
C1 [Sarkar, Aira] Johns Hopkins Univ, Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Sodha, Srushti Jayesh] Univ Sci, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA.
   [Junnuthula, Vijayabhaskarreddy] Univ Helsinki, Fac Pharm, Drug Res Program, Viikinkaari 5, Helsinki 00790, Finland.
   [Kolimi, Praveen] Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, Oxford, MS 38677 USA.
   [Dyawanapelly, Sathish] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Mumbai 400019, India.
C3 Johns Hopkins University; University of Helsinki; University of
   Mississippi; Institute of Chemical Technology - Mumbai
RP Junnuthula, V (通讯作者)，Univ Helsinki, Fac Pharm, Drug Res Program, Viikinkaari 5, Helsinki 00790, Finland.; Dyawanapelly, S (通讯作者)，Inst Chem Technol, Dept Pharmaceut Sci & Technol, Mumbai 400019, India.
EM junnuthula.vijayabhaskarreddy@helsinki.fi;
   sa.dyawanapelly@ictmumbai.edu.in
RI Dyawanapelly, Sathish/AAK-1843-2020; Junnuthula,
   Vijayabhaskarreddy/T-7064-2019; Kolimi, Praveen/AAD-8315-2021
OI Dyawanapelly, Sathish/0000-0002-2310-1651; Junnuthula,
   Vijayabhaskarreddy/0000-0003-2968-2036; Kolimi,
   Praveen/0000-0002-6993-9599
FU Finnish Cultural Foundation; Olavi Martelius foundation
FX The authors are thankful to the Institute of Chemical Tech-nology,
   Mumbai, India for providing facilities to carry out this work. V.J.is
   supported by a personal research grant from the Finnish Cultural
   Foundation (Ingrid, Toini and Olavi Martelius foundation) , and thanks
   Arto Urtti for suggestions that improved the manuscript.
CR Adverum Biotechnologies, 2021, ADV BIOT PRES LONG T
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   AMDF, DRY VS WET AGE REL M
   [Anonymous], RETINAL PHARMA MARKE
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bantseev V, 2020, RETINA-J RET VIT DIS, V40, P1520, DOI 10.1097/IAE.0000000000002614
   Biogen, FDA APPR SAMS BIOEP
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Camardo J, 2003, TRANSPL P, V35, p18S, DOI 10.1016/S0041-1345(03)00356-7
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Cohen MN, 2021, BRIT J OPHTHALMOL, V105, P716, DOI 10.1136/bjophthalmol-2020-316511
   Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159
   Cousins SW, 2016, INVEST OPHTH VIS SCI, V57
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Freeman WR, 2019, INVEST OPHTH VIS SCI, V60
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holz FG, 2022, OPHTHALMOLOGY, V129, P54, DOI 10.1016/j.ophtha.2021.04.031
   Huang D., 2009, INVEST OPHTHALMOL VI, V50, P2966
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Ji MH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.8.4
   Kang-Mieler JJ, 2020, EYE, V34, P1371, DOI 10.1038/s41433-020-0809-0
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.30
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lindner M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23203
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Narayanan R, 2017, CURR PHARM DESIGN, V23, P542, DOI 10.2174/1381612822666161221154424
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Nishimura J, 2014, NEW ENGL J MED, V370, P632, DOI 10.1056/NEJMoa1311084
   Novartis, BROL
   Outlook Therapeutics, OUTL THER REP POS EF
   PanOptica, NEW WAV INN NEOV EYE
   Patel S.S., 2020, INVESTIG OPHTHALMOL, V61, P4286
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Querques G., 2017, F1000RESEARCH, V6, P1
   Ralston PG, 2010, INVEST OPHTH VIS SCI, V51
   REGENXBIO, RGX 314
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Ricca AM, 2015, J OCUL PHARMACOL TH, V31, P2, DOI 10.1089/jop.2014.0062
   Roche, FDA APPR ROCH SUSV 1
   Roche, STUD EV FAR RO686746
   Roche, FDA ACC APPL ROCH FA
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarkar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910594
   Sarkar A, 2021, J CONTROL RELEASE, V329, P1262, DOI 10.1016/j.jconrel.2020.10.054
   Schargus M, 2020, CLIN OPHTHALMOL, V14, P897, DOI 10.2147/OPTH.S207978
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Sharma A, 2022, EYE, V36, P488, DOI 10.1038/s41433-021-01830-5
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Slakter JS, 2015, INVEST OPHTH VIS SCI, V56
   Stevenson CL, 2012, ADV DRUG DELIVER REV, V64, P1590, DOI 10.1016/j.addr.2012.02.005
   Wang J, 2014, INVEST OPHTH VIS SCI, V55
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Yang M, 2016, INVEST OPHTH VIS SCI, V57
   Zelek WM, 2020, AM J RESP CRIT CARE, V202, P1304, DOI 10.1164/rccm.202007-2778LE
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 84
TC 8
Z9 8
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD AUG
PY 2022
VL 27
IS 8
BP 2322
EP 2332
DI 10.1016/j.drudis.2022.04.013This
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 4Y5PT
UT WOS:000861580500001
PM 35460893
DA 2022-11-30
ER

PT J
AU Li, HY
   Rong, SS
   Hong, X
   Guo, R
   Yang, FZ
   Liang, YY
   Li, A
   So, KF
AF Li, Hong-Ying
   Rong, Sheng-Sheng
   Hong, Xi
   Guo, Rui
   Yang, Feng-Zhen
   Liang, Yi-Yao
   Li, Ang
   So, Kwok-Fai
TI 0 Exercise and retinal health
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE Exercise; neuroprotection; retina; microglia; oxidative stress;
   neurotrophic factor; adipokine; autophagy; mitochondrion
ID MACULAR DEGENERATION; PHYSICAL-ACTIVITY; OPTIC-NERVE;
   MOLECULAR-MECHANISMS; VOLUNTARY EXERCISE; ISOMETRIC-EXERCISE; OXIDATIVE
   STRESS; MOUSE MODEL; LEPTIN; PROTECTS
AB Many ocular diseases (such as glaucoma, diabetic retinopathy, age-related macular degeneration, and traumatic eye injuries) can result in the degeneration of retinal cells and the subsequent loss of vision. Somekinds of treatments, such as drugs, stem cell transplantation and surgery are reported to be effective in certain patients. However, no confirmatively effective, convenient and low-price intervention has been available so far. Physical exercise has been reported to exert neuroprotective effects on several neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. Studies investigating the potential impacts of exercise on retinal diseases are rapidly emerging. Here we review these up-to-date findings from both human and animal studies, and discuss the possible mechanisms underlying exercise-elicited protection on retina.
C1 [Li, Hong-Ying; Hong, Xi] Jinan Univ, Med Sch, Cent Lab, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.
   [Li, Hong-Ying; Rong, Sheng-Sheng; Guo, Rui; Yang, Feng-Zhen; Liang, Yi-Yao; Li, Ang; So, Kwok-Fai] Jinan Univ, Guangdong Hongkong Macau Inst CNS Regenerat, CNS Regenerat Collaborat Joint Lab, Minist Educ, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.
   [Li, Hong-Ying; Li, Ang; So, Kwok-Fai] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Guangdong, Peoples R China.
   [Li, Ang; So, Kwok-Fai] Jinan Univ, Guangdong Key Lab Brain Funct & Dis, Guangzhou, Guangdong, Peoples R China.
   [So, Kwok-Fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China.
   [So, Kwok-Fai] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Peoples R China.
C3 Jinan University; Jinan University; Guangzhou Regenerative Medicine &
   Health Guangdong Laboratory (Bioisland Laboratory); Jinan University;
   University of Hong Kong; University of Hong Kong
RP Li, HY (通讯作者)，Jinan Univ, Med Sch, Cent Lab, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.; So, KF (通讯作者)，Jinan Univ, Guangdong Hongkong Macau Inst CNS Regenerat, CNS Regenerat Collaborat Joint Lab, Minist Educ, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.
EM thongying@jnu.edu.cn; hrmaskf@hku.hk
RI Li, Hongying/AAU-2379-2021; Li, Hongying/Q-1909-2016
OI Li, Hongying/0000-0002-1109-0799; So, Kwok-Fai/0000-0003-4039-4246
FU National Natural Science Foundation of China [81771455, 81501171];
   National Key Research and Development Program of China [2016YFC1306702];
   Science and Technology Program of Guangdong [2018B030334001]
FX The work was supported by grants from National Natural Science
   Foundation of China (81771455, 81501171), National Key Research and
   Development Program of China (2016YFC1306702), and Science and
   Technology Program of Guangdong (2018B030334001). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Allen RS, 2018, EUR J NEUROSCI, V47, P1254, DOI 10.1111/ejn.13909
   Almeida C, 2015, PAIN, V156, P504, DOI 10.1097/01.j.pain.0000460339.23976.12
   [Anonymous], 2010, DIABETES CARE, DOI [DOI 10.2337/DC10-9990, DOI 10.2337/DC10-1548]
   Antonopoulos AS, 2017, CARDIOVASC RES, V113, P1074, DOI 10.1093/cvr/cvx106
   Bernardo TC, 2016, BRAIN PATHOL, V26, P648, DOI 10.1111/bpa.12403
   Bouzid MA, 2015, SPORTS MED, V45, P1245, DOI 10.1007/s40279-015-0348-1
   Cheng AW, 2016, CELL METAB, V23, P128, DOI 10.1016/j.cmet.2015.10.013
   Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821
   Chou W, 2018, MOL NEUROBIOL, V55, P8602, DOI 10.1007/s12035-018-1011-2
   Chrenek MA, 2016, ADV EXP MED BIOL, V854, P443, DOI 10.1007/978-3-319-17121-0_59
   Christensen I, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00219
   Chrysostomou V, 2016, AGING CELL, V15, P1082, DOI 10.1111/acel.12512
   Chrysostomou V, 2014, NEUROBIOL AGING, V35, P1722, DOI 10.1016/j.neurobiolaging.2014.01.019
   Crowston JG, 2017, EYE, V31, P196, DOI 10.1038/eye.2016.281
   da Costa RO, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2138169
   de Carvalho-Ferreira JP, 2015, PEPTIDES, V65, P20, DOI 10.1016/j.peptides.2014.11.010
   Escobar KA, 2019, AGING CELL, V18, DOI 10.1111/acel.12876
   Forny-Germano L, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01027
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Ge TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1129-1
   Mourao FAG, 2014, J NEUROCHEM, V131, P65, DOI 10.1111/jnc.12786
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Hanif AM, 2015, INVEST OPHTH VIS SCI, V56, P6839, DOI 10.1167/iovs.15-16792
   Hare W, 2001, SURV OPHTHALMOL, V45, pS284, DOI 10.1016/S0039-6257(01)00200-4
   Harrington ME, 2012, PROG NEUROBIOL, V99, P93, DOI 10.1016/j.pneurobio.2012.07.004
   He XF, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00144
   Higuchi A, 2009, CIRC RES, V104, P1058, DOI 10.1161/CIRCRESAHA.109.194506
   Hu F, 2011, CELL SIGNAL, V23, P1528, DOI 10.1016/j.cellsig.2011.05.008
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Irving AJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0155
   JAMES CB, 1991, GRAEF ARCH CLIN EXP, V229, P341, DOI 10.1007/BF00170692
   Jang Yong Chul, 2018, J Exerc Nutrition Biochem, V22, P1, DOI 10.20463/jenb.2018.0001
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Joers V, 2017, PROG NEUROBIOL, V155, P57, DOI 10.1016/j.pneurobio.2016.04.006
   Kaspar BK, 2005, ANN NEUROL, V57, P649, DOI 10.1002/ana.20451
   Kim DY, 2013, MOL MED REP, V7, P1745, DOI 10.3892/mmr.2013.1439
   Kincaid B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00048
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kohman RA, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-114
   Kohman RA, 2012, BRAIN BEHAV IMMUN, V26, P803, DOI 10.1016/j.bbi.2011.10.006
   LaHue SC, 2016, MOVEMENT DISORD, V31, P1444, DOI 10.1002/mds.26728
   Lawson EC, 2014, J NEUROSCI, V34, P2406, DOI 10.1523/JNEUROSCI.2062-13.2014
   Lee J, 2018, AGING CELL, V17, DOI 10.1111/acel.12679
   Levinson JD, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6950642
   Li HY, 2019, CELL TRANSPLANT, V28, P607, DOI 10.1177/0963689719835181
   Li HY, 2019, NEURAL REGEN RES, V14, P728, DOI 10.4103/1673-5374.247481
   Li HY, 2015, CELL TRANSPLANT, V24, P403, DOI 10.3727/096368915X686896
   Lin JB, 2018, ADV EXP MED BIOL, V1074, P561, DOI 10.1007/978-3-319-75402-4_68
   Lin JB, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.3
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Lovasik JV, 2004, OPTOMETRY VISION SCI, V81, P692, DOI 10.1097/01.opx.0000144748.65471.e5
   Lu YJ, 2017, J ALZHEIMERS DIS, V56, P1469, DOI 10.3233/JAD-160869
   Luksch A, 2003, INVEST OPHTH VIS SCI, V44, P734, DOI 10.1167/iovs.02-0177
   Madeira MH, 2016, TRANSL RES, V169, P112, DOI 10.1016/j.trsl.2015.11.005
   Malekizadeh Y, 2017, CEREB CORTEX, V27, P4769, DOI 10.1093/cercor/bhw272
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Mees LM, 2019, INVEST OPHTH VIS SCI, V60, P1328, DOI 10.1167/iovs.18-25883
   Moreno MC, 2005, FASEB J, V19, P1161, DOI 10.1096/fj.04-3313fje
   Morrison CD, 2009, BBA-MOL BASIS DIS, V1792, P401, DOI 10.1016/j.bbadis.2008.12.004
   Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117
   Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5
   Peirce NS, 1999, BRIT J SPORT MED, V33, P161, DOI 10.1136/bjsm.33.3.161
   Batatinha HAP, 2019, J CELL PHYSIOL, V234, P14883, DOI 10.1002/jcp.28318
   Petzinger GM, 2013, LANCET NEUROL, V12, P716, DOI 10.1016/S1474-4422(13)70123-6
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Qureshi IZ, 2017, J PAK MED ASSOC, V67, P852
   REITMAN JS, 1984, DIABETES CARE, V7, P434, DOI 10.2337/diacare.7.5.434
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Ryan SM, 2016, AGEING RES REV, V27, P77, DOI 10.1016/j.arr.2016.03.007
   Sanchez MIGL, 2016, PHARMACOL THERAPEUT, V165, P132, DOI 10.1016/j.pharmthera.2016.06.004
   Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307
   Schorr M, 2017, NAT REV ENDOCRINOL, V13, P174, DOI 10.1038/nrendo.2016.175
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Signore AP, 2008, J NEUROCHEM, V106, P1977, DOI 10.1111/j.1471-4159.2008.05457.x
   Tittl M, 2005, INVEST OPHTH VIS SCI, V46, P4717, DOI 10.1167/iovs.05-0268
   van de Ven RAH, 2017, TRENDS MOL MED, V23, P320, DOI 10.1016/j.molmed.2017.02.005
   Wang YX, 2019, ACTA OPHTHALMOL, V97, P325, DOI 10.1111/aos.13962
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Wylegala A, 2016, J GLAUCOMA, V25, pE843, DOI 10.1097/IJG.0000000000000454
   Xing Y, 2019, LIFE SCI, V221, P130, DOI 10.1016/j.lfs.2019.02.026
   Xu L, 2016, MOL NEUROBIOL, V53, P6709, DOI 10.1007/s12035-015-9593-4
   Yau SY, 2014, P NATL ACAD SCI USA, V111, P15810, DOI 10.1073/pnas.1415219111
   Yook JS, 2019, P NATL ACAD SCI USA, V116, P10988, DOI 10.1073/pnas.1815197116
   Zhang F, 2007, STROKE, V38, P2329, DOI 10.1161/STROKEAHA.107.482786
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang JY, 2013, J CEREBR BLOOD F MET, V33, P567, DOI 10.1038/jcbfm.2012.202
   Zhang X, 2019, MOL VIS, V25, P462
   Zhao N, 2018, NEUROREPORT, V29, P819, DOI 10.1097/WNR.0000000000001038
   Zhao XF, 2014, CELL REP, V9, P272, DOI 10.1016/j.celrep.2014.08.047
   Zhu MM, 2018, ACTA OPHTHALMOL, V96, pE676, DOI 10.1111/aos.13661
   ZINMAN B, 1984, DIABETES CARE, V7, P515, DOI 10.2337/diacare.7.6.515
   Zwierko T, 2011, J SPORT SCI, V29, P1563, DOI 10.1080/02640414.2011.605166
   Zwierko T, 2010, GRAEF ARCH CLIN EXP, V248, P659, DOI 10.1007/s00417-010-1305-1
NR 96
TC 2
Z9 2
U1 1
U2 11
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PY 2019
VL 37
IS 6
BP 571
EP 581
DI 10.3233/RNN-190945
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JW4DX
UT WOS:000503005000005
PM 31796710
DA 2022-11-30
ER

PT J
AU Bazan, NG
AF Bazan, Nicolas G.
TI Is There a Molecular Logic That Sustains Neuronal Functional Integrity
   and Survival? Lipid Signaling Is Necessary for Neuroprotective Neuronal
   Transcriptional Programs
SO MOLECULAR NEUROBIOLOGY
LA English
DT Review
DE Neuroprotection; Docosahexaenoic acid; Neuroprotectin D1;
   Neuroinflammation; Neurodegenerations; Alzheimer's disease; Age-related
   macular degeneration; c-Rel; BIRC3
ID ALZHEIMERS-DISEASE; CELL-SURVIVAL; TAU-PHOSPHORYLATION; MICE;
   INFLAMMATION; BRAIN; D1; NEUROINFLAMMATION; NEURODEGENERATION;
   DEPOSITION
AB A challenge to civilization is the growing incidence in the loss of sight and cognition due to increased life expectancy. Therefore, we are confronted with a rise in the occurrence of photoreceptor- and neuronal-survival failure, as reflected mainly by age-related macular degeneration (AMD) and Alzheimer's disease (AD). Nervous system development is driven by neuronal apoptotic cell death, and thereafter, for the entire lifespan of an organism, neurons are postmitotic cells. In neurodegenerative diseases, apoptosis and other forms of cells death lead to selective neuronal loss. Although age is the main risk factor, not everyone develops these diseases during aging. Despite decades of important findings about neuronal cell death, the specific mechanisms that regulate neuronal survival remain incompletely understood.
C1 Louisiana State Univ Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans
RP Bazan, NG (通讯作者)，Louisiana State Univ Hlth Sci Ctr, Neurosci Ctr Excellence, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.
EM NBazan@lsuhsc.edu
RI Bazan, Nicolas/AAN-4121-2020
OI Bazan, Nicolas/0000-0002-9243-5444
FU National Institutes of Health [GM103340, NS046741, EY005121]; NATIONAL
   EYE INSTITUTE [R01EY005121] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103340] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
   [R01NS046741] Funding Source: NIH RePORTER
FX This works was supported by National Institutes of Health grants
   GM103340, NS046741, and EY005121 (NGB).
CR AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Bradshaw J, 2004, J NEUROL NEUROSUR PS, V75, P382, DOI 10.1136/jnnp.2002.002576
   Cheng XS, 2013, J ALZHEIMERS DIS, V36, P185, DOI 10.3233/JAD-122173
   Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350
   Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889
   Hjorth E, 2013, J ALZHEIMERS DIS, V35, P697, DOI 10.3233/JAD-130131
   Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005
   Leung R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064971
   Logan S, 2013, P NATL ACAD SCI USA, V110, P5446, DOI 10.1073/pnas.1217251110
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055
   McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025
   Mishra A, 2012, EUR J PHARMACOL, V674, P315, DOI 10.1016/j.ejphar.2011.11.010
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15
   Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032
   Qiao XX, 2001, EUR J NEUROSCI, V14, P474, DOI 10.1046/j.0953-816x.2001.01666.x
   Reale M, 2008, J ALZHEIMERS DIS, V14, P147
   Sarlus H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-99
   Sarlus H, 2012, J CELL MOL MED, V16, P2401, DOI 10.1111/j.1582-4934.2012.01556.x
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Sepulveda-Falla D, 2012, J ALZHEIMERS DIS, V32, P1, DOI 10.3233/JAD-2012-120907
   Serhan CN, 2009, J EXP MED, V206, P15, DOI 10.1084/jem.20081880
   Stark DT, 2011, J NEUROSCI, V31, P13710, DOI 10.1523/JNEUROSCI.3544-11.2011
   Zhao YH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015816, 10.1371/journal.pone.0016470]
NR 29
TC 8
Z9 8
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD AUG
PY 2014
VL 50
IS 1
BP 1
EP 5
DI 10.1007/s12035-014-8897-0
PG 5
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AQ8DX
UT WOS:000343055000001
PM 25236258
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gopinath, SCB
   Misono, TS
   Kumar, PKR
AF Gopinath, Subash C. B.
   Misono, Tomoko S.
   Kumar, Penmetcha K. R.
TI Prospects of ligand-induced aptamers
SO CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY
LA English
DT Review
DE aptamer; microarray; molecular beacon; RNA; signalling
ID IN-VITRO SELECTION; GENE-EXPRESSION; SIGNALING APTAMERS; DNA APTAMER;
   RNA APTAMER; TAT PROTEIN; SENSORS; TRANSLATION; DIVERSITY; BIOSENSOR
AB Aptamers are rare functional nucleic acid ligands that bind with high affinity and specificity to their target ligands. Selected aptamers have been shown to inhibit the functions of their cognate targets both in vitro and in vivo. As a consequence, the first aptamer-based drug to treat age-related macular degeneration has been developed. On another front, aptamers have also successfully shown potential use in diagnostics and imaging technology. The next wave of aptamer applications involves the development of ligand-induced aptamers. These aptamers rely on the principles commonly observed in many ribonucleic acid (RNA)-ligand interactions. In the present review, we describe the various strategies for designing ligand-induced aptamers and their applications, including monitoring different ligands, regulating gene expression and expanding microarray analyses.
C1 [Gopinath, Subash C. B.; Misono, Tomoko S.; Kumar, Penmetcha K. R.] Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Cent 6, Tsukuba, Ibaraki 3058566, Japan.
C3 National Institute of Advanced Industrial Science & Technology (AIST)
RP Kumar, PKR (通讯作者)，Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Cent 6, Tsukuba, Ibaraki 3058566, Japan.
EM pkr-kumar@aist.go.jp
RI Gopinath, Subash/D-2953-2015; Penmetcha, Kumar/K-8834-2017
OI Gopinath, Subash/0000-0002-8347-4687; Penmetcha,
   Kumar/0000-0002-3512-704X
CR Bayer TS, 2005, NAT BIOTECHNOL, V23, P337, DOI 10.1038/nbt1069
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   Famulok M, 1999, CURR TOP MICROBIOL, V243, P123
   GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555
   Gopinath SCB, 2005, NUCLEIC ACIDS RES, V33, P4874, DOI 10.1093/nar/gki809
   Grate D, 2001, BIOORGAN MED CHEM, V9, P2565, DOI 10.1016/S0968-0896(01)00031-1
   Hanson S, 2003, MOL MICROBIOL, V49, P1627, DOI 10.1046/j.1365-2958.2003.03656.x
   Hartig JS, 2002, NAT BIOTECHNOL, V20, P717, DOI 10.1038/nbt0702-717
   Harvey I, 2002, RNA, V8, P452, DOI 10.1017/S135583820202633X
   Hermann T, 2003, BIOPOLYMERS, V70, P4, DOI 10.1002/bip.10410
   Ho HA, 2004, J AM CHEM SOC, V126, P1384, DOI 10.1021/ja037289f
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jayawickreme CK, 1997, CURR OPIN BIOTECH, V8, P629, DOI 10.1016/S0958-1669(97)80040-7
   Jhaveri S, 2000, NAT BIOTECHNOL, V18, P1293, DOI 10.1038/82414
   Jhaveri SD, 2000, J AM CHEM SOC, V122, P2469, DOI 10.1021/ja992393b
   Jiang YX, 2004, ANAL CHEM, V76, P5230, DOI 10.1021/ac049565u
   Matsugami A, 2003, STRUCTURE, V11, P533, DOI 10.1016/S0969-2126(03)00069-8
   McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0
   Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c
   Rademann J, 2000, SCIENCE, V287, P1947, DOI 10.1126/science.287.5460.1947
   Rajendran M, 2003, NUCLEIC ACIDS RES, V31, P5700, DOI 10.1093/nar/gkg764
   Stojanovic MN, 2004, J AM CHEM SOC, V126, P9266, DOI 10.1021/ja032013t
   Stojanovic MN, 2001, J AM CHEM SOC, V123, P4928, DOI 10.1021/ja0038171
   Stojanovic MN, 2000, J AM CHEM SOC, V122, P11547, DOI 10.1021/ja0022223
   Suess B, 2003, NUCLEIC ACIDS RES, V31, P1853, DOI 10.1093/nar/gkg285
   Thiel K, 2004, NAT BIOTECHNOL, V22, P649, DOI 10.1038/nbt0604-649
   Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081
   Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Yamamoto R, 2000, GENES CELLS, V5, P389, DOI 10.1046/j.1365-2443.2000.00331.x
   Yamamoto R., 1998, GENE THER MOL BIOL, V1, P451
   Yamamoto-Fujita R, 2005, ANAL CHEM, V77, P5460, DOI 10.1021/ac050364f
   Yamana K, 2003, BIOORG MED CHEM LETT, V13, P3429, DOI 10.1016/S0960-894X(03)00799-6
NR 36
TC 17
Z9 17
U1 2
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1040-8347
J9 CRIT REV ANAL CHEM
JI Crit. Rev. Anal. Chem.
PY 2008
VL 38
IS 1
BP 34
EP 47
DI 10.1080/10408340701804558
PG 14
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 258TW
UT WOS:000252893400004
DA 2022-11-30
ER

PT J
AU Wang, LL
   Sun, Y
   Huang, K
   Zheng, L
AF Wang, Lei-Lei
   Sun, Yue
   Huang, Kun
   Zheng, Ling
TI Curcumin, a potential therapeutic candidate for retinal diseases
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Review
DE Anti-inflammation; Antioxidative; Curcumin; Epigenetics; Retinal
   diseases
ID PIGMENT EPITHELIAL-CELLS; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   ENDOTHELIAL-CELLS; RETINITIS-PIGMENTOSA; OXIDATIVE STRESS;
   RETINOBLASTOMA PROTEIN; METHANOL INTOXICATION; GANGLION-CELLS; CYCLIN D1
AB Curcumin, the major extraction of turmeric, has been widely used in many countries for centuries both as a spice and as a medicine. In the last decade, researchers have found the beneficial effects of curcumin on multiple disorders are due to its antioxidative, anti-inflammatory, and antiproliferative properties, as well as its novel function as an inhibitor of histone aectyltransferases. In this review, we summarize the recent progress made on studying the beneficial effects of curcumin on multiple retinal diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Recent clinical trials on the effectiveness of phosphatidylcholine formulated curcumin in treating eye diseases have also shown promising results, making curcumin a potent therapeutic drug candidate for inflammatory and degenerative retinal and eye diseases.
C1 [Wang, Lei-Lei; Sun, Yue; Zheng, Ling] Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.
   [Huang, Kun] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Hubei, Peoples R China.
   [Huang, Kun] Wuhan Inst Biotechnol, Ctr Biomed Res, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Huazhong University of Science & Technology
RP Huang, K (通讯作者)，Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Hubei, Peoples R China.
EM kunhuang2008@hotmail.com
OI Zheng, Ling/0000-0002-6545-4180
FU National Basic Research Program of China [2009BC918304, 2012CB524901];
   Natural Science Foundation of China [81222043, 30970607, 81172971,
   81100687, 31271370]; Program for New Century Excellent Talents in
   University [NECT10-0623, NECT11-0170]
FX This work was supported by the National Basic Research Program of China
   (2009BC918304 and 2012CB524901), the Natural Science Foundation of China
   (Nos. 81222043, 30970607, 81172971, 81100687, and 31271370), and the
   Program for New Century Excellent Talents in University (NECT10-0623 and
   NECT11-0170). The authors wish to thank Mitchell Sullivan (University of
   Queensland) for proofreading the manuscript.
CR 2010, 2010, COLD SPRING HARB PER, V2.
   Ahsan H, 1999, CHEM-BIOL INTERACT, V121, P161, DOI 10.1016/S0009-2797(99)00096-4
   Alex AF, 2010, CURR EYE RES, V35, P1021, DOI 10.3109/02713683.2010.506970
   Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   An Jian-bin, 2009, Zhonghua Yan Ke Za Zhi, V45, P210
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   [Anonymous], [No title captured], DOI 10.1155/2007/43603
   Arden GB, 2012, DOC OPHTHALMOL, V124, P15, DOI 10.1007/s10633-011-9305-y
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Balasubramanian V, 2009, J PHYSIOL-LONDON, V587, P2753, DOI 10.1113/jphysiol.2009.170704
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Baltmr A, 2010, EXP EYE RES, V91, P554, DOI 10.1016/j.exer.2010.08.009
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bian ZM, 2001, INVEST OPHTH VIS SCI, V42, P1660
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399
   Burugula B, 2011, INVEST OPHTH VIS SCI, V52, P4263, DOI 10.1167/iovs.10-7103
   Calabrese V, 2008, MOL NUTR FOOD RES, V52, P1062, DOI 10.1002/mnfr.200700316
   CAMPOCHIARO PA, 1993, INT REV CYTOL, V146, P75, DOI 10.1016/S0074-7696(08)60380-0
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chirapapaisan Niphon, 2012, J Med Assoc Thai, V95 Suppl 4, pS76
   Cole GM, 2007, ADV EXP MED BIOL, V595, P197
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Ehring GR, 2000, J PHYSIOL PHARMACOL, V51, P799
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gong L., 2004, YAN KE XUE BAO, V20, P258
   Gong Ling, 2004, Yan Ke Xue Bao, V20, P246
   Gonzalez-Salazar A, 2011, CARDIOVASC TOXICOL, V11, P357, DOI 10.1007/s12012-011-9128-9
   GOVINDARAJAN VS, 1980, CRC CR REV FOOD SCI, V12, P199, DOI 10.1080/10408398009527278
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006
   Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200
   Iyer A, 2012, IMMUNOL CELL BIOL, V90, P39, DOI 10.1038/icb.2011.99
   Jeganathan VSE, 2011, CURR PHARM BIOTECHNO, V12, P369
   Kadiyala CSR, 2012, J BIOL CHEM, V287, P25869, DOI 10.1074/jbc.M112.375204
   Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045
   Kaur H, 2006, DIABETES, V55, P3104, DOI 10.2337/db06-0519
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Khajavi M, 2005, AM J HUM GENET, V77, P841, DOI 10.1086/497541
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Kim YM, 2011, ANTIOXID REDOX SIGN, V14, P137, DOI 10.1089/ars.2010.3153
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2
   Krishnaswamy K, 2008, ASIA PAC J CLIN NUTR, V17, P265
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;318::AID-PTR445&gt;3.0.CO;2-7
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Leiderman YI, 2009, SEMIN OPHTHALMOL, V24, P62, DOI 10.1080/08820530902800082
   Levin LA, 2003, SURV OPHTHALMOL, V48, pS21, DOI 10.1016/S0039-6257(03)00007-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu SC, 2012, BIOCH BIOPHYS ACTA
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marc RE, 2008, MOL VIS, V14, P782
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Marczylo TH, 2007, CANCER CHEMOTH PHARM, V60, P171, DOI 10.1007/s00280-006-0355-x
   Matteucci A, 2005, EXP BRAIN RES, V167, P641, DOI 10.1007/s00221-005-0068-0
   Matteucci A., 2010, INVEST OPHTH VIS SCI, V52, P1070
   Mazzolani F, 2012, CLIN OPHTHALMOL, V6, P801, DOI 10.2147/OPTH.S31859
   Miriyala S, 2007, ADV EXP MED BIOL, V595, P359
   Misko AL, 2012, J NEUROSCI, V32, P4145, DOI 10.1523/JNEUROSCI.6338-11.2012
   Molina-Jijon E, 2011, FREE RADICAL BIO MED, V51, P1543, DOI 10.1016/j.freeradbiomed.2011.07.018
   Moorthy RS, 1997, SURV OPHTHALMOL, V41, P361, DOI 10.1016/S0039-6257(97)00006-4
   Morimoto T, 2008, J CLIN INVEST, V118, P868, DOI 10.1172/JCI33160
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048
   OSAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P1609, DOI 10.1271/bbb.59.1609
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Ozawa Y, 2011, EXP DIABETES RES, DOI 10.1155/2011/108328
   Perrone L, 2009, J CELL PHYSIOL, V221, P262, DOI 10.1002/jcp.21852
   Pinlaor S, 2009, MOL NUTR FOOD RES, V53, P1316, DOI 10.1002/mnfr.200800567
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Priyadarsini KI, 2003, FREE RADICAL BIO MED, V35, P475, DOI 10.1016/S0891-5849(03)00325-3
   Reese BE, 2011, VISION RES, V51, P613, DOI 10.1016/j.visres.2010.07.010
   Rema M, 2007, INDIAN J MED RES, V125, P297
   Rivolta C, 2002, HUM MOL GENET, V11, P1219, DOI 10.1093/hmg/11.10.1219
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609
   Sameermahmood Z, 2008, INVEST OPHTH VIS SCI, V49, P3305, DOI 10.1167/iovs.07-0456
   Seme MT, 1999, J PHARMACOL EXP THER, V289, P361
   Seme MT, 2001, INVEST OPHTH VIS SCI, V42, P834
   Sreenivasan S, 2012, CURR EYE RES, V37, P421, DOI 10.3109/02713683.2011.647224
   Srivastava RK, 2007, CELL CYCLE, V6, P2953, DOI 10.4161/cc.6.23.4951
   Sugiyama Y, 1996, BIOCHEM PHARMACOL, V52, P519, DOI 10.1016/0006-2952(96)00302-4
   Teus MA, 1998, OPHTHALMOLOGY, V105, P2225, DOI 10.1016/S0161-6420(98)91220-9
   Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x
   Vasireddy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021193
   Wang CY, 2012, DIABETES-METAB RES, V28, P329, DOI 10.1002/dmrr.2279
   Wang JJ, 2012, ANTIOXID REDOX SIGN, V17, P282, DOI 10.1089/ars.2011.4381
   Wang L., 2011, PLOS ONE, V6
   Wang LL, 2012, GLIA, V60, P1896, DOI 10.1002/glia.22405
   Wax MB, 2002, MOL NEUROBIOL, V26, P45, DOI 10.1385/MN:26:1:045
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Whitmire W, 2011, MOL VIS, V17, P300
   Williams Andrew R, 2012, J Parasitol Res, V2012, P569287, DOI 10.1155/2012/569287
   Wongcharoen W, 2009, INT J CARDIOL, V133, P145, DOI 10.1016/j.ijcard.2009.01.073
   Woo JM, 2012, MOL VIS, V18, P901
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zheng L, 2007, DIABETOLOGIA, V50, P1987, DOI 10.1007/s00125-007-0734-9
   Zheng L, 2004, DIABETES, V53, P2960, DOI 10.2337/diabetes.53.11.2960
   Zheng L, 2007, DIABETES, V56, P337, DOI 10.2337/db06-0789
   Zhong Q, 2010, J CELL BIOCHEM, V110, P1306, DOI 10.1002/jcb.22644
   Zhou HY, 2011, CURR DRUG TARGETS, V12, P332, DOI 10.2174/138945011794815356
   Zinovjeva VN, 2002, VOP MED KHIM, V48, P419
   Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 119
TC 39
Z9 42
U1 1
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD SEP
PY 2013
VL 57
IS 9
SI SI
BP 1557
EP 1568
DI 10.1002/mnfr.201200718
PG 12
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 261LN
UT WOS:000327666600006
PM 23417969
DA 2022-11-30
ER

PT J
AU Hsueh, YJ
   Chen, YN
   Tsao, YT
   Cheng, CM
   Wu, WC
   Chen, HC
AF Hsueh, Yi-Jen
   Chen, Yen-Ning
   Tsao, Yu-Ting
   Cheng, Chao-Min
   Wu, Wei-Chi
   Chen, Hung-Chi
TI The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative
   Stress-Related Eye Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE oxidative stress; ocular diseases; antioxidant biomarkers; antioxidant
   therapy
ID AGE-RELATED CATARACT; RETINAL-PIGMENT EPITHELIUM; CORNEAL
   ENDOTHELIAL-CELLS; TOTAL OXIDANT STATUS; AQUEOUS-HUMOR; ASCORBIC-ACID;
   VITAMIN-C; DNA-DAMAGE; LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION
AB Oxidative stress is an important pathomechanism found in numerous ocular degenerative diseases. To provide a better understanding of the mechanism and treatment of oxidant/antioxidant imbalance-induced ocular diseases, this article summarizes and provides updates on the relevant research. We review the oxidative damage (e.g., lipid peroxidation, DNA lesions, autophagy, and apoptosis) that occurs in different areas of the eye (e.g., cornea, anterior chamber, lens, retina, and optic nerve). We then introduce the antioxidant mechanisms present in the eye, as well as the ocular diseases that occur as a result of antioxidant imbalances (e.g., keratoconus, cataracts, age-related macular degeneration, and glaucoma), the relevant antioxidant biomarkers, and the potential of predictive diagnostics. Finally, we discuss natural antioxidant therapies for oxidative stress-related ocular diseases.
C1 [Hsueh, Yi-Jen; Chen, Yen-Ning; Tsao, Yu-Ting; Wu, Wei-Chi; Chen, Hung-Chi] Chang Gung Mem Hosp, Dept Ophthalmol, Linkou Branch, Taoyuan 33305, Taiwan.
   [Hsueh, Yi-Jen; Chen, Hung-Chi] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou Branch, Taoyuan 33305, Taiwan.
   [Chen, Yen-Ning; Wu, Wei-Chi; Chen, Hung-Chi] Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan.
   [Cheng, Chao-Min] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 30012, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung
   University; National Tsing Hua University
RP Chen, HC (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, Linkou Branch, Taoyuan 33305, Taiwan.; Chen, HC (通讯作者)，Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou Branch, Taoyuan 33305, Taiwan.; Chen, HC (通讯作者)，Chang Gung Univ, Dept Med, Coll Med, Taoyuan, Taiwan.
EM t6612@seed.net.tw; annie850924@gmail.com; ssherry450047@gmail.com;
   chaomin@mx.nthu.edu.tw; weichi666@gmail.com; mr3756@cgmh.org.tw
RI Hsueh, Yi-Jen/G-3710-2015
OI Hsueh, Yi-Jen/0000-0003-3380-7188; Tsao, Yu-Ting/0000-0002-6231-6014;
   Chen, Yen-Ning/0000-0001-7860-3862; Cheng, Chao-Min/0000-0002-8644-1960;
   Chen, Hung-Chi/0000-0002-1117-7878
FU Chang Gung Memorial Hospital [CLRPG3D0048]; Ministry of Science and
   Technology [CMRPG3L1691];  [110-2221-E-182A-006]
FX FundingThis work was supported by the Chang Gung Memorial Hospital,
   CMRPG3L1691, and the Ministry of Science and Technology,
   110-2221-E-182A-006.
CR Abdelkader H, 2015, J PHARM PHARMACOL, V67, P537, DOI 10.1111/jphp.12355
   Abdul-Maksoud RS, 2020, J GENE MED, V22, DOI 10.1002/jgm.3192
   Adornetto A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00121
   Aitbaev K A, 2019, Adv Gerontol, V32, P20
   Ali SS, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13145
   Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   Allegrini D, 2021, J MED FOOD, DOI 10.1089/jmf.2020.0199
   Aranaz M, 2022, ANAL BIOANAL CHEM, V414, P515, DOI 10.1007/s00216-021-03467-5
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Arnal E, 2011, INVEST OPHTH VIS SCI, V52, P8592, DOI 10.1167/iovs.11-7732
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Aruoma OI, 1998, J AM OIL CHEM SOC, V75, P199, DOI 10.1007/s11746-998-0032-9
   Augustin AJ, 2004, J CATARACT REFR SURG, V30, P424, DOI 10.1016/S0886-3350(03)00577-7
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Balasubramanian SA, 2012, EXP EYE RES, V96, P132, DOI 10.1016/j.exer.2011.12.010
   Balci M, 2011, MOL VIS, V17, P443
   Balmus IM, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107897
   Bamdad S, 2018, CORNEA, V37, P1306, DOI 10.1097/ICO.0000000000001661
   Barros PSM, 2004, CAN J OPHTHALMOL, V39, P19, DOI 10.1016/S0008-4182(04)80048-6
   Batista TM, 2012, MOL VIS, V18, P194
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 2001, INVEST OPHTH VIS SCI, V42, P2293
   Bergandi L, 2018, INT J OPHTHALMOL-CHI, V11, P1145, DOI 10.18240/ijo.2018.07.12
   Beyazyildiz E, 2013, INT J OPHTHALMOL-CHI, V6, P531, DOI 10.3980/j.issn.2222-3959.2013.04.23
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Bozkurt E, 2019, ARQ BRAS OFTALMOL, V82, P136, DOI 10.5935/0004-2749.20190021
   BRAGT PC, 1980, AGENTS ACTIONS, V10, P536, DOI 10.1007/BF02024159
   Brockmann T, 2019, CURR EYE RES, V44, P147, DOI 10.1080/02713683.2018.1538459
   Brubaker RF, 2000, INVEST OPHTH VIS SCI, V41, P1681
   Caglayan M, 2019, CURR EYE RES, V44, P25, DOI 10.1080/02713683.2018.1521980
   Canadananovic V, 2015, VOJNOSANIT PREGL, V72, P823, DOI 10.2298/VSP131212063C
   Cantemir A, 2016, REV CHIM-BUCHAREST, V67, P1538
   Cardenas-Cantu E, 2016, SEMIN OPHTHALMOL, V31, P567, DOI 10.3109/08820538.2014.971822
   Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349
   Chen HC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112270
   Chen XL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0470-y
   Chen Y, 2009, OCUL SURF, V7, P176, DOI 10.1016/S1542-0124(12)70185-4
   Cheng YH, 2019, EXP EYE RES, V179, P179, DOI 10.1016/j.exer.2018.11.017
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho KS, 1999, INVEST OPHTH VIS SCI, V40, P911
   Choy CKM, 2000, INVEST OPHTH VIS SCI, V41, P3293
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Chwa M, 2008, INVEST OPHTH VIS SCI, V49, P4361, DOI 10.1167/iovs.08-1969
   Chwa M, 2006, INVEST OPHTH VIS SCI, V47, P1902, DOI 10.1167/iovs.05-0828
   Cimpean AM, 2013, MOL VIS, V19, P348
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   Cui YH, 2013, AM J CLIN NUTR, V98, P778, DOI 10.3945/ajcn.112.053835
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166915
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Delamere N A, 1996, Subcell Biochem, V25, P313
   Delamere NA, 2004, PROG RETIN EYE RES, V23, P593, DOI 10.1016/j.preteyeres.2004.06.003
   Di Gioia M, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.626842
   Dogru M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23402
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Eghtedari Y, 2022, SURV OPHTHALMOL, V67, P608, DOI 10.1016/j.survophthal.2021.07.008
   Elmazar HM, 2018, J CATARACT REFR SURG, V44, P134, DOI 10.1016/j.jcrs.2017.10.051
   Engin KN, 2010, MOL VIS, V16, P1260
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Fitzpatrick N, 2022, NUTR REV, V80, P513, DOI 10.1093/nutrit/nuab038
   Fuentes-Leon F, 2020, PHOTOCHEM PHOTOBIOL, V96, P1215, DOI 10.1111/php.13307
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Garcia-Layana A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041253
   Geffen N, 2008, J CATARACT REFR SURG, V34, P2146, DOI 10.1016/j.jcrs.2008.08.024
   George Sabu, 2003, Indian Journal of Physiology and Pharmacology, V47, P191
   Gogia R, 1998, CURR EYE RES, V17, P257, DOI 10.1076/ceyr.17.3.257.5213
   Goncu T, 2015, CORNEA, V34, P1019, DOI 10.1097/ICO.0000000000000510
   GONDHOWIARDJO TD, 1993, CORNEA, V12, P146, DOI 10.1097/00003226-199303000-00010
   Gross RL, 2000, INT OPHTHALMOL CLIN, V40, P51, DOI 10.1097/00004397-200010000-00004
   Guan LL, 2021, AM J CLIN DERMATOL, V22, P819, DOI 10.1007/s40257-021-00632-5
   Gujral GS, 2020, INDIAN J OPHTHALMOL, V68, P2935, DOI 10.4103/ijo.IJO_1463_20
   Gulpamuk B, 2017, CURR EYE RES, V42, P1215, DOI 10.1080/02713683.2017.1302592
   Guo CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29753
   Halilovic A, 2016, ANTIOXID REDOX SIGN, V24, P1072, DOI 10.1089/ars.2015.6532
   HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6
   Hara S, 2014, STEM CELLS DEV, V23, P2190, DOI 10.1089/scd.2013.0387
   Harada C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090874
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hsiao FC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01752-y
   Hsueh YJ, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112306
   Hsueh YJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040943
   Huang WH, 1997, CLIN CHIM ACTA, V261, P117, DOI 10.1016/S0009-8981(97)06520-0
   Hull D S, 1989, Lens Eye Toxic Res, V6, P87
   Ilhan A, 2019, ARQ BRAS OFTALMOL, V82, P501, DOI 10.5935/0004-2749.20190102
   Ishii N, 2016, SCI REP-UK, V6, DOI 10.1038/srep25276
   Ishikawa Y, 2012, EXP EYE RES, V94, P85, DOI 10.1016/j.exer.2011.11.010
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joseph R, 2011, EXP EYE RES, V92, P282, DOI 10.1016/j.exer.2011.01.008
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kang EYC, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10121948
   Kao YW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010212
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Katta AV, 2013, J CLIN DIAGN RES, V7, P978, DOI 10.7860/JCDR/2013/4937.3099
   Kau HC, 2006, EYE, V20, P826, DOI 10.1038/sj.eye.6702064
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur J, 2012, J CLIN DIAGN RES, V6, P1629, DOI 10.7860/JCDR/2012/4856.2626
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kettesy B, 2014, WIEN KLIN WOCHENSCHR, V126, P286, DOI 10.1007/s00508-014-0524-6
   Khalimov AR, 2019, OPHTHALMOL RUSSIA, V16, P74, DOI DOI 10.18008/1816-5095-2019-1S-74-78
   Kilic R, 2016, CURR EYE RES, V41, P28, DOI 10.3109/02713683.2015.1004717
   Kim JY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108319
   Kirboga K, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/820853
   Kisic B, 2012, LIPID PEROXIDATION, P457, DOI 10.5772/45942
   Kisic B, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/467130
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Krepler K, 2005, AM J OPHTHALMOL, V139, P266, DOI 10.1016/j.ajo.2004.09.031
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Kunnumakkara AB, 2017, BRIT J PHARMACOL, V174, P1325, DOI 10.1111/bph.13621
   Kurutas EB, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0186-5
   Lackner EM, 2014, CORNEA, V33, P49, DOI 10.1097/ICO.0000000000000012
   Laporte C, 2007, CELL DEATH DIFFER, V14, P266, DOI 10.1038/sj.cdd.4401994
   Lass JH, 2010, ARCH OPHTHALMOL-CHIC, V128, P63, DOI 10.1001/archophthalmol.2010.128.63
   Lee CY, 2019, WORLD J CLIN CASES, V7, P642, DOI 10.12998/wjcc.v7.i5.642
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Lem DW, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072441
   Lema I, 2010, MOL VIS, V16, P2055
   Li JM, 2016, J GLAUCOMA, V25, pE94, DOI 10.1097/IJG.0000000000000269
   Li PC, 2021, MAT SCI ENG C-MATER, V120, DOI 10.1016/j.msec.2020.111753
   Li SJ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2701539
   Li SJ, 2019, ACTA OPHTHALMOL, V97, pE356, DOI 10.1111/aos.13789
   Li SJ, 2017, ONCOTARGET, V8, P2816, DOI 10.18632/oncotarget.13745
   Lim JC, 2017, EXP EYE RES, V156, P117, DOI 10.1016/j.exer.2016.05.027
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Liu CL, 2016, INVEST OPHTH VIS SCI, V57, P2319, DOI 10.1167/iovs.16-19097
   Liu TM, 2020, STEM CELL REP, V14, P210, DOI 10.1016/j.stemcr.2020.01.002
   Lopes AG, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05166-3
   Lovatt M, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101417
   Lu J, 2014, FREE RADICAL BIO MED, V66, P75, DOI 10.1016/j.freeradbiomed.2013.07.036
   Ma XP, 2018, INT J OPHTHALMOL-CHI, V11, P1337, DOI 10.18240/ijo.2018.08.14
   Mancino R, 2011, MOL VIS, V17, P1298
   Martin LM, 2019, OCUL SURF, V17, P186, DOI 10.1016/j.jtos.2019.01.008
   Mathew MC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004567.pub2
   Mazzolani F, 2013, CLIN OPHTHALMOL, V7, P939, DOI 10.2147/OPTH.S45820
   McKay TB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176017
   Merle BMJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062047
   Miric DJ, 2014, EYE, V28, P72, DOI 10.1038/eye.2013.207
   Mironczuk-Chodakowska I, 2018, ADV MED SCI-POLAND, V63, P68, DOI 10.1016/j.advms.2017.05.005
   Miserocchi E, 2020, EUR J OPHTHALMOL, V30, P1390, DOI 10.1177/1120672119892804
   Moreau KL, 2012, TRENDS MOL MED, V18, P273, DOI 10.1016/j.molmed.2012.03.005
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Moschos MM, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-9
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Munia I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030879
   Muz OE, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100295
   Nakka VP, 2016, MOL NEUROBIOL, V53, P532, DOI 10.1007/s12035-014-9029-6
   Nanda GG, 2019, MOL VIS, V25, P295
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Navel V, 2021, ACTA OPHTHALMOL, V99, pE777, DOI 10.1111/aos.14714
   Nebbioso M, 2021, CLIN OPHTHALMOL, V15, P2553, DOI 10.2147/OPTH.S306706
   Nimse SB, 2015, RSC ADV, V5, P27986, DOI 10.1039/c4ra13315c
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nucci C, 2013, MOL VIS, V19, P1841
   Oppenheimer A., 1937, LANCET, V229, P619, DOI [10.1016/S0140-6736(00)98193-5, DOI 10.1016/S0140-6736(00)98193-5]
   Ozer MA, 2017, CURR EYE RES, V42, P803, DOI 10.1080/02713683.2016.1238943
   Ozturk BT, 2017, EYE, V31, P491, DOI 10.1038/eye.2016.254
   Padua IRM, 2018, VET OPHTHALMOL, V21, P151, DOI 10.1111/vop.12490
   Park C, 2019, CUTAN OCUL TOXICOL, V38, P298, DOI 10.1080/15569527.2019.1613425
   Park SI, 2017, OPHTHALMIC RES, V57, P118, DOI 10.1159/000452174
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pradhan N, 2015, J MOL MED, V93, P1095, DOI 10.1007/s00109-015-1277-z
   Price M.O., 2018, CURR OPHTHALMOL REP, V6, P191, DOI DOI 10.1007/S40135-018-0179-Y
   Qin YJ, 2020, CLIN EXP OPHTHALMOL, V48, P1183, DOI 10.1111/ceo.13835
   Radkar P, 2021, OPHTHALMOL THER, V10, P581, DOI 10.1007/s40123-021-00357-y
   Ramdas WD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030359
   Ramdas WD, 2012, EUR J EPIDEMIOL, V27, P385, DOI 10.1007/s10654-012-9672-z
   Ravindran RD, 2011, OPHTHALMOLOGY, V118, P1958, DOI 10.1016/j.ophtha.2011.03.016
   REISS GR, 1986, ARCH OPHTHALMOL-CHIC, V104, P753
   Ringvold A, 1996, EXP EYE RES, V62, P261, DOI 10.1006/exer.1996.0031
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Rosado-Adames N, 2012, CURR OPIN OPHTHALMOL, V23, P3, DOI 10.1097/ICU.0b013e32834e4b5f
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Sacca SC, 2013, MUTAT RES-REV MUTAT, V752, P153, DOI 10.1016/j.mrrev.2013.01.001
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Sacca SC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060668
   Sacca SC, 2015, J CELL PHYSIOL, V230, P510, DOI 10.1002/jcp.24826
   Sacca SC, 2014, CELL MOL LIFE SCI, V71, P2197, DOI 10.1007/s00018-013-1493-z
   Saccaa S.C., 2011, GLAUCOMA CURRENT CLI, P1
   Sadowska-Bartosz I, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3267898
   Saijyothi AV, 2012, EXP EYE RES, V103, P41, DOI 10.1016/j.exer.2012.07.010
   Sant DW, 2018, INVEST OPHTH VIS SCI, V59, P3608, DOI 10.1167/iovs.18-24101
   Schmedt T, 2012, EXP EYE RES, V95, P24, DOI 10.1016/j.exer.2011.08.002
   Sebastia R, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-32
   Selvi R, 2011, INDIAN J MED RES, V134, P83
   Serbecic N, 2005, CELL TISSUE RES, V320, P465, DOI 10.1007/s00441-004-1030-3
   Shen H, 2020, MOL THER, V28, P1645, DOI 10.1016/j.ymthe.2020.04.008
   Shetty R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184628
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Shima N, 2011, INVEST OPHTH VIS SCI, V52, P8711, DOI 10.1167/iovs.11-7592
   Shinde V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66735-x
   Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Singhal SS, 2015, TOXICOL APPL PHARM, V289, P361, DOI 10.1016/j.taap.2015.10.006
   SLOMOVIC AR, 1986, ARCH OPHTHALMOL-CHIC, V104, P536, DOI 10.1001/archopht.1986.01050160092019
   Snytnikova OA, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-017-1281-0
   Soiberman Uri, 2017, Open Ophthalmol J, V11, P252, DOI 10.2174/1874364101711010252
   Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193
   Strimpakos AS, 2008, ANTIOXID REDOX SIGN, V10, P511, DOI 10.1089/ars.2007.1769
   Su LJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5080843
   Sunkireddy P, 2013, COLLOID SURFACE B, V112, P554, DOI 10.1016/j.colsurfb.2013.07.068
   Suranyi E, 2013, EUR J OPHTHALMOL, V23, P623, DOI 10.5301/ejo.5000282
   Takano S, 1997, CURR EYE RES, V16, P589, DOI 10.1076/ceyr.16.6.589.5080
   Tang BH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1803619
   TAYLOR A, 1991, CURR EYE RES, V10, P751, DOI 10.3109/02713689109013869
   Tekin S, 2022, EYE, V36, P2062, DOI 10.1038/s41433-021-01753-1
   Tezel G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061372
   Thiagarajan R, 2013, FREE RADICAL RES, V47, P337, DOI 10.3109/10715762.2013.777155
   Toprak I, 2014, EYE, V28, P285, DOI 10.1038/eye.2013.262
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsao YT, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10199
   Tur VM, 2017, SURV OPHTHALMOL, V62, P770, DOI 10.1016/j.survophthal.2017.06.009
   Umapathy A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/207250
   Vallabh NA, 2017, MITOCHONDRION, V36, P103, DOI 10.1016/j.mito.2017.05.009
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   Ventura ACS, 2001, BRIT J OPHTHALMOL, V85, P18, DOI 10.1136/bjo.85.1.18
   Wang AM, 2014, NUTRITION, V30, P1113, DOI 10.1016/j.nut.2014.02.025
   Wang C, 2019, CELL CYCLE, V18, P932, DOI 10.1080/15384101.2019.1593645
   Wang KH, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4591310
   Wang X, 2015, GENET MOL RES, V14, P6251, DOI 10.4238/2015.June.9.11
   Wang YE, 2018, JAMA OPHTHALMOL, V136, P141, DOI 10.1001/jamaophthalmol.2017.5702
   Wang YW, 2018, ADV CLIN EXP MED, V27, P577, DOI 10.17219/acem/69135
   Wei T, 2015, EXP THER MED, V9, P476, DOI 10.3892/etm.2014.2084
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Wojcik KA, 2014, ACTA BIOCHIM POL, V61, P55
   Wojcik KA, 2013, INT J MOL SCI, V14, P19294, DOI 10.3390/ijms140919294
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Yamazoe K, 2011, J CATARACT REFR SURG, V37, P2130, DOI 10.1016/j.jcrs.2011.05.039
   Yan XY, 2019, J CELL MOL MED, V23, P4030, DOI 10.1111/jcmm.14288
   Yanshole VV, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1495-4
   Yari D, 2018, IRAN J PUBLIC HEALTH, V47, P1567
   Yazu H, 2019, CURR OPHTHALMOL REP, V7, P89, DOI 10.1007/s40135-019-00204-1
   Yin JG, 2011, J CELL PHYSIOL, V226, P2025, DOI 10.1002/jcp.22532
   Yoon CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114169
   Yorgun MA, 2016, CURR EYE RES, V41, P1584, DOI 10.3109/02713683.2016.1141965
   Yuki K, 2010, GRAEF ARCH CLIN EXP, V248, P243, DOI 10.1007/s00417-009-1183-6
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
   Zarei-Ghanavati S, 2020, J CURR OPHTHALMOL, V32, P26, DOI 10.1016/j.joco.2019.06.003
   Zhang Y, 2011, MOL VIS, V17, P2325
   Zhang YK, 2017, INT J OPHTHALMOL-CHI, V10, P1791, DOI 10.18240/ijo.2017.12.01
   Zhang YF, 2015, PUBLIC HEALTH NUTR, V18, P2804, DOI 10.1017/S1368980014003115
   Zheng QX, 2014, EXP EYE RES, V125, P1, DOI 10.1016/j.exer.2014.05.001
   Zhou YF, 2016, CURR EYE RES, V41, P933, DOI 10.3109/02713683.2015.1082186
   Ziaei A, 2013, INVEST OPHTH VIS SCI, V54, P6724, DOI 10.1167/iovs.13-12699
   Zidi S, 2017, INT J IMMUNOPATH PH, V30, P395, DOI 10.1177/0394632017742505
   Zinflou C, 2017, FREE RADICAL BIO MED, V108, P118, DOI 10.1016/j.freeradbiomed.2017.03.022
   Zoric Lepsa, 2005, Vojnosanit Pregl, V62, P909, DOI 10.2298/VSP0512909Z
NR 260
TC 5
Z9 5
U1 8
U2 24
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2022
VL 23
IS 3
AR 1255
DI 10.3390/ijms23031255
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YY2SK
UT WOS:000754642700001
PM 35163178
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Salomon, RG
AF Salomon, Robert G.
TI Carboxyethylpyrroles: From Hypothesis to the Discovery of Biologically
   Active Natural Products
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID MATRIX-METALLOPROTEINASE ACTIVITY; NEWLY-DIAGNOSED GLIOBLASTOMA;
   PEROXIDATION END-PRODUCTS; LOW-DENSITY LIPOPROTEINS; SCAVENGER RECEPTOR
   CD36; ACID HOHA LACTONE; MACULAR DEGENERATION; OXIDIZED PHOSPHOLIPIDS;
   ETHANOLAMINE PHOSPHOLIPIDS; GENOMIC BIOMARKERS
AB Our research on the roles of lipid oxidation in human disease is guided by chemical intuition. For example, we postulated. that 2-(omega-carboxyethyl)pyrrole (CEP) derivatives of primary amines would be produced through covalent adduction of a gamma-hydroxyalkenal generated, in turn, through oxidative fragmentation of docosahexaenoates. Our studies confirmed the natural occurrence of this chemistry, and the biological activities of these natural products and their extensive involvements in human physiology (wound healing) and pathology (age-related macular degeneration, autism, atherosclerosis, sickle cell disease, and tumor growth) continue to emerge. This perspective recounts these discoveries and proposes new frontiers where further developments are likely. Perhaps more significantly, it depicts an effective chemistry-based approach to the discovery of novel biochemistry.
C1 [Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
C3 Case Western Reserve University
RP Salomon, RG (通讯作者)，Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
EM rgs@case.edu
OI Salomon, Robert/0000-0001-9456-3557
FU NIH [EY016813, GM021249]; NATIONAL EYE INSTITUTE [P30EY011373,
   R01EY016813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER
FX Our research on lipid oxidation and carboxyalkylpyrroles was supported
   by NIH Grants EY016813 and GM021249.
CR Agarwal S, 2013, DRUG METAB DISPOS, V41, P33, DOI 10.1124/dmd.112.048322
   Allen WL, 2006, CURR OPIN PHARMACOL, V6, P332, DOI 10.1016/j.coph.2006.02.005
   Ashraf MZ, 2008, J BIOL CHEM, V283, P10408, DOI 10.1074/jbc.M710474200
   Badie B, 2001, MICROSC RES TECHNIQ, V54, P106, DOI 10.1002/jemt.1125
   Biswas S, 2016, BLOOD, V127, P2618, DOI 10.1182/blood-2015-08-664300
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Castellani RJ, 1998, BRAIN RES, V787, P15, DOI 10.1016/S0006-8993(97)01224-9
   Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345
   Choi J, 2011, CHEM RES TOXICOL, V24, P111, DOI 10.1021/tx100305b
   Choi J, 2011, BIOORGAN MED CHEM, V19, P580, DOI 10.1016/j.bmc.2010.10.058
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F., 2013, INT J INFLAMMATION, V2013, P1
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn JH, 2012, CANCER LETT, V314, P24, DOI 10.1016/j.canlet.2011.10.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Fuchs B, 2005, CLIN BIOCHEM, V38, P925, DOI 10.1016/j.clinbiochem.2005.06.006
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Guo JH, 2016, CHEM RES TOXICOL, V29, P1187, DOI 10.1021/acs.chemrestox.6b00152
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu F, 2014, INT J CANCER, V135, P2569, DOI 10.1002/ijc.28908
   Iwamoto FM, 2009, NEUROLOGY, V73, P1200, DOI 10.1212/WNL.0b013e3181bc0184
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Kielland A, 2009, FREE RADICAL BIO MED, V47, P760, DOI 10.1016/j.freeradbiomed.2009.06.013
   Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593
   Kim YW, 2015, CIRC RES, V117, P321, DOI 10.1161/CIRCRESAHA.117.305925
   Kuhlicke J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001364
   Lamszus K, 2003, ACT NEUR S, V88, P169
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Magnuson W, 2014, J NEURO-ONCOL, V117, P133, DOI 10.1007/s11060-014-1363-z
   MEHTA D, 1990, AM REV RESPIR DIS, V142, P157, DOI 10.1164/ajrccm/142.1.157
   Merrell MA, 2006, MOL CANCER RES, V4, P437, DOI 10.1158/1541-7786.MCR-06-0007
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Murphy AA, 1998, J CLIN ENDOCR METAB, V83, P2110, DOI 10.1210/jc.83.6.2110
   Narita Y, 2013, JPN J CLIN ONCOL, V43, P587, DOI 10.1093/jjco/hyt051
   Norden AD, 2008, NEUROLOGY, V70, P779, DOI 10.1212/01.wnl.0000304121.57857.38
   Panigrahi S, 2013, CIRC RES, V112, P103, DOI 10.1161/CIRCRESAHA.112.274241
   PEAKMAN M, 1989, J CLIN PATHOL, V42, P1018, DOI 10.1136/jcp.42.10.1018
   Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Podrez EA, 2007, NAT MED, V13, P1086, DOI 10.1038/nm1626
   Rahme GJ, 2015, ONCOGENE, V34, P53, DOI 10.1038/onc.2013.531
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Rosenson RS, 2009, CARDIOVASC DRUG THER, V23, P93, DOI 10.1007/s10557-008-6148-1
   RYBORG AK, 1995, BRIT J DERMATOL, V133, P398, DOI 10.1111/j.1365-2133.1995.tb02667.x
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Salomon RG, 2000, CHEM RES TOXICOL, V13, P557, DOI 10.1021/tx000007u
   Salomon RG, 2012, CIRC RES, V111, P930, DOI 10.1161/CIRCRESAHA.112.275388
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Sasagawa T, 1998, J NUTR SCI VITAMINOL, V44, P809, DOI 10.3177/jnsv.44.809
   SAYRE LM, 1993, CHEM RES TOXICOL, V6, P19, DOI 10.1021/tx00031a002
   Sayre LM, 1997, J NEUROCHEM, V68, P2092
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   Semenza GL, 2000, ADV EXP MED BIOL, V475, P123
   Shi A, 1999, EXP CLIN ENDOCR DIAB, V107, P337, DOI 10.1055/s-0029-1212123
   Shi AH, 1999, HORM METAB RES, V31, P283, DOI 10.1055/s-2007-978734
   Subbanagounder G, 2002, VASC PHARMACOL, V38, P201, DOI 10.1016/S1537-1891(02)00170-2
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383
   Takano S, 2010, BRAIN TUMOR PATHOL, V27, P89, DOI 10.1007/s10014-010-0271-y
   Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432
   Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591
   Vinnakota K, 2013, NEURO-ONCOLOGY, V15, P1457, DOI 10.1093/neuonc/not115
   Wang F, 2015, AM J TRANSL RES, V7, P607
   Wang H, 2016, CHEM RES TOXICOL, V29, P1198, DOI 10.1021/acs.chemrestox.6b00153
   Wang H, 2015, CHEM RES TOXICOL, V28, P967, DOI 10.1021/acs.chemrestox.5b00001
   Wang H, 2014, CHEM RES TOXICOL, V27, P2015, DOI 10.1021/tx500216a
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989
   Zhang B, 2006, ATHEROSCLEROSIS, V186, P291, DOI 10.1016/j.atherosclerosis.2005.07.029
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 80
TC 6
Z9 6
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893-228X
EI 1520-5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD JAN
PY 2017
VL 30
IS 1
BP 105
EP 113
DI 10.1021/acs.chemrestox.6b00304
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA EI1UF
UT WOS:000392262900011
PM 27750413
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mains, J
   Tan, LE
   Wilson, C
   Urquhart, A
AF Mains, Jenifer
   Tan, Lay Ean
   Wilson, Clive
   Urquhart, Andrew
TI A pharmacokinetic study of a combination of beta adrenoreceptor
   antagonists - In the isolated perfused ovine eye
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Ocular; Pharmacokinetics; Mass spectrometry; Isolated perfused; Beta
   adrenoreceptor antagonist
ID RETINAL-PIGMENT-EPITHELIUM; OCULAR-TISSUES; FLUORESCEIN; ANTERIOR;
   DIFFUSION; MELANINS; DEXTRAN; BINDING; DRUGS; IRIS
AB The treatment of posterior eye diseases, such as diabetic retinopathy and age-related macular degeneration, is of growing interest as the number of people affected by these conditions continues to rise. This study utilises the methods of cassette dosing and the perfused ovine eye model - to reduce animal usage and therefore animal time - to show that for a series of beta adrenoreceptor antagonists, lipophilicity is a key physicochemical property that governs drug distribution within the eye. Following intravitreal injection, lipophilic beta adrenoreceptor antagonists penetrate to the posterior eye, where they bind to the choroid and reside in the retina at greater concentrations than more hydrophilic beta adrenoreceptor antagonists, which preferentially penetrate to the anterior eye. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Mains, Jenifer; Tan, Lay Ean; Wilson, Clive; Urquhart, Andrew] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow G4 0RE, Lanark, Scotland.
C3 University of Strathclyde
RP Urquhart, A (通讯作者)，Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, 161 Cathedral St, Glasgow G4 0RE, Lanark, Scotland.
EM andrew.urquhart@strath.ac.uk
RI Urquhart, Andrew J/B-8194-2014
OI Urquhart, Andrew J/0000-0002-5322-0002
FU AstraZeneca; University of Strathclyde; Engineering and Physical
   Sciences Research Council [EP/E036244/1] Funding Source: researchfish;
   EPSRC [EP/E036244/1] Funding Source: UKRI
FX JM acknowledges AstraZeneca and University of Strathclyde for the
   studentship. We thank Anthony Atkinson from AstraZeneca R&D, Charnwood
   for assistance with UPLC-MS/MS measurements.
CR Ackermann BL, 2004, J AM SOC MASS SPECTR, V15, P1374, DOI 10.1016/j.jasms.2004.06.001
   ARAIE M, 1991, EXP EYE RES, V52, P27, DOI 10.1016/0014-4835(91)90125-X
   Atluri H, 2003, EXP EYE RES, V76, P315, DOI 10.1016/S0014-4835(02)00311-1
   Barry, 2007, ENHANCEMENT DRUG DEL, P473
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Dijkstra BG, 1999, INVEST OPHTH VIS SCI, V40, P2622
   Doughty MJ, 2008, CURR EYE RES, V33, P45, DOI 10.1080/02713680701805742
   DRYJA TP, 1979, INVEST OPHTH VIS SCI, V18, P231
   FATT I, 1975, B MATH BIOL, V37, P85, DOI 10.1016/S0092-8240(75)80010-3
   Frick LW, 1998, PHARM SCI TECHNOL TO, V1, P12, DOI 10.1016/S1461-5347(98)00010-8
   FRIEDMAN AH, 1981, J PHARMACOL METHOD, V5, P215, DOI 10.1016/0160-5402(81)90089-9
   Gottanka J, 2004, INVEST OPHTH VIS SCI, V45, P153, DOI 10.1167/iovs.03-0796
   Han YH, 2001, J PHARMACOL EXP THER, V296, P450
   Hendrickson H, 2006, AAPS J, V8, pE709, DOI 10.1208/aapsj080480
   Hosoya K., 2003, AAPS PHARMSCI, P583
   Hu T, 2007, J PHARMACEUT BIOMED, V43, P263, DOI 10.1016/j.jpba.2006.06.032
   Kadam RS, 2010, J PHARMACOL EXP THER, V332, P1107, DOI 10.1124/jpet.109.161570
   KAISER RJ, 1964, EXP EYE RES, V3, P156, DOI 10.1016/S0014-4835(64)80030-0
   Kathawate J, 2008, INT J HEAT MASS TRAN, V51, P5598, DOI 10.1016/j.ijheatmasstransfer.2008.04.053
   Koeberle M., 2002, INVESTIGATION FACTOR
   Leblanc B, 1998, REGUL TOXICOL PHARM, V28, P124, DOI 10.1006/rtph.1998.1243
   Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P510, DOI 10.1562/2004-10-19-RA-345.1
   Mains J, 2011, EUR J PHARM BIOPHARM, V79, P328, DOI 10.1016/j.ejpb.2011.04.006
   Manitpisitkul P, 2004, DRUG DISCOV TODAY, V9, P652, DOI 10.1016/S1359-6446(04)03137-X
   Nagaraja NV, 1999, J PHARMACEUT BIOMED, V20, P433, DOI 10.1016/S0731-7085(98)00256-8
   Niemeyer G, 2001, PROG RETIN EYE RES, V20, P289, DOI 10.1016/S1350-9462(00)00029-X
   Pitkanen L, 2007, PHARM RES-DORDR, V24, P2063, DOI 10.1007/s11095-007-9342-0
   PRESTON JE, 1989, J PHYSIOL-LONDON, V408, P31, DOI 10.1113/jphysiol.1989.sp017444
   Proksch JW, 2008, J PHARM SCI-US, V97, P3411, DOI 10.1002/jps.21188
   Prota G, 1998, EXP EYE RES, V67, P293, DOI 10.1006/exer.1998.0518
   RIPPS H, 1989, EXP EYE RES, V48, P771, DOI 10.1016/0014-4835(89)90063-8
   Rodgers T, 2005, J PHARM SCI-US, V94, P1237, DOI 10.1002/jps.20323
   Shiels IA, 1999, AUST VET J, V77, P100, DOI 10.1111/j.1751-0813.1999.tb11677.x
   Singtoroj T, 2006, J PHARMACEUT BIOMED, V41, P219, DOI 10.1016/j.jpba.2005.11.006
   Smith M.E., 1999, BASIC SCI REFRACTION
   Stepanova LV, 2005, B EXP BIOL MED+, V139, P50, DOI 10.1007/s10517-005-0209-2
   Steuer H, 2005, INVEST OPHTH VIS SCI, V46, P1047, DOI 10.1167/iovs.04-0925
   Su EN, 1995, EXP EYE RES, V61, P699, DOI 10.1016/S0014-4835(05)80021-1
   Tan LE, 2011, INVEST OPHTH VIS SCI, V52, P1111, DOI 10.1167/iovs.10-5813
   Tan LE., 2010, SIPBS, P272
   Wakamatsu K, 2008, PIGM CELL MELANOMA R, V21, P97, DOI 10.1111/j.1755-148X.2007.00415.x
   White RE, 2001, DRUG METAB DISPOS, V29, P957
   WIEDERHOLT M, 1995, EXP EYE RES, V61, P223, DOI 10.1016/S0014-4835(05)80042-9
   Yu DY, 2003, PROG RETIN EYE RES, V22, P135, DOI 10.1016/S1350-9462(02)00044-7
NR 44
TC 18
Z9 19
U1 1
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD FEB
PY 2012
VL 80
IS 2
BP 393
EP 401
DI 10.1016/j.ejpb.2011.11.006
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 907GU
UT WOS:000301406600019
PM 22120686
DA 2022-11-30
ER

PT J
AU Zhou, Q
   Friedman, DS
   Lu, H
   Duan, XR
   Liang, YB
   Yang, XH
   Wang, FH
   Wang, NL
AF Zhou, Qiang
   Friedman, David S.
   Lu, Hong
   Duan, Xinrong
   Liang, Yuanbo
   Yang, Xiaohui
   Wang, Fenghua
   Wang, Ningli
TI The epidemiology of age-related eye diseases in Mainland China
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE epidemiology; prevalence; visual impairment; blindness; cataract;
   glaucoma; diabetic retinopathy; age-related maculopathy
ID QUALITY-OF-LIFE; VISUAL-ACUITY; DOUMEN COUNTY; CATARACT; POPULATION;
   PREVALENCE; GLAUCOMA; TIBET; MACULOPATHY; BLINDNESS
AB While many papers have been published regarding age-related eye diseases in Mainland China in the past two decades, the variable quality of those reports limit the conclusions that can be drawn. Many of these studies assessed blindness and low vision rates, and these estimates are likely accurate. However, due to lack of standardization of techniques for assessing cataract, glaucoma, age-related macular degeneration, and diabetic retinopathy, estimates of the burden of these diseases on the population are less reliable. Owing to the rapid economic development of China in the last decade, resources to address eyecare problems are more likely to be available. Therefore, an accurate assessment of the burden of various eye diseases is needed in order to improve blindness prevention planning and program development.
C1 [Zhou, Qiang; Duan, Xinrong; Liang, Yuanbo; Yang, Xiaohui; Wang, Fenghua; Wang, Ningli] Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Zhou, Qiang; Lu, Hong] Capital Univ Med Sci, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Friedman, David S.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Friedman, David S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA.
C3 Capital Medical University; Capital Medical University; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University; Johns
   Hopkins Bloomberg School of Public Health
RP Wang, NL (通讯作者)，Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 2 Chongnei St, Beijing 100730, Peoples R China.
EM wningli@trhos.com
OI liang, Yuanbo/0000-0001-9685-7356; Friedman, David/0000-0002-2055-5797
CR BAI ZL, 2005, INT J OPHTHALMOL, V5, P872
   BAI ZL, 2005, INT J OPHTHALMOL, V5, P864
   Bassett KL, 2005, BRIT J OPHTHALMOL, V89, P5, DOI 10.1136/bjo.2004.048744
   Chen Jian-hua, 2003, Zhonghua Yi Xue Za Zhi, V83, P1413
   China National Committee on Aging Office, PROSP CHIN ELD NEXT
   Diabetes Research Cooperation Group of National, 2002, CHIN J ENDOCRINOL ME, V18, P280
   Dunzhu S, 2003, BRIT J OPHTHALMOL, V87, P1443, DOI 10.1136/bjo.87.12.1443
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Foster PJ, 2001, BRIT J OPHTHALMOL, V85, P1277, DOI 10.1136/bjo.85.11.1277
   Foster PJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1105, DOI 10.1001/archopht.118.8.1105
   GAO YQ, 1993, J PRACT OPHTHALMOL, V11, P382
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   He MG, 1999, OPHTHALMOLOGY, V106, P1609, DOI 10.1016/S0161-6420(99)90460-8
   HE MG, 2000, ACAD J SUMS, V21, P232
   HE MG, 1998, GUANGDONG PROVINCE C, V14, P122
   HE MG, 2000, ACAD J SUMS, V21, P212
   He MG, 2006, INVEST OPHTH VIS SCI, V47, P2782, DOI 10.1167/iovs.06-0051
   He Mingguang, 2002, Zhonghua Yan Ke Za Zhi, V38, P594
   He S, 1997, Zhonghua Yan Ke Za Zhi, V33, P381
   Hu C, 1989, Zhonghua Yan Ke Za Zhi, V25, P360
   HU C, 1988, CHIN J OPHTHALMOL, V24, P322
   Hu CN, 1989, CHUNG HUA YEN KO TSA, V25, P115
   HU TS, 1989, ARCH OPHTHALMOL-CHIC, V107, P666, DOI 10.1001/archopht.1989.01070010684027
   HU Z, 1988, CHIN J OCUL FUNDUS D, V4, P193
   KLEIN R, 1986, OPHTHALMOLOGY, V93, P1183
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEIBOWITA HW, 1980, SURV OPHTHALMOL, V24, P351
   Li SL, 1998, CHIN J OCUL FUNDUS D, V14, P119
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   LIN ZQ, 2004, CHIN J PRACT OPHTHAL, V22, P749
   Liu Y, 2001, Zhonghua Yan Ke Za Zhi, V37, P338
   *NAT DIAB PREV CON, 1997, CHINESE J INTERN MED, V36, P384
   Ren BC, 2005, INT J OPHTHALMOL, V5, P1037
   *SUBS FUND DIS CHI, 1987, CHIN J OPHTHALMOL, V23
   Wang GL, 2001, OPHTHALMOL CHN, V10, P2180
   Wang T, 1998, ADV PERIT D, V14, P3
   WANG WW, 2005, CHINESE J CLIN REHAB, V9, P30
   *WHO, 1985, 727 WHO
   World Health Organization, 1997, WHOPBL9761
   Xu J, 1999, Zhonghua Yan Ke Za Zhi, V35, P465
   XU JJ, 1994, CHIN J OPHTHALMOL, V30, P225
   XU JJ, 1999, CHIN J OPHTHALMOL, V35, P348
   Xu Liang, 2005, Zhonghua Yan Ke Za Zhi, V41, P8
   Xu Liang, 2004, Zhonghua Yan Ke Za Zhi, V40, P726
   YU Q, 1994, CHIN J OCUL FUNDUS D, V10, P115
   Yu Q, 1995, CHIN J OPHTHALMOL, V31, P118
   Zhang Bin, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P452
   ZHANG L, 2004, OPHTHALMOL CHN, V13, P172
   Zhao J, 2001, Zhonghua Yan Ke Za Zhi, V37, P3
   ZHAO J, 1999, CHUNG HUA YEN KO TSA, V35, P341
   Zhao Jia-liang, 2005, Zhonghua Yan Ke Za Zhi, V41, P697
   Zhao Jialiang, 2002, Zhonghua Yan Ke Za Zhi, V38, P335
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8
   ZHAO SS, 1990, ISSUES STUD, V26, P47
   ZHU SP, 1994, CHUNG HUA YEN KO TSA, V30, P386
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
   Zou Haidong, 2002, Zhonghua Yan Ke Za Zhi, V38, P744
   ZOU LH, 1991, J PRACT OPHTHALMOL, V9, P250
   张秀娟, 2005, [中华眼科杂志, Chinese Journal of Ophthalmology], V41, P60
NR 60
TC 23
Z9 25
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD NOV-DEC
PY 2007
VL 14
IS 6
BP 399
EP 407
DI 10.1080/09286580701331974
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 245JX
UT WOS:000251932000010
PM 18161614
DA 2022-11-30
ER

PT J
AU Chong, NHV
   Kvanta, A
   Seregard, S
   Bird, AC
   Luthert, PJ
   Steen, B
AF Chong, NHV
   Kvanta, A
   Seregard, S
   Bird, AC
   Luthert, PJ
   Steen, B
TI TIMP-3 mRNA is not overexpressed in Sorsby fundus dystrophy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To assess the expression of MMP (matrix metalloproteinase)-2 and -9 and TIMP (tissue inhibitors of metalloproteinases)-1, 2, and -3 in Sorsby fundus dystrophy.
   DESIGN: Cliniciopathological report
   METHODS: A donor eye with a confirmed S181C mutation in the TIMP-3 gene and an age,matched normal donor eye were studied using in situ hybridization technique with MMP -2 and -9 and TIMP -1, 2, and -3 probes.
   RESULTS: There is a reduction of mRNA expression of MMP 2 and TIMP,3 in the Sorsby retinal pigment epithelium cells.
   CONCLUSION: Increased expression of TIMP-3 mRNA does not cause accumulation of TIMP-3 in the Bruch membrane of Sorsby fundus dystrophy nor is it likely to cause age,related macular degeneration.
C1 Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
   St Eriks Eye Hosp, Retina Dept, Stockholm, Sweden.
   Moorfields Eye Hosp, London, England.
   Inst Ophthalmol, London, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Chong, NHV (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
RI Chong, Victor/Q-6565-2018; Chong, Ngaihang V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; Luthert, Philip/0000-0001-7276-6898
CR Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
NR 5
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2003
VL 136
IS 5
BP 954
EP 955
DI 10.1016/S0002-9394(03)00482-3
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735ZW
UT WOS:000186146000039
PM 14597066
DA 2022-11-30
ER

PT J
AU Zhang, M
   Wang, J
   Pechauer, AD
   Hwang, TS
   Gao, SS
   Liu, L
   Liu, L
   Bailey, ST
   Wilson, DJ
   Huang, D
   Jia, YL
AF Zhang, Miao
   Wang, Jie
   Pechauer, Alex D.
   Hwang, Thomas S.
   Gao, Simon S.
   Liu, Liang
   Liu, Li
   Bailey, Steven T.
   Wilson, David J.
   Huang, David
   Jia, Yali
TI Advanced image processing for optical coherence tomographic angiography
   of macular diseases
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID AMPLITUDE-DECORRELATION ANGIOGRAPHY; AUTOMATIC SEGMENTATION;
   DIABETIC-RETINOPATHY; CHOROIDAL NEOVASCULARIZATION; ABNORMALITIES;
   ALGORITHM; RETINA; LAYERS; RISK
AB This article provides an overview of advanced image processing for three dimensional (3D) optical coherence tomographic (OCT) angiography of macular diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR). A fast automated retinal layers segmentation algorithm using directional graph search was introduced to separates 3D flow data into different layers in the presence of pathologies. Intelligent manual correction methods are also systematically addressed which can be done rapidly on a single frame and then automatically propagated to full 3D volume with accuracy better than 1 pixel. Methods to visualize and analyze the abnormalities including retinal and choroidal neovascularization, retinal ischemia, and macular edema were presented to facilitate the clinical use of OCT angiography. (C) 2015 Optical Society of America
C1 [Zhang, Miao; Wang, Jie; Pechauer, Alex D.; Hwang, Thomas S.; Gao, Simon S.; Liu, Liang; Liu, Li; Bailey, Steven T.; Wilson, David J.; Huang, David; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Zhang, M (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM jiaya@ohsu.edu
RI Hwang, Thomas/AAV-5146-2020; Hwang, Thomas S./AAW-6618-2020; Zhang,
   Miao/F-6574-2017
OI Hwang, Thomas S./0000-0002-0535-4823; Zhang, Miao/0000-0002-3242-5957;
   Gao, Simon/0000-0002-7020-037X; Jia, Yali/0000-0002-2784-1905; Bailey,
   Steven/0000-0003-4949-1464
FU NIH [DP3 DK104397, R01 EY024544, R01 EY023285, P30-EY010572, T32
   EY23211]; CTSA grant [UL1TR000128]; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [P30EY010572, R01EY024544, T32EY023211,
   R01EY023285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [DP3DK104397] Funding Source:
   NIH RePORTER
FX This work was supported by NIH grants DP3 DK104397, R01 EY024544, R01
   EY023285, P30-EY010572, T32 EY23211; CTSA grant UL1TR000128; and an
   unrestricted grant from Research to Prevent Blindness. Financial
   interests: Yali Jia and David Huang have a significant financial
   interest in Optovue. David Huang also has a financial interest in Carl
   Zeiss Meditec. These potential conflicts of interest have been reviewed
   and managed by Oregon Health & Science University.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang D., 2015, OCT ANGIOGRAPHY ATLA
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Ip MS, 2015, OPHTHALMOLOGY, V122, P367, DOI 10.1016/j.ophtha.2014.08.048
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kiss S, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0514-0
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Liu L, 2015, JAMA OPHTHALMOL, V133, P1045, DOI 10.1001/jamaophthalmol.2015.2225
   Liu XM, 2013, IEEE T MED IMAGING, V32, P493, DOI 10.1109/TMI.2012.2223760
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Merickel MB, 2007, PROC SPIE, V6512, DOI 10.1117/12.710588
   MORTENSEN EN, 1995, P 22 ANN C COMP GRAP, P191, DOI DOI 10.1145/218380.218442
   Pechauer AD, 2015, INVEST OPHTH VIS SCI, V56, P3287, DOI 10.1167/iovs.15-16655
   Pope D. L., 1984, Computers in Cardiology (Cat. No. 84CH2078-4), P71
   Silva PS, 2015, OPHTHALMOLOGY, V122, P949, DOI 10.1016/j.ophtha.2015.01.008
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Teng P., 2013, CASEREL OPEN SOURCE
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
NR 34
TC 106
Z9 112
U1 2
U2 16
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD DEC 1
PY 2015
VL 6
IS 12
BP 4661
EP 4675
DI 10.1364/BOE.6.004661
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA CY0UT
UT WOS:000366122800004
PM 26713185
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kahook, MY
   Kimura, AE
   Wong, LJ
   Ammar, DA
   Maycotte, MA
   Mandava, N
AF Kahook, Malik Y.
   Kimura, Alan E.
   Wong, Lisa J.
   Ammar, David A.
   Maycotte, Marco A.
   Mandava, Naresh
TI Sustained Elevation in Intraocular Pressure Associated With Intravitreal
   Bevacizumab Injections
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SAFETY; PHARMACOKINETICS; AVASTIN
AB This retrospective case series reports sustained elevation of intraocular pressure (IOP) after single or repeated intravitreal Injections of bevacizumab (Avastin; Genentech, San Francisco, CA) for wet age-related macular degeneration (AMD). All six cases experienced significant and sustained elevation in IOP after single or repeated intravitreal Injections of bevacizumab. Initiation or advancement of IOP-lowering therapy was required in all cases. The results support the need for further Studies investigating the Incidence of this potential side effect and the need for close long-term Surveillance of IOP after Injection of bevacizumab, particularly in patients with glaucoma or Suspected glaucoma. Future in vitro and In VIVO Studies are needed to better understand the reasons for this observed phenomenon. [Ophthalmic Surg Lasers Imaging 2009;40:293-295.]
C1 [Kahook, Malik Y.; Wong, Lisa J.; Ammar, David A.; Maycotte, Marco A.; Mandava, Naresh] Univ Colorado Denver, Rocky Mt Lions Eye Inst, Dept Ophthalmol, Aurora, CO 80045 USA.
   [Kimura, Alan E.] Colorado Retina Associates, Denver, CO USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Kahook, MY (通讯作者)，Univ Colorado Denver, Rocky Mt Lions Eye Inst, Dept Ophthalmol, 1675 N Ursula St Mail Stop F731, Aurora, CO 80045 USA.
FU Genentech
FX Drs. Kahook, Kimura, and Mandava have received research support from
   Genentech in the past, but no support was received for this manuscript.
   Drs. Wong, Ammar, and Maycote have no financial or proprietary interest
   in the materials presented herein.
CR Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 8
TC 87
Z9 92
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2009
VL 40
IS 3
BP 293
EP 295
DI 10.3928/15428877-20090430-12
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 446RY
UT WOS:000266140000012
PM 19485295
DA 2022-11-30
ER

PT J
AU Fatoba, O
   Itokazu, T
   Yamashita, T
AF Fatoba, Oluwaseun
   Itokazu, Takahide
   Yamashita, Toshihide
TI Complement cascade functions during brain development and
   neurodegeneration
SO FEBS JOURNAL
LA English
DT Review
DE brain development; CNS disorders; complement system; neurodegeneration;
   neuroinflammation
AB The complement system, an essential tightly regulated innate immune system, is a key regulator of normal central nervous system (CNS) development and function. However, aberrant complement component expression and activation in the brain may culminate into marked neuroinflammatory response, neurodegenerative processes and cognitive impairment. Over the years, complement-mediated neuroinflammatory responses and complement-driven neurodegeneration have been increasingly implicated in the pathogenesis of a wide spectrum of CNS disorders. This review describes how complement system contributes to normal brain development and function. We also discuss how pathologic insults such as misfolded proteins, lipid droplet/lipid droplet-associated protein or glycosaminoglycan accumulation could trigger complement-mediated neuroinflammatory responses and neurodegenerative process in neurodegenerative proteinopathies, age-related macular degeneration and neurodegenerative lysosomal storage disorders.
C1 [Fatoba, Oluwaseun; Itokazu, Takahide; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Fatoba, Oluwaseun; Yamashita, Toshihide] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka, Japan.
   [Itokazu, Takahide; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Neuromed Sci, Suita, Osaka, Japan.
C3 Osaka University; Osaka University; Osaka University
RP Fatoba, O; Yamashita, T (通讯作者)，Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM o.fatoba@molneu.med.osaka-u.ac.jp; yamashita@molneu.med.osaka-u.ac.jp
OI Yamashita, Toshihide/0000-0003-4559-7018; FATOBA,
   Oluwaseun/0000-0002-9046-3943
CR Bahrini I, 2015, SCI REP-UK, V5, DOI 10.1038/srep07989
   Bajic G, 2015, EMBO J, V34, P2735, DOI 10.15252/embj.201591881
   BARNUM SR, 1992, BIOCHEM J, V287, P595, DOI 10.1042/bj2870595
   BARNUM SR, 1992, J NEUROIMMUNOL, V38, P275, DOI 10.1016/0165-5728(92)90020-L
   Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200
   Benard M, 2008, MOL IMMUNOL, V45, P3767, DOI 10.1016/j.molimm.2008.05.027
   Berglund R, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb5077
   Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560
   Bigger BW, 2018, MOL GENET METAB, V125, P322, DOI 10.1016/j.ymgme.2018.08.003
   Brubaker WD, 2017, ALZHEIMERS DEMENT, V13, P1397, DOI 10.1016/j.jalz.2017.03.010
   Bubeck D, 2014, BIOCHEMISTRY-US, V53, P1908, DOI 10.1021/bi500157z
   Canova C, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-22
   Carmona-Fontaine C, 2011, DEV CELL, V21, P1026, DOI 10.1016/j.devcel.2011.10.012
   Carroll MC, 2012, IMMUNITY, V37, P199, DOI 10.1016/j.immuni.2012.08.002
   Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chinnery HR, 2010, J NEUROPATH EXP NEUR, V69, P896, DOI 10.1097/NEN.0b013e3181edbc1a
   Chu YX, 2010, P NATL ACAD SCI USA, V107, P7975, DOI 10.1073/pnas.0913449107
   Cimaz R, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-013-0389-0
   Collingridge GL., 2020, COMPLEMENT C3 DEPEND
   Colombo A., 2019, LOSS NPC1 ENHANCES P, P789511
   Cong QF, 2020, NAT NEUROSCI, V23, P1067, DOI 10.1038/s41593-020-0672-0
   Coulthard LG, 2017, J NEUROSCI, V37, P5395, DOI 10.1523/JNEUROSCI.0525-17.2017
   Czirr E, 2017, J EXP MED, V214, P1081, DOI 10.1084/jem.20162011
   Dalrymple A, 2007, J PROTEOME RES, V6, P2833, DOI 10.1021/pr0700753
   Dani M, 2018, BRAIN, V141, P2740, DOI 10.1093/brain/awy188
   Datta D, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1683-1
   Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M
   Dawson VL., 2020, COMPLEMENT COAGULATI
   Dejanovic B, 2018, NEURON, V100, P1322, DOI 10.1016/j.neuron.2018.10.014
   Denny KJ, 2013, J IMMUNOL, V190, P3493, DOI 10.4049/jimmunol.1203072
   DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0333-5
   DiRosario J, 2009, J NEUROSCI RES, V87, P978, DOI 10.1002/jnr.21912
   Du DS, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0942-2
   Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664
   Duda JE, 2000, J NEUROPATH EXP NEUR, V59, P830, DOI 10.1093/jnen/59.9.830
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856
   Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9
   Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004
   Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008
   Gasque P, 1996, IMMUNOLOGY, V89, P338, DOI 10.1046/j.1365-2567.1996.d01-756.x
   Gasque P, 1996, J NEUROIMMUNOL, V66, P29, DOI 10.1016/0165-5728(96)00015-X
   GASQUE P, 1995, J IMMUNOL, V154, P4726
   Gasque P, 1998, J IMMUNOL, V160, P3543
   GASQUE P, 1993, J BIOL CHEM, V268, P25068
   GASQUE P, 1995, J IMMUNOL, V155, P4882
   Gasque P, 1997, AM J PATHOL, V150, P31
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Goedert M, 2017, J PARKINSON DIS, V7, pS53, DOI 10.3233/JPD-179005
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON DL, 1992, J NEUROIMMUNOL, V36, P199, DOI 10.1016/0165-5728(92)90051-L
   GORDON DL, 1992, J NEUROSCI METH, V45, P191, DOI 10.1016/0165-0270(92)90076-P
   Gorelik A, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00169
   Gorelik A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15096
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Green RW, 1999, MOL VIS, V5
   Griffiths MR, 2018, IMMUNOLOGY, V155, P346, DOI 10.1111/imm.12974
   Griffiths MR, 2009, J IMMUNOL, V182, P4368, DOI 10.4049/jimmunol.0800205
   Gyorffy BA, 2018, P NATL ACAD SCI USA, V115, P6303, DOI 10.1073/pnas.1722613115
   Haga S, 1996, NEUROSCI LETT, V216, P191, DOI 10.1016/S0304-3940(96)13040-8
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069
   Hawksworth OA, 2014, STEM CELLS, V32, P3278, DOI 10.1002/stem.1801
   Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006
   Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heldermon CD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000772
   Holtzman DM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002369
   Hong S, 2016, DEV CELL, V38, P126, DOI 10.1016/j.devcel.2016.07.006
   Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373
   Hosokawa M, 2003, GLIA, V42, P417, DOI 10.1002/glia.10234
   Hou LY, 2018, REDOX BIOL, V14, P600, DOI 10.1016/j.redox.2017.11.010
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Houtman J, 2019, EMBO J, V38, DOI 10.15252/embj.201899430
   Hu R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.274
   Ischenko A, 1998, J NEUROCHEM, V71, P2487
   Iseki E, 2000, NEUROSCI LETT, V286, P69, DOI 10.1016/S0304-3940(00)01090-9
   Jacquet M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00453
   Jane-wit D, 2015, P NATL ACAD SCI USA, V112, P9686, DOI 10.1073/pnas.1503535112
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Joubert PE, 2009, CELL HOST MICROBE, V6, P354, DOI 10.1016/j.chom.2009.09.006
   Juul-Madsen K, 2020, J IMMUNOL, V204, P1345, DOI 10.4049/jimmunol.1900494
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kawaguchi A, 2008, DEVELOPMENT, V135, P3113, DOI 10.1242/dev.022616
   Kemper C, 2013, MOL IMMUNOL, V56, P181, DOI 10.1016/j.molimm.2013.05.223
   Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250
   Kidmose RT, 2012, P NATL ACAD SCI USA, V109, P15425, DOI 10.1073/pnas.1208031109
   Kim D, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0538-9
   King BC, 2019, CELL METAB, V29, P202, DOI 10.1016/j.cmet.2018.09.009
   Kjaer TR, 2013, MOL IMMUNOL, V56, P222, DOI 10.1016/j.molimm.2013.05.220
   Klegeris A, 2007, BIOCHEM BIOPH RES CO, V357, P1096, DOI 10.1016/j.bbrc.2007.04.055
   Klein AD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062127
   Klein AD, 2014, PEDIATR ENDOCR REV P, V12, P166
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolev M, 2014, NAT REV IMMUNOL, V14, P811, DOI 10.1038/nri3761
   Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x
   Kuraya M, 2003, INT IMMUNOL, V15, P109, DOI 10.1093/intimm/dxg008
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Larkin PB, 2012, J HUNTINGTONS DIS, V1, P107, DOI 10.3233/JHD-2012-120021
   Leblhuber F, 1998, CLIN CHEM LAB MED, V36, P747, DOI 10.1515/CCLM.1998.132
   Li HH, 2002, J NEUROSCI RES, V69, P30, DOI 10.1002/jnr.10278
   Lian H, 2016, J NEUROSCI, V36, P577, DOI 10.1523/JNEUROSCI.2117-15.2016
   Lian H, 2015, NEURON, V85, P101, DOI 10.1016/j.neuron.2014.11.018
   Liang QL, 2020, P NATL ACAD SCI USA, V117, P9413, DOI 10.1073/pnas.1922713117
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Ling EA, 1998, MICROSC RES TECHNIQ, V41, P43, DOI 10.1002/(SICI)1097-0029(19980401)41:1<43::AID-JEMT5>3.0.CO;2-V
   Linnartz B, 2012, J NEUROSCI, V32, P946, DOI 10.1523/JNEUROSCI.3830-11.2012
   Litvinchuk A, 2018, NEURON, V100, P1337, DOI 10.1016/j.neuron.2018.10.031
   Liu S, 2019, ALZH DEMENT-DADM, V11, P85, DOI 10.1016/j.dadm.2018.11.003
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu WJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07889-z
   Loeffler DA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-29
   Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978
   Lopez ME, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-216
   Lotfi P, 2018, AUTOPHAGY, V14, P1419, DOI 10.1080/15548627.2018.1474313
   LU J, 1994, J ANAT, V185, P75
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Machaczka M, 1999, AM J HEMATOL, V61, P216, DOI 10.1002/(SICI)1096-8652(199907)61:3<216::AID-AJH12>3.0.CO;2-B
   Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Matsushita M, 2013, ARCH IMMUNOL THER EX, V61, P273, DOI 10.1007/s00005-013-0229-y
   MCGEER PL, 1991, BRAIN RES, V544, P315, DOI 10.1016/0006-8993(91)90071-3
   McGlynn R, 2004, J COMP NEUROL, V480, P415, DOI 10.1002/cne.20355
   Mclin VA, 2008, INT J DEV BIOL, V52, P1123, DOI 10.1387/ijdb.072465v
   Meri S, 1998, VOX SANG, V74, P291, DOI 10.1111/j.1423-0410.1998.tb05434.x
   Milnerwood AJ, 2006, HUM MOL GENET, V15, P1690, DOI 10.1093/hmg/ddl092
   Milnerwood AJ, 2007, J PHYSIOL-LONDON, V585, P817, DOI 10.1113/jphysiol.2007.142448
   Moriyama M, 2011, J NEUROSCI, V31, P3981, DOI 10.1523/JNEUROSCI.3617-10.2011
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy KE, 2014, BRAIN, V137, P834, DOI 10.1093/brain/awt367
   Nadarajah B, 2002, NAT REV NEUROSCI, V3, P423, DOI 10.1038/nrn845
   Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298
   Neudorfer O, 1996, QJM-MON J ASSOC PHYS, V89, P691
   Neumann J, 2009, BRAIN, V132, P1783, DOI 10.1093/brain/awp044
   Nilsson G, 1996, J IMMUNOL, V157, P1693
   O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154
   Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899
   Panayiotou E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175767
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Pavese N, 2006, NEUROLOGY, V66, P1638, DOI 10.1212/01.wnl.0000222734.56412.17
   Peng Qi, 2009, Inflammation & Allergy Drug Targets, V8, P236
   Poo MM, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0261-6
   Przedborski S, 2003, J CLIN INVEST, V111, P3, DOI 10.1172/JCI200317522
   Qin Y, 2021, BRAIN BEHAV IMMUN, V91, P324, DOI 10.1016/j.bbi.2020.10.010
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Rao Y, 2002, GENE DEV, V16, P2973, DOI 10.1101/gad.1005802
   Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x
   Ricklin D, 2016, IMMUNOL REV, V274, P33, DOI 10.1111/imr.12500
   Rocha EM, 2015, ANTIOXID REDOX SIGN, V23, P550, DOI 10.1089/ars.2015.6307
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Roginska D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5306790
   Rudilla F, 2012, VACCINE, V30, P2848, DOI 10.1016/j.vaccine.2012.02.052
   Ruthazer ES., 2020, MICROGLIAL TROGOCYTO
   Sayah S, 1997, MOL BRAIN RES, V48, P215, DOI 10.1016/S0169-328X(97)00094-6
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schultz ML, 2011, TRENDS NEUROSCI, V34, P401, DOI 10.1016/j.tins.2011.05.006
   Scolding NJ, 1998, J NEUROIMMUNOL, V84, P69, DOI 10.1016/S0165-5728(97)00241-5
   Serrano-Pozo A, 2011, AM J PATHOL, V179, P1373, DOI 10.1016/j.ajpath.2011.05.047
   Shen Y, 1997, BRAIN RES, V769, P391, DOI 10.1016/S0006-8993(97)00850-0
   Sheng M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005777
   Shi QQ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6295
   Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015
   Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281
   Sidransky E, 2012, LANCET NEUROL, V11, P986, DOI 10.1016/S1474-4422(12)70190-4
   Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170
   Singhrao SK, 1999, LAB INVEST, V79, P1247
   Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4
   Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4
   Song J, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018937
   Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284
   Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469
   Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16
   Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Sun Xue-Zhi, 2002, Journal of Medical Investigation, V49, P97
   Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044
   TAMAGAWA K, 1985, BRAIN DEV-JPN, V7, P599, DOI 10.1016/S0387-7604(85)80008-5
   Tayebi N, 2003, MOL GENET METAB, V79, P104, DOI 10.1016/S1096-7192(03)00071-4
   Tayebi N, 2001, MOL GENET METAB, V73, P313, DOI 10.1006/mgme.2001.3201
   Thomas A, 2000, INT IMMUNOL, V12, P1015, DOI 10.1093/intimm/12.7.1015
   Tonegawa S, 2015, CURR OPIN NEUROBIOL, V35, P101, DOI 10.1016/j.conb.2015.07.009
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324
   Valstar MJ, 2008, J INHERIT METAB DIS, V31, P240, DOI 10.1007/s10545-008-0838-5
   VEDELER C, 1994, IMMUNOLOGY, V82, P542
   Veerhuis R, 1999, EXP NEUROL, V160, P289, DOI 10.1006/exnr.1999.7199
   Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003
   VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003
   Wadhwa M, 2019, BRAIN BEHAV IMMUN, V82, P129, DOI 10.1016/j.bbi.2019.08.004
   Wakselman S, 2008, J NEUROSCI, V28, P8138, DOI 10.1523/JNEUROSCI.1006-08.2008
   WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407
   WALKER DG, 1993, NEUROSCI LETT, V157, P99, DOI 10.1016/0304-3940(93)90652-2
   Walker FO, 2007, SEMIN NEUROL, V27, P143, DOI 10.1055/s-2007-971176
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang C, 2020, SCIENCE, V367, P688, DOI 10.1126/science.aaz2288
   Wang Y, 2011, AM J PATHOL, V178, P1509, DOI 10.1016/j.ajpath.2011.01.006
   Webster SD, 2000, J LEUKOCYTE BIOL, V67, P109, DOI 10.1002/jlb.67.1.109
   Weinhard L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03566-5
   Wlodarczyk A, 2017, EMBO J, V36, P3292, DOI 10.15252/embj.201696056
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com
   Wu T, 2019, CELL REP, V28, P2111, DOI 10.1016/j.celrep.2019.07.060
   Xie CB, 2020, AM J PATHOL, V190, P1138, DOI 10.1016/j.ajpath.2020.02.006
   YAMADA T, 1992, ACTA NEUROPATHOL, V84, P100, DOI 10.1007/BF00427222
   YANG CY, 1993, J NEUROIMMUNOL, V47, P123
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ye XX, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1644-8
   Yin CJ, 2019, NAT MED, V25, P496, DOI 10.1038/s41591-018-0336-8
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Zaal A, 2013, IMMUNOBIOLOGY, V218, P175, DOI 10.1016/j.imbio.2012.02.014
   ZAJICEK J, 1995, LAB INVEST, V73, P128
   Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
   Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com
   Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 229
TC 5
Z9 5
U1 5
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD APR
PY 2022
VL 289
IS 8
SI SI
BP 2085
EP 2109
DI 10.1111/febs.15772
EA MAR 2021
PG 25
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 0P4TX
UT WOS:000623226800001
PM 33599083
OA Bronze
DA 2022-11-30
ER

PT J
AU Whyte, EM
   Rovner, B
AF Whyte, Ellen M.
   Rovner, Barry
TI Depression in late-life: shifting the paradigm from treatment to
   prevention
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE depression; prevention; elderly; stroke; macular degeneration
ID POSTSTROKE DEPRESSION; FOLLOW-UP; MACULAR DEGENERATION; CONSENSUS
   STATEMENT; MOOD DISORDERS; STROKE; DIAGNOSIS; TRIAL; RISK;
   REHABILITATION
AB Late-life depression is very common and is associated with high rates of morbidity and mortality. While the field of geriatric psychiatry is focused on depression treatment, prevention is an enticing option. Prevention of late-life depression would decrease both emotional suffering and depression-associated morbidity and mortality and may decrease dependence on non-mental health professionals to detect depression and to initiate a treatment referral. This paper will review current thinking on prevention research with a particular focus on its application to late-life depression. To illustrate these issues, we discuss recent and ongoing clinical trials of interventions to prevent depression in two populations of older persons: those with age-related macular degeneration (AMD) and those with cerebrovascular disease. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Univ Pittsburgh, Sch Med, TDH WPIC, Pittsburgh, PA 15213 USA.
   Jefferson Hosp Neurosci, Dept Psychiat, Philadelphia, PA USA.
   Jefferson Hosp Neurosci, Dept Neurol, Philadelphia, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Jefferson University; Jefferson University
RP Whyte, EM (通讯作者)，Univ Pittsburgh, Sch Med, TDH WPIC, Room E-835,3811 OHara St, Pittsburgh, PA 15213 USA.
EM whyteem@upmc.edu
FU NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH067710, R01MH061331] Funding
   Source: NIH RePORTER; NIMH NIH HHS [MH067710, MH61331] Funding Source:
   Medline
CR American Heart Association, 2002, HEART STROK STAT UPD
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown LF, 1996, PSYCHIAT RES, V62, P161, DOI 10.1016/0165-1781(96)02914-9
   Caplan G., 1964, PRINCIPLES PREVENTIV
   Charney DS, 2003, ARCH GEN PSYCHIAT, V60, P664, DOI 10.1001/archpsyc.60.7.664
   Commission on Chronic Illness, 1957, CHRON ILLN US
   DZURILLA PJ, 1986, PROBLEM SOLVING THER
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzalez-Torrecillas J L, 1995, Int Psychogeriatr, V7, P547, DOI 10.1017/S1041610295002286
   GORDON R, 1987, PREVENTING MENTAL DI
   Hegel M. T., 2000, FAMILIES SYSTEMS HLT, V18, P423, DOI DOI 10.1037/H0091866
   Jacobi C, 2004, PSYCHOL BULL, V130, P19, DOI 10.1037/0033-2909.130.1.19
   Kazdin AE, 1997, CLIN PSYCHOL REV, V17, P375, DOI 10.1016/S0272-7358(97)00012-3
   Kneebone II, 2000, BRIT J CLIN PSYCHOL, V39, P53, DOI 10.1348/014466500163103
   KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039
   Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337
   Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186
   MAYBERG HS, 1988, AM J PSYCHIAT, V145, P937
   Mrazek P.G., 1994, REDUCING RISKS MENTA
   Mulsant BH, 1999, J CLIN PSYCHIAT, V60, P9
   Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303
   Narushima K, 2002, J NERV MENT DIS, V190, P296, DOI 10.1097/00005053-200205000-00005
   Niedermaier N, 2004, J CLIN PSYCHIAT, V65, P1619, DOI 10.4088/JCP.v65n1206
   Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490
   Paolucci S, 1998, CEREBROVASC DIS, V8, P228, DOI 10.1159/000015856
   Paolucci S, 2001, CEREBROVASC DIS, V12, P264, DOI 10.1159/000047714
   PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014
   Pohjasvaara T, 2001, EUR J NEUROL, V8, P315, DOI 10.1046/j.1468-1331.2001.00182.x
   PRIGERSON HG, 1995, DEPRESSION, V3, P297
   Rasmussen A, 2004, PSYCHOSOMATICS, V45, P91
   ROBINSON RG, 1986, AM J PSYCHIAT, V143, P1238
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
   Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5
   Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519
NR 36
TC 26
Z9 26
U1 0
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6230
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD AUG
PY 2006
VL 21
IS 8
BP 746
EP 751
DI 10.1002/gps.1555
PG 6
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA 082HA
UT WOS:000240376100006
PM 16858747
DA 2022-11-30
ER

PT J
AU Yao, J
   Tao, SL
   Young, MJ
AF Yao, Jing
   Tao, Sarah L.
   Young, Michael J.
TI Synthetic Polymer Scaffolds for Stem Cell Transplantation in Retinal
   Tissue Engineering
SO POLYMERS
LA English
DT Review
DE progenitor cell; transplantation; polymer; tissue engineering; retina
AB Age-related macular degeneration and retinitis pigmentosa are two leading causes of irreversible blindness characterized by photoreceptor loss. Cell transplantation may be one of the most promising approaches of retinal repair. However, several problems hinder the success of retinal regeneration, including cell delivery and survival, limited cell integration and incomplete cell differentiation. Recent studies show that polymer scaffolds can address these three problems. This article reviews the current literature on synthetic polymer scaffolds used for stem cell transplantation, especially retinal progenitor cells. The advantages and disadvantages of different polymer scaffolds, the role of different surface modifications on cell attachment and differentiation, and controlled drug delivery are discussed. The development of material and surface modification techniques is vital in making cell transplantation a clinical success.
C1 [Yao, Jing] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai Med Sch, Shanghai 200031, Peoples R China.
   [Yao, Jing; Young, Michael J.] Harvard Univ, Schepens Eye Res Inst, Dept Ophthalmol, Sch Med, Boston, MA 02114 USA.
   [Tao, Sarah L.] Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA.
C3 Fudan University; Harvard University; Harvard Medical School; Schepens
   Eye Research Institute; The Charles Stark Draper Laboratory, Inc.
RP Young, MJ (通讯作者)，Harvard Univ, Schepens Eye Res Inst, Dept Ophthalmol, Sch Med, 20 Staniford St, Boston, MA 02114 USA.
EM jing.yao@schepens.harvard.edu; stao@draper.com;
   michael.young@schepens.harvard.edu
FU Foundation Fighting Blindness
FX The authors acknowledge the Foundation Fighting Blindness for support.
CR Andersson AS, 2003, BIOMATERIALS, V24, P3427, DOI 10.1016/S0142-9612(03)00208-4
   Atala A, 2000, WORLD J UROL, V18, P364, DOI 10.1007/s003450000152
   Beeley NRF, 2005, J BIOMED MATER RES A, V73A, P437, DOI 10.1002/jbm.a.30294
   Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9
   CASTILLO BV, 1995, CURR EYE RES, V14, P677, DOI 10.3109/02713689508998495
   Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589
   Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Endres M, 2003, TISSUE ENG, V9, P689, DOI 10.1089/107632703768247386
   Flemming RG, 1999, BIOMATERIALS, V20, P573, DOI 10.1016/S0142-9612(98)00209-9
   Foley JD, 2005, BIOMATERIALS, V26, P3639, DOI 10.1016/j.biomaterials.2004.09.048
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Garcia-Giralt N, 2008, J BIOMED MATER RES A, V85A, P1082, DOI 10.1002/jbm.a.31670
   Gerardo-Nava J, 2009, NANOMEDICINE-UK, V4, P11, DOI 10.2217/17435889.4.1.11
   Giavaresi G, 2004, BIOMED PHARMACOTHER, V58, P411, DOI 10.1016/j.biopha.2004.08.001
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   GOURAS P, 1992, INVEST OPHTH VIS SCI, V33, P2579
   Gouras P, 1989, Prog Clin Biol Res, V314, P659
   Grayson ACR, 2004, J BIOMAT SCI-POLYM E, V15, P1281, DOI 10.1163/1568562041959991
   Gunatillake P, 2006, BIOTECHNOL ANN REV, V12, P301, DOI 10.1016/S1387-2656(06)12009-8
   Hadlock T, 1998, ARCH OTOLARYNGOL, V124, P1081, DOI 10.1001/archotol.124.10.1081
   Huang Q, 2002, TISSUE ENG, V8, P469, DOI 10.1089/107632702760184727
   Hunter DD, 1997, MOL CELL NEUROSCI, V10, P7, DOI 10.1006/mcne.1997.0632
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P2748
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Krishnamoorthy R, 2000, MOL BRAIN RES, V77, P125, DOI 10.1016/S0169-328X(00)00035-8
   Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lavik E, 2004, APPL MICROBIOL BIOT, V65, P1, DOI 10.1007/s00253-004-1580-z
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lavik Erin, 2002, Methods Mol Biol, V198, P89
   Leng T, 2004, INVEST OPHTH VIS SCI, V45, P4132, DOI 10.1167/iovs.03-1335
   Libby RT, 1996, INVEST OPHTH VIS SCI, V37, P1651
   Litchfield TM, 1997, EXP EYE RES, V64, P655, DOI 10.1006/exer.1996.0253
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15
   Lund RD, 1997, OPHTHALMIC RES, V29, P305, DOI 10.1159/000268029
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Marletta G, 2007, BIOMATERIALS, V28, P1132, DOI 10.1016/j.biomaterials.2006.10.027
   Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489
   Pomahac B, 1998, CRIT REV ORAL BIOL M, V9, P333, DOI 10.1177/10454411980090030601
   Recknor JB, 2004, BIOMATERIALS, V25, P2753, DOI 10.1016/j.biomaterials.2003.11.045
   Recknor JB, 2006, BIOMATERIALS, V27, P4098, DOI 10.1016/j.biomaterials.2006.03.029
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Schugens C, 1996, J BIOMED MATER RES, V30, P449, DOI 10.1002/(SICI)1097-4636(199604)30:4<449::AID-JBM3>3.0.CO;2-P
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   Singhal S, 2010, EXP EYE RES, V90, P308, DOI 10.1016/j.exer.2009.11.008
   Singhal S, 2008, STEM CELLS, V26, P1074, DOI 10.1634/stemcells.2007-0898
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Sun ZJ, 2009, BIOMATERIALS, V30, P5209, DOI 10.1016/j.biomaterials.2009.06.007
   Sundback CA, 2005, BIOMATERIALS, V26, P5454, DOI 10.1016/j.biomaterials.2005.02.004
   Suzuki T, 2007, CELL TRANSPLANT, V16, P493, DOI 10.3727/000000007783464966
   Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tao SL, 2007, NANO LETT, V7, P1463, DOI 10.1021/nl0700346
   Tao SL, 2003, J CONTROL RELEASE, V88, P215, DOI 10.1016/S0168-3659(03)00005-1
   Temenoff JS, 2000, BIOMATERIALS, V21, P431, DOI 10.1016/S0142-9612(99)00213-6
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tucker B.A., 2010, ARVO ANN M P ARVO AN
   Tucker B, 2008, INVEST OPHTH VIS SCI, V49, P1686, DOI 10.1167/iovs.07-1058
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   VEIS A, 1960, NATURE, V186, P720, DOI 10.1038/186720a0
   Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534
   Wang YD, 2002, NAT BIOTECHNOL, V20, P602, DOI 10.1038/nbt0602-602
   Warfvinge K, 2005, ARCH OPHTHALMOL-CHIC, V123, P1385, DOI 10.1001/archopht.123.10.1385
   Wen XJ, 2006, J BIOMED MATER RES A, V76A, P626, DOI 10.1002/jbm.a.30520
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
   Yao J, 2011, BIOMATERIALS, V32, P1041, DOI 10.1016/j.biomaterials.2010.09.063
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142-9612(96)85762-0
   Yim EKF, 2005, BIOMATERIALS, V26, P5405, DOI 10.1016/j.biomaterials.2005.01.058
   Yim EKF, 2007, EXP CELL RES, V313, P1820, DOI 10.1016/j.yexcr.2007.02.031
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P4936, DOI 10.1167/iovs.02-0640
NR 84
TC 48
Z9 50
U1 3
U2 53
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2073-4360
J9 POLYMERS-BASEL
JI Polymers
PD JUN
PY 2011
VL 3
IS 2
BP 899
EP 914
DI 10.3390/polym3020899
PG 16
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA V27GK
UT WOS:000208601500015
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sjoberg, AP
   Trouw, LA
   Blom, AM
AF Sjoberg, A. P.
   Trouw, L. A.
   Blom, A. M.
TI Complement activation and inhibition: a delicate balance
SO TRENDS IN IMMUNOLOGY
LA English
DT Review
ID C-REACTIVE PROTEIN; AMYLOID-P COMPONENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS;
   APOPTOTIC CELL RECOGNITION; FACTOR-H BINDS; C4B-BINDING PROTEIN; MACULAR
   DEGENERATION; NECROTIC CELLS; EXTRACELLULAR-MATRIX; GLOBULAR HEAD
AB Complement is part of the innate immune defence and not only recognizes microbes but also unwanted host molecules to enhance phagocytosis and clearance. This process of opsonisation must be tightly regulated to prevent immunopathology. Endogenous ligands such as dying cells, extracellular matrix proteins, pentraxins, amyloid deposits, prions and DNA, all bind the complement activator C1q, but also interact with complement inhibitors Cob-binding protein and factor H. This contrasts to the interaction between C1q and immune complexes, in which case no inhibitors bind, resulting in full complement activation. Disturbances to the complement regulation on endogenous ligands can lead to diseases such as age-related macular degeneration, neurological and rheumatic disorders. A thorough understanding of these processes might be crucial to developing new therapeutic strategies.
C1 [Blom, A. M.] Lund Univ, Malmo Univ Hosp, Dept Lab Med, Sect Med Prot Chem, S-20502 Malmo, Sweden.
   [Trouw, L. A.] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands.
   [Sjoberg, A. P.] Univ Copenhagen, Fac Hlth Sci, Dept Cellular & Mol Med, DK-2200 Copenhagen, Denmark.
C3 Lund University; Skane University Hospital; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC;
   University of Copenhagen
RP Blom, AM (通讯作者)，Lund Univ, Malmo Univ Hosp, Dept Lab Med, Sect Med Prot Chem, S-20502 Malmo, Sweden.
EM anna.blom@med.lu.se
RI Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Trouw,
   Leendert/AGK-5202-2022
OI Blom, Anna/0000-0002-1348-1734; Trouw, Leendert/0000-0001-5186-2290
CR Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Arlaud GJ, 2002, MOL IMMUNOL, V39, P383, DOI 10.1016/S0161-5890(02)00143-8
   Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904
   Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8
   Blanquet-Grossard F, 2005, BIOCHEMISTRY-US, V44, P4349, DOI 10.1021/bi047370a
   Blom AM, 2009, ANN RHEUM DIS, V68, P136, DOI 10.1136/ard.2007.085753
   Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4
   Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200
   BOHNSACK JF, 1985, P NATL ACAD SCI USA, V82, P3824, DOI 10.1073/pnas.82.11.3824
   BRISTOW CL, 1986, MOL IMMUNOL, V23, P1045, DOI 10.1016/0161-5890(86)90003-9
   BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531
   Cook HT, 2006, NAT CLIN PRACT RHEUM, V2, P330, DOI 10.1038/ncprheum0191
   DE FRUTOS PG, 1995, J BIOL CHEM, V270, P26950, DOI 10.1074/jbc.270.45.26950
   Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200
   Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Groeneveld TWL, 2005, J IMMUNOL, V175, P4715, DOI 10.4049/jimmunol.175.7.4715
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   HAPPONEN K, 2008, J IMMUNOL IN PRESS
   Heathfield TF, 2004, J BIOL CHEM, V279, P6286, DOI 10.1074/jbc.M307765200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   HICKS PS, 1992, J IMMUNOL, V149, P3689
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105
   Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567
   Kohl J, 2006, ADV EXP MED BIOL, V586, P71
   Korb LC, 1997, J IMMUNOL, V158, P4525
   Kovacs GG, 2004, NEUROBIOL DIS, V15, P21, DOI 10.1016/j.nbd.2003.09.010
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Mabbott NA, 2006, NAT REV MICROBIOL, V4, P201, DOI 10.1038/nrmicro1346
   Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004
   McGrath FDG, 2006, J IMMUNOL, V176, P2950, DOI 10.4049/jimmunol.176.5.2950
   Mihlan M, 2008, MOL IMMUNOL, V45, P4123, DOI 10.1016/j.molimm.2008.08.084
   Mitchell DA, 2007, MOL IMMUNOL, V44, P2997, DOI 10.1016/j.molimm.2006.12.027
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   MOLD C, 1984, J IMMUNOL, V133, P882
   Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R
   Nauta AJ, 2003, TRENDS IMMUNOL, V24, P148, DOI 10.1016/S1471-4906(03)00030-9
   Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231
   Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781
   Okroj M, 2008, MOL IMMUNOL, V46, P62, DOI 10.1016/j.molimm.2008.07.008
   Okroj M, 2007, ANN MED, V39, P517, DOI 10.1080/07853890701477546
   Paidassi H, 2008, FEBS LETT, V582, P3111, DOI 10.1016/j.febslet.2008.08.001
   Paidassi H, 2008, J IMMUNOL, V180, P2329, DOI 10.4049/jimmunol.180.4.2329
   REID KBM, 1984, ACTA PATH MICRO IM C, V92, P11
   Riley-Vargas RC, 2005, J CLIN INVEST, V115, P1241, DOI 10.1172/JCI200523213
   Roumenina LT, 2006, BIOCHEMISTRY-US, V45, P4093, DOI 10.1021/bi052646f
   SCHWALBE R, 1990, J BIOL CHEM, V265, P16074
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Sjoberg AP, 2008, MOL IMMUNOL, V45, P3213, DOI 10.1016/j.molimm.2008.02.023
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612
   Sjoberg AP, 2009, MOL IMMUNOL, V46, P830, DOI 10.1016/j.molimm.2008.09.018
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sorensen IJ, 1996, SCAND J IMMUNOL, V44, P401, DOI 10.1046/j.1365-3083.1996.d01-326.x
   Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374
   Tenner AJ, 2006, ADV EXP MED BIOL, V586, P153
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189
   Trouw LA, 2008, MOL IMMUNOL, V45, P3649, DOI 10.1016/j.molimm.2008.04.025
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Trouw LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002886
   Truedsson L, 2007, AUTOIMMUNITY, V40, P560, DOI 10.1080/08916930701510673
   Veerhuis R, 2005, CNS NEUROL DISORD-DR, V4, P235, DOI 10.2174/1568007054038184
   YING SC, 1993, J IMMUNOL, V150, P169
   Zhou J, 2008, J NEUROCHEM, V106, P2080, DOI 10.1111/j.1471-4159.2008.05558.x
NR 75
TC 257
Z9 275
U1 0
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4906
EI 1471-4981
J9 TRENDS IMMUNOL
JI Trends Immunol.
PD FEB
PY 2009
VL 30
IS 2
BP 83
EP 90
DI 10.1016/j.it.2008.11.003
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 420HI
UT WOS:000264279300005
PM 19144569
DA 2022-11-30
ER

PT J
AU Margolis, L
AF Margolis, Leonid
TI Immunoactivation at the Crossroads of Human Disease
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Review
DE Inflammation; Pathogens; Pathogenesis; Viruses
ID HIV-INFECTION; RHEUMATOID-ARTHRITIS; MACULAR DEGENERATION; INFLAMMATION;
   ATHEROSCLEROSIS; ACTIVATION; AGE; PATHOGENESIS; IMMUNITY; MECHANISMS
AB It is becoming increasingly clear that immunoactivation, which evolved as a system of host defense against pathogens, can become dysregulated and promote the pathogenesis of diverse diseases with both known and unknown etiologies (eg, acquired immune deficiency syndrome, age-related macular degeneration, cancer, as well as aging). Immunoactivation seems to be a "common denominator" or general mechanism of pathogenesis and may explain the association and similarities in pathology among otherwise unrelated human diseases. Identification of general mechanisms of immunoactivation may lead to the development of new therapeutic strategies applicable to many diseases even before detailed knowledge of specific etiology and pathogenesis may be available. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
C1 [Margolis, Leonid] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD)
RP Margolis, L (通讯作者)，NIH, 10 Ctr Dr 10-9D58, Bethesda, MD 20892 USA.
EM margolil@mail.nih.gov
FU Intramural Program, Eunice Kennedy-Shriver National Institute of Child
   Health and Human Development, National Institutes of Health; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [ZIAHD001416] Funding Source: NIH RePORTER
FX Intramural Program, Eunice Kennedy-Shriver National Institute of Child
   Health and Human Development, National Institutes of Health.
CR Alpert Joseph S, 2002, Curr Cardiol Rep, V4, P173, DOI 10.1007/s11886-002-0045-1
   Appay V, 2011, AIDS, V25, P1813, DOI 10.1097/QAD.0b013e32834640e6
   Bhattarai N, 2013, J IMMUNOL, V190, P6351, DOI 10.4049/jimmunol.1300589
   Biancotto A, 2007, BLOOD, V109, P4272, DOI 10.1182/blood-2006-11-055764
   Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Dhabhar FS, 2014, IMMUNOL RES, V58, P193, DOI 10.1007/s12026-014-8517-0
   Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Estes JD, 2008, SEMIN IMMUNOL, V20, P181, DOI 10.1016/j.smim.2008.04.002
   Frostegard J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-117
   Grivel JC, 2011, ARTERIOSCL THROM VAS, V31, P2929, DOI 10.1161/ATVBAHA.111.237081
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220
   Hearps AC, 2012, AIDS, V26, P843, DOI 10.1097/QAD.0b013e328351f756
   Heidt T, 2014, NAT MED, V20, P754, DOI 10.1038/nm.3589
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213
   Lederman MM, 2008, SEMIN IMMUNOL, V20, P187, DOI 10.1016/j.smim.2008.06.001
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Naeger DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008886
   Nusair MB, 2012, CARDIORENAL MED, V2, P117, DOI 10.1159/000337082
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Parrinello CM, 2012, J INFECT DIS, V205, P1788, DOI 10.1093/infdis/jis276
   Pasceri V, 1999, CIRCULATION, V100, P2124, DOI 10.1161/01.CIR.100.21.2124
   Paulsson G, 2000, ARTERIOSCL THROM VAS, V20, P10, DOI 10.1161/01.ATV.20.1.10
   Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813
   Sherer Y, 2006, NAT CLIN PRACT RHEUM, V2, P99, DOI 10.1038/ncprheum0092
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Simak J, 2006, J THROMB HAEMOST, V4, P1296, DOI 10.1111/j.1538-7836.2006.01911.x
   Straub RH, 2003, ARTHRITIS RHEUM-US, V48, P2713, DOI 10.1002/art.11290
   Strindhall J, 2007, EXP GERONTOL, V42, P753, DOI 10.1016/j.exger.2007.05.001
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
NR 35
TC 9
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD JUN
PY 2015
VL 128
IS 6
BP 562
EP 566
DI 10.1016/j.amjmed.2014.12.026
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CI6NR
UT WOS:000354877200012
PM 25637756
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Liu, BY
   Sen, HN
   Nussenblatt, R
AF Liu, Baoying
   Sen, H. Nida
   Nussenblatt, Robert
TI Susceptibility Genes and Pharmacogenetics in Ocular Inflammatory
   Disorders
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Review
DE Age-related macular degeneration; Pharmacogenetics; Uveitis
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; TNF-ALPHA-BLOCKERS;
   MACULAR DEGENERATION; RHEUMATOID-ARTHRITIS; BEHCETS-DISEASE;
   TUBULOINTERSTITIAL NEPHRITIS; PROMOTER POLYMORPHISM; UVEITIS; INFLIXIMAB
AB Ocular inflammatory disorders encompass uveitis, scleritis, keratitis, and other ocular diseases where inflammation may play a role. Although age-related macular degeneration (AMD) is clinically characterized by degenerative changes in the macula, accumulating evidence suggests that inflammation plays an important role in its pathogenesis. Pharmacogenetics is the study of the influence of genetic variation and its effects on drug efficacy or toxicity. There are no pharmacogenetic studies in uveitis and very few in AMD therapies. In this review, the authors describe the susceptibility genes related to uveitis and AMD and the important advances in pharmacogenetic research in relation to AMD and uveitis therapy. They propose polygenic and composite models of treatment responses to fulfill individualized drug therapy in intraocular inflammatory disorders.
C1 [Liu, Baoying; Sen, H. Nida; Nussenblatt, Robert] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Nussenblatt, R (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM drbob@nei.nih.gov
FU NEI Intramural Research Program; NATIONAL EYE INSTITUTE [ZIEEY000482]
   Funding Source: NIH RePORTER
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. This research is
   supported by the NEI Intramural Research Program.
CR Ahmad T, 2003, ARTHRITIS RHEUM, V48, P807, DOI 10.1002/art.10815
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Atan D, 2005, INVEST OPHTH VIS SCI, V46, P4245, DOI 10.1167/iovs.05-0126
   Atan D, 2010, INVEST OPHTH VIS SCI, V51, P4133, DOI 10.1167/iovs.09-4583
   Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888
   BELVEDERE MC, 1986, DIS MARKERS, V4, P243
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bonfioli Adriana A, 2005, Semin Ophthalmol, V20, P199, DOI 10.1080/08820530500231953
   Brezin AP, 2011, OCUL IMMUNOL INFLAMM, V19, P397, DOI 10.3109/09273948.2011.619295
   CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Castaldo P, 2011, CURR DRUG METAB, V12, P278, DOI 10.2174/138920011795101840
   Chang JH, 2005, SURV OPHTHALMOL, V50, P364, DOI 10.1016/j.survophthal.2005.04.003
   Chen Y, 2004, TISSUE ANTIGENS, V63, P41, DOI 10.1111/j.1399-0039.2004.00150.x
   Coulthard LR, 2011, ANN RHEUM DIS, V70, P98, DOI 10.1136/ard.2010.133249
   Cuchacovich M, 2006, SCAND J RHEUMATOL, V35, P435, DOI 10.1080/03009740600904284
   Cui J, 2010, ARTHRITIS RHEUM-US, V62, P1849, DOI 10.1002/art.27457
   Damico Francisco Max, 2005, Semin Ophthalmol, V20, P183, DOI 10.1080/08820530500232126
   Davila L, 2011, NAT REV RHEUMATOL, V7, P537, DOI 10.1038/nrrheum.2011.117
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Shabrawi Y, 2006, OPHTHALMOLOGY, V113, P695, DOI 10.1016/j.ophtha.2006.01.004
   Fabris M, 2002, Reumatismo, V54, P19
   Fabris M, 2002, J RHEUMATOL, V29, P1847
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fisher MC, 2009, J RHEUMATOL, V36, P539, DOI 10.3899/jrheum.080576
   Foeldvari I, 2005, J RHEUMATOL, V32, P362
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galor A, 2008, OPHTHALMOLOGY, V115, P1826, DOI 10.1016/j.ophtha.2008.04.026
   Galor A, 2006, OPHTHALMOLOGY, V113, P2317, DOI 10.1016/j.ophtha.2006.04.038
   Gangaputra S, 2009, OPHTHALMOLOGY, V116, P2188, DOI 10.1016/j.ophtha.2009.04.020
   Gerzenstein SM, 2008, OPHTHALMIC GENET, V29, P166, DOI 10.1080/13816810802320217
   Giansanti F, 2004, EUR J OPHTHALMOL, V14, P445, DOI 10.1177/112067210401400515
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorrono-Echebarria MB, 2001, BRIT J OPHTHALMOL, V85, P1010
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Gul A, 2002, GENES IMMUN, V3, P368, DOI 10.1038/sj.gene.6363863
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0
   Karasneh J, 2003, RHEUMATOLOGY, V42, P860, DOI 10.1093/rheumatology/keg232R
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   Kilmartin DJ, 2001, BRIT J OPHTHALMOL, V85, P281, DOI 10.1136/bjo.85.3.281
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koyano S, 2003, J PHARMACOL EXP THER, V307, P110, DOI 10.1124/jpet.103.054155
   Kuo NW, 2005, INVEST OPHTH VIS SCI, V46, P1565, DOI 10.1167/iovs.04-0932
   LANE SJ, 1994, AM J RESP CELL MOL, V11, P42, DOI 10.1165/ajrcmb.11.1.8018337
   Larson T, 2011, EXPERT OPIN EMERG DR, V16, P309, DOI 10.1517/14728214.2011.537824
   Lee YH, 2010, J RHEUMATOL, V37, P740, DOI 10.3899/jrheum.090707
   Levinson RD, 2003, INVEST OPHTH VIS SCI, V44, P653, DOI 10.1167/iovs.02-0376
   Li ZQ, 2008, J IMMUNOL, V181, P5147, DOI 10.4049/jimmunol.181.7.5147
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Louis M, 2003, J RHEUMATOL, V30, P2557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markomichelakis NN, 2004, AM J OPHTHALMOL, V138, P648, DOI 10.1016/j.ajo.2004.04.066
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menezo V, 2006, CYTOKINE, V35, P200, DOI 10.1016/j.cyto.2006.08.003
   Mizuki N, 2010, NAT GENET, V42, P703, DOI 10.1038/ng.624
   MOTULSKY AG, 1957, JAMA-J AM MED ASSOC, V165, P835, DOI 10.1001/jama.1957.72980250010016
   Munoz-Fernandez S, 2009, EYE, V23, P1130, DOI 10.1038/eye.2008.198
   Nebert DW, 2008, DRUG METAB REV, V40, P187, DOI [10.1080/03602530801952864, 10.1080/03602530801952864 ]
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   NUSSENBLATT RB, 1982, AM J OPHTHALMOL, V94, P147, DOI 10.1016/0002-9394(82)90069-1
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Ohno S, 2004, J RHEUMATOL, V31, P1362
   Pasadhika S, 2009, AM J OPHTHALMOL, V148, P500, DOI 10.1016/j.ajo.2009.05.008
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Plant D, 2012, ARTHRITIS RHEUM-US, V64, P665, DOI 10.1002/art.33381
   Ramos-Casals M, 2007, MEDICINE, V86, P242, DOI 10.1097/MD.0b013e3181441a68
   Ranganathan A, 2005, PHARMACOGENOMICS, V6, P481, DOI 10.2217/14622416.6.5.481
   Remmers EF, 2010, NAT GENET, V42, P698, DOI 10.1038/ng.625
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seitz M, 2007, RHEUMATOLOGY, V46, P93, DOI 10.1093/rheumatology/kel175
   Sfikakis PP, 2001, LANCET, V358, P295, DOI 10.1016/S0140-6736(01)05497-6
   Smith MA, 2010, PHARMACOGENOMICS, V11, P421, DOI [10.2217/pgs.10.4, 10.2217/PGS.10.4]
   Stanford MR, 2005, BRIT J OPHTHALMOL, V89, P1013, DOI 10.1136/bjo.2004.057620
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   Tai HL, 1996, AM J HUM GENET, V58, P694
   Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444
   Tang WM, 1997, AM J OPHTHALMOL, V123, P70, DOI 10.1016/S0002-9394(14)70994-8
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tynjala P, 2008, RHEUMATOLOGY, V47, P339, DOI 10.1093/rheumatology/kem356
   Vogel F, 1959, ERG INN MED KINDERHK, V12, P52, DOI DOI 10.1007/978-3-642-94744-5_2
   Wallace GR, 2011, OCUL IMMUNOL INFLAMM, V19, P10, DOI 10.3109/09273948.2010.543306
   Wallace GR, 2007, HUM IMMUNOL, V68, P122, DOI 10.1016/j.humimm.2006.11.010
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weger M, 2007, MOL VIS, V13, P1274
   Weisman MH, 2006, ARTHRITIS RHEUM-US, V54, P607, DOI 10.1002/art.21573
   Williams EL, 2009, RHEUMATOLOGY, V48, P716, DOI 10.1093/rheumatology/kep080
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 101
TC 3
Z9 4
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD OCT
PY 2012
VL 20
IS 5
BP 315
EP 323
DI 10.3109/09273948.2012.710706
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 015UM
UT WOS:000309471900001
PM 22974049
DA 2022-11-30
ER

PT J
AU Rishi, P
   Venkataraman, A
   Rishi, E
AF Rishi, Pukhraj
   Venkataraman, Anusha
   Rishi, Ekta
TI Combination photodynamic therapy and bevacizumab for choroidal
   neovascularization associated with toxoplasmosis
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; choroidal neovascularization; photodynamic therapy;
   toxoplasmosis
ID INTRAVITREAL BEVACIZUMAB; SURGICAL REMOVAL; VERTEPORFIN
AB A 14-year-old girl presenting with visual loss in both eyes was diagnosed to have healed toxoplasma retinochoroiditis in the right eye with active choroidal neovascularization (CNV) secondary to toxoplasmosis in the left. She underwent combination photodynamic therapy (PDT) and intravitreal bevacizumab as primary treatment. PDT was performed as per the 'Treatment of Age-related Macular Degeneration by Photodynamic therapy' study protocol and was followed by intravitreal bevacizumab after 2 days. CNV regressed at 8 weeks of follow-up and remained stable at 8 months of follow-up. The initial visual acuity improved from 20/120 to 20/30. Combination therapy with PDT and intravitreal bevacizumab appears to be effective in the treatment of CNV secondary to toxoplasma retinochoroiditis.
C1 [Rishi, Pukhraj; Venkataraman, Anusha; Rishi, Ekta] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai 600006, Tamil Nadu, India.
RP Rishi, P (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Chennai 600006, Tamil Nadu, India.
EM docrishi@yahoo.co.in
RI Rishi, Pukhraj/AAZ-5296-2020
CR Atmaca LS, 2004, JPN J OPHTHALMOL, V48, P386, DOI 10.1007/s10384-003-0069-0
   AUGSBURGER JJ, 1980, A GRAEF ARCH KLIN EX, V215, P43, DOI 10.1007/BF00413395
   Ben Yahia Salim, 2008, International Ophthalmology, V28, P311, DOI 10.1007/s10792-008-9218-2
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   GOSHORN EB, 1995, J PEDIATR OPHTHALMOL, V32, P178
   Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097/00006982-200604000-00003
   Melberg NS, 1996, RETINA-J RET VIT DIS, V16, P190, DOI 10.1097/00006982-199616030-00002
   Sivaprasad S, 2008, BRIT J OPHTHALMOL, V92, P451, DOI 10.1136/bjo.2007.124586
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1373
NR 10
TC 12
Z9 13
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 59
IS 1
BP 62
EP U144
DI 10.4103/0301-4738.73728
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V29IJ
UT WOS:000208741800017
PM 21157079
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Prosser, BE
   Johnson, S
   Roversi, P
   Clark, SJ
   Tarelli, E
   Sim, RB
   Day, AJ
   Lea, SM
AF Prosser, Beverly E.
   Johnson, Steven
   Roversi, Pietro
   Clark, Simon J.
   Tarelli, Edward
   Sim, Robert B.
   Day, Antony J.
   Lea, Susan M.
TI Expression, purification, cocrystallization and preliminary
   crystallographic analysis of sucrose octasulfate/human complement
   regulator factor HSCRs 6-8
SO ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS
LA English
DT Article
ID SHORT CONSENSUS REPEAT; FACTOR-H POLYMORPHISM; HEPARIN-BINDING;
   BORRELIA-BURGDORFERI; PROTEIN; IDENTIFICATION; C3B; CRYSTALLIZATION;
   CONVERTASE; TERMINUS
AB Human plasma protein complement factor H (FH) is an inhibitor of the spontaneously activated alternative complement pathway. An allotypic variant of FH, 402His, has been associated with age-related macular degeneration, the leading cause of blindness in the elderly. Crystals of FH domains 6-8 (FH678) containing 402His have been grown in the presence of a polyanionic sucrose octasulfate ligand (an analogue of the natural glycosaminoglycan ligands of FH) using both native and selenomethionine-derivatized protein. Native data sets diffracting to 2.3 angstrom and SeMet data sets of up to 2.8 angstrom resolution have been collected. An anomalous difference Patterson map reveals self- and cross-peaks from two incorporated Se atoms. The corresponding selenium substructure has been solved.
C1 Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.
   St Georges Univ London, Med Biom Ctr, London SW17 0RE, England.
   Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3RE, England.
C3 University of Oxford; University of Manchester; St Georges University
   London; University of Oxford
RP Lea, SM (通讯作者)，Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.
EM susan.lea@bnc.ox.ac.uk
RI Day, Anthony/O-1658-2015; Johnson, Steven J/F-9182-2016; Roversi,
   Pietro/F-8925-2011; Sim, Bob/A-1354-2008; Roversi, Pietro/AAK-4241-2021;
   Lea, Susan M/B-7678-2009
OI Day, Anthony/0000-0002-1415-3134; Johnson, Steven J/0000-0002-7877-3543;
   Roversi, Pietro/0000-0001-9280-9437; Sim, Bob/0000-0002-2855-7455;
   Roversi, Pietro/0000-0001-9280-9437; Lea, Susan M/0000-0001-9287-8053;
   Clark, Simon/0000-0001-8394-8355
FU MRC [G0400775] Funding Source: UKRI; Medical Research Council [G0400775]
   Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Alitalo A, 2001, INFECT IMMUN, V69, P3685, DOI 10.1128/IAI.69.6.3685-3691.2001
   BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655
   Evans P. R, 1993, P CCP4 STUD WEEK DAT, P114
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2
   Leslie A. G. W, 1992, JNT CCP4 ESF EACBM N, V26
   MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041
   Ram S, 1999, MOL IMMUNOL, V36, P915, DOI 10.1016/S0161-5890(99)00114-5
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6
   Stevenson B, 2002, INFECT IMMUN, V70, P491, DOI 10.1128/IAI.70.2.491-497.2002
   Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   White J, 2004, PROTEIN SCI, V13, P2406, DOI 10.1110/ps.03455604
NR 37
TC 13
Z9 16
U1 0
U2 1
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
EI 2053-230X
J9 ACTA CRYSTALLOGR F
JI Acta Crystallogr. F-Struct. Biol. Commun.
PD JUN
PY 2007
VL 63
BP 480
EP 483
DI 10.1107/S1744309107020052
PN 6
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 190FX
UT WOS:000248045100006
PM 17554167
OA Green Published
DA 2022-11-30
ER

PT J
AU Bertho, G
   Oumezziane, IE
   Caradeuc, C
   Guibout, L
   Balducci, C
   Dinan, L
   Dilda, PJ
   Camelo, S
   Lafont, R
   Giraud, N
AF Bertho, Gildas
   Oumezziane, Imed Eddine
   Caradeuc, Cedric
   Guibout, Louis
   Balducci, Christine
   Dinan, Laurence
   Dilda, Pierre J.
   Camelo, Serge
   Lafont, Rene
   Giraud, Nicolas
TI Structural analysis of unstable norbixin isomers guided by pure shift
   nuclear magnetic resonance
SO MAGNETIC RESONANCE IN CHEMISTRY
LA English
DT Article
DE H-1; age-related macular degeneration; broadband homonuclear decoupling;
   NMR; norbixin derivates; pure shift spectroscopy; structural analysis
ID NMR; SENSITIVITY; RESOLUTION; SPECTRA; BIXIN
AB We report the analysis of complex samples obtained during the microwave irradiation/heating of norbixin, which has been identified as a potential therapeutic target for age-related macular degeneration (AMD). In this context, identifying the different isomers that are obtained during its degradation is of primary importance. However, this characterization is challenging because, on the one hand, some of these isomers are unstable, and on the other hand, the H-1 spectra of these isomeric mixtures are poorly resolved. We could successfully apply 1D pure shift experiments to obtain ultrahigh-resolution H-1 nuclear magnetic resonance (NMR) spectra of the norbixin isomer samples and exploit their information content to analyze complementary 2D NMR data and describe accurately their isomeric composition.
C1 [Bertho, Gildas; Oumezziane, Imed Eddine; Caradeuc, Cedric; Giraud, Nicolas] Univ Paris, Lab Chim & Biochim Pharmacol & Toxicol, CNRS, F-75006 Paris, France.
   [Guibout, Louis; Balducci, Christine; Dinan, Laurence; Dilda, Pierre J.; Camelo, Serge; Lafont, Rene] Sorbonne Univ, Biophytis, Paris, France.
   [Lafont, Rene] Sorbonne Univ, Paris Seine Biol Inst BIOSIPE, CNRS, Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Sorbonne Universite; Centre National de la Recherche
   Scientifique (CNRS); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite
RP Bertho, G; Giraud, N (通讯作者)，Univ Paris, Lab Chim & Biochim Pharmacol & Toxicol, CNRS, F-75006 Paris, France.
EM gildas.bertho@parisdescartes.fr; nicolas.giraud@u-paris.fr
RI LAFONT, Rene/GYA-4891-2022
OI Bertho, Gildas/0000-0002-4929-763X; Camelo, Serge/0000-0001-8733-8503;
   Lafont, Rene/0000-0002-8044-540X; Oumeziane, Imed
   Eddine/0000-0002-2582-1783; caradeuc, cedric/0000-0002-5958-9732; Dilda,
   Pierre/0000-0001-9916-8513
CR Aguilar JA, 2018, MAGN RESON CHEM, V56, P983, DOI 10.1002/mrc.4705
   Aguilar JA, 2015, CHEM-EUR J, V21, P6623, DOI 10.1002/chem.201406283
   Aguilar JA, 2010, ANGEW CHEM INT EDIT, V49, P3901, DOI 10.1002/anie.201001107
   Aloui G, 2019, CHEMPHYSCHEM, V20, P1738, DOI 10.1002/cphc.201900244
   Bo Y, 2019, FOOD RES INT, V125, DOI 10.1016/j.foodres.2019.108574
   Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162
   Castaing-Cordier T, 2019, CHEMPHYSCHEM, V20, P736, DOI 10.1002/cphc.201801116
   Fontaine V, 2020, AGING-US, V12, P6151, DOI 10.18632/aging.103014
   Fontaine V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167793
   Foroozandeh M, 2018, CHEM-EUR J, V24, P13988, DOI 10.1002/chem.201800524
   Giraud N, 2009, MAGN RESON CHEM, V47, P300, DOI 10.1002/mrc.2387
   Giraudeau P, 2020, ANALYST, V145, P2457, DOI 10.1039/d0an00142b
   Ilgen J, 2018, J MAGN RESON, V286, P18, DOI 10.1016/j.jmr.2017.11.001
   Kakita VMR, 2018, J MAGN RESON, V293, P77, DOI 10.1016/j.jmr.2018.06.006
   Kelly D.R., 1996, J CHEM RES SYNOP, V10, P446
   Kiraly P, 2018, J MAGN RESON, V293, P19, DOI 10.1016/j.jmr.2018.05.012
   KUPCE E, 1995, J MAGN RESON SER B, V106, P300, DOI 10.1006/jmrb.1995.1049
   Lokesh, 2014, CHEM COMMUN, V50, P8550, DOI 10.1039/c4cc02978j
   Lopez JM, 2020, ANAL CHEM, V92, P12250, DOI 10.1021/acs.analchem.0c01638
   Lopez JM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43374-5
   Mauhart J, 2015, J MAGN RESON, V259, P207, DOI 10.1016/j.jmr.2015.08.011
   Merlet D, 2011, J MAGN RESON, V209, P315, DOI 10.1016/j.jmr.2011.01.030
   Moutzouri P, 2017, CHEM COMMUN, V53, P10188, DOI 10.1039/c7cc04423b
   Pitoux D, 2018, MAGN RESON CHEM, V56, P954, DOI 10.1002/mrc.4715
   Pitoux D, 2015, CHEM-EUR J, V21, P9044, DOI 10.1002/chem.201501182
   Plainchont B, 2016, PHYS CHEM CHEM PHYS, V18, P22827, DOI 10.1039/c6cp01054g
   Rehbein J, 2007, J SEP SCI, V30, P2382, DOI 10.1002/jssc.200700089
   Saito N, 2020, ANAL CHEM, V92, P13652, DOI 10.1021/acs.analchem.0c03154
   Shchukina A, 2019, CHEM COMMUN, V55, P9563, DOI 10.1039/c9cc05222d
   Stark P, 2020, MOLECULES, V25, DOI 10.3390/molecules25215125
   Tassoti S, 2018, CHEMPHYSCHEM, V19, P3166, DOI 10.1002/cphc.201800746
   Timari I, 2019, ANAL CHEM, V91, P2304, DOI 10.1021/acs.analchem.8b04928
   Watermann S, 2021, METABOLITES, V11, DOI 10.3390/metabo11010039
   Zangger K, 1997, J MAGN RESON, V124, P486, DOI 10.1006/jmre.1996.1063
   Zangger K, 2015, PROG NUCL MAG RES SP, V86-87, P1, DOI 10.1016/j.pnmrs.2015.02.002
   Zhao Q, 2020, ANAL CHIM ACTA, V1110, P131, DOI 10.1016/j.aca.2020.03.014
NR 36
TC 0
Z9 0
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0749-1581
EI 1097-458X
J9 MAGN RESON CHEM
JI Magn. Reson. Chem.
PD MAY
PY 2022
VL 60
IS 5
BP 504
EP 514
DI 10.1002/mrc.5252
EA FEB 2022
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Spectroscopy
GA 0J5KI
UT WOS:000751928700001
PM 35075680
DA 2022-11-30
ER

PT J
AU Nakahara, T
   Morita, A
   Yagasaki, R
   Mori, A
   Sakamoto, K
AF Nakahara, Tsutomu
   Morita, Akane
   Yagasaki, Rina
   Mori, Asami
   Sakamoto, Kenji
TI Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target
   in Pathological Ocular Angiogenesis
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Review
DE mammalian target of rapamycin; pathological angiogenesis; retina;
   vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VASCULAR DEVELOPMENT; OXYGEN-INDUCED
   RETINOPATHY; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; SURVIVAL FACTOR; MICE; MOUSE; MODEL
AB Pathological ocular angiogenesis is a causative factor of retinopathy of prematurity, proliferative diabetic retinopathy, and wet age-related macular degeneration. Vascular endothelial growth factor (VECF) plays an important role in pathological angiogenesis, and anti-VEGF agents have been used to treat the ocular diseases that are driven by pathological angiogenesis. However, adverse effects associated with the blockade of VECF signaling, including impairments of normal retinal vascular growth and retinal function, were suggested. Therefore, the development of a safe, effective strategy to prevent pathological ocular angiogenesis is needed. Recent studies have demonstrated that inhibitors of the mammalian target of rapamycin (mTOR) target proliferating endothelial cells within the retinal vasculature. Here, we review the potential of targeting the mTOR pathway to treat pathological ocular angiogenesis.
C1 [Nakahara, Tsutomu; Morita, Akane; Yagasaki, Rina; Mori, Asami; Sakamoto, Kenji] Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.
C3 Kitasato University
RP Nakahara, T (通讯作者)，Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.
EM nakaharat@pharm.kitasato-u.ac.jp
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Dejneka NS, 2004, MOL VIS, V10, P964
   del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Hayashi I, 2015, BIOL PHARM BULL, V38, P1765, DOI 10.1248/bpb.b15-00464
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Ichikawa A, 2014, J NEUROSCI RES, V92, P692, DOI 10.1002/jnr.23358
   Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402
   Kasai A, 2010, ARTERIOSCL THROM VAS, V30, P2182, DOI 10.1161/ATVBAHA.110.209775
   Kwon YS, 2006, EXP MOL MED, V38, P173, DOI 10.1038/emm.2006.21
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Leibinger M, 2012, NEUROBIOL DIS, V46, P314, DOI 10.1016/j.nbd.2012.01.004
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Morita A, 2014, EXP EYE RES, V120, P127, DOI 10.1016/j.exer.2014.01.009
   Nakano A, 2016, EXP EYE RES, V143, P120, DOI 10.1016/j.exer.2015.10.016
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26
   Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003
   Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Uemura A, 2006, J CLIN INVEST, V116, P369, DOI 10.1172/JCI25964
   Uemura AK, 2006, EXP CELL RES, V312, P676, DOI 10.1016/j.yexcr.2005.10.030
   Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113
   Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776
   Xue Q, 2009, ARTERIOSCL THROM VAS, V29, P1172, DOI 10.1161/ATVBAHA.109.185918
   Yagasaki R, 2014, EXP EYE RES, V129, P127, DOI 10.1016/j.exer.2014.11.005
   Yagasaki R, 2014, BIOL PHARM BULL, V37, P1838, DOI 10.1248/bpb.b14-00487
NR 43
TC 20
Z9 22
U1 0
U2 2
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD DEC
PY 2017
VL 40
IS 12
BP 2045
EP 2049
DI 10.1248/bpb.b17-00475
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FO6XE
UT WOS:000417011700005
PM 29199229
OA gold
DA 2022-11-30
ER

PT J
AU Breheny, P
   Huang, JA
AF Breheny, Patrick
   Huang, Jian
TI Penalized methods for bi-level variable selection
SO STATISTICS AND ITS INTERFACE
LA English
DT Article
DE High-dimensional data; Grouping structure; Minimax concave penalty;
   Local coordinate descent algorithms; Genetic association studies
ID MODEL SELECTION; REGRESSION; LASSO; OPTIMIZATION; LIKELIHOOD; SHRINKAGE
AB In many applications, covariates possess a grouping structure that can be incorporated into the analysis to select important groups as well as important members of those groups. This work focuses on the incorporation of grouping structure into penalized regression. We investigate the previously proposed group lasso and group bridge penalties as well as a novel method, group MCP, introducing a framework and conducting simulation studies that shed light on the behavior of these methods. To fit these models, we use the idea of a locally approximated coordinate descent to develop algorithms which are fast and stable even when the number of features is much larger than the sample size. Finally, these methods are applied to a genetic association study of age-related macular degeneration.
C1 [Huang, Jian] Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA.
   [Breheny, Patrick] Univ Kentucky, Dept Biostat, Lexington, KY 40506 USA.
C3 University of Iowa; University of Kentucky
RP Huang, JA (通讯作者)，Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA.
EM jian-huang@uiowa.edu
FU U.S. National Cancer Institute [R01CA120988]; U.S. National Science
   Foundation [DMS-0805670]; National Institute of General Medical Sciences
   [T32GM077973]; NATIONAL CANCER INSTITUTE [R01CA120988] Funding Source:
   NIH RePORTER
FX The authors would like to thank Rob Mullins for the genetic association
   data analyzed in Section 5. They also would like to thank the referee
   for constructive comments that helped to clarify several points in the
   paper. Jian Huang was supported in part by grant R01CA120988 from the
   U.S. National Cancer Institute and award DMS-0805670 from the U.S.
   National Science Foundation. Patrick Breheny was supported by grant
   T32GM077973 from the National Institute of General Medical Sciences.
CR Breiman L, 1996, ANN STAT, V24, P2350
   DONOHO DL, 1994, BIOMETRIKA, V81, P425, DOI 10.1093/biomet/81.3.425
   Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067
   Fan JQ, 2001, J AM STAT ASSOC, V96, P1348, DOI 10.1198/016214501753382273
   FRANK IE, 1993, TECHNOMETRICS, V35, P109, DOI 10.2307/1269656
   Friedman J., 2008, REGULARIZATION PATHS
   Friedman J, 2007, ANN APPL STAT, V1, P302, DOI 10.1214/07-AOAS131
   Hastie T., 2009, ELEMENTS STAT LEARNI
   HUANG J, 2007, 376 U IOW DEP STAT A
   Lange K, 2000, J COMPUT GRAPH STAT, V9, P1, DOI 10.2307/1390605
   McCullagh P., 1999, GEN LINEAR MODELS
   Meier L, 2008, J R STAT SOC B, V70, P53, DOI 10.1111/j.1467-9868.2007.00627.x
   Park MY, 2007, J ROY STAT SOC B, V69, P659, DOI 10.1111/j.1467-9868.2007.00607.x
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Wu TT, 2008, ANN APPL STAT, V2, P224, DOI 10.1214/07-AOAS147
   Yuan M, 2006, J R STAT SOC B, V68, P49, DOI 10.1111/j.1467-9868.2005.00532.x
   Zhang CH, 2007, 2007003 RUTG U DEP S
   Zhao P., 2006, 703 U CAL DEP STAT
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
   Zou H, 2008, ANN STAT, V36, P1509, DOI 10.1214/009053607000000802
   Zou H, 2007, ANN STAT, V35, P2173, DOI 10.1214/009053607000000127
NR 21
TC 146
Z9 152
U1 0
U2 10
PU INT PRESS BOSTON, INC
PI SOMERVILLE
PA PO BOX 43502, SOMERVILLE, MA 02143 USA
SN 1938-7989
EI 1938-7997
J9 STAT INTERFACE
JI Stat. Interface
PY 2009
VL 2
IS 3
BP 369
EP 380
PG 12
WC Mathematical & Computational Biology; Mathematics, Interdisciplinary
   Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Mathematics
GA 660NN
UT WOS:000282650400011
PM 20640242
DA 2022-11-30
ER

PT J
AU Yang, JY
   Yuan, MZ
   Wang, EQ
   Xia, S
   Chen, YX
AF Yang, Jingyuan
   Yuan, Mingzhen
   Wang, Erqian
   Xia, Song
   Chen, Youxin
TI Five-year real-world outcomes of anti-vascular endothelial growth factor
   monotherapy versus combination therapy for polypoidal choroidal
   vasculopathy in a Chinese population: a retrospective study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor therapy; Combination therapy;
   Photodynamic therapy; Polypoidal choroidal vasculopathy; Retinal pigment
   epithelium; Visual acuity
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB MONOTHERAPY;
   CLASSIFICATION; DIAGNOSIS; EFFICACY; EVEREST; SAFETY
AB Background To evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population. Methods Retrospective study. Fifty-three eyes of 46 patients with subtype 1 and 2 PCV followed up for at least 60 months were grouped into three regimens: anti-VEGF monotherapy, PDT combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy. Main outcome measure was best-corrected visual acuity (BCVA) using logarithm of minimal angle of resolution (logMAR). Results The mean BCVA of eyes with subtype 1 PCV (n = 28) deteriorated from 0.69 logMAR at baseline to 1.25 logMAR at months 60 (P = 0.001), while the mean BCVA of eyes with subtype 2 PCV (n = 25) sustained stable from 0.62 logMAR at baseline to 0.57 at months 60 (P = 0.654). No significant differences of visual outcomes were found between the 3 treatment regimens for subtype 1 PCV. Anti-VEGF monotherapy and initial combination treatment had better visual outcomes in eyes with subtype 2 PCV than deferred combination group during part of follow-up significantly. Initial combination group needed a less number of PDT than deferred combination group (P < 0.001). Conclusions Compared with subtype 1 PCV, subtype 2 PCV has a more favorable visual outcome in real world. All the regimens presented unfavorable visual outcomes for subtype 1 PCV. Anti-VEGF monotherapy and initial combination therapy should be superior to deferred combination therapy in the long-term management of subtype 2 PCV. Prospective randomized studies of larger size are needed to determine the long-term efficacy and safety of various treatment for PCV in real world.
C1 [Yang, Jingyuan; Yuan, Mingzhen; Wang, Erqian; Chen, Youxin] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
   [Yang, Jingyuan; Yuan, Mingzhen; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Xia, Song] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China.; Chen, YX (通讯作者)，Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
EM chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
FU National Natural Science Foundation of China (NSFC) [81670879]
FX National Natural Science Foundation of China (NSFC) (81670879).
CR Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chang YS, 2016, J OCUL PHARMACOL TH, V32, P219, DOI 10.1089/jop.2015.0073
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Couturier A, 2014, MOL VIS, V20, P908
   D'Souza P, 2018, RETINA-J RET VIT DIS, V38, P1307, DOI 10.1097/IAE.0000000000001710
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Jang JW, 2018, RETINA PHILADELPHIA
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ratanasukon M, 2018, CLIN OPHTHALMOL, V12, P2177, DOI 10.2147/OPTH.S178228
   Saito M, 2014, GRAEF ARCH CLIN EXP, V252, P227, DOI 10.1007/s00417-013-2433-1
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Wong TY, 2019, AM J OPHTHALMOL
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 30
TC 6
Z9 8
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 21
PY 2019
VL 19
IS 1
AR 237
DI 10.1186/s12886-019-1245-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JU4CU
UT WOS:000501625900003
PM 31752769
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anguita, R
   Tasiopoulou, A
   Shahid, S
   Roth, J
   Sim, SY
   Patel, PJ
AF Anguita, Rodrigo
   Tasiopoulou, Anastasia
   Shahid, Syed
   Roth, Janice
   Sim, Sing Yue
   Patel, Praveen J.
TI A Review of Aflibercept Treatment for Macular Disease
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Aflibercept; VEGF; Neovascular age-related macular degeneration;
   Diabetic macular oedema; Macular oedema associated with vein occlusion;
   Myopic choroidal neovascularization
ID INTRAVITREAL AFLIBERCEPT; DEGENERATION; EDEMA; OUTCOMES; RANIBIZUMAB;
   SAFETY; BURDEN
AB Aflibercept is a fully human recombinant fusion protein that includes the second domain of human VEGF receptor 1 and the third domain of human VEGF receptor 2. Despite the important role played by VEGF in maintaining the physiological condition of the retina under normal conditions, dysregulation of VEGF can result in pathological alterations including hyperpermeability of the retinal capillaries and migration and proliferation of retinal endothelial cells. Over the years, a number of studies have evaluated the use of intravitreal aflibercept in different retinal diseases. In this review, we aim to summarize the scientific evidence and recommendations for use of intravitreal aflibercept in neovascular age-related macular degeneration, diabetic macular oedema, macular oedema associated with retinal vein occlusion, and myopic choroidal neovascularization.
C1 [Anguita, Rodrigo; Tasiopoulou, Anastasia; Shahid, Syed; Roth, Janice; Sim, Sing Yue; Patel, Praveen J.] Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Anguita, Rodrigo; Tasiopoulou, Anastasia; Shahid, Syed; Roth, Janice; Sim, Sing Yue; Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Tasiopoulou, Anastasia] Royal Devon & Exeter Hosp, Exeter, Devon, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Exeter
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England.; Patel, PJ (通讯作者)，UCL Inst Ophthalmol, London, England.
EM praveen.patel1@nhs.net
CR [Anonymous], 2019, EYLEA AFLIBERCEPT IN
   [Anonymous], 2011, REGENERON ANNOUNCES
   Baker CW, 2019, JAMA-J AM MED ASSOC, V321, P1880, DOI 10.1001/jama.2019.5790
   Bayer Vascular Endothelial Growth Factor (VEGF), 2008, TRAP EYE INV EFF SAF
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P608, DOI 10.1016/j.ophtha.2019.11.018
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Brue C, 2016, EYE, V30, P139, DOI 10.1038/eye.2015.199
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Elman MJ, 2015, OPHTHALMOLOGY, V122, P375, DOI 10.1016/j.ophtha.2014.08.047
   Erden B, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/8639243
   Falcao M, 2010, OPEN CIRC VASC J, V3, P30, DOI DOI 10.2174/1877382601003020030
   Garcia-Arumi J, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8310350
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Glassman AR, 2020, OPHTHALMOLOGY, V127, P1201, DOI 10.1016/j.ophtha.2020.03.021
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Jiang Y, 2017, ASIA-PAC J OPHTHALMO, V6, P546, DOI 10.22608/APO.2017459
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Kolar P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/724780
   Konidaris V, 2018, INT OPHTHALMOL, V38, P207, DOI 10.1007/s10792-017-0512-8
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P521, DOI 10.1007/s00417-019-04592-9
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Liesegang T, 2001, EPIDEMIOLOGY RETINAL, P53705
   Lukic M, 2021, EUR J OPHTHALMOL, V31, P1940, DOI 10.1177/1120672120938565
   Lukic M, 2021, EUR J OPHTHALMOL, V31, P1201, DOI 10.1177/1120672120925034
   Lukic M, 2020, EUR J OPHTHALMOL, V30, P557, DOI 10.1177/1120672119833270
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Pearce I, 2020, EYE, V34, P969, DOI 10.1038/s41433-019-0615-8
   Regeneron Pharmaceuticals Vascular Endothelial Growth Factor (VEGF), 2007, TRAP EYE INV EFF SAF
   Reidy, 2009, EPIVISION RNIB
   Rhoades William, 2017, Taiwan J Ophthalmol, V7, P70, DOI 10.4103/tjo.tjo_9_17
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Sangroongruangsri S, 2018, EXPERT REV CLIN PHAR, V11, P903, DOI 10.1080/17512433.2018.1507735
   Schmidt-Erfurth U, 2019, OPHTHALMOLOGICA, V242, P123, DOI 10.1159/000502041
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spooner K, 2019, OPHTHALMOLOGICA, V242, P163, DOI 10.1159/000497492
   Stitt AW, 2013, CLIN SCI, V125, P1, DOI 10.1042/CS20120588
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Virgili G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub5
   Wang EQ, 2013, RETINA-J RET VIT DIS, V33, P1375, DOI 10.1097/IAE.0b013e31827d260a
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P631, DOI 10.1136/bjophthalmol-2017-310941
   Yang LPH, 2014, DRUG AGING, V31, P395, DOI 10.1007/s40266-014-0176-2
NR 61
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2021
VL 10
IS 3
BP 413
EP 428
DI 10.1007/s40123-021-00354-1
EA JUN 2021
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TR1YM
UT WOS:000661022100001
PM 34120317
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Libertini, G
   Ferrara, N
AF Libertini, Giacinto
   Ferrara, Nicola
TI Possible interventions to modify aging
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE aging; programmed aging paradigm; Alzheimer; Parkinson; telomere;
   subtelomere
ID INCREASING CHRONOLOGICAL AGE; ENDOTHELIAL PROGENITOR CELLS; TELOMERASE
   ACTIVITY; MOUSE TELOMERASE; MOTHER CELLS; YEAST-CELLS; EVOLUTION;
   DISEASE; NUCLEASES; APOPTOSIS
AB The programmed aging paradigm interprets aging as a function favored by natural selection at a supra-individual level. This function is implemented, according to the telomere theory, through mechanisms that operate through the subtelomere-telomere-telomerase system. After reviewing some necessary technical and ethical reservations and providing a concise description of aging mechanisms, this work considers interventions that could lead to the control of some highly disabling characteristics of aging, such as Alzheimer's and Parkinson's syndromes and age-related macular degeneration, and afterwards to a full control of aging up to a condition equivalent to that of the species defined as "with negligible senescence". The various steps needed for the development of such interventions are described along general lines.
C1 [Libertini, Giacinto; Ferrara, Nicola] Univ Naples Federico II, Dept Translat Med Sci, I-80138 Naples, Italy.
C3 University of Naples Federico II
RP Libertini, G (通讯作者)，Univ Naples Federico II, Dept Translat Med Sci, I-80138 Naples, Italy.
EM giacinto.libertini@tin.it
RI Ferrara, Nicola/ABG-2180-2021; Ferrara, Nicola/A-2904-2014
OI Ferrara, Nicola/0000-0001-8200-4942
CR Artandi SE, 2002, TRENDS MOL MED, V8, P44, DOI 10.1016/S1471-4914(01)02222-5
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245
   Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500
   Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Buttner S, 2006, J CELL BIOL, V175, P521, DOI 10.1083/jcb.200608098
   Campisi J, 2000, IN VIVO, V14, P183
   Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5
   Chandrasegaran S, 2016, J MOL BIOL, V428, P963, DOI 10.1016/j.jmb.2015.10.014
   Comfort A., 1979, BIOL SENESCENCE
   Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723
   de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991
   Fabrizio P, 2008, BBA-MOL CELL RES, V1783, P1280, DOI 10.1016/j.bbamcr.2008.03.017
   Fabrizio Paola, 2007, Methods Mol Biol, V371, P89
   Femminella G. D., 2016, CNS NEUROL DISORD DR
   Femminella GD, 2014, J ALZHEIMERS DIS, V42, P369, DOI 10.3233/JAD-140513
   Finch CE., 1990, LONGEVITY SENESCENCE
   Fossel M. B., 2004, CELLS AGING HUMAN DI
   Fossel Michael, 2015, TELOMERASE REVOLUTIO
   Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945
   Gorbunova V, 2008, AGE, V30, P111, DOI 10.1007/s11357-008-9053-4
   GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z
   GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9
   Harley CB, 2013, REJUV RES, V16, P386, DOI 10.1089/rej.2013.1430
   Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085
   Harrison MM, 2014, GENE DEV, V28, P1859, DOI 10.1101/gad.248252.114
   Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014
   Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950
   Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287
   Hill K., 1996, ACHE LIFE HIST
   HOLMES DJ, 1995, J GERONTOL A-BIOL, V50, pB59, DOI 10.1093/gerona/50A.2.B59
   Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836
   Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603
   JAZWINSKI SM, 1993, GENETICA, V91, P35, DOI 10.1007/BF01435986
   JONES RB, 1985, MECH AGEING DEV, V29, P143, DOI 10.1016/0047-6374(85)90014-4
   KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083
   KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0
   Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682
   Klapper W, 1998, FEBS LETT, V439, P143, DOI 10.1016/S0014-5793(98)01357-X
   Klapper W, 1998, FEBS LETT, V434, P409, DOI 10.1016/S0014-5793(98)01020-5
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Kuhn T.S., 1962, STRUCTURE SCI REVOLU, V16, P69
   Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x
   Laun P, 2007, NUCLEIC ACIDS RES, V35, P7514, DOI 10.1093/nar/gkm919
   Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345
   Lesur I, 2004, MOL BIOL CELL, V15, P1297, DOI 10.1091/mbc.E03-10-0742
   LIBERTINI G, 1988, J THEOR BIOL, V132, P145, DOI 10.1016/S0022-5193(88)80153-X
   Libertini G, 2015, BIOCHEMISTRY-MOSCOW+, V80, P1529, DOI 10.1134/S0006297915120019
   Libertini G, 2013, BIOCHEMISTRY-MOSCOW+, V78, P1023, DOI 10.1134/S0006297913090083
   Libertini G, 2012, BIOCHEMISTRY-MOSCOW+, V77, P707, DOI 10.1134/S0006297912070024
   Libertini G., 2009, TELOMERES FUNCTION S, P77
   Libertini G., 2016, AGE DORDRECHT, V38
   Libertini G, 2008, THESCIENTIFICWORLDJO, V8, P182, DOI 10.1100/tsw.2008.36
   Libertini Giacinto, 2015, Curr Aging Sci, V8, P56
   Libertini G, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1004, DOI 10.1134/S0006297914100034
   Libertini G, 2009, HANDBOOK ON LONGEVITY: GENETICS, DIET AND DISEASE, P35
   Maringele L, 2004, GENE DEV, V18, P2663, DOI 10.1101/gad.316504
   MEDVEDEV ZA, 1990, BIOL REV, V65, P375, DOI 10.1111/j.1469-185X.1990.tb01428.x
   Mefford HC, 2002, NAT REV GENET, V3, P91, DOI 10.1038/nrg727
   Minkoff EC, 1983, EVOLUTIONARY BIOL
   Nussey DH, 2013, AGEING RES REV, V12, P214, DOI 10.1016/j.arr.2012.07.004
   O'Geen H, 2015, CURR OPIN CHEM BIOL, V29, P72, DOI 10.1016/j.cbpa.2015.10.001
   OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394
   Olovnikov Alexey M, 2015, Curr Aging Sci, V8, P76
   OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7
   Olovnikov AM, 2003, BIOCHEMISTRY-MOSCOW+, V68, P2, DOI 10.1023/A:1022185100035
   Pagano G, 2016, NEUROLOGY, V86, P1400, DOI 10.1212/WNL.0000000000002461
   Pagano G, 2015, J NEUROL NEUROSUR PS, V86, P767, DOI 10.1136/jnnp-2014-308764
   PONTEN J, 1983, J CELL PHYSIOL, V117, P342, DOI 10.1002/jcp.1041170309
   PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818
   Ricklefs RE, 1998, AM NAT, V152, P24, DOI 10.1086/286147
   Robin JD, 2014, GENE DEV, V28, P2464, DOI 10.1101/gad.251041.114
   Rose MR, 1991, EVOLUTIONARY BIOL AG
   ROSEN P, 1985, MED HYPOTHESES, V18, P157, DOI 10.1016/0306-9877(85)90048-9
   Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6
   Skulachev VP, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1191
   Skulachev VP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1418
   Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227
   Slijepcevic P, 1999, CYTOGENET CELL GENET, V85, P196, DOI 10.1159/000015292
   Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7
   Torres GA, 2011, G3-GENES GENOM GENET, V1, P85, DOI 10.1534/g3.111.000125
   Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5
   Vaziri H., 1998, J ANTI-AGING MED, V1, P125
   WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0
   Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x
   WILSON PWF, 1987, AM J CARDIOL, V59, pG91, DOI 10.1016/0002-9149(87)90165-2
   Wright WE, 2005, J AM GERIATR SOC, V53, pS292, DOI 10.1111/j.1532-5415.2005.53492.x
   Zhang F, 2014, HUM MOL GENET, V23, pR40, DOI 10.1093/hmg/ddu125
NR 94
TC 5
Z9 12
U1 0
U2 13
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD DEC
PY 2016
VL 81
IS 12
BP 1413
EP 1428
DI 10.1134/S0006297916120038
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EF1NZ
UT WOS:000390092900003
PM 28259119
DA 2022-11-30
ER

PT J
AU Wan, CK
   He, C
   Sun, L
   Egwuagu, CE
   Leonard, WJ
AF Wan, Chi-Keung
   He, Chang
   Sun, Lin
   Egwuagu, Charles E.
   Leonard, Warren J.
TI Cutting Edge: IL-1 Receptor Signaling is Critical for the Development of
   Autoimmune Uveitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID T(H)17 CELLS; INFLAMMATION; INDUCTION; NLRP3
AB IL-1 beta is a proinflammatory cytokine important for local and systemic immunity. However, aberrant production of this cytokine is implicated in pathogenic mechanisms of a number of inflammatory diseases, including Behcet's disease and age-related macular degeneration. In this study, we report the increased secretion of IL-1 beta in the retina by neutrophils, macrophages, and dendritic cells during ocular inflammation and show that loss of IL-1R signaling confers protection from experimental autoimmune uveitis. Moreover, the amelioration of experimental autoimmune uveitis in Il1r-deficient mice was associated with reduced infiltration of inflammatory cells into the retina and decreased numbers of uveitogenic Th17 cells that mediate uveitis. These findings indicate the possible utility of IL-1R-blocking agents for the treatment of ocular inflammatory diseases.
C1 [Wan, Chi-Keung; Leonard, Warren J.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
   [Wan, Chi-Keung; Leonard, Warren J.] NHLBI, Ctr Immunol, NIH, Bethesda, MD 20892 USA.
   [He, Chang; Sun, Lin; Egwuagu, Charles E.] NEI, Mol Immunol Sect, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Heart Lung &
   Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH
   National Heart Lung & Blood Institute (NHLBI); National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Leonard, WJ (通讯作者)，NHLBI, Lab Mol Immunol, NIH, Bldg 10,Room 7B05,10 Ctr Dr, Bethesda, MD 20892 USA.
EM egwuaguc@nei.nih.gov; wjl@helix.nih.gov
RI Leonard, Warren/AAA-1397-2022; Sun, Lin/I-3146-2016
OI Wan, Edwin/0000-0003-4783-3029
FU Division of Intramural Research, National Heart, Lung, and Blood
   Institute; National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000372,
   ZIAEY000315] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [ZIAHL005408, ZICHL006058, ZIGHL006020] Funding Source:
   NIH RePORTER
FX This work was supported by the Division of Intramural Research, National
   Heart, Lung, and Blood Institute and by the National Eye Institute.
CR Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Gabay C, 2010, NAT REV RHEUMATOL, V6, P232, DOI 10.1038/nrrheum.2010.4
   Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447
   Kim EH, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0086-z
   Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070
   Masters SL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001902
   Oh HM, 2011, J IMMUNOL, V187, P3338, DOI 10.4049/jimmunol.1004019
   Shi GP, 2009, J IMMUNOL, V183, P7547, DOI 10.4049/jimmunol.0900519
   Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001
   van de Veerdonk Frank L, 2011, Trends Immunol, V32, P110, DOI 10.1016/j.it.2011.01.003
   Wan CK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8988
   Wang L, 2011, P NATL ACAD SCI USA, V108, P9542, DOI 10.1073/pnas.1018182108
   Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554
   Zhao RJ, 2014, INT IMMUNOPHARMACOL, V22, P285, DOI 10.1016/j.intimp.2014.06.041
NR 18
TC 25
Z9 28
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JAN 15
PY 2016
VL 196
IS 2
BP 543
EP 546
DI 10.4049/jimmunol.1502080
PG 4
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA DA8QX
UT WOS:000368072100009
PM 26643477
OA Green Accepted, Bronze
DA 2022-11-30
ER

EF